PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX				Shao, GZ; Zhou, RL; Zhang, QY; Zhang, Y; Liu, JJ; Rui, JA; Wei, X; Ye, DX			Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma	ONCOGENE			English	Article						LAPTM4B; hepatocellular carcinoma; differential expression; promoter analysis	HEPATITIS-B-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; MESSENGER-RNA OVEREXPRESSION; CYCLIN D1 OVEREXPRESSION; MEMBRANE-PROTEIN; C-MET; SACCHAROMYCES-CEREVISIAE; MULTIDRUG-RESISTANCE; P53 MUTATION; CELL-LINES	Lysosomal-associated protein transmembrane-4 beta (LAPTM4B), a novel gene upregulated in hepatocellular carcinoma (HCC), was cloned using fluorescence differential display, RACE, and RT-PCR. It contains seven exons and encodes a 35-kDa protein with four putative transmembrane regions. Both the N- and C-termini of the protein are proline-rich, and may serve as potential ligands for the SH3 domain. Immunohistochemical analysis localized the protein predominantly to intracellular membranes. Northern blot showed that the LAPTM4B mRNAs were remarkably upregulated in HCC (87.3%) and correlated inversely with differentiation status. LAPTM4B was also overexpressed in many HCC-derived cell tines. It was also highly expressed in fetal livers and certain adult normal tissues including the heart, skeletal muscle, testis, and ovary. Promoter function assays showed a distinct difference in the gene's activities between BEL7402 and HLE cell lines, suggesting that the transcription factors responsible for regulation of the gene in the two cell lines are different, and that possible negative regulatory cis-elements may exist upstream of the promoter region. It was demonstrated that the N-terminus of LAPTM4B was essential for survival of the cells. Cells harboring the full-length LAPTM4B cDNA expression clone displayed a slightly increased efficiency in colony formation. These results suggest that LAPTM4B is a potential protooncogene, whose overexpression is involved in carcinogenesis and progression of HCC. In normal cells, it may also play important roles such as regulation of cell proliferation and survival.	Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Beijing 100083, Peoples R China; Beijing Union Med Coll Hosp, Dept Basic Surg, Beijing 100032, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Zhou, RL (corresponding author), Peking Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, 38 Xue Yuan Rd, Beijing 100083, Peoples R China.	rlzhou@mail.bjmu.edu.cn						Adra CN, 1996, GENOMICS, V35, P328, DOI 10.1006/geno.1996.0364; Anthony PP, 2001, HISTOPATHOLOGY, V39, P109, DOI 10.1046/j.1365-2559.2001.01188.x; Arii S, 1996, HEPATOLOGY, V24, P316; BEGUM NA, 1995, HEPATOLOGY, V22, P1447, DOI 10.1002/hep.1840220518; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Cabrita MA, 1999, CANCER RES, V59, P4890; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Deane NG, 2001, CANCER RES, V61, P5389; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Feitelson MA, 1999, J CELL PHYSIOL, V181, P188; Fujimoto Y, 1998, J GASTROENTEROL, V33, P368, DOI 10.1007/s005350050098; GRAZIANO P, 2001, GENE, V276, P73; GRIGIONI WF, 1995, HEPATOLOGY, V21, P1543, DOI 10.1016/0270-9139(95)90457-3; Guo XZ, 1998, HEPATOLOGY, V28, P1481, DOI 10.1002/hep.510280606; HE J, 2003, IN PRESS J PEKING U, V35; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hogue DL, 1996, J BIOL CHEM, V271, P9801, DOI 10.1074/jbc.271.16.9801; Hogue DL, 2002, BIOCHEM J, V365, P721, DOI 10.1042/BJ20020205; Hogue DL, 1999, J BIOL CHEM, V274, P12877, DOI 10.1074/jbc.274.18.12877; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Hunziker W, 1996, BIOESSAYS, V18, P379, DOI 10.1002/bies.950180508; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; KENMOCHI K, 1987, LIVER, V7, P18; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; LI DZ, 1993, CARCINOGENESIS, V14, P169, DOI 10.1093/carcin/14.2.169; Lin YW, 1999, EUR J CANCER, V35, P652, DOI 10.1016/S0959-8049(98)00430-4; Liu JJ, 2000, CHINESE MED J-PEKING, V113, P881; Liu JJ, 2000, J BEIJING MED U, V32, P411; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.3.CO;2-N; Masumoto N, 2002, GENE, V291, P169, DOI 10.1016/S0378-1119(02)00593-0; Nakakura EK, 2000, ONCOLOGY-NY, V14, P1085; Ozaki I, 2000, CANCER RES, V60, P6519; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; Pineau P, 2000, J HEPATOL, V33, P152, DOI 10.1016/S0168-8278(00)80172-5; Qin LF, 1998, INT J CANCER, V79, P424, DOI 10.1002/(SICI)1097-0215(19980821)79:4<424::AID-IJC19>3.0.CO;2-4; Radford KJ, 1997, J IMMUNOL, V158, P3353; TANG ZY, 1995, CHINESE MED J-PEKING, V108, P568; Tannapfel A, 2000, INT J CANCER, V89, P350, DOI 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu BY, 1996, CHINESE MED J-PEKING, V109, P922; Yao YJ, 1999, ONCOGENE, V18, P3181, DOI 10.1038/sj.onc.1202659; YEH FS, 1989, CANCER RES, V49, P2506; Zeng JZ, 2002, ONCOGENE, V21, P4932, DOI 10.1038/sj.onc.1205652	49	136	153	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5060	5069		10.1038/sj.onc.1206832	http://dx.doi.org/10.1038/sj.onc.1206832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902989				2022-12-17	WOS:000184578900014
J	Arnott, CH; Scott, KA; Moore, RJ; Hewer, A; Phillips, DH; Parker, P; Balkwill, FR; Owens, DM				Arnott, CH; Scott, KA; Moore, RJ; Hewer, A; Phillips, DH; Parker, P; Balkwill, FR; Owens, DM			Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway	ONCOGENE			English	Article						inflammation; skin; keratinocyte; matrix metalloproteinase; carcinogenesis	PROTEIN-KINASE-C; NF-KAPPA-B; TNF-ALPHA; SIGNAL-TRANSDUCTION; TRANSGENIC MICE; DOWN-REGULATION; PHORBOL ESTER; SKIN TUMORS; MOUSE KERATINOCYTES; TYROSINE KINASE	Tumour necrosis factor-alpha (TNF-alpha) deficient mice (TNF-alpha(-/-) mice) are resistant to skin carcinogenesis. Cellular signalling via the transcription factor complex AP-1 is thought to play a key role in tumour promotion. The induction of a specific subset of AP-1 responsive genes thought to be important for tumour development, namely GM-CSF, MMP-9 and MMP-3, was suppressed in TNF-alpha(-/-) compared to wild-type mouse skin in response to the tumour promotor TPA. The differential induction of these genes correlated with a temporal shift in AP-1 activation and c-Jun expression in TNF-alpha(-/-) compared to wild-type epidermis. The major receptor for TPA-induced signalling in basal keratinocytes, PKCalpha, was also differentially regulated in wild-type compared with TNF-alpha(-/-) epidermis. A marked delay in TPA-induced intracellular translocation and downregulation of PKCalpha was observed in TNF-alpha(-/-) epidermis, which correlated with the deregulated TPA-induced AP-1 activation and c-Jun expression. The frequency of DNA adduct formation and c-Ha-ras mutations was the same in wild-type and TNF-alpha(-/-) epidermis after DMBA treatment, suggesting that TNF-alpha was not involved in tumour initiation. These data suggest that the pro-inflammatory cytokine TNF-alpha is a critical mediator of tumour promotion, acting via a PKCalpha- and AP-1-dependent pathway. This may be one mechanism by which chronic inflammation increases susceptibility to cancer.	Univ London, Barts & London Sch Med & Dent, Canc Res UK Translat Oncol Lab, John Vane Sci Ctr, London EC1M 6BQ, England; Inst Canc Res, Haddow Labs, Sutton SM2 5NG, Surrey, England; Canc Res UK, Prot Phosphorylat Lab, London WC2A 3PX, England; Canc Res UK, Keratinocyte Lab, London WC2A 3PX, England	Cancer Research UK; University of London; Queen Mary University London; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK	Balkwill, FR (corresponding author), Univ London, Barts & London Sch Med & Dent, Canc Res UK Translat Oncol Lab, John Vane Sci Ctr, Charterhouse Sq, London EC1M 6BQ, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Balkwill, Frances/0000-0002-5587-9759; Phillips, David/0000-0001-8509-3485	NCI NIH HHS [CA75638] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA075638] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Angel P, 2001, ONCOGENE, V20, P2413, DOI 10.1038/sj.onc.1204380; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; BENARI ET, 1992, MOL CARCINOGEN, V5, P62, DOI 10.1002/mc.2940050111; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; Bogovski P, 1994, IARC Sci Publ, P1; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FOURNIER A, 1987, NATURE, V330, P767, DOI 10.1038/330767a0; Goodell AL, 1996, J INVEST DERMATOL, V107, P354, DOI 10.1111/1523-1747.ep12363325; Han YP, 2001, J BIOL CHEM, V276, P22341, DOI 10.1074/jbc.M010839200; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HANSEN LA, 1990, CANCER RES, V50, P5740; Hulboy DL, 2001, MOL CELL BIOL, V21, P5478, DOI 10.1128/MCB.21.16.5478-5487.2001; Jansen AP, 2001, INT J CANCER, V93, P635, DOI 10.1002/ijc.1395; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; KOMORI A, 1993, CANCER RES, V53, P1982; Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Lejeune FJ, 1998, CURR OPIN IMMUNOL, V10, P573, DOI 10.1016/S0952-7915(98)80226-4; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MACNAUL KL, 1990, J BIOL CHEM, V265, P17238; Mann A, 2001, CANCER RES, V61, P2311; MILLS KJ, 1992, CARCINOGENESIS, V13, P1113, DOI 10.1093/carcin/13.7.1113; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; MOSER GJ, 1992, CANCER RES, V52, P631; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Pazzaglia S, 2001, MOL CARCINOGEN, V30, P111, DOI 10.1002/1098-2744(200102)30:2<111::AID-MC1019>3.0.CO;2-L; Piscaglia F, 1999, BIOCHEM PHARMACOL, V58, P157, DOI 10.1016/S0006-2952(99)00066-0; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; Robertson FM, 1996, CARCINOGENESIS, V17, P1719, DOI 10.1093/carcin/17.8.1719; Rutberg SE, 1996, ONCOGENE, V13, P167; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Suganuma M, 1999, CANCER RES, V59, P4516; Suganuma M, 1996, CANCER RES, V56, P3711; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wang HQ, 1999, J CELL SCI, V112, P3497; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhong SP, 2001, CANCER RES, V61, P4084	59	136	144	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4728	4738		10.1038/sj.onc.1205588	http://dx.doi.org/10.1038/sj.onc.1205588			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101411				2022-12-17	WOS:000176716300002
J	Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK				Contessa, JN; Hampton, J; Lammering, G; Mikkelsen, RB; Dent, P; Valerie, K; Schmidt-Ullrich, RK			Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells	ONCOGENE			English	Article						radiation; Erb-B; EGFR; Akt; p70 S6 kinase	GROWTH-FACTOR RECEPTOR; MESSENGER-RNA TRANSLATION; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MALIGNANT GLIOMA; IN-VIVO; INHIBITION; GENE; PROLIFERATION; TRANSDUCTION	In this study we have investigated the effects of low dose ionizing radiation (2 Gy) on p70 S6 kinase and Akt signaling with respect to Erb-B receptors in both the A431 squamous and the MDA-MB-231 mammary carcinoma cell lines. Ionizing radiation caused a 2-3-fold increase in p70 S6 kinase activity that was blocked pharmacologically using an EGFR inhibitor (AG1478) alone, or in combination with an Erb-B2 inhibitor (AG825). These results suggested that both EGFR and Erb-B2 receptors could initiate radiation-induced activation of p70 S6K. EGFR dependent Erb-B3 signaling also contributed to p70 S6 kinase activity through recruitment and activation of PI3K, which has been shown to regulate p70 S6 kinase activity. Furthermore, inhibition of the EGFR blocked IR stimulated increases in protein translation, a biologic consequence of p70 S6 kinase activation. We also report that ionizing radiation stimulated Akt activity that was partially independent of PI3K activity, but dependent on Erb-B2 function. Erb-B2 inhibition also correlated with enhanced apoptosis following IR exposure, suggesting an important role for Erb-B2 in cell survival. Together this work demonstrates that the Erb-B receptor tyrosine kinase network stimulates cytoprotective p70 S6 kinase and Akt activity in response to clinically relevant doses of ionizing radiation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA	Virginia Commonwealth University	Schmidt-Ullrich, RK (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiat Oncol, Richmond, VA 23298 USA.		Valerie, Kristoffer/AAL-8299-2021		NCI NIH HHS [CA72955, R01 CA65896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akimoto Tetsuo, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P714; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Contessa JN, 1999, CLIN CANCER RES, V5, P405; Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845; Dent P, 1999, MOL BIOL CELL, V10, P2493, DOI 10.1091/mbc.10.8.2493; Hagan M, 2000, RADIAT RES, V153, P371, DOI 10.1667/0033-7587(2000)153[0371:IRIMAP]2.0.CO;2; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hornstein E, 1999, J BIOL CHEM, V274, P1708, DOI 10.1074/jbc.274.3.1708; Huang SM, 1999, CANCER RES, V59, P1935; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KIM HH, 1994, J BIOL CHEM, V269, P24747; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Lammering G, 2001, INT J RADIAT ONCOL, V51, P775, DOI 10.1016/S0360-3016(01)01714-X; Lammering G, 2001, J NATL CANCER I, V93, P921, DOI 10.1093/jnci/93.12.921; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Liu AX, 1998, CANCER RES, V58, P2973; Milas L, 2000, CLIN CANCER RES, V6, P701; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rao GS, 2000, INT J RADIAT ONCOL, V48, P1519, DOI 10.1016/S0360-3016(00)01358-4; Reardon DB, 1999, ONCOGENE, V18, P4756, DOI 10.1038/sj.onc.1202849; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schmidt-Ullrich RK, 1999, RADIAT ONCOL INVESTI, V7, P321, DOI 10.1002/(SICI)1520-6823(1999)7:6<321::AID-ROI2>3.0.CO;2-Q; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Schwab MS, 1999, MOL CELL BIOL, V19, P2485; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; Todd DG, 1999, J RECEPT SIGNAL TR R, V19, P885, DOI 10.3109/10799899909038430; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	44	136	142	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4032	4041		10.1038/sj.onc.1205500	http://dx.doi.org/10.1038/sj.onc.1205500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037685				2022-12-17	WOS:000175869900009
J	Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C				Smiraglia, DJ; Szymanska, J; Kraggerud, SM; Lothe, RA; Peltomaki, P; Plass, C			Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors	ONCOGENE			English	Article						DNA methylation; nonseminoma; seminoma; RLGS; genome scan	CARCINOMA IN-SITU; DNA METHYLATION; PATTERNS; EXPRESSION; CANCER; PATHOGENESIS; ORIGIN	The genetic nature of testicular germ cell tumors and the molecular mechanisms underlying the morphological and clinical differences between the two subtypes, seminomas and nonseminomas, remains unclear. Genetic studies show that both subtypes exhibit many of the same regional genomic disruptions, although the frequencies vary and few clear differences are found. We demonstrate significant epigenetic differences between seminomas and nonseminomas by restriction landmark genomic scanning. Seminomas show almost no CpG island methylation, in contrast to nonseminomas that show CpG island methylation at a level similar to other solid tumors. We find an average of 1.11% of CpG islands methylation in nonseminomas, but only 0.08% methylated in seminomas. Furthermore, we demonstrate that seminomas are more highly hypomethylated than nonseminomas throughout their genome. Since both subtypes are thought to arise from primordial germ cells, the epigenetic differences seen between these subtypes may reflect the normal developmental switch in primordial germ cells from an undermethylated genome to a normally methylated genome. We discuss these findings in relation to different developmental models for seminomatous and nonseminomatous testicular germ cell tumors.	Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, Columbus, OH 43210 USA; Univ Helsinki, Dept Med Genet, Helsinki, Finland; Norwegian Radium Hosp, Dept Genet, Inst Canc Res, N-0310 Oslo, Norway	University System of Ohio; Ohio State University; University of Helsinki; University of Oslo	Smiraglia, DJ (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Div Human Canc Genet, Med Res Facil, 420 W 12th Ave,Room 470A, Columbus, OH 43210 USA.	Smiraglia.l@postbox.acs.ohio-state.edu	Smiraglia, Dominic/R-2069-2019; Plass, Christoph/H-7192-2014	Smiraglia, Dominic/0000-0001-8852-1510; Lothe, Ragnhild A./0000-0002-1693-1032; Peltomaki, Paivi/0000-0001-8819-2980	NCI NIH HHS [T32 CA 09338-20, P30 CA 16058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009338, P30CA016058] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Bestor TH, 1998, AM J HUM GENET, V62, P1269, DOI 10.1086/301891; Chaganti RSK, 1998, APMIS, V106, P80, DOI 10.1111/j.1699-0463.1998.tb01322.x; Coffigny H, 1999, CYTOGENET CELL GENET, V87, P175, DOI 10.1159/000015460; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Dai ZY, 2001, NEOPLASIA, V3, P314, DOI 10.1038/sj.neo.7900162; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334; Fruhwald MC, 2001, ONCOGENE, V20, P5033, DOI 10.1038/sj.onc.1204613; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Jones PA, 2001, NATURE, V409, P141, DOI 10.1038/35051677; Looijenga LHJ, 1997, AM J PATHOL, V151, P581; Looijenga LHJ, 1998, APMIS, V106, P187, DOI 10.1111/j.1699-0463.1998.tb01335.x; LOOIJENGA LHJ, 1993, LAB INVEST, V68, P211; Lutzker SG, 1998, MOL MED TODAY, V4, P404, DOI 10.1016/S1357-4310(98)01329-X; Murty VVVS, 1998, SEMIN ONCOL, V25, P133; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; PELTOMAKI P, 1991, BIOCHIM BIOPHYS ACTA, V1096, P187, DOI 10.1016/0925-4439(91)90004-S; PELTOMAKI P, 1991, BRIT J CANCER, V63, P851, DOI 10.1038/bjc.1991.189; Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187; Rajpert-De Meyts E, 1998, APMIS, V106, P198; RajpertDeMeyts E, 1996, VIRCHOWS ARCH, V428, P133; ROTH M, 2000, SCAND J UROL NEPHR S, V205, P166; Rush LJ, 2001, BLOOD, V97, P3226, DOI 10.1182/blood.V97.10.3226; Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trasler JM, 1998, SEMIN CELL DEV BIOL, V9, P467, DOI 10.1006/scdb.1998.0225	33	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2002	21	24					3909	3916		10.1038/sj.onc.1205488	http://dx.doi.org/10.1038/sj.onc.1205488			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556KD	12032829				2022-12-17	WOS:000175847200010
J	Kaushansky, K; Drachman, JG				Kaushansky, K; Drachman, JG			The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production	ONCOGENE			English	Review						thrombopoietin; hematopoiesis; megakaryocyte; signal transduction	HUMAN MEGAKARYOCYTE GROWTH; RECOMBINANT HUMAN THROMBOPOIETIN; HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYELOID-LEUKEMIA; PHASE-I TRIAL; MURINE C-MPL; TYROSINE-PHOSPHORYLATION; PERIPHERAL-BLOOD; MESSENGER-RNA; BONE-MARROW	The term thrombopoietin (TPO) was first coined in 1958 and used to describe the Immoral substance responsible for causing the platelet count to rise in response to thrombocytopenic stimuli. Despite much progress during the 1980s in the purification and characterization of the Immoral regulators of lymphocyte, erythrocyte, monocyte and granulocyte production, the successful search to purify and molecularly clone thrombopoietin did not begin until the oncogene v-mpl was discovered in 1990. Since that time the proto-oncogene c-mpl was identified and, based on homology arguments, believed to encode a hematopoietic cytokine receptor, a hypothesis later proven when the cytoplasmic domain was linked to the ligand binding domain of the IL-4 receptor and shown to support the IL-4 induced growth of hematopoietic cells (Skoda et al., 1993). Finally, two different strategies using c-mpl lead to the identification of a novel ligand for the receptor in 1994 (de Sauvage et al., 1994; Lok et al., 1994; Bartley et al., 1994), a protein that displays all the biologic properties of TPO. This review attempts to distill what has been learned of the molecular and cellular biology of TPO and its receptor during the past several years, and links this information to several new insights into human disease and its treatment.	Univ Washington, Sch Med, Div Hematol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Kaushansky, K (corresponding author), Univ Washington, Sch Med, Div Hematol, 1959 NE Pacific St, Seattle, WA 98195 USA.	kkaushan@u.washington.edu						Al-Jefri AH, 2000, PEDIATR HEMAT ONCOL, V17, P299, DOI 10.1080/088800100276280; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Alexander WS, 1996, EMBO J, V15, P6531, DOI 10.1002/j.1460-2075.1996.tb01044.x; ALEXANDER WS, 1995, ONCOGENE, V10, P795; Ballmaier M, 2001, BLOOD, V97, P139, DOI 10.1182/blood.V97.1.139; Ballmaier M, 1997, BLOOD, V90, P612, DOI 10.1182/blood.V90.2.612.612_612_619; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; Basser RL, 2000, J CLIN ONCOL, V18, P2852, DOI 10.1200/JCO.2000.18.15.2852; Basser RL, 1997, BLOOD, V89, P3118; BENIT L, 1994, J VIROL, V68, P5270; Bolwell B, 2000, BONE MARROW TRANSPL, V26, P141, DOI 10.1038/sj.bmt.1702465; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; Case BC, 2000, STEM CELLS, V18, P360, DOI 10.1634/stemcells.18-5-360; Cazzola M, 2000, BLOOD, V95, P3280, DOI 10.1182/blood.V95.11.3280.011k41_3280_3288; Cerutti A, 1997, BRIT J HAEMATOL, V99, P281, DOI 10.1046/j.1365-2141.1997.3823196.x; Chang M, 1996, BLOOD, V88, P3354, DOI 10.1182/blood.V88.9.3354.bloodjournal8893354; CHOI ES, 1995, BLOOD, V85, P402; Cole JL, 1998, BLOOD, V91, P3239, DOI 10.1182/blood.V91.9.3239.3239_3239_3246; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; de Serres M, 1999, STEM CELLS, V17, P203, DOI 10.1002/stem.170203; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Drachman JG, 1999, J BIOL CHEM, V274, P13480, DOI 10.1074/jbc.274.19.13480; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; Drachman JG, 1997, P NATL ACAD SCI USA, V94, P2350, DOI 10.1073/pnas.94.6.2350; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351; Fields KK, 2000, BONE MARROW TRANSPL, V26, P1083, DOI 10.1038/sj.bmt.1702662; Gaur M, 2001, BLOOD, V97, P1653, DOI 10.1182/blood.V97.6.1653; Griesshammer M, 1999, J INTERN MED, V245, P295, DOI 10.1046/j.1365-2796.1999.00452.x; Hacein-Bey S, 2001, HUM GENE THER, V12, P291, DOI 10.1089/10430340150218422; Harker LA, 1996, BLOOD, V88, P511, DOI 10.1182/blood.V88.2.511.bloodjournal882511; Harker LA, 2000, BLOOD, V95, P2514; Harker LA, 1998, BLOOD, V91, P4427, DOI 10.1182/blood.V91.12.4427.412k44_4427_4433; Hashimoto S, 2000, EUR J HAEMATOL, V64, P225, DOI 10.1034/j.1600-0609.2000.90001.x; HILL RJ, 1989, BLOOD CELLS, V15, P141; Hoffman RC, 1996, BIOCHEMISTRY-US, V35, P14849, DOI 10.1021/bi961075b; Hsu HC, 1999, J LAB CLIN MED, V134, P392, DOI 10.1016/S0022-2143(99)90154-3; Hume DA, 2000, BLOOD, V96, P2323, DOI 10.1182/blood.V96.7.2323.h8002323_2323_2328; Ihara K, 1999, P NATL ACAD SCI USA, V96, P3132, DOI 10.1073/pnas.96.6.3132; Ishida Y, 2001, THROMB HAEMOSTASIS, V85, P349; Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299; Jorgensen MJ, 1998, BLOOD, V92, p205A; Kaser A, 2001, BLOOD, V98, P2720, DOI 10.1182/blood.V98.9.2720; Kaushansky K, 1998, NEW ENGL J MED, V339, P746, DOI 10.1056/NEJM199809103391107; KAUSHANSKY K, 1995, J CLIN INVEST, V96, P1683, DOI 10.1172/JCI118210; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; Kimura T, 1998, FEBS LETT, V428, P250, DOI 10.1016/S0014-5793(98)00536-5; KOBAYASHI M, 1995, BLOOD, V86, P2494; Kosugi S, 1996, BRIT J HAEMATOL, V93, P704, DOI 10.1046/j.1365-2141.1996.d01-1702.x; Kurre P, 2001, MOL THER, V3, P920, DOI 10.1006/mthe.2001.0328; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; Kuter DJ, 2001, BLOOD, V98, P1339, DOI 10.1182/blood.V98.5.1339; Li Y, 1996, BRIT J HAEMATOL, V92, P60, DOI 10.1046/j.1365-2141.1996.00297.x; Linden HM, 2000, BIOCHEMISTRY-US, V39, P3044, DOI 10.1021/bi991756h; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; Luoh SM, 2000, MOL CELL BIOL, V20, P507, DOI 10.1128/MCB.20.2.507-515.2000; MCCARTY JM, 1995, BLOOD, V86, P3668, DOI 10.1182/blood.V86.10.3668.bloodjournal86103668; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; Morita H, 1996, FEBS LETT, V395, P228, DOI 10.1016/0014-5793(96)01047-2; Mukai HY, 1996, THROMB HAEMOSTASIS, V76, P675; Murray LJ, 1998, EXP HEMATOL, V26, P207; Muto T, 2000, J BIOL CHEM, V275, P12090, DOI 10.1074/jbc.275.16.12090; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; Nash RA, 2000, BIOL BLOOD MARROW TR, V6, P25, DOI 10.1016/S1083-8791(00)70049-8; Oda A, 1996, BLOOD, V88, P1330, DOI 10.1182/blood.V88.4.1330.bloodjournal8841330; OMalley CJ, 1996, BLOOD, V88, P3288, DOI 10.1182/blood.V88.9.3288.bloodjournal8893288; Onishi M, 1996, BLOOD, V88, P1399, DOI 10.1182/blood.V88.4.1399.bloodjournal8841399; Ooi J, 1998, BIOCHEM BIOPH RES CO, V246, P132, DOI 10.1006/bbrc.1998.8588; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Park H, 1998, J BIOL CHEM, V273, P256, DOI 10.1074/jbc.273.1.256; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; Peck-Radosavljevic M, 1999, EUR J GASTROEN HEPAT, V11, P151, DOI 10.1097/00042737-199902000-00015; Piacibello W, 1998, VOX SANG, V74, P457, DOI 10.1111/j.1423-0410.1998.tb05456.x; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Rojnuckarin P, 2001, BLOOD, V97, P154, DOI 10.1182/blood.V97.1.154; Rouyez MC, 1997, MOL CELL BIOL, V17, P4991, DOI 10.1128/MCB.17.9.4991; Sabath DF, 1999, BLOOD, V94, P365, DOI 10.1182/blood.V94.1.365.413a46_365_367; Schiffer CA, 2000, BLOOD, V95, P2530, DOI 10.1182/blood.V95.8.2530.008k31_2530_2535; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sitnicka E, 1996, BLOOD, V87, P4998, DOI 10.1182/blood.V87.12.4998.bloodjournal87124998; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; Solar GP, 1998, BLOOD, V92, P4, DOI 10.1182/blood.V92.1.4.413k38_4_10; Somlo G, 1999, BLOOD, V93, P2798; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; Stoffel R, 1996, BLOOD, V87, P567, DOI 10.1182/blood.V87.2.567.bloodjournal872567; Strippoli P, 1998, BRIT J HAEMATOL, V103, P311, DOI 10.1046/j.1365-2141.1998.00991.x; Sungaran R, 1997, BLOOD, V89, P101, DOI 10.1182/blood.V89.1.101; Syed RS, 1998, NATURE, V395, P511, DOI 10.1038/26773; Torii Y, 1998, BRIT J HAEMATOL, V103, P1172, DOI 10.1046/j.1365-2141.1998.01113.x; Uppenkamp M, 1998, ANN HEMATOL, V77, P217, DOI 10.1007/s002770050446; Vadhan-Raj S, 2000, ANN INTERN MED, V132, P364, DOI 10.7326/0003-4819-132-5-200003070-00005; VadhanRaj S, 1997, ANN INTERN MED, V126, P673, DOI 10.7326/0003-4819-126-9-199705010-00001; van den Oudenrijn S, 2000, BRIT J HAEMATOL, V110, P441, DOI 10.1046/j.1365-2141.2000.02175.x; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; Wells JA, 1996, P NATL ACAD SCI USA, V93, P1, DOI 10.1073/pnas.93.1.1; Wetzler M, 1997, J CLIN ONCOL, V15, P2262, DOI 10.1200/JCO.1997.15.6.2262; Wiestner A, 1998, NAT GENET, V18, P49, DOI 10.1038/ng0198-49; Wolff SN, 2001, BONE MARROW TRANSPL, V27, P261, DOI 10.1038/sj.bmt.1702772; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yan XQ, 1996, BLOOD, V88, P402, DOI 10.1182/blood.V88.2.402.bloodjournal882402; Yin JAL, 2000, BRIT J HAEMATOL, V108, P743, DOI 10.1046/j.1365-2141.2000.01916.x; Ziegler S, 1998, BLOOD, V92, p713A	108	136	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3359	3367		10.1038/sj.onc.1205323	http://dx.doi.org/10.1038/sj.onc.1205323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032774				2022-12-17	WOS:000175633300009
J	Murga, C; Zohar, M; Teramoto, H; Gutkind, JS				Murga, C; Zohar, M; Teramoto, H; Gutkind, JS			Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappa B	ONCOGENE			English	Article						RhoG; PI3K; Akt; cell survival	PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; PC12 CELLS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PATHWAY; APOPTOSIS; RAS; GTPASES; TARGET	Small GTPases of the Rho family play a central role in cellular processes that involve the reorganization of the actin-based cytoskeleton. Rho-related GTPases, which include Rac and Cdc42, can also regulate gene expression often through the activation of kinase cascades leading to enhanced activity of stress activated protein kinases (SAPKs), including JNK and p38 MAP kinases. As SAPKs are implicated in programmed cell death, these observations suggest that Rho GTPases may promote the initiation of the apoptotic process. However, recent reports suggest that Rho GTPases can have either a protective or a proapoptotic role, depending on the particular cellular context. In an effort to explore the molecular mechanisms underlying these divergent biological activities, we asked whether there was indeed a correlation between the ability to induce SAPKs and apoptosis by Rho family members. We found that although constitutively activated (Q61L) mutants of Rac1, Cdc42, and RhoG, a Rac1 related GTPase of unknown function, potently induce JNK in COS 7 cells, none of these GTPases could induce apoptosis, nor enhance uv-induced cell death. In contrast, Rac1 and RhoG efficiently protected cells from uv-induced apoptosis. Furthermore, we provide evidence that Rac1 and RhoG can activate both apoptotic and anti-apoptotic pathways. Whereas the former is mediated through JNK, the latter is independent on the transcriptional activation of NF-KB, a pro-survival pathway, but results from the direct interaction of these GTPases with phosphatidylinositol 3-kinase (PI3K) and the stimulation of Akt. Together, these findings indicate that members of the Rho family of small GTP-binding proteins can provoke the concomitant stimulation of two counteracting signaling pathways, and that their balance ultimately determines the ability of these GTPases to promote cell survival or death.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Teramoto, H (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Murga, Cristina/E-1965-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Blangy A, 2000, J CELL SCI, V113, P729; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen YR, 2000, INT J ONCOL, V16, P651; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Minamoto T, 2000, CANCER DETECT PREV, V24, P1; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	50	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					207	216		10.1038/sj.onc.1205036	http://dx.doi.org/10.1038/sj.onc.1205036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803464				2022-12-17	WOS:000173026200005
J	DiMaio, D; Mattoon, D				DiMaio, D; Mattoon, D			Mechanisms of cell transformation by papillomavirus E5 proteins	ONCOGENE			English	Review						E5 protein; growth factor receptor; transmembrane protein; V-ATPase; viral oncogene	GROWTH-FACTOR RECEPTOR; FACTOR-BETA RECEPTOR; VACUOLAR H+-ATPASE; MOUSE C127 CELLS; PORE-FORMING PROTEIN; BOVINE PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; AMINO-ACIDS; TUMORIGENIC TRANSFORMATION	The papillomavirus E5 proteins are short, hydrophobic transforming proteins. The transmembrane E5 protein encoded by bovine papillomavirus transforms cells by activating the platelet-derived growth factor beta receptor tyrosine kinase in a ligand-independent fashion. The bovine papillomavirus E5 protein forms a stable complex with the receptor, thereby inducing receptor dimerization and activation, trans-phosphorylation, and recruitment of cellular signaling proteins to the receptor. The E5 proteins of the human papillomaviruses also appear to affect the activity of growth factor receptors and their signaling pathways. The interaction of papillomavirus E5 proteins with a subunit of the vacuolar ATPase may also contribute to transformation. Further analysis of these unique mechanisms of viral transformation will yield new insight into the regulation of growth factor receptor activity and cellular signal transduction pathways.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	Yale University	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NCI NIH HHS [CA37157] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037157, R01CA037157] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adam JL, 2000, VIROLOGY, V272, P315, DOI 10.1006/viro.2000.0376; Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; ANDRESSON T, 1995, J BIOL CHEM, V270, P6830, DOI 10.1074/jbc.270.12.6830; Bohl J, 2001, J VIROL, V75, P513, DOI 10.1128/JVI.75.1.513-521.2001; BOUVARD V, 1994, VIROLOGY, V203, P73, DOI 10.1006/viro.1994.1456; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chen SL, 1996, J VIROL, V70, P3502, DOI 10.1128/JVI.70.6.3502-3508.1996; CHEN SL, 1990, J VIROL, V64, P3226, DOI 10.1128/JVI.64.7.3226-3233.1990; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; CONRAD M, 1994, VIROLOGY, V200, P796, DOI 10.1006/viro.1994.1244; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DiMaio D, 1998, ANNU REV MICROBIOL, V52, P397, DOI 10.1146/annurev.micro.52.1.397; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; FAULKNERVALLE G, 1995, J GEN VIROL, V76, P1239; Ghai J, 1996, P NATL ACAD SCI USA, V93, P12879, DOI 10.1073/pnas.93.23.12879; GOLDSTEIN DJ, 1992, J VIROL, V66, P405, DOI 10.1128/JVI.66.1.405-413.1992; GOLDSTEIN DJ, 1992, VIROLOGY, V190, P889, DOI 10.1016/0042-6822(92)90932-F; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HORWITZ BH, 1989, J VIROL, V63, P4515, DOI 10.1128/JVI.63.11.4515-4519.1989; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 2000, J BIOL CHEM, V275, P9832, DOI 10.1074/jbc.275.13.9832; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEPTAK C, 1991, J VIROL, V65, P7078, DOI 10.1128/JVI.65.12.7078-7083.1991; LEPTAK C, 1991, J VIROL, V66, P1833; Liu DW, 2000, J VIROL, V74, P9083, DOI 10.1128/JVI.74.19.9083-9089.2000; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MARUO T, 1992, CANCER, V69, P1182; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; Oetke C, 2000, ARCH VIROL, V145, P2183, DOI 10.1007/s007050070048; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Petti LM, 2000, CELL GROWTH DIFFER, V11, P395; PIM D, 1992, ONCOGENE, V7, P27; Rho J, 1996, VIRUS RES, V44, P57, DOI 10.1016/0168-1702(96)01348-2; RIESE DJ, 1995, ONCOGENE, V10, P1431; Rodriguez MI, 2000, ONCOGENE, V19, P3727, DOI 10.1038/sj.onc.1203718; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SETTLEMAN J, 1989, MOL CELL BIOL, V9, P5563, DOI 10.1128/MCB.9.12.5563; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; Stoppler MC, 1996, VIROLOGY, V223, P251, DOI 10.1006/viro.1996.0475; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Surti T, 1998, PROTEINS, V33, P601; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P230; Thomsen P, 1999, BBA-MOL CELL RES, V1452, P285, DOI 10.1016/S0167-4889(99)00132-9; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; Tomakidi P, 2000, EUR J CELL BIOL, V79, P407, DOI 10.1078/0171-9335-00060; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vali U, 2001, INT J BIOCHEM CELL B, V33, P227, DOI 10.1016/S1357-2725(01)00015-2; Venuti A, 1998, VIROLOGY, V248, P1, DOI 10.1006/viro.1998.9227; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	73	136	140	0	20	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	2001	20	54					7866	7873		10.1038/sj.onc.1204915	http://dx.doi.org/10.1038/sj.onc.1204915			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753669				2022-12-17	WOS:000172336500006
J	Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F				Condorelli, G; Vigliotta, G; Cafieri, A; Trencia, A; Andalo, P; Oriente, F; Miele, C; Caruso, M; Formisano, P; Beguinot, F			PED/PEA-15: an anti-apoptotic molecule that regulates FAS/TNFR1-induced apoptosis	ONCOGENE			English	Article						apoptosis; TNF alpha; FAS; death signalling; death receptors	DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; CELL-DEATH; FAS; FLICE; RECEPTOR; FADD; INTERACTS; PROTEASES	FED/PEA-15 is a recently cloned 15kDa protein possessing a death effector domain (DED). In MCF-7 and HeLa cells, a fivefold overexpression of PED/PEA-15 blocked Fast and TNF alpha. apoptotic effects. This effect of FED overexpression was blocked by inhibition of PKC activity. In MCF-7 and HeLa cell lysates, PED/ PEA-15 co-precipitated with both FADD and FLICE. PED/PEA-15-FLICE association was inhibited by overexpression of the wild-type but not of a DED-deletion mutant of FADD. Simultaneous overexpression of PED/ PEA-15 with FADD and FLICE inhibited FADD-FLICE co-precipitation by threefold. Based on cleavage of the FLICE substrate PARP, this inhibitory effect was paralleled by a threefold decline in FLICE activation in response to TNF-alpha. TNF alpha, in turn, reduces FED association with the endogenous FADD and FLICE of the cells. Thus, FED/PEA-15 is an endogenous protein inhibiting FAS and TNFR1-mediated apoptosis. At least in part, this function may involve displacement of FADD-FLICE binding through the death effector domain of PED/PEA-15.	Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, I-80131 Naples, Italy; Univ Naples, Ctr Endocrinol Oncol Sperimentale, Sch Med, CNR G Salvatore, I-80131 Naples, Italy	University of Naples Federico II; University of Naples Federico II	Beguinot, F (corresponding author), Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, Sch Med, Via S Pansini 5, I-80131 Naples, Italy.		vigliotta, giovanni/AAW-6401-2020; Vigliotta, Giovanni/GPF-7237-2022; Formisano, Pietro/J-4237-2018; Condorelli, Gerolama/AAC-3472-2022; ORIENTE, Francesco/J-6652-2018	vigliotta, giovanni/0000-0001-5132-0037; Condorelli, Gerolama/0000-0003-0177-8829; Formisano, Pietro/0000-0001-7020-6870; ORIENTE, Francesco/0000-0003-4375-4526				Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Condorelli G, 1998, EMBO J, V17, P3858, DOI 10.1093/emboj/17.14.3858; DARZYNKIEWICZ Z, 1994, METHODS CELL BIOL; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Sambrook J, 1989, MOL CLONING LAB MANU; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464	24	136	144	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 5	1999	18	31					4409	4415		10.1038/sj.onc.1202831	http://dx.doi.org/10.1038/sj.onc.1202831			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	222YT	10442631				2022-12-17	WOS:000081813500002
J	Schreiber, M; Muller, WJ; Singh, G; Graham, FL				Schreiber, M; Muller, WJ; Singh, G; Graham, FL			Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1) in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity	ONCOGENE			English	Article						adenovirus; gene therapy; cyclin dependent kinase inhibitors; cell growth; apoptosis	RETINOBLASTOMA GENE-PRODUCT; D-DEPENDENT KINASES; WILD-TYPE P53; MICE LACKING; POLY(ADP-RIBOSE) POLYMERASE; MOLECULAR CONTROLS; SUPPRESSOR GENES; MAMMALIAN-CELLS; LEUKEMIA-CELLS; IN-VIVO	Cell cycle regulatory proteins are important candidates for therapeutic tumour suppressors. Adenovirus vectors were constructed to overexpress cyclin kinase inhibitors p16(INK4A), p18(INK4C), p19(ISK4D), P21(WAF1/CIP1) and p(27KIP1) under the control of the murine cytomegalovirus immediate early gene promoter, These vectors directed the efficient expression of each of the cyclin kinase inhibitors and induced growth arrest, inhibited DNA synthesis, and prevented phosphorylation of the retinoblastoma protein (pRb) in cell lines expressing functional pRb, In pRb-deficient cells, expression of the cyclin kinase inhibitors was not effective in inhibiting DNA replication or growth arrest, Interestingly, three of the cyclin kinase inhibitors, p16, p18 and p27 were found to induce apoptotic death in transduced HeLa and A549 cells. When the vectors were tested for their ability to inhibit tumorigenicity in a polyomavirus middle T antigen model of murine breast carcinoma, expression of the cyclin kinase inhibitors resulted in a delay in tumour formation that varied from several weeks for the p19 expressing vector to greater than 25 weeks for the p27 expressing vector. When tumours were injected directly with the adenovirus vectors expressing the cyclin kinase inhibitors, only treatment with the vector expressing p16 resulted in a delay in tumour growth.	McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada	McMaster University; McMaster University	Graham, FL (corresponding author), McMaster Univ, Dept Biol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.		Singh, Gurmit/C-6744-2014					Adachi M, 1997, BLOOD, V90, P126; Addison CL, 1997, J GEN VIROL, V78, P1653, DOI 10.1099/0022-1317-78-7-1653; ADDISON CL, 1995, P NATL ACAD SCI USA, V92, P8522, DOI 10.1073/pnas.92.18.8522; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BACCHETTI S, 1993, INT J ONCOL, V3, P781; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; Cox LS, 1997, J PATHOL, V183, P134, DOI 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EASTHAM JA, 1995, CANCER RES, V55, P5151; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gotoh A, 1997, J UROLOGY, V158, P636, DOI 10.1016/S0022-5347(01)64574-9; GRANA X, 1995, ONCOGENE, V11, P211; Hamada K, 1996, CANCER RES, V56, P3047; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HITT M, 1995, METH MOL G, V7, P13; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; JIN XM, 1995, CANCER RES, V55, P3250; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KATAYOSE D, 1995, CELL GROWTH DIFFER, V6, P1207; Katayose Y, 1997, CANCER RES, V57, P5441; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kawakami K, 1996, BIOCHEM BIOPH RES CO, V219, P778, DOI 10.1006/bbrc.1996.0310; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ohno T, 1997, GENE THER, V4, P361, DOI 10.1038/sj.gt.3300403; OMalley BW, 1996, CANCER RES, V56, P1737; Putzer BM, 1998, HUM GENE THER, V9, P707, DOI 10.1089/hum.1998.9.5-707; Sambrook J, 1989, MOL CLONING LAB MANU; Sandig V, 1997, NAT MED, V3, P313, DOI 10.1038/nm0397-313; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; Sellers WR, 1997, J CLIN ONCOL, V15, P3301, DOI 10.1200/JCO.1997.15.11.3301; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Terada Y, 1997, J AM SOC NEPHROL, V8, P51; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; WARNEFORD S, 1991, CELL GROWTH DIFFER, V2, P439; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; Zuo Z, 1998, J BIOL CHEM, V273, P12250, DOI 10.1074/jbc.273.20.12250	70	136	142	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	1999	18	9					1663	1676		10.1038/sj.onc.1202466	http://dx.doi.org/10.1038/sj.onc.1202466			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208428				2022-12-17	WOS:000079025000002
J	Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL				Wong, AKC; Ormonde, PA; Pero, R; Chen, Y; Lian, LB; Salada, G; Berry, S; Lawrence, Q; Dayananth, P; Ha, P; Tavtigian, SV; Teng, DHF; Bartel, PL			Characterization of a carboxy-terminal BRCA1 interacting protein	ONCOGENE			English	Article						BRCA1 interactor; tumor suppressor; mutation; transcription	CANCER SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; E1A PROTEIN; DNA-REPAIR; RAD51	There are several lines of evidence indicating that the carboxy-terminal region of the tumor suppressor protein BRCA1 is a functionally significant domain. Using the yeast two-hybrid and in vitro biochemical assays, we show that a protein, CtIP, interacts specifically with the carboxy-terminal segment of human BRCA1 from residues 1602-1863. A germ line truncation mutation, Y1853ter, that removes the last 11 amino acids from the carboxy-terminus of BRCA1, abolishes not only its transcriptional activation function, but also binding to CtIP. The function of CtIP is unknown, but its reported association with a transcriptional repressor CtBP lends further support that it may have a role in transcription. A sequence based screen of a panel of 89 tumor cell line cDNAs for mutations in the CtIP coding region identified five missense variants. In the pancreatic carcinoma cell line, BxPC3, the non-conservative lysine to glutamic acid change at codon 337 is accompanied with apparent loss of heterozygosity or non-expression of the wild type allele. Thus it is plausible that CtIP may itself be a tumor suppressor acting in the same pathway as BRCA1.	Myriad Genet Inc, Salt Lake City, UT 84108 USA	Myriad Genetics, Inc	Wong, AKC (corresponding author), Myriad Genet Inc, 390 Wakara Way, Salt Lake City, UT 84108 USA.							Bartel PL, 1996, NAT GENET, V12, P72, DOI 10.1038/ng0196-72; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CannonAlbright LA, 1996, SEMIN ONCOL, V23, P1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; McAllister KA, 1997, CANCER RES, V57, P3121; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PIDDER JD, 1996, TRENDS GENET, V12, P272; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V15, P535; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sobol A, 1996, CANCER RES, V56, P3216; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Teng DHF, 1997, CANCER RES, V57, P4177; Thai TH, 1998, HUM MOL GENET, V7, P195, DOI 10.1093/hmg/7.2.195; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	46	136	139	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	1998	17	18					2279	2285		10.1038/sj.onc.1202150	http://dx.doi.org/10.1038/sj.onc.1202150			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134BQ	9811458				2022-12-17	WOS:000076723300001
J	Zhang, CC; Yang, JM; White, E; Murphy, M; Levine, A; Hait, WN				Zhang, CC; Yang, JM; White, E; Murphy, M; Levine, A; Hait, WN			The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells	ONCOGENE			English	Article						drug sensitivity; p53; MAP4; microtubule polymerization	DNA-DAMAGE; ANTICANCER AGENTS; CYCLE CHECKPOINT; GROWTH ARREST; APOPTOSIS; PROTEIN; CANCER; MUTATIONS; DEATH; TAXOL	Mutations in p53 change the sensitivity to cancer chemotherapeutic drugs, Whereas many drugs, including the vinca alkaloids, often become less effective when p53 is transcriptionally inactivated, several, most notably paclitaxel, may become more effective, In studying the underlying mechanism(s), we found that increased MAP4 expression, which occurs with transcriptionally silent p53, is associated with increased sensitivity to paclitaxel and decreased sensitivity to vinca alkaloids, Using murine fibroblasts transfected with MAP4, we directly demonstrated that the changes in drug sensitivity were associated with parallel alterations in drug-induced apoptosis and cell-cycle arrest, Immunofluorescent staining of the microtubule network revealed that cells with increased MAP4 expression displayed an increase in polymerized microtubules and an increased binding of fluorsceinated paclitaxel, Since MAP4 stabilizes polymerized microtubules, overexpression of this gene provides a plausible mechanism to explain the altered sensitivity to microtubule-active drugs in the presence of mutant p53.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Inst Canc, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Princeton University	Hait, WN (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Murphy, Maureen/0000-0001-7644-7296	NATIONAL CANCER INSTITUTE [P20CA057124, R01CA066077, R01CA043888] Funding Source: NIH RePORTER; NCI NIH HHS [CA57124, CA43888, CA66077] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHAPIN SJ, 1995, BIOCHEMISTRY-US, V34, P2289, DOI 10.1021/bi00007a025; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Delia D, 1996, NAT MED, V2, P724, DOI 10.1038/nm0796-724; FAN S, 1996, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; GEWIRTZ DA, 1993, ONCOL RES, V5, P397; GUPTA RS, 1985, JNCI-J NATL CANCER I, V74, P159; GUPTA RS, 1988, BIOCHEM BIOPH RES CO, V153, P598, DOI 10.1016/S0006-291X(88)81137-9; HALL PA, 1993, ONCOGENE, V8, P203; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hawkins DS, 1996, CANCER RES, V56, P892; HORWITZ SB, 1992, TRENDS PHARMACOL SCI, V13, P134; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KONDO S, 1994, CANCER RES, V54, P2928; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lobert S, 1996, BIOCHEMISTRY-US, V35, P6806, DOI 10.1021/bi953037i; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUTZKER S, 1996, DRUG RESISTANCE, P345; MERRITT AJ, 1994, CANCER RES, V54, P614; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Nguyen HL, 1997, J CELL SCI, V110, P281; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; SCUDIERO DA, 1988, CANCER RES, V48, P4827; TISHLER RB, 1995, CANCER RES, V55, P6021; VOLGELSTEIN B, 1992, CELL, V70, P523; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu GS, 1996, NAT MED, V2, P255, DOI 10.1038/nm0396-255a; Yoshida T, 1996, CELL MOTIL CYTOSKEL, V33, P252, DOI 10.1002/(SICI)1097-0169(1996)33:4<252::AID-CM2>3.0.CO;2-B; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	42	136	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1617	1624		10.1038/sj.onc.1201658	http://dx.doi.org/10.1038/sj.onc.1201658			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569030				2022-12-17	WOS:000072743200013
J	Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D				Ivan, M; Bond, JA; Prat, M; Comoglio, PM; WynfordThomas, D			Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells	ONCOGENE			English	Article						met; ras; ret; thyroid; epithelium; paracrine	TYROSINE KINASE; HGF RECEPTOR; MONOCLONAL-ANTIBODIES; SIMIAN VIRUS-40; SCATTER FACTOR; DNA-SYNTHESIS; CANCER; OVEREXPRESSION; GENE; PROTOONCOGENE	Hepatocyte Growth Factor (HGF) receptor, encoded by the protooncogene c-met, is overexpressed in many human tumours, including those of thyroid epithelium. The absence in most cases of any primary structural abnormality of the met gene suggests that overexpression is secondary to mutation of other gene(s). To test this hypothesis we investigated the effect on met expression of two activated oncogenes known to play a major role in thyroid oncogenesis, ras and ret. To minimize the possibility of unknown co-operating events, we introduced these genes directly into normal human thyrocytes in primary culture using amphotropic retroviral vectors and assessed met expression as early as possible in the resulting epithelial colonies. Double immunofluorescence revealed expression of met protein, strictly localized to cells expressing the mutant ras and ret vectors, expression in background normal cells being barely detectable. In contrast, colonies induced to proliferate at a comparable rate by a vector expressing SV40 T showed no increase in met expression. To permit quantitation by Western blotting we also extended these findings to a thyroid cell line (R18) containing a zinc-inducible mutant ras gene. Induction of the oncogene led to a fourfold increase in met protein expression. We conclude that overexpression of met is induced by activation of the ras or ret signalling pathway and not simply by deregulation of the cell cycle per se. The data suggest that the proliferative advantage conferred by these oncogenes may be in part due to the resulting sensitization of tumour epithelium to paracrine HGF secreted by stromal cells.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL RES GRP,CARDIFF CF4 4XN,S GLAM,WALES; UNIV TURIN,DEPT BIOMED SCI & ONCOL,SCH MED,TURIN,ITALY	Cardiff University; University of Turin			Ivan, Mircea/A-8109-2012	Ivan, Mircea/0000-0003-3424-6642; Comoglio, Paolo/0000-0002-7056-5328				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOND J, 1992, MOL CARCINOGEN, V5, P129, DOI 10.1002/mc.2940050208; BOND JA, 1994, ONCOGENE, V9, P281; BOND JA, IN PRESS INT J CANC; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; DAWSON TP, 1995, CANCER RES, V55, P915; DAWSON TP, 1991, BRIT J CANCER, V63, P897, DOI 10.1038/bjc.1991.197; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1995, CANCER RES, V55, P1129; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; DIRENZO MF, 1994, INT J CANCER, V58, P658, DOI 10.1002/ijc.2910580507; Eccles N, 1996, MOL CELL ENDOCRINOL, V117, P247, DOI 10.1016/0303-7207(95)03757-8; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOULDSWORTH J, 1990, CANCER RES, V50, P6417; IGAWA T, 1991, BIOCHEM BIOPH RES CO, V174, P831, DOI 10.1016/0006-291X(91)91493-V; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; JAT PS, 1986, J VIROL, V59, P746, DOI 10.1128/JVI.59.3.746-750.1986; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; LIU C, 1992, ONCOGENE, V7, P181; MATSUMOTO K, 1991, EXP CELL RES, V196, P114, DOI 10.1016/0014-4827(91)90462-4; MATSUMOTO K, 1991, BIOCHEM BIOPH RES CO, V176, P45, DOI 10.1016/0006-291X(91)90887-D; NALDINI L, 1991, ONCOGENE, V6, P501; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SCARPELLI DG, 1994, PATHOLOGY, P794; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STRAIN AJ, 1991, J CLIN INVEST, V87, P1853, DOI 10.1172/JCI115207; SUAREZ HG, 1990, ONCOGENE, V5, P565; Thomas G. A., 1995, Journal of Endocrinology, V144, pRC3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; WILLIAMS DW, 1988, THYROID TUMOURS, P57; WYNFORDTHOMAS D, 1993, CANCER SURV, V16, P115	44	136	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 22	1997	14	20					2417	2423		10.1038/sj.onc.1201083	http://dx.doi.org/10.1038/sj.onc.1201083			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WZ680	9188856				2022-12-17	WOS:A1997WZ68000005
J	Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP				Lakin, ND; Weber, P; Stankovic, T; Rottinghaus, ST; Taylor, AMR; Jackson, SP			Analysis of the ATM protein in wild-type and ataxia telangiectasia cells	ONCOGENE			English	Article						ataxia telangiectasia; ATM; DNA; repair; PI 3-kinase; p53	STRAND BREAK REPAIR; V(D)J RECOMBINATION; DNA-REPAIR; MAMMALIAN PROTEIN; KINASE-ACTIVITY; KU AUTOANTIGEN; GENE; COMPLEX; PRODUCT; PK	Ataxia telangiectasia (A-T) is a human disorder that results in a number of clinical symptoms, including cerebellar degeneration and increased cancer predisposition. Recently the gene that is defective in A-T has been cloned and designated ATM. Here, we describe the production of antisera raised against the similar to 350 kDa ATM protein, Antisera specificity is confirmed by them recognising a similar to 350 kDa polypeptide in wild-type cells but not in A-T cells containing mutations that truncate ATM upstream of the antibody binding sites, We show that ATM is almost exclusively nuclear and is expressed in all cell lines and tissues analysed, However, ATM levels are not regulated in response to u.v. or ionising radiation, These data are consistent with ATM being a component of the DNA damage detection apparatus rather than being an inducible downstream effector of the DNA damage response. In addition, we analyse ATM protein expression in a variety of A-T patients, Strikingly, ATM expression is reduced drastically or absent in all patients analysed, including those predicted to express proteins that should be detected by our antisera, Thus, the A-T phenotype may result not only from mutations that disrupt functional domains of ATM, but also from mutations that destabilise the ATM mRNA or protein, Finally, we report that a group of patients displaying an intermediate A-T phenotype express low levels of apparently full-length ATM, This suggests that the ATM pathway is partially active in these individuals and that there is a correlation between Levels of residual ATM expression and disease severity.	CANC RES CAMPAIGN INST,WELLCOME TRUST,CAMBRIDGE CB2 1QR,ENGLAND; UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1TN,ENGLAND; UNIV BIRMINGHAM,SCH MED,CANC RES CAMPAIGN,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	CRUK Cambridge Institute; Wellcome Trust Sanger Institute; University of Cambridge; University of Birmingham			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014	Jackson, Stephen Philip/0000-0001-9317-7937; Stankovic, Tatjana/0000-0002-3780-274X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Ausubel FM., 2006, ENZYMATIC MANIPULATI; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, P130; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; Jackson S. P., 1993, Gene transcription: a practical approach., P189; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; KAPPELLER R, 1994, BIOESSAYS, V16, P565; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LEHMANN AR, 1995, TRENDS GENET, V11, P375, DOI 10.1016/S0168-9525(00)89112-X; LIU Q, 1995, BIOTECHNIQUES, V18, P470; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McConville CM, 1996, AM J HUM GENET, V59, P320; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1995, CANCER RES, V55, P5991; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1995, CURR BIOL, V5, P496, DOI 10.1016/S0960-9822(95)00101-1; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TELETAR M, 1996, AM J HUM GENET, V59, P40; Uziel T, 1996, GENOMICS, V33, P317, DOI 10.1006/geno.1996.0201; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	48	136	142	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2707	2716						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000145				2022-12-17	WOS:A1996VZ65400021
J	Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J				Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J			Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes	ONCOGENE			English	Article						p53; skin; cancer; mutation; immunohistochemistry; LOH	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMA; SKIN CANCERS; HUMAN TUMORS; GENE; DNA; POLYMORPHISM; POPULATIONS; SUNLIGHT	Microdissection of biopsies with sequencing of exons 4-8 of the p53 gene permitted precise morphological identification of correlation between mutations and/or loss of heterozygosity, immunoreactivity of p53 and type of squamous neoplasia, Seventy-two specimens from ten lesions of sun-exposed sites including normal epidermis were analysed. Irrespective of p53 immunoreactivity and morphological grade dysplasia, in situ or invasive cancer, in each case, carried the identical mutation indicating that invasive skin cancer and its precursors derive from the same original neoplastic clone. Additionally, morphologically normal epidermis showed some sharply demarcated immunoreactive areas. These never had the same p53 mutation as that of the adjacent tumor, indicating that their mutations were separate events and ruling them out as common precursors of cancer, Nonimmunoreactive normal epidermis did not show p53 mutations, Our findings indicate that a large fraction of keratinocytes in sun-exposed human skin carry mutations of p53 and suggest that at least two options exist for such cells (i) innocuous clonal expansion with preserved morphology and normal differentiation or (ii) malignant transformation with the p53 mutation as an early event. Suggestive evidence existed that the p53 mutations were qualitatively different in the two respective groups of lesions.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ren, ZP (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; JIN YS, 1993, CANCER RES, V53, P2140; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; Lever W. F., 1990, HISTOPATHOLOGY SKIN; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Potten C S, 1981, Int Rev Cytol, V69, P271; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO M, 1993, CANCER RES, V53, P2944; STEPHENSON TJ, 1992, BRIT J DERMATOL, V127, P566, DOI 10.1111/j.1365-2133.1992.tb14866.x; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	31	136	140	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					765	773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632898				2022-12-17	WOS:A1996TW68600007
J	GOUBIN, F; DUCOMMUN, B				GOUBIN, F; DUCOMMUN, B			IDENTIFICATION OF BINDING DOMAINS ON THE P21(CIP1) CYCLIN-DEPENDENT KINASE INHIBITOR	ONCOGENE			English	Article						CYCLIN-DEPENDENT KINASE INHIBITORS; P21CIP1; CDK2; PCNA	CELL NUCLEAR ANTIGEN; CONTROL GENE CDC2; SCANNING MUTAGENESIS; PROTEIN; SEQUENCE; SUC1; P21	Members of the recently discovered family of cyclin-dependent kinases inhibitors (CKIs) appear to play an essential regulatory role in the control of cell proliferation. To investigate the molecular basis of the interaction between these proteins and the cyclin-dependent kinases (CDKs), we performed a systematic mutagenesis of the CKI family member p21Cip1 using the alanine-scanning strategy. We have examined the interaction between in vitro translated human cdk2, cyclins A and D1, purified proliferating cell nuclear antigen (PCNA) and a set of human p21Cip1 mutants fused to glutathione S-transferase. Independent domains that are required for the interaction with cdk2 and with PCNA have been identified. The cdk2 binding domain is located in the N-terminal part of the protein, between residues 45 and 60, a region that is fully conserved in the p27Kip1 inhibitor. A PCNA binding region was localised to the C-terminus of the protein, between residues 142 and 163. These findings define protein motifs that are highly conserved between members of the CKI family and that are likely to play an essential function in the regulation of the G1/S transition.	UNIV TOULOUSE 3, PHARMACOL & TOXICOL FONDAMENTALES LAB, CNRS, F-31077 TOULOUSE, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier			DUCOMMUN, Bernard/B-3208-2008	DUCOMMUN, Bernard/0000-0002-7126-8368				BRAMBILLA P, 1992, SPR COLD HARB S QUAN, V56, P515; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DOWNES CS, 1994, BIOESSAYS, V16, P75, DOI 10.1002/bies.950160112; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	40	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784076				2022-12-17	WOS:A1995RE54300002
J	OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B				OOI, J; YAJNIK, V; IMMANUEL, D; GORDON, M; MOSKOW, JJ; BUCHBERG, AM; MARGOLIS, B			THE CLONING OF GRB10 REVEALS A NEW FAMILY OF SH2 DOMAIN PROTEINS	ONCOGENE			English	Article						SH2 DOMAIN; EGF; GRB1O; GRB7; MIG1O; GROWTH FACTOR RECEPTOR	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EGF RECEPTOR; CAENORHABDITIS-ELEGANS; EXPRESSION CLONING; SIGNALING PROTEINS; ADAPTER PROTEIN; BINDING-SITE; HUMAN-BREAST; RAS	SH2 domains function to bind proteins containing phosphotyrosine and are components of proteins that are important signal transducers for tyrosine kinases. We have cloned SH2 domain proteins by screening bacterial expression libraries with the tyrosine phosphorylated carboxyterminus of the epidermal growth factor (EGF) receptor. Here we report the identification of a new SH2 domain protein, Grb10, Grb10 is highly related to Grb7, an SH2 domain protein that we have previously identified, In addition to an SH2 domain, Grb7 and Grb10 have a central domain with similarity to a putative C, elegans gene likely to be involved in neuronal migration. At least three forms of Grb10 exist in fibroblasts apparently due to alternate translational start sites, Grb10 undergoes serine but not tyrosine phosphorylation after EGF treatment resulting in a shift mobility in a large fraction of Grb10 molecules, However Grb10 appears to bind poorly to EGF-Receptor and the true binding partner for the Grb10 SH2 domain is unclear, Grb10 maps to mouse chromosome 11 very close to the EGF-Receptor which is remarkably similar to Grb7 that maps near the EGF-Receptor related HER2 receptor, The finding of multiple family members with evolutionarily conserved domains indicates that these SH2 domain proteins are likely to have an important, although as of yet, unidentified function.	NYU,MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19107	New York University; New York University; Jefferson University				Buchberg, Arthur/0000-0002-0543-5631	NCI NIH HHS [CA58586] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058586] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUCHBERG AM, 1993, MAMM GENOME, V4, pS164, DOI 10.1007/BF00360837; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWEERS M, 1994, HUM MOL GENET, V3, P161, DOI 10.1093/hmg/3.1.161; DIETRICH W, 1992, GENETICS, V131, P423; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Green E.L., 1981, MOUSE BIOMEDICAL RES, P91; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARINI JC, 1993, GENOMICS, V15, P200, DOI 10.1006/geno.1993.1034; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RON D, 1992, BIOTECHNIQUES, V13, P866; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Wadsworth William G., 1992, Current Opinion in Neurobiology, V2, P36, DOI 10.1016/0959-4388(92)90159-I; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	136	143	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	APR 20	1995	10	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731717				2022-12-17	WOS:A1995QU68100019
J	KIESS, M; GILL, RM; HAMEL, PA				KIESS, M; GILL, RM; HAMEL, PA			EXPRESSION OF THE POSITIVE REGULATOR OF CELL-CYCLE PROGRESSION, CYCLIN D3, IS INDUCED DURING DIFFERENTIATION OF MYOBLASTS INTO QUIESCENT MYOTUBES	ONCOGENE			English	Article						CYCLINS; MYOBLAST DIFFERENTIATION; CELL CYCLE; KINASES	RETINOBLASTOMA PROTEIN; CANDIDATE ONCOGENE; PUTATIVE ONCOGENE; DEPENDENT KINASE; DNA-REPLICATION; PRAD1/CYCLIN D1; MYOGENIN GENE; G1 PHASE; MUSCLE; FIBROBLASTS	L(6) cells are committed skeletal muscle precursors which can be induced to differentiate into multinucleated, terminally differentiated myotubes. Upon differentiation, these immature skeletal myotubes enter a quiescent state and are unable to reenter the cell cycle. We have examined expression of a series of genes involved in regulation of progression through the G(1)/S boundary in undifferentiated L(6) cells and during terminal differentiation of L(6) myoblasts. While no change in the level of cyclin D1 transcript and a transient increase in cyclin D2 transcript were observed, a large increase in cyclin D3 expression was found. Immunohistochemistry demonstrated strong staining for cyclin D3 protein in the nuclei of the multinucleated myotubes from 4 independent myoblast cell lines; L(6), L(8), G(8) and C2C12. Immunoprecipitation confirmed a greater than 20-fold increase in the levels of cyclin D3 protein in the differentiated L(6) myotubes as well as its association with a number of proteins. Western assays demonstrated, further, that cyclin D3 was complexed with the cyclin dependent-kinases, cdk2 and cdk4, in differentiated L(6) cells. However, while kinase activity specific for a GST-pRB fusion protein was seen for cyclin D3-containing complexes isolated from undifferentiated cells, the high levels of cyclin D3 in the differentiated myotubes had no associated kinase activity. These data demonstrate that cyclin D3 may also have a function in terminally differentiated, quiescent cells. The lack of cyclin D3-associated kinase activity and its association with a number of different proteins suggest that cyclin D3 may regulate the function of other proteins by direct interaction with these factors.	UNIV TORONTO, DEPT CELLULAR & MOLEC PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto								BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDO T, 1989, CELLULAR MOL BIOL MU; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MONTARRAS D, 1991, NEW BIOL, V3, P592; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QUELLE DE, 1993, 9TH ANN M ONC FRED, P7; ROSENBERG CL, 1993, ONCOGENE, V8, P519; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; WILLIAMS ME, 1993, LEUKEMIA, V7, P241; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAFFE D, 1973, COLD SPRING HARB SYM, V37, P543, DOI 10.1101/SQB.1973.037.01.065; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	58	136	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					159	166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824268				2022-12-17	WOS:A1995QA98000018
J	VOYNOYASENETSKAYA, TA; PACE, AM; BOURNE, HR				VOYNOYASENETSKAYA, TA; PACE, AM; BOURNE, HR			MUTANT ALPHA-SUBUNITS OF G12 AND G13 PROTEINS INDUCE NEOPLASTIC TRANSFORMATION OF RAT-1 FIBROBLASTS	ONCOGENE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; STIMULATES DNA-SYNTHESIS; CYCLIC-AMP ACCUMULATION; MALIGNANT TRANSFORMATION; PHOSPHOLIPASE-C; POSSIBLE INVOLVEMENT; CELL-PROLIFERATION; RECEPTOR SUBTYPES; KINASE ACTIVATION; PITUITARY-TUMORS	Mutationally activated alpha subunits of two G proteins, G(s) and G(i2,)) induce neoplastic transformation of fibroblasts and are found in human tumors. Here we report that mutationally activated alpha subunits of two other G proteins, G12 and G13, induce neoplastic transformation of Rat-1 fibroblasts and NIH3T3 fibroblasts. Constitute activation of these alpha subunits resulted from replacement by leucine of glutamine-229 and glutamine-226 in alpha 12 and alpha 13, respectively. Transient expression of mutant alpha 12 and alpha 13 cDNAs induced focus formation in Rat-1 cells and NIH3T3 cells, and stable expression of these mutant proteins in Rat-1 cells accelerated growth rate, induced growth in soft agar, and increased DNA synthesis. Mitogen-activated protein (MAP) kinase activity, stimulated by EGF, was increased in Rat-1 cells that expressed mutant alpha 12 or alpha 13. The MAP kinase cascade plays a role in mediating neoplastic transformation induced by other GTPases, including ras and the alpha subunit of G(i2). Therefore, we propose that the MAP kinase cascade is an effector pathway affected by alpha 12 and alpha 13 and may contribute to neoplastic transformation by these mutant proteins. We predict that activating somatic mutations in alpha 12 and alpha 13 genes will be found in human tumors, as is the case for mutationally activated alpha subunits of G(s) and G(i2).	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027800, R01GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54427] Funding Source: Medline; NHLBI NIH HHS [HL 07731] Funding Source: Medline; NIGMS NIH HHS [GM 27800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBAS J, 1993, J BIOL CHEM, V268, P22235; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOURNE HR, 1991, P NATO ADV STUDY I C, P253; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CUADRADO A, 1993, ONCOGENE, V8, P2443; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; LANDIS CA, 1990, J CLIN ENDOCR METAB, V71, P1416, DOI 10.1210/jcem-71-6-1416; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LETTORIO JJ, 1986, SCIENCE, V243, P1117; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TOBIN CJ, 1982, NATURE, V300, P143; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU DQ, 1992, J BIOL CHEM, V267, P1811; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZACHARY I, 1987, BIOCHEM BIOPH RES CO, V146, P456, DOI 10.1016/0006-291X(87)90551-1	42	136	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2559	2565						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058319				2022-12-17	WOS:A1994PC05400015
J	REIHSAUS, E; KOHLER, M; KRAISS, S; OREN, M; MONTENARH, M				REIHSAUS, E; KOHLER, M; KRAISS, S; OREN, M; MONTENARH, M			REGULATION OF THE LEVEL OF THE ONCOPROTEIN-P53 IN NON-TRANSFORMED AND TRANSFORMED-CELLS	ONCOGENE			English	Article									UNIV ULM, DEPT BIOCHEM, POB 4066, W-7900 ULM, GERMANY; UNIV ULM, DEPT BIOCHEM, W-7900 ULM, GERMANY	Ulm University; Ulm University			Montenarh, Mathias/AAB-6689-2020					ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; CHEN S, 1983, P NATL ACAD SCI-BIOL, V80, P5670, DOI 10.1073/pnas.80.18.5670; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FISCHERFANTUZZI L, 1985, P NATL ACAD SCI USA, V82, P1891, DOI 10.1073/pnas.82.7.1891; GRONOSTAJSKI RM, 1984, MOL CELL BIOL, V4, P442, DOI 10.1128/MCB.4.3.442; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MICHALOVITZ D, 1987, J VIROL, V61, P2648, DOI 10.1128/JVI.61.8.2648-2654.1987; MILNER J, 1989, ONCOGENE, V4, P665; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MONTENARH M, 1987, J VIROL, V61, P940, DOI 10.1128/JVI.61.3.940-944.1987; MONTENARH M, 1983, J VIROL, V45, P531, DOI 10.1128/JVI.45.2.531-538.1983; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROSENBERG BH, 1981, J VIROL METHODS, V3, P167, DOI 10.1016/0166-0934(81)90051-3; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHEN DW, 1983, P NATL ACAD SCI-BIOL, V80, P5919, DOI 10.1073/pnas.80.19.5919; STURZBECHER HW, 1987, ONCOGENE, V1, P201; THOMAS R, 1983, VIROLOGY, V131, P502, DOI 10.1016/0042-6822(83)90516-0; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	45	136	138	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1990	5	1					137	145						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157179				2022-12-17	WOS:A1990CM62000019
J	VARNUM, BC; LIM, RW; SUKHATME, VP; HERSCHMAN, HR				VARNUM, BC; LIM, RW; SUKHATME, VP; HERSCHMAN, HR			NUCLEOTIDE-SEQUENCE OF A CDNA-ENCODING TIS11, A MESSAGE INDUCED IN SWISS 3T3 CELLS BY THE TUMOR PROMOTER TETRADECANOYL PHORBOL ACETATE	ONCOGENE			English	Note									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT BIOL CHEM,WARREN HALL,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,BIOMED & ENVIRONM SCI LAB,LOS ANGELES,CA 90024; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MED,CHICAGO,IL 60637	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NIGMS NIH HHS [2T32 GM07104, GM24797] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104, R01GM024797] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LIM RW, 1987, ONCOGENE, V1, P263; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TIPPETTS MT, 1988, MOL CELL BIOL, V8, P4570, DOI 10.1128/MCB.8.10.4570	10	136	139	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					119	120						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2915901				2022-12-17	WOS:A1989U567400019
J	Ji, XM; Qian, J; Rahman, SMJ; Siska, PJ; Zou, Y; Harris, BK; Hoeksema, MD; Trenary, IA; Heidi, C; Eisenberg, R; Rathmell, JC; Young, JD; Massion, PP				Ji, Xiangming; Qian, Jun; Rahman, S. M. Jamshedur; Siska, Peter J.; Zou, Yong; Harris, Bradford K.; Hoeksema, Megan D.; Trenary, Irina A.; Heidi, Chen; Eisenberg, Rosana; Rathmell, Jeffrey C.; Young, Jamey D.; Massion, Pierre P.			xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression	ONCOGENE			English	Article							GLUTAMATE TRANSPORTER SLC7A11; CYSTINE/GLUTAMATE ANTIPORTER; GLUTAMINASE EXPRESSION; OXIDATIVE-STRESS; CIGARETTE-SMOKE; GROWTH; APOPTOSIS; INHIBITION; OVEREXPRESSION; SENSITIVITY	Many tumors increase uptake and dependence on glucose, cystine or glutamine. These basic observations on cancer cell metabolism have opened multiple new diagnostic and therapeutic avenues in cancer research. Recent studies demonstrated that smoking could induce the expression of xCT (SLC7A11) in oral cancer cells, suggesting that overexpression of xCT may support lung tumor progression. We hypothesized that overexpression of xCT occurs in lung cancer cells to satisfy the metabolic requirements for growth and survival. Our results demonstrated that 1) xCT was highly expressed at the cytoplasmic membrane in non-small cell lung cancer (NSCLC), 2) the expression of xCT was correlated with advanced stage and predicted a worse 5-year survival, 3) targeting xCT transport activity in xCT overexpressing NSCLC cells with sulfasalazine decreased cell proliferation and invasion in vitro and in vivo and 4) increased dependence on glutamine was observed in xCT overexpressed normal airway epithelial cells. These results suggested that xCT regulate metabolic requirements during lung cancer progression and be a potential therapeutic target in NSCLC.	[Ji, Xiangming; Qian, Jun; Rahman, S. M. Jamshedur; Zou, Yong; Harris, Bradford K.; Hoeksema, Megan D.; Massion, Pierre P.] Vanderbilt Univ, Canc Early Detect & Prevent Initiat, Div Allergy Pulm & Crit Care Med, Vanderbilt Ingram Canc Ctr,Sch Med, Nashville, TN 37232 USA; [Ji, Xiangming] Georgia State Univ, Byrdine F Lewis Sch Nursing & Hlth Profess, Dept Nutr, Atlanta, GA 30302 USA; [Siska, Peter J.; Rathmell, Jeffrey C.] Univ Hosp Regensburg, Dept Internal Med 3, D-93053 Regensburg, Germany; [Trenary, Irina A.; Young, Jamey D.] Vanderbilt Univ, Dept Chem & Biomol Engn, 221 Kirkland Hall, Nashville, TN 37235 USA; [Heidi, Chen] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Eisenberg, Rosana] Vanderbilt Univ, Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN 37212 USA; [Massion, Pierre P.] Tennessee Valley Healthcare Syst, Vet Affairs, Nashville, TN 37212 USA	Vanderbilt University; University System of Georgia; Georgia State University; University of Regensburg; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Massion, PP (corresponding author), Vanderbilt Univ, Canc Early Detect & Prevent Initiat, Div Allergy Pulm & Crit Care Med, Vanderbilt Ingram Canc Ctr,Sch Med, Nashville, TN 37232 USA.; Massion, PP (corresponding author), Tennessee Valley Healthcare Syst, Vet Affairs, Nashville, TN 37212 USA.	pierre.massion@vanderbilt.edu		Siska, Peter/0000-0002-1521-6213	NCI [CA102353]; DoD [W81XWH-11-2-0161]; FAMRI foundation [YFEL141014]; NATIONAL CANCER INSTITUTE [R01CA217987, R01CA102353] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DoD(United States Department of Defense); FAMRI foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI grant CA102353 and DoD W81XWH-11-2-0161 to PPM. This work was also supported by FAMRI foundation YFEL141014 to XJ.	Baek S, 2012, CLIN CANCER RES, V18, P5427, DOI 10.1158/1078-0432.CCR-12-0214; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Cheng TL, 2011, P NATL ACAD SCI USA, V108, P8674, DOI 10.1073/pnas.1016627108; Chung WJ, 2009, J NEUROCHEM, V110, P182, DOI 10.1111/j.1471-4159.2009.06129.x; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Dai ZY, 2007, J MED CHEM, V50, P1896, DOI 10.1021/jm060960h; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Guan J, 2009, CANCER CHEMOTH PHARM, V64, P463, DOI 10.1007/s00280-008-0894-4; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Kobayashi S, 2012, FREE RADICAL BIO MED, V53, P2197, DOI 10.1016/j.freeradbiomed.2012.09.040; Liu RQ, 2007, MOL PHARMACOL, V72, P1637, DOI 10.1124/mol.107.039644; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Lobo C, 2000, BIOCHEM J, V348, P257, DOI 10.1042/0264-6021:3480257; Lora J, 2004, EUR J BIOCHEM, V271, P4298, DOI 10.1111/j.1432-1033.2004.04370.x; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Murphy TA, 2013, BIOTECHNOL BIOENG, V110, P1748, DOI 10.1002/bit.24836; Murphy TA, 2013, METAB ENG, V15, P206, DOI 10.1016/j.ymben.2012.07.008; Nagaraj NS, 2006, TOXICOL LETT, V165, P182, DOI 10.1016/j.toxlet.2006.03.008; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Qian J, 2015, P NATL ACAD SCI USA, V112, P3469, DOI 10.1073/pnas.1421975112; Qian J, 2009, MOL CANCER THER, V8, P101, DOI 10.1158/1535-7163.MCT-08-0973; Robert SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8103; Sato H, 1999, J BIOL CHEM, V274, P11455, DOI 10.1074/jbc.274.17.11455; Sato H, 2000, ANTIOXID REDOX SIGN, V2, P665, DOI 10.1089/ars.2000.2.4-665; Shih AY, 2001, BIOCHEM BIOPH RES CO, V282, P1132, DOI 10.1006/bbrc.2001.4703; Shroff EH, 2015, P NATL ACAD SCI USA, V112, P6539, DOI 10.1073/pnas.1507228112; Singh JA, 2004, ARTHRIT RHEUM-ARTHR, V51, P952, DOI 10.1002/art.20827; Siska PJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93411; Spira A, 2004, P NATL ACAD SCI USA, V101, P10143, DOI 10.1073/pnas.0401422101; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Ye P, 2014, MOL CELL BIOL, V34, P3421, DOI 10.1128/MCB.00221-14; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhu JC, 2009, NAT METHODS, V6, P239, DOI 10.1038/nmeth0409-239	46	135	147	6	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					5007	5019		10.1038/s41388-018-0307-z	http://dx.doi.org/10.1038/s41388-018-0307-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29789716	Green Published, hybrid			2022-12-17	WOS:000443823600008
J	Molenaar, RJ; Maciejewski, JP; Wilmink, JW; van Noorden, CJF				Molenaar, Remco J.; Maciejewski, Jaroslaw P.; Wilmink, Johanna W.; van Noorden, Cornelis J. F.			Wild-type and mutated IDH1/2 enzymes and therapy responses	ONCOGENE			English	Review							ACUTE MYELOID-LEUKEMIA; ISOCITRATE DEHYDROGENASE 1; PREDICT LONGER SURVIVAL; DNA-REPAIR ENZYMES; LOW-GRADE GLIOMAS; MUTANT IDH1; INTRAHEPATIC CHOLANGIOCARCINOMA; OXIDATIVE STRESS; TUMOR-CELLS; IN-VIVO	Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.	[Molenaar, Remco J.; van Noorden, Cornelis J. F.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands; [Molenaar, Remco J.; Wilmink, Johanna W.] Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands; [Molenaar, Remco J.; Maciejewski, Jaroslaw P.] Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Cleveland Clinic Foundation	Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Biol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands.; Molenaar, RJ (corresponding author), Cleveland Clin, Dept Translat Hematol & Oncol Res, Cleveland, OH 44106 USA.	r.j.molenaar@amc.nl		Molenaar, Remco/0000-0001-5651-3997	AMC PhD Scholarship; Dutch Cancer Society (KWF) [UVA 2014-6839, AMC2016.1-10460]; National Institutes of Health (Bethesda, MD; NIH) [R01HL118281, R01HL123904, R01HL132071, R35HL135795]; AA & MDS International Foundation (Rockville, MD); Robert Duggan Charitable Fund (Cleveland, OH); NATIONAL CANCER INSTITUTE [K12CA120780] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL123904, R01HL118281, R01HL132071, R35HL135795] Funding Source: NIH RePORTER	AMC PhD Scholarship; Dutch Cancer Society (KWF)(KWF Kankerbestrijding); National Institutes of Health (Bethesda, MD; NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); AA & MDS International Foundation (Rockville, MD); Robert Duggan Charitable Fund (Cleveland, OH); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by AMC PhD Scholarship (to R.J.M), the Dutch Cancer Society (KWF; UVA 2014-6839, to R.J.M. and C.J.F.v.N and AMC2016.1-10460, to R.J.M., J.W.W. and C.J.F.v.N.), the National Institutes of Health (Bethesda, MD; NIH) grants R01HL118281, R01HL123904, R01HL132071, R35HL135795, a grant from the AA & MDS International Foundation (Rockville, MD), and the Robert Duggan Charitable Fund (Cleveland, OH, all to J.P.M.).	Amatangelo MD, 2017, BLOOD, V130, P732, DOI 10.1182/blood-2017-04-779447; Atai NA, 2011, J HISTOCHEM CYTOCHEM, V59, P489, DOI 10.1369/0022155411400606; Bleeker FE, 2010, ACTA NEUROPATHOL, V119, P487, DOI 10.1007/s00401-010-0645-6; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Boutzen H, 2016, J EXP MED, V213, P483, DOI 10.1084/jem.20150736; Buckner JC, 2016, NEW ENGL J MED, V374, P1344, DOI 10.1056/NEJMoa1500925; Cairncross JG, 2014, J CLIN ONCOL, V32, P783, DOI 10.1200/JCO.2013.49.3726; Calvert AE, 2017, CELL REP, V19, P1858, DOI 10.1016/j.celrep.2017.05.014; Chan SM, 2015, NAT MED, V21, P178, DOI 10.1038/nm.3788; Charitou P, 2015, EMBO REP, V16, P456, DOI 10.15252/embr.201439096; Chaturvedi A, 2013, BLOOD, V122, P2877, DOI 10.1182/blood-2013-03-491571; Chen FY, 2017, CHEM RES TOXICOL, V30, P1102, DOI 10.1021/acs.chemrestox.7b00009; Cimmino L, 2017, CELL, V170, P1079, DOI 10.1016/j.cell.2017.07.032; Cuyas E, 2015, ONCOTARGET, V6, P12279, DOI 10.18632/oncotarget.3733; Dang L, 2017, ANNU REV BIOCHEM, V86, P305, DOI 10.1146/annurev-biochem-061516-044732; Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617; Elhammali A, 2014, CANCER DISCOV, V4, P828, DOI 10.1158/2159-8290.CD-13-0572; Emadi A, 2014, EXP HEMATOL, V42, P247, DOI 10.1016/j.exphem.2013.12.001; Farshidfar F, 2017, CELL REP, V18, P2780, DOI 10.1016/j.celrep.2017.02.033; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Fu YJ, 2012, INT J BIOCHEM CELL B, V44, P770, DOI 10.1016/j.biocel.2012.01.017; Gagne LM, 2017, TRENDS CELL BIOL, V27, P738, DOI 10.1016/j.tcb.2017.06.002; Gentile M, 2017, EXPERT OPIN INV DRUG, V26, P1307, DOI 10.1080/13543784.2017.1386173; Gilbert MR, 2014, ACTA NEUROPATHOL, V127, P221, DOI 10.1007/s00401-013-1194-6; Goyal L, 2015, ONCOLOGIST, V20, P1019, DOI 10.1634/theoncologist.2015-0210; Grassian AR, 2014, CANCER RES, V74, P3317, DOI 10.1158/0008-5472.CAN-14-0772-T; Hartmann C, 2011, CLIN CANCER RES, V17, P4588, DOI 10.1158/1078-0432.CCR-10-3194; Holmgren A, 2010, BIOCHEM BIOPH RES CO, V396, P120, DOI 10.1016/j.bbrc.2010.03.083; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Inoue S, 2016, CANCER CELL, V30, P337, DOI 10.1016/j.ccell.2016.05.018; Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813; Karpel-Massler G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00984-9; Kernytsky A, 2015, BLOOD, V125, P296, DOI 10.1182/blood-2013-10-533604; Khurshed M, 2017, ONCOTARGET, V8, P49165, DOI 10.18632/oncotarget.17106; Kim SY, 2013, BIOCHEM BIOPH RES CO, V433, P260, DOI 10.1016/j.bbrc.2013.02.093; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Koehler A, 2003, ENVIRON TOXICOL CHEM, V22, P2703, DOI 10.1897/02-364; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kolker S, 2002, EUR J NEUROSCI, V16, P21, DOI 10.1046/j.1460-9568.2002.02055.x; Konopleva M, 2016, CANCER DISCOV, V6, P1106, DOI 10.1158/2159-8290.CD-16-0313; Latini A, 2003, EUR J NEUROSCI, V17, P2017, DOI 10.1046/j.1460-9568.2003.02639.x; Lee JH, 2007, FREE RADICAL BIO MED, V42, P44, DOI 10.1016/j.freeradbiomed.2006.09.016; Li KS, 2017, ONCOTARGET, V8, P28865, DOI 10.18632/oncotarget.15868; Li SC, 2013, NEURO-ONCOLOGY, V15, P57, DOI 10.1093/neuonc/nos261; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Losman JA, 2013, GENE DEV, V27, P836, DOI 10.1101/gad.217406.113; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu YX, 2017, CANCER RES, V77, P1709, DOI 10.1158/0008-5472.CAN-16-2773; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mohrenz IV, 2013, APOPTOSIS, V18, P1416, DOI 10.1007/s10495-013-0877-8; Molenaar RJ, 2015, LEUKEMIA, V29, P2134, DOI 10.1038/leu.2015.91; Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961; Molenaar RJ, 2015, CANCER RES, V75, P4790, DOI 10.1158/0008-5472.CAN-14-3603; Molenaar RJ, 2014, BBA-REV CANCER, V1846, P326, DOI 10.1016/j.bbcan.2014.05.004; Molenaar RJ, 2014, NEURO-ONCOLOGY, V16, P1263, DOI 10.1093/neuonc/nou005; Molenaar RJ, 2018, CLIN CANC R IN PRESS; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Navis AC, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-18; Okita Y, 2012, INT J ONCOL, V41, P1325, DOI 10.3892/ijo.2012.1564; Okoye-Okafor UC, 2015, NAT CHEM BIOL, V11, P878, DOI 10.1038/nchembio.1930; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Popovici-Muller J, 2012, ACS MED CHEM LETT, V3, P850, DOI 10.1021/ml300225h; Qi ST, 2012, CANCER SCI, V103, P269, DOI 10.1111/j.1349-7006.2011.02134.x; Saha SK, 2016, CANCER DISCOV, V6, P727, DOI 10.1158/2159-8290.CD-15-1442; Salvemini F, 1999, J BIOL CHEM, V274, P2750, DOI 10.1074/jbc.274.5.2750; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Schumacher T, 2014, NATURE, V512, P324, DOI 10.1038/nature13387; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Shi JL, 2015, TUMOR BIOL, V36, P655, DOI 10.1007/s13277-014-2644-z; Shi JL, 2014, NEUROL SCI, V35, P839, DOI 10.1007/s10072-013-1607-2; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Stein EM, 2017, BLOOD, V130, P722, DOI 10.1182/blood-2017-04-779405; Sulkowski PL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal2463; Tateishi K, 2017, CANCER RES, V77, P4102, DOI 10.1158/0008-5472.CAN-16-2263; Tateishi K, 2015, CANCER CELL, V28, P773, DOI 10.1016/j.ccell.2015.11.006; Tonjes M, 2013, NAT MED, V19, P901, DOI 10.1038/nm.3217; Tran AN, 2014, NEURO-ONCOLOGY, V16, P414, DOI 10.1093/neuonc/not198; van Lith SAM, 2014, NEURO-ONCOLOGY, V16, P1669, DOI 10.1093/neuonc/nou152; van Lith SAM, 2014, BBA-REV CANCER, V1846, P66, DOI 10.1016/j.bbcan.2014.04.004; VANNOORDEN CJF, 1986, HISTOCHEM J, V18, P364, DOI 10.1007/BF01675217; Wahl DR, 2017, CANCER RES, V77, P960, DOI 10.1158/0008-5472.CAN-16-2008; Wang JB, 2014, ASIAN PAC J CANCER P, V15, P427, DOI 10.7314/APJCP.2014.15.1.427; Wang P, 2013, ONCOGENE, V32, P3091, DOI 10.1038/onc.2012.315; Wang P, 2015, CELL REP, V13, P2353, DOI 10.1016/j.celrep.2015.11.029; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xu QY, 2017, CLIN CANCER RES, V23, P4511, DOI 10.1158/1078-0432.CCR-16-2628; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yen K, 2017, CANCER DISCOV, V7, P478, DOI 10.1158/2159-8290.CD-16-1034; Young LC, 2013, J BIOL CHEM, V288, P21376, DOI 10.1074/jbc.M113.491514; Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015; Zhu AX, 2014, ANN SURG ONCOL, V21, P3827, DOI 10.1245/s10434-014-3828-x; Zhu HX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169038	98	135	141	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					1949	1960		10.1038/s41388-017-0077-z	http://dx.doi.org/10.1038/s41388-017-0077-z			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367755	hybrid, Green Published			2022-12-17	WOS:000429899400001
J	Zhang, H; Ye, YL; Li, MX; Ye, SB; Huang, WR; Cai, TT; He, J; Peng, JY; Duan, TH; Cui, J; Zhang, XS; Zhou, FJ; Wang, RF; Li, J				Zhang, H.; Ye, Y-L; Li, M-X; Ye, S-B; Huang, W-R; Cai, T-T; He, J.; Peng, J-Y; Duan, T-H; Cui, J.; Zhang, X-S; Zhou, F-J; Wang, R-F; Li, J.			CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer	ONCOGENE			English	Article							NEUTROPHIL RECRUITMENT; TUMOR MICROENVIRONMENT; ACCUMULATION; ACTIVATION; EXPANSION; INFLAMMATION; METASTASIS; MECHANISM; RESPONSES; BLOCKADE	The accumulation of myeloid-derived suppressor cells (MDSCs) has been observed in solid tumors and is correlated with tumor progression; however, the underlying mechanism is still poorly understood. In this study, we identified a mechanism by which tumor cells induce MDSC accumulation and expansion in the bladder cancer (BC) microenvironment via CXCL2/MIF-CXCR2 signaling. Elevated expression of CXCL2 and MIF and an increased number of CD33(+) MDSCs were detected in BC tissues, and these increases were significantly associated with advanced disease stage and poor patient prognosis (P < 0.01). A positive association was observed between CXCL2 or MIF expression and the number of tumor-infiltrating CD33(+) MDSCs (P < 0.01). Subsequently, we demonstrated that CD45(+) CD33(+) CD11b(+) HLA-DR-MDSCs from fresh BC tissues displayed high levels of suppressive molecules, including Arg1, iNOS, ROS, PDL-1 and P-STAT3, and stronger suppression of T-cell proliferation. Interestingly, these CD45(+) CD33+ CD11b(+) HLA-DR -MDSCs exhibited increased CXCR2 expression compared with that in peripheral blood from BC patients or healthy controls (P < 0.05). Chemotaxis assay revealed that bladder cancer cell line J82 induced MDSC migration via CXCL2/MIF-CXCR2 signaling in vitro. Mechanistic studies demonstrated that J82-induced MDSC trafficking and CXCR2 expression were associated with increased phosphorylation of p38, ERK and p65. Conversely, inhibition of the phosphorylation of p38, ERK or p65 decreased J82-induced MDSC trafficking and CXCR2 expression. CXCL2/MIF-stimulated activation of the mitogen-activated protein kinase and nuclear factor kappa B pathways in MDSCs was MyD88 dependent. Overall, our results identify the CXCL2/MIF-CXCR2 axis as an important mediator in MDSC recruitment and as predictors and potential therapeutic targets in BC patients.	[Zhang, H.; Ye, Y-L; Ye, S-B; Cai, T-T; Zhang, X-S; Zhou, F-J; Li, J.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Zhang, H.; Ye, Y-L; Ye, S-B; Cai, T-T; Zhang, X-S; Zhou, F-J; Li, J.] Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China; [Zhang, H.; Ye, S-B; Cai, T-T; He, J.; Peng, J-Y; Zhang, X-S; Li, J.] Dept Biotherapy, Guangzhou, Guangdong, Peoples R China; [Ye, Y-L; Zhou, F-J] Sun Yat Sen Univ, Dept Urol, Ctr Canc, Guangzhou, Guangdong, Peoples R China; [Li, M-X; Huang, W-R] Shenzhen Univ, Shenzhen Peoples Hosp 2, Key Lab Med Reprogramming Technol, Affiliated Hosp 1, Shenzhen, Peoples R China; [Duan, T-H; Cui, J.] Sun Yat Sen Univ, Coll Life Sci, Key Lab Gene Engn, Minist Educ,State Key Lab Biocontrol, Guangzhou, Guangdong, Peoples R China; [Wang, R-F] Houston Methodist Res Inst, Ctr Inflammat & Epigenet, Houston, TX USA; [Wang, R-F] Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA	State Key Lab Oncology South China; Sun Yat Sen University; Shenzhen University; Sun Yat Sen University; The Methodist Hospital System; The Methodist Hospital - Houston; Cornell University	Wang, RF (corresponding author), Cornell Univ, Weill Cornell Med Coll, Dept Microbiol & Immunol, 1300 York Ave, New York, NY 10065 USA.; Li, J (corresponding author), Sun Yat Sen Univ, Canc Ctr, 651 Dongfeng East Rd, Guangzhou 510060, Guangdong, Peoples R China.	rwang3@houstonmethodist.org; lijiang2@mail.sysu.edu.cn	ye, shubiao/GZM-4506-2022	li, jiang/0000-0001-5596-9159	National Key Basic Research Program of China of the National Natural Science Foundation of China [2014CB745200]; Shenzheng City Science Foundation [81572982, 81372442, 81172164, 2014041470821172]	National Key Basic Research Program of China of the National Natural Science Foundation of China; Shenzheng City Science Foundation	This work was supported by grants from the National Key Basic Research Program of China (2014CB745200) of the National Natural Science Foundation of China and the General Program (Grant Nos. 81572982, 81372442 and 81172164, to LJ) and the Sci-Tech Key Program of the Shenzheng City Science Foundation (Grant No. 2014041470821172, to LJ).	Becht E, 2014, CANCER IMMUNOL IMMUN, V63, P991, DOI 10.1007/s00262-014-1590-3; Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024; Corzo CA, 2009, J IMMUNOL, V182, P5693, DOI 10.4049/jimmunol.0900092; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; De Veirman K, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00349; Dubeykovskaya Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10517; Dubois Raymond N, 2014, Trans Am Clin Climatol Assoc, V125, P358; Errico A, 2015, NAT REV CLIN ONCOL, V12, P63, DOI [10.1038/nrclinonc.2014.221, 10.1038/nrclinonc.2013.247]; Eruslanov E, 2012, INT J CANCER, V130, P1109, DOI 10.1002/ijc.26123; Fang LY, 2013, CANCER RES, V73, P5633, DOI 10.1158/0008-5472.CAN-12-3228; Gabrilovich D, 2015, CANCER CELL, V28, P147, DOI 10.1016/j.ccell.2015.07.007; Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974; Hong EH, 2013, INT J CANCER, V132, P2839, DOI 10.1002/ijc.27974; Huang B, 2007, CANCER LETT, V252, P86, DOI 10.1016/j.canlet.2006.12.012; Huang JR, 2014, J IMMUNOL, V192, P1972, DOI 10.4049/jimmunol.1302623; Huang L, 2015, AM J TRANSL RES, V7, P2141; Jablonska J, 2014, INT J CANCER, V134, P1346, DOI 10.1002/ijc.28551; Jiang JW, 2014, HUM IMMUNOL, V75, P1128, DOI 10.1016/j.humimm.2014.09.025; Kaplan AL, 2014, NAT REV UROL, V11, P59, DOI 10.1038/nrurol.2013.180; Kotsakis A, 2012, J IMMUNOL METHODS, V381, P14, DOI 10.1016/j.jim.2012.04.004; Li ZL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1044712; Liakou Chrysoula I, 2007, Cancer Immun, V7, P10; Lin M, 2015, ANAL CELL PATHOL, V2015, DOI 10.1155/2015/313145; Mao YM, 2013, CANCER RES, V73, P3877, DOI 10.1158/0008-5472.CAN-12-4115; Miller LS, 2006, IMMUNITY, V24, P79, DOI 10.1016/j.immuni.2005.11.011; Mitchell D, 2010, MOL IMMUNOL, V47, P2065, DOI 10.1016/j.molimm.2010.04.004; Mitchell RA, 2014, CELL SIGNAL, V26, P2969, DOI 10.1016/j.cellsig.2014.09.012; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7; Ozao-Choy J, 2009, CANCER RES, V69, P2514, DOI 10.1158/0008-5472.CAN-08-4709; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Raval RR, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-14; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Santegoetst SJAM, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0031-3; Scortegagna M, 2008, BLOOD, V111, P3343, DOI 10.1182/blood-2007-10-115758; Shang K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051848; Talmadge JE, 2007, CLIN CANCER RES, V13, P5243, DOI 10.1158/1078-0432.CCR-07-0182; Thummuri D, 2015, PHARMACOL RES, V99, P63, DOI 10.1016/j.phrs.2015.05.006; Vashistha V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-966; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Weiss JM, 2014, J IMMUNOL, V192, P5821, DOI 10.4049/jimmunol.1400404; Winner M, 2007, CANCER RES, V67, P186, DOI 10.1158/0008-5472.CAN-06-3292; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Yamamoto M, 2008, CANCER RES, V68, P9754, DOI 10.1158/0008-5472.CAN-08-1748; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zhang H, 2015, CANCER IMMUNOL IMMUN, V64, P1587, DOI 10.1007/s00262-015-1765-6; Zhang ZL, 2014, CHIN J CANCER, V33, P165, DOI 10.5732/cjc.012.10312	48	135	139	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2095	2104		10.1038/onc.2016.367	http://dx.doi.org/10.1038/onc.2016.367			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27721403				2022-12-17	WOS:000399782500006
J	Wu, YH; Chang, TH; Huang, YF; Huang, HD; Chou, CY				Wu, Y-H; Chang, T-H; Huang, Y-F; Huang, H-D; Chou, C-Y			COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer	ONCOGENE			English	Article						COL11A1; tumor progression; ovarian carcinoma	GENE-EXPRESSION PROFILES; ETS-1 TRANSCRIPTION FACTOR; SQUAMOUS-CELL CARCINOMA; MATRIX METALLOPROTEINASES; EXTRACELLULAR-MATRIX; CLEAR-CELL; TGF-BETA; IN-SITU; PROTOONCOGENE; METASTASIS	Biomarkers that predict disease progression might assist the development of better therapeutic strategies for aggressive cancers, such as ovarian cancer. Here, we investigated the role of collagen type XI alpha 1 (COL11A1) in cell invasiveness and tumor formation and the prognostic impact of COL11A1 expression in ovarian cancer. Microarray analysis suggested that COL11A1 is a disease progression-associated gene that is linked to ovarian cancer recurrence and poor survival. Small interference RNA-mediated specific reduction in COL11A1 protein levels suppressed the invasive ability and oncogenic potential of ovarian cancer cells and decreased tumor formation and lung colonization in mouse xenografts. A combination of experimental approaches, including real-time RT-PCR, casein zymography and chromatin immunoprecipitation (ChIP) assays, showed that COL11A1 knockdown attenuated MMP3 expression and suppressed binding of Ets-1 to its putative MMP3 promoter-binding site, suggesting that the Ets-1-MMP3 axis is upregulated by COL11A1. Transforming growth factor (TGF)-beta (TGF-beta 1) treatment triggers the activation of smad2 signaling cascades, leading to activation of COL11A1 and MMP3. Pharmacological inhibition of MMP3 abrogated the TGF-beta 1-triggered, COL11A1-dependent cell invasiveness. Furthermore, the NF-YA-binding site on the COL11A1 promoter was identified as the major determinant of TGF-beta 1-dependent COL11A1 activation. Analysis of 88 ovarian cancer patients indicated that high COL11A1 mRNA levels are associated with advanced disease stage. The 5-year recurrence-free and overall survival rates were significantly lower (P=0.006 and P=0.018, respectively) among patients with high expression levels of tissue COL11A1 mRNA compared with those with low expression. We conclude that COL11A1 may promote tumor aggressiveness via the TGF-beta 1-MMP3 axis and that COL11A1 expression can predict clinical outcome in ovarian cancer patients.	[Wu, Y-H] Natl Cheng Kung Univ Hosp, Canc Res Ctr, Tainan 70428, Taiwan; [Chang, T-H] Taipei Med Univ, Grad Inst Biomed Informat, Taipei, Taiwan; [Huang, Y-F; Chou, C-Y] Natl Cheng Kung Univ & Hosp, Dept Obstet & Gynecol, Coll Med, Tainan 70403, Taiwan; [Huang, H-D] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan; [Huang, H-D] Natl Chiao Tung Univ, Inst Bioinformat & Syst Biol, Hsinchu, Taiwan	National Cheng Kung University; National Cheng Kung University Hospital; Taipei Medical University; National Cheng Kung University; National Cheng Kung University Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chou, CY (corresponding author), Natl Cheng Kung Univ & Hosp, Dept Obstet & Gynecol, Coll Med, Tainan 70403, Taiwan.	bryan@mail.nctu.edu.tw; chougyn@mail.ncku.edu.tw	Huang, Hsien-Da/AAA-7376-2019		'To establish centers of excellence for cancer research in Taiwan', Department of Health, Executive Yuan, Taiwan [DOH101-TD-C-111-003]; Taipei Medical University [TMU101-AE1-B44];  [NSC 101-2911-I-009-101];  [NSC 101-2311-B-009-003-MY3];  [NSC 100-2627-B-009-002]	'To establish centers of excellence for cancer research in Taiwan', Department of Health, Executive Yuan, Taiwan; Taipei Medical University; ; ; 	This study was supported by 'To establish centers of excellence for cancer research in Taiwan' (DOH101-TD-C-111-003), Department of Health, Executive Yuan, Taiwan. This work was supported in part by National Science Council under Grant No.: NSC 101-2911-I-009-101, NSC 101-2311-B-009-003-MY3 and NSC 100-2627-B-009-002. The research was supported in part by Taipei Medical University under grant TMU101-AE1-B44.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Alabert C, 2006, ONCOGENE, V25, P3387, DOI 10.1038/sj.onc.1209385; Badea L, 2008, HEPATO-GASTROENTEROL, V55, P2016; Belotti D, 2003, CANCER RES, V63, P5224; Berchuck A, 2005, CLIN CANCER RES, V11, P3686, DOI 10.1158/1078-0432.CCR-04-2398; Bjorklund M, 2005, BBA-REV CANCER, V1755, P37, DOI 10.1016/j.bbcan.2005.03.001; Boudreau N, 1998, CURR OPIN CELL BIOL, V10, P640, DOI 10.1016/S0955-0674(98)80040-9; Bowen KB, 2008, J HISTOCHEM CYTOCHEM, V56, P275, DOI 10.1369/jhc.7A7310.2007; Choi JW, 2011, ONCOL LETT, V2, P1047, DOI 10.3892/ol.2011.391; Chong IW, 2006, ONCOL REP, V16, P981; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Fischer H, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-17; Fischer H, 2001, CARCINOGENESIS, V22, P875, DOI 10.1093/carcin/22.6.875; Gaspar NJ, 2007, MOL PHARMACOL, V72, P152, DOI 10.1124/mol.106.029025; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman R, 2005, AFFYQCREPORT QC REPO; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hartmann LC, 2005, CLIN CANCER RES, V11, P2149, DOI 10.1158/1078-0432.CCR-04-1673; Hau P, 2007, OLIGONUCLEOTIDES, V17, P201, DOI 10.1089/oli.2006.0053; Horvath B, 2005, HEAD NECK-J SCI SPEC, V27, P585, DOI 10.1002/hed.20188; Ito T, 1998, MODERN PATHOL, V11, P209; Ito Y, 2000, AM J CLIN PATHOL, V114, P719, DOI 10.1309/RAVV-8NM1-CJB7-GJFR; Ito Y, 2000, ONCOLOGY-BASEL, V58, P248, DOI 10.1159/000012108; Jazaeri AA, 2005, CLIN CANCER RES, V11, P6300, DOI 10.1158/1078-0432.CCR-04-2682; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Khatun S, 2003, CANCER SCI, V94, P769, DOI 10.1111/j.1349-7006.2003.tb01517.x; Kim HJ, 2010, J CERAM PROCESS RES, V11, P11; Kitange G, 1999, MODERN PATHOL, V12, P618; Knudsen ES, 2012, BREAST CANCER RES TR, V133, P1009, DOI 10.1007/s10549-011-1894-3; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Leroy-Dudal J, 2005, INT J CANCER, V114, P531, DOI 10.1002/ijc.20778; Matsuo N, 2003, J BIOL CHEM, V278, P32763, DOI 10.1074/jbc.M305599200; Nakayama T, 1999, MODERN PATHOL, V12, P61; Nakayama T, 1996, AM J PATHOL, V149, P1931; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; Ozaki I, 2000, CANCER RES, V60, P6519; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Rae MT, 2009, FERTIL STERIL, V92, P703, DOI 10.1016/j.fertnstert.2008.06.040; Saeki H, 2000, CANCER, V89, P1670, DOI 10.1002/1097-0142(20001015)89:8<1670::AID-CNCR4>3.0.CO;2-J; Sato Y, 2000, ADV EXP MED BIOL, V476, P109; Schmalbach CE, 2004, ARCH OTOLARYNGOL, V130, P295, DOI 10.1001/archotol.130.3.295; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Schwartz DR, 2002, CANCER RES, V62, P4722; Shridhar V, 2001, CANCER RES, V61, P5895; Spentzos D, 2004, J CLIN ONCOL, V22, P4700, DOI 10.1200/JCO.2004.04.070; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Stracke M L, 1994, In Vivo, V8, P49; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Vecchi M, 2007, ONCOGENE, V26, P4284, DOI 10.1038/sj.onc.1210208; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Yamamura S, 2012, INT J CANCER, V130, P20, DOI 10.1002/ijc.25961; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	58	135	137	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3432	3440		10.1038/onc.2013.307	http://dx.doi.org/10.1038/onc.2013.307			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23934190				2022-12-17	WOS:000338779300010
J	Wormann, SM; Diakopoulos, KN; Lesina, M; Algul, H				Woermann, S. M.; Diakopoulos, K. N.; Lesina, M.; Alguel, H.			The immune network in pancreatic cancer development and progression	ONCOGENE			English	Review						pancreatic ductal adenocarcinoma; tumor microenvironment; immune system; cytokines; pattern recognition receptors; immune cells	REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; CIRCULATING DENDRITIC CELLS; KAPPA-B ACTIVATION; GROWTH-FACTOR-BETA; SUPPRESSOR-CELLS; MAST-CELLS; INFLAMMATORY CELLS; CARCINOMA-CELLS; MURINE MODEL	The presence of stromal desmoplasia is a hallmark of spontaneous pancreatic ductal adenocarcinoma, forming a unique microenvironment that comprises many cell types. Only recently, the immune system has entered the pathophysiology of pancreatic ductal adenocarcinoma development. Tumor cells in the pancreas seem to dysbalance the immune system, thus facilitating spontaneous cancer development. This review will try to assemble all relevant data to demonstrate the implications of the immune network on spontaneous cancer development.	[Woermann, S. M.; Diakopoulos, K. N.; Lesina, M.; Alguel, H.] Tech Univ Munich, Klinikum Rechts Isar, Med Klin, D-81675 Munich, Germany	Technical University of Munich	Algul, H (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, D-81675 Munich, Germany.	hana.alguel@lrz.tum.de	Lesina, Marina/AAV-3845-2020	Diakopoulos, Kalliope/0000-0002-9236-0489; Algul, Hana/0000-0002-5067-7031				Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21; Algful H, 2007, NAT CLIN PRACT GASTR, V4, P454, DOI 10.1038/ncpgasthep0881; Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529; Andrianifahanana M, 2006, AM J GASTROENTEROL, V101, P2319, DOI 10.1111/j.1572-0241.2006.00871.x; Angst E, 2008, SURGERY, V144, P57, DOI 10.1016/j.surg.2008.03.024; Arlt A, 2002, CANCER RES, V62, P910; Ashida A, 2006, INT J ONCOL, V28, P1345; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bang S, 2006, PANCREAS, V32, P29, DOI 10.1097/01.mpa.0000191651.32420.41; Barber MD, 1999, CLIN SCI, V96, P83, DOI 10.1042/CS19980185; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Bellone G, 1999, AM J PATHOL, V155, P537, DOI 10.1016/S0002-9440(10)65149-8; Bellone G, 2006, CANCER IMMUNOL IMMUN, V55, P684, DOI 10.1007/s00262-005-0047-0; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006; Benson DD, 2012, AM J PHYSIOL-REG I, V302, pR1067, DOI 10.1152/ajpregu.00320.2011; Berkovic MC, 2012, DNA CELL BIOL, V31, P531, DOI 10.1089/dna.2011.1317; Bharadwaj U, 2007, CANCER RES, V67, P5479, DOI 10.1158/0008-5472.CAN-06-3963; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Cai SW, 2011, SURGERY, V149, P576, DOI 10.1016/j.surg.2010.10.009; Chang DZ, 2011, CLIN CANCER RES, V17, P7015, DOI 10.1158/1078-0432.CCR-11-0607; Chen JG, 2011, INT J BIOL SCI, V7, P53, DOI 10.7150/ijbs.7.53; Chen LL, 2010, J IMMUNOL, V184, P2602, DOI 10.4049/jimmunol.0901593; Chen X, 2010, LUNG CANCER, V69, P348, DOI 10.1016/j.lungcan.2009.11.013; Chen Y, 2012, WORLD J GASTROENTERO, V18, P1123, DOI 10.3748/wjg.v18.i10.1123; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clark E J, 2007, HPB (Oxford), V9, P456, DOI 10.1080/13651820701774891; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dallal RM, 2002, SURGERY, V131, P135, DOI 10.1067/msy.2002.119937; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Du J, 2012, MED ONCOL, V29, P2814, DOI 10.1007/s12032-012-0175-2; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Ebrahimi B, 2004, CANCER-AM CANCER SOC, V101, P2727, DOI 10.1002/cncr.20672; Elia AR, 2008, J LEUKOCYTE BIOL, V84, P1472, DOI 10.1189/jlb.0208082; Ellermeier J, 2013, CANCER RES, V73, P1709, DOI 10.1158/0008-5472.CAN-11-3850; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Esposito I, 2002, LAB INVEST, V82, P1481, DOI 10.1097/01.LAB.0000036875.21209.F9; Evans A, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00270; Feurino LW, 2006, CANCER INVEST, V24, P696, DOI 10.1080/07357900600981398; Formentini A, 2009, INT J COLORECTAL DIS, V24, P57, DOI 10.1007/s00384-008-0550-9; Fortis C, 1996, CANCER LETT, V104, P1, DOI 10.1016/0304-3835(96)04213-9; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garbe AI, 2006, CANCER RES, V66, P508, DOI 10.1158/0008-5472.CAN-05-2383; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gnerlich JL, 2010, J IMMUNOL, V185, P4063, DOI 10.4049/jimmunol.0902609; Goedegebuure P, 2011, CURR CANCER DRUG TAR, V11, P734, DOI 10.2174/156800911796191024; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Hamacher R, 2009, CYTOKINE, V46, P182, DOI 10.1016/j.cyto.2009.01.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; He SB, 2011, INT J MOL SCI, V12, P7424, DOI 10.3390/ijms12117424; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hill KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040420; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hirooka S, 2011, ANTICANCER RES, V31, P3827; Hodges Kyle, 2012, Transl Gastrointest Cancer, V1, P138; Huang B, 2008, ONCOGENE, V27, P218, DOI 10.1038/sj.onc.1210904; Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kawai O, 2008, CANCER-AM CANCER SOC, V113, P1387, DOI 10.1002/cncr.23712; Kiefel H, 2010, ONCOGENE, V29, P4766, DOI 10.1038/onc.2010.230; Kim Ji Sung, 2012, Immune Netw, V12, P247, DOI 10.4110/in.2012.12.6.247; Kimsey TF, 2004, CANCER J, V10, P374, DOI 10.1097/00130404-200411000-00007; Kornmann M, 1999, ANTICANCER RES, V19, P125; Kulhankova K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043609; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Kusuda T, 2005, ONCOL REP, V13, P1153; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee BN, 2006, CANCER-AM CANCER SOC, V107, P999, DOI 10.1002/cncr.22092; Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Maker AV, 2011, CLIN CANCER RES, V17, P1502, DOI 10.1158/1078-0432.CCR-10-1561; Makinoshima H, 2009, FEBS LETT, V583, P3697, DOI 10.1016/j.febslet.2009.10.061; Mancino A, 2008, BLOOD, V112, P3723, DOI 10.1182/blood-2008-02-142091; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Matsuo Y, 2009, J SURG RES, V153, P274, DOI 10.1016/j.jss.2008.04.040; Melisi D, 2009, MOL CANCER RES, V7, P624, DOI 10.1158/1541-7786.MCR-08-0201; Monti P, 2004, VIRCHOWS ARCH, V445, P236, DOI 10.1007/s00428-004-1053-x; Monti P, 2003, CANCER RES, V63, P7451; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Moses AGW, 2009, ONCOL REP, V21, P1091, DOI 10.3892/or_00000328; Mroczko B, 2010, J CLIN LAB ANAL, V24, P256, DOI 10.1002/jcla.20395; Muerkoster S, 2004, MED KLIN, V99, P185, DOI 10.1007/s00063-004-1027-4; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nakano O, 2001, CANCER RES, V61, P5132; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Nevala WK, 2009, CLIN CANCER RES, V15, P1931, DOI 10.1158/1078-0432.CCR-08-1980; Niu JG, 2004, J BIOL CHEM, V279, P16452, DOI 10.1074/jbc.M309789200; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Okada S, 1998, JPN J CLIN ONCOL, V28, P12, DOI 10.1093/jjco/28.1.12; Okudaira K, 2007, MICROCIRCULATION, V14, P241, DOI 10.1080/10739680601139393; Ormandy LA, 2006, WORLD J GASTROENTERO, V12, P3275, DOI 10.3748/wjg.v12.i20.3275; Osawa E, 2006, INT J CANCER, V118, P2232, DOI 10.1002/ijc.21639; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; Pilon-Thomas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027729; Pinzon-Charry A, 2007, BRIT J CANCER, V97, P1251, DOI 10.1038/sj.bjc.6604018; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Poch B, 2007, LANGENBECK ARCH SURG, V392, P353, DOI 10.1007/s00423-006-0140-7; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Reid MD, 2011, MODERN PATHOL, V24, P1612, DOI 10.1038/modpathol.2011.113; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sakamoto H, 2012, JPN J CLIN ONCOL, V42, P105, DOI 10.1093/jjco/hyr178; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sawai H, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-8; Sawai H, 2005, MED SCI MONITOR, V11, pBR343; Sawai H, 2003, ONCOLOGY-BASEL, V65, P167, DOI 10.1159/000072343; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schmid MC, 2011, CANCER RES, V71, P6965, DOI 10.1158/0008-5472.CAN-11-0588; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; Scola L, 2009, ANN NY ACAD SCI, V1155, P284, DOI 10.1111/j.1749-6632.2008.03686.x; Sgouroudis E, 2011, AUTOIMMUNITY, V44, P406, DOI 10.3109/08916934.2010.536795; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; Smirne C, 1999, Minerva Gastroenterol Dietol, V45, P21; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Sperveslage J, 2012, INT J CANCER, V131, pE371, DOI 10.1002/ijc.26502; Steinman RM, 2003, PATHOL BIOL, V51, P59, DOI 10.1016/S0369-8114(03)00096-8; Strouch MJ, 2010, CLIN CANCER RES, V16, P2257, DOI 10.1158/1078-0432.CCR-09-1230; Talar-Wojnarowska R, 2009, NEOPLASMA, V56, P56, DOI 10.4149/neo_2009_01_56; Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tang Rui-Fang, 2005, Hepatobiliary Pancreat Dis Int, V4, P460; Tassi E, 2008, J IMMUNOL, V181, P6595, DOI 10.4049/jimmunol.181.9.6595; Tassi E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007234; Tatsumi T, 2002, J EXP MED, V196, P619, DOI 10.1084/jem.20012142; Tjomsland V, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/212810; Tjomsland V, 2011, NEOPLASIA, V13, P664, DOI 10.1593/neo.11332; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Ubukata H, 2010, J SURG ONCOL, V102, P742, DOI 10.1002/jso.21725; Verma G, 2012, CANCER LETT, V320, P86, DOI 10.1016/j.canlet.2012.01.036; Vizio B, 2012, EXP THER MED, V4, P70, DOI 10.3892/etm.2012.553; von Bernstorff W, 2001, CLIN CANCER RES, V7, p925S; Wigmore SJ, 2002, INT J ONCOL, V21, P881; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Xu DH, 2010, J SURG ONCOL, V102, P469, DOI 10.1002/jso.21530; Yamasaki A, 2010, CANCER IMMUNOL IMMUN, V59, P675, DOI 10.1007/s00262-009-0783-7; Yanagimoto H, 2005, CLIN IMMUNOL, V114, P52, DOI 10.1016/j.clim.2004.09.007; Yang MX, 2010, IMMUNOL CELL BIOL, V88, P165, DOI 10.1038/icb.2009.77; Yu X., 2012, TRANSL MED, V2, P105, DOI DOI 10.4172/2161-1025.1000105; Zhang B, 2008, BIOCHEM BIOPH RES CO, V374, P533, DOI 10.1016/j.bbrc.2008.07.060; Zhang DL, 2008, ANN CLIN LAB SCI, V38, P113; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795; Zhang YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-4; Zischek C, 2009, ANN SURG, V250, P747, DOI 10.1097/SLA.0b013e3181bd62d0; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	179	135	139	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2956	2967		10.1038/onc.2013.257	http://dx.doi.org/10.1038/onc.2013.257			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851493				2022-12-17	WOS:000337232200002
J	Yachida, S; Iacobuzio-Donahue, CA				Yachida, S.; Iacobuzio-Donahue, C. A.			Evolution and dynamics of pancreatic cancer progression	ONCOGENE			English	Review						pancreatic cancer; metastasis; clonal evolution; genetics	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; TGF-BETA; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; CLONAL EVOLUTION; STROMAL CELLS; METASTASIS; MUTATIONS	Efficient metastasis is believed as the result of multiple genetic, epigenetic and/or post-translational events in the lifetime of a carcinoma. At the genetic level, these events may be categorized into those that occur during carcinogenesis, and those that occur during subclonal evolution. This review summarizes current knowledge of the genetics of pancreatic cancer from its initiation within a normal cell until the time that is has disseminated to distant organs, many features of which can be extrapolated to other solid tumor types. The implications of these findings to personalize genome analyses of an individual patient's tumor are also discussed.	[Yachida, S.; Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA; [Yachida, S.] Natl Canc Ctr, Res Inst, Div Refractory Canc Res, Tokyo 104, Japan; [Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; National Cancer Center - Japan; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Iacobuzio-Donahue, CA (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 1550 Orleans St,CRBII 343, Baltimore, MD 21231 USA.	CIACOBU@jhmi.edu	Iacobuzio-Donahue, Christine/ABF-1295-2020	Iacobuzio-Donahue, Christine/0000-0002-4672-3023	NCI [CA140599]; NATIONAL CANCER INSTITUTE [R01CA140599] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23390326] Funding Source: KAKEN	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by NCI CA140599 (CID).	Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Ballard MS, 2012, ADV CANCER RES, V114, P187, DOI 10.1016/B978-0-12-386503-8.00005-3; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Canto MI, 2012, GASTROENTEROLOGY, V142, P796, DOI 10.1053/j.gastro.2012.01.005; Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64; Crane CH, 2012, J CLIN ONCOL, V30, P4049, DOI 10.1200/JCO.2012.45.1799; Crane CH, 2011, J CLIN ONCOL, V29, P3037, DOI 10.1200/JCO.2010.33.8038; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Dai JL, 1998, CANCER RES, V58, P4592; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood-2012-01-405977; Egawa S, 2004, PANCREAS, V28, P235, DOI 10.1097/00006676-200404000-00004; Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P71, DOI 10.1016/j.semcancer.2010.12.004; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gisselsson D, 2011, ADV CANCER RES, V112, P1, DOI 10.1016/B978-0-12-387688-1.00001-6; Goedegebuure P, 2011, CURR CANCER DRUG TAR, V11, P734, DOI 10.2174/156800911796191024; Grau AM, 1997, CANCER RES, V57, P3929; Grubor V, 2009, BLOOD, V113, P1294, DOI 10.1182/blood-2008-05-158865; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacobuzio-Donahue CA, 2012, GUT, V61, P1085, DOI 10.1136/gut.2010.236026; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Macgregor-Das AM, 2013, J SURG ONCOL, V107, P8, DOI 10.1002/jso.23213; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matthaei H, 2011, NAT REV GASTRO HEPAT, V8, P141, DOI 10.1038/nrgastro.2011.2; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Murakami M, 2010, MOL BIOL REP, V37, P1279, DOI 10.1007/s11033-009-9502-x; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Nishimori H, 2012, J BIOL CHEM, V287, P20037, DOI 10.1074/jbc.M112.353094; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Oshima M, 2013, ANN SURG IN PRESS; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Park CY, 2011, CANCER SCI, V102, P1889, DOI 10.1111/j.1349-7006.2011.02014.x; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Salnikov AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046391; Semenza GL, 2013, ONCOGENE, V32, P4057, DOI 10.1038/onc.2012.578; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shin EJ, 2012, GASTROENTEROL CLIN N, V41, P143, DOI 10.1016/j.gtc.2011.12.001; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Warshaw AL, 2012, CURR OPIN GASTROEN, V28, P488, DOI 10.1097/MOG.0b013e3283567f2c; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 1998, CANCER RES, V58, P4740; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	88	135	138	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5253	5260		10.1038/onc.2013.29	http://dx.doi.org/10.1038/onc.2013.29			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23416985	Green Accepted			2022-12-17	WOS:000326922100001
J	Linger, RMA; Cohen, RA; Cummings, CT; Sather, S; Migdall-Wilson, J; Middleton, DHG; Lu, X; Baron, AE; Franklin, WA; Merrick, DT; Jedlicka, P; DeRyckere, D; Heasley, LE; Graham, DK				Linger, R. M. A.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; Middleton, D. H. G.; Lu, X.; Baron, A. E.; Franklin, W. A.; Merrick, D. T.; Jedlicka, P.; DeRyckere, D.; Heasley, L. E.; Graham, D. K.			Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer	ONCOGENE			English	Article						targeted therapy; receptor tyrosine kinase; MerTK; signal transduction; xenograft; chemosensitivity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; ELEMENT-BINDING PROTEIN; NF-KAPPA-B; GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; THERAPEUTIC TARGETS; PROLONGS SURVIVAL; DISEASE-ACTIVITY; DRUG-RESISTANCE	Non-small cell lung cancer (NSCLC) is a prevalent and devastating disease that claims more lives than breast, prostate, colon and pancreatic cancers combined. Current research suggests that standard chemotherapy regimens have been optimized to maximal efficiency. Promising new treatment strategies involve novel agents targeting molecular aberrations present in subsets of NSCLC. We evaluated 88 human NSCLC tumors of diverse histology and identified Mer and Axl as receptor tyrosine kinases (RTKs) overexpressed in 69% and 93%, respectively, of tumors relative to surrounding normal lung tissue. Mer and Axl were also frequently overexpressed and activated in NSCLC cell lines. Ligand-dependent Mer or Axl activation stimulated MAPK, AKT and FAK signaling pathways indicating roles for these RTKs in multiple oncogenic processes. In addition, we identified a novel pro-survival pathway-involving AKT, CREB, Bcl-xL, survivin, and Bcl-2-downstream of Mer, which is differentially modulated by Axl signaling. We demonstrated that short hairpin RNA (shRNA) knockdown of Mer or Axl significantly reduced NSCLC colony formation and growth of subcutaneous xenografts in nude mice. Mer or Axl knockdown also improved in vitro NSCLC sensitivity to chemotherapeutic agents by promoting apoptosis. When comparing the effects of Mer and Axl knockdown, Mer inhibition exhibited more complete blockade of tumor growth while Axl knockdown more robustly improved chemosensitivity. These results indicate that Mer and Axl have complementary and overlapping roles in NSCLC and suggest that treatment strategies targeting both RTKs may be more effective than singly-targeted agents. Our findings validate Mer and Axl as potential therapeutic targets in NSCLC and provide justification for development of novel therapeutic compounds that selectively inhibit Mer and/or Axl.	[Linger, R. M. A.; Cohen, R. A.; Cummings, C. T.; Sather, S.; Migdall-Wilson, J.; DeRyckere, D.; Graham, D. K.] Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Aurora, CO 80045 USA; [Middleton, D. H. G.] Univ Colorado, Program Canc Biol, Aurora, CO 80045 USA; [Lu, X.; Baron, A. E.] Univ Colorado, Dept Biostat & Informat, Aurora, CO 80045 USA; [Franklin, W. A.; Merrick, D. T.; Jedlicka, P.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Merrick, D. T.] Denver VA Med Ctr, Dept Pathol, Denver, CO USA; [Heasley, L. E.] Denver VA Med Ctr, Dept Craniofacial Biol, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Graham, DK (corresponding author), Univ Colorado, Dept Pediat, Sect Hematol Oncol & Bone Marrow Transplantat, Anschutz Med Campus,Mail Stop 8302,12800 East 19t, Aurora, CO 80045 USA.	doug.graham@ucdenver.edu		Maller, Justine/0000-0001-6930-7375; Cummings, Christopher/0000-0002-2978-2494	Uniting Against Lung Cancer: Elliot's Legacy (RMAL); Lung Cancer Research Foundation (RMAL); American Cancer Society [RSG-08-291-01-LIB]; National Institutes of Health [RO1CA137078]; University of Colorado Cancer Center SPORE in Lung Cancer [NIH 5P50CA058187]; Damon Runyon Cancer Research Foundation [CI-39-07]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187, R01CA127105, R01CA137078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER	Uniting Against Lung Cancer: Elliot's Legacy (RMAL); Lung Cancer Research Foundation (RMAL); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Colorado Cancer Center SPORE in Lung Cancer; Damon Runyon Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by grants from Uniting Against Lung Cancer: Elliot's Legacy (RMAL), the Lung Cancer Research Foundation (RMAL), the American Cancer Society (RSG-08-291-01-LIB, DKG) and the National Institutes of Health (RO1CA137078, DKG). RMA Linger received a Career Development Award from the University of Colorado Cancer Center SPORE in Lung Cancer (NIH 5P50CA058187). DK Graham is the Damon Runyon-Novartis Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-39-07). The authors wish to thank Karen Helm, Christine Childs and Lester Acosta in the University of Colorado Cancer Center Flow Cytometry Core for their expert technical assistance, Randall Wong in the University of Colorado Denver Diabetes and Endocrinology Research Center Molecular Biology Core Facility (NIH P30 DK57516) for cell line authentication services, Patricia Lenhart for help optimizing Mer and Axl immunohistochemistry of human tissues, and Storey Wilson and Andrea Abeyta for technical assistance with the Aperio imaging system used to digitize stained tumor microarray slides.	Aggarwal S, 2008, CANCER RES, V68, P981, DOI 10.1158/0008-5472.CAN-06-0249; Alciato F, 2010, J LEUKOCYTE BIOL, V87, P869, DOI 10.1189/jlb.0909610; Allen MP, 2002, MOL CELL BIOL, V22, P599, DOI 10.1128/MCB.22.2.599-613.2002; Allen MP, 2002, J BIOL CHEM, V277, P38133, DOI 10.1074/jbc.M200826200; [Anonymous], 2011, SEER CANC STAT REV 1; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Balogh I, 2005, ARTERIOSCL THROM VAS, V25, P1280, DOI 10.1161/01.ATV.0000163845.07146.48; Brandao Luis, 2011, Critical Reviews in Oncogenesis, V16, P47; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Brose MS, 2002, CANCER RES, V62, P6997; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Ekman C, 2011, RHEUMATOLOGY, V50, P1064, DOI 10.1093/rheumatology/keq459; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Grosso S, 2009, MOL CANCER THER, V8, P1924, DOI 10.1158/1535-7163.MCT-09-0168; Gustafsson A, 2009, CLIN CANCER RES, V15, P4742, DOI 10.1158/1078-0432.CCR-08-2514; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Han ZY, 1996, CANCER RES, V56, P1621; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Janku F, 2011, J THORAC ONCOL, V6, P1601, DOI 10.1097/JTO.0b013e31822944b3; Jansen FH, 2012, J PROTEOME RES, V11, P728, DOI 10.1021/pr2006473; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Linger RM, 2010, EXPERT OPIN THER TAR, V14, P1073, DOI 10.1517/14728222.2010.515980; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Macleod K, 2005, CANCER RES, V65, P6789, DOI 10.1158/0008-5472.CAN-04-2684; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Mudduluru G, 2011, BIOL CELL, V103, P21, DOI 10.1042/BC20100094; Nielsen-Preiss SM, 2007, ENDOCRINOLOGY, V148, P2806, DOI 10.1210/en.2007-0039; Oliver L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019820; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Pratilas CA, 2008, CANCER RES, V68, P9375, DOI 10.1158/0008-5472.CAN-08-2223; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Reeve JG, 1996, BRIT J CANCER, V73, P1193, DOI 10.1038/bjc.1996.230; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Shankar SL, 2006, J NEUROSCI, V26, P5638, DOI 10.1523/JNEUROSCI.5063-05.2006; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shinoura N, 1999, CANCER RES, V59, P4119; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Society AC, 2012, CANC FACTS FIG 2012; Sunaga N, 2011, MOL CANCER THER, V10, P336, DOI 10.1158/1535-7163.MCT-10-0750; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; Wallin JJ, 2011, MOL CANCER THER, V10, P2426, DOI 10.1158/1535-7163.MCT-11-0446; Wimmel A, 2001, EUR J CANCER, V37, P2264, DOI 10.1016/S0959-8049(01)00271-4; Wu J, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3316; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632; Yamamoto H, 2008, CANCER RES, V68, P6913, DOI 10.1158/0008-5472.CAN-07-5084; Ye X, 2010, ONCOGENE, V29, P5254, DOI 10.1038/onc.2010.268; Zhang LQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034100; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	65	135	154	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2013	32	29					3420	3431		10.1038/onc.2012.355	http://dx.doi.org/10.1038/onc.2012.355			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	22890323	Green Accepted			2022-12-17	WOS:000322014900003
J	Cheli, Y; Giuliano, S; Fenouille, N; Allegra, M; Hofman, V; Hofman, P; Bahadoran, P; Lacour, JP; Tartare-Deckert, S; Bertolotto, C; Ballotti, R				Cheli, Y.; Giuliano, S.; Fenouille, N.; Allegra, M.; Hofman, V.; Hofman, P.; Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.			Hypoxia and MITF control metastatic behaviour in mouse and human melanoma cells	ONCOGENE			English	Article						metastasis; MITF; mesenchymal transition; hypoxia; Bhlhb2; differentiation	EPITHELIAL-MESENCHYMAL TRANSITION; LESS-THAN-OR-EQUAL-TO-1 MM; CYCLE PROGRESSION; GENE-EXPRESSION; STEM-CELLS; IN-VITRO; DIFFERENTIATION; GROWTH; SPARC; DEC1	Melanomas are very aggressive neoplasms with notorious resistance to therapeutics. It was recently proposed that the remarkable phenotypic plasticity of melanoma cells allows for the rapid development of both resistance to chemotherapeutic drugs and invasive properties. Indeed, the capacity of melanoma cells to form distant metastases is the main cause of mortality in melanoma patients. Therefore, the identification of the mechanism controlling melanoma phenotype is of paramount importance. In the present report, we show that deletion of microphthalmia-associated transcription factor (MITF), the master gene in melanocyte differentiation, is sufficient to increase the metastatic potential of mouse and human melanoma cells. MITF silencing also increases fibronectin and Snail, two mesenchymal markers that might explain the increased invasiveness in vitro and in vivo. Furthermore, ablation of this population by Forskolin-induced differentiation or MITF-forced expression significantly decreases tumour and metastasis formation, suggesting that eradication of low-MITF cells might improve melanoma treatment. Moreover, we demonstrate that a hypoxic microenvironment decreases MITF expression through an indirect, hypoxia-inducible factor 1 (HIF1)alpha-dependant transcriptional mechanism, and increases the tumourigenic and metastatic properties of melanoma cells. We identified Bhlhb2, a new factor in melanoma biology, as the mediator of hypoxia/HIF1 alpha inhibitory effect on MITF expression. Our results reveal a hypoxia-HIF1 alpha-BHLHB2-MITF cascade controlling the phenotypic plasticity in melanoma cells and favouring metastasis development. Targeting this pathway might be helpful in the design of new anti-melanoma therapies. Oncogene (2012) 31, 2461-2470; doi:10.1038/onc.2011.425; published online 26 September 2011	[Ballotti, R.] INSERM, Equipe Labellisee Ligue Contre Canc, Ctr Mediterraneen Med Mol, Team 1,Equipe 1,U895, F-06204 Nice 3, France; [Cheli, Y.; Giuliano, S.; Fenouille, N.; Allegra, M.; Hofman, P.; Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.] Univ Nice Sophia Antipolis, UFR Med, Nice, France; [Hofman, V.; Hofman, P.] ERI21 EA 4319, Nice, France; [Hofman, V.; Hofman, P.] Human Biobank, Nice, France; [Bahadoran, P.; Lacour, J-P; Tartare-Deckert, S.; Bertolotto, C.; Ballotti, R.] CHU NICE, Dept Dermatol, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Ballotti, R (corresponding author), INSERM, Equipe Labellisee Ligue Contre Canc, Ctr Mediterraneen Med Mol, Team 1,Equipe 1,U895, 151 Route St Antoine de Ginestiere, F-06204 Nice 3, France.	ballotti@unice.fr	Hofman, Paul/P-7654-2018; Bertolotto, Corine/AAF-6634-2021; Fenouille, Nina/AAI-1027-2021; TARTARE-DECKERT, Sophie/P-6057-2015; CHELI, Yann/O-5783-2016	Hofman, Paul/0000-0003-0431-9353; Bertolotto, Corine/0000-0001-6971-7753; veronique, HOFMAN/0000-0003-0943-1627; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; CHELI, Yann/0000-0001-9839-4332; Bahadoran, Philippe/0000-0002-2481-0556; BALLOTTI, Robert/0000-0002-7322-4908	'Fondation de France'; Societe Francaise de Dermatologie; ARC	'Fondation de France'(Fondation de France); Societe Francaise de Dermatologie; ARC(Australian Research Council)	We thank Giorgetti-Peraldi Sophie, Regazzetti Claire and Karine Bille for their help. Bhlhb2 reporter plasmid and expression vector were a kind gift from Dr S Egan (Toronto, Canada). This work was supported by the 'Fondation de France', and Societe Francaise de Dermatologie. YC has been supported by ARC's fellowships. The authors greatly acknowledge the C3M Imaging core facility (microscopy and imaging platform Cote d'Azur, MICA) and the C3M animal room facility.	AGARWAL KC, 1983, INT J CANCER, V32, P801, DOI 10.1002/ijc.2910320622; Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481; Bedogni B, 2005, CANCER CELL, V8, P443, DOI 10.1016/j.ccr.2005.11.005; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bhawal UK, 2011, J PATHOL, V224, P420, DOI 10.1002/path.2878; Botton T, 2009, J INVEST DERMATOL, V129, P1208, DOI 10.1038/jid.2008.346; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755-148X.2009.00653.x; Cho Y, 2009, MOL PHARMACOL, V76, P1360, DOI 10.1124/mol.109.057000; Choi SM, 2008, NUCLEIC ACIDS RES, V36, P6372, DOI 10.1093/nar/gkn620; Corsetti RL, 2000, ANN SURG ONCOL, V7, P456, DOI 10.1007/s10434-000-0456-4; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Eichhoff OM, 2010, MELANOMA RES, V20, P349, DOI 10.1097/CMR.0b013e32833bd89e; Fenouille N, 2011, PIGM CELL MELANOMA R, V24, P219, DOI 10.1111/j.1755-148X.2010.00790.x; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; King R, 2001, AM J SURG PATHOL, V25, P51, DOI 10.1097/00000478-200101000-00005; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Nakashima A, 2008, MOL CELL BIOL, V28, P4080, DOI 10.1128/MCB.02168-07; Olbryt M, 2006, GENE EXPRESSION, V13, P191, DOI 10.3727/000000006783991818; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Robert G, 2006, CANCER RES, V66, P7516, DOI 10.1158/0008-5472.CAN-05-3189; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sanchez-Martin M, 2002, HUM MOL GENET, V11, P3231, DOI 10.1093/hmg/11.25.3231; SHAW HM, 1987, ARCH SURG-CHICAGO, V122, P1147; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059	40	135	141	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2012	31	19					2461	2470		10.1038/onc.2011.425	http://dx.doi.org/10.1038/onc.2011.425			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996743				2022-12-17	WOS:000303985300008
J	Brisson, L; Gillet, L; Calaghan, S; Besson, P; Le Guennec, JY; Roger, S; Gore, J				Brisson, L.; Gillet, L.; Calaghan, S.; Besson, P.; Le Guennec, J-Y; Roger, S.; Gore, J.			Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H+ efflux in caveolae	ONCOGENE			English	Article						cancer; caveolae; invasion; Na (broken vertical bar)/H (broken vertical bar) exchanger; voltage-gated sodium channels	GATED SODIUM-CHANNELS; CATHEPSIN-B; EXPRESSION; EXCHANGER	Na(V)1.5 sodium channels enhance the invasiveness of breast cancer cells through the acidic-dependent activation of cysteine cathepsins. Here, we showed that the Na+/H+ exchanger type 1 (NHE1) was an important regulator of H+ efflux in breast cancer cells MDA-MB-231 and that its activity was increased by Na(V)1.5. Na(V)1.5 and NHE1 were colocalized in membrane rafts containing caveolin-1. The inhibition of Na(V)1.5 or NHE1 induced a similar reduction in cell invasiveness and extracellular matrix degradation; no additive effect was observed when they were simultaneously inhibited. Our study suggests that NaV1.5 and NHE1 are functionally coupled and enhance the invasiveness of cancer cells by increasing H+ efflux. Oncogene (2011) 30, 2070-2076; doi:10.1038/onc.2010.574; published online 20 December 2010	[Brisson, L.; Gillet, L.; Besson, P.; Roger, S.; Gore, J.] Univ Tours, Fac Med, INSERM, U921, F-37032 Tours, Region Center, France; [Calaghan, S.] Univ Leeds, Inst Syst & Membrane Biol, Leeds, W Yorkshire, England; [Le Guennec, J-Y] Univ Montpellier 2, INSERM, Physiopathol cardiovasc U637, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; University of Leeds; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Roger, S (corresponding author), Univ Tours, Fac Med, INSERM, U921, 10 Blvd Tonnelle, F-37032 Tours, Region Center, France.	sebastien.roger@univ-tours.fr	Brisson, Lucie/R-1179-2016; LE GUENNEC, Jean-Yves/P-1067-2016	Brisson, Lucie/0000-0001-7811-1382; Roger, Sebastien/0000-0002-9852-5248; Gillet, Ludovic/0000-0002-4990-6212; Calaghan, Sarah/0000-0002-9145-2576	Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (Inserm); Association CANCEN; Ligue Nationale Contre le Cancer; Region Centre	Ministere de la Recherche et des Technologies; 'Institut National de la Sante et de la Recherche Medicale' (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association CANCEN; Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Region Centre(Region Centre-Val de Loire)	We thank Dr Lin-Hua Jiang (University of Leeds, UK) for comments about the manuscript. We are grateful to Dr Ming Lei (University of Manchester, UK) for the generous gift of the anti-Na<INF>V</INF>1.5 antibody. This work was supported by the 'Ministere de la Recherche et des Technologies' and the 'Institut National de la Sante et de la Recherche Medicale' (Inserm), the 'Association CANCEN' and a grant from the 'Ligue Nationale Contre le Cancer'. Lucie Brisson and Ludovic Gillet were recipients of fellowships from the 'Region Centre'.	Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Busco G, 2010, FASEB J, V24, P3903, DOI 10.1096/fj.09-149518; Calaghan S, 2008, J MOL CELL CARDIOL, V45, P88, DOI 10.1016/j.yjmcc.2008.04.004; Cardone RA, 2005, NAT REV CANCER, V5, P786, DOI 10.1038/nrc1713; Diaz D, 2007, J CELL PHYSIOL, V210, P469, DOI 10.1002/jcp.20871; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fraser SP, 2005, CLIN CANCER RES, V11, P5381, DOI 10.1158/1078-0432.CCR-05-0327; Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922; Gillet L, 2009, J BIOL CHEM, V284, P8671, DOI 10.1074/jbc.M806891200; Giusti I, 2008, NEOPLASIA, V10, P481, DOI 10.1593/neo.08178; GORE J, 1994, AM J PHYSIOL, V266, pC110, DOI 10.1152/ajpcell.1994.266.1.C110; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Kraus M, 1996, TUMOR BIOL, V17, P133, DOI 10.1159/000217977; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laniado ME, 1997, AM J PATHOL, V150, P1213; MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214; Moellering RE, 2008, CLIN EXP METASTAS, V25, P411, DOI 10.1007/s10585-008-9145-7; Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Roger S, 2003, BBA-BIOMEMBRANES, V1616, P107, DOI 10.1016/j.bbamem.2003.07.001; Roger S, 2007, INT J BIOCHEM CELL B, V39, P774, DOI 10.1016/j.biocel.2006.12.007; Roger S, 2006, CURR PHARM DESIGN, V12, P3681, DOI 10.2174/138161206778522047; ROZHIN J, 1994, CANCER RES, V54, P6517; Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8; Tekpli X, 2008, J CELL PHYSIOL, V216, P207, DOI 10.1002/jcp.21395; Xu SZ, 2005, NAT BIOTECHNOL, V23, P1289, DOI 10.1038/nbt1148; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305	27	135	144	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2070	2076		10.1038/onc.2010.574	http://dx.doi.org/10.1038/onc.2010.574			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21170089	Green Submitted			2022-12-17	WOS:000289977400010
J	Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G				Yoon, YS; Lee, JH; Hwang, SC; Choi, KS; Yoon, G			TGF beta 1 induces prolonged mitochondrial ROS generation through decreased complex IV activity with senescent arrest in Mv1Lu cells	ONCOGENE			English	Article						mitochondrial dysfunction; TGF beta 1; senescence; reactive oxygen species; complex IV defect	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MESENCHYMAL TRANSDIFFERENTIATION; OXIDATIVE STRESS; DOWN-REGULATION; CANCER; ACTIVATION; APOPTOSIS; TRIGGERS; ACCUMULATION	Transforming growth factor beta 1 (TGF beta 1) is a well-characterized cytokine that suppresses epithelial cell growth. We report here that TGF beta 1 arrested lung epithelial Mv1Lu cells at G1 phase of the cell cycle with acquisition of senescent phenotypes in the presence of 10% serum, whereas it gradually induced apoptosis with lower concentrations of serum. The senescent arrest was accompanied by prolonged generation of reactive oxygen species (ROS) and persistent disruption of mitochondrial membrane potential (Delta psi m). We demonstrated that the sustained ROS overproduction was derived from mitochondrial respiratory defect via decreased complex IV activity and was involved in the arrest. Moreover, we verified that hepatocyte growth factor released Mv1Lu cells from the arrest by protecting mitochondrial respiration, thereby preventing both the Delta psi m disruption and the ROS generation. Our present results suggest the TGF beta 1-induced senescent arrest as another plausible mechanism to suppress cellular growth in vivo and provide a new biochemical association between the mitochondrial functional defects and the cytokine-induced senescent arrest, emphasizing the importance of maintenance of mitochondrial function in cellular protection from the arrest.	Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 443721, South Korea; Ajou Univ, Sch Med, Dept Pulm & Crit Care Med, Suwon 443721, South Korea; Ajou Univ, Sch Med, Inst Med Sci, Suwon 443721, South Korea	Ajou University; Ajou University; Ajou University	Yoon, G (corresponding author), Ajou Univ, Sch Med, Dept Biochem & Mol Biol, San 5,Wonchon Dong, Suwon 443721, South Korea.	ypeace@ajou.ac.kr		Choi, Kyeong Sook/0000-0003-2331-0856; Hwang, Sung Chul/0000-0003-2401-619X				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; BOVERIS A, 1999, OXIDAT STRESS DIS, V2, P1; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chang BD, 1999, CANCER RES, V59, P3761; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COOPER JA, 1983, NATURE, V302, P218, DOI 10.1038/302218a0; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ellenrieder V, 2001, CANCER RES, V61, P4222; Esposti MD, 2001, METHOD CELL BIOL, V65, P75; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Frippiat C, 2001, J BIOL CHEM, V276, P2531, DOI 10.1074/jbc.M006809200; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mathon NE, 2001, NAT REV CANCER, V1, P203, DOI 10.1038/35106045; Parekh TV, 1998, CELL GROWTH DIFFER, V9, P423; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SASTRE J, 1999, OXIDAT STRESS DIS, V2, P181; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Suh Y, 2002, NAT MED, V8, P3, DOI 10.1038/nm0102-3; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Taipale J, 1996, J BIOL CHEM, V271, P4342; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; Untergasser G, 2003, EXP GERONTOL, V38, P1179, DOI 10.1016/j.exger.2003.08.008; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; Yoon G, 2002, BIOCHEM J, V366, P613, DOI 10.1042/BJ20011445; Yoon YS, 2003, J BIOL CHEM, V278, P51577, DOI 10.1074/jbc.M308489200; Zhao H, 2002, BIOCHEM BIOPH RES CO, V294, P464, DOI 10.1016/S0006-291X(02)00484-9	48	135	138	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2005	24	11					1895	1903		10.1038/sj.onc.1208262	http://dx.doi.org/10.1038/sj.onc.1208262			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	905BH	15688038				2022-12-17	WOS:000227542000008
J	Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH				Afonja, O; Juste, D; Das, S; Matsuhashi, S; Samuels, HH			Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis	ONCOGENE			English	Article						PDCD4; apoptosis; retinoic acid receptor; breast cancer; cell cycle	RETINOIC ACID RECEPTORS; MAMMARY EPITHELIAL-CELLS; TRANSFORMATION SUPPRESSOR; GROWTH-INHIBITION; CYCLIN D1; PROTEIN; ARREST; ALPHA; CARCINOMA; DEATH	The growth of human breast tumor cells is regulated through signaling involving cell surface growth factor receptors and nuclear receptors of the steroid/thyroid/retinoid receptor gene family. Retinoic acid receptors (RARs), members of the steroid/thyroid hormone receptor gene family, are ligand-dependent transcription factors, which have in vitro and in vivo growth inhibitory activity against breast cancer cells. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. Additionally, RAR-agonists and synthetic retinoids such as Ferentinide have been shown to induce apoptosis in malignant breast cells but not normal breast cells. To better de. ne the genes involved in RAR-mediated growth inhibition of breast cancer cells, we used oligonucleotide microarray analysis to create a database of genes that are potentially regulated by RAR-agonists in breast cancer cells. We found that PDCD4 (programmed cell death 4), a tumor suppressor gene presently being evaluated as a target for chemoprevention, was induced about three-fold by the RARalpha-selective agonist Am580, in T-47D breast cancer cells. RAR pan-agonists and Am580, but not retinoid X receptors (RXR)-agonists, stimulate the expression of PDCD4 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not induce PDCD4 expression in breast cancer cell lines, which were not growth inhibited by retinoids. We also observed that antiestrogen and the HER-2/neu antagonist, Herceptin (Trastuzumab), also induced PDCD4 expression in T-47D cells, suggesting that PDCD4 may play a central role in growth inhibition in breast cancer cells. Transient overexpression of PDCD4 in T-47D (ER+, RAR(+)) and MDA-MB-231 (ER-, RAR(-)) cells resulted in apoptotic death, suggesting a role for PDCD4 in mediating apoptosis in breast cancer cells. PDCD4 protein expression has previously been reported in small ductal epithelium of normal breast. To date, there has been no report of induction of PDCD4 expression by RAR-agonists, antiestrogen or HER2/neu antagonist in breast cancer cells and its potential role in apoptosis in these cells.	NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Saga Med Sch, Dept Internal Med, Saga 8498501, Japan	New York University; New York University; Saga University	Afonja, O (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave, New York, NY 10016 USA.	afonjo01@popmail.med.nyu.edu			NCI NIH HHS [K12CA01713] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K12CA001713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R01DK016636, R37DK016636] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AMOS B, 1990, METHOD ENZYMOL, V190, P217; Azzoni L, 1998, J IMMUNOL, V161, P3493; Bange J, 2001, NAT MED, V7, P548, DOI 10.1038/87872; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dietze EC, 2002, MICROSC RES TECHNIQ, V59, P23, DOI 10.1002/jemt.10174; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; Fitzgerald P, 1997, CANCER RES, V57, P2642; Gianni M, 1996, BLOOD, V87, P1520, DOI 10.1182/blood.V87.4.1520.bloodjournal8741520; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grunt TW, 2003, CANCER LETT, V189, P147, DOI 10.1016/S0304-3835(02)00512-8; Gumireddy K, 2003, CLIN CANCER RES, V9, P4052; Han QX, 1997, DIAGN MOL PATHOL, V6, P42, DOI 10.1097/00019606-199702000-00007; Jansen Aaron P., 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P938; Jansen AP, 2004, MOL CANCER THER, V3, P103; Jurisicova A, 1998, MOL REPROD DEV, V51, P243, DOI 10.1002/(SICI)1098-2795(199811)51:3&lt;243::AID-MRD3&gt;3.0.CO;2-P; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Lombet A, 2001, EUR J BIOCHEM, V268, P1352, DOI 10.1046/j.1432-1327.2001.02002.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1994, NUTR REV, V52, P32; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; MATSUHASHI S, 1987, EXP CELL RES, V170, P351, DOI 10.1016/0014-4827(87)90312-0; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Niu MY, 2001, ONCOGENE, V20, P3506, DOI 10.1038/sj.onc.1204453; Offterdinger M, 2003, J CELL PHYSIOL, V195, P260, DOI 10.1002/jcp.10237; Onishi Y, 1998, GENE, V215, P453, DOI 10.1016/S0378-1119(98)00313-8; Orlandi M, 2003, MED PRIN PRACT, V12, P164, DOI 10.1159/000070753; Pratt MAC, 2003, J CELL BIOCHEM, V90, P692, DOI 10.1002/jcb.10682; Raffo P, 2000, ANTICANCER RES, V20, P1535; ROMAN SD, 1993, CANCER RES, V53, P5940; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1999, CELL GROWTH DIFFER, V10, P49; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Soejima H, 1999, CYTOGENET CELL GENET, V87, P113, DOI 10.1159/000015408; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Suzuki T, 2001, BREAST CANCER RES TR, V65, P31, DOI 10.1023/A:1006433929792; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Toma S, 1997, INT J CANCER, V70, P619, DOI 10.1002/(SICI)1097-0215(19970304)70:5<619::AID-IJC21>3.0.CO;2-6; Veselska R, 2003, ONCOL REP, V10, P1049; Wilcken NRC, 1997, CLIN CANCER RES, V3, P849; Wilcken NRC, 1997, INT J CANCER, V70, P291, DOI 10.1002/(SICI)1097-0215(19970127)70:3<291::AID-IJC8>3.3.CO;2-B; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Ye XF, 2004, INT J BIOCHEM CELL B, V36, P98, DOI 10.1016/S1357-2725(03)00143-2; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; Yoshinaga Hidetoshi, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P121; Zhang ZH, 2001, ONCOGENE, V20, P4450, DOI 10.1038/sj.onc.1204588	58	135	145	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 21	2004	23	49					8135	8145		10.1038/sj.onc.1207983	http://dx.doi.org/10.1038/sj.onc.1207983			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865HE	15361828				2022-12-17	WOS:000224692500011
J	Califice, S; Castronovo, V; Bracke, M; van den Brule, F				Califice, S; Castronovo, V; Bracke, M; van den Brule, F			Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3	ONCOGENE			English	Article						galectin-3; prostate cancer; nucleus; cytoplasm	HUMAN BREAST-CARCINOMA; IGE-BINDING-PROTEIN; CELL-CYCLE ARREST; INDUCED APOPTOSIS; OVEREXPRESSION PROTECTS; SURFACE EXPRESSION; EPITHELIAL-CELLS; 3T3 FIBROBLASTS; NITRIC-OXIDE; LINE LNCAP	Galectin-3, a multifunctional lectin, is involved during cancer progression. Previous observations showed that both cytosolic expression and nuclear exclusion of galectin-3 in human prostate cancer cells were associated to progression of the disease. In this study, we examined the biological roles of galectin-3 when expressed either in the nucleus or in the cytosol. LNCaP, a galectin-3-negative human prostate cancer cell line, was used to generate transfectants expressing galectin-3 either in the nucleus or in the cytosol. No changes in cell morphology, proliferation, attachment to laminin-1 or androgen dependency were observed. Cytoplasmic galectin-3 induced significantly increased Matrigel invasion, anchorage-independent growth and in vivo tumor growth and angiogenesis, and decreased inducible apoptosis. Surprisingly, nuclear galectin-3 affected these parameters in an opposite fashion with an overall antitumoral activity. Thus, our study demonstrates that galectin-3 exerts opposite biological activities according to its cellular localization: nuclear galectin-3 plays antitumor functions and cytoplasmic galectin-3 promotes tumor progression.	Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium; State Univ Ghent Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Univ Liege, Dept Gynecol, Liege, Belgium	University of Liege; Ghent University; Ghent University Hospital; University of Liege	van den Brule, F (corresponding author), Univ Liege, Expt Canc Res Ctr, Metastasis Res Lab, B-4000 Liege 1, Belgium.	f.vandenbrule@ulg.ac.be						Abdulkadir SA, 2002, MOL CELL BIOL, V22, P1495, DOI 10.1128/MCB.22.5.1495-1503.2002; Akahani S, 1997, CANCER RES, V57, P5272; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bieberich CJ, 1996, J BIOL CHEM, V271, P31779, DOI 10.1074/jbc.271.50.31779; Bowen C, 2000, CANCER RES, V60, P6111; Bracke M E, 2001, Methods Mol Med, V58, P91, DOI 10.1385/1-59259-137-X:091; CALIFICE S, IN PRESS INT J ONCOL; COWLES EA, 1990, J BIOL CHEM, V265, P17706; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Davidson PJ, 2002, GLYCOBIOLOGY, V12, P329, DOI 10.1093/glycob/12.5.329; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gaudin JC, 2000, BIOL CELL, V92, P49, DOI 10.1016/S0248-4900(00)88763-8; Gelmann EP, 2003, PROSTATE, V55, P111, DOI 10.1002/pros.10210; GILLES C, 1993, INT J CANCER, V53, P872, DOI 10.1002/ijc.2910530527; GRITZMACHER CA, 1988, J IMMUNOL, V141, P2801; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HERRMANN J, 1993, J BIOL CHEM, V268, P26704; HO MK, 1982, J IMMUNOL, V128, P1221; Honjo Y, 2001, CLIN CANCER RES, V7, P661; Honjo Y, 2000, CLIN CANCER RES, V6, P4635; Hughes RC, 2001, BIOCHIMIE, V83, P667; Kim HRC, 1999, CANCER RES, V59, P4148; Kim MJ, 2002, CANCER RES, V62, P2999; Kleeff J, 2000, INT J CANCER, V86, P399, DOI 10.1002/(SICI)1097-0215(20000501)86:3<399::AID-IJC15>3.0.CO;2-G; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Korkmaz KS, 2000, GENE, V260, P25, DOI 10.1016/S0378-1119(00)00453-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; LeMarer N, 1996, ANTICANCER RES, V16, P2767; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Locigno R, 2002, INT J ONCOL, V20, P69; LOTZ MM, 1993, P NATL ACAD SCI USA, V90, P3466, DOI 10.1073/pnas.90.8.3466; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Muenchen HJ, 2000, CLIN CANCER RES, V6, P1969; Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0; NANGIAMAKKER P, 1995, INT J ONCOL, V7, P1079; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paron I, 2003, BIOCHEM BIOPH RES CO, V302, P545, DOI 10.1016/S0006-291X(03)00151-7; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Sanjuan X, 1997, GASTROENTEROLOGY, V113, P1906, DOI 10.1016/S0016-5085(97)70010-6; SATO S, 1994, J BIOL CHEM, V269, P4424; Song YK, 2002, AM J PATHOL, V160, P1069, DOI 10.1016/S0002-9440(10)64927-9; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Takenaka Y, 2004, MOL CELL BIOL, V24, P4395, DOI 10.1128/MCB.24.10.4395-4406.2004; Tsay YG, 1999, EXP CELL RES, V252, P250, DOI 10.1006/excr.1999.4643; van den Brule FA, 2000, INT J CANCER, V89, P361, DOI 10.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.3.CO;2-L; VANDENBRULE F, 2000, LECT PATHOLOGY; VandenBrule FA, 1997, INT J ONCOL, V11, P261; VANDENBRULE FA, 1995, BIOCHEM BIOPH RES CO, V209, P760, DOI 10.1006/bbrc.1995.1564; VandenBrule FA, 1996, HUM PATHOL, V27, P1185, DOI 10.1016/S0046-8177(96)90313-5; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; Warfield PR, 1997, INVAS METAST, V17, P101; WIERDER R, 1999, CELL GROWTH DIFFER, P1; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200; Yoshii T, 2001, INT J ONCOL, V18, P787; Yu F, 2002, J BIOL CHEM, V277, P15819, DOI 10.1074/jbc.M200154200	70	135	138	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2004	23	45					7527	7536		10.1038/sj.onc.1207997	http://dx.doi.org/10.1038/sj.onc.1207997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	858FH	15326483				2022-12-17	WOS:000224176500009
J	Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R				Amin, HM; McDonnell, TJ; Ma, YP; Lin, Q; Fujio, Y; Kunisada, K; Leventaki, V; Das, P; Rassidakis, GZ; Cutler, C; Medeiros, LJ; Lai, R			Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma	ONCOGENE			English	Article						STAT3; anaplastic large cell lymphoma; NPM-ALK; adenoviral vectors; apoptosis; cell cycle	RECEPTOR TYROSINE KINASE; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; NEGATIVE REGULATORS; EXPRESSION; GENE; PROTEINS; MEDIATE; T(2/5); LINES	Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK(+) ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK(+) ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK(+) ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705(tyrosine --> phenylalanine), a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G, cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.	Univ Texas, MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Grad Sch Med, Dept Mol Med, Osaka, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Amin, HM (corresponding author), Univ Alberta, Dept Lab Med & Pathol, Fac Med & Dent, Walter MacKenzie Hlth Sci Ctr 4B1, 8440 112 St, Edmonton, AB T6G 2B7, Canada.	raymondmail_65@yahoo.com	Fujio, Yasushi/H-3421-2017; Leventaki, Vasiliki/N-8175-2018; Rassidakis, George/V-9553-2019	Fujio, Yasushi/0000-0003-0828-2930; 				Alexander WS, 1999, J LEUKOCYTE BIOL, V66, P588, DOI 10.1002/jlb.66.4.588; Altieri DC, 2001, TRENDS MOL MED, V7, P542, DOI 10.1016/S1471-4914(01)02243-2; Aoki Y, 2003, BLOOD, V101, P1535, DOI 10.1182/blood-2002-07-2130; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2001, BLOOD, V97, P1056, DOI 10.1182/blood.V97.4.1056; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chai SK, 1997, J IMMUNOL, V159, P4720; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Delsol G, 2001, WHO CLASSIFICATION T, P230; Duyster J, 2001, ONCOGENE, V20, P5623, DOI 10.1038/sj.onc.1204594; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; EPSTEIN AL, 1979, CANCER RES, V39, P1748; Fagerlund R, 2002, J BIOL CHEM, V277, P30072, DOI 10.1074/jbc.M202943200; Falini B, 1999, BLOOD, V93, P2697; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gascoyne RD, 1999, BLOOD, V93, P3913, DOI 10.1182/blood.V93.11.3913.411k22_3913_3921; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kube D, 2001, BLOOD, V98, P762, DOI 10.1182/blood.V98.3.762; Kunisada K, 1998, CIRCULATION, V98, P346, DOI 10.1161/01.CIR.98.4.346; Mahboubi K, 2001, LAB INVEST, V81, P327, DOI 10.1038/labinvest.3780241; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Mora LB, 2002, CANCER RES, V62, P6659; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Negoro S, 2001, CIRCULATION, V104, P979, DOI 10.1161/hc3401.095947; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; SCHLETTE EJ, 2004, IN PRESS J CLIN ONCO; Slupianek A, 2001, CANCER RES, V61, P2194; STEIN H, 1985, BLOOD, V66, P848; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wood GS, 1996, BLOOD, V88, P1765, DOI 10.1182/blood.V88.5.1765.bloodjournal8851765; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	47	135	154	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2004	23	32					5426	5434		10.1038/sj.onc.1207703	http://dx.doi.org/10.1038/sj.onc.1207703			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	836XB	15184887				2022-12-17	WOS:000222588400002
J	Miyazono, K; Maeda, S; Imamura, T				Miyazono, K; Maeda, S; Imamura, T			Coordinate regulation of cell growth and differentiation by TGF-beta superfamily and Runx proteins	ONCOGENE			English	Article						TGF-beta; BMP; Smad; Runx; leukemia; gastric cancer	E3 UBIQUITIN LIGASE; BONE MORPHOGENETIC PROTEIN-2; CONSTANT-REGION GENE; CORE-BINDING FACTOR; OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; FUNCTIONAL COOPERATION; IGA PRODUCTION; SMAD; EXPRESSION	Runx proteins regulate various biological processes, including growth and differentiation of hematopoietic cells, lymphocytes, osteoblasts, and gastric epithelial cells. Some of the biological activities of Runx proteins are reminiscent of those of transforming growth factor (TGF)-beta superfamily cytokines. Consistent with this notion, receptor-regulated Smads (R-Smads), signal mediators of the TGF-beta superfamily cytokines, and Runx proteins have been shown to physically interact with each other. R-Smads activated by TGF-beta and Runx proteins cooperatively induce synthesis of IgA in B lymphocytes, and those activated by bone morphogenetic proteins and Runx2 induce osteoblastic differentiation. Moreover, the R-Smad-Runx signaling pathways are regulated by an E3 ubiquitin ligase Smurf1, as well as a signal transducer of interferons, STAT1. Since Runxl and Runx3 are involved in the development of some cancers including acute leukemia and gastric cancer, it will be of interest to examine in detail whether TGF-beta-specific R-Smads and Runx proteins coordinately regulate growth and differentiation of hematopoietic cells and gastric epithelial cells.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp						Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Fukuchi M, 2002, CANCER RES, V62, P7162; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang G, 2001, EMBO J, V20, P723, DOI 10.1093/emboj/20.4.723; Inoue K, 2002, NAT NEUROSCI, V5, P946, DOI 10.1038/nn925; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2003, CURR OPIN GENET DEV, V13, P43, DOI 10.1016/S0959-437X(03)00007-8; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kim S, 2003, GENE DEV, V17, P1979, DOI 10.1101/gad.1119303; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097-4644(19990401)73:1<114::AID-JCB13>3.3.CO;2-D; Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; LIN YCA, 1992, J IMMUNOL, V149, P2914; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Murakami G, 2003, MOL BIOL CELL, V14, P2809, DOI 10.1091/mbc.E02-07-0441; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NILSSON L, 1993, INT IMMUNOL, V5, P271; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pardali E, 2000, J BIOL CHEM, V275, P3552, DOI 10.1074/jbc.275.5.3552; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Shi MJ, 1998, J IMMUNOL, V161, P6751; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a; Taniuchi I, 2002, CELL, V111, P621, DOI 10.1016/S0092-8674(02)01111-X; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Woolf E, 2003, P NATL ACAD SCI USA, V100, P7731, DOI 10.1073/pnas.1232420100; Xie XQ, 1999, EUR J IMMUNOL, V29, P488, DOI 10.1002/(SICI)1521-4141(199902)29:02<488::AID-IMMU488>3.0.CO;2-N; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang Y, 2000, J BIOL CHEM, V275, P16979, DOI 10.1074/jbc.M001526200; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	56	135	153	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 24	2004	23	24					4232	4237		10.1038/sj.onc.1207131	http://dx.doi.org/10.1038/sj.onc.1207131			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156178				2022-12-17	WOS:000221586000007
J	Feber, A; Clark, J; Goodwin, G; Dodson, AR; Smith, PH; Fletcher, A; Edwards, S; Flohr, P; Falconer, A; Roe, T; Kovacs, G; Dennis, N; Fisher, C; Wooster, R; Huddart, R; Foster, CS; Cooper, CS				Feber, A; Clark, J; Goodwin, G; Dodson, AR; Smith, PH; Fletcher, A; Edwards, S; Flohr, P; Falconer, A; Roe, T; Kovacs, G; Dennis, N; Fisher, C; Wooster, R; Huddart, R; Foster, CS; Cooper, CS			Amplification and overexpression of E2F3 in human bladder cancer	ONCOGENE			English	Article						E2F3 gene; bladder cancer; 6p22 amplicon	COMPARATIVE GENOMIC HYBRIDIZATION; CHROMOSOMAL IMBALANCES; GENETIC ALTERATIONS; CELL-CYCLE; CARCINOMA; EXPRESSION; PROGRESSION; FUSION; TUMORS; PRCC	We demonstrate that, in human bladder cancer, amplification of the E2F3 gene, located at 6p22, is associated with overexpression of its encoded mRNA transcripts and high levels of expression of E2F3 protein. Immunohistochemical analyses of E2F3 protein levels have established that around one-third (33/101) of primary transitional cell carcinomas of the bladder overexpress nuclear E2F3 protein, with the proportion of tumours containing over-expressed nuclear E2F3 increasing with tumour stage and grade. When considered together with the established role of E2F3 in cell cycle progression, these results suggest that the E2F3 gene represents a candidate bladder cancer oncogene that is activated by DNA amplification and overexpression.	Inst Canc Res, Sect Mol Carcinogenesis & Male Urol Canc Res, Sutton SM2 5NG, Surrey, England; Univ Liverpool, Dept Pathol & Mol Genet, Liverpool L69 3GA, Merseyside, England; Royal Marsden NHS Trust, Sutton SM2 5PT, Surrey, England; Heidelberg Univ, Heidelberg Klinikum, D-69120 Heidelberg, Germany; Royal Marsden NHS Trust, London SW3 6JJ, England; Sanger Ctr, Cambridge CB10 1SA, England	University of London; Institute of Cancer Research - UK; University of Liverpool; Royal Marsden NHS Foundation Trust; Ruprecht Karls University Heidelberg; Royal Marsden NHS Foundation Trust; Wellcome Trust Sanger Institute	Cooper, CS (corresponding author), Inst Canc Res, Sect Mol Carcinogenesis & Male Urol Canc Res, Sutton SM2 5NG, Surrey, England.	colin.cooper@icr.ac.uk		Feber, Andrew/0000-0001-5282-0498; huddart, robert/0000-0003-3604-1990				Bruch J, 2000, CANCER RES, V60, P4526; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Cornford PA, 2000, CANCER RES, V60, P7099; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Hovey RM, 1998, CANCER RES, V58, P3555; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Humbert PO, 2000, GENE DEV, V14, P690; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Markl IDC, 1998, CANCER RES, V58, P5348; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Richter J, 1999, CANCER RES, V59, P5687; RIEGER KM, 1995, BRIT J CANCER, V72, P683, DOI 10.1038/bjc.1995.394; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Simon R, 2000, INT J ONCOL, V17, P1025; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Stein JP, 1998, J NATL CANCER I, V90, P1072, DOI 10.1093/jnci/90.14.1072; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Tomovska S, 2001, INT J ONCOL, V18, P1239; Veltman JA, 2003, CANCER RES, V63, P2872; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	29	135	145	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1627	1630		10.1038/sj.onc.1207274	http://dx.doi.org/10.1038/sj.onc.1207274			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716298				2022-12-17	WOS:000189219500017
J	Liu, X; Yan, S; Zhou, TH; Terada, Y; Erikson, RL				Liu, X; Yan, S; Zhou, TH; Terada, Y; Erikson, RL			The MAP kinase pathway is required for entry into mitosis and cell survival	ONCOGENE			English	Article						MAP kinase pathway; Cdc2; Plk1; RNAi	POLO-LIKE KINASE; XENOPUS EGG EXTRACTS; SPINDLE ASSEMBLY CHECKPOINT; ACTIVATED PROTEIN-KINASES; H3 PHOSPHORYLATION; G(2)/M TRANSITION; MAMMALIAN-CELLS; IN-VITRO; CYCLE; PLX1	In this communication, we examined the role of the MAP kinase pathway in the G2/M phase of the cell cycle. Activation of the Plk1 and MAP kinase pathways was initially evaluated in FT210 cells, which arrest at G2 phase at the restrictive temperature (39degreesC), due to a mutation in the cdc2 gene. Previous studies had shown that these cells enter mitosis at the nonpermissive temperature upon incubation with okadaic acid, a protein phosphatase 1 and 2A inhibitor. We show that treatment of FT210 cells at 39degreesC with okadaic acid activated Plk1, as shown by hyperphosphorylation and elevated protein kinase activity, and also induced activation of the MAP kinase pathway. The specific Mek inhibitor PD98059 antagonized the okadaic acid-induced activation of both Plk1 and MAP kinases. This suggests that activation of the MAP kinase pathway may contribute to the okadaic acid-induced activation of Plk1 in FT210 cells at 39degreesC. We also found that PD98059 strongly attenuated progression of HeLa cells through mitosis, and active Mek colocalizes with Plk1 at mitotic structures. To study the potential function of the MAP kinase pathway during mitosis, RNAi was used to specifically deplete five members of this pathway (Raf1, Mek1/2, Erk1/2). Each of these five protein kinases is required for cell proliferation and survival, and depletion of any of these proteins eventually leads to apoptosis. Treatment with Mek inhibitors also inhibited cell proliferation and caused apoptosis. A dramatic increase of Plk1 activities and a moderate increase of Cdc2 activities in Raf1-depleted cells indicate that Raf1-depleted cells arrest in the late G2 or M phase. Mek1 and Erk1 depletion also caused cell cycle arrest at G2, suggesting that these enzymes are required for the G2/M transition, whereas the loss of Mek2 or Erk2 caused arrest at G1.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Liu, X (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	liu13@fas.harvard.edu	zhou, tianhua/K-4908-2013	zhou, tianhua/0000-0002-1791-2124	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059172] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59172] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrieu A, 1998, J CELL SCI, V111, P1751; Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gowdy PM, 1998, J CELL SCI, V111, P3401; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1997, TRENDS CELL BIOL, V7, P63, DOI 10.1016/S0962-8924(96)10051-9; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MILTENBERGER RJ, 1993, J BIOL CHEM, V268, P15674; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Takenaka K, 1997, J CELL BIOL, V136, P1091, DOI 10.1083/jcb.136.5.1091; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Walter SA, 2003, J BIOL CHEM, V278, P18221, DOI 10.1074/jbc.M212556200; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Wojnowski L, 1998, MECH DEVELOP, V76, P141, DOI 10.1016/S0925-4773(98)00111-7; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yarm FR, 2002, MOL CELL BIOL, V22, P6209, DOI 10.1128/MCB.22.17.6209-6221.2002; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547	48	135	141	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					763	776		10.1038/sj.onc.1207188	http://dx.doi.org/10.1038/sj.onc.1207188			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737111				2022-12-17	WOS:000188304900015
J	De Vos, J; Thykjaer, T; Tarte, K; Ensslen, M; Raynaud, P; Requirand, G; Pellet, F; Pantesco, V; Reme, T; Jourdan, M; Rossi, JF; Orntoft, T; Klein, B				De Vos, J; Thykjaer, T; Tarte, K; Ensslen, M; Raynaud, P; Requirand, G; Pellet, F; Pantesco, V; Reme, T; Jourdan, M; Rossi, JF; Orntoft, T; Klein, B			Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays	ONCOGENE			English	Article						myeloma; plasma cell; DNA microarray; c-myc; abl; cystathionine beta synthase	HUMAN MULTIPLE-MYELOMA; DOWN-SYNDROME; C-MYC; CYTOSINE-ARABINOSIDE; IN-VITRO; S-PHASE; IDENTIFICATION; LEUKEMIA; CANCER; CDNA	The DNA microarray technology enables the identification of the large number of genes involved in the complex deregulation of cell homeostasis taking place in cancer. Using Affymetrix microarrays, we have compared the gene expression profiles of highly purified malignant plasma cells from nine patients with multiple myeloma (MM) and eight myeloma cell lines to those of highly purified nonmalignant plasma cells (eight samples) obtained by in vitro differentiation of peripheral blood B cells. Two unsupervised clustering algorithms classified these 25 samples into two distinct clusters: a malignant plasma cell cluster and a normal plasma cell cluster. Two hundred and fifty genes were significantly up-regulated and 159 down-regulated in malignant plasma samples compared to normal plasma samples. For some of these genes, an overexpression or downregulation of the encoded protein was confirmed (cyclin D1, c-myc, BMI-1, cystatin c, SPARC, RB). Two genes over-expressed in myeloma cells (ABL and cystathionine beta synthase) code for enzymes that could be a therapeutic target with specific drugs. These data provide a new insight into the understanding of myeloma disease and prefigure that the development of DNA microarray could help to develop an 'a la carte' treatment in cancer disease.	CHU Montpellier, INSERM, U475, F-34000 Montpellier, France; CHU Montpellier, Serv Hematol & Oncol Med, F-34000 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34000 Montpellier, France; Mol Diagnost Lab, Dept Clin Biochem, DK-8200 Aarhus N, Denmark	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier 5, France.		De Vos, John/A-5703-2010	De Vos, John/0000-0003-1880-4130				Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Avet-Loiseau H, 2001, BLOOD, V98, P3082, DOI 10.1182/blood.V98.10.3082; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Cornford PA, 2000, CANCER RES, V60, P7099; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; De Vos J, 2001, BLOOD, V98, P771, DOI 10.1182/blood.V98.3.771; Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hilbert DM, 1996, IMMUNITY, V5, P81, DOI 10.1016/S1074-7613(00)80312-X; HIRST M, 1994, J BIOL CHEM, V269, P23830; Huang HT, 2000, CANCER RES, V60, P6868; Jego G, 1999, BLOOD, V94, P701, DOI 10.1182/blood.V94.2.701.414k16_701_712; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V91, P664; KANTARJIAN H, 1984, EUR J CANCER CLIN ON, V20, P227, DOI 10.1016/0277-5379(84)90188-3; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; KLEIN B, 1991, BLOOD, V78, P1198; LARGAESPADA DA, 1992, ONCOGENE, V7, P811; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Ng MHL, 1997, BLOOD, V89, P2500, DOI 10.1182/blood.V89.7.2500; Oritani K, 1996, J CELL BIOL, V134, P771, DOI 10.1083/jcb.134.3.771; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Pellat-Deceunynck C, 2000, EUR J IMMUNOL, V30, P803, DOI 10.1002/1521-4141(200003)30:3<803::AID-IMMU803>3.0.CO;2-P; PETTERSSON M, 1992, BLOOD, V79, P495; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; Rao PH, 1998, BLOOD, V92, P1743; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; SAMAL B, 1994, MOL CELL BIOL, V14, P1431, DOI 10.1128/MCB.14.2.1431; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tanaka K, 2001, BBA-MOL BASIS DIS, V1536, P1, DOI 10.1016/S0925-4439(01)00026-6; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; Taub JW, 2000, CANCER RES, V60, P6421; Taub JW, 1999, BLOOD, V94, P1393; Taub JW, 1996, BLOOD, V87, P3395, DOI 10.1182/blood.V87.8.3395.bloodjournal8783395; Thykjaer T, 2001, CANCER RES, V61, P2492; van Golen KL, 2000, CANCER RES, V60, P5832; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	47	135	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6848	6857		10.1038/sj.onc.1205868	http://dx.doi.org/10.1038/sj.onc.1205868			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360412				2022-12-17	WOS:000178315800016
J	Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ				Huang, SY; Bucana, CD; Van Arsdall, M; Fidler, IJ			Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells	ONCOGENE			English	Article						Stat1; angiogenesis; tumor growth; metastasis	SIGNAL-TRANSDUCTION PATHWAY; FIBROBLAST-GROWTH-FACTOR; PHASE RESPONSE FACTOR; DNA-BINDING PROTEINS; HUMAN-MELANOMA CELLS; NF-KAPPA-B; INTERFERON-ALPHA; TRANSCRIPTIONAL ACTIVATION; TARGETED DISRUPTION; GENE-EXPRESSION	Stat1 is deficient or inactive in many types of human tumors whereas some tumors have activated Stat1. Whether Stat1 affects tumor growth and metastasis is unclear. In the present study, we used Stat1 knockout tumor cells to determine (1) whether Stat1 can regulate angiogenesis, growth, and metastasis of tumor cells; and (2) whether Stat1 is required for the inhibitory effect of IFN-beta on the expression of angiogenic factor bFGF. Highly tumorigenic and metastatic RAD-105 tumor cells derived from a fibrosarcoma of a Stat1 knockout mouse were reconstituted with a Stat1 expression vector. The reconstitution of Stat1 suppressed the tumorigenicity and metastasis of RAD-105 cells in nude mice which correlated with a decreased microvessel density and decreased expression of proangiogenic molecules bFGF, MMP-2, and MMP-9 in vivo. Moreover, noncytotoxic concentrations of IFN-beta significantly inhibited the in vitro expression of bFGF in the Stat1-reconstituted cells but not in the Stat1-deficient cells, which was consistent with decreased bFGF expression of Stat1-reconstituted tumors in vivo. Therefore, Stat1 is essential for IFN-mediated inhibition of bFGF production, suggesting that tumor-intrinsic Stat1 is an important mediator for antiangiogenic signals, such as IFN. Collectively, these data demonstrate that Stat1 expressed by tumor cells is a negative regulator of tumor angiogenesis and, hence, tumor growth and metastasis.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	ifidler@mdanderson.org			NATIONAL CANCER INSTITUTE [R35CA042107, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [R35 CA 42107, CA 16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Arenberg DA, 1996, J EXP MED, V184, P981, DOI 10.1084/jem.184.3.981; BALKWILL FR, 1977, INT J CANCER, V20, P500, DOI 10.1002/ijc.2910200405; Bielenberg DR, 1999, INT J ONCOL, V14, P401; Bielenberg DR, 1998, J INVEST DERMATOL, V111, P864, DOI 10.1046/j.1523-1747.1998.00378.x; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; BROUTYBOYE D, 1980, SCIENCE, V208, P516, DOI 10.1126/science.6154315; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dinney CPN, 1998, CANCER RES, V58, P808; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; FABRA A, 1992, DIFFERENTIATION, V52, P101, DOI 10.1111/j.1432-0436.1992.tb00504.x; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; Folkman J, 1992, Semin Cancer Biol, V3, P65; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358; Huang S, 2000, CLIN CANCER RES, V6, P2573; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; LIN SL, 1986, SCIENCE, V233, P356, DOI 10.1126/science.3726533; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Min W, 1996, MOL CELL BIOL, V16, P359; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pestka S, 1997, Semin Oncol, V24, pS9; Qin HW, 1998, J IMMUNOL, V161, P6664; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SEN GC, 1992, J BIOL CHEM, V267, P5017; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Slaton JW, 1999, CLIN CANCER RES, V5, P2726; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779	58	135	140	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2002	21	16					2504	2512		10.1038/sj.onc.1205341	http://dx.doi.org/10.1038/sj.onc.1205341			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	540FG	11971185				2022-12-17	WOS:000174918400007
J	Lin, RJ; Sternsdorf, T; Tini, M; Evans, RM				Lin, RJ; Sternsdorf, T; Tini, M; Evans, RM			Transcriptional regulation in acute promyelocytic leukemia	ONCOGENE			English	Review						APL; X-RAR alpha; PML; PLZF; coreprescor; HDAC; CBP/p300; POD	PML-RAR-ALPHA; ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE COMPLEX; CREB-BINDING-PROTEIN; ACID-INDUCED DIFFERENTIATION; TRANS-RETINOIC ACID; NUCLEAR-BODIES; N-COR; MOLECULAR PATHOGENESIS; FUSION PROTEINS	It has been 10 years since the seminal discovery that a mutant form of a retinoid acid receptor (RAR alpha) is associated with acute promyelocytic leukemia (APL). This finding, coupled with the remarkable success of retinoic acid (RA), the natural ligand of RAR alpha, in the treatment of APL, has made APL a unique model system in the study of oncogenic conversion of transcription factors in hematological malignancies. Indeed, subsequent basic and clinical studies showed that chromosomal translocation involving the RAR alpha gene is the cytogenetic hallmark of APL and that these mutant forms of RARs are the oncogenes in APL that interfere with the proliferation and differentiation pathways controlled by both RAR and their fusion partners. However, it was not until recently that the role of aberrant transcriptional regulation in the pathogenesis of APL was revealed. In this review, we summarize the biochemical and biological mechanisms of transcriptional regulation by mutant RARs and their corresponding wild-type fusion partner PML and PLZF. These studies have been instrumental in our understanding of the process of leukemogenesis in general and have laid the scientific foundation for the novel concept of transcription therapy in the treatment of human cancer.	Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute	Evans, RM (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	evans@salk.edu	, MT/AAU-2370-2020; Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965; Lin, Richard/0000-0002-0834-7880				Ahn JH, 1998, MOL CELL BIOL, V18, P4899, DOI 10.1128/MCB.18.8.4899; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Boisvert FM, 2001, J CELL BIOL, V152, P1099, DOI 10.1083/jcb.152.5.1099; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; Doucas V, 2000, BIOCHEM PHARMACOL, V60, P1197, DOI 10.1016/S0006-2952(00)00413-5; DOUCAS V, 1996, BIOCHIM BIOPHYS ACTA, V1288, P25; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Ferbeyre G, 2000, GENE DEV, V14, P2015; Ferrara FF, 2001, CANCER RES, V61, P2; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Glass CK, 2000, GENE DEV, V14, P121; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guidez F, 2000, BLOOD, V96, P2557; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; He LZ, 2000, MOL CELL, V6, P1131, DOI 10.1016/S1097-2765(00)00111-8; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hodges M, 1998, AM J HUM GENET, V63, P297, DOI 10.1086/301991; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kogan SC, 1999, ONCOGENE, V18, P5261, DOI 10.1038/sj.onc.1202996; Kuwata T, 2000, BLOOD, V95, P3349, DOI 10.1182/blood.V95.11.3349; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Lawson ND, 1999, EXP HEMATOL, V27, P1355, DOI 10.1016/S0301-472X(99)00085-5; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, CURR OPIN CELL BIOL, V12, P641, DOI 10.1016/S0955-0674(00)00144-7; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1999, TRENDS GENET, V15, P179, DOI 10.1016/S0168-9525(99)01710-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TX, 2000, BLOOD, V96, P1496, DOI 10.1182/blood.V96.4.1496.h8001496_1496_1504; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Mirzoeva OK, 2001, MOL CELL BIOL, V21, P281, DOI 10.1128/MCB.21.1.281-288.2001; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Park DJ, 1999, J CLIN INVEST, V103, P1399, DOI 10.1172/JCI2887; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 2000, BLOOD, V95, P2683; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Shao WL, 2000, BLOOD, V96, P2233; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sitterlin D, 1997, ONCOGENE, V14, P1067, DOI 10.1038/sj.onc.1200916; Sternsdorf T, 1997, IMMUNOBIOLOGY, V198, P307, DOI 10.1016/S0171-2985(97)80051-4; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; STUURMAN N, 1997, CELL MOL BIOL LETT, V2, P137; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trost M, 2000, J BIOL CHEM, V275, P7373, DOI 10.1074/jbc.275.10.7373; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; Tsukamoto T, 2000, NAT CELL BIOL, V2, P871, DOI 10.1038/35046510; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vallian S, 1997, EXP CELL RES, V237, P371, DOI 10.1006/excr.1997.3801; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; VanLint C, 1996, GENE EXPRESSION, V5, P245; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Wallrath L, 1998, CURR OPIN GENET DEV, V8, P147, DOI 10.1016/S0959-437X(98)80135-4; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang JW, 2000, J BIOSCIENCES, V25, P275, DOI 10.1007/BF02703936; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 1999, NAT GENET, V23, P287, DOI 10.1038/15463	132	135	146	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7204	7215		10.1038/sj.onc.1204853	http://dx.doi.org/10.1038/sj.onc.1204853			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704848				2022-12-17	WOS:000171891900008
J	Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C				Scheel, C; Schaefer, KL; Jauch, A; Keller, M; Wai, D; Brinkschmidt, C; van Valen, F; Boecker, W; Dockhorn-Dworniczak, B; Poremba, C			Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas	ONCOGENE			English	Article						telomere maintenance; osteosarcomas; telomerase activity; alternative lengthening of telomeres; chromosomal instability	TUMOR-CELLS; P53 GENE; CELLULAR SENESCENCE; CATALYTIC SUBUNIT; IMMORTAL CELLS; BREAST-LESIONS; CANCER; EXPRESSION; MAINTENANCE; IDENTIFICATION	Telomere maintenance is regarded as a key mechanism in overcoming cellular senescence in tumor cells and in most cases is achieved by the activation of telomerase, However there is at least one alternative mechanism of telomere lengthening (ALT) which is characterized by heterogeneous and elongated telomeres in the absence of telomerase activity (TA). We evaluated the prevalence of TA, gene expression of telomerase subunits and ALT in relation to telomere morphology and function in matrix producing bone tumors and in osteosarcoma cell lines and present evidence of a direct association of ALT with telomere dysfunction and chromosomal instability. Telomere fluorescence in situ hybridization (T-FISH) in ALT cells revealed elongated and shortened telomeres, partly in unusual configurations and loci, dicentric marker chromosomes and signal-free chromosome ends, Free ends give rise to end-to-end associations and may induce breakage-fusion-bridge cycles resulting in an increased number of complex chromosomal rearrangements, as detected by multiplex-FISH (M-FISH). We propose that ALT cannot be seen as an equivalent to telomerase activity in telomere maintenance, Its association with telomere dysfunction and chromosomal instability may have major implications for tumor progression.	Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; Univ Munster, Dept Expt Orthoped, D-48149 Munster, Germany; Univ Heidelberg, Dept Human Genet, Heidelberg, Germany	University of Munster; University of Munster; Ruprecht Karls University Heidelberg	Poremba, C (corresponding author), Univ Munster, Gerhard Domagk Inst Pathol, Domagkstr 17, D-48149 Munster, Germany.							Aue G, 1998, ANN SURG ONCOL, V5, P627, DOI 10.1007/BF02303833; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Avilion AA, 1996, CANCER RES, V56, P645; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; Bouffler SD, 1996, MUTAT RES-REV GENET, V366, P129, DOI 10.1016/S0165-1110(96)90033-0; Brinkschmidt C, 1998, BRIT J CANCER, V77, P2223, DOI 10.1038/bjc.1998.370; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bryce LA, 2000, NEOPLASIA, V2, P197, DOI 10.1038/sj.neo.7900092; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Eils R, 1998, CYTOGENET CELL GENET, V82, P160, DOI 10.1159/000015092; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Hiyama E, 1996, INT J ONCOL, V9, P453; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Ito H, 1998, CLIN CANCER RES, V4, P1603; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Landers JE, 1997, CANCER RES, V57, P3562; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; McClintock B, 1941, GENETICS, V26, P234; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; Perrem K, 1999, ONCOGENE, V18, P3383, DOI 10.1038/sj.onc.1202752; Poremba C, 1999, J CLIN ONCOL, V17, P2020, DOI 10.1200/JCO.1999.17.7.2020; Poremba C, 1998, INT J ONCOL, V12, P641; Poremba C, 2000, J CLIN ONCOL, V18, P2582, DOI 10.1200/JCO.2000.18.13.2582; Radig K, 1998, HUM PATHOL, V29, P1310, DOI 10.1016/S0046-8177(98)90263-5; Ramakrishnan S, 1998, CANCER RES, V58, P622; ROMANO JW, 1989, ONCOGENE, V4, P1483; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; Sumida T, 1999, INT J CANCER, V80, P1, DOI 10.1002/(SICI)1097-0215(19990105)80:1<1::AID-IJC1>3.0.CO;2-U; Takakura M, 1998, CANCER RES, V58, P1558; Takubo K, 1997, J SURG ONCOL, V66, P88, DOI 10.1002/(SICI)1096-9098(199710)66:2<88::AID-JSO3>3.0.CO;2-H; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; Wynford-Thomas D, 1999, J PATHOL, V187, P100; Zhu XL, 1996, P NATL ACAD SCI USA, V93, P6091, DOI 10.1073/pnas.93.12.6091	49	135	137	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3835	3844		10.1038/sj.onc.1204493	http://dx.doi.org/10.1038/sj.onc.1204493			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439347				2022-12-17	WOS:000169494700009
J	McFarland, EDC; Izumi, KM; Mosialos, G				McFarland, EDC; Izumi, KM; Mosialos, G			Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappa B	ONCOGENE			English	Review						Rel; NF-kappa B; herpesvirus; LMP1; Epstein-Barr virus; TRAF; TRADD; RIP; transformation; TNF	LYMPHOCYTE GROWTH TRANSFORMATION; TERMINAL CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; NUCLEAR-PROTEIN; INFECTION MEMBRANE-PROTEIN-1; BCL-2 EXPRESSION; GENETIC-ANALYSIS; FINGER PROTEIN; BINDING-SITE; CELL-LINES	Epstein-Barr virus (EBV) transforms resting primary human B lymphocytes into indefinitely proliferating lymphoblastoid cell lines irt vitro and is associated with several human malignancies in vivo. Recombinant EBV genetic analyses combined with in vitro B lymphocyte transformation assays demonstrate that latent infection membrane protein 1 (LMP1) is essential for EBV-mediated lymphocyte transformation. LMP1 has no intrinsic enzymatic activity but instead aggregates cellular proteins of the tumor necrosis factor receptor signaling pathway to activate transcription factor NF-kappa B. Mutants rendering LMP1 defective in these protein interactions are impaired in their abilities to activate NF-kappa B in reporter gene assays. Concordantly, EBV recombinants with LMP1 mutations that are compromised for NF-kappa B activation are impaired for growth transformation. Thus, EBV-mediated growth transformation is genetically and biochemically linked to LMP1-mediated activation of NF-kappa B.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Mosialos, G (corresponding author), Brigham & Womens Hosp, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA047006, R29CA071705, R35CA047006, F32CA076727] Funding Source: NIH RePORTER; NCI NIH HHS [CA47006, CA71705, CA76727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asso-Bonnet M, 1998, ONCOGENE, V17, P1607, DOI 10.1038/sj.onc.1202365; Babcock GJ, 1998, IMMUNITY, V9, P395, DOI 10.1016/S1074-7613(00)80622-6; BAICHWAL VR, 1988, ONCOGENE, V2, P461; BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Brodeur SR, 1997, J BIOL CHEM, V272, P19777, DOI 10.1074/jbc.272.32.19777; Busch LK, 1999, J IMMUNOL, V162, P2555; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 1996, ONCOGENE, V13, P2243; Eliopoulos AG, 1998, ONCOGENE, V16, P1731, DOI 10.1038/sj.onc.1201694; EPSTEIN MA, 1967, BRIT MED J, V2, P290, DOI 10.1136/bmj.2.5547.290; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FINKE J, 1992, BLOOD, V80, P459; Floettmann JE, 1997, ONCOGENE, V15, P1851, DOI 10.1038/sj.onc.1201359; Franken M, 1996, J VIROL, V70, P7819, DOI 10.1128/JVI.70.11.7819-7826.1996; Fries KL, 1996, J VIROL, V70, P8653, DOI 10.1128/JVI.70.12.8653-8659.1996; Gires O, 1999, EMBO J, V18, P3064, DOI 10.1093/emboj/18.11.3064; Gires O, 1997, EMBO J, V16, P6131, DOI 10.1093/emboj/16.20.6131; HAMILTONDUTOIT SJ, 1991, J CLIN PATHOL, V44, P676, DOI 10.1136/jcp.44.8.676; HAMILTONDUTOIT SJ, 1993, AM J PATHOL, V143, P1072; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; Hatzivassiliou E, 1998, J IMMUNOL, V160, P1116; HELLER M, 1982, J VIROL, V44, P311, DOI 10.1128/JVI.44.1.311-320.1982; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1969, J NATL CANCER I, V43, P1147; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENLE W, 1967, SCIENCE, V157, P1064, DOI 10.1126/science.157.3792.1064; HENLE W, 1979, SCI AM, V241, P48, DOI 10.1038/scientificamerican0779-48; Henle W., 1970, BIBL HAEMATOL, P706; HENNESSY K, 1985, P NATL ACAD SCI USA, V82, P5944, DOI 10.1073/pnas.82.17.5944; HENNESSY K, 1986, P NATL ACAD SCI USA, V83, P5693, DOI 10.1073/pnas.83.15.5693; HENNESSY K, 1983, SCIENCE, V220, P1396, DOI 10.1126/science.6304878; HENNESSY K, 1985, SCIENCE, V227, P1238, DOI 10.1126/science.2983420; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HO M, 1985, J INFECT DIS, V152, P876, DOI 10.1093/infdis/152.5.876; HUEN DS, 1995, ONCOGENE, V10, P549; Izuhara K, 1996, J BIOL CHEM, V271, P619, DOI 10.1074/jbc.271.2.619; IZUMI KM, 1994, J VIROL, V68, P4369, DOI 10.1128/JVI.68.7.4369-4376.1994; Izumi KM, 1999, MOL CELL BIOL, V19, P5759; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P12592, DOI 10.1073/pnas.94.23.12592; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kawanishi M, 1997, VIROLOGY, V228, P244, DOI 10.1006/viro.1996.8370; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Kaye KM, 1996, P NATL ACAD SCI USA, V93, P11085, DOI 10.1073/pnas.93.20.11085; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kilger E, 1998, EMBO J, V17, P1700, DOI 10.1093/emboj/17.6.1700; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANG DJ, 1977, AM J EPIDEMIOL, V105, P480, DOI 10.1093/oxfordjournals.aje.a112407; Lee MA, 1999, J VIROL, V73, P2974, DOI 10.1128/JVI.73.4.2974-2982.1999; LIEBOWITZ D, 1986, J VIROL, V58, P233, DOI 10.1128/JVI.58.1.233-237.1986; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LONGNECKER R, 1990, J VIROL, V64, P2319, DOI 10.1128/JVI.64.5.2319-2326.1990; LONGNECKER R, 1993, J VIROL, V67, P2006, DOI 10.1128/JVI.67.4.2006-2013.1993; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MACMAHON EME, 1991, LANCET, V338, P969, DOI 10.1016/0140-6736(91)91837-K; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MANNICK JB, 1991, J VIROL, V65, P6826, DOI 10.1128/JVI.65.12.6826-6837.1991; Miller WE, 1997, J VIROL, V71, P586, DOI 10.1128/JVI.71.1.586-594.1997; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NIEDOBITEK G, 1991, J PATHOL, V165, P17, DOI 10.1002/path.1711650105; NILSSON K, 1971, INT J CANCER, V8, P443, DOI 10.1002/ijc.2910080312; POPE JH, 1969, INT J CANCER, V4, P255, DOI 10.1002/ijc.2910040302; POPE JH, 1968, INT J CANCER, V3, P857, DOI 10.1002/ijc.2910030619; RICKINSON AB, 1975, NATURE, V258, P236, DOI 10.1038/258236a0; RICKINSON AB, 1980, INT J CANCER, V25, P59, DOI 10.1002/ijc.2910250108; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; ROBERTSON ES, 1994, J VIROL, V68, P1449, DOI 10.1128/JVI.68.3.1449-1458.1994; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SHIBATA D, 1992, AM J PATHOL, V140, P769; SMITH PR, 1993, J VIROL, V67, P3217, DOI 10.1128/JVI.67.6.3217-3225.1993; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TOMKINSON B, 1992, J VIROL, V66, P2893, DOI 10.1128/JVI.66.5.2893-2903.1992; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WEISS LM, 1987, AM J PATHOL, V129, P86; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; ZimberStrobl U, 1996, EMBO J, V15, P7070, DOI 10.1002/j.1460-2075.1996.tb01098.x	95	135	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 22	1999	18	49					6959	6964		10.1038/sj.onc.1203217	http://dx.doi.org/10.1038/sj.onc.1203217			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259LZ	10602470				2022-12-17	WOS:000083896500012
J	Habano, W; Nakamura, S; Sugai, T				Habano, W; Nakamura, S; Sugai, T			Microsatellite instability in the mitochondrial DNA of colorectal carcinomas: Evidence for mismatch repair systems in mitochondrial genome	ONCOGENE			English	Article						genomic instability; mitochondrial DNA; colorectal carcinoma	CRYPT-ISOLATION TECHNIQUE; II RECEPTOR GENE; CANCER-CELLS; NUCLEAR-DNA; MUTATIONS; DISEASES; COLON; CARCINOGENESIS; DEFICIENCY; EXPRESSION	The role, if any, that alterations play in the carcinogenic process remains unclear. To determine whether mtDNA instability occurs in cancers, nine microsatellite sequences in the mtDNA mere examined in 45 sporadic colorectal carcinomas. Alteration in a polycytidine (C)n tract within a noncoding displacement-loop (D-loop) region was detected in 20 carcinomas (44%), three of which also exhibited frameshift mutations in a polyadenosine (A)8 or polycytidine (C)6 tract within NADH dehydrogenase (ND) genes. Interestingly, all three mutant genes were predicted to encode truncated ND proteins, which lacked a large portion of the C-terminus. These results suggested that certain repair systems, like the mismatch repair systems in the nuclear genome, are required for mtDNA maintenance and that defects in these systems can lead to target mitochondrial gene mutations in colorectal carcinomas.	Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, Morioka, Iwate 020, Japan	Iwate University	Nakamura, S (corresponding author), Iwate Univ, Sch Med, Cent Clin Lab, Div Pathol, 19-1 Uchimaru, Morioka, Iwate 020, Japan.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLEN JA, 1980, NATURE, V287, P244, DOI 10.1038/287244a0; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BACKER JM, 1980, SCIENCE, V209, P297, DOI 10.1126/science.6770466; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BERNARDI G, 1979, TRENDS BIOCHEM SCI, V4, P197, DOI 10.1016/0968-0004(79)90079-3; BISHOP JM, 1993, CELL, V75, P235; BOYER JC, 1995, CANCER RES, V55, P6063; BURGART LJ, 1995, AM J PATHOL, V147, P1105; CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351; FUKUDA M, 1985, J MOL BIOL, V186, P257, DOI 10.1016/0022-2836(85)90102-0; Habano W, 1996, LAB INVEST, V74, P933; Habano W, 1998, ONCOGENE, V16, P1259, DOI 10.1038/sj.onc.1201651; HEERDT BG, 1994, CANCER RES, V54, P3912; HEERDT BG, 1990, CANCER RES, V50, P1596; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JONASSON J, 1977, J CELL SCI, V24, P255; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; NAKAMURA S, 1994, GASTROENTEROLOGY, V106, P100, DOI 10.1016/S0016-5085(94)94651-5; NAKAMURA S, 1993, GUT, V34, P1240, DOI 10.1136/gut.34.9.1240; OBERLEY LW, 1979, CANCER RES, V39, P1141; OZAWA T, 1995, BBA-MOL BASIS DIS, V1271, P177, DOI 10.1016/0925-4439(95)00026-Z; PARSONS R, 1995, CANCER RES, V55, P5548; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; REENAN RAG, 1992, GENETICS, V132, P975; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203; SHAY JW, 1987, MUTAT RES, V186, P149, DOI 10.1016/0165-1110(87)90028-5; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; WILKIE D, 1983, INT REV CYTOL, P157; Yoshida T, 1996, J SURG ONCOL, V63, P9	41	135	154	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	1998	17	15					1931	1937		10.1038/sj.onc.1202112	http://dx.doi.org/10.1038/sj.onc.1202112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	128TW	9788436				2022-12-17	WOS:000076423500006
J	Fuchs, SY; Fried, VA; Ronai, Z				Fuchs, SY; Fried, VA; Ronai, Z			Stress-activated kinases regulate protein stability	ONCOGENE			English	Review						signal transduction; protein stability; stress kinases; regulation of protein ubiquitination; p53; ATF2; c-Jun; NF kappa B; JAK-STAT	KAPPA-B-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; SITE-SPECIFIC PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAY; TUMOR-SUPPRESSOR PROTEIN; RECEPTOR TYROSINE KINASE; C-JUN KINASE; BETA-CATENIN; IN-VIVO; INDUCED DEGRADATION	Proteasome inhibitors have been used to demonstrate that many proteins of the signal transduction pathways are regulated by degradation via the ubiquitin-proteasome pathway. The key question is what events target specific proteins for ubiquitination at one time and prevent ubiquitination at other times? In this review, we develop the notion that there is a direct relationship between the phosphorylation/dephosphorylation cascade of the signal transduction pathways and the targeting of the regulatory proteins for ubiquitination. We present examples where phosphorylation appears to alter the interaction between the targeting systems and the substrate by modifying the targeting system, the substrate, or both. These interacting systems are seen in the response of p53, c-jun and ATF-2 in cells subjected to stress or DNA damage and to the normal regulated response in a variety of pathways including the I kappa B-NF kappa B and JAK-STAT pathways, The interweaving of the two post-translational networks, phosphorylation and ubiquitination, provides a powerful insight into global regulatory control pathways.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; New York Medical College	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.			RONAI, ZEEV/0000-0002-3859-0400				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, CELL GROWTH DIFFER, V6, P1437; Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; BROWN JP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Callus BA, 1998, BLOOD, V91, P3182, DOI 10.1182/blood.V91.9.3182.3182_3182_3192; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chun K T, 1996, Prog Cell Cycle Res, V2, P115; CONNOR LH, 1995, J ROY ANTHROPOL INST, V1, P537, DOI 10.2307/3034574; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; FUCHS SY, 1998, IN PRESS ONCOGENE, V17; FUCHS SY, 1998, IN PRESS GENES DEV; FUCHS SY, 1998, IN PRESS P NATL ACAD; Grimley PM, 1998, BLOOD, V91, P3017, DOI 10.1182/blood.V91.8.3017.3017_3017_3027; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; LEEMILLER SP, 1992, MOL CELL BIOL, V12, P5041; LIN A, 1994, SCIENCE, V266, P286; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; MAHESWARAN S, 1995, GENE DEV, V9, P143; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MENON SD, 1995, J BIOL CHEM, V270, P1881; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Musti AM, 1996, BIOL CHEM, V377, P619, DOI 10.1515/bchm3.1996.377.10.619; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Sears C, 1998, J BIOL CHEM, V273, P1409, DOI 10.1074/jbc.273.3.1409; SEEDORF K, 1995, J BIOL CHEM, V270, P18953, DOI 10.1074/jbc.270.32.18953; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; YAN MH, 1994, NATURE, V372, P798; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; YEE NS, 1994, J BIOL CHEM, V269, P31991; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	87	135	136	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1483	1490		10.1038/sj.onc.1202184	http://dx.doi.org/10.1038/sj.onc.1202184			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779995				2022-12-17	WOS:000076161900016
J	Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A				Allen, JD; Verhoeven, E; Domen, J; vanderValk, M; Berns, A			Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc	ONCOGENE			English	Article						lymphomagenesis; leukemogenesis; transgenic mice; X-inactivation; oncogene; pim-2	E-MU-MYC; MURINE LEUKEMIA-VIRUS; PUTATIVE ONCOGENE PIM-1; T-CELL LYMPHOMAS; MESSENGER-RNA; BONE-MARROW; B-CELLS; N-MYC; MICE; ACTIVATION	Evidence from proviral tagging experiments has suggested that pim-2 is similar in oncogenic behavior to its well characterized relative pim-1. While expression in tissues differs, both genes expressed in mitogenically stimulated hematopoietic cells and their transcription is induced in response to the same cytokines, Expression of a pim-2 transgene in lymphoid cells predisposed mice to T-cell lymphomas like those promoted by pim-1 transgenes, Moreover, strong collaboration with an E mu-myc transgene was manifested as pre-B cell leukemia in neonate bi-transgenic animals, Remarkably, this collaboration was attenuated but not prevented by X-inactivation of one of the transgenes. The addition of pim-2 to the fold increases the prominence of the pim proto-oncogene family in tumorigenesis.	NETHERLANDS CANC INST,DIV MOL GENET,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute								ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; ALLEN JD, 1995, J IMMUNOL, V154, P1531; ANSON R, 1989, P NATL ACAD SCI USA, V86, P8857; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; CUYPERS HT, 1984, CELL, V37, P141; DAUTRY F, 1988, J BIOL CHEM, V263, P17615; DOMEN J, 1993, BLOOD, V82, P1445; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; DOMEN J, 1993, LEUKEMIA, pS108; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HARRISON PTC, 1984, LAB ANIM, V18, P325, DOI 10.1258/002367784780865324; HOGAN B, 1994, MANIPULATING MOUSE E; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; LAIRD PW, 1993, NUCLEIC ACIDS RES, V21, P4750, DOI 10.1093/nar/21.20.4750; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LILLY M, 1992, ONCOGENE, V7, P727; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; Nagata Y, 1995, FEBS LETT, V377, P497, DOI 10.1016/0014-5793(95)01386-5; RENAULD JC, 1994, ONCOGENE, V9, P1327; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; SELTEN G, 1985, EMBO J, V4, P1793, DOI 10.1002/j.1460-2075.1985.tb03852.x; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176; WINGETT D, 1991, J IMMUNOL, V147, P3653; YIP SM, 1995, BLOOD, V85, P3494	33	135	146	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1133	1141		10.1038/sj.onc.1201288	http://dx.doi.org/10.1038/sj.onc.1201288			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294606				2022-12-17	WOS:A1997XU99100002
J	Bertrand, P; Rouillard, D; Boulet, A; Levalois, C; Soussi, T; Lopez, BS				Bertrand, P; Rouillard, D; Boulet, A; Levalois, C; Soussi, T; Lopez, BS			Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein	ONCOGENE			English	Article						homologous recombination; p53; genetic instability; tumoral progression	WILD-TYPE P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; GENE AMPLIFICATION; CYCLE CHECKPOINT; DNA; INSTABILITY; ARREST; MUTATIONS; SEQUENCE	Homologous recombination plays an essential role in processes involved in genome stability/instability, such as molecular evolution, gene diversification, meiotic chromosome segregation, DNA repair and chromosomal rearrangements, p53 devoid cells exhibit predisposition to neoplasia, defects in G(1) checkpoint and high genetic instability but a normal rate of point mutations, We investigated the effect of a p53 mutation, on spontaneous homologous recombination between intrachromosomal direct repeat sequences, in mouse L cells. In these cells, wild type for the p53 gene, we have overexpressed the mutant p53(175)(Arg>His) protein leading to a p53 mutant phenotype, as verified by the absence of a G(1) arrest after gamma-irradiation. We show that the rate of spontaneous recombination is increased from five- to 20-fold in the mutant p53 lines, Moreover, this increase is observed in gene conversion as well as in deletion events, Our results provide new insights into the molecular mechanisms of genetic instability due to a defect of p53.	CEA,UMR 217 CNRS,DSV,DRR,F-92265 FONTENAY ROSES,FRANCE; INST CURIE,SECT RECH,F-75231 PARIS 05,FRANCE; INST CURIE,UMR 218 CNRS,SECT RECH,F-75231 PARIS 05,FRANCE	CEA; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS)			Lopez, Bernard S/O-7308-2017	Lopez, Bernard S/0000-0001-5088-0155; soussi, thierry/0000-0001-8184-3293; BERTRAND, Pascale/0000-0002-9019-742X				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BEAMISH H, 1994, RADIAT RES, V138, P783; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BOLLAG RJ, 1992, MOL CELL BIOL, V12, P1546, DOI 10.1128/MCB.12.4.1546; BOUFFLER SD, 1995, CANCER RES, V55, P3883; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P6225, DOI 10.1073/pnas.93.13.6225; FINN GK, 1989, MOL CELL BIOL, V9, P4009, DOI 10.1128/MCB.9.9.4009; Hainaut Pierre, 1995, Current Opinion in Oncology, V7, P76; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P5643, DOI 10.1093/nar/15.14.5643; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luo CM, 1996, J BIOL CHEM, V271, P4497; Luria SE, 1943, GENETICS, V28, P491; MESELSON MS, 1975, P NATL ACAD SCI USA, V72, P358, DOI 10.1073/pnas.72.1.358; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1994, INT J RADIAT BIOL, V66, pS141; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NAGASAWA H, 1995, CANCER RES, V55, P1842; NISHINO H, 1995, ONCOGENE, V11, P263; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Sambrook J, 1989, MOL CLONING LAB MANU; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; Smith Martin L., 1995, Current Opinion in Oncology, V7, P69; STRUZBECHER HW, 1996, EMBO J, V15, P1992; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TYLER J, 1996, NATURE, V381, P643; WALDMAN AS, 1991, NUCLEIC ACIDS RES, V19, P5943, DOI 10.1093/nar/19.21.5943; WANG YY, 1988, MOL CELL BIOL, V8, P196, DOI 10.1128/MCB.8.1.196; Wiesmuller L, 1996, J VIROL, V70, P737; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOSHIMURA Y, 1993, NUCLEIC ACIDS RES, V21, P1665, DOI 10.1093/nar/21.7.1665	47	135	138	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 6	1997	14	9					1117	1122		10.1038/sj.onc.1200931	http://dx.doi.org/10.1038/sj.onc.1200931			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WM070	9070661				2022-12-17	WOS:A1997WM07000014
J	Takenaga, K; Nakamura, Y; Sakiyama, S				Takenaga, K; Nakamura, Y; Sakiyama, S			Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells	ONCOGENE			English	Article						S100A4; metastasis; invasion; motility; Lewis lung carcinoma	NONMUSCLE MYOSIN; PEL98 PROTEIN; MTS1; MOTILITY; INVASION; P9KA; ADENOCARCINOMA; IDENTIFICATION; TRANSFECTION; INDUCTION	S100A4 (also known as pEL98/mts1/p9Ka/18A2/42A/calvasculin/FSP1/CAPL), a member of S100-related calcium-binding proteins, has been implicated to play a role in metastasis. In the present study, we examined the effect of antisense S100A4 RNA on metastatic potential of Lewis lung carcinoma (LLC) cells. High-metastatic All cells were transfected with the expression vector containing S100A4 cDNA in an inverted (antisense) orientation under the transcriptional control of the mouse metallothionein promoter. Treatment of a stably transfected clone (AS10 cells) with Zn2+ resulted in the suppression of the experimental metastatic ability, which was accompanied with the expression of antisense S100A4 RNA and the suppression of the S100A4 expression at both the mRNA and the protein levels. To further confirm the effect of antisense S100A4 RNA, we established several clones after retroviral transduction with an antisense S100A4 construct. Notably, reduced metastatic potential was also evident in these clones. In the antisense S100A4 RNA-expressing cells, cell motility and in vitro invasiveness were found to be suppressed.	CHIBA CANC CTR,RES INST,DIV BIOCHEM,CHUOH KU,CHIBA 260,JAPAN	Chiba Cancer Center	Takenaga, K (corresponding author), CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,666-2 NITONA,CHIBA 260,JAPAN.							AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1994, J BIOL CHEM, V269, P18992; Glinsky GV, 1996, CANCER LETT, V101, P43, DOI 10.1016/0304-3835(96)04112-2; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; KANTOR JD, 1993, CANCER RES, V53, P1971; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMI MS, 1993, ANTICANCER RES, V13, P299; LIOTTA LA, 1988, BREAST CANCER RES TR, V11, P113, DOI 10.1007/BF01805835; LIOTTA LA, 1991, CANCER RES, V51, pS5054; PARKER C, 1994, DNA CELL BIOL, V13, P1021, DOI 10.1089/dna.1994.13.1021; Sambrook J, 1989, MOL CLONING LAB MANU; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, CELL STRUCT FUNCT, V19, P133, DOI 10.1247/csf.19.133; TAKENAGA K, 1994, BIOCHEM BIOPH RES CO, V202, P94, DOI 10.1006/bbrc.1994.1898; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; YAMADA KM, 1990, CANCER RES, V50, P4485	29	135	144	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					331	337		10.1038/sj.onc.1200820	http://dx.doi.org/10.1038/sj.onc.1200820			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018119				2022-12-17	WOS:A1997WD51600009
J	MAYOL, X; GARRIGA, J; GRANA, X				MAYOL, X; GARRIGA, J; GRANA, X			CELL CYCLE-DEPENDENT PHOSPHORYLATION OF THE RETINOBLASTOMA-RELATED PROTEIN P130	ONCOGENE			English	Article						P130; RETINOBLASTOMA PROTEIN; CELL CYCLE; PHOSPHORYLATION; T98G CELLS; CYCLINS; CDKS	GENE-PRODUCT; INHIBITION; P107; E2F; TRANSACTIVATION; BINDING; CLONING; MEMBER; FAMILY	The retinoblastoma-related protein p130 is a putative negative regulator of cell proliferation in mammalian cells. In this study, p130 is exist in multiple phosphorylated forms in human cells. In glioblastoma T98G cells synchronized by serum deprivation, specific phosphorylated forms of p130 are found at different times after serum re-stimulation. Two phosphorylated forms of p130 only found in serum-arrested T98G cells and in early G(1) phase associate with the adenovirus oncoprotein E1A in vitro. One of these two forms corresponds to the in vivo E1A-associated p130 in 293 cells, which express endogenous E1A protein. Moreover, p130 undergoes an abrupt shift to a unique phosphorylated form in mid G(1) which is the only p130 form found during the remaining phases of the cell cycle. This phosphorylated form possesses an associated histone H1 kinase activity that is most active in late S phase and G(2)/M. The cell cycle-dependent expression pattern of cyclins in T98G cells is compatible with cyclin D1/CDK complexes driving the shift to this phosphorylated p130 form in mid G(1). These results suggest that the putative growth inhibitory function of p130 is regulated by phosphorylation of this protein. They also suggest that differential phosphorylation of p130 during the cell cycle plays distinct roles in the regulation of p130 function.			MAYOL, X (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,3307 N BROAD ST,PHILADELPHIA,PA 19140, USA.		Mayol, Xavier/C-1391-2012	Mayol, Xavier/0000-0001-7288-195X; Grana, Xavier/0000-0001-7134-0473				ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAGNINO L, 1995, CELL GROWTH DIFFER, V6, P191; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERMANN CH, 1991, J VIROL, V65, P5848; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; KITAGAWA M, 1995, ONCOGENE, V10, P229; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MAYOL X, 1993, ONCOGENE, V8, P2561; NEVINS JR, 1994, CURR OPIN GENE DEV, V4, P1130; PEEPER DS, 1995, ONCOGENE, V10, P39; POLLACK IF, 1990, J NEUROSURG, V73, P106, DOI 10.3171/jns.1990.73.1.0106; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	40	135	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					801	808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651744				2022-12-17	WOS:A1995RQ46900024
J	ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A				ANDRES, AC; REID, HH; ZURCHER, G; BLASCHKE, RJ; ALBRECHT, D; ZIEMIECKI, A			EXPRESSION OF 2 NOVEL EPH-RELATED RECEPTOR PROTEIN-TYROSINE KINASES IN MAMMARY-GLAND DEVELOPMENT AND CARCINOGENESIS	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; MEDICAL PROGRESS; FAMILY; GENE; MOUSE; IDENTIFICATION; RNA; ONCOGENE; CLONING	To investigate the involvement of protein tyrosine kinases (PTKs) in the growth control of mammary epithelial cells, we have used PCR based cloning to identify PTKs expressed in a mouse mammary epithelial cell line. This approach led to the isolation of two receptor PTKs of the eph-related subfamily; myk-1, a novel member expressed predominantly in lung, heart and mammary gland and myk-2, a close relative of the human eck gene. Northern blot analysis of RNA from mouse mammary glands at different stages of development revealed that myk-1 and myk-2 expression is induced at puberty and differentially regulated during the estrus cycle. myk-1 and myk-2 expression was downregulated during the pregnancy induced differentiation of the mammary gland. Over-expression of myk-1 and myk-2 was found in the undifferentiated and invasive mammary tumors of transgenic mice expressing the Haras oncogene. In contrast, no elevated expression of either gene could be detected in the well differentiated and non-metastatic mammary tumors of c-myc expressing transgenic mice. These results indicate that myk-1 and myk-2 expression is induced during the proliferation of the mammary gland and down-regulated by its differentiation.	UNIV BERN, CLIN & EXPTL RES LAB, CH-3004 BERN, SWITZERLAND	University of Bern								ANDRES AC, 1991, ONCOGENE, V6, P771; BERNS LMJ, 1992, CANCER RES, V52, P1036; Boehme Beatrix, 1993, Oncogene, V8, P2857; CANTLEY LC, 1991, CELL, V64, P235; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DESANTES K, 1992, CANCER RES, V52, P1961; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRATOCHWIL K, 1969, DEV BIOL, V20, P46, DOI 10.1016/0012-1606(69)90004-9; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; Lofts F J, 1992, Cancer Treat Res, V61, P161; Maniatis T., 1982, MOL CLONING; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REICHMANN E, 1989, J CELL BIOL, V108, P1127, DOI 10.1083/jcb.108.3.1127; RUSSO J, 1989, DEV ONCOL, V58, P133; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Vonderhaar B K, 1988, Cancer Treat Res, V40, P251; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	38	135	152	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1461	1467						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152808				2022-12-17	WOS:A1994NH40100019
J	NISHI, T; LEE, PSY; OKA, K; LEVIN, VA; TANASE, S; MORINO, Y; SAYA, H				NISHI, T; LEE, PSY; OKA, K; LEVIN, VA; TANASE, S; MORINO, Y; SAYA, H			DIFFERENTIAL EXPRESSION OF 2 TYPES OF THE NEUROFIBROMATOSIS TYPE-1 (NF1) GENE TRANSCRIPTS RELATED TO NEURONAL DIFFERENTIATION	ONCOGENE			English	Article							GTPASE-ACTIVATING PROTEIN; SACCHAROMYCES-CEREVISIAE; BLASTOMA CELLS; PC12 CELLS; RAS P21; ENCODES; GAP; DOMAIN; LOCUS; IRA1	A 360 residue region encoded by the neurofibromatosis type 1 (NF1) gene shows significant homology to the catalytic domains of both mammalian GTPase-activating proteins (GAP) and yeast IRA proteins. This GAP-related domain of the NF1 gene (NF1-GRD), like the GAP and IRA protein, has been reported to mediate hydrolysis of Ras-bound GTP to GDP, resulting in inactivation of Ras protein. In the present study, we identified two different types of NF1-GRD cDNA. One (type 1) is identical to the previously reported sequence, and the other (type II) contained an additional 63 bp insertion that encodes for a region of 21 amino acids in the center of the NF1-GRD molecule. Alternative splicing is the most likely mechanism by which these two types of transcripts arise. Our observations reveal that the type I transcript is predominantly expressed in undifferentiated cells, whereas the type 11 transcript predominates in differentiated cells. Furthermore, the expression pattern of type I and type II NF1-GRD mRNA immediately changed in SH-SY5Y neuroblastoma cells when neuronal differentiation programs were induced by retinoic acid treatment. We propose that the differential expression of type I and type 11 NF1-GRD transcripts might be an 'on/off' switch that regulates the catalytic activity of the NF1 gene product, which plays an important role in the regulation of neuronal differentiation.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA; KUMAMOTO UNIV, SCH MED, DEPT BIOCHEM, KUMAMOTO 860, JAPAN	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University			Saya, Hideyuki/J-4325-2013		NCRR NIH HHS [RR5511-27] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADEM A, 1987, DEV BRAIN RES, V33, P235, DOI 10.1016/0165-3806(87)90156-8; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Crowe FW, 1956, CLIN PATHOLOGICAL GE; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; PREIS PN, 1988, CANCER RES, V48, P6530; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; ROSS RA, 1985, CANCER RES, V45, P1628; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	24	135	139	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1991	6	9					1555	1559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1923522				2022-12-17	WOS:A1991GX27400009
J	GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR				GIORDANO, A; MCCALL, C; WHYTE, P; FRANZA, BR			HUMAN CYCLIN-A AND THE RETINOBLASTOMA PROTEIN INTERACT WITH SIMILAR BUT DISTINGUISHABLE SEQUENCES IN THE ADENOVIRUS E1A-GENE PRODUCT	ONCOGENE			English	Note							LARGE T-ANTIGEN; E1A PROTEINS; FUNCTIONAL DOMAINS; SEPARATE DOMAINS; TERMINAL REGION; DNA-SYNTHESIS; CELL-CYCLE; M-PHASE; TRANSFORMATION; GROWTH	The adenovirus early region 1A (E1A) proteins associate with several cellular proteins in adenovirus infected or transformed cells. Recently, two of the cellular proteins that bind to E1A encoded proteins have been identified. p105 has been shown to be the product of the retinoblastoma tumor suppressing gene. p60 has been shown to be a human cyclin A. Previously studies have shown that E1A protein sequences encoded by conserved domains 1 and 2 are required for interactions with the retinoblastoma protein (pRB). We have demonstrated here that amino acids 30 to 60 and 121 to 127 within the E1A proteins are required for interaction with p60/cyclin A. These are the same sites within conserved domains 1 and 2 that are required for E1A protein association with pRB. However, the association of p60/cyclin A does not appear to require pRB. We also demonstrate that another cellular protein, 130K, interacts with E1A at essentially the same sites. It is interesting that mutations in these regions destroy the ability of E1A to function as an oncogene, thereby raising the possibility that interaction with several different cellular proteins may be needed for transformation by E1A.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	Fred Hutchinson Cancer Center	GIORDANO, A (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.		Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9; JELSMA TN, 1988, VIROLOGY, V163, P494, DOI 10.1016/0042-6822(88)90290-5; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LEWIS JB, 1980, CELL, V21, P303, DOI 10.1016/0092-8674(80)90138-5; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; NEVINS JR, 1979, J VIROL, V32, P727, DOI 10.1128/JVI.32.3.727-733.1979; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QUINLAN MP, 1987, P NATL ACAD SCI USA, V84, P3283, DOI 10.1073/pnas.84.10.3283; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; SPECTOR DJ, 1978, J MOL BIOL, V126, P395, DOI 10.1016/0022-2836(78)90048-7; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; VANDENELSEN P, 1983, VIROLOGY, V128, P377; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	54	135	136	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					481	485						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1826347				2022-12-17	WOS:A1991FT34400021
J	Paz, H; Pathak, N; Yang, J				Paz, H.; Pathak, N.; Yang, J.			Invading one step at a time: the role of invadopodia in tumor metastasis	ONCOGENE			English	Review						invadopodia; tumor invasion; metastasis	FIBROBLAST ACTIVATION PROTEIN; TYPE-1 MATRIX-METALLOPROTEINASE; BREAST-CANCER CELLS; EPITHELIAL-MESENCHYMAL TRANSITIONS; DIPEPTIDYL-PEPTIDASE-IV; SRC FAMILY KINASES; PHASE-II TRIAL; PODOSOME FORMATION; MAMMARY-TUMORS; IN-VIVO	The ability to degrade extracellular matrix is critical for tumor cells to invade and metastasize. Recent studies show that tumor cells use specialized actin-based membrane protrusions termed invadopodia to perform matrix degradation. Invadopodia provide an elegant way for tumor cells to precisely couple focal matrix degradation with directional movement. Here we discuss several key components and regulators of invadopodia that have been uniquely implicated in tumor invasion and metastasis. Furthermore, we discuss existing and new therapeutic opportunities to target invadopodia for anti-metastasis treatment.	[Paz, H.; Pathak, N.; Yang, J.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Pathak, N.; Yang, J.] Univ Calif San Diego, Program Biomed Sci, La Jolla, CA 92093 USA; [Yang, J.] Univ Calif San Diego, Dept Pediat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Yang, J (corresponding author), Univ Calif San Diego, Dept Pharmacol, Program Biomed Sci, 9500 Gilman Dr,MC0636, La Jolla, CA 92093 USA.	jingyang@ucsd.edu			National Institutes of Health [1DP2OD002420]; National Cancer Institute [1RO1CA168689]; American Cancer Society [RSG-09-282-01-CSM]; Hartwell Foundation; DOD Breast Cancer Program [W81XWH-13-1-0132]; NIH IRACDA [5K12GM068524]; NIH [5T32GM007752]; NATIONAL CANCER INSTITUTE [R01CA168689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM068524, T32GM007752] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD002420] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Hartwell Foundation; DOD Breast Cancer Program(United States Department of Defense); NIH IRACDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We apologize to the many researchers in this field whose work we were unable to cite due to space restrictions. Our research on tumor metastasis is supported by grants from National Institutes of Health 1DP2OD002420, National Cancer Institute 1RO1CA168689, American Cancer Society grant RSG-09-282-01-CSM, The Hartwell Foundation and DOD Breast Cancer Program W81XWH-13-1-0132 to JY, by the NIH IRACDA training grant 5K12GM068524 to HP, and by the NIH Pre-doctoral Training grant in Pharmaceutical Science 5T32GM007752 to NP.	Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Albrechtsen R, 2011, EXP CELL RES, V317, P195, DOI 10.1016/j.yexcr.2010.10.003; Alexander NR, 2008, CURR BIOL, V18, P1295, DOI 10.1016/j.cub.2008.07.090; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Anbalagan M, 2012, BREAST CANCER RES TR, V132, P391, DOI 10.1007/s10549-011-1513-3; [Anonymous], 2013, ANTICANCER RES, V33, P2345; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Balzer EM, 2010, ONCOGENE, V29, P6402, DOI 10.1038/onc.2010.360; Basu B, 2012, INT J BIOCHEM CELL B, V44, P393, DOI 10.1016/j.biocel.2011.11.015; Beaty BT, 2013, MOL BIOL CELL, V24, P1661, DOI 10.1091/mbc.E12-12-0908; Blouw B, 2008, EUR J CELL BIOL, V87, P555, DOI 10.1016/j.ejcb.2008.02.008; Bowden ET, 2006, EXP CELL RES, V312, P1240, DOI 10.1016/j.yexcr.2005.12.012; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Branch KM, 2012, BIOL OPEN, V1, P711, DOI 10.1242/bio.20121867; Bravo-Cordero JJ, 2007, EMBO J, V26, P1499, DOI 10.1038/sj.emboj.7601606; Buschman MD, 2009, MOL BIOL CELL, V20, P1302, DOI 10.1091/mbc.E08-09-0949; Busek P, 2004, INT J BIOCHEM CELL B, V36, P408, DOI 10.1016/S1357-2725(03)00262-0; Chan PC, 2012, CANCER RES, V72, P2405, DOI 10.1158/0008-5472.CAN-11-3078; Chen DH, 2006, CANCER RES, V66, P9977, DOI 10.1158/0008-5472.CAN-06-1499; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; Christiansen VJ, 2007, ARCH BIOCHEM BIOPHYS, V457, P177, DOI 10.1016/j.abb.2006.11.006; Chuma M, 2004, J HEPATOL, V41, P629, DOI 10.1016/j.jhep.2004.06.018; Courtneidge SA, 2005, COLD SH Q B, V70, P167, DOI 10.1101/sqb.2005.70.014; Crimaldi L, 2009, EXP CELL RES, V315, P2581, DOI 10.1016/j.yexcr.2009.06.012; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Destaing O, 2010, MOL BIOL CELL, V21, P4108, DOI 10.1091/mbc.E10-07-0580; Devy L, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/191670; Devy L, 2009, CANCER RES, V69, P1517, DOI 10.1158/0008-5472.CAN-08-3255; Diaz B, 2013, J CELL BIOL, V201, P279, DOI 10.1083/jcb.201209151; Diaz B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000368; Eager RM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-263; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eisenach PA, 2012, J BIOL CHEM, V287, P11533, DOI 10.1074/jbc.M111.306340; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Fischer E, 2012, CLIN CANCER RES, V18, P6208, DOI 10.1158/1078-0432.CCR-12-0644; Fosang AJ, 1998, FEBS LETT, V430, P186, DOI 10.1016/S0014-5793(98)00667-X; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Gertler F, 2011, TRENDS CELL BIOL, V21, P81, DOI 10.1016/j.tcb.2010.10.001; Ghersi G, 2006, CANCER RES, V66, P4652, DOI 10.1158/0008-5472.CAN-05-1245; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Ito S, 2001, INT J CANCER, V93, P212, DOI 10.1002/ijc.1318; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kelley LC, 2010, J CELL SCI, V123, P3923, DOI 10.1242/jcs.075200; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kveiborg M, 2005, CANCER RES, V65, P4754, DOI 10.1158/0008-5472.CAN-05-0262; Kveiborg M, 2008, INT J BIOCHEM CELL B, V40, P1685, DOI 10.1016/j.biocel.2008.01.025; Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li YS, 2001, CANCER RES, V61, P6906; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Linder S, 2007, TRENDS CELL BIOL, V17, P107, DOI 10.1016/j.tcb.2007.01.002; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Meadows SA, 2007, BIOCHEMISTRY-US, V46, P4598, DOI 10.1021/bi062227y; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; MUELLER SC, 1991, J CELL SCI, V99, P213; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Naing A, 2013, INVEST NEW DRUG, V31, P967, DOI 10.1007/s10637-013-9929-8; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Nyalendo C, 2008, CARCINOGENESIS, V29, P1655, DOI 10.1093/carcin/bgn159; Nyalendo C, 2007, J BIOL CHEM, V282, P15690, DOI 10.1074/jbc.M608045200; O'Brien P, 2008, BBA-PROTEINS PROTEOM, V1784, P1130, DOI 10.1016/j.bbapap.2008.01.006; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Oikawa T, 2008, J CELL BIOL, V182, P157, DOI 10.1083/jcb.200801042; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Parekh A, 2011, BIOPHYS J, V100, P573, DOI 10.1016/j.bpj.2010.12.3733; Parekh A, 2009, CELL ADHES MIGR, V3, P288, DOI 10.4161/cam.3.3.8888; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Perentes JY, 2011, CANCER RES, V71, P4527, DOI 10.1158/0008-5472.CAN-10-4376; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Pignatelli J, 2012, J CELL BIOL, V197, P421, DOI 10.1083/jcb.201108143; Sanchez-Bailon MP, 2012, CELL SIGNAL, V24, P1276, DOI 10.1016/j.cellsig.2012.02.011; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Puls LN, 2011, ONCOLOGIST, V16, P566, DOI 10.1634/theoncologist.2010-0408; Pure E, 2009, EXPERT OPIN THER TAR, V13, P967, DOI 10.1517/14728220903103841; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roussos ET, 2011, J CELL SCI, V124, P2120, DOI 10.1242/jcs.086231; Roussos ET, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2784; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Roy R, 2011, J BIOL CHEM, V286, P20758, DOI 10.1074/jbc.M110.216036; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Steeg PS, 2012, NATURE, V485, pS58, DOI 10.1038/485S58a; Steffen A, 2008, CURR BIOL, V18, P926, DOI 10.1016/j.cub.2008.05.044; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Szabova L, 2008, ONCOGENE, V27, P3274, DOI 10.1038/sj.onc.1210982; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Toth M, 2003, BIOCHEM BIOPH RES CO, V308, P386, DOI 10.1016/S0006-291X(03)01405-0; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105; Weaver AM, 2008, CANCER LETT, V265, P157, DOI 10.1016/j.canlet.2008.02.066; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamaguchi H, 2012, EUR J CELL BIOL, V91, P902, DOI 10.1016/j.ejcb.2012.04.005; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	126	134	139	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2014	33	33					4193	4202		10.1038/onc.2013.393	http://dx.doi.org/10.1038/onc.2013.393			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MB	24077283	Green Accepted			2022-12-17	WOS:000341155800001
J	Reynolds, MR; Lane, AN; Robertson, B; Kemp, S; Liu, Y; Hill, BG; Dean, DC; Clem, BF				Reynolds, M. R.; Lane, A. N.; Robertson, B.; Kemp, S.; Liu, Y.; Hill, B. G.; Dean, D. C.; Clem, B. F.			Control of glutamine metabolism by the tumor suppressor Rb	ONCOGENE			English	Article						retinoblastoma protein; metabolism; glutamine; cancer; tumor suppressor	ENERGY-METABOLISM; CELL-PROLIFERATION; GROWTH-FACTOR; G(1) CONTROL; FACTOR-I; INHIBITION; PROTEIN; CANCER; GLYCOLYSIS; APOPTOSIS	Retinoblastoma (Rb) protein is a tumor suppressor that is dysregulated in a majority of human cancers. Rb functions to inhibit cell cycle progression in part by directly disabling the E2F family of cell cycle-promoting transcription factors. Because the de novo synthesis of multiple glutamine-derived anabolic precursors is required for cell cycle progression, we hypothesized that Rb also may directly regulate proteins involved in glutamine metabolism. We examined glutamine metabolism in mouse embryonic fibroblasts (MEFs) isolated from mice that have triple knock-outs (TKO) of all three Rb family members (Rb-1, Rbl1 and Rbl2) and found that loss of global Rb function caused a marked increase in C-13-glutamine uptake and incorporation into glutamate and tricarboxylic acid cycle (TCA) intermediates in part via upregulated expression of the glutamine transporter ASCT2 and the activity of glutaminase 1 (GLS1). The Rb-controlled transcription factor E2F-3 altered glutamine uptake by direct regulation of ASCT2 mRNA and protein expression, and E2F-3 was observed to associate with the ASCT2 promoter. We next examined the functional consequences of the observed increase in glutamine uptake and utilization and found that glutamine exposure potently increased oxygen consumption, whereas glutamine deprivation selectively decreased ATP concentration in the Rb TKO MEFs but not the wildtype (WT) MEFs. In addition, TKO MEFs exhibited elevated production of glutathione from exogenous glutamine and had increased expression of gamma-glutamylcysteine ligase relative to WT MEFs. Importantly, this metabolic shift towards glutamine utilization was required for the proliferation of Rb TKO MEFs but not for the proliferation of the WT MEFs. Last, addition of the TCA cycle intermediate alpha-ketoglutarate to the Rb TKO MEFs reversed the inhibitory effects of glutamine deprivation on ATP, GSH levels and viability. Taken together, these studies demonstrate that the Rb/E2F cascade directly regulates a major energetic and anabolic pathway that is required for neoplastic growth.	[Reynolds, M. R.; Lane, A. N.; Robertson, B.; Kemp, S.; Hill, B. G.; Clem, B. F.] Univ Louisville, Dept Med, Louisville, KY 40202 USA; [Reynolds, M. R.; Hill, B. G.; Dean, D. C.; Clem, B. F.] Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Reynolds, M. R.; Robertson, B.; Kemp, S.; Liu, Y.; Dean, D. C.; Clem, B. F.] Univ Louisville, Mol Targets Grp, Louisville, KY 40202 USA; [Lane, A. N.] Univ Louisville, James Graham Brown Canc Ctr, Struct Biol Program, Louisville, KY 40202 USA; [Liu, Y.; Dean, D. C.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA; [Hill, B. G.] Univ Louisville, Inst Mol Cardiol, Diabetes & Obes Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville	Clem, BF (corresponding author), Univ Louisville, Dept Med, 505 S Hancock St,CTRB,Rm 422, Louisville, KY 40202 USA.	bfclem01@louisville.edu	Hill, Bradford/I-4154-2013	Hill, Bradford/0000-0001-5332-8286	Brown Foundation; NCCRR [1P20 RR18733]; Center of Biomedical Research Excellence in Molecular Targets grant from the National Center for Research Resources [3P20RR018733-09-BFC];  [RR024489]; NATIONAL CANCER INSTITUTE [R01CA166327] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024489, P20RR018733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106396] Funding Source: NIH RePORTER	Brown Foundation; NCCRR; Center of Biomedical Research Excellence in Molecular Targets grant from the National Center for Research Resources; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge Jason Chesney, Sucheta Telang and John Eaton for their insightful discussions, and thank Tyler Jacks for the kind gift of the TKO MEFs. NMR experiments were carried out at the James Graham Brown Cancer Center NMR facility, supported in part by the Brown Foundation and NCCRR grant 1P20 RR18733. This work was supported by a Center of Biomedical Research Excellence in Molecular Targets (3P20RR018733-09-BFC) grant from the National Center for Research Resources and by RR024489 (BGH).	Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Ciavarra G, 2010, J CELL BIOL, V191, P291, DOI 10.1083/jcb.201005067; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Clem BF, 2011, ONCOGENE, V30, P3370, DOI 10.1038/onc.2011.51; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Fan TWM, 2011, METABOLOMICS, V7, P257, DOI 10.1007/s11306-010-0249-0; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill BG, 2009, BIOCHEM J, V424, P99, DOI 10.1042/BJ20090934; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liu M, 2010, CIRC RES, V107, P967, DOI 10.1161/CIRCRESAHA.110.220673; Liu Y, 2007, BIOCHEM J, V408, P79, DOI 10.1042/BJ20070344; Lora J, 2004, EUR J BIOCHEM, V271, P4298, DOI 10.1111/j.1432-1033.2004.04370.x; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McClellan KA, 2009, MOL CELL BIOL, V29, P4701, DOI 10.1128/MCB.01767-08; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Perez J, 2010, BIOCHEM J, V428, P255, DOI 10.1042/BJ20100090; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Takahashi C, 2012, CANCER SCI, V103, P1182, DOI 10.1111/j.1349-7006.2012.02284.x; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Warburg O, 1924, BIOCHEM Z, V152, P319; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	43	134	138	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					556	566		10.1038/onc.2012.635	http://dx.doi.org/10.1038/onc.2012.635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23353822	Green Accepted			2022-12-17	WOS:000331125100004
J	Shi, XB; Xue, L; Ma, AH; Tepper, CG; Gandour-Edwards, R; Kung, HJ; White, RWD				Shi, X-B; Xue, L.; Ma, A-H; Tepper, C. G.; Gandour-Edwards, R.; Kung, H-J; White, R. W. deVere			Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen; androgen receptor; miRNA; tumor suppressor	GROUP PROTEIN I(Y); DNA METHYLATION; MICRORNA GENES; EXPRESSION; P53; HYPERMETHYLATION; CARCINOMA; APOPTOSIS; INTERACT; THERAPY	Although prostate cancer (CaP) is the most frequently diagnosed malignant tumor in American men, the mechanisms underlying the development and progression of CaP remain largely unknown. Recent studies have shown that downregulation of the microRNA miR-124 occurs in several types of human cancer, suggesting a tumor suppressive function of miR-124. Until now, however, it has been unclear whether miR-124 is associated with CaP. In the present study, we completed a series of experiments to understand the functional role of miR-124 in CaP. We detected the expression level of miR-124 in clinical CaP tissues, evaluated the influence of miR-124 on the growth of CaP cells and investigated the mechanism underlying the dysregulation of miR-124. We found that (i) miR-124 directly targets the androgen receptor (AR) and subsequently induces an upregulation of p53; (ii) miR-124 is significantly downregulated in malignant prostatic cells compared to benign cells, and DNA methylation causes the reduced expression of miR-124; and (iii) miR-124 can inhibit the growth of CaP cells in vitro and in vivo. Data from this study revealed that loss of miR-124 expression is a common event in CaP, which may contribute to the pathogenesis of CaP. Our studies also suggest that miR-124 is a potential tumor suppressive gene in CaP, and restoration of miR-124 expression may represent a novel strategy for CaP therapy.	[Shi, X-B; Xue, L.; White, R. W. deVere] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Ma, A-H; Tepper, C. G.; Kung, H-J] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Gandour-Edwards, R.] Univ Calif Davis, Sch Med, Dept Pathol, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	White, RWD (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	rwdeverewhite@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NIH [1RO1CA136597]; Department of Defense [PCRP PC080488]; LANIE Foundation; NCI [CA136597]; DOD [PC080488]; NATIONAL CANCER INSTITUTE [P30CA093373, R01CA165263, R01CA136597, R01CA092069] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); LANIE Foundation; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH 1RO1CA136597 (R deVere White), Department of Defense PCRP PC080488 (R deVere White) and The LANIE Foundation. We thank Dr Mukta Webber for providing the RWPE-1 cell line and Dr Johng Rhim for the pRNS-1-1 cell line. We are also grateful to Dr Melanie C Bradnam for her editorial assistance and Stephanie Soares for critically reading the manuscript. This work was supported by NCI grant (no. CA136597) and DOD grant (no. PC080488).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Baroukh N, 2007, J BIOL CHEM, V282, P19575, DOI 10.1074/jbc.M611841200; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Cao XW, 2007, GENE DEV, V21, P531, DOI 10.1101/gad.1519207; Chang BL, 2007, CANCER RES, V67, P4098, DOI 10.1158/0008-5472.CAN-06-4570; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen Y, 1996, CELL GROWTH DIFFER, V7, P1571; Davis BN, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-18; Frasca F, 2006, CANCER RES, V66, P2980, DOI 10.1158/0008-5472.CAN-05-2637; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Furuta M, CARCINOGENESIS, V31, P766; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; GRAFF JR, 1995, CANCER RES, V55, P5195; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Koivisto P, 1997, CANCER RES, V57, P314; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065; Lou W, 1999, CANCER RES, V59, P2329; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Matsuyama H, 2003, PROSTATE, V54, P103, DOI 10.1002/pros.10173; Mazar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024922; Mirosevich J, 2006, PROSTATE, V66, P1013, DOI 10.1002/pros.20299; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Olive V, 2010, INT J BIOCHEM CELL B, V42, P1348, DOI 10.1016/j.biocel.2010.03.004; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Perinchery G, 1999, INT J ONCOL, V14, P495; Pierantoni GM, 2006, CELL DEATH DIFFER, V13, P1554, DOI 10.1038/sj.cdd.4401839; Qi J, CANC CELL, V18, P23; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Sadar MD, 2011, CANCER RES, V71, P1208, DOI 10.1158/0008-5472.CAN_10-3398; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Shi XB, 1996, DIAGN MOL PATHOL, V5, P271, DOI 10.1097/00019606-199612000-00008; Shi XB, 2008, J CELL MOL MED, V12, P1456, DOI 10.1111/j.1582-4934.2008.00420.x; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sinkkonen L, 2008, NAT STRUCT MOL BIOL, V15, P259, DOI 10.1038/nsmb.1391; Takaha N, 2002, CANCER RES, V62, P647; TAMIMI Y, 1993, CANCER RES, V53, P5512; Tepper CG, 2002, CANCER RES, V62, P6606; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673; White RD, 1997, EUR UROL, V31, P1; Woodson K, 2004, CANCER LETT, V205, P181, DOI 10.1016/j.canlet.2003.11.027; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yu XP, 2005, ANN NY ACAD SCI, V1061, P77, DOI 10.1196/annals.1336.009	54	134	147	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4130	4138		10.1038/onc.2012.425	http://dx.doi.org/10.1038/onc.2012.425			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23069658	Green Accepted, hybrid			2022-12-17	WOS:000323748500008
J	Zhao, F; Mancuso, A; Bui, TV; Tong, X; Gruber, JJ; Swider, CR; Sanchez, PV; Lum, JJ; Sayed, N; Melo, JV; Perl, AE; Carroll, M; Tuttle, SW; Thompson, CB				Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Swider, C. R.; Sanchez, P. V.; Lum, J. J.; Sayed, N.; Melo, J. V.; Perl, A. E.; Carroll, M.; Tuttle, S. W.; Thompson, C. B.			Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1 alpha-induced metabolic reprograming	ONCOGENE			English	Article						imatinib (Gleevec, STI571); resistance; HIF-1 alpha; pentose phosphate pathway; glucose metabolism; cell survival	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; HYPOXIA-INDUCIBLE FACTOR; EXPRESSION LEVELS; POSITIVE CELLS; CLINICAL RESISTANCE; PENTOSE-PHOSPHATE; CYCLE ACTIVITY; GROWTH-FACTOR; SENSITIVITY	As chronic myeloid leukemia (CML) progresses from the chronic phase to blast crisis, the levels of BCR-ABL increase. In addition, blast-transformed leukemic cells display enhanced resistance to imatinib in the absence of BCR-ABL-resistance mutations. In this study, we show that when BCR-ABL-transformed cell lines were selected for imatinib resistance in vitro, the cells that grew out displayed a higher BCR-ABL expression comparable to the increase seen in accelerated forms of the disease. This enhanced expression of BCR-ABL was associated with an increased rate of glycolysis but with a decreased rate of proliferation. The higher level of BCR-ABL expression in the selected cells correlated with a nonhypoxic induction of hypoxia-inducible factor-1 alpha (HIF-1 alpha) that was required for cells to tolerate enhanced BCR-ABL signaling. HIF-1 alpha induction resulted in an enhanced rate of glycolysis but with reduced glucose flux through both the tricarboxylic acid cycle and the oxidative arm of the pentose phosphate pathway (PPP). The reduction in oxidative PPP-mediated ribose synthesis was compensated by the HIF1 alpha-dependent activation of the nonoxidative PPP enzyme, transketolase, in imatinib-resistant CML cells. In both primary cultures of cells from patients exhibiting blast transformation and in vivo xenograft tumors, use of oxythiamine, which can inhibit both the pyruvate dehydrogenase complex and transketolase, resulted in enhanced imatinib sensitivity of tumor cells. Together, these results suggest that oxythiamine can enhance imatinib efficacy in patients who present an accelerated form of the disease. Oncogene (2010) 29, 2962-2972; doi:10.1038/onc.2010.67; published online 15 March 2010	[Zhao, F.; Mancuso, A.; Bui, T. V.; Tong, X.; Gruber, J. J.; Sayed, N.; Thompson, C. B.] Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Swider, C. R.; Sanchez, P. V.; Perl, A. E.; Carroll, M.] Univ Penn, Sch Med, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA; [Lum, J. J.] BC Canc Agcy, Trev & Joyce Deeley Res Ctr, Victoria, BC, Canada; [Melo, J. V.] SA Pathol, Div Haematol, Adelaide, SA, Australia; [Melo, J. V.] Ctr Canc Biol, Adelaide, SA, Australia; [Tuttle, S. W.] Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; British Columbia Cancer Agency; SA Pathology; Centre for Cancer Biology; University of Pennsylvania	Thompson, CB (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, Abramson Canc Ctr, 421 Curie Blvd, Philadelphia, PA 19104 USA.	craig@mail.med.upenn.edu	Mancuso, Anthony/AAP-9358-2020	Lum, Julian/0000-0002-5624-3541	NCI; NIH; NATIONAL CANCER INSTITUTE [K01CA129151, P01CA104838, R01CA105463, R01CA092660] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Thompson laboratory, especially Tullia Lindsten, Mondira Kundu, Uma Sachdeva and Scott Olejniczak, for helpful suggestions during the study and careful critique of the paper. We thank Dr E Buchdunger (Novartis, Basel, Switzerland) for providing imatinib and Dr EP Reddy (Temple University, Philadelphia) for providing cell lines expressing either the WT or mutant (T315I) form of BCR-ABL. We are grateful to Dr MC Simon (University of Pennsylvania), Dr JL Riley (University of Pennsylvania) and Dr DA Tuveson (Cancer Research UK Cambridge Research Institute, UK) for providing experimental reagents. This work was supported in part by grants from the NCI and NIH.	Barnes DJ, 2005, CANCER RES, V65, P8912, DOI 10.1158/0008-5472.CAN-05-0076; Barnes K, 2005, ONCOGENE, V24, P3257, DOI 10.1038/sj.onc.1208461; Bell EL, 2007, ESSAYS BIOCHEM, V43, P17, DOI 10.1042/bse0430017; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chamberlain BR, 1996, ANN CLIN BIOCHEM, V33, P352, DOI 10.1177/000456329603300413; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dewar AL, 2005, IMMUNOL CELL BIOL, V83, P48, DOI 10.1111/j.1440-1711.2004.01296.x; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Giuntoli S, 2006, LEUKEMIA, V20, P1291, DOI 10.1038/sj.leu.2404224; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; Gumireddy K, 2005, P NATL ACAD SCI USA, V102, P1992, DOI 10.1073/pnas.0408283102; Gupte SA, 2006, AM J PHYSIOL-HEART C, V290, pH2228, DOI 10.1152/ajpheart.00615.2005; Haseloff RF, 2006, PROTEOMICS, V6, P1803, DOI 10.1002/pmic.200500182; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; KATZ J, 1967, BIOCHEMISTRY-US, V6, P2227, DOI 10.1021/bi00859a046; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; Khorashad JS, 2006, LEUKEMIA, V20, P658, DOI 10.1038/sj.leu.2404137; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Kominsky DJ, 2009, CLIN CANCER RES, V15, P3442, DOI 10.1158/1078-0432.CCR-08-3291; Kress S, 1998, J CANCER RES CLIN, V124, P315, DOI 10.1007/s004320050175; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Modi H, 2007, BLOOD, V109, P5411, DOI 10.1182/blood-2006-06-032490; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Sherbenou DW, 2007, J CLIN INVEST, V117, P2067, DOI 10.1172/JCI31988; Thompson JE, 2007, EXP HEMATOL, V35, P21, DOI 10.1016/j.exphem.2006.08.017; Tuttle SW, 2007, J BIOL CHEM, V282, P36790, DOI 10.1074/jbc.M700327200; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; ZAHAREVITZ DW, 1992, EUR J BIOCHEM, V210, P293, DOI 10.1111/j.1432-1033.1992.tb17420.x; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	36	134	139	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	20					2962	2972		10.1038/onc.2010.67	http://dx.doi.org/10.1038/onc.2010.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20228846	Green Accepted			2022-12-17	WOS:000277890400007
J	Taliaferro-Smith, L; Nagalingam, A; Zhong, D; Zhou, W; Saxena, NK; Sharma, D				Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.			LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells	ONCOGENE			English	Article						adiponectin; LKB1; invasion; migration; breast cancer	FATTY-ACID OXIDATION; ACTIVATED PROTEIN-KINASE; BODY-MASS INDEX; TUMOR-SUPPRESSOR; GLOBULAR ADIPONECTIN; THERAPEUTIC TARGET; METABOLIC SYNDROME; SERUM ADIPONECTIN; SIGNALING PATHWAY; SKELETAL-MUSCLE	Adiponectin is widely known as an adipocytokine with therapeutic potential for its markedly protective function in the pathogenesis of obesity-related disorders, metabolic syndrome, systemic insulin resistance, cardiovascular disease and more recently carcinogenesis. In the present study, we show that adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Further analysis of the underlying molecular mechanisms revealed that adiponectin treatment increased AMP-activated protein kinase (AMPK) phosphorylation and activity as evident by increased phosphorylation of downstream target of AMPK, acetyl-coenzyme A carboxylase and inhibition of p70S6 kinase (S6K). Intriguingly, we discovered that adiponectin treatment increases the expression of tumor suppressor gene LKB1 in breast cancer cells. Overexpression of LKB1 in breast cancer cells further increased adiponectin-mediated phosphorylation of AMPK. Using isogenic LKB1 knockdown cell line pair, we found that LKB1 is required for adiponectin-mediated modulation of AMPK -S6K axis and more importantly, inhibition of adhesion, migration and invasion of breast cancer cells. Taken together these data present a novel mechanism involving specific upregulation of tumor suppressor gene LKB1 by which adiponectin inhibits adhesion, invasion and migration of breast cancer cells. Our findings indicate the possibility of using adiponectin analogues to inhibit invasion and migration of breast cancer cells. Oncogene (2009) 28, 2621 -2633; doi: 10.1038/onc.2009.129; published online 1 June 2009	[Taliaferro-Smith, L.; Nagalingam, A.; Zhong, D.; Zhou, W.; Saxena, N. K.; Sharma, D.] Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Saxena, N. K.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	Emory University	Sharma, D (corresponding author), Winship Canc Inst, Dept Hematol & Med Oncol, Rm 4010,1701 Uppergate Dr, Atlanta, GA 30322 USA.	nksaxen@emory.edu; dsharma@emory.edu			NCI NIH HHS [R01CA131294, R01 CA131294, 5P01CA116676-030002] Funding Source: Medline; NIDDK NIH HHS [K01 DK077137-01A1, R03 DK089130, R03 DK089130-02, K01 DK077137-05, K01 DK077137, R03 DK089130-03, K01 DK077137-04, K01 DK076742, K01 DK077137-02, K01DK076742] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA116676, R01CA131294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R03DK089130, K01DK076742, K01DK077137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933; Arditi JD, 2007, HORM METAB RES, V39, P9, DOI 10.1055/s-2007-956518; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Barb D, 2006, EXPERT OPIN INV DRUG, V15, P917, DOI 10.1517/13543784.15.8.917; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Boudeau J, 2004, J CELL SCI, V117, P6365, DOI 10.1242/jcs.01571; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Cacicedo JM, 2004, BIOCHEM BIOPH RES CO, V324, P1204, DOI 10.1016/j.bbrc.2004.09.177; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Chen DC, 2006, CANCER LETT, V237, P109, DOI 10.1016/j.canlet.2005.05.047; Chen MB, 2005, J CLIN ENDOCR METAB, V90, P3665, DOI 10.1210/jc.2004-1980; Daling JR, 2001, CANCER, V92, P720, DOI 10.1002/1097-0142(20010815)92:4<720::AID-CNCR1375>3.0.CO;2-T; Dieudonne MN, 2006, BIOCHEM BIOPH RES CO, V345, P271, DOI 10.1016/j.bbrc.2006.04.076; Dos Santos E, 2008, ONCOL REP, V20, P971, DOI 10.3892/or_00000098; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fenton H, 2006, APPL IMMUNOHISTO M M, V14, P146, DOI 10.1097/01.pai.0000176157.07908.20; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Goldstein BJ, 2004, J CLIN ENDOCR METAB, V89, P2563, DOI 10.1210/jc.2004-0518; Grossmann ME, 2008, BRIT J CANCER, V98, P370, DOI 10.1038/sj.bjc.6604166; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Jarde T, 2008, HISTOPATHOLOGY, V53, P484, DOI 10.1111/j.1365-2559.2008.03121.x; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Kelesidis I, 2006, BRIT J CANCER, V94, P1221, DOI 10.1038/sj.bjc.6603051; Korner A, 2007, J CLIN ENDOCR METAB, V92, P1041, DOI 10.1210/jc.2006-1858; Liu J, 2008, CARCINOGENESIS, V29, P2195, DOI 10.1093/carcin/bgn194; Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; Maahs DM, 2005, CIRCULATION, V111, P747, DOI 10.1161/01.CIR.0000155251.03724.A5; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Mantzoros C, 2004, J CLIN ENDOCR METAB, V89, P1102, DOI 10.1210/jc.2003-031804; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Miyoshi Y, 2003, CLIN CANCER RES, V9, P5699; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Nakayama S, 2008, BREAST CANCER RES TR, V112, P405, DOI 10.1007/s10549-007-9874-3; Petrelli JM, 2002, CANCER CAUSE CONTROL, V13, P325, DOI 10.1023/A:1015288615472; Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5; Rosenau F, 2004, CHEMBIOCHEM, V5, P153, DOI 10.1002/cbic.200300761; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Sapkota GP, 2002, BIOCHEM J, V362, P481, DOI 10.1042/0264-6021:3620481; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Saxena NK, 2007, J BIOL CHEM, V282, P13316, DOI 10.1074/jbc.M609798200; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Saxena NK, 2008, CANCER RES, V68, P9712, DOI 10.1158/0008-5472.CAN-08-1952; Schaffler A, 2007, NAT CLIN PRACT ENDOC, V3, P345, DOI 10.1038/ncpendmet0456; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shen Z, 2002, CLIN CANCER RES, V8, P2085; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066; Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029; Takahata C, 2007, CANCER LETT, V250, P229, DOI 10.1016/j.canlet.2006.10.006; Tiainen M, 2002, HUM MOL GENET, V11, P1497, DOI 10.1093/hmg/11.13.1497; Vona-Davis L, 2007, ENDOCR-RELAT CANCER, V14, P189, DOI 10.1677/ERC-06-0068; Wang Y, 2005, J BIOL CHEM, V280, P18341, DOI 10.1074/jbc.M501149200; Wang Y, 2006, CANCER RES, V66, P11462, DOI 10.1158/0008-5472.CAN-06-1969; Witters LA, 2006, TRENDS BIOCHEM SCI, V31, P13, DOI 10.1016/j.tibs.2005.11.009; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yoon MJ, 2006, DIABETES, V55, P2562, DOI 10.2337/db05-1322; Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500; Zhong DS, 2008, CANCER RES, V68, P7270, DOI 10.1158/0008-5472.CAN-08-1484; Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18	71	134	141	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2009	28	29					2621	2633		10.1038/onc.2009.129	http://dx.doi.org/10.1038/onc.2009.129			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	473MO	19483724	Green Accepted			2022-12-17	WOS:000268211200001
J	Oh, H; Irvine, KD				Oh, H.; Irvine, K. D.			In vivo analysis of Yorkie phosphorylation sites	ONCOGENE			English	Article						Warts; hippo; yorkie; Drosophila; tumor; phosphorylation	CELL CONTACT INHIBITION; YES-ASSOCIATED PROTEIN; ORGAN SIZE CONTROL; TEAD/TEF FAMILY; GROWTH-CONTROL; HIPPO PATHWAY; DROSOPHILA; YAP; APOPTOSIS; MECHANISM	The co-activator Yorkie (Yki) mediates transcriptional regulation effectedby the Drosophila Fat-Warts (Wts) Hippo (Hpo) pathways. Yki is inhibitedby Wts-mediated phosphorylation, and a Wts phosphorylation site at Ser168 has been identified. Here we identify two additional Wts phosphorylation sites on Yki, and examine the respective contribution of all three sites to Yki nuclear localization and activity. Our results show that although Ser168 is the most critical site, all three phosphorylation sites influence Yki localization and activity in vivo, and can be sites of regulation by Wts. Thus, investigations of the role of Yki and its mammalian homolog Yes-associated protein (YAP) in development and oncogenesis should include evaluations of additional sites. The WW domains of Yki are not required for its phosphorylation, but instead are positively required for its activity. We also identify two potential sites of phosphorylation by an unknown kinase, which could influence phosphorylation of Ser168 by Wts, suggesting that there are additional mechanisms for regulating Yki/YAP activity.	[Oh, H.; Irvine, K. D.] Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Howard Hughes Med Inst, Piscataway, NJ 08855 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Howard Hughes Med Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08855 USA.	irvine@waksman.rutgers.edu			Howard Hughes Medical Institute; NIH [1F32GM079817]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM079817] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P Beachy, D Pan, J Jiang, G Halder and the Bloomington Drosophila Stock Center for antibodies, plasmids and Drosophila stocks, and C Rauskolb for comments on the paper. This research was supported by the Howard Hughes Medical Institute and NIH post-doctoral fellowship 1F32GM079817 to HO.	Basu S, 2003, MOL CELL, V11, P11, DOI 10.1016/S1097-2765(02)00776-1; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034; Groth AC, 2004, GENETICS, V166, P1775, DOI 10.1534/genetics.166.4.1775; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zeng Q, 2008, CANCER CELL, V13, P188, DOI 10.1016/j.ccr.2008.02.011; Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	20	134	140	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2009	28	17					1916	1927		10.1038/onc.2009.43	http://dx.doi.org/10.1038/onc.2009.43			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	439PX	19330023	Green Accepted			2022-12-17	WOS:000265640600004
J	Crane, CA; Panner, A; Murray, JC; Wilson, SP; Xu, H; Chen, L; Simko, JP; Waldman, FM; Pieper, RO; Parsa, AT				Crane, C. A.; Panner, A.; Murray, J. C.; Wilson, S. P.; Xu, H.; Chen, L.; Simko, J. P.; Waldman, F. M.; Pieper, R. O.; Parsa, A. T.			PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer	ONCOGENE			English	Article						PI(3) kinase; B7-H1; immunoresistance; breast cancer; prostate cancer; T cell	CELL CARCINOMA PATIENTS; MHC CLASS-II; B7-H1 EXPRESSION; POTENTIAL MECHANISM; MOLECULE B7-H1; TUMOR; MELANOMA; TRANSLATION; PHOSPHATASE; PROGNOSIS	Immune escape describes a critical event whereby tumor cells adopt an immunoresistant phenotype to escape adaptive surveillance. We show that expression of a pivotal negative regulator of T-cell function, B7-H1, correlates with PI(3) kinase activation in breast and prostate cancer patients. B7-H1-mediated immunoresistance can be attenuated by inhibitors of the PI(3) kinase pathway, and is dependent on S6K1-mediated translational regulation of B7-H1 protein. Breast and prostate carcinoma cells with activated PI(3) kinase lose the immunoresistant phenotype after treatment with B7-H1 siRNA. Conversely, breast and prostate carcinoma cells with minimal PI(3) kinase activation adopt an immunoresistant phenotype when engineered to overexpress B7-H1 protein. These observations describe a mechanism for immune escape from tumor dormancy in humans that relates to oncogenesis.	[Crane, C. A.; Panner, A.; Murray, J. C.; Wilson, S. P.; Pieper, R. O.; Parsa, A. T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Xu, H.; Chen, L.] Johns Hopkins Univ, Sch Med, Dept Dermatol & Oncol, Baltimore, MD USA; [Simko, J. P.] Univ Calif San Francisco, Dept Pathol & Urol, San Francisco, CA 94143 USA; [Waldman, F. M.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Johns Hopkins University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Parsa, AT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	parsaa@neurosurg.ucsf.edu	Murray, Joseph C/J-8916-2014	Murray, Joseph C/0000-0001-6159-7814; Wilson, Sean/0000-0001-8667-6236	National Institute of Neurological Disorder and Stroke; National Cancer Institute; Seibrandt Vaccine Fund; Khatib Foundation; NATIONAL CANCER INSTITUTE [P50CA097257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS046671] Funding Source: NIH RePORTER	National Institute of Neurological Disorder and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Seibrandt Vaccine Fund; Khatib Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Pramod Srivastava and C David James for critical review of the manuscript, as well as the UCSF cancer center for providing tissue with known PI3K activation status. ATP was supported in part by a K08 grant from the National Institute of Neurological Disorder and Stroke, a career development award from Brain Specialized Programs of Research Excellence (SPORE) of the National Cancer Institute, the Seibrandt Vaccine Fund and the Khatib Foundation.	Baleeiro RB, 2008, MOL IMMUNOL, V45, P3502, DOI 10.1016/j.molimm.2008.04.005; Bui JD, 2007, CURR OPIN IMMUNOL, V19, P203, DOI 10.1016/j.coi.2007.02.001; Chang YC, 2008, BLOOD, V111, P5054, DOI 10.1182/blood-2007-12-130609; Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Inman BA, 2007, CANCER-AM CANCER SOC, V109, P1499, DOI 10.1002/cncr.22588; Johnson LE, 2007, CANCER IMMUNOL IMMUN, V56, P885, DOI 10.1007/s00262-006-0241-8; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Kozikowski AP, 2003, J AM CHEM SOC, V125, P1144, DOI 10.1021/ja0285159; Krambeck AE, 2007, CLIN CANCER RES, V13, P1749, DOI 10.1158/1078-0432.CCR-06-2129; Liu VC, 2007, J IMMUNOL, V178, P2883, DOI 10.4049/jimmunol.178.5.2883; Loos M, 2008, CANCER LETT, V268, P98, DOI 10.1016/j.canlet.2008.03.056; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; Meyer RG, 2007, LUNG CANCER, V58, P88, DOI 10.1016/j.lungcan.2007.05.003; Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394; Mittenclorf EA, 2007, CANCER-AM CANCER SOC, V110, P1677, DOI 10.1002/cncr.22978; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Penn I, 1996, TRANSPLANTATION, V61, P274, DOI 10.1097/00007890-199601270-00019; Powell DJ, 2006, J IMMUNOL, V177, P6527, DOI 10.4049/jimmunol.177.9.6527; Roth TJ, 2007, CANCER RES, V67, P7893, DOI 10.1158/0008-5472.CAN-07-1068; Routh JC, 2008, J UROLOGY, V179, P1954, DOI 10.1016/j.juro.2008.01.056; Schartner JM, 2005, GLIA, V51, P279, DOI 10.1002/glia.20201; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Siva A, 2008, CANCER IMMUNOL IMMUN, V57, P987, DOI 10.1007/s00262-007-0429-6; Slingluff CL, 2007, CLIN CANCER RES, V13, P6386, DOI 10.1158/1078-0432.CCR-07-0486; Slovin SF, 2008, CANCER J, V14, P26, DOI 10.1097/PPO.0b013e318161bffa; Small EJ, 2007, CLIN CANCER RES, V13, P1810, DOI 10.1158/1078-0432.CCR-06-2318; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thompson RH, 2007, CLIN CANCER RES, V13, p709S, DOI 10.1158/1078-0432.CCR-06-1868; Thompson RH, 2006, CANCER RES, V66, P3381, DOI 10.1158/0008-5472.CAN-05-4303; Thompson RH, 2004, P NATL ACAD SCI USA, V101, P17174, DOI 10.1073/pnas.0406351101; Wang L, 2008, P NATL ACAD SCI USA, V105, P9331, DOI 10.1073/pnas.0710441105; Wintterle S, 2003, CANCER RES, V63, P7462; Zang X, 2007, P NATL ACAD SCI USA, V104, P19458, DOI 10.1073/pnas.0709802104	37	134	146	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					306	312		10.1038/onc.2008.384	http://dx.doi.org/10.1038/onc.2008.384			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850006	Green Accepted			2022-12-17	WOS:000262501100014
J	Thomas, M; Narayan, N; Pim, D; Tomaic, V; Massimi, P; Nagasaka, K; Kranjec, C; Gammoh, N; Banks, L				Thomas, M.; Narayan, N.; Pim, D.; Tomaic, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L.			Human papillomaviruses, cervical cancer and cell polarity	ONCOGENE			English	Review						HPV; E6; PDZ; cell polarity	LARGE TUMOR-SUPPRESSOR; PDZ DOMAIN PROTEIN; HUMAN DISCS LARGE; ANCHORAGE-INDEPENDENT GROWTH; HEMATOPOIETIC STEM-CELLS; LIPID PHOSPHATASE PTEN; TYPE-16 E6 PROTEIN; BINDING MOTIF; HPV E6; HUMAN HOMOLOG	Human papillomaviruses (HPVs) are the causative agents of a number of human cancers, of which cervical cancer is the most important. This occurs following persistent infection with a limited number of viral subtypes and is characterized by continued expression of the viral E6 and E7 oncoproteins. A unique characteristic of the cancer-causing HPV types is the presence of a PDZ recognition motif on the carboxy terminus of the E6 oncoprotein. Through this motif, E6 directs the proteasome-mediated degradation of cellular proteins involved in the regulation of cell polarity and in cell proliferation control. The se include components of the Scrib and Par polarity complexes, as well as a number of other PDZ domain-containing substrates. Thus, PVs are now providing novel insights into the functioning of many of these cellular proteins, and into which of these functions, in particular, are relevant for maintaining normal cellular homeostasis. In this review, we discuss the biological consequences of papillomaviral targeting of these cell polarity regulators, both with respect to the viral life cycle and, most importantly, to the development of HPV-induced malignancy.	[Thomas, M.; Narayan, N.; Pim, D.; Tomaic, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L.] Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	International Center for Genetic Engineering & Biotechnology (ICGEB)	Banks, L (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99, I-34012 Trieste, Italy.	banks@icgeb.org	Nagasaka, Kazunori/AAM-4311-2020	Nagasaka, Kazunori/0000-0002-0696-5175; Kranjec, Christian/0000-0001-9713-7406	ICGEB Fellowship Programme; Associazione Italiana per la Ricerca sul Cancro; Association for International Cancer Research; YKK Scholarship Foundation; Kanzawa Medical Research Foundation	ICGEB Fellowship Programme; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Association for International Cancer Research; YKK Scholarship Foundation; Kanzawa Medical Research Foundation(Kanzawa Medical Research Foundation)	We gratefully acknowledge research support provided by the ICGEB Fellowship Programme, the Associazione Italiana per la Ricerca sul Cancro and the Association for International Cancer Research. K Nagasaka is supported by the YKK Scholarship Foundation and the Kanzawa Medical Research Foundation.	Adey NB, 2000, CANCER RES, V60, P35; Alvarez-Salas LM, 1998, P NATL ACAD SCI USA, V95, P1189, DOI 10.1073/pnas.95.3.1189; ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1989, ONCOGENE, V4, P1529; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Bohl J, 2007, J BIOL CHEM, V282, P9392, DOI 10.1074/jbc.M610002200; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; CAVATORTA AL, 2008, GENE; Chetkovich DM, 2002, J NEUROSCI, V22, P5791; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Doorbar J, 2006, CLIN SCI, V110, P525, DOI 10.1042/CS20050369; DOW L, 2008, ONCOGENE; Eckert RL, 2002, J INVEST DERM SYMP P, V7, P36, DOI 10.1046/j.1523-1747.2002.19634.x; Efimova T, 2003, J BIOL CHEM, V278, P34277, DOI 10.1074/jbc.M302759200; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Favre-Bonvin A, 2005, J VIROL, V79, P4229, DOI 10.1128/JVI.79.7.4229-4237.2005; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Filippova M, 2007, J VIROL, V81, P4116, DOI 10.1128/JVI.01924-06; Firestein BL, 2001, MOL BIOL CELL, V12, P3465, DOI 10.1091/mbc.12.11.3465; Fuja TJ, 2004, CANCER RES, V64, P942, DOI 10.1158/0008-5472.CAN-03-2100; Garcia-Mata R, 2007, MOL CELL BIOL, V27, P8683, DOI 10.1128/MCB.00157-07; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2002, J GEN VIROL, V83, P283, DOI 10.1099/0022-1317-83-2-283; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; Hampson L, 2004, INT J ONCOL, V25, P1249; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Handa K, 2007, J VIROL, V81, P1379, DOI 10.1128/JVI.01712-06; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; Higuchi M, 2007, J VIROL, V81, P11900, DOI 10.1128/JVI.00532-07; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; James MA, 2006, J VIROL, V80, P5301, DOI 10.1128/JVI.01942-05; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Javier RT, 2008, ONCOGENE, V27, P7031, DOI 10.1038/onc.2008.352; Jeansonne B, 2003, CELL MOL BIOL, V49, P13; Jeong KW, 2007, ONCOGENE, V26, P487, DOI 10.1038/sj.onc.1209837; Jing M, 2007, J VIROL, V81, P2231, DOI 10.1128/JVI.01979-06; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kuhne C, 2000, ONCOGENE, V19, P5884, DOI 10.1038/sj.onc.1203988; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee CH, 2004, J VIROL, V78, P12366, DOI 10.1128/JVI.78.22.12366-12377.2004; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Mantovani F, 2001, J CELL SCI, V114, P4285; Margolis B, 2005, J CELL SCI, V118, P5157, DOI 10.1242/jcs.02597; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Massimi P, 2006, ONCOGENE, V25, P4276, DOI 10.1038/sj.onc.1209457; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MASSIMI P, 2008, EXP CELL R IN PRESS; McLaughlin M, 2002, J BIOL CHEM, V277, P6406, DOI 10.1074/jbc.M108724200; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; NARAYAN N, 2008, J CELL SCI IN PRESS; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Ohashi M, 2004, VIROLOGY, V320, P52, DOI 10.1016/j.virol.2003.11.014; OSTROW RS, 1991, VIROLOGY, V181, P424; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Riley RR, 2003, CANCER RES, V63, P4862; Roberts S, 2007, EXP CELL RES, V313, P2521, DOI 10.1016/j.yexcr.2007.05.017; Sabio G, 2005, EMBO J, V24, P1134, DOI 10.1038/sj.emboj.7600578; Schimanski CC, 2005, ONCOGENE, V24, P3100, DOI 10.1038/sj.onc.1208520; Shai A, 2008, CANCER RES, V68, P2622, DOI 10.1158/0008-5472.CAN-07-5266; Shai A, 2007, CANCER RES, V67, P1626, DOI 10.1158/0008-5472.CAN-06-3344; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sonoda T, 2006, BIOCHEM BIOPH RES CO, V350, P748, DOI 10.1016/j.bbrc.2006.09.109; Spanos WC, 2008, J VIROL, V82, P2493, DOI 10.1128/JVI.02188-07; Spanos WC, 2008, HEAD NECK-J SCI SPEC, V30, P139, DOI 10.1002/hed.20673; STEELE C, 1992, CANCER RES, V52, P4706; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Tamguney T, 2007, J CELL SCI, V120, P4071, DOI 10.1242/jcs.015230; Tanentzapf G, 2003, NAT CELL BIOL, V5, P46, DOI 10.1038/ncb896; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Thomas M, 2008, VIROLOGY, V376, P371, DOI 10.1016/j.virol.2008.03.021; Topffer S, 2007, J GEN VIROL, V88, P2956, DOI 10.1099/vir.0.83123-0; TOMAIC V, 2008, ONCOGENE IN PRESS; Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Vazquez F, 2006, P NATL ACAD SCI USA, V103, P3633, DOI 10.1073/pnas.0510570103; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Watson RA, 2003, J CELL SCI, V116, P4925, DOI 10.1242/jcs.00809; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Wood CE, 2007, J VIROL, V81, P6339, DOI 10.1128/JVI.00233-07; Wu H, 2007, MOL CELL, V28, P886, DOI 10.1016/j.molcel.2007.10.028; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yamanaka T, 2006, J CELL SCI, V119, P2107, DOI 10.1242/jcs.02938; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Zhang HC, 2007, CELL SIGNAL, V19, P261, DOI 10.1016/j.cellsig.2006.06.008; Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747; Zhang Y, 2007, J VIROL, V81, P3618, DOI 10.1128/JVI.02044-06; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	136	134	139	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					7018	7030		10.1038/onc.2008.351	http://dx.doi.org/10.1038/onc.2008.351			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029942				2022-12-17	WOS:000261108200013
J	Liu, Y; Borchert, GL; Surazynski, A; Hu, CA; Phang, JM				Liu, Y.; Borchert, G. L.; Surazynski, A.; Hu, C. -A; Phang, J. M.			Proline oxidase activates both intrinsic and extrinsic pathways for apoptosis: the role of ROS/superoxides, NFAT and MEK/ERK signaling	ONCOGENE			English	Article						proline oxidase; apoptosis; superoxide radicals; NFAT; ERK; metabolism	COLORECTAL-CANCER CELLS; MITOCHONDRIAL SUPEROXIDE ANIONS; T-CELLS; P53-INDUCED GENE-6; PROTEIN-KINASES; RECEPTOR GENE; EXPRESSION; DEATH; PUMA; FAS	Proline oxidase (POX), often considered a 'housekeeping enzyme' might play an important role in apoptosis. We have shown that POX generated proline-dependent reactive oxygen species (ROS), specifically superoxide radicals, and induced apoptosis through the mitochondrial (intrinsic) pathway. In our current report, we used DLD-1 colorectal cancer cells stably transfected with the POX gene under the control of a tetracycline-inducible promoter and found POX-stimulated expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), DR5 and cleavage of caspase-8. Importantly, apoptosis measured by flow cytometry was partially inhibited by Z-IETD-FMK, a specific inhibitor of caspase-8. These findings suggest that the extrinsic (death receptor) pathway also is activated by POX. Furthermore, the mechanism of this effect on the extrinsic pathway, specifically, the induction of TRAIL by POX, may be mediated by NFAT transcription factors. Additionally, POX expression also dramatically decreased phosphorylation of MEK and ERK, and the decrease was partially reversed by expression of manganese superoxide dismutase (MnSOD). Overexpression of constitutively active form of MEK, acMEK, partially blocked POX-induced apoptosis. These findings suggest the involvement of MEK/ERK signaling and further confirm the role of ROS/superoxides in POX-induced apoptosis. Combined with previously published data, we conclude that POX may induce apoptosis through both intrinsic and extrinsic pathways and is involved in nuclear factor of activated T cells (NFAT) signaling and regulation of the MEK/ERK pathway. It is suggested that, as a nutrition factor, POX may modulate apoptosis signals induced by p53 or other anti-cancer agents and enhance apoptosis in stress situations.	Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA; SAIC Federick Inc, Basic Res Program, Frederick, MD USA; Univ New Mexico, Hlth Sci Ctr, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University of New Mexico; University of New Mexico's Health Sciences Center	Liu, Y (corresponding author), Natl Canc Inst, Ctr Canc Res, Comparat Carcinogenesis Lab, Metab & Canc Susceptibil Sect, Frederick, MD 21702 USA.	liuy@ncifcrf.gov; phang@ncifcrf.gov	Surażynski, Arkadiusz/ABG-2795-2020	Surażynski, Arkadiusz/0000-0003-4475-873X	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC000157] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC010743] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams E, 1970, Int Rev Connect Tissue Res, V5, P1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Delwing D, 2003, BRAIN RES, V991, P180, DOI 10.1016/j.brainres.2003.08.014; Donald SP, 2001, CANCER RES, V61, P1810; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Dussmann H, 2003, J BIOL CHEM, V278, P12645, DOI 10.1074/jbc.M210826200; HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3; Hamilton G, 2004, J CLIN ONCOL, V22, p235S; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083; Loo G, 2003, J NUTR BIOCHEM, V14, P64, DOI 10.1016/S0955-2863(02)00251-6; Lu KP, 2003, CANCER CELL, V4, P175, DOI 10.1016/S1535-6108(03)00218-6; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; MCCAFFREY PG, 1994, J BIOL CHEM, V269, P30445; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Phang J. M., 2001, METABOLIC MOL BASES, P1821; PHANG JM, 1982, J CELL PHYSIOL, V110, P255, DOI 10.1002/jcp.1041100306; PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wenzel U, 2004, CARCINOGENESIS, V25, P703, DOI 10.1093/carcin/bgh079; Wenzel U, 2003, INT J CANCER, V106, P666, DOI 10.1002/ijc.11294; Wilson DJ, 1999, CELL IMMUNOL, V194, P67, DOI 10.1006/cimm.1999.1486; Wu GS, 2000, ADV EXP MED BIOL, V465, P143; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	38	134	137	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 14	2006	25	41					5640	5647		10.1038/sj.onc.1209564	http://dx.doi.org/10.1038/sj.onc.1209564			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16619034				2022-12-17	WOS:000240599100005
J	Ribatti, D; Nico, B; Vacca, A				Ribatti, D.; Nico, B.; Vacca, A.			Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma	ONCOGENE			English	Review						angiogenesis; bone marrow; microenvironment; multiple myeloma	ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; RECEPTOR C-MET; NF-KAPPA-B; CELL-GROWTH; DRUG-RESISTANCE; UP-REGULATION; PLASMA-CELLS; FACTOR VEGF; HEMATOLOGIC MALIGNANCIES	Tumor microenvironment is essential for tumor cell proliferation, angiogenesis, invasion and metastasis through its provision of survival signals, secretion of growth and pro-angiogenic factors, and direct adhesion molecule interactions. This review examines its importance in the induction of an angiogenic response in multiple myeloma (MM). The encouraging results of preclinical and clinical trials in which MM has been treated by targeting the tumor microenvironment are also discussed.	Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, I-70124 Bari, Italy; Univ Bari, Sch Med, Dept Internal Med & Clin Oncol, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Ribatti, D (corresponding author), Univ Bari, Sch Med, Dept Human Anat & Histol, Policlin, Piazza Giulio Cesare,11, I-70124 Bari, Italy.	ribatti@anatomia.uniba.it	Vacca, Angelo/AAC-9558-2022	Vacca, Angelo/0000-0002-4567-8216				Akiyama M, 2002, CANCER RES, V62, P3876; Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Andersen NF, 2005, BRIT J HAEMATOL, V128, P210, DOI 10.1111/j.1365-2141.2004.05299.x; Asosingh K, 2004, BLOOD, V103, P3131, DOI 10.1182/blood-2003-08-2946; Barille S, 1997, BLOOD, V90, P1649, DOI 10.1182/blood.V90.4.1649.1649_1649_1655; Bellamy WT, 1999, CANCER RES, V59, P728; Bernardini G, 2003, J IMMUNOL METHODS, V273, P83, DOI 10.1016/S0022-1759(02)00420-9; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Bisping G, 2003, BLOOD, V101, P2775, DOI 10.1182/blood-2002-09-2907; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998; Broek IV, 2004, LEUKEMIA, V18, P976, DOI 10.1038/sj.leu.2403331; Bruno B, 2005, LEUKEMIA, V19, P1729, DOI 10.1038/sj.leu.2403905; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736; Costes V, 1998, BRIT J HAEMATOL, V103, P1152, DOI 10.1046/j.1365-2141.1998.01101.x; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; Crivellato E, 2003, LEUKEMIA LYMPHOMA, V44, P517, DOI 10.1080/1042819021000047001; Crivellato E, 2002, LEUKEMIA LYMPHOMA, V43, P2201, DOI 10.1080/1042819021000016159; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Davies FE, 2003, BLOOD, V102, P4504, DOI 10.1182/blood-2003-01-0016; De Vos J, 2002, ONCOGENE, V21, P6848, DOI 10.1038/sj.onc.1205868; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Derksen PWB, 2002, BLOOD, V99, P1405, DOI 10.1182/blood.V99.4.1405; Dhodapkar MV, 1998, BLOOD, V91, P2679, DOI 10.1182/blood.V91.8.2679.2679_2679_2688; Di Raimondo F, 2000, HAEMATOLOGICA, V85, P800; Dominici M, 2001, LEUKEMIA, V15, P171, DOI 10.1038/sj.leu.2401984; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; GEN I, 2000, BLOOD, V96, P2856; Giuliani N, 2003, BLOOD, V102, P638, DOI 10.1182/blood-2002-10-3257; Grand EK, 2004, LEUKEMIA, V18, P962, DOI 10.1038/sj.leu.2403347; GRUBER BL, 1995, BLOOD, V86, P2488; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Hazlehurst LA, 2003, CANCER RES, V63, P7900; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hedvat CV, 2003, BRIT J HAEMATOL, V122, P728, DOI 10.1046/j.1365-2141.2003.04481.x; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2005, BEST PRACT RES CL HA, V18, P509, DOI 10.1016/j.beha.2005.01.003; Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, MOL CANCER THER, V1, P539; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood-2002-08-2640; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Johnson LL, 1998, CURR OPIN CHEM BIOL, V2, P466, DOI 10.1016/S1367-5931(98)80122-1; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaushal GP, 1999, BRIT J HAEMATOL, V104, P365, DOI 10.1046/j.1365-2141.1999.01180.x; Khakoo AY, 2005, ANNU REV MED, V56, P79, DOI 10.1146/annurev.med.56.090203.104149; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; LeBlanc R, 2002, CANCER RES, V62, P4996; Leek RD, 1999, BRIT J CANCER, V79, P991, DOI 10.1038/sj.bjc.6690158; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Lin B, 2002, CANCER RES, V62, P5019; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakayama T, 2004, J CLIN INVEST, V114, P1317, DOI 10.1172/JCI200422089; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; Ochiai N, 2003, BLOOD, V102, P3349, DOI 10.1182/blood-2003-03-0851; Ogata A, 1997, J IMMUNOL, V159, P2212; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Pellegrino A, 2005, BRIT J HAEMATOL, V129, P248, DOI 10.1111/j.1365-2141.2005.05443.x; Pellegrino A, 2004, CANCER LETT, V207, P221, DOI 10.1016/j.canlet.2003.10.036; Podar K, 2005, BLOOD, V105, P1383, DOI 10.1182/blood-2004-07-2909; Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood-2003-10-3527; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04-06-0334; Ria R, 2003, LEUKEMIA, V17, P1961, DOI 10.1038/sj.leu.2403076; Ribatti D, 2005, LEUKEMIA, V19, P1525, DOI 10.1038/sj.leu.2403852; Ribatti D, 2004, J CELL MOL MED, V8, P294, DOI 10.1111/j.1582-4934.2004.tb00319.x; Ribatti D, 2004, CLIN EXP ALLERGY, V34, P1660, DOI 10.1111/j.1365-2222.2004.02104.x; Ribatti D, 1999, BRIT J CANCER, V79, P451, DOI 10.1038/sj.bjc.6690070; Ribatti D, 2003, J HEMATOTH STEM CELL, V12, P11, DOI 10.1089/152581603321210091; Roccaro AM, 2006, CANCER RES, V66, P184, DOI 10.1158/0008-5472.CAN-05-1195; Sato N, 2002, JPN J CANCER RES, V93, P459, DOI 10.1111/j.1349-7006.2002.tb01278.x; Seidel C, 1998, BLOOD, V91, P806, DOI 10.1182/blood.V91.3.806.806_806_812; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Tai YT, 2002, BLOOD, V99, P1419, DOI 10.1182/blood.V99.4.1419; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood-2004-10-3913; Trudel S, 2004, BLOOD, V103, P3521, DOI 10.1182/blood-2003-10-3650; Tu YP, 2000, CANCER RES, V60, P6763; Urashima M, 1996, BLOOD, V87, P1928; Urashima M, 1997, BLOOD, V90, P754, DOI 10.1182/blood.V90.2.754.754_754_765; Vacca A, 2006, LEUKEMIA, V20, P193, DOI 10.1038/sj.leu.2404067; Vacca A, 2005, J CLIN ONCOL, V23, P5334, DOI 10.1200/JCO.2005.03.723; Vacca A, 1999, BLOOD, V93, P3064; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Vacca A, 2003, HAEMATOLOGICA, V88, P176; Vacca A, 2001, EXP HEMATOL, V29, P993, DOI 10.1016/S0301-472X(01)00674-9; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Van Valckenborgh E, 2005, LEUKEMIA, V19, P1628, DOI 10.1038/sj.leu.2403866; Van Valckenborgh E, 2002, INT J CANCER, V101, P512, DOI 10.1002/ijc.10642; Van Valckenborgh E, 2002, BRIT J CANCER, V86, P796, DOI 10.1038/sj.bjc.6600137; VANDERKERKEN K, 1977, BRIT J CANCER, V76, P451; Vincent L, 2005, CANCER RES, V65, P3185, DOI 10.1158/0008-5472.CAN-04-3598; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhang H, 2005, BLOOD, V105, P3286, DOI 10.1182/blood-2004-06-2101; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629	118	134	137	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2006	25	31					4257	4266		10.1038/sj.onc.1209456	http://dx.doi.org/10.1038/sj.onc.1209456			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	066OU	16518413				2022-12-17	WOS:000239240100001
J	Sensi, M; Nicolini, G; Petti, C; Bersani, I; Lozupone, F; Molla, A; Vegetti, C; Nonaka, D; Mortarini, R; Parmiani, G; Fais, S; Anichini, A				Sensi, M.; Nicolini, G.; Petti, C.; Bersani, I.; Lozupone, F.; Molla, A.; Vegetti, C.; Nonaka, D.; Mortarini, R.; Parmiani, G.; Fais, S.; Anichini, A.			Mutually exclusive NRAS(Q61R) and BRAF(V600E) mutations at the single-cell level in the same human melanoma	ONCOGENE			English	Article						melanoma; BRAF; NRAS; MASA-PCR; SCID	N-RAS MUTATIONS; B-RAF; BRAF MUTATIONS; COLORECTAL TUMORS; K-RAS; EXPRESSION; KINASE; GROWTH; GENE; ACTIVATION	BRAF or NRAS mutations have been found in 80% of human sporadic melanomas, but only one of these genetic alterations could be detected in each tumour. This suggests that BRAF and NRAS 'double mutants' may not provide advantage for tumour growth, or may even be selected against during tumorigenesis. However, by applying mutant-allele-specific-amplification-PCR method to short-term melanoma lines, one out of 14 tumours was found to harbour both BRAF(V600E) and the activating NRAS(Q61R) mutations. On the other hand, analysis of 21 melanoma clones isolated by growth in soft agar from this tumour indicated that 16/21 clones harboured a BRAF(V600E), but were wild-type for NRAS, whereas the remaining had the opposite genotype (NRAS(Q61R)/wild-type BRAF). When compared to BRAF(V600E) clones, NRAS(Q61R) clones displayed reduced growth in soft agar, but higher proliferative ability in vitro in liquid medium and even in vivo after grafting into SCID/SCID mice. These data suggest that NRAS and BRAF activating mutations can coexist in the same melanoma, but are mutually exclusive at the single-cell level. Moreover, the presence of NRAS(Q61R) or BRAF(V600E) is associated with distinct in vitro and in vivo growth properties of neoplastic cells.	Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, I-20133 Milan, Italy; Ist Nazl Studio & Cura Tumori, Dept Pathol, I-20133 Milan, Italy; Ist Super Sanita, Dept Drug Res & Evaluat Pharmacogenet, Drug Resistance & Expt Therapeut Sect, I-00161 Rome, Italy; Ist Nazl Studio & Cura Tumori, Unit Immunotherapy Human Tumors, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Istituto Superiore di Sanita (ISS); Fondazione IRCCS Istituto Nazionale Tumori Milan	Sensi, M (corresponding author), Ist Nazl Studio & Cura Tumori, Dept Expt Oncol, Human Tumor Immunobiol Unit, Via Venezian 1, I-20133 Milan, Italy.	marialuisa.sensi@istitutotumori.mi.it	Lozupone, Francesco/H-2998-2016; Anichini, Andrea/K-1434-2016; Fais, Stefano/J-8638-2016; Sensi, Marialuisa/K-5631-2014; Mortarini, Roberta/C-9483-2017	Lozupone, Francesco/0000-0002-4959-9400; Anichini, Andrea/0000-0001-5096-5538; Fais, Stefano/0000-0001-9060-2766; Sensi, Marialuisa/0000-0002-7643-0248; Mortarini, Roberta/0000-0001-7732-0561				ANICHINI A, 1989, J IMMUNOL, V142, P3692; BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Brose MS, 2002, CANCER RES, V62, P6997; Daniotti M, 2004, ONCOGENE, V23, P5968, DOI 10.1038/sj.onc.1207780; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Downward J, 2004, ONCOGENE, V23, P8376, DOI 10.1038/sj.onc.1208073; Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022; Gorden A, 2003, CANCER RES, V63, P3955; Gray-Schopfer VC, 2005, CANCER METAST REV, V24, P165, DOI 10.1007/s10555-005-5865-1; HASEGAWA Y, 1995, ONCOGENE, V10, P1441; Hendrix MJC, 2003, ANN NY ACAD SCI, V995, P151, DOI 10.1111/j.1749-6632.2003.tb03218.x; Jiveskog S, 1998, J INVEST DERMATOL, V111, P757, DOI 10.1046/j.1523-1747.1998.00376.x; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Lilleberg SL, 2004, ANN NY ACAD SCI, V1022, P250, DOI 10.1196/annals.1318.039; Linard B, 2002, J IMMUNOL, V168, P4802, DOI 10.4049/jimmunol.168.9.4802; Loewe R, 2004, J INVEST DERMATOL, V123, P733, DOI 10.1111/j.0022-202X.2004.23402.x; Lozupone F, 2004, CANCER RES, V64, P378, DOI 10.1158/0008-5472.CAN-03-1501; LUPETTI R, 1994, MELANOMA RES, V4, P11, DOI 10.1097/00008390-199402000-00003; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Miller CJ, 2004, J INVEST DERMATOL, V123, P990, DOI 10.1111/j.0022-202X.2004.23468.x; Omholt K, 2003, CLIN CANCER RES, V9, P6483; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rak J, 2004, SEMIN CANCER BIOL, V14, P93, DOI 10.1016/j.semcancer.2003.09.014; Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; Sivertsson A, 2002, CLIN CHEM, V48, P2164; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Xu XL, 2003, CANCER RES, V63, P4561	39	134	136	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3357	3364		10.1038/sj.onc.1209379	http://dx.doi.org/10.1038/sj.onc.1209379			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16462768				2022-12-17	WOS:000238448100001
J	Xi, SC; Gooding, WE; Grandis, JR				Xi, SC; Gooding, WE; Grandis, JR			In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy	ONCOGENE			English	Article						signal transducers and activators of transcription; head and neck cancer; epidermal growth factor receptor; STAT3 decoy; cisplatin	ENDOTHELIAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; CONSTITUTIVE ACTIVATION; TUMOR ANGIOGENESIS; TYROSINE KINASE; SRC ONCOPROTEIN; NECK-CANCER; KAPPA-B	The development of more effective prevention and treatment strategies for solid tumors is limited by an incomplete understanding of the critical growth pathways that are activated in carcinogenesis. Signal transducers and activators of transcription ( STAT) proteins have been linked to transformation and tumor progression. Several approaches have been used to block STAT3 in cancer cells resulting in reduced proliferation and apoptosis. We tested the hypothesis that blocking STAT3 activation using a transcription factor decoy approach would decrease tumor growth and STAT3 target gene expression in vivo. In a xenograft model of squamous cell carcinoma of the head and neck (SCCHN), daily administration of the STAT3 decoy ( 25 mug) resulted in decreased tumor volumes, abrogation of STAT3 activation, and decreased expression of STAT3 target genes ( VEGF, Bcl-xL, and cyclin D1) compared to treatment with a mutant control decoy. Blockade of STAT3 with the STAT3 decoy also induced apoptosis and decreased proliferation, an effect that was augmented when the STAT3 decoy was combined with cisplatin, both in vitro and in vivo. These results suggest that a transcription factor decoy approach may be used to target STAT3 in cancers that demonstrate increased STAT3 activation including SCCHN.	Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Inst Canc, Dept Biostat, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Grandis, JR (corresponding author), Eye & Ear Inst Pittsburgh, Suite 500,200 Lothrop St, Pittsburgh, PA 15213 USA.	jgrandis@pitt.edu			NCI NIH HHS [R01CA 101840-01, 1 P50 CA097190-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097190, R01CA101840] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 2000, LARYNGOSCOPE, V110, P868, DOI 10.1097/00005537-200005000-00016; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Grunstein J, 1999, CANCER RES, V59, P1592; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Kawamura I, 1999, GENE THER, V6, P91, DOI 10.1038/sj.gt.3300819; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Leong PL, 2003, P NATL ACAD SCI USA, V100, P4138, DOI 10.1073/pnas.0534764100; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Lim R, 2000, J NEUROCHEM, V74, P596, DOI 10.1046/j.1471-4159.2000.740596.x; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Mayer F, 2003, ANN ONCOL, V14, P825, DOI 10.1093/annonc/mdg242; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NABEL EG, 1990, SCIENCE, V249, P1285, DOI 10.1126/science.2119055; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Park SH, 1999, J BIOL CHEM, V274, P7421, DOI 10.1074/jbc.274.11.7421; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Rak J, 2000, CANCER RES, V60, P490; Takeda T, 1997, J ENDOCRINOL, V153, pR1, DOI 10.1677/joe.0.153R001; Takeuchi S, 1999, MOL BRAIN RES, V74, P208, DOI 10.1016/S0169-328X(99)00298-3; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Veikkola T, 2000, CANCER RES, V60, P203; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; von Knethen A, 1998, ONCOGENE, V17, P387, DOI 10.1038/sj.onc.1201926; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang LH, 2000, BLOOD, V95, P1249, DOI 10.1182/blood.V95.4.1249.004k39_1249_1257; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; WONG P, 1994, MOL CELL BIOL, V14, P914, DOI 10.1128/MCB.14.2.914; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	50	134	148	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					970	979		10.1038/sj.onc.1208316	http://dx.doi.org/10.1038/sj.onc.1208316			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15592503	Bronze			2022-12-17	WOS:000226749200003
J	Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS				Foster, CS; Falconer, A; Dodson, AR; Norman, AR; Dennis, N; Fletcher, A; Southgate, C; Dowe, A; Dearnaley, D; Jhavar, S; Eeles, R; Feber, A; Cooper, CS			Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome	ONCOGENE			English	Article						E2F3 gene; prostate cancer; EZH2 gene	RENAL-CELL CARCINOMA; BLADDER-CANCER; BREAST-CANCER; GENE; PROLIFERATION; EXPRESSION; TFE3; P53; EZH2; ADENOCARCINOMAS	E2F transcription factors, including EM, directly modulate expression of EZH2. Recently, overexpression of the EZH2 gene has been implicated in the development of human prostate cancer. In tissue microrarray studies we now show that expression of high levels of nuclear E2F3 occurs in a high proportion (98/147, 67%) of human prostate cancers, but is a rare event in non-neoplastic prostatic epithelium suggesting a role for E2F3 overexpression in prostate carcinogenesis. Patients with prostate cancer exhibiting immunohistochemically detectable nuclear E2F3 expression have poorer overall survival (P=0.0022) and cause-specific survival (P=0.0047) than patients without detectable E2F3 expression. When patients are stratified according to the maximum percentage of EM-positive nuclei identified within their prostate cancers (up to 20, 21-40%, etc.), there is an increasingly significant association between E2F3 staining and risk of death both for overall survival (P=0.0014) and for cause-specific survival (P=0.0004). Multivariate analyses select E2F3 expression as an independent factor predicting overall survival (unstratified P=0.0103, stratified P=0.0086) and cause-specific survival (unstratified P=0.0288, stratified P=0.0072). When these results are considered together with published data on EZH2 and on the E2F3 control protein pRB, we conclude that the pRB-E2F3-EZH2 control axis may have a critical role in modulating aggressiveness of individual human prostate cancer.	Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England; Univ Liverpool, Dept Pathol & Mol Genet, Liverpool, Merseyside, England; Canc Res Inst, Sect Canc Genet, Male Urol Canc Res Ctr, Sutton, Surrey, England; Royal Marsden NHS Trust, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of Liverpool; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Cooper, CS (corresponding author), Canc Res Inst, Sect Mol Carcinogenesis, Male Urol Canc Res Ctr, Sutton, Surrey, England.	colin.cooper@icr.ac.uk	Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; Eeles, Rosalind/0000-0002-3698-6241; Feber, Andrew/0000-0001-5282-0498				Bostwick D G, 1999, Semin Urol Oncol, V17, P222; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; BROOKS JD, 1995, PROSTATE, V26, P35, DOI 10.1002/pros.2990260108; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 1997, ONCOGENE, V15, P2233, DOI 10.1038/sj.onc.1201394; CORDONCARDO C, 1994, CANCER RES, V54, P794; Cornford P, 1999, AM J PATHOL, V154, P137, DOI 10.1016/S0002-9440(10)65260-1; Cox D.R., 1984, ANAL SURVIVAL DATA; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Foster CS, 2000, PROSTATE, P4; Foster CS, 2000, SCAND J UROL NEPHROL, V34, P19, DOI 10.1080/003655900750169284; FOSTER CS, 2001, CURR DIAGN PATHOL, V7, P4; GAO X, 1995, ONCOGENE, V11, P1395; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Greene FL, 2002, AJCC CANC STAGING HD; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; Humbert PO, 2000, GENE DEV, V14, P690; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kibel AS, 2000, UROLOGY, V55, P316, DOI 10.1016/S0090-4295(99)00478-1; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Konishi N, 2002, JPN J CANCER RES, V93, P767, DOI 10.1111/j.1349-7006.2002.tb01318.x; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Osman I, 1999, CLIN CANCER RES, V5, P2082; Shaaban AM, 2002, AM J SURG PATHOL, V26, P421, DOI 10.1097/00000478-200204000-00003; Sidhar SK, 1996, HUM MOL GENET, V5, P1333, DOI 10.1093/hmg/5.9.1333; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Sobin LH, 1997, TNM CLASSIFICATION M, P170; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Tomovska S, 2001, INT J ONCOL, V18, P1239; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	36	134	143	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 5	2004	23	35					5871	5879		10.1038/sj.onc.1207800	http://dx.doi.org/10.1038/sj.onc.1207800			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	841OV	15184867				2022-12-17	WOS:000222941100001
J	Ferber, MJ; Thorland, EC; Brink, AA; Rapp, AK; Phillips, LA; McGovern, R; Gostout, BS; Cheung, TH; Chung, TKH; Fu, WY; Smith, DI				Ferber, MJ; Thorland, EC; Brink, AA; Rapp, AK; Phillips, LA; McGovern, R; Gostout, BS; Cheung, TH; Chung, TKH; Fu, WY; Smith, DI			Preferential integration of human papillomavirus type 18 near the c-myc locus in cervical carcinoma	ONCOGENE			English	Article						common fragile sites; cervical cancer; human papillomavirus; viral integration; c-myc	COMMON FRAGILE SITES; VIRAL INTEGRATION; E2 PROTEIN; CELLS; HPV16; CLONING; GENE; DNA; PHOSPHORYLATION; PROTOONCOGENE	The development of cervical cancer is highly associated with human papillomavirus (HPV) infection. Greater than 99% of all cervical tumors contain HPV DNA. Integration of high-risk HPV has been temporally associated with the acquisition of a malignant phenotype. Recent work from our lab has shown that HPV16, the most common high-risk HPV associated with cervical carcinoma, preferentially integrates at loci containing human common fragile sites (CFSs). CFSs are regions of genomic instability that have also been associated with deletions, translocations, and gene amplification during cancer development. The current work shows that HPV18, the second most prevalent high-risk HPV type found in cervical tumors, preferentially targets the CFSs. We identified 27 unique HPV18 integrations in cervical tumors, of which 63% ( P<0.001) occur in CFSs. However, the distribution of HPV18 integrations found were profoundly different from those found for HPV16. Specifically, 30% of all HPV18 integrations occurred within the chromosomal band 8q24 near the c-myc proto-oncogene. None of the HPV16 integrations occurred in this region. Previous low-resolution mapping suggested that c-myc may be a target of HPV integration. Our data at nucleotide resolution confirm that in HPV18-positive cervical tumors, the region surrounding c-myc is indeed a hot spot of viral integration. These results demonstrate that CFSs are preferred sites of integration for HPV18 in cervical tumors. In addition, we have identified multiple cellular genes that have been disrupted by HPV18 integration in cervical tumors. Our results suggest that the sites of HPV18 integration are nonrandom and may play an important role in the development of cervical tumors.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2333 AL Leiden, Netherlands; Mayo Clin & Mayo Fdn, Div Expt Pathol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Obstet & Gynaecol, Rochester, MN 55905 USA; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China	Mayo Clinic; Mayo Clinic; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Mayo Clinic; Mayo Clinic; Chinese University of Hong Kong; Prince of Wales Hospital	Smith, DI (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.	smith.david@mayo.edu		CHUNG, Tony/0000-0002-6362-8546	NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA 48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad SI, 2002, BIOESSAYS, V24, P439, DOI 10.1002/bies.10082; Bechtold V, 2003, J VIROL, V77, P2021, DOI 10.1128/JVI.77.3.2021-2028.2003; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Boxer LM, 2001, ONCOGENE, V20, P5595, DOI 10.1038/sj.onc.1204595; Boyer SN, 1996, CANCER RES, V56, P4620; Brink AATP, 2002, CANCER GENET CYTOGEN, V134, P145, DOI 10.1016/S0165-4608(01)00620-3; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; CHO KR, 1998, GENETIC BASIS HUMAN, P631; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CROOK T, 1988, P NATL ACAD SCI USA, V85, P8820, DOI 10.1073/pnas.85.23.8820; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; EIDELMAN FJ, 1993, J CELL BIOL, V123, P467, DOI 10.1083/jcb.123.2.467; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; Fretland AJ, 2000, CHEM-BIOL INTERACT, V129, P41, DOI 10.1016/S0009-2797(00)00197-6; Gallego MI, 1997, MOL CARCINOGEN, V19, P114, DOI 10.1002/(SICI)1098-2744(199707)19:2<114::AID-MC6>3.0.CO;2-F; GLOVER TW, 1987, AM J HUM GENET, V41, P882; GLOVER TW, 1988, AM J HUM GENET, V43, P265; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Greenspan DL, 1997, CANCER RES, V57, P4692; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOWLEY PM, 1996, FIELDS VIROLOGY, P2045; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Koopman LA, 1999, CANCER RES, V59, P5615; KURMAN RJ, 1988, AM J OBSTET GYNECOL, V159, P293, DOI 10.1016/S0002-9378(88)80070-X; LAZO PA, 1989, CANCER RES, V49, P4305; Le Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281, DOI 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V; Liu CX, 2000, GENOMICS, V69, P271, DOI 10.1006/geno.2000.6331; Macville M, 1999, CANCER RES, V59, P141; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MCBRIDE AA, 1991, J BIOL CHEM, V266, P18411; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Munger K, 2002, FRONT BIOSCI-LANDMRK, V7, pD641, DOI 10.2741/munger; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pillutla RC, 1998, GENOMICS, V54, P351, DOI 10.1006/geno.1998.5604; POPESCU NC, 1989, CANCER GENET CYTOGEN, V42, P157, DOI 10.1016/0165-4608(89)90084-8; POPESCU NC, 1990, HUM GENET, V84, P383; RASSOOL FV, 1991, P NATL ACAD SCI USA, V88, P6657, DOI 10.1073/pnas.88.15.6657; Ratsch A, 2002, EXP CELL RES, V273, P12, DOI 10.1006/excr.2001.5429; Sarkar G, 1993, PCR Methods Appl, V2, P318; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schwartz SM, 2001, J CLIN ONCOL, V19, P1906, DOI 10.1200/JCO.2001.19.7.1906; SHAH KV, 1996, FIELDS VIROLOGY, P2077; SIMMONS DL, 1992, J IMMUNOL, V148, P267; Thorland EC, 2003, ONCOGENE, V22, P1225, DOI 10.1038/sj.onc.1206170; Thorland EC, 2000, CANCER RES, V60, P5916; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wentzensen N, 2002, ONCOGENE, V21, P419, DOI 10.1038/sj.onc.1205104; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; Zimonjic DB, 1997, CANCER RES, V57, P1166	57	134	142	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2003	22	46					7233	7242		10.1038/sj.onc.1207006	http://dx.doi.org/10.1038/sj.onc.1207006			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732PP	14562053				2022-12-17	WOS:000185955000016
J	Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C				Dammann, R; Schagdarsurengin, U; Liu, LM; Otto, N; Gimm, O; Dralle, H; Boehm, B; Pfeifer, GP; Hoang-Vu, C			Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma	ONCOGENE			English	Article						pancreatic adenocarcinoma; neuroendocrine pancreatic tumor; pancreatitis; methylation; RASSF1; K-ras; p16	TUMOR-SUPPRESSOR GENE; CPG ISLAND METHYLATION; CANCER CELL-LINES; EPIGENETIC INACTIVATION; ULCERATIVE-COLITIS; CLINICAL-FEATURES; DNA METHYLATION; BREAST CANCERS; LUNG; ADENOCARCINOMA	Recently, we have characterized the Ras association domain family 1A gene (RASSF1A) at the segment 3p21.3, which is frequently lost in variety of human cancers and epigenetically inactivated in many types of primary tumors, such as lung, breast, kidney, prostate and thyroid carcinomas. Here, we investigated the methylation status of the RASSF1A CpG island promoter in the pathogenesis of pancreatic cancer. RASSF1A hypermethylation was detected in 29 out of 45 (64%) primary adenocarcinomas, in 10 out of 12 (83%) endocrine tumors and in eight out of 18 (44%) pancreatitis samples. In seven out of eight pancreas cancer cell lines, RASSF1A was silenced and was retranscribed after treatment with 5-aza-2'-deoxycytidine. Additionally, we analysed the aberrant methylation frequency of cell cycle inhibitor p16(INK4a) and K-ras gene mutations in the pancreatic samples. p16 inactivation was detected in 43% of adenocarcinomas, in 17% of neuroendocrine tumors, in 18% of pancreatitis and in 63% of pancreas cancer cell lines. K-ras mutations were detected in 16 out of 45 (36%) primary adenocarcinomas. Pancreatic adenocarcinomas with K-ras mutation have significantly less RASSF1A methylation and vice versa (P = 0.001, X-2 test). In conclusion, our data indicate that inactivation of the RASSF1A gene is a frequent event in pancreatic cancer and suggest an inverse correlation between RASSF1A silencing and K-ras activation.	Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, D-06097 Halle Saale, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Klin & Poliklin Allgemein Viszeral & Gefasschirur, D-06097 Halle Saale, Germany; Univ Ulm, Dept Internal Med, Div Endocrinol, D-89070 Ulm, Germany	Martin Luther University Halle Wittenberg; City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg; Ulm University	Dammann, R (corresponding author), Univ Halle Wittenberg, Inst Humangenet & Med Biol, AG Tumorgenet, Fak Med, Magdeburger Str 2, D-06097 Halle Saale, Germany.		Schagdarsurengin, Undraga/AAH-4312-2020; Dralle, Henning/ABD-4454-2020; Boehm, Bernhard Otto/F-8750-2015; Schagdarsurengin, Undraga/AAH-4346-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938; 	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Barghom A, 2001, J PATHOL, V194, P451, DOI 10.1002/path.886; BOS JL, 1989, CANCER RES, V49, P4682; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Chan AOO, 2003, ONCOGENE, V22, P924, DOI 10.1038/sj.onc.1206123; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2003, HISTOL HISTOPATHOL, V18, P665, DOI 10.14670/HH-18.665; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Furuya N, 1997, GASTROENTEROLOGY, V113, P593, DOI 10.1053/gast.1997.v113.pm9247481; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Gunzburg WH, 2001, TRENDS MOL MED, V7, P30, DOI 10.1016/S1471-4914(00)01865-7; HAHN SA, 1995, CANCER RES, V55, P4670; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hruban R H, 1998, J Hepatobiliary Pancreat Surg, V5, P383, DOI 10.1007/s005340050062; HRUBAN RH, 1993, AM J PATHOL, V143, P545; Hruban RH, 2000, AM J PATHOL, V156, P1821, DOI 10.1016/S0002-9440(10)65054-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; Issa JPJ, 2001, CANCER RES, V61, P3573; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kuzmin I, 2002, CANCER RES, V62, P3498; Kwong J, 2002, CLIN CANCER RES, V8, P131; Laghi L, 2002, ONCOGENE, V21, P4301, DOI 10.1038/sj.onc.1205533; Lerman MI, 2000, CANCER RES, V60, P6116; Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814; Moore PS, 2001, AM J PATHOL, V158, P317, DOI 10.1016/S0002-9440(10)63971-5; Muscarella P, 1998, CANCER RES, V58, P237; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Perugini RA, 1998, CRIT REV EUKAR GENE, V8, P377, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.70; Pfeifer GP, 2002, BIOL CHEM, V383, P907, DOI 10.1515/BC.2002.097; Sato T, 2000, HEPATO-GASTROENTEROL, V47, P875; Schagdarsurengin U, 2002, CANCER RES, V62, P3698; Schutte M, 1997, CANCER RES, V57, P3126; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; TADA M, 1991, CANCER, V67, P634, DOI 10.1002/1097-0142(19910201)67:3<634::AID-CNCR2820670318>3.0.CO;2-7; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; Tomizawa Y, 2002, CLIN CANCER RES, V8, P2362; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wilentz RE, 2000, AM J PATHOL, V156, P1641, DOI 10.1016/S0002-9440(10)65035-3; Yamamoto H, 2001, CANCER RES, V61, P3139; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	51	134	155	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 12	2003	22	24					3806	3812		10.1038/sj.onc.1206582	http://dx.doi.org/10.1038/sj.onc.1206582			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	690LQ	12802288				2022-12-17	WOS:000183551000015
J	Zhu, J; Lallemand-Breitenbach, V; de The, H				Zhu, J; Lallemand-Breitenbach, V; de The, H			Pathways of retinoic acid- or arsenic trioxide-induced PML/RAR alpha catabolism, role of oncogene degradation in disease remission	ONCOGENE			English	Article						proteasome; clinical trials; SUMO; nuclear bodies; differentiation; apoptosis	ACUTE PROMYELOCYTIC LEUKEMIA; PML-RAR-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; I-TRANSFORMED-CELLS; RECEPTOR-ALPHA; FUSION PROTEIN; HISTONE DEACETYLASE; INDUCED APOPTOSIS; NUCLEAR-BODIES; NB4 CELLS	Although there is evidence to suggest that PML/RAR alpha expression is not the sole genetic event required for the development of acute promyelocytic leukemia (APL), there is little doubt that the fusion protein plays a central role in the initiation of leukemogenesis. The two therapeutic agents, retinoic acid and arsenic, that induce clinical remissions in APL, both target the oncogenic fusion protein, representing the first example of oncogene-directed cancer therapy. This review focuses on the molecular mechanisms accounting for PML/RAR alpha degradation. Each drug targets a specific moiety of the fusion protein (RAR alpha for retinoic acid, PML for arsenic) to the proteasome. Moreover, both activate a common caspase-dependent cleavage in the PML part of the fusion protein. Specific molecular determinants (the AF2 transactivator domain of RAR alpha for retinoic acid and the K160 SUMO-binding site in PML for arsenic) are respectively implicated in RA- or arsenic-triggered catabolism. The respective roles of PML/RAR alpha activation versus its catabolism are discussed with respect to differentiation or apoptosis induction in the context of single or dual therapies.	Univ Paris 07, Hop St Louis, Lab Assoc Comite Paris Ligue Francaise Contre Can, CNRS UPR 9051, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	de The, H (corresponding author), Univ Paris 07, Hop St Louis, Lab Assoc Comite Paris Ligue Francaise Contre Can, CNRS UPR 9051, 1 Av C Vellefaux, F-75475 Paris 10, France.	dethe@chu-stlouis.fr		Lallemand, Valerie/0000-0001-9852-204X				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bazarbachi A, 1999, BLOOD, V93, P278, DOI 10.1182/blood.V93.1.278.401k22_278_283; Benoit G, 1999, EMBO J, V18, P7011, DOI 10.1093/emboj/18.24.7011; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Chen GQ, 1997, BLOOD, V89, P3345; Chen GQ, 1996, BLOOD, V88, P1052; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; DANIEL MT, 1993, BLOOD, V82, P1858; Du CC, 1999, BLOOD, V94, P793, DOI 10.1182/blood.V94.2.793.414k43_793_802; Duprez E, 2000, LEUKEMIA, V14, P255, DOI 10.1038/sj.leu.2401683; Duprez E, 1996, ONCOGENE, V12, P2451; Duprez E, 1996, ONCOGENE, V12, P2443; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; El-Sabban ME, 2000, BLOOD, V96, P2849; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Everett RD, 1999, J CELL SCI, V112, P4581; Fabunmi RP, 2001, J CELL SCI, V114, P29; Ferbeyre G, 2000, GENE DEV, V14, P2015; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; Gianni M, 1998, BLOOD, V91, P4300, DOI 10.1182/blood.V91.11.4300.411k41_4300_4310; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; GUIOCHONMANTEL A, 1995, MOL ENDOCRINOL, V9, P1791, DOI 10.1210/me.9.12.1791; Hamadeh HK, 1999, BIOCHEM BIOPH RES CO, V263, P446, DOI 10.1006/bbrc.1999.1395; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; HUANG W, 1993, BLOOD, V82, P1264, DOI 10.1182/blood.V82.4.1264.bloodjournal8241264; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jansen JH, 1999, BLOOD, V94, P39, DOI 10.1182/blood.V94.1.39.413a26_39_45; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; Jing YK, 2001, BLOOD, V97, P264, DOI 10.1182/blood.V97.1.264; Kastner P, 2001, BLOOD, V97, P1314, DOI 10.1182/blood.V97.5.1314; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Koken MHM, 1999, ONCOGENE, V18, P1113, DOI 10.1038/sj.onc.1202414; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Lallemand-Breitenbach V, 1999, J EXP MED, V189, P1043, DOI 10.1084/jem.189.7.1043; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; NERVI C, 1992, CANCER RES, V52, P3687; Nervi C, 1998, BLOOD, V92, P2244; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Perletti L, 2001, BMC Mol Biol, V2, P4, DOI 10.1186/1471-2199-2-4; Puccetti E, 2000, CANCER RES, V60, P3409; Quenech'Du N, 1998, LEUKEMIA, V12, P1829, DOI 10.1038/sj.leu.2401171; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Quignon F, 1997, BBA-REV CANCER, V1333, pM53, DOI 10.1016/S0304-419X(97)00025-5; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; Rego EM, 2000, P NATL ACAD SCI USA, V97, P10173, DOI 10.1073/pnas.180290497; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Slack JL, 1998, BLOOD, V91, P3347, DOI 10.1182/blood.V91.9.3347.3347_3347_3356; Stadler M, 1995, ONCOGENE, V11, P2565; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stitzel ML, 2001, GENE DEV, V15, P128, DOI 10.1101/gad.863801; Testa U, 1998, J CLIN INVEST, V101, P2278, DOI 10.1172/JCI1332; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; Yih LH, 2000, CANCER RES, V60, P6346; Yoshida H, 1996, CANCER RES, V56, P2945; Zheng J, 1999, INT J CANCER, V82, P286, DOI 10.1002/(SICI)1097-0215(19990719)82:2<286::AID-IJC21>3.0.CO;2-K; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	84	134	144	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2001	20	49					7257	7265		10.1038/sj.onc.1204852	http://dx.doi.org/10.1038/sj.onc.1204852			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704854				2022-12-17	WOS:000171891900014
J	Li, W; Fan, JH; Woodley, DT				Li, W; Fan, JH; Woodley, DT			Nck/Dock: an adapter between cell surface receptors and the actin cytoskeleton	ONCOGENE			English	Review						Src-homology domains; adapters; tyrosine kinases; signal transduction; cytoskeleton	PHOTORECEPTOR AXON GUIDANCE; GUANINE-NUCLEOTIDE EXCHANGE; INTEGRIN-LINKED KINASE; SMOOTH-MUSCLE-CELLS; ONLY PROTEIN PINCH; GROWTH-FACTOR; TYROSINE KINASE; P21-ACTIVATED KINASE; SIGNAL-TRANSDUCTION; EPH RECEPTORS	In response to extracellular signals, cell surface receptors engage in connections with multiple intracellular signaling pathways, leading to the cellular responses such as survival, migration, proliferation and differentiation. The 'pY --> SH2/SH3 --> effector' connection is a frequently used scheme by many cell surface receptors, in which SH2/SH3-containing adapters connect protein tyrosine phosphorylation to a variety of downstream effector pathways. Following the initial landmark finding that Grb2 adapter links the receptors to the Ras pathway leading to DNA synthesis, recent studies have revealed that the biological function of the SH2/SH3 adapter Nck/Dock is to link cell surface receptors to the actin cytoskeleton. For example, in the evolutionarily-conserved signaling network, GEF-Rae-Nck-Pak, Nck 'fixes up' the interaction of Pak with its upstream activator, Rac. The activated Pak then regulates the cytoskeletal dynamics. The fact that the majority of the more than 20 Nck-SH3-associated effectors are regulators of the actin cytoskeleton suggests that Nck/Dock regulates, via binding to distinct effectors, various cell type-specific motogenic responses. This review focuses on our current understanding of Nck/Dock function. Due to the number and complexity of the terminologies used in this review, a 'Glossary of Terms' is provided to help reduce confusions.	Univ So Calif, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Norris Cotton Canc Ctr, Los Angeles, CA 90033 USA; Greater Los Angeles Vet Adm Healthcare Syst, Los Angeles, CA USA	University of Southern California; Norris Cotton Cancer Center; University of Southern California; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Li, W (corresponding author), Univ So Calif, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90033 USA.	wli@hsc.usc.edu			NCI NIH HHS [CA65567] Funding Source: Medline; NIAMS NIH HHS [AR46538] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adler CE, 2000, J BIOL CHEM, V275, P36472, DOI 10.1074/jbc.M005424200; Anand-Apte B, 1997, J BIOL CHEM, V272, P30688, DOI 10.1074/jbc.272.49.30688; Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Becker E, 2000, MOL CELL BIOL, V20, P1537, DOI 10.1128/MCB.20.5.1537-1545.2000; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Braverman LE, 1999, J BIOL CHEM, V274, P5542, DOI 10.1074/jbc.274.9.5542; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Chen M, 1998, J BIOL CHEM, V273, P25171, DOI 10.1074/jbc.273.39.25171; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Desai CJ, 1999, DEVELOPMENT, V126, P1527; DEUEL TF, 1991, ANNU REV MED, V42, P567, DOI 10.1146/annurev.me.42.020191.003031; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Drescher U, 1997, CURR BIOL, V7, pR799, DOI 10.1016/S0960-9822(06)00409-X; Ellis C, 1996, ONCOGENE, V12, P1727; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; Godwin SL, 1997, J BIOL CHEM, V272, P11307; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Hock B, 1998, ONCOGENE, V17, P255, DOI 10.1038/sj.onc.1201907; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hummel T, 2000, GENE DEV, V14, P863; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V246, P95, DOI 10.1006/bbrc.1998.8578; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Jones SM, 2000, ONCOGENE, V19, P5558, DOI 10.1038/sj.onc.1203858; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; Kitamura Y, 1997, BIOCHEM J, V322, P873, DOI 10.1042/bj3220873; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KROLL J, 1997, J BIOL CHEM, V252, P32421; Ku GM, 2001, EMBO J, V20, P457, DOI 10.1093/emboj/20.3.457; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; Mayer BJ, 1999, MOL BIOTECHNOL, V13, P201, DOI 10.1385/MB:13:3:201; Mayer BJ, 2001, J CELL SCI, V114, P1253; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Morrione A, 2000, INT J MOL MED, V5, P151; Newsome TP, 2000, CELL, V101, P283, DOI 10.1016/S0092-8674(00)80838-7; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NOBES CD, 1995, J CELL SCI, V108, P225; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; Park D, 1997, MOL CELLS, V7, P231; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PIERCE GF, 1995, ANNU REV MED, V46, P467; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Rosenkranz S, 1999, J BIOL CHEM, V274, P28335, DOI 10.1074/jbc.274.40.28335; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Ruan WJ, 1999, NEURON, V24, P595, DOI 10.1016/S0896-6273(00)81115-0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Smith JM, 1999, J BIOL CHEM, V274, P27956, DOI 10.1074/jbc.274.39.27956; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; Su YC, 2000, MOL CELL BIOL, V20, P4736, DOI 10.1128/MCB.20.13.4736-4744.2000; Treisman JE, 1997, GENE, V186, P119, DOI 10.1016/S0378-1119(96)00694-4; Tu YZ, 2001, FEBS LETT, V491, P193, DOI 10.1016/S0014-5793(01)02195-0; Tu YZ, 1998, MOL BIOL CELL, V9, P3367, DOI 10.1091/mbc.9.12.3367; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wu CY, 1999, J CELL SCI, V112, P4485; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Yamakawa K, 1998, HUM MOL GENET, V7, P227, DOI 10.1093/hmg/7.2.227; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zigmond SH, 2000, J CELL BIOL, V150, pF117, DOI 10.1083/jcb.150.6.F117	124	134	135	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2001	20	44					6403	6417		10.1038/sj.onc.1204782	http://dx.doi.org/10.1038/sj.onc.1204782			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	483NF	11607841				2022-12-17	WOS:000171640600014
J	Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K				Okamoto, T; Izumi, H; Imamura, T; Takano, H; Ise, T; Uchiumi, T; Kuwano, M; Kohno, K			Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression	ONCOGENE			English	Article						Y-box binding proteins; p53; protein binding; transcriptional regulation	COLD-SHOCK DOMAIN; C-TERMINAL DOMAIN; HUMAN MDR1 GENE; DNA-BINDING; MESSENGER-RNA; ACTIVATION; PHOSPHORYLATION; SEQUENCE; DAMAGE; PROMOTER	The Y-box binding protein, YB-1, belongs to a family of multifunctional proteins which regulate gene expression on both transcriptional and translational levels. The tumor suppressor gene p53 displays growth suppressive properties by regulating gene expression through transcriptional regulation, We now demonstrate that YB-1 directly interacts with p53 using an in vitro pull-down assay. Using immunochemical co-precipitation methods, we also found that the two proteins are bound in vivo. Deletion analysis showed that three independent domains of YB-1, one at the N-terminal and two at the C-terminal, interact with p53. Conversely, a 14 amino acid sequence at the C-terminal of p53 was required for its interaction with YB-1, Gel mobility shift assays showed that the interaction of YB-1 with p53 stimulated the sequence-specific DNA binding of p53 to its consensus sequence, By contrast, this interaction inhibited the binding of YB-1, Using a p53-responsive p21 promoter linked to a reporter gene, it can be shown that antisense expression of YB-1 inhibits the induction of this promoter by p53 in transient transfection assays, These findings delineate a straightforward mechanism for gene expression through p53-YB-1 interaction.	Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Biochem Med, Fukuoka 8128582, Japan	University of Occupational & Environmental Health - Japan; Kyushu University	Kohno, K (corresponding author), Univ Occupat & Environm Hlth, Dept Biol Mol, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.							ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bargou RC, 1997, NAT MED, V3, P378; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; GOLDSMITH ME, 1993, J BIOL CHEM, V268, P5856; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu W, 1998, BIOL REPROD, V59, P1266, DOI 10.1095/biolreprod59.5.1266; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Herbert TP, 1999, NUCLEIC ACIDS RES, V27, P1747, DOI 10.1093/nar/27.7.1747; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; Ise T, 1999, CANCER RES, V59, P342; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; KOHNO K, 1994, J BIOL CHEM, V269, P20503; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LENZ J, 1990, P NATL ACAD SCI USA, V87, P3396, DOI 10.1073/pnas.87.9.3396; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MIYASHITA T, 1995, CELL, V80, P293; Oda Y, 1998, CLIN CANCER RES, V4, P2273; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Raj GV, 1996, J VIROL, V70, P5944, DOI 10.1128/JVI.70.9.5944-5953.1996; Ruzanov PV, 1999, J CELL SCI, V112, P3487; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Thottassery JV, 1997, P NATL ACAD SCI USA, V94, P11037, DOI 10.1073/pnas.94.20.11037; UCHIUMI T, 1993, CELL GROWTH DIFFER, V4, P147; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	46	134	141	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6194	6202		10.1038/sj.onc.1204029	http://dx.doi.org/10.1038/sj.onc.1204029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175333				2022-12-17	WOS:000166210500002
J	Shimizu, S; Shinohara, Y; Tsujimoto, Y				Shimizu, S; Shinohara, Y; Tsujimoto, Y			Bax and Bcl-x(L) independently regulate apoptotic changes of yeast mitochondria that require VDAC but not adenine nucleotide translocator	ONCOGENE			English	Article						ANT; VDAC; Bax; mitochondria; yeast	PERMEABILITY TRANSITION PORE; CYTOCHROME-C RELEASE; ADP/ATP CARRIER; PROTEASE CASCADE; BCL-2; EXPRESSION; MEMBRANE; PROTEINS; CHANNEL; FAMILY	Mitochondria play an essential role in apoptosis by releasing apoptogenic molecules such as cytochrome c and AlF, and some caspases, which are all regulated by Bcl-2 family proteins. Pro-apoptotic Pas and Bah have been shown to induce cytochrome c release and loss of membrane potential (Delta psi) leading to AIF release in the isolated mitochondria. We have previously shown that Bas and Bah open the voltage-dependent anion channel (VDAC) allowing cytochrome c to pass through the channel, and Bcl-x(L) closes the channel. However, it has been reported that it is adenine nucleotide translocator (ANT) with which Bax/Bcl-x(L) interacts that modulate the channel activity. Here, we investigated the role of ANT and VDAC in the changes of isolated mitochondria triggered by Bas and by chemicals that induce permeability transition (PT), In rat and yeast mitochondria, Bas did not affect the ADP/ATP exchange activity of ANT. VDAC-deficient but not ANT-deficient feast mitochondria showed resistance to cytochrome c release, Delta psi loss, and swelling caused by Bas and PT inducers. Bcl-x(L) showed similar inhibition of all these changes in ANT-deficient and wild type yeast mitochondria, Furthermore, Bas induces cytochrome c release in wild type yeast cells but not VDAC1-deficient yeast cells. These data indicate that VDAC, but not ANT, is essential for apoptotic mitochondrial changes. The data also indicate that Bcl-xL acid Bas possess an ability to regulate mitochondrial membrane permeability independently of other Bcl-2 family members.	Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, Osaka 5650871, Japan; Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci, Osaka, Japan	Osaka University; Tokushima University; Japan Science & Technology Agency (JST)	Tsujimoto, Y (corresponding author), Osaka Univ, Grad Sch Med, Biomed Res Ctr, Dept Med Genet, 2-2 Yamadaoka, Osaka 5650871, Japan.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BLANCHLYDYSON E, 1997, MOL CELL BIOL, V17, P5727; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775; DAUM G, 1982, J BIOL CHEM, V257, P3028; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8; Jung DW, 1997, J BIOL CHEM, V272, P21104, DOI 10.1074/jbc.272.34.21104; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KAWAGOE K, 1994, GENOMICS, V23, P566, DOI 10.1006/geno.1994.1544; KLINGENBERG M, 1994, BBA-BIOENERGETICS, V1187, P241, DOI 10.1016/0005-2728(94)90119-8; Lee AC, 1998, J MEMBRANE BIOL, V161, P173, DOI 10.1007/s002329900324; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233; Nouraini S, 2000, MOL CELL BIOL, V20, P1604, DOI 10.1128/MCB.20.5.1604-1615.2000; Priault M, 1999, FEBS LETT, V456, P232, DOI 10.1016/S0014-5793(99)00957-6; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 1996, ONCOGENE, V12, P2251; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	39	134	143	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4309	4318		10.1038/sj.onc.1203788	http://dx.doi.org/10.1038/sj.onc.1203788			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980606				2022-12-17	WOS:000089271900001
J	Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R				Suzuki, S; Higuchi, M; Proske, RJ; Oridate, N; Hong, WK; Lotan, R			Implication of mitochondria-derived reactive oxygen species, cytochrome C and caspase-3 in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells	ONCOGENE			English	Article						reactive oxygen species; 4HPR; apoptosis; mitochondrial respiratory chain; caspase-3; cytochrome c	TUMOR-NECROSIS-FACTOR; TRANS-RETINOIC ACID; RESPIRATORY-CHAIN; ELECTRON-TRANSPORT; FREE-RADICALS; PERMEABILITY TRANSITION; SUPEROXIDE FORMATION; HEART-MITOCHONDRIA; MEDIATED APOPTOSIS; COMPLEX-I	N-(4-Hydroxyphenyl)retinamide (4HPR) is currently used in cancer prevention and therapy trials. It is thought that its effects result from induction of apoptosis, 4HPR-induced apoptosis in human cervical carcinoma C33A cells involves enhanced generation of reactive oxygen species (ROS). In this study we explored the mechanism by which 4HPR increases ROS and induces apoptosis in these cells. 4HPR induced cytochrome c release from mitochondria to cytoplasm, activated caspase-3, and caused a membrane permeability transition (MPT). All these 4HPR's effects, as web as the induction of apoptosis, were inhibited by antioxidants, which decrease ROS. Thenoyltrifluoroacetone, a mitochondrial respiratory chain (MRC) complex II inhibitor, and carbonylcyanide m-chlorophenyl hydrazone, which uncouples electron transfer and ATP synthesis and inhibits ROS generation by MRC, inhibited 4HPR-induced ROS generation very effectively. Rotenone, an MRC complex I inhibitor was less effective and azide, an MRC complex IV inhibitor, exhibited a marginal effect, In contrast, antimycin A, an MRC complex III inhibitor, enhanced 4HPR-induced ROS generation. These findings suggest that 4HPR enhances ROS generation by affecting a target between complex II and complex III, presumably coenzyme Q. This effect is followed by release of cytochrome c, increased caspase-3 activity, induction of MPT and eventual DNA fragmentation and cell death.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Inst Mol Med Prevent Human Dis, Res Ctr Cardiovasc Dis, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Lotan, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Suzuki, Seigo/G-5378-2012; Oridate, Nobuhiko/ABC-4116-2020; Oridate, Nobuhiko/G-5365-2012	Oridate, Nobuhiko/0000-0002-6968-3028; 	NCI NIH HHS [P01 CA52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; BEYER RE, 1992, BIOCHEM CELL BIOL, V70, P390, DOI 10.1139/o92-061; BEZKOROVAINY A, 1996, METABOLISM OXIDATIVE; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CARACENI P, 1995, BBA-MOL CELL RES, V1268, P249, DOI 10.1016/0167-4889(95)00077-6; DAWSON TL, 1993, AM J PHYSIOL, V264, P961; Delia D, 1997, CARCINOGENESIS, V18, P943, DOI 10.1093/carcin/18.5.943; FEDYK ER, 1994, INT J IMMUNOPHARMACO, V16, P533, DOI 10.1016/0192-0561(94)90105-8; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Formelli F, 1996, FASEB J, V10, P1014, DOI 10.1096/fasebj.10.9.8801162; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; GOODMAN Y, 1994, BRAIN RES, V654, P171, DOI 10.1016/0006-8993(94)91586-5; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; Higuchi M, 1996, J IMMUNOL, V157, P297; Higuchi M, 1998, ONCOGENE, V17, P2515, DOI 10.1038/sj.onc.1202485; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HU HP, 1992, BIOCHIM BIOPHYS ACTA, V1112, P161, DOI 10.1016/0005-2736(92)90387-2; HUNT NH, 1992, BIOCHIM BIOPHYS ACTA, V1133, P261, DOI 10.1016/0167-4889(92)90046-E; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kruidering M, 1997, J PHARMACOL EXP THER, V280, P638; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LOTAN R, 1995, J NATL CANCER I, V87, P1655, DOI 10.1093/jnci/87.22.1655; Marchetti P, 1996, CANCER RES, V56, P2033; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; NOHL H, 1987, FEBS LETT, V214, P269, DOI 10.1016/0014-5793(87)80068-6; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Oishi K, 1997, SCAND J IMMUNOL, V45, P21, DOI 10.1046/j.1365-3083.1997.d01-365.x; Oridate N, 1996, CLIN CANCER RES, V2, P855; Oridate N, 1997, J NATL CANCER I, V89, P1191, DOI 10.1093/jnci/89.16.1191; ORIDATE N, 1995, INT J ONCOL, V7, P433; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; SANFORD KK, 1992, J CLIN INVEST, V90, P2069, DOI 10.1172/JCI116089; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Schweizer M., 1997, OXIDATIVE STRESS MOL, P169; Shimizu S, 1996, CANCER RES, V56, P2161; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SUN SY, 1999, IN PRESS CANC RES; TAYLOR DE, 1995, ARCH BIOCHEM BIOPHYS, V316, P70, DOI 10.1006/abbi.1995.1011; TRUDEL S, 1991, BIOCHEM J, V276, P611, DOI 10.1042/bj2760611; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zou CP, 1998, CLIN CANCER RES, V4, P1345	59	134	136	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6380	6387		10.1038/sj.onc.1203024	http://dx.doi.org/10.1038/sj.onc.1203024			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597238				2022-12-17	WOS:000083934100023
J	Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T				Saretzki, G; Sitte, N; Merkel, U; Wurm, RE; von Zglinicki, T			Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments	ONCOGENE			English	Article						telomeres; p53; check point; cell cycle; DNA damage	HUMAN OVARIAN-CARCINOMA; HUMAN FIBROBLASTS; HUMAN CANCER; G(1) ARREST; LIFE-SPAN; P53; GROWTH; TUMOR; ACTIVATION; EXPRESSION	It has been repeatedly suspected that telomere shortening might be one possible trigger of the p53-dependent cell cycle arrest, although the mechanism of this arrest remained unclear. Telomeres in human cells under mild oxidative stress accumulate single-strand damage faster than interstitial repetitive sequences, In MRC-5 fibroblasts and U87 glioblastoma cells, which both express wild-type p53, oxidative stress-mediated production of single-strand damage in telomeres is concomitant to the accumulation of p53 and p21 and to cell cycle arrest. This response can be modeled by treatment of cells with short single stranded telomeric G-rich DNA fragments. The arrest is transient in U87 cells. Recovery from it is accompanied by up-regulation of telomerase activity and elongation of telomeres, Overexpression of mutated p53 is sufficient to reverse the phenotype of inhibition as well as the delayed activation of telomerase, These data suggest that the production of G-rich single stranded fragments during the course of telomere shortening is sufficient to trigger a p53 dependent cell cycle arrest.	Inst Pathol, D-10098 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Radiat Therapy, D-10098 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	von Zglinicki, T (corresponding author), Inst Pathol, Schumannstr 20-21, D-10098 Berlin, Germany.		Saretzki, Gabriele Christine/I-7175-2019	Saretzki, Gabriele Christine/0000-0003-2100-8223; von Zglinicki, Thomas/0000-0002-5939-0248				ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Joo OH, 1998, MUTAT RES-FUND MOL M, V401, P121, DOI 10.1016/S0027-5107(97)00321-7; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KORNBLUTH S, 1992, MOL CELL BIOL, V12, P3216, DOI 10.1128/MCB.12.7.3216; Krauskopf A, 1996, NATURE, V383, P354, DOI 10.1038/383354a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leteurtre F, 1997, LEUKEMIA, V11, P1681, DOI 10.1038/sj.leu.2400784; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linke SP, 1997, CANCER RES, V57, P1171; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; NAGASAWA H, 1995, CANCER RES, V55, P1842; NEGRINI M, 1994, CANCER RES, V54, P1818; Petersen S, 1998, EXP CELL RES, V239, P152, DOI 10.1006/excr.1997.3893; Poulos NE, 1996, CANCER RES, V56, P1719; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; Wright WE, 1996, EMBO J, V15, P1734, DOI 10.1002/j.1460-2075.1996.tb00519.x; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; YAGINUMA Y, 1992, CANCER RES, V52, P4196	38	134	138	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5148	5158		10.1038/sj.onc.1202898	http://dx.doi.org/10.1038/sj.onc.1202898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498864				2022-12-17	WOS:000082555700003
J	Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K				Ueda, Y; Hijikata, M; Takagi, S; Chiba, T; Shimotohno, K			New p73 variants with altered C-terminal structures have varied transcriptional activities	ONCOGENE			English	Article						p73; splicing variant; p53; transcriptional activity	CELL-LINES; P53 PROTEIN; GENE	p73 has been identified as a protein which shares significant homology with the tumor suppressor p53, We found two new types of splicing variant mRNAs for p73 expressed in MCF-7 cells which we named p73 gamma and epsilon. Sequence analysis revealed that these mRNAs encode variant p73 proteins bearing distinct carboxy-terminal structures, which are also different from the previously reported variants p73 alpha and beta, The mRNAs encoding p73 gamma and epsilon as well as alpha. and beta were confirmed to be expressed in normal human tissues in varied patterns. All of these splicing variants activated promoter with the p53-binding consensus sequence, but to different degrees. Furthermore, suppressive effects of p73 alpha, gamma and epsilon, but not beta, on endogenous p53 activity were observed when transiently expressed in HepG2 and MCF-7 cells. These results suggested that the carboxy-terminal regions of p73 which were altered by alternative splicing affect these transactivation abilities and modulate the functions of p73 molecules.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Hijikata, M (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.		Ueda, Yoshihide/S-7620-2016	Ueda, Yoshihide/0000-0003-3196-3494				BARTEK J, 1990, ONCOGENE, V5, P893; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDIERY WS, 1994, CANCER RES, V54, P1169; HASSAPOGLIDOU S, 1993, ONCOGENE, V8, P1501; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; PUISIEUX A, 1993, FASEB J, V7, P1407, DOI 10.1096/fasebj.7.14.8224613; SIEBERT PD, 1992, NATURE, V359, P557, DOI 10.1038/359557a0; TOMINAGA O, 1993, ONCOGENE, V8, P2653	16	134	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 2	1999	18	35					4993	4998		10.1038/sj.onc.1202817	http://dx.doi.org/10.1038/sj.onc.1202817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231QQ	10490834	Green Submitted			2022-12-17	WOS:000082321700012
J	Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F				Dumon, S; Santos, SCR; Debierre-Grockiego, F; Gouilleux-Gruart, V; Cocault, L; Boucheron, C; Mollat, P; Gisselbrecht, S; Gouilleux, F			IL-3 dependent regulation of Bcl-x(L) gene expression by STAT5 in a bone marrow derived cell line	ONCOGENE			English	Article						apoptosis; STAT5; Bcl-x(L); transcription	COLONY-STIMULATING FACTOR; RECEPTOR-BETA-CHAIN; BCL-X GENE; DNA-BINDING; HEMATOPOIETIC-CELLS; GROWTH-HORMONE; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; INDUCED PROLIFERATION; SIGNAL-TRANSDUCTION	Activation of the Jak/STAT pathway by cytokines has been shown to regulate differentiation, proliferation or apoptosis in hematopoeitic cells. Among the Stat proteins, STAT5 is activated by a broad range of cytokines. In order to study the role of STAT5 in hematopoietic cells, we stably expressed a dominant negative form of STAT5 (STAT5A Delta 749) in the IL-3 dependent bone marrow derived Ba/F3 cell line. Ba/F3 cells expressing STAT5A Delta 749 were found to be more sensitive to apoptosis than parental or control Ba/F3 cells after IL-3 withdrawal. Analysis of the expression of the cell death regulators, Bcl-2 and Bcl-x, revealed that the level of Bcl-x was lower in Ba/F3 cells expressing STAT5A Delta 749 than in control cells. IL-3 regulation of Bcl-x expression at protein and mRNA levels was impaired in these cells while that of Bcl-2 expression was unaffected. We further demonstrated that the Bcl-x gene promoter contained a proximal STAT consensus sequence that bound STAT5. Transactivation of a Bcl-x gene promoter reporter construct by STAT5 was observed in Ba/F3 cells. Introduction of a mutation in the STAT binding site abolished this transactivation. These data indicate that Bcl-x is probably a STAT5 target gene. They also support the involvement of STAT5 in hematopoietic cell survival.	Inst Cochin Genet Mol, INSERM U363, F-75014 Paris, France; CHU Amiens, Immunol Lab, F-80054 Amiens, France; Hoescht Marion Roussel, Romainville, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Picardie Universites; Universite de Picardie Jules Verne (UPJV); CHU Amiens	Gouilleux, F (corresponding author), Inst Cochin Genet Mol, INSERM U363, 27 Rue Fbg St Jacques, F-75014 Paris, France.		Debierre-Grockiego, Francoise/AAD-4322-2021; Santos, Susana/AAM-8902-2021	PETIT, Laurence/0000-0002-2475-9367; Constantino Rosa Santos, Susana/0000-0002-5711-1292; Gouilleux, Fabrice/0000-0001-6047-1718				Ahmed M, 1998, ONCOGENE, V16, P489, DOI 10.1038/sj.onc.1201556; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BROOME HE, 1995, J IMMUNOL, V155, P2311; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chai SK, 1997, J IMMUNOL, V159, P4720; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; delPeso L, 1997, SCIENCE, V278, P687; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Grillot DAM, 1997, J IMMUNOL, V158, P4750; HELM MH, 1995, SCIENCE, V267, P1347; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Iwatsuki K, 1997, J BIOL CHEM, V272, P8149, DOI 10.1074/jbc.272.13.8149; KANZANSKY AV, 1995, MOL ENDOCRINOL, V9, P1598; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; LEVERRIER Y, 1999, IN PRESS CELL DEATH; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Meyer J, 1998, BLOOD, V91, P1901, DOI 10.1182/blood.V91.6.1901.1901_1901_1908; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; Park J R, 1996, Curr Opin Hematol, V3, P191; Pircher TJ, 1997, MOL CELL ENDOCRINOL, V133, P169, DOI 10.1016/S0303-7207(97)00164-0; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rui H, 1998, J BIOL CHEM, V273, P28, DOI 10.1074/jbc.273.1.28; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; Schindler C, 1998, TRENDS CELL BIOL, V8, P97, DOI 10.1016/S0962-8924(98)01233-1; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas J, 1998, ONCOGENE, V16, P1399, DOI 10.1038/sj.onc.1201672; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Verdier F, 1998, MOL CELL BIOL, V18, P5852, DOI 10.1128/MCB.18.10.5852; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1995, EMBO J, V14, P854, DOI 10.1002/j.1460-2075.1995.tb07064.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; Zamorano J, 1998, J IMMUNOL, V160, P3502	68	134	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	1999	18	29					4191	4199		10.1038/sj.onc.1202796	http://dx.doi.org/10.1038/sj.onc.1202796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435632	Green Published			2022-12-17	WOS:000081542400003
J	Hoffman, B; Liebermann, DA				Hoffman, B; Liebermann, DA			The proto-oncogene c-myc and apoptosis	ONCOGENE			English	Article						c-myc; proliferation; apoptosis; tumorigenesis	ORNITHINE DECARBOXYLASE GENE; CELL-CYCLE PROGRESSION; MYELOID-LEUKEMIA CELLS; WILD-TYPE P53; GROWTH ARREST; TRANSCRIPTIONAL REPRESSION; TRANSGENIC MICE; DNA-BINDING; TERMINAL DIFFERENTIATION; HISTONE DEACETYLASE	Deregulated expression of c-Myc not only promotes proliferation, but also can either induce or sensitize cells to apoptosis, Inappropriate expression of c-Myc under conditions which inhibit growth and down-regulate endogenous c-Myc expression, including serum deprivation and exposure to cytotoxic agents including the anticancer agents vinblastine, etoposide, Ara-C, and nocodazole, usually results in programmed cell death in many different cell types. Also, inappropriate Myc expression is associated with an apoptotic response elicited by induction of differentiation. The proapoptotic property of c-Myc requires an intact N-terminal transactivation domain and bHLHZip domain, as well as interaction with Max, thereby implicating c-Myc target genes in this apoptotic process. Although some target genes, namely cdc25A and ODC, have been shown to participate in Myc-mediated apoptosis, no target gene has yet been identified which is essential for this apoptotic response. It is possible that the response of cells inappropriately expressing c-Myc is due not only to the growth arrest signals per se, but also to signals elicited by specific growth inhibitors in the context of a particular biological setting. Also regulating the response of the cells is expression of other oncogenes and tumor suppressor genes, as well as paracrine and autocrine survival factors. Apoptosis associated with inappropriate Myc expression limits the tumorigenic effect of the c-myc proto-oncogene, Mechanisms which inhibit apoptosis should enhance or promote tumorigenesis.	Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Hoffman, B (corresponding author), Temple Univ, Fels Inst Canc Res & Mol Biol, Sch Med, 3307 N Broad St, Philadelphia, PA 19140 USA.							Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; ALNEMRI ES, 1992, CANCER RES, V52, P491; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Braun K, 1998, DNA CELL BIOL, V17, P789, DOI 10.1089/dna.1998.17.789; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DiazJullien C, 1996, BBA-PROTEIN STRUCT M, V1296, P219, DOI 10.1016/0167-4838(96)00072-6; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fanidi A, 1998, J VIROL, V72, P8392, DOI 10.1128/JVI.72.10.8392-8395.1998; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; GREEN DR, 1994, IMMUNOL REV, V142, P321, DOI 10.1111/j.1600-065X.1994.tb00895.x; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Hoffman B, 1996, CURR TOP MICROBIOL, V211, P17; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HSU B, 1995, ONCOGENE, V11, P175; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; Kangas AL, 1998, ONCOGENE, V16, P387, DOI 10.1038/sj.onc.1201779; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LINDEMAN GJ, 1995, ONCOGENE, V10, P1013; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MOSHIER JA, 1993, CANCER RES, V53, P2618; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Rao G, 1996, ONCOGENE, V12, P1165; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; Rupnow BA, 1998, CANCER LETT, V127, P211, DOI 10.1016/S0304-3835(98)00045-7; Ryan KM, 1997, ONCOGENE, V14, P2835, DOI 10.1038/sj.onc.1201124; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; Selvakumaran M, 1996, BLOOD, V88, P1248, DOI 10.1182/blood.V88.4.1248.bloodjournal8841248; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shichiri M, 1998, MOL ENDOCRINOL, V12, P172, DOI 10.1210/me.12.2.172; Shim H, 1998, P NATL ACAD SCI USA, V95, P1511, DOI 10.1073/pnas.95.4.1511; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; Wu SJ, 1996, ONCOGENE, V12, P621; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhan Y, 1997, MOL CELL BIOL, V17, P6755, DOI 10.1128/MCB.17.11.6755; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	92	134	140	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 24	1998	17	25					3351	3357		10.1038/sj.onc.1202592	http://dx.doi.org/10.1038/sj.onc.1202592			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916997				2022-12-17	WOS:000078048200016
J	Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I				Thomas, RS; Tymms, MJ; McKinlay, LH; Shannon, MF; Seth, A; Kola, I			ETS1, NF kappa B and AP1 synergistically transactivate the human GM-CSF promoter	ONCOGENE			English	Article						GM-CSF; transcription; ETS1; NF kappa B; API	COLONY-STIMULATING FACTOR; PROTEIN-KINASE-C; AP-1 TRANSCRIPTION FACTORS; DNA-BINDING ACTIVITY; T-CELLS; MESSENGER-RNA; MICE LACKING; INFLAMMATORY RESPONSES; COSTIMULATORY SIGNALS; COOPERATIVE BINDING	Activation of helper T cells results in coordinate expression of a number of cytokines involved in differentiation, proliferation and activation of the haematopoietic system, Granulocyte-macrophage colony stimulating factor (GM-CSF) is one such cytokine, whose increased expression results mostly from increases in transcription, Cis-acting elements with NF kappa B, AP1 and ETS-like binding motifs have been identified in the promoter region of the GM-CSF gene, and are important or essential for transcriptional activity following T cell activation, ETS1 is a transcription factor of the ETS family that is expressed in T cells, We have previously shown that ETS1 can transactivate GM-CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation, Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors, Here we show that ETS1 can transactivate a GM-CSF reporter construct in unstimulated Jurkat cells, providing that either NF kappa B or AP1 transcription factors are supplied by co-transfection, We confirm that binding of endogenous NF kappa B and AP1 is induced following PMA/ionomycin treatment of T cells, Transactivation by ETS1, NF kappa B and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent, Our results suggest that constitutive ETS1, and inducible NF kappa B and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.	MONASH UNIV, MOL GENET & DEV GRP, INST REPROD & DEV, MELBOURNE, VIC 3168, AUSTRALIA; INST MED & VET SCI, DIV HUMAN IMMUNOL, HANSON CTR CANC RES, ADELAIDE, SA 5000, AUSTRALIA; UNIV TORONTO, WOMENS COLL HOSP, DEPT PATHOL, TORONTO, ON, CANADA	Monash University; Institute Medical & Veterinary Science Australia; University of Toronto; Womens College Hospital			Kola, Ismail/C-5254-2013; Thomas, Ross/C-6434-2008					ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BRORSON KA, 1991, J IMMUNOL, V147, P3601; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; Cockerill PN, 1996, CELL GROWTH DIFFER, V7, P917; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FISHER CL, 1991, J IMMUNOL, V146, P1743; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Himes SR, 1996, J VIROL, V70, P4001, DOI 10.1128/JVI.70.6.4001-4008.1996; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; IWAI Y, 1993, J IMMUNOL, V150, P4386; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KERPPOLA T, 1995, NATURE, V373, P199, DOI 10.1038/373199a0; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOIZUMI S, 1990, ONCOGENE, V5, P675; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOYANONAKAGAWA N, 1993, INT IMMUNOL, V5, P345, DOI 10.1093/intimm/5.4.345; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, J BIOL CHEM, V269, P30089; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MAJERUS MA, 1992, NUCLEIC ACIDS RES, V20, P2699, DOI 10.1093/nar/20.11.2699; MAKOVER D, 1991, ONCOGENE, V6, P455; MASUDA ES, 1994, BIOCHEM BIOPH RES CO, V205, P1518, DOI 10.1006/bbrc.1994.2839; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MIYAJIMA A, 1988, FASEB J, V2, P2462, DOI 10.1096/fasebj.2.9.2836253; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; OSBORNE CS, 1995, J IMMUNOL, V155, P226; Pazin MJ, 1996, GENE DEV, V10, P37, DOI 10.1101/gad.10.1.37; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RADLERPOHL A, 1993, ANN NY ACAD SCI, V684, P127, DOI 10.1111/j.1749-6632.1993.tb32277.x; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; ROMANOSPICA V, 1995, J IMMUNOL, V154, P2724; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SHANNON MF, 1995, J LEUKOCYTE BIOL, V57, P767, DOI 10.1002/jlb.57.5.767; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUGIMOTO K, 1990, INT IMMUNOL, V2, P787, DOI 10.1093/intimm/2.8.787; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; THOMAS RS, 1995, ONCOGENE, V11, P2135; TSUBOI A, 1994, BIOCHEM BIOPH RES CO, V199, P1064, DOI 10.1006/bbrc.1994.1337; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Yang BS, 1996, MOL CELL BIOL, V16, P538; Ye JP, 1996, MOL CELL BIOL, V16, P157; YE JP, 1994, NUCLEIC ACIDS RES, V22, P5672, DOI 10.1093/nar/22.25.5672	77	134	136	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	1997	14	23					2845	2855		10.1038/sj.onc.1201125	http://dx.doi.org/10.1038/sj.onc.1201125			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190901				2022-12-17	WOS:A1997XD64300013
J	Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D				Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D			HIV-tat protein is a heparin-binding angiogenic growth factor	ONCOGENE			English	Article						HIV; tat; heparin; growth factor; angiogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH; KAPOSIS-SARCOMA; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL DOMAINS; BASEMENT-MEMBRANE; ENDOTHELIAL-CELLS; BASIC DOMAIN; RECEPTOR; GENE	Transgenic animal studies have linked the expression of the HIV-1 tat gene to the appearance of Kaposi's sarcoma (KS)-like lesions. We have recently shown that recombinant tat is angiogenic in vivo, and that tat angiogenic response is enhanced by heparin. Also in the rabbit cornea model, recombinant HIV-1 tat alone is poorly angiogenic, but gives a good response when combined with heparin. Like many angiogenic growth factors, tat has a basic domain similar to that of several heparin binding angiogenic factors, including FGF, VEGF and HGF, suggesting that this region is important in endothelial cell activation. We show that tat binds heparin sepharose with a high affinity, similar to bFGF. Binding of tat to the cell surface is also modulated by heparin. Biological activities of tat, such as induction of endothelial cell growth, migration and invasion in vitro are all enhanced by low concentrations and inhibited by high concentrations of heparin, as has been shown for other heparin-binding angiogenic factors. Heparan sulfate is also effective, whereas the unsulfated polysaccharide K5 does not enhance tat activity. Furthermore, a peptide encompassing the tat basic domain is able to induce growth and migration of endothelial cells, while an adjacent peptide is not. Our data indicate that the tat basic domain plays a key role in its vascular cell activation properties, and strongly suggest that extracellular HIV-tat is essentially a 'new' heparin-binding angiogenic factor.	UNIV BRESCIA, DEPT BIOMED SCI & BIOTECHNOL, BRESCIA, ITALY; UNIV FLORENCE, DEPT PHARMACOL, FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, TURIN, ITALY	University of Brescia; University of Florence; University of Turin	Albini, A (corresponding author), IST NAZL RIC CANC, I-16132 GENOA, ITALY.		Noonan, Douglas M/A-8620-2010; Bussolino, Federico/AES-3951-2022; Presta, Marco/B-4345-2010; Rubartelli, Anna/AAA-1259-2021; Benelli, Roberto/AAF-3143-2019; Rusnati, Marco/F-1168-2010; Bussolino, Federico/K-2500-2016	Noonan, Douglas M/0000-0001-8058-0719; Benelli, Roberto/0000-0002-9769-0954; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Bussolino, Federico/0000-0002-5348-1341; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; ALBINI A, 1987, CANCER RES, V47, P3239; ARMES J, 1989, ADV CANCER RES, V53, P73; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CORALLINI A, 1993, CANCER RES, V53, P5569; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GEIER SA, 1993, AIDS, V7, P746, DOI 10.1097/00002030-199305000-00027; GEIER SA, 1993, J AQUIR IMMUNE DEFIC, V6, P262; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOFMAN FM, 1993, BLOOD, V82, P2774; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGLIONE D, 1993, ONCOGENE, V8, P925; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MORTARINI R, 1992, CANCER RES, V52, P4499; NEWSOME DA, 1984, AM J OPHTHALMOL, V98, P590, DOI 10.1016/0002-9394(84)90245-9; PASSANITI A, 1992, LAB INVEST, V67, P519; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; TESSLER S, 1994, J BIOL CHEM, V269, P12456; THOMPSON EW, 1991, CANCER RES, V51, P2670; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZICHE M, 1989, LAB INVEST, V61, P629; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	60	134	141	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					289	297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570206				2022-12-17	WOS:A1996TR53800008
J	CHOI, SS; PARK, IC; YUN, JW; SUNG, YC; HONG, SI; SHIN, HS				CHOI, SS; PARK, IC; YUN, JW; SUNG, YC; HONG, SI; SHIN, HS			A NOVEL BCL-2 RELATED GENE, BFL-1, IS OVEREXPRESSED IN STOMACH-CANCER AND PREFERENTIALLY EXPRESSED IN BONE-MARROW	ONCOGENE			English	Article						PROGRAMMED CELL DEATH (APOPTOSIS); BCL-2 RELATED GENES; CARCINOGENESIS	PROGRAMMED CELL-DEATH; SEQUENCE SIMILARITY; C-MYC; APOPTOSIS; PROTOONCOGENE; THYMOCYTES; SURVIVAL; PROTEIN; MICE	Programmed cell death (apoptosis) is an active process which is genetically encoded and plays an important role in several cellular activities such as embryonic development, deletion of autoreactive T-cells and homeostasis. Several genes regulating apoptosis have been reported, including p53, one of the tumor suppressor genes, c-myc, one of the proto-oncogenes, and various kinds of Bcl-2 related genes, A new cDNA clone which is homologous to Bcl-2, named as Bfl-1 were isolated from a human fetal liver at 22 week of gestation. This clone was identified by computer analysis of random cDNA sequences that were obtained in an effort to expand the expressed sequence tag (EST) databases to be used for human genome analysis. The homology was recognized by 72% amino acid identity to the murine Al gene, a member of the Bcl-2-related genes. The homology to the BH1 and BH2 domains of Bcl-2 was especially significant, suggesting that Bfl-1 is a new member of the Bcl-2-related genes. Bfl-1 is abundantly expressed in the bone marrow and at a low level in some other tissues. Interestingly, a correlation was noted between the expression level of Bh-l gene and the development of stomach cancer in eight sets of clinical samples. It is conceivable that Bfl-1 is involved in the promotion of the cell survival in the stomach cancer development or progression.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790784, SOUTH KOREA; KOREA CANC CTR HOSP, DEPT CLIN PATHOL, SEOUL 139240, SOUTH KOREA	Pohang University of Science & Technology (POSTECH); National Cancer Center - Korea (NCC)								BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, IN PRESS MAMMALIAN G; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; HAGUE A, 1994, ONCOGENE, V9, P3367; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANG HM, 1994, MOL CELLS, V4, P27; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; LIN EY, 1993, J IMMUNOL, V151, P1979; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; McConkey David J., 1994, Trends in Cell Biology, V4, P370, DOI 10.1016/0962-8924(94)90087-6; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Osborne Barbara A., 1994, Trends in Cell Biology, V4, P394; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; REED JC, 1988, NATURE, V336, P259, DOI 10.1038/336259a0; Sambrook J., 1989, MOL CLONING, V1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0	49	134	150	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	1995	11	9					1693	1698						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478596				2022-12-17	WOS:A1995TD09400003
J	GRUDA, MC; KOVARY, K; METZ, R; BRAVO, R				GRUDA, MC; KOVARY, K; METZ, R; BRAVO, R			REGULATION OF FRA-1 AND FRA-2 PHOSPHORYLATION DIFFERS DURING THE CELL-CYCLE OF FIBROBLASTS AND PHOSPHORYLATION IN-VITRO BY MAP KINASE AFFECTS DNA-BINDING ACTIVITY	ONCOGENE			English	Article							DEPENDENT PROTEIN-KINASE; IMMEDIATE-EARLY GENE; FOS-JUN INTERACTION; SWISS 3T3 CELLS; C-JUN; LEUCINE ZIPPER; TRANSCRIPTIONAL ACTIVATION; SIGNAL-TRANSDUCTION; G0-TO-G1 TRANSITION; NEGATIVE REGULATOR	The Fos family of transcription factors, c-Fos, FosB, Fra-1 and Fra-2, are rapidly induced in quiescent fibroblasts following serum or growth factor stimulation. The Fos proteins show distinct patterns of expression during cell growth with only Fra-1 and Fra-2 maintained at significant levels in growing cells, suggesting that the different family members direct unique functions for cell growth. Post-translational modification of Fos proteins has been observed following serum stimulation, which may allow an additional level of regulation. Our studies show that the synthesis and post-translational modification of Fra-1 and Fra-2 in Swiss 3T3 cells is serum-dependent during G(1) following the transition from G(0) and during asynchronous growth but is serum-independent during S phase and mitosis. Post-translational modification of Fra-1 and Fra-2 causes a significant shift in their gel mobility which is eliminated by alkaline phosphatase treatment. Several kinases can phosphorylate Fra-1 and Fra-2 in vitro, including cAMP-dependent kinase (PKA), protein kinase C (PKC), cyclin-dependent kinase 1-cdc2 (cdc2), and mitogen activated protein (MAP) kinase. From these, MAP kinase is the only one that causes a shift in gel mobility similar to that observed in vivo. One dimensional phosphopeptide maps of Fra-1 and Fra-2 phosphorylated by MAP kinase in vitro are similar to those of in vivo labeled Fra-1 and Fra-2, suggesting that MAP kinase may also phosphorylate Fra-1 and Fra-2 in vivo. We have also determined that phosphorylation of Fra-1 and Fra-2 by MAP kinase increases their DNA binding activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC BIOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Kovary, Karla/E-3979-2013					ABATE C, 1991, ONCOGENE, V6, P2179; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ABATE C, 1993, P NATL ACAD SCI USA, V90, P6766, DOI 10.1073/pnas.90.14.6766; BAKER SJ, 1992, MOL CELL BIOL, V12, P4694, DOI 10.1128/MCB.12.10.4694; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRAVO R, 1990, GROWTH FACTORS DIFFE; BRAVO R, 1980, J CELL BIOL, V84, P796; CARROLL D, 1989, J BIOL CHEM, V264, P7345; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT RP, 1992, ONCOGENE, V7, P841; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GILLE H, 1992, NATURE, V358, P433; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAU LF, 1991, HORMONAL CONTROL REG; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MATSUI M, 1990, ONCOGENE, V5, P249; MEEK DW, 1992, BIOCHEM J, V287, P1; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELECH SL, 1987, J BIOL CHEM, V262, P11598; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RYSECK RP, 1991, ONCOGENE, V6, P533; RYSECK RP, 1990, ONCOGENE, V5, P1091; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Summers MD, 1987, TEXAS AGR EXPT STATI; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUZUKI T, 1992, NUCLEIC ACIDS RES, V19, P5537; TAYLOR LK, 1993, P NATL ACAD SCI USA, V90, P368, DOI 10.1073/pnas.90.2.368; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; YOSHIDA T, 1991, BIOCHEM BIOPH RES CO, V174, P934, DOI 10.1016/0006-291X(91)91508-A; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	67	134	135	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2537	2547						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058317				2022-12-17	WOS:A1994PC05400013
J	COHEN, JA; WEINER, DB; MORE, KF; KOKAI, Y; WILLIAMS, WV; MAGUIRE, HC; LIVOLSI, VA; GREENE, MI				COHEN, JA; WEINER, DB; MORE, KF; KOKAI, Y; WILLIAMS, WV; MAGUIRE, HC; LIVOLSI, VA; GREENE, MI			EXPRESSION PATTERN OF THE NEU (NGL) GENE-ENCODED GROWTH-FACTOR RECEPTOR PROTEIN (P185NEU) IN NORMAL AND TRANSFORMED EPITHELIAL TISSUES OF THE DIGESTIVE-TRACT	ONCOGENE			English	Article									UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Weiner, David B/H-8579-2014	Williams, William/0000-0003-3611-9284				ALLEN DC, 1987, J CLIN PATHOL, V40, P157, DOI 10.1136/jcp.40.2.157; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BERGER MS, 1988, CANCER RES, V48, P1238; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; CICLITIRA PJ, 1987, J PATHOL, V151, P293, DOI 10.1002/path.1711510409; CLINE MJ, 1987, CANCER, V60, P2669, DOI 10.1002/1097-0142(19871201)60:11<2669::AID-CNCR2820601116>3.0.CO;2-4; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIXON WJ, 1969, INTRO STATISTICAL AN; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; FURTH ME, 1987, ONCOGENE, V1, P47; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORI S, 1987, VIRCHOWS ARCH B, V54, P8, DOI 10.1007/BF02899192; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SCHEJTER ED, 1986, CELL, V46, P1092; SEFTON BM, 1978, J VIROL, V28, P957, DOI 10.1128/JVI.28.3.957-971.1978; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONDIK EJ, 1986, NIH872789 NCI PUBL; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; STOICA G, 1984, AM J PATHOL, V116, P319; SU TS, 1985, BIOCHEM BIOPH RES CO, V132, P264, DOI 10.1016/0006-291X(85)91017-4; TANAKA T, 1986, CANCER RES, V46, P1465; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TROJANOWSKI JQ, 1983, J HISTOCHEM CYTOCHEM, V31, P1217, DOI 10.1177/31.10.6350434; TSUBOI K, 1987, BIOCHEM BIOPH RES CO, V146, P699, DOI 10.1016/0006-291X(87)90585-7; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1444, DOI 10.1056/NEJM197806292982604; WILLIAMSON RCN, 1978, NEW ENGL J MED, V298, P1393, DOI 10.1056/NEJM197806222982505; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1988, ONCOGENE, V2, P283; YOKOTA J, 1986, LANCET, V1, P765; ZHANG XK, 1987, BIOCHEM BIOPH RES CO, V142, P932, DOI 10.1016/0006-291X(87)91503-8; ZHOU DJ, 1987, CANCER RES, V47, P6123	50	134	158	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					81	88						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2563577				2022-12-17	WOS:A1989U567400012
J	Ricoult, SJH; Yecies, JL; Ben-Sahra, I; Manning, BD				Ricoult, S. J. H.; Yecies, J. L.; Ben-Sahra, I.; Manning, B. D.			Oncogenic PI3K and K-Ras stimulate de novo lipid synthesis through mTORC1 and SREBP	ONCOGENE			English	Article							STEAROYL-COA DESATURASE; ELEMENT-BINDING PROTEINS; UNSATURATED FATTY-ACIDS; TUBEROUS SCLEROSIS; MAMMALIAN TARGET; CELL-GROWTH; COMPLEX 1; CANCER PATHOGENESIS; TSC1-TSC2 COMPLEX; SIGNALING AXIS	An enhanced capacity for de novo lipid synthesis is a metabolic feature of most cancer cells that distinguishes them from their cells of origin. However, the mechanisms through which oncogenes alter lipid metabolism are poorly understood. We find that expression of oncogenic PI3K (H1047R) or K-Ras (G12V) in breast epithelial cells is sufficient to induce de novo lipogenesis, and this occurs through the convergent activation of the mechanistic target of rapamycin complex 1 (mTORC1) downstream of these common oncogenes. Oncogenic stimulation of mTORC1 signaling in this isogenic setting or a panel of eight breast cancer cell lines leads to activation of the sterol regulatory element-binding proteins (SREBP1 and SREBP2) that are required for oncogene-induced lipid synthesis. The SREBPs are also required for the growth factor-independent growth and proliferation of oncogene-expressing cells. Finally, we find that elevated mTORC1 signaling is associated with increased mRNA and protein levels of canonical SREBP targets in primary human breast cancer samples. These data suggest that the mTORC1/SREBP pathway is a major mechanism through which common oncogenic signaling events induce de novo lipid synthesis to promote aberrant growth and proliferation of cancer cells.	[Ricoult, S. J. H.; Yecies, J. L.; Ben-Sahra, I.; Manning, B. D.] Harvard Univ, Dept Genet & Complex Dis, TH Chan Sch Publ Hlth, 665 Huntington Ave,SPH2-117, Boston, MA 02115 USA; [Yecies, J. L.] Genentech Inc, San Francisco, CA 94080 USA	Harvard University; Harvard T.H. Chan School of Public Health; Roche Holding; Genentech	Manning, BD (corresponding author), Harvard Univ, Dept Genet & Complex Dis, TH Chan Sch Publ Hlth, 665 Huntington Ave,SPH2-117, Boston, MA 02115 USA.	bmanning@hsph.harvard.edu	Manning, Brendan/ABD-6528-2021	Manning, Brendan/0000-0003-3895-5956	NSF [DGE-1144152]; LAM Foundation; Sanofi Innovation Award; NIH [R01-CA181390, P01-CA120964]; NATIONAL CANCER INSTITUTE [R01CA181390, P01CA120964, R35CA197459] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); LAM Foundation; Sanofi Innovation Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NSF predoctoral fellowship DGE-1144152 (to SJHR), a postdoctoral fellowship from the LAM Foundation (to IB-S), a Sanofi Innovation Award (to BDM) and NIH Grants R01-CA181390 and P01-CA120964 (to BDM).	Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chakrabarti P, 2010, DIABETES, V59, P775, DOI 10.2337/db09-1602; Clendening JW, 2012, ONCOGENE, V31, P4967, DOI 10.1038/onc.2012.6; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Griffiths B, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-3; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Howell JJ, 2013, BIOCHEM SOC T, V41, P906, DOI 10.1042/BST20130041; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110; Kasiske BL, 2008, AM J TRANSPLANT, V8, P1384, DOI 10.1111/j.1600-6143.2008.02272.x; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Krycer JR, 2012, BIOCHEM J, V446, P191, DOI 10.1042/BJ20120545; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; LI J, 1994, INT J CANCER, V57, P348, DOI 10.1002/ijc.2910570310; Li SJ, 2010, P NATL ACAD SCI USA, V107, P3441, DOI 10.1073/pnas.0914798107; Li SY, 2011, BIOCHEM BIOPH RES CO, V412, P197, DOI 10.1016/j.bbrc.2011.07.038; Liu XL, 2012, BBA-MOL BASIS DIS, V1822, P1716, DOI 10.1016/j.bbadis.2012.07.008; Luyimbazi D, 2010, MOL CANCER THER, V9, P2770, DOI 10.1158/1535-7163.MCT-09-0980; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; MEDES G, 1953, CANCER RES, V13, P27; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Migita T, 2008, CANCER RES, V68, P8547, DOI 10.1158/0008-5472.CAN-08-1235; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Morrisett JD, 2002, J LIPID RES, V43, P1170, DOI 10.1194/jlr.M100392-JLR200; NAKANISHI S, 1970, EUR J BIOCHEM, V16, P161, DOI 10.1111/j.1432-1033.1970.tb01068.x; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Owen JL, 2012, P NATL ACAD SCI USA, V109, P16184, DOI 10.1073/pnas.1213343109; Peterson TR, 2011, CELL, V146, P408, DOI 10.1016/j.cell.2011.06.034; Porstmann T, 2005, ONCOGENE, V24, P6465, DOI 10.1038/sj.onc.1208802; Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007; Ricoult SJH, 2013, EMBO REP, V14, P242, DOI 10.1038/embor.2013.5; Roongta UV, 2011, MOL CANCER RES, V9, P1551, DOI 10.1158/1541-7786.MCR-11-0126; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Soliman GA, 2010, LIPIDS, V45, P1089, DOI 10.1007/s11745-010-3488-y; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; TWETO J, 1971, J BIOL CHEM, V246, P2468; Wang BT, 2011, P NATL ACAD SCI USA, V108, P15201, DOI 10.1073/pnas.1103746108; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Williams KJ, 2013, CANCER RES, V73, P2850, DOI 10.1158/0008-5472.CAN-13-0382-T; Yecies JL, 2011, CELL METAB, V14, P21, DOI 10.1016/j.cmet.2011.06.002; Young RM, 2013, GENE DEV, V27, P1115, DOI 10.1101/gad.198630.112; Zhang CB, 2009, AM J PHYSIOL-ENDOC M, V296, pE862, DOI 10.1152/ajpendo.90651.2008; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	65	133	136	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2016	35	10					1250	1260		10.1038/onc.2015.179	http://dx.doi.org/10.1038/onc.2015.179			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG0NY	26028026	Green Accepted			2022-12-17	WOS:000371763100005
J	Bonora, M; Wieckowski, MR; Chinopoulos, C; Kepp, O; Kroemer, G; Galluzzi, L; Pinton, P				Bonora, M.; Wieckowski, M. R.; Chinopoulos, C.; Kepp, O.; Kroemer, G.; Galluzzi, L.; Pinton, P.			Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition	ONCOGENE			English	Review							ADENINE-NUCLEOTIDE TRANSLOCASE; PERIPHERAL BENZODIAZEPINE-RECEPTOR; DEPENDENT ANION CHANNEL; CYTOCHROME-C RELEASE; COMPRISE VDAC MOLECULES; RAT-LIVER MITOCHONDRIA; CYCLOPHILIN-D; PHOSPHATE CARRIER; HEXOKINASE-II; INHIBITOR PROTEIN	The term mitochondrial permeability transition (MPT) is commonly used to indicate an abrupt increase in the permeability of the inner mitochondrial membrane to low molecular weight solutes. Widespread MPT has catastrophic consequences for the cell, de facto marking the boundary between cellular life and death. MPT results indeed in the structural and functional collapse of mitochondria, an event that commits cells to suicide via regulated necrosis or apoptosis. MPT has a central role in the etiology of both acute and chronic diseases characterized by the loss of post-mitotic cells. Moreover, cancer cells are often relatively insensitive to the induction of MPT, underlying their increased resistance to potentially lethal cues. Thus, intense efforts have been dedicated not only at the understanding of MPT in mechanistic terms, but also at the development of pharmacological MPT modulators. In this setting, multiple mitochondrial and extramitochondrial proteins have been suspected to critically regulate the MPT. So far, however, only peptidylprolyl isomerase F (best known as cyclophilin D) appears to constitute a key component of the so-called permeability transition pore complex (PTPC), the supramolecular entity that is believed to mediate MPT. Here, after reviewing the structural and functional features of the PTPC, we summarize recent findings suggesting that another of its core components is represented by the c subunit of mitochondrial ATP synthase.	[Bonora, M.; Pinton, P.] Univ Ferrara, ICSI, Dept Morphol Surg & Expt Med, LTTA,Sect Pathol Oncol & Expt Biol, I-44100 Ferrara, Italy; [Wieckowski, M. R.] M Nencki Inst Expt Biol, Dept Biochem, PL-02093 Warsaw, Poland; [Chinopoulos, C.] Semmelweis Univ, Dept Med Biochem, H-1085 Budapest, Hungary; [Kepp, O.; Kroemer, G.; Galluzzi, L.] Ctr Rech Cordeliers, INSERM U1138, Equipe Labelisee Ligue Natl Canc 11, F-75006 Paris, France; [Kepp, O.; Kroemer, G.; Galluzzi, L.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Kepp, O.; Kroemer, G.] Gustave Roussy Comprehens Canc Ctr, Metab & Cell Biol Platforms, Villejuif, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France; [Galluzzi, L.] Gustave Roussy Comprehens Canc Ctr, Villejuif, France	University of Ferrara; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; Semmelweis University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy	Galluzzi, L (corresponding author), Ctr Rech Cordeliers, Equipe Labelisee Ligue Natl Canc 11, 15 Rue Ecole Med, F-75006 Paris, France.	deadoc@vodafone.it; pnp@unife.it	Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/AAG-6432-2019; Bonora, Massimo/AAC-3609-2022; Galluzzi, Lorenzo/AAG-6294-2019; KROEMER, Guido/B-4263-2013; Kepp, Oliver/N-2763-2017; Kroemer, Guido/AAY-9859-2020; Pinton, Paolo/J-8025-2012; Galluzzi, Lorenzo/AAH-3286-2021	Bonora, Massimo/0000-0002-5752-3318; KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; Pinton, Paolo/0000-0001-7108-6508; 	Italian Association for Cancer Research (AIRC); Telethon [GGP11139B]; University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca); Italian Ministry of Health grant; Polish National Science Center [UMO-2011/11/M/NZ3/02128]; Polish Ministry of Science and Higher Education [W100/HFSC/2011]; BIO-IMAGing in Research Innovation and Education [FP7-REGPOT-2010-1]; Hungarian Academy of Sciences (MTA-SE Lendulet Neurobiochemistry Research Division) [95003]; Hungarian Scientific Research Fund [K 100918]; Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon); University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca)(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health grant(Ministry of Health, Italy); Polish National Science Center; Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland); BIO-IMAGing in Research Innovation and Education; Hungarian Academy of Sciences (MTA-SE Lendulet Neurobiochemistry Research Division); Hungarian Scientific Research Fund(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI)	This article was supported by: the Italian Association for Cancer Research (AIRC); Telethon (GGP11139B); local funds from the University of Ferrara; the Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca); and an Italian Ministry of Health grant to PP. MRW is supported by the Polish National Science Center (UMO-2011/11/M/NZ3/02128), Polish Ministry of Science and Higher Education grant W100/HFSC/2011 and BIO-IMAGing in Research Innovation and Education (FP7-REGPOT-2010-1). CC is supported by the Hungarian Academy of Sciences (MTA-SE Lendulet Neurobiochemistry Research Division grant 95003) and the Hungarian Scientific Research Fund (grant K 100918). GK is supported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).	Acin-Perez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021; Alavian KN, 2011, NAT CELL BIOL, V13, P1224, DOI 10.1038/ncb2330; Alcala S, 2008, ONCOGENE, V27, P44, DOI 10.1038/sj.onc.1210600; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Arai S, 2013, NATURE, V493, P703, DOI 10.1038/nature11778; Arbel N, 2012, J BIOL CHEM, V287, P23152, DOI 10.1074/jbc.M112.345918; Ariga T, 2002, J BIOL CHEM, V277, P24870, DOI 10.1074/jbc.M202582200; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 2003, EUR J BIOCHEM, V270, P1875, DOI 10.1046/j.1432-1033.2003.03557.x; Arzoine L, 2009, J BIOL CHEM, V284, P3946, DOI 10.1074/jbc.M803614200; Azarashvili T, 2007, CELL CALCIUM, V42, P27, DOI 10.1016/j.ceca.2006.11.004; Azarashvili T, 2014, CELL CALCIUM, V55, P69, DOI 10.1016/j.ceca.2013.12.002; Azarashvili TS, 2002, J BIOENERG BIOMEMBR, V34, P279, DOI 10.1023/A:1020204518513; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Baker LA, 2012, P NATL ACAD SCI USA, V109, P11675, DOI 10.1073/pnas.1204935109; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bonora M, 2013, CELL CYCLE, V12, P674, DOI 10.4161/cc.23599; Bonora M, 2012, PURINERG SIGNAL, V8, P343, DOI 10.1007/s11302-012-9305-8; Borner C, 2014, CELL DEATH DIFFER, V21, P187, DOI 10.1038/cdd.2013.169; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BULYGIN VV, 1991, BIOCHEM J, V276, P149, DOI 10.1042/bj2760149; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Campanella M, 2009, TRENDS BIOCHEM SCI, V34, P343, DOI 10.1016/j.tibs.2009.03.006; Campanella M, 2008, BIOCHEM PHARMACOL, V76, P1628, DOI 10.1016/j.bcp.2008.09.034; Chelli B, 2001, BIOCHEM PHARMACOL, V61, P695, DOI 10.1016/S0006-2952(00)00588-8; Chen YB, 2011, J CELL BIOL, V195, P263, DOI 10.1083/jcb.201108059; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chiara F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.184; Chiara F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001852; Chinopoulos C, 2006, FEBS J, V273, P433, DOI 10.1111/j.1742-4658.2005.05103.x; Chinopoulos C, 2012, MITOCHONDRION, V12, P41, DOI 10.1016/j.mito.2011.04.007; Chinopoulos C, 2011, J NEUROSCI RES, V89, P1897, DOI 10.1002/jnr.22659; Chinopoulos C, 2011, FEBS LETT, V585, P1255, DOI 10.1016/j.febslet.2011.04.004; Chinopoulos C, 2011, FEBS J, V278, P1112, DOI 10.1111/j.1742-4658.2011.08026.x; Chinopoulos C, 2010, FASEB J, V24, P2405, DOI 10.1096/fj.09-149898; Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; CROMPTON M, 1988, BIOCHEM J, V255, P357; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Das S, 2008, CIRC RES, V103, P983, DOI 10.1161/CIRCRESAHA.108.178970; Daum B, 2013, P NATL ACAD SCI USA, V110, P15301, DOI 10.1073/pnas.1305462110; Davies KM, 2012, P NATL ACAD SCI USA, V109, P13602, DOI 10.1073/pnas.1204593109; Decaudin D, 2002, CANCER RES, V62, P1388; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Devenish RJ, 2008, INT REV CEL MOL BIO, V267, P1, DOI 10.1016/S1937-6448(08)00601-1; Dienhart M, 2002, J BIOL CHEM, V277, P39289, DOI 10.1074/jbc.M205720200; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; DROBINSKAYA IY, 1985, FEBS LETT, V182, P419, DOI 10.1016/0014-5793(85)80346-X; Faccenda D, 2013, CELL DEATH DIFFER, V20, P686, DOI 10.1038/cdd.2012.163; Faccenda Danilo, 2012, Int J Cell Biol, V2012, P367934, DOI 10.1155/2012/367934; Feniouk Boris A., 2008, V45, P279, DOI 10.1007/400_2007_043; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272; Fujimoto K, 2010, P NATL ACAD SCI USA, V107, P10214, DOI 10.1073/pnas.0914209107; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Galkin MA, 1999, FEBS LETT, V448, P123, DOI 10.1016/S0014-5793(99)00347-6; Galluzzi L, 2008, ONCOGENE, V27, P4633, DOI 10.1038/onc.2008.114; Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000018; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145; Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479; Galluzzi L, 2012, EMBO REP, V13, P322, DOI 10.1038/embor.2012.19; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Garcia JJ, 2006, BIOCHEMISTRY-US, V45, P12695, DOI 10.1021/bi060339j; Genova ML, 2008, BBA-BIOENERGETICS, V1777, P740, DOI 10.1016/j.bbabio.2008.04.007; Giorgi C, 2012, CELL CALCIUM, V52, P36, DOI 10.1016/j.ceca.2012.02.008; Giorgi C, 2010, SCIENCE, V330, P1247, DOI 10.1126/science.1189157; Giorgio V, 2013, P NATL ACAD SCI USA, V110, P5887, DOI 10.1073/pnas.1217823110; Giorgio V, 2009, J BIOL CHEM, V284, P33982, DOI 10.1074/jbc.M109.020115; Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P15671, DOI 10.1073/pnas.0707326104; Goldin N, 2008, ONCOGENE, V27, P4636, DOI 10.1038/onc.2008.108; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Greie JC, 2004, EUR J BIOCHEM, V271, P3036, DOI 10.1111/j.1432-1033.2004.04235.x; Habersetzer J, 2013, INT J BIOCHEM CELL B, V45, P99, DOI 10.1016/j.biocel.2012.05.017; Hagen T, 2003, AM J PHYSIOL-GASTR L, V285, pG274, DOI 10.1152/ajpgi.00052.2003; Halestrap AP, 2009, J MOL CELL CARDIOL, V46, P821, DOI 10.1016/j.yjmcc.2009.02.021; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Juhaszova M, 2004, J CLIN INVEST, V113, P1535, DOI 10.1172/JCI200419906; Juhaszova M, 2009, CIRC RES, V104, P1240, DOI 10.1161/CIRCRESAHA.109.197996; Kahan BD, 2003, NAT REV IMMUNOL, V3, P831, DOI 10.1038/nri1204; KALASHNIKOVA TY, 1988, EUR J BIOCHEM, V177, P213, DOI 10.1111/j.1432-1033.1988.tb14364.x; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Karch J, 2013, ELIFE, V2, DOI 10.7554/eLife.00772; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Kiss G, 2014, FASEB J, V28, P1682, DOI 10.1096/fj.13-243030; Kiss G, 2013, FASEB J, V27, P2392, DOI 10.1096/fj.12-220202; Klaffschenkel RA, 2012, ARTIF CELL BLOOD SUB, V40, P56, DOI 10.3109/10731199.2011.585617; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Korzick DH, 2007, AM J PHYSIOL-HEART C, V293, pH2056, DOI 10.1152/ajpheart.00403.2007; Krestinina OV, 2009, BIOCHEMISTRY-MOSCOW+, V74, P421, DOI 10.1134/S0006297909040105; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kugler W, 2008, CELL ONCOL, V30, P435, DOI 10.3233/CLO-2008-0431; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leung AWC, 2008, J BIOL CHEM, V283, P26312, DOI 10.1074/jbc.M805235200; LIGHTOWLERS RN, 1988, BIOCHIM BIOPHYS ACTA, V933, P241, DOI 10.1016/0005-2728(88)90031-X; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; LoGuidice A, 2010, TOXICOL SCI, V118, P276, DOI 10.1093/toxsci/kfq226; Malia TJ, 2007, BIOCHEMISTRY-US, V46, P514, DOI 10.1021/bi061577h; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Marchi S, 2014, J PHYSIOL-LONDON, V592, P829, DOI 10.1113/jphysiol.2013.268235; Marchi S, 2014, BBA-BIOENERGETICS, V1837, P461, DOI 10.1016/j.bbabio.2013.10.015; Martel C, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/213403; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Masgras I, 2012, BBA-BIOENERGETICS, V1817, P1860, DOI 10.1016/j.bbabio.2012.02.022; Mayr JA, 2010, HUM MOL GENET, V19, P3430, DOI 10.1093/hmg/ddq254; MCENERY MW, 1992, P NATL ACAD SCI USA, V89, P3170, DOI 10.1073/pnas.89.8.3170; McGeoch JEM, 1999, MOL GENET METAB, V66, P387, DOI 10.1006/mgme.1999.2822; McGeoch JEM, 1997, BRAIN RES, V766, P188, DOI 10.1016/S0006-8993(97)00618-5; Metelkin E, 2009, FEBS J, V276, P6942, DOI 10.1111/j.1742-4658.2009.07394.x; Millay DP, 2008, NAT MED, V14, P442, DOI 10.1038/nm1736; Minagawa Y, 2013, J BIOL CHEM, V288, P32700, DOI 10.1074/jbc.M113.506329; Minauro-Sanmiguel F, 2005, P NATL ACAD SCI USA, V102, P12356, DOI 10.1073/pnas.0503893102; MINKOV IB, 1979, BIOCHEM BIOPH RES CO, V89, P1300, DOI 10.1016/0006-291X(79)92150-8; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9813, DOI 10.1073/pnas.86.24.9813; Munoz-Pinedo C, 2006, P NATL ACAD SCI USA, V103, P11573, DOI 10.1073/pnas.0603007103; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Masahiro N, 2007, J MOL CELL CARDIOL, V43, P564, DOI 10.1016/j.yjmcc.2007.08.010; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Okuno D, 2011, J BIOCHEM, V149, P655, DOI 10.1093/jb/mvr049; Palma E, 2009, HUM MOL GENET, V18, P2024, DOI 10.1093/hmg/ddp126; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; PASTORINO JG, 1994, J BIOL CHEM, V269, P31041; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2008, J BIOENERG BIOMEMBR, V40, P171, DOI 10.1007/s10863-008-9148-8; Patergnani S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-19; Pauleau AL, 2008, CELL DEATH DIFFER, V15, P616, DOI 10.1038/sj.cdd.4402295; Pediaditakis P, 2010, BIOCHEM J, V431, P411, DOI 10.1042/BJ20091741; Peng R, 2013, CELL DEATH DIFFER, V20, P744, DOI 10.1038/cdd.2013.4; Perciavalle RM, 2012, NAT CELL BIOL, V14, P575, DOI 10.1038/ncb2488; PETRONILLI V, 1993, J BIOL CHEM, V268, P1011; Poncet D, 2006, J CELL BIOL, V174, P985, DOI 10.1083/jcb.200604069; Pucci B, 2008, J CELL PHYSIOL, V217, P442, DOI 10.1002/jcp.21513; Ramachandran A, 2011, FREE RADICAL RES, V45, P156, DOI 10.3109/10715762.2010.520319; Rasola A, 2010, P NATL ACAD SCI USA, V107, P726, DOI 10.1073/pnas.0912742107; ROOS I, 1980, EUR J BIOCHEM, V110, P319, DOI 10.1111/j.1432-1033.1980.tb04870.x; ROVERI OA, 1980, BIOCHIM BIOPHYS ACTA, V589, P241, DOI 10.1016/0005-2728(80)90041-9; Roy SS, 2009, MOL CELL, V33, P377, DOI 10.1016/j.molcel.2009.01.018; Rubinstein JL, 2003, EMBO J, V22, P6182, DOI 10.1093/emboj/cdg608; Rubinstein JL, 2002, J MOL BIOL, V321, P613, DOI 10.1016/S0022-2836(02)00671-X; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640; Schindler A, 2013, CELL SIGNAL, V25, P2685, DOI 10.1016/j.cellsig.2013.08.035; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; Schroers A, 1997, J BIOL CHEM, V272, P10558; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 1997, J BIOL CHEM, V272, P12295, DOI 10.1074/jbc.272.19.12295; Shargorodsky L, 2012, APOPTOSIS, V17, P647, DOI 10.1007/s10495-012-0725-2; Shchepina LA, 2002, ONCOGENE, V21, P8149, DOI 10.1038/sj.onc.1206053; Shimabukuro K, 2006, BIOPHYS J, V90, P1028, DOI 10.1529/biophysj.105.067298; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Smeele KMA, 2011, CIRC RES, V108, P1165, DOI 10.1161/CIRCRESAHA.111.244962; Stephens AN, 2003, BBA-BIOENERGETICS, V1607, P181, DOI 10.1016/j.bbabio.2003.09.010; Strauss M, 2008, EMBO J, V27, P1154, DOI 10.1038/emboj.2008.35; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; SWANLJUNG P, 1973, BIOCHIM BIOPHYS ACTA, V305, P519, DOI 10.1016/0005-2728(73)90073-X; Symersky J, 2012, P NATL ACAD SCI USA, V109, P13961, DOI 10.1073/pnas.1207912109; Szabadkai G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00140; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1993, FEBS LETT, V330, P206, DOI 10.1016/0014-5793(93)80274-X; SZABO I, 1993, FEBS LETT, V330, P201, DOI 10.1016/0014-5793(93)80273-W; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; TEDESCHI H, 1965, BIOCHIM BIOPHYS ACTA, V104, P612, DOI 10.1016/0304-4165(65)90372-7; Thomas B, 2012, ANTIOXID REDOX SIGN, V16, P855, DOI 10.1089/ars.2010.3849; Todt F, 2013, CELL DEATH DIFFER, V20, P333, DOI 10.1038/cdd.2012.131; Traba J, 2012, CELL DEATH DIFFER, V19, P650, DOI 10.1038/cdd.2011.139; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vander Heiden MG, 1999, MOL CELL, V3, P159; Varanyuwatana P, 2012, MITOCHONDRION, V12, P120, DOI 10.1016/j.mito.2011.04.006; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Veenman L, 2010, APOPTOSIS, V15, P753, DOI 10.1007/s10495-010-0460-5; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; von Ballmoos C, 2009, ANNU REV BIOCHEM, V78, P649, DOI 10.1146/annurev.biochem.78.081307.104803; Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001; Wallimann T, 1998, BIOFACTORS, V8, P229, DOI 10.1002/biof.5520080310; Wang SB, 2013, TRENDS CARDIOVAS MED, V23, P14, DOI 10.1016/j.tcm.2012.08.005; Whelan RS, 2012, P NATL ACAD SCI USA, V109, P6566, DOI 10.1073/pnas.1201608109; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wittig I, 2008, BBA-BIOENERGETICS, V1777, P592, DOI 10.1016/j.bbabio.2008.04.027; Wittig I, 2008, MOL CELL PROTEOMICS, V7, P995, DOI 10.1074/mcp.M700465-MCP200; Wittig I, 2010, BBA-BIOENERGETICS, V1797, P1004, DOI 10.1016/j.bbabio.2010.02.021; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	219	133	135	0	94	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1475	1486		10.1038/onc.2014.96	http://dx.doi.org/10.1038/onc.2014.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI					2022-12-17	WOS:000351416800001
J	Zhang, N; Wang, X; Huo, Q; Sun, M; Cai, C; Liu, Z; Hu, G; Yang, Q				Zhang, N.; Wang, X.; Huo, Q.; Sun, M.; Cai, C.; Liu, Z.; Hu, G.; Yang, Q.			MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin	ONCOGENE			English	Article						miR-30a; metadherin; breast cancer; metastasis	ASTROCYTE-ELEVATED GENE-1; CANCER PROGRESSION; EXPRESSION; CELLS; HETEROZYGOSITY; IDENTIFICATION; APOPTOSIS; INVASION; REGIONS; HEAD	Accumulating data have shown the involvement of microRNAs in cancerous processes as either oncogenes or tumor suppressor genes. Here, we established miR-30a as a tumor suppressor gene in breast cancer development and metastasis. Ectopic expression of miR-30a in breast cancer cell lines resulted in the suppression of cell growth and metastasis in vitro. Consistently, the xenograft mouse model also unveiled the suppressive effects of miR-30a on tumor growth and distal pulmonary metastasis. With dual luciferase reporter assay, we revealed that miR-30a could bind to the 3'-untranslated region of metadherin (MTDH) gene, thus exerting inhibitory effect on MTDH. Furthermore, we demonstrated that silence of MTDH could recapitulate the effects of miR-30a overexpression, while overexpression of MTDH could partially abrogate miR-30a-mediated suppression. Of significance, expression level of miR-30a was found to be significantly lower in primary breast cancer tissues than in the paired normal tissues. Further evaluation verified that miR-30a was negatively correlated with the extent of lymph node and lung metastasis in patients with breast cancer. Taken together, our findings indicated miR-30a inhibits breast cancer proliferation and metastasis by directly targeting MTDH, and miR-30a can serve as a prognostic marker for breast cancer. Manipulation of miR-30a may provide a promising therapeutic strategy for breast cancer treatment.	[Zhang, N.; Wang, X.; Huo, Q.; Sun, M.; Cai, C.; Yang, Q.] Shandong Univ, Dept Breast Surg, Qilu Hosp, Jinan 250012, Peoples R China; [Liu, Z.] Shandong Univ, Sch Med, Inst Cell Biol, Jinan 250012, Peoples R China; [Hu, G.] Chinese Acad Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Hu, G.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China; [Yang, Q.] Shandong Univ, Key Lab Expt Teratol, Minist Educ, Sch Med, Jinan 250012, Peoples R China; [Yang, Q.] Shandong Univ, Sch Med, Inst Mol Med & Genet, Jinan 250012, Peoples R China	Shandong University; Shandong University; Chinese Academy of Sciences; Shanghai Jiao Tong University; Shandong University; Shandong University	Yang, Q (corresponding author), Shandong Univ, Dept Breast Surg, Qilu Hosp, Wenhua Xi Rd 107, Jinan 250012, Peoples R China.	qifengy@gmail.com	Zhang, Ning/GNP-1966-2022; yang, qiang/GYJ-0971-2022; Zhang, Ning/GOJ-8058-2022	Zhang, Ning/0000-0002-6430-4236; Hu, Guohong/0000-0002-2980-5166; Yang, Qifeng/0000-0003-0576-8513	National Natural Science Foundation of China [30772133, 81072150, 81172529, 81272903]; Shandong Science and Technology Development Plan [2012GZC22115]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Science and Technology Development Plan	We thank Shi Yan, Cunzhong Yuan and Ning Yang for collecting the clinical samples. This work was supported by National Natural Science Foundation of China (no. 30772133; no. 81072150; no. 81172529; no. 81272903) and Shandong Science and Technology Development Plan (no. 2012GZC22115):	Agrawal R, 2009, DEVELOPMENT, V136, P3927, DOI 10.1242/dev.037432; Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Brown DM, 2004, CANCER CELL, V5, P365, DOI 10.1016/S1535-6108(04)00079-0; Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chappell SA, 1997, BRIT J CANCER, V75, P1324, DOI 10.1038/bjc.1997.224; Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Hu GH, 2009, CLIN CANCER RES, V15, P5615, DOI 10.1158/1078-0432.CCR-09-0049; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Hui ABY, 2011, CLIN CANCER RES, V17, P7539, DOI 10.1158/1078-0432.CCR-11-2102; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Kikuno N, 2007, ONCOGENE, V26, P7647, DOI 10.1038/sj.onc.1210572; Kong XL, 2012, CANCER BIOL THER, V13, P43, DOI 10.4161/cbt.13.1.18868; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lagana A, 2009, DATABASE, V2009; Lee SG, 2009, ONCOGENE, V28, P2476, DOI 10.1038/onc.2009.93; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li C, 2011, J SURG ONCOL, V103, P184, DOI 10.1002/jso.21788; Li J, 2008, CLIN CANCER RES, V14, P3319, DOI 10.1158/1078-0432.CCR-07-4054; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Nohata N, 2011, J HUM GENET, V56, P595, DOI 10.1038/jhg.2011.66; Noviello C, 1996, CLIN CANCER RES, V2, P1601; Ouzounova M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-139; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Rodriguez-Gonzalez FG, 2011, BREAST CANCER RES TR, V127, P43, DOI 10.1007/s10549-010-0940-x; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128; Xia ZB, 2010, CLIN NEUROL NEUROSUR, V112, P413, DOI 10.1016/j.clineuro.2010.02.007; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yoo BK, 2009, J CLIN INVEST, V119, P465, DOI 10.1172/JCI36460; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Zhang N, 2013, J BIOL CHEM, V288, P9396, DOI 10.1074/jbc.M112.395913; Zhang N, 2010, CANCER SCI, V101, P2375, DOI 10.1111/j.1349-7006.2010.01680.x; Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064; Zou ZY, 2012, J BIOL CHEM, V287, P4148, DOI 10.1074/jbc.M111.307405	52	133	140	0	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3119	3128		10.1038/onc.2013.286	http://dx.doi.org/10.1038/onc.2013.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851509				2022-12-17	WOS:000338410000005
J	Lok, BH; Carley, AC; Tchang, B; Powell, SN				Lok, B. H.; Carley, A. C.; Tchang, B.; Powell, S. N.			RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination	ONCOGENE			English	Article						BRCA1; PALB2; BRCA2; RAD52; synthetic lethality; RAD51	CANCER SUSCEPTIBILITY GENE; REPLICATION PROTEIN-A; STRAND BREAK REPAIR; DNA-REPAIR; POLY(ADP-RIBOSE) POLYMERASE; CELLS; PHOSPHORYLATION; COMPLEX; TUMORS; DAMAGE	Synthetic lethality is an approach to study selective cell killing based on genotype. Previous work in our laboratory has shown that loss of RAD52 is synthetically lethal with BRCA2 deficiency, while exhibiting no impact on cell growth and viability in BRCA2-proficient cells. We now show that this same synthetically lethal relationship is evident in cells with deficiencies in BRCA1 or PALB2, which implicates BRCA1, PALB2 and BRCA2 in an epistatic relationship with one another. When RAD52 was depleted in BRCA1- or PALB2-deficient cells, a severe reduction in plating efficiency was observed, with many abortive attempts at cell division apparent in the double-depleted background. In contrast, when RAD52 was depleted in a BRCA1- or PALB2-wildtype background, a negligible decrease in colony survival was observed. The frequency of ionizing radiation-induced RAD51 foci formation and double-strand break-induced homologous recombination (HR) was decreased by 3- and 10-fold, respectively, when RAD52 was knocked down in BRCA1- or PALB2-depleted cells, with minimal effect in BRCA1- or PALB2-proficient cells. RAD52 function was independent of BRCA1 status, as evidenced by the lack of any defect in RAD52 foci formation in BRCA1-depleted cells. Collectively, these findings suggest that RAD52 is an alternative repair pathway of RAD51-mediated HR, and a target for therapy in cells deficient in the BRCA1-PALB2-BRCA2 repair pathway.	[Lok, B. H.; Carley, A. C.; Tchang, B.; Powell, S. N.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10065 USA; [Lok, B. H.] NYU, Langone Med Ctr, Sch Med, Dept Med, New York, NY USA; [Lok, B. H.] NYU, Langone Med Ctr, Sch Med, Dept Radiat Oncol, New York, NY USA; [Tchang, B.] Cornell Univ, Weill Cornell Grad Sch Med Sci, New York, NY USA; [Powell, S. N.] Suny Downstate Med Ctr, Coll Med, New York, NY USA	Memorial Sloan Kettering Cancer Center; New York University; NYU Langone Medical Center; New York University; NYU Langone Medical Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Powell, SN (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, 1250 1st Ave,Box 33, New York, NY 10065 USA.	Powells@mskcc.org		Lok, Benjamin/0000-0002-3675-8847	Howard Hughes Medical Institute Medical Research Training Fellowship; Radiological Society of North America Research Medical Student Grant; National Cancer Institute; Susan G. Komen for the Cure; NATIONAL CANCER INSTITUTE [R01CA107640, P30CA008748] Funding Source: NIH RePORTER	Howard Hughes Medical Institute Medical Research Training Fellowship(Howard Hughes Medical Institute); Radiological Society of North America Research Medical Student Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the Howard Hughes Medical Institute Medical Research Training Fellowship, the Radiological Society of North America Research Medical Student Grant (BHL) and by grants from the National Cancer Institute and the Susan G. Komen for the Cure (SNP).	Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374; Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng ZH, 2011, P NATL ACAD SCI USA, V108, P686, DOI 10.1073/pnas.1010959107; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Holloman WK, 2011, NAT STRUCT MOL BIOL, V18, P748, DOI 10.1038/nsmb.2096; Iglehart JD, 2009, NEW ENGL J MED, V361, P189, DOI 10.1056/NEJMe0903044; Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202; Kojic M, 2011, MOL MICROBIOL, V79, P180, DOI 10.1111/j.1365-2958.2010.07440.x; Konstantinopoulos PA, 2010, J CLIN ONCOL, V28, P3555, DOI 10.1200/JCO.2009.27.5719; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Qing Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002148; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Singleton MR, 2002, P NATL ACAD SCI USA, V99, P13492, DOI 10.1073/pnas.212449899; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; Sy SMH, 2009, P NATL ACAD SCI USA, V106, P7155, DOI 10.1073/pnas.0811159106; Wang WY, 2010, CLIN CANCER RES, V16, P1016, DOI 10.1158/1078-0432.CCR-09-2796; Willers H, 2009, MOL CANCER RES, V7, P1304, DOI 10.1158/1541-7786.MCR-09-0149; Xia B, 2006, MOL CELL, V22, P719, DOI 10.1016/j.molcel.2006.05.022; Zhang F, 2009, MOL CANCER RES, V7, P1110, DOI 10.1158/1541-7786.MCR-09-0123; Zhang F, 2009, CURR BIOL, V19, P524, DOI 10.1016/j.cub.2009.02.018; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004	35	133	136	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2013	32	30					3552	3558		10.1038/onc.2012.391	http://dx.doi.org/10.1038/onc.2012.391			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	22964643	Green Accepted			2022-12-17	WOS:000322220800008
J	Shih, MC; Chen, JY; Wu, YC; Jan, YH; Yang, BM; Lu, PJ; Cheng, HC; Huang, MS; Yang, CJ; Hsiao, M; Lai, JM				Shih, M-C; Chen, J-Y; Wu, Y-C; Jan, Y-H; Yang, B-M; Lu, P-J; Cheng, H-C; Huang, M-S; Yang, C-J; Hsiao, M.; Lai, J-M			TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer	ONCOGENE			English	Article						TOPK; AKT; PTEN; migration; prognosis marker; lung adenocarcinoma	ORIGINATED PROTEIN-KINASE; PDZ-BINDING KINASE; MITOTIC KINASE; DISEASE RECURRENCE; EXPRESSION; PTEN; PHOSPHORYLATION; SURVIVAL; PBK/TOPK; INVASION	We integrated four gene expression profile data sets, namely two different pair-matched stage I lung adenocarcinoma data sets, secondary metastatic tumors vs benign tumors and lung tumor metastasizes to the brain, and we identified one kinase, T-LAK Cell-Originated Protein Kinase (TOPK), as a putative gene that promotes metastasis. To delineate the role of TOPK in lung cancer, we showed that overexpression of TOPK, but not a catalytically inactive form of TOPK, can enhance the migration and invasion of lung fibroblasts or cells with low TOPK expression. In addition, TOPK-induced cell migration was shown to be a PI3K/AKT-dependent event. TOPK concurrently promoted AKT phosphorylation at Ser(473) and decreased the phosphatase and tensin homolog (PTEN) levels, whereas TOPK knockdown had the reverse effects. LY294002, a PI3K inhibitor, did not inhibit the TOPK-induced decrease in PTEN, and co-expression of PTEN significantly reduced TOPK-induced AKT phosphorylation in a dose-dependent manner; these results indicate that the TOPK-mediated PTEN decrease has an upstream role in regulating PI3K/AKT-stimulated migration. Using immunohistochemical analysis of lung cancer tissue samples, we showed that a high TOPK expression level correlates strongly with reduced overall and disease-free survivals. Moreover, an inverse correlation between TOPK and PTEN expression was present and is consistent with the biochemical findings. Finally, a combination of high TOPK and low PTEN expression was inversely correlated with overall and disease-free survivals, independent of other pathologic staging factors. Our results suggest that TOPK is a potential therapeutic target in lung cancer that promotes cell migration by modulating a PI3K/PTEN/AKT-dependent signaling pathway; they also suggest that high TOPK expression, either alone or in combination with a low level of PTEN, may serve as a prognostic marker for lung cancer. Oncogene (2012) 31, 2389-2400; doi: 10.1038/onc.2011.419; published online 26 September 2011	[Shih, M-C; Chen, J-Y; Yang, B-M; Lai, J-M] Fu Jen Catholic Univ, Coll Sci & Engn, Dept Life Sci, New Taipei City 24205, Taiwan; [Wu, Y-C] Taipei Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taipei, Taiwan; [Jan, Y-H; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lu, P-J; Cheng, H-C] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 70101, Taiwan; [Huang, M-S; Yang, C-J] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan	Fu Jen Catholic University; Taipei Veterans General Hospital; Academia Sinica - Taiwan; National Cheng Kung University; Kaohsiung Medical University; Kaohsiung Medical University Hospital	Lai, JM (corresponding author), Fu Jen Catholic Univ, Coll Sci & Engn, Dept Life Sci, 510 Zhongzheng Rd, New Taipei City 24205, Taiwan.	jmlai@mail.fju.edu.tw	Lai, Jin-Mei/AAM-4119-2020; Hsiao, Michael/U-6238-2019	Hsiao, Michael/0000-0001-8529-9213; Jan, Yi-Hua/0000-0001-7344-7602	National Science Council (Taiwan) [NSC95-2311-B-030-002-MY3, NSC99-2627-B-030-001]; Center of Excellence for Cancer Research at Taipei Veterans General Hospital [DOH100-TD-C-111-007]	National Science Council (Taiwan)(Ministry of Science and Technology, Taiwan); Center of Excellence for Cancer Research at Taipei Veterans General Hospital(Taipei Veterans General Hospital)	We thank Dr Chi-Ying F Huang (Yang-Ming University, Taipei, Taiwan) for providing lung cancer microarray data. This work was supported by grants from National Science Council (Taiwan) (NSC95-2311-B-030-002-MY3 and NSC99-2627-B-030-001) to JM Lai and Center of Excellence for Cancer Research at Taipei Veterans General Hospital (DOH100-TD-C-111-007) to YC Wu.	Abe Y, 2000, J BIOL CHEM, V275, P21525, DOI 10.1074/jbc.M909629199; Abe Y, 2007, J MOL BIOL, V370, P231, DOI 10.1016/j.jmb.2007.04.067; Akca H, 2011, LUNG CANCER, V73, P302, DOI 10.1016/j.lungcan.2011.01.012; AlKattan K, 1997, EUR J CARDIO-THORAC, V12, P380, DOI 10.1016/S1010-7940(97)00198-X; Auperin A, 2010, LANCET, V375, P1267, DOI 10.1016/S0140-6736(10)60059-1; Ayllon V, 2007, ONCOGENE, V26, P3451, DOI 10.1038/sj.onc.1210142; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005052; Chen TC, 2009, J PROTEOME RES, V8, P4943, DOI 10.1021/pr900325f; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Gaudet S, 2000, P NATL ACAD SCI USA, V97, P5167, DOI 10.1073/pnas.090102397; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Hu F, 2010, ONCOGENE, V29, P5464, DOI 10.1038/onc.2010.275; Hung JJ, 2009, THORAX, V64, P192, DOI 10.1136/thx.2007.094912; Kratz JR, 2009, CLIN LUNG CANCER, V10, P151, DOI 10.3816/CLC.2009.n.021; Le Chevalier T, 2004, NEW ENGL J MED, V350, P351, DOI 10.1056/nejmoa031644; Matsumoto S, 2004, BIOCHEM BIOPH RES CO, V325, P997, DOI 10.1016/j.bbrc.2004.10.133; Nandi A, 2004, BLOOD CELL MOL DIS, V32, P240, DOI 10.1016/j.bcmd.2003.10.004; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Oh SM, 2007, CANCER RES, V67, P5186, DOI 10.1158/0008-5472.CAN-06-4506; Omuro AMP, 2005, CANCER-AM CANCER SOC, V103, P2344, DOI 10.1002/cncr.21033; Park JH, 2006, CANCER RES, V66, P9186, DOI 10.1158/0008-5472.CAN-06-1601; Simons-Evelyn M, 2001, BLOOD CELL MOL DIS, V27, P825, DOI 10.1006/bcmd.2001.0452; Soria JC, 2002, CLIN CANCER RES, V8, P1178; Strauss GM, 2008, J CLIN ONCOL, V26, P5043, DOI 10.1200/JCO.2008.16.4855; Su LJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-140; Sugimura H, 2007, ANN THORAC SURG, V83, P409, DOI 10.1016/j.athoracsur.2006.08.046; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Zhu F, 2007, GASTROENTEROLOGY, V133, P219, DOI 10.1053/j.gastro.2007.04.048; Zlobec I, 2010, BRIT J CANCER, V102, P151, DOI 10.1038/sj.bjc.6605452; Zykova TA, 2006, CLIN CANCER RES, V12, P6884, DOI 10.1158/1078-0432.CCR-06-0410	33	133	137	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	19					2389	2400		10.1038/onc.2011.419	http://dx.doi.org/10.1038/onc.2011.419			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	941SP	21996732				2022-12-17	WOS:000303985300002
J	Papagiannakopoulos, T; Friedmann-Morvinski, D; Neveu, P; Dugas, JC; Gill, RM; Huillard, E; Liu, C; Zong, H; Rowitch, DH; Barres, BA; Verma, IM; Kosik, KS				Papagiannakopoulos, T.; Friedmann-Morvinski, D.; Neveu, P.; Dugas, J. C.; Gill, R. M.; Huillard, E.; Liu, C.; Zong, H.; Rowitch, D. H.; Barres, B. A.; Verma, I. M.; Kosik, K. S.			Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases	ONCOGENE			English	Article						microRNA; glioma stem cells; miR-128; EGFR; PDGFR alpha	GROWTH-FACTOR RECEPTOR; STEM-CELL; IN-VIVO; MICRORNAS; BRAIN; EGFR; MODULATION; MECHANISMS; RENEWAL; SET	MicroRNAs (miRNAs) carry out post-transcriptional control of a multitude of cellular processes. Aberrant expression of miRNA can lead to diseases, including cancer. Gliomas are aggressive brain tumors that are thought to arise from transformed glioma-initiating neural stem cells (giNSCs). With the use of giNSCs and human glioblastoma cells, we investigated the function of miRNAs in gliomas. We identified pro-neuronal miR-128 as a candidate glioma tumor suppressor miRNA. Decreased expression of miR-128 correlates with aggressive human glioma subtypes. With a combination of molecular, cellular and in vivo approaches, we characterize miR-128's tumor suppressive role. miR-128 represses giNSC growth by enhancing neuronal differentiation. miR-128 represses growth and mediates differentiation by targeting oncogenic receptor tyrosine kinases (RTKs) epithelial growth factor receptor and platelet-derived growth factor receptor-alpha. Using an autochthonous glioma mouse model, we demonstrated that miR-128 repressed gliomagenesis. We identified miR-128 as a glioma tumor suppressor that targets RTK signaling to repress giNSC self-renewal and enhance differentiation. Oncogene (2012) 31, 1884-1895; doi:10.1038/onc.2011.380; published online 29 August 2011	[Papagiannakopoulos, T.; Gill, R. M.; Kosik, K. S.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Papagiannakopoulos, T.; Neveu, P.; Gill, R. M.; Kosik, K. S.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; [Friedmann-Morvinski, D.; Verma, I. M.] Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; [Neveu, P.] Univ Calif Santa Barbara, Kavli Inst Theoret Phys, Santa Barbara, CA 93106 USA; [Dugas, J. C.; Barres, B. A.] Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; [Huillard, E.; Rowitch, D. H.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Huillard, E.; Rowitch, D. H.] Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA USA; [Liu, C.; Zong, H.] Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; [Rowitch, D. H.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA; [Rowitch, D. H.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Salk Institute; University of California System; University of California Santa Barbara; Stanford University; University of California System; University of California San Francisco; University of Oregon; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kosik, KS (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Room 6139A, Santa Barbara, CA 93106 USA.	kosik@lifesci.ucsb.edu	Neveu, Pierre/C-1170-2009; Liu, Chong/J-4826-2014	Liu, Chong/0000-0001-6578-5919; Friedmann-Morvinski, Dinorah/0000-0002-6394-9876; Neveu, Pierre/0000-0003-4939-3418; Rowitch, David/0000-0002-0079-0060	WM Keck Foundation; Miriam and Sheldon Adelson Medical Foundation; National Science Foundation [PHY05-51164]; Myelin Repair Foundation; National Multiple Sclerosis Society; NIH [R55-CA136495, R01-CA136495]; The Pew Charitable Trusts; NATIONAL CANCER INSTITUTE [R01CA136495, R55CA136495] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053670] Funding Source: NIH RePORTER	WM Keck Foundation(W.M. Keck Foundation); Miriam and Sheldon Adelson Medical Foundation; National Science Foundation(National Science Foundation (NSF)); Myelin Repair Foundation; National Multiple Sclerosis Society(National Multiple Sclerosis Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); The Pew Charitable Trusts; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Israel Hernandez, Diego Piedrahita and Yngo Garcia for providing assistance with animal experiments, and Na Xu, Min Jeong Kye and Cecilia Conaco for scientific conversations and suggestions. Judith Czerny assisted in constructing target 3'-UTR constructs. Support for the project was from the WM Keck Foundation (KSK), the Miriam and Sheldon Adelson Medical Foundation (KSK), the National Science Foundation under grant No. PHY05-51164 (PN), the Myelin Repair Foundation (JCD and BAB), and the National Multiple Sclerosis Society (JCD and BAB). HZ work is supported by NIH grants (R55-CA136495, R01-CA136495). HZ is a Pew Scholar in Biomedical Sciences, supported by The Pew Charitable Trusts. DHR is an HHMI investigator.	Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Boockvar JA, 2003, MOL CELL NEUROSCI, V24, P1116, DOI 10.1016/j.mcn.2003.09.011; Cheng LC, 2009, NAT NEUROSCI, V12, P399, DOI 10.1038/nn.2294; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Conti A, 2009, J NEURO-ONCOL, V93, P325, DOI 10.1007/s11060-009-9797-4; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 2002, NEURON, V36, P1021, DOI 10.1016/S0896-6273(02)01133-9; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013; Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Krichevsky AM, 2006, STEM CELLS, V24, P857, DOI 10.1634/stemcells.2005-0441; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Liu TL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000804; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Marumoto T, 2009, NAT MED, V15, P110, DOI 10.1038/nm.1863; Mukasa A, 2010, P NATL ACAD SCI USA, V107, P2616, DOI 10.1073/pnas.0914356107; Neveu P, 2010, CELL STEM CELL, V7, P671, DOI 10.1016/j.stem.2010.11.012; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Sugahara KN, 2010, SCIENCE, V328, P1031, DOI 10.1126/science.1183057; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visvanathan J, 2007, GENE DEV, V21, P744, DOI 10.1101/gad.1519107; Wuchty S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014681; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740; Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443	38	133	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	15					1884	1895		10.1038/onc.2011.380	http://dx.doi.org/10.1038/onc.2011.380			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	926CW	21874051	Green Accepted			2022-12-17	WOS:000302809900002
J	Chen, KF; Liu, CY; Lin, YC; Yu, HC; Liu, TH; Hou, DR; Chen, PJ; Cheng, AL				Chen, K-F; Liu, C-Y; Lin, Y-C; Yu, H-C; Liu, T-H; Hou, D-R; Chen, P-J; Cheng, A-L			CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells	ONCOGENE			English	Article						HCC; CIP2A; bortezomib; proteasome inhibitor; PP2A; apoptosis	PROTEASOME INHIBITORS; CANCER; PP2A; PHOSPHATASES; MECHANISMS; SORAFENIB; MYC	Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein phosphatase 2A (PP2A), mediates the apoptotic effect of bortezomib in HCC. Silencing PP2A by small interference RNA (siRNA) abolishes bortezomib-induced down-regulation of phospho-Akt and apoptosis. Bortezomib increases PP2A activity in sensitive HCC cells, including Sk-Hep1, Hep3B and Huh-7, but not in resistant PLC5 cells. Bortezomib down-regulates CIP2A in a dose-and time-dependent manner in all sensitive HCC cells, whereas no alterations in CIP2A were found in resistant PLC5 cells. Knockdown of CIP2A by siRNA restored bortezomib's effects on apoptosis and PP2A activity in PLC5 cells. Moreover, over-expression of CIP2A up-regulated phospho-Akt and protected Sk-Hep1 cells from bortezomib-induced apoptosis. It is significant that, ectopic expression of CIP2A decreased Akt-related PP2A activity, whereas silencing CIP2A increased this activity, indicating that CIP2A negatively regulates Akt-related PP2A activity in HCC cells, furthermore, our in vivo data showed that bortezomib down-regulates CIP2A and up-regulates PP2A activity in Huh-7 tumors, but not in PLC5 tumors. In conclusion, inhibition of CIP2A determines the effects of bortezomib on apoptosis and PP2A-dependent Akt inactivation in HCC. Oncogene (2010) 29, 6257-6266; doi:10.1038/onc.2010.357; published online 23 August 2010	[Cheng, A-L] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 10016, Taiwan; [Cheng, A-L] Natl Taiwan Univ, Coll Med, Dept Internal Med, Taipei, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 10016, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J] Natl Taiwan Univ, Coll Med, Dept Med Res, Taipei 10764, Taiwan; [Chen, K-F; Yu, H-C; Liu, T-H; Chen, P-J; Cheng, A-L] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei 10016, Taiwan; [Liu, C-Y] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Liu, C-Y] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Lin, Y-C] Far Eastern Mem Hosp, Dept Internal Med, Taipei, Taiwan; [Hou, D-R] Natl Cent Univ, Dept Chem, Tao Yuan, Taiwan; [Cheng, A-L] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10016, Taiwan; [Cheng, A-L] Natl Taiwan Univ, Coll Med, Dept Oncol, Taipei 10764, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Far Eastern Memorial Hospital; National Central University; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Cheng, AL (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, 7 Chung Shan S Rd, Taipei 10016, Taiwan.	alcheng@ntu.edu.tw	Liu, Tsung-Hao/D-3357-2016	Liu, Tsung-Hao/0000-0002-8891-4426; Chen, Pei-Jer/0000-0001-8316-3785; Cheng, Ann-Lii/0000-0002-9152-6512; HOU, Duen-Ren/0000-0003-1072-2915; Chen, Kuen-Feng/0000-0002-4686-7019	National Taiwan University Hospital [NTUH98P03, NTUH98FTN21]; National Science Council, Taiwan [NSC97-2314-B-002-182, NSC98-2314-B-002-067-MY3, NSC98-3112-B-002-037]	National Taiwan University Hospital(National Taiwan University); National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	Supported by NTUH98P03, NTUH98FTN21 from National Taiwan University Hospital and NSC97-2314-B-002-182, NSC98-2314-B-002-067-MY3, NSC98-3112-B-002-037 from the National Science Council, Taiwan.	Bielinski VA, 2007, EXP CELL RES, V313, P3117, DOI 10.1016/j.yexcr.2007.05.008; Chen KF, 2008, CANCER RES, V68, P6698, DOI 10.1158/0008-5472.CAN-08-0257; Chen KF, 2010, J HEPATOL, V52, P88, DOI 10.1016/j.jhep.2009.10.011; Chen KF, 2009, J BIOL CHEM, V284, P11121, DOI 10.1074/jbc.M806268200; Come C, 2009, CLIN CANCER RES, V15, P5092, DOI 10.1158/1078-0432.CCR-08-3283; Davis NB, 2004, J CLIN ONCOL, V22, P115, DOI 10.1200/JCO.2004.07.165; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Hoo LS, 2002, ONCOGENE, V21, P5006, DOI 10.1038/sj.onc.1205625; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Khanna A, 2009, JNCI-J NATL CANCER I, V101, P793, DOI 10.1093/jnci/djp103; Li WJ, 2008, CLIN CANCER RES, V14, P3722, DOI 10.1158/1078-0432.CCR-07-4137; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McConkey DJ, 2008, DRUG RESIST UPDATE, V11, P164, DOI 10.1016/j.drup.2008.08.002; Mumby M, 2007, CELL, V130, P21, DOI 10.1016/j.cell.2007.06.034; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; Nikiforov MA, 2007, P NATL ACAD SCI USA, V104, P19488, DOI 10.1073/pnas.0708380104; Ocio EM, 2008, LANCET ONCOL, V9, P1157, DOI 10.1016/S1470-2045(08)70304-8; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Richardson P, 2008, ASH ANN M, V112, P870; Verslype C, 2009, ANN ONCOL, V20, P1, DOI 10.1093/annonc/mdp281; Voorhees PM, 2006, ANNU REV PHARMACOL, V46, P189, DOI 10.1146/annurev.pharmtox.46.120604.141300; Yu CR, 2006, MOL CANCER THER, V5, P2378, DOI 10.1158/1535-7163.MCT-06-0235	24	133	143	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	47					6257	6266		10.1038/onc.2010.357	http://dx.doi.org/10.1038/onc.2010.357			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	685CG	20729919				2022-12-17	WOS:000284601700007
J	Sporn, JC; Kustatscher, G; Hothorn, T; Collado, M; Serrano, M; Muley, T; Schnabel, P; Ladurner, AG				Sporn, J. C.; Kustatscher, G.; Hothorn, T.; Collado, M.; Serrano, M.; Muley, T.; Schnabel, P.; Ladurner, A. G.			Histone macroH2A isoforms predict the risk of lung cancer recurrence	ONCOGENE			English	Article						Epigenetics; chromatin; metabolism; PARP; proliferation; cancer	ONCOGENE-INDUCED SENESCENCE; CELLULAR SENESCENCE; MARKERS; P53	Lung cancer is the leading cause of cancer deaths. Despite optimal diagnosis and early treatment, many patients die of recurrent disease. There are no sufficiently useful biomarkers to predict the risk of tumor recurrence. Here, we show that expression of histone macroH2A1.1 and macroH2A2 predicts lung cancer recurrence, identifying these histone variants as a novel tool for an improved risk stratification of cancer patients. Moreover, macroH2A isoforms are highly expressed in cells undergoing senescence, a known antitumor mechanism, suggesting macroH2A1.1 may be a useful biomarker for senescent cells in tumors. Oncogene (2009) 28, 3423-3428; doi: 10.1038/onc.2009.26; published online 3 August 2009	[Sporn, J. C.; Kustatscher, G.; Ladurner, A. G.] EMBL, Gene Express Unit, D-69117 Heidelberg, Germany; [Hothorn, T.] Univ Munich, Inst Stat, Munich, Germany; [Collado, M.; Serrano, M.] Spanish Natl Canc Ctr, Madrid, Spain; [Muley, T.] Univ Heidelberg, Thoraxklin, Heidelberg, Germany; [Schnabel, P.] Univ Heidelberg, Dept Pathol, D-6900 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL); University of Munich; Centro Nacional de Investigaciones Oncologicas (CNIO); Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Ladurner, AG (corresponding author), EMBL, Gene Express Unit, Meyerhofstr 1, D-69117 Heidelberg, Germany.	ladurner@embl.de	Collado, Manuel/K-8140-2014; Hothorn, Torsten/A-3639-2010; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Hothorn, Torsten/0000-0001-8301-0471; Serrano, Manuel/0000-0001-7177-9312; Ladurner, Andreas/0000-0003-3835-232X; Kustatscher, Georg/0000-0001-8955-0866	EMBL; NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity	EMBL; NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity	We thank Dr Esther Herpel for lung cancer tissue microarrays. AGL is supported by the EMBL, the NoE The Epigenome and the Marie Curie RTN Chromatin Plasticity.	Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; D'Amico TA, 2008, ANN THORAC SURG, V85, pS737, DOI 10.1016/j.athoracsur.2007.11.047; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hothorn T, 2006, AM STAT, V60, P257, DOI 10.1198/000313006X118430; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; PEHRSON JR, 1992, SCIENCE, V257, P1398; Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhu CQ, 2006, J CLIN PATHOL, V59, P790, DOI 10.1136/jcp.2005.031351	18	133	139	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2009	28	38					3423	3428		10.1038/onc.2009.26	http://dx.doi.org/10.1038/onc.2009.26			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	497ZD	19648962				2022-12-17	WOS:000270103300009
J	Enomoto, M; Hayakawa, S; Itsukushima, S; Ren, DY; Matsuo, M; Tamada, K; Oneyama, C; Okada, M; Takumi, T; Nishita, M; Minami, Y				Enomoto, M.; Hayakawa, S.; Itsukushima, S.; Ren, D. Y.; Matsuo, M.; Tamada, K.; Oneyama, C.; Okada, M.; Takumi, T.; Nishita, M.; Minami, Y.			Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling	ONCOGENE			English	Article						Wnt5a; Ror2; MMP-13; invadopodia; osteosarcoma	RECEPTOR TYROSINE KINASE; BETA-CATENIN; DISHEVELLED PHOSPHORYLATION; TUMOR-SUPPRESSOR; INVASION; WNT-5A; ROR2; EXPRESSION; PATHWAY; CANCER	The receptor tyrosine kinase Ror2 regulates cell migration by acting as a receptor or co-receptor for Wnt5a. Although Wnt5a has been implicated in the invasiveness of several types of tumors, the role of Ror2 in tumor invasion remains elusive. Here we show that osteosarcoma cell lines SaOS-2 and U2OS show invasive properties in vitro by activating Wnt5a/Ror2 signaling in a cell-autonomous manner. The suppressed expression of either Wnt5a or Ror2 in osteosarcoma cells inhibits cell invasiveness accompanying decreased invadopodia formation. Gene-expression pro. ling identified matrix metalloproteinase 13 (MMP-13) as one of the genes whose expression is downregulated in SaOS-2 cells following suppression of Ror2 expression. Reduced expression or activity of MMP-13 suppresses invasiveness of SaOS-2 cells. Moreover, expression of MMP-13 and cell invasiveness by Wnt5a/Ror2 signaling can be abrogated by an inhibitor of the Src-family protein tyrosine kinases (SFKs), suggesting the role of the SFKs in MMP-13 expression through Wnt5a/Ror2 signaling. We further show that activation of an SFK is inhibited by the suppressed expression of Ror2. Collectively, these results indicate that Wnt5a/Ror2 signaling involves the activation of a SFK, leading to MMP-13 expression, and that constitutively active Wnt5a/Ror2 signaling confers invasive properties on osteosarcoma cells in a cell-autonomous manner. Oncogene (2009) 28, 3197-3208; doi: 10.1038/onc.2009.175; published online 29 June 2009	[Nishita, M.] Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Chuo Ku, Kobe, Hyogo 6500017, Japan; [Enomoto, M.; Matsuo, M.] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Tamada, K.; Takumi, T.] Osaka Biosci Inst, Osaka, Japan; [Oneyama, C.; Okada, M.] Osaka Univ, Dept Oncogene Res, Microbial Dis Res Inst, Osaka, Japan	Kobe University; Kobe University; Osaka University	Nishita, M (corresponding author), Kobe Univ, Grad Sch Med, Dept Physiol & Cell Biol, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nishita@med.kobe-u.ac.jp; minami@kobe-u.ac.jp			a Grant-in-Aid for Scientific Research in Priority Areas (YM); a Grant-in-Aid for Scientific Research (B) (YM); a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM),; Ministry of Education, Culture, Sports, Science, and Technology, Japan; Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN)	a Grant-in-Aid for Scientific Research in Priority Areas (YM)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); a Grant-in-Aid for Scientific Research (B) (YM)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM),(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Education, Culture, Sports, Science, and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN)	We thank M Endo for critical reading of the paper. We also thank K Mizuno for pEYFP-Actin. This work was supported by a Grant-in-Aid for Scientific Research in Priority Areas (YM), a Grant-in-Aid for Scientific Research (B) (YM), a Grant from the Global Center of Excellence Program 'Education and Research on Signal Transduction Medicine in the Coming Generation' (YM), a Grant-in-Aid for Young Scientists (B) (MN) from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, a Grant from Hyogo Science and Technology Association (MN) and a Grant from Takeda Science Foundation (MN).	Akbarzadeh S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001873; Albini A, 1998, Pathol Oncol Res, V4, P230; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Cortesio CL, 2008, J CELL BIOL, V180, P957, DOI 10.1083/jcb.200708048; Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6; Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710; Gonzalez-Sancho JM, 2004, MOL CELL BIOL, V24, P4757, DOI 10.1128/MCB.24.11.4757-4768.2004; Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999-008-0344-y; He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; IOZZO RV, 1995, CANCER RES, V55, P3495; Kani S, 2004, J BIOL CHEM, V279, P50102, DOI 10.1074/jbc.M409039200; Kodama A, 2004, J CELL BIOL, V167, P203, DOI 10.1083/jcb.200408047; Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370; Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008-5472.CAN-06-2359; Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X; Masckauchan TNH, 2006, MOL BIOL CELL, V17, P5163, DOI 10.1091/mbc.E06-04-0320; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; Nomachi A, 2008, J BIOL CHEM, V283, P27973, DOI 10.1074/jbc.M802325200; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Olson DJ, 1998, EXP CELL RES, V241, P134, DOI 10.1006/excr.1998.4030; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Qian D, 2007, DEV BIOL, V306, P121, DOI 10.1016/j.ydbio.2007.03.011; Schlessinger K, 2007, J CELL BIOL, V178, P355, DOI 10.1083/jcb.200701083; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; Weaver AM, 2006, CLIN EXP METASTAS, V23, P97, DOI 10.1007/s10585-006-9014-1; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamamoto S, 2008, DEV CELL, V15, P23, DOI 10.1016/j.devcel.2008.05.007	34	133	140	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2009	28	36					3197	3208		10.1038/onc.2009.175	http://dx.doi.org/10.1038/onc.2009.175			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	492QF	19561643	Bronze			2022-12-17	WOS:000269673400003
J	Muller, P; Hrstka, R; Coomber, D; Lane, DP; Vojtesek, B				Muller, P.; Hrstka, R.; Coomber, D.; Lane, D. P.; Vojtesek, B.			Chaperone-dependent stabilization and degradation of p53 mutants	ONCOGENE			English	Article						chaperones; p53 mutant; stabilization; degradation; CHIP	HISTONE DEACETYLASE INHIBITORS; LI-FRAUMENI-SYNDROME; HEAT-SHOCK PROTEINS; PROTEASOMAL DEGRADATION; MONOCLONAL-ANTIBODIES; WILD-TYPE; HSP90; CELLS; TUMOR; LIGASE	p53 missense mutant proteins commonly show increased stability compared to wild-type p53, which is thought to depend largely on the inability of mutant p53 to induce the ubiquitin ligase MDM2. However, recent work using mouse models has shown that the accumulation of mutant p53 occurs only in tumour cells, indicating that stabilization requires additional factors. To clarify the stabilization of p53 mutants in tumours, we analysed factors that affect their folding and degradation. Although all missense mutants that we studied are more stable than wild-type p53, the levels correlate with individual structural characteristics, which may be reflected in different gain-of-function properties. In the absence of Hsp90 activity, the less stable unfolded p53 mutants preferentially associate in a complex with Hsp70 and CHIP (carboxy terminus of Hsp70-interacting protein), and we show that CHIP is responsible for ubiquitination and degradation of these mutants. The demonstration of a complex interplay between Hsp90, Hsp70 and CHIP that regulate the stability of different p53 mutant proteins improves our understanding of the pro-tumorigenic effects of increased Hsp90 activity during multi-stage carcinogenesis. Understanding the roles of Hsp90, Hsp70 and CHIP in cancers may also provide an important avenue through which to target p53 to enhance treatment of human cancers.	[Muller, P.; Hrstka, R.; Vojtesek, B.] Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Brno 65653, Czech Republic; [Muller, P.; Coomber, D.; Lane, D. P.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	Masaryk Memorial Cancer Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Vojtesek, B (corresponding author), Masaryk Mem Canc Inst, Dept Clin & Expt Pathol, Zluty Kopec 7, Brno 65653, Czech Republic.	vojtesek@mou.cz	Hrstka, Roman/AAM-4430-2020; Lane, David P/C-4920-2008; Muller, Petr/AAK-5014-2021; 高, 雨莉/HGU-8187-2022; Muller, Petr/F-7762-2015	Hrstka, Roman/0000-0002-6139-2664; Muller, Petr/0000-0002-8404-4494; Muller, Petr/0000-0002-8404-4494; Lane, David/0000-0003-0551-3545				Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Barrette RW, 2006, CLIN VACCINE IMMUNOL, V13, P802, DOI 10.1128/CVI.00422-05; BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; Blagosklonny MV, 2005, CANCER RES, V65, P7386, DOI 10.1158/0008-5472.CAN-04-3433; Blagosklonny MV, 2004, CELL CYCLE, V3, P1537, DOI 10.4161/cc.3.12.1278; Blagosklonny MV, 1997, ONCOGENE, V15, P1889, DOI 10.1038/sj.onc.1201374; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; King FW, 2001, EMBO J, V20, P6297, DOI 10.1093/emboj/20.22.6297; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Milner J, 1997, PATHOL BIOL, V45, P797; Nagata Y, 1999, ONCOGENE, V18, P6037, DOI 10.1038/sj.onc.1202978; Nenutil R, 2005, J PATHOL, V207, P251, DOI 10.1002/path.1838; Nimmanapalli R, 2003, CANCER RES, V63, P5126; O'Shea CC, 2005, CANCER CELL, V8, P61, DOI 10.1016/j.ccr.2005.06.009; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; VOJTESEK B, 1993, BRIT J CANCER, V67, P1254, DOI 10.1038/bjc.1993.234; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Wang PL, 2001, ONCOGENE, V20, P2318, DOI 10.1038/sj.onc.1204316; Wang Y, 2007, BIOCHEM BIOPH RES CO, V356, P998, DOI 10.1016/j.bbrc.2007.03.076; Workman P, 2004, TRENDS MOL MED, V10, P47, DOI 10.1016/j.molmed.2003.12.005; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200; Zylicz M, 2001, EMBO J, V20, P4634, DOI 10.1093/emboj/20.17.4634	41	133	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2008	27	24					3371	3383		10.1038/sj.onc.1211010	http://dx.doi.org/10.1038/sj.onc.1211010			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18223694				2022-12-17	WOS:000256309900002
J	Bockbrader, KM; Tan, MJ; Sun, Y				Bockbrader, KM; Tan, MJ; Sun, Y			A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells	ONCOGENE			English	Article						apoptosis; IAPs; Smac; anticancer drug; breast cancer	STRUCTURAL BASIS; LUNG-CANCER; CHEMOTHERAPEUTIC-AGENTS; PROTECTS CELLS; IAP FAMILY; XIAP; SMAC/DIABLO; ACTIVATION; INHIBITOR; CASPASE-3	Inhibitor of apoptosis protein (IAP) suppresses apoptosis through binding and inhibiting active caspases-3,-7 and -9 via its baculoviral IAP repeat (BIR) domains. During apoptosis the caspase inhibition by IAPs can be negatively regulated by a mitochondrial protein second mitochondrial-derived activator of caspase (Smac). Smac physically interacts with multiple IAPs and relieves their inhibitory effect on caspases-3,-7 and -9. Recently, a small molecule Smac-mimic compound (Smac-mimic), which potentiates TNF-related apoptosis-inducing ligand (TRAIL) and tumor necrosis factor (TNF)-alpha mediated cell death in glioblastoma T98G cells and HeLa cells, was identified and characterized. To determine the efficacy of this compound in breast cancer cells, we first measured protein expression of three IAPs: XIAP, cIAP-1, and cIAP-2 in nine independent breast cancer cell lines. Three cell lines were chosen: a high IAPs expressing line MDAMB231, and two low IAPs expressing lines, T47D and MDA-MB-453. The cell lines were tested for their sensitivity to Smac-mimic alone or in combination with TRAIL or etoposide. Acting alone, Smac-mimic was quite potent with a cytotoxic IC50 of 3.8 nM in high IAPs expressing MDA-MB-231 cells, but was inactive at a much higher concentration in low IAPs expressing T47D and MDA-MB-453 cells. In fact, as low as 2.5 nM of Smac-mimic alone was sufficient to activate caspase-3 and induce apoptosis in MDA-MB-231 cells. In combinational treatments with TRAIL or etoposide, Smac-mimic significantly sensitized cells to growth suppression in MDA-MB-231 cells, but to a lesser extent in T47D and MDA-MB-453 cells. Furthermore, it significantly synergized MDA-MB-231, but not T47D cells to apoptosis induced by either TRAIL or etoposide. Thus, in these cell lines, Smac-mimic acts in an apparent IAPs dependent manner to induce apoptosis alone as well as sensitizes breast cancer cells to TRAIL or etoposide induced apoptosis via caspase-3 activation.	Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Div Canc Biol, Dept Radiat Oncol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287				Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cao C, 2004, ONCOGENE, V23, P7047, DOI 10.1038/sj.onc.1207929; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Garber K, 2005, NAT BIOTECHNOL, V23, P409, DOI 10.1038/nbt0405-409; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(02)02075-5; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Nguyen JT, 2003, P NATL ACAD SCI USA, V100, P7533, DOI 10.1073/pnas.1031631100; Oost TK, 2004, J MED CHEM, V47, P4417, DOI 10.1021/jm040037k; Pardo OE, 2003, MOL CELL BIOL, V23, P7600, DOI 10.1128/MCB.23.21.7600-7610.2003; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(01)00274-4; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Scott FL, 2005, EMBO J, V24, P645, DOI 10.1038/sj.emboj.7600544; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang L, 2003, CANCER RES, V63, P6815; Yang LL, 2003, CANCER RES, V63, P831; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	37	133	155	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2005	24	49					7381	7388		10.1038/sj.onc.1208888	http://dx.doi.org/10.1038/sj.onc.1208888			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	982FA	16044155				2022-12-17	WOS:000233142100014
J	Strizzi, L; Bianco, C; Normanno, N; Salomon, D				Strizzi, L; Bianco, C; Normanno, N; Salomon, D			Cripto-1: A multifunctional modulator during embryogenesis and oncogenesis	ONCOGENE			English	Review						Cripto-1; embryogenesis; oncogenesis; EHT; engiogenesis; therapy	MAMMARY EPITHELIAL-CELLS; EMBRYONIC STEM-CELLS; GROWTH-FACTOR-ALPHA; ONE-EYED-PINHEAD; EGF-CFC FAMILY; DIFFERENTIAL IMMUNOHISTOCHEMICAL DETECTION; CERVICAL-CARCINOMA CELLS; HUMAN BREAST CARCINOMAS; FACTOR-RELATED PROTEINS; TRANSGENIC MICE	It is increasingly evident that genes known to perform critical roles during early embryogenesis, particularly during stem cell renewal, pluripotentiality and survival, are also expressed during the development of cancer. In this regard, oncogenesis may be considered as the recapitulation of embryogenesis in an inappropriate temporal and spatial manner. The epidermal growth factor-Cripto-1/FRL1/cryptic family of proteins consists of extracellular and cell-associated proteins that have been identified in several vertebrate species. During early embryogenesis, epidermal growth factor-Cripto-1/FRL1/ cryptic proteins perform an obligatory role as coreceptors for the transforming growth factor-beta subfamily of proteins, which includes Nodal. Cripto-1 has also been shown to function as a ligand through a Nodal/Alk4-independent signaling pathway that involves binding to glypican-1 and the subsequent activation through src of phosphoinositol-3 kinase/Akt and ras/mitogen-activated protein kinase intracellular pathways. Expression of Cripto-1 is increased in several human cancers and its overexpression is associated with the development of mammary tumors in mice. Here, we review the role of Cripto-1 during embryogenesis, cell migration, invasion and angiogenesis and how these activities may relate to cellular transformation and tumorigenesis. We also briefly discuss evidence suggesting that Cripto-1 may be involved in stem cell maintenance.	NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, NIH,Ctr Canc Res, Bethesda, MD 20892 USA; ITN Fdn Pascale, Div Haematol Oncol, I-80131 Naples, Italy; ITN Fdn Pascale, Dept Expt Oncol, I-80131 Naples, Italy	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS Fondazione Pascale; IRCCS Fondazione Pascale	Salomon, D (corresponding author), NCI, Tumor Growth Factor Sect, Mammary Biol & Tumorigenesis Lab, NIH,Ctr Canc Res, Bldg 37,Room 118B, Bethesda, MD 20892 USA.	salomond@mail.nih.gov	Normanno, Nicola/AAT-1107-2021	Normanno, Nicola/0000-0002-7158-2605	NATIONAL CANCER INSTITUTE [ZIABC009003, Z01BC009003] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackland ML, 2003, LAB INVEST, V83, P435, DOI 10.1097/01.LAB.0000059927.97515.FD; Adkins HB, 2003, J CLIN INVEST, V112, P575, DOI 10.1172/JCI200317788; Baldassarre G, 1997, ONCOGENE, V15, P927, DOI 10.1038/sj.onc.1201260; Bamford RN, 2000, NAT GENET, V26, P365, DOI 10.1038/81695; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Besser D, 2004, J BIOL CHEM, V279, P45076, DOI 10.1074/jbc.M404979200; Bianco C, 2005, J NATL CANCER I, V97, P132, DOI 10.1093/jnci/dji011; Bianco C, 2004, GROWTH FACTORS, V22, P133, DOI 10.1080/08977190410001723290; Bianco C, 2003, CANCER RES, V63, P1192; Bianco C, 2002, MOL CELL BIOL, V22, P2586, DOI 10.1128/MCB.22.8.2586-2597.2002; Bianco C, 1999, J BIOL CHEM, V274, P8624, DOI 10.1074/jbc.274.13.8624; Bianco C, 2001, BREAST CANCER RES TR, V66, P1, DOI 10.1023/A:1010648923432; Bianco C, 2002, J CELL PHYSIOL, V190, P74, DOI 10.1002/jcp.10037; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Byrne RL, 1998, J PATHOL, V185, P108; Casaroli-Marano RP, 1999, INVEST OPHTH VIS SCI, V40, P2062; Chen CH, 2004, CURR BIOL, V14, P618, DOI 10.1016/j.cub.2004.02.042; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; CIARDIELLO F, 1991, CANCER RES, V51, P1051; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Colas JF, 2000, GENE, V255, P205, DOI 10.1016/S0378-1119(00)00337-1; Conlon FL, 1999, DEV BIOL, V213, P85, DOI 10.1006/dbio.1999.9330; D'Antonio A, 2002, INT J ONCOL, V21, P941; Dandachi N, 2001, J PATHOL, V193, P181, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH752>3.0.CO;2-V; De Angelis E, 1999, INT J ONCOL, V14, P437; de la Cruz JM, 2002, HUM GENET, V110, P422, DOI 10.1007/s00439-002-0709-3; De Santis ML, 1997, CELL GROWTH DIFFER, V8, P1257; De Santis ML, 2000, CELL DEATH DIFFER, V7, P189, DOI 10.1038/sj.cdd.4400588; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; DONO R, 1993, DEVELOPMENT, V118, P1157; Ebert AD, 1999, CANCER RES, V59, P4502; Ebert AD, 2000, EXP CELL RES, V257, P223, DOI 10.1006/excr.2000.4881; Endo Y, 2005, J BIOL CHEM, V280, P777, DOI 10.1074/jbc.M406391200; Escaffit F, 2005, EXP CELL RES, V302, P206, DOI 10.1016/j.yexcr.2004.08.033; Fontanini G, 1998, CLIN CANCER RES, V4, P241; FRIESS H, 1994, INT J CANCER, V56, P668, DOI 10.1002/ijc.2910560511; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; Gray PC, 2003, P NATL ACAD SCI USA, V100, P5193, DOI 10.1073/pnas.0531290100; Griffin KJP, 2003, DEV BIOL, V264, P456, DOI 10.1016/j.ydbio.2003.09.008; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hamada H, 2002, NAT REV GENET, V3, P103, DOI 10.1038/nrg732; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; Harms PW, 2003, GENE DEV, V17, P2624, DOI 10.1101/gad.1127703; James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kemler R, 2004, DEVELOPMENT, V131, P5817, DOI 10.1242/dev.01458; Kenney N., 1997, PATHOGENESIS, V1, P57; Kenney NJ, 1996, MOL CARCINOGEN, V15, P44; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Kleber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006; Kodjabachian L, 2001, CURR BIOL, V11, pR655, DOI 10.1016/S0960-9822(01)00385-2; Kopper L, 2004, PATHOL ONCOL RES, V10, P69, DOI 10.1007/BF02893458; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; KUNIYASU H, 1991, JPN J CANCER RES, V82, P969, DOI 10.1111/j.1349-7006.1991.tb01929.x; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liguori G, 1996, MAMM GENOME, V7, P344, DOI 10.1007/s003359900100; LIU D, 1994, INT J CANCER, V56, P603, DOI 10.1002/ijc.2910560423; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu X, 2003, CANCER RES, V63, P7760; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Matsui Y, 2005, BIOESSAYS, V27, P136, DOI 10.1002/bies.20178; Minchiotti G, 2000, MECH DEVELOP, V90, P133, DOI 10.1016/S0925-4773(99)00235-X; Minchiotti G, 2001, DEVELOPMENT, V128, P4501; Mincione G, 1998, J CELL PHYSIOL, V176, P383, DOI 10.1002/(SICI)1097-4652(199808)176:2<383::AID-JCP17>3.0.CO;2-4; Miyoshi K, 2002, ONCOGENE, V21, P5548, DOI 10.1038/sj.onc.1205686; Miyoshi K, 2002, P NATL ACAD SCI USA, V99, P219, DOI 10.1073/pnas.012414099; Morkel M, 2003, DEVELOPMENT, V130, P6283, DOI 10.1242/dev.00859; Muller WJ, 1998, BIOCHEM SOC SYMP, P149; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Niemeyer CC, 1999, INT J CANCER, V81, P588, DOI 10.1002/(SICI)1097-0215(19990517)81:4<588::AID-IJC14>3.0.CO;2-I; Niemeyer CC, 1998, CELL DEATH DIFFER, V5, P440, DOI 10.1038/sj.cdd.4400368; Niikura H, 1997, INT J GYNECOL PATHOL, V16, P60, DOI 10.1097/00004347-199701000-00010; Normanno N, 2004, J CELL PHYSIOL, V198, P31, DOI 10.1002/jcp.10375; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Ohlstein B, 2004, CURR OPIN CELL BIOL, V16, P693, DOI 10.1016/j.ceb.2004.09.003; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; Parish CL, 2005, STEM CELLS, V23, P471, DOI 10.1634/stemcells.2004-0294; Parisi S, 2003, J CELL BIOL, V163, P303, DOI 10.1083/jcb.200303010; Polakis P, 2000, GENE DEV, V14, P1837; QI CF, 1994, BRIT J CANCER, V69, P903, DOI 10.1038/bjc.1994.174; Reissmann E, 2001, GENE DEV, V15, P2010, DOI 10.1101/gad.201801; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Robb L, 2004, SEMIN CELL DEV BIOL, V15, P543, DOI 10.1016/j.semcdb.2004.04.005; Rodriguez-Esteban C, 2001, DEVELOPMENT, V128, P3189; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; SAEKI T, 1992, CANCER RES, V52, P3467; SAEKI T, 1994, INT J ONCOL, V5, P445; SAEKI T, 1994, INT J ONCOL, V5, P215; Salomon DS, 2000, ENDOCR-RELAT CANCER, V7, P199, DOI 10.1677/erc.0.0070199; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Schiffer SG, 2001, J BIOL CHEM, V276, P37769; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Seno M, 1998, GROWTH FACTORS, V15, P215, DOI 10.3109/08977199809002118; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; Shen MM, 1997, DEVELOPMENT, V124, P429; Sonntag KC, 2005, MOL CELL NEUROSCI, V28, P417, DOI 10.1016/j.mcn.2004.06.003; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; STROMBERG K, 1994, INT J GYNECOL PATHOL, V13, P342, DOI 10.1097/00004347-199410000-00008; SU ZZ, 1993, ONCOGENE, V8, P1211; SUN Y, 2005, IN PRESS AM J PATHOL; Tabata T, 2004, DEVELOPMENT, V131, P703, DOI 10.1242/dev.01043; Tanegashima K, 2004, INT J DEV BIOL, V48, P275, DOI 10.1387/ijdb.041805kt; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Teuliere J, 2005, DEVELOPMENT, V132, P267, DOI 10.1242/dev.01583; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 1999, CANCER METAST REV, V18, P31, DOI 10.1023/A:1006256219004; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; TSUTSUMI M, 1994, JPN J CANCER RES, V85, P118, DOI 10.1111/j.1349-7006.1994.tb02069.x; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; Warga RA, 2003, DEV BIOL, V261, P391, DOI 10.1016/S0012-1606(03)00328-2; Wechselberger C, 2005, ONCOGENE, V24, P4094, DOI 10.1038/sj.onc.1208417; Wechselberger C, 2001, EXP CELL RES, V266, P95, DOI 10.1006/excr.2001.5195; Wei CL, 2005, STEM CELLS, V23, P166, DOI 10.1634/stemcells.2004-0162; WEILS RA, 1984, J CELL BIOL, V98, P1397; Welss T, 2003, INT J CANCER, V104, P66, DOI 10.1002/ijc.10912; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Xu CH, 1999, DEVELOPMENT, V126, P483; Yamashita YM, 2005, J CELL SCI, V118, P665, DOI 10.1242/jcs.01680; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Yeo CY, 2001, MOL CELL, V7, P949, DOI 10.1016/S1097-2765(01)00249-0; Yook JI, 2005, J BIOL CHEM, V280, P11740, DOI 10.1074/jbc.M413878200; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6; Zhang YQ, 2004, DIABETES, V53, P2024, DOI 10.2337/diabetes.53.8.2024	136	133	146	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5731	5741		10.1038/sj.onc.1208918	http://dx.doi.org/10.1038/sj.onc.1208918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123806				2022-12-17	WOS:000231452800008
J	Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F				Reid, G; Metivier, R; Lin, CY; Denger, S; Ibberson, D; Ivacevic, T; Brand, H; Benes, V; Liu, ET; Gannon, F			Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A	ONCOGENE			English	Article						valproic acid; trichostatin A; oestrogen signalling; sirtuin; transcriptional repression	BREAST-CANCER CELLS; HISTONE DEACETYLASE; SODIUM-BUTYRATE; PROTEASOMAL DEGRADATION; DNA METHYLATION; ER-ALPHA; EXPRESSION; EPILEPSY; TARGET; WOMEN	Valproate (VPA) and trichostatin A (TSA), inhibitors of zinc-dependent deacetylase activity, induce reduction in the levels of mRNA encoding oestrogen receptor-alpha (ER alpha), resulting in subsequent clearance of ER alpha protein from breast and ovarian cell lines. Inhibition of oestrogen signalling may account for the endocrine disorders, menstrual abnormalities, osteoporosis and weight gain that occur in a proportion of women treated with VPA for epilepsy or for bipolar mood disorder. Transcriptome pro. ling revealed that VPA and TSA also modulate the expression of, among others, key regulatory components of the cell cycle. Meta-analysis of genes directly responsive to oestrogen indicates that VPA and TSA have a generally antioestrogenic profile in ER alpha positive cells. Concomitant treatment with cycloheximide prevented most of these changes in gene expression, including downregulation of ER alpha mRNA, indicating that a limited number of genes signal a hyperacetylated state within cells. Three members of the NAD-dependent deacetylases, the sirtuins, are upregulated by VPA and by TSA and sirtuin activity contributes to loss of ER alpha expression. However, prolonged inhibition of the sirtuins by sirtinol also induces loss of ER alpha from cells. Mechanistically, we show that VPA invokes reversible promoter shutoff of the ER alpha, pS2 and cyclin D1 promoters, by inducing recruitment of methyl cytosine binding protein 2 (MeCP2) with concomitant exclusion of the maintenance methylase DNMT1. Furthermore, we demonstrate that, in the presence of VPA, local DNA methylation, deacetylation and demethylation of activated histones and recruitment of inhibitory complexes occurs on the pS2 promoter.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Genome Inst Singapore, Singapore 138672, Singapore	European Molecular Biology Laboratory (EMBL); Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Reid, G (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.	george.reid@embl.de	Liu, Edison/C-4141-2008; Gannon, Frank/G-1194-2015	Lin, Chin-Yo/0000-0002-4461-6216; Reid, George/0000-0002-0298-693X; Benes, Vladimir/0000-0002-0352-2547				Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carroll JS, 2000, J BIOL CHEM, V275, P38221, DOI 10.1074/jbc.M004424200; Clarke M, 1998, LANCET, V351, P1451; Cuzick J, 2002, LANCET, V360, P817; Davis T, 2000, CLIN CANCER RES, V6, P4334; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; deSilva M, 1996, LANCET, V347, P709, DOI 10.1016/S0140-6736(96)90074-4; Duncan S, 2001, EPILEPSIA, V42, P60, DOI 10.1046/j.1528-1157.2001.042suppl.3060.x; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Green PS, 2000, ANN NY ACAD SCI, V924, P93; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; Kim MS, 2003, CANCER RES, V63, P7291; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; KUEBAYASHI J, 2003, BREAST CANC, V10, P112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Lombardi G, 2001, MOL CELL ENDOCRINOL, V178, P51, DOI 10.1016/S0303-7207(01)00420-8; LONDON SJ, 1992, JAMA-J AM MED ASSOC, V267, P941, DOI 10.1001/jama.267.7.941; Luef G, 2002, METABOLISM, V51, P1274, DOI 10.1053/meta.2002.34708; MACMAHON B, 1973, JNCI-J NATL CANCER I, V50, P21, DOI 10.1093/jnci/50.1.21; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Munster PN, 2001, CANCER RES, V61, P8492; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; NELSON JE, 1992, ANAL BIOCHEM, V207, P197, DOI 10.1016/0003-2697(92)90523-A; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; O'Donovan C, 2002, J CLIN PSYCHIAT, V63, P322, DOI 10.4088/JCP.v63n0409; PARKER MI, 1986, J BIOL CHEM, V261, P2786; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Rattya J, 2001, NEUROLOGY, V57, P440, DOI 10.1212/WNL.57.3.440; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rosano GMC, 2001, INT J FERTIL WOMEN M, V46, P248; Sato Y, 2001, NEUROLOGY, V57, P445, DOI 10.1212/WNL.57.3.445; Sewack GF, 1997, J BIOL CHEM, V272, P31118, DOI 10.1074/jbc.272.49.31118; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; STEVENS MS, 1984, BIOCHEM BIOPH RES CO, V119, P132, DOI 10.1016/0006-291X(84)91628-0; Tran CP, 1998, AM J PHYSIOL-GASTR L, V275, pG85, DOI 10.1152/ajpgi.1998.275.1.G85; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	51	133	136	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 21	2005	24	31					4894	4907		10.1038/sj.onc.1208662	http://dx.doi.org/10.1038/sj.onc.1208662			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15870696				2022-12-17	WOS:000230646500003
J	Rahman, R; Latonen, L; Wiman, KG				Rahman, R; Latonen, L; Wiman, KG			hTERT antagonizes p53-induced apoptosis independently of telomerase activity	ONCOGENE			English	Article						telomerase; p53; apoptosis	WILD-TYPE P53; FACTOR-I RECEPTOR; HUMAN-CELLS; TUMOR SUPPRESSION; DOWN-REGULATION; CANCER-CELLS; DNA-DAMAGE; MUTANT P53; LIFE-SPAN; EXPRESSION	The p53 tumor suppressor controls cell growth and survival through transcriptional regulation of gene expression. Previously, we found that the human telomerase reverse transcriptase (hTERT) gene is downregulated by p53. To investigate if hTERT downregulation has a role in p53-dependent apoptosis, we tested if constitutive expression of telomerase could inhibit p53-induced apoptosis. Here we show that constitutive hTERT expression results in increased survival following activation of exogenous temperature-sensitive p53 in BL41 Burkitt lymphoma cells. Similarly, constitutive hTERT expression inhibited wild-type p53-dependent apoptosis in response to mitomycin C or 5-fluorouracil in HCT116 colon carcinoma cells carrying endogenous p53. A telomerase-inactive hTERT mutant was equally efficient in antagonizing p53-induced apoptosis. These findings support the notion that hTERT has antiapoptotic activity and demonstrate that p53-mediated downregulation of hTERT is critical for efficient p53-dependent apoptosis.	Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, SE-17176 Stockholm, Sweden; Univ Helsinki, Haartman Inst, Biomedicum, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol & Canc Biol Program, Biomedicum, FIN-00014 Helsinki, Finland	Karolinska Institutet; University of Helsinki; University of Helsinki	Wiman, KG (corresponding author), Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@cck.ki.se	Latonen, Leena/C-8787-2016; Wiman, Klas/AAB-8399-2021	Latonen, Leena/0000-0003-4502-2193; Wiman, Klas/0000-0002-7113-524X				Attardi LD, 1999, CELL MOL LIFE SCI, V55, P48, DOI 10.1007/s000180050269; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cao Y, 2002, ONCOGENE, V21, P3130, DOI 10.1038/sj.onc.1205419; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Gorbunova V, 2002, J BIOL CHEM, V277, P38540, DOI 10.1074/jbc.M202671200; Gorbunova V, 2003, CELL CYCLE, V2, P534, DOI 10.4161/cc.2.6.515; Greider CW, 1996, SCI AM, V274, P92, DOI 10.1038/scientificamerican0296-92; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Holt SE, 1999, MOL CARCINOGEN, V25, P241, DOI 10.1002/(SICI)1098-2744(199908)25:4<241::AID-MC2>3.0.CO;2-9; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Norrback KF, 2001, EUR J HAEMATOL, V67, P309, DOI 10.1034/j.1600-0609.2001.00588.x; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Smith LL, 2003, NAT CELL BIOL, V5, P474, DOI 10.1038/ncb985; Stampfer MR, 2003, ONCOGENE, V22, P5238, DOI 10.1038/sj.onc.1206667; Stewart SA, 2002, P NATL ACAD SCI USA, V99, P12606, DOI 10.1073/pnas.182407599; Vaziri H, 1996, EXP GERONTOL, V31, P295, DOI 10.1016/0531-5565(95)02025-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WANG YS, 1993, ONCOGENE, V8, P3427; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890	32	133	142	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2005	24	8					1320	1327		10.1038/sj.onc.1208232	http://dx.doi.org/10.1038/sj.onc.1208232			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898QZ	15608686				2022-12-17	WOS:000227092600002
J	Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW				Dang, DT; Chen, XM; Feng, J; Torbenson, M; Dang, LH; Yang, VW			Overexpression of Kruppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity	ONCOGENE			English	Article						Kruppel-like factor 4; tumorigenecity; RKO; colorectal cancer	ZINC-FINGER PROTEIN; CARCINOMA CELLS; GENE-EXPRESSION; IN-VIVO; TRANSCRIPTION; DIFFERENTIATION; GROWTH; GKLF; PROLIFERATION; PROGRESSION	Kruppel-like factor 4 (KLF4) is a zinc-finger-containing transcription factor, the expression of which is enriched in the postmitotic cells of the intestinal epithelium. KLF4 is a target gene of the tumor suppressor adenomatous polyposis coli (APC). We sought to determine the role of KLF4 in suppressing the tumorigenecity of RKO colon cancer cells, which do not express KLF4. We utilized an established system in RKO cells, in which an inducible promoter controls expression of KLF4. Four independent assays were used to assess the effects of KLF4 induction on tumor cells. We find that KLF4 overexpression reduces colony formation, cell migration and invasion, and in vivo tumorigenecity. The mechanism of action of KLF4 does not involve apoptosis. These findings, along with our previous findings that KLF4 induces G1/S arrest, suggest that KLF4 is a cell cycle checkpoint protein that can reduce tumorigenecity of colon cancer cells.	Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21205 USA; Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA	Johns Hopkins University; Emory University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Emory University	Dang, DT (corresponding author), Johns Hopkins Univ, Sch Med, Div Gastroenterol, Dept Med, 720 Rutland Ave,Ross 918, Baltimore, MD 21205 USA.				NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, K08DK059970] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA084197, R01 CA084197-04, CA84197] Funding Source: Medline; NIDDK NIH HHS [R01 DK052230-06, DK52230, DK59970, K08 DK059970, R01 DK052230] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam PJ, 2000, J BIOL CHEM, V275, P37798, DOI 10.1074/jbc.M006323200; Behr R, 2002, MECH DEVELOP, V115, P167, DOI 10.1016/S0925-4773(02)00127-2; Brembeck FH, 2000, J BIOL CHEM, V275, P28230; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Dang DT, 2002, NUCLEIC ACIDS RES, V30, P2736, DOI 10.1093/nar/gkf400; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang DT, 2000, FEBS LETT, V476, P203, DOI 10.1016/S0014-5793(00)01727-0; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; Foster KW, 2000, CANCER RES, V60, P6488; Geiman DE, 2000, NUCLEIC ACIDS RES, V28, P1106, DOI 10.1093/nar/28.5.1106; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; Katz JP, 2002, DEVELOPMENT, V129, P2619; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Luo J, 2002, PROSTATE, V51, P189, DOI 10.1002/pros.10087; Nickenig G, 2002, FASEB J, V16, P1077, DOI 10.1096/fj.01-0570com; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Panigada M, 1999, MECH DEVELOP, V81, P103, DOI 10.1016/S0925-4773(98)00237-8; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Rigas A, 2002, CANCER INVEST, V20, P657, DOI 10.1081/CNV-120002491; Rozic JG, 2001, INT J CANCER, V93, P497, DOI 10.1002/ijc.1376; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; Suh E, 1996, MOL CELL BIOL, V16, P619; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Yet SF, 1998, J BIOL CHEM, V273, P1026, DOI 10.1074/jbc.273.2.1026; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200	31	133	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3424	3430		10.1038/sj.onc.1206413	http://dx.doi.org/10.1038/sj.onc.1206413			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776194	Green Accepted			2022-12-17	WOS:000183128500009
J	Dranoff, G				Dranoff, G			GM-CSF-secreting melanoma vaccines	ONCOGENE			English	Article						GM-CSF; melanoma; cancer vaccine; tumor antigen	COLONY-STIMULATING FACTOR; T-CELL RESPONSES; TUMOR-INFILTRATING LYMPHOCYTES; MHC CLASS-I; DENDRITIC CELLS; IMMUNE-RESPONSES; CANCER ANTIGENS; NKT CELLS; CTLA-4; SPECIFICITY	The development of biochemical and genetic schemes to characterize cancer antigens led to the recognition that malignant melanoma frequently evokes a host response. While the generation of brisk T-cell infiltrates in early stage disease is correlated with prolonged survival, host reactions in most cases are insufficient to impede tumor progression. One variable that may limit the potency of the host response against nascent melanoma is the mixture of cytokines present in the tumor microenvironment. In a murine melanoma model, we identified granulocyte-macrophage colony stimulating factor (GM-CSF) as the most potent molecule for augmenting tumor immunity following gene transfer into melanoma cells. Vaccination with irradiated melanoma cells engineered to secrete GMCSF enhances host responses through improved tumor antigen presentation by recruited dendritic cells and macrophages. Melanoma-specific CD4(+) and CD8(+) T-cells, CD1d-restricted NKT-cells, and antibodies mediate tumor rejection. Initial testing of this immunization strategy in patients with metastatic melanoma revealed the consistent induction of cellular and humoral antitumor responses that provoked the extensive necrosis of distant metastases without significant toxicity.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dranoff, G (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Dana 510E,44 Binney St, Boston, MA 02115 USA.	glenn_dranoff@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA074886, P01CA039542] Funding Source: NIH RePORTER; NCI NIH HHS [CA39542, CA74886] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BERKNER KL, 1988, BIOTECHNIQUES, V6, P616; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Boon T, 1996, J EXP MED, V183, P725, DOI 10.1084/jem.183.3.725; Chambers CA, 2001, ANNU REV IMMUNOL, V19, P565, DOI 10.1146/annurev.immunol.19.1.565; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO;2-0; Doyle AM, 2001, J EXP MED, V194, P893, DOI 10.1084/jem.194.7.893; DRANOFF G, 1995, ADV IMMUNOL, V58, P417, DOI 10.1016/S0065-2776(08)60624-0; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; FORNI G, 1988, CANCER METAST REV, V7, P289, DOI 10.1007/BF00051371; FORNI G, 1985, J IMMUNOL, V134, P1305; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hodi FS, 2002, P NATL ACAD SCI USA, V99, P6919, DOI 10.1073/pnas.102025999; HOUGHTON AN, 1994, J EXP MED, V180, P1, DOI 10.1084/jem.180.1.1; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; INABA K, 1993, P NATL ACAD SCI USA, V90, P3038, DOI 10.1073/pnas.90.7.3038; Jager E, 2000, P NATL ACAD SCI USA, V97, P4760, DOI 10.1073/pnas.97.9.4760; Kawano T, 1997, SCIENCE, V278, P1626, DOI 10.1126/science.278.5343.1626; Mach N, 2000, CURR OPIN IMMUNOL, V12, P571, DOI 10.1016/S0952-7915(00)00144-8; Mach N, 2000, CANCER RES, V60, P3239; Mihm MC, 1996, LAB INVEST, V74, P43; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Murtaza A, 1999, INT IMMUNOL, V11, P407, DOI 10.1093/intimm/11.3.407; OLD LJ, 1981, CANCER RES, V41, P361; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Pulendran B, 1997, J IMMUNOL, V159, P2222; Reddy A, 1997, BLOOD, V90, P3640, DOI 10.1182/blood.V90.9.3640; Reilly RT, 2001, CANCER RES, V61, P880; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Scanlan MJ, 1999, INT J CANCER, V83, P456, DOI 10.1002/(SICI)1097-0215(19991112)83:4<456::AID-IJC4>3.0.CO;2-5; Shen ZH, 1997, J IMMUNOL, V158, P2723; SHENK T, 1996, FIELDS VIROLOGY, P2111; Smyth MJ, 2002, CURR OPIN IMMUNOL, V14, P165, DOI 10.1016/S0952-7915(02)00316-3; Soiffer R, 1998, P NATL ACAD SCI USA, V95, P13141, DOI 10.1073/pnas.95.22.13141; SUPEK F, 1994, J BIOL CHEM, V269, P24102; TEPPER RI, 1994, HUM GENE THER, V5, P153, DOI 10.1089/hum.1994.5.2-153; Thompson CB, 1997, IMMUNITY, V7, P445, DOI 10.1016/S1074-7613(00)80366-0; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; YAMAGUCHI H, 1990, P NATL ACAD SCI USA, V87, P3333, DOI 10.1073/pnas.87.9.3333; Young JW, 1996, J EXP MED, V183, P7, DOI 10.1084/jem.183.1.7; Zeng G, 2001, P NATL ACAD SCI USA, V98, P3964, DOI 10.1073/pnas.061507398	51	133	147	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3188	3192		10.1038/sj.onc.1206459	http://dx.doi.org/10.1038/sj.onc.1206459			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789295				2022-12-17	WOS:000183096600021
J	Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P				Heighway, J; Knapp, T; Boyce, L; Brennand, S; Field, JK; Betticher, DC; Ratschiller, D; Gugger, M; Donovan, M; Lasek, A; Rickert, P			Expression profiling of primary non-small cell lung cancer for target identification	ONCOGENE			English	Article						lung; cancer; microarray; expression; target identification	TUMOR-SUPPRESSOR; GENE-EXPRESSION; OVARIAN-CANCER; MESSENGER-RNA; S100A2; CLASSIFICATION; ADENOCARCINOMA; DISTINCT; MUTATION; PROTEINS	Using a panel of cDNA microarrays comprising 47 650 transcript elements, we have carried out a dual-channel analysis of gene expression in 39 resected primary human non-small cell lung tumours versus normal lung tissue. Whilst similar to11000 elements were scored as differentially expressed at least twofold in at least one sample, 96 transcripts were scored as over-represented fourfold or more in at least seven out of 39 tumours and 30 sequences 16-fold in at least two out of 39 tumours, including 24 transcripts in common. Transcripts (178) were found under-represented fourfold in at least seven out of 39 tumours, 31 of which are under-represented 16-fold in at least two out of 39 lesions. The relative expression levels of representative genes from these lists were analysed by comparative multiplex RT-PCR and found to be broadly consistent with the microarray data. Two dramatically over-represented genes, previously designated as potential tumour suppressors in breast (maspin) and lung and breast (S100A2) cancers, were analysed more extensively and demonstrate the effectiveness of this approach in identifying potential lung cancer diagnostic or therapeutic targets. Whilst it has been reported that S100A2 is downregulated in NSCLC at an early stage, our microarray, cmRT-PCR, Western and immunohistochemistry data indicate that it is strongly expressed in the majority of tumours.	Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, Liverpool, Merseyside, England; Univ Bern, Inst Med Oncol, CH-3010 Bern, Switzerland; Incyte Genom Inc, Palo Alto, CA 94304 USA	University of Liverpool; University of Bern; Incyte	Heighway, J (corresponding author), Univ Liverpool, Roy Castle Int Ctr Lung Canc Res, Target Identificat Grp, 200 London Rd, Liverpool, Merseyside, England.		Betticher, Daniel C/G-5849-2013; Field, John K./AAD-5674-2020	Field, John K./0000-0003-3951-6365				Agrawal D, 2002, J NATL CANCER I, V94, P513; Bertucci F, 2001, LANCET ONCOL, V2, P674, DOI 10.1016/S1470-2045(01)00557-5; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bonomi P, 2002, SEMIN ONCOL, V29, P78, DOI 10.1053/sonc.2002.31528; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Feng G, 2001, CANCER RES, V61, P7999; Folkman J, 2000, NAT REV MOL CELL BIO, V1, P76, DOI 10.1038/35036100; FRAIRE AE, 1987, CANCER, V60, P370, DOI 10.1002/1097-0142(19870801)60:3<370::AID-CNCR2820600314>3.0.CO;2-W; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Giordano TJ, 2001, AM J PATHOL, V159, P1231, DOI 10.1016/S0002-9440(10)62509-6; Hayashi K, 2001, CANCER RES, V61, P2361; HEIGHWAY J, 2003, METHODS MOL MED; Hough CD, 2001, CANCER RES, V61, P3869; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ilg EC, 1996, INT J CANCER, V68, P325, DOI 10.1002/(SICI)1097-0215(19961104)68:3<325::AID-IJC10>3.0.CO;2-7; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671; Kolligs FT, 2000, GENE DEV, V14, P1319; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Liu D, 2000, BRIT J CANCER, V83, P1473, DOI 10.1054/bjoc.2000.1488; Maass N, 2001, CLIN CANCER RES, V7, P812; Matsumoto Y, 2001, JPN J CANCER RES, V92, P1133, DOI 10.1111/j.1349-7006.2001.tb01069.x; Nacht M, 2001, P NATL ACAD SCI USA, V98, P15203, DOI 10.1073/pnas.261414598; Pabon C, 2001, BIOTECHNIQUES, V31, P874, DOI 10.2144/01314mt05; Seftor REB, 1998, CANCER RES, V58, P5681; Sunday ME, 1999, ONCOGENE, V18, P4336, DOI 10.1038/sj.onc.1202810; THURLBECK WM, 1995, PATHOLOGY LUNG, P445; Topcu Z, 2001, J CLIN PHARM THER, V26, P405, DOI 10.1046/j.1365-2710.2001.00368.x; Umekita Y, 2002, INT J CANCER, V100, P452, DOI 10.1002/ijc.10500; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Wicki R, 1997, CELL CALCIUM, V22, P243, DOI 10.1016/S0143-4160(97)90063-4; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41; Zhu Y, 2001, CANCER RES, V61, P7825	33	133	144	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 31	2002	21	50					7749	7763		10.1038/sj.onc.1205979	http://dx.doi.org/10.1038/sj.onc.1205979			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	606VW	12400018				2022-12-17	WOS:000178756200015
J	Kitada, S; Pedersen, IM; Schimmer, AD; Reed, JC				Kitada, S; Pedersen, IM; Schimmer, AD; Reed, JC			Dysregulation of apoptosis genes in hematopoietic malignancies	ONCOGENE			English	Review						apoptosis; programmed cell death; malignancy	NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; BUTYRATE-INDUCED APOPTOSIS; BCL-2 PROTEIN EXPRESSION; NECROSIS-FACTOR RECEPTOR; ACUTE MYELOID LEUKEMIAS; TRAIL-INDUCED APOPTOSIS; NON-HODGKINS-LYMPHOMA; CELL-SURFACE ANTIGEN	Ever since the discovery of Bel-2 and the elucidation of its role in apoptosis, tremendous interest has arisen in prospects for triggering suicide of malignant cells by exploiting knowledge emerging from apoptosis research. In this review, we summarize information about the multiple genetic lesions which have been identified in apoptosis-regulatory genes of hematopoietic and lymphoid neoplasms. Emerging data about the structural and biochemical details of apoptosis proteins and their upstream regulators have reveal novel strategies for therapeutic intervention, some of which are under interrogation in clinical trials currently.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org		Schimmer, Aaron/0000-0003-4023-3899				Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; AHMED NN, 1993, ONCOGENE, V8, P1957; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Anthoney DA, 1996, CANCER RES, V56, P1374; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Banker DE, 1998, CLIN CANCER RES, V4, P3051; Barkett M, 2001, BBA-GEN SUBJECTS, V1526, P25, DOI 10.1016/S0304-4165(01)00092-7; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225; Bladergroen BA, 2001, J IMMUNOL, V166, P3218, DOI 10.4049/jimmunol.166.5.3218; Borlado LR, 2000, FASEB J, V14, P895; Boultwood J, 2001, J CLIN PATHOL, V54, P512, DOI 10.1136/jcp.54.7.512; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Britos-Bray M, 1998, BLOOD, V92, P4344, DOI 10.1182/blood.V92.11.4344.423a01_4344_4352; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; CAMPOS L, 1993, BLOOD, V81, P3091; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chang BS, 1997, EMBO J, V16, P968, DOI 10.1093/emboj/16.5.968; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Dalton WS, 1999, SEMIN ONCOL, V26, P23; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; de Groot Rolf P., 2000, Molecular Cell Biology Research Communications, V3, P299, DOI 10.1006/mcbr.2000.0231; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Ergin M, 2001, EXP HEMATOL, V29, P1082, DOI 10.1016/S0301-472X(01)00688-9; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FU TB, 1994, CANCER RES, V54, P6297; Gascoyne RD, 1997, BLOOD, V90, P244; GAUWERKY CE, 1988, ONCOGENE, V2, P431; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gil J, 1999, CANCER RES, V59, P2034; Gill S, 1999, BRIT J CANCER, V80, P1565, DOI 10.1038/sj.bjc.6990561; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Graubert TA, 1997, J CLIN INVEST, V100, P904, DOI 10.1172/JCI119606; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Gronbaek K, 1998, BLOOD, V92, P3018; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hague A, 1997, INT J CANCER, V72, P898, DOI 10.1002/(SICI)1097-0215(19970904)72:5<898::AID-IJC30>3.0.CO;2-2; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Hess JL, 1998, NAT GENET, V20, P220, DOI 10.1038/3014; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Holmes-McNary M, 2000, CANCER RES, V60, P3477; Houldsworth J, 1996, BLOOD, V87, P25; HUANG MT, 1994, CANCER RES, V54, P701; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamihira S, 1999, BRIT J HAEMATOL, V107, P851, DOI 10.1046/j.1365-2141.1999.01792.x; Karanewsky DS, 1998, BIOORG MED CHEM LETT, V8, P2757, DOI 10.1016/S0960-894X(98)00498-3; Karnolsky I N, 2000, Folia Med (Plovdiv), V42, P5; KAUFMANN SH, 1991, EXP CELL RES, V192, P524, DOI 10.1016/0014-4827(91)90072-3; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kornblau SM, 2000, CLIN CANCER RES, V6, P1401; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kupper M, 2001, BRIT J HAEMATOL, V112, P768, DOI 10.1046/j.1365-2141.2001.02566.x; Landowski TH, 1997, BLOOD, V90, P4266, DOI 10.1182/blood.V90.11.4266.4266_4266_4270; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Liu TC, 2000, BRIT J HAEMATOL, V109, P250, DOI 10.1046/j.1365-2141.2000.01969.x; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lowin B, 1995, Curr Top Microbiol Immunol, V198, P1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mandal M, 1996, CELL GROWTH DIFFER, V7, P311; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; McConkey DJ, 1996, J IMMUNOL, V156, P2624; Medh RD, 2000, CELL TISSUE RES, V301, P101, DOI 10.1007/s004419900159; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; MIYASHITA T, 1995, CELL, V80, P293; Morgan JA, 1999, CANCER RES, V59, P6205; Motegi M, 2000, AM J PATHOL, V156, P807, DOI 10.1016/S0002-9440(10)64948-6; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; Niitsu N, 1999, LEUKEMIA, V13, P1434, DOI 10.1038/sj.leu.2401502; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OEHM A, 1992, J BIOL CHEM, V267, P10709; Ong YL, 2000, BRIT J HAEMATOL, V111, P182, DOI 10.1046/j.1365-2141.2000.02315.x; Osorio LM, 2001, EUR J HAEMATOL, V66, P342, DOI 10.1034/j.1600-0609.2001.066005342.x; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Ozes ON, 1999, NATURE, V401, P82; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Pepper C, 1997, BRIT J CANCER, V76, P935, DOI 10.1038/bjc.1997.487; Pepper C, 1998, LEUKEMIA LYMPHOMA, V28, P355, DOI 10.3109/10428199809092690; Perucho M, 1996, BIOL CHEM, V377, P675; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Radich JP, 2001, HEMATOL ONCOL CLIN N, V15, P21, DOI 10.1016/S0889-8588(05)70198-2; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; REED JC, 1993, LEUKEMIA LYMPHOMA, V10, P157, DOI 10.3109/10428199309145877; Reed JC, 1999, J NATL CANCER I, V91, P1099, DOI 10.1093/jnci/91.13.1099; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rinkenberger JL, 1997, CURR OPIN GENET DEV, V7, P589, DOI 10.1016/S0959-437X(97)80004-4; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shikami M, 1999, LEUKEMIA, V13, P358, DOI 10.1038/sj.leu.2401343; Shinobu N, 1999, J BIOL CHEM, V274, P17003, DOI 10.1074/jbc.274.24.17003; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Simms LA, 1998, ONCOGENE, V17, P2003, DOI 10.1038/sj.onc.1202109; Slupianek A, 2001, CANCER RES, V61, P2194; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Soulier J, 2001, GENE CHROMOSOME CANC, V31, P248, DOI 10.1002/gcc.1141; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stankovic T, 2001, BLOOD, V97, P1517, DOI 10.1182/blood.V97.5.1517; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; Suh N, 1999, CANCER RES, V59, P5671; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Takita J, 2001, ONCOGENE, V20, P4424, DOI 10.1038/sj.onc.1204521; TANAKA S, 1992, BLOOD, V79, P229; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(00)00094-0; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Wuchter C, 2001, LEUKEMIA, V15, P921, DOI 10.1038/sj.leu.2402131; Wyllie AH, 1997, EUR J CELL BIOL, V73, P189; Wyllie AH, 1997, BRIT MED BULL, V53, P451; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yan MH, 1999, J BIOL CHEM, V274, P10287, DOI 10.1074/jbc.274.15.10287; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Yuille MR, 1998, LEUKEMIA, V12, P1696, DOI 10.1038/sj.leu.2401176; Zapata JM, 2000, J IMMUNOL, V165, P5084, DOI 10.4049/jimmunol.165.9.5084; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	208	133	140	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3459	3474		10.1038/sj.onc.1205327	http://dx.doi.org/10.1038/sj.onc.1205327			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032782				2022-12-17	WOS:000175633300017
J	Scheijen, B; Griffin, JD				Scheijen, B; Griffin, JD			Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease	ONCOGENE			English	Review						leukemia; lymphoma; protein tyrosine kinase; signal transduction; translocation	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; CHRONIC MYELOGENOUS LEUKEMIA; ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; ACUTE MYELOID-LEUKEMIA; SRC HOMOLOGY-2 DOMAIN; FACTOR-BETA-RECEPTOR; INTERNAL TANDEM DUPLICATION; C-FES PROTOONCOGENE	Tyrosine kinase oncogenes are formed as a result of mutations that induce constitutive kinase activity. Many of these tyrosine kinase oncogenes that are derived from genes, such as c-Abl, c-Fes, FIt3, c-Fms, c-Kit and PDGFRbeta, that are normally involved in the regulation of hematopoiesis or hematopoietic cell function. Despite differences in structure, normal function, and subcellular location, many of the tyrosine kinase oncogenes signal through the same pathways, and typically enhance proliferation and prolong viability. They represent excellent potential drug targets, and it is likely that additional mutations will be identified in other kinases, their immediate downstream targets, or in proteins regulating their function.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Griffin, JD (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	james_griffin@dfci.harvard.edu	Scheijen, Blanca/E-3523-2016	Scheijen, Blanca/0000-0001-8029-9230				Abe A, 1997, BLOOD, V90, P4271, DOI 10.1182/blood.V90.11.4271.4271_4271_4277; Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Afar DEH, 1997, IMMUNITY, V6, P773, DOI 10.1016/S1074-7613(00)80452-5; Agami R, 1999, NATURE, V399, P809; ALAI M, 1992, J BIOL CHEM, V267, P18021; Alimandi M, 1997, ONCOGENE, V15, P585, DOI 10.1038/sj.onc.1201221; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Amarante-Mendes GP, 1998, ONCOGENE, V16, P1383, DOI 10.1038/sj.onc.1201664; ANDERSON SM, 1995, J IMMUNOL, V155, P1660; Andreasson P, 1997, GENE CHROMOSOME CANC, V20, P299; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; ASHMUN RA, 1989, BLOOD, V73, P827; Aziz N, 1999, MOL CELL BIOL, V19, P1101; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 1998, ONCOGENE, V17, P941, DOI 10.1038/sj.onc.1202024; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Beghini A, 2000, BLOOD, V95, P726, DOI 10.1182/blood.V95.2.726; Benharroch D, 1998, BLOOD, V91, P2076, DOI 10.1182/blood.V91.6.2076; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BirchenallRoberts MC, 1997, J BIOL CHEM, V272, P8905; BIRG F, 1992, BLOOD, V80, P2584; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; BITTER MA, 1990, AM J SURG PATHOL, V14, P305, DOI 10.1097/00000478-199004000-00001; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 2001, J BIOL CHEM, V276, P22133, DOI 10.1074/jbc.M101878200; Brasel K, 1996, BLOOD, V88, P2004, DOI 10.1182/blood.V88.6.2004.bloodjournal8862004; BRASEL K, 1995, LEUKEMIA, V9, P1212; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Brizzi MF, 1999, J BIOL CHEM, V274, P16965, DOI 10.1074/jbc.274.24.16965; Brizzi MF, 1996, ONCOGENE, V13, P2067; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; BROSNAN CF, 1993, ADV NEUROL, V59, P349; Carlberg K, 1997, J BIOL CHEM, V272, P15943, DOI 10.1074/jbc.272.25.15943; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carow CE, 1996, BLOOD, V87, P1089, DOI 10.1182/blood.V87.3.1089.bloodjournal8731089; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Caruana G, 1999, ONCOGENE, V18, P5573, DOI 10.1038/sj.onc.1202939; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; Chen KY, 1997, CANCER RES, V57, P3511; Chen M, 2000, MOL CELL BIOL, V20, P7867, DOI 10.1128/MCB.20.21.7867-7880.2000; Cheng HY, 1999, MOL CELL BIOL, V19, P8335; Cheng HY, 2001, MOL CELL BIOL, V21, P6170, DOI 10.1128/MCB.21.18.6170-6180.2001; Chian RJ, 2001, BLOOD, V98, P1365, DOI 10.1182/blood.V98.5.1365; Coffin CM, 1998, SEMIN DIAGN PATHOL, V15, P102; Coffin CM, 2001, MODERN PATHOL, V14, P569, DOI 10.1038/modpathol.3880352; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cong F, 1999, MOL CELL BIOL, V19, P8314; Cook JR, 2001, AM J SURG PATHOL, V25, P1364, DOI 10.1097/00000478-200111000-00003; Coutinho S, 2000, BLOOD, V96, P618; Csar XF, 2001, J BIOL CHEM, V276, P26211, DOI 10.1074/jbc.M100213200; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; Dai ZH, 2001, J BIOL CHEM, V276, P28954, DOI 10.1074/jbc.M101170200; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DAYNES RA, 1991, J EXP MED, V174, P1323, DOI 10.1084/jem.174.6.1323; de Jong R, 1997, J BIOL CHEM, V272, P32649, DOI 10.1074/jbc.272.51.32649; De Sepulveda P, 1999, EMBO J, V18, P904; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DELWICHE F, 1985, J CLIN INVEST, V76, P137, DOI 10.1172/JCI111936; DEPARSEVAL N, 1993, CYTOKINE, V5, P8, DOI 10.1016/1043-4666(93)90018-Z; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Di Cristofano A, 1998, J BIOL CHEM, V273, P4827, DOI 10.1074/jbc.273.9.4827; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; Falini B, 1998, AM J PATHOL, V153, P875, DOI 10.1016/S0002-9440(10)65629-5; FELDMAN RA, 1983, J VIROL, V45, P782, DOI 10.1128/JVI.45.2.782-791.1983; FELLER SM, 1995, ONCOGENE, V10, P1465; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FERRARI S, 1994, LEUKEMIA, V8, pS91; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; Foss B, 2001, EUR J HAEMATOL, V66, P365, DOI 10.1034/j.1600-0609.2001.066006365.x; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gari M, 1999, BRIT J HAEMATOL, V105, P894, DOI 10.1046/j.1365-2141.1999.01449.x; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; GERSUK GM, 1991, SCAND J IMMUNOL, V33, P521, DOI 10.1111/j.1365-3083.1991.tb02522.x; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; Gong JG, 1999, NATURE, V399, P806; GOTOH A, 1994, LEUKEMIA, V8, P115; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; GREER P, 1994, MOL CELL BIOL, V14, P6755, DOI 10.1128/MCB.14.10.6755; Grey A, 2000, ENDOCRINOLOGY, V141, P2129, DOI 10.1210/en.141.6.2129; Griffin CA, 1999, CANCER RES, V59, P2776; GROFFEN J, 1983, VIROLOGY, V125, P480, DOI 10.1016/0042-6822(83)90219-2; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Hackenmiller R, 2000, IMMUNITY, V13, P397, DOI 10.1016/S1074-7613(00)00039-X; Haigh J, 1996, CELL GROWTH DIFFER, V7, P931; HANAZONO Y, 1993, BLOOD, V81, P3193; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANNUM C, 1994, NATURE, V368, P643, DOI 10.1038/368643a0; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Hardin JD, 1996, CELL IMMUNOL, V172, P100, DOI 10.1006/cimm.1996.0220; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Hernandez L, 1999, BLOOD, V94, P3265; HIRAYAMA F, 1995, BLOOD, V85, P1762, DOI 10.1182/blood.V85.7.1762.bloodjournal8571762; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Hongyo T, 2000, CANCER RES, V60, P2345; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; Huber M, 1998, EMBO J, V17, P7311, DOI 10.1093/emboj/17.24.7311; HUDAK S, 1995, BLOOD, V85, P2747, DOI 10.1182/blood.V85.10.2747.bloodjournal85102747; Iijima Y, 2000, BLOOD, V95, P2126; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Ito Y, 2001, J BIOL CHEM, V276, P18130, DOI 10.1074/jbc.M007294200; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; IZUHARA K, 1994, J BIOL CHEM, V269, P18623; JACOBSEN SEW, 1995, J EXP MED, V181, P1357, DOI 10.1084/jem.181.4.1357; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Jiang H, 2001, J IMMUNOL, V166, P2627, DOI 10.4049/jimmunol.166.4.2627; Jonuleit T, 2000, BLOOD, V96, P1933, DOI 10.1182/blood.V96.5.1933.h8001933_1933_1939; JUCKER M, 1992, ONCOGENE, V7, P943; Jucker M, 1997, J BIOL CHEM, V272, P2104; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Kaminski WE, 2001, BLOOD, V97, P1990, DOI 10.1182/blood.V97.7.1990; KARLSSON T, 1995, ONCOGENE, V10, P1475; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; Kelly LM, 2002, BLOOD, V99, P310, DOI 10.1182/blood.V99.1.310; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; KIN Y, 2001, J BIOL CHEM, V13, P13; Kiyoi H, 1997, LEUKEMIA, V11, P1447, DOI 10.1038/sj.leu.2400756; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; Kubota Y, 1998, CELL GROWTH DIFFER, V9, P247; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Kulkarni S, 2000, CANCER RES, V60, P3592; Lagasse E, 1997, CELL, V89, P1021, DOI 10.1016/S0092-8674(00)80290-1; Lamant L, 1999, BLOOD, V93, P3088; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; Lavagna-Sevenier C, 1998, LEUKEMIA, V12, P301, DOI 10.1038/sj.leu.2400921; Lavagna-Sevenier C, 1998, J BIOL CHEM, V273, P14962, DOI 10.1074/jbc.273.24.14962; Law SF, 1996, MOL CELL BIOL, V16, P3327; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee AWM, 2000, MOL CELL BIOL, V20, P6779, DOI 10.1128/MCB.20.18.6779-6798.2000; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Li JZ, 1998, J BIOL CHEM, V273, P13828, DOI 10.1074/jbc.273.22.13828; Li JZ, 1996, J BIOL CHEM, V271, P32930, DOI 10.1074/jbc.271.51.32930; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lindahl P, 1998, DEVELOPMENT, V125, P3313; LINNEKIN D, 1995, J BIOL CHEM, V270, P4950, DOI 10.1074/jbc.270.9.4950; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lisovsky M, 1996, BLOOD, V88, P3987, DOI 10.1182/blood.V88.10.3987.bloodjournal88103987; Liu SK, 1998, ONCOGENE, V17, P3073, DOI 10.1038/sj.onc.1202337; Liu Y, 2001, MOL CELL BIOL, V21, P3047, DOI 10.1128/MCB.21.9.3047-3056.2001; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Lu LW, 2001, EXP HEMATOL, V29, P596, DOI 10.1016/S0301-472X(01)00621-X; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; Lynch DH, 1997, NAT MED, V3, P625, DOI 10.1038/nm0697-625; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MACKAREHTSCHIAN K, 1995, IMMUNITY, V3, P147, DOI 10.1016/1074-7613(95)90167-1; Magnusson MK, 2001, BLOOD, V98, P2518, DOI 10.1182/blood.V98.8.2518; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; Manfredini R, 1997, BLOOD, V89, P135, DOI 10.1182/blood.V89.1.135.135_135_145; Maraskovsky E, 2000, BLOOD, V96, P878, DOI 10.1182/blood.V96.3.878.015k15_878_884; Maraskovsky E, 1996, J EXP MED, V184, P1953, DOI 10.1084/jem.184.5.1953; Marchetto S, 1999, LEUKEMIA, V13, P1374, DOI 10.1038/sj.leu.2401527; MARU Y, 1995, MOL CELL BIOL, V15, P835; MASON DY, 1990, BRIT J HAEMATOL, V74, P161; Mason DY, 1998, CANCER RES, V58, P1057; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; McClanahan T, 1996, BLOOD, V88, P3371, DOI 10.1182/blood.V88.9.3371.bloodjournal8893371; McGlynn H, 1997, LEUKEMIA RES, V21, P919, DOI 10.1016/S0145-2126(97)00024-6; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; McKenna HJ, 1996, EXP HEMATOL, V24, P378; McMahon KA, 2001, BIOCHEM J, V358, P431, DOI 10.1042/0264-6021:3580431; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MECKLINGGILL KA, 1992, BIOCHIM BIOPHYS ACTA, V1137, P65, DOI 10.1016/0167-4889(92)90101-G; Meech SJ, 2001, BLOOD, V98, P1209, DOI 10.1182/blood.V98.4.1209; MEIERHOFF G, 1995, LEUKEMIA, V9, P1368; Meshinchi S, 2001, BLOOD, V97, P89, DOI 10.1182/blood.V97.1.89; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nakao M, 1996, LEUKEMIA, V10, P1911; NAKATA Y, 1995, BRIT J HAEMATOL, V91, P661, DOI 10.1111/j.1365-2141.1995.tb05364.x; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nicholls SE, 1999, EXP HEMATOL, V27, P663, DOI 10.1016/S0301-472X(98)00072-1; Niebylski J, 2000, MARINE MARITIME, V1, P61; Ning ZQ, 2001, LEUKEMIA LYMPHOMA, V41, P513, DOI 10.3109/10428190109060342; Ning ZQ, 2001, BLOOD, V97, P3559, DOI 10.1182/blood.V97.11.3559; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; ODA T, 1994, J BIOL CHEM, V269, P22925; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Park WY, 1998, CANCER LETT, V129, P29, DOI 10.1016/S0304-3835(98)00077-9; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Piacibello W, 2000, J HEMATOTH STEM CELL, V9, P945, DOI 10.1089/152581600750062408; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; POLLARD JW, 1991, DEV BIOL, V148, P273, DOI 10.1016/0012-1606(91)90336-2; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Pulendran B, 2000, J IMMUNOL, V165, P566, DOI 10.4049/jimmunol.165.1.566; Pulford K, 1999, AM J PATHOL, V154, P1657, DOI 10.1016/S0002-9440(10)65421-1; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RAMBALDI A, 1988, J CLIN INVEST, V81, P1030, DOI 10.1172/JCI113413; RAO P, 1995, J BIOL CHEM, V270, P6886, DOI 10.1074/jbc.270.12.6886; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; RIDGE SA, 1990, P NATL ACAD SCI USA, V87, P1377, DOI 10.1073/pnas.87.4.1377; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; Rogers JA, 2000, CELL GROWTH DIFFER, V11, P581; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; Rombouts WJC, 2000, LEUKEMIA, V14, P675, DOI 10.1038/sj.leu.2401731; Ronnstrand L, 1999, ONCOGENE, V18, P3696, DOI 10.1038/sj.onc.1202705; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSNET O, 1993, BLOOD, V82, P1110, DOI 10.1182/blood.V82.4.1110.bloodjournal8241110; Ross TS, 1998, BLOOD, V91, P4419, DOI 10.1182/blood.V91.12.4419.412k43_4419_4426; ROTTAPEL R, 1994, ONCOGENE, V9, P1755; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; Saito Y, 2001, MOL CELL BIOL, V21, P6387, DOI 10.1128/MCB.21.19.6387-6394.2001; Salgia R, 1996, EXP HEMATOL, V24, P310; Salgia R, 1996, J BIOL CHEM, V271, P25198, DOI 10.1074/jbc.271.41.25198; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Sattler M, 1997, J BIOL CHEM, V272, P10248; Sattler M, 1997, ONCOGENE, V15, P2379, DOI 10.1038/sj.onc.1201422; Sattler M, 1996, ONCOGENE, V12, P839; Sattler M, 2001, J BIOL CHEM, V276, P2451, DOI 10.1074/jbc.M006250200; Savvides SN, 2000, NAT STRUCT BIOL, V7, P486; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Schwaller J, 2001, BLOOD, V97, P3910, DOI 10.1182/blood.V97.12.3910; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shi CS, 2000, BLOOD, V95, P776, DOI 10.1182/blood.V95.3.776.003k23_776_782; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHIOTA M, 1994, ONCOGENE, V9, P1567; Siebert R, 1999, BLOOD, V94, P3614; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, CANCER RES, V61, P2194; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SMITHGALL TE, 1991, J NATL CANCER I, V83, P42, DOI 10.1093/jnci/83.1.42; SONOYAMA J, 2002, J BIOL CHEM, V4, P4; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; Stein H, 2000, BLOOD, V96, P3681; Sternberg DW, 2001, BLOOD, V98, P3390, DOI 10.1182/blood.V98.12.3390; Sun XG, 2000, J BIOL CHEM, V275, P17237, DOI 10.1074/jbc.C000099200; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tallquist MD, 2000, GENE DEV, V14, P3179, DOI 10.1101/gad.844700; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; Theis S, 1998, ONCOGENE, V17, P557, DOI 10.1038/sj.onc.1201973; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; TOBAL K, 1990, LEUKEMIA, V4, P486; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Tort F, 2001, LAB INVEST, V81, P419, DOI 10.1038/labinvest.3780249; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; van Dijk TB, 2000, BLOOD, V96, P3406; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; Vosseller K, 1997, MOL BIOL CELL, V8, P909, DOI 10.1091/mbc.8.5.909; Wang BL, 1996, ONCOGENE, V13, P193; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; WELCH PJ, 1995, MOL CELL BIOL, V15, P5542; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WELLMANN A, 1995, BLOOD, V86, P2321, DOI 10.1182/blood.V86.6.2321.bloodjournal8662321; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Whang YE, 2000, P NATL ACAD SCI USA, V97, P5486, DOI 10.1073/pnas.97.10.5486; Whitman SP, 2001, CANCER RES, V61, P7233; WIKTORJEDRZEJCZAK W, 1990, P NATL ACAD SCI USA, V87, P4828, DOI 10.1073/pnas.87.12.4828; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wlodarska I, 1998, BLOOD, V92, P2688, DOI 10.1182/blood.V92.8.2688.420a42_2688_2695; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; Xu F, 1999, BRIT J HAEMATOL, V105, P155, DOI 10.1111/j.1365-2141.1999.01284.x; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; YAN XQ, 1993, J IMMUNOL, V150, P2440; YANG M, 1995, BRIT J HAEMATOL, V91, P285, DOI 10.1111/j.1365-2141.1995.tb05291.x; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YATES KE, 1995, ONCOGENE, V10, P1239; YEE SP, 1989, MOL CELL BIOL, V9, P5491, DOI 10.1128/MCB.9.12.5491; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; YU G, 1989, J BIOL CHEM, V264, P10276; YU G, 1987, J BIOL CHEM, V262, P17543; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466; Zhang SL, 2000, BIOCHEM BIOPH RES CO, V277, P195, DOI 10.1006/bbrc.2000.3662; Zhang SL, 2000, J EXP MED, V192, P719, DOI 10.1084/jem.192.5.719; Zhang SL, 1999, BIOCHEM BIOPH RES CO, V254, P440, DOI 10.1006/bbrc.1998.9959; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zirngibl R, 2001, EXP CELL RES, V266, P87, DOI 10.1006/excr.2001.5217	371	133	168	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2002	21	21					3314	3333		10.1038/sj.onc.1205317	http://dx.doi.org/10.1038/sj.onc.1205317			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	552RL	12032772				2022-12-17	WOS:000175633300007
J	Harley, CB				Harley, CB			Telomerase is not an oncogene	ONCOGENE			English	Article						telomere; telomerase; aging; cancer; immortalization; genetic instability	CATALYTIC SUBUNIT; REVERSE-TRANSCRIPTASE; LIFE-SPAN; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; RNA COMPONENT; CELLS; EXPRESSION; LENGTH; GENE	In the decade since the telomere hypothesis of cellular aging was proposed, the two essential genes for human telomerase were cloned and characterized, allowing experimental proof of the causal relationships between telomere loss and replicative senescence, and telomerase activation and immortalization. These relationships were established using a variety of cultured human cell types from both normal and tumor tissues, and were largely confirmed in the telomerase knockout mouse. Taken together, the data provide strong support for the potential utility of telomerase detection and inhibition for cancer, and telomerase activation for degenerative diseases. The specificity of the promoter for the telomerase catalytic gene and the antigenicity of the protein product, hTERT, provide additional strategies for killing telomerase-positive tumor cells. Unfortunately, the strong link between telomerase and cancer has led some to confuse telomerase activation with cancer, and others to overstate the cancer risk of telomerase activation therapies for degenerative diseases. This review clarifies the difference between telomerase, which does not cause growth deregulation, and oncogenes, which do. It also addresses the concept of telomerase repression as a tumor suppressor mechanism early in life, with detrimental tissue degeneration and tumor-promoting consequences late in life. This extended view of the telomere hypothesis helps explain how telomerase inhibition can be therapeutic in cancer patients, while controlled telomerase activation for degenerative diseases may actually reduce, rather than increase, the frequency of age-related tumorigenesis.	Geron Corp, Menlo Pk, CA 94025 USA	Geron Corporation	Harley, CB (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Pk, CA 94025 USA.	charley@geron.com						Amit M, 2000, DEV BIOL, V227, P271, DOI 10.1006/dbio.2000.9912; Bandyopadhyay D, 2001, EXP GERONTOL, V36, P1265, DOI 10.1016/S0531-5565(01)00098-5; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1989, ANNU REV GENET, V23, P163; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BRYAN TM, 1997, HUM MOL GENET, V6, P1; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Dessain SK, 2000, CANCER RES, V60, P537; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; Engelhardt M, 2000, CANCER RES, V60, P610; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Franco S, 2001, EXP CELL RES, V268, P14, DOI 10.1006/excr.2001.5264; Funk WD, 2000, EXP CELL RES, V258, P270, DOI 10.1006/excr.2000.4945; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Goytisolo FA, 2000, J EXP MED, V192, P1625, DOI 10.1084/jem.192.11.1625; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; Halvorsen TL, 2000, J ENDOCRINOL, V166, P103, DOI 10.1677/joe.0.1660103; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Herrera E, 1999, EMBO J, V18, P2950, DOI 10.1093/emboj/18.11.2950; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J IMMUNOL, V155, P3711; Hooijberg E, 2000, J IMMUNOL, V165, P4239, DOI 10.4049/jimmunol.165.8.4239; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Komata T, 2001, CANCER RES, V61, P5796; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; MacKenzie KL, 2000, EXP CELL RES, V259, P336, DOI 10.1006/excr.2000.4982; Majumdar AS, 2001, GENE THER, V8, P568, DOI 10.1038/sj.gt.3301421; Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197; McSharry BP, 2001, J GEN VIROL, V82, P855, DOI 10.1099/0022-1317-82-4-855; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Migliaccio M, 2000, J IMMUNOL, V165, P4978, DOI 10.4049/jimmunol.165.9.4978; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Mitchell JR, 2000, MOL CELL, V6, P361, DOI 10.1016/S1097-2765(00)00036-8; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; O'Hare MJ, 2001, P NATL ACAD SCI USA, V98, P646, DOI 10.1073/pnas.98.2.646; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Reynolds CP, 1997, EUR J CANCER, V33, P1929, DOI 10.1016/S0959-8049(97)00287-6; Rudolph KL, 2000, SCIENCE, V287, P1253, DOI 10.1126/science.287.5456.1253; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Salmon P, 2000, MOL THER, V2, P404, DOI 10.1006/mthe.2000.0141; Seigneurin-Venin S, 2000, BIOCHEM BIOPH RES CO, V272, P362, DOI 10.1006/bbrc.2000.2735; Seigneurin-Venin S, 2000, GENE THER, V7, P619, DOI 10.1038/sj.gt.3301132; Smith S, 2000, CURR BIOL, V10, P1299, DOI 10.1016/S0960-9822(00)00752-1; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Taylor RS, 1996, J INVEST DERMATOL, V106, P759, DOI 10.1111/1523-1747.ep12345811; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; Ulaner GA, 1997, MOL HUM REPROD, V3, P769, DOI 10.1093/molehr/3.9.769; Ulaner GA, 1998, CANCER RES, V58, P4168; Usselmann B, 2001, AM J GASTROENTEROL, V96, P1106; Vaziri H, 1999, ONCOGENE, V18, P7676, DOI 10.1038/sj.onc.1203016; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; VONZGLINICKI T, 2000, ANN NY ACAD SCI, P99; Vulliamy T, 2001, NATURE, V413, P432, DOI 10.1038/35096585; Weng NP, 1996, J EXP MED, V183, P2471, DOI 10.1084/jem.183.6.2471; Weng NP, 1997, P NATL ACAD SCI USA, V94, P10827, DOI 10.1073/pnas.94.20.10827; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wood LD, 2001, ONCOGENE, V20, P278, DOI 10.1038/sj.onc.1204072; Wright WE, 1996, DEV GENET, V18, P173; Wright WE, 2001, CURR OPIN GENET DEV, V11, P98, DOI 10.1016/S0959-437X(00)00163-5; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yudoh K, 2001, J BONE MINER RES, V16, P1453, DOI 10.1359/jbmr.2001.16.8.1453; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	84	133	151	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2002	21	4					494	502		10.1038/sj.onc.1205076	http://dx.doi.org/10.1038/sj.onc.1205076			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850774				2022-12-17	WOS:000173390500001
J	Seeler, JS; Dejean, A				Seeler, JS; Dejean, A			SUMO: of branched proteins and nuclear bodies	ONCOGENE			English	Article						SUMO/Sentrin; ubiquitin; PML; SP100; Ubc9	UBIQUITIN-LIKE PROTEIN; GTPASE-ACTIVATING PROTEIN; ACUTE PROMYELOCYTIC LEUKEMIA; COVALENT MODIFICATION; MODIFIER SUMO-1; PORE COMPLEX; UBC9 INTERACTS; GENE ENCODES; PML; CONJUGATION	SUMO belongs to a growing number of ubiquitin-like proteins that covalently modify their target proteins. Although some evidence supports a role of SUMO modification in regulating protein stability, most studied examples support a model by which SUMO alters the interaction properties of its targets, often affecting their subcellular localization behavior. Examination of the PML nuclear bodies, whose principal components are SUMO-modified, has revealed this modification to be essential for their structural and functional integrity. This and other examples thus support the view that SUMO regulates the stability not of individual proteins, but rather that of entire multiprotein complexes.	Inst Pasteur, INSERM U 163, Unite Recombust & Express Genet, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Dejean, A (corresponding author), Inst Pasteur, INSERM U 163, Unite Recombust & Express Genet, 28 Rue Dr Roux, F-75724 Paris 15, France.		Dejean, Anne/L-5145-2018	Seeler, Jacob-Sebastian/0000-0001-8209-8555				Adamson AL, 2001, J VIROL, V75, P2388, DOI 10.1128/JVI.75.5.2388-2399.2001; Ahn JH, 2001, J VIROL, V75, P3859, DOI 10.1128/JVI.75.8.3859-3872.2001; ALKHODAIRY F, 1995, J CELL SCI, V108, P475; Apionishev S, 2001, GENES CELLS, V6, P215, DOI 10.1046/j.1365-2443.2001.00413.x; Bayer P, 1998, J MOL BIOL, V280, P275, DOI 10.1006/jmbi.1998.1839; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Boddy MN, 1996, ONCOGENE, V13, P971; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Giorgino F, 2000, P NATL ACAD SCI USA, V97, P1125, DOI 10.1073/pnas.97.3.1125; Gong LM, 2000, J BIOL CHEM, V275, P14212, DOI 10.1074/jbc.275.19.14212; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; GOODSON ML, 2001, J BIOL CHEM, V15, P15; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Guldner HH, 1999, J CELL SCI, V112, P733; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawabe Y, 2000, J BIOL CHEM, V275, P20963, DOI 10.1074/jbc.C000273200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Lee GW, 1998, J BIOL CHEM, V273, P6503, DOI 10.1074/jbc.273.11.6503; Lehembre F, 2000, MOL CELL BIOL, V20, P1072, DOI 10.1128/MCB.20.3.1072-1082.2000; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Lehming N, 1998, P NATL ACAD SCI USA, V95, P7322, DOI 10.1073/pnas.95.13.7322; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; LOEB KR, 1992, J BIOL CHEM, V267, P7806; Long XM, 2000, J BIOL CHEM, V275, P40765, DOI 10.1074/jbc.M003949200; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Muller S, 1999, J VIROL, V73, P5137; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Okura T, 1996, J IMMUNOL, V157, P4277; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; RODRIGUEZ MS, 2000, J BIOL CHEM, V21, P21; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Schwienhorst I, 2000, MOL GEN GENET, V263, P771, DOI 10.1007/s004380000254; Seeler JS, 1998, P NATL ACAD SCI USA, V95, P7316, DOI 10.1073/pnas.95.13.7316; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Shen ZY, 1996, GENOMICS, V36, P271, DOI 10.1006/geno.1996.0462; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Suzuki T, 1999, J BIOL CHEM, V274, P31131, DOI 10.1074/jbc.274.44.31131; Takahashi Y, 1999, BIOCHEM BIOPH RES CO, V259, P582, DOI 10.1006/bbrc.1999.0821; Tanaka K, 1999, MOL CELL BIOL, V19, P8660; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	84	133	133	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 29	2001	20	49					7243	7249		10.1038/sj.onc.1204758	http://dx.doi.org/10.1038/sj.onc.1204758			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	487TM	11704852				2022-12-17	WOS:000171891900012
J	Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ				Hammond, DE; Urbe, S; Woude, GFV; Clague, MJ			Down-regulation of MET, the receptor for hepatocyte growth factor	ONCOGENE			English	Article						Met; hepatocyte growth factor; endocytosis; proteasome	LIGAND-INDUCED INTERNALIZATION; TYROSINE KINASE RECEPTOR; FACTOR SCATTER FACTOR; FACTOR BETA-RECEPTOR; UBIQUITIN; PROTEIN; DEGRADATION; ENDOCYTOSIS; POLYUBIQUITINATION; IDENTIFICATION	The ligand-dependent degradation of activated tyrosine kinase receptors provides a means by which mitogenic signalling can be attenuated. In many cell types the ligand-dependent degradation of the tyrosine kinase receptor Met is completely dependent on the activity of the 26S proteasome (Jeffers et al,, 1997b), We now show that degradation also requires trafficking to late endosomal compartments and the activity of acid dependent proteases as determined by the effects of a dominant negative form of dynamin (K44A) and a vacuolar-ATPase inhibitor, concanamycin, We show that in the presence of the proteasome inhibitor lactacystin, Met fails to redistribute from the plasma membrane to intracellular compartments. This observation is most consistent with the interpretation that proteasome activity is required for Met internalization and only indirectly for its degradation.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England; Van Andel Res Inst, Grand Rapids, MI 49503 USA	University of Liverpool; Van Andel Institute	Clague, MJ (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Clague, Michael J/A-7199-2008	Clague, Michael J/0000-0003-3355-9479; Hammond, Dean/0000-0002-6326-8739; Urbe, Sylvie/0000-0003-4735-9814				Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Di Fiore PP, 1999, CURR OPIN CELL BIOL, V11, P483, DOI 10.1016/S0955-0674(99)80069-6; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GIORDANO S, 1989, ONCOGENE, V4, P1383; Govers R, 1999, EMBO J, V18, P28, DOI 10.1093/emboj/18.1.28; Govers R, 1997, EMBO J, V16, P4851, DOI 10.1093/emboj/16.16.4851; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOU D, 1994, J BIOL CHEM, V269, P14244; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; MORI S, 1995, BIOCHEM BIOPH RES CO, V217, P224, DOI 10.1006/bbrc.1995.2767; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707	38	133	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2001	20	22					2761	2770		10.1038/sj.onc.1204475	http://dx.doi.org/10.1038/sj.onc.1204475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	432TP	11420688				2022-12-17	WOS:000168712000004
J	Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR				Zhang, ZT; Pak, J; Huang, HY; Shapiro, E; Sun, TT; Pellicer, A; Wu, XR			Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation	ONCOGENE			English	Article						urothelial carcinoma; progression pathways; Ha-ras oncogene; transgenic mice; uroplakin	TRANSITIONAL-CELL-CARCINOMA; HUMAN BLADDER-TUMORS; URINARY-BLADDER; TRANSGENIC MICE; IN-SITU; GENETIC ALTERATIONS; ONCOGENIC RAS; K-RAS; CANCER; EXPRESSION	Urothelial tumors develop along two distinctive phenotypic pathways (superficial papillary non-invasive tumors versus flat carcinoma in situ lesions), with markedly different biological behavior and prognosis. Although multiple genetic alterations have been identified in human bladder cancer, their cause-effect relationship with the two pathways has not been firmly established, Using a urothelium-specific promoter of the uroplakin TT gene, we showed earlier in transgenic mice that the urothelial expression of SV40T antigen, which inactivates p53 and pRb, induced carcinoma in situ and invasive and metastatic bladder cancer. In striking contrast, we demonstrate here that the urothelial expression of an activated Ha-ras in transgenic mice caused urothelial hyperplasia and superficial papillary non-invasive bladder tumors. These results provide strong, direct experimental evidence that the two phenotypical pathways of bladder tumorigenesis are caused by distinctive genetic defects, Our results indicate that Ha-ras activation can induce urothelial proliferation in vivo; and that urothelial hyperplasia is a precursor of low-grade, superficial papillary bladder tumors. Our transgenic models provide unique opportunities to study the detailed molecular events underlying different types of bladder neoplasms, and can serve as useful preclinical models for evaluating the in vivo efficacy of preventive and therapeutic agents that act on various signaling pathways in bladder cancer.	NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Dept Vet Affairs Med Ctr, New York, NY 10010 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, Dept Microbiol, New York, NY 10016 USA	New York University; New York University; New York University; New York University; New York University	Wu, XR (corresponding author), NYU, Sch Med, Dept Urol, 550 1st Ave,Room Skirball 10U, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015; Sun, Tung-Tien/J-4425-2015	Sun, Tung-Tien/0000-0002-6841-1063; Pellicer, Angel/0000-0002-5062-0692; Wu, Xue-Ru/0000-0001-6058-6291	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039753, R01DK056903, P01DK052206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56903, DK52769, DK52206, DK39753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Balazs M, 1997, GENE CHROMOSOME CANC, V19, P84, DOI 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.3.CO;2-U; Benedict WF, 1999, ONCOGENE, V18, P1197, DOI 10.1038/sj.onc.1202452; BOS JL, 1989, CANCER RES, V49, P4682; BRINSTER RL, 1981, CELL, V27, P223, DOI 10.1016/0092-8674(81)90376-7; BRINSTER RL, 1986, HARVEY LECT, V80, P1; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BURCHILL SA, 1994, BRIT J UROL, V73, P516, DOI 10.1111/j.1464-410X.1994.tb07636.x; BURCHILL SA, 1991, BR J CANCER S13, V63, P62; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Campbell SC, 1998, CANCER RES, V58, P1298; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Cordon-Cardo C, 1994, Important Adv Oncol, P71; COROMINAS M, 1991, ENVIRON HEALTH PERSP, V93, P19, DOI 10.2307/3431163; CZERNIAK B, 1992, HUM PATHOL, V23, P1199, DOI 10.1016/0046-8177(92)90285-B; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DUNN TL, 1988, J PATHOL, V156, P59, DOI 10.1002/path.1711560112; ENOMOTO T, 1990, CARCINOGENESIS, V11, P2233; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FITZGERALD JM, 1995, J NATL CANCER I, V87, P129, DOI 10.1093/jnci/87.2.129; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Grossman H B, 1996, Oncology (Williston Park), V10, P1617; KNOWLES MA, 1993, CANCER RES, V53, P133; KOSS LG, 1992, J CELL BIOCHEM, P23; KUNZE E, 1990, PATHOLOGY TUMOURS LA, V1, P345; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEVESQUE P, 1993, INT J CANCER, V55, P785, DOI 10.1002/ijc.2910550516; LIN JH, 1995, P NATL ACAD SCI USA, V92, P679, DOI 10.1073/pnas.92.3.679; MASUI T, 1993, TERATOGEN CARCIN MUT, V13, P225, DOI 10.1002/tcm.1770130504; MESSING EM, 1992, SEMIN SURG ONCOL, V8, P285, DOI 10.1002/ssu.2980080507; Ogawa K, 1998, MOL CARCINOGEN, V21, P70, DOI 10.1002/(SICI)1098-2744(199801)21:1<70::AID-MC9>3.0.CO;2-T; OHTANI M, 1986, CANCER RES, V46, P2001; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Orntoft TF, 1998, UROL RES, V26, P223, DOI 10.1007/s002400050050; OYASU R, 1995, FOOD CHEM TOXICOL, V33, P747, DOI 10.1016/0278-6915(95)00042-Z; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; RASSOULZADEGAN M, 1987, ONCOGENE RES, V1, P1; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; SAITO S, 1992, Keio Journal of Medicine, V41, P80; SANDGREN EP, 1989, ONCOGENE, V4, P715; SCHALKEN JA, 1992, SEMIN SURG ONCOL, V8, P274, DOI 10.1002/ssu.2980080505; SCHNEIDER BL, 1992, MOL CARCINOGEN, V6, P1, DOI 10.1002/mc.2940060102; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SPRUCK CH, 1994, CANCER RES, V54, P784; STEINBERG GD, 1992, UROL CLIN N AM, V19, P735; THEODORESCU D, 1990, P NATL ACAD SCI USA, V87, P9047, DOI 10.1073/pnas.87.22.9047; Vageli D, 1996, CANCER LETT, V107, P241, DOI 10.1016/0304-3835(96)04372-8; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; WAGNER U, 1995, HUM PATHOL, V26, P970, DOI 10.1016/0046-8177(95)90086-1; WALKER BE, 1960, AM J ANAT, V107, P95, DOI 10.1002/aja.1001070202; YAMAMOTO S, 1995, CARCINOGENESIS, V16, P2363, DOI 10.1093/carcin/16.10.2363; YE DW, 1993, UROL RES, V21, P39; Zhang ZT, 1999, CANCER RES, V59, P3512	56	133	137	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					1973	1980		10.1038/sj.onc.1204315	http://dx.doi.org/10.1038/sj.onc.1204315			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360181				2022-12-17	WOS:000168043800005
J	Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J				Foray, N; Randrianarison, V; Marot, D; Perricaudet, M; Lenoir, G; Feunteun, J			Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2	ONCOGENE			English	Article						BRCA1; BRCA2; DNA repair; radiation	DOUBLE-STRAND BREAKS; SUSCEPTIBILITY GENE BRCA2; ATAXIA-TELANGIECTASIA; CANCER-CELLS; REPAIR DEFICIENCY; CHROMOSOME-DAMAGE; CYCLE ARREST; DNA-REPAIR; P53; RADIATION	There is now evidence to suggest that BRCA1 and BRCA2 are involved in the response of cells to DNA damage and cell cycle checkpoint control. This report examines the death pathways of human cells with various BRCA1 and BRCA2 genotypes after exposure to gamma-rays, A lack of functional BRCA1 and BRCA2 led to defective repair of DNA double-strand breaks in irradiated cells. This impairment resulted in a relaxation of cell cycle checkpoints, production of micronuclei, and a loss of proliferative capacity, Heterozygous BRCA1 and BRCA2 mutations also led to enhanced radiosensitivity, with an impaired proliferative capacity after irradiation. The existence of a phenotype related to radiosensitivity in BRCA1(+/-) and BRCA2(+/-) cells raises the question of the response of heterozygous women to radiation.	Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS UMR 1582, Lab Vectorol & Transfert Genes, F-94805 Villejuif, France; Univ Lyon 1, CNRS UMR 5641, Lab Genet & Canc, F-69365 Lyon, France	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Feunteun, J (corresponding author), Inst Gustave Roussy, CNRS UMR 1599, Lab Genet Oncol, Rue Camille Desmoulins, F-94805 Villejuif, France.		Foray, Nicolas/I-4755-2018; Foray, Nicolas/Q-2363-2019; Feunteun, Jean/AAZ-1267-2020	Foray, Nicolas/0000-0002-1282-1303; Foray, Nicolas/0000-0002-1282-1303; Feunteun, Jean/0000-0003-1212-9189				Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978; BADIE C, 1995, CANCER RES, V55, P1232; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; Barboule N, 1997, ONCOGENE, V15, P2867, DOI 10.1038/sj.onc.1201469; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Chong J P, 1996, Prog Cell Cycle Res, V2, P83; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; DAMICO AV, 1994, RADIOTHER ONCOL, V33, P3, DOI 10.1016/0167-8140(94)90079-5; Davies MA, 1998, CANCER RES, V58, P5285; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; EVANS HH, 1993, RADIAT RES, V134, P307, DOI 10.2307/3578190; Fajac A, 1996, INT J CANCER, V68, P67, DOI 10.1002/(SICI)1097-0215(19960927)68:1<67::AID-IJC13>3.0.CO;2-3; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Foray N, 1996, RADIAT RES, V146, P53, DOI 10.2307/3579395; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Johnston PJ, 1997, MUTAT RES-DNA REPAIR, V385, P1, DOI 10.1016/S0921-8777(97)00034-7; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI CY, 1995, ONCOGENE, V11, P1885; LIN JY, 1995, ONCOGENE, V10, P2387; LIU N, 1993, MUTAGENESIS, V8, P503, DOI 10.1093/mutage/8.6.503; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Otto AM, 1996, J CANCER RES CLIN, V122, P603, DOI 10.1007/BF01221192; Paglin S, 1997, BIOCHEM BIOPH RES CO, V237, P678, DOI 10.1006/bbrc.1997.7117; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; SCOTT D, 1994, LANCET, V344, P1444, DOI 10.1016/S0140-6736(94)90615-7; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shiloh Yosef, 1998, Biochimica et Biophysica Acta, V1378, pR11, DOI 10.1016/S0304-419X(98)00020-1; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	133	134	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7334	7342		10.1038/sj.onc.1203165	http://dx.doi.org/10.1038/sj.onc.1203165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602489				2022-12-17	WOS:000084119400019
J	Kaneko, Y; Watanabe, N; Morisaki, H; Akita, H; Fujimoto, A; Tominaga, K; Terasawa, M; Tachibana, A; Ikeda, K; Nakanishi, M				Kaneko, Y; Watanabe, N; Morisaki, H; Akita, H; Fujimoto, A; Tominaga, K; Terasawa, M; Tachibana, A; Ikeda, K; Nakanishi, M			Cell cycle-dependent and ATM-independent expression of human Chk1 kinase	ONCOGENE			English	Article						chk1; checkpoint; DNA damage; ATM; cdc25; cell cycle	DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; S-PHASE; FEEDBACK CONTROLS; PROTEIN-KINASE; PATHWAY; GENE; REPLICATION	Checkpoint genes cause cell cycle arrest when DNA is damaged or DNA replication is blocked. Although a human homolog of Chk1 (hChk1) has recently been reported to be involved in the DNA damage checkpoint through phosphorylation of CaS25A, B, and C, it is not known at which phase(s) of the cell cycle hChk1 functions and how hChk1 causes cell cycle arrest in response to DNA damage. In the present study, we demonstrate that in normal human fibroblasts (MJ90), hChk1 is expressed specifically at the S to M phase of the cell cycle at both the RNA and protein levels and that it is localized to the nucleus at this time. hChk1 activity, as determined by phosphorylation of Cdc25C, is readily detected at the S to M phase of the cell cycle, and DNA damage induced by UV or ionizing radiation does not enhance the expression of hChk1 or its activity. Furthermore, hChk1 exists in an active form at the S to M phase in fibroblasts derived from patients with ataxia telangiectasia (AT) which lack the functional AT mutated (ATM) gene product, suggesting that hChk1 expression is independent of functional ATM, Taken together with the findings that phosphorylation of Cdc25C on serine 216 is increased at the S to M phase, it is suggested that at this particular phase of the cell cycle, even in the absence of DNA damage, hChk1 phosphorylates Cdc25C on serine 216, which is considered to be a prerequisite for the G2/M checkpoint. Thus, hChk1 may play an important role in keeping Cdc25C prepared for responding to DNA damage by phosphorylating its serine residue at 216 during the S to M phase.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; RIKEN, Tsukuba Life Sci Ctr, Gene Bank, Ibaraki, Osaka 3050074, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan	RIKEN; Kyoto University	Nakanishi, M (corresponding author), Nagoya City Univ, Sch Med, Dept Biochem, Mizuho Ku, Kawasumi 1,Mizuho Cho, Nagoya, Aichi 4678601, Japan.		Watanabe, Nobumoto/N-6959-2015; Tominaga, Kaoru/AAL-4250-2020	Watanabe, Nobumoto/0000-0002-2130-1334; Tominaga, Kaoru/0000-0001-8799-528X				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Carr AM, 1996, SCIENCE, V271, P314, DOI 10.1126/science.271.5247.314; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CUNLIFFE PN, 1975, BRIT J RADIOL, V48, P374, DOI 10.1259/0007-1285-48-569-374; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENOCH T, 1991, COLD SPRING HARB SYM, V56, P409; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; GATTI RA, 1991, MEDICINE, V70, P99, DOI 10.1097/00005792-199103000-00003; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HUMPHREY T, 1995, CURR BIOL, V5, P376, DOI 10.1016/S0960-9822(95)00077-7; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; LYNDALL D, 1995, SCIENCE, V270, P1488; MOCKINNON PJ, 1987, HUM GENET, V75, P197; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4532; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Stewart E, 1996, CURR OPIN CELL BIOL, V8, P781, DOI 10.1016/S0955-0674(96)80078-0; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450	38	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 24	1999	18	25					3673	3681		10.1038/sj.onc.1202706	http://dx.doi.org/10.1038/sj.onc.1202706			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211BN	10391675				2022-12-17	WOS:000081140200001
J	Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K				Suzuki, A; Tsutomi, Y; Miura, M; Akahane, K			Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21	ONCOGENE			English	Article						Fas; caspase 3; p21; ILP; serineproteinase	CELL-DEATH; ICE/CED-3 PROTEASE; INVOLVEMENT; INHIBITION; ACTIVATION; RECEPTOR; COMPLEX; KINASE; PCNA; CDK	The death mediator caspase acts as the dominant regulator during cell death induction. The CPP32 subfamily, including caspase 3 (CPP32/Yama/Apopain), is essential for the cell death signaling, We recently reported that activation of caspase 3 is regulated by complex formation with p21 or ILP, In the present study, we investigated the binding domain with p21 and ILP to further characterize the caspase 3 inactivation machinery, Our results show that caspase 3 contains p21 binding domain in the N-terminus and ILP binding domain in the active site, Further, the caspase 3 binding domain in p21 was independent of the Cdk- or PCNA-binding domain. We also found caspase 3 protection by p21 from the p3-site cleavage serineproteinase contributes to the suppression machinery. Here, we propose the caspase 3 inactivation system by p21 and ILP as new essential system in the regulation of cell death.	Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan; Osaka Univ, Sch Med, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 565, Japan; Daiichi Pharmaceut Co Ltd, New Prod Res Lab 4, Tokyo R&D Ctr, Edogawa Ku, Tokyo 134, Japan	Daiichi Sankyo Company Limited; Osaka University; Daiichi Sankyo Company Limited	Suzuki, A (corresponding author), Daiichi Pharmaceut Co Ltd, Drug Safety Res Lab, Tokyo R&D Ctr, Edogawa Ku, 16-13 Kitakasai 1 Chome, Tokyo 134, Japan.							Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Hasegawa J, 1996, CANCER RES, V56, P1713; LI Y, 1994, ONCOGENE, V9, P2261; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Suzuki A, 1997, EXP CELL RES, V233, P48, DOI 10.1006/excr.1997.3546; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; SUZUKI A, 1998, IN PRESS ONCOGENE; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747	23	133	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 4	1999	18	5					1239	1244		10.1038/sj.onc.1202409	http://dx.doi.org/10.1038/sj.onc.1202409			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022130				2022-12-17	WOS:000078510700013
J	Budde, A; Grummt, I				Budde, A; Grummt, I			p53 represses ribosomal gene transcription	ONCOGENE			English	Article						p53; RNA polymerase I; transcriptional repression; pre-rRNA synthesis	RNA-POLYMERASE-I; WILD-TYPE P53; DNA-BINDING; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; GROWTH ARREST; PROMOTER; SPACER; IDENTIFICATION; MUTATIONS	Induction of the tumor suppressor protein p53 restricts cellular proliferation. Since actively growing cells require the ongoing synthesis of ribosomal RNA to sustain cellular biosynthesis, we studied the effect of p53 on ribosomal gene transcription by RNA polymerase I (Pol I). We have measured rDNA transcriptional activity in different cell lines which either lack or overexpress p53 and demonstrate that wild-type but not mutant p53 inhibits cellular pre-rRNA synthesis. Conversely, pre-rRNA levels are elevated both in cells which express mutant p53 and in fibroblasts from p53 knock-out mice. Transient transfection assays with a set of rDNA deletion mutants demonstrate that intergenic spacer sequences are dispensable and the minimal rDNA promoter is sufficient for p53-mediated repression of Pol I transcription, However, in a cell-free transcription system, recombinant p53 does not inhibit rDNA transcription, indicating that p53 does not directly interfere with the basal Pol I transcriptional machinery. Thus, repression of Pol I transcription by p53 may be a consequence of p53-induced growth arrest.	Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Grummt, I (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Biol Cell 2, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRUMMT I, 1985, CELL, V43, P801, DOI 10.1016/0092-8674(85)90253-3; GRUMMT I, 1985, P NATL ACAD SCI USA, V82, P722, DOI 10.1073/pnas.82.3.722; GRUMMT I, 1998, IN PRESS PROG NUCL A; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HALEVY O, 1991, ONCOGENE, V6, P1593; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; KASS S, 1987, MOL CELL BIOL, V7, P2891, DOI 10.1128/MCB.7.8.2891; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUHN A, 1990, P NATL ACAD SCI USA, V87, P7527, DOI 10.1073/pnas.87.19.7527; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE HB, 1993, PSYCHOANAL QUART, V62, P651; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MICHELS S, 1990, LAB INVEST, V62, P67; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PAALMAN MH, 1995, MOL CELL BIOL, V15, P4648; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PFLEIDERER C, 1990, NUCLEIC ACIDS RES, V18, P4727, DOI 10.1093/nar/18.16.4727; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Staib C, 1996, VIROLOGY, V219, P237, DOI 10.1006/viro.1996.0241; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	133	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1119	1124		10.1038/sj.onc.1202402	http://dx.doi.org/10.1038/sj.onc.1202402			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023689				2022-12-17	WOS:000078510600030
J	Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB				Fukasawa, K; Wiener, F; VandeWoude, GF; Mai, SB			Genomic instability and apoptosis are frequent in p53 deficient young mice	ONCOGENE			English	Article						p53; genomic instability; gene amplification; centrosome; Myc; apoptosis	CELL-CYCLE CONTROL; WILD-TYPE P53; DIHYDROFOLATE-REDUCTASE GENE; C-MYC; CANCER-CELLS; AMPLIFICATION; OVEREXPRESSION; CHECKPOINT; ONCOGENES; MOUSE	The loss of p53 tumor suppressor functions results in genetic instability, characteristically associated with changes in chromosome ploidy and gene amplification. In vivo, we find that cells from various organs of 4 to 6-week old p53-nullizygous (p53 (-/-)) mice display aneuploidy and frequent gene amplification as well as evidence for apoptosis. Regardless of tissue types, many p53 (-/-) cells contain multiple centrosomes and abnormally formed mitotic spindles. Thus, chromosome vivo may be associated with abnormal Moreover, we observed a significant increase in the number of cells overexpressing c-Myc in p53 (-/-) mice. Consistent with previous studies showing that c-Myc overexpression is associated with gene amplification in vitro, many of the p53 (-/-) cells exhibited, in the same cell, c-Myc overexpression and amplified c-myc, dihydrofolate reductase (DHFR), and carbamoyl-phosphate synthetase-aspartate transcarbamoyl-dihydroorotase (CAD) genes. Furthermore, apoptosis was frequently observed in cells isolated from p53 (-/-) mice. The apoptotic cells contained abnormally amplified centrosomes, displayed aneuploidy, high levels of c-Myc expression, as web as gene amplification. These results indicate that a high number of aberrant cells is eliminated by p53-independent pathways in vivo.	MANITOBA CANC TREATMENT & RES FDN, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; UNIV CINCINNATI, COLL MED, DEPT CELL BIOL NEUROBIOL & ANAT, CINCINNATI, OH USA; KAROLINSKA INST, CTR MICROBIOL & TUMOR BIOL, S-17177 STOCKHOLM, SWEDEN	University of Manitoba; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; University System of Ohio; University of Cincinnati; Karolinska Institutet			Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; BISHOP JM, 1995, GENE DEV, V9, P1309, DOI 10.1101/gad.9.11.1309; BLYTH K, 1995, ONCOGENE, V10, P1717; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DENIS N, 1991, ONCOGENE, V6, P1453; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEO S, 1994, ONCOGENE, V9, P955; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hessel H, 1996, HISTOCHEM CELL BIOL, V106, P481, DOI 10.1007/s004180050067; HSU B, 1995, ONCOGENE, V11, P175; HUANG AP, 1994, ONCOGENE, V9, P491; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; KARN J, 1989, ONCOGENE, V4, P773; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KUSCHAK TI, 1997, UNPUB; LI X, 1995, CYTOMETRY, V20, P172, DOI 10.1002/cyto.990200210; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; MAI S, 1997, UNPUB; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oakley B R, 1992, Trends Cell Biol, V2, P1, DOI 10.1016/0962-8924(92)90125-7; ORREN DK, 1995, MOL CELL BIOL, V15, P3722; OTTO E, 1989, J BIOL CHEM, V264, P3390; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PIENTA KJ, 1989, CANCER RES, V49, P2525; RAGIMOV N, 1993, ONCOGENE, V8, P1183; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STARK G, 1993, ADV CANCER RES, V48, P87; STEWART N, 1995, ONCOGENE, V10, P109; TEMIN HM, 1988, CANCER RES, V48, P1697; VANDERBLIEK AM, 1986, MOL CELL BIOL, V6, P1671, DOI 10.1128/MCB.6.5.1671; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WAHL GM, 1989, CANCER RES, V49, P1333; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	49	133	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	1997	15	11					1295	1302		10.1038/sj.onc.1201482	http://dx.doi.org/10.1038/sj.onc.1201482			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XV845	9315097				2022-12-17	WOS:A1997XV84500007
J	Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ				Marhin, WW; Chen, SJ; Facchini, LM; Fornace, AJ; Penn, LZ			Myc represses the growth arrest gene gadd45	ONCOGENE			English	Article						gadd45; Myc; cell cycle; p53; growth arrest	HUMAN C-MYC; ENHANCER-BINDING-PROTEIN; DNA-DAMAGING AGENTS; CELL-CYCLE ARREST; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; ORNITHINE DECARBOXYLASE; MAMMALIAN-CELLS; IN-VIVO; EXPRESSION	The c-Myc protein strongly stimulates cellular proliferation, inducing cells to exit G0/G1 and enter the cell cycle. At a molecular level, Myc prevents growth arrest and drives cell cycle progression through the transcriptional regulation of Myc-target genes. Expression of the growth arrest and DNA damage inducible gene 45 (gadd45) is elevated in response to DNA damaging agents, such as ionizing radiation via a p53-dependent mechanism, upon nutrient deprivation, or during differentiation. Gadd35 holds a vital role in growth arrest as ectopic expression confers a strong block to proliferation. Exposure of quiescent cells to mitogen stimulates a rapid increase in c-Myc expression which is followed by the subsequent reduction in gadd45 expression. The kinetics of these two regulatory events suggest that Myc suppresses the expression of gadd45, contributing to G0/G1 phase exit of the cell cycle. Indeed, ectopic Myc expression in primary and immortalized fibroblasts results in the suppression of gadd45 mRNA levels, by a mechanism which is independent of cell cycle progression. Using an inducible MycER(TM) system, rapid suppression of gadd45 mRNA is first evident approximately 0.5 h following Myc activation. The reduction in gadd45 mRNA. expression occurs at the transcriptional level and is mediated by a p53-independent pathway. Moreover, Myc suppression and p53 induction of gadd45 following exposure to ionizing radiation are noncompetitive co-regulatory events. Myc suppression of gadd45 defines a novel pathway through which Myc promotes cell cycle entry and prevents growth arrest of transformed cells.	UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; ONTARIO CANC INST,TORONTO,ON M5G 2M9,CANADA; NCI,MOL PHARMACOL LAB,DIV BASIC SCI,NIH,BETHESDA,MD 20892	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Penn, Linda/0000-0001-8133-5459				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; CHEN IT, 1995, ONCOGENE, V11, P1931; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Constance CM, 1996, MOL CELL BIOL, V16, P3878; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEAN M, 1986, J BIOL CHEM, V261, P9161; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FREYTAG SO, 1990, CELL GROWTH DIFFER, V1, P339; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GARTE SJ, 1993, CRIT REV ONCOGENESIS, V4, P435; GAUBATZ S, 1995, EMBO J, V14, P1508, DOI 10.1002/j.1460-2075.1995.tb07137.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GUSTINCICH S, 1993, CELL GROWTH DIFFER, V4, P753; HALL PA, 1995, ONCOGENE, V10, P2427; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JACKMAN J, 1994, CANCER RES, V54, P5656; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG D, 1993, ONCOGENE, V8, P2805; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANIA L, 1980, VIROLOGY, V101, P217, DOI 10.1016/0042-6822(80)90497-3; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LUCAS JM, 1993, BIOCHEM BIOPH RES CO, V194, P1446, DOI 10.1006/bbrc.1993.1987; MARHIN MW, 1996, ONCOGENE, V12, P43; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARTIN KJ, 1991, BIOESSAYS, V13, P499, DOI 10.1002/bies.950131003; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Papathanasiou M A, 1991, Cancer Treat Res, V57, P13; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; Smith ML, 1996, MUTAT RES-REV GENET, V340, P109, DOI 10.1016/S0165-1110(96)90043-3; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Vairapandi M, 1996, ONCOGENE, V12, P2579; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WATERS CM, 1991, ONCOGENE, V6, P797; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	83	133	134	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2825	2834		10.1038/sj.onc.1201138	http://dx.doi.org/10.1038/sj.onc.1201138			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190899				2022-12-17	WOS:A1997XD64300011
J	Mukhopadhyay, T; Roth, JA				Mukhopadhyay, T; Roth, JA			Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol	ONCOGENE			English	Article						p53; lung cancer; apoptosis; methoxyestradiol; gene expression	TUMOR-SUPPRESSOR PROTEIN; BINDING-SITE; CYCLE; EXPRESSION; ESTROGEN; METABOLITE; CARCINOMA; GROWTH; DEATH; MCF-7	2-methoxyestradiol (2-MeOE(2)) treatment caused significant growth inhibition of H460 and A549 human lung cancer cell lines which contain wild-type p53, However, 2-MeOE(2) had a little effect on the p53 negative H358 and p53 mutated H322 cell lines, Western blot analysis indicated that 2-MeOE(2) treatment resulted in an eightfold increase in the endogenous wild-type p53 protein, while the level of the mutant p53 protein remained unchanged, TdT staining indicated that following 2-MeOE(2)-mediated increases in wildtype p53 protein, cells bypass the G(1)-S checkpoint of the cell cycle with 30 to 40% undergoing apoptosis. Introduction of anti-sense wt-p53 into wt-p53 cells abrogated the 2-MeOE(2) effect, A significant portion of lung cancer retains the wild-type p53 gene therefore, 2-MeOE(2) may have therapeutic application.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	Mukhopadhyay, T (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,SECT THORAC MOL ONCOL,DEPT THORAC & CARDIOVASC SURG,BOX 109,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIZUYOKOTA E, 1995, CANCER RES, V55, P1863; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; CANVER CC, 1994, J THORAC CARDIOV SUR, V108, P153; CUSHMAN M, 1995, J MED CHEM, V38, P2041, DOI 10.1021/jm00012a003; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; FUJIWARA T, 1994, CANCER RES, V54, P2287; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HERMEKING H, 1995, CELL BIOL INT, V19, P705; HURD C, 1995, J BIOL CHEM, V270, P28507, DOI 10.1074/jbc.270.48.28507; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOTTERING ML, 1992, CANCER RES, V52, P5926; MAXWELL SA, 1996, IN PRESS ELECTROPHOR; MILNER J, 1990, ONCOGENE, V5, P1683; MUKHOPADHYAY T, 1993, CANCER RES, V53, P4362; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; THOMPSON AM, 1990, BRIT J CANCER, V62, P78, DOI 10.1038/bjc.1990.233; TISHLER RB, 1995, CANCER RES, V55, P6021; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG TTY, 1995, CANCER RES, V55, P2487; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; Zamai L, 1996, CYTOMETRY, V23, P303, DOI 10.1002/(SICI)1097-0320(19960401)23:4<303::AID-CYTO6>3.3.CO;2-B	27	133	144	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					379	384		10.1038/sj.onc.1200835	http://dx.doi.org/10.1038/sj.onc.1200835			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018125				2022-12-17	WOS:A1997WD51600015
J	CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S				CHADENEAU, C; SIEGEL, P; HARLEY, CB; MULLER, WJ; BACCHETTI, S			TELOMERASE ACTIVITY IN NORMAL AND MALIGNANT MURINE TISSUES	ONCOGENE			English	Article						TELOMERASE; MAMMARY TUMORIGENESIS; MOUSE TISSUES; PROLIFERATIVE LIFE-SPAN	HUMAN FIBROBLASTS; SENESCENCE; IDENTIFICATION; CELLS; MOUSE; MICE	Telomere shortening may contribute to the limited lifespan of somatic cells and telomerase, the enzyme that elongates telomeric DNA and maintains telomere length, may be essential for unlimited cell proliferation irt vivo and in vitro. Telomerase is not expressed in most human somatic cells but is a nearly ubiquitous tumour marker, being activated in malignant cells from many cancers, Inhibition of telomerase may lead to telomere shortening and eventually limit the proliferative capacity of malignant cells and hence be of therapeutic value, With the intent of characterizing an animal model for inhibition studies, we investigated telomerase activity during mammary tumorigenesis in transgenic mice overexpressing the neu gene, We detected activity in primary mammary tumours and lung metastases but also in normal mammary glands and other organs, Activity Tvas elevated in tumors versus normal tissues and was enhanced by short-term culturing of normal cells, Telomerase activity was also present in somatic tissues from the non-transgenic parental strain and the outbred Mus spretus strain, As we recently detected telomerase activity in normal human hemopoietic tissues, mouse models of tumorigenesis may provide useful experimental systems for assessing the outcome of in vivo inhibition of telomerase in both malignant and normal cells.	MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8N 3Z5,CANADA; MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8N 3Z5,CANADA; GERON CORP,MENLO PK,CA 94025	McMaster University; McMaster University; Geron Corporation			Chadeneau, Corinne/AAT-6790-2021	Chadeneau, Corinne/0000-0001-8808-1738				ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BACCHETTI S, 1995, IN PRESS INT J ONC, V7; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; COUNTER CM, 1995, BLOOD, V9, P2315; COUNTER CM, 1994, EMBO J, V91, P2900; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HIRTE HW, 1994, CANCER, V74, P900, DOI 10.1002/1097-0142(19940801)74:3<900::AID-CNCR2820740317>3.0.CO;2-N; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NILSSON P, 1994, ONCOGENE, V9, P3043; NOWELL PC, 1986, CANCER RES, V46, P2203; OHTOSHI T, 1991, AM J RESP CELL MOL, V4, P255, DOI 10.1165/ajrcmb/4.3.255; OLOVNIKO.AM, 1971, DOKL AKAD NAUK SSSR+, V201, P1496; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	37	133	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 7	1995	11	5					893	898						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RU798	7675448				2022-12-17	WOS:A1995RU79800010
J	BERBERICH, SJ; POSTEL, EH				BERBERICH, SJ; POSTEL, EH			PUF/NM23-H2/NDPK-B TRANSACTIVATES A HUMAN C-MYC PROMOTER-CAT GENE VIA A FUNCTIONAL NUCLEASE HYPERSENSITIVE ELEMENT	ONCOGENE			English	Article						PUF; NM23; NDPK; C-MYC; NUCLEASE HYPERSENSITIVE METASTASIS	NUCLEOSIDE DIPHOSPHATE KINASE; REGULATORY ELEMENTS; CHROMATIN STRUCTURE; TUMOR-METASTASIS; LEUKEMIA-CELLS; RNA LEVELS; TRANSCRIPTION; BINDING; RIBONUCLEOPROTEIN; DIFFERENTIATION	We have isolated the transacting factor PuF that, through its interaction with a nuclease hypersensitive element (NHE) located upstream of the c-myc gene, transactivates the human c-myc gene in vitro (Postel et al., 1989). PuF was recently identified as being encoded by the nonmetastatic 23-H2 (nm23-H2)/nucleoside diphosphate kinase-B (NDPK-B) gene (Postel ct al., 1993). In addition to its ability to transactivate the c-myc gene in vitro, PuF/NDPK-B catalyzes the shuttling of gamma-phosphates between nucleoside triphosphates and diphosphates (Gilles et al., 1991; Postel and Ferrone, 1994) and has been postulated to suppress tumor metastasis (Stahl et al., 1991). Here we have extended our studies of PuF and c-myc transcription by testing whether PuF affects c-myc transcription using a transient transfection assay. A plasmid containing the human c-myc promoter-NHE region was cloned upstream of the bacterial chloramphenicol acetyltransferase (CAT) gene. When cotransfected with a PuF expression vector, CAT activity was elevated 3-4 fold relative to transfections containing the myc-CAT plasmid. In contrast, a myc-CAT reporter plasmid in which the NHE element was deleted showed no increase in CAT activity when cotransfected with the PuF expression vector. From these results we conclude that PuF transactivates the c-myc gene via the nuclease hypersensitive element.	PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University	BERBERICH, SJ (corresponding author), WRIGHT STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, DAYTON, OH 45435 USA.				NCI NIH HHS [R01CA5584] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCINAS M, 1994, ONCOGENE, V9, P2699; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DANG CV, 1991, BIOCHIM BIOPHYS ACTA, V1072, P103, DOI 10.1016/0304-419X(91)90009-A; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSSO LE, 1985, CANCER RES, V45, P5035; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; POSTEL EH, 1992, ANN NY ACAD SCI, V660, P57, DOI 10.1111/j.1749-6632.1992.tb21057.x; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POSTEL EH, 1994, J BIOL CHEM, V269, P8627; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAHL JA, 1991, CANCER RES, V51, P445; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	31	133	133	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	1995	10	12					2343	2347						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RE543	7784082				2022-12-17	WOS:A1995RE54300009
J	VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S				VIGON, I; FLORINDO, C; FICHELSON, S; GUENET, JL; MATTEI, MG; SOUYRI, M; COSMAN, D; GISSELBRECHT, S			CHARACTERIZATION OF THE MURINE MPL PROTOONCOGENE, A MEMBER OF THE HEMATOPOIETIC CYTOKINE RECEPTOR FAMILY - MOLECULAR-CLONING, CHROMOSOMAL LOCATION AND EVIDENCE FOR A FUNCTION IN CELL-GROWTH	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; MYELOPROLIFERATIVE LEUKEMIA-VIRUS; AFFINITY INTERLEUKIN-5 RECEPTOR; IL-6 SIGNAL TRANSDUCER; GM-CSF RECEPTOR; EXPRESSION CLONING; INHIBITORY FACTOR; BINDING-PROTEIN; ERYTHROPOIETIN RECEPTOR; PROGENITOR CELLS	The v-mpl oncogene transduced in the myeloproliferative leukemia virus (MPLV) encodes a truncated form of a putative receptor protein that belongs to the cytokine receptor superfamily. We previously reported the cloning of complete human c-MPL cDNA. In the present report, we show that the murine Mpl proto-oncogene is located at the D-band of murine chromosome 4, in a region in synteny with human chromosome 1p34, where MPL was previously located. RNA blot analysis of murine hematopoietic tissues and cells lines indicated that Mpl is expressed in immature hematopoietic precursor cells. Molecular cloning of murine proto-oncogene c-Mpl cDNAs is also reported. Two cDNA species were isolated. One potentially encodes a transmembrane protein. The extracellular domain of this protein has two repeats of the cytokine receptor domain common to all members of this receptor family. The cytoplasmic domain has no protein kinase or phosphatase motifs, but does contain a sequence that has been shown to be essential for the transmission of a growth signal in several other members of the family. Comparison of murine and human putative proteins indicated that they shared 81% amino acid identity, the most conserved region being the cytoplasmic domain (91% identity). The other Mpl cDNA clones potentially encode a soluble form of this receptor chain. A chimeric receptor containing the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor fused to the transmembrane and cytoplasmic domains of Mpl was able to induce G-CSF responsiveness when transfected into the interleukin 3 (IL-3)-dependent cell line BAF/BO3. This demonstrated that the cytoplasmic Mpl domain is most probably implicated in proliferative signal transduction.	IMMUNEX RES & DEV CORP,SEATTLE,WA 98101; INST PASTEUR,GENET MAMMIFERES LAB,F-75724 PARIS 15,FRANCE; HOP ENFANTS,GRP HOSP TIMONE,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	VIGON, I (corresponding author), HOP COCHIN,ICGM,INSERM,U363,27 RUE FAUBOURG ST JACQUES,F-75674 PARIS 14,FRANCE.		Souyri, Michele/L-5845-2017					BOUTIN JM, 1988, P NATL ACAD SCI USA, V88, P7744; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES SS, 1990, BLOOD, V76, P31; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; LECONIAT M, 1989, HUM GENET, V83, P194; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; NADEAU JH, 1986, GENETICS, V114, P1239; PALACIOS R, 1984, NATURE, V309, P126, DOI 10.1038/309126a0; RENAULD JC, 1992, P NATL ACAD SCI USA, V89, P5690, DOI 10.1073/pnas.89.12.5690; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TAKAKI S, 1991, EMBO J, V10, P2833, DOI 10.1002/j.1460-2075.1991.tb07832.x; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; WENDLING F, 1989, BLOOD, V73, P1161; WEYDERT A, 1992, CR ACAD SCI III-VIE, V314, P429; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	44	133	139	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2607	2615						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8397366				2022-12-17	WOS:A1993LX34300001
J	TORNALETTI, S; ROZEK, D; PFEIFER, GP				TORNALETTI, S; ROZEK, D; PFEIFER, GP			THE DISTRIBUTION OF UV PHOTOPRODUCTS ALONG THE HUMAN P53 GENE AND ITS RELATION TO MUTATIONS IN SKIN-CANCER	ONCOGENE			English	Article							SQUAMOUS-CELL CARCINOMAS; LIGATION-MEDIATED PCR; TUMOR SUPPRESSOR GENE; XERODERMA PIGMENTOSUM; ESCHERICHIA-COLI; N-RAS; METHYLATION ANALYSIS; PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; MAMMALIAN-CELLS	Mutations in the p53 gene have been found in a large proportion of human skin cancers. These mutations show the same characteristics as mutations induced by UV light in experimental systems. To establish correlations between formation of DNA adducts by a known carcinogen nd incidence of mutations within a specific human gene, we have investigated the formation of UV-induced photoproducts along exons 5-9 of the p53 gene after UV irradiation of human cells. The two major types of DNA photoproducts, cyclobutane pyrimidine dimers and pyrimidine (64) pyrimidone photoproducts [(6-4) photoproducts], were mapped at the DNA sequence level by strand cleavage at the sites of photoproducts. This was followed by ligation-mediated polymerase chain reaction (LMPCR) to amplify gene-specific fragments. In human skin cancers, mutations were most frequently found at codons 151/152, 245, 248, 278 and 286 of the p53 gene. The frequency of UV photoproducts is particularly high at codon 286, which is within a run of 12 adjacent pyrimidines. High levels of both photoproducts were also seen at codons 151 and 278. However, UV-induced DNA adducts are barely detectable at codons 245 and 248, which are mutation hotspots also for internal malignancies. At these positions, the frequency of photoproducts is much lower than at surrounding dipyrimidine sequences. These findings have some implications on molecular mechanisms of mutagenesis in the human genome.	CITY HOPE NATL MED CTR,BECKMAN RES INT,DEPT BIOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NIEHS NIH HHS [1RO1ES06070-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006070] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBINO AP, 1989, ONCOGENE, V4, P1363; ANATHASWAMY HN, 1990, PHOTOCHEM PHOTOBIOL, V52, P1119; ARMSTRONG JD, 1990, P NATL ACAD SCI USA, V87, P9005, DOI 10.1073/pnas.87.22.9005; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBACID M, 1990, EUR J CLIN INVEST, V20, P225, DOI 10.1111/j.1365-2362.1990.tb01848.x; BOURRE F, 1987, NUCLEIC ACIDS RES, V15, P8861, DOI 10.1093/nar/15.21.8861; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1988, PHOTOCHEM PHOTOBIOL, V48, P59; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; CHUMAKOV PM, 1991, GENBANK LOCUS HUMP53; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; GLICKMAN BW, 1986, P NATL ACAD SCI USA, V83, P6945, DOI 10.1073/pnas.83.18.6945; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HASELTINE WA, 1980, NATURE, V285, P634, DOI 10.1038/285634a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JONES PA, 1991, CANCER RES, V51, P3617; KEIJZER W, 1989, CANCER RES, V49, P1229; KRESS S, 1992, CANCER RES, V52, P6400; LIPPKE JA, 1981, P NATL ACAD SCI-BIOL, V78, P3388, DOI 10.1073/pnas.78.6.3388; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MILLER JH, 1985, J MOL BIOL, V182, P45, DOI 10.1016/0022-2836(85)90026-9; MITCHELL DL, 1990, NUCLEIC ACIDS RES, V18, P963, DOI 10.1093/nar/18.4.963; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; MOLES JP, 1993, ONCOGENE, V8, P583; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; Pfeifer G P, 1992, PCR Methods Appl, V2, P107; PFEIFER GP, 1992, MOL CELL BIOL, V12, P1798, DOI 10.1128/MCB.12.4.1798; PFEIFER GP, 1991, P NATL ACAD SCI USA, V88, P1374, DOI 10.1073/pnas.88.4.1374; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFEIFER GP, 1993, METHODS MOL BIOL SEL, P153; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P445, DOI 10.1002/mc.2940040606; RADY P, 1992, CANCER RES, V52, P3804; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SANCAR A, 1984, J BIOL CHEM, V259, P6028; SHUKLA VK, 1989, ONCOGENE RES, V5, P121; SUAREZ HG, 1989, CANCER RES, V49, P1223; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; TORMANEN VT, 1992, ONCOGENE, V7, P1729; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	54	133	134	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2051	2057						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336934				2022-12-17	WOS:A1993LP17100004
J	SAJJADI, FG; PASQUALE, EB				SAJJADI, FG; PASQUALE, EB			5 NOVEL AVIAN EPH-RELATED TYROSINE KINASES ARE DIFFERENTIALLY EXPRESSED	ONCOGENE			English	Article							GROWTH-FACTOR; PROTEIN-KINASES; RECEPTOR; GENE; FAMILY; IDENTIFICATION; ENCODES; OVEREXPRESSION; PP60C-SRC; ONCOGENE	We have identified cDNA clones that encode five new avian receptor-like tyrosine kinases of the Eph subclass, by screening two chicken embryonic cDNA libraries with DNA probes. We have designated them Cek6 to Cek10. The identification of these kinases indicates that the Eph subclass comprises at least 10 members and, therefore, represents a very large family of receptor-like tyrosine kinases. Variants of Cek10 and of Cek5 (a previously identified Eph-related kinase) containing amino acid insertion sequences in the juxtamembrane domain were also isolated. The Cek5 variant is expressed in the brain, but not in other tissues of the 10-day chick embryo. Analysis of 10-day chick embryo mRNAs shows the newly identified tyrosine kinases to be all expressed in both the embryonic brain and body tissues. In adult tissues, they display distinct patterns of expression. Cek6, Cek7, Cek8, Cek9 and Cek10 are likely to play significant roles in embryonic signal transduction pathways, including those involved in neural development. Their distinct tissue distributions in the adult suggest that the different members of the Eph family may each serve specific functions.	LA JOLLA CANC RES FDN,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NICHD NIH HHS [HD26351] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026351, R29HD026351] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHAN J, 1991, ONCOGENE, V6, P1057; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KRAMER H, 1991, NATURE, V352, P207, DOI 10.1038/352207a0; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MARU Y, 1990, ONCOGENE, V5, P445; MERCOLA M, 1988, DEVELOPMENT, V102, P451; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SAJJADI FG, 1991, NEW BIOL, V3, P769; Sambrook J., 1989, MOL CLONING LAB MANU; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	35	133	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1807	1813						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	8510926				2022-12-17	WOS:A1993LG68200012
J	NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S				NAKAGOSHI, H; KANEIISHII, C; SAWAZAKI, T; MIZUGUCHI, G; ISHII, S			TRANSCRIPTIONAL ACTIVATION OF THE C-MYC GENE BY THE C-MYB AND B-MYB GENE-PRODUCTS	ONCOGENE			English	Article							RNA INHIBITS PROLIFERATION; DNA-BINDING ACTIVITY; V-MYB; PROTO-ONCOGENE; OLIGOMER COMPLEMENTARY; NUCLEOTIDE-SEQUENCE; CELLULAR PROGENITOR; MYELOID-LEUKEMIA; EXPRESSION; CELLS	To identify the target genes modulated by the myb gene product (Myb), a co-transfection assay with a Myb expression plasmid was performed. Both c-Myb and B-Myb, another member of the myb gene family, trans-activated the human c-myc promoter. DNAase I footprint analysis using the bacterially expressed c-Myb, identified multiple c-Myb binding sites in the c-myc promoter region. Deletion analysis of the c-myc promoter suggested that some number of Myb binding sites, not a specific Myb binding site, is important for the c-Myb-induced trans-activation of the c-myc promoter. Using the c-myc-chloramphenicol acetyltransferase (CAT) construct as a reporter in a co-transfection assay, the domains of c-Myb required for trans-activation were examined. The functional domains of c-Myb identified using the c-myc promoter were almost the same as those identified previously with the artificial target gene containing Myb binding sites, but unlike the case with the artificial target gene the N-terminal half of the previously identified negative regulatory domains and the C-terminal 136 amino acids were required for the maximal trans-activation of the c-myc promoter. These results indicate that there are some differences in the regulation of Myb-dependent trans-activation in different target genes.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC GENET LAB,TSUKUBA,IBARAKI 305,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; SCI UNIV TOKYO,DEPT PHARMACEUT SCI,SHINJUKU KU,TOKYO 162,JAPAN	RIKEN; Osaka University; Tokyo University of Science			NAKAGOSHI, Hideki/B-2145-2011; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; GEARWIRTZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, NATURE, V312, P280, DOI 10.1038/312280a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NAGASE T, 1990, GENE, V94, P249, DOI 10.1016/0378-1119(90)90395-8; NAKAGOSHI H, 1989, NUCLEIC ACIDS RES, V17, P7315, DOI 10.1093/nar/17.18.7315; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ONCLERCQ R, 1988, J VIROL, V62, P4533, DOI 10.1128/JVI.62.12.4533-4537.1988; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; TAYA Y, 1984, EMBO J, V3, P2943, DOI 10.1002/j.1460-2075.1984.tb02236.x; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANG BS, 1991, MOL CELL BIOL, V11, P2291, DOI 10.1128/MCB.11.4.2291; ZOBEL A, 1991, ONCOGENE, V6, P1397	47	133	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1233	1240						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594249				2022-12-17	WOS:A1992HU64200022
J	Calabretta, S; Bielli, P; Passacantilli, I; Pilozzi, E; Fendrich, V; Capurso, G; Delle Fave, G; Sette, C				Calabretta, S.; Bielli, P.; Passacantilli, I.; Pilozzi, E.; Fendrich, V.; Capurso, G.; Delle Fave, G.; Sette, C.			Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells	ONCOGENE			English	Article							PYRUVATE-KINASE; EMERGING ROLE; RNA; APOPTOSIS; M2; TRANSCRIPTION; ACTIVATION; PATHWAYS; REVEALS; ISOFORM	Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and incurable disease. Poor prognosis is due to multiple reasons, including acquisition of resistance to gemcitabine, the first-line chemotherapeutic approach. Thus, there is a strong need for novel therapies, targeting more directly the molecular aberrations of this disease. We found that chronic exposure of PDAC cells to gemcitabine selected a subpopulation of cells that are drug-resistant (DR-PDAC cells). Importantly, alternative splicing (AS) of the pyruvate kinase gene (PKM) was differentially modulated in DR-PDAC cells, resulting in promotion of the cancer-related PKM2 isoform, whose high expression also correlated with shorter recurrence-free survival in PDAC patients. Switching PKM splicing by antisense oligonucleotides to favor the alternative PKM1 variant rescued sensitivity of DR-PDAC cells to gemcitabine and cisplatin, suggesting that PKM2 expression is required to withstand drug-induced genotoxic stress. Mechanistically, upregulation of the polypyrimidine-tract binding protein (PTBP1), a key modulator of PKM splicing, correlated with PKM2 expression in DR-PDAC cell lines. PTBP1 was recruited more efficiently to PKM pre-mRNA in DR-than in parental PDAC cells. Accordingly, knockdown of PTBP1 in DR-PDAC cells reduced its recruitment to the PKM pre-mRNA, promoted splicing of the PKM1 variant and abolished drug resistance. Thus, chronic exposure to gemcitabine leads to upregulation of PTBP1 and modulation of PKM AS in PDAC cells, conferring resistance to the drug. These findings point to PKM2 and PTBP1 as new potential therapeutic targets to improve response of PDAC to chemotherapy.	[Calabretta, S.; Passacantilli, I.; Sette, C.] Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy; [Calabretta, S.; Passacantilli, I.; Capurso, G.; Delle Fave, G.] Univ Roma La Sapienza, Dept Sci Med Chirurg & Translat Med, Via Grottarossa, I-00189 Rome, Italy; [Bielli, P.; Sette, C.] Fdn Santa Lucia, Lab Neuroembryol, Rome, Italy; [Pilozzi, E.] Univ Roma La Sapienza, Dept Clin & Mol Med, Piazzale Aldo Moro 5, I-00185 Rome, Italy; [Fendrich, V.] Univ Marburg, Dept Surg, Marburg, Germany	University of Rome Tor Vergata; Sapienza University Rome; IRCCS Santa Lucia; Sapienza University Rome; Philipps University Marburg	Sette, C (corresponding author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Via Montpellier 1, I-00133 Rome, Italy.; Delle Fave, G (corresponding author), Univ Roma La Sapienza, Dept Sci Med Chirurg & Translat Med, Via Grottarossa, I-00189 Rome, Italy.	gianfranco.dellefave@uniroma1.it; claudio.sette@uniroma2.it	PILOZZI, Emanuela/AAC-1854-2022; Sette, Claudio/S-4307-2019; Capurso, Gabriele/AAB-1389-2019; Bielli, Pamela/K-1208-2018	PILOZZI, Emanuela/0000-0002-7110-9172; Sette, Claudio/0000-0003-2864-8266; Capurso, Gabriele/0000-0002-0019-8753; Bielli, Pamela/0000-0003-3347-8345	Association for International Cancer Research (AICR) [12-0150]; Associazione Italiana Ricerca sul Cancro (AIRC) [14581]; Fondazione Santa Lucia Ricerca Corrente; Worldwide Cancer Research [12-0150] Funding Source: researchfish	Association for International Cancer Research (AICR); Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Santa Lucia Ricerca Corrente; Worldwide Cancer Research	We thank Andrea D'Ascenzo and Enrico Duranti for help with immunohistochemistry; Dr Chiara Naro for helpful suggestions throughout the study; and Dr Vittoria Pagliarini for critical reading of the manuscript. This work was supported by Association for International Cancer Research (AICR) (grant 12-0150), Associazione Italiana Ricerca sul Cancro (AIRC) (grant 14581) and Fondazione Santa Lucia Ricerca Corrente.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Amin EM, 2011, CANCER CELL, V20, P768, DOI 10.1016/j.ccr.2011.10.016; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Bielli P, 2014, NUCLEIC ACIDS RES, V42, P12070, DOI 10.1093/nar/gku922; Bielli P, 2014, EMBO REP, V15, P419, DOI 10.1002/embr.201338241; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bonomi Serena, 2013, Int J Cell Biol, V2013, P962038, DOI 10.1155/2013/962038; Braunschweig U, 2013, CELL, V152, P1252, DOI 10.1016/j.cell.2013.02.034; Busa R, 2010, NUCLEIC ACIDS RES, V38, P3005, DOI 10.1093/nar/gkq004; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Cerwenka H, 1999, ANTICANCER RES, V19, P849; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Cooper TA, 2009, CELL, V136, P777, DOI 10.1016/j.cell.2009.02.011; Costello BA, 2014, INVEST NEW DRUG, V32, P710, DOI 10.1007/s10637-014-0096-3; David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Dutertre M, 2011, RNA BIOL, V8, P740, DOI 10.4161/rna.8.5.16016; Goldberg MS, 2012, J EXP MED, V209, P217, DOI 10.1084/jem.20111487; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hayes GM, 2007, CANCER RES, V67, P2072, DOI 10.1158/0008-5472.CAN-06-2969; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jiang YH, 2014, MOL CELL, V53, P75, DOI 10.1016/j.molcel.2013.11.001; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kole R, 2012, NAT REV DRUG DISCOV, V11, P125, DOI 10.1038/nrd3625; Llorian M, 2010, NAT STRUCT MOL BIOL, V17, P1114, DOI 10.1038/nsmb.1881; Maimon A, 2014, CELL REP, V7, P501, DOI 10.1016/j.celrep.2014.03.041; Mercatante DR, 2002, J BIOL CHEM, V277, P49374, DOI 10.1074/jbc.M209236200; Michl P, 2013, GUT, V62, P317, DOI 10.1136/gutjnl-2012-303588; Nakajima S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084899; Naro Chiara, 2013, Int J Cell Biol, V2013, P151839, DOI 10.1155/2013/151839; Omenn GS, 2010, DIS MARKERS, V28, P241, DOI [10.1155/2010/705847, 10.3233/DMA-2010-0702]; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Paronetto MP, 2007, J CELL BIOL, V176, P929, DOI 10.1083/jcb.200701005; Paronetto MP, 2010, CANCER RES, V70, P229, DOI 10.1158/0008-5472.CAN-09-2788; Proussakova OV, 2003, J BIOL CHEM, V278, P36236, DOI 10.1074/jbc.M305896200; Sawa H, 1998, ONCOGENE, V16, P1701, DOI 10.1038/sj.onc.1201691; Sette Claudio, 2013, Int J Cell Biol, V2013, P421606, DOI 10.1155/2013/421606; Shi HS, 2010, CANCER SCI, V101, P1447, DOI 10.1111/j.1349-7006.2010.01562.x; Shultz JC, 2011, MOL CANCER RES, V9, P889, DOI 10.1158/1541-7786.MCR-11-0061; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Tamada M, 2012, CLIN CANCER RES, V18, P5554, DOI 10.1158/1078-0432.CCR-12-0859; Tang SC, 2014, WORLD J GASTROENTERO, V20, P10825, DOI 10.3748/wjg.v20.i31.10825; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ZX, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120133; Xue YC, 2009, MOL CELL, V36, P996, DOI 10.1016/j.molcel.2009.12.003; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Zhang J, 2013, CANCER DISCOV, V3, P1228, DOI 10.1158/2159-8290.CD-13-0253; Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581	50	132	133	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2016	35	16					2031	2039		10.1038/onc.2015.270	http://dx.doi.org/10.1038/onc.2015.270			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ9AH	26234680	Green Published, Green Accepted			2022-12-17	WOS:000374505600003
J	Suzuki, HI; Katsura, A; Matsuyama, H; Miyazono, K				Suzuki, H. I.; Katsura, A.; Matsuyama, H.; Miyazono, K.			MicroRNA regulons in tumor microenvironment	ONCOGENE			English	Review							CANCER-ASSOCIATED FIBROBLASTS; BREAST-CANCER; SUPPRESSOR-CELLS; GENE-EXPRESSION; MESSENGER-RNAS; METASTASIS; MIRNA; HYPOXIA; MACROPHAGES; DISTINCT	Cancer initiation and progression are defined by the behavior of cancer cells per se and the development of tumor tissues, both of which are modulated by crosstalk between cancer cells and the surrounding microenvironment. Advances in cancer research have highlighted the significance of constant evolution of the tumor microenvironment, leading to tumor formation, metastasis and refractoriness to therapy. MicroRNAs (miRNAs) are small non-coding RNAs that function as major players of posttranscriptional gene regulation in diverse biological processes. They function as both tumor suppressors and promoters in many aspects of the autonomous behavior of cancer cells. Theoretically, dysfunction in the gene regulatory networks of cancer cells is one of the major driving forces for alterations of ostensibly normal surrounding cells. In this context, the core targets of miRNAs, termed miRNA regulons, are currently being expanded to include various modulators of the tumor microenvironment. Recent advances have highlighted two important roles played by miRNAs in the evolution of tumor microenvironments: miRNAs in tumor cells transform the microenvironment via non-cell-autonomous mechanisms, and miRNAs in neighboring cells stabilize cancer hallmark traits. These observations epitomize the distal and proximal functions of miRNAs in tumor microenvironments, respectively. Such regulation by miRNAs affects tumor angiogenesis, immune invasion and tumor-stromal interactions. This review summarizes recent findings on the mechanisms of miRNA-mediated regulation of tumor microenvironments, with a perspective on the design of therapeutic interventions.	[Suzuki, H. I.; Katsura, A.; Matsuyama, H.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Tokyo 1130033, Japan	University of Tokyo	Miyazono, K (corresponding author), Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono@m.u-tokyo.ac.jp		Suzuki, Hiroshi/0000-0003-4682-5086	MEXT of Japan [24689018, 23112702, 22112002]; Cell Science Research Foundation; JSPS Postdoctoral Fellowship for Research Abroad; Grants-in-Aid for Scientific Research [22112002] Funding Source: KAKEN	MEXT of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); JSPS Postdoctoral Fellowship for Research Abroad(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank members of the Department of Molecular Pathology, the University of Tokyo, Tokyo, Japan. This work was supported by KAKENHI (Grants-in-Aid for Young Scientists (A) (No. 24689018, to HIS) and for Scientific Research on Innovative Areas 'RNA regulation' (No. 23112702, to HIS) and 'Integrative research on cancer microenvironment network' (No. 22112002, to KM)) from the MEXT of Japan, the Cell Science Research Foundation and JSPS Postdoctoral Fellowship for Research Abroad. We apologize to colleagues whose work was not cited because of space limitations.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; Aprelikova O, 2013, ONCOGENE, V32, P3246, DOI 10.1038/onc.2012.351; Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674; Aucher A, 2013, J IMMUNOL, V191, P6250, DOI 10.4049/jimmunol.1301728; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Ben-Moshe NB, 2012, NUCLEIC ACIDS RES, V40, P10614, DOI 10.1093/nar/gks841; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Cai X, 2012, J MOL CELL BIOL, V4, P341, DOI 10.1093/jmcb/mjs044; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Carroll AP, 2013, J MOL CELL BIOL, V5, P73, DOI 10.1093/jmcb/mjt004; Ceppi P, 2014, ONCOGENE, V33, P269, DOI 10.1038/onc.2013.55; Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790; Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672; Cirri P, 2011, AM J CANCER RES, V1, P482; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Cubillos-Ruiz JR, 2012, CANCER RES, V72, P1683, DOI 10.1158/0008-5472.CAN-11-3160; Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025; Dangi-Garimella S, 2011, ONCOGENE, V30, P1002, DOI 10.1038/onc.2010.485; Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Gould SJ, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20389; Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hasebe T, 2010, HUM PATHOL, V41, P262, DOI 10.1016/j.humpath.2009.07.021; HE L, 2004, NAT REV GENET, V5, P522; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Huang JC, 2007, NAT METHODS, V4, P1045, DOI 10.1038/nmeth1130; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Ishimoto T, 2014, CARCINOGENESIS, V35, P1003, DOI 10.1093/carcin/bgt402; Ivan M, 2014, ADV EXP MED BIOL, V772, P205, DOI 10.1007/978-1-4614-5915-6_10; Jafarifar F, 2011, EMBO J, V30, P1324, DOI 10.1038/emboj.2011.38; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kosaka N, 2013, J BIOL CHEM, V288, P10849, DOI 10.1074/jbc.M112.446831; Kosaka Nobuyoshi, 2012, Frontiers in Genetics, V2, P97, DOI 10.3389/fgene.2011.00097; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Kroh EM, 2010, METHODS, V50, P298, DOI 10.1016/j.ymeth.2010.01.032; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Li LM, 2014, J IMMUNOL, V192, P1034, DOI 10.4049/jimmunol.1301309; Li XL, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/762183; Lin CW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2876; Liu B, 2010, BIOINFORMATICS, V26, P3105, DOI 10.1093/bioinformatics/btq576; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Loayza-Puch F, 2010, ONCOGENE, V29, P2638, DOI 10.1038/onc.2010.23; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Movahedi K, 2008, BLOOD, V111, P4233, DOI 10.1182/blood-2007-07-099226; Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867; Muramatsu F, 2013, ONCOGENE, V32, P414, DOI 10.1038/onc.2012.68; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Nouraee N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073009; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Sempere LF, 2011, EXPERT REV MOL DIAGN, V11, P813, DOI [10.1586/ERM.11.69, 10.1586/erm.11.69]; Sempere LF, 2010, CLIN CANCER RES, V16, P4246, DOI 10.1158/1078-0432.CCR-10-1152; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shen GM, 2013, ACTA PHARMACOL SIN, V34, P336, DOI 10.1038/aps.2012.195; Squadrito ML, 2013, TRENDS IMMUNOL, V34, P350, DOI 10.1016/j.it.2013.02.003; Squadrito ML, 2012, CELL REPORTS, V1, P141, DOI 10.1016/j.celrep.2011.12.005; Sugihara H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081839; Suzuki HI, 2013, LEUKEMIA, V27, P2107, DOI 10.1038/leu.2013.121; Suzuki HI, 2012, ENZYMES, V32, P163, DOI 10.1016/B978-0-12-404741-9.00008-8; Suzuki HI, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1439; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2010, J MOL MED, V88, P1085, DOI 10.1007/s00109-010-0650-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; Turchinovich A., 2013, Frontiers in Genetics, V4, P119, DOI 10.3389/fgene.2013.00119; Ulitsky I, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq570; Vader P, 2014, TRENDS MOL MED, V20, P385, DOI 10.1016/j.molmed.2014.03.002; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; van Hamburg JP, 2009, ARTHRITIS RHEUM-US, V60, P750, DOI 10.1002/art.24329; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wei J, 2013, CANCER RES, V73, P3913, DOI 10.1158/0008-5472.CAN-12-4318; Wentz-Hunter KK., 2011, MOL BIOL INT, V2011, P839872, DOI [DOI 10.4061/2011/839872, 10.4061/2011/839872]; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840; Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107; Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610; Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989; Zhang Y, 2014, TRENDS CELL BIOL, V24, P153, DOI 10.1016/j.tcb.2013.09.007; Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690	115	132	141	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2015	34	24					3085	3094		10.1038/onc.2014.254	http://dx.doi.org/10.1038/onc.2014.254			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK3FD	25132266	Green Published, hybrid			2022-12-17	WOS:000356101100001
J	Suh, Y; Yoon, CH; Kim, RK; Lim, EJ; Oh, YS; Hwang, SG; An, S; Yoon, G; Gye, MC; Yi, JM; Kim, MJ; Lee, SJ				Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Oh, Y. S.; Hwang, S-G; An, S.; Yoon, G.; Gye, M. C.; Yi, J-M; Kim, M-J; Lee, S-J			Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells	ONCOGENE			English	Article						Claudin-1; epithelial-mesenchymal transition; ERK signaling	HUMAN HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; BREAST-CANCER; TIGHT JUNCTIONS; REDUCED EXPRESSION; METASTASIS; INVASION; GROWTH; GENE; FAMILY	Claudins (CLDNs) are a family of integral membrane proteins central to the formation of tight junctions, structures that are involved in paracellular transport and cellular growth and differentiation, and are critical for the maintenance of cellular polarity. Recent studies have provided evidence that CLDNs are aberrantly expressed in diverse types of human cancers, including hepatocellular carcinomas (HCCs). However, little is known about how CLDN expression is involved in cancer progression. In this study, we show that CLDN1 has a causal role in the epithelial-mesenchymal transition (EMT) in human liver cells, and that the c-Abl-Ras-Raf-1-ERK1/ 2 signaling axis is critical for the induction of malignant progression by CLDN1. Overexpression of CLDN1 induced expression of the EMT-regulating transcription factors Slug and Zeb1, and thereby led to repression of E-cadherin, b-catenin expression, enhanced expression of N-cadherin and Vimentin, a loss of cell adhesion, and increased cell motility in normal liver cells and HCC cells. In line with these findings, inhibition of either c-Abl or ERK clearly attenuated CLDN1-induced EMT, as evidenced by a reversal of N-cadherin and E-cadherin expression patterns, and restored normal motility. Collectively, these results indicate that CLDN1 is necessary for the induction of EMT in human liver cells, and that activation of the c-Abl-Ras-Raf-1-ERK1/ 2 signaling pathway is required for CLDN1-induced acquisition of the malignant phenotype. The present observations suggest that CLDN1 could be exploited as a biomarker for liver cancer metastasis and might provide a pivotal point for therapeutic intervention in HCC.	[Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Dept Chem, Seoul 133791, South Korea; [Oh, Y. S.; Gye, M. C.] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 133791, South Korea; [Hwang, S-G; Kim, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Yoon, G.] Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 441749, South Korea; [Yi, J-M] Dongnam Inst Radiol & Med Sci, Res Ctr, Pusan, South Korea	Hanyang University; Hanyang University; Korea Institute of Radiological & Medical Sciences; Konkuk University; Ajou University; Korea Institute of Radiological & Medical Sciences	Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Chem, Lab Mol Biochem, 17 Haengdang Dong, Seoul 133791, South Korea.	sj0420@hanyang.ac.kr	Yoon, Changhwan/AAK-7842-2021	Yoon, Changhwan/0000-0002-8420-9818; Gye, Myung Chan/0000-0001-5682-3709	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST); Korean government, through its National Nuclear Technology Program [2012M2A2A7035878]; Converging Research Center Program [2011K000877]; Ministry of Education, Science and Technology	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean government, through its National Nuclear Technology Program(Korean Government); Converging Research Center Program; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Research Foundation (NRF) and Ministry of Education, Science and Technology (MEST), Korean government, through its National Nuclear Technology Program (2012M2A2A7035878) and Converging Research Center Program Grant (2011K000877) funded by the Ministry of Education, Science and Technology.	Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Balda MS, 2008, J CELL SCI, V121, P3677, DOI 10.1242/jcs.023887; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Brennan K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/460607; Cheung ST, 2005, CLIN CANCER RES, V11, P551; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Kummar S, 2003, CLIN ONCOL-UK, V15, P288, DOI 10.1016/S0936-6555(03)00067-0; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Michl P, 2003, CANCER RES, V63, P6265; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mullin JM, 1997, J EXP ZOOL, V279, P484, DOI 10.1002/(SICI)1097-010X(19971201)279:5<484::AID-JEZ11>3.0.CO;2-8; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Oshima T, 2008, ONCOL REP, V19, P953; Palacios J, 2003, MODERN PATHOL, V16, P674, DOI 10.1097/01.MP.0000073974.42583.F7; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; REN J, 1990, CANCER RES, V50, P358; Roberts LR, 2008, NEW ENGL J MED, V359, P420, DOI 10.1056/NEJMe0802241; Sakaguchi T, 2008, J SURG RES, V147, P123, DOI 10.1016/j.jss.2007.07.013; Si SH, 2004, WORLD J GASTROENTERO, V10, P2019, DOI 10.3748/wjg.v10.i14.2019; Silberman I, 2008, CELL CYCLE, V7, P3847, DOI 10.4161/cc.7.24.7267; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Suzuki J, 2007, J BIOCHEM, V141, P453, DOI 10.1093/jb/mvm059; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Wels C, 2011, J INVEST DERMATOL, V131, P1877, DOI 10.1038/jid.2011.142; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	47	132	138	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4873	4882		10.1038/onc.2012.505	http://dx.doi.org/10.1038/onc.2012.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160379	Bronze			2022-12-17	WOS:000325717800003
J	Bastid, J; Cottalorda-Regairaz, A; Alberici, G; Bonnefoy, N; Eliaou, JF; Bensussan, A				Bastid, J.; Cottalorda-Regairaz, A.; Alberici, G.; Bonnefoy, N.; Eliaou, J-F; Bensussan, A.			ENTPD1/CD39 is a promising therapeutic target in oncology	ONCOGENE			English	Review						regulatory T cells; immunotherapy; antibody	REGULATORY T-CELLS; ADENOSINE-MEDIATED INHIBITION; LOW-DOSE CYCLOPHOSPHAMIDE; SYNERGISTIC UP-REGULATION; A(2A) RECEPTOR AGONISTS; IN-VIVO EXPANSION; EXTRACELLULAR ATP; CAUSES REGRESSION; IMMUNE-RESPONSES; CD39 EXPRESSION	Regulatory T cells (Tregs) are a subpopulation of CD4(+) T cells that are essential for maintaining the homeostasis of the immune system, limiting self-reactivity and excessive immune responses against foreign antigens. In cancer, infiltrated Tregs inhibit the effector lymphocytes and create a favorable environment for the growth of the tumor. Although Tregs mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities. Here, we review the recent literature supporting CD39 as a promising therapeutic target in oncology. In vitro and in vivo experiments involving knockout models and surrogate inhibitors of CD39 provide evidence in support of the anticancer activity of CD39 inhibition and predict a favorable safety profile for CD39 inhibitory compounds. In addition, we report the ongoing development of CD39-blocking monoclonal antibodies as potential anticancer drugs. Indeed, CD39 antagonistic antibodies could represent novel therapeutic tools for selectively inhibiting Treg function without depletion, a major limitation of current Treg-targeting strategies. Oncogene (2013) 32, 1743-1751; doi: 10.1038/onc.2012.269; published online 2 July 2012	[Bastid, J.; Cottalorda-Regairaz, A.; Alberici, G.] Espace Europeen, OREGA Biotech, F-69130 Ecully, France; [Bonnefoy, N.] Univ Lyon, Lyon, France; [Bonnefoy, N.; Eliaou, J-F] INSERM, U851, F-69008 Lyon, France; [Bonnefoy, N.; Eliaou, J-F] Univ Lyon 1, US8, UMS3444, F-69365 Lyon, France; [Eliaou, J-F] Univ Montpellier I, Ctr Hosp Reg Univ Montpellier, Dept Immunol, Montpellier, France; [Eliaou, J-F] Univ Montpellier I, Fac Med, Montpellier, France; [Bensussan, A.] INSERM, UMR S 976, Paris, France; [Bensussan, A.] Univ Paris Diderot, Sorbonne Paris Cite, Lab Immunol Dermatol & Oncol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Bastid, J (corresponding author), Espace Europeen, OREGA Biotech, Dept Oncol, Batiment G,15 Chemin Saquin, F-69130 Ecully, France.	jeremy.bastid@orega-biotech.com; armand.bensussan@inserm.fr	Bonnefoy, Nathalie/J-2536-2012; Bensussan, Armand/E-5434-2017	Bonnefoy, Nathalie/0000-0003-4814-6722; Bensussan, Armand/0000-0002-0409-2497	INSERM; ANR; OSEO	INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); ANR(French National Research Agency (ANR)); OSEO	We would like to acknowledge our collaborators, Dr Patrice Hemon, INSERM UMR-S 976 and Ms Caroline Laheurte, INSERM U851. This work was supported by an INSERM and ANR grant (Emergence-BIO 2008 awarded to AB) and OSEO (OSEO aide au transfert awarded to NB).	Beyer M, 2006, BLOOD, V107, P3940, DOI 10.1182/blood-2005-09-3671; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; CHAHWALA SB, 1984, J BIOL CHEM, V259, P3717; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Colombo MP, 2007, NAT REV CANCER, V7, P880, DOI 10.1038/nrc2250; Couper KN, 2009, J IMMUNOL, V182, P3985, DOI 10.4049/jimmunol.0803053; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Curti A, 2007, BLOOD, V109, P2871, DOI 10.1182/blood-2006-07-036863; Dannull J, 2005, J CLIN INVEST, V115, P3623, DOI 10.1172/JCI25947; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; EPPELL BA, 1989, J IMMUNOL, V143, P4141; Feng LL, 2011, NEOPLASIA, V13, P206, DOI 10.1593/neo.101332; Friedman DJ, 2009, P NATL ACAD SCI USA, V106, P16788, DOI 10.1073/pnas.0902869106; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028; GOUTTEFANGEAS C, 1992, EUR J IMMUNOL, V22, P2681, DOI 10.1002/eji.1830221031; Gouttefangeas C, 1995, LEUCOCYTE TYPING 5; Greten TF, 2010, J IMMUNOTHER, V33, P211, DOI 10.1097/CJI.0b013e3181bb499f; Griffiths RW, 2007, CANCER IMMUNOL IMMUN, V56, P1743, DOI 10.1007/s00262-007-0318-z; Hausler SFM, 2011, CANCER IMMUNOL IMMUN, V60, P1405, DOI 10.1007/s00262-011-1040-4; Hasko G, 2012, ARTERIOSCL THROM VAS, V32, P865, DOI 10.1161/ATVBAHA.111.226852; Hilchey SP, 2009, J IMMUNOL, V183, P6157, DOI 10.4049/jimmunol.0900475; Huang S, 1997, BLOOD, V90, P1600, DOI 10.1182/blood.V90.4.1600.1600_1600_1610; Huber S, 2004, J IMMUNOL, V173, P6526, DOI 10.4049/jimmunol.173.11.6526; Jackson SW, 2007, AM J PATHOL, V171, P1395, DOI 10.2353/ajpath.2007.070190; Jones Emma, 2002, Cancer Immun, V2, P1; Koziak K, 1999, THROMB HAEMOSTASIS, V82, P1538; Kunzli BM, 2007, AM J PHYSIOL-GASTR L, V292, pG223, DOI 10.1152/ajpgi.00259.2006; Kunzli BM, 2011, PURINERG SIGNAL, V7, P231, DOI 10.1007/s11302-011-9228-9; Le Buanec H, 2011, P NATL ACAD SCI USA, V108, P18995, DOI 10.1073/pnas.1113301108; Leach DR, 1996, AIDS RES HUM RETRO S, V27, P1734, DOI DOI 10.1126/SCIENCE.271.5256.1734; Leibovich SJ, 2002, AM J PATHOL, V160, P2231, DOI 10.1016/S0002-9440(10)61170-4; Lokshin A, 2006, CANCER RES, V66, P7758, DOI 10.1158/0008-5472.CAN-06-0478; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; Mandapathil M, 2010, J BIOL CHEM, V285, P7176, DOI 10.1074/jbc.M109.047423; Mandapathil M, 2009, CLIN CANCER RES, V15, P6348, DOI 10.1158/1078-0432.CCR-09-1143; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Morse MA, 2008, BLOOD, V112, P610, DOI 10.1182/blood-2008-01-135319; Muller CE, 2006, BIOORG MED CHEM LETT, V16, P5943, DOI 10.1016/j.bmcl.2006.09.003; Nikolova M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002110; Nishikawa H, 2010, INT J CANCER, V127, P759, DOI 10.1002/ijc.25429; Novitskiy SV, 2008, BLOOD, V112, P1822, DOI 10.1182/blood-2008-02-136325; Odashima M, 2005, GASTROENTEROLOGY, V129, P26, DOI 10.1053/j.gastro.2005.05.032; Oh U, 2009, ARCH NEUROL-CHICAGO, V66, P471, DOI 10.1001/archneurol.2009.16; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Ohta A, 2009, J IMMUNOL, V183, P5487, DOI 10.4049/jimmunol.0901247; Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; PRIEBE T, 1990, CANCER RES, V50, P4328; Pulte D, 2011, CL LYMPH MYELOM LEUK, V11, P367, DOI 10.1016/j.clml.2011.06.005; Pulte ED, 2007, THROMB RES, V121, P309, DOI 10.1016/j.thromres.2007.04.008; Ramanathan M, 2007, MOL BIOL CELL, V18, P14, DOI 10.1091/mbc.E06-07-0596; RAPAPORT E, 1983, CANCER RES, V43, P4402; Rasku MA, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-12; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Ribas A, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.lba9011; Ring S, 2011, J INVEST DERMATOL, V131, P1494, DOI 10.1038/jid.2011.50; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Schuler PJ, 2011, J IMMUNOL METHODS, V369, P59, DOI 10.1016/j.jim.2011.04.004; Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292; Sun XF, 2010, GASTROENTEROLOGY, V139, P1030, DOI 10.1053/j.gastro.2010.05.007; Tarhini AA, 2010, ONCOTARGETS THER, V3, P15; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsukimoto M, 2006, J IMMUNOL, V177, P2842, DOI 10.4049/jimmunol.177.5.2842; Valzasina B, 2006, CANCER RES, V66, P4488, DOI 10.1158/0008-5472.CAN-05-4217; Valzasina B, 2005, BLOOD, V105, P2845, DOI 10.1182/blood-2004-07-2959; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; Wall MJ, 2008, NEUROPHARMACOLOGY, V55, P1251, DOI 10.1016/j.neuropharm.2008.08.005; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; White N, 2009, PURINERG SIGNAL, V5, P327, DOI 10.1007/s11302-009-9156-0; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Williams BA, 1997, BIOCHEM BIOPH RES CO, V231, P264, DOI 10.1006/bbrc.1997.6077; Wolf AM, 2003, CLIN CANCER RES, V9, P606; Wolf D, 2005, CLIN CANCER RES, V11, P8326, DOI 10.1158/1078-0432.CCR-05-1244; Yang JC, 2007, J IMMUNOTHER, V30, P825, DOI 10.1097/CJI.0b013e318156e47e; Yang ZZ, 2006, BLOOD, V107, P3639, DOI 10.1182/blood-2005-08-3376; Yegutkin GG, 2011, EUR J IMMUNOL, V41, P1231, DOI 10.1002/eji.201041292; Yu P, 2005, J EXP MED, V201, P779, DOI 10.1084/jem.20041684; Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283; Zhoua Q, 2009, AM J TRANSPLANT, V9, P2303, DOI 10.1111/j.1600-6143.2009.02777.x	87	132	139	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1743	1751		10.1038/onc.2012.269	http://dx.doi.org/10.1038/onc.2012.269			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22751118				2022-12-17	WOS:000317043900001
J	Pla, AF; Ong, HL; Cheng, KT; Brossa, A; Bussolati, B; Lockwich, T; Paria, B; Munaron, L; Ambudkar, IS				Pla, A. Fiorio; Ong, H. L.; Cheng, K. T.; Brossa, A.; Bussolati, B.; Lockwich, T.; Paria, B.; Munaron, L.; Ambudkar, I. S.			TRPV4 mediates tumor-derived endothelial cell migration via arachidonic acid-activated actin remodeling	ONCOGENE			English	Article						Ca2+ signals; TRP channels; endothelial cells; cell migration; actin remodeling; tumor angiogenesis	PROTEIN-KINASE; ION CHANNELS; CA2+ ENTRY; ANGIOGENESIS; GROWTH; TRANSLOCATION; EXPRESSION; CALCIUM; PROLIFERATION; CONTRIBUTES	Changes in intracellular calcium [Ca2+](i) levels control critical cytosolic and nuclear events that are involved in the initiation and progression of tumor angiogenesis in endothelial cells (ECs). Therefore, the mechanism(s) involved in agonist-induced Ca-i(2+) signaling is a potentially important molecular target for controlling angiogenesis and tumor growth. Several studies have shown that blood vessels in tumors differ from normal vessels in their morphology, blood flow and permeability. We had previously reported a key role for arachidonic acid (AA)-mediated Ca2+ entry in the initial stages of tumor angiogenesis in vitro. In this study we assessed the mechanism involved in AA-induced EC migration. We report that TRPV4, an AA-activated channel, is differentially expressed in EC derived from human breast carcinomas (BTEC) as compared with 'normal' EC (HMVEC). BTEC display a significant increase in TRPV4 expression, which was correlated with greater Ca2+ entry, induced by AA or 4 alpha PDD (a selective TRPV4 agonist) in the tumor-derived ECs. Wound-healing assays revealed a key role of TRPV4 in regulating cell migration of BTEC but not HMVEC. Knockdown of TRPV4 expression completely abolished AA-induced BTEC migration, suggesting that TRPV4 mediates the pro-angiogenic effects promoted by AA. Furthermore, pre-incubation of BTEC with AA induced actin remodeling and a subsequent increase in the surface expression of TRPV4. This was consistent with the increased plasma membrane localization of TRPV4 and higher AA-stimulated Ca2+ entry in the migrating cells. Together, the data presented herein demonstrate that: (1) TRPV4 is differentially expressed in tumor-derived versus 'normal' EC; (2) TRPV4 has a critical role in the migration of tumor-derived but not 'normal' EC migration; and (3) AA induces actin remodeling in BTEC, resulting in a corresponding increase of TRPV4 expression in the plasma membrane. We suggest that the latter is critical for migration of EC and thus in promoting angiogenesis and tumor growth. Oncogene (2012) 31, 200-212; doi:10.1038/onc.2011.231; published online 20 June 2011	[Pla, A. Fiorio; Brossa, A.; Munaron, L.] Univ Turin, Dept Anim & Human Biol, I-10123 Turin, Italy; [Pla, A. Fiorio; Munaron, L.] Ctr Complex Syst Mol Biol & Med SysBioM, Turin, Italy; [Pla, A. Fiorio; Munaron, L.] Nanostruct Interfaces & Surfaces Ctr Excellence, Turin, Italy; [Ong, H. L.; Cheng, K. T.; Lockwich, T.; Paria, B.; Ambudkar, I. S.] NIDCR, Secretory Physiol Sect, Mol Physiol & Therapeut Branch, NIH, Bethesda, MD USA; [Brossa, A.; Bussolati, B.] Univ Turin, Ctr Mol Biotechnol, Dept Internal Med, Turin, Italy	University of Turin; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Turin	Pla, AF (corresponding author), Univ Turin, Dept Anim & Human Biol, V Accademia Albertina 13, I-10123 Turin, Italy.	alessandra.fiorio@unito.it	Bussolati, Benedetta/AAA-9058-2022; Fiorio Pla, Alessandra/B-6646-2012	Bussolati, Benedetta/0000-0002-3663-5134; Fiorio Pla, Alessandra/0000-0003-4576-1594; munaron, luca/0000-0001-9247-4446; Brossa, Alessia/0000-0002-5973-5007; Ong, Hwei Ling/0000-0002-7551-6883	University of Torino; Regione Piemonte (Ricerca Scientifica Applicata Sanita'); National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000438] Funding Source: NIH RePORTER	University of Torino; Regione Piemonte (Ricerca Scientifica Applicata Sanita')(Regione Piemonte); National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work was supported by the University of Torino, Regione Piemonte (Ricerca Scientifica Applicata Sanita') and the National Institute of Dental and Craniofacial Research (Intramural Research). We thank Dr Kenneth Yamada (NIDCR, NIH, Bethesda, MD, USA) for the beta-actin-mCherry and Dr Michael X. Zhu (Department of Physiology and Cell Biology, Ohio State University, OH, USA) for the TRPV4-GFP construct.	Antoniotti S, 2003, J CELL PHYSIOL, V197, P370, DOI 10.1002/jcp.10359; Becker D, 2005, J CELL SCI, V118, P2435, DOI 10.1242/jcs.02372; Becker D, 2009, EUR J CELL BIOL, V88, P141, DOI 10.1016/j.ejcb.2008.10.002; Bhati R, 2008, AM J PATHOL, V172, P1381, DOI 10.2353/ajpath.2008.070988; Birnbaumer L, 2009, ANNU REV PHARMACOL, V49, P395, DOI 10.1146/annurev.pharmtox.48.113006.094928; Boels K, 2001, J CELL SCI, V114, P3599; Bussolati B, 2006, EXP CELL RES, V312, P913, DOI 10.1016/j.yexcr.2005.12.004; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Bussolati B, 2011, FASEB J; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Collino F, 2008, AM J PHYSIOL-RENAL, V294, pF1185, DOI 10.1152/ajprenal.00442.2007; Everaerts W, 2010, PROG BIOPHYS MOL BIO, V103, P2, DOI 10.1016/j.pbiomolbio.2009.10.002; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Gao X, 2003, J BIOL CHEM, V278, P27129, DOI 10.1074/jbc.M302517200; Goswami C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011654; Grange C, 2006, ONCOL REP, V15, P381; Hamdollah Zadeh MA, 2008, MICROCIRCULATION, V15, P605, DOI 10.1080/10739680802220323; Hartmannsgruber V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000827; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hyde CAC, 2009, INT IMMUNOPHARMACOL, V9, P701, DOI 10.1016/j.intimp.2009.02.003; Kwan HY, 2007, BBA-MOL BASIS DIS, V1772, P907, DOI 10.1016/j.bbadis.2007.02.013; Liedtke W, 2005, CELL MOL LIFE SCI, V62, P2985, DOI 10.1007/s00018-005-5181-5; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Ma X, 2010, ARTERIOSCL THROM VAS, V30, P2249, DOI 10.1161/ATVBAHA.110.212084; Meves H, 2008, BRIT J PHARMACOL, V155, P4, DOI 10.1038/bjp.2008.216; Moes M, 2010, CELL MOL LIFE SCI, V67, P1547, DOI 10.1007/s00018-010-0267-0; Morenilla-Palao C, 2004, J BIOL CHEM, V279, P25665, DOI 10.1074/jbc.M311515200; Munaron L, 2009, CURR MED CHEM, V16, P4691, DOI 10.2174/092986709789878210; Mutai H, 2005, NEUROSCIENCE, V132, P1115, DOI 10.1016/j.neuroscience.2005.01.046; Nie D, 2002, CELL MOL LIFE SCI, V59, P799, DOI 10.1007/s00018-002-8468-9; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Patton AM, 2003, CURR PHARM DESIGN, V9, P543, DOI 10.2174/1381612033391559; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PEPPELENBOSCH MP, 1995, J NEUROSCI METH, V58, P49, DOI 10.1016/0165-0270(94)00158-D; Pla AF, 2005, J NEUROSCI, V25, P2687, DOI 10.1523/JNEUROSCI.0951-04.2005; Pla AF, 2001, CELL CALCIUM, V30, P235, DOI 10.1054/ceca.2001.0234; Pla AF, 2008, MOL CANCER RES, V6, P535, DOI 10.1158/1541-7786.MCR-07-0271; Pla AF, 2010, MOL CANCER RES, V8, P1466, DOI 10.1158/1541-7786.MCR-10-0002; Pocock TM, 2004, AM J PHYSIOL-HEART C, V286, pH1015, DOI 10.1152/ajpheart.00826.2003; Prevarskaya N, 2010, TRENDS MOL MED, V16, P107, DOI 10.1016/j.molmed.2010.01.005; Roberts LA, 2003, J CELL PHYSIOL, V196, P196, DOI 10.1002/jcp.10303; Shin EA, 1999, FEBS LETT, V452, P355, DOI 10.1016/S0014-5793(99)00657-2; Singh BB, 2004, MOL CELL, V15, P635, DOI 10.1016/j.molcel.2004.07.010; St Croix B, 2000, SCIENCE, V289, P1197; Suzuki M, 2003, J BIOL CHEM, V278, P51448, DOI 10.1074/jbc.M308212200; Thodeti CK, 2009, CIRC RES, V104, P1123, DOI 10.1161/CIRCRESAHA.108.192930; Troidl C, 2009, J CELL MOL MED, V13, P2613, DOI 10.1111/j.1582-4934.2008.00579.x; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; Van Buren JJ, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-17; Waning J, 2007, CELL CALCIUM, V42, P17, DOI 10.1016/j.ceca.2006.11.005; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Yu PC, 2010, CIRC RES, V106, P1221, DOI 10.1161/CIRCRESAHA.109.207670	53	132	136	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2012	31	2					200	212		10.1038/onc.2011.231	http://dx.doi.org/10.1038/onc.2011.231			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	879CN	21685934	Green Accepted			2022-12-17	WOS:000299307400006
J	Ying, M; Wang, S; Sang, Y; Sun, P; Lal, B; Goodwin, CR; Guerrero-Cazares, H; Quinones-Hinojosa, A; Laterra, J; Xia, S				Ying, M.; Wang, S.; Sang, Y.; Sun, P.; Lal, B.; Goodwin, C. R.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Laterra, J.; Xia, S.			Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition	ONCOGENE			English	Article						glioblastoma; cancer stem cell; retinoic acid; differentiation; Notch	HEPATOCYTE GROWTH-FACTOR; 13-CIS-RETINOIC ACID; EMBRYONAL CARCINOMA; DIFFERENTIATION THERAPY; NEURAL DIFFERENTIATION; U87MG CELLS; PHASE-II; CANCER; APOPTOSIS; GLIOMA	It is necessary to understand mechanisms by which differentiating agents influence tumor-initiating cancer stem cells. Toward this end, we investigated the cellular and molecular responses of glioblastoma stem-like cells (GBM-SCs) to all-trans retinoic acid (RA). GBM-SCs were grown as non-adherent neurospheres in growth factor supplemented serum-free medium. RA treatment rapidly induced morphology changes, induced growth arrest at G1/G0 to S transition, decreased cyclin D1 expression and increased p27 expression. Immunofluorescence and western blot analysis indicated that RA induced the expression of lineage-specific differentiation markers Tuj1 and GFAP and reduced the expression of neural stem cell markers such as CD133, Msi-1, nestin and Sox-2. RA treatment dramatically decreased neurosphere-forming capacity, inhibited the ability of neurospheres to form colonies in soft agar and inhibited their capacity to propagate subcutaneous and intracranial xenografts. Expression microarray analysis identified similar to 350 genes that were altered within 48 h of RA treatment. Affected pathways included retinoid signaling and metabolism, cell-cycle regulation, lineage determination, cell adhesion, cell-matrix interaction and cytoskeleton remodeling. Notch signaling was the most prominent of these RA-responsive pathways. Notch pathway downregulation was confirmed based on the downregulation of HES and HEY family members. Constitutive activation of Notch signaling with the Notch intracellular domain rescued GBM neurospheres from the RA-induced differentiation and stem cell depletion. Our findings identify mechanisms by which RA targets GBM-derived stem-like tumor-initiating cells and novel targets applicable to differentiation therapies for glioblastoma. Oncogene (2011) 30, 3454-3467; doi:10.1038/onc.2011.58; published online 7 March 2011	[Xia, S.] Hugo W Moser Res Inst Kennedy Krieger, Johns Hopkins Sch Med, Dept Neurooncol, Baltimore, MD 21205 USA; [Ying, M.; Sun, P.; Lal, B.; Laterra, J.; Xia, S.] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA; [Guerrero-Cazares, H.; Quinones-Hinojosa, A.; Laterra, J.] Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [Guerrero-Cazares, H.] Johns Hopkins Sch Med, Dept Neurosurg, Baltimore, MD USA; [Laterra, J.] Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Xia, S (corresponding author), Hugo W Moser Res Inst Kennedy Krieger, Johns Hopkins Sch Med, Dept Neurooncol, 707 N Broadway,Room 400K, Baltimore, MD 21205 USA.	xia@kennedykrieger.org		Guerrero-Cazares, Hugo/0000-0003-1307-719X; Goodwin, C. Rory/0000-0002-6540-2751	Maryland Stem Cell Research Fund (MSCRFE) [2009-0126-00]; MSCRF; NIH [NS43987, KO8]; James McDonnell Foundation; HHMI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER	Maryland Stem Cell Research Fund (MSCRFE); MSCRF; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); James McDonnell Foundation; HHMI(Howard Hughes Medical Institute); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by the Maryland Stem Cell Research Fund (MSCRFE) 2009-0126-00 (SX); MSCRF (MY, HG); NIH NS43987 and the James McDonnell Foundation (JL); as well as NIH KO8 and HHMI grants (AQ). Dr CR Goodwin is a UNCF-Merck Science postdoc fellow. We thank Dr Jiang Qian and Ms Yanqing Yang from Wilmer Eye Institute, Johns Hopkins University, for their assistance with microarray analysis.	Al-Hajj M, 2004, CURR OPIN GENET DEV, V14, P43, DOI 10.1016/j.gde.2003.11.007; An J, 2005, PROTEOMICS, V5, P1656, DOI 10.1002/pmic.200401049; Bain G., 2000, Functional and Integrative Genomics, V1, P127, DOI 10.1007/s101420000014; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bar EE, 2007, STEM CELLS, V25, P2524, DOI 10.1634/stemcells.2007-0166; Butowski N, 2005, INT J RADIAT ONCOL, V61, P1454, DOI 10.1016/j.ijrobp.2004.08.023; Chalmers AJ, 2007, DNA REPAIR, V6, P1391, DOI 10.1016/j.dnarep.2007.03.019; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Das A, 2008, J NEURO-ONCOL, V87, P9, DOI 10.1007/s11060-007-9485-1; Dragnev KH, 2003, CANCER BIOL THER, V2, pS150; Fan X, 2010, STEM CELLS, V28, P5, DOI 10.1002/stem.254; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761; Goodwin CR, 2010, CANCER RES, V70, P2932, DOI 10.1158/0008-5472.CAN-09-3570; Harris Thomas M, 2002, Funct Integr Genomics, V2, P105, DOI 10.1007/s10142-002-0062-6; Jaeckle KA, 2003, J CLIN ONCOL, V21, P2305, DOI 10.1200/JCO.2003.12.097; Johannessen TCA, 2008, CANCER TREAT REV, V34, P558, DOI 10.1016/j.ctrv.2008.03.125; Jurcic Joseph G, 2007, Curr Oncol Rep, V9, P337, DOI 10.1007/s11912-007-0045-9; Kageyama R, 2009, CURR OPIN CELL BIOL, V21, P733, DOI 10.1016/j.ceb.2009.08.009; Karmakar S, 2008, CANCER, V112, P596, DOI 10.1002/cncr.23223; Kumar Hari R, 2008, Expert Rev Neurother, V8, P1497, DOI 10.1586/14737175.8.10.1497; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Massard C, 2006, ANN ONCOL, V17, P1620, DOI 10.1093/annonc/mdl074; Mongan NP, 2007, DIFFERENTIATION, V75, P853, DOI 10.1111/j.1432-0436.2007.00206.x; Murata-Ohsawa M, 2005, LEUKEMIA RES, V29, P197, DOI 10.1016/j.leukres.2004.05.020; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Niles RM, 2004, MUTAT RES-FUND MOL M, V555, P81, DOI 10.1016/j.mrfmmm.2004.05.020; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piccirillo SGM, 2007, EXPERT OPIN BIOL TH, V7, P1129, DOI 10.1517/14712598.7.8.1129; Ray J, 2006, MOL CELL NEUROSCI, V31, P560, DOI 10.1016/j.mcn.2005.11.010; Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236; Sangster-Guity N, 2004, CANCER BIOL THER, V3, P1109, DOI 10.4161/cbt.3.11.1190; See SJ, 2004, NEURO-ONCOLOGY, V6, P253, DOI 10.1215/S1152851703000607; Sell S, 2006, TUMOR BIOL, V27, P59, DOI 10.1159/000092323; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Shi YH, 2008, CRIT REV ONCOL HEMAT, V65, P43, DOI 10.1016/j.critrevonc.2007.06.004; Shih AH, 2006, NEOPLASIA, V8, P1072, DOI 10.1593/neo.06526; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sivasankaran B, 2009, CANCER RES, V69, P458, DOI 10.1158/0008-5472.CAN-08-2610; Soprano DR, 2007, VITAM HORM, V75, P69, DOI 10.1016/S0083-6729(06)75003-8; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vescovi AL, 1999, EXP NEUROL, V156, P71, DOI 10.1006/exnr.1998.6998; Walsh J, 2003, APMIS, V111, P197, DOI 10.1034/j.1600-0463.2003.1110124.x; Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261; Wei Y, 2002, DIFFERENTIATION, V70, P204, DOI 10.1046/j.1432-0436.2002.700409.x; Wilson A, 2006, FEBS LETT, V580, P2860, DOI 10.1016/j.febslet.2006.03.024; Yu XB, 2008, CELL STEM CELL, V2, P461, DOI 10.1016/j.stem.2008.03.001; Yung WKA, 1996, CLIN CANCER RES, V2, P1931; Zhang R, 2007, NEUROCHEM RES, V32, P2194, DOI 10.1007/s11064-007-9417-7	54	132	136	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2011	30	31					3454	3467		10.1038/onc.2011.58	http://dx.doi.org/10.1038/onc.2011.58			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21383690	Green Accepted			2022-12-17	WOS:000293508100006
J	Knauf, JA; Sartor, MA; Medvedovic, M; Lundsmith, E; Ryder, M; Salzano, M; Nikiforov, YE; Giordano, TJ; Ghossein, RA; Fagin, JA				Knauf, J. A.; Sartor, M. A.; Medvedovic, M.; Lundsmith, E.; Ryder, M.; Salzano, M.; Nikiforov, Y. E.; Giordano, T. J.; Ghossein, R. A.; Fagin, J. A.			Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF beta signaling	ONCOGENE			English	Article						BRAF; TGF beta; epithelial-mesenchymal transition; thyroid	GROWTH-FACTOR-BETA; GENE-EXPRESSION DATA; FALSE DISCOVERY RATE; BRAF(V600E) MUTATION; HIGH PREVALENCE; CARCINOMA; CELLS; METASTASIS; ACTIVATION; MICE	Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTCs) that are locally invasive and have well-defined foci of poorly differentiated thyroid carcinoma (PDTC). To investigate the PTC-PDTC progression, we performed a microarray analysis using RNA from paired samples of PDTC and PTC collected from the same animals by laser capture microdissection. Analysis of eight paired samples revealed a profound deregulation of genes involved in cell adhesion and intracellular junctions, with changes consistent with an epithelial-mesenchymal transition (EMT). This was confirmed by immunohistochemistry, as vimentin expression was increased and E-cadherin lost in PDTC compared with adjacent PTC. Moreover, PDTC stained positively for phospho-Smad2, suggesting a role for transforming growth factor (TGF)beta in mediating this process. Accordingly, TGF beta-induced EMT in primary cultures of thyroid cells from Tg-Braf mice, whereas wild-type thyroid cells retained their epithelial features. TGF beta-induced Smad2 phosphorylation, transcriptional activity and induction of EMT required mitogen-activated protein kinase (MAPK) pathway activation in Tg-Braf thyrocytes. Hence, tumor initiation by oncogenic BRAF renders thyroid cells susceptible to TGF beta-induced EMT, through a MAPK-dependent process. Oncogene (2011) 30, 3153-3162; doi:10.1038/onc.2011.44; published online 7 March 2011	[Knauf, J. A.; Lundsmith, E.; Ryder, M.; Salzano, M.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Knauf, J. A.; Lundsmith, E.; Ryder, M.; Salzano, M.; Fagin, J. A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA; [Sartor, M. A.; Medvedovic, M.] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA; [Nikiforov, Y. E.] Univ Cincinnati, Dept Pathol, Cincinnati, OH USA; [Giordano, T. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Ghossein, R. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Michigan System; University of Michigan; Memorial Sloan Kettering Cancer Center	Knauf, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	knaufj@mskcc.org	Sartor, Maureen/L-2902-2019	Salzano, Marcella/0000-0002-1856-8281; Knauf, Jeffrey/0000-0003-4456-8792; Giordano, Thomas/0000-0003-0641-8873	NIH [CA 50706]; Margot Rosenberg Pulitzer Foundation; NATIONAL CANCER INSTITUTE [R29CA050706, R01CA050706, R01CA072597] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Margot Rosenberg Pulitzer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH CA 50706, and a grant from the Margot Rosenberg Pulitzer Foundation. We are grateful to the MSKCC Genetically Engineered Mouse Phenotyping core facility and Dr Katia Manova of the MSKCC Molecular Cytology core for help with immunohistochemical experiments.	Ball DW, 2007, J CLIN ENDOCR METAB, V92, P4712, DOI 10.1210/jc.2007-1184; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; Franco AT, 2011, P NATL ACAD SCI USA, V108, P1615, DOI 10.1073/pnas.1015557108; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Guo JH, 2004, TOXICOL APPL PHARM, V194, P79, DOI 10.1016/j.taap.2003.09.002; Inoue Y, 2008, CANCER SCI, V99, P2107, DOI 10.1111/j.1349-7006.2008.00925.x; Jechlinger M, 2002, J MAMMARY GLAND BIOL, V7, P415, DOI 10.1023/A:1024090116451; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kimura ET, 2003, CANCER RES, V63, P1454; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Leboeuf R, 2008, J CLIN ENDOCR METAB, V93, P2194, DOI 10.1210/jc.2007-2825; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Montero-Conde C, 2008, ONCOGENE, V27, P1554, DOI 10.1038/sj.onc.1210792; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P1385, DOI 10.1210/endo-123-3-1385; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ricarte-Filho JC, 2009, CANCER RES, V69, P4885, DOI 10.1158/0008-5472.CAN-09-0727; Riesco-Eizaguirre G, 2009, CANCER RES, V69, P8317, DOI 10.1158/0008-5472.CAN-09-1248; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Saltman B, 2006, SURGERY, V140, P899, DOI 10.1016/j.surg.2006.07.027; Sartor MA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-538; Sartor MA, 2010, BIOINFORMATICS, V26, P456, DOI 10.1093/bioinformatics/btp683; Sartor MA, 2009, BIOINFORMATICS, V25, P211, DOI 10.1093/bioinformatics/btn592; Savage NDL, 2008, J IMMUNOL, V181, P2220, DOI 10.4049/jimmunol.181.3.2220; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215; TSUSHIMA T, 1988, ENDOCRINOLOGY, V123, P1187, DOI 10.1210/endo-123-2-1187; Vasko V, 2007, P NATL ACAD SCI USA, V104, P2803, DOI 10.1073/pnas.0610733104; Weinberg RA, 2008, NAT CELL BIOL, V10, P1021, DOI 10.1038/ncb0908-1021; Wiseman SM, 2007, ARCH SURG-CHICAGO, V142, P717, DOI 10.1001/archsurg.142.8.717; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrighton KH, 2009, CELL RES, V19, P8, DOI 10.1038/cr.2008.327; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5	53	132	135	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3153	3162		10.1038/onc.2011.44	http://dx.doi.org/10.1038/onc.2011.44			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21383698	Green Accepted			2022-12-17	WOS:000292726300004
J	Neganova, I; Zhang, X; Atkinson, S; Lako, M				Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.			Expression and functional analysis of G1 to S regulatory components reveals an important role for CDK2 in cell cycle regulation in human embryonic stem cells	ONCOGENE			English	Article						human embryonic stem cell; cell cycle regulation; G1/S transition; CDK2; CYCLIN D1; CYCLIN D2	ES CELLS; DIFFERENTIATION; DERIVATION; ESTABLISHMENT; BLASTOCYSTS; INHIBITION; FEATURES; CULTURE; PHASE; LINES	One of the characteristic features of human embryonic stem cells (hESCs) is the competence for self-renewal and pluripotency. To date, little is known about cell cycle regulation in these cells and how the cell cycle machinery influences hESCs properties. A common feature of human, murine and primate ESCs is the presence of a short G1 phase, which has been viewed as a time window during which stem cells are exposed to differentiation signals. We used the hESCs differentiation model and comparisons to human embryonic carcinoma (EC) cells to study the key regulators of G1 to S transition in hESCs. Our studies show that hESCs express all G1-specific CYCLINs (D1, D2, D3 and E) and cyclin-dependent kinases (CDK) (CDK2, CDK4 and CDK6) at variable levels. In contrast to murine ESCs, most of the cell cycle regulators in hESCs show cell cycle-dependent expression, thus revealing important differences in the expression of cell cycle regulatory components between these two embryonic cell types. Knockdown of CDK2 using RNA interference resulted in hESCs arrest at G1 phase of the cell cycle and differentiation to extraembryonic lineages. This suggests an important role for CDK2 in cell cycle regulation in hESCs that are likely to bear significant impacts on the maintenance of their pluripotent phenotype.	[Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.] Newcastle Univ, NE Inst Stem Cell Res, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Neganova, I.; Zhang, X.; Atkinson, S.; Lako, M.] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Lako, M (corresponding author), Newcastle Univ, NE Inst Stem Cell Res, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	majlinda.Lako@ncl.ac.uk	Lako, Majlinda/B-6297-2013	lako, majlinda/0000-0003-1327-8573; Atkinson, Stuart P./0000-0002-8218-3730	BBSRC [BBS/B/14779]; Newcastle University; MRC [G0301182]; BBSRC [BB/E012841/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BBS/B/14779, BB/E012841/1] Funding Source: researchfish; Medical Research Council [G0301182] Funding Source: researchfish	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Newcastle University; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We are grateful to Mr I Dimmick and Dr R Stewart for help with the. ow cytometry analysis, Dr A Hampl for useful discussions, A Khnykina for help with. gure preparation, Dr S Pryzborski for providing the EC cells, and Mr G Anyfantis and Mr D Kirk for technical assistance. This study was supported by BBSRC Grant no. BBS/B/14779, MRC Grant G0301182 and Newcastle University.	Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Becker KA, 2006, J CELL PHYSIOL, V209, P883, DOI 10.1002/jcp.20776; Becker KA, 2007, J CELL PHYSIOL, V210, P517, DOI 10.1002/jcp.20903; BLOMEN V, 2007, CELL MOL LIFE SCI, V24, P1789; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Brons IGM, 2007, NATURE, V448, P191, DOI 10.1038/nature05950; Calegari F, 2003, J CELL SCI, V116, P4947, DOI 10.1242/jcs.00825; Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005; Carpenter MK, 2003, CLONING STEM CELLS, V5, P79, DOI 10.1089/153623003321512193; Enver T, 2005, HUM MOL GENET, V14, P3129, DOI 10.1093/hmg/ddi345; Faast R, 2004, ONCOGENE, V23, P491, DOI 10.1038/sj.onc.1207133; Fluckiger AC, 2006, STEM CELLS, V24, P547, DOI 10.1634/stemcells.2005-0194; Ghule PN, 2007, J CELL PHYSIOL, V213, P9, DOI 10.1002/jcp.21119; Neganova I, 2008, J ANAT, V213, P30, DOI 10.1111/j.1469-7580.2008.00931.x; Pera MF, 2004, DEVELOPMENT, V131, P5515, DOI 10.1242/dev.01451; Savatier P, 2004, HDB STEM CELL ELSEVI, P53; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Stojkovic M, 2004, REPRODUCTION, V128, P259, DOI 10.1530/rep.1.00243; Stojkovic M, 2004, STEM CELLS, V22, P790, DOI 10.1634/stemcells.22-5-790; Tesar PJ, 2007, NATURE, V448, P196, DOI 10.1038/nature05972; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; WANG N, 1980, CANCER RES, V40, P796; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Zaehres H, 2005, STEM CELLS, V23, P299, DOI 10.1634/stemcells.2004-0252	25	132	138	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2009	28	1					20	30		10.1038/onc.2008.358	http://dx.doi.org/10.1038/onc.2008.358			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18806832				2022-12-17	WOS:000262294100003
J	Pickering, MT; Stadler, BM; Kowalik, TF				Pickering, M. T.; Stadler, B. M.; Kowalik, T. F.			miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression	ONCOGENE			English	Article						checkpoint; DNA damage; E2F1; miRNA	DOUBLE-STRAND BREAKS; E2F1 TRANSCRIPTION FACTOR; GEL-ELECTROPHORESIS; DNA; APOPTOSIS; PHOSPHORYLATION; EXPRESSION; MICRORNAS; ONCOGENE; CANCERS	The stringent regulation of cell cycle progression helps to maintain genetic stability in cells. MicroRNAs (miRNAs) are critical regulators of gene expression in diverse cellular pathways, including developmental patterning, hematopoietic differentiation and antiviral defense. Here, we show that two c-Myc-regulated miRNAs, miR-17 and miR-20a, govern the transition through G1 in normal diploid human cells. Inhibition of these miRNAs leads to a G1 checkpoint due to an accumulation of DNA double-strand breaks, resulting from premature temporal accumulation of the E2F1 transcription factor. Surprisingly, gross changes in E2F1 levels were not required to initiate the DNA damage response and checkpoint, as these responses could occur with a less than twofold change in E2F1 protein levels. Instead, our findings indicate that the precise timing of E2F1 expression dictates S-phase entry and that accurate timing of E2F1 accumulation requires converging signals from the Rb/E2F pathway and the c-Myc-regulated miR-17 and miR-20a miRNAs to circumvent a G1 checkpoint arising from the untimely accumulation of E2F1. These data provide a mechanistic view of miRNA-based regulation of E2F1 in the context of the emerging model that miRNAs coordinate the timing of cell cycle progression.	[Pickering, M. T.; Stadler, B. M.; Kowalik, T. F.] Univ Massachusetts, Dept Mol Genet & Microbiol, Sch Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Kowalik, TF (corresponding author), Univ Massachusetts, Dept Mol Genet & Microbiol, Sch Med, 55 Lake Ave N, Worcester, MA 01605 USA.	timothy.kowalik@umassmed.edu		Pickering, Mary/0000-0002-0515-7248	Dimes Foundation [6-FY06-344]; NIH [AI0766189, 5 P30 DK32520]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER	Dimes Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported in parts by research grants from the March of Dimes Foundation (6-FY06-344) and the NIH (AI0766189 and 5 P30 DK32520). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Frame FM, 2006, ONCOGENE, V25, P3258, DOI 10.1038/sj.onc.1209352; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hong SL, 2008, CELL CYCLE, V7, P391, DOI 10.4161/cc.7.3.5286; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Lomazzi M, 2002, NAT GENET, V31, P190, DOI 10.1038/ng891; Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; OLIVE PL, 1991, CANCER RES, V51, P4671; OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L; PERSSON H, 1985, MOL CELL BIOL, V5, P2903, DOI 10.1128/MCB.5.11.2903; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sylvestre Y, 2007, J BIOL CHEM, V282, P2135, DOI 10.1074/jbc.M608939200; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yao G, 2008, NAT CELL BIOL, V10, P476, DOI 10.1038/ncb1711	29	132	139	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2009	28	1					140	145		10.1038/onc.2008.372	http://dx.doi.org/10.1038/onc.2008.372			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392HP	18836483	Green Accepted			2022-12-17	WOS:000262294100014
J	Noborio-Hatano, K; Kikuchi, J; Takatoku, M; Shimizu, R; Wada, T; Ueda, M; Nobuyoshi, M; Oh, I; Sato, K; Suzuki, T; Ozaki, K; Mori, M; Nagai, T; Muroi, K; Kano, Y; Furukawa, Y; Ozawa, K				Noborio-Hatano, K.; Kikuchi, J.; Takatoku, M.; Shimizu, R.; Wada, T.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; Ozaki, K.; Mori, M.; Nagai, T.; Muroi, K.; Kano, Y.; Furukawa, Y.; Ozawa, K.			Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma	ONCOGENE			English	Article						myeloma; bortezomib; drug resistance; cell adhesion; VLA-4	NF-KAPPA-B; MARROW STROMAL CELLS; BONE-MARROW; CAM-DR; BINDING-SITES; APOPTOSIS; LEUKEMIA; SUPPRESSES; ACTIVATION; MOLECULES	Multiple myeloma ( MM) is incurable, mainly because of cell adhesion-mediated drug resistance (CAM-DR). In this study, we performed functional screening using short hairpin RNA (shRNA) to de. ne the molecule(s) responsible for CAM-DR of MM. Using four bona. de myeloma cell lines (KHM-1B, KMS12-BM, RPMI8226 and U266) and primary myeloma cells, we identified CD29 (beta 1-integrin), CD44, CD49d (alpha 4-integrin, a subunit of VLA-4), CD54 ( intercellular adhesion molecule-1 (ICAM-1)), CD138 (syndecan-1) and CD184 (CXC chemokine receptor-4 (CXCR4)) as major adhesion molecules expressed on MM. shRNA-mediated knockdown of CD49d but not CD44, CD54, CD138 and CD184 significantly reversed CAM-DR of myeloma cells to bortezomib, vincristine, doxorubicin and dexamethasone. Experiments using blocking antibodies yielded almost identical results. Bortezomib was relatively resistant to CAM-DR because of its ability to specifically down-regulate CD49d expression. This property was unique to bortezomib and was not observed in other anti-myeloma drugs. Pretreatment with bortezomib was able to ameliorate CAM-DR of myeloma cells to vincristine and dexamethasone. These results suggest that VLA-4 plays a critical role in CAM-DR of MM cells. The combination of bortezomib with conventional anti-myeloma drugs may be effective in overcoming CAM-DR of MM.	[Kikuchi, J.; Shimizu, R.; Wada, T.; Furukawa, Y.] Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, Shimotsuke, Tochigi 3290498, Japan; [Noborio-Hatano, K.; Takatoku, M.; Ueda, M.; Nobuyoshi, M.; Oh, I.; Sato, K.; Suzuki, T.; Ozaki, K.; Mori, M.; Nagai, T.; Muroi, K.; Furukawa, Y.; Ozawa, K.] Jichi Med Univ, Dept Internal Med, Div Hematol, Shimotsuke, Tochigi 3290498, Japan	Jichi Medical University; Jichi Medical University	Furukawa, Y (corresponding author), Jichi Med Univ, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Shimotsuke, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418	Ministry of Health, Welfare, and Labor of Japan; Ministry of Education, Science, Sports, and Technology of Japan; Jichi Medical School Young Investigator Award	Ministry of Health, Welfare, and Labor of Japan(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Science, Sports, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Jichi Medical School Young Investigator Award	This study was supported in part by grants from the Ministry of Health, Welfare, and Labor of Japan, and Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Technology of Japan. KN-H and JK are winners of the Jichi Medical School Young Investigator Award.	Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Cook G, 1997, ACTA HAEMATOL-BASEL, V97, P81; Corso A, 2005, CANCER, V104, P118, DOI 10.1002/cncr.21104; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Davies AM, 2007, CLIN CANCER RES, V13, p4647S, DOI 10.1158/1078-0432.CCR-07-0334; Dolcet X, 2005, VIRCHOWS ARCH, V446, P475, DOI 10.1007/s00428-005-1264-9; Drexler Hans G, 2003, Hum Cell, V16, P101, DOI 10.1111/j.1749-0774.2003.tb00140.x; Duechler M, 2005, LEUKEMIA, V19, P260, DOI 10.1038/sj.leu.2403592; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Horton TM, 2006, CANCER CHEMOTH PHARM, V58, P13, DOI 10.1007/s00280-005-0135-z; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kikuchi J, 2005, LEUKEMIA, V19, P1934, DOI 10.1038/sj.leu.2403951; Kikuchi J, 2007, STEM CELLS, V25, P2439, DOI 10.1634/stemcells.2007-0207; Kirschner KM, 2006, J BIOL CHEM, V281, P31930, DOI 10.1074/jbc.M602668200; Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Matsunaga T, 2003, NAT MED, V9, P1158, DOI 10.1038/nm909; Michigami T, 2000, BLOOD, V96, P1953, DOI 10.1182/blood.V96.5.1953.h8001953_1953_1960; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Miyakoshi S, 2006, BLOOD, V107, P3492, DOI 10.1182/blood-2005-11-4541; Mori T, 2005, MOL CELL BIOL, V25, P5183, DOI 10.1128/MCB.25.12.5183-5195.2005; Mori Y, 2004, BLOOD, V104, P2149, DOI 10.1182/blood-2004-01-0236; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; NOBORIOHATANO K, 2007, JPN J CLIN HEMATOL, V48, pA1093; Odgerel T, 2008, ONCOGENE, V27, P3102, DOI 10.1038/sj.onc.1210980; Olson DL, 2005, MOL CANCER THER, V4, P91; Pearse RN, 2001, P NATL ACAD SCI USA, V98, P11581, DOI 10.1073/pnas.201394498; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; Schmidmaier R, 2006, INT J BIOL MARKER, V21, P218, DOI 10.1177/172460080602100404; TAKATOKU M, 2004, JPN J CLIN HEMATOL, V45, P144; Tatsumi T, 1996, JPN J CANCER RES, V87, P837, DOI 10.1111/j.1349-7006.1996.tb02108.x; Yanamandra N, 2006, CLIN CANCER RES, V12, P591, DOI 10.1158/1078-0432.CCR-05-1792; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	41	132	134	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					231	242		10.1038/onc.2008.385	http://dx.doi.org/10.1038/onc.2008.385			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18850009				2022-12-17	WOS:000262501100007
J	Parthun, MR				Parthun, M. R.			Hat1: the emerging cellular roles of a type B histone acetyltransferase	ONCOGENE			English	Review						histone; chromatin; acetylation; acetyltransferase; chromatin assembly	ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; CHROMATIN REPLICATION; H4 ACETYLTRANSFERASE; NEGATIVE REGULATOR; ACETYLATION SITES; CRYSTAL-STRUCTURE; MAIZE EMBRYOS; HIR PROTEINS	Hat1 is the sole known example of a type B histone acetyltransferase. While it has long been presumed that type B histone acetyltransferases participate in the acetylation of newly synthesized histones during the process of chromatin assembly, definitive evidence linking these enzymes to this process has been scarce. This review will discuss recent results that have begun to shed light on the roles of Hat1 and also address several outstanding questions relating to the cellular function of this enzyme.	Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Parthun, MR (corresponding author), Ohio State Univ, Dept Mol & Cellular Biochem, 411 Hamilton Hall,1645 Neil Ave, Columbus, OH 43210 USA.	parthun.1@osu.edu			NIGMS NIH HHS [R01 GM062970, R01 GM62970] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062970] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Ahmad A, 2001, NUCLEIC ACIDS RES, V29, P629, DOI 10.1093/nar/29.3.629; Ahmad S, 2000, IETE J RES, V46, P2, DOI 10.1080/03772063.2000.11416128; Ai X, 2004, MOL CELL, V14, P195, DOI 10.1016/S1097-2765(04)00184-4; Akey CW, 2003, CURR OPIN STRUC BIOL, V13, P6, DOI 10.1016/S0959-440X(03)00002-2; Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Barman HK, 2006, BIOCHEM BIOPH RES CO, V345, P1547, DOI 10.1016/j.bbrc.2006.05.079; Benson LJ, 2007, J BIOL CHEM, V282, P836, DOI 10.1074/jbc.M607464200; Benson LJ, 2006, J BIOL CHEM, V281, P9287, DOI 10.1074/jbc.M512956200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Chang L, 1997, BIOCHEMISTRY-US, V36, P469, DOI 10.1021/bi962069i; CHICOINE LG, 1986, J BIOL CHEM, V261, P1071; DECKER RS, 1987, J BIOL CHEM, V262, P10863; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Eberharter A, 1996, FEBS LETT, V386, P75, DOI 10.1016/0014-5793(96)00401-2; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Enomoto S, 1998, GENE DEV, V12, P219, DOI 10.1101/gad.12.2.219; Furuyama T, 2006, P NATL ACAD SCI USA, V103, P6172, DOI 10.1073/pnas.0601686103; Gaillard PHL, 1997, EMBO J, V16, P6281, DOI 10.1093/emboj/16.20.6281; Gaillard PHL, 1996, CELL, V86, P887, DOI 10.1016/S0092-8674(00)80164-6; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Imhof A, 1999, BIOCHEMISTRY-US, V38, P13085, DOI 10.1021/bi9912490; JACKSON V, 1976, J MOL BIOL, V104, P471, DOI 10.1016/0022-2836(76)90282-5; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; John S, 2000, GENE DEV, V14, P1196; Kaufman PD, 1998, MOL CELL BIOL, V18, P4793, DOI 10.1128/MCB.18.8.4793; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; Krawitz DC, 2002, MOL CELL BIOL, V22, P614, DOI 10.1128/MCB.22.2.614-625.2002; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; Lim DA, 2006, MOL CELL NEUROSCI, V31, P131, DOI 10.1016/j.mcn.2005.10.005; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LOPEZRODAS G, 1991, BIOCHEMISTRY-US, V30, P3728, DOI 10.1021/bi00229a020; LOUIE AJ, 1973, COLD SPRING HARB SYM, V38, P803, DOI 10.1101/SQB.1974.038.01.084; Loyola A, 2004, BBA-GENE STRUCT EXPR, V1677, P3, DOI 10.1016/j.bbaexp.2003.09.012; Lusser A, 1999, NUCLEIC ACIDS RES, V27, P4427, DOI 10.1093/nar/27.22.4427; Ma XJ, 1998, P NATL ACAD SCI USA, V95, P6693, DOI 10.1073/pnas.95.12.6693; MacDonald N, 2005, MOL CELL, V20, P199, DOI 10.1016/j.molcel.2005.08.032; Makowski AM, 2001, J BIOL CHEM, V276, P43499, DOI 10.1074/jbc.C100549200; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; Meijsing SH, 2001, GENE DEV, V15, P3169, DOI 10.1101/gad.929001; MINGARRO I, 1993, J BIOL CHEM, V268, P13248; Mosammaparast N, 2002, J BIOL CHEM, V277, P862, DOI 10.1074/jbc.M106845200; Park IK, 2002, BLOOD, V99, P488, DOI 10.1182/blood.V99.2.488; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S; Poveda A, 2004, J BIOL CHEM, V279, P16033, DOI 10.1074/jbc.M314228200; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Qin S, 2006, MOL CELL BIOL, V26, P3649, DOI 10.1128/MCB.26.9.3649-3658.2006; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; RICHMAN R, 1988, J CELL BIOL, V106, P1017, DOI 10.1083/jcb.106.4.1017; Ruiz-Garcia AB, 1998, J BIOL CHEM, V273, P12599, DOI 10.1074/jbc.273.20.12599; RUIZCARRILLO A, 1975, SCIENCE, V190, P117, DOI 10.1126/science.1166303; Seiden-Long IM, 2006, ONCOGENE, V25, P91, DOI 10.1038/sj.onc.1209005; Sharp JA, 2001, CURR BIOL, V11, P463, DOI 10.1016/S0960-9822(01)00140-3; Singer MS, 1998, GENETICS, V150, P613; Smith ER, 1998, P NATL ACAD SCI USA, V95, P3561, DOI 10.1073/pnas.95.7.3561; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SURES I, 1980, BIOCHEMISTRY-US, V19, P943, DOI 10.1021/bi00546a019; Suter B, 2004, GENETICS, V167, P579, DOI 10.1534/genetics.103.024851; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Trievel RC, 1999, P NATL ACAD SCI USA, V96, P8931, DOI 10.1073/pnas.96.16.8931; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Vermaak D, 1999, MOL CELL BIOL, V19, P5847; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; WIEGAND RC, 1981, J BIOL CHEM, V256, P4578; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	86	132	135	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5319	5328		10.1038/sj.onc.1210602	http://dx.doi.org/10.1038/sj.onc.1210602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694075				2022-12-17	WOS:000248674300002
J	Rothhammer, T; Bataille, F; Spruss, T; Eissner, G; Bosserhoff, AK				Rothhammer, T.; Bataille, F.; Spruss, T.; Eissner, G.; Bosserhoff, A-K			Functional implication of BMP4 expression on angiogenesis in malignant melanoma	ONCOGENE			English	Article						malignant melanoma; endothelium; migration; invasion; angiogenesis	BONE MORPHOGENETIC PROTEIN-2; VASCULOGENIC MIMICRY; TUMOR ANGIOGENESIS; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; GENE-THERAPY; ID PROTEINS; IN-VITRO; GROWTH; CANCER	Analyses of malignant melanomas revealed a strong expression of bone morphogenic proteins (BMPs) and their autocrine effect in promoting cell invasion and migration. Here, we report a paracrine effect of BMPs on the vascular network. Both BMP2 and BMP4 induced tube formation as well as the migratory efficiency of microvascular endothelial cells. Melanoma cells with reduced BMP activity attracted less endothelial cells in invasion assays than control cells. Furthermore, reduction of BMPs in melanoma cells had a strong effect on vasculogenic mimicry. Tube formation on matrigel was analysed for melanoma cells as well as in co-cultures of endothelial and melanoma cells. Melanoma cells with reduced BMP activity were not capable of forming cordlike structures by themselves and additionally inhibited tube formation of the endothelial cells. Genes involved in angiogenesis turned out to be strongly downregulated in these cell clones. Tumors derived from cells with impaired BMP activity showed reduced tumor growth or large necrotic areas owing to lack of angiogenesis in in vivo analyses.	Univ Regensburg, Univ Hosp, Inst Pathol & Mol Pathol, D-93053 Regensburg, Germany; Univ Regensburg, Inst Pharm, D-93053 Regensburg, Germany; Univ Regensburg, Univ Hosp, Dept Hematol & Oncol, D-93053 Regensburg, Germany	University of Regensburg; University of Regensburg; University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022	Bosserhoff, Anja/0000-0001-8147-394X				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Alani RM, 2004, CANCER BIOL THER, V3, P498, DOI 10.4161/cbt.3.6.930; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Benezra R, 2001, ONCOGENE, V20, P8334, DOI 10.1038/sj.onc.1205160; Benezra R, 2001, TRENDS CARDIOVAS MED, V11, P237, DOI 10.1016/S1050-1738(01)00117-7; Botchkarev VA, 2004, DIFFERENTIATION, V72, P512, DOI 10.1111/j.1432-0436.2004.07209005.x; Cavallaro U, 2000, J NEURO-ONCOL, V50, P63, DOI 10.1023/A:1006414621286; Deckers MML, 2002, ENDOCRINOLOGY, V143, P1545, DOI 10.1210/en.143.4.1545; Ding Z, 2005, LYMPHOLOGY, V38, P87; Folberg R, 2000, AM J PATHOL, V156, P361, DOI 10.1016/S0002-9440(10)64739-6; Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x; Hatakeyama S, 1997, BIOCHEM MOL BIOL INT, V42, P497; HATAKEYAMA S, 1993, BIOCHEM BIOPH RES CO, V190, P695, DOI 10.1006/bbrc.1993.1105; Hendrix MJC, 2003, ONCOGENE, V22, P3070, DOI 10.1038/sj.onc.1206447; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; Ide H, 1997, CANCER RES, V57, P5022; Jones N, 2000, CANCER METAST REV, V19, P13, DOI 10.1023/A:1026555121511; Kiyozuka Y, 2001, ANTICANCER RES, V21, P1723; Kleeff J, 1999, GASTROENTEROLOGY, V116, P1202, DOI 10.1016/S0016-5085(99)70024-7; Langenfeld EM, 2004, MOL CANCER RES, V2, P141; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; McDonald DM, 2000, CANCER METAST REV, V19, P109, DOI 10.1023/A:1026529222845; McDonald DM, 2000, AM J PATHOL, V156, P383, DOI 10.1016/S0002-9440(10)64740-2; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; Pache G, 2006, AM J PHYSIOL-RENAL, V291, pF654, DOI 10.1152/ajprenal.00214.2004; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Peng HR, 2002, J CLIN INVEST, V110, P751, DOI 10.1172/JCI200215153; Peters KG, 2004, RECENT PROG HORM RES, V59, P51, DOI 10.1210/rp.59.1.51; Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432-005-0024-1; Rothhammer T, 2005, CANCER RES, V65, P448; Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559; Seftor EA, 2002, CRIT REV ONCOL HEMAT, V44, P17, DOI 10.1016/S1040-8428(01)00199-8; Straume O, 2005, BRIT J CANCER, V93, P933, DOI 10.1038/sj.bjc.6602792; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; Turgeman G, 2001, J GENE MED, V3, P240; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Valdimarsdottir G, 2002, CIRCULATION, V106, P2263, DOI 10.1161/01.CIR.0000033830.36431.46; Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Yamamoto Y, 2004, NATURWISSENSCHAFTEN, V91, P519, DOI 10.1007/s00114-004-0575-z	44	132	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4158	4170		10.1038/sj.onc.1210182	http://dx.doi.org/10.1038/sj.onc.1210182			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17173062				2022-12-17	WOS:000247252700011
J	Billottet, C; Grandage, VL; Gale, RE; Quattropani, A; Rommel, C; Vanhaesebroeck, B; Khwaja, A				Billottet, C.; Grandage, V. L.; Gale, R. E.; Quattropani, A.; Rommel, C.; Vanhaesebroeck, B.; Khwaja, A.			A selective inhibitor of the p110 delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16	ONCOGENE			English	Article						AML; PI3K; P110 delta; Akt; PKB; VP16; NF-kappa B	ACUTE MYELOID-LEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; B-CELL; SIGNALING PATHWAY; DRUG-RESISTANCE; HUMAN CANCER; P110 DELTA; KAPPA-B; MUTATIONS	Current therapy for acute myeloid leukaemia (AML) is suboptimal with a high incidence of relapse. There is strong evidence that constitutive phosphoinositide 3-kinase (PI3K) activity plays a significant role in the pathophysiology of AML. PI3K products are derived from the activity of a number of PI3K catalytic isoforms (class I, II and III) but the relative contribution of these enzymes in AML remains unknown. As non-isoform-selective inhibitors of PI3K such as LY294002 may produce unwanted toxicity to normal tissues, we have investigated the role of the leukocyte-restricted p110 delta PI3K isoform in 14 cases of AML. p110d was detected in all cases whereas the expression levels of the other class I PI3Ks varied more widely, and were often undetectable. The p110 delta-selective compound IC87114 inhibited constitutive phosphorylation of the PI3K target Akt/PKB and reduced cell number to a mean of 66 +/- 5% (range 14-88%). In eight cases, the combination of IC87114 and VP16 (a topoisomerase II inhibitor) was synergistic in reducing viable cell number, and was associated with a reduction in constitutive NF-kappa B activity. IC87114 did not have direct adverse effects or enhance the activity of VP16 on the proliferation and survival of normal haemopoietic progenitors. Overall, our results identify the p110d isoform as a potential therapeutic target in AML and support a clinical approach to use isoform-selective over broad-spectrum PI3K inhibitors.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Dept Haematol, London, England; UCL, Sch Med, London W1N 8AA, England; Serono Pharmaceut Res Inst, Geneva, Switzerland; UCL, Dept Biochem & Mol Biol, London, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London; UCL Medical School; University of London; University College London	Vanhaesebroeck, B (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	bartvanh@ludwig.ucl.ac.uk; a.khwaja@ucl.ac.uk	SHAKOORI, ABDUL RAUF/Q-9373-2019; Khwaja, Asim/C-1509-2008	Billottet, Clotilde/0000-0003-1819-984X				Aggerholm A, 2000, EUR J HAEMATOL, V65, P109, DOI 10.1034/j.1600-0609.2000.90181.x; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020; Bilancio A, 2006, BLOOD, V107, P642, DOI 10.1182/blood-2005-07-3041; Bousquet M, 2005, BRIT J HAEMATOL, V131, P411, DOI 10.1111/j.1365-2141.2005.05784.x; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Brognard J, 2001, CANCER RES, V61, P3986; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chantry D, 1997, J BIOL CHEM, V272, P19236, DOI 10.1074/jbc.272.31.19236; Cheong JW, 2003, BRIT J HAEMATOL, V122, P454, DOI 10.1046/j.1365-2141.2003.04452.x; Clayton E, 2002, J EXP MED, V196, P753, DOI 10.1084/jem.20020805; Cornillet-Lefebvre P, 2006, LEUKEMIA, V20, P374, DOI 10.1038/sj.leu.2404054; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fruman DA, 2004, BIOCHEM SOC T, V32, P315, DOI 10.1042/BST0320315; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kaspers GJL, 2003, RECENT RES CANCER, V161, P196; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Knight ZA, 2004, BIOORGAN MED CHEM, V12, P4749, DOI 10.1016/j.bmc.2004.06.022; Koizumi T., 2002, Patent US, Patent No. [6,403,588 B1, 11, 6403588]; Kubota Y, 2004, LEUKEMIA, V18, P1438, DOI 10.1038/sj.leu.2403402; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Luo JM, 2003, LEUKEMIA, V17, P1, DOI 10.1038/sj.leu.2402725; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Nanri T, 2005, LEUKEMIA, V19, P1361, DOI 10.1038/sj.leu.2403803; NEUBAUER A, 1994, BLOOD, V83, P1603; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Okkenhaug K, 2004, BIOCHEM SOC T, V32, P332, DOI 10.1042/BST0320332; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021; Reif K, 2004, J IMMUNOL, V173, P2236, DOI 10.4049/jimmunol.173.4.2236; ROBERTSON AJ, 2001, Patent No. 0153266; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647; Sadhu C, 2001, [No title captured], Patent No. [WO0181346, 0181346]; Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sargent JM, 2003, RECENT RESULTS CANC, V161, P13; Sawyer C, 2003, CANCER RES, V63, P1667; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sujobert P, 2005, BLOOD, V106, P1063, DOI 10.1182/blood-2004-08-3225; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; WANTZIN GL, 1977, EUR J CANCER, V13, P647, DOI 10.1016/0014-2964(77)90050-0; Warner JK, 2004, ONCOGENE, V23, P7164, DOI 10.1038/sj.onc.1207933; Watts MJ, 2002, BRIT J HAEMATOL, V118, P117, DOI 10.1046/j.1365-2141.2002.03561.x; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Wymann MP, 2003, TRENDS PHARMACOL SCI, V24, P366, DOI 10.1016/S0165-6147(03)00163-9; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Zhao S, 2004, LEUKEMIA, V18, P267, DOI 10.1038/sj.leu.2403220	67	132	194	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6648	6659		10.1038/sj.onc.1209670	http://dx.doi.org/10.1038/sj.onc.1209670			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16702948				2022-12-17	WOS:000241569700009
J	Nagar, S; Remmel, RP				Nagar, S; Remmel, RP			Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer	ONCOGENE			English	Review						drug metabolism; uridine diphosphoglucuronosyltransferase; genetic polymorphisms	HUMAN UDP-GLUCURONOSYLTRANSFERASE; HUMAN LIVER-MICROSOMES; SINGLE-NUCLEOTIDE POLYMORPHISMS; SERUM BILIRUBIN CONCENTRATIONS; UGT1A1 PROMOTER POLYMORPHISM; 1A7 GENETIC POLYMORPHISMS; IN-VITRO GLUCURONIDATION; CRIGLER-NAJJAR-SYNDROME; N-HYDROXY-PHIP; GILBERTS-SYNDROME	The uridine diphosphoglucuronosyltransferases (UGTs) belong to a superfamily of enzymes that catalyse the glucuronidation of numerous endobiotics and xenobiotics. Several human hepatic and extrahepatic UGT isozymes have been characterized with respect to their substrate specificity, tissue expression and gene structure. Genetic polymorphisms have been identified for almost all the UGT family members. A wide variety of anticancer drugs, dietary chemopreventives and carcinogens are known to be conjugated by members of both UGT1A and UGT2B subfamilies. This review examines in detail each UGT isozyme known to be associated with cancer and carcinogenesis. The cancer-related substrates for several UGTs are summarized, and the functionally relevant genetic polymorphisms of UGTs are reviewed. A number of genotype-phenotype association studies have been carried out to characterize the role of UGT pharmacogenetics in several types of cancer, and these examples are discussed here. In summary, this review focuses on the role of the human UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.	Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA; Univ Minnesota, Coll Pharm, Dept Med Chem, Minneapolis, MN USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Minnesota System; University of Minnesota Twin Cities	Nagar, S (corresponding author), Temple Univ, Sch Pharm, Dept Pharmaceut Sci, 3307 N Broad St, Philadelphia, PA 19140 USA.	swati.nagar@temple.edu	Remmel, Rory/N-2453-2015; , Swati/AAC-3195-2020					Adegoke OJ, 2004, BREAST CANCER RES TR, V85, P239, DOI 10.1023/B:BREA.0000025419.26423.b8; Andersen A, 1999, CANCER CHEMOTH PHARM, V44, P422, DOI 10.1007/s002800050999; Ando M, 2002, JPN J CANCER RES, V93, P591, DOI 10.1111/j.1349-7006.2002.tb01295.x; Ando Y, 1998, PHARMACOGENETICS, V8, P357, DOI 10.1097/00008571-199808000-00010; Ando Y, 2000, CANCER RES, V60, P6921; AONO S, 1993, BIOCHEM BIOPH RES CO, V197, P1239, DOI 10.1006/bbrc.1993.2610; Araki J, 2005, EUR J CANCER, V41, P2360, DOI 10.1016/j.ejca.2005.04.043; Balram C, 2002, PHARMACOGENETICS, V12, P81, DOI 10.1097/00008571-200201000-00012; Barbier O, 2000, DRUG METAB DISPOS, V28, P497; Barua AB, 2004, J NUTR, V134, p286S, DOI 10.1093/jn/134.1.286S; Belanger A, 2003, TRENDS ENDOCRIN MET, V14, P473, DOI 10.1016/j.tem.2003.10.005; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; Bhasker CR, 2000, PHARMACOGENETICS, V10, P679, DOI 10.1097/00008571-200011000-00002; Bigler J, 2001, CANCER RES, V61, P3566; Biondi ML, 1999, CLIN CHEM, V45, P897; Borlak J, 2000, HEPATOLOGY, V32, P792, DOI 10.1053/jhep.2000.18193; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; BURCHELL B, 1989, PHARMACOL THERAPEUT, V43, P261, DOI 10.1016/0163-7258(89)90122-8; Burchell Brian, 2003, Am J Pharmacogenomics, V3, P37, DOI 10.2165/00129785-200303010-00006; Butler LM, 2005, CANCER EPIDEM BIOMAR, V14, P1626, DOI 10.1158/1055-9965.EPI-04-0682; Carlini LE, 2005, CLIN CANCER RES, V11, P1226; Chan AT, 2005, JNCI-J NATL CANCER I, V97, P457, DOI 10.1093/jnci/dji066; Chen YK, 2005, WORLD J GASTROENTERO, V11, P118, DOI 10.3748/wjg.v11.i1.118; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Cheng ZQ, 1998, TOXICOL SCI, V45, P52, DOI 10.1093/toxsci/45.1.52; Chouinard S, 2004, ENDOCR RES, V30, P717, DOI 10.1081/ERC-200044014; Ciotti M, 1997, PHARMACOGENETICS, V7, P485, DOI 10.1097/00008571-199712000-00007; Clarke DJ, 1997, BIOCHEM SOC T, V25, pS562, DOI 10.1042/bst025s562; Coffman BL, 1997, DRUG METAB DISPOS, V25, P1; Court MH, 2001, J PHARMACOL EXP THER, V299, P998; Court MH, 2004, J PHARMACOL EXP THER, V310, P656, DOI 10.1124/jpet.104.067660; Daidoji T, 2005, DRUG METAB DISPOS, V33, P1466, DOI 10.1124/dmd.105.004416; Desai AA, 2003, PHARMACOGENETICS, V13, P517, DOI 10.1097/00008571-200308000-00010; Duguay Y, 2004, CLIN PHARMACOL THER, V75, P223, DOI 10.1016/j.clpt.2003.10.006; Duguay Y, 2004, CANCER RES, V64, P1202, DOI 10.1158/0008-5472.CAN-03-3295; Ehmer U, 2004, HEPATOLOGY, V39, P970, DOI 10.1002/hep.20131; Elahi A, 2003, CANCER-AM CANCER SOC, V98, P872, DOI 10.1002/cncr.11587; Fang JL, 2004, CANCER EPIDEM BIOMAR, V13, P102, DOI 10.1158/1055-9965.EPI-03-0070; Fisher MB, 2000, DRUG METAB DISPOS, V28, P560; Gagne JF, 2002, MOL PHARMACOL, V62, P608, DOI 10.1124/mol.62.3.608; Gestl SA, 2002, AM J PATHOL, V160, P1467, DOI 10.1016/S0002-9440(10)62572-2; Girard H, 2004, PHARMACOGENETICS, V14, P501, DOI 10.1097/01.fpc.0000114754.08559.27; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; GREEN MD, 1994, DRUG METAB DISPOS, V22, P799; Green MD, 1998, DRUG METAB DISPOS, V26, P507; Gregory PA, 2000, PHARMACOGENETICS, V10, P809, DOI 10.1097/00008571-200012000-00006; Guillemette C, 2000, PHARMACOGENETICS, V10, P629, DOI 10.1097/00008571-200010000-00006; Guillemette C, 2000, CANCER RES, V60, P950; Guillemette C, 2001, CANCER EPIDEM BIOMAR, V10, P711; Hagenauer B, 2001, DRUG METAB DISPOS, V29, P407; Hirota T, 2003, DRUG METAB DISPOS, V31, P677, DOI 10.1124/dmd.31.5.677; Holthe M, 2003, PHARMACOGENOMICS J, V3, P17, DOI 10.1038/sj.tpj.6500139; Holthe M, 2002, EUR J CLIN PHARMACOL, V58, P353, DOI 10.1007/s00228-002-0490-1; Huang YH, 2002, PHARMACOGENETICS, V12, P287, DOI 10.1097/00008571-200206000-00004; Iida A, 2002, J HUM GENET, V47, P505, DOI 10.1007/s100380200075; Innocenti F, 2005, PHARMACOGENET GENOM, V15, P295, DOI 10.1097/01213011-200505000-00004; Innocenti F, 2004, J CLIN ONCOL, V22, P1382, DOI 10.1200/JCO.2004.07.173; Innocenti F, 2001, DRUG METAB DISPOS, V29, P686; Ito M, 2002, EUR J CLIN PHARMACOL, V58, P11, DOI 10.1007/s00228-001-0417-2; Iwai M, 2004, J HUM GENET, V49, P123, DOI 10.1007/s10038-003-0119-y; Iyer L, 1999, CLIN PHARMACOL THER, V65, P576, DOI 10.1016/S0009-9236(99)70078-0; Jeong EJ, 2005, DRUG METAB DISPOS, V33, P785, DOI 10.1124/dmd.104.001883; Jinno H, 2003, J PHARMACOL EXP THER, V306, P688, DOI 10.1124/jpet.103.051250; Jinno H, 2003, DRUG METAB DISPOS, V31, P528, DOI 10.1124/dmd.31.5.528; Jinno H, 2003, DRUG METAB DISPOS, V31, P108, DOI 10.1124/dmd.31.1.108; Kaku T, 2004, BIOCHEM PHARMACOL, V67, P2093, DOI 10.1016/j.bcp.2004.02.014; Kalies KU, 1998, EUR J BIOCHEM, V254, P1, DOI 10.1046/j.1432-1327.1998.2540001.x; Kaniwa N, 2005, DRUG METAB DISPOS, V33, P458, DOI 10.1124/dmd.104.001800; Kiang TKL, 2005, PHARMACOL THERAPEUT, V106, P97, DOI 10.1016/j.pharmthera.2004.10.013; King CD, 1999, ARCH BIOCHEM BIOPHYS, V365, P156, DOI 10.1006/abbi.1999.1155; Kohle C, 2003, BIOCHEM PHARMACOL, V65, P1521, DOI 10.1016/S0006-2952(03)00074-1; KOIWAI O, 1995, HUM MOL GENET, V4, P1183, DOI 10.1093/hmg/4.7.1183; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1331, DOI 10.1124/jpet.104.081950; Krishnaswamy S, 2005, J PHARMACOL EXP THER, V313, P1340, DOI 10.1124/jpet.104.081968; Krishnaswamy S, 2003, DRUG METAB DISPOS, V31, P133, DOI 10.1124/dmd.31.1.133; Kuehl GE, 2003, DRUG METAB DISPOS, V31, P1361, DOI 10.1124/dmd.31.11.1361; Lampe JW, 1999, PHARMACOGENETICS, V9, P341, DOI 10.1097/00008571-199906000-00009; Lampe JW, 2000, CANCER EPIDEM BIOMAR, V9, P329; Lazarus P, 2005, PHARMACOGENET GENOM, V15, P769, DOI 10.1097/01.fpc.0000175596.52443.ef; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; Levesque B, 1999, PHARMACOGENETICS, V9, P207; Levesque E, 1998, ENDOCRINOLOGY, V139, P2375, DOI 10.1210/en.139.5.2375; Levesque E, 1997, PHARMACOGENETICS, V7, P317, DOI 10.1097/00008571-199708000-00007; Levesque E, 2001, BIOCHEMISTRY-US, V40, P3869, DOI 10.1021/bi002607y; Lin GF, 2005, TOXICOL SCI, V85, P502, DOI 10.1093/toxsci/kfi068; Lu H, 2003, DRUG METAB DISPOS, V31, P452, DOI 10.1124/dmd.31.4.452; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MacLeod SL, 2000, ANN SURG ONCOL, V7, P777, DOI 10.1007/s10434-000-0777-3; Malfatti MA, 2004, CHEM RES TOXICOL, V17, P1137, DOI 10.1021/tx049898m; Malfatti MA, 2001, CARCINOGENESIS, V22, P1087, DOI 10.1093/carcin/22.7.1087; Marcuello E, 2004, BRIT J CANCER, V91, P678, DOI 10.1038/sj.bjc.6602042; Mathijssen RHJ, 2003, CLIN CANCER RES, V9, P3246; MCCAGUE R, 1990, BIOCHEM PHARMACOL, V39, P1459, DOI 10.1016/0006-2952(90)90427-M; Meech R, 1998, ARCH BIOCHEM BIOPHYS, V356, P77, DOI 10.1006/abbi.1998.0750; MINERS JO, 1991, PHARMACOL THERAPEUT, V51, P347, DOI 10.1016/0163-7258(91)90065-T; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; Monaghan G, 1997, MAMM GENOME, V8, P692, DOI 10.1007/s003359900539; Monaghan G, 1996, LANCET, V347, P578, DOI 10.1016/S0140-6736(96)91273-8; Nagar S, 2004, PHARMACOGENETICS, V14, P487, DOI 10.1097/01.fpc.0000114771.78957.cb; Nakajima Miki, 2005, Drug Metab Pharmacokinet, V20, P227, DOI 10.2133/dmpk.20.227; Nong SH, 2005, J PAEDIATR CHILD H, V41, P300, DOI 10.1111/j.1440-1754.2005.00616.x; Nowell SA, 2005, BREAST CANCER RES TR, V91, P249, DOI 10.1007/s10549-004-7751-x; Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4; Oguri T, 2004, ANTICANCER RES, V24, P2893; Ouzzine M, 1999, J BIOL CHEM, V274, P31401, DOI 10.1074/jbc.274.44.31401; OWENS IS, 1995, PROG NUCLEIC ACID RE, V51, P305, DOI 10.1016/S0079-6603(08)60882-X; Paoluzzi L, 2004, J CLIN PHARMACOL, V44, P854, DOI 10.1177/0091270004267159; Park J, 2004, J UROLOGY, V171, P2484, DOI 10.1097/01.ju.0000117748.44313.43; Peters WHM, 2003, J HEPATOL, V38, P3, DOI 10.1016/S0168-8278(02)00306-9; Platzer P, 1998, ANTICANCER RES, V18, P2695; Riedy M, 2000, PHARMACOGENETICS, V10, P251, DOI 10.1097/00008571-200004000-00006; RITTER JK, 1991, J BIOL CHEM, V266, P1043; Rosing H, 1998, ANTI-CANCER DRUG, V9, P587, DOI 10.1097/00001813-199808000-00002; Rouits E, 2004, CLIN CANCER RES, V10, P5151, DOI 10.1158/1078-0432.CCR-03-0548; Saeki M, 2004, DRUG METAB DISPOS, V32, P1048; Saeki Mayumi, 2005, Drug Metab Pharmacokinet, V20, P144, DOI 10.2133/dmpk.20.144; Saeki Mayumi, 2005, Drug Metab Pharmacokinet, V20, P85, DOI 10.2133/dmpk.20.85; Saeki Mayumi, 2003, Drug Metab Pharmacokinet, V18, P146, DOI 10.2133/dmpk.18.146; Saeki Mayumi, 2002, Drug Metab Pharmacokinet, V17, P488, DOI 10.2133/dmpk.17.488; Sai K, 2004, CLIN PHARMACOL THER, V75, P501, DOI 10.1016/j.clpt.2004.01.010; Samokyszyn VM, 2000, J BIOL CHEM, V275, P6908, DOI 10.1074/jbc.275.10.6908; Sparks R, 2004, BREAST CANCER RES, V6, pR488, DOI 10.1186/bcr818; Staines AG, 2004, BIOCHEM J, V384, P637, DOI 10.1042/BJ20040997; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1999, BIOCHEM J, V338, P489, DOI 10.1042/0264-6021:3380489; Strassburg CP, 2002, GUT, V50, P851, DOI 10.1136/gut.50.6.851; Tang KS, 2005, WORLD J GASTROENTERO, V11, P3250, DOI 10.3748/wjg.v11.i21.3250; te Morsche RHM, 2001, HEPATOLOGY, V33, P765, DOI 10.1053/jhep.2001.0103303le03; Tseng CS, 2005, AM J GASTROENTEROL, V100, P1758, DOI 10.1111/j.1572-0241.2005.41857.x; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turgeon D, 2003, DRUG METAB DISPOS, V31, P670, DOI 10.1124/dmd.31.5.670; van der Logt EMJ, 2004, CARCINOGENESIS, V25, P2407, DOI 10.1093/carcin/bgh251; Verlaan M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032599; Verlaan M, 2004, PHARMACOGENETICS, V14, P351, DOI 10.1097/00008571-200406000-00004; Villeneuve L, 2003, J PHARMACOL EXP THER, V307, P117, DOI 10.1124/jpet.103.054072; Vogel A, 2002, Z GASTROENTEROL, V40, P497, DOI 10.1055/s-2002-32805; Vogel A, 2001, GASTROENTEROLOGY, V121, P1136, DOI 10.1053/gast.2001.28655; Wang Y, 2004, CLIN CANCER RES, V10, P2441, DOI 10.1158/1078-0432.CCR-1187-3; Watanabe Y, 2003, DRUG METAB DISPOS, V31, P589, DOI 10.1124/dmd.31.5.589; Wells PG, 2004, DRUG METAB DISPOS, V32, P281, DOI 10.1124/dmd.32.3.281; Wiener D, 2004, DRUG METAB DISPOS, V32, P72, DOI 10.1124/dmd.32.1.72; Wiener D, 2004, CANCER RES, V64, P1190, DOI 10.1158/0008-5472.CAN-03-3219; Yamanaka H, 2005, DRUG METAB DISPOS, V33, P23, DOI 10.1124/dmd.104.001701; Yamanaka H, 2004, PHARMACOGENETICS, V14, P329, DOI 10.1097/00008571-200405000-00008; Yueh MF, 2001, CARCINOGENESIS, V22, P943, DOI 10.1093/carcin/22.6.943; Zenser TV, 2002, MUTAT RES-FUND MOL M, V506, P29, DOI 10.1016/S0027-5107(02)00149-5; Zheng Z, 2001, JNCI-J NATL CANCER I, V93, P1411, DOI 10.1093/jnci/93.18.1411; Zhou QY, 2005, BRIT J CLIN PHARMACO, V59, P415, DOI 10.1111/j.1365-2125.2004.02330.x	149	132	138	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	11					1659	1672		10.1038/sj.onc.1209375	http://dx.doi.org/10.1038/sj.onc.1209375			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020JL	16550166				2022-12-17	WOS:000235904700008
J	Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R				Deep, G; Singh, RP; Agarwal, C; Kroll, DJ; Agarwal, R			Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin	ONCOGENE			English	Article						prostate cancer; silibinin; silymarin; cell cycle arrest; cyclin-dependent kinase	DEPENDENT KINASE INHIBITORS; THISTLE SILYBUM-MARIANUM; CARCINOMA DU145 CELLS; DNA-DAMAGE; CHECKPOINT CONTROL; BREAST-CANCER; MILK THISTLE; FLAVONOID ANTIOXIDANT; CDC25B PHOSPHATASE; MAMMALIAN-CELLS	Here, we assessed and compared the anticancer efficacy and associated mechanisms of silymarin and silibinin in human prostate cancer (PCA) PC3 cells; silymarin is comprised of silibinin and its other stereoisomers, including isosilybin A, isosilybin B, silydianin, silychristin and isosilychristin. Silymarin and silibinin (50-100 mu g/ml) inhibited cell proliferation, induced cell death, and caused G1 and G2-M cell cycle arrest in a dose/time-dependent manner. Molecular studies showed that G1 arrest was associated with a decrease in cyclin D1, cyclin D3, cyclin E, cyclin-dependent kinase (CDK)4, CDK6 and CDK2 protein levels, and CDK2 and CDK4 kinase activity, together with an increase in CDK inhibitors (CDKIs) Kip1/p27 and Cip1/p21. Further, both agents caused cytoplasmic sequestration of cyclin D1 and CDK2, contributing to G1 arrest. The G2-M arrest by silibinin and silymarin was associated with decreased levels of cyclin B1, cyclin A, pCdc2 (Tyr15), Cdc2, and an inhibition of Cdc2 kinase activity. Both agents also decreased the levels of Cdc25B and cell division cycle 25C (Cdc25C) phosphatases with an increased phosphorylation of Cdc25C at Ser216 and its translocation from nucleus to the cytoplasm, which was accompanied by an increased binding with 14-3-3 beta. Both agents also increased checkpoint kinase (Chk)2 phosphorylation at Thr68 and Ser19 sites, which is known to phosphorylate Cdc25C at Ser216 site. Chk2-specific small interfering RNA largely attenuated the silymarin and silibinin-induced G2-M arrest. An increase in the phosphorylation of histone 2AX and ataxia telangiectasia mutated was also observed. These findings indicate that silymarin and silibinin modulate G1 phase cyclins-CDKs-CDKIs for G1 arrest, and the Chk2-Cdc25C-Cdc2/cyclin B1 pathway for G2-M arrest, together with an altered subcellular localization of critical cell cycle regulators. Overall, we observed comparable effects for both silymarin and silibinin at equal concentrations by weight, suggesting that silibinin could be a major cell cycle-inhibitory component in silymarin. However, other silibinin stereo-isomers present in silymarin also contribute to its efficacy, and could be of interest for future investigation.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80202 USA; Ctr Organ & Med Chem, Nat Prod Lab, Res Triangle Pk, NC USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	Rajesh.Agarwal@UCHSC.edu	Deep, Gagan/H-1853-2012		NATIONAL CANCER INSTITUTE [R01CA104286, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102514, R01 CA104286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ADELAIDE J, 1995, BRIT J CANCER, V71, P64, DOI 10.1038/bjc.1995.13; Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; *AM CANC SOC, 2008, CANC FACTS FIG 2008, P1; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; BARTKOVA J, 1995, CANCER RES, V55, P949; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buscemi G, 2004, ONCOGENE, V23, P7691, DOI 10.1038/sj.onc.1207986; Caputi M, 1999, AM J RESP CELL MOL, V20, P746, DOI 10.1165/ajrcmb.20.4.3366; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Drobnjak M, 2000, CLIN CANCER RES, V6, P1891; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Flora K, 1998, AM J GASTROENTEROL, V93, P139, DOI 10.1111/j.1572-0241.1998.00139.x; Gabrielli BG, 1996, J CELL SCI, V109, P1081; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GILLETT C, 1994, CANCER RES, V54, P1812; GRANA X, 1995, ONCOGENE, V11, P211; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Hou DX, 2004, J BIOMED BIOTECHNOL, P321, DOI 10.1155/S1110724304403040; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim NC, 2003, ORG BIOMOL CHEM, V1, P1684, DOI 10.1039/b300099k; Koivisto P, 1998, AM J PATHOL, V152, P1; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Lammer C, 1998, J CELL SCI, V111, P2445; Langner C, 2004, VIRCHOWS ARCH, V445, P631, DOI 10.1007/s00428-004-1121-2; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lyon MA, 2002, NAT REV DRUG DISCOV, V1, P961, DOI 10.1038/nrd963; Mallikarjuna G, 2004, CANCER RES, V64, P6349, DOI 10.1158/0008-5472.CAN-04-1632; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; McDonald ER, 2000, INT J ONCOL, V16, P871; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Neuhouser ML, 2004, NUTR CANCER, V50, P1, DOI 10.1207/s15327914nc5001_1; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Owa T, 2001, CURR MED CHEM, V8, P1487, DOI 10.2174/0929867013371996; Pares A, 1998, J HEPATOL, V28, P615, DOI 10.1016/S0168-8278(98)80285-7; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SEKI T, 1992, MOL BIOL CELL, V3, P1373, DOI 10.1091/mbc.3.12.1373; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Sharma G, 2003, ANTICANCER RES, V23, P2649; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Singh RP, 2004, CLIN CANCER RES, V10, P8641, DOI 10.1158/1078-0432.CCR-04-1435; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200; Sumrejkanchanakij P, 2003, ONCOGENE, V22, P8723, DOI 10.1038/sj.onc.1206870; Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189; Takagaki N, 2005, INT J ONCOL, V26, P185; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Thelen P, 2004, J UROLOGY, V171, P1934, DOI 10.1097/01.ju.0000121329.37206.1b; Turowski P, 2003, MOL BIOL CELL, V14, P2984, DOI 10.1091/mbc.E02-08-0515; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; von Zglinicki T, 2005, MECH AGEING DEV, V126, P111, DOI 10.1016/j.mad.2004.09.034; WAGNER H, 1974, ARZNEIMITTEL-FORSCH, V24, P466; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang ES, 2003, J BIOL CHEM, V278, P46862, DOI 10.1074/jbc.M306340200; Ye RQ, 2004, DNA REPAIR, V3, P235, DOI 10.1016/j.dnarep.2003.10.014; Ye RQ, 2001, J BIOL CHEM, V276, P4828, DOI 10.1074/jbc.M004894200; Yih LH, 2000, CANCER RES, V60, P6346; Yim D, 2005, CANCER RES, V65, P1035; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zheng Xiang-Yi, 2004, Ai Zheng, V23, P215; Zi XL, 1998, CANCER RES, V58, P1920; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	85	132	138	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2006	25	7					1053	1069		10.1038/sj.onc.1209146	http://dx.doi.org/10.1038/sj.onc.1209146			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	012SX	16205633				2022-12-17	WOS:000235361000010
J	Marriott, SJ; Semmes, OJ				Marriott, SJ; Semmes, OJ			Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response	ONCOGENE			English	Review						HTLV-I; tax; cell cycle; DNA repair; genome instability	VIRUS TYPE-1 TAX; ANAPHASE-PROMOTING COMPLEX; NUCLEOTIDE EXCISION-REPAIR; ONCOGENE PRODUCT TAX; MITOTIC CHECKPOINT GENES; KAPPA-B PATHWAY; MICROSATELLITE INSTABILITY; SPINDLE CHECKPOINT; LEUKEMIA-LYMPHOMA; TRANSCRIPTIONAL ACTIVATION	Human T-cell lymphotropic virus type I (HTLV-I) is the etiologic agent of adult T-cell leukemia (ATL), a rapidly progressing, clonal malignancy of CD4+ T lymphocytes. Fewer than one in 20 infected individuals typically develop ATL and the onset of this cancer occurs after decades of relatively symptom-free infection. Leukemic cells from ATL patients display extensive and varied forms of chromosomal abnormalities and this genomic instability is thought to be a major contributor to the development of ATL. HTLV-I encodes a regulatory protein, Tax, which is necessary and sufficient to transform cells and is therefore considered to be the viral oncoprotein. Tax interacts with numerous cellular proteins to reprogram cellular processes including, but not limited to, transcription, cell cycle regulation, DNA repair, and apoptosis. This review presents an overview of the impact of HTLV-I infection in general, and Tax expression in particular, on cell cycle progression and the repair of DNA damage. The contribution of these activities to genome instability and cellular transformation will be discussed.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23508 USA	Baylor College of Medicine; Eastern Virginia Medical School	Marriott, SJ (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Pl, Houston, TX 77030 USA.	susanm@bcm.tmc.edu	Semmes, Oliver/GQA-5179-2022		NATIONAL CANCER INSTITUTE [R01CA076595, R01CA077371, R01CA055684, U01CA085067] Funding Source: NIH RePORTER; NCI NIH HHS [CA-76595, CA-55684, CA-77371, CA-85067] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Akagi T, 1996, ONCOGENE, V12, P1645; ARLETT CF, 1989, MUTAGENESIS, V4, P482, DOI 10.1093/mutage/4.6.482; Ball K L, 1997, Prog Cell Cycle Res, V3, P125; Benhamou S, 2000, MUTAT RES-REV MUTAT, V462, P149, DOI 10.1016/S1383-5742(00)00032-6; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; CHIECOBIANCHI L, 1988, LEUKEMIA, V2, pS223; De La Fuente C, 2000, J VIROL, V74, P7270, DOI 10.1128/JVI.74.16.7270-7283.2000; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; Franzese O, 2002, AIDS RES HUM RETROV, V18, P249, DOI 10.1089/088922202753472810; Fujimoto T, 1999, CANCER GENET CYTOGEN, V109, P1, DOI 10.1016/S0165-4608(98)00141-1; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038/sj.onc.1206468; Gatza ML, 2003, ONCOGENE, V22, P5141, DOI 10.1038/sj.onc.1206549; Haller K, 2002, MOL CELL BIOL, V22, P3327, DOI 10.1128/MCB.22.10.3327-3338.2002; Hanawalt P C, 1986, Basic Life Sci, V38, P489; Haoudi A, 2003, J BIOL CHEM, V278, P37736, DOI 10.1074/jbc.M301649200; Haoudi A, 2003, VIROLOGY, V305, P229, DOI 10.1006/viro.2002.1642; Harper Jane V., 2004, V296, P113; Hatta Y, 1997, BRIT J HAEMATOL, V99, P665; Hatta Y, 1997, LEUKEMIA, V11, P984, DOI 10.1038/sj.leu.2400686; Hatta Y, 1998, BRIT J HAEMATOL, V101, P341, DOI 10.1046/j.1365-2141.1998.00710.x; Hatta Y, 2002, LEUKEMIA, V16, P1069, DOI 10.1038/sj.leu.2402458; Hayami Y, 1999, LEUKEMIA LYMPHOMA, V32, P345, DOI 10.3109/10428199909167395; Herdegen T, 1998, BRAIN RES REV, V28, P370, DOI 10.1016/S0165-0173(98)00018-6; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; ITOYAMA T, 1990, CANCER GENET CYTOGEN, V49, P157, DOI 10.1016/0165-4608(90)90137-Y; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jeang KT, 2004, J BIOL CHEM, V279, P31991, DOI 10.1074/jbc.R400009200; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Jeong SJ, 2004, BLOOD, V104, P1490, DOI 10.1182/blood-2003-12-4174; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; KAMADA Y, 1992, CANCER, V70, P861, DOI 10.1002/1097-0142(19920815)70:4&lt;861::AID-CNCR2820700423&gt;3.0.CO;2-4; Kao SY, 2000, J BIOL CHEM, V275, P35926, DOI 10.1074/jbc.M004397200; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kawata S, 2003, J VIROL, V77, P7291, DOI 10.1128/JVI.77.13.7291-7299.2003; Kehn K, 2005, ONCOGENE, V24, P525, DOI 10.1038/sj.onc.1208105; Kehn Kylene, 2004, Retrovirology, V1, P6, DOI 10.1186/1742-4690-1-6; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Kino T, 2004, DNA CELL BIOL, V23, P193, DOI 10.1089/104454904773819789; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; LABAER J, 1997, GENE DEV, V8, P1750; Lemasson I, 1998, J BIOL CHEM, V273, P23598, DOI 10.1074/jbc.273.36.23598; Lemoine FJ, 2002, ONCOGENE, V21, P7230, DOI 10.1038/sj.onc.1205898; Lemoine FJ, 2001, DIS MARKERS, V17, P129, DOI 10.1155/2001/263567; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lemoine FJ, 2000, AIDS RES HUM RETROV, V16, P1623, DOI 10.1089/08892220050193056; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Liang MH, 2002, J VIROL, V76, P4022, DOI 10.1128/JVI.76.8.4022-4033.2002; Liu BY, 2005, P NATL ACAD SCI USA, V102, P63, DOI 10.1073/pnas.0406424101; Liu BY, 2003, MOL CELL BIOL, V23, P5269, DOI 10.1128/MCB.23.15.5269-5281.2003; Low KG, 1997, J VIROL, V71, P1956, DOI 10.1128/JVI.71.3.1956-1962.1997; Majone F, 2000, J BIOL CHEM, V275, P32906, DOI 10.1074/jbc.C000538200; MAJONE F, 1993, VIROLOGY, V193, P456, DOI 10.1006/viro.1993.1145; MARUYAMA K, 1990, CANCER RES, V50, pS5697; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; Morimoto H, 2005, AM J HEMATOL, V78, P100, DOI 10.1002/ajh.20259; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Neuveut C, 2000, Prog Cell Cycle Res, V4, P157; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Ohshima K, 1998, CANCER LETT, V132, P203, DOI 10.1016/S0304-3835(98)00188-8; Ohshima K, 2000, CANCER LETT, V158, P141, DOI 10.1016/S0304-3835(00)00512-7; Ohtani K, 2000, J BIOL CHEM, V275, P11154, DOI 10.1074/jbc.275.15.11154; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; Park HU, 2004, ONCOGENE, V23, P4966, DOI 10.1038/sj.onc.1207644; PARRY JM, 1987, MUTAT RES, V181, P267, DOI 10.1016/0027-5107(87)90104-7; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Ressler S, 1997, J VIROL, V71, P1181, DOI 10.1128/JVI.71.2.1181-1190.1997; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SAGGIORO D, 1994, LEUKEMIA LYMPHOMA, V12, P281; SAKASHITA A, 1992, BLOOD, V79, P477; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; SANDBERG AA, 1980, CANCER, V46, P2221, DOI 10.1002/1097-0142(19801115)46:10<2221::AID-CNCR2820461019>3.0.CO;2-8; Santiago F, 1999, J VIROL, V73, P9917, DOI 10.1128/JVI.73.12.9917-9927.1999; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; Semmes OJ, 1996, VIROLOGY, V217, P373, DOI 10.1006/viro.1996.0126; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Sinha-Datta U, 2004, BLOOD, V104, P2523, DOI 10.1182/blood-2003-12-4251; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; Suzuki T, 1999, ONCOGENE, V18, P4137, DOI 10.1038/sj.onc.1202766; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; THOMSON EJ, 1988, MUTAGENESIS, V3, P415, DOI 10.1093/mutage/3.5.415; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Tsumuki H, 2001, RHEUMATOL INT, V20, P175; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; Uchida N, 1999, LEUKEMIA RES, V23, P311, DOI 10.1016/S0145-2126(98)00170-2; Van Orden K, 2000, GENE EXPRESSION, V9, P29; Van PL, 2001, J VIROL, V75, P396, DOI 10.1128/JVI.75.1.396-407.2001; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; Wasch R, 2005, ONCOGENE, V24, P1, DOI 10.1038/sj.onc.1208017; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	115	132	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2005	24	39					5986	5995		10.1038/sj.onc.1208976	http://dx.doi.org/10.1038/sj.onc.1208976			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960WH	16155605				2022-12-17	WOS:000231623400008
J	Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG				Kaur, B; Brat, DJ; Devi, NS; Van Meir, EG			Vasculostatin, a proteolytic fragment of Brain Angiogenesis Inhibitor 1, is an antiangiogenic and antitumorigenic factor	ONCOGENE			English	Article						brain angiogenesis inhibitor; central nervous system; cancer; glioma; proteolytic cleavage; thrombospondin	TUMOR-GROWTH; ENDOTHELIAL-CELLS; REGULATES ANGIOGENESIS; THROMBOSPONDIN-1; PROTEIN; RECEPTOR; BAI1; OVEREXPRESSION; SUPPRESSION; CARCINOMA	Brain angiogenesis inhibitor 1 (BAI1) is a transmembrane protein with unknown function expressed primarily in normal but not tumoral brain. The finding of thrombospondin type 1 repeats in its extracellular domain suggested an antiangiogenic function, but the mechanisms by which a transmembrane receptor could inhibit angiogenesis remained unexplained. Here we demonstrate that BAI1 is proteolytically cleaved at a conserved G-protein-coupled receptor proteolytic cleavage site (GPS), releasing its 120 kDa extracellular domain. We named this secreted fragment Vasculostatin as it inhibited migration of endothelial cells in vitro and dramatically reduced in vivo angiogenesis. Both constitutive and doxycycline-induced expression of Vasculostatin elicited dose-dependent suppression of tumor growth and vascular density in mice, implicating Vasculostatin in the regulation of vascular homeostasis and tumor prevention. Generation of a soluble antiangiogenic factor by cleavage of a pre-existing transmembrane protein represents a novel mechanism for regulating vascular homeostasis and preventing tumorigenesis. Modulation of this cleavage or delivery of Vasculostatin may constitute novel treatment modalities for cancer and other diseases of aberrant angiogenesis, especially in the brain.	Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Dept Hematol Oncol, Atlanta, GA 30322 USA; Emory Univ, Winship Canc Inst, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Winship Canc Inst, Dept Neurosurg, Mol Neurooncol Lab, 1365C Clifotn Rd NE,Room C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	kaur, Balveen/E-3355-2011	Van Meir, Erwin G./0000-0003-2444-7707	NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS041403] Funding Source: NIH RePORTER; NCI NIH HHS [CA86335] Funding Source: Medline; NINDS NIH HHS [NS41403] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cao RH, 1999, P NATL ACAD SCI USA, V96, P5728, DOI 10.1073/pnas.96.10.5728; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carpizo D, 2000, CANCER METAST REV, V19, P159, DOI 10.1023/A:1026570331022; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; de Fraipont F, 2001, TRENDS MOL MED, V7, P401, DOI 10.1016/S1471-4914(01)02102-5; Detmar M, 2000, J DERMATOL SCI, V24, pS78, DOI 10.1016/S0923-1811(00)00145-6; Duda DG, 2002, BRIT J CANCER, V86, P490, DOI 10.1038/sj.bjc.6600067; FERRARA N, 1991, ENDOCRINOLOGY, V129, P896, DOI 10.1210/endo-129-2-896; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Gray JX, 1996, J IMMUNOL, V157, P5438; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; Hatanaka H, 2000, INT J MOL MED, V5, P181; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Huwiler KG, 2002, BIOCHEMISTRY-US, V41, P14329, DOI 10.1021/bi026463u; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kaur B, 2003, AM J PATHOL, V162, P19, DOI 10.1016/S0002-9440(10)63794-7; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; Lee JH, 2001, INT J ONCOL, V18, P355; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Mengerink KJ, 2002, J BIOL CHEM, V277, P943, DOI 10.1074/jbc.M109673200; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mori K, 2002, NEUROSCI RES, V43, P69, DOI 10.1016/S0168-0102(02)00018-4; MULLER G, 1987, P NATL ACAD SCI USA, V84, P5600, DOI 10.1073/pnas.84.16.5600; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Shiratsuchi T, 1997, CYTOGENET CELL GENET, V79, P103, DOI 10.1159/000134693; Simantov R, 2003, FRONT BIOSCI-LANDMRK, V8, pS874, DOI 10.2741/1168; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Van Meir EG, 1997, INT J CANCER, V71, P310; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Volpert OV, 2002, NAT MED, V8, P349, DOI 10.1038/nm0402-349; Volpert OV, 2002, CANCER CELL, V2, P473, DOI 10.1016/S1535-6108(02)00209-X; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	50	132	136	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3632	3642		10.1038/sj.onc.1208317	http://dx.doi.org/10.1038/sj.onc.1208317			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15782143				2022-12-17	WOS:000229221800010
J	Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E				Maschler, S; Wirl, G; Spring, H; Bredow, DV; Sordat, I; Beug, H; Reichmann, E			Tumor cell invasiveness correlates with changes in integrin expression and localization	ONCOGENE			English	Article						TGF beta; Ras; EMT; invasion; fibronectin receptor; laminin receptor	EPITHELIAL-MESENCHYMAL TRANSITIONS; EXTRACELLULAR-MATRIX PROTEINS; ALPHA-6-BETA-4 INTEGRIN; MOLECULAR-MECHANISMS; SIGNALING PATHWAYS; CANCER-CELLS; IN-VIVO; CARCINOMA; PROGRESSION; METASTASIS	In nontumorigenic mammary epithelial cells (EpH4), transforming growth factor-beta (TGF beta 1) causes cell cycle arrest/apoptosis, but induces epitheliomesenchymal transition (EMT) in Ha-Ras-transformed EpH4 cells (EpRas). EMT is closely correlated with late-stage tumor progression and results in fibroblastic, migratory cells displaying a mesenchymal gene expression program (FibRas). EpRas and FibRas cells showed strongly increased cell substrate adhesion to fibronectin, collagens I/IV and laminin 1. Furthermore, Ras transformation caused enhanced or de-novo expression of the integrin subunits beta 1, alpha 2 and alpha 3, or alpha 5 and alpha 6, respectively, the latter subunits being even more strongly expressed in FibRas cells. Importantly, polarized EpRas cells expressed integrin subunits beta 1 and beta 6 at distinct (apical and lateral) membrane domains, while FibRas cells coexpressed these integrins and alpha 5 at the entire plasma membrane. During EMT, EpRas cells formed an alpha 5 beta 1 complex and deposited its ligand fibronectin into the extracellular matrix. Function-blocking alpha 5 antibodies attenuated migration, and caused massive apoptosis in EpRas cells undergoing TGF beta 1-induced EMT in collagen gels, but failed to affect EpRas- or FibRas-derived structures. We conclude that functional alpha 5b1 integrin is centrally implicated in EMT induction. Importantly, FibRas cells also failed to deposit the alpha 6 beta 4 ligand laminin 5, suggesting that alpha 6 beta 4 is no longer functional after EMT and replaced by mesenchymal integrins such as alpha 5 beta 1.	Res Inst Mol Pathol, A-1030 Vienna, Austria; German Canc Inst, Heidelberg, Germany; Swiss Canc Res Inst, Lausanne, Switzerland; Univ Childrens Hosp, Dept Surg, Zurich, Switzerland	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University Children's Hospital Zurich	Maschler, S (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	maschler@imp.univie.ac.at						ABERDAM D, 1994, CELL ADHES COMMUN, V2, P115, DOI 10.3109/15419069409004431; Birchmeier C, 1996, ACTA ANAT, V156, P217; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Defilippi P, 1997, ONCOGENE, V14, P1933, DOI 10.1038/sj.onc.1201027; DEFILIPPI P, 1991, J CELL BIOL, V114, P855, DOI 10.1083/jcb.114.4.855; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Harabayashi T, 1999, J UROLOGY, V161, P1364, DOI 10.1016/S0022-5347(01)61685-9; Henning K, 1999, HISTOPATHOLOGY, V34, P305; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; JUHASZ I, 1993, AM J PATHOL, V143, P1458; Maschler S, 2004, ONCOGENE, V23, P3622, DOI 10.1038/sj.onc.1207403; Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Palecek SP, 1996, J CELL SCI, V109, P941; PELLEGRINI G, 1992, J CLIN INVEST, V89, P1783, DOI 10.1172/JCI115782; Putz E, 1999, CANCER RES, V59, P241; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; STREULI CH, 1993, J CELL BIOL, V120, P253, DOI 10.1083/jcb.120.1.253; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; WIRL G, 1995, J CELL SCI, V108, P2445; Witkowski CM, 2000, CARCINOGENESIS, V21, P325, DOI 10.1093/carcin/21.2.325; ZAMBRUNO G, 1995, J CELL BIOL, V129, P853, DOI 10.1083/jcb.129.3.853; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	38	132	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 17	2005	24	12					2032	2041		10.1038/sj.onc.1208423	http://dx.doi.org/10.1038/sj.onc.1208423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906YU	15688013				2022-12-17	WOS:000227681900007
J	Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H				Nitta, M; Kobayashi, O; Honda, S; Hirota, T; Kuninaka, S; Marumoto, T; Ushio, Y; Saya, H			Spindle checkpoint function is required for mitotic catastrophe induced by DNA-damaging agents	ONCOGENE			English	Article						mitotic catastrophe; spindle checkpoint; DNA damage; p53; time lapse; BubR1	HUMAN LUNG CANCERS; ASSEMBLY CHECKPOINT; MAMMALIAN-CELLS; FREQUENT IMPAIRMENT; LYMPHOMA-CELLS; P53 MUTATION; TUMOR-CELLS; SENSITIVITY; ARREST; LINES	Mitotic catastrophe is an important mechanism for the induction of cell death in cancer cells by antineoplastic agents that damage DNA. This process is facilitated by defects in the G(1) and G(2) checkpoints of the cell cycle that are apparent in most cancer cells and which allow the cells to enter mitosis with DNA damage. We have now characterized the dynamics of mitotic catastrophe induced by DNA-damaging agents in p53-deficient cancer cells. Cells that entered mitosis with DNA damage transiently arrested at metaphase for more than 10 h without segregation of chromosomes and subsequently died directly from metaphase. In those metaphase arrested precatastrophic cells, anaphase-promoting complex appeared to be inactivated and BubR1 was persistently localized at kinetochores, suggesting that spindle checkpoint is activated after the DNA damage. Furthermore, suppression of spindle checkpoint function by BubR1 or Mad2 RNA interference in the DNA damaged cells led to escape from catastrophic death and to subsequent abnormal mitosis. Dysfunction of the spindle checkpoint in p53-deficient cancer cells is thus likely a critical factor in resistance to DNA-damaging therapeutic agents.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Neurosurg, Kumamoto 8608556, Japan	Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013					Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Borel F, 2002, J CELL SCI, V115, P2829; BRACHMAN DG, 1993, CANCER RES, V53, P3667; Bradford CR, 2003, HEAD NECK-J SCI SPEC, V25, P654, DOI 10.1002/hed.10274; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2000, GENE DEV, V14, P1584; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Erenpreisa JE, 2000, CELL BIOL INT, V24, P61, DOI 10.1006/cbir.1999.0466; FAN SJ, 1995, CANCER RES, V55, P1649; FAN SJ, 1994, CANCER RES, V54, P5824; FINGERT HJ, 1986, CANCER RES, V46, P2463; Garber PM, 2002, GENETICS, V161, P521; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Maringele L, 2002, GENE DEV, V16, P1919, DOI 10.1101/gad.225102; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Masuda A, 2003, AM J PATHOL, V163, P1109, DOI 10.1016/S0002-9440(10)63470-0; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Ru HY, 2002, ONCOGENE, V21, P4673, DOI 10.1038/sj.onc.1205585; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Servomaa K, 1996, CELL PROLIFERAT, V29, P219, DOI 10.1046/j.1365-2184.1996.01009.x; Shannon KB, 2002, MOL BIOL CELL, V13, P3706, DOI 10.1091/mbc.E02-03-0137; Sudo T, 2004, CANCER RES, V64, P2502, DOI 10.1158/0008-5472.CAN-03-2013; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Vogt U, 2002, J CANCER RES CLIN, V128, P141, DOI 10.1007/s00432-001-0305-2; Wang H, 2001, GENE DEV, V15, P1361, DOI 10.1101/gad.893201; Wang XH, 2002, CANCER RES, V62, P1662	41	132	143	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 26	2004	23	39					6548	6558		10.1038/sj.onc.1207873	http://dx.doi.org/10.1038/sj.onc.1207873			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	849IB	15221012				2022-12-17	WOS:000223530800002
J	Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM				Kanazawa, S; Soucek, L; Evan, G; Okamoto, T; Peterlin, BM			c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis	ONCOGENE			English	Article						c-Myc; P-TEFb; CycT1; apoptosis; proliferation; transcription	RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; ELONGATION; TAT; TRANSFORMATION; PROGRESSION; ACTIVATION; MUTATIONS; INTERACTS; NETWORK	c-Myc promotes cellular proliferation, sensitizes cells to apoptosis and prevents differentiation. It binds cyclin T1 structurally and functionally from the positive transcription elongation factor b (P-TEFb). The cyclin-dependent kinase 9 (Cdk9) in P-TEFb then phosporylates the C-terminal domain of RNA polymerase II, which is required for the transition from initiation to elongation of eukaryotic transcription. Inhibiting P-TEFb blocks the transcription of its target genes as well as cellular proliferation and apoptosis induced by c-Myc.	Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Nagoya City Univ, Sch Med, Dept Mol Genet, Nagoya, Aichi 467, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Nagoya City University	Peterlin, BM (corresponding author), Univ Calif San Francisco, Rosalind Russell Med Res Ctr, Dept Med, Box 0703,3rd & Parnassus Ave, San Francisco, CA 94143 USA.		Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019	Soucek, Laura/0000-0002-4750-7971; 				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; CLARK HM, 1994, CANCER RES, V54, P3383; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; EBERHARDY SR, 2002, J BIOL CHEM; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; Kim YK, 2002, MOL CELL BIOL, V22, P4622, DOI 10.1128/MCB.22.13.4622-4637.2002; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lis JT, 2000, GENE DEV, V14, P792; Nasi S, 2001, FEBS LETT, V490, P153, DOI 10.1016/S0014-5793(01)02118-4; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	26	132	138	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 28	2003	22	36					5707	5711		10.1038/sj.onc.1206800	http://dx.doi.org/10.1038/sj.onc.1206800			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	713NY	12944920				2022-12-17	WOS:000184865900021
J	Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ				Mackay, A; Jones, C; Dexter, T; Silva, RLA; Bulmer, K; Jones, A; Simpson, P; Harris, RA; Jat, PS; Neville, AM; Reis, LFL; Lakhani, SR; O'Hare, MJ			cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells	ONCOGENE			English	Article						ERBB2 (HER2/neu); breast cancer; cDNA microarray; expression profiling; tissue array	METASTATIC BREAST-CANCER; GALACTOSIDE-BINDING-PROTEIN; MONOCLONAL-ANTIBODY; PROGNOSTIC-SIGNIFICANCE; MEMBRANE-PROTEIN; GROWTH-FACTOR; CARCINOMA CELLS; P-CADHERIN; PHASE-II; EXPRESSION	To investigate changes in gene expression associated with ERBB2, expression profiting of immortalized human mammary luminal epithelial cells and variants expressing a moderate and high level of ERBB2 has been carried out using cDNA microarrays corresponding to approximately 6000 unique genes/ESTs. A total of 61 significantly up- or downregulated (>2.0-fold) genes were identified and further validated by RT-PCR analysis as well as microarray comparisons with a spontaneously ERBB2-overexpressing breast cancer cell line and ERBB2-positive primary breast tumors. The expression and clinical relevance of proteins predicted to be associated with ERBB2 overexpression in breast cancers were analysed together with their clinical relevance by antibody screening using a tissue array. Differentially regulated genes include those involved in cell-matrix interactions including proline 4-hydroxylase (P4HA2), galectin 1 (LGALS1) and galectin 3 (LGALS3), fibronectin 1 (FN1) and p-cadherin (CDH3), and cell proliferation (CRIP1, IGFBP3) and transformation (S100P, S100A4). A number of genes associated with MYC signalling were also differentially expressed, including NDRG1, USF2 and the epithelial membrane proteins 1 and 3 (EMP1, EMP3). These data represent profiles of the transcriptional changes associated with ERBB2-related pathways in the breast, and identify novel and potentially useful targets for prognosis and therapy.	UCL, LICR UCL Breast Canc Lab, London W1W 7EJ, England; Inst Canc Res, Breakthrough Toby Robins Breast Canc Res Ctr, London SW3 6JB, England; Ludwig Inst Canc Res, Sao Paulo, Brazil; UCL, Ludwig Inst Canc Res, London, England; Royal Marsden Hosp, London SW3 6JJ, England	University of London; University College London; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; University of London; University College London; Royal Marsden NHS Foundation Trust	Mackay, A (corresponding author), UCL, LICR UCL Breast Canc Lab, Charles Bell House,Riding House St, London W1W 7EJ, England.	alan.mackay@ucl.ac.uk	Simpson, Peter/F-1225-2010; Lakhani, Sunil R/I-1970-2018; Jones, Chris/ABE-6059-2021; Reis, Luiz F. L./C-4556-2013	Simpson, Peter/0000-0002-4816-8289; Lakhani, Sunil R/0000-0003-4067-2760; Jones, Chris/0000-0001-8118-2296; Reis, Luiz/0000-0002-4040-2456				Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; BALDINI A, 1993, GENOMICS, V15, P216, DOI 10.1006/geno.1993.1039; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Ben-Porath I, 1998, GENOMICS, V49, P443, DOI 10.1006/geno.1998.5238; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Bieche I, 1996, CANCER RES, V56, P3886; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Chen Y, 1997, GENOMICS, V41, P40, DOI 10.1006/geno.1997.4524; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Cuny M, 2000, CANCER RES, V60, P1077; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; De Iorio P, 2001, ANTICANCER RES, V21, P1395; Gamallo C, 2001, MODERN PATHOL, V14, P650, DOI 10.1038/modpathol.3880367; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hippo Y, 2001, CANCER RES, V61, P889; Houston SJ, 1999, BRIT J CANCER, V79, P1220, DOI 10.1038/sj.bjc.6690196; Hughes RC, 2001, BIOCHIMIE, V83, P667; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Liehr T, 1999, GENOMICS, V58, P106, DOI 10.1006/geno.1999.5803; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Mazzucchelli L, 2002, AM J PATHOL, V160, P7, DOI 10.1016/S0002-9440(10)64342-8; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Miles DW, 1999, INT J CANCER, V84, P354, DOI 10.1002/(SICI)1097-0215(19990820)84:4<354::AID-IJC4>3.0.CO;2-6; Moon BK, 2001, AM J PATHOL, V159, P1055, DOI 10.1016/S0002-9440(10)61780-4; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Pegram MD, 1998, J CLIN ONCOL, V16, P2659, DOI 10.1200/JCO.1998.16.8.2659; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Ross, 1998, Oncologist, V3, P237; Ross JS, 1999, SEMIN CANCER BIOL, V9, P125, DOI 10.1006/scbi.1998.0083; Rudland PS, 2000, CANCER RES, V60, P1595; Schiemann S, 1997, ANTICANCER RES, V17, P13; Scorilas A, 1999, BRIT J CANCER, V81, P1385, DOI 10.1038/sj.bjc.6693404; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Soler AP, 1999, CANCER-AM CANCER SOC, V86, P1263, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1263::AID-CNCR23>3.3.CO;2-U; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stoll BA, 1997, BRIT J CANCER, V76, P1652, DOI 10.1038/bjc.1997.612; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Werbajh SE, 1998, FEBS LETT, V440, P277, DOI 10.1016/S0014-5793(98)01473-2; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A	49	132	144	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2680	2688		10.1038/sj.onc.1206349	http://dx.doi.org/10.1038/sj.onc.1206349			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730682				2022-12-17	WOS:000182569000016
J	Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S				Qiang, YW; Endo, Y; Rubin, JS; Rudikoff, S			Wnt signaling in B-cell neoplasia	ONCOGENE			English	Article						Wnt; beta-catenin; myeloma; morphology; Rho	BETA-CATENIN; PROTEIN; RECEPTOR; RHO; PROLIFERATION; INTERLEUKIN-6; WINGLESS; MYELOMA; TRANSDUCTION; ACTIVATION	Wnts comprise a family of secreted proteins that interact with receptors consisting of a Frizzled (Fz) family member alone or complexed with LDL receptor-related proteins (LRP5/6). Wnt signaling plays a crucial role in both development and differentiation, and activation of a 'canonical' Writ pathway resulting in P-catenin stabilization is associated with several types of human cancers. To date, little is known about potential Wnt signaling in mature lymphocytes or lymphoid neoplasia. Herein, we have analysed Wnt signaling in mature B cells (lymphomas) and plasma cells (multiple myeloma). Both Fz and LRP5/6 mRNAs were expressed in myeloma lines, but LRP5/6 were not observed in lymphomas. In myelomas, a canonical Wnt signaling pathway was activated following treatment with Wnt-3a as assessed by accumulation of beta-catenin, but beta-catenin levels actually decreased in lymphoma cells. Wnt-3a treatment further led to striking morphological changes in myeloma cells accompanied by rearrangement of the actin cytoskeleton. Morphological changes were associated with a second Wnt pathway dependent on Rho activation. These results suggest that Writ responsiveness is a stage-specific phenomenon in B-cell development and that the morphological changes associated with Wnt signaling may play a role in the motility and metastatic potential of myeloma cells.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37, Bethesda, MD 20892 USA.	Rudikoff@helix.nih.gov	Qiang, Ya-Wei/Q-2206-2019	Qiang, Ya-Wei/0000-0002-2479-1412	DIVISION OF BASIC SCIENCES - NCI [Z01BC005553] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIABC010251, Z01BC010251] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATAILLE R, 1992, HEMATOL ONCOL CLIN N, V6, P285, DOI 10.1016/S0889-8588(18)30345-9; BERGUI L, 1989, J EXP MED, V170, P613, DOI 10.1084/jem.170.2.613; Brandon C, 2000, BLOOD, V96, P4132, DOI 10.1182/blood.V96.13.4132.h8004132_4132_4141; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Ge NL, 2000, BLOOD, V96, P2856; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lattanzio G, 1997, AM J PATHOL, V151, P689; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Little RD, 2002, AM J HUM GENET, V70, P11, DOI 10.1086/338450; LU ZY, 1995, BLOOD, V86, P3123; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Niesvizky R, 1997, CANCER INVEST, V15, P85, DOI 10.3109/07357909709018921; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Semenov MV, 1997, GENOMICS, V42, P302, DOI 10.1006/geno.1997.4713; Shibamoto S, 1998, GENES CELLS, V3, P659; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Winter CG, 2001, CELL, V105, P81, DOI 10.1016/S0092-8674(01)00298-7; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Yamane T, 2001, J IMMUNOL, V167, P765, DOI 10.4049/jimmunol.167.2.765; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; ZHANG XG, 1994, BLOOD, V83, P3654; Zhurinsky J, 2000, J CELL SCI, V113, P3127	39	132	138	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2003	22	10					1536	1545		10.1038/sj.onc.1206239	http://dx.doi.org/10.1038/sj.onc.1206239			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652ZZ	12629517				2022-12-17	WOS:000181411900011
J	Thompson, PM; Gotoh, T; Kok, M; White, PS; Brodeur, GM				Thompson, PM; Gotoh, T; Kok, M; White, PS; Brodeur, GM			CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system	ONCOGENE			English	Article						chromodomain; chromatin; remodeling; neural development	ACUTE PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE COMPLEX; DNA-BINDING PROTEIN; MOLECULAR ANALYSIS; TRANSCRIPTIONAL REPRESSION; MI-2 AUTOANTIGEN; RETINOIC ACID; NEUROBLASTOMA; SIN3; 1P36	Chromatin remodeling is one of the mechanisms by which gene expression is regulated developmentally. Chromatin structure is controlled at least in part by post-translational modification of histones, as well as by chromodomain proteins. We have identified a novel gene encoding a protein with chromatin remodeling, helicase and DNA-binding motifs. This gene, called CHD5, is the fifth member of the CHD gene family identified in humans. This gene is most homologous to CHD3 and CHD4, which encode proteins that are part of the nucleosome remodeling and histone deacetylation (NuRD) complex. CHD5 is preferentially expressed in total brain, fetal brain, and cerebellum. It is also moderately expressed in the adrenal gland, but expression is undetectable in almost all other tissues examined. CHD5 maps within a small region of deletion on 1p36.3 in human neuroblastomas, a common pediatric tumor. We examined a panel of neuroblastoma cell lines for CHD5 expression, which was consistently low or undetectable in all these lines. Expression was also examined in a panel of 137 primary neuroblastomas, and low expression was highly correlated with 1p deletion, MYCN amplification, advanced stage, and unfavorable histology. These findings suggest that this gene may play a role in the development of the nervous system, and it may also play a role in the pathogenesis of neural tumors.	Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Brodeur, GM (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Abramson Res Ctr, Rm 902-D,3615 Civ Ctr Blvd, Philadelphia, PA 19104 USA.				NCI NIH HHS [CA-39771] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brodeur GM, 1997, J PEDIAT HEMATOL ONC, V19, P93, DOI 10.1097/00043426-199703000-00001; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; GE Q, 1995, J CLIN INVEST, V96, P1730, DOI 10.1172/JCI118218; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Harper SE, 1996, P NATL ACAD SCI USA, V93, P8536, DOI 10.1073/pnas.93.16.8536; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; Kasten MM, 1996, MOL CELL BIOL, V16, P4215; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kitamura K, 2000, BRIT J HAEMATOL, V108, P696, DOI 10.1046/j.1365-2141.2000.01933.x; Kozak M, 2000, GENOMICS, V70, P396, DOI 10.1006/geno.2000.6412; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Maris JM, 1996, GENOMICS, V35, P289, DOI 10.1006/geno.1996.0359; MULLER J, 1995, EMBO J, V14, P1209, DOI 10.1002/j.1460-2075.1995.tb07104.x; Reese MG, 2000, GENOME RES, V10, P483, DOI 10.1101/gr.10.4.483; Schmidt DR, 1999, BIOCHEMISTRY-US, V38, P14711, DOI 10.1021/bi991614n; Schreiber-Agus N, 1998, BIOESSAYS, V20, P808, DOI 10.1002/(SICI)1521-1878(199810)20:10<808::AID-BIES6>3.0.CO;2-U; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Slavotinek A, 1999, J MED GENET, V36, P657; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1111/j.1574-6968.1999.tb13575.x; Thompson PM, 2001, CANCER RES, V61, P679; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; Wong AKC, 2000, CANCER RES, V60, P6171; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Wu YQ, 1999, HUM MOL GENET, V8, P313, DOI 10.1093/hmg/8.2.313; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	42	132	142	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1002	1011		10.1038/sj.onc.1206211	http://dx.doi.org/10.1038/sj.onc.1206211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592387				2022-12-17	WOS:000180926100006
J	Versteege, I; Medjkane, S; Rouillard, D; Delattre, O				Versteege, I; Medjkane, S; Rouillard, D; Delattre, O			A key role of the hSNF5/INI1 tumour suppressor in the control of the G1-S transition of the cell cycle	ONCOGENE			English	Article						hSNF5; INI1; SWI/SNF; malignant rhabdoid tumour; cell cycle; chromatin	SWI-SNF COMPLEX; RETINOBLASTOMA PROTEIN; RHABDOID TUMORS; SWI/SNF FAMILY; HUMAN CANCER; S-PHASE; C-MYC; MUTATIONS; GENE; RB	The hSNF5/INI1 gene encodes a member of the SWI/ SNF chromatin remodelling complexes. It was recently identified as a tumour suppressor gene mutated in sporadic and hereditary Malignant Rhabdoid Tumours (MRT). However, the role of hSNF5/INI1 loss-of-function in tumour development is still unknown. Here, we show that the ectopic expression of wild-type hSNF5/ INI1, but not that of truncated versions, leads to a cell cycle arrest by inhibiting the entry into S phase of MRT cells. This G1 arrest is associated with down-regulation of a subset of E2F targets including cyclin A, E2F1 and CDC6. This arrest can be reverted by coexpression of cyclin D1, cyclin E or viral E1A, whereas it cannot be counteracted by pRB-binding deficient E1A mutants. Moreover, hSNF5/INI1 is not able to arrest cells lacking a functional pRB. These observations suggest that the hSNF5/INI1-induced G1 arrest is dependent upon the presence of a functional pRB. However, the observation that a constitutively active pRB can efficiently arrest MRT cells indicates that hSNF5/INI1, at the difference of the ATPase subunits of the SWI/SNF complex, is dispensable for pRB function. Altogether, these data show that hSNF5/INI1 is a potent regulator of the entry into S phase, an effect that may account for its tumour suppressor role.	Inst Curie, Lab Pathol Mol Canc, INSERM, U509, F-75248 Paris 05, France; Inst Curie, UMR 147, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM, U509, 26 Rue Ulm, F-75248 Paris 05, France.	olivier.delattre@curie.fr		Medjkane, Souhila/0000-0001-7973-7707; delattre, olivier/0000-0002-8730-2276				Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 1999, CANCER RES, V59, P74; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HERRERA VLM, 1988, SCIENCE, V241, P221, DOI 10.1126/science.2838907; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Klochendler-Yeivin A, 2002, CURR OPIN GENET DEV, V12, P73, DOI 10.1016/S0959-437X(01)00267-2; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Savla J, 2000, JNCI-J NATL CANCER I, V92, P648, DOI 10.1093/jnci/92.8.648; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; Sif S, 1998, GENE DEV, V12, P2842, DOI 10.1101/gad.12.18.2842; Staehling-Hampton K, 1999, GENETICS, V153, P275; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Taylor MD, 2000, AM J HUM GENET, V66, P1403, DOI 10.1086/302833; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wong AKC, 2000, CANCER RES, V60, P6171; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	43	132	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2002	21	42					6403	6412		10.1038/sj.onc.1205841	http://dx.doi.org/10.1038/sj.onc.1205841			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	592FD	12226744				2022-12-17	WOS:000177925300001
J	Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T				Osada, H; Tatematsu, Y; Yatabe, Y; Nakagawa, T; Konishi, H; Harano, T; Tezel, E; Takada, M; Takahashi, T			Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers	ONCOGENE			English	Article						lung cancer; 14-3-3 sigma; methylation; MSP	SIGMA GENE; SMALL-CELL; HYPERMETHYLATION; IDENTIFICATION; INVOLVEMENT; IMPAIRMENT; CHECKPOINT; EXPRESSION; PROTEIN; P53	One isoform of the 14-3-3 family, 14-3-3sigma, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3sigma is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3sigma gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3sigma gene. Among nonsmall cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3sigma (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or significant reduction in 14-3-3sigma expression in vivo, while a loss or reduction of 14-3-3sigma expression was very rare in primary NSCLC specimens (I of 22 tissues, 5%). This is the first description that indicates lung cancers frequently show significant inactivation of the 14-3-3sigma gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3sigma gene in lung tumorigenesis in a histological type-specific manner.	Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Chikusa Ku, Nagoya, Aichi 4348681, Japan; Rinku Gen Med Ctr, Osaka 5988577, Japan	Aichi Cancer Center; Aichi Cancer Center	Osada, H (corresponding author), Aichi Canc Ctr, Res Inst, Div Mol Oncol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	hosada@aichi-cc.jp	YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014; Osada, Hiroyuki/AAY-6254-2020	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Konishi, Hiroyuki/0000-0003-1131-4905				Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dhar S, 2000, MOL CELL BIOL, V20, P7764, DOI 10.1128/MCB.20.20.7764-7772.2000; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Haruki N, 2001, AM J PATHOL, V159, P1345, DOI 10.1016/S0002-9440(10)62521-7; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; KELLEY MJ, 1995, JNCI-J NATL CANCER I, V87, P756, DOI 10.1093/jnci/87.10.756; Konishi H, 2002, CANCER RES, V62, P271; MINNA JD, 1997, CANC PRINCIPLES PRAC, V1, P849; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Osada H, 2001, CANCER RES, V61, P8331; Osada H, 1996, BIOCHEM BIOPH RES CO, V229, P582, DOI 10.1006/bbrc.1996.1847; SEKIDO Y, 1998, BIOCHIM BIOPHYS ACTA, V1378, P21; Suzuki H, 2000, CANCER RES, V60, P4353; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TESTA JR, 1996, LUNG CANC PRINCIPLES, P55; TRAVIS WD, 1991, AM J SURG PATHOL, V15, P529, DOI 10.1097/00000478-199106000-00003; TSUCHIYA E, 1995, J CANCER RES CLIN, V121, P577, DOI 10.1007/BF01197773; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438	21	132	141	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2418	2424		10.1038/sj.onc.1205303	http://dx.doi.org/10.1038/sj.onc.1205303			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948426				2022-12-17	WOS:000174635600015
J	Recio, JA; Merlino, G				Recio, JA; Merlino, G			Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1	ONCOGENE			English	Article						melanoma; HGF/SF; p38; ATF-2; c-Met	FACTOR SCATTER FACTOR; ELEMENT-BINDING PROTEIN; FOCAL ADHESION KINASE; TYROSINE KINASE; C-MET; LEUCINE ZIPPER; SOMATIC MUTATIONS; RESPONSE ELEMENT; GENE-EXPRESSION; RECEPTOR	Members of the mitogen-activated protein kinase (MAPK) superfamily, including p38 kinase and SAPK/JNK, play a central role in mediating cellular response to environmental stress. growth factors and cytokines. Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine capable of eliciting mitogenic, motogenic and morphogenetic activities in responsive cells, and has been implicated in tumor development and metastasis. Binding of HGF/SF to its tyrosine kinase receptor c-Met stimulates multiple signal transduction pathways, leading to the activation of numerous transcription factors. We here report that HGF/SF can induce cyclin D1 expression in mouse melanoma cells. and that this up-regulation is mediated in part by the activating transcription factor-2 (ATF-2). HGF/SF-mediated phosphorylation of ATF-2 was reduced in the presence of either the p38 kinase-specific inhibitor SB203580, a dominant negative p38 mutant, the SAPK/JNK inhibitor JNK-interacting protein-1 (JIP-1), or the phosphatidylinositol 3-kinase (PI3K)-specific inhibitor LY294002. Activation of p38 kinase by HGF/SF was partially blocked by the PI3K-specific inhibitor as well. The upstream kinases for p38, MKK3/6, did not become activated following HGF/SF exposure, and ATF-2 activation was undiminished by transient transfection of a dominant negative MKK6 mutant. However, transcriptional up-regulation of cyclin D1 by HGF/SF was partially inhibited by the p38 kinase-specific inhibitor, and cyclin D1 protein induction was partially blocked by a dominant negative ATF-2 mutant. Notably, the p38 kinase-specific inhibitor was able to block melanoma cell proliferation but not motility. We conclude that the ATF-2 transcription factor becomes activated by HGF/SF through p38 MAPK and SAPK/JNK. Moreover, the p38-ATF-2 pathway can help mediate proliferation signals in tumor cells through transcriptional activation of key cell cycle regulators.	NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Merlino, G (corresponding author), NCI, Mol Biol Lab, Mol Genet Sect, NIH, Bldg 37,Room 5002,MSC 4264, Bethesda, MD 20892 USA.	gmerlino@helix.nih.gov		Recio, Juan Angel/0000-0002-7320-3832				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; ALLEN RE, 1995, J CELL PHYSIOL, V165, P307, DOI 10.1002/jcp.1041650211; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; Awasthi V, 2000, AM J PHYSIOL-LUNG C, V279, pL942, DOI 10.1152/ajplung.2000.279.5.L942; Bales ES, 1999, J INVEST DERMATOL, V113, P1039, DOI 10.1046/j.1523-1747.1999.00812.x; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Beviglia L, 1999, INT J CANCER, V83, P640, DOI 10.1002/(SICI)1097-0215(19991126)83:5<640::AID-IJC13>3.0.CO;2-D; Chen HC, 1998, J BIOL CHEM, V273, P25777, DOI 10.1074/jbc.273.40.25777; Chen RF, 2000, RARE METALS, V19, P231; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chuang SM, 2000, CARCINOGENESIS, V21, P1491, DOI 10.1093/carcin/21.8.1491; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coupland SE, 2000, J PATHOL, V191, P120; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FILMUS J, 1994, ONCOGENE, V9, P3627; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Halaban R, 2000, PIGM CELL RES, V13, P4, DOI 10.1034/j.1600-0749.2000.130103.x; Huang S, 2000, J BIOL CHEM, V275, P12266, DOI 10.1074/jbc.275.16.12266; Huguier S, 1998, MOL CELL BIOL, V18, P7020, DOI 10.1128/MCB.18.12.7020; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; Lai JF, 2000, J BIOL CHEM, V275, P7474, DOI 10.1074/jbc.275.11.7474; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Macfarlane WM, 1997, J BIOL CHEM, V272, P20936, DOI 10.1074/jbc.272.33.20936; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakanishi K, 1999, CLIN EXP METASTAS, V17, P507, DOI 10.1023/A:1006685218766; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Otsuka T, 1998, CANCER RES, V58, P5157; Park WS, 1999, CANCER RES, V59, P307; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; ROSEN EM, 1997, J BIOL CHEM, V270, P27780; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Shambaugh GE, 1996, J NEUROPATH EXP NEUR, V55, P1009, DOI 10.1097/00005072-199609000-00008; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; Spector M, 2000, EXP CELL RES, V258, P109, DOI 10.1006/excr.2000.4907; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tolnay E, 1998, J CANCER RES CLIN, V124, P291, DOI 10.1007/s004320050171; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Weimar IS, 1998, LEUKEMIA, V12, P1195, DOI 10.1038/sj.leu.2401080; YAMASHITA J, 1994, CANCER RES, V54, P1630; Yao Y, 1996, AM J PATHOL, V149, P1707; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177; Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727; Zohn IE, 1998, MOL CELL BIOL, V18, P1225, DOI 10.1128/MCB.18.3.1225	70	132	144	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2002	21	7					1000	1008		10.1038/sj.onc.1205150	http://dx.doi.org/10.1038/sj.onc.1205150			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	516WQ	11850817				2022-12-17	WOS:000173580100003
J	Soncini, C; Berdo, I; Draetta, G				Soncini, C; Berdo, I; Draetta, G			Ras-GAP SH3 domain binding protein (G3BP) is a modulator of USP10, a novel human ubiquitin specific protease	ONCOGENE			English	Article						de-ubiqitinating enzyme; G3BP; ubiquitin	FACETS DEUBIQUITINATING ENZYME; CHROMOSOMAL LOCALIZATION; SACCHAROMYCES-CEREVISIAE; ISOPEPTIDASE-T; DEGRADATION; GENE; INTERACTS; PATHWAY; UNP; PHOSPHORYLATION	Degradation of cellular proteins through ubiquitination is a fundamental strategy for regulating biological pathways. De-ubiquitination, i,e, the removal of ubiquitin from proteins and peptides to which ubiquitin is attached, is catalyzed by processing proteases known as de-ubiquitinating enzymes, We are studying the biology of a family of de-ubiquitinating enzymes, the mammalian ubiquitin-specific proteases (USPs), some of which appear to play a role in growth control. Given the fact that the modes of regulation of USPs and of their substrate specificity are poorly understood, we decided to attempt the identification of USP interacting proteins, Using the yeast two-hybrid system (2HS), we have isolated a cDNA clone whose product specifically interacts with USP10 but not with other USP baits tested. The isolated clone encodes a protein known to interact with the Ras-GTPase activating protein (G3BP), This interaction was further confirmed by performing a 2HS with G3BP, which led to the isolation of USP10 encoding cDNAs. We validated the interaction between the two proteins by performing in vitro binding assays and immunoprecipitations in human cells, G3BP does not appear to be a substrate of USP10; it rather inhibits the ability of USP10 to disassemble ubiquitin chains. The USP10/G3BP complex appears to co-immunoprecipitate with ubiquitinated species that could be substrates of USP10.	European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Draetta, G (corresponding author), European Inst Oncol, Dept Expt Oncol, Via Ripamonti 435, I-20141 Milan, Italy.			SONCINI, MARIACHIARA/0000-0002-2066-9751				Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Cadavid ALM, 2000, DEVELOPMENT, V127, P1727; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; D'Andrea A, 1998, CRIT REV BIOCHEM MOL, V33, P337, DOI 10.1080/10409239891204251; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; Frederick A, 1998, ONCOGENE, V16, P153, DOI 10.1038/sj.onc.1201537; Gallouzi IE, 1998, MOL CELL BIOL, V18, P3956, DOI 10.1128/MCB.18.7.3956; GRAY DA, 1995, ONCOGENE, V10, P2179; Guitard E, 2001, CANCER LETT, V162, P213, DOI 10.1016/S0304-3835(00)00638-8; GUPTA K, 1993, ONCOGENE, V8, P2307; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li QH, 1997, P NATL ACAD SCI USA, V94, P12515, DOI 10.1073/pnas.94.23.12515; Lin HJ, 2000, MOL CELL BIOL, V20, P6568, DOI 10.1128/MCB.20.17.6568-6578.2000; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Parker F, 1996, MOL CELL BIOL, V16, P2561; Sloper-Mould KE, 1999, J BIOL CHEM, V274, P26878, DOI 10.1074/jbc.274.38.26878; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Taya S, 1999, GENES CELLS, V4, P757, DOI 10.1046/j.1365-2443.1999.00297.x; Taya S, 1998, J CELL BIOL, V142, P1053, DOI 10.1083/jcb.142.4.1053; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wilkinson KD, 1998, UBIQUITIN BIOL CELL, P99; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; Zhu YA, 1997, J BIOL CHEM, V272, P51	39	132	141	0	9	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3869	3879		10.1038/sj.onc.1204553	http://dx.doi.org/10.1038/sj.onc.1204553			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439350				2022-12-17	WOS:000169494700012
J	Manna, SK; Kuo, MT; Aggarwal, BB				Manna, SK; Kuo, MT; Aggarwal, BB			Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1	ONCOGENE			English	Article						TNF; NF-kappa B; AP-1; ROI; gamma-GCS	INDUCED CELL-DEATH; MANGANESE SUPEROXIDE-DISMUTASE; HUMAN-IMMUNODEFICIENCY-VIRUS; ALPHA-INDUCED APOPTOSIS; C-JUN KINASE; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; HEAVY SUBUNIT; MITOCHONDRIAL-FUNCTION; GLUTATHIONE REGULATION	Tumor necrosis factor (TNF) is a highly pleiotropic cytokine whose activity is at least partially regulated by the redox status of the cell. The cellular redox status is controlled primarily by glutathione, a major cellular antioxidant, whose synthesis is regulated by the rate-limiting enzyme gamma-glutamylcysteine synthetase (gamma-GCS). In the present report we investigated the effect of gamma-GCS overexpression on the TNF-induced activation of nuclear transcription factors NF-kappa B and AP-I, stress-activated protein kinase/c-Jun amino-terminal kinase (JNK) and apoptosis, Transfection of cells with gamma-GCS cDNA blocked TNF-induced NF-kappa B activation, cytoplasmic I kappa-B alpha degradation, nuclear translocation of p65, and NF-kappa B-dependent gene transcription. gamma-GCS overexpression also completely suppressed NF-kappa B activation induced by phorbol ester and okadaic acid, whereas that induced by H2O2, ceramide, and lipopolysaccharide was minimally affected. gamma-GCS also abolished the activation of AP-1 induced by TNF and inhibited TNF-induced activation of JNK and mitogen-activated protein kinase kinase. TNF-mediated cytotoxicity and activation of caspase-3 were both abrogated in gamma-GCS-overexpressing cells. Overall, our results indicate that most of the pleiotropic actions of TNF are regulated by glutathione-controlled redox status of the cell.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Cytokine Res Lab, Houston, TX 77030 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA 72404-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; delArco PG, 1996, J BIOL CHEM, V271, P26335; DROGE W, 1994, FASEB J, V8, P1131; ESPOSITO F, 1994, BIOCHEM J, V301, P649, DOI 10.1042/bj3010649; FernandezCheca JC, 1997, AM J PHYSIOL-GASTR L, V273, pG7, DOI 10.1152/ajpgi.1997.273.1.G7; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GARCIARUIZ C, 1995, MOL PHARMACOL, V48, P825; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Goossens V, 1996, J BIOL CHEM, V271, P192, DOI 10.1074/jbc.271.1.192; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Haridas V, 1998, J IMMUNOL, V160, P3152; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HUANG CS, 1993, J BIOL CHEM, V268, P19675; HUANG CS, 1993, J BIOL CHEM, V268, P20578; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; Kinscherf R, 1998, FASEB J, V12, P461, DOI 10.1096/fasebj.12.6.461; Kuo MT, 1996, CANCER RES, V56, P3642; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1998, TRENDS BIOCHEM SCI, V13, P185; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Morales A, 1997, J BIOL CHEM, V272, P30371, DOI 10.1074/jbc.272.48.30371; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MULCAHY RT, 1995, CANCER RES, V55, P4771; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Obrador E, 1997, BIOCHEM J, V325, P183, DOI 10.1042/bj3250183; PHELPS DT, 1995, AM J PHYSIOL-LUNG C, V269, pL551, DOI 10.1152/ajplung.1995.269.4.L551; ROEDERER M, 1990, P NATL ACAD SCI USA, V87, P4884, DOI 10.1073/pnas.87.12.4884; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHRODER FH, 1989, PROSTATE, P17; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; Sen CK, 1997, BIOCHEM BIOPH RES CO, V237, P645, DOI 10.1006/bbrc.1997.7206; SHOJI Y, 1995, IMMUNOLOGY, V84, P543; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tewari M, 1996, CURR OPIN GENET DEV, V6, P39, DOI 10.1016/S0959-437X(96)90008-8; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Yamane Y, 1998, J BIOL CHEM, V273, P31075, DOI 10.1074/jbc.273.47.31075; YAO KS, 1995, CANCER RES, V55, P4367; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	74	132	135	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4371	4382		10.1038/sj.onc.1202811	http://dx.doi.org/10.1038/sj.onc.1202811			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439045				2022-12-17	WOS:000081732700010
J	Lee, CW; La Thangue, NB				Lee, CW; La Thangue, NB			Promoter specificity and stability control of the p53-related protein p73	ONCOGENE			English	Article						p73; p53-related; promoter specificity; stability	TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INDUCE APOPTOSIS; CANCER-CELLS; DNA-BINDING; P53 PROTEIN; GROWTH; SUPPRESSION; P300/CBP	The p53 family of proteins play instrumental roles in mediating the cellular response to stress. The p53-related gene product, p73, occurs as two distinct protein isoforms, referred to as alpha and beta, which differ in the length of the C-terminal region and arise through alternative splicing of the p73 RNA. Here, we describe an analysis of the transcription properties of p73 and show that although there are certain similarities between transcriptional activation mediated by p73 and p53, such as in their sensitivity to adenovirus E1A and the requirement for p300/CBP co-activator proteins, significant differences are apparent in the response mechanisms. Thus, we find that p73 shows a degree of specificity for the promoters of target genes that is quantitatively distinct from the response mediated by p53. For example, p73 activates the GADD45 gene more efficiently than p53, whereas the reverse situation was apparent for the p21 gene. These effects are, in part, due to the influence of a regulatory domain present in the extended C-terminal of the alpha isoform. Moreover, we provide evidence that this domain regulates protein abundance by influencing the proteasome-dependent degradation of p73. These data define a novel level of isoform-specific control in regulating p73 activity, and thereby highlight a significant difference between the mechanisms that govern the transcriptional activity of p53 and p73.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHEN XB, 1995, CANCER RES, V55, P4257; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUNA RMD, 1995, NATURE, V378, P203; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NOTOMO S, 1998, CANCER RES, V58, P1380; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Prabhu NS, 1998, INT J ONCOL, V13, P5; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sambrook J., 1989, MOL CLONING, P1666; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Sunahara M, 1998, INT J ONCOL, V13, P319; Takahashi H, 1998, CANCER RES, V58, P2076; WALDMAN T, 1995, CANCER RES, V55, P5187; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	42	132	135	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 22	1999	18	29					4171	4181		10.1038/sj.onc.1202793	http://dx.doi.org/10.1038/sj.onc.1202793			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218FK	10435630				2022-12-17	WOS:000081542400001
J	Elenius, K; Choi, CJ; Paul, S; Santiestevan, E; Nishi, E; Klagsbrun, M				Elenius, K; Choi, CJ; Paul, S; Santiestevan, E; Nishi, E; Klagsbrun, M			Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase	ONCOGENE			English	Article						alternative splicing; chemotaxis; EGF receptor; survival	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR FAMILY; EGF-RECEPTOR; MICE LACKING; TYROSINE PHOSPHORYLATION; PROTEIN; CELLS; SURVIVAL; MEMBER	Receptor tyrosine kinases regulate cell behavior by activating specific signal transduction cascades. Epidermal growth factor (EGF) receptor tyrosine kinases include ErbB1, ErbB2, ErbB3 and ErbB4, ErbB4 is a tyrosine kinase receptor that binds neuregulins (NRG) and several other EGF family members. Reverse transcriptase polymerase chain reaction (RT-PCR) analysis identified two isoforms of ErbB4 that differed in their cytoplasmic domain sequences. Specifically, RT-PCR using primers flanking the putative phosphatidyl inositol 3-kinase (PI3-K) binding site of ErbB4 generated two specific bands when human and mouse heart and kidney tissues were analysed. Cloning and sequencing of these RT-PCR products revealed that one of the ErbB4 isoforms (ErbB4 CYT-2) lacked a 16 amino acid sequence including a putative PI3-K binding site, that was present in the other isoform (ErbB4 CYT-1), RT-PCR analysis of mouse tissues suggested that the expression of ErbB4 CYT-1 and ErbB4 CYT-2 was tissue-specific. Heart, breast and abdominal aorta expressed predominantly ErbB4 CYT-1 whereas neural tissues and kidney expressed predominantly ErbB4 CYT-2. To ascertain whether the absence of the putative PI3-K binding site in ErbB4 CYT-2 also resulted in the loss of PI3-K activity, NIH3T3 cell lines overexpressing ErbB4 CYT-1 or ErbB4 CYT-2 were produced. NRG-1 bound to and stimulated equivalent tyrosine phosphorylation of both isoforms. However, unlike ErbB4 CYT-1, the ErbB4 CYT-2 isoform was unable to bind the p85 subunit of PI3-K and to stimulate PI3-K activity in these cells. Furthermore, tyrosine phosphorylation of p85 or association of PI3-K activity with phosphotyrosine,vas not induced in NRG-1 treated cells expressing ErbB4 CYT-2, indicating that this isoform was incapable of activating PU-K even indirectly. It was concluded that a novel naturally occurring ErbB4 isoform exists with a deletion of the cytoplasmic domain sequence required for the activation of the PI3-K intracellular signal transduction pathway and that this is the only PD-K binding site in ErbB4.	Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Turku Univ, Med Res Labs, Turku 20520, Finland	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; University of Turku	Klagsbrun, M (corresponding author), Childrens Hosp, Dept Surg, Boston, MA 02115 USA.		Elenius, Klaus/AAI-7594-2021; Nishi, Eiichiro/A-8246-2019	Elenius, Klaus/0000-0001-5700-0827; Nishi, Eiichiro/0000-0002-8188-8026	NCI NIH HHS [CA 37392] Funding Source: Medline; NIGMS NIH HHS [GM 47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037392, R37CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; Canoll PD, 1996, NEURON, V17, P229, DOI 10.1016/S0896-6273(00)80155-5; CARPENTER G, 1991, PEPTIDE GROWTH FACTO, P69; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; Cohen BM, 1996, J BIOL CHEM, V271, P4813; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Komurasaki T, 1997, ONCOGENE, V15, P2841, DOI 10.1038/sj.onc.1201458; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Levkowitz G, 1996, ONCOGENE, V12, P1117; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, ONCOGENE, V12, P345; Riethmacher D, 1997, NATURE, V389, P725, DOI 10.1038/39593; Sawyer C, 1998, ONCOGENE, V17, P919, DOI 10.1038/sj.onc.1202015; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; Sibilia M, 1998, EMBO J, V17, P719, DOI 10.1093/emboj/17.3.719; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIMONJIC DB, 1995, ONCOGENE, V10, P1235	55	132	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	1999	18	16					2607	2615		10.1038/sj.onc.1202612	http://dx.doi.org/10.1038/sj.onc.1202612			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	189LU	10353604				2022-12-17	WOS:000079907100008
J	Bissonnette, N; Hunting, DJ				Bissonnette, N; Hunting, DJ			p21-induced cycle arrest in G(1) protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage	ONCOGENE			English	Article						DNA; p21(Waf1/Cip1); PARP; RNA polymerase III apoptosis; p53	CASEIN KINASE-II; CELLULAR TUMOR-ANTIGEN; HUMAN CANCER-CELLS; WILD-TYPE P53; DEPENDENT KINASES; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; P53-MEDIATED APOPTOSIS; ATAXIA-TELANGIECTASIA; POTENTIAL MEDIATOR	Cells expressing the R273H mutant of p53, which lacks sequence specific DNA binding capacity, do not undergo cell cycle arrest in G(1) following exposure to ionizing or UV radiation because of their inability to induce p21(Waf1/Cip1), a cyclin-dependent kinase inhibitor and downstream mediator of p53-dependent DNA damage-induced growth arrest. Following UV-irradiation or treatment with an inhibitor of RNA pol II, we observed a rapid induction of the apoptotic process, as evidenced by DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase. Using mimosine, a p21(Waf1/Cip1) inducer that bypasses the requirement for transcriptional transactivation by p53, we demonstrated that a G(1) cell cycle arrest can prevent apoptosis following UV-irradiation or treatment with an RNA polymerase II inhibitor, Serum starvation, which also synchronized cells in G(1) but did not induce p21(Waf1/Cip1), did not protect cells from apoptosis, These results demonstrate that restoring a late G(1) checkpoint by inducing p21(Waf1/Cip1) expression can protect cells from DNA damage induced apoptosis, Our results suggest that p21(Waf2/Cip1) can interrupt the apoptotic process at a point downstream from p53 accumulation but upstream from caspase-3 activation.	Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada	University of Sherbrooke	Hunting, DJ (corresponding author), Univ Sherbrooke, Fac Med, MRC, Grp Radiat Sci, Sherbrooke, PQ J1H 5N4, Canada.							ADDISON C, 1990, ONCOGENE, V5, P423; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Bissonnette N, 1997, BIOCHEM CELL BIOL, V75, P351, DOI 10.1139/bcb-75-4-351; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chernov MV, 1997, ONCOGENE, V14, P2503, DOI 10.1038/sj.onc.1201104; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DelSal G, 1996, ONCOGENE, V12, P177; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P85024; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1990, GENE DEV, V4, P74; FISCELLA M, 1994, ONCOGENE, V9, P3249; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Guerra B, 1997, ONCOGENE, V14, P2683, DOI 10.1038/sj.onc.1201112; Guillot C, 1997, ONCOGENE, V14, P45, DOI 10.1038/sj.onc.1200803; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARPER JW, 1993, CELL, V75, P805; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kastan MB, 1996, BIOESSAYS, V18, P617, DOI 10.1002/bies.950180804; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHANNA KK, 1995, ONCOGENE, V11, P609; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; McDonald E, 1996, CANCER RES, V56, P2250; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Park DS, 1997, J NEUROSCI, V17, P1256, DOI 10.1523/jneurosci.17-04-01256.1997; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK D, 1994, GENE DEV, V10, P1945; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE BD, 1995, ONCOGENE, V11, P73; Schroter M, 1996, EUR J CELL BIOL, V69, P143; SELBY PC, 1997, NUCLEIC ACIDS RES, V25, P787; Sheikh MS, 1997, ONCOGENE, V14, P1875, DOI 10.1038/sj.onc.1201004; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STURZBECHER HW, 1990, ONCOGENE, V5, P795; Tarunina M, 1996, ONCOGENE, V13, P589; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATSON JV, 1987, CYTOMETRY, V8, P1, DOI 10.1002/cyto.990080101; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANKULOV K, 1995, J BIOL CHEM, V270, P23922, DOI 10.1074/jbc.270.41.23922; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANDOMENI RO, 1989, BIOCHEM J, V262, P469, DOI 10.1042/bj2620469	82	132	134	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 2	1998	16	26					3461	3469		10.1038/sj.onc.1201899	http://dx.doi.org/10.1038/sj.onc.1201899			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZX689	9692554				2022-12-17	WOS:000074544100013
J	Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX				Xu, HJ; Zhou, YL; Ji, W; Perng, GS; Kruzelock, R; Kong, CT; Bast, RC; Mills, GB; Li, J; Hu, SX			Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; senescence; telomerase	BREAST-CARCINOMA CELLS; REPLICATIVE SENESCENCE; HUMAN FIBROBLASTS; GENE-EXPRESSION; IMMORTAL CELLS; RB PROTEIN; P53 GENE; SUPPRESSION; APOPTOSIS; FAILURE	Normal human diploid cells senesce in vitro and in vivo after a limited number of cell divisions, This process known as cellular senescence is an underlying cause of aging and a critical barrier for development of human cancers, We demonstrate here that reexpression of functional pRB alone in RB/p53-defective tumor cells via a modified tetracycline-regulated gene expression system resulted in a stable growth arrest at the G0/G1 phase of the cell cycle, preventing tumor cells from entering S phase in response to a variety of mitogenic stimuli, These cells displayed multiple morphological changes consistent with cellular senescence and expressed a senescence-associated beta-galactosidase biomarker, Further studies indicated that telomerase activity, which was assumably essential for an extended proliferative life-span of neoplastic cells, was abrogated or repressed in the tumor cell lines after induction of pRB (but not p53) expression, Strikingly, when returned to an nonpermissive medium for pRB expression, the pRB-induced senescent tumor cells resumed DNA synthesis, attempted to divide but most died in the process, a phenomenon similar to postsenescent crisis of SV40 T-antigen-transformed human diploid fibroblasts in late passage, These observations provide direct evidence that overexpression of pRB alone in RB/p53-defective tumor cells is sufficient to reverse their immortality and cause a phenotype that is, by all generally accepted criteria, indistinguishable from replicative senescence, The results suggest that pRB may play a causal role in the intrinsic cellular senescence program.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT HEMATOL,DIV MED,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,DIV MED,HOUSTON,TX 77030; BEIJING INST GERIATR,DEPT BIOCHEM,BEIJING 100730,PEOPLES R CHINA; BEIJING UNION MED COLL HOSP,BEIJING 100730,PEOPLES R CHINA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Xu, HJ (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL ONCOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381, USA.		Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA67274] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; Berry DE, 1996, ONCOGENE, V12, P1809; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHEN PL, 1992, CELL GROWTH DIFFER, V3, P119; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; DELANGE T, 1994, P NATL ACAD SCI USA, V91, P2882, DOI 10.1073/pnas.91.8.2882; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, BIOTECHNIQUES, V19, P213; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Li J, 1996, ONCOGENE, V13, P2379; LINSKENS MHK, 1995, SCIENCE, V267, P17, DOI 10.1126/science.7848496; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STEIN GH, 1985, J CELL PHYSL, V125, P35; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG E, 1995, CANCER RES, V55, P2284; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; XU HJ, 1991, ONCOGENE, V6, P1139; XU HJ, 1997, GENE THERAPY ADV PHA, V40, P233; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	37	132	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 20	1997	15	21					2589	2596		10.1038/sj.onc.1201446	http://dx.doi.org/10.1038/sj.onc.1201446			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YG732	9399646				2022-12-17	WOS:A1997YG73200008
J	Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE				Wang, MS; Liu, YLE; Greene, J; Sheng, SJ; Fuchs, A; Rosen, EM; Shi, YE			Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4	ONCOGENE			English	Article						TIMP; MMP; mammary carcinoma; nude mice; angiogenesis	INVASIVE TUMORS; IV COLLAGENASES; MESSENGER-RNAS; STROMAL CELLS; UP-REGULATION; CHICK-EMBRYO; IN-VIVO; EXPRESSION; TIMP-2; ANGIOGENESIS	We recently identified, cloned, and characterized a novel human tissue inhibitor of metalloproteinases-4, TIMP-4 (Greene et al., 1996), To determine if TIMP-4 can modulate the in vivo growth of human breast cancers, Ne transfected a full-length TIMP-4 cDNA into MDA-MB-435 human breast cancer cells and studied the orthotopic growth of TIMP-4-transfected (TIMP4-435) versus control (neo-435) clones in the mammary fat pad of athymic nude mice, TIMP4-435 clones expressed TIMP-4 mRNA and produced anti-metalloproteinase (MMP) activity, while neo-435 clones did not express TIMP-4 mRNA or produce detectable anti-MMP activity. Overexpression of TIMP-4 inhibited the invasion potential of the cells in the in vitro invasion assay, When injected orthotopically into nude mice, TIMP-4 transfectants were significantly inhibited in tumor growth by 4-10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with controls. These results suggest the therapeutic potential of TIMP-4 in treating cancer malignant progression.	LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW HYDE PK,NY 11040; LONG ISL JEWISH MED CTR,ALBERT EINSTEIN COLL MED,DEPT RADIAT ONCOL,NEW HYDE PK,NY 11040; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; GlaxoSmithKline; Human Genome Sciences Inc; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R29CA068064] Funding Source: NIH RePORTER; NCI NIH HHS [CA68064-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAM L, 1994, INT J CANCER, V59, P262, DOI 10.1002/ijc.2910590219; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; BARSKY SH, 1983, LAB INVEST, V49, P140; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERRETTONI BA, 1986, J BONE JOINT SURG AM, V68A, P308, DOI 10.2106/00004623-198668020-00021; DECLERCK YA, 1992, CANCER RES, V52, P701; Denhardt D T, 1992, Matrix Suppl, V1, P281; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; HARAN EF, 1994, CANCER RES, V54, P5511; Heppner KJ, 1996, AM J PATHOL, V149, P273; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HLATKY L, 1994, CANCER RES, V54, P6083; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; Imren S, 1996, CANCER RES, V56, P2891; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KHOKHA R, 1992, CLIN EXP METASTAS, V10, P365, DOI 10.1007/BF00133464; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAMSZUS K, 1997, IN PRESS LAB INVEST; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUZAWA K, 1996, NEUROPATHOL EXP NEUR, V55, P88; MCLESKEY SW, 1993, CANCER RES, V53, P2168; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; OHBA Y, 1995, BBA-GEN SUBJECTS, V1245, P1, DOI 10.1016/0304-4165(95)00065-J; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POLETTE M, 1993, PATHOL RES PRACT, V189, P1052; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; PYKE C, 1993, AM J PATHOL, V142, P359; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Shi Y. E., 1995, V74, P215; SHI YE, 1993, CANCER RES, V53, P1409; SHI YE, 1993, CLIN EXP METASTAS, V11, P251, DOI 10.1007/BF00121168; SPYRATOS F, 1989, LANCET, V2, P1115; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; TRYGGVASON K, 1993, BREAST CANCER RES TR, V24, P209, DOI 10.1007/BF01833261; TSUCHIYA Y, 1993, CANCER RES, V53, P1397; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; VISSCHER DW, 1994, INT J CANCER, V59, P339, DOI 10.1002/ijc.2910590308; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WOLFF JEA, 1993, BRAIN RES, V604, P79, DOI 10.1016/0006-8993(93)90354-P	47	132	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2767	2774		10.1038/sj.onc.1201245	http://dx.doi.org/10.1038/sj.onc.1201245			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190892				2022-12-17	WOS:A1997XD64300004
J	Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM				Lallemand, D; Spyrou, G; Yaniv, M; Pfarr, CM			Variations in Jun and Fos protein expression and AP-1 activity in cycling, resting and stimulated fibroblasts	ONCOGENE			English	Article						Jun; Fos; AP-1; NIH3T3; cell cycle	TRANSCRIPTION FACTOR AP-1; PROGRAMMED CELL-DEATH; LACKING C-FOS; DNA-BINDING; MOUSE FIBROBLASTS; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; G0-TO-G1 TRANSITION; EMBRYO FIBROBLASTS; NEGATIVE REGULATOR	We have analysed the different Jun and Fos proteins as NIH3T3 fibroblasts pass from exponential growth to quiescence and during the first 24 h after their re-entry into the cell cycle following serum stimulation, We show that these proteins can be divided into 3 subgroups based on their pattern of expression. The first contains c-Jun, Jun-D and Fra-2 which are expressed at high level in cycling cells and are only mildly induced by serum. The second contains Jun-B, c-Fos, Fos-B and Delta Fos-B whose levels are low in cycling cells but increase strongly and rapidly after stimulation by serum. The third group contains only Fra-1, which is absent from cycling cells and behaves as a delayed early response protein after serum stimulation, AP-I binding activity is low both in cycling and quiescent fibroblasts but increases after stimulation by serum with kinetics matching the induction of the various Jun and Fos proteins. Antibody supershift analyses demonstrate that the composition of AP-I binding activity reflects the relative abundance of each Jun and Fos protein. Furthermore, the state of post-translational modification varies continuously for all of the AP-1 proteins as growth conditions change. These data indicate that AP-1 activity during the G(0)-G(1) transition is finely regulated and complex, involving changes both in protein expression and in posttranslational modification.	INST PASTEUR, UNITE VIRUS ONCOGENES, UA 1149 CNRS, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE; KAROLINSKA INST, NOVUM, DEPT BIOSCI, S-14157 HUDDINGE, SWEDEN	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Karolinska Institutet			Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017	lallemand, dominique/0000-0002-0212-7342				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; CARILLO S, 1996, BIOCHEM J, V270, P623; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHATTON B, 1994, ONCOGENE, V9, P375; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HERBER, 1994, ONCOGENE, V9, P2105; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MILLER AD, 1984, CELL, V36, P51; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PIETTE J, 1988, P NATL ACAD SCI USA, V85, P3401, DOI 10.1073/pnas.85.10.3401; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STANCOVSKI I, 1995, MOL CELL BIOL, V15, P7106; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	132	133	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	1997	14	7					819	830		10.1038/sj.onc.1200901	http://dx.doi.org/10.1038/sj.onc.1200901			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047389				2022-12-17	WOS:A1997WJ11200008
J	Krane, IM; Leder, P				Krane, IM; Leder, P			NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice	ONCOGENE			English	Article						neu differentiation factor; heregulin; erbB; breast cancer	NEU ONCOGENE; TYROSINE KINASE; POINT MUTATION; TUMOR CELLS; LIGAND; PROTEIN; ACTIVATION; DIFFERENTIATION; GLYCOPROTEIN; ASSOCIATION	Neu differentiation factor (NDF), a member of the neuregulin family of ligands of erbB receptors, induces both differentiative and mitogenic effects on cultured human mammary epithelial cells, Since members of the epidermal growth factor receptor family, including Neu/erbB2, have been implicated in mammary carcinoma, we wished to know whether a potential ligand of this family, NDF, could induce such effects in the mammary gland in vivo, We therefore targeted expression of NDF to the mammary gland of transgenic mice using the mouse mammary tumor virus (MMTV) promoter in a fusion a clear, but subtle effect on adult virgin gland of female transgenic animals, Terminal end bud structures (TEBs), which normally disappear from the mammary gland at the age of similar to 8 weeks in wild type mice, persist in glands of virgin MMTV-NDF transgenic females, suggesting that NDF inhibits signals that normally lead to the terminal differentiation of these structures, Further, female mice, bred continuously to maximize expression of the transgene in the mammary gland,develop mammary adenocarcinomas at a median age of 12 months, Since these tumors arise in a solitary fashion, we infer that NDF is necessary, but not sufficient for their formation, In order to explore the signal transduction pathways potentially activated by NDF, we examined expression of the receptors erbB2, erbB3 and erbB4 in mammary epithelial cells established from induced tumor, All three receptors were though only the erbB3 receptor was phosphorylated, suggesting that overexpression of NDF might operate through this receptor, Additionally, about 50% of MMTV-NDF transgenic mice developed Harderian (lachrymal) gland hyperplasia, a benign tumor that does not progress to frank malignacy.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Daniel CW, 1987, MAMMARY GLAND DEV RE; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RUSSO J, 1995, CANCER LETT, V90, P81, DOI 10.1016/0304-3835(94)03681-8; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; Sambrook J, 1989, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	37	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1781	1788						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622899				2022-12-17	WOS:A1996UG45800021
J	Kevil, C; Carter, P; Hu, B; DeBenedetti, A				Kevil, C; Carter, P; Hu, B; DeBenedetti, A			Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation	ONCOGENE			English	Article						FGF-2; eIF-4E/F; breast cancer; translation/secretion	FIBROBLAST GROWTH-FACTOR; 5' NONTRANSLATED REGION; MOUTH-DISEASE-VIRUS; MESSENGER-RNA; PROTEIN-SYNTHESIS; INTERNAL INITIATION; MALIGNANT TRANSFORMATION; CELLS; EXPRESSION; SITE	The FGF-2 mRNA of most mammals contains a long and inhibitory 5' UTR in addition to at least two CUG codons upstream and in frame with the AUG start codon. These CUGs are used for translation initiation to generate several polypeptides, Cells overexpressing the translation initiation factor 4E produce and secrete large amounts of FGF-2, and particularly the largest, CUG1-initiated form. Overexpression of FGF-2 ia due to a translational enhancement of its mRNA, as indicated by its association with large polyribosomes in contrast to control cells, where it partitions mostly in fractions lighter than 80 S or small polyribosomes. Breast carcinomas expressing elevated eIF-4E also exhibit the large FGF-2 isoforms, which could play an important role in tumor angiogenesis. Translation of in vitro transcribed rat FGF-2 in reticulocyte lysates resulted in synthesis of four polypeptides, of similar size to those observed in vivo. Addition of purified eIF-4E preferentially increased translation of CUG1- and AUG-initiated isoforms. Since the different isoforms of FGF-2 may have different roles and intracellular distribution, the effects of the eIF-4 factors on FGF-2 expression could be important for the control of cell proliferation and differentiation.	LOUISIANA STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71105 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport				Kevil, Christopher/0000-0003-0863-7260				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BARVE SS, 1994, J IMMUNOL, V152, P1171; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HALABAN R, 1988, ONCOGENE RES, V3, P177; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN R, 1990, J VIROL, V64, P4625; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2445, DOI 10.1093/nar/21.10.2445; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MORRISON RS, 1990, CANCER RES, V50, P2524; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; Sonenberg Nahum, 1993, Gene Expression, V3, P317; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS AAM, 1992, NEW BIOL, V4, P404; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WELLSTEIN A, 1991, MOL F ONCOLOGY; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	65	132	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2339	2348						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570185				2022-12-17	WOS:A1995TK70200018
J	MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM				MYERS, SM; ENG, C; PONDER, BAJ; MULLIGAN, LM			CHARACTERIZATION OF RET PROTOONCOGENE 3'-SPLICING VARIANTS AND POLYADENYLATION SITES - A NOVEL C-TERMINUS FOR RET	ONCOGENE			English	Article						RET; 3' SPLICING; UTR; POLYADENYLATION	NEUROBLASTOMA CELL-LINES; MYOTONIC-DYSTROPHY; MESSENGER-RNA; TYROSINE KINASE; EXPRESSION; PROTOONCOGENE; GENE; MUTATIONS; ISOFORMS; SEQUENCE	The RET proto-oncogene, which encodes a receptor tyrosine kinase, displays multiple alternative splicing variants. Splicing of sequences 3' of exon 19 to generate several coding and untranslated region (UTR) sequences has been previously reported. We have sequenced the full length RET coding region and characterized the transcripts and 3' UTRs generated by alternative splicing of the RET 3' terminus. These analyses were performed using both RET cDNA cloned from a pheochromocytoma library and reverse transcriptase PCR products generated using RNA from a neuroblastoma cell line (LA-N-2). Three different carboxyl termini were identified. In addition to the nine and 51 terminal amino acid forms already known, we identified a third with 43 terminal amino acids predicted to encode a novel RET protein isoform. A total of 3621 base pairs of DNA 3' of exon 19, which spans the alternatively spliced exons and RET UTRs, was sequenced. Four polyadenylation sites were identified. The observed combinations of polyadenylation sites and 3' coding sequence suggest that RET transcripts with up to 10 different 3' sequences and up to 40 different full length RET transcripts may exist.	QUEENS UNIV,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT PAEDIAT,KINGSTON,ON K7L 3N6,CANADA; UNIV CAMBRIDGE,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115	Queens University - Canada; Queens University - Canada; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Eng, Charis/0000-0002-3693-5145				ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANGRIST M, 1995, HUM MOL GENET, V4, P821, DOI 10.1093/hmg/4.5.821; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BORRELLO MG, 1994, ONCOGENE, V9, P1661; Borson N D, 1992, PCR Methods Appl, V2, P144; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CECCHERINI I, 1994, ONCOGENE, V9, P3025; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GARDNER E, 1994, HUM MOL GENET, V3, P1771, DOI 10.1093/hmg/3.10.1771; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOPPENER J, 1994, 5TH INT WORKSH MULT, P70; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IKEDA I, 1990, ONCOGENE, V5, P1291; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; JHIANG SM, 1991, NUCLEIC ACIDS RES, V19, P4303, DOI 10.1093/nar/19.15.4303; KWOK JBJ, 1993, ONCOGENE, V8, P2575; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MOQADAM F, 1994, CLONTECHNIQUES, V9, P6; MULLIGAN L, 1995, IN PRESS J INT MED; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PESOLE G, 1994, GENE, V140, P219, DOI 10.1016/0378-1119(94)90547-9; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; ROMANO A, 1994, ONCOGENE, V9, P2923; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; Sambrook J., 1989, MOL CLONING LAB MANU; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SINGH IN, 1990, J NEUROSCI RES, V25, P476, DOI 10.1002/jnr.490250405; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WEST GJ, 1977, CANCER RES, V37, P1372	50	132	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2039	2045						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478523				2022-12-17	WOS:A1995TF29700014
J	PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER				PIERCEALL, WE; WOODARD, AS; MORROW, JS; RIMM, D; FEARON, ER			FREQUENT ALTERATIONS IN E-CADHERIN AND ALPHA-CATENIN AND BETA-CATENIN EXPRESSION IN HUMAN BREAST-CANCER CELL-LINES	ONCOGENE			English	Article						BREAST CANCER; E-CADHERIN; A-CATENIN; BETA-CATENIN; CYTOSKELETON; CELL-CELL INTERACTIONS	ADHESION MOLECULE; CYTOPLASMIC DOMAIN; COLORECTAL-CANCER; PROSTATE-CANCER; P-CADHERIN; CARCINOMAS; PROTEIN; PLAKOGLOBIN; ASSOCIATION; INVASIVENESS	Alterations in intercellular junction and membrane cytoskeletal proteins may underlie some of the morphological, invasive and metastatic properties of cancer. E-cadherin, a transmembrane protein that functions in epithelial cell-cell interactions at adherens junctions, is linked to the membrane cytoskeletal matrix through interactions with alpha- and beta-catenin. We have carried out studies of E-cadherin and alpha- and beta-catenin in 18 breast cancer cell lines to determine the prevalence and nature of alterations in these genes in breast cancer. Ten lines failed to express E-cadherin protein at detectable levels and seven failed to produce detectable levels of E-cadherin transcripts. In a line lacking E-cadherin expression (SK-BR-3) a homozygous deletion of a large portion of the E-cadherin gene was noted. Localized sequence alterations in E-cadherin transcripts were not identified in any lines. In contrast to the results of a previous study, no relationship was identified between E-caderin expression and HER-2/NEU expression. Two of the 18 lines had no detectable alpha-catenin protein and six others had reduced levels. The two lines lacking alpha-catenin protein had reduced or undetectable levels of alpha-catenin transcripts, while no consistent changes in alpha-catenin transcript levels were seen in the lines with reduced, but detectable, levels of alpha-catenin protein. Similarly, although two lines lacked beta-catenin protein, in most lines the levels of beta-catenin transcripts and protein were not well correlated with one another. Our findings suggest that alterations in E-cadherin and alpha- and beta-catenin expression are frequent in human breast cancer-derived cell lines, and that in some cases the decreased expression may result from mutations in the genes. Furthermore, the frequent alterations in the expression of these proteins argue that loss of function in the E-cadherin-catenin pathway may be critical in the development of many breast cancers.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT BIOL,NEW HAVEN,CT 06510	Yale University; Yale University				Rimm, David/0000-0001-5820-4397				BECKER KF, 1994, CANCER RES, V54, P3845; BEHRENS J, 1991, P NATL ACAD SCI USA, V88, P11495, DOI 10.1073/pnas.88.24.11495; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BRABANT G, 1993, CANCER RES, V53, P4987; BRINGUIER PP, 1993, CANCER RES, V5, P3241; BUSSEMAKERS MJG, 1994, BIOCHEM BIOPH RES CO, V203, P1284, DOI 10.1006/bbrc.1994.2321; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; CARTER BS, 1991, P NATL ACAD SCI USA, V87, P8751; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V16, P156; CROALL DE, 1986, BIOCHIM BIOPHYS ACTA, V882, P287, DOI 10.1016/0304-4165(86)90250-3; DOKI Y, 1993, CANCER RES, V53, P3421; DORUDI S, 1993, AM J PATHOL, V142, P981; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KADOWAKI T, 1994, CANCER RES, V54, P291; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; LINDBLOM A, 1993, CANCER RES, V53, P3707; MAYER B, 1993, CANCER RES, V53, P1690; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MOLL R, 1993, AM J PATHOL, V143, P1731; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; ODA T, 1993, BIOCHEM BIOPH RES CO, V193, P897, DOI 10.1006/bbrc.1993.1710; OKA H, 1993, CANCER RES, V53, P1696; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PFIEFER M, 1990, CELL, V63, P1167; PRESS MF, 1993, CANCER RES, V53, P4960; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; REALE MA, 1994, CANCER RES, V54, P4493; RIMM DL, 1995, LAB INVEST, V72, P590; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SATO T, 1990, CANCER RES, V50, P7184; SCHIPPER JH, 1991, CANCER RES, V52, P2916; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; SHIMOYAMA Y, 1991, CANCER LETT, V57, P131, DOI 10.1016/0304-3835(91)90206-W; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOMMERS CL, 1994, CANCER RES, V54, P3544; SOMMERS CL, 1991, CELL GROWTH DIFFER, V2, P365; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; UMBAS R, 1992, CANCER RES, V52, P5104; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	66	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1319	1326						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478552				2022-12-17	WOS:A1995RY96700012
J	LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A				LIU, Q; NEUHAUSEN, S; MCCLURE, M; FRYE, C; WEAVERFELDHAUS, J; GRUIS, NA; EDDINGTON, K; ALLALUNISTURNER, MJ; SKOLNICK, MH; FUJIMURA, FK; KAMB, A			CDKN2 (MTS1) TUMOR-SUPPRESSOR GENE-MUTATIONS IN HUMAN TUMOR-CELL LINES	ONCOGENE			English	Article						P16; TUMOR SUPPRESSOR; MELANOMA; LOH; MUTATION	ACUTE LYMPHOBLASTIC-LEUKEMIA; POLYPOSIS-COLI GENE; P53 GENE; HOMOZYGOUS DELETIONS; BLADDER-CANCER; LUNG-CANCER; COLORECTAL CARCINOMAS; INTERFERON GENES; CRITICAL REGION; CHROMOSOME-9	Tumor suppressor gene CDKN2 (also called MTS1, CDK4I and p16(INK4)) is located in 9p21 and deleted homozygously in a high percentage of tumor cell lines. We have examined the sequence of CDKN2 in 154 tumor cell lines that are not homozygously deleted for CDKN2. Overall, 18% (27/154) of the cell lines carried mutations in CDKN2. These mutations were found in cell lines derived from melanoma, bladder, lung and prostate cancers, as well as sarcomas of various origin. The spectrum of the CDKN2 mutations found in melanoma cell lines indicated a major role for ultraviolet light in generating the mutations, suggesting the mutations occurred in vivo. The frequency of loss of heterozygosity in 9p21 in this set of lines is only slightly higher than the background rate of aneuploidy, suggesting that a second 9p21 tumor suppressor gene, if it exists, must lie near CDKN2.	MYRIAD DIAGNOST SERV INC,SALT LAKE CITY,UT 84108; UNIV UTAH,MED CTR,DEPT MED INFORMAT,SALT LAKE CITY,UT 84132; LEIDEN UNIV,DEPT HUMAN GENET,LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT DERMATOL,2333 AA LEIDEN,NETHERLANDS; CROSS CANC INST,DEPT RADIAT ONCOL,EDMONTON,AB T6G 1Z2,CANADA	Utah System of Higher Education; University of Utah; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); University of Alberta	LIU, Q (corresponding author), MYRIAD GENET INC,421 WAKARA WAY,SALT LAKE CITY,UT 84108, USA.			Gruis, Nelleke/0000-0002-5210-9150	NCI NIH HHS [CA-48711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA048711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BODNER SM, 1992, ONCOGENE, V7, P743; BRASH DE, 1987, P NATL ACAD SCI USA, V84, P3782, DOI 10.1073/pnas.84.11.3782; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1993, ONCOGENE, V8, P1083; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1993, CANCER RES, V53, P4761; DALBAGNI G, 1993, LANCET, V342, P469, DOI 10.1016/0140-6736(93)91595-D; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P680; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FOUNTAIN JW, 1990, CANCER SURV, V9, P645; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUIS NA, 1994, IN PRESS J PATHOLOGY; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; HUTCHINSON F, 1994, MUTAT RES-FUND MOL M, V309, P11, DOI 10.1016/0027-5107(94)90037-X; JAMES CD, 1993, CANCER RES, V53, P3674; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; MERLO A, 1994, CANCER RES, V54, P640; MIDDLETON PG, 1991, LEUKEMIA, V5, P680; MORI T, 1994, CANCER RES, V54, P3396; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; TSAI YC, 1990, CANCER RES, V50, P44; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563	43	132	139	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1061	1067						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700630				2022-12-17	WOS:A1995QN35300005
J	ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E				ABRAHAM, SE; LOBO, S; YACIUK, P; WANG, HGH; MORAN, E			P300, AND P300-ASSOCIATED PROTEINS, ARE COMPONENTS OF TATA-BINDING PROTEIN (TBP) COMPLEXES	ONCOGENE			English	Article							E2F TRANSCRIPTION FACTOR; HUMAN ADENOVIRUS TYPE-5; TFIID COMPLEX; DNA-SYNTHESIS; E1A GENE; PRODUCTS; DOMAINS; COACTIVATORS; ACTIVATION; ANTIBODIES	The transforming proteins encoded by the adenovirus E1A gene bind to a 300-kDa cellular product, p300, via the N-terminal E1A sequences. Residues important for p300 binding are required for the transformation function of E1A and for other E1A-mediated gene-regulating functions, including activation of cell cycle-regulated products and repression of tissue-specific enhancer activity. Recent evidence indicates that p300 is a DNA-binding protein with specific affinity for known enhancer motifs, suggesting that p300 may be a component of transcription factor complexes. The possibility that upstream element-binding factors might interact with basal transcription factors led us to investigate whether p300 interacts, directly or indirectly, with the TATA-binding protein (TBP). We report here that TBP-specific immunoprecipitations show a 300-kDa protein co-precipitating with TBP. This protein is lost from the precipitated material if the lysates are boiled in sodium dodecyl sulfate prior to immunoprecipitation, implying that its presence does not result from non-specific antibody cross-reactivity, but is dependent on specific association with TBP. The TBP-associated 300-kDa protein and p300 originally defined by EIA association show indistinguishable partial proteolytic digest patterns, indicating that these are identical or closely related species. Moreover, p300-specific complexes and TBP-specific complexes include at least two additional common polypeptide species, phosphoproteins of 64 and 59 kDa. These results suggest that p300 interacts with TBP, possibly through intermediate protein-protein associations. They thus provide additional biochemical evidence for postulated protein-protein interactions between upstream regulatory factors and the basal transcriptional machinery.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory					NATIONAL CANCER INSTITUTE [R01CA055330, R01CA053592] Funding Source: NIH RePORTER; NCI NIH HHS [CA-53592, CA-55330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; DYSON N, 1992, CANCER SURV, V12, P161; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LISCHWE MA, 1977, J BIOL CHEM, V252, P4976; LOBO SM, 1991, GENE DEV, V5, P1477, DOI 10.1101/gad.5.8.1477; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1992, TRENDS GENET, V8, P284, DOI 10.1016/0168-9525(92)90255-3; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X	41	132	134	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1639	1647						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502484				2022-12-17	WOS:A1993LE06400028
J	DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR				DAVIDOFF, AM; PENCE, JC; SHORTER, NA; IGLEHART, JD; MARKS, JR			EXPRESSION OF P53 IN HUMAN NEUROBLASTOMA-DERIVED AND NEUROEPITHELIOMA-DERIVED CELL-LINES	ONCOGENE			English	Article							NEURO-BLASTOMA CELLS; TUMOR-ANTIGEN; TRANSFORMED-CELLS; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODIES; ACTIVATING MUTATIONS; HOST PROTEIN; T-ANTIGEN; GENE	Overexpression of the nuclear phosphoprotein p53 has been detected in many different transformed human cell lines and primary adult tumors. Elevated steady-state levels of p53 appear to be the result of an increase in the stability of the protein and, in adult cancers, high levels of the protein are associated with mutation of the p53 gene. In this study, overexpression of p53 was detected in 4 out of 5 human neuroblastoma-derived cell lines. The protein expressed by each of these four lines had a significantly prolonged half-life relative to the p53 protein in immortalized rodent fibroblasts and normal bovine adrenal medullary cells. However, no mutations were detected in the highly conserved regions of the p53 gene in these four neuroblastoma lines and the protein being expressed was not recognized by the mutant-specific anti-p53 monoclonal antibody, PAb 240. Upon retinoic acid-induced differentiation of the LA-N-5 neuroblastoma cell line, the level of p53 protein declined, as did the level of p53 mRNA, but the half-life of the protein remained unchanged. The high level of protein observed in the undifferentiated cell lines appears to result from expression of a stable wild-type p53 protein and increased transcription. In contrast, p53 protein was undetectable in two neuroepithelioma-derived cell lines; the p53 gene in one of these lines contained a nonsense mutation, while the other transcribed truncated p53 mRNA.	DUKE UNIV,MED CTR,DEPT SURG,BOX 3873,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PEDIAT,DURHAM,NC 27710	Duke University; Duke University					NATIONAL CANCER INSTITUTE [F32CA008899] Funding Source: NIH RePORTER; NCI NIH HHS [1 F32 CA08899-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1990, ONCOGENE, V5, P893; BRODEUR GM, 1981, CANCER RES, V41, P4678; CHANDRASEKARAN K, 1981, P NATL ACAD SCI-BIOL, V78, P6953, DOI 10.1073/pnas.78.11.6953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Crawford L V, 1984, Mol Biol Med, V2, P261; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFROMENTEL CC, 1985, EXP CELL RES, V160, P83, DOI 10.1016/0014-4827(85)90238-1; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P569; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVITSKY K, 1983, INT J CANCER, V32, P597, DOI 10.1002/ijc.2910320513; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MARKS JR, 1989, J VIROL, V63, P790, DOI 10.1128/JVI.63.2.790-797.1989; MARKS JR, 1991, CANCER RES, V51, P2979; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PENCE JC, 1990, CANCER RES, V50, P5177; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHOHAT O, 1987, ONCOGENE, V1, P277; SIDELL N, 1988, CANCER RES, V48, P2226; SIDELL N, 1985, ADV NEUROBLASTOMA RE, P39; SOUSSI T, 1987, ONCOGENE, V1, P71; WILSON SP, 1983, METHOD ENZYMOL, V103, P305	39	132	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					127	133						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741160				2022-12-17	WOS:A1992HC22700017
J	KOIZUMI, S; FISHER, RJ; FUJIWARA, S; JORCYK, C; BHAT, NK; SETH, A; PAPAS, TS				KOIZUMI, S; FISHER, RJ; FUJIWARA, S; JORCYK, C; BHAT, NK; SETH, A; PAPAS, TS			ISOFORMS OF THE HUMAN ETS-1 PROTEIN - GENERATION BY ALTERNATIVE SPLICING AND DIFFERENTIAL PHOSPHORYLATION	ONCOGENE			English	Article									FREDERICK CANC RES FACIL,PROGRAM RESOURCES INC,NUCLEIC ACID & PROT SYNTH LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	KOIZUMI, S (corresponding author), NCI,MOLEC ONCOL LAB,FREDERICK,MD 21701, USA.		Fisher, Robert/B-1431-2009					BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BHAT NK, 1989, J IMMUNOL, V142, P672; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELDER JH, 1977, J BIOL CHEM, V252, P6510; FUJIWARA S, 1988, ONCOGENE, V2, P99; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; FUJIWARA S, IN PRESS MOL CELL BI; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MITSUHASHI T, 1988, P NATL ACAD SCI USA, V85, P5804, DOI 10.1073/pnas.85.16.5804; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PEARSON RB, 1985, J BIOL CHEM, V260, P4471; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1988, ONCOGENE RES, V3, P239; SACCHI N, 1988, LEUKEMIA, V2, P12; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; SETH A, 1989, ONCOGENE RES, V5, P61; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; WANG LH, 1987, ONCOGENE RES, V1, P43; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294	29	132	133	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					675	681						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2189104				2022-12-17	WOS:A1990DG37400007
J	MCKENZIE, SJ; MARKS, PJ; LAM, T; MORGAN, J; PANICALI, DL; TRIMPE, KL; CARNEY, WP				MCKENZIE, SJ; MARKS, PJ; LAM, T; MORGAN, J; PANICALI, DL; TRIMPE, KL; CARNEY, WP			GENERATION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES SPECIFIC FOR THE HUMAN NEU ONCOGENE PRODUCT, P185	ONCOGENE			English	Article									DUPONT CO,BILLERICA,MA 01862	DuPont	MCKENZIE, SJ (corresponding author), APPL BIO TECHNOL,CAMBRIDGE,MA 02142, USA.							BERGER MS, 1988, CANCER RES, V48, P1238; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1986, P NATL ACAD SCI USA, V83, P9129, DOI 10.1073/pnas.83.23.9129; DREBIN JA, 1988, ONCOGENE, V2, P273; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEPPALA I, 1981, SCAND J IMMUNOL, V14, P335, DOI 10.1111/j.1365-3083.1981.tb00573.x; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STOW ND, 1976, J GEN VIROL, V33, P447, DOI 10.1099/0022-1317-33-3-447; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHOU DJ, 1987, CANCER RES, V47, P6123	21	132	166	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2566965				2022-12-17	WOS:A1989U768800003
J	Peng, F; Wang, JH; Fan, WJ; Meng, YT; Li, MM; Li, TT; Cui, B; Wang, HF; Zhao, Y; An, F; Guo, T; Liu, XF; Zhang, L; Lv, L; Lv, DK; Xu, LZ; Xie, JJ; Lin, WX; Lam, EWF; Xu, J; Liu, Q				Peng, F.; Wang, J-H; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; Zhao, Y.; An, F.; Guo, T.; Liu, X-F; Zhang, L.; Lv, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Lin, W-X; Lam, E. W-F; Xu, J.; Liu, Q.			Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia	ONCOGENE			English	Article							PYRUVATE-DEHYDROGENASE KINASE; OXIDATIVE-PHOSPHORYLATION; LUNG-CANCER; DICHLOROACETATE; LONG; GLIOBLASTOMA; METABOLISM; ACTIVATION; PROGRESSION; GENERATION	Glycolysis is critical for cancer stem cell reprogramming; however, the underlying regulatory mechanisms remain elusive. Here, we show that pyruvate dehydrogenase kinase 1 (PDK1) is enriched in breast cancer stem cells (BCSCs), whereas depletion of PDK1 remarkably diminishes ALDH(+) subpopulations, decreases stemness-related transcriptional factor expression, and inhibits sphere-formation ability and tumor growth. Conversely, high levels of PDK1 enhance BCSC properties and are correlated with poor overall survival. In mouse xenograft tumor, PDK1 is accumulated in hypoxic regions and activates glycolysis to promote stem-like traits. Moreover, through screening hypoxia-related long non-coding RNAs (lncRNAs) in PDK1-positive tissue, we find that lncRNA H19 is responsible for glycolysis and BCSC maintenance. Furthermore, H19 knockdown decreases PDK1 expression in hypoxia, and ablation of PDK1 counteracts H19-mediated glycolysis and self-renewal ability in vitro and in vivo. Accordingly, H19 and PDK1 expression exhibits strong correlations in primary breast carcinomas. H19 acting as a competitive endogenous RNA sequesters miRNA let-7 to release Hypoxia-inducible factor 1 alpha, leading to an increase in PDK1 expression. Lastly, aspirin markedly attenuates glycolysis and cancer stem-like characteristics by suppressing both H19 and PDK1. Thus, these novel findings demonstrate that the glycolysis gatekeeper PDK1 has a critical role in BCSC reprogramming and provides a potential therapeutic strategy for breast malignancy.	[Peng, F.; Fan, W-J; Meng, Y-T; Li, M-M; Li, T-T; Cui, B.; Wang, H-F; An, F.; Liu, X-F; Zhang, L.; Lv, D-K; Xu, L-Z; Xie, J-J; Xu, J.; Liu, Q.] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China; [Peng, F.; Fan, W-J; Meng, Y-T; Li, M-M; Liu, Q.] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Wang, J-H; Zhao, Y.] Dalian Med Univ, Affiliated Hosp 1, Dept Oncol, Dalian, Peoples R China; [Guo, T.] Dalian Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Dalian, Peoples R China; [Lv, L.] Dalian Med Univ, Affiliated Hosp 2, Dept Pathol, Dalian, Peoples R China; [Xu, L-Z] Dalian Med Univ, Affiliated Hosp 2, Internal Med Dept Oncol, Dalian, Peoples R China; [Lin, W-X] Dalian Maternal & Child Care Serv Ctr, Dalian, Liaoning, Peoples R China; [Lin, W-X] Imperial Coll London, Dept Surg & Canc, London, England	Dalian Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Dalian Medical University; Imperial College London	Xu, J; Liu, Q (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Western Sect 9, Lvshun South St, Dalian 116044, Liaoning, Peoples R China.	xujie@dmu.edu.cn; liuq9@mail.sysu.edu.cn	Lam, Eric W-F/AAW-8566-2020; Fan, Wenjun/GLV-2107-2022	Lam, Eric W-F/0000-0003-1274-3576; Fan, Wenjun/0000-0002-5432-4524; Peng, Fei/0000-0003-0772-0273	Innovative Research Team in University of Ministry of Education of China [IRT13049]; National Natural Science Foundation of China [81630005, 81573025, 81201686, 81602588, 81502579, 81602585]; Liaoning high-level talent innovation program [NSF2014029102, NSF 2015020264, 201601231]; Dalian high-level talent innovation program [2016RD12]; CRUK [A12011]; Breast Cancer Now [PR070, PhD016]; MRC [MR/N012097/1] Funding Source: UKRI; Cancer Research UK [12011] Funding Source: researchfish; Medical Research Council [MR/N012097/1] Funding Source: researchfish	Innovative Research Team in University of Ministry of Education of China(Ministry of Education, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning high-level talent innovation program; Dalian high-level talent innovation program; CRUK(Cancer Research UK); Breast Cancer Now; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Quentin Liu's lab members for their critical commends and technical support. This work is supported by Innovative Research Team in University of Ministry of Education of China (No. IRT13049), National Natural Science Foundation of China (No. 81630005 and No. 81573025 to QL, No. 81201686 to JX, No. 81602588 to L-ZX, No. 81502579 to Z-JH, No. 81602585 to F-MZ), the Liaoning (NSF2014029102 to QL, NSF 2015020264 to JX, 201601231 to L-ZX), Dalian high-level talent innovation program (2016RD12 to QL). Eric W-F Lam's work is supported by CRUK (A12011) and Breast Cancer Now (2012 May PR070; 2012 Nov PhD016).	Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chang YN, 2016, GENE, V575, P1, DOI 10.1016/j.gene.2015.08.049; Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004; Choudhry H, 2015, ONCOGENE, V34, P4482, DOI 10.1038/onc.2014.378; Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003; Cuesta E, 2005, EUR J PHARMACOL, V517, P158, DOI 10.1016/j.ejphar.2005.05.024; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007; Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662; Feuerecker B, 2015, AM J CANCER RES, V5, P812; Fiorillo M, 2016, ONCOTARGET, V7, P34084, DOI 10.18632/oncotarget.9122; Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011; Forman JJ, 2008, P NATL ACAD SCI USA, V105, P14879, DOI 10.1073/pnas.0803230105; Goswami CP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-970; Guo H, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0892-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho N, 2015, EXP CELL RES, V331, P73, DOI 10.1016/j.yexcr.2014.12.006; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112; Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188; Jiang ZF, 2017, BIOCHEM BIOPH RES CO, V483, P32, DOI 10.1016/j.bbrc.2017.01.015; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Kornfeld JW, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00057; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Li ZK, 2014, CANCER SCI, V105, P951, DOI 10.1111/cas.12461; Lin AF, 2016, NAT CELL BIOL, V18, P213, DOI 10.1038/ncb3295; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Ma X. Y., 2014, NAT COMMUN, V5; Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677; Paldino E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/859871; Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552; Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X; Ruggieri V, 2015, ONCOTARGET, V6, P1217, DOI 10.18632/oncotarget.2721; Rupaimoole R, 2015, CELL REP, V13, P2395, DOI 10.1016/j.celrep.2015.11.047; Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Sancho P, 2016, BRIT J CANCER, V114, P1305, DOI 10.1038/bjc.2016.152; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419; Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9; Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038; Tordonato C, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00072; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang TH, 2016, ONCOTARGET, V7, P43588, DOI 10.18632/oncotarget.9635; Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004; Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944; Zhang K, 2014, GENE, V547, P1, DOI 10.1016/j.gene.2014.06.043; Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828; Zhang Y, 2015, ONCOTARGET, V6, P9999, DOI 10.18632/oncotarget.3171; Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60; Zhou ML, 2016, STEM CELLS, V34, P55, DOI 10.1002/stem.2219; Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935	69	131	139	8	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1062	1074		10.1038/onc.2017.368	http://dx.doi.org/10.1038/onc.2017.368			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29106390	Green Published, hybrid			2022-12-17	WOS:000425905700009
J	Jiang, L; Xiao, L; Sugiura, H; Huang, X; Ali, A; Kuro-O, M; Deberardinis, RJ; Boothman, DA				Jiang, L.; Xiao, L.; Sugiura, H.; Huang, X.; Ali, A.; Kuro-o, M.; Deberardinis, R. J.; Boothman, D. A.			Metabolic reprogramming during TGF beta 1-induced epithelial-to-mesenchymal transition	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; ATP CITRATE LYASE; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; CELL-GROWTH; INHIBITION; EXPRESSION; APOPTOSIS; SREBP	Metastatic progression, including extravasation and micrometastatic outgrowth, is the main cause of cancer patient death. Recent studies suggest that cancer cells reprogram their metabolism to support increased proliferation through increased glycolysis and biosynthetic activities, including lipogenesis pathways. However, metabolic changes during metastatic progression, including alterations in regulatory gene expression, remain undefined. We show that transforming growth factor beta 1 (TGF beta 1)-induced epithelial-to-mesenchymal transition (EMT) is accompanied by coordinately reduced enzyme expression required to convert glucose into fatty acids, and concomitant enhanced respiration. Overexpressed Snail1, a transcription factor mediating TGF beta 1-induced EMT, was sufficient to suppress carbohydrate-responsive-element-binding protein (ChREBP, a master lipogenic regulator), and fatty acid synthase (FASN), its effector lipogenic gene. Stable FASN knockdown was sufficient to induce EMT, stimulate migration and extravasation in vitro. FASN silencing enhanced lung metastasis and death in vivo. These data suggest that a metabolic transition that suppresses lipogenesis and favors energy production is an essential component of TGF beta 1-induced EMT and metastasis.	[Jiang, L.; Deberardinis, R. J.] Childrens Med Ctr Res Inst, Dallas, TX 75390 USA; [Xiao, L.; Sugiura, H.; Huang, X.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol & Radiat Oncol, Dallas, TX 75390 USA; [Sugiura, H.; Kuro-o, M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Ali, A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Kuro-o, M.] Jichi Med Univ, Ctr Mol Med, Shimotsuke, Tochigi, Japan	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Jichi Medical University	Deberardinis, RJ (corresponding author), Childrens Med Ctr Res Inst, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ralph.Deberardinis@utsouthwestern.edu; David.Boothman@utsouthwestern.edu	Boothman, David/Q-7776-2019	Huang, Xiumei/0000-0002-7306-0288; Sugiura, Hidekazu/0000-0003-2950-4512	DOE/NASA grant [DE-FG-022179-18-21]; NIH [R01 CA139217, RO1 CA157996]; CPRIT [RP130272]; imaging core of the Simmons Cancer Center Support Grant [5P30 CA142543-03]; NATIONAL CANCER INSTITUTE [R01CA157996, P30CA142543, R01CA139217] Funding Source: NIH RePORTER	DOE/NASA grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT; imaging core of the Simmons Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Xiuquan Luo for his aid in the BLI measurements and animal injections. This work was supported by DOE/NASA grant DE-FG-022179-18-21 and by NIH R01 CA139217 to DAB and NIH RO1 CA157996 and CPRIT RP130272 to RJD. We are grateful to the imaging core of the Simmons Cancer Center Support Grant (5P30 CA142543-03).	Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019; Araki S, 2010, J CLIN INVEST, V120, P290, DOI 10.1172/JCI39194; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773; Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; De Schrijver E, 2003, CANCER RES, V63, P3799; Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018; Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047; Ferreira LMR, 2012, ONCOGENE, V31, P3999, DOI 10.1038/onc.2011.576; Goetz EM, 2011, ONCOGENE, V30, P3745, DOI 10.1038/onc.2011.92; Hanai J, 2012, J CELL PHYSIOL, V227, P1709, DOI 10.1002/jcp.22895; Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Huang XM, 2012, CANCER RES, V72, P3038, DOI 10.1158/0008-5472.CAN-11-3135; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kim JH, 2007, J KOREAN MED SCI, V22, P898, DOI 10.3346/jkms.2007.22.5.898; Kim WS, 1999, ANTICANCER RES, V19, P301; Klokov D, 2013, ONCOGENE, V32, P479, DOI 10.1038/onc.2012.64; Kurosu H, 2007, J BIOL CHEM, V282, P26687, DOI 10.1074/jbc.M704165200; Liu XP, 2013, NAT CELL BIOL, V15, P829, DOI 10.1038/ncb2765; Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928; Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018; Pallis AG, 2012, CANCER TREAT REV, V38, P861, DOI 10.1016/j.ctrv.2011.12.006; Semenza GL, 2012, TRENDS MOL MED, V18, P534, DOI 10.1016/j.molmed.2012.08.001; Shao W, 2012, CELL METAB, V16, P414, DOI 10.1016/j.cmet.2012.09.002; Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213; Uyeda K, 2002, BIOCHEM PHARMACOL, V63, P2075, DOI 10.1016/S0006-2952(02)01012-2; Yang L, 2008, CANCER RES, V68, P9107, DOI 10.1158/0008-5472.CAN-08-2556; Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhou HJ, 2014, BIOMATERIALS, V35, P1597, DOI 10.1016/j.biomaterials.2013.11.020	32	131	136	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3908	3916		10.1038/onc.2014.321	http://dx.doi.org/10.1038/onc.2014.321			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284588	Green Accepted			2022-12-17	WOS:000358544200003
J	Molina, JR; Agarwal, NK; Morales, FC; Hayashi, Y; Aldape, KD; Cote, G; Georgescu, MM				Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Aldape, K. D.; Cote, G.; Georgescu, M-M			PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma	ONCOGENE			English	Article						glioblastoma; PTEN; NHERF1; PHLPP; Akt	MEMBRANE ASSOCIATION; BREAST-CANCER; PDZ DOMAIN; PROTEIN; BINDING; GROWTH; AKT; PHOSPHATASE; RECEPTOR; CELLS	The phosphatidylinositol-3-OH kinase (PI3K)-Akt pathway is activated in cancer by genetic or epigenetic events and efforts are under way to develop targeted therapies. phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor is the major brake of the pathway and a common target for inactivation in glioblastoma, one of the most aggressive and therapy-resistant cancers. To achieve potent inhibition of the PI3K-Akt pathway in glioblastoma, we need to understand its mechanism of activation by investigating the interplay between its regulators. We show here that PTEN modulates the PI3K-Akt pathway in glioblastoma within a tumor suppressor network that includes Na+/H+ exchanger regulatory factor 1 (NHERF1) and pleckstrin-homology domain leucine-rich repeat protein phosphatases 1 (PHLPP1). The NHERF1 adaptor, previously characterized by our group as a PTEN ligand and regulator, shows also PTEN-independent Akt-modulating effects that led us to identify the PHLPP1/PHLPP2 Akt phosphatases as NHERF1 ligands. NHERF1 interacts via its PDZ domains with PHLPP1/PHLPP2 and scaffolds heterotrimeric complexes with PTEN. Functionally, PHLPP1 requires NHERF1 for membrane localization and growth-suppressive effects. PHLPP1 loss boosts Akt phosphorylation only in PTEN-negative cells and cooperates with PTEN loss for tumor growth. In a panel of low-grade and high-grade glioma patient samples, we show for the first time a significant disruption of all three members of the PTEN-NHERF1-PHLPP1 tumor suppressor network in high-grade tumors, correlating with Akt activation and patient's abysmal survival. We thus propose a PTEN-NHERF1-PHLPP PI3K-Akt pathway inhibitory network that relies on molecular interactions and can undergo parallel synergistic hits in glioblastoma. Oncogene (2012) 31, 1264-1274; doi:10.1038/onc.2011.324; published online 1 August 2011	[Molina, J. R.; Agarwal, N. K.; Morales, F. C.; Hayashi, Y.; Georgescu, M-M] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Aldape, K. D.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Cote, G.] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Georgescu, MM (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, 6767 Bertner Ave, Houston, TX 77030 USA.	mgeorges@mdanderson.org	Georgescu, Maria-Magdalena/AAJ-6359-2020		 [NCI-CA107201];  [NCI-CA16672]; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA107201] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank NCI-CA107201 and the corresponding ARRA supplement (M-M. Georgescu), and NCI-CA16672 that partially supported the DNA sequencing and animal breeding.	Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887; Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cardone RA, 2007, MOL BIOL CELL, V18, P1768, DOI 10.1091/mbc.E06-07-0617; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Georgescu MM, 2008, CURR MOL MED, V8, P459, DOI 10.2174/156652408785748031; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Hayashi Y, 2010, NEOPLASIA, V12, P1013, DOI 10.1593/neo.10780; Kreimann EL, 2007, ONCOGENE, V26, P5290, DOI 10.1038/sj.onc.1210336; Lazar CS, 2004, MOL BIOL CELL, V15, P5470, DOI 10.1091/mbc.E04-03-0239; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; Molina JR, 2010, CANCER RES, V70, P6697, DOI 10.1158/0008-5472.CAN-10-1271; Molina JR, 2010, NEOPLASIA, V12, P453, DOI 10.1593/neo.10126; Morales FC, 2007, MOL CELL BIOL, V27, P2527, DOI 10.1128/MCB.01372-06; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Pan Y, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1846; Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shenolikar S, 2001, FEBS LETT, V489, P233, DOI 10.1016/S0014-5793(01)02109-3; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Shimizu K, 1999, FEBS LETT, V458, P363, DOI 10.1016/S0014-5793(99)01190-4; Song J, 2007, HISTOPATHOLOGY, V51, P40, DOI 10.1111/j.1365-2559.2007.02730.x; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Walker SM, 2004, BIOCHEM J, V379, P301, DOI 10.1042/BJ20031839; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204	40	131	133	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1264	1274		10.1038/onc.2011.324	http://dx.doi.org/10.1038/onc.2011.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804599	Green Accepted			2022-12-17	WOS:000301344600006
J	Shimizu, S; Konishi, A; Nishida, Y; Mizuta, T; Nishina, H; Yamamoto, A; Tsujimoto, Y				Shimizu, S.; Konishi, A.; Nishida, Y.; Mizuta, T.; Nishina, H.; Yamamoto, A.; Tsujimoto, Y.			Involvement of JNK in the regulation of autophagic cell death	ONCOGENE			English	Article						JNK; autophagic cell death; Atg5	SIGNAL-TRANSDUCTION; PHOSPHORYLATION; ACTIVATION; APOPTOSIS; BAX; TRANSLOCATION; MITOCHONDRIA	Programmed cell death is a crucial process in the normal development and physiology of metazoans, and it can be divided into several categories that include type I death (apoptosis) and type II death (autophagic cell death). The Bcl-2 family proteins are well-characterized regulators of apoptosis, among which multidomain pro-apoptotic members (such as Bax and Bak) function as a mitochondrial gateway at which various apoptotic signals converge. Although embryonic fibroblasts from Bax/Bak double-knockout (DKO) mice are resistant to apoptosis, we have previously reported that these cells still die by autophagy in response to various death stimuli. In this study, we found that jun N-terminal kinase (JNK) was activated in etoposide-and staurosporine-treated, but not serum-starved, Bax/Bak DKO cells, and that autophagic cell death was suppressed by the addition of a JNK inhibitor and by a dominant-negative mutant of JNK. Studies with sek1(-/-)mkk7(-/-) cells revealed that disruption of JNK prevented the induction of autophagic cell death. Co-activation of JNK and autophagy induced autophagic cell death. Activation of JNK occurred downstream of the induction of autophagy, and was dependent on the autophagic process. These results indicate that JNK activation is crucial for the autophagic death of Bax/Bak DKO cells. Oncogene (2010) 29, 2070-2082; doi: 10.1038/onc.2009.487; published online 18 January 2010	[Shimizu, S.; Nishida, Y.; Mizuta, T.] Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Bunkyo Ku, Tokyo 1035802, Japan; [Shimizu, S.; Nishida, Y.; Tsujimoto, Y.] Osaka Univ, Sch Med, Dept Med Genet, Suita, Osaka 565, Japan; [Konishi, A.] Tokyo Med & Dent Univ, Med Res Inst, Med Top Track Program, Bunkyo Ku, Tokyo 1035802, Japan; [Nishina, H.] Tokyo Med & Dent Univ, Med Res Inst, Dept Dev & Regenerat Biol, Bunkyo Ku, Tokyo 1035802, Japan; [Yamamoto, A.] Nagahama Inst Biosci & Technol, Dept Biosci, Nagahama, Japan	Tokyo Medical & Dental University (TMDU); Osaka University; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Shimizu, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Pathol Cell Biol, Bunkyo Ku, Yushima 1-5-45, Tokyo 1035802, Japan.	shimizu.pcb@mri.tmd.ac.jp; tsujimot@gene.med.osaka-u.ac.jp	Konishi, Akimitsu/J-4024-2019	Konishi, Akimitsu/0000-0002-3291-0821	National Institute of Biomedical Innovation (NIBIO); Japanese Ministry of Education, Science, Sports and Culture; Japanese Ministry of Health, Labor and Welfare; Uehara Memorial Foundation; Naito Foundation	National Institute of Biomedical Innovation (NIBIO)(National Institute of Biomedical Innovation); Japanese Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japanese Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation)	We thank Dr N Mizushima for providing us with MEFs from Atg5 <SUP>/</SUP> and Atg5<SUP>+/+</SUP> mice and pCAGGS-GFP-LC3 plasmid. We also thank Drs R Davis and Y Gotoh for providing PCMV5-JNK1 APF plasmid and pCDNA3 MKK7-JNK1 WT plasmid, respectively. This study was partly supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO); a grant for Scientific Research on Priority Areas, SORST of Japan Science and Technology Corp; a grant for the 21st Century COE Program; a grant for Creative Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture; and a grant for Comprehensive Research on Aging and Health from the Japanese Ministry of Health, Labor and Welfare. This study was also supported by grants from the Uehara Memorial Foundation and the Naito Foundation.	Baehrecke EH, 2002, NAT REV MOL CELL BIO, V3, P779, DOI 10.1038/nrm931; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cheng Y, 2008, BIOCHEM BIOPH RES CO, V376, P483, DOI 10.1016/j.bbrc.2008.09.018; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Harris CA, 2001, J BIOL CHEM, V276, P37754; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; KLINONSKY DJ, 2005, CURR BIOL, V15, pR282; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nishitai G, 2004, J BIOL CHEM, V279, P1621, DOI 10.1074/jbc.M310335200; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shimizu S, 1996, ONCOGENE, V12, P2251; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103	28	131	134	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2010	29	14					2070	2082		10.1038/onc.2009.487	http://dx.doi.org/10.1038/onc.2009.487			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	579UX	20101227				2022-12-17	WOS:000276402800006
J	Garcia-Maceira, P; Mateo, J				Garcia-Maceira, P.; Mateo, J.			Silibinin inhibits hypoxia-inducible factor-1 alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy	ONCOGENE			English	Article						hypoxia-inducible factor-1 alpha; silibinin; cancer; mTOR; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MAMMALIAN TARGET; FACTOR 1-ALPHA; VEGF EXPRESSION; GENE-EXPRESSION; NITRIC-OXIDE; O-2 TENSION; FACTOR-I; MTOR; RAPAMYCIN	The hypoxia-inducible factor 1 (HIF-1) plays a critical role for tumour adaptation to microenvironmental hypoxia, and represents an appealing chemotherapeutic target. Silibinin is a nontoxic flavonoid reported to exhibit anticancer properties. However, the mechanisms by which silibinin inhibits tumour growth are not fully understood. In this study, silibinin was found to inhibit hypoxiainduced HIF-1 alpha accumulation and HIF-1 transcriptional activity in human cervical (HeLa) and hepatoma (Hep3B) cells. Neither HIEF-1 alpha protein degradation rate nor HIEF-1 alpha steady-state mRNA level was affected by silibinin. Rather, we found that suppression of HIF-1 alpha accumulation by silibinin correlated with strong dephosphorylation of mammalian target of rapamycin (mTOR) and its effectors ribosomal protein S6 kinase (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), a pathway known to regulate HIEF-1 alpha expression at the translational level. Silibinin also activated Akt, a mechanistic feature exhibited by established mTOR inhibitors in many tumour cells. Moreover, silibinin reduced hypoxia-induced vascular endothelial growth factor (VEGF) release by HeLa and Hep3B cells, and this effect was potentiated by the PI3K/Akt inhibitor LY294002. Finally, silibinin was found to be a potent inhibitor of cell proliferation. These results show that silibinin is an effective inhibitor of HIF-1 and provide new perspectives into the mechanism of its anticancer activity.	[Garcia-Maceira, P.; Mateo, J.] CNIC, Dept Regenerat Cardiol, E-28029 Madrid, Spain	Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Mateo, J (corresponding author), CNIC, Dept Regenerat Cardiol, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jmateo@cnic.es	de Castro, Jesus Mateo/N-4434-2014	de Castro, Jesus Mateo/0000-0003-4459-7083	ISCIII [FIS03-0924, FIS07-1168]; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Spanish Ministry of Health and Consumer Affairs; Pro-CNIC Foundation	ISCIII(Instituto de Salud Carlos III); Centro Nacional de Investigaciones Cardiovasculares (CNIC); Spanish Ministry of Health and Consumer Affairs(Spanish Government); Pro-CNIC Foundation	This work was supported by grants from ISCIII (FIS03-0924 and FIS07-1168 to JM). PG-M holds a fellowship from the Centro Nacional de Investigaciones Cardiovasculares (CNIC)-Bancaja predoctoral program. CNIC is supported by the Spanish Ministry of Health and Consumer Affairs and the Pro-CNIC Foundation.	Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Bhatia N, 1999, CANCER LETT, V147, P77, DOI 10.1016/S0304-3835(99)00276-1; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brown JM, 1998, CANCER RES, V58, P1408; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978; Chen PN, 2005, CHEM-BIOL INTERACT, V156, P141, DOI 10.1016/j.cbi.2005.08.005; Deep G, 2008, ONCOGENE, V27, P3986, DOI 10.1038/onc.2008.45; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Gu M, 2007, CANCER RES, V67, P3483, DOI 10.1158/0008-5472.CAN-06-3955; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Lah JJ, 2007, WORLD J GASTROENTERO, V13, P5299, DOI 10.3748/wjg.v13.i40.5299; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mateo J, 2003, BIOCHEM J, V376, P537, DOI 10.1042/BJ20031155; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pore N, 2004, MOL BIOL CELL, V15, P4841, DOI 10.1091/mbc.E04-05-0374; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Saller R, 2001, DRUGS, V61, P2035, DOI 10.2165/00003495-200161140-00003; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Singh RP, 2008, CANCER RES, V68, P2043, DOI 10.1158/0008-5472.CAN-07-6247; Singh RP, 2005, ONCOGENE, V24, P1188, DOI 10.1038/sj.onc.1208276; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972; Varghese L, 2005, CLIN CANCER RES, V11, P8441, DOI 10.1158/1078-0432.CCR-05-1646; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wright G, 2003, J BIOL CHEM, V278, P20235, DOI 10.1074/jbc.M301391200; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zi XL, 1998, CLIN CANCER RES, V4, P1055; Zi ZL, 1999, P NATL ACAD SCI USA, V96, P7490, DOI 10.1073/pnas.96.13.7490	49	131	135	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					313	324		10.1038/onc.2008.398	http://dx.doi.org/10.1038/onc.2008.398			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18978810				2022-12-17	WOS:000262550300001
J	Whiteman, EL; Liu, CJ; Fearon, ER; Margolis, B				Whiteman, E. L.; Liu, C-J; Fearon, E. R.; Margolis, B.			The transcription factor snail represses Crumbs3 expression and disrupts apico-basal polarity complexes	ONCOGENE			English	Article						Crumbs; Snail; apico-basal polarity; tight junction; epithelial to mesenchymal transition	EPITHELIAL-MESENCHYMAL TRANSITIONS; E-CADHERIN; PROTEIN	In epithelial cells, the tight junction divides the plasma membrane into distinct apical and basolateral domains. Polarization is essential for epithelial cell function, and apico-basal cell polarity is lost during the epithelial to mesenchymal transition (EMT), a program of events characterized not only by loss of cell polarity, but also by enhanced cell motility and increased cell invasion. Among several apically localized protein complexes, the Crumbs and Par protein complexes have pivotal roles in control of epithelial polarity and apical membrane formation. Here, we demonstrate that the Snail transcriptional repressor antagonizes expression of the Crumbs polarity complex. We show that Snail abolishes localization of the Crumbs and Par complexes to the tight junction, decreases Crumbs complex protein levels and suppresses Crumbs3 transcription. Evidence that Snail acts directly to antagonize Crumbs3 promoter activity is presented. Strikingly, we note that reexpression of exogenous Crumbs3 in Snail- expressing Madin-Darby Canine Kidney cells partially restores cell-cell junctions. Moreover, we find that the EMT inducer transforming growth factor-beta elicits transcriptional repression of Crumbs3 and results in a measurable loss of Crumbs3 protein. Our findings provide new insights into the links between the transcriptional repression function of Snail and its role in antagonizing key apico-basal polarity factors during EMT.	[Margolis, B.] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA; [Fearon, E. R.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Fearon, E. R.; Margolis, B.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; [Margolis, B.] Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1528 Biomed Sci Res Bldg,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	bmargoli@umich.edu			NCI NIH HHS [5-T32-CA09676, T32 CA009676] Funding Source: Medline; NIDDK NIH HHS [R01 DK058208-06, R01 DK069605-04, R01 DK058208, P60 DK020572, DK069605, 5-P60-DK20572, R01 DK069605, DK058208] Funding Source: Medline; NIGMS NIH HHS [F32 GM079906, 5-F32-GM07996] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020572, R01DK069605, R01DK058208] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM079906] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Hajra KM, 2002, CANCER RES, V62, P1613; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Straight SW, 2006, J BIOL CHEM, V281, P37738, DOI 10.1074/jbc.M607059200; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Whiteman EL, 2003, ENDOCRINOLOGY, V144, P3811, DOI 10.1210/en.2003-0480	12	131	137	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 19	2008	27	27					3875	3879		10.1038/onc.2008.9	http://dx.doi.org/10.1038/onc.2008.9			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18246119	Green Accepted			2022-12-17	WOS:000256904700012
J	Yoo, YG; Na, TY; Seo, HW; Seong, JK; Park, CK; Shin, YK; Lee, MO				Yoo, Y-G; Na, T-Y; Seo, H-W; Seong, J. K.; Park, C. K.; Shin, Y. K.; Lee, M-O			Hepatitis B virus X protein induces the expression of MTA1 and HDAC1, which enhances hypoxia signaling in hepatocellular carcinoma cells	ONCOGENE			English	Article						HBx; metastasis-associated protein; histone deacetylase; hepatitis B virus; hypoxia-inducible factor-1 alpha	HISTONE DEACETYLASE INHIBITORS; INDUCIBLE FACTOR 1-ALPHA; HBX PROTEIN; HEPATOMA-CELLS; GROWTH-FACTOR; METASTASIS; ACETYLATION; GENE; HIF-1-ALPHA; ACTIVATION	Expression level of metastasis-associated protein 1 (MTA1) is closely related to tumor growth and metastasis in various cancers. Although increased expression level of MTA1 was observed in hepatocellular carcinoma (HCC), role of MTA1 complex containing histone deacetylase (HDAC) in hepatitis B virus (HBV)-associated hepatocarcinogenesis has not been studied. Here, we demonstrated that HBx strongly induced the expression of MTA1 and HDAC1 genes at transcription level. MTA1 and HDAC1/2 physically associated with hypoxia-inducible factor-1 alpha (HIF-1 alpha) in vivo in the presence of HBx, which was abolished by knockdown of MTA1 by short interfering RNA (siRNA). HBx induced deacetylation of the oxygen-dependent degradation domain of HIF-1 alpha, which was accompanied with dissociation of prolyl hydroxylases and von Hippel-Lindau tumor suppressor from HIF-1 alpha. These results indicate that HBx-induced deacetylation is important for proteasomal degradation of HIF-1 alpha. Further, we observed that protein levels of MTA1 and HDAC1 were increased in the liver of HBx-transgenic mice. Also, there was a higher expression of HDAC1 in HCC than in the adjacent non-tumorous cirrhotic nodules in 10 out of 12 human HBV-associated HCC specimens. Together, our data indicate a positive cross talk between HBx and the MTA1/HDAC complex in stabilizing HIF-1 alpha, which may play a critical role in angiogenesis and metastasis of HBV-associated HCC.	[Yoo, Y-G; Na, T-Y; Seo, H-W; Shin, Y. K.; Lee, M-O] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Yoo, Y-G; Na, T-Y; Seo, H-W; Lee, M-O] Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; [Seong, J. K.] Seoul Natl Univ, Coll Vet Med, Seoul 151742, South Korea; [Park, C. K.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Shin, Young Kee/C-8929-2011	Shin, Young Kee/0000-0003-0896-718X; Seong, Je Kyung/0000-0003-1177-6958				Armeanu S, 2005, J HEPATOL, V42, P210, DOI 10.1016/j.jhep.2004.10.020; Arnesen T, 2005, FEBS LETT, V579, P6428, DOI 10.1016/j.febslet.2005.10.036; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Bilton R, 2006, TRENDS CELL BIOL, V16, P616, DOI 10.1016/j.tcb.2006.10.002; Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010; Caron C, 2003, BIOESSAYS, V25, P58, DOI 10.1002/bies.10202; Chan DW, 2006, J PATHOL, V208, P372, DOI 10.1002/path.1901; Chang CC, 2006, JNCI-J NATL CANCER I, V98, P984, DOI 10.1093/jnci/djj242; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; Cougot D, 2005, J CLIN VIROL, V34, pS75, DOI 10.1016/S1386-6532(05)80014-9; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; Frati A, 2002, J EXP CLIN CANC RES, V21, P321; Glozak MA, 2005, GENE, V363, P15, DOI 10.1016/j.gene.2005.09.010; Hamatsu T, 2003, ONCOL REP, V10, P599; Huang GW, 2005, WORLD J GASTROENTERO, V11, P1705; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim SH, 2007, ONCOL REP, V17, P647; KONDO Y, 1991, HUM PATHOL, V22, P125, DOI 10.1016/0046-8177(91)90033-L; Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lara-Pezzi E, 2001, ONCOGENE, V20, P3323, DOI 10.1038/sj.onc.1204451; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Mishra SK, 2003, J BIOL CHEM, V278, P19209, DOI 10.1074/jbc.M301968200; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Murray-Rust TA, 2006, FEBS LETT, V580, P1911, DOI 10.1016/j.febslet.2006.02.012; Nicolson GL, 2003, CLIN EXP METASTAS, V20, P19, DOI 10.1023/A:1022534217769; Ou DP, 2006, DIGEST LIVER DIS, V38, P262, DOI 10.1016/j.dld.2005.10.027; Pathil A, 2006, HEPATOLOGY, V43, P425, DOI 10.1002/hep.21054; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wada H, 2006, LIVER INT, V26, P414, DOI 10.1111/j.1478-3231.2006.01243.x; Wang LH, 2007, CLIN CANCER RES, V13, P102, DOI 10.1158/1078-0432.CCR-06-1467; Wu BK, 2006, BIOCHEM BIOPH RES CO, V340, P916, DOI 10.1016/j.bbrc.2005.12.089; Yeo MG, 2005, MOL ENDOCRINOL, V19, P950, DOI 10.1210/me.2004-0209; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Zhang XD, 2006, J LAB CLIN MED, V147, P58, DOI 10.1016/j.lab.2005.10.003	50	131	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	24					3405	3413		10.1038/sj.onc.1211000	http://dx.doi.org/10.1038/sj.onc.1211000			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	307HL	18264140				2022-12-17	WOS:000256309900005
J	Wang, Q; Sun, Z; Yang, HS				Wang, Q.; Sun, Z.; Yang, H-S			Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells	ONCOGENE			English	Article						Pdcd4; invasion; beta-catenin; AP-1; E-cadherin; stably knockdown	E-CADHERIN EXPRESSION; INITIATION-FACTOR 4A; RECEPTOR U-PAR; NF-KAPPA-B; TRANSFORMATION SUPPRESSOR; AP-1 TRANSACTIVATION; CANCER; CARCINOGENESIS; TUMORIGENESIS; TRANSLATION	Programmed cell death 4 (Pdcd4) is a tumor suppressor that inhibits neoplastic transformation and tumor invasion. Tissue microarray analysis showed that Pdcd4 expression is downregulated in colon adenocarcinoma and carcinoma relative to adjacent normal tissues. To address the issue of whether reduced Pdcd4 expression is sufficient to promote tumor progression, we knocked down Pdcd4 expression in colon tumor HT29 cells using pdcd4 short hairpin RNA (shRNA). Pdcd4 knockdown results in a. broblast-like transition, while the control cells (expressing LacZ shRNA) remain as clumped similar to the parental cells. In addition, expression of pdcd4 shRNA in HT29 cells promotes invasion. In an effort to characterize the molecular mechanism underlying these observations, we discovered that knockdown of Pdcd4 results in reduction of E-cadherin expression, and accumulation of active beta-catenin in the nucleus. The active beta-catenin binds with T-cell factor 4 (Tcf4) and activates beta-catenin/Tcf-dependent transcription. Furthermore, Pdcd4 knockdown dramatically increases AP-1-dependent transcription. Thus, the mechanism by which reduced Pdcd4 expression promotes invasion appears to involve the activation of beta-catenin/Tcf and AP-1-dependent transcription.	[Wang, Q.; Sun, Z.; Yang, H-S] Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA; [Yang, H-S] Univ Kentucky, Coll Med, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Yang, HS (corresponding author), Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY 40536 USA.	hyang3@uky.edu	Yang, Hsin-Sheng/A-6419-2008; Yang, Hsin-Sheng/AAF-6793-2020	Yang, Hsin-Sheng/0000-0002-0566-3036; Yang, Hsin-Sheng/0000-0002-0566-3036				Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bonome T, 2005, CANCER RES, V65, P10602, DOI 10.1158/0008-5472.CAN-05-2240; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gao F, 2007, ONCOL REP, V17, P123; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; Kemler R, 1992, Semin Cell Biol, V3, P149; KINSELLA AR, 1994, CLIN EXP METASTAS, V12, P335, DOI 10.1007/BF01753841; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Laufs S, 2006, CELL CYCLE, V5, P1760; Lee S, 2006, ONCOL REP, V16, P747; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Matsuhashi S, 2007, EXP DERMATOL, V16, P179, DOI 10.1111/j.1600-0625.2006.00531.x; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Portereiko MF, 2006, PLANT CELL, V18, P1862, DOI 10.1105/tpc.106.040824; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; VANAKEN J, 1993, PATHOL RES PRACT, V189, P975; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2006, MOL CELL BIOL, V26, P1297, DOI 10.1128/MCB.26.4.1297-1306.2006; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634	33	131	137	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1527	1535		10.1038/sj.onc.1210793	http://dx.doi.org/10.1038/sj.onc.1210793			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828298				2022-12-17	WOS:000253815800004
J	Moasser, MM				Moasser, M. M.			Targeting the function of the HER2 oncogene in human cancer therapeutics	ONCOGENE			English	Review						HER2; ErbB2; trastuzumab; herceptin; kinase inhibitor; breast cancer	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; METASTATIC BREAST-CANCER; PHASE-II TRIAL; DEPENDENT CELLULAR CYTOTOXICITY; HERCEPTIN-INDUCED INHIBITION; MULTIPLE SIGNALING PATHWAYS; TUMOR NECROSIS FACTOR; CELLS IN-VITRO; MONOCLONAL-ANTIBODIES	The year 2007 marks exactly two decades since human epidermal growth factor receptor- 2 ( HER2) was functionally implicated in the pathogenesis of human breast cancer ( Slamon et al., 1987). This finding established the HER2 oncogene hypothesis for the development of some human cancers. An abundance of experimental evidence compiled over the past two decades now solidly supports the HER2 oncogene hypothesis. A direct consequence of this hypothesis was the promise that inhibitors of oncogenic HER2 would be highly effective treatments for HER2- driven cancers. This treatment hypothesis has led to the development and widespread use of anti- HER2 antibodies ( trastuzumab) in clinical management resulting in significantly improved clinical antitumor efficacies that have transformed the clinical practice of oncology. In the shadows of this irrefutable clinical success, scientific studies have not yet been able to mechanistically validate that trastuzumab inhibits oncogenic HER2 function and it remains possible that the current clinical advances are a consequence of the oncogene hypothesis, but not a translation of it. These looming scientific uncertainties suggest that the full promise of the treatment hypothesis may not yet have been realized. The coming decade will see a second generation of HER2- targeting agents brought into clinical testing and a renewed attempt to treat HER2- driven cancers through the inactivation of HER2. Here, I review the development of treatments that target HER2 in the context of the HER2 oncogene hypothesis, and where we stand with regards to the clinical translation of the HER2 oncogene hypothesis.	Univ Calif San Francisco, Dept Med, Ctr Comprehens Canc, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Moasser, MM (corresponding author), Univ Calif San Francisco, Dept Med, Ctr Comprehens Canc, UCSF Box 0875, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu			NATIONAL CANCER INSTITUTE [R01CA122216] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122216, R01 CA122216-02, R01 CA122216-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams CW, 2006, CANCER IMMUNOL IMMUN, V55, P717, DOI 10.1007/s00262-005-0058-x; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Akita RW, 2003, SEMIN ONCOL, V30, P15, DOI 10.1016/S0093-7754(03)00187-8; Albain K, 2002, BREAST CANCER RES TR, V76, pS33; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Austin CD, 2004, MOL BIOL CELL, V15, P5268, DOI 10.1091/mbc.E04-07-0591; Baasner S, 1996, ONCOGENE, V13, P901; BACUS SS, 1992, CANCER RES, V52, P2580; Baker AF, 2005, CLIN CANCER RES, V11, P4338, DOI 10.1158/1078-0432.CCR-05-0422; Barbacci EG, 2003, CANCER RES, V63, P4450; Baselga J, 2005, J CLIN ONCOL, V23, P5323, DOI 10.1200/JCO.2005.08.326; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Baselga J, 1998, CANCER RES, V58, P2825; BASELGA J, 2007, P AM SOC CLIN ONC, V25; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; Belimezi MM, 2006, CANCER IMMUNOL IMMUN, V55, P1091, DOI 10.1007/s00262-005-0100-z; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; BLACKWELL K, 2004, P AM SOC CLIN ONC, V22; BLACKWELL KL, 2006, P AM SOC CLIN ONC, V23; Bookman MA, 2003, J CLIN ONCOL, V21, P283, DOI 10.1200/JCO.2003.10.104; Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721; Brand FX, 2006, ANTICANCER RES, V26, P463; Brandt R, 2001, ONCOGENE, V20, P5459, DOI 10.1038/sj.onc.1204709; Burstein H, 2004, ANN ONCOL, V15, P27; Burstein HJ, 2003, J CLIN ONCOL, V21, P2889, DOI 10.1200/JCO.2003.02.018; Campos S, 2005, J CLIN ONCOL, V23, P5597, DOI 10.1200/JCO.2005.08.091; Carson WE, 2001, EUR J IMMUNOL, V31, P3016, DOI 10.1002/1521-4141(2001010)31:10<3016::AID-IMMU3016>3.0.CO;2-J; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; Chen JS, 2003, DRUG RESIST UPDATE, V6, P129, DOI 10.1016/S1368-7646(03)00040-2; Cho HS, 2003, NATURE, V421, P756, DOI 10.1038/nature01392; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Christianson TA, 1998, CANCER RES, V58, P5123; Citri A, 2002, EMBO J, V21, P2407, DOI 10.1093/emboj/21.10.2407; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; Cooley S, 1999, EXP HEMATOL, V27, P1533, DOI 10.1016/S0301-472X(99)00089-2; CORTES JE, 2005, P AM SOC CLIN ONC, V23; Cuello M, 2001, CANCER RES, V61, P4892; De Lorenzo C, 2005, CARCINOGENESIS, V26, P1890, DOI 10.1093/carcin/bgi146; Deshane J, 1996, CANCER GENE THER, V3, P89; Diermeier S, 2005, EXP CELL RES, V304, P604, DOI 10.1016/j.yexcr.2004.12.008; Discafani CM, 1999, BIOCHEM PHARMACOL, V57, P917, DOI 10.1016/S0006-2952(98)00356-6; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1988, ONCOGENE, V2, P273; Egeblad M, 2001, INT J CANCER, V94, P185, DOI 10.1002/ijc.1459; Emlet DR, 2006, BRIT J CANCER, V94, P1144, DOI 10.1038/sj.bjc.6603078; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; FINN RS, 2004, P AM ASS CAN RES, V45; FLEMING G, 2005, P AM SOC CLIN ONC, V23; FLEMING GF, 2003, P AM SOC CLIN ONC, V22; Friess T, 2005, CLIN CANCER RES, V11, P5300, DOI 10.1158/1078-0432.CCR-04-2642; FUJII A, 2005, P AM ASS CAN RES, V46; Fujita T, 2006, BRIT J CANCER, V94, P247, DOI 10.1038/sj.bjc.6602926; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225; Ghossein RA, 2001, SEMIN SURG ONCOL, V20, P304, DOI 10.1002/ssu.1048; Gomez HL, 2005, BREAST CANCER RES TR, V94, pS63; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HURWITZ E, 1995, P NATL ACAD SCI USA, V92, P3353, DOI 10.1073/pnas.92.8.3353; IWATA H, 2006, SAN ANT BR CAN S; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; JANI JP, 2004, P AM ASS CAN RES, V45; JANI JP, 2004, P AM SOC CLIN ONC, V22; Juhl H, 1997, J BIOL CHEM, V272, P29482, DOI 10.1074/jbc.272.47.29482; Kiewe P, 2006, CLIN CANCER RES, V12, P3085, DOI 10.1158/1078-0432.CCR-05-2436; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; Kita Y, 1996, BIOCHEM BIOPH RES CO, V226, P59, DOI 10.1006/bbrc.1996.1311; Klapper LN, 1997, ONCOGENE, V14, P2099, DOI 10.1038/sj.onc.1201029; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Kubo M, 2003, ANTICANCER RES, V23, P4443; KUMAR PS, 2006, SEMIN ONCOL, V33, P386; Kurokawa H, 2000, CANCER RES, V60, P5887; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Le XF, 2005, CELL CYCLE, V4, P87, DOI 10.4161/cc.4.1.1360; Lee S, 2002, CANCER RES, V62, P5703; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Lenferink AEG, 2001, CANCER RES, V61, P6583; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Liu PCC, 2006, CANCER BIOL THER, V5, P657, DOI 10.4161/cbt.5.6.2708; Longva KE, 2005, INT J CANCER, V116, P359, DOI 10.1002/ijc.21015; Lydon NB, 1998, INT J CANCER, V76, P154, DOI 10.1002/(SICI)1097-0215(19980330)76:1<154::AID-IJC24>3.0.CO;2-B; Marches R, 2004, INT J CANCER, V112, P492, DOI 10.1002/ijc.20378; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; Mass Robert D, 2005, Clin Breast Cancer, V6, P240, DOI 10.3816/CBC.2005.n.026; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; McKillop D, 2005, MOL CANCER THER, V4, P641, DOI 10.1158/1535-7163.MCT-04-0329; Menard S, 2003, ONCOGENE, V22, P6570, DOI 10.1038/sj.onc.1206779; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MIKNIS G, 2005, P AM ASS CAN RES, V24; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Moasser MM, 2001, CANCER RES, V61, P7184; Mohsin SK, 2005, J CLIN ONCOL, V23, P2460, DOI 10.1200/JCO.2005.00.661; Molina MA, 2002, CLIN CANCER RES, V8, P347; Molina MA, 2001, CANCER RES, V61, P4744; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Moulder SL, 2001, CANCER RES, V61, P8887; Moyer JD, 1997, CANCER RES, V57, P4838; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; NAITO K, 2002, P AM ASS CAN RES, V43; Neve RM, 2001, BIOCHEM BIOPH RES CO, V280, P274, DOI 10.1006/bbrc.2000.4104; Normanno N, 2002, ANN ONCOL, V13, P65, DOI 10.1093/annonc/mdf020; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; PHENEGER T, 2005, P AACRNCIEORTE C; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; QIAN XL, 1994, ONCOGENE, V9, P1507; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Repka T, 2003, CLIN CANCER RES, V9, P2440; REWCASTLE GW, 1995, J MED CHEM, V38, P3482, DOI 10.1021/jm00018a008; ROBERTSON JFR, 2003, P AM SOC CLIN ONC, V22; Robinson MO, 2006, EJC SUPPL, V4, P169, DOI 10.1016/S1359-6349(06)70564-X; Roh H, 2000, CANCER RES, V60, P560; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; SARUP JC, 1991, GROWTH REGULAT, V1, P72; Schiffer IB, 2003, CANCER RES, V63, P7221; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; She QB, 2003, CLIN CANCER RES, V9, P4340; SHEPARD HM, 1991, J CLIN IMMUNOL, V11, P117, DOI 10.1007/BF00918679; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Sliwkowski MX, 2003, NAT STRUCT BIOL, V10, P158, DOI 10.1038/nsb0303-158; SOLCA F, 2006, P AACRNCIEORTC C; Spector NL, 2005, J CLIN ONCOL, V23, P2502, DOI 10.1200/JCO.2005.12.157; SRINIVAS U, 1993, CANCER IMMUNOL IMMUN, V36, P397, DOI 10.1007/BF01742256; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Suzuki E, 2007, CLIN CANCER RES, V13, P1875, DOI 10.1158/1078-0432.CCR-06-1335; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533; Tan AR, 2004, J CLIN ONCOL, V22, P3080, DOI 10.1200/JCO.2004.08.189; Tokuda Y, 1996, BRIT J CANCER, V73, P1362, DOI 10.1038/bjc.1996.259; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Traxler P, 2004, CANCER RES, V64, P4931, DOI 10.1158/0008-5472.CAN-03-3681; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; Tsou HR, 2005, J MED CHEM, V48, P1107, DOI 10.1021/jm040159c; VANLEEUWEN F, 1990, ONCOGENE, V5, P497; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wakeling AE, 2002, CANCER RES, V62, P5749; Warburton C, 2004, CLIN CANCER RES, V10, P2512, DOI 10.1158/1078-0432.CCR-03-0244; WARD WHJ, 1994, BIOCHEM PHARMACOL, V48, P659, DOI 10.1016/0006-2952(94)90042-6; Wehrman TS, 2006, P NATL ACAD SCI USA, V103, P19063, DOI 10.1073/pnas.0605218103; WEINER DB, 1989, ONCOGENE, V4, P1175; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WINER EP, 2002, SAN ANT BR CAN S; Wissner A, 2003, J MED CHEM, V46, P49, DOI 10.1021/jm020241c; Wong TW, 2006, CLIN CANCER RES, V12, P6186, DOI 10.1158/1078-0432.CCR-06-0642; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Xie W, 1999, ONCOGENE, V18, P3593, DOI 10.1038/sj.onc.1202673; XU FG, 1993, INT J CANCER, V53, P401, DOI 10.1002/ijc.2910530310; Yakes FM, 2002, CANCER RES, V62, P4132; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569; Yokoyama H, 2006, BRIT J CANCER, V95, P1504, DOI 10.1038/sj.bjc.6603459; YOSHIDA S, 2002, P AM ASS CAN RES, V43	166	131	151	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6577	6592		10.1038/sj.onc.1210478	http://dx.doi.org/10.1038/sj.onc.1210478			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17486079	Green Accepted			2022-12-17	WOS:000250081500001
J	Ambrosini, G; Sambol, EB; Carvajal, D; Vassilev, LT; Singer, S; Schwartz, GK				Ambrosini, G.; Sambol, E. B.; Carvajal, D.; Vassilev, L. T.; Singer, S.; Schwartz, G. K.			Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1	ONCOGENE			English	Article						MDM2; nutlin-3a; E2F1; DNA damage; apoptosis	UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; MDM2 ANTAGONISTS; E2F-1-INDUCED APOPTOSIS; S-PHASE; PATHWAY; PROTEIN; P73; DEGRADATION; ONCOPROTEIN	MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wildtype E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73 alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1- dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.	Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Sarcoma Dis Management Program Lab, New York, NY 10021 USA; F Hoffmann La Roche & Co Ltd, Roche Res Ctr, Discovery Oncol, Nutley, NJ USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Roche Holding	Schwartz, GK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, 1275 York Ave, New York, NY 10021 USA.	Schwartg@mskcc.org		Singer, Samuel/0000-0001-9713-8230				Banerjee D, 1998, CANCER RES, V58, P4292; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang YY, 1997, CANCER RES, V57, P3640; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lin WC, 2001, GENE DEV, V15, P1833; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meng RD, 1999, INT J ONCOL, V14, P5; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Muller M J, 2001, Obes Rev, V2, P15; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2005, J MED CHEM, V48, P4491, DOI 10.1021/jm058174k; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	36	131	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3473	3481		10.1038/sj.onc.1210136	http://dx.doi.org/10.1038/sj.onc.1210136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146434				2022-12-17	WOS:000246799200003
J	Poppe, M; Feller, SM; Romer, G; Wessler, S				Poppe, M.; Feller, S. M.; Romer, G.; Wessler, S.			Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility	ONCOGENE			English	Article						c-Abl; CagA; helicobacter pylori; Src	GASTRIC EPITHELIAL-CELLS; IV SECRETION SYSTEM; TYROSINE KINASES; PATHOGENICITY ISLAND; FAMILY KINASES; GROWTH-FACTOR; PROTEIN; CRK; TRANSLOCATION; SRC	Helicobacter pylori induces a strong motogenic response in infected gastric epithelial host cells, which is enhanced by translocation of the pathogenic factor cytotoxinassociated gene A (CagA) into host cells via a specialized type IV secretion system. Once injected into the cytosol CagA is rapidly tyrosine phosphorylated by Src family kinases followed by Src inactivation. Hence, it remained unknown why CagA is constantly phosphorylated in sustained H. pylori infections to induce cell migration, whereas other substrates of Src kinases are dephosphorylated. Here, we identify the non- receptor tyrosine kinase c-Abl as a crucial mediator of H. pylori-induced migration and novel CagA kinase in epithelial cells. Upon H. pylori infection c-Abl directly interacts with CagA and localizes in focal adhesion complexes and membrane ruf. es, which are highly dynamic cytoskeletal structures necessary for cell motility. Selective inhibition of c-Abl kinase activity by STI571 or shRNA abrogates sustained CagA phosphorylation and epithelial cell migration, indicating a pivotal role of c-Abl in H. pylori infection and pathogenicity. These results implicate c-Abl as a novel molecular target for therapeutic intervention in H. pylor-related gastric diseases.	Paul Ehrlich Inst, Jr Res Grp, D-63225 Langen, Hessen, Germany; Weatherall Inst Mol Med, Canc Res UK, Oxford, England	Paul Ehrlich Institute; Cancer Research UK; University of Oxford	Wessler, S (corresponding author), Paul Ehrlich Inst, Jr Res Grp, Paul Ehrlich Str 51-59, D-63225 Langen, Hessen, Germany.	wessi@pei.de	Wessler, Silja/C-6309-2015	Wessler, Silja/0000-0001-7011-6162				Al-Ghoul L, 2004, BIOCHEM BIOPH RES CO, V322, P860, DOI 10.1016/j.bbrc.2004.07.199; Amieva MR, 2003, SCIENCE, V300, P1430, DOI 10.1126/science.1081919; Argent RH, 2005, J CLIN MICROBIOL, V43, P791, DOI 10.1128/JCM.43.2.791-795.2005; Asahi M, 2000, J EXP MED, V191, P593, DOI 10.1084/jem.191.4.593; Backert S, 2001, MOL MICROBIOL, V42, P631, DOI 10.1046/j.1365-2958.2001.02649.x; Backert S, 2000, CELL MICROBIOL, V2, P155, DOI 10.1046/j.1462-5822.2000.00043.x; Bagnoli F, 2005, P NATL ACAD SCI USA, V102, P16339, DOI 10.1073/pnas.0502598102; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Bauer B, 2005, INFECT IMMUN, V73, P4643, DOI 10.1128/IAI.73.8.4643-4652.2005; Churin Y, 2003, J CELL BIOL, V161, P249, DOI 10.1083/jcb.200208039; CorthesyTheulaz I, 1996, INFECT IMMUN, V64, P3827; Echarri A, 2001, CURR BIOL, V11, P1759, DOI 10.1016/S0960-9822(01)00538-3; Escalante M, 2000, J BIOL CHEM, V275, P24787, DOI 10.1074/jbc.M000711200; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Hantschel O, 2004, NAT REV MOL CELL BIO, V5, P33, DOI 10.1038/nrm1280; Hatakeyama M, 2004, NAT REV CANCER, V4, P688, DOI 10.1038/nrc1433; Hernandez SE, 2004, TRENDS CELL BIOL, V14, P36, DOI 10.1016/j.tcb.2003.11.003; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ito Y, 2001, MOL CELL BIOL, V21, P6233, DOI 10.1128/MCB.21.18.6233-6242.2001; Kain KH, 2001, J BIOL CHEM, V276, P16185, DOI 10.1074/jbc.M100095200; Lewis JM, 1998, J BIOL CHEM, V273, P14225, DOI 10.1074/jbc.273.23.14225; Machuy N, 2004, CELL DEATH DIFFER, V11, P290, DOI 10.1038/sj.cdd.4401336; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0; Moese S, 2004, INFECT IMMUN, V72, P3646, DOI 10.1128/IAI.72.6.3646-3649.2004; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; SCHMITT W, 1994, MOL MICROBIOL, V12, P307, DOI 10.1111/j.1365-2958.1994.tb01019.x; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Selbach M, 2004, PROTEOMICS, V4, P2961, DOI 10.1002/pmic.200400915; Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050; Selbach M, 2002, J BIOL CHEM, V277, P6775, DOI 10.1074/jbc.C100754200; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Stein M, 2000, P NATL ACAD SCI USA, V97, P1263, DOI 10.1073/pnas.97.3.1263; Stein M, 2002, MOL MICROBIOL, V43, P971, DOI 10.1046/j.1365-2958.2002.02781.x; Suzuki M, 2005, J EXP MED, V202, P1235, DOI 10.1084/jem.20051027; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Van Etten RA, 2003, CURR BIOL, V13, pR608, DOI 10.1016/S0960-9822(03)00528-1; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; *WHO, 1994, IARC MON EV CARC RIS, V61, P1; Woodring PJ, 2002, J CELL BIOL, V156, P879, DOI 10.1083/jcb.200110014; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704	46	131	138	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3462	3472		10.1038/sj.onc.1210139	http://dx.doi.org/10.1038/sj.onc.1210139			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160020				2022-12-17	WOS:000246799200002
J	Li, Y; Prives, C				Li, Y.; Prives, C.			Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?	ONCOGENE			English	Review						mutant p53; p63; p73; protein-protein interaction	SQUAMOUS-CELL CARCINOMA; LI-FRAUMENI-SYNDROME; TRANSCRIPTIONAL REGULATION; P53-DEPENDENT APOPTOSIS; P73-DEPENDENT APOPTOSIS; PHYSICAL INTERACTION; CORE DOMAIN; DNA-DAMAGE; COMMON; MUTATIONS	Although still controversial, the presence of mutant p53 in cancer cells may result in more aggressive tumors and correspondingly worse outcomes. The means by which mutant p53 exerts such pro-oncogenic activity are currently under extensive investigation and different models have been proposed. We focus here on a proposed mechanism by which a subset of tumor-derived p53 mutants physically interact with p53 family members, p63 and p73, and negatively regulate their proapoptotic function. Both cell-based assays and knock-in mice expressing mutant forms of p53 support this model. As more than half of human tumors harbor mutant forms of p53 protein, approaches aimed at disrupting the pathological interactions among p53 family members might be of clinical value.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	clp3@columbia.edu						Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Bensaad K, 2003, J BIOL CHEM, V278, P10546, DOI 10.1074/jbc.M208233200; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LANZA M, 2006, CELL CYCLE, V5; Laptenko O, 2006, CELL DEATH DIFFER, V13, P951, DOI 10.1038/sj.cdd.4401916; Lokshin M, 2005, COLD SH Q B, V70, P121, DOI 10.1101/sqb.2005.70.046; Lokshin M, 2007, NUCLEIC ACIDS RES, V35, P340, DOI 10.1093/nar/gkl1047; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004; van Bokhoven H, 2002, AM J HUM GENET, V71, P1, DOI 10.1086/341450; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Willis AC, 2003, ONCOGENE, V22, P5481, DOI 10.1038/sj.onc.1206505; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438; Wu GJ, 2003, CANCER RES, V63, P2351; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540	45	131	138	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2007	26	15					2220	2225		10.1038/sj.onc.1210311	http://dx.doi.org/10.1038/sj.onc.1210311			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	152XE	17401431				2022-12-17	WOS:000245394800011
J	Wen, XF; Yang, G; Mao, W; Thornton, A; Liu, J; Bast, RC; Le, XF				Wen, X-F; Yang, G.; Mao, W.; Thornton, A.; Liu, J.; Bast, R. C., Jr.; Le, X-F			HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy	ONCOGENE			English	Article						HER2; trastuzumab; TSP-1; IL-8; VEGF; p38; PI3K; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; METASTATIC BREAST-CANCER; KINASE INHIBITOR P27(KIP1); RECEPTOR TYROSINE KINASES; CELL-CYCLE ARREST; P38 MAP KINASE; TUMOR-GROWTH; ANTI-HER2 ANTIBODY; UP-REGULATION; IN-VITRO	We determined the impact of HER2 signaling on two proangiogenic factors, vascular endothelial growth factor ( VEGF) and interleukin-8(IL-8), and on an antiangiogenic factor, thrombospondin-1 (TSP-1). Re-expression of HER2 in MCF-7 and T-47D breast cancer cells that endogenously express low levels of HER2 resulted in elevated expression of VEGF and IL-8 and decreased expression of TSP-1. Inhibition of HER2 with a humanized anti-HER2 antibody ( trastuzumab, or Herceptin (R)) or a retrovirus-mediated small interfering RNA against HER2 (siHER2) decreased VEGF and IL-8 expression, but increased TSP-1 expression in BT474 breast cancer cells that express high levels of HER2. These in vitro results were further evaluated by treatment of BT474 xenografts in immunosuppressed mice with trastuzumab. Trastuzumab inhibited growth of BT474 xenografts and decreased microvascular density associated with down-regulation of VEGF and IL-8 and with upregulation of TSP-1 expression. Inhibiting the PI3K-AKT pathway decreased VEGF and IL-8 expression. AKT1 overexpession increased VEGF and IL-8 expression, but did not increase TSP- 1 expression. A p38 kinase inhibitor, SB203580, instead blocked TSP- 1 expression and a p38 activator, MKK6, increased TSP- 1 expression. Trastuzumab stimulated sustained p38 activation and SB203580 attenuated the TSP- 1 upregulation induced by trastuzumab. HER2 signaling therefore influences the equilibrium between pro- and antiangiogenic factors via distinct signaling pathways. Trastuzumab inhibits angiogenesis and tumor growth, at least in part, through activation of the HER2-p38-TSP-1 pathway and inhibition of the HER2-PI3K-AKT-VEGF/IL-8 pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Le, XF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Div Canc Med,Unit 355, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rbast@mdanderson.org; xfle@mdanderson.org	Bast, Robert C/E-6585-2011	Bast, Robert C/0000-0003-4621-8462	NCI NIH HHS [CA39930, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA039930] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bar-Eli M, 1999, PATHOBIOLOGY, V67, P12, DOI 10.1159/000028045; Baselga J, 2004, SEMIN ONCOL, V31, P51, DOI 10.1053/j.seminoncol.2004.07.022; Baselga J, 1998, CANCER RES, V58, P2825; Benoy IH, 2004, CLIN CANCER RES, V10, P7157, DOI 10.1158/1078-0432.CCR-04-0812; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Chelouche-Lev D, 2004, EUR J CANCER, V40, P2509, DOI 10.1016/j.ejca.2004.05.024; Chen JJW, 2003, CLIN CANCER RES, V9, P729; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Crown J, 2003, BREAST CANCER RES TR, V79, pS11; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; De Larco JE, 2001, AM J PATHOL, V158, P639, DOI 10.1016/S0002-9440(10)64005-9; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; Finn Richard S, 2003, Cancer Chemother Biol Response Modif, V21, P223; Freund A, 2003, ONCOGENE, V22, P256, DOI 10.1038/sj.onc.1206113; Green AR, 1997, INT J CANCER, V72, P937; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kos KS, 2003, CANCER-AM CANCER SOC, V98, P1377, DOI 10.1002/cncr.11656; Kumar R, 2001, SEMIN ONCOL, V28, P27, DOI 10.1016/S0093-7754(01)90279-9; Le XF, 2005, CELL CYCLE, V4, P87, DOI 10.4161/cc.4.1.1360; Le XF, 2005, J BIOL CHEM, V280, P2092, DOI 10.1074/jbc.M403080200; Le XF, 2003, J BIOL CHEM, V278, P23441, DOI 10.1074/jbc.M300848200; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; Le XF, 2000, CANCER RES, V60, P3522; Loureiro RMB, 2005, BIOCHEM BIOPH RES CO, V326, P455, DOI 10.1016/j.bbrc.2004.11.053; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Miller KD, 2005, J CLIN ONCOL, V23, P792, DOI 10.1200/JCO.2005.05.098; Nahta R, 2003, CLIN CANCER RES, V9, P5078; Naito T, 2004, AM J PHYSIOL-RENAL, V286, pF278, DOI 10.1152/ajprenal.00139.2003; Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053; Petit AMV, 1997, AM J PATHOL, V151, P1523; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Ribatti D, 1998, INT J CANCER, V77, P449; Rodriguez-Manzaneque JC, 2001, P NATL ACAD SCI USA, V98, P12485, DOI 10.1073/pnas.171460498; Rofstad EK, 2002, BRIT J CANCER, V86, P301, DOI 10.1038/sj.bjc.6600052; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; Shahied LS, 2004, J BIOL CHEM, V279, P53907, DOI 10.1074/jbc.M407888200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Spiridon CI, 2004, CLIN CANCER RES, V10, P3542, DOI 10.1158/1078-0432.CCR-03-0549; Stein Steven, 2004, Clin Breast Cancer, V4 Suppl 3, pS117, DOI 10.3816/CBC.2004.s.005; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Xiong SB, 2001, CANCER RES, V61, P1727; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Yen L, 2002, MOL BIOL CELL, V13, P4029, DOI 10.1091/mbc.e02-02-0084; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhang HT, 2003, CANCER BIOL THER, V2, pS122	55	131	135	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6986	6996		10.1038/sj.onc.1209685	http://dx.doi.org/10.1038/sj.onc.1209685			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16715132				2022-12-17	WOS:000241732300009
J	Pei, XH; Xiong, Y				Pei, XH; Xiong, Y			Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues	ONCOGENE			English	Review						p16; p21; cyclin; CDK; CDK inhibitor; PCNA	DEPENDENT-KINASE INHIBITOR; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-SUPPRESSOR P16(INK4A); GROWTH-FACTOR-BETA; MICE LACKING JUNB; CYCLIN-D; DNA-REPLICATION; NUCLEAR ANTIGEN; G1 CYCLIN; TGF-BETA	p21 and p16, first identified as two small molecular weight proteins in CDK and cyclin immunocomplexes, represent two distinct families constituting a total of seven CDK inhibitors in mammalian cells. The physiological functions of these genes are believed to be broadly involved in connecting various cellular pathways to cell cycle control. Extensive studies over the past 10 years have led to a fairly clear understanding of their biochemical and cellular mechanisms and have also left some unresolved and controversial issues.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu	Pei, Xin-Hai/P-1812-2014	pei, xin-hai/0000-0001-6441-1691	NCI NIH HHS [CA68377] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068377] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1997, BLOOD, V90, P126; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Ball KL, 1997, CURR BIOL, V7, P71, DOI 10.1016/S0960-9822(06)00029-7; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blais A, 2002, J BIOL CHEM, V277, P31679, DOI 10.1074/jbc.M204554200; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Chen IT, 1996, ONCOGENE, V12, P595; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Emmerich J, 2004, GENETICS, V168, P867, DOI 10.1534/genetics.104.027417; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; Geng Y, 2001, P NATL ACAD SCI USA, V98, P194, DOI 10.1073/pnas.011522998; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1998, GENE DEV, V12, P3882, DOI 10.1101/gad.12.24.3882; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Jiang H, 1998, MOL CELL BIOL, V18, P5284, DOI 10.1128/MCB.18.9.5284; Kenner L, 2004, J CELL BIOL, V164, P613, DOI 10.1083/jcb.200308155; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI Y, 1994, ONCOGENE, V9, P2261; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Meyer CA, 2000, EMBO J, V19, P4533, DOI 10.1093/emboj/19.17.4533; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Milne TA, 2005, P NATL ACAD SCI USA, V102, P749, DOI 10.1073/pnas.0408836102; Mitra J, 1999, MOL CELL BIOL, V19, P3916; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Moons DS, 2002, ENDOCRINOLOGY, V143, P3001, DOI 10.1210/en.143.8.3001; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Narimatsu M, 1997, BIOCHEM BIOPH RES CO, V238, P764, DOI 10.1006/bbrc.1997.7387; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Olashaw N, 2004, CELL CYCLE, V3, P263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Parry D, 1999, MOL CELL BIOL, V19, P1775; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Passegue E, 2001, CELL, V104, P21, DOI 10.1016/S0092-8674(01)00188-X; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Pei XH, 2004, MOL CELL BIOL, V24, P6653, DOI 10.1128/mcb.24.15.6653-6664.2004; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith KS, 2003, MOL CELL, V12, P393, DOI 10.1016/S1097-2765(03)00277-6; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; Sugimoto M, 2002, ONCOGENE, V21, P8067, DOI 10.1038/sj.onc.1206019; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Thullberg M, 2000, FEBS LETT, V470, P161, DOI 10.1016/S0014-5793(00)01307-7; Tong W, 2001, MOL CELL BIOL, V21, P1319, DOI 10.1128/MCB.21.4.1319-1328.2001; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1998, NUCLEIC ACIDS RES, V26, P3925, DOI 10.1093/nar/26.17.3925; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; Watanabe H, 1998, P NATL ACAD SCI USA, V95, P1392, DOI 10.1073/pnas.95.4.1392; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	126	131	134	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2005	24	17					2787	2795		10.1038/sj.onc.1208611	http://dx.doi.org/10.1038/sj.onc.1208611			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	917MI	15838515				2022-12-17	WOS:000228465800005
J	Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP				Alli, PM; Pinn, ML; Jaffee, EM; McFadden, JM; Kuhajda, FP			Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice	ONCOGENE			English	Article						fatty acid synthase; HER2; neu; transgenic	BREAST-CANCER; PROSTATE-CANCER; IMMUNOHISTOCHEMICAL EXPRESSION; FOOD-INTAKE; OVEREXPRESSION; PROGRESSION; CARCINOMAS; HER-2/NEU; CELLS; GENE	High levels of fatty acid synthase (FAS) have been found in cancer precursor lesions of the colon, stomach, esophagus, oral cavity, prostate, and breast. Inhibition of FAS with C75 has led to a significant antitumor effect in both human breast and prostate cancer xenografts. Recently, HER2/neu, which has also been identified in preneoplastic breast lesions, has been shown to regulate FAS expression through the PI3K/Akt signal transduction pathway rendering them susceptible to FAS inhibition. Utilizing the neu-N transgenic mouse model of mammary cancer, weekly treatment of the neu-N mice with C75 (30 mg/kg) for 10 weeks significantly delayed tumor progression. Only 20% of the C75-treated transgenic mice developed mammary carcinoma by 220 days, compared to 50% in the vehicle control animals. Two C75-treated animals never developed mammary cancer. Analysis of mammary tissue following 10 weeks of C75 treatment revealed a significant delay in mammary maturation as manifested by a reduction of the number and caliber of mammary ducts and budding epithelial structures. Apoptotic changes were increased, DNA synthesis was decreased, and the expressions of FAS, neu, Akt, phospho-Akt, and p21(waf1) were all decreased when compared to vehicle controls and FVB/N mice. Importantly, these effects were restricted to the breast epithelial cells that overexpressed neu, not involving other normal duct structures in the skin, liver, or kidney. C247, an FAS inhibitor chemically distinct from C75, significantly delayed mammary maturation similar to C75. Thus, pharmacological inhibition of FAS affects the expression of key oncogenes involved in both cancer development and maintenance of the malignant phenotype. Moreover, these data identify FAS as a potential novel drug target for breast cancer chemoprevention.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; FASgen Inc, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Kuhajda, FP (corresponding author), Johns Hopkins Univ, Sch Med, Bldg AA,Room 154A,4940 Eastern Ave, Baltimore, MD 21224 USA.	fkuhajda@jhmi.edu		Jaffee, Elizabeth/0000-0003-3841-6549	NCI NIH HHS [1R44CA99435, 1P50CA88843] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA088843, R44CA099435] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alo PL, 2001, AM J CLIN PATHOL, V116, P129; Boggio K, 2000, CANCER RES, V60, P359; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bull JH, 2001, BRIT J CANCER, V84, P1512, DOI 10.1054/bjoc.2001.1816; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Fabian CJ, 2001, BREAST CANCER RES, V3, P99, DOI 10.1186/bcr279; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Jordan VC, 2000, J STEROID BIOCHEM, V74, P269, DOI 10.1016/S0960-0760(00)00103-5; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; Kuhajda FP, 2000, P NATL ACAD SCI USA, V97, P3450, DOI 10.1073/pnas.050582897; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kusakabe T, 2002, HISTOPATHOLOGY, V40, P71, DOI 10.1046/j.1365-2559.2002.01289.x; Lofts F J, 1992, Cancer Treat Res, V61, P161; Loftus TM, 2000, SCIENCE, V288, P2379, DOI 10.1126/science.288.5475.2379; McFadden JM, 2002, ORG LETT, V4, P3859, DOI 10.1021/ol026685k; MCFADDEN JM, 2004, UNPUB J MED CHEM; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Mueller SO, 2002, ENDOCRINOLOGY, V143, P2357, DOI 10.1210/en.143.6.2357; Nemoto T, 2001, PATHOBIOLOGY, V69, P297, DOI 10.1159/000064636; Pflug BR, 2003, PROSTATE, V57, P245, DOI 10.1002/pros.10297; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 2001, PROSTATE, V47, P102, DOI 10.1002/pros.1052; Rashid A, 1997, AM J PATHOL, V150, P201; Reilly R T, 2001, Curr Opin Investig Drugs, V2, P133; Reilly R Todd, 2002, Methods Mol Med, V69, P233; Reilly RT, 2000, CANCER RES, V60, P3569; Reilly RT, 2001, CANCER RES, V61, P880; Thupari JN, 2004, AM J PHYSIOL-ENDOC M, V287, pE97, DOI 10.1152/ajpendo.00261.2003; Thupari JN, 2002, P NATL ACAD SCI USA, V99, P9498, DOI 10.1073/pnas.132128899; Visca P, 1999, CLIN CANCER RES, V5, P4111; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG HQ, 2003, P AM ASSOC CANC RES, V44, P1100; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu RL, 2002, MODERN PATHOL, V15, P116, DOI 10.1038/modpathol.3880503; Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zhou WB, 2003, CANCER RES, V63, P7330	42	131	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					39	46		10.1038/sj.onc.1208174	http://dx.doi.org/10.1038/sj.onc.1208174			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15489885				2022-12-17	WOS:000226125800006
J	Sloan, EK; Stanley, KL; Anderson, RL				Sloan, EK; Stanley, KL; Anderson, RL			Caveolin-1 inhibits breast cancer growth and metastasis	ONCOGENE			English	Article						caveolin-1; breast cancer; invasion; metastasis; bone metastases	TUMOR-SUPPRESSOR GENE; ENDOPLASMIC-RETICULUM; PROSTATE-CANCER; NULL MICE; EXPRESSION; CHOLESTEROL; D7S522; REGION; 7Q31.1	Caveolin-1 was identified in a screen for genes involved in breast cancer progression. Caveolin-1 is the major protein component of caveolae, flask-shaped invaginations found in a number of different cell types. Using an orthotopic model of spontaneous breast cancer metastasis, caveolin-1 was found to be expressed in low and non-metastatic primary tumors, but at much lower levels in highly metastatic 4T1.2 and 4T1.13 tumors. Exogenous expression of caveolin-1 at moderate levels in 4T1.2 cells was sufficient to suppress primary tumor growth after inoculation of cells into the mammary gland. Expression of high levels of caveolin-1 also inhibited subsequent metastasis to distant organs. Cells expressing high levels of caveolin-1 showed reduced capacity to invade Matrigel, diminished response to laminin-1 stimulation and decreased metastasis to lung and bone. This study provides the first functional evidence that caveolin-1 regulates primary breast tumor growth and spontaneous metastasis of breast cancer.	Peter MacCallum Canc Ctr, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center	Anderson, RL (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	robin.anderson@petermac.org	Anderson, Robin/I-2306-2013; Anderson, Robin/K-6966-2019; Anderson, Robin/S-1005-2017	Sloan, Erica/0000-0002-2355-1433; Anderson, Robin/0000-0002-6841-7422	NCI NIH HHS [R01 CA 90291] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090291] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bender FC, 2000, CANCER RES, V60, P5870; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hayashi K, 2001, CANCER RES, V61, P2361; Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505; Li LK, 2001, CANCER RES, V61, P4386; Liu J, 2001, AM J PHYSIOL-CELL PH, V280, pC823, DOI 10.1152/ajpcell.2001.280.4.C823; Mundy DI, 2002, J CELL SCI, V115, P4327, DOI 10.1242/jcs.00117; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Park DS, 2002, MOL BIOL CELL, V13, P3416, DOI 10.1091/mbc.02-05-0071; Parker BS, 2004, CAN META BIO TREAT, V6, P1; Pol A, 2004, MOL BIOL CELL, V15, P99, DOI 10.1091/mbc.E03-06-0368; Razani B, 2001, J BIOL CHEM, V276, P38121; SAGER R, 1994, COLD SPRING HARB SYM, V59, P537, DOI 10.1101/SQB.1994.059.01.060; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Tester AM, 2002, CLIN EXP METASTAS, V19, P377, DOI 10.1023/A:1016381416463; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891	35	131	145	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7893	7897		10.1038/sj.onc.1208062	http://dx.doi.org/10.1038/sj.onc.1208062			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334058				2022-12-17	WOS:000224331600015
J	Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ				Kopitz, J; Andre, S; von Reitzenstein, C; Versluis, K; Kaltner, H; Pieters, RJ; Wasano, K; Kuwabara, I; Liu, FT; Cantz, M; Heck, AJR; Gabius, HJ			Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells	ONCOGENE			English	Article						apoptosis; cell growth; galectin; ganglioside; mass spectrometry; neuroblastoma	CARBOHYDRATE-BINDING PROTEINS; TOXIN B-SUBUNIT; MEMBRANE GANGLIOSIDE SIALIDASE; ADHERENS JUNCTION PROTEIN; ANIMAL LECTINS; ENDOGENOUS LECTINS; MASS-SPECTROMETRY; PLASMA-MEMBRANE; TUMOR BIOLOGY; HUMAN GLIOMAS	The extracellular functions of galectin-7 (p53-induced gene 1) are largely unknown. On the surface of neuroblastoma cells (SK-N-MC), the increased GM(1) density, a result of upregulated ganglioside sialidase activity, is a key factor for the switch from proliferation to differentiation. We show by solid-phase and cell assays that the sugar chain of this ganglioside is a ligand for galectin-7. In serum-supplemented proliferation assays, galectin-7 reduced neuroblastoma cell growth without the appearance of features characteristic for classical apoptosis. The presence of galectin-3 blocked this effect, which mechanistically resembles that of galectin-1. By virtue of carbohydrate binding, galectin-7 thus exerts neuroblastoma growth control similar to galectin-1 despite their structural differences. In addition to p53-linked proapoptotic activity intracellularly, galectin-7, acting as a lectin on the cell surface, appears to be capable of reducing cancer cell proliferation in susceptible systems.	Univ Heidelberg Klinikum, Inst Mol Pathol, D-69120 Heidelberg, Germany; Univ Munich, Tierarztliche Fak, Inst Physiol Chem, D-80539 Munich, Germany; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Med Chem, NL-3508 TB Utrecht, Netherlands; Kyushu Univ, Fac Med, Dept Anat & Cell Biol, Fukuoka 8120054, Japan; Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA	Ruprecht Karls University Heidelberg; University of Munich; Utrecht University; Utrecht University; Utrecht University; Kyushu University; University of California System; University of California Davis	Kopitz, J (corresponding author), Univ Heidelberg Klinikum, Inst Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	juergen_kopitz@med.uni-heidelberg.de	Heck, Albert/D-7098-2011; Liu, FU-TONG/A-5749-2019; Pieters, Roland J/A-9254-2008	Heck, Albert/0000-0002-2405-4404; Liu, FU-TONG/0000-0002-3354-1001; Pieters, Roland J/0000-0003-4723-3584; Gabius, Hans-Joachim/0000-0003-3467-3900; Andre, Sabine/0000-0003-0850-0432; Kaltner, Herbert/0000-0003-4680-8411				AGRWAL N, 1993, J BIOL CHEM, V268, P14932; Ahmad N, 2002, CAN J CHEM, V80, P1096, DOI 10.1139/V02-162; Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; Andre S, 2000, PHARMACEUT RES, V17, P985, DOI 10.1023/A:1007535506705; Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Andre S, 2001, CHEMBIOCHEM, V2, P822, DOI 10.1002/1439-7633(20011105)2:11<822::AID-CBIC822>3.0.CO;2-W; Andre S, 1997, BIOCONJUGATE CHEM, V8, P845, DOI 10.1021/bc970164d; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Borriello A, 2002, HAEMATOLOGICA, V87, P196; Brewer CF, 2002, BBA-GEN SUBJECTS, V1572, P255, DOI 10.1016/S0304-4165(02)00312-4; Camby I, 2002, J NEUROPATH EXP NEUR, V61, P585, DOI 10.1093/jnen/61.7.585; Camby I, 2001, BRAIN PATHOL, V11, P12; CHIU ML, 1992, J CELL BIOL, V119, P1689, DOI 10.1083/jcb.119.6.1689; CHIU ML, 1994, J BIOL CHEM, V269, P31770; Cooper DNW, 2002, BBA-GEN SUBJECTS, V1572, P209, DOI 10.1016/S0304-4165(02)00310-0; Danguy A, 2002, BBA-GEN SUBJECTS, V1572, P285, DOI 10.1016/S0304-4165(02)00315-X; Dobo A, 2001, ANAL CHEM, V73, P4763, DOI 10.1021/ac010713f; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; FRIGERI LG, 1990, J BIOL CHEM, V265, P20763; Gabius HJ, 2000, NATURWISSENSCHAFTEN, V87, P108, DOI 10.1007/s001140050687; GABIUS HJ, 1990, ANAL BIOCHEM, V189, P91, DOI 10.1016/0003-2697(90)90050-J; GABIUS HJ, 1987, CANCER INVEST, V5, P39, DOI 10.3109/07357908709020305; Gabius HJ, 2002, BBA-GEN SUBJECTS, V1572, P165, DOI 10.1016/S0304-4165(02)00306-9; Gabius HJ, 2001, BIOCHIMIE, V83, P659, DOI 10.1016/S0300-9084(01)01311-6; Gabius HJ, 2001, ANAT HISTOL EMBRYOL, V30, P3, DOI 10.1046/j.1439-0264.2001.00305.x; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GABIUS S, 1990, BIOCHEM BIOPH RES CO, V169, P239, DOI 10.1016/0006-291X(90)91459-6; Gauthier L, 2002, P NATL ACAD SCI USA, V99, P13014, DOI 10.1073/pnas.202323999; Giudicelli V, 1997, GLYCOBIOLOGY, V7, pR8; Gunnersen JM, 2000, GLIA, V32, P146, DOI 10.1002/1098-1136(200011)32:2<146::AID-GLIA40>3.3.CO;2-V; Hadari YR, 2000, J CELL SCI, V113, P2385; Hakamori S, 1998, ACTA ANAT, V161, P79; Hippo Y, 2001, CANCER RES, V61, P889; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; Hirabayashi J, 1997, TRENDS GLYCOSCI GLYC, V9, P1, DOI DOI 10.4052/TIGG.9.1; Horie H, 2000, NEUROSCI RES, V38, P131, DOI 10.1016/S0168-0102(00)00142-5; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Itzkowitz SH, 1997, GASTROENTEROLOGY, V113, P2003; Kaltner H, 1998, ACTA ANAT, V161, P162; Kayser K, 2001, J PATHOL, V193, P175, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH772>3.0.CO;2-T; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kitanaka C, 2002, J NATL CANCER I, V94, P358; KOHNKEGODT B, 1989, BIOCHEMISTRY-US, V28, P6531, DOI 10.1021/bi00442a001; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Kopitz J, 1997, EUR J CELL BIOL, V73, P1; Kopitz J, 1996, GLYCOBIOLOGY, V6, P367, DOI 10.1093/glycob/6.3.367; KOPITZ J, 1994, BIOCHEM BIOPH RES CO, V199, P1188, DOI 10.1006/bbrc.1994.1356; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kuwabara I, 2002, J BIOL CHEM, V277, P3487, DOI 10.1074/jbc.M109360200; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; Liu FT, 2002, BBA-GEN SUBJECTS, V1572, P263, DOI 10.1016/S0304-4165(02)00313-6; LIU FT, 2000, LECTINS PATHOLOGY, P51; Lu JX, 1997, MOL CARCINOGEN, V20, P204, DOI 10.1002/(SICI)1098-2744(199710)20:2<204::AID-MC7>3.0.CO;2-M; Lutomski D, 1997, GLYCOBIOLOGY, V7, P1193, DOI 10.1093/glycob/7.8.1193; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; Magnaldo T, 1998, DIFFERENTIATION, V63, P159, DOI 10.1046/j.1432-0436.1998.6330159.x; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; Nagy N, 2002, GUT, V50, P392, DOI 10.1136/gut.50.3.392; Nangia-Makker P, 2000, CANCER METAST REV, V19, P51, DOI 10.1023/A:1026540129688; OCHIENG J, 1993, BIOCHEMISTRY-US, V32, P4455, DOI 10.1021/bi00067a038; OHANNESIAN DW, 1997, GLYCOSCIENCES STATUS, P459; OUTENREATH RL, 1992, J NEUROCYTOL, V21, P788, DOI 10.1007/BF01237904; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; POWELL JT, 1984, BIOCHEM J, V223, P769, DOI 10.1042/bj2230769; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Rabinovich GA, 2002, BBA-GEN SUBJECTS, V1572, P274, DOI 10.1016/S0304-4165(02)00314-8; Rappl G, 2002, LEUKEMIA, V16, P840, DOI 10.1038/sj.leu.2402438; RAZ A, 1987, CANCER METAST REV, V6, P433, DOI 10.1007/BF00144274; Reuter G, 1999, CELL MOL LIFE SCI, V55, P368, DOI 10.1007/s000180050298; Rodighiero C, 2001, J BIOL CHEM, V276, P36939, DOI 10.1074/jbc.M104245200; Rodriguez JA, 2001, J NEUROSCI, V21, P8387, DOI 10.1523/JNEUROSCI.21-21-08387.2001; ROFF CF, 1983, J BIOL CHEM, V258, P657; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Sato M, 2002, J BIOCHEM, V131, P255, DOI 10.1093/oxfordjournals.jbchem.a003096; SHAPER NL, 2000, CARBOHYDRATES CHEM 2, P175; Simmons DA, 2002, BIOCHEMISTRY-US, V41, P1906, DOI 10.1021/bi011697j; Solis D, 2001, CELLS TISSUES ORGANS, V168, P5, DOI 10.1159/000016802; Timmons PM, 1999, INT J DEV BIOL, V43, P229; van den Bremer ETJ, 2002, PROTEIN SCI, V11, P1738, DOI 10.1110/ps.0200502; van Dongen WD, 2000, ANALYST, V125, P583, DOI 10.1039/a907957b; Varela PF, 1999, J MOL BIOL, V294, P537, DOI 10.1006/jmbi.1999.3273; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vrasidas I, 2001, EUR J ORG CHEM, V2001, P4685; Wasano K, 1999, J HISTOCHEM CYTOCHEM, V47, P75, DOI 10.1177/002215549904700108; Wollina U, 2002, J CANCER RES CLIN, V128, P103, DOI 10.1007/s00432-001-0304-3; WOO HJ, 1991, J BIOL CHEM, V266, P18419; Wu AM, 2002, BIOCHEM J, V367, P653, DOI 10.1042/BJ20020600; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yamaoka K., 1993, LECTINS GLYCOBIOLOGY, P492	95	131	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 18	2003	22	40					6277	6288		10.1038/sj.onc.1206631	http://dx.doi.org/10.1038/sj.onc.1206631			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	724UZ	13679866				2022-12-17	WOS:000185506200017
J	Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A				Stoica, GE; Franke, TF; Moroni, M; Mueller, S; Morgan, E; Iann, MC; Winder, AD; Reiter, R; Wellstein, A; Martin, MB; Stoica, A			Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway	ONCOGENE			English	Article						estradiol; estrogen receptor-alpha; ErbB2; Akt	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER-CELLS; SIGNAL-TRANSDUCTION PATHWAYS; STEROID-HORMONE RECEPTORS; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MCF-7 CELLS; TYROSINE KINASE; BINDING-SITES; TAMOXIFEN RESISTANCE	Epidermal growth factor (EGF), insulin-like growth factor-I (IGF-I), and heregulin-beta1 (HRG-beta1), can modulate the expression and activity of the estrogen receptor-alpha (ER-alpha) via the phosphatidylinositol 3-kinase (PI 3-K)/Akt pathway in the ER-alpha-positive breast cancer cell line, MCF-7. Estradiol can also rapidly activate PI 3-K/Akt in these cells (nongenomic effect). The recent study examines whether Akt is involved in the ER-alpha regulation by estradiol (genomic effect). Stable transfection of parental MCF-7 cells with a dominant-negative Akt mutant, as well as the PI 3-K inhibitors wortmannin and LY 294,002, blocked the effect of estradiol on ER-alpha expression and activity by 70-80 and 55-63%, respectively. Stable transfection of MCF-7 cells with a constitutively active Akt mimicked the effect of estradiol. The changes in ER-alpha expression and activity were abrogated in response to estradiol by an arginine to cysteine mutation in the pleckstrin homology (PH) domain of Akt (R25C), suggesting the involvement of this amino acid in the interaction between Akt and ER-alpha. Experiments employing selective ErbB inhibitors demonstrate that the effect of estradiol on ER-a expression and activity is mediated by ErbB2 and not by EGFR. Moreover, anchorage-dependent and -independent growth assays, cell cycle and membrane ruffling analyses showed that Akt exerts estrogen-like activity on cell growth and membrane ruffling and that a selective ErbB2 inhibitor, but not anti-ErbB2 antibodies directed to the extracellular domain, can block these effects. In the presence of constitutively active Akt, tamoxifen only partially inhibits cell growth. In contrast, in cells stably transfected with either a dominant-negative Akt or with R25C-Akt, as well as in parental cells in the presence of a selective ErbB2 inhibitor, the effect of estradiol on anchorage-dependent and -independent cell growth was inhibited by 50-75 and 100%, respectively. Dominant-negative Akt inhibited membrane ruffling by 54%; however, R25C-Akt did not have any effect, suggesting that kinase activity plays an important role in this process. Scatchard analysis demonstrated a 67% reduction in estrogen-binding capacity in cells transfected with constitutively active Akt. No change in binding affinity of estradiol to the receptor was observed upon transfection with either Akt mutant. Taken together, our results suggest that estradiol treatment results in binding to membrane ER-alpha and interaction with a heterodimer containing ErbB2, leading to tyrosine phosphorylation. This results in the activation of PI 3-K and Akt. Akt, in turn, may interact with nuclear ER-alpha, altering its expression and activity.	Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20057 USA; Georgetown Univ, Sch Nursing & Hlth Studies, Washington, DC 20057 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Georgetown University; Georgetown University; Columbia University	Stoica, A (corresponding author), E411 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.			Wellstein, Anton/0000-0002-0570-4950	NATIONAL CANCER INSTITUTE [P30CA051008, P50CA058185] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA-51008, P50-CA-58185] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALIMANDI M, 1995, ONCOGENE, V10, P1813; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARTEAGA CL, 1988, MOL ENDOCRINOL, V2, P1064, DOI 10.1210/mend-2-11-1064; AURICCHIO F, 1995, CELL GROWTH DIFFER, V6, P105; Bacus SS, 1996, AM J PATHOL, V148, P549; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; GUIOCHONMANTEL A, 1996, J STEROID BIOCHEM, V56, P1; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; Hellyer NJ, 2001, J BIOL CHEM, V276, P42153, DOI 10.1074/jbc.M102079200; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Kato  S, 2001, Breast Cancer, V8, P3, DOI 10.1007/BF02967472; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIM HH, 1994, J BIOL CHEM, V269, P24747; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; LEITZEL K, 1995, J CLIN ONCOL, V13, P1129, DOI 10.1200/JCO.1995.13.5.1129; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lobenhofer EK, 2000, CELL GROWTH DIFFER, V11, P99; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; Martin MB, 2000, ENDOCRINOLOGY, V141, P4503, DOI 10.1210/en.141.12.4503; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; MCLESKEY SW, 1993, CANCER RES, V53, P2168; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Nemere I, 1998, BIOCHEM BIOPH RES CO, V248, P443, DOI 10.1006/bbrc.1998.8492; NICHOLSON S, 1990, J STEROID BIOCHEM, V37, P811, DOI 10.1016/0960-0760(90)90424-J; Normanno N, 1997, J MAMMARY GLAND BIOL, V2, P143, DOI 10.1023/A:1026351730785; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REDDY KB, 1994, CELL GROWTH DIFFER, V5, P1275; REDDY KB, 1992, CANCER RES, V52, P3636; SACEDA M, 1988, MOL ENDOCRINOL, V2, P1157, DOI 10.1210/mend-2-12-1157; Salomon D S, 1988, Cancer Treat Res, V40, P363; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; SAPINO A, 1986, CANCER RES, V46, P2526; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P209; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371; Stoica GE, 2003, MOL ENDOCRINOL, V17, P818, DOI 10.1210/me.2002-0330; Stoica GE, 2003, ONCOGENE, V22, P2073, DOI 10.1038/sj.onc.1206311; Sweeney CJ, 2001, CANCER, V92, P2639, DOI 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vasudevan N, 2001, P NATL ACAD SCI USA, V98, P12267, DOI 10.1073/pnas.221449798; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; Watson CS, 1999, P SOC EXP BIOL MED, V220, P9, DOI 10.1046/j.1525-1373.1999.d01-2.x; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; WELLSTEIN A, 1992, J BIOL CHEM, V267, P2582; Wen Y, 2000, CANCER RES, V60, P6841; Wosikowski K, 1997, CLIN CANCER RES, V3, P2405; WRIGHT C, 1992, J CLIN PATHOL, V45, P459, DOI 10.1136/jcp.45.5.459-b; ZEILLINGER R, 1989, ONCOGENE, V4, P109; Zhang K, 1996, J BIOL CHEM, V271, P3884	91	131	140	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 11	2003	22	39					7998	8011		10.1038/sj.onc.1206769	http://dx.doi.org/10.1038/sj.onc.1206769			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722QT	12970748				2022-12-17	WOS:000185388200015
J	Dupin, E; Le Douarin, NM				Dupin, E; Le Douarin, NM			Development of melanocyte precursors from the vertebrate neural crest	ONCOGENE			English	Article						neural crest; quail; chick; embryo; pigment cell; stem cell factor; endothelin 3	ENDOTHELIN-B RECEPTOR; C-KIT ANTIBODY; STEEL FACTOR; AVIAN EMBRYO; COAT COLOR; IN-VITRO; MONOCLONAL-ANTIBODY; CLONAL ANALYSIS; CELLS; DIFFERENTIATION	Pigment cells that differentiate in the vertebral skin arise from the neural crest (NC), a transitory structure formed at the dorsal borders of the neural plate and which gives rise to migratory cells of multiple fates. How NC cells become committed to the melanocytic lineage and what factors control the survival, proliferation and differentiation of melanocyte precursors remain largely unknown. These issues are of great importance for understanding the mechanisms of several pigment cell pathologies including melanomas. Recent in vivo and in vitro analyses of the fate of single NC cells have indicated that multipotent cells yield melanocyte precursors that become spatially and temporally segregated from other, non melanogenic, NC-derived cell types. The proper development of subsets of NC precursors is governed by environmental local cytokines acting in a paracrine manner. The conjunction of recent studies in mammals and birds reviewed here focuses on the action of endothelin 3 in controlling both the emergence and the maintenance of the NC-derived melanocyte phenotype.	CNRS, Lab Embryol Cellulaire & Mol, UMR 7128, F-94736 Nogent Sur Marne, France	Centre National de la Recherche Scientifique (CNRS)	Le Douarin, NM (corresponding author), CNRS, Lab Embryol Cellulaire & Mol, UMR 7128, 49 Bis Ave Belle Gabrielle, F-94736 Nogent Sur Marne, France.		Dupin, Elisabeth/X-8757-2019	Dupin, Elisabeth/0000-0003-0287-0256				ABO T, 1981, J IMMUNOL, V127, P1024; Anderson DJ, 1997, TRENDS GENET, V13, P276, DOI 10.1016/S0168-9525(97)01187-6; BAROFFIO A, 1991, DEVELOPMENT, V112, P301; BAROFFIO A, 1988, P NATL ACAD SCI USA, V85, P5325, DOI 10.1073/pnas.85.14.5325; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; BRONNERFRASER M, 1989, NEURON, V3, P755, DOI 10.1016/0896-6273(89)90244-4; COHEN AM, 1975, DEV BIOL, V46, P262, DOI 10.1016/0012-1606(75)90104-9; COULY GF, 1993, DEVELOPMENT, V117, P409; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; DUPIN E, 1995, DEV BIOL, V168, P529, DOI 10.1006/dbio.1995.1100; DUPIN E, 2003, P NATL AC SCI US APR; ERICKSON CA, 1992, DEV BIOL, V151, P251, DOI 10.1016/0012-1606(92)90231-5; Etchevers HC, 2001, DEVELOPMENT, V128, P1059; Galli SJ, 1993, ADV IMMUNOL, P1, DOI DOI 10.1016/S0065-2776(08)60508-8; Greenstein-Baynash A., 1994, CELL, V79, P1277; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; ITO K, 1993, DEV BIOL, V157, P517, DOI 10.1006/dbio.1993.1154; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; KITAMURA K, 1992, DEVELOPMENT, V114, P367; LAHAV R, 1994, DIFFERENTIATION, V58, P133; Lahav R, 1998, P NATL ACAD SCI USA, V95, P14214, DOI 10.1073/pnas.95.24.14214; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Le Douarin N.M., 1982, NEURAL CREST; Le Douarin NM, 1999, NEURAL CREST; Lecoin L, 1998, P NATL ACAD SCI USA, V95, P3024, DOI 10.1073/pnas.95.6.3024; LECOIN L, 1998, MOL BASIS EPITHELIAL, P131; MORRISONGRAHAM K, 1993, DEV BIOL, V159, P346, DOI 10.1006/dbio.1993.1246; MURPHY M, 1992, DEV BIOL, V153, P396, DOI 10.1016/0012-1606(92)90124-Y; Nataf V, 1998, MECH DEVELOP, V73, P217, DOI 10.1016/S0925-4773(98)00048-3; NATAF V, 1993, EXP CELL RES, V207, P171, DOI 10.1006/excr.1993.1177; Nataf V, 2000, PIGM CELL RES, V13, P172, DOI 10.1034/j.1600-0749.2000.130309.x; Nataf V, 1996, P NATL ACAD SCI USA, V93, P9645, DOI 10.1073/pnas.93.18.9645; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; REID K, 1995, DEV BIOL, V169, P568, DOI 10.1006/dbio.1995.1170; Reid K, 1996, DEVELOPMENT, V122, P3911; REITH AD, 1991, GENOME ANAL, V3, P10; RICHARDSON MK, 1993, DEV BIOL, V157, P348, DOI 10.1006/dbio.1993.1140; SAKURAI T, 1992, TRENDS PHARMACOL SCI, V13, P103; Shin MK, 1999, NATURE, V402, P496, DOI 10.1038/990040; SIEBERBLUM M, 1989, SCIENCE, V243, P1608, DOI 10.1126/science.2564699; SIEBERBLUM M, 1980, DEV BIOL, V80, P96, DOI 10.1016/0012-1606(80)90501-1; STEMPLE DL, 1992, CELL, V71, P973, DOI 10.1016/0092-8674(92)90393-Q; Stone JG, 1997, J CELL SCI, V110, P1673; TEILLET M-A, 1971, Annales d'Embryologie et de Morphogenese, V4, P95; TEILLET MA, 1970, CR ACAD SCI D NAT, V270, P3095; VINCENT M, 1983, DEV BRAIN RES, V9, P235, DOI 10.1016/0165-3806(83)90058-5; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x; Yoshida H, 1996, DEVELOPMENT, V122, P1207; YOSHIDA H, 1993, DEV GROWTH DIFFER, V35, P209	53	131	148	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3016	3023		10.1038/sj.onc.1206460	http://dx.doi.org/10.1038/sj.onc.1206460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789276				2022-12-17	WOS:000183096600001
J	Li, G; Satyamoorthy, K; Meier, F; Berking, C; Bogenrieder, T; Herlyn, M				Li, G; Satyamoorthy, K; Meier, F; Berking, C; Bogenrieder, T; Herlyn, M			Function and regulation of melanoma-stromal fibroblast interactions: when seeds meet soil	ONCOGENE			English	Review						melanoma; stromal fibroblast; tumor progression; adherens junction; gap junction; stem cell	HEPATOCYTE GROWTH-FACTOR; E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; NORMAL HUMAN MELANOCYTES; EPITHELIAL TUMOR-CELLS; SKIN EQUIVALENT MODEL; PROSTATE-CANCER CELLS; FACTOR SCATTER FACTOR; N-CADHERIN; MALIGNANT-MELANOMA	Melanoma development and progression not only involve genetic and epigenetic changes that take place within the melanocytic cells, but also involve processes that are determined collectively by contextual factors including intercellular adhesions and communications. In this review, we focus on melanoma-stromal fibroblast crosstalk by direct cell-cell contact and by growth factors/ cytokines/chemokines interacting with their respective receptors. The interactions between melanoma cells and stromal fibroblasts create a context that promotes tumor growth, migration/invasion, and angiogenesis. An understanding of this process and developing new experimental and screening models are of great importance for the development of effective therapeutical strategies to treat melanoma.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Cell & Mol Biol Program, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.upenn.edu	Satyamoorthy, Kapaettu/H-3254-2015	Satyamoorthy, Kapaettu/0000-0002-2368-5490	NCI NIH HHS [CA-47159, CA-10815, CA-76674, CA-25874, CA-80999] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA025874, P30CA010815, R01CA080999, R01CA076674, R01CA047159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi Y, 1998, CANCER RES, V58, P4008; AlAlousi S, 1996, J CUTAN PATHOL, V23, P506, DOI 10.1111/j.1600-0560.1996.tb01442.x; AlAlousi S, 1996, J CUTAN PATHOL, V23, P118, DOI 10.1111/j.1600-0560.1996.tb01284.x; ALBINO AP, 1991, CANCER RES, V51, P4815; ARCHAMBAULT M, 1995, J INVEST DERMATOL, V104, P859, DOI 10.1111/1523-1747.ep12607034; Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bechetoille N, 2000, MELANOMA RES, V10, P427, DOI 10.1097/00008390-200010000-00004; Berking C, 2001, HISTOL HISTOPATHOL, V16, P669, DOI 10.14670/HH-16.669; Berking C, 2001, CANCER RES, V61, P8306; Bermont L, 2000, INT J CANCER, V85, P117, DOI 10.1002/(SICI)1097-0215(20000101)85:1<117::AID-IJC21>3.3.CO;2-O; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bissell MJ, 1999, CANCER RES, V59, p1757S; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Danen EHJ, 1996, MELANOMA RES, V6, P127, DOI 10.1097/00008390-199604000-00007; Davies G, 2001, CLIN CANCER RES, V7, P3289; DeLuca SM, 1999, EXP CELL RES, V251, P3, DOI 10.1006/excr.1999.4577; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; EDELMAN GM, 1983, P NATL ACAD SCI-BIOL, V80, P4384, DOI 10.1073/pnas.80.14.4384; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Eves P, 2000, BRIT J DERMATOL, V142, P210, DOI 10.1046/j.1365-2133.2000.03287.x; FORSBERG K, 1993, INT J CANCER, V53, P556, DOI 10.1002/ijc.2910530405; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; Gabbiani G, 1996, PATHOL RES PRACT, V192, P708, DOI 10.1016/S0344-0338(96)80092-6; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hajra KM, 2002, CANCER RES, V62, P1613; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Halaban R, 1996, SEMIN ONCOL, V23, P673; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Herlyn M, 2000, MELANOMA RES, V10, P303, DOI 10.1097/00008390-200008000-00001; Herlyn M, 2002, MELANOMA RES, V12, P3, DOI 10.1097/00008390-200202000-00002; HERLYN M, 1987, CANCER RES, V47, P3057; HERLYN M, 1994, PIGM CELL RES, V7, P81, DOI 10.1111/j.1600-0749.1994.tb00025.x; HERLYN M, 1985, CANCER RES, V45, P5670; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 2000, AM J PATHOL, V156, P1515, DOI 10.1016/S0002-9440(10)65023-7; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Husmark J, 1999, INT J CANCER, V83, P692, DOI 10.1002/(SICI)1097-0215(19991126)83:5<692::AID-IJC21>3.0.CO;2-1; Javaherian A, 1998, CANCER RES, V58, P2200; Jouneau A, 2000, PIGM CELL RES, V13, P260, DOI 10.1034/j.1600-0749.2000.130408.x; Kanter-Lewensohn L, 1998, MELANOMA RES, V8, P389, DOI 10.1097/00008390-199810000-00002; Kawamura-Kodama K, 1999, J INVEST DERMATOL, V112, P62, DOI 10.1046/j.1523-1747.1999.00479.x; Krasagakis K, 1999, J CELL PHYSIOL, V178, P179, DOI 10.1002/(SICI)1097-4652(199902)178:2<179::AID-JCP7>3.0.CO;2-5; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Li G, 2000, MOL MED TODAY, V6, P163, DOI 10.1016/S1357-4310(00)01692-0; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Li G, 2001, ONCOGENE, V20, P8125, DOI 10.1038/sj.onc.1205034; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; Meier F., 1998, FRONT BIOSCI J VIS L, V3, P1005, DOI [10.2741/a341, DOI 10.2741/A341]; MINTZ B, 1993, P NATL ACAD SCI USA, V90, P8817, DOI 10.1073/pnas.90.19.8817; Miura H, 2001, UROLOGY, V58, P1064, DOI 10.1016/S0090-4295(01)01427-3; Moinfar F, 2000, CANCER RES, V60, P2562; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nakazawa K, 1997, PIGM CELL RES, V10, P382, DOI 10.1111/j.1600-0749.1997.tb00696.x; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; Olumi AF, 1999, CANCER RES, V59, P5002; ONO I, 1995, J DERMATOL SCI, V10, P241, DOI 10.1016/0923-1811(95)00454-Z; Otsuka T, 1998, CANCER RES, V58, P5157; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Perris R, 1997, TRENDS NEUROSCI, V20, P23, DOI 10.1016/S0166-2236(96)10063-1; PIERCE GF, 1995, J CLIN INVEST, V96, P1336, DOI 10.1172/JCI118169; Pla P, 2001, J CELL PHYSIOL, V189, P121, DOI 10.1002/jcp.10008; POSER I, 2001, J BIOL CHEM, V25, P25; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; REED JA, 1994, AM J PATHOL, V145, P97; RODECK U, 1994, CANCER RES, V54, P575; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Rusciano D, 1998, TUMOR BIOL, V19, P335, DOI 10.1159/000030026; Sanders DSA, 1999, J CLIN PATHOL-MOL PA, V52, P151, DOI 10.1136/mp.52.3.151; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; Satyamoorthy K, 1997, MELANOMA RES, V7, pS35; Satyamoorthy K, 2002, CELL GROWTH DIFFER, V13, P87; Satyamoorthy K, 2001, CANCER RES, V61, P7318; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Sefton M, 1998, DEVELOPMENT, V125, P3111; Shih Ie-Ming, 1994, In Vivo (Attiki), V8, P113; SHIH IM, 1994, AM J PATHOL, V145, P837; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; Sporn MB, 1996, LANCET, V347, P1377, DOI 10.1016/S0140-6736(96)91015-6; Sporn MB, 2000, CARCINOGENESIS, V21, P525, DOI 10.1093/carcin/21.3.525; STOKER AW, 1990, J CELL BIOL, V111, P217, DOI 10.1083/jcb.111.1.217; Stoler DL, 1999, P NATL ACAD SCI USA, V96, P15121, DOI 10.1073/pnas.96.26.15121; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TANG A, 1994, J CELL SCI, V107, P983; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; TODD C, 1993, ARCH DERMATOL RES, V285, P455, DOI 10.1007/BF00376817; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 1999, AM J PATHOL, V155, P787, DOI 10.1016/S0002-9440(10)65177-2; Vaccariello M, 1999, J INVEST DERMATOL, V113, P384, DOI 10.1046/j.1523-1747.1999.00701.x; VALYINAGY IT, 1993, LAB INVEST, V69, P152; VanBelle P, 1996, AM J PATHOL, V148, P1887; Voura EB, 1998, MICROSC RES TECHNIQ, V43, P265, DOI 10.1002/(SICI)1097-0029(19981101)43:3<265::AID-JEMT9>3.0.CO;2-Z; Wang YP, 1997, NAT MED, V3, P887, DOI 10.1038/nm0897-887; Washington C, 2000, AM J PATHOL, V157, P323, DOI 10.1016/S0002-9440(10)64543-9; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Yokoyama K, 2001, ORAL ONCOL, V37, P65, DOI 10.1016/S1368-8375(00)00059-2	115	131	137	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2003	22	20					3162	3171		10.1038/sj.onc.1206455	http://dx.doi.org/10.1038/sj.onc.1206455			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	682MV	12789292				2022-12-17	WOS:000183096600018
J	Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S				Yamazaki, K; Sakamoto, M; Ohta, T; Kanai, Y; Ohki, M; Hirohashi, S			Overexpression of KIT in chromophobe renal cell carcinoma	ONCOGENE			English	Article						gene-expression profiling; KIT; renal cell carcinoma	GASTROINTESTINAL STROMAL TUMORS; GROWTH-FACTOR RECEPTOR; C-KIT; TYROSINE KINASE; LUNG-CANCER; SUPPRESSOR PROTEIN; MET PROTOONCOGENE; CLASSIFICATION; MUTATIONS; GENE	We analysed gene-expression profiles in 15 surgical specimens of conventional, papillary, and chromophobe renal cell carcinomas (RCCs) using high-density oligonucleotide arrays. From about 12 000 genes targeted by the array, 67 were upregulated specifically in each histological type of RCC. The oncogene KIT was one of the genes whose expression was upregulated specifically in chromophobe RCCs. Immunohistochemical analysis demonstrated the KIT gene product on the cell membrane of chromophobe RCC in all cases, although it was not detected in conventional RCCs or non-neoplastic kidneys except for weak staining in the cytoplasm of renal tubules. These results suggest that each histological subtype of RCC has a unique gene-expression profile, and in particular indicates for the first time that KIT could be a useful marker for chromophobe RCC. As overexpression of KIT might be involved in tumor growth, KIT could be a new therapeutic target in this special type of RCC.	Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, Tokyo 1600016, Japan; Natl Canc Ctr, Res Inst, Canc Genom Div, Chuou Ku, Tokyo 1040045, Japan; Org Pharmaceut Safety & Res, Chiyoda Ku, Tokyo 1000013, Japan; Natl Canc Ctr, Res Inst, Div Pathol, Chuou Ku, Tokyo 1040045, Japan	Keio University; National Cancer Center - Japan; National Cancer Center - Japan	Sakamoto, M (corresponding author), Keio Univ, Sch Med, Dept Pathol, Shinjuku Ku, 35 Shinaimachi, Tokyo 1600016, Japan.		Kanai, Yae/AAE-6987-2019; Sakamoto, Michiie/N-2917-2015	Yamazaki, Ken/0000-0002-7220-7479				Caruana G, 1998, ONCOGENE, V16, P179, DOI 10.1038/sj.onc.1201494; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; FREEMAN MR, 1989, CANCER RES, V49, P6221; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GNERRA JR, 1994, NAT GENET, V7, P85; HIBI K, 1991, ONCOGENE, V6, P2291; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; ISHIKAWA J, 1990, INT J CANCER, V45, P1018, DOI 10.1002/ijc.2910450606; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kenck C, 1996, J PATHOL, V179, P157, DOI 10.1002/(SICI)1096-9896(199606)179:2<157::AID-PATH557>3.0.CO;2-S; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; Nakopoulou L, 1997, PATHOL RES PRACT, V193, P299; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; Rubin BP, 2001, CANCER RES, V61, P8118; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; SPEICHER MR, 1994, AM J PATHOL, V145, P356; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Takahashi M, 2001, P NATL ACAD SCI USA, V98, P9754, DOI 10.1073/pnas.171209998; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Tuveson DA, 2001, ONCOGENE, V20, P5054, DOI 10.1038/sj.onc.1204704; Wang WL, 2000, ONCOGENE, V19, P3521, DOI 10.1038/sj.onc.1203698; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	29	131	139	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 13	2003	22	6					847	852		10.1038/sj.onc.1206153	http://dx.doi.org/10.1038/sj.onc.1206153			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584564				2022-12-17	WOS:000180864300007
J	Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR				Rippin, TM; Bykov, VJN; Freund, SMV; Selivanova, G; Wiman, KG; Fersht, AR			Characterization of the p53-rescue drug CP-31398 in vitro and in living cells	ONCOGENE			English	Article						tumour suppressor; DNA binding; stability; NMR	P53 CORE DOMAIN; DNA-BINDING; RESCUE; MUTATIONS	The Pfizer compound CP-31398 has been reported to stabilize the core domain of the tumour suppressor p53 in vitro and be an effective anti-cancer drug by virtue of rescuing destabilized mutants of p53. We did not detect any interaction between the p53 core domain and CP-31398 in vitro by a wide range of quantitative biophysical techniques over a wide range of conditions. CP-31398 did not stabilize p53 in our experiments. However, we found that CP-31398 intercalated with DNA and also altered and destabilized the DNA-p53 core domain complex. We analysed by NMR TROSY the interaction of the domain with a DNA oligomer and identified the changes in the complex on the binding of CP-31398. CP-31398 also decreased sequence-specific DNA binding of wild-type p53 and His-273 mutant p53. CP-31398 had a non-specific toxic effect independent of mutant p53 expression in several cell lines carrying Tet-regulated mutant p53. CP-31398 caused a small increase in MDM-2 expression and a more pronounced p53-independent increase in Bax expression. CP-31398 did, however, induce the PAb1620 epitope (characteristic of native p53) in cells expressing His-175 mutant p53. This was prevented by cycloheximide, suggesting that,my stabilizing action of CP-31398 would have to be on newly synthesized p53. One of the unstable mutants that was reported to have been rescued by CP-31398, R249S, does not bind DNA when folded at lower temperatures.	Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England; Karolinska Hosp, CCK, Karolinska Inst, Dept Pathol Oncol, SE-17176 Stockholm, Sweden; Cambridge Ctr Prot Engn, MRC Ctr, Cambridge CB2 2QH, England	University of Cambridge; Karolinska Institutet; Karolinska University Hospital; MRC Laboratory Molecular Biology; University of Cambridge	Fersht, AR (corresponding author), Univ Cambridge, Chem Lab, Hills Rd, Cambridge CB2 2QH, England.	arf10@cam.ac.uk	Fersht, Alan R/B-2189-2008; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Nakade Bykov, Vladimir/0000-0002-7199-8942; Selivanova, Galina/0000-0002-8698-4332				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bullock AN, 2000, ONCOGENE, V19, P1245, DOI 10.1038/sj.onc.1203434; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jayaraman L, 1997, METHOD ENZYMOL, V283, P245; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE W, 1994, STRUCT BIOL, V1, P877; Nikolova PV, 2000, EMBO J, V19, P370, DOI 10.1093/emboj/19.3.370; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Prives C, 1999, J PATHOL, V187, P112; Selivanova G, 1996, NUCLEIC ACIDS RES, V24, P3560, DOI 10.1093/nar/24.18.3560; Wong KB, 1999, P NATL ACAD SCI USA, V96, P8438, DOI 10.1073/pnas.96.15.8438	15	131	141	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2002	21	14					2119	2129		10.1038/sj.onc.1205362	http://dx.doi.org/10.1038/sj.onc.1205362			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	533XJ	11948395				2022-12-17	WOS:000174555300001
J	Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP				Mullan, PB; Quinn, JE; Gilmore, PM; McWilliams, S; Andrews, H; Gervin, C; McCabe, N; McKenna, S; White, P; Song, YH; Maheswaran, S; Liu, E; Haber, DA; Johnston, PG; Harkin, DP			BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents	ONCOGENE			English	Article						BRCA1; GADD45; antimicrotubule agents; G2/M arrest; cell death	TRANSCRIPTION-COUPLED REPAIR; RETRACTED ARTICLE. SEE; DNA-DAMAGE RESPONSE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; INDUCTION; INSTABILITY; CENTROSOME; CHECKPOINT	BRCA1 is a tumour suppressor gene implicated in the predisposition to early onset breast and ovarian cancer. We have generated cell lines with inducible expression of BRCA1 to evaluate its role in mediating the cellular response to various chemotherapeutic drugs commonly used in the treatment of breast and ovarian cancer. Induction of BRCA1 in the presence of Taxol and Vincristine resulted in a dramatic increase in cell death; an effect that was preceded by an acute arrest at the G2/M phase of the cell cycle and which correlated with BRCA1 mediated induction of GADD45. A proportion of the arrested cells were blocked in mitosis suggesting activation of both a G2 and a mitotic spindle checkpoint. In contrast, no specific interaction was observed between BRCA1 induction and treatment of cells with a range of DNA damaging agents including Cisplatin and Adriamycin. Inducible expression of GADD45 in the presence of Taxol induced both G2 and mitotic arrest in these cells consistent with a role for GADD45 in contributing to these effects. Our results support a role for both BRCA1 and GADD45 in selectively regulating a G2/M checkpoint in response to antimicrotubule agents and raise the possibility that their expression levels in cells may contribute to the toxicity observed with these compounds.	Queens Univ Belfast, Canc Res Ctr, Dept Oncol, Belfast BT9 7AB, Antrim, North Ireland; Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Pediat Surg, Boston, MA 02114 USA; NIH, Div Clin Sci, Bethesda, MD 20892 USA	Queens University Belfast; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA	Harkin, DP (corresponding author), Queens Univ Belfast, Belfast City Hosp, Canc Res Ctr, Dept Oncol, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk	Liu, Edison/C-4141-2008	Song, Young-Han/0000-0002-0758-3654	Breast Cancer Now [2000:119] Funding Source: Medline	Breast Cancer Now		Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Dumontet C, 1999, J CLIN ONCOL, V17, P1061, DOI 10.1200/JCO.1999.17.3.1061; Futamura M, 2000, CANCER RES, V60, P1531; GAYTHER SA, 1998, NEOPLASIA, V4, P365; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haber D, 2000, LANCET, V355, P2090, DOI 10.1016/S0140-6736(00)02371-0; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Larson JS, 1997, CANCER RES, V57, P3351; Leadon SA, 1997, CANCER RES, V57, P3784; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Schmidt M, 2000, ONCOGENE, V19, P2423, DOI 10.1038/sj.onc.1203546; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	131	141	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6123	6131		10.1038/sj.onc.1204712	http://dx.doi.org/10.1038/sj.onc.1204712			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593420				2022-12-17	WOS:000171206300003
J	Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E				Rozovskaia, T; Feinstein, E; Mor, O; Foa, R; Blechman, J; Nakamura, T; Croce, CM; Cimino, G; Canaani, E			Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality	ONCOGENE			English	Article						Meis1; HoxA9; acute lymphocytic leukemias	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; CHROMOSOME-TRANSLOCATION; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; FUSION; CELLS; HRX; T(7-11)(P15-P15)	Rearrangements of the human ALL-1 gene are frequently encountered in acute lymphocytic leukemias (ALL) and acute myeloid leukemias (AML), These rearrangements are mostly due to chromosome translocations and result in production of chimeric proteins composed of the N-terminal fragment of ALL-1 and the C-terminal segments of the partner proteins. The most common chromosome translocation involving ALL-I is the t(4:11) associated with ALL. ALL-1 is the human homologue of Drosophila trithorax and directly activates transcription of multiple Hox genes. A preliminary DNA microarray screen indicated that the Meis1, HoxA9 and AC133 genes were overexpressed in ALLs with t(4:11), compared to ALLs with very similar phenotype but without the chromosomal abnormality. These genes, as well as additional five Hox genes, were subjected to comprehensive semi-quantitative or quantitative RT-PCR analysis in 57 primary ALL and AML tumors. Meis1 and HoxA9 were found expressed in 13/14 of ALLs with the t(4:11) and in 8/8 of AMLs with ALL-1 rearrangements. The two genes were not consistently transcribed in other types of ALL, AC133 was transcribed in 13/14 of ALLs with t(4:11), but in only 4/8 of AMLs with ALL-1 rearrangements. HoxA10 was expressed in most leukemias with ALL-1 alterations, but was also transcribed in PrePreB CD10(-) ALLs lacking the t(4 : 11). Expression of HoxA5, HoxA7, HoxC8 and HoxC10 did not correlate with ALL-1 rearrangements. Coexpression of Meis1 and HoxA9, overexpression of HoxA10, and overexpression or fusion of HoxA9 were previously implicated in certain acute myeloid leukemias in mice and humans. The present work suggests that upregulation of Meis1, HoxA9, and possibly HoxA10 might also play a role in pathogenesis of acute lymphocytic and acute myeloid leukemias associated with ALL-1 fusions.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Philadelphia, PA 19107 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ouark Biotech Inc, Pleasanton, CA USA; Univ La Sapienza, Dept Human Biopathol, I-00161 Rome, Italy	Jefferson University; Weizmann Institute of Science; Sapienza University Rome	Canaani, E (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, BLSB, Room 608,233 S 10th St, Philadelphia, PA 19107 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; CIMINO, Giuseppe/0000-0002-7781-0816	NATIONAL CANCER INSTITUTE [P01CA050507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afonja O., 1997, Blood, V90, p67A; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Buhring HJ, 1999, BLOOD, V94, P832, DOI 10.1182/blood.V94.2.832.414a50_832_833; CHEN CS, 1993, BLOOD, V81, P2386; CIMINO G, 1995, LEUKEMIA, V9, P391; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; GRIESINGER F, 1994, LEUKEMIA, V8, P542; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Hanson RD, 1999, P NATL ACAD SCI USA, V96, P14372, DOI 10.1073/pnas.96.25.14372; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOFFMAN R, 2000, HEMATOLOGY BASIC PRI; HUNGER SP, 1993, BLOOD, V81, P3197; Johansson B, 1998, LEUKEMIA, V12, P779, DOI 10.1038/sj.leu.2401012; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Lee G, 1999, WINTROBES CLIN HEMAT; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PUI CH, 1991, BLOOD, V77, P440; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; Rozovskaia T, 1999, MOL CELL BIOL, V19, P6441; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; Schnabel CA, 2000, ONCOGENE, V19, P608, DOI 10.1038/sj.onc.1203371; Shen WF, 1999, MOL CELL BIOL, V19, P3051; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Tillib S, 1999, MOL CELL BIOL, V19, P5189; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	39	131	138	0	7	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 15	2001	20	7					874	878		10.1038/sj.onc.1204174	http://dx.doi.org/10.1038/sj.onc.1204174			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	401JL	11314021				2022-12-17	WOS:000166924400011
J	Fitzgerald, K; Harrington, A; Leder, P				Fitzgerald, K; Harrington, A; Leder, P			Ras pathway signals are required for notch-mediated oncogenesis	ONCOGENE			English	Article						Notch; Ras; transformation; compound; inhibition	PROTEIN-KINASE-C; DEVELOPING DROSOPHILA EYE; BREAST-CANCER; NEOPLASTIC TRANSFORMATION; SELECTIVE INHIBITOR; IN-VIVO; EXPRESSION; MAMMARY; ELEGANS; TRANSDUCTION	The Notch genes of C, elegans, Drosophila melanogaster and vertebrates encode receptors responsible for cell fate decisions during development. These Notch receptors and their ligands, Delta and Jagged, have been implicated in several human diseases. Truncated, constitutively active mutant forms of the Notch receptor appear to be involved in human T-cell leukemia, mammary carcinomas in mice, and a tumorous germline phenotype in C, elegans. Since activated Notch induces solitary tumors in transgenic mice, it is highly likely that collaborating genetic events are required for tumor formation, We have assessed four signal transduction pathways to determine which might play additional roles in malignant transformation in concert with activated Notch4. Our results suggest that transformation by Notch does not, as might have been expected, depend on the Src-like kinases Lck and Fyn, nor upon signals from protein kinase A and C (PKA, PKC). Rather, transformation by Notch requires active signals from the Erk/MAP kinase and PI-3 kinase pathways downstream of Ras.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.							Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Davidson N E, 1996, Cancer Treat Res, V83, P91; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HENNIPMAN A, 1989, CANCER RES, V49, P516; JACOBS C, 1983, CANCER RES, V43, P1696; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Joutel A, 1998, SEMIN CELL DEV BIOL, V9, P619, DOI 10.1006/scdb.1998.0261; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; Levitan D, 1998, DEVELOPMENT, V125, P3101; LIEBER T, 1993, GENE DEV, V7, P1949, DOI 10.1101/gad.7.10.1949; Matsuo T, 1997, DEVELOPMENT, V124, P2671; Miller DT, 1998, DEVELOPMENT, V125, P2327; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; NISHIZUKA Y, 1988, ACTA HAEMATOL JAPON, V51, P1321; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Ordentlich P, 1998, MOL CELL BIOL, V18, P2230, DOI 10.1128/MCB.18.4.2230; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Price JV, 1997, GENETICS, V147, P1139; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Tanyi J, 1999, Pathol Oncol Res, V5, P90, DOI 10.1053/paor.1999.0201; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612; WILKINSON HA, 1995, GENETICS, V141, P513	42	131	134	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 31	2000	19	37					4191	4198		10.1038/sj.onc.1203766	http://dx.doi.org/10.1038/sj.onc.1203766			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980592				2022-12-17	WOS:000089032900001
J	Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS				Shammas, MA; Simmons, CG; Corey, DR; Reis, RJS			Telomerase inhibition by peptide nucleic acids reverses 'immortality' of transformed human cells	ONCOGENE			English	Article						telomere; telomerase; peptide nucleic acid; cell transformation; immortality; cancer	HUMAN-DIPLOID FIBROBLASTS; LARGE T-ANTIGEN; SV40-MEDIATED IMMORTALIZATION; CELLULAR SENESCENCE; QUADRUPLEX DNA; LIFE-SPAN; RNA; CANCER; IDENTIFICATION; RECOMBINATION	Telomerase activity, the ability to add telomeric repeats to the ends of chromosomes, has been detected in most immortal cell lines including tumor cells, but is low or absent in most diploid, mortal cells such as those of somatic tissues. Peptide nucleic acids (PNAs), analogs of DNA or RNA which bind to complementary nucleic acids with very high affinity, were co-electroporated into immortal human cells along with a selectable plasmid, Introduction of PNAs inverse-complementary to telomerase RNA effectively inhibited telomerase activity in intact cells, shortened telomeres, reduced colony size, and arrested cell proliferation after a lag period of 5-30 cell generations, consistent with suppression of their 'immortality', Electroporation of selection plasmid alone had no effect, while PNAs of altered sequence were markedly less effective in each assay. This constitutes the first demonstration of cell growth arrest through telomerase inhibition, upon treatment of intact cells with an exogenous compound which call be efficiently delivered in vivo, The phenotype of telomerase-inhibited transformed cells differs from senescence of normal diploid fibroblasts, but rather resembles the crisis state of incompletely transformed cells.	Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA; John L McClellan Mem Vet Adm Med Ctr, Little Rock, AR 72205 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Reis, RJS (corresponding author), Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA.		Shmookler Reis, Robert/C-4112-2009					Banga SS, 1997, ONCOGENE, V14, P313, DOI 10.1038/sj.onc.1200842; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CACHIANES G, 1993, BIOTECHNIQUES, V15, P255; Cheng RZ, 1997, EXP CELL RES, V234, P300, DOI 10.1006/excr.1997.3649; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRISTOFALO VJ, 1973, EXP CELL RES, V76, P419, DOI 10.1016/0014-4827(73)90394-7; DEMIDOV VV, 1994, BIOCHEM PHARMACOL, V48, P1310, DOI 10.1016/0006-2952(94)90171-6; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; Fedoroff OY, 1998, BIOCHEMISTRY-US, V37, P12367, DOI 10.1021/bi981330n; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fletcher TM, 1996, BIOCHEMISTRY-US, V35, P15611, DOI 10.1021/bi961228v; Hamilton SE, 1997, BIOCHEMISTRY-US, V36, P11873, DOI 10.1021/bi970438k; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; Hayflick L, 1977, HDB BIOL AGING, P159; Holt Shawn E., 1996, Methods in Cell Science, V18, P237, DOI 10.1007/BF00132889; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kondo S, 1998, FASEB J, V12, P801, DOI 10.1096/fasebj.12.10.801; Kondo S, 1998, ONCOGENE, V16, P3323, DOI 10.1038/sj.onc.1201885; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; MARTIN GM, 1970, LAB INVEST, V23, P86; MOERMAN EJ, 1986, METHODS DIABETES RES, V2, P283; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Norton JC, 1996, NAT BIOTECHNOL, V14, P615, DOI 10.1038/nbt0596-615; NORTON JC, 1995, BIOORGAN MED CHEM, V3, P437, DOI 10.1016/0968-0896(95)00033-D; Ozer HL, 1996, EXP GERONTOL, V31, P303, DOI 10.1016/0531-5565(95)00024-0; Pai RB, 1998, CANCER RES, V58, P1909; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Pitts AE, 1998, P NATL ACAD SCI USA, V95, P11549, DOI 10.1073/pnas.95.20.11549; Pooga M, 1998, NAT BIOTECHNOL, V16, P857, DOI 10.1038/nbt0998-857; REID LH, 1991, MOL CELL BIOL, V11, P2769, DOI 10.1128/MCB.11.5.2769; REIS RJS, 1983, J BIOL CHEM, V258, P9078; Rubelj I, 1997, J GERONTOL A-BIOL, V52, pB229, DOI 10.1093/gerona/52A.5.B229; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Shammas MA, 1997, GENETICS, V146, P1417; Sharma S, 1997, ANN ONCOL, V8, P1063, DOI 10.1023/A:1008206420505; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; Simmons CG, 1997, BIOORG MED CHEM LETT, V7, P3001, DOI 10.1016/S0960-894X(97)10136-6; SMITH JR, 1978, P NATL ACAD SCI USA, V75, P1353, DOI 10.1073/pnas.75.3.1353; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; Wheelhouse RT, 1998, J AM CHEM SOC, V120, P3261, DOI 10.1021/ja973792e; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Xia SJJ, 1996, MUTAT RES-DNA REPAIR, V364, P1, DOI 10.1016/0921-8777(96)00015-8; Xia SJJ, 1997, MOL CELL BIOL, V17, P7151, DOI 10.1128/MCB.17.12.7151; Zakian VA, 1997, CELL, V91, P1, DOI 10.1016/S0092-8674(01)80001-5	52	131	143	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	1999	18	46					6191	6200		10.1038/sj.onc.1203069	http://dx.doi.org/10.1038/sj.onc.1203069			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597217				2022-12-17	WOS:000083934100002
J	Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P				Hall-Jackson, CA; Goedert, M; Hedge, P; Cohen, P			Effect of SB 203580 on the activity of c-Raf in vitro and in vivo	ONCOGENE			English	Article						c-Raf; MAP kinase; SB203580; EGF; SAPK2; p38	P38 MAP KINASE; PROTEIN-KINASE; SUBSTRATE-SPECIFICITY; CELLULAR STRESSES; PLASMA-MEMBRANE; SAP KINASES; ACTIVATION; INHIBITOR; INSULIN; INTERLEUKIN-1	The inhibition of SAPK2a/p38 (a mitogen activated protein (MAP) kinase family member) by SE 203580 depends on the presence of threonine at residue 106. Nearly all other protein kinases are insensitive to this drug because a more bulky residue occupies this site (Eyers et al,, 1998), Raf is one of the few protein kinases that possesses threonine at this position, and we show that SE 203580 inhibits c-Raf with an IC50 of 2 mu M in vitro. However, SB 203580 does not suppress either growth factor or phorbol ester-induced activation of the classical MAP kinase cascade in mammalian cells. One of the reasons for this is that SE 203580 also triggers a remarkable activation of c-Raf in vivo (when measured in the absence of the drug). The SB203580-induced activation of c-Raf occurs without any increase in the GTP-loading of Ras, is not prevented by inhibitors of the MAPK cascade, protein kinase C or phosphatidylinositide 3-kinase, and is not triggered by the binding of this drug to SAPK2a/p38. The paradoxical activation of c-Raf by SE 203580 (and by another structurally unrelated c-Raf inhibitor) suggests that inhibitors of the kinase activity of c-Raf may not be effective as anti-cancer drugs.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Zeneca Pharmaceut, Macclesfield SK10 4TG, Cheshire, England	University of Dundee; MRC Laboratory Molecular Biology	Hall-Jackson, CA (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.							ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; Alessi DR, 1997, FEBS LETT, V402, P121, DOI 10.1016/S0014-5793(96)01510-4; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Badger AM, 1996, J PHARMACOL EXP THER, V279, P1453; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; COHEN P, 1994, BIOCHEM J, V303, P21; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Doza YN, 1998, ONCOGENE, V17, P19, DOI 10.1038/sj.onc.1202168; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOULD GW, 1995, BIOCHEM J, V311, P735, DOI 10.1042/bj3110735; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; LAW NM, 1996, EMERGING DRUGS PROSP, P241; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Tong L, 1997, NAT STRUCT BIOL, V4, P311, DOI 10.1038/nsb0497-311; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wilson KP, 1997, CHEM BIOL, V4, P423, DOI 10.1016/S1074-5521(97)90194-0; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	30	131	135	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2047	2054		10.1038/sj.onc.1202603	http://dx.doi.org/10.1038/sj.onc.1202603			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321729				2022-12-17	WOS:000079346200002
J	Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P				Blattner, C; Tobiasch, E; Litfen, M; Rahmsdorf, HJ; Herrlich, P			DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation	ONCOGENE			English	Article						ultraviolet irradiation; gamma irradiation; actinomycin D; p53 stabilization	CASEIN KINASE-II; TUMOR-SUPPRESSOR PROTEIN; ALTERNATIVELY SPLICED P53; FULL-LENGTH P53; IN-VIVO; BINDING FUNCTION; NUCLEAR ACCUMULATION; TERMINAL DOMAIN; CELL-CYCLE; RETROVIRAL VECTORS	Abundance and activity of p53 are predominantly regulated posttranslationally, Structural disturbance in transcribed genes induced by radiation, e.g. DNA damage, or by transcriptional inhibitors cause p53 protein stabilization by a yet unknown mechanism. Using stable and transient transfections for the analysis of p53 mutant proteins, we have ruled out a role in stabilization by UV, gamma irradiation or actinomycin C for the following putative phosphorylation sites in the p53 protein: serines 6, 9, 15, 33, 315 and 392, and threonine 18. By double mutation combinations of phosphorylations were also ruled out; 6,9; 15,18; 15,37, These mutations eliminate modifications by casein kinases I and II, DNA-PK, ATM, CDK and JNK, Also the 30 carboxyterminal amino acids are not required for induced p53 stabilization. Thus neither phosphorylations of individual amino acids nor interactions of the carboxyterminus of p53 with cellular macromolecules appear to play a role in the stabilization process. The only single prerequisite for induced stabilization of p53 is its prior destabilization by Mdm2, However, the level of active Mdm2 must be controlled carefully: overexpression of Mdm2 inhibits UV induced p53 stabilization.	Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany	Helmholtz Association; Karlsruhe Institute of Technology	Herrlich, P (corresponding author), Univ Karlsruhe, Forschungszentrum Karlsruhe, Genet Inst, POB 3640, D-76021 Karlsruhe, Germany.		Blattner, Christine/ABI-2152-2020; Blattner, Christine/H-2105-2013	Blattner, Christine/0000-0002-7250-5273; Blattner, Christine/0000-0002-7250-5273				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BLATTNER C, 1994, ENVIRON MOL MUTAGEN, V24, P3, DOI 10.1002/em.2850240103; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Candeias SM, 1997, BIOCHIMIE, V79, P607, DOI 10.1016/S0300-9084(97)82010-X; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen LH, 1998, P NATL ACAD SCI USA, V95, P195, DOI 10.1073/pnas.95.1.195; COHEN PA, 1998, IN PRESS ONCOGENE; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; Fried LM, 1996, P NATL ACAD SCI USA, V93, P13825, DOI 10.1073/pnas.93.24.13825; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang LC, 1996, CANCER RES, V56, P2940; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1996, CANCER RES, V56, P2649; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; Molinari M, 1996, ONCOGENE, V13, P2077; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; Okorokov AL, 1997, EMBO J, V16, P6008, DOI 10.1093/emboj/16.19.6008; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; RENZING J, 1995, ONCOGENE, V10, P1865; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Wagner P, 1998, ONCOGENE, V16, P105, DOI 10.1038/sj.onc.1201510; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; Youmell M, 1998, BIOCHEM BIOPH RES CO, V245, P514, DOI 10.1006/bbrc.1998.8471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	77	131	135	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	1999	18	9					1723	1732		10.1038/sj.onc.1202480	http://dx.doi.org/10.1038/sj.onc.1202480			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	174GB	10208433				2022-12-17	WOS:000079025000007
J	Venturini, L; You, J; Stadler, M; Galien, R; Lallemand, VR; Koken, MHM; Mattei, MG; Ganser, A; Chambon, P; Losson, R; de The, H				Venturini, L; You, J; Stadler, M; Galien, R; Lallemand, VR; Koken, MHM; Mattei, MG; Ganser, A; Chambon, P; Losson, R; de The, H			TIF1 gamma, a novel member of the transcriptional intermediary factor 1 family	ONCOGENE			English	Article						TIF1; transcriptional control; RBCC; PHD; bromodomain	ACUTE PROMYELOCYTIC LEUKEMIA; NUCLEAR RECEPTOR COACTIVATORS; ACTIVATION FUNCTION AF-2; HUMAN ESTROGEN-RECEPTOR; ZINC-FINGER PROTEINS; RING FINGER; REPRESSOR DOMAIN; GENE; EXPRESSION; CELLS	We report the cloning and characterization of a novel member of the Transcriptional Intermediary Factor 1 (TIF1) gene family, human TIF1 gamma, Similar to TIF1 alpha and TIF1 beta, the structure of TIF1 beta is characterized by multiple domains: RING finger, B boxes, Coiled coil, PHD/TTC, and bromodomain, Although structurally related to TIF1 alpha and TIF1 beta, TIF1 gamma presents several functional differences. In contrast to TIF1 alpha, but like TIF1 beta, TIF1 gamma does not interact with nuclear receptors in yeast two-hybrid or GST pull-down assays and does not interfere with retinoic acid response in transfected mammalian cells. Whereas TIF1 alpha and TIF1 beta were previously found to interact with the KRAB silencing domain of KOX1 and with the HP1 alpha, MOD1 (HP1 beta) and MOD2 (HP1 gamma) heterochromatinic proteins, suggesting that they may participate in a complex involved in heterochromatin-induced gene repression, TIF1 gamma does not interact with either the KRAB domain of KOX1 or the HP1 proteins. Nevertheless, TIF1 gamma, like TIF1 alpha and TIF1 beta, exhibits a strong silencing activity when tethered to a promoter. Since deletion of a novel motif unique to the three TIF1 proteins, called TIF1 signature sequence (TSS), abrogates transcriptional repression by TIF1 gamma, this motif likely participates in TIF1 dependent repression.	Hop St Louis, CNRS, UPR 9051, Lab Associe Comite Paris de la Ligue Canc, F-75010 Paris, France; Hannover Med Sch, Abt Hamatol & Onkol, D-30625 Hannover, Germany; Univ Strasbourg 1, Inst Genet Biol Mol, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France; CU Strasbourg, Strasbourg, France; INSERM U406, Marseille, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Hannover Medical School; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm)	de The, H (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 20 N Pine St, Baltimore, MD 21201 USA.		koken, marcel/N-1349-2019; koken, marcel/J-8154-2012	koken, marcel/0000-0002-0839-0125				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELLINI M, 1995, J CELL BIOL, V131, P563, DOI 10.1083/jcb.131.3.563; Boddy MN, 1997, J CELL SCI, V110, P2197; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DANIEL MT, 1993, BLOOD, V82, P1858; Dent AL, 1996, BLOOD, V88, P1423, DOI 10.1182/blood.V88.4.1423.bloodjournal8841423; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRIGNANI F, 1994, BLOOD, V83, P10; Grimwade D, 1997, CURR TOP MICROBIOL, V220, P81; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Kim SS, 1996, P NATL ACAD SCI USA, V93, P15299, DOI 10.1073/pnas.93.26.15299; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LeDouarin B, 1997, BIOCHEM SOC T, V25, P605, DOI 10.1042/bst0250605; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LI XX, 1994, EXP CELL RES, V213, P473, DOI 10.1006/excr.1994.1225; Losson R, 1997, BIOL CHEM, V378, P579; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Mitelman F, 1993, HUMAN GENE MAPPING, P773; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; Moosmann P, 1997, BIOL CHEM, V378, P669, DOI 10.1515/bchm.1997.378.7.669; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; QUIGNON F, 1997, BIOCHIM BIOPHYS ACTA, V1333, P753; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; Sambrook J., 1989, MOL CLONING; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	48	131	137	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	1999	18	5					1209	1217		10.1038/sj.onc.1202655	http://dx.doi.org/10.1038/sj.onc.1202655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FU	10022127				2022-12-17	WOS:000078510700010
J	Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P				Porte, D; Tuckermann, J; Becker, M; Baumann, B; Teurich, S; Higgins, T; Owen, MJ; Schorpp-Kistner, M; Angel, P			Both AP-1 and Cbfa1-like factors are required for the induction of interstitial collagenase by parathyroid hormone	ONCOGENE			English	Article						AP-1; collagenase; parathyroid hormone; osteoblast; Cbfa; bone development; Runt	ACUTE MYELOID-LEUKEMIA; HUMAN MATRIX METALLOPROTEINASE; RAT OSTEOBLASTIC CELLS; C-FOS GENE; TARGETED DISRUPTION; POLYOMAVIRUS ENHANCER; MOLECULAR-CLONING; PROMOTER ACTIVITY; OSTEOCALCIN GENE; MESSENGER-RNA	PTH is a major regulator of calcium homeostasis by mobilizing calcium through bone resorption, We show that the expression of collagenase-3 (MMP-13), a member of the family of matrix metalloproteinases, required for the cleavage of collagens in the bone, is increased upon PTH injection in mice. A cis-acting element in the collagenase-3 promoter was identified which, together with AP-1, is required for induction by PTH, This element contains CCACA motifs which are required for binding of the 65 kDa osteoblast-specific splice variant of Cbfa1. Introduction of mutations in this binding site that interfere with protein interaction also eliminates PTH inducibilty and transactivation by Cbfa/Runt proteins, While DNA binding activity of AP-1 is increased upon PTH treatment, high basal level of Cbfa/ Runt binding activity is detectable in untreated cells which is not further increased by PTH, suggesting that AP-1 and Cbfa1 contribute to transcriptional activation through different mechanisms, In agreement with the critical role of both proteins defined in tissue culture cells, expression of collagenase-3 is reduced in mice lacking c-fos and is completely absent in cbfa1(-/-)embryos. These data provide the first evidence for a critical role of Cbfa1, a major regulator of bone de development, in PTH-dependent processes such as bone resorption.	Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, D-69120 Heidelberg, Germany; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany; Imperial Canc Res Fund, Lincolns Inn Fields, London WC2A 3PX, England	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; Cancer Research UK	Angel, P (corresponding author), Deutsch Krebsforschungszentrum, Abt Signaltransdukt & Wachstumskontrolle, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAE SC, 1993, ONCOGENE, V8, P809; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLOHISY JC, 1992, MOL ENDOCRINOL, V6, P1834, DOI 10.1210/me.6.11.1834; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Evans DB, 1996, J BONE MINER RES, V11, P1066; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GACK S, 1994, J BIOL CHEM, V269, P10363; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HEATH JK, 1984, BIOCHIM BIOPHYS ACTA, V802, P151, DOI 10.1016/0304-4165(84)90046-1; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg Henry M., 1996, P68; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MATTOT V, 1995, J CELL SCI, V108, P529; MINDEN A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pF85; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Pendas AM, 1997, J BIOL CHEM, V272, P4281, DOI 10.1074/jbc.272.7.4281; Pollock JH, 1996, J BONE MINER RES, V11, P754; QUINN CO, 1990, J BIOL CHEM, V265, P22342; Rajakumar RA, 1996, MOL ENDOCRINOL, V10, P867, DOI 10.1210/me.10.7.867; SATAKE M, 1988, ONCOGENE, V3, P69; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCOTT DK, 1992, MOL ENDOCRINOL, V6, P2153, DOI 10.1210/me.6.12.2153; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Yang RJ, 1996, J BIOL CHEM, V271, P29839, DOI 10.1074/jbc.271.47.29839; Yu XP, 1997, ENDOCRINOLOGY, V138, P3085, DOI 10.1210/en.138.8.3085; Zaiman AL, 1996, J VIROL, V70, P5618, DOI 10.1128/JVI.70.8.5618-5629.1996	54	131	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					667	678		10.1038/sj.onc.1202333	http://dx.doi.org/10.1038/sj.onc.1202333			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989817				2022-12-17	WOS:000078394400012
J	Canman, CE; Lim, DS				Canman, CE; Lim, DS			The role of ATM in DNA damage responses and cancer	ONCOGENE			English	Review						ataxia telangiectasia; cell cycle; DNA damage; apoptosis	DEPENDENT PROTEIN-KINASE; ATAXIA-TELANGIECTASIA CELLS; RADIATION-INDUCED PHOSPHORYLATION; CYCLE CHECKPOINT PATHWAY; P53-MEDIATED G(1) ARREST; DOUBLE-STRAND BREAKS; ABL TYROSINE KINASE; IONIZING-RADIATION; C-ABL; SACCHAROMYCES-CEREVISIAE	Ataxia-telangiectasia (AT) is a complex, autosomal recessive disorder characterized by cerebellar ataxia, believed to result from progressive neurodegeneration, and telangiectasia, dilation of blood vessels within the eyes and parts of the facial region. AT patients suffer from recurrent infections caused by both cellular and humoral immune deficiencies and as a population, are significantly predisposed to cancer, particularly lymphomas and leukemias. Early attempts at treating these malignancies with radiotherapy revealed another hallmark of AT, a profound hypersensitivity to the cytotoxic effects of ionizing radiation (IR) which is recapitulated at the cellular level in culture. Predisposition to cancer and radiosensitivity observed in AT has been linked to chromosomal instability, abnormalities in genetic recombination, and defective signaling to programmed cell death and several cell cycle checkpoints activated by DNA damage. These earlier observations predicted that the gene defective in AT may encode a protein which plays a crucial role in sensing DNA damage and transducing signals that promote cell survival. Through the combined efforts of linkage analysis and positional cloning, a single gene was identified on chromosome 11q22-33 by Shiloh and colleagues and was found to be mutated in all four complementation groups previously characterized in cell lines derived from AT patients (Savitsky et al,, 1995a,b), The predicted ATM gene product shows considerable homology to an emerging family of high molecular weight, phosphatidylinositol -3 kinase (PI-3 K)-related proteins involved in eukaryotic cell cycle control, DNA repair, and DNA recombination (Zakian, 1995), This landmark discovery has triggered a resurgence of biochemical and genetic studies focusing on ATM function which has brought forth insights regarding ATM activity and its role in DNA damage signaling.	St Jude Childrens Res Hosp, Dept Hematol & Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Canman, CE (corresponding author), St Jude Childrens Res Hosp, Dept Hematol & Oncol, 332 N Lauderdale St D-1034, Memphis, TN 38105 USA.		Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555; , Christine/0000-0001-8892-7430				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Bentley NJ, 1996, EMBO J, V15, P6641, DOI 10.1002/j.1460-2075.1996.tb01054.x; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Canman C E, 1997, Adv Pharmacol, V41, P429, DOI 10.1016/S1054-3589(08)61068-6; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CARDENAS ME, 1995, EMBO J, V5892, P5907; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Cheng XB, 1996, RADIOTHER ONCOL, V39, P43, DOI 10.1016/0167-8140(96)01712-4; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Concannon P, 1997, HUM MUTAT, V10, P100, DOI 10.1002/(SICI)1098-1004(1997)10:2<100::AID-HUMU2>3.0.CO;2-O; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duchaud E, 1996, CANCER RES, V56, P1400; DULLIC V, 1994, CELL, V76, P1013; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Enokido Y, 1996, EUR J NEUROSCI, V8, P1812, DOI 10.1111/j.1460-9568.1996.tb01325.x; Featherstone C, 1998, CURR BIOL, V8, pR622, DOI 10.1016/S0960-9822(98)70392-6; Gabra H, 1996, CANCER RES, V56, P950; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOGA A, 1995, ONCOGENE, V11, P791; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; HAMPTON GM, 1994, CANCER RES, V54, P4586; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson SP, 1996, CANCER SURV, V28, P261; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Khanna KK, 1997, J BIOL CHEM, V272, P9489; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laake K, 1997, GENE CHROMOSOME CANC, V18, P175, DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.0.CO;2-Z; Lakin ND, 1996, ONCOGENE, V13, P2707; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P849; Luo CM, 1996, J BIOL CHEM, V271, P4497; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MCKINNON PJ, 1985, EUR J CELL BIOL, V39, P161; Metcalfe JA, 1996, NAT GENET, V13, P350, DOI 10.1038/ng0796-350; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MEYN MS, 1995, CANCER RES, V55, P5991; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Monaco C, 1997, GENOMICS, V46, P217, DOI 10.1006/geno.1997.5036; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, CANCER RES, V57, P3386; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NEGRINI M, 1995, CANCER RES, V55, P3003; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Niu HW, 1997, J BIOL CHEM, V272, P12634, DOI 10.1074/jbc.272.19.12634; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULES RS, 1995, CANCER RES, V55, P1763; Plug AW, 1997, NAT GENET, V17, P457, DOI 10.1038/ng1297-457; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; PURDIE CA, 1994, ONCOGENE, V9, P603; Rathmell WK, 1997, CANCER RES, V57, P68; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Telatar M, 1996, AM J HUM GENET, V59, P40; Uhrhammer Nancy, 1998, Cancer Research, V58, P3480; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; WALDMAN T, 1995, CANCER RES, V55, P5187; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; WESTPHAL CH, 1998, IN PRESS CANC RES; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WINQVIST R, 1995, CANCER RES, V55, P2660; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WOOD KA, 1995, J NEUROSCI, V15, P5851; Wright J, 1996, AM J HUM GENET, V59, P839; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; YAUN ZM, 1996, NATURE, V382, P272; Yavuzer U, 1998, GENE DEV, V12, P2188, DOI 10.1101/gad.12.14.2188; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	143	131	152	0	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 24	1998	17	25					3301	3308		10.1038/sj.onc.1202577	http://dx.doi.org/10.1038/sj.onc.1202577			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	157EW	9916992				2022-12-17	WOS:000078048200011
J	Whelan, RDH; Parker, PJ				Whelan, RDH; Parker, PJ			Loss of protein kinase C function induces an apoptotic response	ONCOGENE			English	Article						protein kinase C; dominant negative; apoptosis	PHORBOL ESTER RECEPTOR; DOWN-REGULATION; PERMISSIVE ACTIVATION; FLOW-CYTOMETRY; ISOTYPE-ALPHA; CELL-DEATH; PKC; DIFFERENTIATION; INVOLVEMENT; SUPPRESSION	A correlation has been observed between the dephosphorylation and downregulation of cPKC and the induction of apoptosis. This relationship is shown to be causal in COS cells where expression of dominant negative PKC alpha is shown to induce apoptosis. This response is rescued by co-expression of wild-type PKC alpha. The results demonstrate that PKC provides a survival signal that can be supplied by PKC alpha alone.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England	Cancer Research UK	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933				Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNANCIN F, 1997, IN PRESS J BIOL CHEM; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; Chmura SJ, 1996, CANCER RES, V56, P2711; DEKKER LV, 1992, FEBS LETT, V312, P195, DOI 10.1016/0014-5793(92)80934-9; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Emoto Y, 1996, BLOOD, V87, P1990; Freemerman AJ, 1996, MOL PHARMACOL, V49, P788; Geier A, 1996, CANCER INVEST, V14, P435, DOI 10.3109/07357909609018901; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KILEY S, 1990, J BIOL CHEM, V265, P15704; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Leszczynski D, 1996, LIFE SCI, V58, P599, DOI 10.1016/0024-3205(95)02329-1; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; Pongracz J, 1996, LEUKEMIA RES, V20, P319, DOI 10.1016/0145-2126(95)00074-7; Romanova LY, 1996, BIOCHEMISTRY-US, V35, P9900, DOI 10.1021/bi9525886; Rusnak JM, 1996, EXP CELL RES, V224, P189, DOI 10.1006/excr.1996.0127; RYVES WJ, 1991, FEBS LETT, V288, P5, DOI 10.1016/0014-5793(91)80989-G; Sakakura C, 1996, FEBS LETT, V379, P177, DOI 10.1016/0014-5793(95)01508-6; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Tchilian EZ, 1996, IMMUNOLOGY, V87, P566, DOI 10.1046/j.1365-2567.1996.515580.x; YOUNG S, 1988, EUR J BIOCHEM, V173, P247, DOI 10.1111/j.1432-1033.1988.tb13991.x; Zong ZP, 1996, BIOCHEM BIOPH RES CO, V219, P480, DOI 10.1006/bbrc.1996.0259	32	131	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					1939	1944		10.1038/sj.onc.1201725	http://dx.doi.org/10.1038/sj.onc.1201725			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591777				2022-12-17	WOS:000073079400005
J	deWinter, JP; Roelen, BAJ; tenDijke, P; vanderBurg, B; vandenEijndenvanRaaij, A				deWinter, JP; Roelen, BAJ; tenDijke, P; vanderBurg, B; vandenEijndenvanRaaij, A			DPC4 (SMAD4) mediates transforming growth factor-beta 1 (TGF-beta 1) induced growth inhibition and transcriptional response in breast tumour cells	ONCOGENE			English	Article						DPC4; Smad; TGF-beta; activin; tumour suppressor	MAMMARY EPITHELIAL-CELLS; FACTOR-BETA; CANCER-CELLS; EXPRESSION; RECEPTOR; ACTIVIN; RESPONSIVENESS; IDENTIFICATION; PROLIFERATION; ESTROGEN	A family of structurally related proteins homologous to the Drosophila mothers against dpp (MAD) gene product have been implicated in signal transduction by members of the TGF-beta superfamily, One of these MAD related proteins (DPC4) has been cloned as a candidate tumour suppressor in pancreas carcinomas, suggesting a role for DPC4 in growth regulation by TGF-beta related proteins, The involvement of DPC4 in TGF-beta 1 induced growth inhibition and transcriptional response is demonstrated here, by the introduction of DPC4 in the TGF-beta and activin insensitive breast tumour cell line MDA-MB-468, from which the DPC4 gene is deleted, Transfection of DPC4 in this cell line restores both growth inhibition and the induction of a TGF-beta sensitive reporter construct (3TPlux) by TGF-beta 1, In contrast, a DPC4 splice variant lacking amino acid residues 223-301 and cloned from another TGF-beta and activin resistant breast tumour cell line (MDA-MB-231), does not restore the induction of the 3TPlux reporter by TGF-beta 1, We also show that in this latter cell line activin resistance is partly due to the absence of a functional activin type IB receptor, These results indicate that DPC4 is part of the TGF-beta signalling cascade and mediates TGF-beta induced growth inhibition, Together with the deletion of DPC4 from pancreas carcinomas these results suggest a role for DPC4 as a tumour suppressor.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,NL-3584 CT UTRECHT,NETHERLANDS; LUDWIG INST CANC RES,S-75124 UPPSALA,SWEDEN	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Ludwig Institute for Cancer Research			Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				Attisano L, 1996, MOL CELL BIOL, V16, P1066; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; deWinter JP, 1996, EXP CELL RES, V224, P323, DOI 10.1006/excr.1996.0142; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Gucev ZS, 1996, CANCER RES, V56, P1545; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HOSOBUCHI M, 1989, IN VITRO CELL DEV B, V25, P705; JENG MH, 1993, MOL CELL ENDOCRINOL, V97, P115, DOI 10.1016/0303-7207(93)90217-8; JI HJ, 1994, J CELL BIOCHEM, V54, P332, DOI 10.1002/jcb.240540309; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; NAKAO A, IN PRESS J BIOL CHEM; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; ROELEN BAJ, 1994, DEV BIOL, V166, P716, DOI 10.1006/dbio.1994.1350; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; Schutte M, 1996, CANCER RES, V56, P2527; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SUN LZ, 1994, J BIOL CHEM, V269, P26449; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VANDENEIJNDENVANRAAIJ AJM, 1988, BIOCHEM BIOPH RES CO, V157, P16, DOI 10.1016/S0006-291X(88)80004-4; VANDENEIJNDENVANRAAIJ AJM, 1992, DEV BIOL, V154, P356, DOI 10.1016/0012-1606(92)90074-Q; VANDERBURG B, 1995, MOL CELL ENDOCRINOL, V112, P143, DOI 10.1016/0303-7207(95)03600-C; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	42	131	136	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1891	1899		10.1038/sj.onc.1201017	http://dx.doi.org/10.1038/sj.onc.1201017			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150356				2022-12-17	WOS:A1997WV80400002
J	Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM				Cortez, D; Stoica, G; Pierce, JH; Pendergast, AM			The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway	ONCOGENE			English	Article						BCR-ABL; apoptosis; Ras; tyrosine phosphorylation	HEMATOPOIETIC-CELLS; PC12 CELLS; TRANSFORMATION; DEATH; ONCOGENE; PROLIFERATION; PROTEIN	BCR-ABL is a deregulated tyrosine kinase that is expressed in Philadelphia chromosome (Ph(1)) positive human leukemias, When expressed in hematopoietic cells, BCR-ABL causes cytokine independent proliferation, induces tumorigenic growth and prevents apoptosis in response to cytokine deprivation or DNA damage, One mechanism by which BCR-ABL signals in cells is by activating the small guanine nucleotide binding protein Ras, BCR-ABL-transformed cells have constitutively high levels of active, GTP-bound Ras, Here we use 32D cells that inducibly express a dominant negative Ras protein to define the Ras requirements in BCR-ABL-transformed cells, Dominant negative Ras inhibits BCR-ABL-mediated Ras activation, and induces cell death by an apoptotic mechanism, Therefore, BCR-ABL inhibits apoptosis through activation of a Ras-dependent signaling pathway.	DUKE UNIV,MED CTR,DEPT MOL CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27710; GEORGETOWN UNIV,SCH MED,DEPT BIOCHEM,WASHINGTON,DC 20007; NIH,CELL & MOL BIOL LAB,BETHESDA,MD 20892	Duke University; Duke University; Georgetown University; National Institutes of Health (NIH) - USA				Pendergast, Ann Marie/0000-0002-1250-6880	NATIONAL CANCER INSTITUTE [R01CA061033] Funding Source: NIH RePORTER; NCI NIH HHS [CA61033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; MANDANAS RA, 1993, BLOOD, V82, P1838; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	23	131	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2589	2594						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000132				2022-12-17	WOS:A1996VZ65400008
J	Wolthuis, RMF; Bauer, B; vantVeer, LJ; deVriesSmits, AMM; Cool, RH; Spaargaren, M; Wittinghofer, A; Burgering, BMT; Bos, JL				Wolthuis, RMF; Bauer, B; vantVeer, LJ; deVriesSmits, AMM; Cool, RH; Spaargaren, M; Wittinghofer, A; Burgering, BMT; Bos, JL			RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein	ONCOGENE			English	Article						Rlf; Rap 1A; Ras; RalGDS; exchange factor; two-hybrid	NUCLEOTIDE DISSOCIATION STIMULATOR; RAS-P21 GTPASE; R-RAS; KINASE; INTERACTS; DOMAIN; ACTIVATION; RAF-1; IDENTIFICATION; RECOGNITION	The small GTPase Rap 1A is a close relative of Ras that, when overexpressed, is able to revert oncogenic transformation induced by active Ras. We screened a mouse embryonic cDNA library using the yeast two-hybrid system and isolated the cDNA of a novel Rap 1A-interacting protein. The open reading frame encodes for an 84 kDa protein with a Cdc25-homology domain which shares approximately 30% identity with Ral guanine nucleotide dissociation stimulator (RalGDS) and RalGDS-like (Rg1). The C-terminal region reveals a striking conservation of sequences with the Ras-binding domain of RalGDS. We designated this protein Rlf, for RalGDS-like factor. In the yeast system, Rlf interacts with Rap 1A, H-Ras and R-Ras, but not with Rac and Rho. In addition, we found that Rlf interacts with Rap 1A(Val12) but not with Rap 1A(Asn17). In vitro binding studies revealed that a C-terminally located 91 amino acid region of Rlf is sufficient for direct association with the GTP-bound form of Ras and Rap 1A. The observed dissociation constants are 0.6 mu M and 0.4 mu M, respectively. No significant association with Ras-GDP or Rap 1A-GDP could be detected. These binding characteristics indicate that Rlf is a putative effector for Ras and Rap 1A.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3508 TA UTRECHT, NETHERLANDS; MAX PLANCK INST F MOL PHYSIOL, ABT STRUKT BIOL, D-44139 DORTMUND, GERMANY; NETHERLANDS CANC INST, DIV MOLEC PATHOL, NL-1066 CX AMSTERDAM, NETHERLANDS	Utrecht University; Max Planck Society; Netherlands Cancer Institute			Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109; Cool, Robbert/0000-0002-9845-2202; Wolthuis, Rob/0000-0002-3109-1588				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LopezBarahona M, 1996, ONCOGENE, V12, P463; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	131	133	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					353	362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710374				2022-12-17	WOS:A1996VA25200014
J	RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J				RENAULD, JC; VANDERLUGT, N; VINK, A; VANROON, M; GODFRAIND, C; WARNIER, G; MERZ, H; FELLER, A; BERNS, A; VANSNICK, J			THYMIC LYMPHOMAS IN INTERLEUKIN-9 TRANSGENIC MICE	ONCOGENE			English	Article							CELL GROWTH-FACTOR; ENHANCING ACTIVITY MEA; CD4+ T-CELLS; FACTOR P40; EXPRESSION; CDNA; PROLIFERATION; GLYCOPROTEIN; SEQUENCES; P40/IL-9	Transgenic mice overexpressing the interleukin 9 gene were generated to study the biological activity of this cytokine in vivo. Although no major histological or morphological modifications of the lymphoid system were observed in most animals, similar to 7% of transgenic mice developed thymic lymphomas at the age of 3-9 months. The tumor cells, which were clonal, with unique T cell rearrangements, were double positive for the expression of CD4 and CD8. The need for additional transforming events, suggested by the low incidence of spontaneous tumors, was further indicated by the high susceptibility of the transgenic animals to injections of low doses of N-methyl-N-nitrosourea, a chemical carcinogen with a thymic tropism. Expression of interleukin 9 was required for optimal tumor growth in vivo, as one of the tumors studied, which had lost the transgene, was much more efficiently transplanted into transgenic than in normal mice. Moreover, the in vitro proliferative activity of interleukin 9 on cell lines derived from such transgene-negative tumors suggests that an autocrine loop mediates the proliferation of these cells in vivo. Taken together, these results indicate that dysregulated IL-9 expression could be involved in the development of some T cell malignancies.	UNIV CATHOLIQUE LOUVAIN,DEPT PATHOL,B-1200 BRUSSELS,BELGIUM; UNIV LUBECK,INST PATHOL,W-2400 LUBECK,GERMANY; NETHERLANDS CANC INST,AMSTERDAM,NETHERLANDS	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Lubeck; Netherlands Cancer Institute	RENAULD, JC (corresponding author), UNIV CATHOLIQUE LOUVAIN,LUDWIG INST CANC RES,BRUSSELS BRANCH & EXPTL MED,B-1200 BRUSSELS,BELGIUM.		Feller, Alfred/E-3853-2010; Renauld, Jean-Christophe/B-7268-2012	Renauld, Jean-Christophe/0000-0003-1736-2131				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BREUER M, 1989, NATURE, V340, P61, DOI 10.1038/340061a0; BRUCE J, 1981, J IMMUNOL, V127, P2496; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DONAHUE RE, 1990, BLOOD, V75, P2271; DRUEZ C, 1990, J IMMUNOL, V145, P2494; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; GRUSS HJ, 1992, CANCER RES, V52, P1026; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOUSSIAU FA, 1993, J IMMUNOL, V150, P2634; HULTNER L, 1990, EXP HEMATOL, V18, P873; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; KELLEHER K, 1991, BLOOD, V77, P1436; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; MERZ H, 1991, BLOOD, V78, P1311; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD J-C, 1990, Cytokine, V2, P9, DOI 10.1016/1043-4666(90)90037-T; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RICH BE, 1993, J EXP MED, V177, P305, DOI 10.1084/jem.177.2.305; SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130; SIU G, 1984, NATURE, V311, P344, DOI 10.1038/311344a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUDA T, 1990, J IMMUNOL, V144, P1783; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6934, DOI 10.1073/pnas.85.18.6934; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; VANSNICK J, 1989, J EXP MED, V169, P363, DOI 10.1084/jem.169.1.363; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WILDE D, 1982, J IMMUNOL, V131, P2178; WILLIAMS DE, 1990, BLOOD, V76, P906; YANG YC, 1989, BLOOD, V74, P1880	36	131	134	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1994	9	5					1327	1332						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152793				2022-12-17	WOS:A1994NH40100003
J	ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SEQUENCE AND EXPRESSION OF A CDNA-ENCODING MYD118 - A NOVEL MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE INDUCED BY MULTIPLE CYTOKINES	ONCOGENE			English	Note							LEUKEMIA-INHIBITORY FACTOR; HEPATOCYTE-STIMULATING FACTOR; NEURONAL DIFFERENTIATION; CELLS; DISSECTION; IDENTITY; CLONING; PROTEIN	We report here the full length cDNA sequence and the deduced amino acid sequence of MyD118, a novel myeloid differentiation primary response gene transiently expressed in M1D + myeloid precursors following induction of terminal differentiation and growth arrest by IL6. MyD118 expression was observed to be induced also in the absence of protein synthesis, following stimulation of M1D + cells by IL1, LPS and Leukemia Inhibitory Factor (LIF). Detectable levels of MyD118 RNA were observed in myeloid precursor enriched murine bone marrow, but not in several other nonmyeloid murine tissues.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline; NICHD NIH HHS [5T32HD07152] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHABO Y, 1988, BLOOD, V72, P1543; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	15	131	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					165	167						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899477				2022-12-17	WOS:A1991EY03900024
J	DEMILIA, J; BULOVAS, K; DERCOLE, K; WOLF, B; STEELE, G; SUMMERHAYES, IC				DEMILIA, J; BULOVAS, K; DERCOLE, K; WOLF, B; STEELE, G; SUMMERHAYES, IC			EXPRESSION OF THE C-ERBB-2 GENE-PRODUCT (P185) AT DIFFERENT STAGES OF NEOPLASTIC PROGRESSION IN THE COLON	ONCOGENE			English	Article									NEW ENGLAND DEACONESS HOSP,DEPT SURG,CANC BIOL LAB,50 BINNEY ST,BOSTON,MA 02115						NCI NIH HHS [CA44704] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BERGER MS, 1988, CANCER RES, V48, P1238; COHEN JA, 1989, ONCOGENE, V4, P81; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; KOKAI Y, 1988, P NATL ACAD SCI USA, V85, P5389, DOI 10.1073/pnas.85.15.5389; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1988, CANCER RES, V48, P1517; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YOKOTA J, 1986, LANCET, V1, P765; ZHOU DJ, 1987, CANCER RES, V47, P6123	28	131	133	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1233	1239						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2571966				2022-12-17	WOS:A1989AU50800011
J	Neri, F; Dettori, D; Incarnato, D; Krepelova, A; Rapelli, S; Maldotti, M; Parlato, C; Paliogiannis, P; Oliviero, S				Neri, F.; Dettori, D.; Incarnato, D.; Krepelova, A.; Rapelli, S.; Maldotti, M.; Parlato, C.; Paliogiannis, P.; Oliviero, S.			TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway	ONCOGENE			English	Article							EMBRYONIC STEM-CELLS; LARGE GENE LISTS; DNA METHYLATION; EPIGENETIC INACTIVATION; BREAST-CANCER; MAMMALIAN DEVELOPMENT; COLORECTAL-CANCER; POTENTIAL ROLES; 5-HYDROXYMETHYLCYTOSINE; MUTATIONS	Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-methylcytosine (5mC) to promote the demethylation process. The reaction intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in embryonic stem cells and tissues but strongly depleted in human cancers. Genetic mutations of TET2 gene were associated with leukaemia, whereas TET1 downregulation has been shown to promote malignancy in breast cancer. Here we report that TET1 is downregulated in colon tumours from the initial stage. TET1 silencing in primary epithelial colon cells increase their cellular proliferation while its re-expression in colon cancer cells inhibits their proliferation and the growth of tumour xenografts even at later stages. We found that TET1 binds to the promoter of the DKK gene inhibitors of the WNT signalling to maintain them hypomethylated. Downregulation of TET1 during colon cancer initiation leads to repression, by DNA methylation, the promoters of the inhibitors of the WNT pathway resulting in a constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation mediated by TET1 controlling the WNT signalling is a key player of tumour growth. These results provide new insights for understanding how tumours escape cellular controls.	[Neri, F.; Dettori, D.; Incarnato, D.; Krepelova, A.; Rapelli, S.; Maldotti, M.; Parlato, C.; Oliviero, S.] Human Genet Fdn HuGeF, Epigenet, Turin, Italy; [Incarnato, D.; Krepelova, A.; Rapelli, S.] Univ Siena, Dipartimento Biotecnol Chim & Farm, I-53100 Siena, Italy; [Paliogiannis, P.] Univ Sassari, Dipartimento Sci Chirurg Microchirurg & Med, I-07100 Sassari, Italy; [Oliviero, S.] Univ Turin, Dipartimento Sci Vita & Biol Sistemi, Turin, Italy	University of Siena; University of Sassari; University of Turin	Oliviero, S (corresponding author), Human Genet Fdn, Epigenet, Via Nizza52, I-10126 Turin, Italy.	salvatore.oliviero@hugef-torino.org	Neri, Francesco/A-3321-2014; Paliogiannis, Panagiotis/M-6870-2016; oliviero, salvatore/R-6657-2019	Neri, Francesco/0000-0003-3903-1974; Paliogiannis, Panagiotis/0000-0001-5485-6056; oliviero, salvatore/0000-0002-3405-765X; Krepelova, Anna/0000-0002-2775-1336; PARLATO, CATERINA/0000-0001-5304-3117; Maldotti, Mara/0000-0002-3299-9053	Associazione Italiana Ricerca sul Cancro (AIRC) [IG 2011/11982]	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the Associazione Italiana Ricerca sul Cancro (AIRC) IG 2011/11982. We thank Carola Ponzetto and Riccardo Taulli for the critical reading of the manuscript.	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bacher U, 2010, ANN HEMATOL, V89, P643, DOI 10.1007/s00277-010-0920-6; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111; Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12; Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Haffner MC, 2011, ONCOTARGET, V2, P627; He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Incarnato D, 2013, NUCLEIC ACIDS RES, V41, P8421, DOI 10.1093/nar/gkt629; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ivanov M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r83; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kallin EM, 2012, MOL CELL, V48, P266, DOI 10.1016/j.molcel.2012.08.007; Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kosmider O, 2009, BLOOD, V114, P3285, DOI 10.1182/blood-2009-04-215814; Krepelova A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088933; Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946; Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620; Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91; Neri F, 2013, CELL, V155, P121, DOI 10.1016/j.cell.2013.08.056; Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Pfeifer GP, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-10; Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643; Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026; Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003; Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47; Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111; Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67	49	130	140	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4168	4176		10.1038/onc.2014.356	http://dx.doi.org/10.1038/onc.2014.356			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25362856	Green Submitted			2022-12-17	WOS:000359199800003
J	Gao, J; Li, N; Dong, Y; Li, S; Xu, L; Li, X; Li, Y; Li, Z; Ng, SS; Sung, JJ; Shen, L; Yu, J				Gao, J.; Li, N.; Dong, Y.; Li, S.; Xu, L.; Li, X.; Li, Y.; Li, Z.; Ng, S. S.; Sung, J. J.; Shen, L.; Yu, J.			miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer	ONCOGENE			English	Article							COLON-CANCER; INHIBITS MIGRATION; P53; EXPRESSION; INVASION; MIR-21; CELLS; SIRT1; COMBINATION; RELAPSE	Although surgery remains the mainstay of curative treatment for colorectal cancer (CRC), many patients still have high chance to experience disease relapse. It is therefore imperative to identify prognostic markers that can help predict the clinical outcomes of CRC. Aberrant microRNA expression holds great potential as diagnostic and prognostic biomarker for CRC. Here we aimed to investigate clinical potential of miR-34a-5p as a prognostic marker for CRC recurrence and its functional significance. First, we validated that miR-34a-5p was downregulated in CRC tumour tissues (P<0.05). The expression level of tissue miR-34a-5p was then evaluated in two independent cohorts of 268 CRC patients. miR-34a-5p expression was positively correlated with disease-free survival in two independent cohorts (cohort I: n = 205, P<0.001; cohort II: n = 63, P = 0.006). Moreover, the expression of miR-34a-5p was an independent prognostic factor for CRC recurrence by multivariate analysis (P<0.001 for cohort I, P = 0.007 for cohort II). Ectopic expression of miR-34a-5p in p53 wild-type colon cancer cell HCT116 significantly inhibited cell growth, migration, invasion and metastasis. miR-34a-5p induced cell apoptosis, cell cycle arrest at G1 phase and p53 transcription activity in HCT116 cells, but not in the HCT116 p53 knockout (p53(-/-))cells. miR-34a-5p significantly suppressed the HCT116 growth in vivo, whereas it showed no effect on the HCT116 p53(-/-) xenograft, indicating that the growth-inhibiting effect by miR-34a-5p was dependent on p53. In addition, the expression level of miR-34a-5p in patients with p53-positive expression was higher than that in patients with p53-negative expression (P<0.01). In conclusion, miR-34a-5p inhibits recurrence of CRC through inhibiting cell growth, migration and invasion, inducing cell apoptosis and cell cycle arrest in a p53-dependent manner.	[Gao, J.; Li, N.; Li, S.; Li, Y.; Shen, L.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing 100871, Peoples R China; [Gao, J.; Dong, Y.; Xu, L.; Li, X.; Sung, J. J.; Yu, J.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, CUHK Shenzhen Res Inst, State Key Lab Digest Dis,Inst Digest Dis,Dept Med, Shatin, Hong Kong, Peoples R China; [Dong, Y.; Ng, S. S.] Chinese Univ Hong Kong, Dept Surg, Shatin, Hong Kong, Peoples R China; [Li, Z.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Pathol, Beijing 100871, Peoples R China	Peking University; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci,CUHK Shenzhen Res Inst, Inst Digest Dis,Dept Med & Therapeut,State Key La, Shatin, Hong Kong, Peoples R China.	lin100@medmail.com.cn; junyu@cuhk.edu.hk	Li, Xiao-xing/B-9114-2008; Sung, Joseph J. Y./R-3203-2018; Yu, Jun/D-8569-2015	Li, Xiao-xing/0000-0001-8791-7505; Sung, Joseph J. Y./0000-0003-3125-5199; Yu, Jun/0000-0001-5008-2153	National Natural Science Foundation of China [81301853, 81072034]; National High Technology Research and Development Program [2012AA 02A 504, 2012AA 02A 506]; Shenzhen Technology and Innovation Project Fund, Shenzhen [JSGG20130412171021059]; China 863 program [2012AA02A506]; Shenzhen Municipal Science and Technology R D fund [JCYJ20120619152326450]; Shenzhen Virtual University Park Support Scheme	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology Research and Development Program(National High Technology Research and Development Program of China); Shenzhen Technology and Innovation Project Fund, Shenzhen; China 863 program(National High Technology Research and Development Program of China); Shenzhen Municipal Science and Technology R D fund; Shenzhen Virtual University Park Support Scheme	This work was supported by National Natural Science Foundation of China (No. 81301853, 81072034), National High Technology Research and Development Program (No. 2012AA 02A 504, 2012AA 02A 506), Shenzhen Technology and Innovation Project Fund, Shenzhen (JSGG20130412171021059), China 863 program (2012AA02A506), Shenzhen Municipal Science and Technology R & D fund (JCYJ20120619152326450) and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014; Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chen Q, 2014, CELL MOL BIOL LETT, V19, P52, DOI 10.2478/s11658-013-0115-y; Christensen LL, 2013, INT J CANCER, V133, P67, DOI 10.1002/ijc.28010; Dong Y, 2011, BRIT J CANCER, V104, P893, DOI 10.1038/bjc.2011.57; Dong YJ, 2013, MOL CANCER RES, V11, P1051, DOI 10.1158/1541-7786.MCR-13-0061; Gallardo E, 2009, CARCINOGENESIS, V30, P1903, DOI 10.1093/carcin/bgp219; Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Ji Q, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-266; Kjaer-Frifeldt S, 2012, BRIT J CANCER, V107, P1169, DOI 10.1038/bjc.2012.365; Leng ZW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056082; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035; Ma YM, 2013, CURR PHARM DESIGN, V19, P1253; Mandke P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042034; Mirakhorli M, 2013, MOL MED REP, V7, P613, DOI 10.3892/mmr.2012.1226; Mitrea DM, 2012, BIOL CHEM, V393, P259, DOI 10.1515/hsz-2011-0254; Nair VS, 2012, JNCI-J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Tobiume Kei, 2005, J Nippon Med Sch, V72, P192, DOI 10.1272/jnms.72.192; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Wang ZW, 2010, CANCER LETT, V292, P141, DOI 10.1016/j.canlet.2009.11.012; Wu CW, 2014, CLIN CANCER RES, V20, P2994, DOI 10.1158/1078-0432.CCR-13-1750; Wu CW, 2012, GUT, V61, P739, DOI 10.1136/gut.2011.239236; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yamakuchi M, 2009, CELL CYCLE, V8, P712, DOI 10.4161/cc.8.5.7753; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166; Yang MM, 2013, EUR J CANCER, V49, P604, DOI 10.1016/j.ejca.2012.09.031; Zhang X, 2011, ANN ONCOL, V22, P2257, DOI 10.1093/annonc/mdq758; Zhu HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052393	37	130	136	1	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	31					4142	4152		10.1038/onc.2014.348	http://dx.doi.org/10.1038/onc.2014.348			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN9PE	25362853				2022-12-17	WOS:000358780500012
J	Xiao, L; Hu, ZY; Dong, X; Tan, Z; Li, W; Tang, M; Chen, L; Yang, L; Tao, Y; Jiang, Y; Li, J; Yi, B; Li, B; Fan, S; You, S; Deng, X; Hu, F; Feng, L; Bode, AM; Dong, Z; Sun, LQ; Cao, Y				Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Yi, B.; Li, B.; Fan, S.; You, S.; Deng, X.; Hu, F.; Feng, L.; Bode, A. M.; Dong, Z.; Sun, L-Q; Cao, Y.			Targeting Epstein-Barr virus oncoprotein LMP1-mediated glycolysis sensitizes nasopharyngeal carcinoma to radiation therapy	ONCOGENE			English	Article							LATENT MEMBRANE-PROTEIN-1; TUMOR-SUPPRESSOR; CANCER; GROWTH; DYSREGULATION; TRANSCRIPTION; MITOCHONDRIA; MAINTENANCE; TRAFFICKING; METABOLISM	Our goal in this work was to illustrate the Epstein-Barr virus (EBV)-modulated global biochemical profile and provide a novel metabolism-related target to improve the therapeutic regimen of nasopharyngeal carcinoma (NPC). We used a metabolomics approach to investigate EBV-modulated metabolic changes, and found that the exogenous overexpression of the EBV-encoded latent membrane protein 1 (LMP1) significantly increased glycolysis. The deregulation of several glycolytic genes, including hexokinase 2 (HK2), was determined to be responsible for the reprogramming of LMP1-mediated glucose metabolism in NPC cells. The upregulation of HK2 elevated aerobic glycolysis and facilitated proliferation by blocking apoptosis. More importantly, HK2 was positively correlated with LMP1 in NPC biopsies, and high HK2 levels were significantly associated with poor overall survival of NPC patients following radiation therapy. Knockdown of HK2 effectively enhanced the sensitivity of LMP1-overexpressing NPC cells to irradiation. Finally, c-Myc was demonstrated to be required for LMP1-induced upregulation of HK2. The LMP1-mediated attenuation of the PI3-K/Akt-GSK3beta-FBW7 signaling axis resulted in the stabilization of c-Myc. These findings indicate a close relationship between EBV and glycolysis in NPC. Notably, LMP1 is the key regulator of the reprogramming of EBV-mediated glycolysis in NPC cells. Given the importance of EBV-mediated deregulation of glycolysis, anti-glycolytic therapy might represent a worthwhile avenue of exploration in the treatment of EBV-related cancers.	[Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Cent S Univ, Xiangya Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Xiao, L.; Hu, Z-Y; Dong, X.; Tan, Z.; Li, W.; Tang, M.; Chen, L.; Yang, L.; Tao, Y.; Jiang, Y.; Li, J.; Cao, Y.] Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Hu, Z-Y] First Hosp Changsha City, Changsha, Hunan, Peoples R China; [Tang, M.; Hu, F.; Feng, L.] Cent S Univ, Xiangya Hosp 2, Metab Syndrome Res Ctr, Changsha 410078, Hunan, Peoples R China; [Sun, L-Q] Cent S Univ, Xiangya Hosp, Ctr Mol Med, Changsha 410078, Hunan, Peoples R China; [Yi, B.] Cent S Univ, Xiangya Hosp, Clin Biochem Lab, Changsha 410078, Hunan, Peoples R China; [Li, B.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [Fan, S.] Cent S Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410078, Hunan, Peoples R China; [You, S.; Deng, X.] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA; [You, S.] Cent S Univ, Xiangya Hosp 2, Dept Endocrinol, Changsha 410078, Hunan, Peoples R China; [Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Emory University; Central South University; University of Minnesota System	Sun, LQ (corresponding author), Cent S Univ, Xiangya Hosp, Ctr Mol Med, Xiangya Rd 110, Changsha 410078, Hunan, Peoples R China.	lunquansun@csu.edu.cn; ycao98@vip.sina.com		Jiang, Yiqun/0000-0003-3262-9498	National Basic Research Program of China [2011CB504305]; National High Technology Research and Development Program of China [2012AA02A501]; National Natural Science Foundation of China (NSFC) [30930101, 81161120410]; China Postdoctoral Science Foundation funded project [2011M501300]	National Basic Research Program of China(National Basic Research Program of China); National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation funded project(China Postdoctoral Science Foundation)	We thank Dr Ryan Michalek, Dr Sheng Quan and Dr Lining Guo at Metabolon for metabolomics analysis. We also thank Dr Giovanni Melillo from Bristol-Myers Squibb for their critical comments and suggestions. This study was supported by National Basic Research Program of China, No. 2011CB504305; The National High Technology Research and Development Program of China, No. 2012AA02A501; National Natural Science Foundation of China (NSFC), No. 30930101 and 81161120410; and China Postdoctoral Science Foundation funded project, No. 2011M501300.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Ascherio A, 2010, J NEUROIMMUNE PHARM, V5, P271, DOI 10.1007/s11481-010-9201-3; Bhatt AP, 2012, P NATL ACAD SCI USA, V109, P11818, DOI 10.1073/pnas.1205995109; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Darekar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042072; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107; Diamond DL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000719; Garcia-Cao I, 2012, CELL, V149, P49, DOI 10.1016/j.cell.2012.02.030; Gimenez-Cassina A, 2009, J BIOL CHEM, V284, P3001, DOI 10.1074/jbc.M808698200; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu JY, 2005, CLIN CANCER RES, V11, P4658, DOI 10.1158/1078-0432.CCR-04-1798; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kohio HP, 2013, VIROLOGY, V444, P301, DOI 10.1016/j.virol.2013.06.026; Kondo S, 2006, CANCER RES, V66, P9870, DOI 10.1158/0008-5472.CAN-06-1679; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liu WS, 2012, INT J RADIAT ONCOL, V82, P561, DOI 10.1016/j.ijrobp.2010.11.055; Lu ZX, 2008, CANCER LETT, V265, P226, DOI 10.1016/j.canlet.2008.02.019; Ma XQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024647; Mainou BA, 2005, ONCOGENE, V24, P6917, DOI 10.1038/sj.onc.1208846; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Marquitz AR, 2012, P NATL ACAD SCI USA, V109, P9593, DOI 10.1073/pnas.1202910109; Meckes DG, 2013, J VIROL, V87, P1301, DOI 10.1128/JVI.02519-12; Noch E, 2012, MOL CANCER THER, V11, P14, DOI 10.1158/1535-7163.MCT-11-0517; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Reitman ZJ, 2011, P NATL ACAD SCI USA, V108, P3270, DOI 10.1073/pnas.1019393108; Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166; Shin HJ, 2011, J BIOL CHEM, V286, P29872, DOI 10.1074/jbc.M111.259978; Sommermann TG, 2011, CANCER RES, V71, P7291, DOI 10.1158/0008-5472.CAN-11-1715; Soni V, 2007, ADV EXP MED BIOL, V597, P173; Tang LQ, 2013, J CLIN ONCOL, V31, P2861, DOI 10.1200/JCO.2012.46.0816; Terrin L, 2008, J VIROL, V82, P10175, DOI 10.1128/JVI.00321-08; Vastag L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002124; Wakisaka N, 2004, MOL CELL BIOL, V24, P5223, DOI 10.1128/MCB.24.12.5223-5234.2004; Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yang HN, 2006, P NATL ACAD SCI USA, V103, P10397, DOI 10.1073/pnas.0604008103; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Yuan SP, 2008, FASEB J, V22, P2809, DOI 10.1096/fj.08-107417	45	130	135	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 11	2014	33	37					4568	4578		10.1038/onc.2014.32	http://dx.doi.org/10.1038/onc.2014.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AP3UZ	24662831	Green Published, hybrid			2022-12-17	WOS:000342004800004
J	Cremona, CA; Behrens, A				Cremona, C. A.; Behrens, A.			ATM signalling and cancer	ONCOGENE			English	Review						ATM; signalling; cancer	DNA-DAMAGE RESPONSE; NF-KAPPA-B; DOUBLE-STRAND BREAKS; INHIBITS HOMOLOGOUS RECOMBINATION; ONCOGENE-INDUCED SENESCENCE; ATAXIA-TELANGIECTASIA; OXIDATIVE STRESS; KINASE-ACTIVITY; ACTIVATES ATM; DEPENDENT PHOSPHORYLATION	ATM, the protein kinase mutated in the rare human disease ataxia telangiectasia (A-T), has been the focus of intense scrutiny over the past two decades. Initially this was because of the unusual radiosensitive phenotype of cells from A-T patients, and latterly because investigating ATM signalling has yielded valuable insights into the DNA damage response, redox signalling and cancer. With the recent explosion in genomic data, ATM alterations have been revealed both in the germline as a predisposing factor for cancer and as somatic changes in tumours themselves. Here we review these findings, as well as advances in the understanding of ATM signalling mechanisms in cancer and ATM inhibition as a strategy for cancer treatment.	[Cremona, C. A.; Behrens, A.] Canc Res UK London Res Inst, Mammalian Genet Lab, London WC2A 3LY, England	Cancer Research UK	Behrens, A (corresponding author), Canc Res UK London Res Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@cancer.org.uk		Cremona, Catherine/0000-0002-5962-7399; Behrens, Axel/0000-0002-1557-1143	ERC [281661]; Cancer Research UK; Cancer Research UK [15679] Funding Source: researchfish	ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank N. Kanu for comments on the manuscript. We apologise to colleagues whose work was not cited due to space considerations. This work was supported by an ERC Grant (281661 ATMINDDR) to AB. The London Research Institute is supported by Cancer Research UK.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ai LB, 2012, J BIOL CHEM, V287, P18330, DOI 10.1074/jbc.M112.339317; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Ando K, 2012, MOL CELL, V47, P681, DOI 10.1016/j.molcel.2012.06.024; Armata HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024813; Armata HL, 2010, MOL CELL BIOL, V30, P5787, DOI 10.1128/MCB.00347-10; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Batey MA, 2013, MOL CANCER THER, V12, P959, DOI 10.1158/1535-7163.MCT-12-0707; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Bhatia N, 2013, J INVEST DERMATOL, V133, P759, DOI 10.1038/jid.2012.355; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Bonanni B, 2012, J CLIN ONCOL, V30, P2593, DOI 10.1200/JCO.2011.39.3769; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Brunton H, 2011, MOL CELL BIOL, V31, P4022, DOI 10.1128/MCB.05289-11; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burdak-Rothkamm S, 2008, CANCER RES, V68, P7059, DOI 10.1158/0008-5472.CAN-08-0545; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Cheng WH, 2008, MOL BIOL CELL, V19, P3923, DOI 10.1091/mbc.E07-07-0698; Chiba N, 2012, P NATL ACAD SCI USA, V109, P2760, DOI 10.1073/pnas.1018867108; Cosentino C, 2011, EMBO J, V30, P546, DOI 10.1038/emboj.2010.330; Daniel JA, 2012, J CELL BIOL, V198, P295, DOI 10.1083/jcb.201204035; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Darlington Y, 2012, ONCOGENE, V31, P1155, DOI 10.1038/onc.2011.303; Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Duan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019532; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; Gamper AM, 2012, J BIOL CHEM, V287, P12445, DOI 10.1074/jbc.M112.352310; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goldgar DE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2919; Golding SE, 2012, CELL CYCLE, V11, P1167, DOI 10.4161/cc.11.6.19576; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Goodarzi AA, 2009, BIOCHEM SOC T, V37, P569, DOI 10.1042/BST0370569; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guarini A, 2012, HAEMATOL-HEMATOL J, V97, P47, DOI 10.3324/haematol.2011.049270; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Halaby MJ, 2008, CELL SIGNAL, V20, P1555, DOI 10.1016/j.cellsig.2008.04.011; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; He L, 2011, BIOCHEM BIOPH RES CO, V409, P489, DOI 10.1016/j.bbrc.2011.05.032; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hollestelle A, 2010, CURR OPIN GENET DEV, V20, P268, DOI 10.1016/j.gde.2010.02.009; Hong YS, 2012, INT J ONCOL, V41, P76, DOI 10.3892/ijo.2012.1448; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Ichijima Y, 2011, GENE DEV, V25, P959, DOI 10.1101/gad.2030811; Ichijima Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008821; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2007, J IMMUNOL, V178, P103, DOI 10.4049/jimmunol.178.1.103; Jazayeri A, 2008, EMBO J, V27, P1953, DOI 10.1038/emboj.2008.128; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jinushi M, 2012, CANCER RES, V72, P56, DOI 10.1158/0008-5472.CAN-11-2028; Jurado S, 2012, J EXP MED, V209, P1629, DOI 10.1084/jem.20120785; Jurado S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001170; Kalev P, 2012, CANCER RES, V72, P6414, DOI 10.1158/0008-5472.CAN-12-1667; Kanu N, 2007, EMBO J, V26, P2933, DOI 10.1038/sj.emboj.7601733; Kanu N, 2010, J BIOL CHEM, V285, P38534, DOI 10.1074/jbc.M110.145896; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kozlov SV, 2011, J BIOL CHEM, V286, P9107, DOI 10.1074/jbc.M110.204065; Kruger A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001959; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034456; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Llorca O, 2003, ONCOGENE, V22, P3867, DOI 10.1038/sj.onc.1206649; Loizou JI, 2011, CANCER CELL, V19, P587, DOI 10.1016/j.ccr.2011.03.022; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mahajan K, 2012, J BIOL CHEM, V287, P22112, DOI 10.1074/jbc.M112.357384; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; McNees CJ, 2005, EMBO J, V24, P2447, DOI 10.1038/sj.emboj.7600704; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Miles PD, 2007, AM J PHYSIOL-ENDOC M, V293, pE70, DOI 10.1152/ajpendo.00259.2006; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Okamoto K, 2013, NATURE, V494, P502, DOI 10.1038/nature11873; Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286; Palmieri D, 2011, ONCOGENE, V30, P3024, DOI 10.1038/onc.2011.21; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Penicud K, 2014, ONCOGENE, V33, P525, DOI 10.1038/onc.2012.597; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Pietzner J, 2013, HUM MOL GENET, V22, P493, DOI 10.1093/hmg/dds448; Pospelova TV, 2009, CELL CYCLE, V8, P4112, DOI 10.4161/cc.8.24.10215; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004; Ray A, 2009, MOL CELL BIOL, V29, P6206, DOI 10.1128/MCB.00503-09; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reiman A, 2011, BRIT J CANCER, V105, P586, DOI 10.1038/bjc.2011.266; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reliene R, 2006, DNA REPAIR, V5, P852, DOI 10.1016/j.dnarep.2006.05.003; Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Ripka S, 2010, GUT, V59, P1101, DOI 10.1136/gut.2009.189720; Roberts NJ, 2012, CANCER DISCOV, V2, P41, DOI 10.1158/2159-8290.CD-11-0194; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roossink F, 2012, INT J CANCER, V131, P2056, DOI 10.1002/ijc.27488; Sahu RP, 2009, BRIT J CANCER, V100, P1425, DOI 10.1038/sj.bjc.6605039; Salimi M, 2012, MED ONCOL, V29, P1502, DOI 10.1007/s12032-011-0043-5; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHALCH DS, 1970, NEW ENGL J MED, V282, P1396, DOI 10.1056/NEJM197006182822503; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Semlitsch M, 2011, DNA REPAIR, V10, P848, DOI 10.1016/j.dnarep.2011.05.004; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Shiotani B, 2009, MOL CELL, V33, P547, DOI 10.1016/j.molcel.2009.01.024; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Skowronska A, 2012, J CLIN ONCOL, V30, P4524, DOI 10.1200/JCO.2011.41.0852; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Sullivan KD, 2012, NAT CHEM BIOL, V8, P646, DOI [10.1038/nchembio.965, 10.1038/NCHEMBIO.965]; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taubes G, 2012, SCIENCE, V335, P286, DOI [10.1126/science.335.6064.28, 10.1126/science.335.6064.29]; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Tian B, 2009, NAT CELL BIOL, V11, P211, DOI 10.1038/ncb1829; Umesako S, 2005, BREAST CANCER RES, V7, pR164, DOI 10.1186/bcr968; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vadnais C, 2012, NUCLEIC ACIDS RES, V40, P4483, DOI 10.1093/nar/gks041; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423; Wang L, 2012, MOL CANCER THER, V11, P2401, DOI 10.1158/1535-7163.MCT-12-0448; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039446; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; White JS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000758; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Wuerzberger-Davis SM, 2007, ONCOGENE, V26, P641, DOI 10.1038/sj.onc.1209815; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036; Yamamoto K, 2012, J CELL BIOL, V198, P305, DOI 10.1083/jcb.201204098; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yin H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024080; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Zannini L, 2012, J MOL CELL BIOL, V4, P294, DOI 10.1093/jmcb/mjs035; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zha S, 2008, P NATL ACAD SCI USA, V105, P9302, DOI 10.1073/pnas.0803520105; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang TY, 2012, CELL REP, V2, P1498, DOI 10.1016/j.celrep.2012.11.002; Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	199	130	133	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3351	3360		10.1038/onc.2013.275	http://dx.doi.org/10.1038/onc.2013.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23851492				2022-12-17	WOS:000338779300001
J	Wu, J; Ru, NY; Zhang, Y; Li, Y; Wei, D; Ren, Z; Huang, XF; Chen, ZN; Bian, H				Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Ren, Z.; Huang, X-F; Chen, Z-N; Bian, H.			HAb18G/CD147 promotes epithelial-mesenchymal transition through TGF-beta signaling and is transcriptionally regulated by Slug	ONCOGENE			English	Article						hepatocarcinogenesis; epithelial-mesenchymal transition; PI3K/Akt; hepatocellular carcinoma; CD147; TGF-beta	GROWTH-FACTOR-BETA; FETAL-RAT HEPATOCYTES; HEPATOCELLULAR-CARCINOMA; TUMOR PROGRESSION; DOWN-REGULATION; EXPRESSION; METASTASIS; INVASION; RECEPTOR; PATHWAYS	Epithelial-mesenchymal transition (EMT) induced by transforming growth factor-beta (TGF-beta) is implicated in hepatocarcinogenesis and hepatocellular carcinoma (HCC) metastasis. HAb18G/CD147, which belongs to the CD147 family, is an HCC-associated antigen that has a crucial role in tumor invasion and metastasis. The goal of this study was to investigate the role of HAb18G/CD147 during EMT in hepatocarcinogenesis. Human normal hepatic cell lines QZG and L02, primary mouse hepatocytes and nude mouse models were used to determine the role of HAb18G/CD147 in EMT, and the involvement of the TGF-beta-driven pathway. A dual-luciferase reporter assay and ChIP were used to investigate the transcriptional regulation of the CD147 gene. Samples from patients with liver disease were assessed to determine the relationship between HAb18G/CD147 and typical markers for EMT. Our results show that upregulation of HAb18G/CD147 is induced by TGF-beta coupled with downregulation of E-cadherin and upregulation of N-cadherin and vimentin. The expression of HAb18G/CD147 is controlled by the cell survival PI3K/Akt/GSK3 beta signaling pathway, and is directly regulated by the transcription factor Slug. Transfection of CD147 also induces an elevated expression of TGF-beta. CD147-transfected hepatocytes have mesenchymal phenotypes that accelerate tumor formation and tumor metastasis in vivo. Immunohistochemistry analysis shows a negative correlation between HAb18G/CD147 and E-cadherin expression (r(s) = -0.3622, P = 0.0105), and a positive correlation between HAb18G/CD147 and Slug expression (r(s) = 0.3064, P = 0.0323) in human HCC tissues. Our study uncovers a novel role of HAb18G/CD147 in mediating EMT in the process of HCC progression and showed that CD147 is a Slug target gene in the signaling cascade TGF-beta -> PI3K/Akt -> GSK3 beta -> Snail -> Slug -> CD147. Our results suggest that CD147 may be a potential target for the treatment and prevention of HCC. Oncogene (2011) 30, 4410-4427; doi:10.1038/onc.2011.149; published online 2 May 2011	[Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Cell Engn Res Ctr, Xian 710032, Shaanxi, Peoples R China; [Wu, J.; Ru, N-Y; Zhang, Y.; Li, Y.; Wei, D.; Chen, Z-N; Bian, H.] Fourth Mil Med Univ, Dept Cell Biol, State Key Lab Canc Biol, Xian 710032, Shaanxi, Peoples R China; [Ren, Z.] Third Mil Med Univ, Dept Microbiol, Chongqing, Peoples R China; [Huang, X-F] Fourth Mil Med Univ, Cent Lab, Sch Basic Med, Xian 710032, Shaanxi, Peoples R China	Air Force Military Medical University; Air Force Military Medical University; Army Medical University; Air Force Military Medical University	Chen, ZN (corresponding author), Fourth Mil Med Univ, Cell Engn Res Ctr, 17 Changle W Rd, Xian 710032, Shaanxi, Peoples R China.	znchen@fmmu.edu.cn; hjbian@fmmu.edu.cn			National Natural Science Foundation of China [30870944, 30671196]; Hi-tech Research and Development Programme of China [2009CB521706]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Hi-tech Research and Development Programme of China(National High Technology Research and Development Program of China)	We thank Professor Xiao-Long Ji (Department of Pathology, General Hospital of the Chinese People's Armed Police Forces, Beijing, China), Professor Wei Zhang (Department of Pathology, Tangdu Hospital of Fourth Military Medical University, Xi'an, China) and Professor Qiao-Nan Guo (Department of Pathology, Southwest Hospital of Third Military Medical University, Chongqing, China) for their pathology analyses. We thank Professor Mien-Chie Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) for providing pEGFP-Snail1, and Dr Ling-Min Kong and Xia Ke in our lab for providing pGL3-CD147 (-1761/+37), pGL3-CD147 (-644/+37) and pGL3-CD147 (-338/+37). Financial support: This work was supported by grants from the National Natural Science Foundation of China (Nos. 30870944 and 30671196), and the Hi-tech Research and Development Programme of China (No. 2009CB521706). Writing assistance was provided by American Journal Experts, USA.	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Belton RJ, 2008, J BIOL CHEM, V283, P17805, DOI 10.1074/jbc.M801876200; Chen ZN, 2006, INT J RADIAT ONCOL, V65, P435, DOI 10.1016/j.ijrobp.2005.12.034; Elsharkawy AM, 2007, HEPATOLOGY, V46, P590, DOI 10.1002/hep.21802; Fransvea E, 2008, HEPATOLOGY, V47, P1557, DOI 10.1002/hep.22201; Gabison EE, 2005, AM J PATHOL, V166, P209, DOI 10.1016/S0002-9440(10)62245-6; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Gou XC, 2009, CANCER SCI, V100, P837, DOI 10.1111/j.1349-7006.2009.01113.x; Huet E, 2008, FASEB J, V22, P1144, DOI 10.1096/fj.07-8748com; Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Labbe E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Liu FF, 2010, BREAST CANCER RES TR, V124, P677, DOI 10.1007/s10549-010-0790-6; Matsuzaki K, 2009, FRONT BIOSCI-LANDMRK, V14, P2923, DOI 10.2741/3423; Murata M, 2009, HEPATOLOGY, V49, P1203, DOI 10.1002/hep.22765; Nitta T, 2008, HEPATOLOGY, V48, P909, DOI 10.1002/hep.22397; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Sidhu SS, 2010, ONCOGENE, V29, P4145, DOI 10.1038/onc.2010.166; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Taura K, 2010, HEPATOLOGY, V51, P1027, DOI 10.1002/hep.23368; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Tsai JF, 1997, BRIT J CANCER, V76, P244, DOI 10.1038/bjc.1997.369; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vigneswaran N, 2006, EXP MOL PATHOL, V80, P147, DOI 10.1016/j.yexmp.2005.09.011; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu J, 2007, MOL CANCER RES, V5, P605, DOI 10.1158/1541-7786.MCR-06-0286; Xu J, 2007, HEPATOLOGY, V45, P269, DOI 10.1002/hep.21465; Yan L, 2007, AM J HEMATOL, V82, P949, DOI 10.1002/ajh.21030; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Yang YA, 2006, CANCER CELL, V9, P445, DOI 10.1016/j.ccr.2006.04.025; Yi JY, 2005, J BIOL CHEM, V280, P10870, DOI 10.1074/jbc.M413223200; Yoshino J, 2007, BIOCHEM BIOPH RES CO, V362, P63, DOI 10.1016/j.bbrc.2007.07.146	40	130	143	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2011	30	43					4410	4427		10.1038/onc.2011.149	http://dx.doi.org/10.1038/onc.2011.149			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532623				2022-12-17	WOS:000296356500004
J	Ansieau, S; Morel, AP; Hinkal, G; Bastid, J; Puisieux, A				Ansieau, S.; Morel, A-P; Hinkal, G.; Bastid, J.; Puisieux, A.			TWISTing an embryonic transcription factor into an oncoprotein	ONCOGENE			English	Review						TWIST; embryogenesis; EMT; failsafe program escape; cell dissemination	EPITHELIAL-MESENCHYMAL TRANSITION; SAETHRE-CHOTZEN-SYNDROME; HUMAN BREAST-CANCER; LYMPH-NODE METASTASIS; E-CADHERIN EXPRESSION; BHLH PROTEIN TWIST; GROWTH-FACTOR-BETA; HEPATOCELLULAR-CARCINOMA; UP-REGULATION; STEM-CELLS	Over the past decade, the reactivation of TWIST embryonic transcription factors has been described as a frequent event and a marker of poor prognosis in an impressive array of human cancers. Growing evidence now supports the premise that these cancers hijack TWIST's embryonic functions, granting oncogenic and metastatic properties. In this review, we report on the history and recent breakthroughs in understanding TWIST protein functions and the emerging role of the associated epithelial-mesenchymal transition (EMT) in tumorigenesis. We then broaden the discussion to address the general contribution of reactivating embryonic programs in cancerogenesis. Oncogene (2010) 29, 3173-3184; doi: 10.1038/onc.2010.92; published online 12 April 2010	[Ansieau, S.; Puisieux, A.] Ctr Leon Berard, INSERM, U590, F-69008 Lyon, France; [Bastid, J.; Puisieux, A.] Univ Lyon 1, Inst Sci Pharmaceut & Biol, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Ansieau, S (corresponding author), Ctr Leon Berard, INSERM, U590, 28 Rue Laennec, F-69008 Lyon, France.	ansieau@lyon.fnclcc.fr; puisieux@lyon.fnclcc.fr	Ansieau, Stephane/I-6195-2016; MOREL, Anne-Pierre/AAN-7072-2021	PUISIEUX, Alain/0000-0002-9938-3798; ANSIEAU, Stephane/0000-0003-0989-2108	Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes); l'Association pour la Recherche sur le Cancer (ARC); l'Institut National du Cancer (INCa); la Fondation de France; la Fondation Albert et Jeanne Rollet du Coudray	Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes); l'Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); l'Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); la Fondation de France(Fondation de France); la Fondation Albert et Jeanne Rollet du Coudray	Because of size restriction, unfortunately we could not refer to all significant contributions in this field. We therefore apologize to non-cited scientists. Our researches are supported by the Ligue contre le Cancer (Comites de l'Ain, de la Drome et Rhone-Alpes), l'Association pour la Recherche sur le Cancer (ARC), l'Institut National du Cancer (INCa), la Fondation de France and la Fondation Albert et Jeanne Rollet du Coudray.	Alborzi A, 1996, J CRAN GENET DEV BIO, V16, P94; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Ansieau S, 2008, CELL CYCLE, V7, P3659, DOI 10.4161/cc.7.23.7049; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BATE M, 1991, DEVELOPMENT, V113, P79; Baum B, 2008, SEMIN CELL DEV BIOL, V19, P294, DOI 10.1016/j.semcdb.2008.02.001; Baylies MK, 1996, SCIENCE, V272, P1481, DOI 10.1126/science.272.5267.1481; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Bourgeois P, 1998, HUM MOL GENET, V7, P945, DOI 10.1093/hmg/7.6.945; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Brouzes E, 2004, BIOL CELL, V96, P471, DOI 10.1016/j.biolcel.2004.04.009; Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544; Castanon I, 2001, DEVELOPMENT, V128, P3145; Cates JMM, 2008, APPL IMMUNOHISTO M M, V16, P251, DOI 10.1097/PAI.0b013e318156e9b4; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Connerney J, 2008, DEV BIOL, V318, P323, DOI 10.1016/j.ydbio.2008.03.037; Connerney J, 2006, DEV DYNAM, V235, P1345, DOI 10.1002/dvdy.20717; Cripps RM, 1998, DEV BIOL, V203, P106, DOI 10.1006/dbio.1998.9040; Demontis S, 2006, CELL DEATH DIFFER, V13, P335, DOI 10.1038/sj.cdd.4401744; Desprat N, 2008, DEV CELL, V15, P470, DOI 10.1016/j.devcel.2008.07.009; DI CE, 1999, LAB INVEST, V79, P1261; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dong YF, 2007, MOL ENDOCRINOL, V21, P2805, DOI 10.1210/me.2007-0199; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105; ElGhouzzi V, 1997, NAT GENET, V15, P42; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Entz-Werle N, 2005, INT J CANCER, V117, P349, DOI 10.1002/ijc.21068; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508; Farge E, 2003, CURR BIOL, V13, P1365, DOI 10.1016/S0960-9822(03)00576-1; Fendrich V, 2009, EUR J ENDOCRINOL, V160, P695, DOI 10.1530/EJE-08-0662; Feng Y, 2009, ORAL SURG ORAL MED O, V108, P565, DOI 10.1016/j.tripleo.2009.05.041; Firulli AB, 2008, CURR MED CHEM, V15, P2641, DOI 10.2174/092986708785908987; Firulli BA, 2005, NAT GENET, V37, P373, DOI 10.1038/ng1525; Fondrevelle ME, 2009, UROL ONCOL-SEMIN ORI, V27, P268, DOI 10.1016/j.urolonc.2007.12.012; Gee HE, 2008, NATURE, V455, DOI 10.1038/nature07362; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gort EH, 2008, ONCOGENE, V27, P1501, DOI 10.1038/sj.onc.1210795; Gort EH, 2008, CANCER EPIDEM BIOMAR, V17, P3325, DOI 10.1158/1055-9965.EPI-08-0472; Gripp KW, 2000, HUM MUTAT, V15, P150, DOI 10.1002/(SICI)1098-1004(200002)15:2<150::AID-HUMU3>3.0.CO;2-D; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hasselblatt M, 2009, CANCER RES, V69, P2219, DOI 10.1158/0008-5472.CAN-08-3176; Hayashi M, 2007, J CELL SCI, V120, P1350, DOI 10.1242/jcs.000067; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hinoi E, 2006, GENE DEV, V20, P2937, DOI 10.1101/gad.1482906; Hiscox S, 2006, INT J CANCER, V118, P290, DOI 10.1002/ijc.21355; Hoek K, 2004, CANCER RES, V64, P5270, DOI 10.1158/0008-5472.CAN-04-0731; HOPWOOD ND, 1989, CELL, V59, P893, DOI 10.1016/0092-8674(89)90612-0; Horikawa T, 2007, CANCER RES, V67, P1970, DOI 10.1158/0008-5472.CAN-06-3933; Hosono S, 2007, BRIT J CANCER, V96, P314, DOI 10.1038/sj.bjc.6603533; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu L, 2008, CANCER RES, V68, P4296, DOI 10.1158/0008-5472.CAN-08-0067; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181; Kajiyama H, 2006, ONCOLOGY-BASEL, V71, P394, DOI 10.1159/000107108; Kajiyama H, 2007, INT J ONCOL, V31, P277; Kojc N, 2009, VIRCHOWS ARCH, V454, P549, DOI 10.1007/s00428-009-0771-5; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kwok WK, 2005, CANCER RES, V65, P5153, DOI 10.1158/0008-5472.CAN-04-3785; Kyo S, 2006, HUM PATHOL, V37, P431, DOI 10.1016/j.humpath.2005.12.021; Lee MS, 1999, J CELL BIOCHEM, V75, P566, DOI 10.1002/(SICI)1097-4644(19991215)75:4<566::AID-JCB3>3.0.CO;2-0; Lee TK, 2006, CLIN CANCER RES, V12, P5369, DOI 10.1158/1078-0432.CCR-05-2722; Lee YM, 1997, J BIOL CHEM, V272, P17531, DOI 10.1074/jbc.272.28.17531; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920; Li Chang-hai, 2006, Zhonghua Wai Ke Za Zhi, V44, P1353; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Liu YQ, 2008, DEVELOPMENT, V135, P579, DOI 10.1242/dev.007047; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Man TK, 2005, CANCER RES, V65, P8142, DOI 10.1158/0008-5472.CAN-05-0985; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Mironchik Y, 2005, CANCER RES, V65, P10801, DOI 10.1158/0008-5472.CAN-05-0712; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakaya Y, 2008, DEV GROWTH DIFFER, V50, P755, DOI 10.1111/j.1440-169X.2008.01070.x; Nierodzik ML, 2006, CANCER CELL, V10, P355, DOI 10.1016/j.ccr.2006.10.002; Niesner U, 2008, J EXP MED, V205, P1889, DOI 10.1084/jem.20072468; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Niu RF, 2007, J EXP CLIN CANC RES, V26, P385; Ohuchida K, 2007, INT J CANCER, V120, P1634, DOI 10.1002/ijc.22295; OKA H, 1993, CANCER RES, V53, P1696; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Ou DL, 2008, ANTICANCER RES, V28, P1355; Pan DN, 2009, CELL, V137, P73, DOI 10.1016/j.cell.2009.01.051; Park SM, 2007, CELL CYCLE, V6, P2585, DOI 10.4161/cc.6.21.4845; Pham CG, 2007, MOL CELL BIOL, V27, P3920, DOI 10.1128/MCB.01219-06; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2006, BRIT J CANCER, V94, P13, DOI 10.1038/sj.bjc.6602876; Rho JK, 2009, LUNG CANCER, V63, P219, DOI 10.1016/j.lungcan.2008.05.017; Rice DPC, 2000, DEVELOPMENT, V127, P1845; Rodrigues CO, 2008, DEVELOPMENT, V135, P1903, DOI 10.1242/dev.011296; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Satoh K, 2008, AM J PATHOL, V172, P926, DOI 10.2353/ajpath.2008.070346; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Sharabi AB, 2008, PLOS BIOL, V6, P2786, DOI 10.1371/journal.pbio.0060316; Sharif MN, 2006, J EXP MED, V203, P1891, DOI 10.1084/jem.20051725; Shibata K, 2008, ANN ONCOL, V19, P81, DOI 10.1093/annonc/mdm344; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Smit MA, 2008, CANCER CELL, V14, P5, DOI 10.1016/j.ccr.2008.06.012; Smit MA, 2009, MOL CELL BIOL, V29, P3722, DOI 10.1128/MCB.01164-08; Song LB, 2006, CANCER LETT, V242, P258, DOI 10.1016/j.canlet.2005.11.013; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Stasinopoulos IA, 2005, J BIOL CHEM, V280, P2294, DOI 10.1074/jbc.M411018200; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; THISSE B, 1987, NUCLEIC ACIDS RES, V15, P3439, DOI 10.1093/nar/15.8.3439; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; UMBAS R, 1994, CANCER RES, V54, P3929; Valdes-Mora F, 2009, ANN SURG ONCOL, V16, P78, DOI 10.1245/s10434-008-0166-x; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Vesuna F, 2008, BIOCHEM BIOPH RES CO, V367, P235, DOI 10.1016/j.bbrc.2007.11.151; Waldmann J, 2009, ANN SURG ONCOL, V16, P1997, DOI 10.1245/s10434-009-0480-y; Wang SM, 1997, GENE, V187, P83, DOI 10.1016/S0378-1119(96)00727-5; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Watanabe O, 2004, ANTICANCER RES, V24, P3851; Whitehead J, 2008, HFSP J, V2, P286, DOI 10.2976/1.2955566; WOLF C, 1991, DEV BIOL, V143, P363, DOI 10.1016/0012-1606(91)90086-I; Wong MC, 2008, DEV BIOL, V317, P417, DOI 10.1016/j.ydbio.2008.02.020; Xie FW, 2009, CLIN EXP METASTAS, V26, P1025, DOI 10.1007/s10585-009-9292-5; Xie SQ, 2001, J BIOL CHEM, V276, P43305, DOI 10.1074/jbc.M106050200; Xu J, 2007, J HUAZHONG U SCI-MED, V27, P668, DOI 10.1007/s11596-007-0612-1; Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang L, 2008, WD SCI P COMP ENG, V1, P295, DOI 10.1142/9789812799470_0048; Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221; Yin ZZ, 1997, DEVELOPMENT, V124, P4971; Yoshida J, 2009, MED MOL MORPHOL, V42, P82, DOI 10.1007/s00795-008-0436-5; Yuen HF, 2007, J CLIN PATHOL, V60, P510, DOI 10.1136/jcp.2006.039099; Zhang YQ, 2007, PATHOLOGY, V39, P470, DOI 10.1080/00313020701570053; Zhang Z, 2007, HUM PATHOL, V38, P598, DOI 10.1016/j.humpath.2006.10.004; Zhu Q, 2008, J HUAZHONG U SCI-MED, V28, P144, DOI 10.1007/s11596-008-0207-5; Zhuo WL, 2008, BIOCHEM BIOPH RES CO, V369, P1098, DOI 10.1016/j.bbrc.2008.02.143	150	130	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3173	3184		10.1038/onc.2010.92	http://dx.doi.org/10.1038/onc.2010.92			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20383196				2022-12-17	WOS:000278321100001
J	van Zijl, F; Mair, M; Csiszar, A; Schneller, D; Zulehner, G; Huber, H; Eferl, R; Beug, H; Dolznig, H; Mikulits, W				van Zijl, F.; Mair, M.; Csiszar, A.; Schneller, D.; Zulehner, G.; Huber, H.; Eferl, R.; Beug, H.; Dolznig, H.; Mikulits, W.			Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge	ONCOGENE			English	Article						TGF-beta; PDGF; tumor-stroma interaction; epithelial to mesenchymal transition; spheroid	GROWTH-FACTOR; TGF-BETA; STELLATE CELLS; LIVER FIBROSIS; HEPATOCELLULAR-CARCINOMA; DIFFERENTIAL EXPRESSION; RAT-LIVER; PROGRESSION; HEPATOCYTES; MYOFIBROBLASTS	The tumor-stroma crosstalk is a dynamic process fundamental in tumor development. In hepatocellular carcinoma (HCC), the progression of malignant hepatocytes frequently depends on transforming growth factor (TGF)-beta provided by stromal cells. TGF-beta induces an epithelial to mesenchymal transition (EMT) of oncogenic Ras-transformed hepatocytes and an upregulation of platelet-derived growth factor (PDGF) signaling. To analyse the influence of the hepatic tumor-stroma crosstalk onto tumor growth and progression, we co-injected malignant hepatocytes and myofibroblasts (MFBs). For this, we either used in vitro-activated p19(ARF) MFBs or in vivo-activated MFBs derived from physiologically inflamed livers of Mdr2/p19(ARF) double-null mice. We show that co-transplantation of MFBs with Ras-transformed hepatocytes strongly enhances tumor growth. Genetic interference with the PDGF signaling decreases tumor cell growth and maintains plasma membrane-located E-cadherin and beta-catenin at the tumor-host border, indicating a blockade of hepatocellular EMT. We further generated a collagen gel-based three dimensional HCC model in vitro to monitor the MFB-induced invasion of micro-organoid HCC spheroids. This invasion was diminished after inhibition of TGF-beta or PDGF signaling. These data suggest that the TGF-beta/PDGF axis is crucial during hepatic tumor-stroma crosstalk, regulating both tumor growth and cancer progression. Oncogene (2009) 28, 4022-4033; doi:10.1038/onc.2009.253; published online 31 August 2009	[van Zijl, F.; Schneller, D.; Zulehner, G.; Huber, H.; Mikulits, W.] Med Univ Vienna, Div Inst Canc Res, Dept Med 1, A-1090 Vienna, Austria; [Mair, M.; Eferl, R.] Ludwig Boltzmann Inst Canc Res, Vienna, Austria; [Csiszar, A.; Beug, H.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Dolznig, H.] Med Univ Vienna, Inst Clin Pathol, A-1090 Vienna, Austria	Medical University of Vienna; Ludwig Boltzmann Institute; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Medical University of Vienna	Mikulits, W (corresponding author), Med Univ Vienna, Div Inst Canc Res, Dept Med 1, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Csiszar, Agnes/I-2747-2019; Dolznig, Helmut/L-7005-2015; Mikulits, Wolfgang/AAH-4043-2021	Csiszar, Agnes/0000-0001-7911-3427; Dolznig, Helmut/0000-0002-6063-3585; Eferl, Robert/0000-0002-6074-7144; Mikulits, Wolfgang/0000-0003-4612-7106	FWF [P19598-B13, SFB F28]; 'Hochschuljubilaumsstiftung der Stadt Wien'; Herzfelder Family Foundation; European Union [HEALTH-F4-2008-202047]	FWF(Austrian Science Fund (FWF)); 'Hochschuljubilaumsstiftung der Stadt Wien'; Herzfelder Family Foundation; European Union(European Commission)	Mdr2 null mice were kindly provided by Dr Ilan Stein. We thank Dr Takako Sasaki for the fibulin-2 antibody. This work was supported by the Austrian Science Fund, FWF, grant numbers P19598-B13 (to WM) and SFB F28 (to RE, HB and WM), the 'Hochschuljubilaumsstiftung der Stadt Wien' (to WM), the Herzfelder Family Foundation (to WM), and the European Union, FP7 Health Research, project number HEALTH-F4-2008-202047 (to WM).	Amann T, 2009, CANCER SCI, V100, P646, DOI 10.1111/j.1349-7006.2009.01087.x; Benckert C, 2003, CANCER RES, V63, P1083; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Breuhahn K, 2006, ONCOGENE, V25, P3787, DOI 10.1038/sj.onc.1209556; Campbell JS, 2007, DIFFERENTIATION, V75, P843, DOI 10.1111/j.1432-0436.2007.00235.x; Campbell JS, 2005, P NATL ACAD SCI USA, V102, P3389, DOI 10.1073/pnas.0409722102; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Dooley S, 2008, GASTROENTEROLOGY, V135, P642, DOI 10.1053/j.gastro.2008.04.038; Fickert P, 2004, GASTROENTEROLOGY, V127, P261, DOI 10.1053/j.gastro.2004.04.009; Fischer ANM, 2007, ONCOGENE, V26, P3395, DOI 10.1038/sj.onc.1210121; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Forbes SJ, 2004, GASTROENTEROLOGY, V126, P955, DOI 10.1053/j.gastro.2004.02.025; Friedman SL, 2004, NAT CLIN PRACT GASTR, V1, P98, DOI 10.1038/ncpgasthep0055; Gabbiani G, 2003, J PATHOL, V200, P500, DOI 10.1002/path.1427; Geerts A, 2001, SEMIN LIVER DIS, V21, P311, DOI 10.1055/s-2001-17550; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Gressner AM, 2002, FRONT BIOSCI-LANDMRK, V7, pD793, DOI 10.2741/gressner; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Herzig M, 2007, ONCOGENE, V26, P2290, DOI 10.1038/sj.onc.1210029; Ikegami T, 2007, CELLS TISSUES ORGANS, V185, P213, DOI 10.1159/000101322; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Kensler TW, 2003, NAT REV CANCER, V3, P321, DOI 10.1038/nrc1076; Kisseleva T, 2006, J HEPATOL, V45, P429, DOI 10.1016/j.jhep.2006.04.014; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; KNITTEL T, 1992, GASTROENTEROLOGY, V102, P1724, DOI 10.1016/0016-5085(92)91736-N; Lahsnig C, 2009, ONCOGENE, V28, P638, DOI 10.1038/onc.2008.418; Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933; Lee JS, 2005, SEMIN LIVER DIS, V25, P125, DOI 10.1055/s-2005-871192; Lee TK, 2006, CANCER RES, V66, P9948, DOI 10.1158/0008-5472.CAN-06-1092; Magness ST, 2004, HEPATOLOGY, V40, P1151, DOI 10.1002/hep.20427; Marra F, 2002, FRONT BIOSCI, V7, pD1899, DOI 10.2741/marra; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Morini Sergio, 2005, Italian Journal of Anatomy and Embryology, V110, P193; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Nitta T, 2008, HEPATOLOGY, V48, P909, DOI 10.1002/hep.22397; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pinzani M, 1996, AM J PATHOL, V148, P785; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; RAMADORI G, 1990, VIRCHOWS ARCH B, V59, P349, DOI 10.1007/BF02899424; Roderfeld M, 2006, FASEB J, V20, P444, DOI 10.1096/fj.05-4828com; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Russo FP, 2006, GASTROENTEROLOGY, V130, P1807, DOI 10.1053/j.gastro.2006.01.036; Sasaki T, 1996, J CELL SCI, V109, P2895; Sherman M, 2005, SEMIN LIVER DIS, V25, P143, DOI 10.1055/s-2005-871194; Sprenger H, 1999, J HEPATOL, V30, P88, DOI 10.1016/S0168-8278(99)80011-7; Stock P, 2007, MOL CANCER THER, V6, P1932, DOI 10.1158/1535-7163.MCT-06-0720; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Witz IP, 2008, CANCER RES, V68, P9, DOI 10.1158/0008-5472.CAN-07-2917; Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200	59	130	131	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 12	2009	28	45					4022	4033		10.1038/onc.2009.253	http://dx.doi.org/10.1038/onc.2009.253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	530AC	19718050	Green Accepted, Bronze			2022-12-17	WOS:000272560300007
J	Liu, L; Chen, L; Chung, J; Huang, S				Liu, L.; Chen, L.; Chung, J.; Huang, S.			Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins	ONCOGENE			English	Article						rapamycin; mammalian target of rapamycin; F-actin; lamellipodia; focal adhesion kinase	RICTOR-MTOR COMPLEX; GROWTH-FACTOR; MAMMALIAN TARGET; TYROSINE PHOSPHORYLATION; CELL-GROWTH; SIGNALING PATHWAY; BINDING PARTNER; MUSCLE-CELLS; AMINO-ACID; KINASE	An early event of cell migration is characterized as the rapid reorganization of the actin cytoskeleton. Recently, we have demonstrated that rapamycin inhibits tumor cell motility. To understand the underlying mechanism, this study was set to determine whether rapamycin inhibition of cell motility is related to its prevention of F-actin reorganization. We found that rapamycin prevented type I insulin-like growth factor (IGF-I)-stimulated F-actin reorganization in human rhabdomyosarcoma (Rh30), Ewing sarcoma (Rh1), glioblastoma (U-373) and prostate carcinoma (PC-3) cells, and concurrently inhibited phosphorylation of focal adhesion proteins, including focal adhesion kinase (FAK), paxillin and p130(Cas) in the cells. The effect of rapamycin was blocked by expression of a rapamycin-resistant mutant of mTOR (mTORrr), but not a kinase-dead mTORrr. Downregulation of raptor mimicked the effect of rapamycin. Cells infected with a recombinant adenovirus expressing constitutively active and rapamycin-resistant mutant of p70 S6 kinase 1 (S6K1) conferred to resistance to rapamycin. Further, IGF-I failed to stimulate F-actin reorganization and phosphorylation of the focal adhesion proteins in the S6K1-downregulated cells. Expression of constitutively hypophosphorylated eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1-5A) inhibited IGF-I-stimulated F-actin reorganization, but did not alter the cellular protein or phosphorylation levels of the focal adhesion proteins. The results suggest that rapamycin inhibits IGF-I-induced F-actin reorganization and phosphorylation of the focal adhesion proteins by disruption of mTOR-raptor complex. Both S6K1 and 4E-BP1 pathways, mediated by the mTOR-raptor complex, are involved in the regulation of IGF-I-stimulated F-actin reorganization, but only the former controls IGF-I-stimulated phosphorylation of the focal adhesion proteins.	[Liu, L.; Chen, L.; Chung, J.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; [Chung, J.; Huang, S.] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Huang, S (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	shuan1@lsuhsc.edu	Huang, Shile/I-1632-2019	Huang, Shile/0000-0002-3239-1072	NIH [R01 CA115414]; Louisiana Board of Regents [LEQSF(2006-09)-RD-A-18]; Feist-Weiller Cancer Center Award; Louisiana State University Health Sciences Center, Shreveport, LA, USA; NATIONAL CANCER INSTITUTE [R01CA115414] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisiana Board of Regents; Feist-Weiller Cancer Center Award; Louisiana State University Health Sciences Center, Shreveport, LA, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Robert T Abraham, Peter J Houghton, John C Lawrence, John Blenis and David M Sabatini for providing cell lines or constructs. This study was supported in part by NIH Grant R01 CA115414 ( SH), Louisiana Board of Regents (LEQSF(2006-09)-RD-A-18) (SH), and the Feist-Weiller Cancer Center Award (SH), Louisiana State University Health Sciences Center, Shreveport, LA, USA.	Berven LA, 2004, EXP CELL RES, V296, P183, DOI 10.1016/j.yexer.2003.12.032; Boffa DJ, 2004, CLIN CANCER RES, V10, P293, DOI 10.1158/1078-0432.CCR-0629-3; Casamassima A, 1998, J BIOL CHEM, V273, P26149, DOI 10.1074/jbc.273.40.26149; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Konstantopoulos N, 1996, BIOCHEM J, V314, P387, DOI 10.1042/bj3140387; Leopoldt D, 2001, J CELL PHYSIOL, V188, P106, DOI 10.1002/jcp.1102; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Leventhal PS, 1997, J BIOL CHEM, V272, P5214, DOI 10.1074/jbc.272.8.5214; Liu L, 2006, ONCOGENE, V25, P7029, DOI 10.1038/sj.onc.1209691; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523-1755.2003.00805.x; Malik RK, 1996, J BIOL CHEM, V271, P29785, DOI 10.1074/jbc.271.47.29785; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Sekulic A, 2000, CANCER RES, V60, P3504; Shu LL, 2002, J BIOL CHEM, V277, P16726, DOI 10.1074/jbc.M112285200; SMITH MA, 2006, PEDIAT BLOOD CANC, V50, P703; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wan X, 2007, ONCOGENE, V26, P1932, DOI 10.1038/sj.onc.1209990; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206	47	130	135	2	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2008	27	37					4998	5010		10.1038/onc.2008.137	http://dx.doi.org/10.1038/onc.2008.137			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GL	18504440	Green Accepted			2022-12-17	WOS:000258914800003
J	Tsutsumi, S; Scroggins, B; Koga, F; Lee, MJ; Trepel, J; Felts, S; Carreras, C; Neckers, L				Tsutsumi, S.; Scroggins, B.; Koga, F.; Lee, M-J; Trepel, J.; Felts, S.; Carreras, C.; Neckers, L.			A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion	ONCOGENE			English	Article						heat shock protein 90; cell motility; cancer metastasis; molecularly targeted small molecules	FOCAL ADHESION KINASE; CANCER CELLS; METASTASIS; MIGRATION; MELANOMA; EXPRESSION; GELDANAMYCIN; PHENOTYPES; SELECTION; ACTIN	Heat shock protein 90 ( Hsp90) is a molecular chaperone that maintains function of numerous intracellular signaling nodes utilized by cancer cells for proliferation and survival. Hsp90 is also detected on the plasma membrane of tumor cells and its expression has been suggested to correlate with metastatic potential. Given the abundance and diverse functions of the intracellular pool of this protein, the precise contribution of cell surface Hsp90 to cell motility and tumor metastasis remains to be determined. In this study we utilized the small molecule DMAG- N- oxide, a novel cell- impermeable Hsp90 inhibitor, to specifically examine the role of cell surface Hsp90 in cell motility. We observed that, while not affecting intracellular Hsp90 function, DMAG- N- oxide significantly retarded tumor cell migration and integrin/extracellular matrix- dependent cytoskeletal reorganization. Concomitant with these findings, targeting cell surface Hsp90 significantly inhibited tumor cell motility and invasion in vitro, and had a dramatic impact on melanoma cell lung colonization in vivo. These data indicate that cell surface Hsp90 plays an important role in modulating cancer cell migration that is independent of the function of the intracellular Hsp90 pool, and that small molecule inhibitors of surface Hsp90 may provide a new approach to targeting the metastatic phenotype.	[Tsutsumi, S.; Scroggins, B.; Koga, F.; Neckers, L.] NCI, NIH, Urol Oncol Branch, Bethesda, MD 20892 USA; [Lee, M-J; Trepel, J.] NCI, Med Oncol Branch, Bethesda, MD 20892 USA; [Felts, S.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN USA; [Felts, S.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN USA; [Carreras, C.] Kosan Biosci, Hayward, CA USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic; Mayo Clinic; Bristol-Myers Squibb; Kosan Biosciences, Inc.	Neckers, L (corresponding author), NCI, NIH, Urol Oncol Branch, 9000 ROckville Pike,Bldg 10-CRC,1-5940, Bethesda, MD 20892 USA.	len@helix.nih.gov	Koga, Fumitaka/AAO-2779-2021; KOGA, Fumitaka/AAM-8739-2021; Koga, Fumitaka/AAO-4655-2021; , Fumitaka/AAO-2957-2021	KOGA, Fumitaka/0000-0001-7888-0085; , Fumitaka/0000-0001-7888-0085	NATIONAL CANCER INSTITUTE [ZIASC010074, ZIABC011032, ZICSC006743, Z01SC006659] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 SC006659-25, Z01 SC010074-12] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arlander SJH, 2006, J BIOL CHEM, V281, P2989, DOI 10.1074/jbc.M508687200; Banerjee S, 2005, ADV MATER, V17, P17, DOI 10.1002/adma.200401340; Becker B, 2004, EXP DERMATOL, V13, P27, DOI 10.1111/j.0906-6705.2004.00114.x; BRUNSON KW, 1978, NATURE, V272, P543, DOI 10.1038/272543a0; Cranmer LD, 2005, MELANOMA RES, V15, P325, DOI 10.1097/00008390-200510000-00002; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; ERKELLERYUKSEL FM, 1992, J AUTOIMMUN, V5, P803, DOI 10.1016/0896-8411(92)90194-U; Eustace BK, 2004, NAT CELL BIOL, V6, P507, DOI 10.1038/ncb1131; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; Heath Elisabeth I, 2005, Clin Prostate Cancer, V4, P138, DOI 10.3816/CGC.2005.n.024; Munster PN, 2001, CANCER RES, V61, P2945; Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X; Neckers Len, 2005, Expert Opin Emerg Drugs, V10, P137, DOI 10.1517/14728214.10.1.137; Nguyen DM, 2000, ANN THORAC SURG, V70, P1853, DOI 10.1016/S0003-4975(00)01810-5; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Sidera K, 2004, J BIOL CHEM, V279, P45379, DOI 10.1074/jbc.M405486200; Solit DB, 2002, CLIN CANCER RES, V8, P986; Stellas D, 2007, CLIN CANCER RES, V13, P1831, DOI 10.1158/1078-0432.CCR-06-1585; Tian ZQ, 2004, BIOORGAN MED CHEM, V12, P5317, DOI 10.1016/j.bmc.2004.07.053; Wehrle-Haller B, 2003, INT J BIOCHEM CELL B, V35, P39, DOI 10.1016/S1357-2725(02)00071-7; Whitesell L, 2003, CURR CANCER DRUG TAR, V3, P349, DOI 10.2174/1568009033481787; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu JC, 2001, MOL THER, V4, P297, DOI 10.1006/mthe.2001.0460; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x	29	130	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2008	27	17					2478	2487		10.1038/sj.onc.1210897	http://dx.doi.org/10.1038/sj.onc.1210897			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286KN	17968312	Green Accepted			2022-12-17	WOS:000254844900012
J	Shih, JW; Tsai, Y; Chao, CH; Lee, YHW				Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu			Candidate tumor suppressor DDX3 RNA helicase specifically represses cap-dependent translation by acting as an eIF4E inhibitory protein	ONCOGENE			English	Article						cap-dependent translation; HCVIRES; DEAD box RNA helicase; DDX3; eIF4E inhibitory protein; tumor suppressor	HEPATITIS-C VIRUS; MESSENGER-RNA; CORE PROTEIN; EUKARYOTIC TRANSLATION; CELL-GROWTH; BINDING-PROTEIN; INITIATION; TRANSFORMATION; REQUIREMENT; EXPRESSION	DDX3 is a human RNA helicase with plethoric functions. Our previous studies have indicated that DDX3 is a transcriptional regulator and functions as a tumor suppressor. In this study, we use a bicistronic reporter to demonstrate that DDX3 specifically represses cap-dependent translation but enhances hepatitis C virus internal ribosome entry site-mediated translation in vivo in a helicase activity-independent manner. To elucidate how DDX3 modulates translation, we identified translation initiation factor eukaryotic initiation factor 4E (eIF4E) as a DDX3-binding partner. Interestingly, DDX3 utilizes a consensus eIF4E-binding sequence YIPPHLR to interact with the functionally important dorsal surface of eIF4E in a similar manner to other eIF4E-binding proteins. Furthermore, cap affinity chromatography analysis suggests that DDX3 traps eIF4E in a translationally inactive complex by blocking interaction with eIF4G. Point mutations within the consensus eIF4E-binding motif in DDX3 impair its ability to bind eIF4E and result in a loss of DDX3's regulatory effects on translation. All these features together indicate that DDX3 is a new member of the eIF4E inhibitory proteins involved in translation initiation regulation. Most importantly, this DDX3-mediated translation regulation also confers the tumor suppressor function on DDX3. Altogether, this study demonstrates regulatory roles and action mechanisms for DDX3 in translation, cell growth and likely viral replication.	[Shih, J-W; Tsai, Y.; Chao, C-H; Lee, Y-H Wu] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, Taipei 112, Taiwan	National Yang Ming Chiao Tung University	Lee, YHW (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Sect 2, 155 Li Nong St, Taipei 112, Taiwan.	yhwulee@ym.edu.tw	Shih, Jing-Wen/J-4555-2017	Shih, Jing-Wen/0000-0002-0417-9015; Lee Wu, Yan-Hwa/0000-0001-7299-7354; Chao, Chi-Hong/0000-0001-9890-4902				Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Chuang RY, 1997, SCIENCE, V275, P1468, DOI 10.1126/science.275.5305.1468; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; delaCruz J, 1997, P NATL ACAD SCI USA, V94, P5201, DOI 10.1073/pnas.94.10.5201; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Gebauer F, 2004, NAT REV MOL CELL BIO, V5, P827, DOI 10.1038/nrm1488; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hwang LH, 1998, BIOCHEM BIOPH RES CO, V252, P455, DOI 10.1006/bbrc.1998.9673; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; Kao CF, 2004, ONCOGENE, V23, P2472, DOI 10.1038/sj.onc.1207368; Linder P, 2003, BIOL CELL, V95, P157, DOI 10.1016/S0248-4900(03)00032-7; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Niessing D, 2002, GENE DEV, V16, P2576, DOI 10.1101/gad.240002; Ohlmann T, 1996, EMBO J, V15, P1371, DOI 10.1002/j.1460-2075.1996.tb00479.x; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Park SH, 1998, CYTOGENET CELL GENET, V81, P178, DOI 10.1159/000015022; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Rocak S, 2004, NAT REV MOL CELL BIO, V5, P232, DOI 10.1038/nrm1335; Rousseau D, 1996, ONCOGENE, V13, P2415; Sachs AB, 2000, NAT STRUCT BIOL, V7, P356, DOI 10.1038/75120; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Svitkin YV, 2005, MOL CELL BIOL, V25, P10556, DOI 10.1128/MCB.25.23.10556-10565.2005; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; YANG HS, 2004, NAT STRUCT MOL BIOL, V23, P26; Yedavalli VSRK, 2004, CELL, V119, P381, DOI 10.1016/j.cell.2004.09.029; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	38	130	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 24	2008	27	5					700	714		10.1038/sj.onc.1210687	http://dx.doi.org/10.1038/sj.onc.1210687			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667941				2022-12-17	WOS:000252674900014
J	Han, EKH; Leverson, JD; McGonigal, T; Shah, OJ; Woods, KW; Hunter, T; Giranda, VL				Han, E. K-H; Leverson, J. D.; McGonigal, T.; Shah, O. J.; Woods, K. W.; Hunter, T.; Giranda, V. L.			Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition	ONCOGENE			English	Article						A-443654; Akt; phosphorylation; rapamycin; mTOR	PROTEIN-KINASE; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PATHWAY; RAPAMYCIN; SURVIVAL; AKT/PKB; CANCER; PROGRESS	Rapamycin, a natural product inhibitor of the Raptor-mammalian target of rapamycin complex (mTORC1), is known to induce Protein kinase B (Akt/PKB) Ser-473 phosphorylation in a subset of human cancer cell lines through inactivation of S6K1, stabilization of insulin receptor substrate (IRS)-1, and increased signaling through the insulin/insulin-like growth factor-I/phosphatidylinositol 3-kinase (PI3K) axis. We report that A-443654, a potent small-molecule inhibitor of Akt serine/threonine kinases, induces Akt Ser-473 phosphorylation in all human cancer cell lines tested, including PTEN- and TSC2-deficient lines. This phenomenon is dose-dependent, manifests coincident with Akt inhibition and likely represents an alternative, rapid-feedback pathway that can be functionally dissociated from mTORC1 inhibition. Experiments performed in TSC2(-/-) cells indicate that TSC2 and IRS-1 cooperate with, but are dispensable for, A-443654-mediated Akt phosphorylation. This feedback event does require PI3K activity, however, as it can be inhibited by LY294002 or wortmannin. Small interfering RNA-mediated knockdown of mTOR or Rictor, components of the rapamycin-insensitive mTORC2 complex, but not the mTORC1 component Raptor, also inhibited Akt Ser-473 phosphorylation induced by A-443654. Our data thus indicate that Akt phosphorylation and activity are coupled in a manner not previously appreciated and provide a novel mode of Akt regulation that is distinct from the previously described rapamycin-induced IRS-1 stabilization mechanism.	Abbott Labs, Global Pharmaceut Res Div, Abbott Pk, IL 60064 USA; Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA 92037 USA	Abbott Laboratories; Salk Institute	Han, EKH (corresponding author), Abbott Labs, Global Pharmaceut Res Div, Dept R47S,Bldg AP9A, Abbott Pk, IL 60064 USA.	edward.k.han@abbott.com						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Barnett SF, 2005, CURR TOP MED CHEM, V5, P109, DOI 10.2174/1568026053507714; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cheung PCF, 2003, EMBO J, V22, P5793, DOI 10.1093/emboj/cdg552; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Granville CA, 2006, CLIN CANCER RES, V12, P679, DOI 10.1158/1078-0432.CCR-05-1654; Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Thompson JE, 2004, J CLIN ONCOL, V22, P4217, DOI 10.1200/jco.2004.01.103; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	27	130	137	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2007	26	38					5655	5661		10.1038/sj.onc.1210343	http://dx.doi.org/10.1038/sj.onc.1210343			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	200ZS	17334390				2022-12-17	WOS:000248801900011
J	Kilic, M; Kasperczyk, H; Fulda, S; Debatin, KM				Kilic, M.; Kasperczyk, H.; Fulda, S.; Debatin, K-M			Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance	ONCOGENE			English	Article						hypoxia; apoptosis; Hif-1 alpha; rhabdomyosarcoma; Ewing sarcoma	PANCREATIC-CANCER CELLS; HIF-1; GENE; HIF-1-ALPHA; EXPRESSION; FACTOR-1-ALPHA; ACTIVATION; SUPPRESSION; MECHANISM; PATHWAY	Hypoxia inducible factor-1 (HIF-1) is the major transcription factor and key regulator of adoptive responses to hypoxia. Although it usually promotes tumor cell survival under hypoxia, it has also been implied to trigger apoptosis. Although the impact of hypoxia has been extensively studied in many adult solid tumors, its role in most childhood tumors, for example, in rhabdomyosarcoma (RMS) or Ewing sarcoma (ES), has not yet been addressed. Here, we report that hypoxia protects A204 RMS and A673 ES cells against anticancer drug- or tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis and that Hif-1 alpha plays a key role in conferring apoptosis resistance under hypoxia. Although a functional HIF-1 pathway and proapoptotic proteins such as p53 and Bcl-2/E1B 19 kDa interacting protein 3 were activated under hypoxia in both A204 RMS and A673 ES cells, these cells remained refractory to apoptosis. Concomitant analysis of antiapoptotic proteins revealed that hypoxia induced expression of Bcl-2 and inhibitor of apoptosis proteins (IAP)-2 as well as proteins associated with anaerobic metabolism such as the glucose transporter protein GLUT-1 and the glycolytic enzyme Aldolase A. Specific downregulation of Hif-1 alpha by RNA interference significantly enhanced apoptosis under hypoxia by preventing the hypoxia-mediated increase in GLUT-1 expression without altering expression levels of the antiapoptotic proteins Bcl-2 or cIAP-2. Moreover, glucose deprivation-induced apoptosis of A204 RMS and A673 ES cells was inhibited under hypoxic conditions in a Hif-1 alpha-dependent manner. As GLUT-1 was induced via Hif-1 alpha under hypoxia in A204 RMS and A673 ES, these findings suggest that the Hif-1 alpha-mediated increase in glucose uptake plays an important role in conferring apoptosis resistance. Thus, hypoxia-inducible genes may represent novel targets for therapeutic intervention in some pediatric tumors, which warrants further investigation.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de; klaus-michael.debatin@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blum R, 2005, CANCER RES, V65, P999; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Dagher R, 1999, Oncologist, V4, P34; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fulda S, 1997, CANCER RES, V57, P3823; Ganjavi H, 2005, CANCER GENE THER, V12, P397, DOI 10.1038/sj.cgt.7700798; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hochachka PW, 2001, COMP BIOCHEM PHYS B, V130, P435, DOI 10.1016/S1096-4959(01)00408-0; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Murphy BJ, 1999, CANCER RES, V59, P1315; ORMEROD MG, 1992, FLOW CYTOMETRY PRACT; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P150, DOI 10.1006/bbrc.2002.6421; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Sowter HM, 2003, CANCER RES, V63, P6130; Sowter HM, 2001, CANCER RES, V61, P6669; Webster KA, 2000, ADV EXP MED BIOL, V475, P161; West DC, 2000, CURR OPIN ONCOL, V12, P323, DOI 10.1097/00001622-200007000-00008; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334; Zhong H, 1999, CANCER RES, V59, P5830	48	130	140	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2027	2038		10.1038/sj.onc.1210008	http://dx.doi.org/10.1038/sj.onc.1210008			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043658	Bronze			2022-12-17	WOS:000245313400005
J	Telang, S; Yalcin, A; Clem, AL; Bucala, R; Lane, AN; Eaton, JW; Chesney, J				Telang, S.; Yalcin, A.; Clem, A. L.; Bucala, R.; Lane, A. N.; Eaton, J. W.; Chesney, J.			Ras transformation requires metabolic control by 6-phosphofructo-2-kinase	ONCOGENE			English	Article						ras; metabolism; phosphofructokinase	6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE GENE PFKFB3; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FRUCTOSE 2,6-BISPHOSPHATE; ACTIVATED RAS; HUMAN CANCERS; NUCLEIC-ACID; GLYCOLYSIS; EXPRESSION; GLUCOSE; CELLS	Neoplastic cells transport large amounts of glucose in order to produce anabolic precursors and energy within the inhospitable environment of a tumor. The ras signaling pathway is activated in several cancers and has been found to stimulate glycolytic flux to lactate. Glycolysis is regulated by ras via the activity of 6-phosphofructo-2-kinase/fructose- 2,6-bisphosphatases (PFK2/FBPase), which modulate the intracellular concentration of the allosteric glycolytic activator, fructose-2,6-bisphosphate (F2,6BP). We report herein that sequential immortalization and ras-transformation of mouse fibroblasts or human bronchial epithelial cells paradoxically decreases the intracellular concentration of F2,6BP. This marked reduction in the intracellular concentration of F2,6BP sensitizes transformed cells to the antimetabolic effects of PFK2/FBPase inhibition. Moreover, despite co-expression of all four mRNA species (PFKFB1-4), heterozygotic genomic deletion of the inducible PFKFB3 gene in ras-transformed mouse lung fibroblasts suppresses F2,6BP production, glycolytic flux to lactate, and growth as soft agar colonies or tumors in athymic mice. These data indicate that the PFKFB3 protein product may serve as an essential downstream metabolic mediator of oncogenic ras, and we propose that pharmacologic inhibition of this enzyme should selectively suppress the high rate of glycolysis and growth by cancer cells.	Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, Louisville, KY 40202 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	University of Louisville; Yale University	Chesney, J (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, Mol Targets Program, 580 S Preston St, Louisville, KY 40202 USA.	jason.chesney@louisville.edu	Yalcin, Abdullah/AAA-6938-2022; Yalcin, Abdullah/ABI-4164-2020	Yalcin, Abdullah/0000-0001-8519-8375	NCI NIH HHS [1 R01 CA11642801] Funding Source: Medline; NCRR NIH HHS [1P20 RR18733] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018733] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Atsumi T, 2002, CANCER RES, V62, P5881; Blum R, 2005, CANCER RES, V65, P999; Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001; Boros LG, 2000, CANCER RES, V60, P1183; Chesney J, 2005, BIOCHEM BIOPH RES CO, V331, P139, DOI 10.1016/j.bbrc.2005.02.193; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CHESNEY J, 2001, BIOTECHNOL INT, V3, P213; Hamilton JA, 1997, MOL ENDOCRINOL, V11, P490, DOI 10.1210/me.11.4.490; HUE L, 1993, ADV ENZYME REGUL, V33, P97; Kessler R, 2001, MOL BRAIN RES, V87, P190, DOI 10.1016/S0169-328X(01)00014-6; KOLE HK, 1991, ARCH BIOCHEM BIOPHYS, V286, P586, DOI 10.1016/0003-9861(91)90084-V; Mahlknecht U, 2003, INT J ONCOL, V23, P883; Manzano A, 1998, CYTOGENET CELL GENET, V83, P214, DOI 10.1159/000015181; Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053; Minchenko O, 2003, FEBS LETT, V554, P264, DOI 10.1016/S0014-5793(03)01179-7; MUELLERKLIESER W, 1986, BRIT J CANCER, V53, P345, DOI 10.1038/bjc.1986.58; Navarro-Sabate A, 2001, GENE, V264, P131, DOI 10.1016/S0378-1119(00)00591-6; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; RACKER E, 1985, P NATL ACAD SCI USA, V82, P3535, DOI 10.1073/pnas.82.11.3535; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Sakai A, 1996, J BIOCHEM-TOKYO, V119, P506; Sakakibara R, 1997, J BIOCHEM-TOKYO, V122, P122; Sakakibara R, 1999, BIOCHEM BIOPH RES CO, V257, P177, DOI 10.1006/bbrc.1999.0429; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; TAETLE R, 1987, CANCER TREAT REP, V71, P297; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VANSCHAFTINGEN E, 1981, P NATL ACAD SCI-BIOL, V78, P3483; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; Vizan P, 2005, CANCER RES, V65, P5512, DOI 10.1158/0008-5472.CAN-05-0074; Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; Warburg O, 1924, BIOCHEM Z, V152, P319; Wechatekar K, 2005, CLIN RADIOL, V60, P1143, DOI 10.1016/j.crad.2005.05.018; Zhong H, 1999, CANCER RES, V59, P5830	38	130	140	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7225	7234		10.1038/sj.onc.1209709	http://dx.doi.org/10.1038/sj.onc.1209709			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16715124				2022-12-17	WOS:000242244700001
J	Poulikakos, PI; Xiao, GH; Gallagher, R; Jablonski, S; Jhanwar, SC; Testa, JR				Poulikakos, P. I.; Xiao, G-H; Gallagher, R.; Jablonski, S.; Jhanwar, S. C.; Testa, J. R.			Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK	ONCOGENE			English	Article						NF2; merlin; invasion; FAK; mesothelioma	FOCAL-ADHESION KINASE; MEDIATES CONTACT INHIBITION; NEUROFIBROMATOSIS TYPE-2; MALIGNANT MESOTHELIOMA; GENE-PRODUCT; MERLIN PHOSPHORYLATION; MEMBRANE ORGANIZATION; PLASMA-MEMBRANE; UNITED-STATES; ERM PROTEINS	The neuro. bromatosis type 2 NF2 gene product, merlin, is a tumor suppressor frequently inactivated in malignant mesothelioma (MM). To investigate a possible correlation between merlin inactivation and MM invasiveness, we restored merlin expression in NF2-deficient MM cells. Re-expression of merlin markedly inhibited cell motility, spreading and invasiveness, properties connected with the malignant phenotype of MM cells. To test directly whether merlin inactivation promotes invasion in a nonmalignant system, we used small interfering RNA to silence Nf2 in mouse embryonic fibroblasts (MEFs) and found that downregulation of merlin resulted in enhanced cell spreading and invasion. To delineate signaling events connected with this phenotype, we investigated the effect of merlin expression on focal adhesion kinase (FAK), a key component of cellular pathways affecting migration and invasion. Expression of merlin attenuated FAK phosphorylation at the critical phosphorylation site Tyr397 and disrupted the interaction of FAK with its binding partners Src and p85, the regulatory subunit of phosphatidylinositol-3-kinase. In addition, NF2-null MM cells stably overexpressing FAK showed increased invasiveness, which decreased significantly when merlin expression was restored. Collectively, these findings suggest that merlin inactivation is a critical step in MM pathogenesis and is related, at least in part, with upregulation of FAK activity.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Cell Imaging Facil, Philadelphia, PA 19111 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA	Fox Chase Cancer Center; Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 333 Cottman Ave, Philadelphia, PA 19111 USA.	Joseph.Testa@fccc.edu			NCI NIH HHS [CA-06927, CA-114047, CA-45745] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA114047, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Carbone M, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30227; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheng JQ, 1999, GENE CHROMOSOME CANC, V24, P238, DOI 10.1002/(SICI)1098-2264(199903)24:3<238::AID-GCC9>3.0.CO;2-M; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; GUSELLA JF, 1999, BIOCHIM BIOPHYS ACTA, V1423, P29; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Hirokawa Y, 2004, CANCER J, V10, P20, DOI 10.1097/00130404-200401000-00006; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; James MF, 2004, J CELL SCI, V117, P2951, DOI 10.1242/jcs.01156; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lee WC, 1999, INT J ONCOL, V14, P181; Manchanda N, 2005, J BIOL CHEM, V280, P12517, DOI 10.1074/jbc.C400583200; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2005, ONCOGENE, V24, P1150, DOI 10.1038/sj.onc.1208283; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; OWENS LV, 1995, CANCER RES, V55, P2752; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Price B, 2004, AM J EPIDEMIOL, V159, P107, DOI 10.1093/aje/kwh025; Price B, 1997, AM J EPIDEMIOL, V145, P211, DOI 10.1093/oxfordjournals.aje.a009093; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; SEKIDO Y, 1995, CANCER RES, V55, P1227; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Srivastava J, 2005, MOL BIOL CELL, V16, P1481, DOI 10.1091/mbc.e04-08-0721; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Watermann DO, 2005, BRIT J CANCER, V93, P694, DOI 10.1038/sj.bjc.6602744; Wells A, 2000, ADV CANCER RES, V78, P31; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200	51	130	132	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2006	25	44					5960	5968		10.1038/sj.onc.1209587	http://dx.doi.org/10.1038/sj.onc.1209587			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16652148				2022-12-17	WOS:000240826300005
J	Sridhar, SC; Miranti, CK				Sridhar, SC; Miranti, CK			Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases	ONCOGENE			English	Review						tetraspanin; integrin; c-Met; HGF; metastasis	HEPATOCYTE GROWTH-FACTOR; PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; FREQUENT DOWN-REGULATION; METASTASIS-SUPPRESSOR; TRANSMEMBRANE-4 SUPERFAMILY; GENE-EXPRESSION; EGF RECEPTOR; LUNG-CANCER; ALPHA-6-BETA-4 INTEGRIN	KAI1/CD82, a tetraspanin protein, was. first identified as a metastasis suppressor in prostate cancer. How loss of CD82 expression promotes cancer metastasis is unknown. Restoration of CD82 expression to physiological levels in the metastatic prostate cell line PC3 inhibits integrinmediated cell migration and invasion, but does not affect integrin expression. Integrin-dependent activation of the receptor kinase c-Met is dramatically reduced in CD82expressing cells, as is c-Met activation by its ligand HGF/SF. CD82 expression also reduced integrin-induced activation and phosphorylation of the cytoplasmic tyrosine kinase Src, and its downstream substrates p130Cas and FAK Y861. Inhibition of c-Met expression or Src kinase function reduced matrigel invasion of PC3 cells to the same extent as CD82 expression. These data indicate that CD82 functions to suppress integrin-induced invasion by regulating signaling to c-Met and Src kinases, and suggests that CD82 loss may promote metastasis by removing a negative regulator of c-Met and Src signaling.	Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, Grand Rapids, MI 49503 USA	Van Andel Institute	Miranti, CK (corresponding author), Van Andel Res Inst, Lab Integrin Signaling & Tumorigenesis, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.	cindy.miranti@vai.org	Miranti, Cindy/AAJ-3783-2020					Adachi M, 1996, CANCER RES, V56, P1751; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 2001, J CELL SCI, V114, P4143; Bill HM, 2004, MOL CELL BIOL, V24, P8586, DOI 10.1128/MCB.24.19.8586-8599.2004; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bouchard P, 2001, ORG DIVERS EVOL, V1, P17, DOI 10.1078/1439-6092-00003; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Brader S, 2004, TUMORI J, V90, P2, DOI 10.1177/030089160409000102; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Cannon KS, 2001, EMBO J, V20, P2443, DOI 10.1093/emboj/20.10.2443; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Chung J, 2004, J BIOL CHEM, V279, P32287, DOI 10.1074/jbc.M403809200; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Danilkovitch-Miagkova A, 2000, J BIOL CHEM, V275, P14783, DOI 10.1074/jbc.C000028200; Davies G, 2004, PROSTATE, V60, P317, DOI 10.1002/pros.20068; Davis TL, 2001, PROSTATE, V46, P240; De Miguel MP, 1999, CYTOKINE, V11, P722, DOI 10.1006/cyto.1998.0443; Di Lorenzo D, 2002, ENDOCRINOLOGY, V143, P4544, DOI 10.1210/en.2002-220448; Dong Jin-Tang, 1997, Current Opinion in Oncology, V9, P101; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Dong JT, 1996, CANCER RES, V56, P4387; FIXMAN ED, 1995, ONCOGENE, V10, P237; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Guo XZ, 1996, CANCER RES, V56, P4876; Hammond C, 1998, J IMMUNOL, V161, P3282; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hay RV, 2003, CLIN CANCER RES, V9, p3839S; He B, 2005, J BIOL CHEM, V280, P3346, DOI 10.1074/jbc.M406680200; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Hemler ME, 2003, ANNU REV CELL DEV BI, V19, P397, DOI 10.1146/annurev.cellbio.19.111301.153609; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; IMAI T, 1995, J IMMUNOL, V155, P1229; Jee B, 2003, EXP MOL MED, V35, P30, DOI 10.1038/emm.2003.5; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; Lagaudriere-Gesbert C, 1998, EUR J IMMUNOL, V28, P4332, DOI 10.1002/(SICI)1521-4141(199812)28:12<4332::AID-IMMU4332>3.0.CO;2-8; Lee CC, 2004, ONCOGENE, V23, P5193, DOI 10.1038/sj.onc.1207646; Lee JH, 2004, CANCER RES, V64, P4235, DOI 10.1158/0008-5472.CAN-04-0275; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; Liu FS, 2000, GYNECOL ONCOL, V78, P10, DOI 10.1006/gyno.2000.5801; Liu FS, 2001, AM J PATHOL, V159, P1629, DOI 10.1016/S0002-9440(10)63009-X; Liu L, 2003, WORLD J GASTROENTERO, V9, P1231, DOI 10.3748/wjg.v9.i6.1231; Lombardi DP, 1999, CANCER RES, V59, P5724; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maggiora P, 1997, J CELL PHYSIOL, V173, P183, DOI 10.1002/(SICI)1097-4652(199711)173:2<183::AID-JCP18>3.3.CO;2-Y; Mannion BA, 1996, J IMMUNOL, V157, P2039; MAYGARDEN SJ, 1992, ARCH PATHOL LAB MED, V116, P269; Miranti CK, 2002, METHOD CELL BIOL, V69, P359, DOI 10.1016/S0091-679X(02)69023-5; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Miyazaki T, 2000, CANCER-AM CANCER SOC, V89, P955, DOI 10.1002/1097-0142(20000901)89:5<955::AID-CNCR3>3.0.CO;2-Z; Mora LB, 2002, CANCER RES, V62, P6659; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Nakaigawa N, 2000, ONCOGENE, V19, P2996, DOI 10.1038/sj.onc.1203628; Nakashiro K, 2003, ONCOL REP, V10, P1149; Nishimura K, 1999, PROSTATE, V41, P145; Nishimura K, 1998, Int J Urol, V5, P276, DOI 10.1111/j.1442-2042.1998.tb00603.x; Odintsova E, 2000, CURR BIOL, V10, P1009, DOI 10.1016/S0960-9822(00)00652-7; Odintsova E, 2003, J CELL SCI, V116, P4557, DOI 10.1242/jcs.00793; Ono M, 2000, BIOCHEM BIOPH RES CO, V279, P744, DOI 10.1006/bbrc.2000.4030; Owens DM, 2001, CANCER RES, V61, P5248; Perlino E, 2000, AM J PATHOL, V157, P1727, DOI 10.1016/S0002-9440(10)64809-2; PISTERS LL, 1995, J UROLOGY, V154, P293, DOI 10.1016/S0022-5347(01)67297-5; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; Schmelz M, 2002, NEOPLASIA, V4, P243, DOI 10.1038/sj.neo.7900223; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Shinomiya N, 2004, CANCER RES, V64, P7962, DOI 10.1158/0008-5472.CAN-04-1043; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Skacel M, 2001, HUM PATHOL, V32, P1392, DOI 10.1053/hupa.2001.29676; SRIDHAR SC, 2005, IN PRESS; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Tamura M, 1999, JNCI-J NATL CANCER I, V91, P1820, DOI 10.1093/jnci/91.21.1820; Testa JE, 1999, CANCER RES, V59, P3812; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Tokuhara T, 2001, CLIN CANCER RES, V7, P4109; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186; van Leenders G, 2002, PROSTATE, V51, P98, DOI 10.1002/pros.10073; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang R, 1996, P NATL ACAD SCI USA, V93, P8425, DOI 10.1073/pnas.93.16.8425; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Wu De-hua, 2003, Di Yi Jun Yi Da Xue Xue Bao, V23, P714; Yu Y, 1997, CLIN CANCER RES, V3, P1045; Yunta M, 2003, CELL SIGNAL, V15, P559, DOI 10.1016/S0898-6568(02)00147-X; Zhang XA, 2003, CANCER RES, V63, P2665; Zhang XA, 2003, J BIOL CHEM, V278, P27319, DOI 10.1074/jbc.M303039200; Zhang XA, 2001, J BIOL CHEM, V276, P25005, DOI 10.1074/jbc.M102156200	102	130	140	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2006	25	16					2367	2378		10.1038/sj.onc.1209269	http://dx.doi.org/10.1038/sj.onc.1209269			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	032HC	16331263				2022-12-17	WOS:000236764300009
J	Mishra, L; Shetty, K; Tang, Y; Stuart, A; Byers, SW				Mishra, L; Shetty, K; Tang, Y; Stuart, A; Byers, SW			The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer	ONCOGENE			English	Review						TGF-beta; Wnt; Smad; ELF; cancer; stem cells	TRANSFORMING-GROWTH-FACTOR; II RECEPTOR GENE; NONPOLYPOSIS COLORECTAL-CANCER; TUMOR-SUPPRESSOR SMAD4/DPC4; HEPATIC PROGENITOR CELLS; POLYPOSIS-COLI GENE; BONE-MARROW; JUVENILE POLYPOSIS; EPITHELIAL-CELLS; MUTANT MICE	The past three decades have seen an unremitting quest to identify and understand gastrointestinal stem cells, their plasticity in differentiating across cell types, as well as their role in normal, regenerative, and cancer cells. A fascinating hallmark of stem cells is their ability to undergo assymetric cell division, which entails replication of the DNA followed by division of the nucleus and partitioning of the cytoplasm to yield two different daughter cells: a stem cell as well as a committed progenitor cell, the latter proliferating into differentiated progeny. We are only just beginning to understand how normally quiescent, tissue-specific stem cells interpret a vast array of signals to develop into the gastrointestinal system. These signaling pathways include the transforming growth factor-beta (TGF-beta) superfamily, Wnt, FGFs, Hedgehog, Hox proteins that originate from surrounding mesodermal/stromal tissue as well as endodermal/epithelial tissue. TGF-beta and wnt proteins are key morphogens that ultimately influence cell division and cell fate, so that gut endodermal stem cells enter the cell cycle, and undergo cell division that ultimately leads to differentiated cells such as functional hepatocytes, gastric parietal cells, or gut epithelial cells. Disruptions and errors in this process usually lead to tissue-specific gastrointestinal cancers such as hepatocellular cancers, gastric adenocarcinomas, and colonic adenocarcinomas. An increasingly complex and coherent view of stem/progenitor cell signaling networks, which coordinate cell growth, proliferation, stress management, and survival, is helping to de. ne the fragile areas where malignancies are likely to develop and shows promise for the development of better cancer therapies.	Georgetown Univ, Lab GI Dev Biol, Dept Surg, Washington, DC 20007 USA; DVAMC, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Cell Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Mishra, L (corresponding author), Georgetown Univ, Lab GI Dev Biol, Dept Surg, Med Dent Bldg,NW 210-12,3900 Reservoir Rd,NW, Washington, DC 20007 USA.	lopamishra@yahoo.com			NATIONAL CANCER INSTITUTE [R01CA106614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058196, R01DK056111] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106614] Funding Source: Medline; NIDDK NIH HHS [R01 DK58637, R01 DK58196, R01 DK56111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Akiyama Y, 1997, GASTROENTEROLOGY, V112, P33, DOI 10.1016/S0016-5085(97)70216-6; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; ALPINI G, 2004, PATHOPHYSIOLOGY BILI; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Attisano L, 1998, CURR OPIN CELL BIOL, V10, P188, DOI 10.1016/S0955-0674(98)80141-5; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Beck KA, 1996, AM J PHYSIOL-CELL PH, V270, pC1263, DOI 10.1152/ajpcell.1996.270.5.C1263; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bissell M J, 1981, Int Rev Cytol, V70, P27, DOI 10.1016/S0074-7696(08)61130-4; BISSELL MJ, 1982, J THEOR BIOL, V99, P31, DOI 10.1016/0022-5193(82)90388-5; Bjerknes M, 1999, AM J PATHOL, V154, P1831, DOI 10.1016/S0002-9440(10)65439-9; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Bonner-Weir S, 2002, J PATHOL, V197, P519, DOI 10.1002/path.1158; Brittan M, 2002, J PATHOL, V197, P492, DOI 10.1002/path.1155; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Chang J, 1997, CANCER RES, V57, P2856; Clements D, 2001, INT REV CYTOL, V203, P383; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DE M, 2000, J CELL SCI, V113, P2331; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Dubreuil RR, 2001, CELL TISSUE RES, V306, P167, DOI 10.1007/s004410100422; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Einstein M, 2001, MOL CELL BIOL, V21, P5122, DOI 10.1128/MCB.21.15.5122-5131.2001; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Forbes S, 2002, J PATHOL, V197, P510, DOI 10.1002/path.1163; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Ganz T, 2000, NAT IMMUNOL, V1, P99, DOI 10.1038/77884; Goggins M, 1998, CANCER RES, V58, P5329; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Grady W, 1998, Gastrointest Endosc, V48, P647; Grady WM, 1999, CANCER RES, V59, P320; GRANA X, 1995, ONCOGENE, V11, P211; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAGGITT RC, 1986, AM J SURG PATHOL, V10, P871, DOI 10.1097/00000478-198612000-00006; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1998, CANCER RES, V58, P1124; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Horne-Badovinac S, 2003, SCIENCE, V302, P662, DOI 10.1126/science.1085397; HOUSSAINT E, 1981, CELL DIFFER DEV, V10, P243, DOI 10.1016/0045-6039(81)90007-5; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; Hu XT, 2001, J HEMATOTH STEM CELL, V10, P67, DOI 10.1089/152581601750098255; Huang J, 1996, P NATL ACAD SCI USA, V93, P9049, DOI 10.1073/pnas.93.17.9049; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jacoby RF, 1997, AM J MED GENET, V70, P361, DOI 10.1002/(SICI)1096-8628(19970627)70:4<361::AID-AJMG6>3.0.CO;2-W; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KARAM SM, 1999, FRONT BIOSCI, V4, P286; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; KOYAMA S, 1989, J CLIN INVEST, V83, P1768, DOI 10.1172/JCI114080; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEDOUARI.N, 1967, CR ACAD SCI D NAT, V264, P1872; LEMIRE JM, 1991, AM J PATHOL, V139, P535; Lengyel J A, 1998, Cell Res, V8, P273; Libbrecht L, 2000, J PATHOL, V192, P373, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH700&gt;3.0.CO;2-5; Libbrecht L, 2001, AM J SURG PATHOL, V25, P1388, DOI 10.1097/00000478-200111000-00006; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Lu SL, 1996, CANCER RES, V56, P4595; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; Massague J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsumoto A, 2002, ANAT EMBRYOL, V205, P53, DOI 10.1007/s00429-001-0226-5; Mishra B, 2004, LIVER INT, V24, P637, DOI 10.1111/j.1478-3231.2004.0958.x; Mishra L, 1998, INT J DEV BIOL, V42, P221; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Monga SPS, 2001, CELL TRANSPLANT, V10, P81; MOSES HL, 1991, CIBA F SYMP, V157, P66; Murphy SJ, 2004, MOL BIOL CELL, V15, P2853, DOI 10.1091/mbc.E04-02-0097; Murtaugh LC, 2003, ANNU REV CELL DEV BI, V19, P71, DOI 10.1146/annurev.cellbio.19.111301.144752; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 2002, TRENDS MOL MED, V8, P361, DOI 10.1016/S1471-4914(02)02376-6; Nucci MR, 1997, HUM PATHOL, V28, P1396, DOI 10.1016/S0046-8177(97)90230-6; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PARSONS R, 1995, CANCER RES, V55, P5548; Pasche B, 1999, CANCER RES, V59, P5678; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Preston SL, 2003, CANCER RES, V63, P3819; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Redman RS, 2005, J ORAL PATHOL MED, V34, P23, DOI 10.1111/j.1600-0714.2004.00246.x; Reiss M, 1997, ONCOL RES, V9, P447; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Roberts DJ, 2000, DEV DYNAM, V219, P109, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1047>3.3.CO;2-Y; Rorke EA, 2000, EXP CELL RES, V259, P149, DOI 10.1006/excr.2000.4953; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012; Satterwhite DJ, 2004, CELL CYCLE, V3, P1069; Schutte M, 1996, CANCER RES, V56, P2527; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; SHAFRITZ DA, 1987, MONOGR PATHOL, V28, P136; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; SIEWEKE MH, 1990, SCIENCE, V248, P1656, DOI 10.1126/science.2163544; SIMON TC, 1995, CURR OPIN GENET DEV, V5, P577, DOI 10.1016/0959-437X(95)80026-3; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Sormunen RT, 1999, J PATHOL, V187, P416; SPORN MB, 1990, ANN NY ACAD SCI, V593, P1, DOI 10.1111/j.1749-6632.1990.tb16095.x; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stainier DYR, 2005, SCIENCE, V307, P1902, DOI 10.1126/science.1108709; Stainier DYR, 2002, GENE DEV, V16, P893, DOI 10.1101/gad.974902; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Taketo MM, 2000, CYTOKINE GROWTH F R, V11, P147, DOI 10.1016/S1359-6101(99)00038-6; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tang Y, 2005, CANCER RES, V65, P4228, DOI 10.1158/0008-5472.CAN-04-4585; Tang Y, 2003, SCIENCE, V299, P574, DOI 10.1126/science.1075994; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Theise ND, 2002, SEMIN CELL DEV BIOL, V13, P411, DOI 10.1016/S1084952102001283; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Tosh D, 2005, J HEPATOL, V42, pS75, DOI 10.1016/j.jhep.2004.12.009; Tran Hien, 2003, Sci STKE, V2003, pRE5, DOI 10.1126/stke.2003.172.re5; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wells JM, 1999, ANNU REV CELL DEV BI, V15, P393, DOI 10.1146/annurev.cellbio.15.1.393; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; YOUNES M, 1989, AM J PATHOL, V135, P1197; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	155	130	141	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5775	5789		10.1038/sj.onc.1208924	http://dx.doi.org/10.1038/sj.onc.1208924			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123810				2022-12-17	WOS:000231452800012
J	Holland, EC; Sonenberg, N; Pandolfi, PP; Thomas, G				Holland, EC; Sonenberg, N; Pandolfi, PP; Thomas, G			Signaling control of mRNA translation in cancer pathogenesis	ONCOGENE			English	Review						mRNA translation; PTEN; TSC1/2; mTOR; Rheb; eIF4E; prostate cancer; glioblastoma	INITIATION-FACTOR 4E; CAP-BINDING PROTEIN; AMINO-ACID-TRANSPORT; CELL-GROWTH; MAMMALIAN TARGET; PROSTATE-CANCER; S6 KINASE; PHOSPHORYLATION SITES; TUMOR SUPPRESSION; RAPAMYCIN TOR	The regulation of translation and the control of ribosome biogenesis are essential cellular processes whose impact on cell growth and proliferation is manifested at a number of specific levels. Disruption in one or more of the steps that control protein biosynthesis has been associated with alterations in the regulation of cell growth and cell cycle progression. Consistent with this, tumor suppressors and proto-oncogenes have been found to act on these functions and may therefore regulate malignant progression by affecting the protein synthetic machinery. Although many studies have correlated deregulation of protein biosynthesis with cancer, it remains to be established whether this process is necessary and/or sufficient for neoplastic transformation and metastasis.	Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA; McGill Univ, Dept Biochem, Montreal, PQ, Canada; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Friedrich Miescher Inst Biomed Res, CH-4058 Basel, Switzerland	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; McGill University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Friedrich Miescher Institute for Biomedical Research	Holland, EC (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org; nahum.sonenberg@mcgill.ca; p-pandolfi@ski.mskcc.org; george.thomas@fmi.ch	Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149				ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; ANTONETTI DA, 1993, J BIOL CHEM, V268, P25277; Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200; Backman SA, 2001, NAT GENET, V29, P396, DOI 10.1038/ng782; Backman SA, 2002, CURR OPIN NEUROBIOL, V12, P516, DOI 10.1016/S0959-4388(02)00354-9; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320; Blommaart EFC, 1997, HISTOCHEM J, V29, P365, DOI 10.1023/A:1026486801018; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; De Benedetti A, 1999, INT J BIOCHEM CELL B, V31, P59, DOI 10.1016/S1357-2725(98)00132-0; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GOMEZ M, 1999, TUBEROUS SCLEROSIS, V340; Gray IC, 1998, BRIT J CANCER, V78, P1296, DOI 10.1038/bjc.1998.674; GRESSNER AM, 1974, J BIOL CHEM, V249, P6917; Grewe M, 1999, CANCER RES, V59, P3581; Grunwald V, 2002, CANCER RES, V62, P6141; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P637; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Huang Shile, 2002, Curr Opin Investig Drugs, V3, P295; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Jefferson LS, 2001, J NUTR, V131, p2460S, DOI 10.1093/jn/131.9.2460S; Kenerson HL, 2002, CANCER RES, V62, P5645; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Kwon CH, 2001, NAT GENET, V29, P404, DOI 10.1038/ng781; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; Meric F, 2002, MOL CANCER THER, V1, P971; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; MUNOZ M, 1995, EXP PHYSIOL, V80, P745, DOI 10.1113/expphysiol.1995.sp003883; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Raught B, 2000, COLD SPRING HARBOR M, V39, P245; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; RAUGHT B, 2004, IN PRESS EMBO J; Rousseau D, 1996, ONCOGENE, V13, P2415; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Saucedo LJ, 2003, NAT CELL BIOL, V5, P680, DOI 10.1038/ncb0703-680c; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; TERADA N, 1993, J CELL PHYSIOL, V154, P7, DOI 10.1002/jcp.1041540103; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; THOMAS G, 1979, P NATL ACAD SCI USA, V76, P3952, DOI 10.1073/pnas.76.8.3952; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Volarevic S, 2000, SCIENCE, V288, P2045, DOI 10.1126/science.288.5473.2045; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WICKER LS, 1990, EUR J IMMUNOL, V20, P2277, DOI 10.1002/eji.1830201017; Wool I. G., 1996, TRANSLATIONAL CONTRO, P685; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	104	130	135	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2004	23	18					3138	3144		10.1038/sj.onc.1207590	http://dx.doi.org/10.1038/sj.onc.1207590			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	813AJ	15094763	Green Published			2022-12-17	WOS:000220879700002
J	Ionov, Y; Nowak, N; Perucho, M; Markowitz, S; Cowell, JK				Ionov, Y; Nowak, N; Perucho, M; Markowitz, S; Cowell, JK			Manipulation of nonsense mediated decay identifies gene mutations in colon cancer Cells with microsatellite instability	ONCOGENE			English	Article						NMD; microsatellite instability; p300	MESSENGER-RNA DECAY; COLORECTAL-CANCER; MAMMALIAN-CELLS; SURVEILLANCE; RETINOBLASTOMA; TRANSLATION; EXPRESSION; INACTIVATION; SEQUENCES; MECHANISM	Cancer cells showing microsatellite instability (MSI) demonstrate a high frequency of acquired frameshift mutations that result in the generation of nonsense mutations. RNA transcripts carrying these nonsense mutations are usually targeted for degradation through the nonsense mediated decay (NMD) pathway. Blocking this pathway with drugs such as emitine, results in the 'stabilization' of these mutant transcripts, which can now be detected on cDNA arrays. Unfortunately, emetine also induces a stress response that results in upregulation of additional transcripts which contribute to the analysis of the array. As a result, identifying which genes truly carry nonsense mutations is made more difficult. To overcome this, we have combined the emetine treatment with actinomycin D, which effectively prevents the upregulation of stress response genes while still stabilizing mutant transcripts. When we applied this modified approach to the analysis of MSI-positive colon cancer cells, we identified mutations in the UVRAG and p300 genes.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; Burnham Inst, La Jolla Canc Ctr, La Jolla, CA 92037 USA; Case Western Reserve Univ, Howard Hughes Med Inst, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Roswell Park Cancer Institute; Sanford Burnham Prebys Medical Discovery Institute; Case Western Reserve University; Howard Hughes Medical Institute; Case Western Reserve University; University Hospitals of Cleveland	Ionov, Y (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Yurij.Ionov@RoswellPark.org		Perucho, Manuel/0000-0002-2169-2662; Cowell, John/0000-0002-2079-5950				BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COWELL JK, 2001, MOL GENETICS CANC; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Iida A, 2000, HUM GENET, V106, P277, DOI 10.1007/s004390051038; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Jiang W, 1997, BIOCHEMISTRY-US, V36, P14786, DOI 10.1021/bi9717892; KIM HG, 1994, AM J PATHOL, V145, P148; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; KRATZKE RA, 1994, ONCOGENE, V9, P1321; Laurila IP, 1999, AGR FOOD SCI FINLAND, V8, P1; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; LOSSON R, 1979, P NATL ACAD SCI USA, V76, P5134, DOI 10.1073/pnas.76.10.5134; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mendell JT, 2002, SCIENCE, V298, P419, DOI 10.1126/science.1074428; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Perucho M, 1996, BIOL CHEM, V377, P675; Salahshor S, 1999, GENE CHROMOSOME CANC, V26, P247, DOI 10.1002/(SICI)1098-2264(199911)26:3<247::AID-GCC9>3.3.CO;2-8; Samowitz WS, 2001, AM J PATHOL, V158, P1517, DOI 10.1016/S0002-9440(10)64102-8; Sun XL, 2000, RNA, V6, P1, DOI 10.1017/S1355838200991660; TEITZ T, 1990, GENE, V87, P295, DOI 10.1016/0378-1119(90)90316-J; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498	28	130	136	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	2004	23	3					639	645		10.1038/sj.onc.1207178	http://dx.doi.org/10.1038/sj.onc.1207178			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737099				2022-12-17	WOS:000188304900002
J	Knauf, JA; Kuroda, H; Basu, S; Fagin, JA				Knauf, JA; Kuroda, H; Basu, S; Fagin, JA			RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase	ONCOGENE			English	Article						thyroid; RET/PTC; differentiation; RAS; MEK	TISSUE-SPECIFIC EXPRESSION; RECEPTOR TYROSINE KINASE; SODIUM/IODIDE SYMPORTER GENE; TRANSCRIPTION FACTOR PAX8; PAPILLARY CARCINOMAS; EPITHELIAL-CELLS; AUTOPHOSPHORYLATION SITES; ONCOGENE ACTIVATION; UPSTREAM ENHANCER; MAMMALIAN-CELLS	Constitutive activation of the RET proto-oncogene in papillary thyroid carcinomas results from rearrangements linking the promoter(s) and N-terminal domains of unrelated genes to the C-terminus of RET tyrosine kinase (RET/PTC). RET/PTC expression has been demonstrated to inhibit transcription of thyroid-specific genes. To study the signal transduction pathways responsible for this, we generated PCCL3 thyroid cells with doxycycline-inducible expression of RET/PTC3, RET/PTC3(Y541F), or PTC2/PDZ. Acute expression of RET/PTCY541F appropriately interacted with She, an intermediate in the activation of the Ras pathway, but failed to activate PLCgamma. By contrast, PTC2/PDZ failed to bind She, but interacted normally with PLCgamma. Acute expression of RET/PTC3 or RET/PTC3Y541F, but not PTC2/PDZ, inhibited TSH-induced Tg and NIS expression, suggesting that activation of Shc-Ras, but not PLCgamma, is required for RET/PTC-induced dedifferentiation. Accordingly, acute expression of H-Ras(V12) or of a constitutively active MEK1 also blocked TSH-induced expression of Tg and NIS. Moreover, MEK inhibitors restored Tg and NIS levels. In conclusion, activation of the Ras/Raf/MEK/MAPK pathway through She mediates RET/PTC-induced thyroid cell dedifferentiation. This suggests that inhibition of this pathway may promote redifferentiation in poorly differentiated thyroid carcinomas with constitutive activation of either Ras or RET/PTC.	Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Knauf, JA (corresponding author), Univ Cincinnati, Coll Med, Div Endocrinol & Metab, Mail Locat 0547, Cincinnati, OH 45267 USA.			Knauf, Jeffrey/0000-0003-4456-8792	NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706, R01CA072597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002781] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA050706, R01 CA072597, CA72597, CA50706] Funding Source: Medline; NIDDK NIH HHS [KO1DK02781] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Bounacer A, 1997, BIOCHIMIE, V79, P619, DOI 10.1016/S0300-9084(97)82012-3; Chun JT, 2001, EXP CLIN ENDOCR DIAB, V109, P23, DOI 10.1055/s-2001-11021; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; De Vita G, 1998, CELL GROWTH DIFFER, V9, P97; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Durick K, 1996, J BIOL CHEM, V271, P12691, DOI 10.1074/jbc.271.22.12691; FABBRO D, 1994, CANCER RES, V54, P4744; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gire V, 2000, ONCOGENE, V19, P737, DOI 10.1038/sj.onc.1203399; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ITO T, 1993, CANCER RES, V53, P2940; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Jhiang SM, 1998, RECENT RES CANCER, V154, P265; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Mascia A, 2002, J ENDOCRINOL, V172, P163, DOI 10.1677/joe.0.1720163; Medina DL, 2000, THYROID, V10, P295, DOI 10.1089/thy.2000.10.295; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Mercalli E, 2001, ONCOGENE, V20, P3475, DOI 10.1038/sj.onc.1204462; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; Missero C, 1998, MOL CELL ENDOCRINOL, V140, P37, DOI 10.1016/S0303-7207(98)00027-6; Missero C, 2000, MOL CELL BIOL, V20, P2783, DOI 10.1128/MCB.20.8.2783-2793.2000; Mizuno T, 1997, ONCOGENE, V15, P1455, DOI 10.1038/sj.onc.1201313; Mizuno T, 2000, ONCOGENE, V19, P438, DOI 10.1038/sj.onc.1203343; Nikiforov YE, 1997, CANCER RES, V57, P1690; Ohno M, 1999, MOL CELL BIOL, V19, P2051; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Powell DJ, 1998, CANCER RES, V58, P5523; Puxeddu E, 2001, ENDOCRIN METAB CLIN, V30, P493, DOI 10.1016/S0889-8529(05)70196-1; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; Santoro M, 2000, BRIT J CANCER, V82, P315, DOI 10.1054/bjoc.1999.0921; Santoro M, 2002, ANN NY ACAD SCI, V963, P116, DOI 10.1111/j.1749-6632.2002.tb04102.x; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; Santoro M, 1996, ONCOGENE, V12, P1821; Schmitt TL, 2002, THYROID, V12, P273, DOI 10.1089/10507250252949388; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Trapasso F, 1999, EUR J ENDOCRINOL, V140, P447, DOI 10.1530/eje.0.1400447; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vecchio G, 2000, CLIN CHEM LAB MED, V38, P113, DOI 10.1515/CCLM.2000.017; Velasco JA, 1998, ENDOCRINOLOGY, V139, P2796, DOI 10.1210/en.139.6.2796; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	55	130	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 10	2003	22	28					4406	4412		10.1038/sj.onc.1206602	http://dx.doi.org/10.1038/sj.onc.1206602			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	698BZ	12853977				2022-12-17	WOS:000183978900010
J	Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A				Sciacca, L; Mineo, R; Pandini, G; Murabito, A; Vigneri, R; Belfiore, A			In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A	ONCOGENE			English	Article						insulin; isoforms; IGF-I receptor; IGF-II; cell invasion; apoptosis	GROWTH-FACTOR-II; BREAST-CANCER CELLS; MONOCLONAL-ANTIBODIES; AUTOPHOSPHORYLATION; ACTIVATION; MECHANISM; MIGRATION; PATHWAYS; TUMORS	One of the two isoforms of the human insulin receptor (isoform A or IR-A) binds IGF-II with high affinity and is predominantly expressed in fetal tissues and malignant cells. We evaluated the biological relevance of IR-A in human myosarcoma cells. Six myosarcoma cell lines were studied. All produced high amounts of IGF-II and five of them predominantly expressed IR-A. SKUT-1 leiomyosarcoma cells, that do not express the IGF-IR, were identified as a suitable model to study the effects of IR-A in the absence of the interference of IGF-IR. In these cells, which express high levels of IR with an IR-A relative abundance of approximate to95%, IGF-II elicits biological effects exclusively via IR-A activation and IGF-I is almost ineffective. Blockade of autocrine IGF-II reduced unstimulated cell viability and migration. Although both insulin and IGF-II activate IR-A, these two ligands showed a different ability to activate different intracellular signaling pathways and to elicit different biological effects. Insulin was more potent than IGF-II in activating the PI3-K/Akt pathway and in protecting cells from apoptosis. In contrast, IGF-II was more potent than insulin in activating the Shc/ERK pathway and in stimulating cell migration. These data indicate that IGF-II sensitive IR-A is the predominant IR isoform in a variety of myosarcoma cells. In SKUT-1 leiomyoma cells this fetal IR isoform may vicariate the IGF-IR for cell response to both insulin and IGF-II. Acting on the same IR-A receptor IGF-II is more potent than insulin in stimulating cancer cell migration.	Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, I-88100 Catanzaro, Italy; Univ Catania, Dipartimento Med Interna & Med Specialist, Osped Garibaldi, I-95123 Catania, Italy; Ist Mediterraneo Oncol, IMO, Catania, Italy	Magna Graecia University of Catanzaro; University of Catania; Mediterranean Institute of Oncology	Belfiore, A (corresponding author), Univ Catanzaro, Cattedra Endocrinol, Dipartimento Med Clin & Sperimentale, Policlin Mater Domini, Via T Campanella 115, I-88100 Catanzaro, Italy.		Pandini, Giuseppe/AAB-9650-2019; Sciacca, Laura/B-9368-2014; SCIACCA, Laura/AAS-2896-2020; Belfiore, Antonino/B-4652-2011; Vigneri, Riccardo/M-3968-2017	Pandini, Giuseppe/0000-0003-3747-7649; Sciacca, Laura/0000-0002-3258-7200; SCIACCA, Laura/0000-0002-3258-7200; Belfiore, Antonino/0000-0002-6181-4193; Vigneri, Riccardo/0000-0002-4401-3140				BACH LA, 1994, ENDOCRINOLOGY, V135, P2168, DOI 10.1210/en.135.5.2168; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Bartucci M, 2001, CANCER RES, V61, P6747; Belfiore A, 1996, MOL ENDOCRINOL, V10, P1318, DOI 10.1210/me.10.11.1318; Cullen K J, 1992, Cancer Treat Res, V61, P413; CULLEN KJ, 1992, BREAST CANCER RES TR, V22, P21, DOI 10.1007/BF01833330; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; FORSAYETH JR, 1987, J BIOL CHEM, V262, P4134; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; GANDERTON RH, 1992, BIOCHEM J, V288, P195, DOI 10.1042/bj2880195; HEO DS, 1990, CANCER RES, V50, P3681; Hiromura K, 2002, KIDNEY INT, V61, P1312, DOI 10.1046/j.1523-1755.2002.00257.x; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; KULL FC, 1983, J BIOL CHEM, V258, P6561; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; ROTH RA, 1982, P NATL ACAD SCI-BIOL, V79, P7312, DOI 10.1073/pnas.79.23.7312; RUBIN R, 1995, LAB INVEST, V73, P311; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STRAUSS G, 1994, J INTERN MED, V236, P97, DOI 10.1111/j.1365-2796.1994.tb01127.x; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2002, J CLIN ENDOCR METAB, V87, P245, DOI 10.1210/jc.87.1.245; VU TH, 1995, J CLIN ENDOCR METAB, V80, P1670, DOI 10.1210/jc.80.5.1670	28	130	140	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 28	2002	21	54					8240	8250		10.1038/sj.onc.1206058	http://dx.doi.org/10.1038/sj.onc.1206058			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	616VK	12447687				2022-12-17	WOS:000179323900002
J	Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O				Dauphinot, L; De Oliveira, C; Melot, T; Sevenet, N; Thomas, V; Weissman, BE; Delattre, O			Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57(KIP2) and c-Myc expression	ONCOGENE			English	Article						Ewing tumour; cell cycle; EWS-FLI-1; c-Myc; p57(KIP2)	DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; DNA-BINDING; P53 MUTATIONS; GENE; FUSION; DOMAIN; PROTEIN; TRANSLOCATION; ONCOPROTEINS	Ewing tumour is characterized by specific chromosome translocations which fuse EU'S to a subset of genes encoding ETS transcription factors, most frequently FLI-1. We report the analysis of the expression of various cell cycle regulators both in Ewing tumour derived cell lines and in different cellular models with either inducible or constitutive EWS-FLI-1 cDNA expression. In Ewing cell lines, cyclin D1, CDK4, Rb, p27(KIP1) and c-Myc were consistently highly expressed whereas p57(KIP2), p15(INK4B) and p14(ARF) demonstrated undetectable or low expression levels. The amount of p16(INK4A), p21(CIP1), p18(INKAC) and CDK6 was variable from one cell line to the other, The inducible expression of EWS-FLI-1 led to a strong upregulation of c-MSc and a considerable downregulation of p57(KIP2). Other proteins did not show evident modification. High c-Myc and very low p57(KIP2) expression levels were also observed in neuroblastoma NGP cells constitutively expressing EWS-FLI-1 as compared to parental cells. Analysis of the p57(KIP2) promoter indicated that EWS-FLI-1 downregulates, possibly through an indirect mechanism, the transcription of this gene, Finally, we show that ectopic expression of p57(KIP2) in Ewing cells blocks proliferation through a complete G1 arrest. These results suggest that the modulation of p57(KIP2) expression by EWS-FLI-1 is a fundamental step in Ewing tumorigenesis.	Inst Curie, Lab Pathol Mol Canc, INSERM U509, F-75248 Paris 05, France; Univ N Carolina, Lineberger Canc Ctr 345, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; University of North Carolina; University of North Carolina Chapel Hill	Delattre, O (corresponding author), Inst Curie, Lab Pathol Mol Canc, INSERM U509, 26 Rue Ulm, F-75248 Paris 05, France.			delattre, olivier/0000-0002-8730-2276				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Arvand A, 1998, ONCOGENE, V17, P2039, DOI 10.1038/sj.onc.1202129; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; de Medina SGD, 1998, HUM PATHOL, V29, P1005, DOI 10.1016/S0046-8177(98)90208-8; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Feinberg AP, 1999, CANCER RES, V59, p1743S; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hashimoto Y, 1998, J BIOL CHEM, V273, P16544, DOI 10.1074/jbc.273.26.16544; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Hatada I, 1996, HUM MOL GENET, V5, P783, DOI 10.1093/hmg/5.6.783; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Im YH, 2000, CANCER RES, V60, P1536; Jaishankar S, 1999, ONCOGENE, V18, P5592, DOI 10.1038/sj.onc.1202940; KOMURO H, 1993, CANCER RES, V53, P5284; KOVAR H, 1993, ONCOGENE, V8, P2683; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MAO XH, 1994, J BIOL CHEM, V269, P18216; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; Melot T, 1997, HYBRIDOMA, V16, P457, DOI 10.1089/hyb.1997.16.457; PETER M, 1995, BRIT J CANCER, V72, P96, DOI 10.1038/bjc.1995.283; Reid LH, 1996, CANCER RES, V56, P1214; REMVIKOS Y, 1991, BRIT J CANCER, V64, P501, DOI 10.1038/bjc.1991.338; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; Thompson AD, 1996, ONCOGENE, V13, P2649; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Xing EP, 1999, CLIN CANCER RES, V5, P2704	35	130	138	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2001	20	25					3258	3265		10.1038/sj.onc.1204437	http://dx.doi.org/10.1038/sj.onc.1204437			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	440ET	11423975				2022-12-17	WOS:000169163500009
J	Zheng, L; Li, S; Boyer, TG; Lee, WH				Zheng, L; Li, S; Boyer, TG; Lee, WH			Lessons learned from BRCA1 and BRCA2	ONCOGENE			English	Review						BRCA1; BRCA2; breast cancer; tumor suppressor; transcription regulation; DNA damage repair	CANCER SUSCEPTIBILITY GENE; DOUBLE-STRAND BREAKS; CELL-CYCLE CHECKPOINT; DNA-DAMAGE RESPONSE; HUMAN RAD51 PROTEIN; EARLY EMBRYONIC LETHALITY; POLYMERASE-II HOLOENZYME; MAMMARY EPITHELIAL-CELLS; C-TERMINAL REGION; INTERACT IN-VIVO	BRCA1 and BRCA2 are breast cancer susceptibility genes. Mutations within BRCA1 and BRCA1 are responsible for most familial breast cancer cases. Targeted deletion of Brca1 or Brca2 in mice has revealed an essential function for their encoded products, BRCA1 and BRCA2, in cell proliferation during embryogenesis. Mouse models established from conditional expression of mutant Brca1 alleles develop mammary gland tumors, providing compelling evidence that BRCA1 functions as a breast cancer suppressor. Human cancer cells and mouse cells deficient in BRCA1 or BRCA2 exhibit radiation hypersensitivity and chromosomal abnormalities, thus revealing a potential role for both BRCA1 and BRCA2 in the maintenance of genetic stability through participation in the cellular response to DIVA damage. Functional analyses of the BRCA1 and BRCA2 gene products have established their dual participation in transcription regulation and DNA damage repair. Potential insight into the molecular basis for these functions of BRCA1 and BRCA2 has been provided by studies that implicate these two tumor suppressors in both the maintenance of genetic stability and the regulation of cell growth and differentiation.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, 15355 Lambda Dr, San Antonio, TX 78245 USA.			LI, SHANG/0000-0002-6226-3362				ALANI E, 1989, GENETICS, V122, P47; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertwistle D, 1997, CANCER RES, V57, P5485; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bressan DA, 1999, MOL CELL BIOL, V19, P7681; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chamankhah M, 1999, NUCLEIC ACIDS RES, V27, P2072, DOI 10.1093/nar/27.10.2072; Chamankhah M, 2000, GENETICS, V155, P569; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen PL, 1998, P NATL ACAD SCI USA, V95, P5287, DOI 10.1073/pnas.95.9.5287; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; Clark AJ, 1996, BIOESSAYS, V18, P767, DOI 10.1002/bies.950180912; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; EASTON DF, 1993, AM J HUM GENET, V52, P678; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Friedman LS, 1998, CANCER RES, V58, P1338; Fuks F, 1998, ONCOGENE, V17, P2531, DOI 10.1038/sj.onc.1202475; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gerecke EE, 2000, GENETICS, V154, P1125; Glass CK, 2000, GENE DEV, V14, P121; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; IVANOV EL, 1992, GENETICS, V132, P651; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; JOHZUKA K, 1995, GENETICS, V139, P1521; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kleiman FE, 1999, SCIENCE, V285, P1576, DOI 10.1126/science.285.5433.1576; KOIPALLY J, 2000, J BIOL CHEM, V13, P13; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li L, 1999, MOL CELL BIOL, V19, P5619; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Lu KP, 1996, NATURE, V380, P544; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCKEE RH, 1980, MUTAT RES, V70, P37, DOI 10.1016/0027-5107(80)90056-1; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milner J, 1997, NATURE, V386, P772, DOI 10.1038/386772a0; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nordling M, 1998, CANCER RES, V58, P1372; Nugent CI, 1998, CURR BIOL, V8, P657, DOI 10.1016/S0960-9822(98)70253-2; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAINTER RB, 1987, J CELL SCI, P207; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Prives C, 1999, J PATHOL, V187, P112; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Schlegel BP, 2000, P NATL ACAD SCI USA, V97, P3148, DOI 10.1073/pnas.070452397; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Siddique H, 1998, ONCOGENE, V16, P2283, DOI 10.1038/sj.onc.1202003; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Su TT, 2000, NAT CELL BIOL, V2, pE28; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Suzuki M, 1997, FASEB J, V11, pA1155; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Tsubouchi H, 1998, MOL CELL BIOL, V18, P260, DOI 10.1128/MCB.18.1.260; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang Y, 2000, GENE DEV, V14, P927; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu VPCC, 2000, GENE DEV, V14, P1400; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	164	130	139	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2000	19	53					6159	6175		10.1038/sj.onc.1203968	http://dx.doi.org/10.1038/sj.onc.1203968			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156530				2022-12-17	WOS:000166121400010
J	Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL				Bugge, TH; Lund, LR; Kombrinck, KK; Nielsen, BS; Holmback, K; Drew, AF; Flick, MJ; Witte, DP; Dano, K; Degen, JL			Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice	ONCOGENE			English	Article						cancer; gene targeting; mammary carcinoma; metastasis; plasminogen	LEWIS LUNG-CARCINOMA; ASCITES TUMOR-GROWTH; BREAST-CANCER; UROKINASE RECEPTOR; MESSENGER-RNA; ACTIVATOR ACTIVITY; COLORECTAL-CANCER; STROMA FORMATION; MELANOMA-CELLS; INHIBITION	To investigate the role of plasmin(ogen) in mammary tumor development and progression, plasminogen-deficient mice were crossed with transgenic mice expressing Polyoma middle T antigen under the control of the mouse mammary tumor virus long terminal repeat. Virgin females carrying the Polyoma middle T antigen uniformly developed multiple, bilateral mammary tumors, regardless of the presence or absence of circulating plasminogen. Both the age at which these tumors became palpable and subsequent tumor growth were indistinguishable between plasminogen-deficient mice and plasminogen-expressing littermates. Hoowever, plasminogen was found to greatly modify the metastatic potential in this model system; lung metastasis in plasminogen-deficient mice was significantly reduced as compared to littermate controls with respect to frequency of occurrence, total number of metastases, and total metastatic tumor burden. Plasminogen activators, as well as other key factors that govern the conversion of plasminogen to plasmin, were expressed within the mammary tumors, suggesting that the plasminogen/plasmin system may promote metastasis by contributing to tumor-associated extracellular proteolysis. The data provide direct evidence that plasmin(ogen) is a tumor progression factor in PymT-induced mammary cancer, and support the hypothesis that hemostatic factors play an important role in tumor biology.	Childrens Hosp Res Fdn, Div Dev Biol, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Div Pathol, Cincinnati, OH 45229 USA; Finsen Lab, DK-2100 Copenhagen, Denmark	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation	Degen, JL (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, IDR NRB Room 2025,3333 Burnet Ave, Cincinnati, OH 45229 USA.				NHLBI NIH HHS [HL47826] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047826] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson IC, 1996, CANCER RES, V56, P715; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BROWN LF, 1988, CANCER RES, V48, P1920; BRUNNER G, 1991, J CELL BIOL, V114, P1275, DOI 10.1083/jcb.114.6.1275; Bugge TH, 1997, BLOOD, V90, P4522; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Coleman JL, 1997, CELL, V89, P1111, DOI 10.1016/S0092-8674(00)80298-6; COLLEN D, 1994, MOL BASIS BLOOD DIS, P725; Conway JG, 1996, CLIN EXP METASTAS, V14, P115, DOI 10.1007/BF00121208; CRAWFORD HC, 1994, INVAS METAST, V14, P234; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; DUFFY MJ, 1992, CLIN EXP METASTAS, V10, P145, DOI 10.1007/BF00132746; DUFFY MJ, 1990, CANCER RES, V50, P6827; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; FOEKENS JA, 1992, CANCER RES, V52, P6101; FRAKI JE, 1983, BRIT J DERMATOL, V108, P39, DOI 10.1111/j.1365-2133.1983.tb04577.x; GANESH S, 1994, CANCER RES, V54, P4065; GRODAHLHANSEN J, 1993, CANCER RES, V53, P2513; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HARRIS NL, 1982, AM J PATHOL, V108, P119; HEARING VJ, 1988, CANCER RES, V48, P1270; HEINERT G, 1988, J UROLOGY, V140, P1466; HEISS MM, 1995, NAT MED, V1, P1035, DOI 10.1038/nm1095-1035; Holmback K, 1996, EMBO J, V15, P5760, DOI 10.1002/j.1460-2075.1996.tb00962.x; JANICKE F, 1989, LANCET, V2, P1049; KOBAYASHI H, 1994, THROMB HAEMOSTASIS, V71, P474; KOBAYASHI H, 1994, INT J CANCER, V57, P727, DOI 10.1002/ijc.2910570520; KOHN EC, 1995, CANCER RES, V55, P1856; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; KRISTENSEN P, 1991, J HISTOCHEM CYTOCHEM, V39, P341, DOI 10.1177/39.3.1899685; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Martin DC, 1996, ONCOGENE, V13, P569; Min HY, 1996, CANCER RES, V56, P2428; MOCHAN E, 1984, J RHEUMATOL, V11, P123; MUELLER BM, 1995, P NATL ACAD SCI USA, V92, P205, DOI 10.1073/pnas.92.1.205; MULCAHY HE, 1994, LANCET, V344, P583, DOI 10.1016/S0140-6736(94)91968-2; NAGY JA, 1995, CANCER RES, V55, P376; NAGY JA, 1995, CANCER RES, V55, P369; NEKARDA H, 1994, LANCET, V343, P117, DOI 10.1016/S0140-6736(94)90845-1; Nielsen BS, 1996, LAB INVEST, V74, P168; ODEKON LE, 1994, J CELL PHYSIOL, V158, P398, DOI 10.1002/jcp.1041580303; OKA T, 1991, CANCER RES, V51, P3522; OSSOWSKI L, 1991, CANCER RES, V51, P274; OSSOWSKI L, 1988, CELL, V52, P321, DOI 10.1016/S0092-8674(88)80025-4; OSSOWSKI L, 1983, CELL, V35, P611, DOI 10.1016/0092-8674(83)90093-4; PEDERSEN H, 1994, CANCER RES, V54, P4671; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; PRENDERGAST GC, 1990, MOL CELL BIOL, V10, P1265, DOI 10.1128/MCB.10.3.1265; PYKE C, 1991, CANCER RES, V51, P4067; PYKE C, 1993, CANCER RES, V53, P1911; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 1995, INT J CANCER, V63, P840, DOI 10.1002/ijc.2910630615; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; ROMER J, 1991, J INVEST DERMATOL, V97, P803, DOI 10.1111/1523-1747.ep12486833; SAFTIG P, 1995, EMBO J, V14, P3599, DOI 10.1002/j.1460-2075.1995.tb00029.x; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SALONEN EM, 1987, ACTA OPHTHALMOL, V65, P3; SAPPINO AP, 1987, CANCER RES, V47, P4043; Schuster V, 1997, BLOOD, V90, P958, DOI 10.1182/blood.V90.3.958.958_958_966; SCHWARTZ MK, 1995, CLIN CHIM ACTA, V237, P67, DOI 10.1016/0009-8981(95)06065-L; Shapiro RL, 1996, CANCER RES, V56, P3597; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SKRIVER L, 1984, Journal of Cell Biology, V99, P752; SLEDGE GW, 1995, J NATL CANCER I, V87, P1546, DOI 10.1093/jnci/87.20.1546; SOEDA E, 1980, NATURE, V283, P445, DOI 10.1038/283445a0; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; WERB Z, 1977, NEW ENGL J MED, V296, P1017, DOI 10.1056/NEJM197705052961801; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Xiao Q, 1997, P NATL ACAD SCI USA, V94, P10335, DOI 10.1073/pnas.94.19.10335; YU H, 1990, CANCER RES, V50, P7623	80	130	135	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3097	3104		10.1038/sj.onc.1201869	http://dx.doi.org/10.1038/sj.onc.1201869			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671388				2022-12-17	WOS:000074261300002
J	Westermarck, J; Seth, A; Kahari, VM				Westermarck, J; Seth, A; Kahari, VM			Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors	ONCOGENE			English	Article						collagenase; ETS, AP-1; transcription; fibroblast	C-JUN; EXTRACELLULAR-MATRIX; OKADAIC ACID; AP-1; PROMOTER; CELLS; FAMILY; PROTEINS; ONCOGENE; DNA	Expression of interstitial collagenase (MMP-1) has been detected in stromal fibroblasts of various malignant tumors, Here, we have studied the effect of three structurally different ETS transcription factors (ETS-1, ERGB/Fli-1, and PU.1) on MMP-1 promoter activity in NIH3T3 fibroblasts, ETS-1 increased the activity of 3.8 kb MMP-1 promoter construct up to tenfold, while ERGB/FLi-1 or PU.1 alone had no marked effect on basal promoter activity, ETS-1 also markedly potentiated enhancement of MMP-1 promoter by both c-Jun and JunB, whereas ERGB/FLi-1 augmented only the effect of c-Jun, Interestingly, PU.1 abolished induction of MMP-1 promoter by both c-Jun and JunB, Stimulation of MMP-1 promoter by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid was differentially augmented by ETS-1 and ERGB/Fli-1, and abrogated by PU.1, Cotransfection studies with MMP-1 promoter 5'-deletion constructs revealed that AP-1 site was necessary for PU.1-elicited suppression, As compared to control cell lines, PU.1-positive stable cells exhibited clearly weaker binding of c-Jun and JunD containing AP-1 complexes to MMP-1 promoter AP-1 element, as well as marked reduction in basal level and induction of c-jun mRNA by 12-O-tetradecanoyl phorbol-13-acetate and okadaic acid, suggesting a novel mechanism for PU.1-mediated inhibition of AP-1 dependent gene expression, These results show that three structurally distinct ETS transcription factors differently modulate AP-1 dependent upregulation of MMP-1 gene expression.	UNIV TURKU,CENT HOSP,DEPT DERMATOL,FIN-20520 TURKU,FINLAND; UNIV TURKU,DEPT MED BIOCHEM,FIN-20520 TURKU,FINLAND; UNIV TURKU,MEDICITY RES LAB,FIN-20520 TURKU,FINLAND; UNIV TORONTO,DEPT PATHOL,TORONTO,ON M5S,CANADA; UNIV TORONTO,MRC,PERIODONTAL PHYSIOL GRP,TORONTO,ON M5S,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S,CANADA	University of Turku; University of Turku; University of Turku; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Westermarck, Jukka/AAL-6464-2020; Kähäri, Veli-Matti/E-5144-2011; Kahari, Veli-Matti/T-4925-2019	Westermarck, Jukka/0000-0001-7478-3018; Kähäri, Veli-Matti/0000-0003-2421-9368; Kahari, Veli-Matti/0000-0003-2421-9368				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BERGELSON S, 1994, BIOCHEM BIOPH RES CO, V200, P290, DOI 10.1006/bbrc.1994.1447; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BISWAS C, 1995, CANCER RES, V55, P434; BOLON I, 1995, AM J PATHOL, V147, P1298; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN HM, 1995, ONCOGENE, V11, P1549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5924; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COFFER P, 1994, ONCOGENE, V9, P911; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAY ST, 1992, AM J PATHOL, V141, P301; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HEWITT RE, 1991, INT J CANCER, V49, P666, DOI 10.1002/ijc.2910490507; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KAHARI VM, 1992, J BIOL CHEM, V267, P26134; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MATRISIAN LM, 1994, ANN NY ACAD SCI, V732, P42, DOI 10.1111/j.1749-6632.1994.tb24723.x; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MULLER D, 1991, INT J CANCER, V48, P550, DOI 10.1002/ijc.2910480412; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Neyns B, 1996, ONCOGENE, V12, P1247; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; POLETTE M, 1991, INVAS METAST, V11, P76; SCHONTHAL A, 1991, NEW BIOL, V3, P977; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1994, ONCOGENE, V9, P469; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; URBANSKI SJ, 1992, BRIT J CANCER, V66, P1188, DOI 10.1038/bjc.1992.434; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205	58	130	133	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2651	2660		10.1038/sj.onc.1201111	http://dx.doi.org/10.1038/sj.onc.1201111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178763				2022-12-17	WOS:A1997XB97800004
J	Fujitani, Y; Hibi, M; Fukada, T; TakahashiTezuka, M; Yoshida, H; Yamaguchi, T; Sugiyama, K; Yamanaka, Y; Nakajima, K; Hirano, T				Fujitani, Y; Hibi, M; Fukada, T; TakahashiTezuka, M; Yoshida, H; Yamaguchi, T; Sugiyama, K; Yamanaka, Y; Nakajima, K; Hirano, T			An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT	ONCOGENE			English	Article						JAK; STAT; yeast two-hybrid system; JH2 domain	PROTEIN-TYROSINE KINASES; CILIARY NEUROTROPHIC FACTOR; COLONY-STIMULATING FACTOR; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; TRANSCRIPTIONAL ACTIVATION; MOLECULAR-CLONING; CATALYTIC SUBUNIT; RESPONSE ELEMENTS; GROWTH-FACTOR	JAK is believed to be an essential tyrosine kinase that mediates signals from the cytokine receptor to its downstream events. JAK associates with the cytoplasmic domain of the type I cytokine receptor superfamily and upon the ligand stimulation it can be activated, resulting in the receptor phosphorylation. In signaling from gp130, a common signal transducer for the IL-6 family cytokines, STAT3, a transcription factor that contains an SH2 domain, is recruited by phosphotyrosines on gp130 and is subsequently phosphorylated by gp130-associated JAKs. In this study, we attempted to find a new target for JAK that is directly activated by JAK, independent of gp130 tyrosine phosphorylation, by using a yeast two-hybrid system. Tn the process we found that the JH2 domain of JAK1, JAK2 or JAK3 could specifically associate with the carboxy-terminal portion of STAT5, but not with STAT3 or STAT1. The interaction was confirmed using both a transient expression system in a cell line and a GST-fusion protein binding assay. Furthermore, we showed that the activation of STAT5 via gp130 did not need any phosphotyrosines on gp130 while that of STAT3 strictly depended on phosphotyrosines on gp130. Mutations of STAT5 that eliminated the interaction with JAK1 reduced the activation of STAT5 upon the gp130 stimulation, although such mutants could be still activated through erythropoietin receptor. These results indicate that STAT5 are activated through cytokine receptors by two distinct mechanisms, one dependent on receptor tyrosine phosphorylation and the other mediated by the JAK-STAT direct interaction.	OSAKA UNIV,SCH MED,BIOMED RES CTR,DEPT MOL ONCOL,SUITA,OSAKA 565,JAPAN; NIPPON BOEHRINGER INGELHEIM CO LTD,KAWANISHI,HYOGO 66601,JAPAN	Osaka University; Boehringer Ingelheim			Hirano, Toshio/C-8194-2009; Hibi, Masahiko/I-6215-2014	Hibi, Masahiko/0000-0002-9142-4444; Yamanaka, Yojiro/0000-0003-1483-8691				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; [Anonymous], 1989, Ann N Y Acad Sci, V557, P1; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; FREDERIC WQ, 1996, MOL CELL BIOL, V16, P1622; Friedman MC, 1996, P NATL ACAD SCI USA, V93, P2077, DOI 10.1073/pnas.93.5.2077; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; FUKADA T, 1996, IN PRESS IMMUNITY; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gupta S, 1996, EMBO J, V15, P1075, DOI 10.1002/j.1460-2075.1996.tb00445.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JW, 1993, CELL, V75, P805; HARPUR AG, 1992, ONCOGENE, V7, P1347; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HIRANO T, 1994, CYTOKINE HDB, P145; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1996, CELL, V84, P311; IKEDA EI, 1993, P NATL AACAD SCI US, V90, P123; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; Lin JX, 1996, J BIOL CHEM, V271, P10738, DOI 10.1074/jbc.271.18.10738; MACKIEWICZ A, 1995, ANN NY ACAD SCI, V762, P1; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; Roberts A. B., 1990, PEPTIDE GROWTH FACTO, P633; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAKAI I, 1995, J BIOL CHEM, V270, P18420, DOI 10.1074/jbc.270.31.18420; Sambrook J, 1989, MOL CLONING LAB MANU; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMSON AW, 1994, CYTOKINE HDB; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YANG XO, 1992, SCIENCE, V257, P680, DOI 10.1126/science.1496382; YOSHIKAWA A, 1995, EMBO J, V14, P5288, DOI 10.1002/j.1460-2075.1995.tb00213.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	80	130	137	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					751	761		10.1038/sj.onc.1200907	http://dx.doi.org/10.1038/sj.onc.1200907			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047382				2022-12-17	WOS:A1997WJ11200001
J	Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M				Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M			Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential	ONCOGENE			English	Article						c-KIT; tumor metastasis; melanoma; apoptosis	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; TUMOR NECROSIS FACTOR; W-MUTANT MICE; NUDE-MICE; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; DNA FRAGMENTATION; HUMAN PIEBALDISM; RNA EXPRESSION	Expression of the tyrosine-kinase receptor encoded by the c-KIT proto-oncogene progressively decreases during local tumor growth and invasion of human melanomas, To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into the c-KIT negative highly metastatic human melanoma cell line A375SM and subsequently analysed its tumorigenic and metastatic potential, A375SM parental cells, A375SM-NOT (neo, control), and A375SM-KIT-positive cells were injected s.c. and i.v. into nude mice, A375SM-KIT cells produced significantly slower growing s.c. tumors and fewer lung metastases than control cells. Exposure of c-KIT-positive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for c-KIT, triggered apoptosis of these cells but not of c-KIT-negative melanoma cells or normal melanocytes. Since SCF is produced by keratinocytes and other dermal cells in the skin, these results suggest that the loss of c-KIT receptor expression may allow malignant melanoma cells to escape SCF/c-KIT-mediated apoptosis, hence contributing to tumor growth and eventually metastasis, The antitumor and antimetastatic properties of SCF may be useful in treating human melanomas in early stages.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; AMGEN INC,THOUSAND OAKS,CA 91320; IMMUNEX RES & DEV CORP,SEATTLE,WA 98103	University of Texas System; UTMD Anderson Cancer Center; Amgen					NATIONAL CANCER INSTITUTE [R21CA064137, R01CA041524] Funding Source: NIH RePORTER; NCI NIH HHS [CA64137, CA 41524] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P3775; ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDRE C, 1989, ONCOGENE, V4, P1047; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FIDLER IJ, 1990, CANCER RES, V50, P6130; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HUANG SY, 1994, CANCER IMMUNOL IMMUN, V39, P231, DOI 10.1007/BF01525986; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; LASSAM N, 1992, ONCOGENE, V7, P51; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; LUCA M, 1995, ONCOGENE, V11, P1399; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORITA E, 1994, ARCH DERMATOL RES, V286, P273, DOI 10.1007/BF00387600; NATALI P, 1990, CANCER RES, V50, P1271; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADIZADEH S, 1993, SCIENCE, V261, P345; REAL FX, 1986, CANCER RES, V46, P4726; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SINGH RK, 1995, CANCER RES, V55, P3669; SINGH RK, 1994, CANCER RES, V54, P3242; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; VILE RG, 1994, CANCER RES, V54, P6228; WILKS AF, 1993, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3342; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	63	130	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2339	2347						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957075				2022-12-17	WOS:A1996VX10800006
J	Bates, S; Rowan, S; Vousden, KH				Bates, S; Rowan, S; Vousden, KH			Characterisation of human cyclin G(1) and G(2): DNA damage inducible genes	ONCOGENE			English	Article						cyclins; p53; DNA damage	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GROWTH ARREST; G1 ARREST; BAX GENE; APOPTOSIS	Several genes have been identified as targets for transcriptional activation by the p53 tumour suppressor protein. Rodent cyclin G was previously identified as a p53 responsive gene and in order to assess the role played by cyclin G as a mediator of p53 function in humans cells we have isolated full length human cyclin G(1) and identified a related gene designated cyclin G(2). Both human G-cyclins are induced by the DNA damaging agent actinomycin-D and although the induction of cyclin G(1) is clearly p53 dependent, activation of cyclin G(2) expression was observed in the absence of p53. Based on sequence similarity, the G-cyclins and the recently identified cyclin I form a distinct sub-group within the larger cyclin family, possibly reflecting some degree of functional similarity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; KATO J, 1993, GENE DEV, V7, P331; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LEW DJ, 1991, CELL, V66, P1191; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAKAMURA T, 1995, EXP CELL RES, V21, P534; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POON RYC, 1994, J CELL SCI, V107, P2789; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WALDMAN T, 1995, CANCER RES, V55, P5187; WU LT, 1994, ONCOL REP, V1, P705; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	52	130	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1103	1109						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806701				2022-12-17	WOS:A1996VG76600025
J	SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG				SEGATTO, O; PELICCI, G; GIULI, S; DIGIESI, G; DIFIORE, PP; MCGLADE, J; PAWSON, T; PELICCI, PG			SHC PRODUCTS ARE SUBSTRATES OF ERBB-2 KINASE	ONCOGENE			English	Article							EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; AUTOPHOSPHORYLATION SITES; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; EGF RECEPTOR; NEU ONCOGENE; HUMAN-BREAST; PROTEIN; PHOSPHORYLATION	The shc gene encodes three widely expressed proteins of 46, 52 and 66 kDa. Overexpression of p46shc and p52shc in NIH3T3 fibroblasts induces a tumorigenic phenotype. Shc products are phosphorylated on tyrosine by the activated epidermal growth factor receptor (EGFR) and become physically associated with EGFR via their SH2 domain. Thus Shc oncoproteins may play a role in mitogenic signal transduction. Here we report that Shc products are substrates also of the erbB-2 kinase and form complexes with the erbB-2 product in intact cells. In vitro, the bacterially expressed Shc SH2 domain is sufficient to reconstitute the high affinity Shc/erbB-2 interaction. The erbB-2 region required for Shc binding was narrowed down to the most COOH-terminal 179 residues of gp185erbB-2; within this region, phosphorylation of one or more of the erbB-2 autophosphorylation sites is required for Shc/gp185erbB-2 complex formation as well as optimal phosphorylation of Shc products by the erbB-2 kinase. Thus, Shc proteins may play a role in signal transduction by gp185erbB-2.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, TORONTO M5G 1X5, ONTARIO, CANADA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV PERUGIA, MONTELUCE POLICLIN, IST CLIN MED 1, I-06100 PERUGIA, ITALY	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Perugia	SEGATTO, O (corresponding author), IST REGINA ELENA, CTR RIC SPERIMENTALE, IMMUNOL LAB, VIA MESSI ORO 156, I-00158 ROME, ITALY.		Pawson, Tony J/E-4578-2013; Pelicci, Giuliana/AAA-8921-2022; Di Fiore, Pier Paolo/K-2130-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Pelicci, Giuliana/0000-0003-0986-8255; Di Fiore, Pier Paolo/0000-0002-2252-0950; Segatto, Oreste/0000-0003-2561-1142				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JANCHILL JL, 1969, J VIROL, V4, P549; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KOCH CA, 1991, SCIENCE, V252, P669; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHAVASHAIO H, 1989, EMBO J, V8, P159; LONARDO F, 1990, New Biologist, V2, P992; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; ROTIN D, 1992, J BIOL CHEM, V267, P9678; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1992, ONCOGENE, V7, P1339; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TODDERUD G, 1990, SCIENCE, V249, P296, DOI 10.1126/science.2374928; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	45	130	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8101647				2022-12-17	WOS:A1993LP17100010
J	NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E				NEUBAUER, A; NEUBAUER, B; HE, M; EFFERT, P; IGLEHART, D; FRYE, RA; LIU, E			ANALYSIS OF GENE AMPLIFICATION IN ARCHIVAL TISSUE BY DIFFERENTIAL POLYMERASE CHAIN-REACTION	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; BREAST-CANCER; DNA AMPLIFICATION; INTERFERON GENE; EXPRESSION; CARCINOMA; SEQUENCE; ERBB-2	Oncogene amplification is found in many human tumors, and its detection may have important prognostic value. However, analysis of gene amplification may be hampered by inadequate tissue or poor DNA quality. We have previously described a polymerase chain reaction (PCR)-based procedure called differential PCR that can detect variations in gene dosage using miniscule amounts of tumor DNA [Frye, R.A., Benz, C.C. & Liu, E. (1989). Oncogene, 4, 1153-1157]. We now report the optimization of this technique for the analysis of oncogene amplification in paraffin-embedded archival tissues. We find that differential PCR is able to detect amplification of the HER2 (c-erbB-2) and the epidermal growth factor receptor (EGFR) genes and can be used to arrive at a semiquantitative estimate of gene dosage. Furthermore, our approach can determine gene amplification in samples in which the DNA is significantly degraded. Using differential PCR on paraffin-embedded tissues from cases previously investigated by standard DNA extraction and dot-blot procedures, good correlation between the two methods was found. Approaches are described to overcome technical problems posed by factors that affect the differential PCR, including the method of DNA extraction and extreme fragmentation of the DNA (< 200 base pairs). Furthermore, the resulting analytical algorithm reported herein has proved effective in detecting oncogene amplification in archival breast cancer specimens from standard pathology laboratories. Thus, differential PCR will be particularly helpful in the analysis of tumor specimens that are archived, small in size or rare in occurrence.	UNIV N CAROLINA, LINEBERGER CANC RES CTR, DEPT MED & GENET, CB 7295, CHAPEL HILL, NC 27599 USA; DUKE UNIV, DEPT SURG, DURHAM, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University			Liu, Edison/C-4141-2008					ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BALLABIO A, 1990, HUM GENET, V84, P571; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; CALLAHAN R, 1989, BREAST CANCER RES TR, V13, P191, DOI 10.1007/BF02106570; EHRLICH HA, 1989, PCR TECHNOLOGY; FRYE RA, 1989, ONCOGENE, V4, P1153; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRAY PW, 1982, NATURE, V298, P859, DOI 10.1038/298859a0; IGLEHART JD, 1990, CANCER RES, V50, P6701; IMPRAIM CC, 1987, BIOCHEM BIOPH RES CO, V142, P710, DOI 10.1016/0006-291X(87)91472-0; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LIU E, 1992, ONCOGENE, V7, P1027; Maniatis T., 1982, MOL CLONING; MIES C, 1991, AM J SURG PATHOL, V15, P169, DOI 10.1097/00000478-199102000-00010; NEUBAUER A, 1990, NUCLEIC ACIDS RES, V18, P993, DOI 10.1093/nar/18.4.993; OHNO S, 1982, NUCLEIC ACIDS RES, V10, P967, DOI 10.1093/nar/10.3.967; RESNICK RM, 1990, JNCI-J NATL CANCER I, V82, P1477, DOI 10.1093/jnci/82.18.1477; SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TSUDA H, 1990, CANCER, V65, P1794, DOI 10.1002/1097-0142(19900415)65:8<1794::AID-CNCR2820650821>3.0.CO;2-Y; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; ZHOU DJ, 1989, ONCOGENE, V4, P105	24	130	134	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1992	7	5					1019	1025						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP642	1349162				2022-12-17	WOS:A1992HP64200025
J	HRABARENEVEY, S; TURLER, H; KRESS, M; SALOMON, C; WEIL, R				HRABARENEVEY, S; TURLER, H; KRESS, M; SALOMON, C; WEIL, R			SV40-INDUCED EXPRESSION OF MOUSE GENE-24P3 INVOLVES A POST-TRANSCRIPTIONAL MECHANISM	ONCOGENE			English	Article									INST RECH SCI CANC,UNITE ONCOL MOLEC,F-94802 VILLEJUIF,FRANCE		HRABARENEVEY, S (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,30 QUAI ERNEST ANSERMET,CH-1211 GENEVA 4,SWITZERLAND.							ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANDERSON KP, 1984, P NATL ACAD SCI-BIOL, V81, P4023, DOI 10.1073/pnas.81.13.4023; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUCK N, 1978, P NATL ACAD SCI USA, V75, P2473, DOI 10.1073/pnas.75.5.2473; BRICKELL PM, 1985, NATURE, V316, P162, DOI 10.1038/316162a0; CAFFARELLI E, 1987, EMBO J, V6, P3493, DOI 10.1002/j.1460-2075.1987.tb02674.x; CARNEIRO M, 1984, J MOL BIOL, V178, P869, DOI 10.1016/0022-2836(84)90316-4; CARROLL RB, 1988, ONCOGENE, V2, P437; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COLE CN, 1979, J VIROL, V30, P683, DOI 10.1128/JVI.30.3.683-691.1979; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DARLIX JL, 1984, P NATL ACAD SCI-BIOL, V81, P5425, DOI 10.1073/pnas.81.17.5425; DEFROMENTEL CC, 1986, EXP CELL RES, V164, P35, DOI 10.1016/0014-4827(86)90452-0; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; FEUNTEUN J, 1978, P NATL ACAD SCI USA, V75, P4455, DOI 10.1073/pnas.75.9.4455; FLAVELL AJ, 1977, J MOL BIOL, V115, P237, DOI 10.1016/0022-2836(77)90099-7; FRIED V, 1986, CANCER CELLS DNA TUM; FRISKE RJ, 1979, COLD SPRING HARB SYM, V39, P325; FULTON R, 1985, NUCLEIC ACIDS RES, V13, P6467, DOI 10.1093/nar/13.18.6467; FYRBERG EA, 1980, CELL, V19, P365, DOI 10.1016/0092-8674(80)90511-5; GAUCHAT JF, 1986, NUCLEIC ACIDS RES, V14, P9339, DOI 10.1093/nar/14.23.9339; GEHRING MR, 1987, J BIOL CHEM, V262, P446; GOAD WB, 1982, NUCLEIC ACIDS RES, V10, P247, DOI 10.1093/nar/10.1.247; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; GUTMAN D, 1988, SCIENCE, V241, P1492, DOI 10.1126/science.3047873; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HRABARENEVEY S, 1987, THESIS U GENEVA SWIT; HUYNH TV, 1985, DNA CLONING PRACTICA; KAO HT, 1986, NUCLEIC ACIDS RES, V14, P7253, DOI 10.1093/nar/14.18.7253; KHANDJIAN EW, 1982, P NATL ACAD SCI-BIOL, V79, P1139, DOI 10.1073/pnas.79.4.1139; KHANDJIAN EW, 1980, P NATL ACAD SCI-BIOL, V77, P1476, DOI 10.1073/pnas.77.3.1476; KHANDJIAN EW, 1986, MOL BIOL REP, V11, P107, DOI 10.1007/BF00364822; KHANDJIAN EW, 1988, ONCOGENE, V3, P195; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; Maniatis T., 1982, MOL CLONING; MARTIN RG, 1979, CELL, V17, P635, DOI 10.1016/0092-8674(79)90271-X; MARTIN RG, 1979, J VIROL, V31, P596, DOI 10.1128/JVI.31.3.596-607.1979; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATTER JM, 1983, NUCLEIC ACIDS RES, V11, P6611, DOI 10.1093/nar/11.19.6611; MAY E, 1973, P NATL ACAD SCI USA, V70, P1654, DOI 10.1073/pnas.70.6.1654; MAY E, 1971, P NATL ACAD SCI USA, V68, P1280; MCKNIGHT S, 1986, CELL, V46, P795, DOI 10.1016/0092-8674(86)90061-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUELLER C, 1978, CELL, V15, P579, DOI 10.1016/0092-8674(78)90026-0; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PUSTELL J, 1982, NUCLEIC ACIDS RES, V10, P4765, DOI 10.1093/nar/10.15.4765; PUVION E, 1988, EXP CELL RES, V177, P73, DOI 10.1016/0014-4827(88)90026-2; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; SALZMAN NP, 1986, PAPOVAVIRUSES, V1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SCHUTZBANK T, 1982, CELL, V30, P481, DOI 10.1016/0092-8674(82)90245-8; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHENK TE, 1976, J VIROL, V18, P664, DOI 10.1128/JVI.18.2.664-671.1976; SINGH K, 1985, NATURE, V314, P553, DOI 10.1038/314553a0; SINGH K, 1985, MOL CELL BIOL, V5, P2590, DOI 10.1128/MCB.5.10.2590; SIVE HL, 1984, MOL CELL BIOL, V4, P2723, DOI 10.1128/MCB.4.12.2723; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; STIMAC E, 1984, MOL CELL BIOL, V4, P2082, DOI 10.1128/MCB.4.10.2082; SUKHATME VP, 1988, CELL, V56, P337; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TOPP WC, 1981, VIROLOGY, V111, P341, DOI 10.1016/0042-6822(81)90338-X; TURLER H, 1985, J VIROL, V53, P579; VANHEUVERSWYN H, 1979, J VIROL, V30, P936, DOI 10.1128/JVI.30.3.936-941.1979; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; WEIL R, 1978, BIOCHIM BIOPHYS ACTA, V516, P301, DOI 10.1016/0304-419X(78)90012-4; YAMAMOTO KR, 1976, ANNU REV BIOCHEM, V45, P721, DOI 10.1146/annurev.bi.45.070176.003445; YAMAMOTO M, 1983, P NATL ACAD SCI-BIOL, V80, P7524, DOI 10.1073/pnas.80.24.7524	80	130	141	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					601	608						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2542864				2022-12-17	WOS:A1989U768800010
J	Jin, L; Chun, J; Pan, C; Alesi, GN; Li, D; Magliocca, KR; Kang, Y; Chen, ZG; Shin, DM; Khuri, FR; Fan, J; Kang, S				Jin, L.; Chun, J.; Pan, C.; Alesi, G. N.; Li, D.; Magliocca, K. R.; Kang, Y.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Fan, J.; Kang, S.			Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis	ONCOGENE			English	Article							LACTATE-DEHYDROGENASE; TYROSINE PHOSPHORYLATION; REDOX HOMEOSTASIS; DOWN-REGULATION; SRC ACTIVATION; NECK-CANCER; HEAD; PROGRESSION; CARCINOMA; METABOLISM	Metastases remain the major cause of death from cancer. Recent molecular advances have highlighted the importance of metabolic alterations in cancer cells, including the Warburg effect that describes an increased glycolysis in cancer cells. However, how this altered metabolism contributes to tumour metastasis remains elusive. Here, we report that phosphorylation-induced activation of lactate dehydrogenase A (LDHA), an enzyme that catalyses the interconversion of pyruvate and lactate, promotes cancer cell invasion, anoikis resistance and tumour metastasis. We demonstrate that LDHA is phosphorylated at tyrosine 10 by upstream kinases, HER2 and Src. Targeting HER2 or Src attenuated LDH activity as well as invasive potential in head and neck cancer and breast cancer cells. Inhibition of LDH activity by small hairpin ribonucleic acid or expression of phospho-deficient LDHA Y10F sensitized the cancer cells to anoikis induction and resulted in attenuated cell invasion and elevated reactive oxygen species, whereas such phenotypes were reversed by its product lactate or antioxidant N-acetylcysteine, suggesting that Y10 phosphorylation-mediated LDHA activity promotes cancer cell invasion and anoikis resistance through redox homeostasis. In addition, LDHA knockdown or LDHA Y10F rescue expression in human cancer cells resulted in decreased tumour metastasis in xenograft mice. Furthermore, LDHA phosphorylation at Y10 positively correlated with progression of metastatic breast cancer in clinical patient tumour samples. Our findings demonstrate that LDHA phosphorylation and activation provide pro-invasive, antianoikis and pro-metastatic advantages to cancer cells, suggesting that Y10 phosphorylation of LDHA may represent a promising therapeutic target and a prognostic marker for metastatic human cancers.	[Jin, L.; Chun, J.; Pan, C.; Alesi, G. N.; Li, D.; Chen, Z. G.; Shin, D. M.; Khuri, F. R.; Kang, S.] Emory Univ, Winship Canc Inst, Sch Med, Dept Hematol Med Oncol, Atlanta, GA 30322 USA; [Magliocca, K. R.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Fan, J.] Emory Univ, Winship Canc Inst, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA	Emory University; Emory University; Princeton University; Emory University	Kang, S (corresponding author), Emory Univ, Winship Canc Inst, Sch Med, Hematol & Med Oncol, 1365-C Clifton Rd NE, Atlanta, GA 30322 USA.	smkang@emory.edu	Khuri, Fadlo R./AAU-4942-2020	Khuri, Fadlo R./0000-0002-8638-7618; Kang, Yibin/0000-0002-1626-6730	NIH [R01 CA175316, F31 CA183365]; ACS grant [RSG-11-08101]; NATIONAL CANCER INSTITUTE [R01CA175316] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ACS grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NIH grants R01 CA175316 (Sumin Kang), F31 CA183365 (Gina N. Alesi), and ACS grant RSG-11-08101 (Sumin Kang).	Alesi GN, 2016, ONCOGENE, V35, P5412, DOI 10.1038/onc.2016.79; Baumann F, 2009, NEURO-ONCOLOGY, V11, P368, DOI 10.1215/15228517-2008-106; Beckert S, 2006, WOUND REPAIR REGEN, V14, P321, DOI 10.1111/j.1743-6109.2006.00127.x; Birkeland AC, 2016, JAMA OTOLARYNGOL, V142, P559, DOI 10.1001/jamaoto.2016.0335; Bonuccelli G, 2010, CELL CYCLE, V9, P3506, DOI 10.4161/cc.9.17.12731; Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003; Bui T, 2006, CANCER CELL, V9, P419, DOI 10.1016/j.ccr.2006.05.012; De Souza JA, 2012, CLIN CANCER RES, V18, P2336, DOI 10.1158/1078-0432.CCR-11-2825; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fury MG, 2011, ANTICANCER RES, V31, P249; Gao S, 2016, BIOMED PHARMACOTHER, V81, P388, DOI 10.1016/j.biopha.2016.04.029; Granchi C, 2011, J MED CHEM, V54, P1599, DOI 10.1021/jm101007q; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Jin LT, 2013, MOL CELL BIOL, V33, P2574, DOI 10.1128/MCB.01677-12; Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Li D, 2013, J BIOL CHEM, V288, P32528, DOI 10.1074/jbc.M113.500561; Li J, 2016, NEUROREPORT, V27, P110, DOI 10.1097/WNR.0000000000000506; Mandal M, 2008, CANCER-AM CANCER SOC, V112, P2088, DOI 10.1002/cncr.23410; Miao P, 2013, IUBMB LIFE, V65, P904, DOI 10.1002/iub.1216; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Puls LN, 2011, ONCOLOGIST, V16, P566, DOI 10.1634/theoncologist.2010-0408; Rizwan A, 2013, CLIN CANCER RES, V19, P5158, DOI 10.1158/1078-0432.CCR-12-3300; Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002; Sheng SL, 2012, FEBS J, V279, P3898, DOI 10.1111/j.1742-4658.2012.08748.x; Stabile LP, 2013, CLIN CANCER RES, V19, P380, DOI 10.1158/1078-0432.CCR-12-1555; Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004; Xian ZY, 2015, TUMOR BIOL, V36, P8093, DOI 10.1007/s13277-015-3540-x; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yu Y, 2001, BIOCHEM PHARMACOL, V62, P81, DOI 10.1016/S0006-2952(01)00636-0; Zhang X, 2002, CANCER-AM CANCER SOC, V95, P1663, DOI 10.1002/cncr.10837; Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690	51	129	137	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3797	3806		10.1038/onc.2017.6	http://dx.doi.org/10.1038/onc.2017.6			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28218905	Green Accepted			2022-12-17	WOS:000404848200001
J	Cui, H; Seubert, B; Stahl, E; Dietz, H; Reuning, U; Moreno-Leon, L; Ilie, M; Hofman, P; Nagase, H; Mari, B; Kruger, A				Cui, H.; Seubert, B.; Stahl, E.; Dietz, H.; Reuning, U.; Moreno-Leon, L.; Ilie, M.; Hofman, P.; Nagase, H.; Mari, B.; Krueger, A.			Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes	ONCOGENE			English	Article							BREAST EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; LIVER METASTASIS; GENE-EXPRESSION; TUMOR-CELLS; HYPOXIA; MICRORNA-210; TIMP-1; CARCINOMA; PROTEINS	Tissue inhibitor of metalloproteinases-1 (TIMP-1) recently emerged as a pro-metastatic factor highly associated with poor prognosis in a number of cancers. This correlation seemed paradox as TIMP-1 is best described as an inhibitor of pro-tumourigenic matrix metalloproteinases. Only recently, TIMP-1 has been revealed as a signalling molecule that can regulate cancer progression independent of its inhibitory properties. In the present study, we demonstrate that an increase of both exogenous and endogenous TIMP-1 led to the upregulation of miR-210 in a CD63/PI3K/AKT/HIF-1-dependent pathway in lung adenocarcinoma cells. TIMP-1 induced P110/P85 PI3K-signalling and AKT phosphorylation. It also led to increase of HIF-1 alpha protein levels positively correlating with HIF-1-regulated mRNA expression and upregulation of the microRNA miR-210. Downstream targets of miR-210, namely FGFRL1, E2F3, VMP-1, RAD52 and SDHD, were decreased in the presence of TIMP-1. Upon the overexpression of TIMP-1 in tumour cells, miR-210 was accumulated in exosomes in vitro and in vivo. These exosomes promoted tube formation activity in human umbilical vein endothelial cell (HUVECs), which was reflected in increased angiogenesis in A549L-derived tumour xenografts. Activation and elevation of PI3K, AKT, HIF-1A and miR-210 in tumours additionally confirmed our in vitro data. This new pro-tumourigenic signalling function of TIMP-1 may explain why elevated TIMP-1 levels in lung cancer patients are highly correlated with poor prognosis.	[Cui, H.; Seubert, B.; Krueger, A.] Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Ismaninger Str 22, D-80290 Munich, Germany; [Stahl, E.; Dietz, H.] Tech Univ Munich, Walter Schottky Inst, Dept Phys, D-80290 Munich, Germany; [Reuning, U.] Tech Univ Munich, Klinikum Rechts Isar, Klin Forsch Grp Frauenklin, D-80290 Munich, Germany; [Moreno-Leon, L.; Ilie, M.; Hofman, P.; Mari, B.] Univ Nice Sophia Antipolis, F-06189 Nice, France; [Moreno-Leon, L.; Mari, B.] UNSA, CNRS, Inst Pharmacol Mol & Cellulaire, UMR 6097, Sophia Antipolis, France; [Ilie, M.; Hofman, P.] Ctr Hosp Univ Nice, Lab Clin & Expt Pathol, Nice, France; [Ilie, M.; Hofman, P.] Ctr Hosp Univ Nice, Hosp Integrated Biobank, Nice, France; [Nagase, H.] Univ Oxford, Kennedy Inst Rheumatol, Nuffield Dept Orthopaed Rheumatol & Muscolosketal, London, England	Technical University of Munich; Technical University of Munich; University of Munich; Technical University of Munich; UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; CHU Nice; University of Oxford	Kruger, A (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Inst Expt Onkol & Therapieforsch, Ismaninger Str 22, D-80290 Munich, Germany.	achim.krueger@lrz.tu-muenchen.de	Mari, Bernard/Q-5832-2019; Moreno Leon, Laura/AGP-7137-2022; Hofman, Paul/P-7654-2018	Mari, Bernard/0000-0002-0422-9182; Moreno Leon, Laura/0000-0002-5560-1765; Hofman, Paul/0000-0003-0431-9353; Ilie, Marius/0000-0002-2014-1236; Cui, Haissi/0000-0003-3358-8958	Deutsche Forschungsgesellschaft [KR2047/1-2, KR2047/3-1]	Deutsche Forschungsgesellschaft(German Research Foundation (DFG))	We thank Katja Honert for expert technical assistance in cell culture experiments and Susanne Schaten for immunohistochemical advice. We are grateful to Carolin Wander for cloning pRRL.PPT.SF.CD63-mCherry and Dominik Alterauge for cloning pRRL.PPT.SF.N-TIMP-1 and pRRL.PPT.SF.TIMP-1_T2G. We thank Georg Sedlmeier for help with experiments regarding the TIMP-1 variants. Financial support came from the Deutsche Forschungsgesellschaft KR2047/1-2 and KR2047/3-1 to AK.	Alaiti MA, 2012, J CELL MOL MED, V16, P2413, DOI 10.1111/j.1582-4934.2012.01557.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600-0854.2011.01225.x; Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003; Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006; Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015; Chan YC, 2012, MICROCIRCULATION, V19, P215, DOI 10.1111/j.1549-8719.2011.00154.x; Crosby ME, 2009, CANCER RES, V69, P1221, DOI 10.1158/0008-5472.CAN-08-2516; Cruz-Munoz W, 2008, CRIT REV CL LAB SCI, V45, P291, DOI 10.1080/10408360801973244 ; Cui H, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00134; De Lorenzo MS, 2003, IN VIVO, V17, P45; Fasanaro P, 2008, J BIOL CHEM, V283, P15878, DOI 10.1074/jbc.M800731200; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Gouyer V, 2005, CANCER-AM CANCER SOC, V103, P1676, DOI 10.1002/cncr.20965; Grosso S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.71; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hauser S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018989; Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004; Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006; Ilie MI, 2013, VIRCHOWS ARCH, V463, P437, DOI 10.1007/s00428-013-1453-x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jung KK, 2006, EMBO J, V25, P3934, DOI 10.1038/sj.emboj.7601281; Jung YS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038773; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242-10; Kim HW, 2009, J BIOL CHEM, V284, P33161, DOI 10.1074/jbc.M109.020925; King HW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-421; Kopitz C, 2007, CANCER RES, V67, P8615, DOI 10.1158/0008-5472.CAN-07-0232; Kruger A, 2010, BBA-MOL CELL RES, V1803, P95, DOI 10.1016/j.bbamcr.2009.09.016; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lasser C, 2012, JOVE-J VIS EXP, DOI 10.3791/3037; Li GY, 1999, CANCER RES, V59, P6267; Liu H, 2008, ANGIOGENESIS, V11, P223, DOI 10.1007/s10456-008-9102-8; Liu XW, 2005, CANCER RES, V65, P898; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Lu Y, 2011, MOL CELLS, V31, P225, DOI 10.1007/s10059-011-0023-9; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Murphy G, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-11-233; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Pesta M, 2011, ANTICANCER RES, V31, P4031; Puissegur MP, 2011, CELL DEATH DIFFER, V18, P465, DOI 10.1038/cdd.2010.119; Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006; Rauvala M, 2005, GYNECOL ONCOL, V99, P656, DOI 10.1016/j.ygyno.2005.07.009; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Salomon C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068451; Schambach A, 2006, GENE THER, V13, P1524, DOI 10.1038/sj.gt.3302807; Schelter F, 2011, CLIN EXP METASTAS, V28, P91, DOI 10.1007/s10585-010-9360-x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shimoda M, 2013, PROTEOMICS, V13, P1624, DOI 10.1002/pmic.201200458; Stetler-Stevenson WG, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127re6; Taube ME, 2006, ONCOGENE, V25, P3041, DOI 10.1038/sj.onc.1209336; Tsuchiya S, 2011, J BIOL CHEM, V286, P420, DOI 10.1074/jbc.M110.170852; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Wang CS, 2006, ANN CLIN LAB SCI, V36, P23; Wang HP, 2014, NAT IMMUNOL, V15, P393, DOI 10.1038/ni.2846; Wilczynski J, 2011, ARCH IMMUNOL THER EX, V59, P301, DOI 10.1007/s00005-011-0132-3; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; Xia YF, 2012, NAT CELL BIOL, V14, P257, DOI 10.1038/ncb2428; Xiao F, 2013, GLYCOBIOLOGY, V23, P524, DOI 10.1093/glycob/cwt004; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614; Ylisirnio S, 2001, CLIN CANCER RES, V7, P1633; Ylisirnio S, 2000, ANTICANCER RES, V20, P1311; Yoshiji H, 1998, INT J CANCER, V75, P81, DOI 10.1002/(SICI)1097-0215(19980105)75:1<81::AID-IJC13>3.3.CO;2-J; Zhang Z, 2009, CELL CYCLE, V8, P2756, DOI 10.4161/cc.8.17.9387	76	129	136	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	28					3640	3650		10.1038/onc.2014.300	http://dx.doi.org/10.1038/onc.2014.300			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM4TZ	25263437				2022-12-17	WOS:000357679100003
J	Pendas-Franco, N; Garcia, JM; Pena, C; Valle, N; Palmer, HG; Heinaniemi, M; Carlberg, C; Jimenez, B; Bonilla, F; Munoz, A; Gonzalez-Sancho, JM				Pendas-Franco, N.; Garcia, J. M.; Pena, C.; Valle, N.; Palmer, H. G.; Heinaeniemi, M.; Carlberg, C.; Jimenez, B.; Bonilla, F.; Munoz, A.; Gonzalez-Sancho, J. M.			DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1 alpha, 25-dihydroxyvitamin D-3	ONCOGENE			English	Article						DICKKOPF-4; vitamin D; colon cancer; Wnt; beta-catenin	WNT SIGNALING PATHWAY; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; GENE FAMILY; VITAMIN-D; DIFFERENTIATION; PROTEIN; TARGET	Aberrant activation of the Wnt/beta-catenin signaling pathway is a hallmark of colon cancer. We show that the Wnt antagonist DICKKOPF-4 (DKK-4) gene is repressed by 1 alpha, 25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) in human colon cancer cells. This effect correlated with the inhibition of the DKK-4 promoter. Chromatin immunoprecipitation assays revealed that 1,25(OH)(2)D-3 induces early and transient binding of the vitamin D receptor (VDR) and the SMRT corepressor to the region adjacent to the transcription start site of DKK-4. Additionally, we demonstrate that the DKK-4 gene is a new downstream target of TCF/beta-catenin. Remarkably, expression of DKK-4 messenger RNA (mRNA) was not detected in a series of 29 human normal (N) colon biopsies but expression was upregulated in all the matched tumour (T) tissues. An inverse correlation existed between the expression of DKK-4 and VDR RNA in the Ts. Ectopic DKK-4 expression increased the migration and invasion properties of colon cancer cells and conditioned media (CM) from DKK-4-expressing cells enhanced the capacity to migrate and form capillary-like tubules of human primary microvascular endothelial cells. In conclusion, DKK-4 is upregulated in colon cancer and is associated with the acquisition of malignant properties by neoplastic cells. DKK-4 downregulation is a novel effect of 1,25(OH)(2)D-3 that may contribute to its anticancer action.	[Pendas-Franco, N.; Valle, N.; Jimenez, B.; Munoz, A.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, E-28029 Madrid, Spain; [Garcia, J. M.; Pena, C.; Bonilla, F.] Hosp Univ Puerta Hierro, Madrid, Spain; [Palmer, H. G.] Cambridge Res Inst, Cambridge, England; [Heinaeniemi, M.; Carlberg, C.] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Jimenez, B.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; CRUK Cambridge Institute; University of Cambridge; University of Luxembourg; Autonomous University of Madrid	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, Arturo Duperier 4, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014; Heinaniemi, Merja/AAS-4530-2020; Heinäniemi, Merja/C-5051-2014; Valle, Noelia/AAA-2975-2019; Gonzalez-Sancho, Jose/AAA-6010-2019; Palmer, Héctor G./AAG-8332-2019; Carlberg, Carsten/C-9075-2011; Seoane, Joan/AAG-9173-2019	Munoz, Alberto/0000-0003-3890-4251; Heinaniemi, Merja/0000-0001-6190-3439; Heinäniemi, Merja/0000-0001-6190-3439; Valle, Noelia/0000-0002-3377-5035; Gonzalez-Sancho, Jose/0000-0001-5875-1964; Carlberg, Carsten/0000-0003-2633-0684; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Seoane, Joan/0000-0002-6541-5974; Palmer, Hector/0000-0002-9823-5638				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bazzi H, 2007, DEV BIOL, V305, P498, DOI 10.1016/j.ydbio.2007.02.035; Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007; Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Ordonez-Moran P, 2005, FRONT BIOSCI-LANDMRK, V10, P2723, DOI 10.2741/1731; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pendas-Franco N, 2007, DIFFERENTIATION, V75, P193, DOI 10.1111/j.1432-0436.2006.00131.x; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Xi Y, 2008, ONCOL REP, V19, P257	25	129	133	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4467	4477		10.1038/onc.2008.88	http://dx.doi.org/10.1038/onc.2008.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408752				2022-12-17	WOS:000257881700009
J	Kim, MS; Chang, X; Yamashita, K; Nagpal, JK; Baek, JH; Wu, G; Trink, B; Ratovitski, EA; Mori, M; Sidransky, D				Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Baek, J. H.; Wu, G.; Trink, B.; Ratovitski, E. A.; Mori, M.; Sidransky, D.			Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma	ONCOGENE			English	Article						promoter methylation; DFNA5; colon cancer	CELLULAR RETINOL-BINDING-PROTEIN-1; DNA METHYLATION; HYPERMETHYLATION; EXPRESSION; IDENTIFICATION; INACTIVATION; CANCERS; ICERE-1; PROFILE	To identify novel methylated gene promoters, we compared differential RNA expression profiles of colorectal cancer (CRC) cell lines with or without treatment of 5-aza-2'-deoxycytidine (5-aza-dC). Out of 1776 genes that were initially 'absent (that is, silenced)' by gene expression array analysis, we selected 163 genes that were increased after 5-aza-dC treatment in at least two of three CRC cell lines. The microarray results were confirmed by Reverse Transcription-PCR, and CpG island of the gene promoters were amplified and sequenced for examination of cancer-specific methylation. Among the genes identified, the deafness, autosomal dominant 5 gene, DFNA5, promoter was found to be methylated in primary tumor tissues with high frequency (65%, 65/100). Quantitative methylation-specific PCR of DFNA5 clearly discriminated primary CRC tissues from normal colon tissues (3%, 3/100). The mRNA expression of DFNA5 in four of five colon cancer tissues was significantly downregulated as compared to normal tissues. Moreover, forced expression of full-length DFNA5 in CRC cell lines markedly decreased the cell growth and colony-forming ability whereas knockdown of DFNA5 increased cell growth in culture. Our data implicate DFNA5 as a novel tumor suppressor gene in CRC and a valuable molecular marker for human cancer.	[Kim, M. S.; Chang, X.; Yamashita, K.; Nagpal, J. K.; Trink, B.; Ratovitski, E. A.; Sidransky, D.] Johns Hopkins Univ, Head & Neck Canc Res Div, Dept Otolaryngol, Baltimore, MD 21231 USA; [Baek, J. H.] Johns Hopkins Univ, Inst Cell Engn, Dept Med Genet, Baltimore, MD 21231 USA; [Wu, G.] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Detroit, MI USA; [Mori, M.] Kyushu Univ, Dept Surg Oncol, Med Inst Bioregulat, Beppu, Oita, Japan	Johns Hopkins University; Johns Hopkins University; Barbara Ann Karmanos Cancer Institute; Wayne State University; Kyushu University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Oncol & Otolaryngol, Div Head & Neck Canc Res Inst, Johns Hopkins Canc Res Bldg 2,1150 Orleans St, Baltimore, MD 21231 USA.	dsidran1@jhmi.edu						Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x; Brakenhoff RH, 1997, J IMMUNOL, V159, P4879; Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001; Esteller M, 2002, CANCER RES, V62, P5902; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jeronimo C, 2004, J CLIN PATHOL, V57, P872, DOI 10.1136/jcp.2003.014555; Kim JM, 2005, CLIN CANCER RES, V11, P473; Kim MS, 2006, CANCER RES, V66, P3409, DOI 10.1158/0008-5472.CAN-05-1608; Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3; Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28; Luo LP, 2005, INT J CANCER, V115, P747, DOI 10.1002/ijc.20936; Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6; Rochester MA, 2005, CANCER GENE THER, V12, P90, DOI 10.1038/sj.cgt.7700775; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Van Laer L, 1998, NAT GENET, V20, P194; VANCAMP G, 1995, HUM MOL GENET, V4, P2159; Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5	24	129	139	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2008	27	25					3624	3634		10.1038/sj.onc.1211021	http://dx.doi.org/10.1038/sj.onc.1211021			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	309NW	18223688				2022-12-17	WOS:000256468500014
J	Ingram, WJ; Mccue, KI; Tran, TH; Hallahan, AR; Wainwright, BJ				Ingram, W. J.; McCue, K. I.; Tran, T. H.; Hallahan, A. R.; Wainwright, B. J.			Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling	ONCOGENE			English	Article						Sonic Hedgehog; Hes1; Notch; C3H/10T1/2; MNS70; gene expression profiling	GENE-EXPRESSION; HUMAN HOMOLOG; CELL DIFFERENTIATION; MICROARRAY ANALYSIS; NEURAL DEVELOPMENT; IDENTIFICATION; GROWTH; ROLES; MEDULLOBLASTOMAS; CERULOPLASMIN	Aberrant regulation of signalling mechanisms that normally orchestrate embryonic development, such as the Hedgehog, Wnt and Notch pathways, is a common feature of tumorigenesis. In order to better understand the neoplastic events mediated by Hedgehog signalling, we identified over 200 genes regulated by Sonic Hedgehog in multipotent mesodermal cells. Widespread crosstalk with other developmental signalling pathways is evident, suggesting a complex network of interactions that challenges the often over-simplistic representation of these pathways as simple linear entities. Hes1, a principal effector of the Notch pathway, was found to be a target of Sonic Hedgehog in both C3H/10T1/2 mesodermal and MNS70 neural cells. Desert Hedgehog also elicited a strong Hes1 response. While Smoothened function was found necessary for upregulation of Hes1 in response to Sonic Hedgehog, the mechanism does not require gamma-secretase-mediated cleavage of Notch receptors, and appears to involve transcription factors other than RBP-J kappa. Thus, we have defined a novel mechanism for Hes1 regulation in stem-like cells that is independent of canonical Notch signalling.	[Ingram, W. J.; McCue, K. I.; Tran, T. H.; Wainwright, B. J.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Ingram, W. J.; Hallahan, A. R.] Univ Queensland, Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld, Australia	University of Queensland; Royal Children's Hospital Brisbane; University of Queensland	Wainwright, BJ (corresponding author), Univ Queensland, Inst Mol Biosci, Bldg 80,St Lucia Campus, Brisbane, Qld 4072, Australia.	b.wainwright@imb.uq.edu.au	Hallahan, Andrew R/F-1757-2010; Ingram, Wendy J/F-7317-2010	Ingram, Wendy J/0000-0002-7063-1081; Wainwright, Brandon/0000-0003-0406-2092				Alexandre C, 1999, DEVELOPMENT, V126, P5689; Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arias AM, 2002, CURR OPIN GENET DEV, V12, P524, DOI 10.1016/S0959-437X(02)00336-2; Baonza A, 2001, DEVELOPMENT, V128, P3889; Blokzijl A, 2003, J CELL BIOL, V163, P723, DOI 10.1083/jcb.200305112; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; CHAKRABORTY PK, 1984, ACTA MED OKAYAMA, V38, P315; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Dakubo GD, 2006, J NEURO-ONCOL, V79, P221, DOI 10.1007/s11060-006-9132-2; Das I, 2004, J BIOL CHEM, V279, P30771, DOI 10.1074/jbc.M309252200; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Fu WM, 2003, DEVELOPMENT, V130, P5229, DOI 10.1242/dev.00764; Geling A, 2002, EMBO REP, V3, P688, DOI 10.1093/embo-reports/kvf124; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallahan AR, 2004, CANCER RES, V64, P7794, DOI 10.1158/0008-5472.CAN-04-1813; Hansson EM, 2004, SEMIN CANCER BIOL, V14, P320, DOI 10.1016/j.semcancer.2004.04.011; Hays R, 1999, DEVELOPMENT, V126, P2891; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Hirata H, 2002, SCIENCE, V298, P840, DOI 10.1126/science.1074560; Ingram WJ, 2002, ONCOGENE, V21, P8196, DOI 10.1038/sj.onc.1205975; Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208; Iso T, 2001, MOL CELL BIOL, V21, P6071, DOI 10.1128/MCB.21.17.6071-6079.2001; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jia J, 2006, CELL MOL LIFE SCI, V63, P1249, DOI 10.1007/s00018-005-5519-z; Johansson FK, 2005, ONCOGENE, V24, P3896, DOI 10.1038/sj.onc.1208553; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kageyama R, 2005, EXP CELL RES, V306, P343, DOI 10.1016/j.yexcr.2005.03.015; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Kappler R, 2004, INT J ONCOL, V25, P113; Kato M, 2001, BIOCHEM BIOPH RES CO, V289, P472, DOI 10.1006/bbrc.2001.5976; Kinto N, 1997, FEBS LETT, V404, P319, DOI 10.1016/S0014-5793(97)00014-8; KUNAPULI SP, 1987, LIFE SCI, V40, P2225, DOI 10.1016/0024-3205(87)90057-9; Kwon C, 2004, DEVELOPMENT, V131, P2681, DOI 10.1242/dev.01127; Li XM, 2002, MICROCIRCULATION, V9, P13, DOI 10.1038/sj.mn.7800118; Lowndes SA, 2004, ONCOL RES, V14, P529, DOI 10.3727/0965040042707952; McGlinn E, 2005, MECH DEVELOP, V122, P1218, DOI 10.1016/j.mod.2005.06.012; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Murata K, 2005, MOL CELL BIOL, V25, P4262, DOI 10.1128/MCB.25.10.4262-4271.2005; Nakagawa Y, 1996, DEVELOPMENT, V122, P2449; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pathi S, 2001, MECH DEVELOP, V106, P107, DOI 10.1016/S0925-4773(01)00427-0; Pietsch T, 1997, CANCER RES, V57, P2085; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Shawber C, 1996, DEVELOPMENT, V122, P3765; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; Varela AS, 1997, CANCER LETT, V121, P139, DOI 10.1016/S0304-3835(97)00340-6; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Woodward WA, 2005, J CELL SCI, V118, P3585, DOI 10.1242/jcs.02532; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399	62	129	135	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2008	27	10					1489	1500		10.1038/sj.onc.1210767	http://dx.doi.org/10.1038/sj.onc.1210767			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	267ZR	17873912				2022-12-17	WOS:000253548200016
J	Sorli, SC; Le Gonidec, S; Knibiehler, B; Audigier, Y				Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.			Apelin is a potent activator of tumour neoangiogenesis	ONCOGENE			English	Article						breast cancer; neoangiogenesis; G protein-coupled receptors	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-COUPLED RECEPTOR; VASCULAR DEVELOPMENT; ANGIOGENIC FACTOR; HUMAN APJ; X-MSR; EXPRESSION; VEGF; LIGAND; CELLS	Our laboratory has previously shown that apelin is mitogenic for endothelial cells. We have postulated that apelin represents an angiogenic factor secreted by tumour cells in order to promote the formation of new vessels necessary for tumour growth. We first demonstrate that apelin and its receptor are not expressed by the mouse TS/A mammary carcinoma cells. We therefore established clones of this tumoral cell type stably overexpressing the apelin cDNA (TS/A-apelin clones). Comparison of the in vitro proliferation rates between TS/A-mock and TS/A-apelin cells did not reveal any difference and confirmed the lack of receptor expression by tumour cells. On the other hand, apelin overexpression clearly increased the in vivo tumour growth and this increase was associated with an earlier onset of tumour development. In tumours derived from TS/A-apelin clones, the expression of the endothelial marker CD31 was increased and revealed the formation of large intratumoral vessels lined with CD31 positive cells. These data suggest that apelin behaves as a potent activator of tumour neoangiogenesis by a paracrine effect on host vessels. The pathological relevance of this finding is demonstrated by hypoxia-induced upregulation of apelin gene and its overexpression in one-third of human tumours.	[Sorli, S. C.; Le Gonidec, S.; Knibiehler, B.; Audigier, Y.] INSERM, U589, 12MR, Canc Dept, F-31432 Toulouse 4, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Audigier, Y (corresponding author), INSERM, U589, 12MR, Canc Dept, BP 84225,1 Ave Jean Poulhes, F-31432 Toulouse 4, France.	yves.audigier@toulouse.inserm.fr		Le Gonidec, Sophie/0000-0002-8141-690X				AUDIGIER Y, 2006, AFCS NATURE MOL PAGE; BREIER G, 1992, DEVELOPMENT, V114, P521; Brugarolas J, 2004, CANCER CELL, V6, P7, DOI 10.1016/j.ccr.2004.06.020; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Cox CM, 2006, DEV BIOL, V296, P177, DOI 10.1016/j.ydbio.2006.04.452; Devic E, 1996, MECH DEVELOP, V59, P129, DOI 10.1016/0925-4773(96)00585-0; Devic E, 1999, MECH DEVELOP, V84, P199, DOI 10.1016/S0925-4773(99)00081-7; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Graeven U, 2001, CANCER RES, V61, P7282; Habata Y, 1999, BBA-MOL CELL RES, V1452, P25, DOI 10.1016/S0167-4889(99)00114-7; Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kasai A, 2004, BIOCHEM BIOPH RES CO, V325, P395, DOI 10.1016/j.bbrc.2004.10.042; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masri B, 2005, CELL SIGNAL, V17, P415, DOI 10.1016/j.cellsig.2004.09.018; Masri B, 2004, FASEB J, V18, P1909, DOI 10.1096/fj.04-1930fje; Masri B, 2002, BIOCHEM BIOPH RES CO, V290, P539, DOI 10.1006/bbrc.2001.6230; Masri B, 2006, J BIOL CHEM, V281, P18317, DOI 10.1074/jbc.M600606200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; PLATE KH, 1993, CANCER RES, V53, P5822; Prewett M, 1999, CANCER RES, V59, P5209; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; RAK J, 1995, CANCER RES, V55, P4575; Saint-Geniez M, 2002, MECH DEVELOP, V110, P183, DOI 10.1016/S0925-4773(01)00558-5; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHWEIKI D, 1992, NATURE, V359, P845; Sorli SC, 2006, DRUG DISCOV TODAY, V11, P1100, DOI 10.1016/j.drudis.2006.10.011; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wood JM, 2000, CANCER RES, V60, P2178	37	129	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7692	7699		10.1038/sj.onc.1210573	http://dx.doi.org/10.1038/sj.onc.1210573			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17563744				2022-12-17	WOS:000251537800011
J	Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C				Cordes, N; Seidler, J; Durzok, R; Geinitz, H; Brakebusch, C			beta 1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury	ONCOGENE			English	Article						beta 1-integrin; ECM; Akt; PI3K; p130Cas; ionizing radiation	FOCAL ADHESION KINASE; EXTRACELLULAR-MATRIX; TYROSINE PHOSPHORYLATION; HUMAN-TUMOR; INTEGRINS; GROWTH; FAK; EXPRESSION; PROTEINS; MICROENVIRONMENT	Integrin-mediated adhesion to extracellular matrix proteins confers resistance to radiation- or drug-induced genotoxic injury. To analyse the underlying mechanisms specific for beta 1-integrins, wild-type beta 1A-integrin-expressing GD25 beta 1A cells were compared to GD25 beta 1B cells, which express signaling-incompetent beta 1B variants. Cells grown on fibronectin, collagen-III, beta 1-integrin-IgG or poly-l-lysine were exposed to 0-6 Gy X-rays in presence or depletion of growth factors and phosphatidylinositol-3 kinase (PI3K) inhibitors (LY294002, wortmannin). In order to test the relevance of these findings in tumor cells, human A-172 glioma cells were examined under the same conditions after siRNA-mediated silencing of beta 1-integrins. We found that beta 1A-integrin-mediated adhesion to fibronectin, collagen-III or beta 1-IgG was essential for cell survival after radiation- induced genotoxic injury. Mediated by PI3K, pro-survival beta 1A-integrin/Akt signaling was critically involved in this process. Additionally, the beta 1-integrin downstream targets p130Cas and paxillin-impaired survival-regulating PI3K-dependent JNK. In A-172 glioma cells, beta 1-integrin knockdown and PI3K inhibition confirmed the central role of beta 1-integrins in Akt- and p130Cas/paxillin-mediated prosurvival signaling. These findings suggest beta 1-integrins as critical regulators of cell survival after radiation- induced genotoxic injury. Elucidation of the molecular circuitry of prosurvival beta 1-integrin-mediated signaling in tumor cells may promote the development of innovative molecular-targeted therapeutic antitumor strategies.	Tech Univ Dresden, Med Fac, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Tech Univ, Klinikum Isar, Dept Radiat Oncol, Munich, Germany; Max Planck Inst Biochem, Dept Mol Med, Martinsried, Germany	Technische Universitat Dresden; Technical University of Munich; Max Planck Society	Cordes, N (corresponding author), Tech Univ Dresden, Med Fac, Fetscherstr 74-PF 86, D-01307 Dresden, Germany.	Nils.Cordes@mailbox.tu-dresden.de		Cordes, Nils/0000-0001-5684-629X; Brakebusch, Cord/0000-0002-9342-1634				Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Armulik A, 2000, EXP CELL RES, V254, P55, DOI 10.1006/excr.1999.4722; Armulik A, 2002, FRONT BIOSCI-LANDMRK, V7, pD219, DOI 10.2741/armulik; Barcellos-Hoff MH, 2001, J MAMMARY GLAND BIOL, V6, P213, DOI 10.1023/A:1011317009329; Beinke C, 2003, INT J RADIAT BIOL, V79, P721, DOI 10.1080/09553000310001610231; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cook JA, 2004, SEMIN RADIAT ONCOL, V14, P259, DOI 10.1016/j.semradonc.2004.04.001; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2003, BRIT J CANCER, V89, P2122, DOI 10.1038/sj.bjc.6601429; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Fornaro M, 2000, MOL BIOL CELL, V11, P2235, DOI 10.1091/mbc.11.7.2235; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Oguey D, 2000, GENE THER, V7, P1292, DOI 10.1038/sj.gt.3301236; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2001, J CELL SCI, V114, P2553; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shen Y, 1999, MOL BIOL CELL, V10, P2507, DOI 10.1091/mbc.10.8.2507; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Unger Meredith, 2003, Methods Mol Biol, V223, P315; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	46	129	131	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1378	1390		10.1038/sj.onc.1209164	http://dx.doi.org/10.1038/sj.onc.1209164			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16247454				2022-12-17	WOS:000235708200011
J	Zhao, CY; Lam, EWF; Sunters, A; Enmark, E; De Bella, MT; Coombes, RC; Gustafsson, JA; Dahlman-Wright, K				Zhao, CY; Lam, EWF; Sunters, A; Enmark, E; De Bella, MT; Coombes, RC; Gustafsson, JA; Dahlman-Wright, K			Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation	ONCOGENE			English	Article						ER beta; DNA methylation; mRNA isoform; breast cancer	MESSENGER-RNA EXPRESSION; QUANTITATIVE-ANALYSIS; CPG ISLANDS; WILD-TYPE; ER-BETA; ALPHA; CLONING; PROMOTER; PROSTATE; GENE	Two novel estrogen receptor beta (ERbeta) mRNA isoforms that diverge in their 5'-untranslated regions, ERbeta mRNA (0K-1) and ERbeta mRNA (0N-1), have recently been identified. This indicates that transcription of the human ERbeta gene occurs from at least two different promoters, named promoter 0K and promoter 0N. The aim of this study was to investigate the expression of ERbeta isoforms in primary cultures of normal breast epithelial cells, a panel of breast cancer cell lines and in normal breast and breast cancer tissues; and to examine whether methylation of the two ERbeta promoters is involved in regulation of ERbeta gene expression. Using quantitative real-time PCR techniques, we found that ERbeta mRNA levels were significantly lower in breast cancer cell lines than in primary cultures of normal breast epithelial cells. Bisulfite genomic sequencing analysis revealed that two promoters of the ERbeta gene exhibit distinct methylation patterns. Promoter 0N was unmethylated in normal breast epithelial cells, but extensively methylated in breast cancer cell lines. In contrast, promoter 0K was unmethylated in both normal and malignant breast epithelial cells. We demonstrated a significant correlation between promoter 0N hypermethylation and loss of ERbeta mRNA expression in breast cancer cell lines. Treatment of breast cancer cells with demethylating agent effectively reactivated the expression of ERbeta mRNA. The observations from the cell lines were also reflected in primary breast cancer tumors. Thus, expression of ERbeta mRNA in breast tumors was found to be inversely associated with the degree of methylation of promoter 0N. Our results suggest that a decreased level of ERbeta mRNA may be associated with breast tumorigenesis, and that DNA methylation is an important mechanism for ERbeta gene silencing in breast cancer.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Canc Res UK Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Sect Canc Cell Biol, London W12 0NN, England	Karolinska Institutet; Cancer Research UK; Imperial College London; Imperial College London	Zhao, CY (corresponding author), Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden.		Lam, Eric W-F/AAW-8566-2020	Lam, Eric W-F/0000-0003-1274-3576; Coombes, Raoul Charles/0000-0002-4811-1100				Bieche I, 2001, ONCOGENE, V20, P8109, DOI 10.1038/sj.onc.1204917; Dotzlaw H, 1999, CANCER RES, V59, P529; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; Fuqua SAW, 1999, CANCER RES, V59, P5425; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; GOMM JJ, 1995, ANAL BIOCHEM, V226, P91, DOI 10.1006/abio.1995.1196; Gustafsson JA, 2000, J STEROID BIOCHEM, V74, P245, DOI 10.1016/S0960-0760(00)00130-8; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1; Iwao K, 2000, CANCER, V89, P1732, DOI 10.1002/1097-0142(20001015)89:8<1732::AID-CNCR13>3.0.CO;2-2; Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lewandowski S, 2002, FEBS LETT, V524, P1, DOI 10.1016/S0014-5793(02)03015-6; Leygue E, 1999, CANCER RES, V59, P1175; Leygue E, 1998, CANCER RES, V58, P3197; Li LC, 2000, BIOCHEM BIOPH RES CO, V275, P682, DOI 10.1006/bbrc.2000.3363; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738; Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A; Ogawa S, 1998, BIOCHEM BIOPH RES CO, V243, P122, DOI 10.1006/bbrc.1997.7893; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Omoto Y, 2002, EUR J CANCER, V38, P380, DOI 10.1016/S0959-8049(01)00383-5; Palmieri C, 2002, ENDOCR-RELAT CANCER, V9, P1, DOI 10.1677/erc.0.0090001; Sasaki M, 2002, J NATL CANCER I, V94, P384; Skliris GP, 2001, BRIT J CANCER, V84, P1095, DOI 10.1054/bjoc.2001.1721; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473	31	129	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7600	7606		10.1038/sj.onc.1207100	http://dx.doi.org/10.1038/sj.onc.1207100			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576822				2022-12-17	WOS:000186113000007
J	Woerner, SM; Benner, A; Sutter, C; Schiller, M; Yuan, YP; Keller, G; Bork, P; Doeberitz, MV; Gebert, JF				Woerner, SM; Benner, A; Sutter, C; Schiller, M; Yuan, YP; Keller, G; Bork, P; Doeberitz, MV; Gebert, JF			Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes	ONCOGENE			English	Article						mismatch repair; coding microsatellite; microsatellite instability; Real Common Target genes; ByStander genes	MICROSATELLITE MUTATOR PHENOTYPE; FREQUENT FRAMESHIFT MUTATIONS; REPEATED SEQUENCES REVEAL; II RECEPTOR GENE; MISMATCH REPAIR; COLORECTAL CANCERS; REPLICATION FIDELITY; BETA RECEPTOR; COLON-CANCER; INSTABILITY	DNA mismatch repair deficiency is observed in about 15% of human colorectal, gastric, and endometrial tumors and in lower frequencies in a minority of other tumors thereby causing insertion/deletion mutations at short repetitive sequences, recognized as microsatellite instability (MSI). Evolution of tumors, including those with MSI, is a continuous process of mutation and selection favoring neoplastic growth. Mutations in microsatellite-bearing genes that promote tumor cell growth in general (Real Common Target genes) are assumed to be the driving force during MSI carcinogenesis. Thus, microsatellite mutations in these genes should occur more frequently than mutations in microsatellite genes without contribution to malignancy (ByStander genes). So far, only a few Real Common Target genes have been identified by functional studies. Thus, comprehensive analysis of microsatellite mutations will provide important clues to the understanding of MSI-driven carcinogenesis. Here, we evaluated published mutation frequencies on 194 repeat tracts in 137 genes in MSI-H colorectal, endometrial, and gastric carcinomas and propose a statistical model that aims to identify Real Common Target genes. According to our model nine genes including BAX and TGFbetaRII were identified as Real Common Targets in colorectal cancer, one gene in gastric cancer, and three genes in endometrial cancer. Microsatellite mutations in five additional genes seem to be counterselected in gastrointestinal tumors. Overall, the general applicability, the capacity to unlimited data analysis, the inclusion of mutation data generated by different groups on different sets of tumors make this model a useful tool for predicting Real Common Target genes with specificity for MSI-H tumors of different organs, guiding subsequent functional studies to the most likely targets among numerous microsatellite harboring genes.	Heidelberg Univ, Inst Pathol, Dept Mol Pathol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Cent Unit, D-69120 Heidelberg, Germany; European Mol Biol Lab, D-69117 Heidelberg, Germany; Tech Univ Munich, Inst Pathol, D-81675 Munich, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL); Technical University of Munich; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Gebert, JF (corresponding author), Heidelberg Univ, Inst Pathol, Dept Mol Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	Johannes_gebert@med.uni-heidelberg.de	Bork, Peer/F-1813-2013; Yuan, Yanping/D-5257-2013; Woerner, Stefan/A-2187-2010; von Knebel Doeberitz, Magnus/D-2372-2016	Bork, Peer/0000-0002-2627-833X; Yuan, Yanping/0000-0003-4284-3973; von Knebel Doeberitz, Magnus/0000-0002-0498-6781				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Bicknell DC, 1996, CURR BIOL, V6, P1695, DOI 10.1016/S0960-9822(02)70795-1; Boland CR, 1998, CANCER RES, V58, P5248; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2002, CANCER RES, V62, P1609; Duval A, 2002, CANCER RES, V62, P2447; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; Hediger MA, 2002, NAT MED, V8, P445, DOI 10.1038/nm0502-445; Huet S., 1996, STAT TOOLS NONLINEAR, DOI [10.1007/978-1-4757-2523-0.41, DOI 10.1007/978-1-4757-2523-0.41]; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Loeb LA, 2001, CANCER RES, V61, P3230; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mignone F, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-3-reviews0004; Mori Y, 2001, CANCER RES, V61, P6046; MYEROFF LL, 1995, CANCER RES, V55, P5545; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; PERUCHO M, 1994, COLD SPRING HARB SYM, V59, P339, DOI 10.1101/SQB.1994.059.01.038; Perucho M, 1999, CANCER RES, V59, P249; Piao Z, 2000, CANCER RES, V60, P4701; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Sagher D, 1999, MUTAT RES-FUND MOL M, V423, P73, DOI 10.1016/S0027-5107(98)00227-9; Sakurada K, 2001, GENE CHROMOSOME CANC, V30, P207, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1080>3.0.CO;2-V; Schwartz S, 1999, CANCER RES, V59, P2995; Sia EA, 1997, MOL CELL BIOL, V17, P2851, DOI 10.1128/MCB.17.5.2851; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Zhang L, 2001, CANCER RES, V61, P3801	38	129	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2226	2235		10.1038/sj.onc.1206421	http://dx.doi.org/10.1038/sj.onc.1206421			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700659				2022-12-17	WOS:000182231500002
J	Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC				Nagashima, M; Shiseki, M; Pedeux, RM; Okamura, S; Kitahama-Shiseki, M; Miura, K; Yokota, J; Harris, CC			A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis	ONCOGENE			English	Article						PHD-finger motif; ING1; ING3; p53	CANDIDATE TUMOR-SUPPRESSOR; ALTERNATIVE TRANSCRIPTS; DNA-BINDING; P53; ACETYLATION; P33(ING1); GENE; DEACETYLASE; EXPRESSION; MUTATIONS	A candidate tumor suppressor gene, p33ING1, was previously identified by using the genetic suppressor element methodology. p33ING1 cooperates with p53 and plays a significant role in p53-mediated cellular processes. Recently, we have identified p33ING2, which shows a sequence homology similar to p33ING1 and modulates p53 function. In the present study, we identified and characterized another 'ING family' gene. The estimated molecular weight of the encoded protein is 46.8 kDa, thus, we named it p47ING3. The p47ING3 gene is located at chromosome 7q31.3 and consists of 12 exons that encode 418 amino acids. A computational domain search revealed a C-terminal PHD-finger motif. Such motifs are common in proteins involved in chromatin remodeling. p47ING3 is highly expressed in some normal human tissues or organs, including the spleen, testis, skeletal muscle, and heart. p47ING3 expression levels varied among cancer cell lines. p47ING3 overexpression resulted in a decreased population of cells in S phase, a diminished colony-forming efficiency, and induced apoptosis in RKO cells, but not in RKO-E6 cells with inactivated p53. p47ING3 activates p53-transactivated promoters, including promoters of p21/waf1 and bax. Thus, we have isolated a novel ING family gene, p47ING3, which modulates p53-mediated transcription, cell cycle control, and apoptosis.	NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, NIH, 37 Convent Dr,Bldg 37,Rm 2C05, Bethesda, MD 20892 USA.	curtis_harris@nih.gov	PEDEUX, Rémy M/I-2603-2014	PEDEUX, Rémy M/0000-0002-2553-7934; Miura, Koh/0000-0001-7303-9430	NATIONAL CANCER INSTITUTE [ZIABC005795, Z01BC005795] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; Garkavtsev I, 1999, NAT GENET, V23, P373, DOI 10.1038/15566; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Helbing CC, 1997, CANCER RES, V57, P1255; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hollstein M, 1999, MUTAT RES-FUND MOL M, V431, P199, DOI 10.1016/S0027-5107(99)00162-1; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Liu L, 1999, MOL CELL BIOL, V19, P1202; Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MIYASHITA T, 1995, CELL, V80, P293; Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798; Nourani A, 2001, MOL CELL BIOL, V21, P7629, DOI 10.1128/MCB.21.22.7629-7640.2001; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Saito A, 2000, J HUM GENET, V45, P177, DOI 10.1007/s100380050206; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Skowyra D, 2001, J BIOL CHEM, V276, P8734, DOI 10.1074/jbc.M007664200; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675	26	129	136	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					343	350		10.1038/sj.onc.1206115	http://dx.doi.org/10.1038/sj.onc.1206115			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545155				2022-12-17	WOS:000180379100003
J	Chesire, DR; Isaacs, WB				Chesire, DR; Isaacs, WB			Ligand-dependent inhibition of beta-catenin/TCF signaling by androgen receptor	ONCOGENE			English	Article						androgen receptor; beta-catenin; TCF/LEF; prostate; nuclear signaling	HUMAN-PROSTATE-CANCER; GROWTH-FACTOR-BETA; CREB-BINDING-PROTEIN; TRANSCRIPTIONAL ACTIVATION; WNT/BETA-CATENIN; CARCINOMA-CELLS; TUMOR-SUPPRESSOR; MAMMARY-GLAND; TARGET GENES; CYCLIN D1	beta-catenin signaling may contribute to prostate cancer (CaP) progression. Although beta-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and non-CaP cells (HEK-293, TSU, SW480, HCT-116) that beta-catenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the ligand-dependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/beta-catenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant beta-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for beta-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNA-binding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for beta-catenin interaction. Further supporting this hypothesis, TCF/LEF overexpression counteracts androgen-induced suppression of CRT, and requires beta-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of beta-catenin/TCF4 interaction. These results from TCF4 over-expression analyses, taken together, provide further evidence that AR-mediated suppression of CRT is a consequence of limiting amounts of beta-catenin, and not AR target gene expression. Our analyses point to a reciprocal balance between AR and CRT function that may shape critical processes during normal prostate development and tumor progression.	Johns Hopkins Med Inst, Brady Urol Inst, Res Labs, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Johns Hopkins Oncol Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Isaacs, WB (corresponding author), Johns Hopkins Univ Hosp, Dept Urol, Marburg 115,600 N Wolfe St, Baltimore, MD 21287 USA.	wisaacs@jhmi.edu			NCI NIH HHS [CA58236] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058236] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Brisken C, 2000, GENE DEV, V14, P650; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chesire DR, 2002, ONCOGENE, V21, P2679, DOI 10.1038/sj.onc.1205352; Chesire DR, 2000, PROSTATE, V45, P323, DOI 10.1002/1097-0045(20001201)45:4<323::AID-PROS7>3.0.CO;2-W; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; Cude KJ, 1999, J MOL MED, V77, P419, DOI 10.1007/s001090050372; Culig Z, 1998, PROSTATE, V35, P63, DOI 10.1002/(SICI)1097-0045(19980401)35:1<63::AID-PROS9>3.0.CO;2-I; CULIG Z, 1994, CANCER RES, V54, P5474; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Dyer BW, 2000, ANAL BIOCHEM, V282, P158, DOI 10.1006/abio.2000.4605; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Gerstein AV, 2002, GENE CHROMOSOME CANC, V34, P9, DOI 10.1002/gcc.10037; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/ng0501-53; Hsu W, 2001, J CELL BIOL, V155, P1055, DOI 10.1083/jcb.200107066; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUSMANN DA, 1990, ENDOCRINOLOGY, V126, P2359, DOI 10.1210/endo-126-5-2359; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Knudsen KE, 1999, CANCER RES, V59, P2297; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Linja MJ, 2001, CANCER RES, V61, P3550; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; McDonald S, 2000, CANCER RES, V60, P2317; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Park JJ, 2000, CANCER RES, V60, P5946; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Samowitz WS, 1999, CANCER RES, V59, P1442; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Song CZ, 1999, P NATL ACAD SCI USA, V96, P11776, DOI 10.1073/pnas.96.21.11776; SONNENSCHEIN C, 1989, CANCER RES, V49, P3474; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tan J, 1997, MOL ENDOCRINOL, V11, P450, DOI 10.1210/me.11.4.450; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tindall DJ, 1999, PROSTATE, V38, P166, DOI 10.1002/(SICI)1097-0045(19990201)38:2<166::AID-PROS11>3.0.CO;2-A; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; van Bokhoven A, 2001, CANCER RES, V61, P6340; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Voeller HJ, 1998, CANCER RES, V58, P2520; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; Wen Y, 2000, CANCER RES, V60, P6841; Yan D, 2001, P NATL ACAD SCI USA, V98, P14973, DOI 10.1073/pnas.261574498; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yu DC, 1999, CANCER RES, V59, P1498; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	95	129	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2002	21	55					8453	8469		10.1038/sj.onc.1206049	http://dx.doi.org/10.1038/sj.onc.1206049			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466965				2022-12-17	WOS:000179480100008
J	Blondel, D; Regad, T; Poisson, N; Pavie, B; Harper, F; Pandolfi, PP; de The, H; Chelbi-Alix, MK				Blondel, D; Regad, T; Poisson, N; Pavie, B; Harper, F; Pandolfi, PP; de The, H; Chelbi-Alix, MK			Rabies virus P and small P products interact directly with PML and reorganize PML nuclear bodies	ONCOGENE			English	Article						interferon; PML; RING finger; SUMO; rabies virus; P protein	ACUTE PROMYELOCYTIC LEUKEMIA; EPSTEIN-BARR-VIRUS; PROTEIN PML; RAR-ALPHA; ADENOVIRUS INFECTION; SP100 PROTEINS; MESSENGER-RNA; PHOSPHOPROTEIN; CELLS; INTERFERONS	The interferon-induced promyelocytic leukaemia (PML) protein localizes both in the nucleoplasm and in matrix-associated multi-protein complexes known as nuclear bodies (NBs). NBs are disorganized in acute promyelocytic leukaemia or during some viral infections, suggesting that PML NBs could be a part of cellular defense mechanism. Rabies virus, a member of the rhabdoviridae family, replicates in the cytoplasm. Rabies phosphoprotein P and four other amino-terminally truncated products (P2, P3, P4, P5) are all translated from P mRNA. P and P2 are located in the cytoplasm, whereas P3, P4 and P5 are found mostly in the nucleus. Infection with rabies virus reorganized PML NBs. PML NBs became larger and appeared as dense aggregates when analysed by confocal or electron microscopy, respectively. The expression of P sequesters PML in the cytoplasm where both proteins colocalize, whereas that of P3 results in an increase in PML body size, as observed in infected cells. The P and P3 interacted directly in vivo and in vitro with PML. The C-terminal domain of P and the PML RING finger seem to be involved in this binding. Moreover, PML -/- primary mouse embryonic fibroblasts expressed viral proteins at a higher level and produced 20 times more virus than wild-type cells, suggesting that the absence of all PML isoforms resulted in an increase in rabies virus replication.	Inst Lwoff, CNRS, UPR 9045, F-94801 Villejuif, France; CNRS, UMR 2472, F-91198 Gif Sur Yvette, France; Inst Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Hop St Louis, CNRS, UPR 9051, F-75475 Paris, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Memorial Sloan Kettering Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Chelbi-Alix, MK (corresponding author), Inst Lwoff, CNRS, UPR 9045, 7 Rue Guy Moquet, F-94801 Villejuif, France.	mchelbi@infobiogen.fr	Regad, Tarik/A-6095-2012	Regad, Tarik/0000-0003-4028-6368; Pavie, Benjamin/0000-0002-0249-3844				Ahn JH, 1999, J VIROL, V73, P10458, DOI 10.1128/JVI.73.12.10458-10471.1999; Bell P, 2000, J VIROL, V74, P11800, DOI 10.1128/JVI.74.24.11800-11810.2000; Bonilla WV, 2002, J VIROL, V76, P3810, DOI 10.1128/JVI.76.8.3810-3818.2002; Borden KLB, 1998, J VIROL, V72, P758, DOI 10.1128/JVI.72.1.758-766.1998; BOURHY H, 1993, VIROLOGY, V194, P70, DOI 10.1006/viro.1993.1236; CARVALHO T, 1995, J CELL BIOL, V131, P45, DOI 10.1083/jcb.131.1.45; Chelbi-Alix MK, 1998, J VIROL, V72, P1043, DOI 10.1128/JVI.72.2.1043-1051.1998; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; CHENIK M, 1995, J VIROL, V69, P707, DOI 10.1128/JVI.69.2.707-712.1995; Chenik M, 1998, J VIROL, V72, P1925, DOI 10.1128/JVI.72.3.1925-1930.1998; CHENIK M, 1994, J GEN VIROL, V75, P2889, DOI 10.1099/0022-1317-75-11-2889; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Djavani M, 2001, J VIROL, V75, P6204, DOI 10.1128/JVI.75.13.6204-6208.2001; Duprez E, 1999, J CELL SCI, V112, P381; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; Gaudin Y, 1999, J GEN VIROL, V80, P1647, DOI 10.1099/0022-1317-80-7-1647; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Goodbourn S, 2000, J GEN VIROL, V81, P2341, DOI 10.1099/0022-1317-81-10-2341; Gupta AK, 2000, J VIROL, V74, P91, DOI 10.1128/JVI.74.1.91-98.2000; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jacob Y, 2001, J VIROL, V75, P9613, DOI 10.1128/JVI.75.20.9613-9622.2001; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 1999, J VIROL, V73, P5137; Negorev D, 2001, ONCOGENE, V20, P7234, DOI 10.1038/sj.onc.1204764; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; Puvion-Dutilleul F, 1999, BIOL CELL, V91, P617, DOI 10.1016/S0248-4900(00)88526-3; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; Raux H, 1997, J GEN VIROL, V78, P119, DOI 10.1099/0022-1317-78-1-119; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rose JK, 2001, FIELDS VIROLOGY, P1221; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Stadler M, 1995, ONCOGENE, V11, P2565; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	46	129	138	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2002	21	52					7957	7970		10.1038/sj.onc.1205931	http://dx.doi.org/10.1038/sj.onc.1205931			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	612VY	12439746				2022-12-17	WOS:000179097200005
J	Morotti, A; Mila, S; Accornero, P; Tagliabue, E; Ponzetto, C				Morotti, A; Mila, S; Accornero, P; Tagliabue, E; Ponzetto, C			K252a inhibits the oncogenic properties of Met, the HGF receptor	ONCOGENE			English	Article						K252a; Met; tyrosine kinase inhibitors; anticancer drugs	HEPATOCYTE GROWTH-FACTOR; ABL TYROSINE KINASE; CHRONIC MYELOID-LEUKEMIA; FACTOR SCATTER FACTOR; LIGAND-INDEPENDENT ACTIVATION; C-MET; GASTRIC-CARCINOMA; CELL-LINES; SELECTIVE INHIBITOR; POINT MUTATION	The ATP analog K252a is a potent inhibitor for receptor tyrosine kinases of the Trk family. Here we show that nanomolar concentrations of K252a prevent HGF-mediated scattering in MLP-29 cells (30 nM), reduce Met-driven proliferation in GTL-16 gastric carcinoma cells (100 nM), and cause reversion in NIH3T3 fibroblasts transformed by the oncogenic form of the receptor, Tpr-Met (75 nM). K252a inhibits Met autophosphorylation in cultured cells and in immunoprecipitates and prevents activation of its downstream effectors MAPKinase and Akt. Interestingly, K252a seems to be more effective at inhibiting the mutated form of Met (M1268T) found in papillary carcinoma of the kidney than the wild type receptor. Pretreatment of both Tpr-Met-transformed NIH3T3 fibroblasts and of GTL-16 gastric carcinoma cells with K252a results in loss of their ability to form lung metastases in nude mice upon injection into the caudal vein. These observations suggest that K252a derivatives, which are active in vivo as anti-cancer drugs in models of Trk-driven malignancies, should also be effective for treatment of Met-mediated tumors.	Univ Turin, Dept Anat Pharmacol & Forens Med, I-10126 Turin, Italy; Ist Nazl Tumori, I-20133 Milan, Italy	University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan	Ponzetto, C (corresponding author), Univ Turin, Dept Anat Pharmacol & Forens Med, Cso Massimo Azeglio 52, I-10126 Turin, Italy.		Accornero, Paolo/B-1396-2008; Morotti, Alessandro/J-7590-2018	Morotti, Alessandro/0000-0002-8407-2903				Abounader R, 1999, J NATL CANCER I, V91, P1548, DOI 10.1093/jnci/91.18.1548; AKINAGA S, 1992, CANCER CHEMOTH PHARM, V29, P266, DOI 10.1007/BF00685943; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOROS P, 1995, LANCET, V345, P293, DOI 10.1016/S0140-6736(95)90279-1; Camoratto AM, 1997, INT J CANCER, V72, P673, DOI 10.1002/(SICI)1097-0215(19970807)72:4<673::AID-IJC20>3.0.CO;2-B; Chin LS, 1997, CLIN CANCER RES, V3, P771; Cortner J, 1995, EXS, V74, P89; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Gibbs JB, 2000, J CLIN INVEST, V105, P9, DOI 10.1172/JCI9084; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; Goldman JM, 2001, NEW ENGL J MED, V344, P1084, DOI 10.1056/NEJM200104053441409; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jiang W, 1999, CRIT REV ONCOL HEMAT, V29, P209, DOI 10.1016/S1040-8428(98)00019-5; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kaji M, 1996, CANCER GENE THER, V3, P393; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KOIZUMI S, 1988, J NEUROSCI, V8, P715; Maritano D, 2000, ONCOGENE, V19, P1354, DOI 10.1038/sj.onc.1203431; MATSUDA Y, 1988, J NEUROSCI LETT, V256, P11; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; NYE SH, 1992, MOL BIOL CELL, V3, P667; OBEIDI FAA, 2000, ONCOGENE, V19, P5690; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Park WS, 1999, CANCER RES, V59, P307; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1993, CANCER RES, V53, P5355; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Ruggeri BA, 1999, CURR MED CHEM, V6, P845; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892; TAPLEY P, 1992, ONCOGENE, V7, P371; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; Yu J, 2000, CANCER-AM CANCER SOC, V88, P1801, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1801::AID-CNCR7>3.3.CO;2-L; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	50	129	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 25	2002	21	32					4885	4893		10.1038/sj.onc.1205622	http://dx.doi.org/10.1038/sj.onc.1205622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118367				2022-12-17	WOS:000176874800003
J	Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF				Xia, H; Qi, HL; Li, YF; Pei, J; Barton, J; Blackstad, M; Xu, T; Tao, WF			LATS1 tumor suppressor regulates G2/M transition and apoptosis	ONCOGENE			English	Article						LATS1; tumor suppressor; G2/M transition; apoptosis	HUMAN BREAST-CANCER; CELL-CYCLE ARREST; PROTEIN-KINASE; MITOTIC APPARATUS; GENE; P53; MITOSIS; ENCODES; HOMOLOG; MICE	The LATS1 gene is a mammalian member of the novel lats tumor suppressor family. Both lats mosaic flies and LATS1 deficient mice spontaneously develop tumors. Our previous studies have shown that inactivation of Drosophila lats leads to up-regulation of cyclin A in the fly, and the human LATS1 protein associates with CDC2 in early mitosis in HeLa cells, suggesting that the lats gene family may negatively regulate cell proliferation by modulating CDC2/Cyclin A activity. We demonstrate here that transduction of the human breast cancer cell MCF-7 with recombinant LATS1 adenovirus (Ad-LATS1), but not with EGFP adenovirus (Ad-EGFP), inhibits in vitro cell proliferation. Ectopic expression of LATS1 in MCF-7 cells specifically downregulates Cyclin A and Cyclin B protein levels and dramatically reduces CDC2 kinase activity, leading to a G2/M blockade. Furthermore, Ad-LATS] suppresses anchorage-independent growth of MCF-7 cells in soft agar and tumor formation in athymic nude mice. We also demonstrate that ectopic expression of LATS1 in MCF-7 cells and human lung cancer cell H460 upregulates the level of BAX proteins and induces apoptosis. Finally, we show that LATS1 kinase activity is required for its ability to inhibit cell growth and induce apoptosis. The results indicate that the LATS1 tumor suppressor may play an important role in the control of human tumor development and that LATS1 suppresses tumorigenesis by negatively regulating cell proliferation and modulating cell survival.	Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06536 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University	Tao, WF (corresponding author), Univ Minnesota, Ctr Canc, Div Hematol Oncol & Transplantat, Stem Cell Inst, Minneapolis, MN 55455 USA.							Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gaumann A, 2001, CANCER-AM CANCER SOC, V92, P1237, DOI 10.1002/1097-0142(20010901)92:5<1237::AID-CNCR1443>3.0.CO;2-E; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hori T, 2000, ONCOGENE, V19, P3101, DOI 10.1038/sj.onc.1203659; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; LEE JH, 1990, CANCER RES, V50, P2724; Mazurenko N, 1999, ONCOL REP, V6, P859; MIYASHITA T, 1995, CELL, V80, P293; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morinaga N, 2000, INT J ONCOL, V17, P1125; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Sturm I, 2000, INT J CANCER, V87, P517, DOI 10.1002/1097-0215(20000815)87:4<517::AID-IJC9>3.0.CO;2-B; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Theile M, 1996, ONCOGENE, V13, P677; Turenchalk GS, 1999, BBA-REV CANCER, V1424, pM9, DOI 10.1016/S0304-419X(99)00021-9; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	35	129	133	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1233	1241		10.1038/sj.onc.1205174	http://dx.doi.org/10.1038/sj.onc.1205174			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850843				2022-12-17	WOS:000173729400011
J	Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A				Hafner, C; Knuechel, R; Zanardo, L; Dietmaier, W; Blaszyk, H; Cheville, J; Hofstaedter, F; Hartmann, A			Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract	ONCOGENE			English	Article						urothelial carcinoma; upper and lower urinary tract; LOH; oligoclonality; p53 mutation	TRANSITIONAL-CELL CARCINOMA; MICROSATELLITE INSTABILITY; BLADDER-CANCER; FIELD CANCERIZATION; CLONAL ORIGIN; P53 MUTATION; LOW-GRADE; DELETION	Multifocality and recurrence of urothelial carcinoma may result from either the field effect of carcinogens leading to oligoclonal tumors or monoclonal tumor spread. Previous molecular studies, favoring the monoclonality hypothesis, are mostly limited to the urinary bladder. We investigated genetic alterations in a total of 94 synchronous or metachronous multifocal tumors from 19 patients with at least one tumor both in the upper and lower urinary tract. Loss of heterozygosity (LOH) was determined using eight markers on chromosome 9 and one marker on 17p13 (p53). Microsatellite instability was investigated at six loci and protein expression of MSH2 and MLH1 was evaluated by immunohistochemistry. In addition, exons 5-9 of the p53 gene were sequenced. Deletions at chromosome 9 were found in 73% of tumors and at 17p13 in 18% of tumors. There was no significant difference in the frequency of LOH in the upper and lower urinary tract. Deletions at 9p21 were significantly correlated with invasive tumor growth. The pattern of deletion revealed monoclonality of all tumors in nine patients. In five patients there were at least two tumor clones with different genetic alterations. In four of these patients the different clones occured in the bladder and subsequently in the ureter and renal pelvis. All four patients with p53 mutations revealed identical mutations in all tumors. Thus, multifocal urothelial carcinomas are frequently monoclonal, whereas others show oligoclonality, providing molecular evidence for field cancerization. Intraluminal tumor cell seeding appears to be an important mechanism of multifocal occurence and recurrence of urothelial carcinomas.	Univ Regensburg, Inst Pathol, D-93042 Regensburg, Germany; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA	University of Regensburg; Mayo Clinic	Hartmann, A (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.	arndt.hartmann@klinik.uni-regensburg.de						Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613; Arzimanoglou II, 1998, CANCER-AM CANCER SOC, V82, P1808, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1808::AID-CNCR2>3.0.CO;2-J; Bender CM, 1998, MED RAD DIA IMG, P37; Boland CR, 1998, CANCER RES, V58, P5248; Dietmaier W, 1999, AM J PATHOL, V154, P83, DOI 10.1016/S0002-9440(10)65254-6; Dietmaier W, 1997, CANCER RES, V57, P4749; Franklin WA, 1997, J CLIN INVEST, V100, P2133, DOI 10.1172/JCI119748; HABUCHI T, 1993, LANCET, V342, P1087, DOI 10.1016/0140-6736(93)92066-3; HARRIS AL, 1992, NEW ENGL J MED, V326, P759, DOI 10.1056/NEJM199203123261108; Hartmann A, 2000, LAB INVEST, V80, P709, DOI 10.1038/labinvest.3780074; HENEY NM, 1978, J UROLOGY, V120, P559, DOI 10.1016/S0022-5347(17)57275-4; HERMANEK P, 1998, TNM CLASSIFICATION M; Li MM, 1999, HUM PATHOL, V30, P1197, DOI 10.1016/S0046-8177(99)90037-0; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Paiss Thomas, 1997, Journal of Urology, V157, P161; Partridge M, 1997, ORAL ONCOL, V33, P332; RADOVANOVIC Z, 1985, J CANCER RES CLIN, V110, P181, DOI 10.1007/BF00402737; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SIDRANSKY D, 1992, NEW ENGL J MED, V326, P737, DOI 10.1056/NEJM199203123261104; Simon R, 2001, CANCER RES, V61, P355; Simoneau M, 1999, ONCOGENE, V18, P157, DOI 10.1038/sj.onc.1202277; SPRUCK CH, 1994, CANCER RES, V54, P784; Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621; Takahashi T, 2001, J UROLOGY, V165, P672, DOI 10.1097/00005392-200102000-00092; Takahashi T, 1998, CANCER RES, V58, P5835; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Xu XH, 1996, CLIN CANCER RES, V2, P1795; Yamamoto S, 1998, CARCINOGENESIS, V19, P855, DOI 10.1093/carcin/19.5.855	28	129	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4910	4915		10.1038/sj.onc.1204671	http://dx.doi.org/10.1038/sj.onc.1204671			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521204				2022-12-17	WOS:000170271800017
J	Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M				Oya, M; Ohtsubo, M; Takayanagi, A; Tachibana, M; Shimizu, N; Murai, M			Constitutive activation of nuclear factor-kappa B prevents TRAIL-induced apoptosis in renal cancer cells	ONCOGENE			English	Article						renal cell carcinoma; TRAIL; NF-kappa B; I kappa B alpha; apoptosis	APO2 LIGAND; FAMILY; EXPRESSION; CARCINOMA; DEATH; RECEPTORS; MEMBER; INDUCTION	TRAIL has gained much attention for its specific induction of apoptosis in cancer cells but not in normal cells. This phenomenon has been explained thus: that cancer cells dominantly express death receptors while normal cells express decoy receptors, However, recent reports have shown that some cancer cell lines are resistant to TRAIL-induced apoptosis despite the that some cancer cell line! -induced apoptosis despite absence of decoy receptors and the presence of death receptors, This suggested the existance of an inhibitory factor. We herein showed that NF-kappaB is a key molecule underlying the TRAIL-resistant mechanism in renal cell carcinoma (RCC) cell lines. We observed that NF-kappaB is constitutively activated in resistant cell lines. Forced expression of antisense cDNA of Ik-Ba, a specific inhibitor of NF-kappaB, in TRAIL-sensitive cell lines with a low NF-kappaB activity result in constitutive activation of NF-kappaB and resistance to TRAIL-induced apoptosis, Adenoviral expression of a stable form of I kappaB alpha in the TRAIL-resistant cell lines induced apoptosis, These data suggest that RCC can be classified into two subsets: TRAIL-sensitive RCC with a low NF-KB activity and TRAIL-resistant RCC with constitutively activated NF kappaB, In the former group TRAIL can be a treatment option, while in the latter group a molecular approach targeting NF-kappaB appears to be a promising therapy.	Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan	Keio University; Keio University	Oya, M (corresponding author), Keio Univ, Sch Med, Dept Urol, Shinjuku Ku, Tokyo 1608582, Japan.		Oya, Mototsugu/K-8592-2013					Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blay JY, 1997, INT J CANCER, V72, P424, DOI 10.1002/(SICI)1097-0215(19970729)72:3<424::AID-IJC9>3.0.CO;2-R; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Frank S, 1999, BIOCHEM BIOPH RES CO, V257, P454, DOI 10.1006/bbrc.1999.0493; Gilmore TD, 1996, ONCOGENE, V13, P1367; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Keane MM, 1999, CANCER RES, V59, P734; Kim KH, 2000, CLIN CANCER RES, V6, P335; Kothny-Wilkes G, 1998, J BIOL CHEM, V273, P29247, DOI 10.1074/jbc.273.44.29247; Mulders P, 1997, CANCER RES, V57, P5189; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; RITCHIE AWS, 1983, SEMIN ONCOL, V10, P390; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Sumitomo M, 1999, HUM GENE THER, V10, P37, DOI 10.1089/10430349950019174; Tachibana M, 2000, CELL TISSUE RES, V301, P353, DOI 10.1007/s004410000235; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang XD, 1999, CANCER RES, V59, P2747	29	129	140	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3888	3896		10.1038/sj.onc.1204525	http://dx.doi.org/10.1038/sj.onc.1204525			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439352				2022-12-17	WOS:000169494700014
J	Toone, WM; Morgan, BA; Jones, N				Toone, WM; Morgan, BA; Jones, N			Redox control of AP-1-like factors in yeast and beyond	ONCOGENE			English	Review						AP-1; yeast; redox-control; stress	OXIDATIVE STRESS-RESPONSE; ATF1 TRANSCRIPTION FACTOR; ACTIVATED PROTEIN-KINASE; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; NUCLEAR EXPORT; GENE-EXPRESSION; BUDDING YEAST; CELL-CYCLE	Cells have evolved complex and efficient strategies for dealing with variable and often-harsh environments. A key aspect of these stress responses is the transcriptional activation of genes encoding defense and repair proteins. In yeast members of the AP-1 family of proteins are required for the transcriptional response to oxidative stress. This sub-family of AP-1 (called yAP-1) proteins are sensors of the redox-state of the cell and are activated directly by oxidative stress conditions. yAP-1 proteins are bZIP-containing factors that share homology to the mammalian AP-1 factor complex and bind to very similar DNA sequence sites, The generation of reactive oxygen species and the resulting potential for oxidative stress is common to all aerobically growing organisms, Furthermore, many of the features of this response appear to be evolutionarily conserved and consequently the study of model organisms, such as yeast, will have widespread utility. The important structural features of these factors, signaling pathways controlling their activity and the nature of the target genes they control will be discussed.	Christie Hosp NHS Trust, CRC, Cell Regulat Grp, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research; Newcastle University - UK	Jones, N (corresponding author), Christie Hosp NHS Trust, CRC, Cell Regulat Grp, Paterson Inst Canc Res, Wilmslow Rd, Manchester M20 4BX, Lancs, England.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Alvarez ME, 1998, CELL, V92, P773, DOI 10.1016/S0092-8674(00)81405-1; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; Bauer CE, 1999, ANNU REV MICROBIOL, V53, P495, DOI 10.1146/annurev.micro.53.1.495; Bobrowicz P, 1997, YEAST, V13, P819, DOI 10.1002/(SICI)1097-0061(199707)13:9<819::AID-YEA142>3.0.CO;2-Y; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Coleman ST, 1999, MOL CELL BIOL, V19, P8302; Cottarel G, 1997, GENETICS, V147, P1043; Degols G, 1996, MOL CELL BIOL, V16, P2870; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HUANG RP, 1993, DNA CELL BIOL, V12, P265, DOI 10.1089/dna.1993.12.265; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Izawa S, 1999, J BIOL CHEM, V274, P28459, DOI 10.1074/jbc.274.40.28459; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Millar JBA, 1999, BIOCHEM SOC SYMP, P49; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Ohmiya R, 1999, J BIOCHEM, V125, P1061, DOI 10.1093/oxfordjournals.jbchem.a022387; Pascual-Ahuir M, 2001, MOL CELL BIOL, V21, P16, DOI 10.1128/MCB.21.1.16-25.2001; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Samejima I, 1997, EMBO J, V16, P6162, DOI 10.1093/emboj/16.20.6162; Samejima I, 1998, MOL BIOL CELL, V9, P2325, DOI 10.1091/mbc.9.8.2325; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; SHIMANUKI M, 1995, J CELL SCI, V108, P569; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Stitzel ML, 2001, GENE DEV, V15, P128, DOI 10.1101/gad.863801; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; TODA T, 1992, MOL CELL BIOL, V12, P5474, DOI 10.1128/MCB.12.12.5474; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Toone WM, 1998, GENES CELLS, V3, P485, DOI 10.1046/j.1365-2443.1998.00211.x; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; VIDO K, 2001, IN PRESS J BIOL CHEM; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Wemmie JA, 1997, J BIOL CHEM, V272, P7908, DOI 10.1074/jbc.272.12.7908; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Wu XS, 1996, MOL CELL BIOL, V16, P1035; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zhang XT, 2000, MOL MICROBIOL, V36, P618, DOI 10.1046/j.1365-2958.2000.01877.x; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2000, BIOCHEM PHARMACOL, V59, P1, DOI 10.1016/S0006-2952(99)00289-0	75	129	137	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 30	2001	20	19					2336	2346		10.1038/sj.onc.1204384	http://dx.doi.org/10.1038/sj.onc.1204384			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	430HP	11402331				2022-12-17	WOS:000168568700002
J	Fujii, H; Biel, MA; Zhou, WB; Weitzman, SA; Baylin, SB; Gabrielson, E				Fujii, H; Biel, MA; Zhou, WB; Weitzman, SA; Baylin, SB; Gabrielson, E			Methylation of the HIC-1 candidate tumor suppressor gene in human breast cancer	ONCOGENE			English	Article						breast cancer; methylation; tumor suppressor gene; HIC-1; chromosome 17	ALLELIC LOSS; DNA HYPERMETHYLATION; CHROMOSOME 17P13.3; MUTATIONS; 17P; PROGRESSION; CARCINOMA; PROTEIN; LOCUS; D17S5	HIC-1 (hypermethylated in cancer) is a candidate tumor suppressor gene which is located at 17p13.3, a region which frequently undergoes allelic loss in breast and other human cancers, HIC-1 is proposed to be commonly inactivated in human cancers by hypermethylation of a normally unmethylated dense CpG island which encompasses the entire gene, To study whether HIC-1 inactivation may be important to the development of breast cancer, we first measured methylation of the HIC-1 gene in normal breast ductal tissues from microdissected frozen breast tissues and from epithelial cells purified from mammoplasty specimens. Surprisingly, in all normal breast ductal tissues we found approximately equal amounts of densely methylated HIC-1 and completely unmethylated HIC-1, This is in contrast to most normal tissues, in which all copies of HIC-1 are completely unmethylated. We then evaluated 39 primary breast cancer tissues and found virtually complete methylation of the HIC-1 gene in 26 (67%) of the cases. We also found loss of heterozygosity at the telomeric portion of chromosomal arm 17p in 22 of the 26 cases with strongly methylated HIC-1, suggesting that loss of an unmethylated HIC-1 allele mag contribute to the inactivation of HIC-1 in cells with a pre-existing methylated allele, Finally, by RNase protection analysis, HIC-1 was found to be expressed in microdissected normal breast ductal tissues and unmethylated tumors but not in tumors with hypermethylation of the HIC-1 gene. These results indicate that hypermethylation of HIC-1 and associated loss of HIC-1 expression is common in primary breast cancer. Furthermore, the HIC-1 gene is densely methylated in approximately one-half of the alleles in normal breast epithelium, which may predispose this tissue to inactivation of this gene by loss of heterozygosity.	Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21224 USA; Northwestern Univ, Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA	Johns Hopkins University; Johns Hopkins University; Northwestern University	Gabrielson, E (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21224 USA.				NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES66204, CA 43318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; Batova A, 1997, CANCER RES, V57, P832; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; CAVENEE WK, 1991, CANCER, V67, P2431, DOI 10.1002/1097-0142(19910515)67:10<2431::AID-CNCR2820671005>3.0.CO;2-#; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DENG G, 1994, CANCER RES, V54, P499; Fujii H, 1996, GENE CHROMOSOME CANC, V16, P35, DOI 10.1002/(SICI)1098-2264(199605)16:1<35::AID-GCC5>3.0.CO;2-4; Fujii H, 1996, CANCER RES, V56, P5260; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1997, CANCER RES, V57, P837; MAKOS M, 1993, CANCER RES, V53, P2715; MAKOS M, 1993, CANCER RES, V53, P2719; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MAKOSWALES M, 1995, NAT MED, V1, P570; MERLO A, 1995, NAT MED, V1, P1; MIKI T, 1994, BLOOD, V83, P26; Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0; Phillips NJ, 1996, CANCER LETT, V102, P85, DOI 10.1016/0304-3835(96)04169-9; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SATO T, 1991, CANCER RES, V51, P5794; Schultz DC, 1996, CANCER RES, V56, P1997; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107	28	129	140	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2159	2164		10.1038/sj.onc.1201976	http://dx.doi.org/10.1038/sj.onc.1201976			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572497				2022-12-17	WOS:000073177200014
J	Yuan, ZM; Utsugisawa, T; Ishiko, T; Nakada, S; Huang, YY; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Utsugisawa, T; Ishiko, T; Nakada, S; Huang, YY; Kharbanda, S; Weichselbaum, R; Kufe, D			Activation of protein kinase C delta by the c-Abl tyrosine kinase in response to ionizing radiation	ONCOGENE			English	Article						protein kinase C delta; c-Abl tyrosine kinase; ionizing radiation; genotoxic stress	STRESS-RESPONSE; SH3 DOMAINS; PHOSPHORYLATION; GROWTH; DNA; CELL; PATHWAY; ARREST; GENE; P53	The c-Abl protein tyrosine kinase is activated by ionizing radiation (IR) and certain other DNA-damaging agents. The present studies demonstrate that c-Abl associates constitutively with protein kinase C delta (PkC delta). The results show that the SH3 domain of c-Abl interacts directly with PKC delta. c-Abl phosphorylates and activates PKC delta in vitro. We also show that IR treatment of cells is associated with c-Abl-dependent phosphorylation of PKC delta and translocation of PKC delta to the nucleus. These findings support a functional interaction between c-Abl and PKC delta in the cellular response to genotoxic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, Boston, MA 02115 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Chicago	Yuan, ZM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Div Canc Pharmacol, 44 Binney St, Boston, MA 02115 USA.		Utsugisawa, Taiju/ABD-7059-2021					Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; GODDARD JM, 1986, P NATL ACAD SCI USA, V83, P2172, DOI 10.1073/pnas.83.7.2172; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, ONCOGENE, V11, P791; HENKEMEYER MJ, 1988, MOL CELL BIOL, V8, P843, DOI 10.1128/MCB.8.2.843; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Kharbanda S, 1996, CANCER RES, V56, P3617; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MOORE KL, 1994, DEV BIOL, V164, P444, DOI 10.1006/dbio.1994.1214; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLSON EN, 1993, CELL GROWTH DIFFER, V4, P699; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Wen ST, 1996, EMBO J, V15, P1583, DOI 10.1002/j.1460-2075.1996.tb00503.x; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	46	129	131	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1643	1648		10.1038/sj.onc.1201698	http://dx.doi.org/10.1038/sj.onc.1201698			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582011				2022-12-17	WOS:000072807600001
J	Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P				Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P			Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin	ONCOGENE			English	Article						beta-catenin; LEF1; wnt-1; cancer	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR LEF-1; APC GENE-PRODUCT; ALPHA-ENHANCER; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; XENOPUS EMBRYOS; CELL-ADHESION; E-CADHERIN; IN-VIVO	Signal transduction by beta-catenin involves its posttranslational stabilization and import to the nucleus where it interacts with transcription factors, Recent implications for beta-catenin signaling in cancer prompted us to examine colon cancer cell lines for the expression of LEF-1, a transcription factor that binds to beta-catenin, The analysis of several cell lines revealed the expression of LEF1 mRNA and a constitutive association of the LEF-1 protein with beta-catenin, In contrast to the colon cells, PC12 and 293 cells did not contain a beta-catenin-LEF-1 complex, even though both proteins were detected in cell lysates, In these cells, the association of endogenous LEF1 and beta-catenin was induced by stimulation with the wnt-1 proto-oncogene. The complex formed following transient stimulation with wnt-1 and also persisted in cells stably expressing wnt-1. Ectopic overexpression of beta-catenin in 293 cells also induced the assembly of the beta-catenin-LEF-1 complex and activated gene transcription from a LEF-1-dependent promotor, Expression of mutant oncogenic forms of beta-catenin identified in cancer cells resulted in higher levels of transcriptional activity, The results suggest that a cancer pathway driven by wnt-1, or mutant forms of beta-catenin, may involve the formation of a persistent transcriptionally active complex of beta-catenin and LEF1.	ONYX PHARMACEUT,RICHMOND,CA 94806; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine				Rubinfeld, Bonnee/0000-0001-9861-6775				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Inomata M, 1996, CANCER RES, V56, P2213; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LOEB DM, 1993, J NEUROSCI, V13, P2919; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	37	129	131	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2833	2839		10.1038/sj.onc.1201462	http://dx.doi.org/10.1038/sj.onc.1201462			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419974				2022-12-17	WOS:A1997YJ80300009
J	Smith, DP; Houghton, C; Ponder, BAJ				Smith, DP; Houghton, C; Ponder, BAJ			Germline mutation of RET codon 883 in two cases of de novo MEN 2B	ONCOGENE			English	Article						multiple endocrine neoplasia type 2B; RET protooncogene; germline mutation	MULTIPLE ENDOCRINE NEOPLASIA; MEDULLARY-THYROID CARCINOMA; RECEPTOR TYROSINE KINASE; AUTOPHOSPHORYLATION SITES; PROTOONCOGENE MUTATIONS; HIRSCHSPRUNG DISEASE; POINT MUTATION; ACTIVATION; DOMAIN; IDENTIFICATION	Germline mutations in the RET proto-oncogene are seen in the majority of patients with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2). The clinical subtypes of MEN 2 (MEN 2A, MEN 2B and familial MTC) all have medullary thyroid carcinoma, but vary in the involvement of pheochromocytoma, parathyroid adenoma/hyperplasia and developmental abnormalities. A single RET mutation, resulting in the substitution M918T, has been identified in 94% of cases of MEN 2B (which consists of MTC, pheochromocytoma and developmental abnormalities). Here we report the identification of a new germline RET mutation (A883F) in two de novo cases of MEN 2B. Identification of this new mutation will contribute to understanding the molecular basis of MEN 2B, and will assist in the clinical management of families harbouring this mutation.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT PATHOL,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; BOLINO A, 1995, ONCOGENE, V10, P2415; Borrello MG, 1995, ONCOGENE, V11, P2419; Carlomagno F, 1996, EMBO J, V15, P2717, DOI 10.1002/j.1460-2075.1996.tb00632.x; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Iwashita T, 1996, ONCOGENE, V12, P481; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P213, DOI 10.1046/j.1365-2265.1996.505292.x; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Pignon JM, 1997, BRIT J HAEMATOL, V96, P374, DOI 10.1046/j.1365-2141.1997.d01-2042.x; Ponder BAJ, 1996, ADV CANCER RES, V70, P179, DOI 10.1016/S0065-230X(08)60875-1; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Toogood AA, 1995, CLIN ENDOCRINOL, V43, P759, DOI 10.1111/j.1365-2265.1995.tb00547.x; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; Webster MK, 1996, MOL CELL BIOL, V16, P4081; ZHANG B, 1991, J BIOL CHEM, V266, P990	40	129	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 4	1997	15	10					1213	1217		10.1038/sj.onc.1201481	http://dx.doi.org/10.1038/sj.onc.1201481			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294615				2022-12-17	WOS:A1997XU99100011
J	Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR				Cheng, JQ; Altomare, DA; Klein, MA; Lee, WC; Kruh, GD; Lissy, NA; Testa, JR			Transforming activity and mitosis-related expression of the AKT2 oncogene: Evidence suggesting a link between cell cycle regulation and oncogenesis	ONCOGENE			English	Article						AKT2; transformation; cell cycle; serine/threonine kinase	PROTEIN-KINASE-B; SIGNAL-TRANSDUCTION; C-AKT; MOLECULAR-CLONING; V-AKT; PRODUCT; LOCALIZATION; CARCINOMAS; SUBFAMILY; DOMAINS	The AKT2 oncogene encodes a protein-serine/threonine kinase containing a pleckstrin homology domain characteristic of many signaling proteins. Recently, it was shown that AKT2 kinase activity can be induced by platelet-derived growth factor through phosphatidylinositol-3-OH kinase, suggesting that AKT2 may be an important signal mediator that contributes to the control of cell proliferation, We previously reported amplification and overexpression of AKT2 in human cancers, To investigate the transforming activity of AKT2, we used a retrovirus-based construct to express AKT2 in NIH3T3 cells. Overexpression of AKT2 was found to transform NIH3T3 cells, as determined by growth in soft agar and tumor formation in nude mice, The oncogenic activity of AKT2 was diminished by truncation of a 70-amino acid proline-rich region at the carboxyl-terminus. To facilitate the characterization of AKT2, we generated monoclonal and polyclonal antibodies against this protein. AKT2 was localized to the cytoplasm by cell fractionation experiments, immunocytochemistry, and immunofluorescence, Protein levels were more abundant in mitotic cells than in interphase cells. Western blot analysis of synchronized pancreatic cancer cells demonstrated that the expression level of AKT2 protein in mitotic cells is three to fivefold higher than in their interphase counterparts, A time-course study of phytohemagglutinin-stimulated lymphocytes revealed that AKT2 mRNA and AKT2 protein levels are highest 48-72h after addition of mitogen, when cells are actively dividing. These data suggest that AKT2 could play a significant role in cell cycle progression and that the oncogenic activity of overexpressed AKT2 may be mediated by aberrant regulation of cellular proliferation.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [R01 CA077429, P30 CA006927, CA-06927, CA 09035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077429, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Arranz E, 1996, CANCER GENET CYTOGEN, V87, P1, DOI 10.1016/0165-4608(95)00230-8; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MCKENZIE SJ, 1989, ONCOGENE, V4, P543; Miwa W, 1996, BIOCHEM BIOPH RES CO, V225, P968, DOI 10.1006/bbrc.1996.1280; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; RICHMAN DP, 1980, J CELL BIOL, V85, P459, DOI 10.1083/jcb.85.2.459; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SMITH DB, 1994, CURRENT PROTOCOLS MO; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; WILLINGHAM MC, 1990, FOCUS, V12, P62	32	129	142	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 12	1997	14	23					2793	2801		10.1038/sj.onc.1201121	http://dx.doi.org/10.1038/sj.onc.1201121			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XD643	9190895				2022-12-17	WOS:A1997XD64300007
J	Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA				Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA			RET activation by germline MEN2A and MEN2B mutations	ONCOGENE			English	Article						RET; receptor tyrosine kinase; multiple endocrine neoplasia type 2; inherited cancer syndrome; oncogene	MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA CELL-LINES; PROTO-ONCOGENE; TYROSINE KINASE; PROTOONCOGENE; EXPRESSION; DIFFERENTIATION; CARCINOMAS; SEQUENCE; GENE	The RET proto-oncogene encodes a receptor tyrosine kinase (TK), It has been shown that distinct germline mutations in the RET proto-oncogene are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC) as well as Hirschsprung disease (HSCR), a congenital disorder characterised by absent enteric innervation, In this study, we have transfected NIH3T3 and PC12 phaeochromocytoma cells with MEN2A (Cys634-->Arg) and MEN2B (Met918-->Thr) RET constructs, Both caused transformation of the NIH3T3 cells and differentiation of PC12 cells, The Bet (MEN2A) and Bet (MEN2B) proteins were constitutively phosphorylated on tyrosine, and their in vitro kinase activity was significantly higher than that of the wild type protein, The MTC cell line TT carries a Cys634-->Trp MEN2A mutation, and we have shown by immunoelectronmicroscopy that Ret is clustered on the cell surface in a manner reminiscent of ligand-induced aggregation of cell surface receptors, RET is activated, as RET/PTC oncogene, by somatic rearrangements which link the TK domain to a constitutive dimerization interface in papillary thyroid carcinomas, We have compared the biological and biochemical activity of the TK domains of the wild type and MEN 2B Ret in the context of the RET/PTC, The results show that the MEN2B mutation significantly increases the TK domain enzymatic activity suggesting that dimerization may be still necessary for MEN 2B Bet to express its full activity.	IST NAZL TUMORI,DIV EXPTL ONCOL A,I-20133 MILAN,ITALY; UNIV CAMBRIDGE,ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16147 GENOA,ITALY; IST NAZL TUMORI,DIV ANAT PATHOL & CYTOL,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan			Bocciardi, Renata/J-8577-2016; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Bocciardi, Renata/0000-0001-8415-3802; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349; Eng, Charis/0000-0002-3693-5145; Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIEDLER JL, 1978, CANCER RES, V38, P3751; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUNONE G, 1995, CELL RES, V217, P92; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; FABIEN N, 1994, INT J ONCOL, V4, P623; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Leong S, 1981, ADV THYROID NEOPLASI, P95; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAUE F, 1994, ENDOCRINOLOGY METABO, pR12; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOPSI L, 1992, ULTRASTRUCT PATHOL, V16, P351, DOI 10.3109/01913129209061363; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	44	129	129	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2419	2427						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570194				2022-12-17	WOS:A1995TK70200027
J	LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J				LUKAS, J; BARTKOVA, J; WELCKER, M; PETERSEN, OW; PETERS, G; STRAUSS, M; BARTEK, J			CYCLIN D2 IS A MODERATELY OSCILLATING NUCLEOPROTEIN REQUIRED FOR G1 PHASE PROGRESSION IN SPECIFIC CELL-TYPES	ONCOGENE			English	Article						CELL CYCLE; D-TYPE CYCLINS; ONCOGENE; G1 REGULATION	HUMAN BREAST-CANCER; RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; NUCLEAR-PROTEIN; GROWTH-FACTOR; D1; CLONING; G(1); PHOSPHORYLATION; DIFFERENTIATION	To explore regulation and function of cyclin D2, a candidate cell cycle-regulatory proto-oncogene, we examined subcellular localisation, cell type- and cell cycle-dependent expression, and requirement of cyclin D2 protein for G1 progression, in a panel of 40 human normal and cancer cell types. Except for lymphoid cells and sarcoma cell lines, expression of cyclin D2 was considerably more restricted than that of cyclin D1, whereas both D-type cyclin proteins were low or undetectable in cells lacking functional retinoblastoma gene product. In G1 cells, the cyclin D2 protein was more resistant to extraction and localised predominantly to nuclei, whereas it became more soluble and distributed in both nuclei and cytoplasm from G1/S transition onwards. Centrifugal elutriation and multiparameter flow cytometry analyses of several cell types showed moderate cell cycle oscillation with maximum levels of the cyclin D2 protein reached in late G1. Microinjection and/or electroporation of antibodies to cyclin D2 during G1 arrested the cyclin D2-expressing lymphocytes, breast myoepithelium, and U-2-OS sarcoma cells in G1 phase, whereas cyclin D2-negative cell types were unaffected by such treatment. Consistent with the putative protooncogenic role of cyclin D2 in specific cell types, our data show that this G1 cyclin has properties closely resembling those of cyclin D1, including the essential positive role in regulation of G1.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN 0, DENMARK; UNIV COPENHAGEN, PANUM INST, INST MED ANAT A, STRUCT CELL BIOL UNIT, DK-2200 COPENHAGEN N, DENMARK; IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND; MAX PLANCK GESELL, MAX DELBRUCK HAUS, D-13122 BERLIN, GERMANY	Danish Cancer Society; University of Copenhagen; Cancer Research UK; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Max Planck Society			Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Welcker, Markus/0000-0001-6723-4790; Petersen, Ole William/0000-0003-1691-749X				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; HANNA Z, 1993, ONCOGENE, V8, P1661; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MORK C, 1990, DIFFERENTIATION, V43, P146; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PALMERO I, 1993, ONCOGENE, V8, P1049; PETERSEN OW, 1988, DIFFERENTIATION, V39, P197, DOI 10.1111/j.1432-0436.1988.tb00094.x; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; TAM SW, 1994, ONCOGENE, V9, P2663; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	56	129	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	1995	10	11					2125	2134						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RB703	7784057				2022-12-17	WOS:A1995RB70300007
J	HENNIGAN, RF; HAWKER, KL; OZANNE, BW				HENNIGAN, RF; HAWKER, KL; OZANNE, BW			FOS-TRANSFORMATION ACTIVATES GENES ASSOCIATED WITH INVASION	ONCOGENE			English	Article							C-FOS; BINDING-PROTEIN; CELL-LINE; CATHEPSIN-L; DIFFERENTIAL EXPRESSION; SIGNAL-TRANSDUCTION; METASTATIC CELLS; EARLY RESPONSE; GROWTH-FACTORS; FIBROBLASTS	Fos oncoproteins transform cells by functioning as transcription factors. Over-expression of c-fos results in minimal morphological transformation while the two viral isolates, FBJ and FBR v-fos, result in full morphological transformation. Fos-transformed cells are serum dependent for proliferation but not for morphological transformation. To identify Fos target genes which might be involved in morphological transformation me screened a cDNA library constructed from RNA isolated from serum starved FBR-transformed cells with cDNA probes prepared from both FBR-transformed cells and untransformed parental fibroblasts, 208F. We identified 10 genes which are differentially expressed between FBR and 208F cells. One is a novel gene. Nine are upregulated in c-fos- and FBJ-transformed cells and also in mutant c-Ha-Ras-transformed 208Fs. All nine of the upregulated genes have been associated previously with invasion or metastasis. We demonstrate that the FBR-transformed cells are invasive in an in vitro assay and that their ability to invade is enhanced by platelet derived growth factor. We conclude that the fos oncogenes target genes involved in morphological transformation, and invasion.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND; UNIV TEXAS, SW MED CTR, DEPT MICROBIOL, DALLAS, TX 75235 USA	Beatson Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								Angel P, 1992, Matrix Suppl, V1, P156; ANGEL P, 1987, J CELL BIOCHEM, V42, P193; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BECKNER ME, 1993, J NATL CANCER I, V1990, P1836; BURCK KB, 1988, ONCOGENES INTRO CONC; CHAUHAN SS, 1991, CANCER RES, V51, P1478; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1989, ONCOGENE HDB; DAVIES BR, 1993, ONCOGENE, V8, P999; DELARCOJ, 1978, P NATL ACAD SCI USA, V70, P369; DENHARDT DT, 1987, ONCOGENE, V2, P55; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; EPNER DE, 1993, CANCER RES, V53, P1995; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FINKEL MP, 1966, SCIENCE, V151, P698, DOI 10.1126/science.151.3711.698; FINKEL MP, 1975, FRONT RAD THER ONCOL, V10, P205; FRIGERI LG, 1992, J IMMUNOL, V148, P861; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIRAI SI, 1990, ONCOGENE, V5, P39; IWAMOTO Y, 1987, SCIENCE, V238, P1132, DOI 10.1126/science.2961059; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JIA SH, 1988, J BIOL CHEM, V263, P6009; KANE SE, 1988, MOL CELL BIOL, V8, P3316, DOI 10.1128/MCB.8.8.3316; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; KOLCH W, 1993, ONCOGENE, V8, P361; KONDOH N, 1992, CANCER RES, V52, P791; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LESTER BR, 1992, CANCER METAST REV, V11, P31, DOI 10.1007/BF00047601; LITZJACKSON S, 1992, BLOOD, V79, P2404; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOTAN R, 1983, CANCER RES, V43, P2088; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERCOLA D, 1988, GENE, V72, P253, DOI 10.1016/0378-1119(88)90151-5; MILLER AD, 1984, CELL, V36, P51; MINAFRA S, 1992, J CELL SCI, V102, P323; OCHIENG J, 1992, BIOCHEM BIOPH RES CO, V186, P1674, DOI 10.1016/S0006-291X(05)81601-8; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PARK AJ, 1991, J BIOL CHEM, V266, P1584; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; PRICE CHG, 1972, BRIT J CANCER, V26, P15, DOI 10.1038/bjc.1972.5; RAZ A, 1990, INT J CANCER, V46, P871, DOI 10.1002/ijc.2910460520; RAZ A, 1984, EMBO J, V3, P2979, DOI 10.1002/j.1460-2075.1984.tb02244.x; RAZ A, 1986, CANCER RES, V46, P3667; RAZ A, 1981, CANCER RES, V41, P3642; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; Sambrook J., 1989, MOL CLONING LAB MANU; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3212; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TROEN BR, 1991, CELL GROWTH DIFFER, V2, P23; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERMA IM, 1992, PROG CLIN BIOL RES, V376, P41; WICK M, 1992, ONCOGENE, V7, P859; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	71	129	131	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1994	9	12					3591	3600						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970719				2022-12-17	WOS:A1994PT39200022
J	GALANG, CK; DER, CJ; HAUSER, CA				GALANG, CK; DER, CJ; HAUSER, CA			ONCOGENIC RAS CAN INDUCE TRANSCRIPTIONAL ACTIVATION THROUGH A VARIETY OF PROMOTER ELEMENTS, INCLUDING TANDEM C-ETS-2 BINDING-SITES	ONCOGENE			English	Article							NF-KAPPA-B; C-JUN ACTIVITY; GENE-EXPRESSION; PROTEIN-KINASE; SIGNAL TRANSDUCTION; REQUIRES RAF-1; DOMAIN; CELLS; PHOSPHORYLATION; TRANSACTIVATION	Oncogenic Ras activates the transcription of a variety of viral and cellular genes through promoter elements consisting of two closely linked binding sites for transcription factors from several distinct families. To better understand what constitutes a promoter oncogene response element (ORE), various transcription factor binding site configurations were inserted into a reporter gene, and transactivation by oncogenic Ras was measured by cotransfection assays in NIH3T3 cells. We show that a single copy of two closely linked binding sites for either AP-1, Ets, NF-kappa B, or single closely linked Ets and AP-1 binding sites, are sufficient to confer at least 10-fold transactivation by similar amounts of oncogenic Ras. Single binding sites for these factors, or several other pairings of binding sites, are not sufficient to confer Ras responsiveness. The effect of altered ORE binding site spacing and orientation was systematically analysed, and limited flexibility was observed. The novel observation that two adjacent c-Ets-2 binding sites are sufficient to act as an ORE, indicates that Ets family proteins are a target of the Ras pathway distinct from AP-1. This ORE also mediates equivalent transactivation by c-Ets-2, and mutant OREs show a parallel decrease in Ras and c-Ets-2 responsiveness. Together, these data help to define transcriptional targets of the Ras signal transduction pathway.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA; UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	Sanford Burnham Prebys Medical Discovery Institute; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Der, Channing/0000-0002-7751-2747	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD028525] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA42978] Funding Source: Medline; NICHD NIH HHS [HD28525] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AOYAMA A, 1993, CRIT REV ONCOGENESIS, V4, P53; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BORTNER DM, 1993, CRIT REV ONCOGENESIS, V4, P137; BOS JL, 1989, CANCER RES, V49, P4682; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; COFFER P, 1994, ONCOGENE, V9, P911; DER CJ, 1988, ONCOGENE, V3, P105; FINCO TS, 1993, J BIOL CHEM, V268, P17676; FUJIWARA S, 1990, MOL CELL BIOL, V10, P1249, DOI 10.1128/MCB.10.3.1249; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; HERBOMEL P, 1990, New Biologist, V2, P1063; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MAVROTHALASSITIS GJ, 1991, CELL GROWTH DIFFER, V2, P215; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PETTERSSON M, 1990, J MOL BIOL, V214, P373, DOI 10.1016/0022-2836(90)90187-Q; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETH A, 1993, ONCOGENE, V8, P1783; SIF S, 1993, ONCOGENE, V8, P2501; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	53	129	130	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					2913	2921						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084596				2022-12-17	WOS:A1994PG82200017
J	ROMANO, JW; EHRHART, JC; DUTHU, A; KIM, CM; APPELLA, E; MAY, P				ROMANO, JW; EHRHART, JC; DUTHU, A; KIM, CM; APPELLA, E; MAY, P			IDENTIFICATION AND CHARACTERIZATION OF A P53 GENE MUTATION IN A HUMAN OSTEO-SARCOMA CELL-LINE	ONCOGENE			English	Article									INST RECH SCI CANC,UNITE ONCOL MOLEC,F-94802 VILLEJUIF,FRANCE		ROMANO, JW (corresponding author), NCI,CELL BIOL LAB,BETHESDA,MD 20892, USA.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BENEDICT WF, 1987, ADV VIRAL ONCOL, V7, P19; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CALABRETTA B, 1986, CANCER RES, V46, P5738; CARLONI G, 1988, FEBS LETT, V229, P333, DOI 10.1016/0014-5793(88)81151-7; CHO HY, 1976, SCIENCE, V194, P951, DOI 10.1126/science.62397; Crawford L V, 1984, Mol Biol Med, V2, P261; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LUBBERT M, 1989, ONCOGENE, V4, P643; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCALLISTER RM, 1971, CANCER-AM CANCER SOC, V27, P397, DOI 10.1002/1097-0142(197102)27:2<397::AID-CNCR2820270224>3.0.CO;2-X; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MORA PT, 1982, MOL CELL BIOL, V2, P763, DOI 10.1128/MCB.2.7.763; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RHIM JS, 1975, INT J CANCER, V15, P23, DOI 10.1002/ijc.2910150104; RHIM JS, 1975, NATURE, V256, P751, DOI 10.1038/256751a0; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11383, DOI 10.1093/nar/16.23.11383; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; SOUSSI T, 1987, ONCOGENE, V2, P71; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	51	129	134	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1989	4	12					1483	1488						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2531855				2022-12-17	WOS:A1989CB65900010
J	KONIECZNY, SF; DROBES, BL; MENKE, SL; TAPAROWSKY, EJ				KONIECZNY, SF; DROBES, BL; MENKE, SL; TAPAROWSKY, EJ			INHIBITION OF MYOGENIC DIFFERENTIATION BY THE H-RAS ONCOGENE IS ASSOCIATED WITH THE DOWN REGULATION OF THE MYOD1 GENE	ONCOGENE			English	Article									PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [CA 42835] Funding Source: Medline; NICHD NIH HHS [HD 24489] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD024489] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENIS N, 1987, EXP CELL RES, V172, P212, DOI 10.1016/0014-4827(87)90107-8; DEVLIN BH, 1983, DEV BIOL, V95, P176; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; FREEMAN GJ, 1983, P NATL ACAD SCI-BIOL, V80, P4094, DOI 10.1073/pnas.80.13.4094; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOSSETT LA, 1988, J CELL BIOL, V106, P2127, DOI 10.1083/jcb.106.6.2127; HARRINGTON MA, 1988, BIOESSAYS, V8, P100, DOI 10.1002/bies.950080403; HARRINGTON MA, 1988, MOL CELL BIOL, V8, P4322, DOI 10.1128/MCB.8.10.4322; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; KONIECZNY SF, 1982, DEV BIOL, V91, P11, DOI 10.1016/0012-1606(82)90003-3; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; KONIECZNY SF, 1984, CELL, V38, P791, DOI 10.1016/0092-8674(84)90274-5; KONIECZNY SF, 1987, MOL CELL BIOL, V7, P3065, DOI 10.1128/MCB.7.9.3065; KONIECZNY SF, 1986, MOL BIOL MUSCLE DEV, P21; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LATHROP B, 1985, J CELL BIOL, V100, P1540, DOI 10.1083/jcb.100.5.1540; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LINKHART TA, 1980, J SUPRAMOL STR CELL, V14, P483, DOI 10.1002/jss.400140407; MACKALL J, 1979, ANAL BIOCHEM, V95, P270, DOI 10.1016/0003-2697(79)90216-1; Maniatis T., 1982, MOL CLONING; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIWA T, 1987, P NATL ACAD SCI USA, V84, P6702, DOI 10.1073/pnas.84.19.6702; MULLIGAN RC, 1980, SCIENCE, V209, P1422, DOI 10.1126/science.6251549; MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; OLWIN BB, 1986, BIOCHEMISTRY-US, V25, P3487, DOI 10.1021/bi00360a001; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PINNEY DF, 1988, CELL, V53, P781, DOI 10.1016/0092-8674(88)90095-5; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WICE B, 1987, J BIOL CHEM, V262, P1810	49	129	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					473	481						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2654809				2022-12-17	WOS:A1989U567700012
J	Bu, L; Baba, H; Yoshida, N; Miyake, K; Yasuda, T; Uchihara, T; Tan, P; Ishimoto, T				Bu, Luke; Baba, Hideo; Yoshida, Naoya; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Tan, Patrick; Ishimoto, Takatsugu			Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment	ONCOGENE			English	Review							CARCINOMA-ASSOCIATED FIBROBLASTS; EPITHELIAL-MESENCHYMAL TRANSITION; PANCREATIC STELLATE CELL; BREAST-CANCER; STROMAL FIBROBLASTS; GENE-EXPRESSION; ACTIVATION PROTEIN; COLON-CANCER; SERINE-PROTEASE; STEM-CELLS	Increasing lines of evidence show that the malignant behavior of cancer is not exclusively attributable to cancer cells but also radically influenced by cancerous stroma activity and controlled through various mechanisms by the microenvironment. In addition to structural components, such as the extracellular matrix, stromal cells, such as macrophages, endothelial cells, and specifically cancer-associated fibroblasts (CAFs), have attracted substantial attention over recent decades. CAFs provide routes for aggressive carcinomas and contribute to invasion and metastasis through the biochemical alteration and regulation of cancer-related pathways. However, another facet of CAFs that has been neglected by numerous studies is that CAFs might serve as a negative regulator of cancer progression under certain circumstances. The various origins of CAFs, the diverse tissues in which they reside and their interactions with different cancer cells appear to be responsible for this inconsistency. This review summarizes the latest knowledge regarding CAF heterogeneity and offers a novel perspective and a beneficial approach for obtaining an improved understanding of CAFs.	[Bu, Luke; Baba, Hideo; Yoshida, Naoya; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Grad Sch Life Sci, Dept Gastroenterol Surg, Kumamoto, Japan; [Bu, Luke; Miyake, Keisuke; Yasuda, Tadahito; Uchihara, Tomoyuki; Ishimoto, Takatsugu] Kumamoto Univ, Int Res Ctr Med Sci, Gastrointestinal Canc Biol, Kumamoto, Japan; [Tan, Patrick] Duke NUS Med Sch, Canc & Stem Cell Biol, Singapore, Singapore	Kumamoto University; Kumamoto University; National University of Singapore	Ishimoto, T (corresponding author), Kumamoto Univ, Grad Sch Life Sci, Dept Gastroenterol Surg, Kumamoto, Japan.; Ishimoto, T (corresponding author), Kumamoto Univ, Int Res Ctr Med Sci, Gastrointestinal Canc Biol, Kumamoto, Japan.	taka1516@kumamoto-u.ac.jp	Ishimoto, Takatsugu/AAP-1356-2020	Ishimoto, Takatsugu/0000-0003-1852-1835	Japan Society for the Promotion of Science KAKENHI [16H06257, 17K10639, 18K08543]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported, in part, by the Japan Society for the Promotion of Science KAKENHI (grant numbers 16H06257, 17K10639, and 18K08543).	Albrengues J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10204; Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062; Bauer M, 2010, ONCOGENE, V29, P1732, DOI 10.1038/onc.2009.463; Berdiel-Acer M, 2014, MOL ONCOL, V8, P1290, DOI 10.1016/j.molonc.2014.04.006; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Bochet L, 2013, CANCER RES, V73, P5657, DOI 10.1158/0008-5472.CAN-13-0530; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brechbuhl HM, 2017, CLIN CANCER RES, V23, P1710, DOI 10.1158/1078-0432.CCR-15-2851; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599; Chen WJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4472; Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100; Cheng F, 2016, P NATL ACAD SCI USA, V113, pE4320, DOI 10.1073/pnas.1519197113; Chronopoulos A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12630; Cirri P, 2011, AM J CANCER RES, V1, P482; Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Costea DE, 2013, CANCER RES, V73, P3888, DOI 10.1158/0008-5472.CAN-12-4150; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Driskell RR, 2013, NATURE, V504, P277, DOI 10.1038/nature12783; Enkelmann A, 2011, J CANCER RES CLIN, V137, P751, DOI 10.1007/s00432-010-0932-6; Erdogan B, 2017, J CELL BIOL, V216, P3799, DOI 10.1083/jcb.201704053; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Fuchigami T, 2014, BIOCHEM BIOPH RES CO, V451, P491, DOI 10.1016/j.bbrc.2014.07.137; Fukumura D, 1998, CELL, V94, P715, DOI 10.1016/S0092-8674(00)81731-6; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gardner H, 1996, DEV BIOL, V175, P301, DOI 10.1006/dbio.1996.0116; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Giulianelli S, 2008, INT J CANCER, V123, P2518, DOI 10.1002/ijc.23802; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Harper J, 2014, SEMIN CANCER BIOL, V25, P69, DOI 10.1016/j.semcancer.2013.12.005; Hasegawa T, 2014, INT J CANCER, V134, P1785, DOI 10.1002/ijc.28520; Hayashi Y, 2016, CARCINOGENESIS, V37, P972, DOI 10.1093/carcin/bgw085; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hosein AN, 2010, CANCER RES, V70, P5770, DOI 10.1158/0008-5472.CAN-10-0673; Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596; Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625; Huber MA, 2003, J INVEST DERMATOL, V120, P182, DOI 10.1046/j.1523-1747.2003.12035.x; Ishii G, 2016, ADV DRUG DELIVER REV, V99, P186, DOI 10.1016/j.addr.2015.07.007; Ishimoto T, 2017, GASTROENTEROLOGY, V153, P191, DOI 10.1053/j.gastro.2017.03.046; Ishimoto T, 2016, INT J CANCER, V138, P1337, DOI 10.1002/ijc.29627; Izumi D, 2016, INT J CANCER, V138, P1207, DOI 10.1002/ijc.29864; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Jung EJ, 2007, INT J CANCER, V120, P2331, DOI 10.1002/ijc.22434; Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kawase A, 2008, INT J CANCER, V123, P1053, DOI 10.1002/ijc.23611; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kisselbach L, 2009, CYTOTECHNOLOGY, V59, P31, DOI 10.1007/s10616-009-9190-3; Kisseleva T, 2012, P NATL ACAD SCI USA, V109, P9448, DOI 10.1073/pnas.1201840109; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Kuen J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182039; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Lawrenson K, 2015, INT J CANCER, V136, P1390, DOI 10.1002/ijc.29092; Li L, 2009, INT J CANCER, V125, P1796, DOI 10.1002/ijc.24463; Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51; Li YY, 2018, EBIOMEDICINE, V36, P209, DOI 10.1016/j.ebiom.2018.09.006; Liao D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007965; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lynch MD, 2018, J CLIN INVEST, V128, P26, DOI 10.1172/JCI93555; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304; Murata T, 2011, CANCER RES, V71, P6633, DOI 10.1158/0008-5472.CAN-11-0034; Nakagawa H, 2004, ONCOGENE, V23, P7366, DOI 10.1038/sj.onc.1208013; Nardi F, 2018, J CELL SCI, V131, DOI 10.1242/jcs.213579; Neri S, 2015, INT J CANCER, V137, P784, DOI 10.1002/ijc.29464; Ohlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692; Osterreicher CH, 2011, P NATL ACAD SCI USA, V108, P308, DOI 10.1073/pnas.1017547108; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Olumi AF, 1999, CANCER RES, V59, P5002; Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Patel AK, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0087-x; Paulsson J, 2014, SEMIN CANCER BIOL, V25, P61, DOI 10.1016/j.semcancer.2014.02.006; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Prasad A, 2004, J BIOL CHEM, V279, P9115, DOI 10.1074/jbc.M308083200; Qin X, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1604-0; Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Ramirez-Montagut T, 2004, ONCOGENE, V23, P5435, DOI 10.1038/sj.onc.1207730; Ranogajec I, 2012, MED ONCOL, V29, P561, DOI 10.1007/s12032-011-9984-y; Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021; Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353; Rupp C, 2015, ONCOGENE, V34, P815, DOI 10.1038/onc.2014.18; Saito RA, 2010, CANCER RES, V70, P2644, DOI 10.1158/0008-5472.CAN-09-3644; Salem AF, 2012, CELL CYCLE, V11, P4167, DOI 10.4161/cc.22316; Sanz-Moreno V, 2011, CANCER CELL, V20, P229, DOI 10.1016/j.ccr.2011.06.018; SCHOR SL, 1986, INT J CANCER, V37, P831, DOI 10.1002/ijc.2910370606; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shyer AE, 2015, CELL, V161, P569, DOI 10.1016/j.cell.2015.03.041; STRUTZ F, 1995, NEPHROL DIAL TRANSPL, V10, P1504; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; TARIN D, 1969, J ANAT, V105, P189; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Tran E, 2013, J EXP MED, V210, P1125, DOI 10.1084/jem.20130110; Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486; True LD, 2010, MODERN PATHOL, V23, P1346, DOI 10.1038/modpathol.2010.122; Vered M, 2010, INT J CANCER, V127, P1356, DOI 10.1002/ijc.25358; Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248; VIRCHOW R, 1989, NUTR REV, V47, P23; Vizoso M, 2015, CARCINOGENESIS, V36, P1453, DOI 10.1093/carcin/bgv146; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410; Weigel MT, 2013, ANN ONCOL, V24, P126, DOI 10.1093/annonc/mds240; Witkiewicz AK, 2009, AM J PATHOL, V174, P2023, DOI 10.2353/ajpath.2009.080873; Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6; Ye F, 2008, CANCER INVEST, V26, P569, DOI 10.1080/07357900701837044; Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150; Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369; Yu T, 2017, ONCOGENE, V36, P2131, DOI 10.1038/onc.2016.370; Yu Y, 2014, BRIT J CANCER, V110, P724, DOI 10.1038/bjc.2013.768; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; Zhang AB, 2017, CANCER MED-US, V6, P463, DOI 10.1002/cam4.993; Zhao LY, 2012, INT J BIOCHEM CELL B, V44, P2051, DOI 10.1016/j.biocel.2012.08.005; Zhao XL, 2017, J PATHOL, V243, P376, DOI 10.1002/path.4958	132	128	135	4	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4887	4901		10.1038/s41388-019-0765-y	http://dx.doi.org/10.1038/s41388-019-0765-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30816343				2022-12-17	WOS:000472145900001
J	Nguyen, HG; Yang, JC; Kung, HJ; Shi, XB; Tilki, D; Lara, PN; White, RWD; Gao, AC; Evans, CP				Nguyen, H. G.; Yang, J. C.; Kung, H-J; Shi, X-B; Tilki, D.; Lara, P. N., Jr.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.			Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model	ONCOGENE			English	Article							ANDROGEN RECEPTOR; APOPTOSIS; DEPRIVATION; METFORMIN; SURVIVAL; RAPTOR; PHOSPHORYLATION; COMBINATION; INHIBITION; INDUCTION	Macro-autophagy is associated with drug resistance in various cancers and can function as an adaptive response to maintain cell survival under metabolic stresses, including androgen deprivation. Androgen deprivation or treatment with androgen receptor (AR) signaling inhibitor (ARSI), Enzalutamide (MDV-3100, ENZA) or bicalutamide induced autophagy in androgen-dependent and in castration-resistant CaP (castration-resistant prostate cancer (CRPC)) cell lines. The autophagic cascade triggered by AR blockage, correlated with the increased light chain 3-II/I ratio and ATG-5 expression. Autophagy was observed in a subpopulation of C4-2B cells that developed insensitivity to ENZA after sustained exposure in culture. Using flow cytometry and clonogenic assays, we showed that inhibiting autophagy with clomipramine (CMI), chloroquine or metformin increased apoptosis and significantly impaired cell viability. This autophagic process was mediated by AMP-dependent protein kinase (AMPK) activation and the suppression of mammalian target of rapamycin (mTOR) through Raptor phosphorylation (Serine 792). Furthermore, small interfering RNA targeting AMPK significantly inhibited autophagy and promoted cell death in CaP cells acutely or chronically exposed to ENZA or androgen deprivation, suggesting that autophagy is an important survival mechanism in CRPC. Lastly, in vivo studies with mice orthotopically implanted with ENZA-resistant cells demonstrated that the combination of ENZA and autophagy modulators, CMI or metformin significantly reduced tumor growth when compared with control groups (P < 0.005). In conclusion, autophagy is as an important mechanism of resistance to ARSI in CRPC. Antiandrogen-induced autophagy is mediated through the activation of AMPK pathway and the suppression of mTOR pathway. Blocking autophagy pharmacologically or genetically significantly impairs prostate cancer cell survival in vitro and in vivo, implying the therapeutics potential of autophagy inhibitors in the antiandrogen-resistance setting.	[Nguyen, H. G.; Yang, J. C.; Shi, X-B; Tilki, D.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.] Univ Calif Davis, Sch Med, Dept Urol, Sacramento, CA 95817 USA; [Kung, H-J] Univ Calif Davis, Sch Med, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Kung, H-J; Lara, P. N., Jr.; White, R. W. DeVere; Gao, A. C.; Evans, C. P.] Univ Calif Davis, Sch Med, UC Davis Comprehens Canc Ctr, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Evans, CP (corresponding author), Univ Calif Davis, Sch Med, Dept Urol, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	christopher.evans@ucdmc.ucdavis.edu		Nguyen, Hao/0000-0001-8275-5375	DOD [PC111467]; Medivation/Astellas; NIH [RO1 CA 165263 - 13]; Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant [SU2C-AACR-PCF DT0812]; Movember Foundation; NATIONAL CANCER INSTITUTE [R01CA165263, P30CA093373] Funding Source: NIH RePORTER	DOD(United States Department of Defense); Medivation/Astellas; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant; Movember Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported in part by Grants DOD PC111467 and Medivation/Astellas to CPE, NIH RO1 CA 165263 - 13 to H-JK and by a Stand Up To Cancer-Prostate Cancer Foundation-Prostate Dream Team Translational Cancer Research Grant SU2C-AACR-PCF DT0812 to Eric Small, Owen Witte and CPE. This research grant is made possible by the generous support of the Movember Foundation. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research: The costs of publication of this article were defrayed. Mention of trade name, proprietary product or specific equipment does not constitute a guaranty of warranty by the Department of Defense, nor does it imply approval to the exclusion of other products. The views expressed herein represent those of the authors and do not necessarily represent the position of the Department of Defense.	Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Ben Sahra I, 2010, AUTOPHAGY, V6, P670, DOI 10.4161/auto.6.5.12434; Ben Sahra I, 2010, CANCER RES, V70, P2465, DOI 10.1158/0008-5472.CAN-09-2782; Bennett HL, 2013, BJU INT, V111, P672, DOI 10.1111/j.1464-410X.2012.11409.x; Boutin B, 2013, PROSTATE, V73, P1090, DOI 10.1002/pros.22658; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chhipa RR, 2011, CELL SIGNAL, V23, P1466, DOI 10.1016/j.cellsig.2011.04.008; Gillman PK, 2007, BRIT J PHARMACOL, V151, P737, DOI 10.1038/sj.bjp.0707253; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jiang Q, 2012, J UROLOGY, V188, P1361, DOI 10.1016/j.juro.2012.06.004; Kim RH, 2009, AUTOPHAGY, V5, P567, DOI 10.4161/auto.5.4.8252; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kung H- J, 2013, PROSTATE CANC, V16, P497; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee JHW, 2009, J HYDRO-ENVIRON RES, V3, P1, DOI 10.1016/j.jher.2009.05.002; Leprivier G, 2013, CELL, V153, P1064, DOI 10.1016/j.cell.2013.04.055; Li MQ, 2008, AUTOPHAGY, V4, P54, DOI 10.4161/auto.5209; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Liu HY, 2012, ANTICANCER RES, V32, P1627; Luo J, 2013, EUR UROL, V64, P339, DOI 10.1016/j.eururo.2013.05.012; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Rossi M, 2009, J CELL SCI, V122, P3330, DOI 10.1242/jcs.048181; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13; Sotelo J, 2006, ANN INTERN MED, V144, P337, DOI 10.7326/0003-4819-144-5-200603070-00008; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324	37	128	134	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2014	33	36					4521	4530		10.1038/onc.2014.25	http://dx.doi.org/10.1038/onc.2014.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AO2MY	24662833	Green Published, hybrid			2022-12-17	WOS:000341158800007
J	Ke, G; Liang, L; Yang, JM; Huang, X; Han, D; Huang, S; Zhao, Y; Zha, R; He, X; Wu, X				Ke, G.; Liang, L.; Yang, J. M.; Huang, X.; Han, D.; Huang, S.; Zhao, Y.; Zha, R.; He, X.; Wu, X.			MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene	ONCOGENE			English	Article						miR-181a; PRKCD; apoptosis; cervical cancer; radiation therapy	KINASE-C-DELTA; CASPASE ACTIVATION; MICRORNAS; CELLS	The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3'-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G(2)/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3'-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.	[Ke, G.; Huang, X.; Han, D.; Wu, X.] Fudan Univ, Shanghai Canc Ctr, Dept Gynecol Oncol, Shanghai 200433, Peoples R China; [Ke, G.; Huang, X.; Han, D.; Wu, X.] Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Liang, L.; Huang, S.; Zhao, Y.; Zha, R.; He, X.] Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China; [Yang, J. M.] Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA USA; [Yang, J. M.] Penn State Univ, Coll Med, Penn State Hershey Canc Inst, Hershey, PA USA; [Yang, J. M.] Milton S Hershey Med Ctr, Hershey, PA USA	Fudan University; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	He, X (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China.	xhhe@shsci.org; docwuxh@hotmail.com	liang, linhui/AAW-4176-2021; He, Xianghuo/I-1497-2014; Huang, Shenglin/N-9472-2018	He, Xianghuo/0000-0001-8872-668X; Huang, Shenglin/0000-0003-1279-0794	National Natural Science Foundation of China [81072128]; Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai) [09XD1401100]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai)	We are most grateful for the pWPXL, psPAX2 and pMD2.Glentivirus plasmids that were provided by Professor Didier Trono from the School of Life Sciences, EcolePoly technique Federale de Lausanne, 1015 Lausanne, Switzerland. This work was supported by National Natural Science Foundation of China (No. 81072128), and Science and Technology Commission of Shanghai Municipality (Academic leader foundation of Shanghai, 09XD1401100).	Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Chen G, 2010, ONCOL REP, V23, P997, DOI 10.3892/or_00000725; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hamano R, 2011, CLIN CANCER RES, V17, P3029, DOI 10.1158/1078-0432.CCR-10-2532; Hu X, 2001, CANCER RES, V70, P1441; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Weidhaas JB, 2007, CANCER RES, V67, P11111, DOI 10.1158/0008-5472.CAN-07-2858; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zhang BH, 2007, J CELL PHYSIOL, V210, P279, DOI 10.1002/jcp.20869	21	128	141	2	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3019	3027		10.1038/onc.2012.323	http://dx.doi.org/10.1038/onc.2012.323			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	22847611	Bronze			2022-12-17	WOS:000320705700002
J	Zhang, X; Chen, X; Lin, J; Lwin, T; Wright, G; Moscinski, LC; Dalton, WS; Seto, E; Wright, K; Sotomayor, E; Tao, J				Zhang, X.; Chen, X.; Lin, J.; Lwin, T.; Wright, G.; Moscinski, L. C.; Dalton, W. S.; Seto, E.; Wright, K.; Sotomayor, E.; Tao, J.			Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas	ONCOGENE			English	Article						Myc; miR15a/miR-16-1; lymphoma	C-MYC; HISTONE DEACETYLASE; MICRORNA EXPRESSION; BURKITT-LYMPHOMA; DOWN-REGULATION; LUNG-CANCER; MIR-15A; OVEREXPRESSION; MALIGNANCIES; ACTIVATION	Our recent study demonstrated miR-15a/16-1 down-regulation in mantle cell lymphoma (MCL). Here, we investigated mechanisms of miR-15a/16-1 transcriptional repression and its epigenetic regulation by c-Myc and histone deacetylase (HDAC) in MCL. c-Myc expression was detected in MCL cell lines and in the primary MCL samples, and pri-miR-15a/16-1 mRNAs were significantly upregulated in Mino and Jeko-1 cells with c-Myc knockdown by small interfering RNAs (siRNAs). Our co-immunoprecipitation analysis showed that c-Myc interacted with HDAC3. Moreover, using chromatin immunoprecipitation, we demonstrated that both c-Myc and HDAC3 co-localized to the two promoters of the miR-15a/16-1 cluster gene, DLEU2, and inhibition of HDAC3 increased histone acetylation of the DLEU2 promoters. Luciferase reporter assay confirmed the dependence of Myc-mediated DLEU2 transcriptional repression on HDAC3. Treatment with the pan-HDAC inhibitor, suberoylanilide hydroxamic acid and HDAC3 siRNA resulted in increased miR-15a/16-1 expression. The regulatory mechanism of miR-15a/16-1 was further demonstrated in Burkitt lymphoma and Myc over-expressing cell lines. These findings highlight the role of HDAC3 in Myc-induced miR-15a/16-1 changes and reveal novel mechanisms for c-Myc-driven microRNA suppression and malignant transformation in aggressive B-cell malignancies.	[Zhang, X.; Chen, X.; Lin, J.; Lwin, T.; Wright, G.; Moscinski, L. C.; Dalton, W. S.; Seto, E.; Wright, K.; Sotomayor, E.; Tao, J.] Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol & Expt Therapeut Program, Tampa, FL 33613 USA; [Zhang, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Tianjin Medical University	Tao, J (corresponding author), Univ S Florida, Dept Malignant Hematol, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol & Expt Therapeut Program, MCC LAB 2071,12902 Magnolia Dr, Tampa, FL 33613 USA.	Jianguo.Tao@moffitt.org	Wright, George W/M-1660-2017		National Cancer Institutes [R01 CA137123]; Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA137123, R01CA134807] Funding Source: NIH RePORTER	National Cancer Institutes(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Maher Fund; Moffitt Cancer Center Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to the Tissue Procurement, Molecular Core Laboratory and Flow Cytometry Core Facilities at H Lee Moffitt Cancer Center for providing specimens and molecular analysis. We thank Rasa Hamilton for editorial assistance. This work was supported by grants from the National Cancer Institutes (R01 CA137123, to JT), Maher Fund (to JT) and Moffitt Cancer Center Foundation (to JT).	Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69; Bandi N, 2009, CANCER RES, V69, P5553, DOI 10.1158/0008-5472.CAN-08-4277; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davidson-Moncada J, 2010, ANN NY ACAD SCI, V1183, P183, DOI 10.1111/j.1749-6632.2009.05121.x; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Han L, 2007, CANCER BIOL THER, V6, P1284; Hartmann E, 2008, J CLIN ONCOL, V26, P4966, DOI 10.1200/JCO.2007.12.0410; Hernandez L, 1999, LEUKEMIA, V13, P2087, DOI 10.1038/sj.leu.2401599; Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552; Lee EM, 2009, INT J MOL MED, V24, P45, DOI 10.3892/ijmm_00000204; Lerner M, 2009, EXP CELL RES, V315, P2941, DOI 10.1016/j.yexcr.2009.07.001; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Robertus JL, 2010, BRIT J HAEMATOL, V149, P896, DOI 10.1111/j.1365-2141.2010.08111.x; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Sotillo E, 2011, ONCOGENE, V30, P2587, DOI 10.1038/onc.2010.634; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147	29	128	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					3002	3008		10.1038/onc.2011.470	http://dx.doi.org/10.1038/onc.2011.470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	22002311	Green Accepted			2022-12-17	WOS:000305388400009
J	Gao, XN; Lin, J; Li, YH; Gao, L; Wang, XR; Wang, W; Kang, HY; Yan, GT; Wang, LL; Yu, L				Gao, X-N; Lin, J.; Li, Y-H; Gao, L.; Wang, X-R; Wang, W.; Kang, H-Y; Yan, G-T; Wang, L-L; Yu, L.			MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia	ONCOGENE			English	Article						c-kit; microRNAs; DNA methylation; acute myeloid leukemia; proto-oncogenes; tumor suppressor genes	ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN CANCER; PROGNOSTIC IMPACT; DNA METHYLATION; GENE-EXPRESSION; CELL-LINES; MUTATIONS; AML; HYPERMETHYLATION; T(8/21)	Aberrant activation of c-kit proto-oncogene contributes to abnormal cell proliferation by altering the tyrosine kinase signaling and constitutes a crucial impetus for leukemo-genesis. Epigenetic silencing of tumor-suppressive microRNAs (miRNAs) is a key oncogenic mechanism for the activation of oncogenes in tumors. In this study, several miRNAs potentially binding to the 3'-untranslated region of human c-kit mRNA were screened by luciferase reporter assays. Among these miRNAs, miR-193a was embedded in a CpG island and epigenetically repressed by promoter hypermethylation in acute myeloid leukemia (AML) cell lines and primary AML blasts, but not in normal bone marrow cells. Importantly, miR-193a levels were inversely correlated with c-kit levels measured in 9 leukemia cell lines and 27 primary AML samples. Restoring miR-193a expression in AML cells harboring c-kit mutation and/or overexpression, either by synthetic miR-193a transfection or by DNA hypomethylating agent 5-azacytidine (5-aza) treatment, resulted in a significant reduction in c-kit expression at both RNA and protein levels and inhibition of cell growth. The growth-inhibitory activity of miR-193a was associated with apoptosis and granulocytic differentiation. Moreover, 5-aza-induced c-kit reduction could be partially blocked by miR-193a inhibitor, leading to a reversal of antiproliferative and proapoptotic effects of 5-aza. These data reveal a critical role for methylation-repressed miR-193a in myeloid leukemogenesis and the therapeutic promise of upregulating miR-193a expression for c-kit-positive AML. Oncogene (2011) 30, 3416-3428; doi:10.1038/onc.2011.62; published online 14 March 2011	[Gao, X-N; Li, Y-H; Gao, L.; Wang, X-R; Wang, W.; Kang, H-Y; Wang, L-L; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Lin, J.; Yan, G-T] Chinese Peoples Liberat Army Gen Hosp, Basic Med Inst, Beijing 100853, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	chunhuiliyu@yahoo.com	yang, xiao-jun/B-1927-2009	Yu, Li/0000-0001-6872-2665	National Natural Science Foundation of China [81000221, 90919044, 30971297]; National 973 Project of China [2005CB522400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 973 Project of China(National Basic Research Program of China)	We thank Y Ding, Y-Y Xu, N Wang, C-W Xu, M Li, M-X Chen and W-D Han for excellent technical assistance. We also thank Professor X-F Zheng and H-J Fu from Beijing Institute of Radiation Medicine, China, for presenting the modified pGL3-control plasmid and miRNA expression plasmids. This work was supported by the National Natural Science Foundation of China (nos 81000221, 90919044 and 30971297) and the National 973 Project of China (no. 2005CB522400).	Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025; Agrawal S, 2007, CANCER RES, V67, P1370, DOI 10.1158/0008-5472.CAN-06-1681; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beghini A, 2004, HAEMATOLOGICA, V89, P920; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boissel N, 2006, LEUKEMIA, V20, P965, DOI 10.1038/sj.leu.2404188; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fabbri M, 2008, LEUKEMIA, V22, P1095, DOI 10.1038/leu.2008.30; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397; Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938; Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Heidel F, 2007, CANCER, V109, P907, DOI 10.1002/cncr.22471; Jacquel A, 2007, ONCOGENE, V26, P2445, DOI 10.1038/sj.onc.1210034; Jiao B, 2009, LEUKEMIA, V23, P1598, DOI 10.1038/leu.2009.104; Jun C, 2007, PROG BIOCHEM BIOPHYS, V34, P389; Kindler T, 2004, BLOOD, V103, P3644, DOI 10.1182/blood-2003-06-2071; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Larizza L, 2005, LEUKEMIA LYMPHOMA, V46, P247, DOI 10.1080/10428190400007565; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Lennartsson J, 2005, STEM CELLS, V23, P16, DOI 10.1634/stemcells.2004-0117; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Marcucci G, 2008, NEW ENGL J MED, V358, P1919, DOI 10.1056/NEJMoa074256; Osada H, 2007, CARCINOGENESIS, V28, P2, DOI 10.1093/carcin/bgl185; Paschka P, 2006, J CLIN ONCOL, V24, P3904, DOI 10.1200/JCO.2006.06.9500; Reilly JT, 2003, BLOOD REV, V17, P241, DOI 10.1016/S0268-960X(03)00024-9; Renneville A, 2008, LEUKEMIA, V22, P915, DOI 10.1038/leu.2008.19; Roman-Gomez J, 2009, J CLIN ONCOL, V27, P1316, DOI 10.1200/JCO.2008.19.3441; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Schnittger S, 2006, BLOOD, V107, P1791, DOI 10.1182/blood-2005-04-1466; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Wang YY, 2005, P NATL ACAD SCI USA, V102, P1104, DOI 10.1073/pnas.0408831102; Youssef EM, 2004, CANCER RES, V64, P2411, DOI 10.1158/0008-5472.CAN-03-0164	45	128	139	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	31					3416	3428		10.1038/onc.2011.62	http://dx.doi.org/10.1038/onc.2011.62			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	802KA	21399664				2022-12-17	WOS:000293508100003
J	Switzer, CH; Cheng, RYS; Vitek, TM; Christensen, DJ; Wink, DA; Vitek, MP				Switzer, C. H.; Cheng, R. Y. S.; Vitek, T. M.; Christensen, D. J.; Wink, D. A.; Vitek, M. P.			Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy	ONCOGENE			English	Article						SET/I(2)PP2A; PP2A; Akt; nm23-H1; Rac1	PROTEIN PHOSPHATASE 2A; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE UNDIFFERENTIATED LEUKEMIA; TUMOR-SUPPRESSOR; APOLIPOPROTEIN-E; GENE-EXPRESSION; CARCINOMA CELLS; BLAST CRISIS; HUMAN BREAST; C-MYC	The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112-mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C-3 botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy. Oncogene (2011) 30, 2504-2513; doi: 10.1038/onc.2010.622; published online 7 February 2011	[Switzer, C. H.; Cheng, R. Y. S.; Vitek, T. M.; Wink, D. A.] NCI, Radiat Biol Branch, NIH, Bethesda, MD 20892 USA; [Christensen, D. J.; Vitek, M. P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA; [Vitek, M. P.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University	Wink, DA (corresponding author), NCI, Radiat Biol Branch, NIH, Bldg 10,Room B3-B35, Bethesda, MD 20892 USA.	wink@mail.nih.gov; mikevitek@cognosci.com	Switzer, Christopher/D-9203-2013; Cheng, Robert/E-9799-2013	Cheng, Robert/0000-0003-0287-6439; Azad, Mahan/0000-0002-8633-3513; Vitek, Michael/0000-0001-8140-8048; Wink, David/0000-0002-5652-7480	Intramural NIH HHS [ZIA SC007281-17, ZIA BC010899-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIASC007281, ZIABC010899] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Canela N, 2003, J BIOL CHEM, V278, P1158, DOI 10.1074/jbc.M207497200; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; CHRISTENSEN D, 2011, J IMMUNOL IN PRESS, V186; Compagnone NA, 2000, MOL ENDOCRINOL, V14, P875, DOI 10.1210/me.14.6.875; Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005; Fan ZS, 2003, CELL, V112, P659, DOI 10.1016/S0092-8674(03)00150-8; Feschenko MS, 2002, J PHARMACOL EXP THER, V302, P111, DOI 10.1124/jpet.302.1.111; Freije JMP, 1998, BIOCHEM SOC SYMP, P261; Fukukawa C, 2000, CANCER LETT, V161, P89, DOI 10.1016/S0304-3835(00)00598-X; Gotz J, 2000, MECH DEVELOP, V93, P83, DOI 10.1016/S0925-4773(00)00267-7; Guichard C, 2006, CARCINOGENESIS, V27, P1812, DOI 10.1093/carcin/bgl009; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; Kim HS, 2003, J BIOL CHEM, V278, P37497, DOI 10.1074/jbc.M211739200; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; LoPiccolo J, 2007, ANTI-CANCER DRUG, V18, P861; Ma DQ, 2002, J BIOL CHEM, V277, P1560, DOI 10.1074/jbc.M108359200; Madeira A, 2005, FASEB J, V19, P1905, DOI 10.1096/fj.05-3839fje; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Ouatas T, 2003, CLIN CANCER RES, V9, P3763; Ozbek U, 2007, AM J PATHOL, V171, P654, DOI 10.2353/ajpath.2007.060934; Palmieri D, 2005, JNCI-J NATL CANCER I, V97, P632, DOI 10.1093/jnci/dji111; Perrotti D, 2006, BRIT J CANCER, V95, P775, DOI 10.1038/sj.bjc.6603317; Perrotti D, 2008, CANCER METAST REV, V27, P159, DOI 10.1007/s10555-008-9119-x; Qiao M, 2008, CELL CYCLE, V7, P2991, DOI 10.4161/cc.7.19.6784; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Samanta AK, 2009, ONCOGENE, V28, P1669, DOI 10.1038/onc.2009.7; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; STEEG PS, 1988, CANCER RES, V48, P6550; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; Sundaresan P, 2002, FEBS LETT, V528, P139, DOI 10.1016/S0014-5793(02)03277-5; Switzer CH, 2009, ONCOGENE, V28, P3837, DOI 10.1038/onc.2009.244; ten Klooster JP, 2007, EMBO J, V26, P336, DOI 10.1038/sj.emboj.7601518; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; Westermarck J, 2008, TRENDS MOL MED, V14, P152, DOI 10.1016/j.molmed.2008.02.001; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Zhang QB, 2011, INT J CANCER, V128, P40, DOI 10.1002/ijc.25307; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhu F, 2008, Curr Mol Pharmacol, V1, P213	49	128	131	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2011	30	22					2504	2513		10.1038/onc.2010.622	http://dx.doi.org/10.1038/onc.2010.622			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	771ZE	21297667	Green Accepted			2022-12-17	WOS:000291198400002
J	Eliasz, S; Liang, S; Chen, Y; De Marco, MA; Machek, O; Skucha, S; Miele, L; Bocchetta, M				Eliasz, S.; Liang, S.; Chen, Y.; De Marco, M. A.; Machek, O.; Skucha, S.; Miele, L.; Bocchetta, M.			Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway	ONCOGENE			English	Article						notch signaling; lung cancer; hypoxia; IGF-1R; cancer cell survival	CANCER STEM-CELLS; FACTOR-I GENE; PROTEIN-KINASE; GROWTH; INSULIN; EXPRESSION; TRANSCRIPTION; RESISTANCE; MAINTENANCE; INHIBITION	Hypoxic microenvironment supports cancer stem cell survival, causes poor response to anticancer therapy and tumor recurrence. Inhibition of Notch-1 signaling in adenocarcinoma of the lung (ACL) cells causes apoptosis ifically under hypoxia. Here, we found that Akt-1 activation is a key mediator of Notch-1 pro-survival effects under hypoxia. Notch-1 activates Akt-1 through repression of phosphatase and tensin (PTEN) homolog expression and induction of the insulin-like growth factor 1 receptor (IGF-1R). The latter seems to be the major determinant of Akt-1 stimulation, as Notch-1 signaling affects Akt-1 activation in PTEN-/- ACL cells. Both downregulation of insulin receptor substrate 1 (IRS-1) and dominant-negative IGF-1R sensitized ACL cells to c-secretase inhibitor (GSI)-induced apoptosis. Conversely, overexpression of IGF-1R protected ACL cells from GSI toxicity. Inhibition of Notch-1 caused reduced IGF-1R expression, whereas forced Notch-1 expression yielded opposite effects. Chromatin immunoprecipitation experiments suggested Notch-1 direct regulation of the IGF-1R promoter. Experiments in which human ACL cells were injected in mice confirmed elevated and specific co-expression of Notch-1IC, IGF-1R and pAkt-1 in hypoxic tumor areas. Our data provide a mechanistic explanation for Notch-1-mediated pro-survival function in hypoxic ACL tumor microenvironment. The results identify additional targets that may synergize with Notch-1 inhibition for ACL treatment. Oncogene (2010) 29, 2488-2498; doi:10.1038/onc.2010.7; published online 15 February 2010	[Eliasz, S.; Liang, S.; De Marco, M. A.; Machek, O.; Skucha, S.; Bocchetta, M.] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Inst Oncol, 2160 S 1st Ave,Bldg 112,Room 204, Maywood, IL 60153 USA; [Chen, Y.] NYU, Dept Surg, Langone Med Ctr, New York, NY 10016 USA; [Miele, L.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA	Loyola University Chicago; New York University; NYU Langone Medical Center; University of Mississippi; University of Mississippi Medical Center	Bocchetta, M (corresponding author), Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Inst Oncol, 2160 S 1st Ave,Bldg 112,Room 204, Maywood, IL 60153 USA.	mbocche@lumc.edu	Machek, Ondrej/L-4203-2018	Machek, Ondrej/0000-0003-3955-7853; Miele, Lucio/0000-0002-5853-7287	American Cancer Society [RSG-05-077-MBC]; National Cancer Institute [RO1 CA134503]; Riviera Country Club and Sport Center; NATIONAL CANCER INSTITUTE [R01CA134503] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Riviera Country Club and Sport Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Patricia Simms for help with FACS analyses. Merck & CO., Inc. (Whitehouse Station, NJ, USA) kindly provided the MRK-003 compound. We thank Dr Michele Carbone for critical review of this paper. This work was supported by grants from the American Cancer Society RSG-05-077-MBC, Award Number RO1 CA134503 from the National Cancer Institute and by a grant from the Riviera Country Club and Sport Center. Financial support was from American Cancer Society grant RSG-05-077-MBC, Award Number RO1 CA134503 from the National Cancer Institute and by a grant by the Riviera Country Club and Sport Center (M Bocchetta). Merck Inc. provided the drug MRK-003.	Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Belfiore A, 2007, CURR PHARM DESIGN, V13, P671, DOI 10.2174/138161207780249173; Bendall SC, 2007, NATURE, V448, P1015, DOI 10.1038/nature06027; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; Carelli S, 2006, J CELL PHYSIOL, V208, P354, DOI 10.1002/jcp.20670; Chen Delphine L, 2005, Proc Am Thorac Soc, V2, P541, DOI 10.1513/pats.200507-075DS; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen YB, 2007, CANCER RES, V67, P7954, DOI 10.1158/0008-5472.CAN-07-1229; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Frasca Francesco, 2008, Archives of Physiology and Biochemistry, V114, P23, DOI [10.1080/13813450801969715, 10.1080/13813450801969715 ]; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Haruki N, 2005, CANCER RES, V65, P3555, DOI 10.1158/0008-5472.CAN-04-3132; HEUSON JC, 1972, CANCER RES, V32, P226; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Klinakis A, 2006, P NATL ACAD SCI USA, V103, P9262, DOI 10.1073/pnas.0603371103; Konishi J, 2007, CANCER RES, V67, P8051, DOI 10.1158/0008-5472.CAN-07-1022; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; McLellan AS, 2006, AM J PHYSIOL-CELL PH, V291, pC300, DOI 10.1152/ajpcell.00345.2005; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Milas L, 2009, SEMIN RADIAT ONCOL, V19, P96, DOI 10.1016/j.semradonc.2008.11.004; Moromisato DY, 1996, CRIT CARE MED, V24, P919, DOI 10.1097/00003246-199606000-00008; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Ouellet J, 2008, DEVELOPMENT, V135, P2583, DOI 10.1242/dev.012435; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Palomero T, 2006, P NATL ACAD SCI USA, V103, P18261, DOI 10.1073/pnas.0606108103; Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536; Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Schuurbiers OCJ, 2009, J THORAC ONCOL, V4, P761, DOI 10.1097/JTO.0b013e3181a1084f; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SHEMER J, 1992, ENDOCRINOLOGY, V131, P2793, DOI 10.1210/en.131.6.2793; SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707; Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239; Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Venkateswaran V, 2007, J NATL CANCER I, V99, P1793, DOI 10.1093/jnci/djm231; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; YOYOSHIMA Y, 2008, ENDOCRINOLOGY, V149, P5996	51	128	133	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2010	29	17					2488	2498		10.1038/onc.2010.7	http://dx.doi.org/10.1038/onc.2010.7			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154720	Green Accepted			2022-12-17	WOS:000277169400004
J	Ciechomska, IA; Goemans, GC; Skepper, JN; Tolkovsky, AM				Ciechomska, I. A.; Goemans, G. C.; Skepper, J. N.; Tolkovsky, A. M.			Bcl-2 complexed with Beclin-1 maintains full anti-apoptotic function	ONCOGENE			English	Article						apoptosis; autophagy; Bcl-2; Beclin-1; endoplasmic reticulum; mitochondria	CELL-DEATH; REGULATES AUTOPHAGY; MOLECULAR-BASIS; INHIBITION; PROTEINS; CANCER; MITOCHONDRIA; DOMAIN; TUMORIGENESIS; DEGRADATION	The binding of Bcl-2 to Beclin-1 reduces Beclin-1's capacity to induce autophagy. Here, we have tested whether the interaction is reciprocated by loss of Bcl-2's anti-apoptotic function. We targeted Bcl-2 to mitochondria or endoplasmic reticulum (ER) and induced apoptosis using several apoptotic stimuli that initiate ER and/or mitochondrial signaling pathways (UV radiation, TNF and cycloheximide, staurosporine, thapsigargin and tunicamycin). When Beclin-1 and Bcl-2 were expressed together in HeLa cells, Beclin-1 ( but not Beclin-1 lacking the Bcl-2-binding domain) followed Bcl-2 to the appropriate organelle with complete or near-complete overlap ( comprising 60 and 30% of cells, respectively). The interaction between Beclin-1 and Bcl-2 was verified by immunoprecipitation, and a membrane-proximate localization of Beclin-1 was shown by immunoelectron microscopy. Apoptosis was followed by measuring changes in nuclear morphology, caspase-3 activity, poly-ADP-ribose polymerase cleavage or punctation of mRFP-Bax on mitochondria. Binding of Beclin-1 to Bcl-2 did not modify apoptosis irrespective of Bcl-2 concentration, location or apoptotic stimulus. A similar result was obtained in Atg5-/- cells that are autophagy-deficient, arguing against compensation for the loss of protection by Bcl-2 by autophagy-mediated survival induced by Beclin-1. Hence, although Beclin-1 contains a BH3-only motif typical of pro-apoptotic proteins, it is a negligible modulator of Bcl-2's anti-apoptotic function. Oncogene (2009) 28, 2128-2141; doi: 10.1038/onc.2009.60; published online 6 April 2009	[Ciechomska, I. A.; Goemans, G. C.; Tolkovsky, A. M.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Ciechomska, I. A.] M Nencki Inst Expt Biol, Dept Cell Biol, PL-02093 Warsaw, Poland; [Skepper, J. N.] Univ Cambridge, Dept Physiol Dev & Neurosci, Cambridge CB2 1QW, England	University of Cambridge; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences; University of Cambridge	Tolkovsky, AM (corresponding author), Univ Cambridge, Dept Biochem, Bldg 0,Downing Site, Cambridge CB2 1QW, England.	amt@mole.bio.cam.ac.uk	Ciechomksa, Iwona/R-4706-2016	Ciechomksa, Iwona/0000-0002-8068-0020	Wellcome Trust [064232]	Wellcome Trust(Wellcome TrustEuropean Commission)	We thank our colleagues Beth Levine, Zenyu Yue, Noboru Mizushima, Said Aoufouchi, Christoph Borner, Goeff Butcher and Eiki Kominami for their generous gifts of reagents. This work was funded by program Grant no. 064232 from the Wellcome Trust.	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Akar U, 2008, AUTOPHAGY, V4, P669, DOI 10.4161/auto.6083; Annis MG, 2004, BBA-MOL CELL RES, V1644, P115, DOI 10.1016/j.bbamcr.2003.07.001; Arsov I, 2008, CELL DEATH DIFFER, V15, P1385, DOI 10.1038/cdd.2008.59; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chu CT, 2007, AUTOPHAGY, V3, P663, DOI 10.4161/auto.4625; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Erlich S, 2007, AUTOPHAGY, V3, P561, DOI 10.4161/auto.4713; Feng W, 2007, J MOL BIOL, V372, P223, DOI 10.1016/j.jmb.2007.06.069; Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Goemans CG, 2008, CELL DEATH DIFFER, V15, P545, DOI 10.1038/sj.cdd.4402290; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; Jin SK, 2008, AUTOPHAGY, V4, P563, DOI 10.4161/auto.5830; Jin SK, 2007, AUTOPHAGY, V3, P28, DOI 10.4161/auto.3269; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Ku B, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040025; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Michaelidis TM, 1996, NEURON, V17, P75, DOI 10.1016/S0896-6273(00)80282-2; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Scarlatti F, 2008, CELL DEATH DIFFER, V15, P1318, DOI 10.1038/cdd.2008.51; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sinha S, 2008, AUTOPHAGY, V4, P989, DOI 10.4161/auto.6803; Skepper JN, 2000, J MICROSC-OXFORD, V199, P1, DOI 10.1046/j.1365-2818.2000.00704.x; Swerdlow S, 2008, AUTOPHAGY, V4, P612, DOI 10.4161/auto.5920; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Ullman E, 2008, CELL DEATH DIFFER, V15, P422, DOI 10.1038/sj.cdd.4402234; Yoshimori T, 2004, BIOCHEM BIOPH RES CO, V313, P453, DOI 10.1016/j.bbrc.2003.07.023; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100	53	128	134	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 28	2009	28	21					2128	2141		10.1038/onc.2009.60	http://dx.doi.org/10.1038/onc.2009.60			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	451DQ	19347031				2022-12-17	WOS:000266451300002
J	Schaeffer, EM; Marchionni, L; Huang, Z; Simons, B; Blackman, A; Yu, W; Parmigiani, G; Berman, DM				Schaeffer, E. M.; Marchionni, L.; Huang, Z.; Simons, B.; Blackman, A.; Yu, W.; Parmigiani, G.; Berman, D. M.			Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer	ONCOGENE			English	Article						prostate organogenesis; androgen signaling; prostate cancer; microarray	INTRAEPITHELIAL NEOPLASIA; GENE-EXPRESSION; MURINE PROSTATE; MOUSE PROSTATE; BETA-CATENIN; STEM-CELLS; RECEPTOR; ADENOCARCINOMA; TUMORIGENESIS; GENOME	Cancer cells differentiate along specific lineages that largely determine their clinical and biologic behavior. Distinct cancer phenotypes from different cells and organs likely result from unique gene expression repertoires established in the embryo and maintained after malignant transformation. We used comprehensive gene expression analysis to examine this concept in the prostate, an organ with a tractable developmental program and a high propensity for cancer. We focused on gene expression in the murine prostate rudiment at three time points during the first 48 h of exposure to androgen, which initiates proliferation and invasion of prostate epithelial buds into surrounding urogenital sinus mesenchyme. Here, we show that androgen exposure regulates genes previously implicated in prostate carcinogenesis comprising pathways for the phosphatase and tensin homolog (PTEN), fibroblast growth factor (FGF)/mitogen-activated protein kinase (MAPK), and Wnt signaling along with cellular programs regulating such 'hallmarks' of cancer as angiogenesis, apoptosis, migration and proliferation. We found statistically significant evidence for novel androgen-induced gene regulation events that establish and/or maintain prostate cell fate. These include modulation of gene expression through microRNAs, expression of specific transcription factors, and regulation of their predicted targets. By querying public gene expression databases from other tissues, we found that rather than generally characterizing androgen exposure or epithelial budding, the early prostate development program more closely resembles the program for human prostate cancer. Most importantly, early androgen-regulated genes and functional themes associated with prostate development were highly enriched in contrasts between increasingly lethal forms of prostate cancer, confirming a 'reactivation' of embryonic pathways for proliferation and invasion in prostate cancer progression. Among the genes with the most significant links to the development and cancer, we highlight coordinate induction of the transcription factor Sox9 and suppression of the proapoptotic phospholipid-binding protein Annexin A1 that link early prostate development to early prostate carcinogenesis. These results credential early prostate development as a reliable and valid model system for the investigation of genes and pathways that drive prostate cancer.	[Schaeffer, E. M.; Huang, Z.; Simons, B.; Parmigiani, G.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21231 USA; [Schaeffer, E. M.; Huang, Z.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21231 USA; [Schaeffer, E. M.; Marchionni, L.; Blackman, A.; Yu, W.; Parmigiani, G.; Berman, D. M.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Parmigiani, G.] Johns Hopkins Univ, Sch Med, Dept Biostat, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Berman, DM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, CRB2 Room 545,1550 Orleans St, Baltimore, MD 21231 USA.	berman@jhmi.edu	Marchionni, Luigi/S-6774-2017; Simons, Brian W./G-7352-2015; Thomson, Axel/A-7893-2013	Marchionni, Luigi/0000-0002-7336-8071; Simons, Brian W./0000-0003-0644-211X; berman, david/0000-0001-5985-3698	Evensen Family; Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations;  [NIH5K08DK059375];  [NIHK08 DK081019];  [NIH5P30CA06973-39];  [NSF034211]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059375, K08DK081019] Funding Source: NIH RePORTER	Evensen Family; Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank W Matsui and N Watkins for comments on the manuscript, A DeMarzo and J Epstein for TMAs and YQ Chen for prostate regeneration data. These studies were funded by the Evensen Family, Passano and Patrick C Walsh Prostate Cancer Foundations, and NIH5K08DK059375 (DB) NIHK08 DK081019 (EMS), NIH5P30CA06973-39 (GP) and NSF034211 (GPand LM).	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Ashburner M, 2003, COLD SPRING HARB SYM, V68, P227, DOI 10.1101/sqb.2003.68.227; Bailey P, 1925, ARCH NEURO PSYCHIATR, V14, P192, DOI 10.1001/archneurpsyc.1925.02200140055002; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Berman DM, 2004, DEV BIOL, V267, P387, DOI 10.1016/j.ydbio.2003.11.018; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; Bivalacqua TJ, 2007, AM J PHYSIOL-HEART C, V292, pH1278, DOI 10.1152/ajpheart.00685.2006; Bostwick DG, 2004, MODERN PATHOL, V17, P360, DOI 10.1038/modpathol.3800053; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Cunha GR, 2004, ARCH HISTOL CYTOL, V67, P417, DOI 10.1679/aohc.67.417; Donjacour AA, 2003, DEV BIOL, V261, P39, DOI 10.1016/S0012-1606(03)00250-1; Drews U, 2001, HISTOCHEM CELL BIOL, V116, P427, DOI 10.1007/s00418-001-0335-5; ENGLISH HF, 1987, PROSTATE, V11, P229, DOI 10.1002/pros.2990110304; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Ii M, 2006, EXP BIOL MED, V231, P20; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824; JOST A, 1968, PERSPECT BIOL MED, V11, P371; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kang JS, 2002, CLIN CANCER RES, V8, P117; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092-8674(01)00268-9; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lu J, 2004, DEV BIOL, V273, P418, DOI 10.1016/j.ydbio.2004.05.035; Manolagas SC, 2002, RECENT PROG HORM RES, V57, P385, DOI 10.1210/rp.57.1.385; McMenamin ME, 1999, CANCER RES, V59, P4291; Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002; Mohammadi M, 2005, CYTOKINE GROWTH F R, V16, P107, DOI 10.1016/j.cytogfr.2005.01.008; Nam JS, 2007, DEV BIOL, V311, P124, DOI 10.1016/j.ydbio.2007.08.023; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Olsen SK, 2003, J BIOL CHEM, V278, P34226, DOI 10.1074/jbc.M303183200; Ornstein DK, 2006, UROL ONCOL-SEMIN ORI, V24, P231, DOI 10.1016/j.urolonc.2005.11.035; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shen MM, 2007, CANCER RES, V67, P6535, DOI 10.1158/0008-5472.CAN-07-1271; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Treister NS, 2005, J DENT RES, V84, P160, DOI 10.1177/154405910508400210; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; WILSON JD, 1980, BIOL REPROD, V22, P9, DOI 10.1095/biolreprod22.1.9; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Xu JF, 2005, CANCER EPIDEM BIOMAR, V14, P2563, DOI 10.1158/1055-9965.EPI-05-0356; Yeager N, 2008, CANCER RES, V68, P444, DOI 10.1158/0008-5472.CAN-07-3030; Zeng L, 2005, PROSTATE CANCER P D, V8, P7, DOI 10.1038/sj.pcan.4500757; Zhang TJ, 2006, GENE EXPR PATTERNS, V6, P310, DOI 10.1016/j.modgep.2005.07.005; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1	63	128	137	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7180	7191		10.1038/onc.2008.327	http://dx.doi.org/10.1038/onc.2008.327			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794802	Green Accepted			2022-12-17	WOS:000261384100005
J	Chang, YM; Bai, L; Liu, S; Yang, JC; Kung, HJ; Evans, CP				Chang, Y-M; Bai, L.; Liu, S.; Yang, J. C.; Kung, H-J; Evans, C. P.			Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530	ONCOGENE			English	Article						Src; FAK; prostate cancer; AZD0530; proliferation; migration	FOCAL ADHESION KINASE; NONRECEPTOR TYROSINE KINASES; ANDROGEN-INDEPENDENT GROWTH; BETA-CATENIN; C-MYC; BREAST-CANCER; CYCLIN D1; NEUROENDOCRINE DIFFERENTIATION; SIGNAL-TRANSDUCTION; CARCINOMA-CELLS	Prostate cancer is the most frequently diagnosed cancer in American men. We have previously demonstrated that Src mediates androgen-independent proliferation in prostate cancer. We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials. We show that while both Src and Abl are expressed in all prostate cancer cell lines, Src but not Abl is activated in the prostate. Furthermore, Src activation is inhibited by AZD0530 in a rapid and dose-dependent manner. We show that Src mediates cell proliferation in DU145 and PC3 cells at the G1 phase of cell cycle. Src inhibition resulted in decreased binding of beta-catenin to the promoters of G1 phase cell cycle regulators cyclin D1 and c-Myc. C-Myc may also be regulated at the protein level by extracellular signal-regulated kinase 1/2 and GSK3 beta. Cell motility factors focal adhesion kinase, p130CAS and paxillin activation in DU145 and PC3 cells were also inhibited. Administration of AZD0530 in mice reduced orthotopic DU145 xenograft growth by 45%. We have further delineated the Src-mediated oncogenic growth and migration pathways in prostate cancer and established mechanistic rationale for Src inhibition as novel therapy in the treatment of prostate cancer.	[Evans, C. P.] Univ Calif Davis, Med Ctr, Dept Urol, Sacramento, CA 95817 USA; [Liu, S.; Kung, H-J] Univ Calif Davis, Dept Biol Chem & Mol Med, Sacramento, CA 95817 USA; [Kung, H-J; Evans, C. P.] Univ Calif Davis, Ctr Canc, Sacramento, CA 95817 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	Evans, CP (corresponding author), Univ Calif Davis, Med Ctr, Dept Urol, 4860 Y St Suite 3500, Sacramento, CA 95817 USA.	kung@ucdavis.edu; cpevans@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		National Institutes of Health [KO8 DK60748-01, RO1 DK52659]; Department of Defense [PC040161]; NATIONAL CANCER INSTITUTE [R01CA114575] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078243, K08DK060748, R01DK052659] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This study was supported by National Institutes of Health Grant KO8 DK60748-01 (CPE), RO1 DK52659 (H-JK) and Department of Defense Grant PC040161 (CPE). The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or the Department of Defense.	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Chang YM, 2007, NEOPLASIA, V9, P90, DOI 10.1593/neo.06694; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088; Cronauer MV, 2005, INT J ONCOL, V26, P1033; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Devi GR, 2002, PROSTATE, V53, P200, DOI 10.1002/pros.10151; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; EVANS CP, 1991, INT J CANCER, V49, P109, DOI 10.1002/ijc.2910490120; Farkas A, 2005, J NEUROSCI RES, V80, P855, DOI 10.1002/jnr.20521; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; Gao LF, 2005, CLIN CANCER RES, V11, P6333, DOI 10.1158/1078-0432.CCR-05-0148; Golas JM, 2003, CANCER RES, V63, P375; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Hiscox S, 2006, BREAST CANCER RES TR, V97, P263, DOI 10.1007/s10549-005-9120-9; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031-5039.2005; Kim D, 2007, ONCOGENE, V26, P4571, DOI 10.1038/sj.onc.1210230; Kotha A, 2006, MOL CANCER THER, V5, P621, DOI 10.1158/1535-7163.MCT-05-0268; Lee D, 2006, CLIN LUNG CANCER, V7, P381, DOI 10.3816/CLC.2006.n.020; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Li GP, 2003, CELL BIOCHEM BIOPHYS, V39, P45, DOI 10.1385/CBB:39:1:45; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008-5472.CAN-07-2997; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Prathapam T, 2006, P NATL ACAD SCI USA, V103, P2695, DOI 10.1073/pnas.0511186103; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Rovin JD, 2002, PROSTATE, V53, P124, DOI 10.1002/pros.10114; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Steiner MS, 1998, HUM GENE THER, V9, P747, DOI 10.1089/hum.1998.9.5-747; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; Taj MM, 2001, PROSTATE, V47, P194, DOI 10.1002/pros.1063; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Vinall RL, 2006, ONCOGENE, V25, P2082, DOI 10.1038/sj.onc.1209246; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	64	128	132	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	49					6365	6375		10.1038/onc.2008.250	http://dx.doi.org/10.1038/onc.2008.250			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	363JK	18679417	Green Accepted			2022-12-17	WOS:000260263400006
J	Johnsen, JI; Segerstrom, L; Orrego, A; Elfman, L; Henriksson, M; Kagedal, B; Eksborg, S; Sveinbjornsson, B; Kogner, P				Johnsen, J. I.; Segerstrom, L.; Orrego, A.; Elfman, L.; Henriksson, M.; Kagedal, B.; Eksborg, S.; Sveinbjornsson, B.; Kogner, P.			Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo	ONCOGENE			English	Article						neuroblastoma; mTOR; rapamycin; CCI-779; MYCN; preclinical	C-KIT; CELL-PROLIFERATION; METASTATIC DISEASE; MTOR INHIBITORS; CYCLIN D1; N-MYC; ACTIVATION; RECEPTOR; PATHWAY; CANCER	Mammalian target of rapamycin (mTOR) has been shown to play an important function in cell proliferation, metabolism and tumorigenesis, and proteins that regulate signaling through mTOR are frequently altered in human cancers. In this study we investigated the phosphorylation status of key proteins in the PI3K/AKT/mTOR pathway and the effects of the mTOR inhibitors rapamycin and CCI-779 on neuroblastoma tumorigenesis. Significant expression of activated AKT and mTOR were detected in all primary neuroblastoma tissue samples investigated, but not in non-malignant adrenal medullas. mTOR inhibitors showed antiproliferative effects on neuroblastoma cells in vitro. Neuroblastoma cell lines expressing high levels of MYCN were significantly more sensitive to mTOR inhibitors compared to cell lines expressing low MYCN levels. Established neuroblastoma tumors treated with mTOR inhibitors in vivo showed increased apoptosis, decreased proliferation and inhibition of angiogenesis. Importantly, mTOR inhibitors induced downregulation of vascular endothelial growth factor A (VEGF-A) secretion, cyclin D1 and MYCN protein expression in vitro and in vivo. Our data suggest that mTOR inhibitors have therapeutic efficacy on aggressive MYCN amplified neuroblastomas.	[Johnsen, J. I.; Segerstrom, L.; Elfman, L.; Eksborg, S.; Sveinbjornsson, B.; Kogner, P.] Karolinska Inst, Dept Woman & Child Hlth, Childrens Canc Res Unit, S-17176 Stockholm, Sweden; [Orrego, A.] Karolinska Inst, Dept Pathol & Oncol, S-17176 Stockholm, Sweden; [Henriksson, M.] Karolinska Inst, Dept Microbiol Tumor & Cellbiol, S-17176 Stockholm, Sweden; [Kagedal, B.] Linkoping Univ, Fac Hlth Sci, Div Clin Chem, S-58183 Linkoping, Sweden; [Sveinbjornsson, B.] Univ Tromso, Dept Cell Biol & Histol, Tromso, Norway	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Linkoping University; UiT The Arctic University of Tromso	Segerstrom, L (corresponding author), Karolinska Inst, Dept Woman & Child Hlth, Childrens Canc Res Unit, S-17176 Stockholm, Sweden.	lova.segerstrom@ki.se	Henriksson, Marie Arsenian/F-5010-2015	Kogner, Per/0000-0002-2202-9694; Johnsen, John Inge/0000-0003-1277-812X; Arsenian Henriksson, Marie/0000-0001-6376-7792; Eksborg, Staffan/0000-0001-7326-9471				Aguirre D, 2004, APOPTOSIS, V9, P797, DOI 10.1023/B:APPT.0000045781.46314.e2; Beppu K, 2004, JNCI-J NATL CANCER I, V96, P46, DOI 10.1093/jnci/djh004; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; COHEN PS, 1994, BLOOD, V84, P3465; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Davidoff AM, 2001, J PEDIATR SURG, V36, P30, DOI 10.1053/Jpsu.2001.19998; Dong JJ, 2005, CANCER RES, V65, P1961, DOI 10.1158/0008-5472.CAN-04-2501; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Eggert A, 2002, CANCER RES, V62, P1802; Eggert A, 2000, CLIN CANCER RES, V6, P1900; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Grimmer MR, 2006, CURR OPIN PEDIATR, V18, P634, DOI 10.1097/MOP.0b013e32801080fe; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ho R, 2005, CANCER RES, V65, P9868, DOI 10.1158/0008-5472.CAN-04-2426; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2002, CANCER RES, V62, P6756; Kagedal B, 2004, PIGM CELL RES, V17, P346, DOI 10.1111/j.1600-0749.2004.00153.x; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kim B, 2004, ONCOGENE, V23, P130, DOI 10.1038/sj.onc.1206924; Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399; Klos KS, 2006, CANCER RES, V66, P2028, DOI 10.1158/0008-5472.CAN-04-4559; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Lutz W, 1996, ONCOGENE, V13, P803; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Meitar D, 1996, J CLIN ONCOL, V14, P405, DOI 10.1200/JCO.1996.14.2.405; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ponthan F, 2003, INT J CANCER, V104, P418, DOI 10.1002/ijc.10954; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Schwab M, 2003, LANCET ONCOL, V4, P472, DOI 10.1016/S1470-2045(03)01166-5; Segerstrom L, 2006, PEDIATR RES, V60, P576, DOI 10.1203/01.pdr.0000242494.94000.52; Singleton JR, 1996, CANCER RES, V56, P4522; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Uccini S, 2005, CLIN CANCER RES, V11, P380; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vitali R, 2003, INT J CANCER, V106, P147, DOI 10.1002/ijc.11187; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yaari S, 2005, CLIN CANCER RES, V11, P4321, DOI 10.1158/1078-0432.CCR-04-2071; Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853	43	128	133	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2008	27	20					2910	2922		10.1038/sj.onc.1210938	http://dx.doi.org/10.1038/sj.onc.1210938			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18026138				2022-12-17	WOS:000255502500012
J	Achour, M; Jacq, X; Ronde, P; Alhosin, M; Charlot, C; Chataigneau, T; Jeanblanc, M; Macaluso, M; Giordano, A; Hughes, AD; Schini-Kerth, VB; Bronner, C				Achour, M.; Jacq, X.; Ronde, P.; Alhosin, M.; Charlot, C.; Chataigneau, T.; Jeanblanc, M.; Macaluso, M.; Giordano, A.; Hughes, A. D.; Schini-Kerth, V. B.; Bronner, C.			The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression	ONCOGENE			English	Article						ICBP90; DNMT1; methylation; UHRF1; vascular endothelial growth factor; yeast two-hybrid system	UBIQUITIN LIGASE ACTIVITY; ESTROGEN-RECEPTOR-ALPHA; CCAAT-BINDING-PROTEIN; GROWTH-FACTOR GENE; DNA METHYLTRANSFERASE-1; BREAST-CANCER; CELL-CYCLE; DOWN-REGULATION; DNA-METHYLTRANSFERASE-1 DNMT1; G1/S TRANSITION	Inverted CCAAT box-binding protein of 90 kDa (ICBP90) is over-expressed in several types of cancer, including breast, prostate and lung cancers. In search for proteins that interact with the set and ring-associated (SRA) domain of ICBP90, we used the two-hybrid system and screened a placental cDNA library. Several clones coding for a new domain of DNMT1 were found. The interaction, between the ICBP90 SRA domain and the DNMT1 domain, has been confirmed with purified proteins by glutathione-S-transferase pull-down experiments. We checked whether ICBP90 and DNMT1 are present in the same macromolecular complexes in Jurkat cells and immortalized human vascular smooth muscle cells (HVTs-SM1). Coimmunoprecipitation experiments showed that ICBP90 and DNMT1 are present in the same molecular complex, which was further confirmed by co-localization experiments as assessed by immunocytochemistry. Downregulation of ICBP90 and DNMT1 decreased VEGF gene expression, a major pro-angiogenic factor, whereas those of p16(INK4A) gene and RB1 gene were significantly enhanced. Together, these results indicate that DNMT1 and ICBP90 are involved in VEGF gene expression, possibly via an interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 and an upregulation of p16(INK4A). They further suggest a new role of ICBP90 in the relationship between histone ubiquitination and DNA methylation in the context of tumoral angiogenesis and tumour suppressor genes silencing.	[Achour, M.; Ronde, P.; Alhosin, M.; Charlot, C.; Chataigneau, T.; Jeanblanc, M.; Schini-Kerth, V. B.; Bronner, C.] Univ Louis Pasteur Strasbourg 1, CNRS, UMR 7175, Dept Pharmacol & Pharmacochim,Fac Pharm,Inst Gilb, F-67401 Illkirch Graffenstaden, France; [Jacq, X.] Hybrigen, Paris, France; [Macaluso, M.; Giordano, A.] Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Macaluso, M.; Giordano, A.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Hughes, A. D.] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Natl Heart & Lung Inst, Clin Pharmacol, London SW7 2AZ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; Imperial College London	Bronner, C (corresponding author), Univ Louis Pasteur Strasbourg 1, CNRS, UMR 7175, Dept Pharmacol & Pharmacochim,Fac Pharm,Inst Gilb, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France.	Christian.Bronner@pharma.u-strasbg.fr	Bronner, Christian/R-8488-2016; Alhosin, Mahmoud/AAD-5782-2020; 高, 雨莉/HGU-8187-2022; Hughes, Alun D/C-6636-2009; Hughes, Alun David/N-3781-2013; Alhosin, Mahmoud/H-8101-2017; Giordano, Antonio/F-1927-2010	Bronner, Christian/0000-0002-3101-9279; Alhosin, Mahmoud/0000-0003-2147-1445; Hughes, Alun David/0000-0001-5432-5271; ACHOUR, Mayada/0000-0003-1044-824X; Giordano, Antonio/0000-0002-5959-016X				Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Baumbusch LO, 2001, NUCLEIC ACIDS RES, V29, P4319, DOI 10.1093/nar/29.21.4319; Bonapace IM, 2002, J CELL BIOL, V157, P909, DOI 10.1083/jcb.200201025; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Bronner C, 2007, PHARMACOL THERAPEUT, V115, P419, DOI 10.1016/j.pharmthera.2007.06.003; Caracciolo V, 2006, ONCOGENE, V25, P5294, DOI 10.1038/sj.onc.1209681; Chen Dao-Rong, 2006, Ai Zheng, V25, P308; CHENG CH, 1993, BIOCHEMISTRY-US, V32, P8568, DOI 10.1021/bi00084a025; Chuang JL, 2000, METHOD ENZYMOL, V324, P192; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Crnogorac-Jurcevic T, 2005, GASTROENTEROLOGY, V129, P1454, DOI 10.1053/j.gastro.2005.08.012; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Fournel M, 1999, J BIOL CHEM, V274, P24250, DOI 10.1074/jbc.274.34.24250; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gabellini C, 2006, ONCOGENE, V25, P5326, DOI 10.1038/sj.onc.1209631; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Hopfner R, 2002, ANTICANCER RES, V22, P3165; Hopfner R, 2000, CANCER RES, V60, P121; Hsieh JK, 2000, ARTERIOSCL THROM VAS, V20, P973, DOI 10.1161/01.ATV.20.4.973; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lorenzato M, 2005, HUM PATHOL, V36, P1101, DOI 10.1016/j.humpath.2005.07.016; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Macaluso M, 2007, CANCER RES, V67, P7731, DOI 10.1158/0008-5472.CAN-07-1476; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; Miki K, 2000, ONCOL RES, V12, P335, DOI 10.3727/096504001108747783; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Mortusewicz O, 2005, P NATL ACAD SCI USA, V102, P8905, DOI 10.1073/pnas.0501034102; Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; Naumann K, 2005, EMBO J, V24, P1418, DOI 10.1038/sj.emboj.7600604; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Oak MH, 2005, J NUTR BIOCHEM, V16, P1, DOI 10.1016/j.jnutbio.2004.09.004; Oba-Shinjo SM, 2005, MOL BRAIN RES, V140, P25, DOI 10.1016/j.molbrainres.2005.06.015; Ohta T, 2004, ONCOGENE, V23, P2079, DOI 10.1038/sj.onc.1207371; Papait R, 2007, MOL BIOL CELL, V18, P1098, DOI 10.1091/mbc.E06-09-0874; Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Salimath B, 2000, ONCOGENE, V19, P3470, DOI 10.1038/sj.onc.1203672; Schaaf GJ, 2005, FASEB J, V19, P404, DOI 10.1096/fj.04-2104fje; Suzuki M, 2004, CANCER RES, V64, P3137, DOI 10.1158/0008-5472.CAN-03-3046; Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631; Uemura T, 2000, CELL STRUCT FUNCT, V25, P149, DOI 10.1247/csf.25.149; Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053; Vallbohmer D, 2006, CLIN LUNG CANCER, V8, P39, DOI 10.3816/CLC.2006.n.031; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wang G, 2000, EXP CELL RES, V254, P64, DOI 10.1006/excr.1999.4743	53	128	134	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 3	2008	27	15					2187	2197		10.1038/sj.onc.1210855	http://dx.doi.org/10.1038/sj.onc.1210855			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	283FE	17934516				2022-12-17	WOS:000254621300009
J	Hesson, LB; Cooper, WN; Latif, F				Hesson, L. B.; Cooper, W. N.; Latif, F.			Evaluation of the 3p21.3 tumour-suppressor gene cluster	ONCOGENE			English	Review						3p21.3; RASSFIA; epigenetics; tumor suppressor gene	JAAGSIEKTE SHEEP RETROVIRUS; HOMOZYGOUS DELETION REGION; HUMAN-CHROMOSOME 3P21.3; CELL LUNG-CANCER; ADENOVIRUS E1A-ASSOCIATED PROTEIN; ISLAND PROMOTER HYPERMETHYLATION; FREQUENT EPIGENETIC INACTIVATION; CPG ISLAND; K-RAS; ABERRANT METHYLATION	Deletions of the 3p21.3 region are a frequent and early event in the formation of lung, breast, kidney and other cancers. Intense investigation of allelic losses and the discovery of overlapping homozygous deletions in lung and breast tumour-cell lines have defined a minimal critical 120 kb deletion region containing eight genes and likely to harbor one or more tumour-suppressor genes (TSGs). The candidate genes are HYAL2, FUS1, Ras-associated factor 1 (RASSF1), BLU/ZMYND10, NPR2L, 101F6, PL6 and CACNA2D2. Recent research indicates that several of these genes can suppress the growth of lung and other tumour cells. Furthermore, some genes (RASSF1A and BLU/ZMYND10) are very frequently inactivated by non-classical mechanisms such as promoter hypermethylation resulting in loss of expression. These data indicate that the 120 kb critical deletion region at 3p21.3 may represent a TSG cluster with preferential inactivation of particular genes depending on tumour type. The eight genes within this region and their potential role in cancer will be the focus of this review.	Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Dundee, Coll Life Sci, MRC Protein Phosphorylat Unit, Dundee, Scotland	University of Birmingham; University of Dundee	Latif, F (corresponding author), Univ Birmingham, Biomed Res Inst, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	L.Hesson@dundee.ac.uk; f.latif@bham.ac.uk	Hesson, Luke/HDM-0311-2022		Breast Cancer Now [2005NOV13] Funding Source: Medline	Breast Cancer Now		Abe M, 2005, CANCER RES, V65, P828; Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2003, CANCER RES, V63, P5344; Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; Alden KJ, 2001, J PHARMACOL EXP THER, V297, P727; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Anantharaman V, 2000, TRENDS BIOCHEM SCI, V25, P535, DOI 10.1016/S0968-0004(00)01672-8; Aoyama Y, 2004, ONCOGENE, V23, P3426, DOI 10.1038/sj.onc.1207486; Armesilla AL, 2004, J BIOL CHEM, V279, P31318, DOI 10.1074/jbc.M307557200; Bais AJ, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-22; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Barclay J, 2001, J NEUROSCI, V21, P6095, DOI 10.1523/JNEUROSCI.21-16-06095.2001; Bertrand P, 2005, INT J CANCER, V113, P207, DOI 10.1002/ijc.20562; Bourguignon LYW, 2004, J BIOL CHEM, V279, P26991, DOI 10.1074/jbc.M311838200; Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479; Brodbeck J, 2002, J BIOL CHEM, V277, P7684, DOI 10.1074/jbc.M109404200; Carboni GL, 2003, ONCOGENE, V22, P615, DOI 10.1038/sj.onc.1206134; Chen JD, 2003, CANCER CELL, V4, P405, DOI 10.1016/S1535-6108(03)00269-1; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Chow LSN, 2004, ONCOL REP, V12, P781; Csoka AB, 1999, GENOMICS, V60, P356, DOI 10.1006/geno.1999.5876; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dallol A, 2004, CANCER RES, V64, P4112, DOI 10.1158/0008-5472.CAN-04-0267; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Endoh M, 2005, BRIT J CANCER, V93, P1395, DOI 10.1038/sj.bjc.6602854; Enegd B, 2002, NEUROSURGERY, V50, P1311, DOI 10.1097/00006123-200206000-00023; Falvella FS, 2006, ONCOGENE, V25, P3934, DOI 10.1038/sj.onc.1209422; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fischer WH, 1996, J NEUROCHEM, V66, P2213; Fletcher CF, 2001, FASEB J, V15, P1288, DOI 10.1096/fj.00-0562fje; Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781; Gao BN, 2000, J BIOL CHEM, V275, P12237, DOI 10.1074/jbc.275.16.12237; Gopalan B, 2004, TECHNOL CANCER RES T, V3, P647, DOI 10.1177/153303460400300615; Gurnett CA, 1996, NEURON, V16, P431, DOI 10.1016/S0896-6273(00)80061-6; Harjes E, 2006, STRUCTURE, V14, P881, DOI 10.1016/j.str.2006.03.008; HARJES E, 2006, NEURON, V14, P881; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P1908; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Ito I, 2004, CANCER GENE THER, V11, P733, DOI 10.1038/sj.cgt.7700756; Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041; Ivanov SV, 2004, AM J PATHOL, V165, P1007, DOI 10.1016/S0002-9440(10)63362-7; Ji L, 2002, CANCER RES, V62, P2715; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kitagawa D, 2006, EMBO J, V25, P3286, DOI 10.1038/sj.emboj.7601212; Klugbauer N, 1999, J NEUROSCI, V19, P684; Kochetkova M, 2002, CANCER RES, V62, P4599; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Kondo M, 2001, ONCOGENE, V20, P6258, DOI 10.1038/sj.onc.1204832; Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048; LAI HC, 2006, HYPERMETHYLATION 2 C; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Lepperdinger G, 2001, MATRIX BIOL, V20, P509, DOI 10.1016/S0945-053X(01)00170-6; Lerman MI, 2000, CANCER RES, V60, P6116; Li F, 2004, CANCER RES, V64, P6438, DOI 10.1158/0008-5472.CAN-03-3869; Li JF, 2004, ONCOGENE, V23, P5941, DOI 10.1038/sj.onc.1207789; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; Liu SL, 2007, ONCOGENE, V26, P789, DOI 10.1038/sj.onc.1209850; LOYI PH, 2006, CANC LETT, V234, P184; Lusher ME, 2002, CANCER RES, V62, P5906; Marsit CJ, 2005, INT J CANCER, V114, P219, DOI 10.1002/ijc.20714; Michalowski MB, 2006, CANCER GENET CYTOGEN, V166, P74, DOI 10.1016/j.cancergencyto.2005.09.004; Morris MR, 2003, ONCOGENE, V22, P6794, DOI 10.1038/sj.onc.1206914; Mullegger J, 2002, MECH DEVELOP, V111, P25, DOI 10.1016/S0925-4773(01)00593-7; Muller HM, 2004, LANCET, V363, P1283, DOI 10.1016/S0140-6736(04)16002-9; Novak U, 1999, CANCER RES, V59, P6246; Oh HJ, 2006, CANCER RES, V66, P2562, DOI 10.1158/0008-5472.CAN-05-2951; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Rabizadeh S, 2004, J BIOL CHEM, V279, P29247, DOI 10.1074/jbc.M401699200; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019; Roche J, 1996, ONCOGENE, V12, P1289; Scheel H, 2003, CURR BIOL, V13, pR899, DOI 10.1016/j.cub.2003.11.007; Schenk PW, 2003, MOL PHARMACOL, V64, P259, DOI 10.1124/mol.64.2.259; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486; Shivakumar L, 2002, MOL CELL BIOL, V22, P4309, DOI 10.1128/MCB.22.12.4309-4318.2002; Shuster S, 2002, INT J CANCER, V102, P192, DOI 10.1002/ijc.10668; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Stern R, 2004, EUR J CELL BIOL, V83, P317, DOI 10.1078/0171-9335-00392; Sundaresan V, 1998, ONCOGENE, V17, P1723, DOI 10.1038/sj.onc.1202103; Tommasi S, 2005, CANCER RES, V65, P92; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toyota M, 1999, CANCER RES, V59, P4535; Tsubaki M, 2005, BBA-PROTEINS PROTEOM, V1753, P174, DOI 10.1016/j.bbapap.2005.08.015; Udabage L, 2005, EXP CELL RES, V310, P205, DOI 10.1016/j.yexcr.2005.07.026; Ueda K, 2006, CANCER RES, V66, P9682, DOI 10.1158/0008-5472.CAN-06-1483; Uno F, 2004, CANCER RES, V64, P2969, DOI 10.1158/0008-5472.CAN-03-3702; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Velasco G, 2006, J BIOL CHEM, V281, P16546, DOI 10.1074/jbc.M600573200; Vigdorovich V, 2005, J VIROL, V79, P79, DOI 10.1128/JVI.79.1.79-86.2005; Vos MD, 2003, J BIOL CHEM, V278, P21938, DOI 10.1074/jbc.M211019200; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Vos MD, 2006, J BIOL CHEM, V281, P4557, DOI 10.1074/jbc.M512128200; Vos MD, 2004, CANCER RES, V64, P4244, DOI 10.1158/0008-5472.CAN-04-0339; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wan J, 2006, MOL CELL BIOL, V26, P448, DOI 10.1128/MCB.26.2.448-456.2006; Wei G, 2003, ANTICANCER RES, V23, P2173; Wei MH, 1996, CANCER RES, V56, P1487; Wistuba II, 2000, CANCER RES, V60, P1949; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Zaahl MG, 2004, HUM GENET, V115, P409, DOI 10.1007/s00439-004-1166-y; ZHANG LR, 1995, CANCER RES, V55, P428; Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	121	128	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7283	7301		10.1038/sj.onc.1210547	http://dx.doi.org/10.1038/sj.onc.1210547			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17533367				2022-12-17	WOS:000250955700001
J	Leotlela, PD; Wade, MS; Duray, PH; Rhode, MJ; Brown, HF; Rosenthal, DT; Dissanayake, SK; Earley, R; Indig, FE; Nickoloff, BJ; Taub, DD; Kallioniemi, OP; Meltzer, P; Morin, PJ; Weeraratna, AT				Leotlela, P. D.; Wade, M. S.; Duray, P. H.; Rhode, M. J.; Brown, H. F.; Rosenthal, D. T.; Dissanayake, S. K.; Earley, R.; Indig, F. E.; Nickoloff, B. J.; Taub, D. D.; Kallioniemi, O. P.; Meltzer, P.; Morin, P. J.; Weeraratna, A. T.			Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility	ONCOGENE			English	Article						claudin; melanoma; PKC; motility; tissue array	PROTEIN-KINASE-C; TIGHT JUNCTION PROTEINS; OVARIAN-CANCER; INVASION; ACTIVATION; EXPRESSION; ADHESION; BARRIER; MICE	Serial analysis of gene expression followed by pathway analysis implicated the tight junction protein claudin-1 (CLDN1) in melanoma progression. Tight junction proteins regulate the paracellular transport of molecules, but staining of a tissue microarray revealed that claudin-1 was overexpressed in melanoma, and aberrantly expressed in the cytoplasm of malignant cells, suggesting a role other than transport. Indeed, melanoma cells in culture demonstrate no tight junction function. It has been shown that protein kinase C (PKC) can affect expression of claudin-1 in rat choroid plexus cells, and we observed a correlation between levels of activated PKC and claudin expression in our melanoma cells. To determine if PKC could affect the expression of CLDN1 in human melanoma, cells lacking endogenous claudin-1 were treated with 200 nM phorbol myristic acid (PMA). PKC activation by PMA caused an increase in CLDN1 transcription in 30 min, and an increase in claudin-1 protein by 12 h. Inhibition of PKC signaling in cells with high claudin-1 expression resulted in decreased claudin-1 expression. CLDN1 appears to contribute to melanoma cell invasion, as transient transfection of melanoma cells with CLDN1 increased metalloproteinase 2 (MMP-2) secretion and activation, and subsequently, motility of melanoma cells as demonstrated by wound-healing assays. Conversely, knockdown of CLDN1 by siRNA resulted in the inhibition of motility, as well as decreases in MMP-2 secretion and activation. These data implicate claudin-1 in melanoma progression.	NIA, Immunol Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; VA Healthcare Syst, Boston, MA USA; Univ Maryland Eastern Shore, MARC Scholar, Princess Anne, MD USA; Univ N Carolina, Dept Biol & Marine Biol, Wilmington, NC 28401 USA; NIA, Res Resources Branch, Gerontol Res Ctr, Baltimore, MD 21224 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Univ Turku, VTT Tech Res Ctr Finland, Med Biotechnol Dept, SF-20500 Turku, Finland; Natl Human Genome Res Inst, Canc Genet Branch, Bethesda, MD USA; NIA, Lab Cellular & Mol Biol, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Eastern Shore; University of North Carolina; University of North Carolina Wilmington; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Loyola University Chicago; University of Turku; VTT Technical Research Center Finland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 21, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332	NATIONAL CANCER INSTITUTE [Z01BC010759, ZIABC010759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000395, Z01AG000615, ZICAG000615, Z01AG000395, ZIAAG000442, Z01AG000442, Z01AG000512] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Cohn ML, 2005, J CUTAN PATHOL, V32, P533, DOI 10.1111/j.0303-6987.2005.00324.x; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; da Rocha AB, 2000, PATHOBIOLOGY, V68, P113, DOI 10.1159/000055911; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; DUMONT JA, 1992, CANCER RES, V52, P1195; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Lippoldt A, 2000, NEUROREPORT, V11, P1427, DOI 10.1097/00001756-200005150-00015; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakamura K, 2003, ANTICANCER RES, V23, P1395; Oku N, 2006, CANCER RES, V66, P5251, DOI 10.1158/0008-5472.CAN-05-4478; Park MJ, 2003, INT J ONCOL, V22, P137; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Sawada Norimasa, 2003, Medical Electron Microscopy, V36, P147, DOI 10.1007/s00795-003-0219-y; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4	23	128	135	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3846	3856		10.1038/sj.onc.1210155	http://dx.doi.org/10.1038/sj.onc.1210155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160014				2022-12-17	WOS:000247026400008
J	Yoshida, T; Hisamoto, T; Akiba, J; Koga, H; Nakamura, K; Tokunaga, Y; Hanada, S; Kumemura, H; Maeyama, M; Harada, M; Ogata, H; Yano, H; Kojiro, M; Ueno, T; Yoshimura, A; Sata, M				Yoshida, T.; Hisamoto, T.; Akiba, J.; Koga, H.; Nakamura, K.; Tokunaga, Y.; Hanada, S.; Kumemura, H.; Maeyama, M.; Harada, M.; Ogata, H.; Yano, H.; Kojiro, M.; Ueno, T.; Yoshimura, A.; Sata, M.			Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors	ONCOGENE			English	Article						Ras; Raf-1; ERK; spred; sprouty; HCC	CELL-CYCLE ARREST; PROTEIN-KINASE; MICE LACKING; MAP KINASE; ACTIVATION; EXPRESSION; ERK; PATHWAYS; BINDING; RAS	Aberrant activation of the Ras/Raf-1/extracellular-regulated kinase (ERK) pathway has been shown to be involved in the progression of human hepatocellular carcinoma (HCC). However, the mechanism of dysregulation of ERK activation is poorly understood. Recently, we identified Sprouty-related protein with Ena/vasodilator stimulated phosphoprotein homology-1 domain (Spred) as a physiological inhibitor of the Ras/Raf-1/ERK pathway. In this study, we found that the expression levels of Spred-1 and -2 in human HCC tissue were frequently decreased, comparing with those in adjacent non-tumorous tissue. Moreover, Spred expression levels in HCC tissue were inversely correlated with the incidence of tumor invasion and metastasis. Forced expression of Spred-1 inhibited HCC cell proliferation in vitro and in vivo, which was associated with reduced ERK activation. Spred-1 overexpression also reduced the secretion of matrix metalloproteinase-9 (MMP-9) and MMP-2, which play important roles in tumor invasion and metastasis. In addition, Spred-1 inhibited growth factor-mediated HCC cell motility. These data indicate that the reduction of Spred expression in HCC is one of the causes of the acquisition of malignant features. Thus, Spred could be not only a novel prognostic factor but also a new therapeutic target for human HCC.	Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Ctr 21st Century Program Med Sci, Kurume, Fukuoka, Japan; Kurume Univ, Dept Pathol, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, Kurume, Fukuoka, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 812, Japan	Kurume University; Kurume University; Kyushu University	Yoshida, T (corresponding author), Kurume Univ, Dept Med, Sch Med, Liver Canc Div,Res Ctr Innovat Canc Therapy, 67 Asahi Machi, Kurume, Fukuoka, Japan.	tayoshi@med.kurume-u.ac.jp	Yoshimura, Akihiko/K-5515-2013					Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Chen LX, 2004, FASEB J, V18, P914, DOI 10.1096/fj.03-1204fje; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; Ehrenreiter K, 2005, J CELL BIOL, V168, P955, DOI 10.1083/jcb.200409162; Inoue H, 2005, J EXP MED, V201, P73, DOI 10.1084/jem.20040616; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kato R, 2003, BIOCHEM BIOPH RES CO, V302, P767, DOI 10.1016/S0006-291X(03)00259-6; Koga H, 2001, HEPATOLOGY, V33, P1087, DOI 10.1053/jhep.2001.24024; Liu JF, 2002, BIOCHEM BIOPH RES CO, V293, P1174, DOI 10.1016/S0006-291X(02)00350-9; Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masson V, 2004, FASEB J, V18, P234, DOI 10.1096/fj.04-2140fje; McAllister SS, 2003, MOL CELL BIOL, V23, P216, DOI 10.1128/MCB.23.1.216-228.2003; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Miyoshi K, 2004, ONCOGENE, V23, P5567, DOI 10.1038/sj.onc.1207759; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Nonami A, 2004, J BIOL CHEM, V279, P52543, DOI 10.1074/jbc.M405189200; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sasaki A, 2003, NAT CELL BIOL, V5, P427, DOI 10.1038/ncb978; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Stahl S, 2005, HEPATOLOGY, V42, P353, DOI 10.1002/hep.20768; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wakioka T, 2001, NATURE, V412, P647, DOI 10.1038/35088082; YANO H, 1988, ACTA PATHOL JAPON, V38, P953; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675; Zaragoza C, 2002, MOL PHARMACOL, V62, P927, DOI 10.1124/mol.62.4.927; Zhang DL, 2004, J BIOL CHEM, V279, P19683, DOI 10.1074/jbc.M313145200	34	128	140	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2006	25	45					6056	6066		10.1038/sj.onc.1209635	http://dx.doi.org/10.1038/sj.onc.1209635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	092MN	16652141				2022-12-17	WOS:000241101200003
J	Mitra, SK; Mikolon, D; Molina, JE; Hsia, DA; Hanson, DA; Chi, A; Lim, ST; Bernard-Trifilo, JA; Ilic, D; Stupack, DG; Cheresh, DA; Schlaepfer, DD				Mitra, S. K.; Mikolon, D.; Molina, J. E.; Hsia, D. A.; Hanson, D. A.; Chi, A.; Lim, S-T; Bernard-Trifilo, J. A.; Ilic, D.; Stupack, D. G.; Cheresh, D. A.; Schlaepfer, D. D.			Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors	ONCOGENE			English	Article						FAK; FRNK; VEGF; tumor growth; angiogenesis	FOCAL-ADHESION KINASE; ENDOTHELIAL GROWTH-FACTOR; HUMAN BREAST; CELL MOTILITY; IN-VIVO; ONCOGENIC TRANSFORMATION; PROTEIN-KINASE; CANCER; SRC; PATHWAYS	Elevated focal adhesion kinase (FAK) expression occurs in advanced cancers, yet a signaling role for FAK in tumor progression remains undefined. Here, we suppressed FAK activity in 4T1 breast carcinoma cells resulting in reduced FAK Y925 phosphorylation, Grb2 adaptor protein binding to FAK, and signaling to mitogen-activated protein (MAP) kinase (MAPK). Loss of a FAK-Grb2-MAPK linkage did not affect 4T1 cell proliferation or survival in culture, yet FAK inhibition reduced vascular endothelial growth factor (VEGF) expression and resulted in small avascular tumors in mice. This FAK-Grb2-MAPK linkage was essential in promoting angiogenesis as reconstitution experiments using Src-transformed FAK-null fibroblasts revealed that point mutations affecting FAK catalytic activity (R454) or Y925 phosphorylation (F925) disrupted the ability of FAK to promote MAPK- and VEGF-associated tumor growth. Notably, in both FAK- inhibited 4T1 and Src-transformed FAK- null cells, constitutively activated (CA) mitogen-activated protein kinase kinase 1 (MEK1) restored VEGF production and CA-MEK1 or added VEGF rescued tumor growth and angiogenesis. These studies provide the first biological support for Y925 FAK phosphorylation and de. ne a novel role for FAK activity in promoting a MAPK- associated angiogenic switch during tumor progression.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; StemLifeLine Inc, San Carlos, CA USA	Scripps Research Institute; University of California System; University of California San Diego	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM 21,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		Lim, Steve/0000-0003-0323-8607; ILIC, DUSKO/0000-0003-1647-0026	NATIONAL CANCER INSTITUTE [R37CA050286, R01CA045726, R01CA107263, P01CA078045, R01CA050286, R01CA095262, K01CA087652, R01CA102310] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R24EY014174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007606] Funding Source: NIH RePORTER; NCI NIH HHS [CA102310, CA087652, CA78045, CA50286, CA95262, CA107263, CA45726] Funding Source: Medline; NEI NIH HHS [EY14174] Funding Source: Medline; NIAID NIH HHS [T32 AI07606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Barr MP, 2005, BRIT J CANCER, V92, P328, DOI 10.1038/sj.bjc.6602308; Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Boudreau N, 2003, BREAST CANCER RES, V5, P140, DOI 10.1186/bcr589; Cance WG, 2000, CLIN CANCER RES, V6, P2417; De S, 2005, P NATL ACAD SCI USA, V102, P7589, DOI 10.1073/pnas.0502935102; Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342; Golubovskaya V, 2002, J BIOL CHEM, V277, P38978, DOI 10.1074/jbc.M205002200; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanks SK, 2003, FRONT BIOSCI-LANDMRK, V8, pD982, DOI 10.2741/1114; Haskell H, 2003, CLIN CANCER RES, V9, P2157; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; Hecker TP, 2003, FRONT BIOSCI-LANDMRK, V8, pS705, DOI 10.2741/1115; Heppner GH, 2000, BREAST CANCER RES, V2, P331; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Hsia DA, 2003, J CELL BIOL, V160, P753, DOI 10.1083/jcb.200212114; Ilic D, 2003, CIRC RES, V92, P300, DOI 10.1161/01.RES.0000055016.36679.23; Ilic D, 1998, J CELL BIOL, V143, P547; ILLC D, 1995, NATURE, V377, P539; Jiang BH, 1997, CANCER RES, V57, P5328; Kornberg LJ, 2004, INVEST OPHTH VIS SCI, V45, P4463, DOI 10.1167/iovs.03-1201; Kranenburg O, 2004, BBA-REV CANCER, V1654, P23, DOI 10.1016/j.bbcan.2003.09.004; LARK AL, 2005, MOD PATHOL; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; Lightfoot HM, 2004, BREAST CANCER RES TR, V88, P109, DOI 10.1007/s10549-004-1022-8; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2006, ONCOGENE, V25, P4429, DOI 10.1038/sj.onc.1209482; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moissoglu K, 2003, J BIOL CHEM, V278, P47946, DOI 10.1074/jbc.M302720200; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Peng X, 2004, CARDIOVASC RES, V64, P421, DOI 10.1016/j.cardiores.2004.07.012; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 2004, BBA-MOL CELL RES, V1692, P77, DOI 10.1016/j.bbamcr.2004.04.008; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Seko Y, 1999, BIOCHEM BIOPH RES CO, V262, P290, DOI 10.1006/bbrc.1999.1185; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Sieg DJ, 1999, J CELL SCI, V112, P2677; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Storgard Chris, 2004, V294, P123; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Tschan MP, 2003, J BIOL CHEM, V278, P42750, DOI 10.1074/jbc.M307067200; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Wang DY, 2000, J CELL SCI, V113, P4221; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199	59	128	140	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2006	25	44					5969	5984		10.1038/sj.onc.1209588	http://dx.doi.org/10.1038/sj.onc.1209588			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	088QN	16682956				2022-12-17	WOS:000240826300006
J	Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW				Domingo, E; Niessen, RC; Oliveira, C; Alhopuro, P; Moutinho, C; Espin, E; Armengol, M; Sijmons, RH; Kleibeuker, JH; Seruca, R; Aaltonen, LA; Imai, K; Yamamoto, H; Schwartz, S; Hofstra, RMW			RRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes	ONCOGENE			English	Article						HNPCC; BRAF; MSH6	MISMATCH REPAIR DEFICIENCY; BETHESDA GUIDELINES; BRAF MUTATIONS; CANCER; COLON; HMLH1	Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite instability. Further, it was shown to associate with the silencing of the mismatch repair (MMR) gene MLH1 by hypermethylation. Moreover, BRAF mutations proved to be absent in tumors from hereditary nonpolyposis colorectal cancer syndrome (HNPCC) families with germline mutations in the MMR genes MLH1 and MSH2. These data suggest that the oncogenic activation of BRAF is involved only in sporadic colorectal tumorigenesis. In order to further support this hypothesis, we have extended the analysis of the BRAF gene to a different subset of HNPCC families without germline mutations in MLH1 and MSH2. BRAF-V600E mutations were analysed by automatic sequencing in 38 tumors from HNPCC families with germline mutations in the MSH6 gene and also in HNPCC (suspected) families that do not have mutations in the MMR genes MLH1, MSH2 and MSH6. All patients belong to different families. No mutations were detected in 14 tumors from HNPCC patients with germline mutations in MSH6. Further, no mutations of BRAF were found in tumors from 23 MMR-negative families, from which 13 fulfilled the Amsterdam criteria (HNPCC) and 10 were suspected for HNPCC as they were positive for the Bethesda criteria. Overall, our data reinforce the concept that BRAF is not involved in the colorectal tumorigenesis of HNPCC. The detection of a positive BRAF-V600E mutation in a colorectal cancer suggests a sporadic origin of the disease and the absence of germline alterations of MLH1, MSH2 and also of MSH6. These findings have a potential impact in the genetic testing for HNPCC diagnostics and suggest a potential use of BRAF as exclusion criteria for HNPCC or as a molecular marker of sporadic cancer.	Hosp Univ Vall Hebron, CIBBIM, Barcelona 08035, Spain; Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Univ Porto, Inst Patol & Imunol Mol, P-4200465 Oporto, Portugal; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Groningen Hosp, Dept Clin Genet, Groningen, Netherlands; Univ Groningen Hosp, Dept Gastroenterol, Groningen, Netherlands; Sapporo Med Univ, Dept Internal Med 1, Chuo Ku, Sapporo, Hokkaido 0608543, Japan	Hospital Universitari Vall d'Hebron; University of Groningen; Universidade do Porto; University of Helsinki; University of Groningen; University of Groningen; Sapporo Medical University	Schwartz, S (corresponding author), Hosp Univ Vall Hebron, CIBBIM, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sschwartz@vhebron.net	seruca, raquel/F-8187-2011; Sijmons, Rolf/E-5829-2012; Schwartz, Simo/H-7776-2012; Domingo, Enric/A-9099-2018; Oliveira, Carla/F-8188-2011; Aaltonen, Lauri/A-5375-2010	Sijmons, Rolf/0000-0001-8446-2779; Domingo, Enric/0000-0003-4390-8767; Oliveira, Carla/0000-0001-8340-2264; Aaltonen, Lauri/0000-0001-6839-4286; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Armengol, Manuel/0000-0002-3211-3195; Espin-Basany, Eloy/0000-0002-9139-4548; Hofstra, Robert/0000-0001-7498-3829				Berends MJW, 2002, AM J HUM GENET, V70, P26, DOI 10.1086/337944; Boland CR, 1998, CANCER RES, V58, P5248; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Di Fiore F, 2004, J MED GENET, V41, P18, DOI 10.1136/jmg.2003.012062; Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; Gille JJP, 2002, BRIT J CANCER, V87, P892, DOI 10.1038/sj.bjc.6600565; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Wahlberg S, 1999, GENET TEST, V3, P259, DOI 10.1089/109065799316563; Wang L, 2003, CANCER RES, V63, P5209; Wijnen J, 1999, NAT GENET, V23, P142, DOI 10.1038/13773	19	128	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3995	3998		10.1038/sj.onc.1208569	http://dx.doi.org/10.1038/sj.onc.1208569			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15782118				2022-12-17	WOS:000229435300015
J	Li, B; Yuan, M; Kim, IA; Chang, CM; Bernhard, EJ; Shu, HKG				Li, B; Yuan, M; Kim, IA; Chang, CM; Bernhard, EJ; Shu, HKG			Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin	ONCOGENE			English	Article						epidermal growth factor receptor; cell signaling; radioresistance; phosphatidylinositol-3 kinase; malignant glioma	HUMAN GLIOBLASTOMA CELLS; TUMOR-SUPPRESSOR; ANAPLASTIC ASTROCYTOMA; 3-KINASE/AKT PATHWAY; MALIGNANT GLIOMAS; CANCER-CELLS; GENE; PHOSPHATASE; RESISTANCE; ACTIVATION	Amplification and mutation of the epidermal growth factor receptor (EGFR) are common features of malignant gliomas. The most frequent mutation seen in these tumors involves deletion of exon 2-7 resulting in a constitutively active form of the receptor (EGFRvIII, or deltaEGFR). Since EGFRvIII is found primarily in gliomas and has not been reported in sarcomas, we compared the effects of this altered receptor in immortalized primary astrocytes and fibroblasts. While EGFRvIII displayed ligand-independent autophosphorylation in both cell types, downstream signaling differed. While EGFRvIII increased the proliferative capacity of both astrocytes and fibroblasts consistent with activation of ERK in these cells, EGFRvIII activated AKT only in the immortalized astrocytes. EGFRvIII expression in astrocytes also led to increased radioresistance in that cell type. Furthermore, specific inhibition of phosphotidylinositol-3 kinase (PI-3K) with LY294002 reverted the radioresistant phenotype in the immortalized astrocytes. Thus, selective activation of PI-3K/AKT in astrocytes expressing EGFRvIII appears to be responsible for the observed increase in radio resistance. EGFRvIII's differential ability to activate the PI-3K downstream signal may explain why this mutant receptor is such a prominent lesion in malignant gliomas but less often seen in other tumor types, even those where EGFR signaling has a prominent role.	Univ Penn, Sch Med, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania	Shu, HKG (corresponding author), Univ Penn, Sch Med, Dept Radiat Oncol, John Morgan Bldg,Room 195,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	shu@xrt.upenn.edu	Kim, In Ah/J-5426-2012	Shu, Hui-Kuo/0000-0002-4060-0874				Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Brognard J, 2001, CANCER RES, V61, P3986; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001; Fernandes H, 2001, J BIOL CHEM, V276, P5375, DOI 10.1074/jbc.M005599200; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Gupta AK, 2001, CANCER RES, V61, P4278; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; JUNGBLUTH AA, 2003, P NATL ACAD SCI USA, V6, P6; Klingler-Hoffmann M, 2003, INT J CANCER, V105, P331, DOI 10.1002/ijc.11085; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; NELSON D F, 1988, NCI (National Cancer Institute) Monographs, P279; Rich JN, 2001, CANCER RES, V61, P3556; Sonoda Y, 2001, CANCER RES, V61, P4956; Sonoda Y, 2001, CANCER RES, V61, P6674; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tezuka M, 2001, CLIN CANCER RES, V7, P3206; Vermeulen K, 2003, CELL PROLIFERAT, V36, P165, DOI 10.1046/j.1365-2184.2003.00267.x; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	33	128	137	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2004	23	26					4594	4602		10.1038/sj.onc.1207602	http://dx.doi.org/10.1038/sj.onc.1207602			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZV	15077177				2022-12-17	WOS:000221799000009
J	Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M				Lucca, C; Vanoli, F; Cotta-Ramusino, C; Pellicioli, A; Liberi, G; Haber, J; Foiani, M			Checkpoint-mediated control of replisome-fork association and signalling in response to replication pausing	ONCOGENE			English	Article						checkpoint; genome instability; chromosome replication; ATM pathway; Rad53	DOUBLE-STRAND BREAKS; DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN-A; HOMOLOG MEC1; G2/M ARREST; DAMAGE; PROGRESSION; PHOSPHORYLATION	The replication checkpoint controls the integrity of replicating chromosomes by stabilizing stalled forks, thus preventing the accumulation of abnormal replication and recombination intermediates that contribute to genome instability. Checkpoint-defective cells are susceptible to rearrangements at chromosome fragile sites when replication pauses, and certain human cancer prone diseases suffer checkpoint abnormalities. It is unclear as to how the checkpoint stabilizes stalled forks and how cells sense replication blocks. We have analysed the checkpoint contribution in controlling replisome-fork association when replication pauses. We show that in yeast wild-type cells, stalled forks exhibit stable replisome complexes and the checkpoint sensors Ddc1 and Ddc2, thus activating Rad53 checkpoint kinase. Ddc1/Ddc2 recruitment on stalled forks and Rad53 activation are influenced by the single-strand-binding protein replication factor A (RFA). rad53 forks exhibit a defective association with DNA polymerases alpha, epsilon and delta. Further, in rad53 mutants, stalled forks progressively generate abnormal structures that turn into checkpoint signals by accumulating RFA, Ddc1 and Ddc2. We suggest that, following replication blocks, checkpoint activation mediated by RFA-ssDNA. laments stabilizes stalled forks by controlling replisome - fork association, thus preventing unscheduled recruitment of recombination enzymes that could otherwise cause the pathological processing of the forks.	Ist FIRC Oncol Mol, I-20141 Milan, Italy; Univ Milan, Dipartimento Sci Biomol & Biotecnol, I-20133 Milan, Italy; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	IFOM - FIRC Institute of Molecular Oncology; University of Milan; Brandeis University	Foiani, M (corresponding author), Ist FIRC Oncol Mol, Via Adamello 16, I-20141 Milan, Italy.	foiani@ifom-firc.it	LIBERI, GIORDANO/AAY-7273-2020; Foiani, Marco/M-8234-2014; Pellicioli, Achille/B-8765-2017	LIBERI, GIORDANO/0000-0003-3160-2242; Foiani, Marco/0000-0003-4795-834X; Pellicioli, Achille/0000-0002-1528-9009; Haber, James/0000-0002-1878-0610	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020056, R01GM061766, R01GM020056] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20056, GM61766] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; ARAKI H, 1995, P NATL ACAD SCI USA, V92, P11791, DOI 10.1073/pnas.92.25.11791; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Brush GS, 1996, P NATL ACAD SCI USA, V93, P15075, DOI 10.1073/pnas.93.26.15075; Brush GS, 2000, NUCLEIC ACIDS RES, V28, P3725, DOI 10.1093/nar/28.19.3725; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cimprich KA, 2003, CURR BIOL, V13, pR231, DOI 10.1016/S0960-9822(03)00158-1; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Edwards RJ, 1999, NAT CELL BIOL, V1, P393, DOI 10.1038/15623; Foiani M, 2000, MUTAT RES-FUND MOL M, V451, P187, DOI 10.1016/S0027-5107(00)00049-X; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; Friedman KL, 1995, METHOD ENZYMOL, V262, P613; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Ivessa AS, 2000, CELL, V100, P479, DOI 10.1016/S0092-8674(00)80683-2; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Kamimura Y, 2001, EMBO J, V20, P2097, DOI 10.1093/emboj/20.8.2097; Kondo T, 2001, SCIENCE, V294, P867, DOI 10.1126/science.1063827; Kornberg A., 1992, DNA REPLICATION; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lee SE, 2001, CURR BIOL, V11, P1053, DOI 10.1016/S0960-9822(01)00296-2; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Longhese MP, 1997, EMBO J, V16, P5216, DOI 10.1093/emboj/16.17.5216; Lopes M, 2001, NATURE, V412, P557, DOI 10.1038/35087613; Marini F, 1997, EMBO J, V16, P639, DOI 10.1093/emboj/16.3.639; Melo JA, 2001, GENE DEV, V15, P2809; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; Paciotti V, 2000, GENE DEV, V14, P2046; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pellicioli A, 2001, MOL CELL, V7, P293, DOI 10.1016/S1097-2765(01)00177-0; Pellicioli A, 1999, EMBO J, V18, P6561, DOI 10.1093/emboj/18.22.6561; Rouse J, 2000, EMBO J, V19, P5801, DOI 10.1093/emboj/19.21.5801; Rouse J, 2002, MOL CELL, V9, P857, DOI 10.1016/S1097-2765(02)00507-5; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tercero JA, 2003, MOL CELL, V11, P1323, DOI 10.1016/S1097-2765(03)00169-2; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Umezu K, 1998, GENETICS, V148, P989; Vaze MB, 2002, MOL CELL, V10, P373, DOI 10.1016/S1097-2765(02)00593-2; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	128	130	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1206	1213		10.1038/sj.onc.1207199	http://dx.doi.org/10.1038/sj.onc.1207199			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647447				2022-12-17	WOS:000188892200004
J	King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC				King, KE; Ponnamperuma, RM; Yamashita, T; Tokino, T; Lee, LA; Young, MF; Weinberg, WC			Delta Np63 alpha functions as both a positive and a negative transcriptional regulator and blocks in vitro differentiation of murine keratinocytes	ONCOGENE			English	Article						Delta Np63 alpha; p63; p53 homologues; keratinocytes; epidermal differentiation	SQUAMOUS-CELL CARCINOMAS; P53 GENE DOSAGE; MALIGNANT PROGRESSION; P53-RELATED PROTEIN; SPONTANEOUS TUMORS; P63 EXPRESSION; CORE DOMAIN; P73; HOMOLOG; APOPTOSIS	DeltaNp63 is overexpressed in squamous carcinomas where it is associated with proliferation and is believed to enhance cell growth by blocking p53-mediated transactivation. In normal epithelium, DeltaNp63alpha protein expression is abundant in basal cells and decreases with differentiation. To explore the biological consequences of DeltaNp63alpha overexpression in relation to squamous carcinogenesis, we evaluated its effect on normal squamous differentiation and p53 transactivation function in keratinocytes. Forced overexpression of DeltaNp63alpha in primary murine keratinocytes in vitro inhibits morphological differentiation induced by elevated extracellular [Ca2+], abrogates Ca2+-induced growth arrest, and blocks expression of maturation-specific proteins keratin 10 and filaggrin. This suggests that DeltaNp63 overexpression in squamous carcinomas may serve to maintain the basal cell phenotype and promote cell survival. DeltaNp63alpha blocks transactivation of p53 responsive reporter constructs mediated by endogenous or exogenous p53 at 17 h postinfection, as expected. However, at 41 h, when p53-mediated transactivation is diminished, DeltaNp63alpha: enhances transactivation of these reporter constructs by 2.2-12-fold over control. Maximal DeltaNp63alpha-induced transactivation requires intact p53 responsive elements, but is independent of cellular p53 status. This positive transcriptional function of DeltaNp63alpha appears to be cell-type specific, as it is not observed in primary dermal fibroblasts or Saos-2 cells. These findings support DeltaNp63alpha as a master regulator of keratinocyte differentiation, and suggest a novel function of this protein in the maintenance of epithelial homeostasis.	US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA; Sapporo Med Univ, Sch Med, Sapporo, Hokkaido 0608556, Japan; Univ Colorado, Sch Med, Denver, CO 80262 USA; Denver Hlth Med Ctr, Denver, CO 80262 USA; Natl Inst Dent & Craniofacial Res, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); Sapporo Medical University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Weinberg, WC (corresponding author), US FDA, Ctr Biol Evaluat & Res, 29 Lincoln Dr,HFM-564,Bldg 29B,Room 3NN04, Bethesda, MD 20892 USA.		Weinberg, Wendy/A-8920-2009; Tokino, Takashi/AAI-9887-2021	Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000379] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Dellavalle RP, 2001, J DERMATOL SCI, V27, P82, DOI 10.1016/S0923-1811(01)00105-0; Di Como CJ, 2002, CLIN CANCER RES, V8, P494; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Duijf PHG, 2002, HUM MOL GENET, V11, P799, DOI 10.1093/hmg/11.7.799; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Glickman JN, 2001, HUM PATHOL, V32, P1157, DOI 10.1053/hupa.2001.28951; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hu H, 2002, INT J CANCER, V102, P580, DOI 10.1002/ijc.10739; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishida S, 2000, JPN J CANCER RES, V91, P174, DOI 10.1111/j.1349-7006.2000.tb00929.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Klein C, 2001, J BIOL CHEM, V276, P37390, DOI 10.1074/jbc.M103801200; Lee LA, 1999, J INVEST DERMATOL, V113, P146, DOI 10.1046/j.1523-1747.1999.00651.x; Liefer KM, 2000, CANCER RES, V60, P4016; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moll UM, 2001, BBA-REV CANCER, V1552, P47, DOI 10.1016/S0304-419X(01)00036-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Parsa R, 1999, J INVEST DERMATOL, V113, P1099, DOI 10.1046/j.1523-1747.1999.00780.x; Patturajan M, 2002, CANCER CELL, V1, P369, DOI 10.1016/S1535-6108(02)00057-0; Pelosi G, 2002, J PATHOL, V198, P100, DOI 10.1002/path.1166; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; Reis JS, 2002, J CUTAN PATHOL, V29, P517, DOI 10.1034/j.1600-0560.2002.290902.x; Senoo M, 2002, ONCOGENE, V21, P2455, DOI 10.1038/sj.onc.1205330; Senoo M, 1998, BIOCHEM BIOPH RES CO, V248, P603, DOI 10.1006/bbrc.1998.9013; Senoo M, 2001, BRIT J CANCER, V84, P1235, DOI 10.1054/bjoc.2000.1735; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shimada A, 1999, CANCER RES, V59, P2781; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Veri MC, 2001, MOL CELL BIOL, V21, P6939, DOI 10.1128/MCB.21.20.6939-6950.2001; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WEINBERG WC, 1994, CANCER RES, V54, P5584; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	49	128	133	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 5	2003	22	23					3635	3644		10.1038/sj.onc.1206536	http://dx.doi.org/10.1038/sj.onc.1206536			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	687WD	12789272				2022-12-17	WOS:000183399200014
J	Sugiyama, K; Sugiura, K; Hara, T; Sugimoto, K; Shima, H; Honda, K; Furukawa, K; Yamashita, S; Urano, T				Sugiyama, K; Sugiura, K; Hara, T; Sugimoto, K; Shima, H; Honda, K; Furukawa, K; Yamashita, S; Urano, T			Aurora-B associated protein phosphatases as negative regulators of kinase activation	ONCOGENE			English	Article						Aurora-B; historic H3; protein phosphatase; okadaic acid; substrate specificity	HISTONE H3 PHOSPHORYLATION; MITOTIC CHROMOSOME CONDENSATION; CATALYTIC SUBUNIT; SIGNALING PATHWAY; CENTRAL SPINDLE; CELL-DIVISION; IDENTIFICATION; CYTOKINESIS; MITOSIS; COMPLEX	The human serine/threonine kinase Aurora-B is structurally related to the protein kinase Ip11p from S cerevisiae and aurora from Drosophila melanogaster, which are key regulators of mitosis. The present study shows that human Aurora-B is activated by okadaic acid and forms complexes with the protein serine/threonine phosphatase type I (PP1) or PP2A, but not with PP5. These data identified Aurora-B associated protein phosphatases as negative regulators of kinase activation. We then used a series of substrates based on a histone H3 phosphorylation site (residues 5-15) to determine the substrate specificity of human Aurora-B. We found that this enzyme is an arginine-directed kinase that can phosphorylate histone H3 at serines 10 and 28 in vitro, suggesting that human Aurora-B is a mitotic histone H3 kinase.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagasaki Univ, Sch Med, Dept Nat Med, Atom Bomb Dis Inst, Nagasaki 8528523, Japan; Osaka Prefecture Univ, Div Appl Biochem, Grad Sch Agr & Biol Sci, Sakai, Osaka 5998531, Japan; Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Nagoya University; Nagasaki University; Osaka Metropolitan University; Hokkaido University	Urano, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4660065, Japan.	turano@med.nagoya-u.ac.jp	Yamashita, Shunichi/GVS-9508-2022; Sugiura, Kazumitsu/M-8913-2014	Sugiura, Kazumitsu/0000-0002-5207-4592; Yamashita, Shunichi/0000-0001-6399-6261; Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 1998, J CELL BIOL, V141, P1207, DOI 10.1083/jcb.141.5.1207; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; Cheng AY, 2000, J BIOL CHEM, V275, P1846, DOI 10.1074/jbc.275.3.1846; Chinkers M, 2001, TRENDS ENDOCRIN MET, V12, P28, DOI 10.1016/S1043-2760(00)00335-0; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Giet R, 2001, J CELL BIOL, V152, P669, DOI 10.1083/jcb.152.4.669; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 1999, J BIOL CHEM, V274, P25543, DOI 10.1074/jbc.274.36.25543; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARDIE DG, 1991, METHOD ENZYMOL, V201, P469; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; ISHIZAKA Y, 1992, ONCOGENE, V7, P1441; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Murnion ME, 2001, J BIOL CHEM, V276, P26656, DOI 10.1074/jbc.M102288200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Speliotes EK, 2000, MOL CELL, V6, P211, DOI 10.1016/S1097-2765(00)00023-X; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhong SP, 2001, J BIOL CHEM, V276, P33213, DOI 10.1074/jbc.M103973200	42	128	130	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2002	21	20					3103	3111		10.1038/sj.onc.1205432	http://dx.doi.org/10.1038/sj.onc.1205432			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	548DP	12082625				2022-12-17	WOS:000175373600001
J	Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC				Chauhan, D; Auclair, D; Robinson, EK; Hideshima, T; Li, GL; Podar, K; Gupta, D; Richardson, P; Schlossman, RL; Krett, N; Chen, LB; Munshi, NC; Anderson, KC			Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays	ONCOGENE			English	Article						multiple myeloma; dexamethasone; interleukin-6	NF-KAPPA-B; BRUTONS TYROSINE KINASE; MARROW STROMAL CELLS; GROWTH-FACTOR; INDUCED APOPTOSIS; EXPRESSION; INTERLEUKIN-6; RECEPTOR; TRANSCRIPTION; INDUCTION	Our previous studies have characterized Dexamethasone (Dex)-induced apoptotic signaling pathways in multiple myeloma (MM) cells; however, related transcriptional events are not fully defined. In the present study, gene expression profiles of Dex-treated MM cells were determined using oligonucleotide arrays. Dex triggers early transient induction of many genes involved in cell defense/repair-machinery. This is followed by induction of genes known to mediate cell death and repression of growth/survival-related genes. The molecular and genetic alterations associated with Dex resistance in MM cells are also unknown. We compared the gene expression profiles of Dex-sensitive and Dex-resistant MM cells and identified a number of genes which may confer Dex-resistance. Finally, gene profiling of freshly isolated MM patient cells validates our in vitro MM cell line data, confirming an in vivo relevance of these studies. Collectively, these findings provide insights into the basic mechanisms of Dex activity against MM, as well as mechanisms of Dex-resistance in MM cells. These studies may therefore allow improved therapeutic uses of Dex, based upon targeting genes that regulate MM cell growth and survival.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Northwestern Univ, Med Sch, Robert H Lurie Canc Ctr, Chicago, IL USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol Jerome Lipper Multiple, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANIAN R, 1992, BLOOD, V80, P887; Anderson KC, 1999, SEMIN HEMATOL, V36, P14; ANDERSON KC, 1989, BLOOD, V73, P1915; Anderson KC, 2001, SEMIN HEMATOL, V38, P286, DOI 10.1053/shem.2001.26010; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; CHAUDHRY A, 1994, ANTICANCER RES, V14, P2085; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, J BIOL CHEM, V272, P29995, DOI 10.1074/jbc.272.48.29995; CHAUHAN D, 1994, CANCER RES, V54, P2234; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, APOPTOSIS, V6, P47, DOI 10.1023/A:1009620027205; CHAUHAN D, 1993, BLOOD, V81, P1540; Chauhan D, 2000, J BIOL CHEM, V275, P27845; Combadiere C, 1998, J BIOL CHEM, V273, P23799, DOI 10.1074/jbc.273.37.23799; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Desai SD, 2000, ANN NY ACAD SCI, V922, P306; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feinman R, 1999, BLOOD, V93, P3044; Fischer CP, 1996, ANN SURG, V223, P610, DOI 10.1097/00000658-199605000-00017; Fraticelli P, 2001, J CLIN INVEST, V107, P1173, DOI 10.1172/JCI11517; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; GOLDMANLEIKIN RE, 1989, J LAB CLIN MED, V113, P335; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HARDIN J, 1994, BLOOD, V84, P3063; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; JUGEMORINEAU N, 1995, BRIT J HAEMATOL, V90, P707, DOI 10.1111/j.1365-2141.1995.tb05605.x; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KLEIN B, 1989, BLOOD, V73, P517; Kohler HBK, 2001, VET DERMATOL, V12, P129, DOI 10.1046/j.1365-3164.2001.00237.x; Krett NL, 1997, CLIN CANCER RES, V3, P1781; Kudoh K, 2000, CANCER RES, V60, P4161; Levy Y, 1996, CLIN EXP IMMUNOL, V104, P167, DOI 10.1046/j.1365-2249.1996.d01-637.x; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Matsuda S, 2001, FEBS LETT, V497, P67, DOI 10.1016/S0014-5793(01)02436-X; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MOALLI PA, 1993, CANCER RES, V53, P3877; MOALLI PA, 1992, BLOOD, V79, P213; Mori S, 1998, ANTICANCER RES, V18, P4403; Ogata A, 1997, J IMMUNOL, V159, P2212; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rowland TL, 2001, INT IMMUNOPHARMACOL, V1, P49, DOI 10.1016/S0162-3109(00)00265-4; SALMON SE, 1984, CANCER TREAT REP, V68, P117; Smith MR, 1998, BRIT J HAEMATOL, V102, P1090, DOI 10.1046/j.1365-2141.1998.00850.x; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Tassone P, 2000, CELL DEATH DIFFER, V7, P327, DOI 10.1038/sj.cdd.4400635; UCHIYAMA H, 1993, BLOOD, V82, P3712; Urashima M, 1996, BLOOD, V87, P1928; Volin MV, 2001, AM J PATHOL, V159, P1521, DOI 10.1016/S0002-9440(10)62537-0; Wu C, 1999, J BIOL CHEM, V274, P29591, DOI 10.1074/jbc.274.42.29591; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	67	128	131	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1346	1358		10.1038/sj.onc.1205205	http://dx.doi.org/10.1038/sj.onc.1205205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857078				2022-12-17	WOS:000173861000005
J	Vonderheide, RH				Vonderheide, RH			Telomerase as a universal tumor-associated antigen for cancer immunotherapy	ONCOGENE			English	Article						telomerase; hTERT; tumor-associated antigen; immunotherapy	PULSED DENDRITIC CELLS; CATALYTIC SUBUNIT; MELANOMA PATIENTS; T-CELLS; REVERSE-TRANSCRIPTASE; IMMORTAL CELLS; LIFE-SPAN; EXPRESSION; LYMPHOCYTES; VACCINATION	Although the search for pharmacologic inhibitors of telomerase activity represents a promising approach for telomerase-based anti-cancer therapy, the immunological properties of the telomerase reverse transcriptase hTERT suggest that the enzyme is also an attractive target for novel immunotherapies against cancer. Data from both human and murine systems demonstrate that cytotoxic T-lymphocytes (CTL) can recognize peptides derived from TERT and kill TERT-positive tumor cells of multiple histologies. Given the vast overexpression of hTERT in human tumors and its low-level expression in rare normal tissues, clinical trials have begun that test the credentials of hTERT as a broadly applicable target for immunotherapy of cancer.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Vonderheide, RH (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 421 Curie Blvd, Philadelphia, PA 19104 USA.							Arai J, 2001, BLOOD, V97, P2903, DOI 10.1182/blood.V97.9.2903; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Chames P, 2000, P NATL ACAD SCI USA, V97, P7969, DOI 10.1073/pnas.97.14.7969; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Gilboa E, 1999, IMMUNITY, V11, P263, DOI 10.1016/S1074-7613(00)80101-6; Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Heiser A, 2001, CANCER RES, V61, P3388; Heiser A, 2001, J IMMUNOL, V166, P2953, DOI 10.4049/jimmunol.166.5.2953; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Hsu FJ, 1996, NAT MED, V2, P52, DOI 10.1038/nm0196-52; Jager E, 1996, INT J CANCER, V66, P470, DOI 10.1002/(SICI)1097-0215(19960516)66:4<470::AID-IJC10>3.0.CO;2-C; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Liu KB, 1999, P NATL ACAD SCI USA, V96, P5147, DOI 10.1073/pnas.96.9.5147; Liu KB, 2001, J IMMUNOL, V166, P4826, DOI 10.4049/jimmunol.166.8.4826; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Minev B, 2000, P NATL ACAD SCI USA, V97, P4796, DOI 10.1073/pnas.070560797; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Pittet MJ, 1999, J EXP MED, V190, P705, DOI 10.1084/jem.190.5.705; Ramakrishnan S, 1998, CANCER RES, V58, P622; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Schirle M, 2000, EUR J IMMUNOL, V30, P2216, DOI 10.1002/1521-4141(2000)30:18<2216::AID-IMMU2216>3.3.CO;2-F; Schultze JL, 2001, TRENDS IMMUNOL, V22, P516, DOI 10.1016/S1471-4906(01)02015-4; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Simon RM, 2001, J CLIN ONCOL, V19, P1848, DOI 10.1200/JCO.2001.19.6.1848; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Valmori D, 1999, CANCER RES, V59, P4050; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANPEL A, 1995, IMMUNOL REV, V145, P229, DOI 10.1111/j.1600-065X.1995.tb00084.x; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Vonderheide RH, 2001, CLIN CANCER RES, V7, P3343; Vonderheide RH, 1999, IMMUNITY, V10, P673, DOI 10.1016/S1074-7613(00)80066-7; Yasumoto S, 1996, ONCOGENE, V13, P433; Yee C, 2000, J EXP MED, V192, P1637, DOI 10.1084/jem.192.11.1637; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	47	128	149	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					674	679		10.1038/sj.onc.1205074	http://dx.doi.org/10.1038/sj.onc.1205074			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850795				2022-12-17	WOS:000173390500022
J	Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL				Eischen, CM; Packham, G; Nip, J; Fee, BE; Hiebert, SW; Zambetti, GP; Cleveland, JL			Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1	ONCOGENE			English	Article						c-Myc; E2F-1; Bcl-2; Bcl-X-L; myeloid; apoptosis	CELL-CYCLE ARREST; S-PHASE ENTRY; WILD-TYPE P53; MEDIATED APOPTOSIS; P53-DEPENDENT APOPTOSIS; ORNITHINE-DECARBOXYLASE; TRANSCRIPTION FACTORS; HEMATOPOIETIC-CELLS; SEPARABLE FUNCTIONS; RAT FIBROBLASTS	Malignant transformation occurs in cells that overexpress c-Myc or that inappropriately activate E2F-1. Transformation occurs after the selection of cells that have acquired resistance to apoptosis that is triggered by these oncogenes, and a key mediator of this cell death process is the p53 tumor suppressor. In IL-3-dependent immortal 32D.3 myeloid cells the ARF/p53 apoptotic pathway is inactivated, as these cells fail to express ARF. Nonetheless, both c-Myc and E2F-1 overexpression accelerated apoptosis when these cells were deprived of IL-3. Here we report that c-Myc or E2F-1 overexpression suppresses Bcl-2 protein and RNA levels, and that restoration of Bcl-2 protein effectively blocks the accelerated apoptosis that occurs when c-Myc- or E2F-1-overexpressing cells are deprived of IL-3. Blocking p53 activity with mutant p53 did not abrogate E2F-1-induced suppression of Bcl-2. Analysis of immortal myeloid cells engineered to overexpress c-Myc and E2F-1 DNA binding mutants revealed that DNA binding activity of these oncoproteins is required to suppress Bcl-2 expression. These results suggest that the targeting of Bcl-2 family members is an important mechanism of oncogene-induced apoptosis, and that this occurs independent of the ARF/p53 pathway.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Southampton Gen Hosp, CRC, Wessex Med Oncol Unit, Southampton SO16 6YD, Hants, England; Unilever Res US, Edgewater, NJ 07020 USA; Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Southampton; Unilever; Vanderbilt University; University of Tennessee System; University of Tennessee Health Science Center	Cleveland, JL (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.	john.cleveland@stjude.org	Zambetti, Gerard/N-8093-2018	Zambetti, Gerard/0000-0002-0929-5007; Packham, Graham/0000-0002-9232-5691	NCI NIH HHS [CA64140, CA76379, CA77274, CA81695, CA63260, CA-21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA081695, R01CA064140, R01CA063260, R01CA076379, R01CA077274, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Baudino TA, 2001, MOL CELL BIOL, V21, P691, DOI 10.1128/MCB.21.3.691-702.2001; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dai HQ, 1999, CANCER RES, V59, P4944; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Grillot DAM, 1996, J EXP MED, V183, P381, DOI 10.1084/jem.183.2.381; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HERMEKING H, 1995, ONCOGENE, V11, P1409; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; HSU B, 1995, ONCOGENE, V11, P175; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kataoka M, 2000, ONCOGENE, V19, P1589, DOI 10.1038/sj.onc.1203466; KATO J, 1993, GENE DEV, V7, P331; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lee LA, 1996, J CLIN INVEST, V97, P1687, DOI 10.1172/JCI118595; Lenahan MK, 1996, ONCOGENE, V12, P1847; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lilly M, 1999, ONCOGENE, V18, P4022, DOI 10.1038/sj.onc.1202741; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Mitchell KO, 2000, CANCER RES, V60, P6318; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Nip J, 2001, ONCOGENE, V20, P910, DOI 10.1038/sj.onc.1204171; O'Connor L, 2000, CURR OPIN CELL BIOL, V12, P257, DOI 10.1016/S0955-0674(99)00084-8; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; Packham G, 1997, ONCOGENE, V15, P1219, DOI 10.1038/sj.onc.1201273; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sakamuro D, 1995, ONCOGENE, V11, P2411; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strom DK, 1998, CELL GROWTH DIFFER, V9, P59; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	76	128	130	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					6983	6993		10.1038/sj.onc.1204892	http://dx.doi.org/10.1038/sj.onc.1204892			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704823				2022-12-17	WOS:000171739300002
J	Drane, P; Bravard, A; Bouvard, V; May, E				Drane, P; Bravard, A; Bouvard, V; May, E			Reciprocal down-regulation of p53 and SOD2 gene expression - implication in p53 mediated apoptosis	ONCOGENE			English	Article						p53; superoxide dismutase; apoptosis; gene regulation; NF-kappa B	MANGANESE SUPEROXIDE-DISMUTASE; WILD-TYPE P53; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; NF-KAPPA-B; TRANSCRIPTIONAL REPRESSION; DNA-BINDING; IN-VIVO; MALIGNANT PHENOTYPE; OXIDATIVE STRESS	p53 regulates the transcription of a number of genes among which are different redox-related genes. It has been proposed that these genes can induce a cellular oxidative stress leading to p53-dependent apoptosis (Polyak er al., 1997). MnSOD, the product of superoxide dismutase 2 (SOD2) gene, is one of the major cellular defences against oxidative stress. We demonstrate here that p53 is able to repress SOD2 gene expression and that this repression takes place at promoter level. We show the importance of this regulation for the p53 function, by demonstrating that an overexpression of MnSOD decreases p53-mediated induction of apoptosis. Moreover, we demonstrate that MnSOD overexpression decreases p53-gene expression at the promoter level. These findings raise the hypothesis that p53 and SOD2 genes are mutually regulated leading to the modulation of various cellular processes including apoptosis.	CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, F-92265 Fontenay Aux Roses, France; CEA, Lab Radiobiol Cellulaire, DRR, DSV, F-92265 Fontenay Aux Roses, France	CEA; Centre National de la Recherche Scientifique (CNRS); CEA	May, E (corresponding author), CEA, Lab Cancerogenese Mol, CNRS,UMR 217, DRR,DSV, BP6, F-92265 Fontenay Aux Roses, France.			BRAVARD, Anne/0000-0002-0314-9092				BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; Borgstahl GEO, 1996, BIOCHEMISTRY-US, V35, P4287, DOI 10.1021/bi951892w; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Chernov MV, 1998, P NATL ACAD SCI USA, V95, P2284, DOI 10.1073/pnas.95.5.2284; Cho G, 1997, BIOCHEM MOL BIOL INT, V42, P949; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CHURCH SL, 1992, GENOMICS, V14, P823, DOI 10.1016/S0888-7543(05)80202-2; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Dugimont T, 1998, ONCOGENE, V16, P2395, DOI 10.1038/sj.onc.1201742; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Frei B, 1999, FASEB J, V13, P963, DOI 10.1096/fasebj.13.9.963; Furlong EEM, 1996, MOL CELL BIOL, V16, P5933; Hellin AC, 1998, ONCOGENE, V16, P1187, DOI 10.1038/sj.onc.1201638; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Huang TT, 1999, ANN NY ACAD SCI, V893, P95, DOI 10.1111/j.1749-6632.1999.tb07820.x; Huang YH, 1997, FREE RADICAL BIO MED, V23, P314, DOI 10.1016/S0891-5849(97)00095-6; Iotsova V, 1996, ONCOGENE, V13, P2331; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; Kaluzova M, 2000, BBA-GENE STRUCT EXPR, V1491, P20, DOI 10.1016/S0167-4781(00)00015-4; Kiningham KK, 1999, FASEB J, V13, P1601, DOI 10.1096/fasebj.13.12.1601; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Kuo SY, 1999, J BIOL CHEM, V274, P3345, DOI 10.1074/jbc.274.6.3345; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Lee SG, 2000, ONCOGENE, V19, P468, DOI 10.1038/sj.onc.1203312; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LI JJ, 1995, ONCOGENE, V10, P1989; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCORD JM, 1969, J BIOL CHEM, V244, P6056; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Oberley TD, 1997, HISTOL HISTOPATHOL, V12, P525; Ori A, 1998, EMBO J, V17, P544, DOI 10.1093/emboj/17.2.544; Pani G, 2000, CANCER RES, V60, P4654; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; PRICE BD, 1993, ONCOGENE, V8, P3055; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Shatrov VA, 2000, INT J CANCER, V85, P93, DOI 10.1002/(SICI)1097-0215(20000101)85:1<93::AID-IJC17>3.0.CO;2-I; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheng-Tanner X, 1998, RADIAT RES, V150, P636, DOI 10.2307/3579886; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Wang QJ, 1998, CANCER RES, V58, P5762; Wenk J, 1999, J BIOL CHEM, V274, P25869, DOI 10.1074/jbc.274.36.25869; WISPE JR, 1989, BIOCHIM BIOPHYS ACTA, V994, P30, DOI 10.1016/0167-4838(89)90058-7; WU HY, 1994, J BIOL CHEM, V269, P20067; YonishRouach E, 1995, ONCOGENE, V11, P2197; Zhao RB, 2000, GENE DEV, V14, P981; Zhong WX, 1997, ONCOGENE, V14, P481, DOI 10.1038/sj.onc.1200852	63	128	135	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2001	20	4					430	439		10.1038/sj.onc.1204101	http://dx.doi.org/10.1038/sj.onc.1204101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395DB	11313974				2022-12-17	WOS:000166562500003
J	Ruediger, R; Pham, HT; Walter, G				Ruediger, R; Pham, HT; Walter, G			Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the A alpha subunit gene	ONCOGENE			English	Article						PP2A; A alpha subunit; mutation; human cancer; tumor suppressor	SERINE THREONINE PHOSPHATASES; REGULATORY B-SUBUNITS; PP2A CORE ENZYME; MOLECULAR-CLONING; CATALYTIC SUBUNIT; SEQUENCE-ANALYSIS; TUMOR-ANTIGENS; OKADAIC ACID; PPP2R1B GENE; T-ANTIGENS	The A subunit of protein phosphatase 2A (PP2A) consists of 15 nonidentical repeats. The catalytic C subunit binds to C-terminal repeats 11-15 and regulatory B subunits bind to N-terminal repeats 1-10, Recently, four cancer-associated mutants of the A alpha subunit have been described: Glu64-->Asp in lung carcinoma, Glu64 --> Gly in breast carcinoma, Arg418 --> Trp in melanoma, and Delta 171-589 in breast carcinoma, Based on our model of PP2A, we predicted that Glu64-->Asp and Glu64-->Gly might be defective in B subunit binding, whereas Arg418-->Trp and Delta 171 - 589 might bind neither B nor C subunits, We generated these mutants by site-directed mutagenesis and assayed their ability to associate with different forms of B subunits (B, B', B") or with the catalytic C subunit, The results demonstrate that all mutants are defective in binding either B or B and C subunits, Specifically, the N-terminal mutants, Glu64-->Asp and Glu64-->Gly, are defective in B' but normal in B, B", and C subunit binding, whereas the C-terminal mutants Arg418-->Trp and Delta 171-589 bind none of the B subunits nor the C subunit, The implications of these findings with regard to the potential role of PP2A as a tumor suppressor are discussed.	Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Walter, G (corresponding author), Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA.				NATIONAL CANCER INSTITUTE [R01CA036111] Funding Source: NIH RePORTER; NCI NIH HHS [CA-36111] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Bienz M, 1999, CURR OPIN GENET DEV, V9, P595, DOI 10.1016/S0959-437X(99)00016-7; Brewis N, 2000, AM J PHYSIOL-HEART C, V279, pH1307, DOI 10.1152/ajpheart.2000.279.3.H1307; Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389; Campbell IG, 1999, ONCOGENE, V18, P6367, DOI 10.1038/sj.onc.1203070; CEGIELSKA A, 1994, MOL CELL BIOL, V14, P4616, DOI 10.1128/MCB.14.7.4616; CHEN SC, 1989, J BIOL CHEM, V264, P7267; COHEN P, 1989, J BIOL CHEM, V264, P21435; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KITAGAWA Y, 1988, BIOCHIM BIOPHYS ACTA, V951, P123, DOI 10.1016/0167-4781(88)90032-2; Kremmer E, 1997, MOL CELL BIOL, V17, P1692, DOI 10.1128/MCB.17.3.1692; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Nagase T, 1997, J BIOCHEM, V122, P178; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; Ruediger R, 1997, VIROLOGY, V238, P432, DOI 10.1006/viro.1997.8873; Ruediger R, 1999, J VIROL, V73, P839, DOI 10.1128/JVI.73.1.839-842.1999; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; SILVA OBD, 1987, FEBS LETT, V221, P415, DOI 10.1016/0014-5793(87)80966-3; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268; Tanabe O, 1996, FEBS LETT, V379, P107, DOI 10.1016/0014-5793(95)01500-0; Tehrani MA, 1996, J BIOL CHEM, V271, P5164; Turowski P, 1997, EUR J BIOCHEM, V248, P200, DOI 10.1111/j.1432-1033.1997.t01-1-00200.x; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	45	128	134	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2001	20	1					10	15		10.1038/sj.onc.1204059	http://dx.doi.org/10.1038/sj.onc.1204059			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	391NE	11244497				2022-12-17	WOS:000166361400002
J	Benistant, C; Chapuis, H; Roche, S				Benistant, C; Chapuis, H; Roche, S			A specific function for phosphatidylinositol 3-kinase alpha (p85 alpha-p110 alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85 alpha-p110 beta) in de novo DNA synthesis of human colon carcinoma cells	ONCOGENE			English	Article						phosphatidylinositol 3-kinase; intracellular signalling; carcinoma; DNA synthesis; apoptosis	PHOSPHOINOSITIDE 3-OH KINASE; SIGNALING PATHWAY; LYSOPHOSPHATIDIC-ACID; CATALYTIC SUBUNIT; ACTIVATION; PROTEIN; GAMMA; RAS; TRANSFORMATION; CANCER	We have previously shown an important function of phosphatidylinositol 3-kinase (PI3K)alpha(p85 alpha-p110 alpha) and PI3K beta (p85-alpha-p110 beta) for DNA synthesis induced by various mitogens in non transformed fibroblasts and we now report a specific role of these enzymes in human colon cancer cell growth. Using antibodies specific to p110 alpha and to p110 beta catalytic subunits, increase in PI3K alpha and PI3K beta activities,vas detected in 15/19 human tumour biopsies relative to adjacent normal mucosa of human colon and bladder. Increase in such activities was also observed in adenocarcinoma cell lines CaCo2, CO115, HCT 116, LS 174T and WiDr relative to nontransformed fibroblasts. Maximal PI3K alpha activity was observed for LS 174T and PI3K beta activity for WiDr cells. This was partly correlated with an increase in p110 alpha and p110 beta protein levels both in some primary tumours and established cell lines, suggesting that PI3K overexpression is involved in enzymatic deregulation. Functional consequence of such activation was assessed by a microinjection approach. An injection of neutralizing antibody specific to p110 beta in WiDr, HCT116 and CO 115 cells inhibited de novo DNA synthesis, whereas antibodies specific to p110 gamma had no effect. Neutralizing antibodies specific to p110 alpha induced apoptosis, a response that was reverted by treating cells with the caspase inhibitor z-VAD-fmk. However anti-p110 beta and anti-p110 gamma antibodies did not affect cell survival, We concluded that PI3K alpha and PI3K beta play important roles in human colon cancer cell growth with a specific function for PI3K beta in de novo DNA synthesis and an involvement of PI3K alpha in cell survival.	CRBM, CNRS, UPR 1086, F-34293 Montpellier 05, France; Ctr Hosp Univ, Dept Anathomopathol, Nimes, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; CHU de Nimes	Roche, S (corresponding author), CRBM, CNRS, UPR 1086, 1919 Route Mende, F-34293 Montpellier 05, France.		Benistant, Christine/M-5771-2018	roche, serge/0000-0003-3413-3859				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Gershtein ES, 1999, CLIN CHIM ACTA, V287, P59, DOI 10.1016/S0009-8981(99)00118-7; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Graves JD, 1995, ANN NY ACAD SCI, V766, P320, DOI 10.1111/j.1749-6632.1995.tb26684.x; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kurosu H, 1997, J BIOL CHEM, V272, P24252, DOI 10.1074/jbc.272.39.24252; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; Moore SM, 1998, CANCER RES, V58, P5239; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Phillips WA, 1998, CANCER, V83, P41, DOI 10.1002/(SICI)1097-0142(19980701)83:1<41::AID-CNCR6>3.0.CO;2-H; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROCHE S, 1994, BIOCHEM J, V301, P703, DOI 10.1042/bj3010703; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	35	128	162	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5083	5090		10.1038/sj.onc.1203871	http://dx.doi.org/10.1038/sj.onc.1203871			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042696				2022-12-17	WOS:000089930100005
J	Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G				Bruni, P; Boccia, A; Baldassarre, G; Trapasso, F; Santoro, M; Chiappetta, G; Fusco, A; Viglietto, G			PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27(kip1)	ONCOGENE			English	Article						PTEN; thyroid cancer; growth suppression; AKT; p27(kip1)	TUMOR-SUPPRESSOR; COWDEN-DISEASE; GLIOBLASTOMA CELLS; PROSTATE-CANCER; GENE; MUTATION; PTEN/MMAC1; SURVIVAL; PROTEIN; PKB/AKT	The dual-specificity phosphatase PTEN/MMAC1/TEP1 has recently been identified as the tumor suppressor gene most frequently mutated and/or deleted in human tumors. Germline mutations of PTEN give rise to Cowden Disease (CD), an autosomal dotninantly-inherited cancer syndrome which predisposes to increased risk of developing breast and thyroid tumors. However, PTEN mutations have rarely been detected in sporadic thyroid carcinomas. In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened. However, we report that PTEN expression is reduced both at the mRNA and at the protein level - in five out of eight tumor-derived cell Lines and in 24 out of 61 primary tumors. In most cases, decreased PTEN expression is correlated with increased phosphorylation of the P-TEN-regulated protein kinase Akt/PKB. Moreover, we demonstrate that PTEN may act as a suppressor of thyroid cancerogenesis as the constitutive re-expression of PTEN into two different thyroid tumor cell lines markedly inhibits cell growth. PTEN-dependent inhibition of BrdU incorporation is accompanied by enhanced expression of the cyclin-dependent kinase inhibitor p27(kip1) and can be overcome by simultaneous co-transfection of an excess p27(kip1) antisense plasmid Accordingly, in a subset of thyroid primary carcinomas and tumor-derived cell Lines, a striking correlation between PTEN expression and the level of p27(kip1) protein was observed, In conclusion, our findings demonstrate that inactivation of PTEN may play a role in the development of sporadic thyroid carcinomas and that one key target of PTEN suppressor activity is represented by the cyclin-dependent kinase inhibitor p27(kip1).	Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, I-80131 Naples, Italy; Ist Nazl Tumori, Serv Oncol Sperimentale E, I-80131 Naples, Italy; Univ Magna Groecia, Fac Med & Chirurg Catanzaro, Dipartimento Med Sperimentale & Clin, I-88100 Catanzaro, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Magna Graecia University of Catanzaro	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dip BIol & Patol Cellulare & Mol, CNR,Ctr Endocrinol & Oncol Superimentale, Via S Pansini 5, I-80131 Naples, Italy.		Viglietto, Giuseppe/AAC-2852-2019; Baldassarre, Gustavo/K-1350-2016	Viglietto, Giuseppe/0000-0003-2327-7515; Baldassarre, Gustavo/0000-0002-9750-8825; Fusco, Alfredo/0000-0003-3332-5197				Baldassarre G, 1999, J CLIN INVEST, V104, P865, DOI 10.1172/JCI6443; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheney IW, 1998, CANCER RES, V58, P2331; Cheyney IW, 1999, CANCER RES, V59, P2318; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Dahia PLM, 1997, CANCER RES, V57, P4710; DAMING L, 1998, P NATL ACAD SCI USA, V95, P15406; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; Eng C, 1998, INT J ONCOL, V12, P701; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; HANSSEN AMN, 1995, J MED GENET, V32, P117, DOI 10.1136/jmg.32.2.117; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Longy M, 1996, ANN GENET-PARIS, V39, P35; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Rasheed BKA, 1997, CANCER RES, V57, P4187; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Scala S, 1998, INT J ONCOL, V13, P665; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246	35	128	143	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2000	19	28					3146	3155		10.1038/sj.onc.1203633	http://dx.doi.org/10.1038/sj.onc.1203633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KX	10918569				2022-12-17	WOS:000088019200003
J	Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC				Xia, WY; Lau, YK; Hu, MCT; Li, L; Johnston, DA; Sheng, SJ; El-Naggar, AK; Hung, MC			High tumoral maspin expression is associated with improved survival of patients with oral squamous cell carcinoma	ONCOGENE			English	Article						cancer; maspin; protease inhibitor; tumor suppressor	CANCER CELLS; GENE MASPIN; NECK-CANCER; HEAD; OVEREXPRESSION; SUPPRESSOR; SERPIN; P53; AMPLIFICATION; MUTATION	Maspin, a member of the serpin family of protease inhibitors, is known to have tumor-suppressor functions, However, the association between its expression level and survival has not been demonstrated in human cancer. Using the immunohistochemical technique to examine the expression levels of maspin in 44 cases of oral squamous cell carcinoma (SCC), we found that 66% of the cases expressed low to intermediate levels of maspin and 34% of the cases expressed high levels of maspin, We further examined maspin protein expression in a series of sis SCC cell lines from the head and neck, and found that all but one expressed low or no maspin protein. We also compared the clinicopathological features of the oral SCC cases with the maspin expression level, and found that high maspin expression was associated with the absence of lymph node metastasis, More importantly,,ve showed that higher maspin expression was significantly associated with better rates of overall survival, suggesting that high maspin expression may be a favorable prognostic marker for oral SCC.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Shanghai Second Med Univ, Peoples Hosp 9, Dept Oral Pathol, Shanghai, Peoples R China; Wayne State Univ, Dept Pathol, Detroit, MI 48201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Shanghai Jiao Tong University; Wayne State University	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd,Box 108, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740				AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; BERENSON JR, 1989, ONCOGENE, V4, P1111; FIELD JK, 1989, ONCOGENE, V4, P1463; Pemberton PA, 1997, J HISTOCHEM CYTOCHEM, V45, P1697, DOI 10.1177/002215549704501213; Sager R, 1996, CURR TOP MICROBIOL, V213, P51; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SHENG SJ, 1994, J BIOL CHEM, V269, P30988; Sheng SJ, 1998, P NATL ACAD SCI USA, V95, P499, DOI 10.1073/pnas.95.2.499; SOMERS KD, 1992, CANCER RES, V52, P5997; Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949; Umekita Y, 1997, CANCER LETT, V113, P87, DOI 10.1016/S0304-3835(97)04600-4; WATLING DL, 1992, HEAD NECK-J SCI SPEC, V14, P437, DOI 10.1002/hed.2880140603; Xia WY, 1997, CLIN CANCER RES, V3, P3; YAMAMOTO T, 1986, CANCER RES, V46, P414; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	17	128	138	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2398	2403		10.1038/sj.onc.1203535	http://dx.doi.org/10.1038/sj.onc.1203535			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828881				2022-12-17	WOS:000087018400004
J	Pandita, TK; Lieberman, HB; Lim, DS; Dhar, S; Zheng, W; Taya, Y; Kastan, MB				Pandita, TK; Lieberman, HB; Lim, DS; Dhar, S; Zheng, W; Taya, Y; Kastan, MB			Ionizing radiation activates the ATM kinase throughout the cell cycle	ONCOGENE			English	Article						ATM; p53; kinase activity; cell cycle	ATAXIA-TELANGIECTASIA CELLS; DNA-DAMAGE; CHECKPOINT PATHWAY; P53; PHOSPHORYLATION; GENE; PROTEIN; CANCER; REPAIR; REGION	The ATM protein kinase is a critical intermediate in a number of cellular responses to ionizing irradiation (IR) and possibly other stresses. ATM dysfunction results in abnormal checkpoint responses in multiple phases of the cell cycle, including ct, S and G2, Though downstream targets of the ATM kinase are still being elucidated. it has been demonstrated that ATM acts upstream of p53 in a signal transduction pathway initiated by IR and can phosphorylate p53 at serine 15. The cell cycle stage-specificity of ATM activation and p53Ser15 phosphorylation was investigated in normal lymphoblastoid cell line (GM536). Ionizing radiation was found to enhance the kinase activity of ATM in all phases of the cell cycle. This enhanced activity was apparent immediately after treatment of cells with IR, but was not accompanied by a change in the abundance of the ATM protein. Since IR activates the ATM kinase in all phases of the cell cycle, DNA replication-dependent strand breaks are not required for this activation. Further, since p53 protein is not directly required for IR-induced S and GZ-phase checkpoints, the ATM kinase likely has different functional targets in different phases of the cell cycle. These observations indicate that the ATM kinase is necessary primarily for the immediate response to DNA damage incurred in all phases of the cell cycle.	Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38205 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan	Columbia University; St Jude Children's Research Hospital; National Cancer Center - Japan	Pandita, TK (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Radiol Res, 630 W 168th St, New York, NY 10032 USA.		Pandita, Tej K/AAM-9188-2020; Lim, Dae-Sik/C-1599-2011	Lim, Dae-Sik/0000-0003-2356-7555	NCI NIH HHS [CA71387] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline; NINDS NIH HHS [NS34746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BRIDGES BA, 1982, ATAXIA TELANGIECTASI; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; HARNDEN DG, 1994, INT J RADIAT BIOL, V66, pS13, DOI 10.1080/09553009414551811; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hawley RS, 1996, GENE DEV, V10, P2383, DOI 10.1101/gad.10.19.2383; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Maki CG, 1996, CANCER RES, V56, P2649; Morgan SE, 1997, MOL CELL BIOL, V17, P2020, DOI 10.1128/MCB.17.4.2020; Morgan SE, 1997, CANCER RES, V57, P3386; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1992, RADIAT RES, V131, P214, DOI 10.2307/3578443; Pandita TK, 1999, MOL CELL BIOL, V19, P5096; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smilenov LB, 1999, MOL CELL BIOL, V19, P6963; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401	25	128	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 9	2000	19	11					1386	1391		10.1038/sj.onc.1203444	http://dx.doi.org/10.1038/sj.onc.1203444			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723129				2022-12-17	WOS:000085942700003
J	Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D				Sangfelt, O; Erickson, S; Castro, J; Heiden, T; Gustafsson, A; Einhorn, S; Grander, D			Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins	ONCOGENE			English	Article						interferon; cell cycle; cyclin-dependent kinase inhibitors; pocket proteins	CELL-CYCLE ARREST; DEPENDENT KINASE INHIBITORS; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; TGF-BETA; P21; P27(KIP1); P107; PHOSPHORYLATION; SUPPRESSION	One prominent effect of IFNs is their cell growth-inhibitory activity. The mechanism behind this Inhibition of proliferation is still not fully understood. In this study, the effect of IFN-alpha treatment on cell cycle progression has been analysed in three lymphoid cell lines, Daudi, U-266 and H9, Examination of the growth-arrested cell populations shows that Daudi cells accumulate in a G0-like state, whereas U-266 cells arrest later in G1, H9 cells are completely resistant to IFN-alpha's cell growth-inhibitory effects. The G0/G1-phase arrest is preceded by a rapid induction of the ca clin-dependent kinase inhibitors (CKIs), p21 and p15, In parallel, the activities of the G1 Cdks are significantly reduced. In addition to p21/p15 induction, IFN-alpha regulates the expression of another CKI, p27, presumably by a post-transcriptional mechanism. In the G1 Cdk-complexes, there is first an increased binding of p21 and p15 to their respective kinases. At longer exposure times, when Cdk-bound p15 and p21 decline, p27 starts to accumulate. Furthermore, we found that IFN-alpha not only suppresses the phosphorylation of pRb, but also alters the phosphorylation and expression of the other pocket proteins p130 and p107. These data suggest that induction of p21/p15 is involved in the primary IFN-alpha response inhibiting G1 Cdk activity, whereas increased p27 expression is part of a second set of events which keep these Cdks in their inactive form. Moreover, elevated levels of p27 correlated with a dissociation of cyclin E/Cdk2-p130 or p107 complexes to yield cyclin E/Cdk2-p27 complexes. In resistant H9 cells, which possess a homozygous deletion of the p15/p16 genes and lack p21 protein expression, IFN-alpha causes no detectable changes in p27 expression and, furthermore, no effects are observed on either pocket proteins in this cell line. Taken together, these data suggest that the early decline in G1 Cdk activity, subsequent changes in phosphorylation of pocket proteins, and G1/G0 arrest following IFN-alpha treatment, is not primarily due to loss of the G1 kinase components, but result from the inhibitory action of CKIs on these complexes.	Karolinska Hosp & Inst, Dept Oncol Pathol, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital	Grander, D (corresponding author), Karolinska Hosp, CCK, Res Lab Radiumhemmet, S-17176 Stockholm, Sweden.							APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Brandter LB, 1996, EUR J HAEMATOL, V56, P313; BRENNING G, 1985, SCAND J HAEMATOL, V35, P543; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CORRADINI P, 1994, LEUKEMIA, V8, P758; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DEMAYER E, 1988, INTERFERON OTHER REG; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erickson S, 1998, ONCOGENE, V17, P595, DOI 10.1038/sj.onc.1201965; GERDES J, 1984, J IMMUNOL, V133, P1710; Grander D, 1997, EUR J HAEMATOL, V59, P129; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEIDEN T, 1990, ANTICANCER RES, V10, P1555; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KACZMAREK L, 1986, LAB INVEST, V54, P365; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMCHI A, 1988, MOL CELL BIOL, V8, P2828, DOI 10.1128/MCB.8.7.2828; KIMCHI A, 1992, J CELL BIOCHEM, V50, P1, DOI 10.1002/jcb.240500102; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Mayol X, 1996, ONCOGENE, V13, P237; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Palmero I, 1996, CANCER SURV, V27, P351; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PINES J, 1995, BIOCHEM J, V308, P687; Pokrovskaja K, 1996, CELL GROWTH DIFFER, V7, P1723; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sangfelt O, 1997, CELL GROWTH DIFFER, V8, P343; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shiyanov P, 1996, MOL CELL BIOL, V16, P737; TAYLORPAPADIMIT.J, 1985, INTERFERONS THEIR IM, P81; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	51	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	1999	18	18					2798	2810		10.1038/sj.onc.1202609	http://dx.doi.org/10.1038/sj.onc.1202609			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FK	10362250				2022-12-17	WOS:000080125100002
J	Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA				Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA			Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer	ONCOGENE			English	Article						prostate cancer; alternative splicing; androgen sensitivity; fibroblast growth factor receptors; xenograft cell lines	CARCINOMA CELL-LINE; EPITHELIAL-CELLS; EXPRESSION; GENES; ESTABLISHMENT; SPECIFICITY; CLONING; MODEL; KGF	Progression of prostate cancer from sensitive to androgen insensitive tumor been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer, This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform, We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors, We analysed three web characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice, One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth, Using an RT-PCR based assay, me demonstrated that progressive loss of the FGF-R2(111b) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.	Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Nephrol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Div Urol, Durham, NC USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRIGATI DJ, 1988, J HISTOTECHNOL, V11, P165, DOI 10.1179/his.1988.11.3.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EPSTEIN JI, 1983, HUM PATHOL, V15, P853; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; GRAHAM SD, 1985, PROSTATE, V7, P369, DOI 10.1002/pros.2990070405; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; ISAACS JT, 1978, CANCER RES, V38, P4353; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAIGHN ME, 1979, INVEST UROL, V17, P16; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MANSSON PE, 1989, CANCER RES, V49, P2485; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKEEHAN WL, 1991, CANCER SURV, V11, P165; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	32	128	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3059	3065		10.1038/sj.onc.1201498	http://dx.doi.org/10.1038/sj.onc.1201498			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444954				2022-12-17	WOS:000070968000006
J	Barker, KT; Jackson, LE; Crompton, MR				Barker, KT; Jackson, LE; Crompton, MR			BRK tyrosine kinase expression in a high proportion of human breast carcinomas	ONCOGENE			English	Article						BRK; breast tumour kinase; non-receptor protein tyrosine kinase; breast cancer	GROWTH-FACTOR RECEPTOR; PP60C-SRC PROTEIN-KINASE; MAMMARY-TUMORS; NEU PROTOONCOGENE; TRANSGENIC MICE; PROGNOSTIC VALUE; CELL-LINES; CANCER; INDUCTION; ONCOGENE	BRK is a recently described non receptor protein tyrosine kinase whose mRNA was found to be expressed in human breast tumours and breast cancer cell lines, Expression of BRK in fibroblasts and mammary epithelial cells has been shown to enhance their ability to grow anchorage independently, and mammary epithelial cells expressing BRK acquire a potentiated mitogenic response to epidermal growth factor, In order to investigate further the expression of BRK in breast cancers, we have isolated monoclonal antibodies specifically recognising the protein, Whereas BRK expression was low or undetectable in normal mammary tissue and benign lesions, approximately two-thirds of breast tumours expressed appreciable levels, and 27% of tumours over expressed BRK by fivefold or more (up to 43x), This expression pattern was mirrored in a comparison of cell lines derived either from normal mammary epithelial cells or from carcinomas, BRK expression was found to be constant throughout the cell cycle, and did not vary with cell proliferation rate, A consideration of this expression data, in conjunction with BRK's demonstrated ability to deregulate the proliferation of mammary epithelial cells, supports the hypothesis that the over expression of BRK in a high proportion of breast carcinomas is a functionally important factor in their evolution.	INST CANC RES,SECT CELL BIOL & EXPT PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK								BOLLA M, 1993, BREAST CANCER RES TR, V26, P283, DOI 10.1007/BF00665806; Bosher JM, 1996, ONCOGENE, V13, P1701; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GRIMAUX M, 1989, BREAST CANCER RES TR, V14, P77, DOI 10.1007/BF01805978; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; HENNIPMAN A, 1989, CANCER RES, V49, P516; JACOBS C, 1983, CANCER RES, V43, P1696; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; KAMALATI T, 1996, MAMMARY TUMOUR CELL, P227; LOWER EE, 1993, BREAST CANCER RES TR, V26, P217, DOI 10.1007/BF00665799; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NICHOLSON S, 1991, BRIT J CANCER, V63, P146, DOI 10.1038/bjc.1991.30; NORMANNO N, 1994, BREAST CANCER RES TR, V29, P11, DOI 10.1007/BF00666178; ORMEROD MG, 1994, FLOW CYTOMETRY PRACT, P122; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; ROMAIN S, 1994, BRIT J CANCER, V70, P304, DOI 10.1038/bjc.1994.297; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SAINSBURY JRC, 1987, LANCET, V1, P1398; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Taylor-Papadimitriou J., 1987, The mammary gland. Development, regulation, and function., P181; TOI M, 1989, INT J CANCER, V43, P220, DOI 10.1002/ijc.2910430208; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WHITEHEAD RH, 1983, J NATL CANCER I, V70, P649	32	128	133	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 14	1997	15	7					799	805		10.1038/sj.onc.1201241	http://dx.doi.org/10.1038/sj.onc.1201241			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XQ117	9266966				2022-12-17	WOS:A1997XQ11700006
J	Douville, E; Downward, J				Douville, E; Downward, J			EGF induced SOS phosphorylation in PC12 cells involves P90 RSK-2	ONCOGENE			English	Article						SOS; Rsk; phosphorylation	NUCLEOTIDE EXCHANGE FACTOR; EPIDERMAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX-FORMATION; SIGNAL-TRANSDUCTION; MAP KINASE; S6 KINASE; IN-VIVO; SUBSTRATE RECOGNITION; DEPENDENT ACTIVATION	SOS, the guanine nucleotide exchange factor for Ras, becomes phosphorylated on serine and threonine residues following stimulation of cells with growth factors. These phosphorylations may play a role in negative feedback of Ras stimulation and have been shown to be mediated in part by the MAP kinases Erk-1 and Erk-2. Here we show that in addition to MAP kinase, a major mitogen activated kinase for SOS is p90 Rsk-2, a downstream target of MAP kinase. p90 Rsk-2 phosphorylates SOS in an in gel assay and also in solution in vitro. The ability of p90 Rsk-2 to phosphorylate SOS increases greatly following EGF treatment of PC12 cells and is blocked by expression of N17 Ras or treatment with the MEK inhibitor PD98059. Phosphopeptide mapping revealed that the sites phosphorylated by p90 Rsk-2 in vitro were also phosphorylated in intact cells in response to EGF treatment. Several major sites of in vivo phosphorylation correlated with p90 Rsk-2 phosphorylation sites rather than MAP kinase sites. It is therefore likely that p90 Rsk-2 plays an important role in the down regulation of the Ras activation pathway through SOS.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Byrne JL, 1996, ONCOGENE, V13, P2055; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chen RH, 1996, ONCOGENE, V12, P1493; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CorbalanGarcia S, 1996, ONCOGENE, V12, P1063; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holt KH, 1996, MOL CELL BIOL, V16, P577; Holt KH, 1996, J BIOL CHEM, V271, P8300, DOI 10.1074/jbc.271.14.8300; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KLARLUND JK, 1995, J BIOL CHEM, V270, P23421, DOI 10.1074/jbc.270.40.23421; Klarlund JK, 1996, J BIOL CHEM, V271, P16674, DOI 10.1074/jbc.271.28.16674; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MARTE BM, 1995, ONCOGENE, V10, P167; MARTE BM, 1996, CURR BIOL, V7, P1; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SASTRY L, 1995, ONCOGENE, V11, P1107; SCIMECA JC, 1992, J BIOL CHEM, V267, P17369; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; TOSHIHIRO N, 1996, CELL, V86, P465; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	63	128	129	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	1997	15	4					373	383		10.1038/sj.onc.1201214	http://dx.doi.org/10.1038/sj.onc.1201214			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242373				2022-12-17	WOS:A1997XM23800001
J	Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G				Nielsen, NH; Emdin, SO; Cajander, J; Landberg, G			Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein	ONCOGENE			English	Article						breast cancer; cell cycle; retinoblastoma tumour suppressor protein; cyclins and p16	TUMOR-SUPPRESSOR PROTEIN; D-CDK COMPLEXES; GENE-EXPRESSION; GROWTH-FACTOR; ECTOPIC EXPRESSION; MAMMARY CARCINOMAS; PHASE-TRANSITION; TRANSGENIC MICE; POOR PROGNOSIS; G(1) CONTROL	Inactivation of the retinoblastoma protein (pRB) by mutations or abnormal phosphorylation is a mechanism by which tumour cells can subdue normal growth control. Among molecules involved in control of pRB phosphorylation, cyclin D1 and E have been found to be deregulated and overexpressed in various types of cancers. In order to study the cell cycle regulatory mechanisms in breast cancer, we have analysed the protein expression of cyclin D1 and E in 114 tumour specimens from patients with primary breast cancer using Western blotting. Twenty-five out of 34 tumours with overexpression of cyclin E showed uniform low cyclin D1 expression, and by immunohistochemical analysis of pRB we present evidence for the existence of pRB defects in approximately 40% of these tumours in contrast to no PRE defects in the other group of tumours. This result was supported by a high protein expression of the cyclin-dependent kinase inhibitor p16 in 44% of the tumours with high cyclin E and low D1 expression, and all immunohistochemical pRB defect tumours showed a high p16 protein level. Additionally, an abnormal low pRB phosphorylation in relation to a high proliferative activity and loss of heterozygosity of the retinoblastoma susceptibility gene locus were found in all but one tumour with immunohistochemical defect pRB. Interestingly, tumours with high cyclin E and low D1 expression were generally oestrogen receptor negative suggesting a role for cell cycle regulators in the mechanisms leading to oestrogen independent tumour growth. Furthermore, the prognosis differed markedly for the patients in the various groups of tumours, indicating that the heterogeneous nature of breast cancer pathogenesis and the clinical course in part could be explained by different and distinctive sets of cell cycle defects.	UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT ONCOL,S-90187 UMEA,SWEDEN; UMEA UNIV,DEPT SURG,S-90187 UMEA,SWEDEN	Umea University; Umea University; Umea University								ADNANE J, 1989, ONCOGENE, V4, P1389; AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; BATES S, 1994, ONCOGENE, V9, P1633; BOOKSTEIN R, 1990, NUCLEIC ACIDS RES, V18, P1666, DOI 10.1093/nar/18.6.1666; BORG A, 1991, BRIT J CANCER, V63, P136, DOI 10.1038/bjc.1991.28; BOYNTON RF, 1991, CANCER RES, V51, P5766; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FANTL V, 1990, EUR J CANCER, V26, P423, DOI 10.1016/0277-5379(90)90009-I; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Geng Y, 1996, ONCOGENE, V12, P1173; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HE J, 1994, CANCER RES, V54, P5804; HENRY JA, 1993, INT J CANCER, V53, P774, DOI 10.1002/ijc.2910530512; HERMAN ME, 1994, CANCER RES, V54, P5867; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JIANG W, 1993, ONCOGENE, V8, P3447; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LOVEC H, 1994, ONCOGENE, V9, P323; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1995, CANCER RES, V55, P4818; MCINTOSH GG, 1995, ONCOGENE, V11, P885; Michalides R, 1996, BRIT J CANCER, V73, P728, DOI 10.1038/bjc.1996.128; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; NEVINS JR, 1992, SCIENCE, V258, P424; NIELSEN NH, 1996, IN PRESS BR J CANC; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; RENNER WA, 1995, BIOTECHNOL BIOENG, V47, P476, DOI 10.1002/bit.260470409; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHOTT DR, 1994, CANCER RES, V54, P1393; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; Ueki K, 1996, CANCER RES, V56, P150; VANAGTHOVEN T, 1992, CANCER RES, V52, P5082; VARLEY JM, 1989, ONCOGENE, V4, P725; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WANG NP, 1993, ONCOGENE, V8, P279; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; XU HJ, 1991, ONCOGENE, V6, P1139; YANDELL DW, 1989, AM J HUM GENET, V45, P547; ZHOU P, 1995, ONCOGENE, V11, P517; ZUKERBERG LR, 1995, MODERN PATHOL, V8, P560	73	128	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 23	1997	14	3					295	304		10.1038/sj.onc.1200833	http://dx.doi.org/10.1038/sj.onc.1200833			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WD516	9018115				2022-12-17	WOS:A1997WD51600005
J	Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E				Bourdon, JC; DeguinChambon, V; Lelong, JC; Dessen, P; May, P; Debuire, B; May, E			Further characterisation of the p53 responsive element - Identification of new candidate genes for trans-activation by p53	ONCOGENE			English	Article						consensus sequence; computer search; transactivation; MCK; IGF-BP3	WILD-TYPE P53; DNA-BINDING; PROMOTER; PROTEIN; TRANSACTIVATION; EXPRESSION; PATHWAY; SITE	The p53 protein is known to trans-activate a number of genes by specific binding to a consensus sequence containing two decamers of the type: PuPuPuCA/TT/AGPyPyPy. In order to identify new p53 trans-activated genes, we defined a set of criteria for computer search of p53-responsive elements, Based on experimental data, we proposed an extended consensus sequence composed of the two decamers of the El-Deiry consensus sequence flanked by two additional ones, A maximum of 3 bp substitutions was accepted for the two decamers of the El-Deiry consensus sequence, as well as for each additional decamer, except when the two decamers of the El-Deiry consensus sequence are contiguous, In this case, each additional decamer is allowed to bear one base insertion or deletion between the median C and G, This set of criteria was validated by identifying within the promoter region of the IGF-BP3 gene the existence of a novel p53-responsive element whose functional significance was verified, By limiting our computer search to Vertebrate genes involved in cell cycle regulation, cellular adhesion or metastatic processes and to gene families most often found in HOVERGEN database, 7785 gene sequences were first analysed, Among the oncogenes, kinases, proteases and structural proteins, 55 new genes were selected; six of them were retrieved in more than one species	UNITE CNRS UMS 825,INSERM SC13,SERV BIOINFORMAT VILLEJUIF,F-94801 VILLEJUIF,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bourdon, JC (corresponding author), CNRS,CEA,UMR 217,LAB CANCEROGENESE MOL,FONTENAY ROSES,FRANCE.		JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386				ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; COOK JL, 1995, ONCOGENE, V11, P723; CUBBAGE ML, 1990, J BIOL CHEM, V265, P12642; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELPHIN C, 1994, EUR J BIOCHEM, V223, P683, DOI 10.1111/j.1432-1033.1994.tb19041.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURET L, 1994, NUCLEIC ACIDS RES, V22, P2360, DOI 10.1093/nar/22.12.2360; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEVRERO M, 1991, GENE, V101, P195, DOI 10.1016/0378-1119(91)90411-4; MAY E, 1992, J VIROL, V66, P3347, DOI 10.1128/JVI.66.6.3347-3354.1992; MIYASHITA T, 1995, CELL, V80, P293; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YONISHROUACH E, 1996, BEHRING I MITT, V97, P1; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	27	128	135	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 9	1997	14	1					85	94		10.1038/sj.onc.1200804	http://dx.doi.org/10.1038/sj.onc.1200804			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WB760	9010235				2022-12-17	WOS:A1997WB76000008
J	CLEVELAND, JL; TROPPMAIR, J; PACKHAM, G; ASKEW, DS; LLOYD, P; GONZALEZGARCIA, M; NUNEZ, G; IHLE, JN; RAPP, UR				CLEVELAND, JL; TROPPMAIR, J; PACKHAM, G; ASKEW, DS; LLOYD, P; GONZALEZGARCIA, M; NUNEZ, G; IHLE, JN; RAPP, UR			V-RAF SUPPRESSES APOPTOSIS AND PROMOTES GROWTH OF INTERLEUKIN-3-DEPENDENT MYELOID CELLS	ONCOGENE			English	Article							RECOMBINANT MURINE RETROVIRUS; C-MYC; HEMATOPOIETIC-CELLS; BCL-2 ONCOPROTEIN; KINASE-ACTIVITY; PROTEIN-KINASE; BONE-MARROW; B-CELLS; EXPRESSION; ACTIVATION	Interleukin-3 (IL-3) is required for the proliferation, survival and differentiation of myeloid progenitors. In the absence of IL-3, murine myeloid 32D.3 cells accumulate in the G1 phase of the cell cycle and subsequently undergo programmed cell, death, or apoptosis. Here we demonstrate that enforced expression of the v-raf oncogene suppresses apoptosis of myeloid 32D.3 cells following the withdrawal of IL-3. Surprisingly, steady state levels of Bcl-2, an oncogene known to suppress apoptosis, were not dependent upon IL-3 in 32D.3 cells and its levels were not augmented in v-raf clones. This suggests that ability of v-raf to suppress apoptosis in the absence of ligand is either Bcl-2 independent or that v-raf kinase promotes Bcl-2 function. v-raf also promoted growth of these cells in the presence of IL-3. v-raf clones proliferated at an increased rate due to a shortened G1 phase and had decreased requirements for IL-3 for growth. Therefore, transformation of myeloid cells by v-raf involves signaling pathways which promote both cell cycle progression and cell survival.	UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; NCI, FREDERICK CANC RES FACIL, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21701 USA; NCI, FREDERICK CANC RES FACIL, PROGRAM RESOURCES INC, FREDERICK, MD 21701 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan	CLEVELAND, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA.		Nuñez, Gabriel/A-7160-2014	Askew, David/0000-0002-6477-2515; Troppmair, Jakob/0000-0002-0611-3837	NCI NIH HHS [P0 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK44158, DK42932] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932, R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1986, J CELL BIOCHEM, V30, P195, DOI 10.1002/jcb.240300303; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; EILES M, 1990, EMBO J, V10, P133; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GRIEP AE, 1988, P NATL ACAD SCI USA, V85, P6806, DOI 10.1073/pnas.85.18.6806; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HEIDECKER G, 1989, GENES SIGNAL TRANSDU, P339; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGDON WY, 1988, ONCOGENE RES, V3, P271; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORSE HC, 1986, P NATL ACAD SCI USA, V83, P3934; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; NUNEZ G, 1989, P NATL ACAD SCI USA, V86, P4589, DOI 10.1073/pnas.86.12.4589; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PROWCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIEGEL JN, 1993, J IMMUNOL, V151, P4116; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	61	128	128	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2217	2226						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036007				2022-12-17	WOS:A1994NX62900013
J	SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M				SUZUKI, T; HIRAI, H; FUJISAWA, J; FUJITA, T; YOSHIDA, M			A TRANSACTIVATOR TAX OF HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1 BINDS TO NF-KAPPA-B P50 AND SERUM RESPONSE FACTOR (SRF) AND ASSOCIATES WITH ENHANCER DNAS OF THE NF-KAPPA-B SITE AND CARG BOX	ONCOGENE			English	Article							TRANSCRIPTIONAL ACTIVATION; HTLV-I; PROTEIN-INTERACTION; GENE-EXPRESSION; P40X; RETROVIRUS; PRECURSOR; PROMOTER; ANTIBODIES; INDUCTION	A transcriptional activator of human T-cell leukemia virus type 1 (HTLV-1) activates at least three distinct enhancers: the viral 21-bp enhancer, the NF-kappaB binding site of the IL-2Ralpha gene and the CArG box of the c-fos gene. To understand the mechanisms of Tax transactivations of the NF-kappaB enhancer and CArG box. the interactions of Tax protein with their binding factors were analysed. Using a DNA affinity precipitation (DNAP) assay, we found here that Tax associates with the DNA sequences of the NF-kappaB site and CArG box. These Tax associations with enhancers were observed only in the presence of a nuclear factor(s) and were equal to the activating capacities of Tax mutants. To identify the nuclear factor(s), we defined conditions under which no Tax binding to the NF-kappaB binding site and CArG box was detected with a nuclear extract of 293T cells. Under these conditions, tranfections with cDNAs of the NF-kappaB p50 and serum response factor (SRF) produced a factor(s) that mediated Tax binding to the NF-kappaB site and the CArG box respectively. Furthermore, purified Tax protein interacted with purified NF-kappaB p50 and purified SRF, indicating their direct bindings. These observations indicate that Tax protein associates with enhancer sequences of the NF-kappaB site and CArG box through NF-kappaB p50 and SRF respectively. Previously we demonstrated that Tax interacts with CREB and CREM proteins that bind to the 21-bp enhancer DNA. These results together suggest that indirect binding of Tax to DNA through each enhancer binding protein is a general mechanism for Tax tran-activation of transcription.	UNIV TOKYO,INST MED SCI,DEPT BIOL ANIM,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; ROCKEFELLER UNIV,NEW YORK,NY 10021	University of Tokyo; Rockefeller University								BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GESSAIN A, 1985, LANCET, V2, P1247; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIYOKAWA T, 1985, VIROLOGY, V147, P462, DOI 10.1016/0042-6822(85)90149-7; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LOWENTHAL JW, 1988, P NATL ACAD SCI USA, V85, P4468, DOI 10.1073/pnas.85.12.4468; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OSAME M, 1986, LANCET, V1, P1031; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; YOSHIDA M, 1984, P NATL ACAD SCI-BIOL, V81, P2534, DOI 10.1073/pnas.81.8.2534; YOSHIDA M, 1987, BIOCHIM BIOPHYS ACTA, V907, P145, DOI 10.1016/0304-419X(87)90003-5; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	35	128	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2391	2397						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361755				2022-12-17	WOS:A1993LT36800009
J	IKEDA, I; ISHIZAKA, Y; TAHIRA, T; SUZUKI, T; ONDA, M; SUGIMURA, T; NAGAO, M				IKEDA, I; ISHIZAKA, Y; TAHIRA, T; SUZUKI, T; ONDA, M; SUGIMURA, T; NAGAO, M			SPECIFIC EXPRESSION OF THE RET PROTOONCOGENE IN HUMAN NEUROBLASTOMA CELL-LINES	ONCOGENE			English	Article									NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5 CHOME,CHUO KU,TOKYO 104,JAPAN; FUKUSHIMA MED SCH,DEPT PATHOL 2,FUKUSHIMA 96012,JAPAN; NIPPON MED COLL HOSP,DEPT SURG 1,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; Fukushima Medical University; Nippon Medical School								BIEDLER JL, 1973, CANCER RES, V33, P2643; BONGARZONE I, 1989, ONCOGENE, V4, P1457; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; IKEDA I, 1988, JPN J CANCER RES, V79, P674, DOI 10.1111/j.1349-7006.1988.tb02220.x; ISHIKAWA S, 1979, ACTA PATHOL JAPON, V29, P289; ISHIKAWA S, 1977, ACTA PATHOL JAPON, V27, P697; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; ITOH F, IN PRESS TUMOR RES; JACOBS JP, 1979, J BIOL STAND, V7, P113, DOI 10.1016/S0092-1157(79)80043-8; KANEKO Y, 1987, CANCER RES, V47, P311; KUGA N, 1975, GANN, V66, P547; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAKE K, 1973, AUTONOM NERV SYST JP, V10, P115; NAGAO M, 1990, JPN J CANCER RES, V81, P309, DOI 10.1111/j.1349-7006.1990.tb02566.x; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PAHLMAN S, 1986, LAB INVEST, V54, P554; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SUGIMOTO T, 1984, J NATL CANCER I, V73, P51; SUGIMOTO T, 1986, CANCER RES, V46, P4765; SUZUKI T, 1989, CANCER RES, V49, P1095; SZENTIRMAY Z, 1990, ONCOGENE, V5, P701; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VECCHIO G, 1989, ONCOGENE, V4, P897; WANG LC, 1987, CANCER RES, V47, P4192; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	42	128	141	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1990	5	9					1291	1296						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EC241	2216455				2022-12-17	WOS:A1990EC24100003
J	YUNIS, JJ; BOOT, AJM; MAYER, MG; BOS, JL				YUNIS, JJ; BOOT, AJM; MAYER, MG; BOS, JL			MECHANISMS OF RAS MUTATION IN MYELODYSPLASTIC SYNDROME	ONCOGENE			English	Article									SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NCI NIH HHS [CA23124] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; ECONOMOPOULOS T, 1987, EUR J HAEMATOL, V38, P338; Elandt-Johnson R C, 1980, SURVIVAL MODELS DATA; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; HIRAI H, 1988, BLOOD, V71, P256; HIRAI H, 1987, NATURE, V327, P430, DOI 10.1038/327430a0; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JUNEJA SK, 1983, J CLIN PATHOL, V36, P1129, DOI 10.1136/jcp.36.10.1129; KAPLAN ME, 1976, IN VITRO METHODS CEL; KERKHOFS H, 1987, BRIT J HAEMATOL, V65, P73, DOI 10.1111/j.1365-2141.1987.tb06138.x; LEMOINE NR, 1989, IN PRESS ONCOGENE; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; LYONS J, 1988, BLOOD, V71, P1707; Maniatis T., 1982, MOL CLONING; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PADUA RA, 1988, LEUKEMIA, V2, P503; RASKIND WH, 1984, BLOOD, V63, P1318; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SENNHP, 1988, BLOOD, V72, P931; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; TOKSOZ D, 1987, ONCOGENE, V1, P409; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YUNIS JJ, 1986, BLOOD, V67, P1721; YUNIS JJ, 1988, BRIT J HAEMATOL, V68, P189, DOI 10.1111/j.1365-2141.1988.tb06188.x; 1984, CANCER GENET CYTOGEN, V11, P249; [No title captured]	31	128	134	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					609	614						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2657575				2022-12-17	WOS:A1989U768800011
J	RIOU, G; BARROIS, M; SHENG, ZM; DUVILLARD, P; LHOMME, C				RIOU, G; BARROIS, M; SHENG, ZM; DUVILLARD, P; LHOMME, C			SOMATIC DELETIONS AND MUTATIONS OF C-HA-RAS GENE IN HUMAN CERVICAL CANCERS	ONCOGENE			English	Article									INST GUSTAVE ROUSSY,SERV HISTOPATHOL B,F-94800 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,SERV GYNECOL,F-94800 VILLEJUIF,FRANCE	UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	RIOU, G (corresponding author), INST GUSTAVE ROUSSY,PHARMACOL CLIN & MOLEC LAB,RUE CAMILLE DESMOULINS,F-94800 VILLEJUIF,FRANCE.							ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; CAMPION MJ, 1986, LANCET, V2, P237; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HALL SW, 1983, LANCET, V2, P731; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIU E, 1987, NATURE, V330, P186, DOI 10.1038/330186a0; MANIATIS T, 1982, MOL CLONING LABORATO; MATHEW CGP, 1987, NATURE, V328, P524, DOI 10.1038/328524a0; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; PARKIN DM, 1984, B WORLD HEALTH ORGAN, V62, P163, DOI 10.1139/b84-027; PERUCHO M, 1981, CELL, V27, P185; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RIOU G, 1984, CR ACAD SCI III-VIE, V299, P575; RIOU G, 1987, LANCET, V1, P761; RIOU G, 1985, PAPILLOMAVIRUSES MOL, P47; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SHENG ZM, 1988, ONCOGENE RES, V2, P245; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SUAREZ HG, 1988, ONCOGENE, V2, P403; TERRIER P, 1988, BRIT J CANCER, V57, P43, DOI 10.1038/bjc.1988.6; THEILLET C, 1986, CANCER RES, V46, P4776; YANEZ L, 1987, ONCOGENE, V1, P315; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	41	128	129	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					329	333						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3060795				2022-12-17	WOS:A1988Q436700012
J	SHOHAT, O; GREENBERG, M; REISMAN, D; OREN, M; ROTTER, V				SHOHAT, O; GREENBERG, M; REISMAN, D; OREN, M; ROTTER, V			INHIBITION OF CELL-GROWTH MEDIATED BY PLASMIDS ENCODING P53 ANTISENSE	ONCOGENE			English	Article									WEIZMANN INST SCI,DEPT CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science					NCI NIH HHS [IR01 CA-4002] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMINI S, 1986, MOL CELL BIOL, V6, P2305, DOI 10.1128/MCB.6.7.2305; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; INGLIS SC, 1977, VIROLOGY, V78, P522, DOI 10.1016/0042-6822(77)90128-3; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KIM SK, 1985, CELL, V42, P129, DOI 10.1016/S0092-8674(85)80108-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MELTON DA, 1985, P NATL ACAD SCI USA, V82, P1244; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MORA PT, 1980, NATURE, V288, P722, DOI 10.1038/288722a0; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1985, MOL CELL BIOL, V5, P1887, DOI 10.1128/MCB.5.8.1887; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0	45	128	141	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	3					277	283						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	2455263				2022-12-17	WOS:A1987J970500007
J	Gugnoni, M; Sancisi, V; Gandolfi, G; Manzotti, G; Ragazzi, M; Giordano, D; Tamagnini, I; Tigano, M; Frasoldati, A; Piana, S; Ciarrocchi, A				Gugnoni, M.; Sancisi, V.; Gandolfi, G.; Manzotti, G.; Ragazzi, M.; Giordano, D.; Tamagnini, I.; Tigano, M.; Frasoldati, A.; Piana, S.; Ciarrocchi, A.			Cadherin-6 promotes EMT and cancer metastasis by restraining autophagy	ONCOGENE			English	Article							MITOCHONDRIAL FISSION; PROTEIN GABARAP; CELL-MIGRATION; EXPRESSION; TRANSFORMATION; TRANSITIONS; INHIBITION; INDUCTION; MARKER; BNIP3	The transdifferentiation of epithelial cells toward a mesenchymal condition (EMT) is a complex process that allows tumor cells to migrate to ectopic sites. Cadherins are not just structural proteins, but they act as sensors of the surrounding microenvironment and as signaling centers for cellular pathways. However, the molecular mechanisms underlying these signaling functions remain poorly characterized. Cadherin-6 (CDH6) is a type 2 cadherin, which drives EMT during embryonic development and it is aberrantly re-activated in cancer. We recently showed that CDH6 is a TGF beta target and an EMT marker in thyroid cancer, suggesting a role for this protein in the progression of this type of tumor. Papillary thyroid carcinomas (PTCs) are usually indolent lesions. However, metastatic spreading occurs in about 5% of the cases. The identification of molecular markers that could early predict the metastatic potential of these lesions would be strategic to design more tailored approaches and reduce patients overtreatment. In this work, we assessed the role of CDH6 in the metastatic progression of thyroid cancer. We showed that loss of CDH6 expression profoundly changes cellular architecture, alters the inter-cellular interaction modalities and attenuates EMT features in thyroid cancer cells. Using a yeast two-hybrid screening approach, based on a thyroid cancer patients library, we showed that CDH6 directly interacts with GABARAP, BNIP3 and BNIP3L, and that through these interactions CDH6 restrains autophagy and promotes re-organization of mitochondrial network through a DRP1-mediated mechanism. Analysis of the LIR domains suggests that the interaction with the autophagic machinery may be a common feature of many cadherin family members. Finally, the analysis of CDH6 expression in a unique cohort of human PTCs showed that CDH6 expression marks specifically EMT cells. and it is strongly associated with metastatic behavior and worse outcome of PTCs.	[Gugnoni, M.; Sancisi, V.; Gandolfi, G.; Manzotti, G.; Tigano, M.; Ciarrocchi, A.] Arcispedale S Maria Nuova IRCCS, Dept Sci Direct, Lab Translat Res, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy; [Ragazzi, M.; Tamagnini, I.; Piana, S.] Arcispedale S Maria Nuova IRCCS, Deptartment Oncol & Adv Technol, Pathol Unit, Reggio Emilia, Italy; [Giordano, D.] Arcispedale S Maria Nuova IRCCS, Otolaryngol Unit, Dept Gen Surg, Reggio Emilia, Italy; [Giordano, D.; Frasoldati, A.] Arcispedale S Maria Nuova IRCCS, Specialist Unit, Reggio Emilia, Italy; [Frasoldati, A.] Arcispedale S Maria Nuova IRCCS, Dept Gen Surg, Endocrinol Unit, Reggio Emilia, Italy	IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova	Ciarrocchi, A (corresponding author), Arcispedale S Maria Nuova IRCCS, Dept Sci Direct, Lab Translat Res, Viale Risorgimento 80, I-42123 Reggio Emilia, Italy.	Alessia.Ciarrocchi@asmn.re.it	Sancisi, Valentina/H-6701-2018; Ragazzi, Moira/J-5737-2018; Manzotti, Gloria/J-7235-2016; Frasoldati, Andrea/AAB-3338-2021; PIANA, SIMONETTA/AAC-9158-2019; Ciarrocchi, Alessia/AAA-1130-2019; Gugnoni, Mila/H-6952-2018; Giordano, Davide/AAC-3553-2020	Sancisi, Valentina/0000-0003-4357-1228; Ragazzi, Moira/0000-0002-8761-9265; Manzotti, Gloria/0000-0002-0639-3605; Frasoldati, Andrea/0000-0001-9002-9293; PIANA, SIMONETTA/0000-0003-4875-6977; Ciarrocchi, Alessia/0000-0002-5541-2075; Gugnoni, Mila/0000-0003-4630-3958; Gandolfi, Greta/0000-0001-7498-424X; Tigano, Marco/0000-0002-4353-9220	Italian Association for Cancer Research (AIRC) [MFAG10745]; Italian Ministry of Health [GR-2011-02350937]; fellowship of the Umberto Veronesi Foundation	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Italian Ministry of Health(Ministry of Health, Italy); fellowship of the Umberto Veronesi Foundation(Fondazione Umberto Veronesi)	Additional Materials and Methods are supplied in the Supplementary Information. This work was supported by the Italian Association for Cancer Research (AIRC, MFAG10745) and by the Italian Ministry of Health (GR-2011-02350937). GG is supported by a fellowship of the Umberto Veronesi Foundation.	Akalay I, 2013, CANCER RES, V73, P2418, DOI 10.1158/0008-5472.CAN-12-2432; Boutet A, 2006, EMBO J, V25, P5603, DOI 10.1038/sj.emboj.7601421; BRABANT G, 1993, CANCER RES, V53, P4987; Cai DF, 2014, CELL, V157, P1146, DOI 10.1016/j.cell.2014.03.045; Call G, 2012, ENDOCRINOLOGY, V153, P522, DOI 10.1210/en.2011-1572; Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Cho EA, 1998, DEVELOPMENT, V125, P803; Choi PW, 2016, ONCOTARGET, V7, P4110, DOI 10.18632/oncotarget.6588; Ciarrocchi A, 2011, EUR J CANCER, V47, P934, DOI 10.1016/j.ejca.2010.11.009; Clay MR, 2014, DEVELOPMENT, V141, P2506, DOI 10.1242/dev.105551; Cooper DS, 2009, THYROID, V19, P1167, DOI 10.1089/thy.2009.0110; Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1; Davies L, 2010, ARCH OTOLARYNGOL, V136, P440, DOI 10.1001/archoto.2010.55; Desai SP, 2013, BIOPHYS J, V104, P2077, DOI 10.1016/j.bpj.2013.03.025; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gandolfi G, 2015, INT J CANCER, V137, P1001, DOI 10.1002/ijc.28976; Gomes LC, 2013, BBA-MOL CELL RES, V1833, P205, DOI 10.1016/j.bbamcr.2012.02.012; Gray RS, 2010, CURR OPIN CELL BIOL, V22, P640, DOI 10.1016/j.ceb.2010.08.019; Inoue T, 1997, DEV BIOL, V183, P183, DOI 10.1006/dbio.1996.8501; Inoue YU, 2008, MOL CELL NEUROSCI, V39, P95, DOI 10.1016/j.mcn.2008.05.020; Jia LW, 2011, MOL BIOL CELL, V22, P2031, DOI 10.1091/mbc.E11-01-0038; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kashef J, 2009, GENE DEV, V23, P1393, DOI 10.1101/gad.519409; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Maes H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.94; Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Noren NK, 2003, J BIOL CHEM, V278, P13615, DOI 10.1074/jbc.C200657200; Pellegriti G, 2013, J CANCER EPIDEMIOL, V2013, DOI 10.1155/2013/965212; Peng YF, 2013, AUTOPHAGY, V9, P2056, DOI 10.4161/auto.26398; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Sancisi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075489; Sancisi V, 2012, J CLIN ENDOCR METAB, V97, pE2006, DOI 10.1210/jc.2012-1903; SCHEUMMAN GFW, 1995, J CLIN ENDOCR METAB, V80, P2168, DOI 10.1210/jc.80.7.2168; Schwarten M, 2009, AUTOPHAGY, V5, P690, DOI 10.4161/auto.5.5.8494; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Shimazui T, 1998, CLIN CANCER RES, V4, P2419; Slobodkin MR, 2013, ESSAYS BIOCHEM, V55, P51, DOI [10.1042/BSE0550051, 10.1042/bse0550051]; Smith BR, 2006, THYROID, V16, P109, DOI 10.1089/thy.2006.16.109; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tojkander S, 2012, J CELL SCI, V125, P1855, DOI 10.1242/jcs.098087; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426; Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960; Zaidel-Bar R, 2013, J CELL SCI, V126, P373, DOI 10.1242/jcs.111559; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494	54	127	133	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					667	677		10.1038/onc.2016.237	http://dx.doi.org/10.1038/onc.2016.237			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27375021				2022-12-17	WOS:000394167700008
J	Yu, PF; Huang, Y; Han, YY; Lin, LY; Sun, WH; Rabson, AB; Wang, Y; Shi, YF				Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Rabson, A. B.; Wang, Y.; Shi, Y. F.			TNF alpha-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils	ONCOGENE			English	Article							TUMOR-ASSOCIATED NEUTROPHILS; STEM-CELLS; BONE-MARROW; MIGRATION; MOBILIZATION; IMMUNOSUPPRESSION; INTERLEUKIN-6; CHEMOKINES; CONTRIBUTE; HALLMARKS	Mesenchymal stromal cells (MSCs) tend to infiltrate into tumors and form a major component of the tumor microenvironment. Our previous work demonstrated that tumor necrosis factor a (TNF alpha)-activated MSCs significantly promoted tumor growth. However, the role of TNF alpha-treated MSCs in tumor metastasis remains elusive. Employing a lung metastasis model of murine breast cancer, we found that TNF alpha-activated MSCs strikingly enhanced tumor metastasis compared with normal MSCs. We analyzed the chemokine profiles and found that the expression of CCL5, CCR2 and CXCR2 ligands were enhanced in TNF alpha-activated MSCs. Using genetic or pharmacological strategies to inhibit CCL5 or CCR2, we demonstrated that CCL5 and CCR2 ligands were indispensable in supporting TNF alpha-activated MSCs to promote tumor metastasis. Analysis of immune cells revealed that CXCR2 ligands (CXCL1, CXCL 2 and CXCL5) expressed by TNF alpha-activated MSCs efficiently recruited CXCR2(+) neutrophils into tumor. These neutrophils were responsible for the pro-metastatic effect of MSCs since inhibition of this chemotaxis abolished increased neutrophil recruitment and tumor metastasis. The interaction between neutrophils and tumor cells resulted in markedly elevated metastasis-related genes by tumor cells, including CXCR4, CXCR7, MMP12, MMP13, IL-6 and TGF beta. Importantly, in IL8(high) human breast cancer samples, we also observed similar alterations of gene expression. Collectively, our findings demonstrate that TNF alpha-activated MSCs promote tumor metastasis via CXCR2(+) neutrophil recruitment.	[Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Wang, Y.; Shi, Y. F.] Shanghai Jiao Tong Univ, Shanghai Inst Biol Sci, Chinese Acad Sci, Key Lab Stem Cell Biol,Inst Hlth Sci,Sch Med, Shanghai, Peoples R China; [Yu, P. F.; Huang, Y.; Han, Y. Y.; Lin, L. Y.; Sun, W. H.; Wang, Y.; Shi, Y. F.] Univ Chinese Acad Sci, Shanghai, Peoples R China; [Rabson, A. B.; Shi, Y. F.] Rutgers Robert Wood Johnson Med Sch, Child Hlth Inst New Jersey, New Brunswick, NJ USA; [Shi, Y. F.] Soochow Univ, Inst Translat Med, Affiliated Hosp 1, Suzhou, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Rutgers State University New Brunswick; Rutgers State University Medical Center; Soochow University - China	Wang, Y; Shi, YF (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, 320 Yueyang Rd, Shanghai 200031, Peoples R China.; Wang, Y; Shi, YF (corresponding author), Shanghai Jiao Tong Univ, Univ Chinese Acad Sci, Sch Med, 320 Yueyang Rd, Shanghai 200031, Peoples R China.	yingwang@sibs.ac.cn; yufangshi@sibs.ac.cn	HUANG, YIN/AAH-6871-2020; Shi, Yufang/AAE-4431-2020; Yu, Pengfei/AHC-3497-2022	HUANG, YIN/0000-0001-5602-9871; Shi, Yufang/0000-0001-8964-319X; Yu, Pengfei/0000-0002-3894-5697; Sun, Weihong/0000-0002-6292-903X; wang, ying/0000-0002-2571-9367	Scientific Innovation Project of the Chinese Academy of Sciences [XDA 01040100]; Ministry of Science and Technology of China [2015CB964400]; Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone [ZJ2014-ZD-002]; Programs of National Natural Science of China [81330046, 81273316, 81571612, 81530043]; External Cooperation Program of BIC, Chinese Academy of Sciences [GJHZ201307]; Shanghai Rising-Star Program [14QA1404200]; Youth Innovation Promotion Association, Chinese Academy of Sciences	Scientific Innovation Project of the Chinese Academy of Sciences; Ministry of Science and Technology of China(Ministry of Science and Technology, China); Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone; Programs of National Natural Science of China(National Natural Science Foundation of China (NSFC)); External Cooperation Program of BIC, Chinese Academy of Sciences; Shanghai Rising-Star Program; Youth Innovation Promotion Association, Chinese Academy of Sciences	This study was supported by grants from the Scientific Innovation Project of the Chinese Academy of Sciences (XDA 01040100), the Ministry of Science and Technology of China (2015CB964400), Major Program of Development Fund for Shanghai Zhangjiang National Innovation Demonstration Zone (ZJ2014-ZD-002), the Programs of National Natural Science of China (81330046, 81273316, 81571612, 81530043), the External Cooperation Program of BIC, Chinese Academy of Sciences (GJHZ201307), Shanghai Rising-Star Program (14QA1404200) and Youth Innovation Promotion Association, Chinese Academy of Sciences.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Ardi VC, 2007, P NATL ACAD SCI USA, V104, P20262, DOI 10.1073/pnas.0706438104; Bald T, 2014, NATURE, V507, P109, DOI 10.1038/nature13111; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Chaturvedi P, 2014, P NATL ACAD SCI USA, V111, pE2120, DOI 10.1073/pnas.1406655111; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; De Luca A, 2012, J CELL BIOCHEM, V113, P3363, DOI 10.1002/jcb.24212; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; El-Haibi CP, 2010, J MAMMARY GLAND BIOL, V15, P399, DOI 10.1007/s10911-010-9196-7; Fridlender ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031524; Fridlender ZG, 2012, CARCINOGENESIS, V33, P949, DOI 10.1093/carcin/bgs123; Giacobbe A, 2016, ONCOGENE, V35, P1602, DOI 10.1038/onc.2015.230; Gijsbers K, 2005, EXP CELL RES, V303, P331, DOI 10.1016/j.yexcr.2004.09.027; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; Halpern JL, 2011, CANCER LETT, V308, P91, DOI 10.1016/j.canlet.2011.04.018; Han X, 2014, CELL DEATH DIFFER, V21, P1758, DOI 10.1038/cdd.2014.85; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Hu PP, 2015, TUMOR BIOL, V36, P7789, DOI 10.1007/s13277-015-3484-1; Huang Y, 2014, ONCOGENE, V33, P3830, DOI 10.1038/onc.2013.355; Jochems C, 2011, EXP BIOL MED, V236, P567, DOI 10.1258/ebm.2011.011007; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Katoh H, 2013, CANCER CELL, V24, P631, DOI 10.1016/j.ccr.2013.10.009; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; KUNKEL SL, 1991, EXP LUNG RES, V17, P17, DOI 10.3109/01902149109063278; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Lourenco S, 2015, J IMMUNOL, V194, P3463, DOI 10.4049/jimmunol.1402097; Melino G, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa1033; Memmi EM, 2015, P NATL ACAD SCI USA, V112, P3499, DOI 10.1073/pnas.1500762112; Modi WS, 1999, MOL BIOL EVOL, V16, P180, DOI 10.1093/oxfordjournals.molbev.a026101; Ohnuki H, 2014, CANCER RES, V74, P2038, DOI 10.1158/0008-5472.CAN-13-3118; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416; Rattigan Y, 2010, EXP CELL RES, V316, P3417, DOI 10.1016/j.yexcr.2010.07.002; Ren G, 2014, ONCOGENE, V33, P4016, DOI 10.1038/onc.2013.387; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Ren GW, 2012, CELL STEM CELL, V11, P812, DOI 10.1016/j.stem.2012.08.013; Sasaki M, 2008, J IMMUNOL, V180, P2581, DOI 10.4049/jimmunol.180.4.2581; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Templeton AJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju124; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769; Wu YJ, 2007, STEM CELLS, V25, P2648, DOI 10.1634/stemcells.2007-0226; Xu GW, 2007, BIOCHEM BIOPH RES CO, V361, P745, DOI 10.1016/j.bbrc.2007.07.052; Yan B, 2013, J IMMUNOL, V190, P5882, DOI 10.4049/jimmunol.1201881; Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031; Yang LL, 2008, EURASIP J WIREL COMM, DOI 10.1155/2008/541410; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946; Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397	52	127	129	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					482	490		10.1038/onc.2016.217	http://dx.doi.org/10.1038/onc.2016.217			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27375023	Green Published, hybrid			2022-12-17	WOS:000394166700005
J	Zhang, H; Guttikonda, S; Roberts, L; Uziel, T; Semizarov, D; Elmore, SW; Leverson, JD; Lam, LT				Zhang, H.; Guttikonda, S.; Roberts, L.; Uziel, T.; Semizarov, D.; Elmore, S. W.; Leverson, J. D.; Lam, L. T.			Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines	ONCOGENE			English	Article						Mcl-1; NSCLC; Bcl-x(L)	BCL-2 FAMILY PROTEINS; APOPTOSIS; BAK; INHIBITOR; ABT-737; ACTIVATION; EXPRESSION; RESISTANCE; P53	Non-small-cell lung cancer (NSCLC) is the most deadly type of cancer in the United States and worldwide. Although new therapy is available, the survival rate of NSCLC patients remains low. One hallmark of cancer cells is defects in the apoptotic cell death program. In this study, we investigate the role of B-cell lymphoma 2 (Bcl-2) family members Bcl-2, Bcl-xL and Mcl-1, known to regulate cell survival and death, in a panel of fourteen NSCLC cell lines. NSCLC cell lines express high levels of Mcl-1 and Bcl-xL, but not Bcl-2. Silencing the expression of Mcl-1 with small interfering RNA ( siRNA) oligonucleotides potently killed a subgroup of NSCLC cell lines. In contrast, Bcl-xL siRNA had no effect in these lines unless Mcl-1 siRNA was also introduced. Interestingly, high MCL1 to BCL-xl messenger RNA determines whether the cells depend on Mcl-1 for survival. We further investigated the role of Mcl-1 in NSCLC cells using a Mcl-1-dependent cell line, H23. The expression of a complementary DNA containing only the coding region of MCL1 rescued H23 cells from the toxicity of a 30 untranslated region (UTR) targeting Mcl-1 siRNA but not a siRNA targeting the coding region of MCL1. Furthermore, we show that Mcl-1 sequesters the BH3-only protein Noxa and Bim and the apoptotic effector Bak. Not surprisingly, Noxa, Bim, or Bak knockdown partially rescued H23 cells from toxicity mediated by Mcl-1 siRNA to different degrees. Collectively, our results indicate that targeting Mcl-1 may improve therapy for a subset of NSCLC patients. Oncogene (2011) 30, 1963-1968; doi: 10.1038/onc.2010.559; published online 6 December 2010	[Lam, L. T.] Abbott Labs, Canc Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA	Abbott Laboratories	Lam, LT (corresponding author), Abbott Labs, Canc Res, Global Pharmaceut Res & Dev, AP10,100 Abbott Pk Rd, Abbott Pk, IL 60064 USA.	Lloyd.Lam@abbott.com						Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Berrieman HK, 2005, CANCER-AM CANCER SOC, V103, P1415, DOI 10.1002/cncr.20907; Borner MM, 1999, BRIT J CANCER, V79, P952, DOI 10.1038/sj.bjc.6690152; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Keuling AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006651; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li J, 2008, CANCER CHEMOTH PHARM, V61, P525, DOI 10.1007/s00280-007-0499-3; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Linardou H, 2009, NAT REV CLIN ONCOL, V6, P352, DOI 10.1038/nrclinonc.2009.62; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Reed J. C., 2004, SCI STKE, V2004, pre9, DOI DOI 10.1126/STKE.2392004RE9; RODENHUIS S, 1992, CANCER RES, V52, pS2665; Song LX, 2005, CANCER BIOL THER, V4, P267, DOI 10.4161/cbt.4.3.1496; Sun S, 2007, J CLIN INVEST, V117, P2740, DOI 10.1172/JCI31809; Tagscherer KE, 2008, ONCOGENE, V27, P6646, DOI 10.1038/onc.2008.259; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Wesarg E, 2007, INT J CANCER, V121, P2387, DOI 10.1002/ijc.22977; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	26	127	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	16					1963	1968		10.1038/onc.2010.559	http://dx.doi.org/10.1038/onc.2010.559			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	753MA	21132008				2022-12-17	WOS:000289777700012
J	Amente, S; Bertoni, A; Morano, A; Lania, L; Avvedimento, EV; Majello, B				Amente, S.; Bertoni, A.; Morano, A.; Lania, L.; Avvedimento, E. V.; Majello, B.			LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription	ONCOGENE			English	Article						Myc; LSD1; transcription; histone; methylation; oxidative burst	AP-ENDONUCLEASE APE1/REF-1; C-MYC; BINDING; ACTIVATION; LSD1; ACETYLATION; MECHANISM; COFACTOR; GLYCOSYLASE; RECRUITS	Myc is a transcription factor that significantly contributes to cancer progression by modulating the expression of important genes through binding to a DNA sequence, CACGTG, called E-box. We find that on Myc binding to chromatin, the lysine-demethylating enzyme, LSD1, triggers a transient demethylation of lysine 4 in the histone H3. In addition, we demonstrate that Myc binds and recruits LSD1 to the E-box chromatin and the formation of this complex is stimulated by cAMP-PKA. Demethylation by LSD1 produces H2O2, which locally oxidizes guanine and induces the recruitment of 8-oxoguanine-DNA glycosylase (OGG1) and of the nuclease Ape1 on the E-box chromatin. Inhibition of oxidation or silencing of LSD1, OGG1 or Ape1 significantly reduce transcription and inhibit mRNA accumulation of Myc-target genes. Collectively, these data highlight the role of transient LSD1-mediated demethylation of H3K4 leading to local DNA oxidation as driving force in the assembly of the Myc-induced transcription initiation complex. Oncogene (2010) 29, 3691-3702; doi: 10.1038/onc.2010.120; published online 26 April 2010	[Amente, S.; Lania, L.; Majello, B.] Univ Naples Federico II, Dept Struct & Funct Biol, I-80126 Naples, Italy; [Amente, S.; Lania, L.; Avvedimento, E. V.] Naples Oncogenom Ctr CEINGE, Naples, Italy; [Bertoni, A.; Morano, A.; Avvedimento, E. V.] L Califano Univ Naples Federico II, Dept Biol Cellular & Mol Pathol, Naples, Italy	University of Naples Federico II; University of Naples Federico II	Majello, B (corresponding author), Univ Naples Federico II, Dept Struct & Funct Biol, Via Cinthia, I-80126 Naples, Italy.	majello@unina.it	Morano, Annalisa/K-6955-2012; Amente, Stefano/AAU-7605-2020	Morano, Annalisa/0000-0002-5609-4742; Amente, Stefano/0000-0003-0612-6096; Majello, Barbara/0000-0003-2789-3585	Italian Association for Cancer Research (AIRC)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We thank R Dalla Favera for critical reading of the paper and A Fusco for stimulating discussions and support. This work was supported by grants from the Italian Association for Cancer Research (AIRC) and by a core grant to NOGEC (AIRC). SA is a recipient of a postdoctoral fellowship from AIRC.	Anand R, 2007, J BIOL CHEM, V282, P35425, DOI 10.1074/jbc.R700027200; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhakat KK, 2009, ANTIOXID REDOX SIGN, V11, P621, DOI [10.1089/ars.2008.2198, 10.1089/ARS.2008.2198]; Bhakat KK, 2003, METHOD ENZYMOL, V371, P292; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Chattopadhyay R, 2008, MOL CELL BIOL, V28, P7066, DOI 10.1128/MCB.00244-08; Chen DS, 2003, J BIOL CHEM, V278, P38586, DOI 10.1074/jbc.M304286200; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015; Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gargano B, 2007, CELL CYCLE, V6, P2031, DOI 10.4161/cc.6.16.4554; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456; Kirmizis A, 2009, NAT STRUCT MOL BIOL, V16, P449, DOI 10.1038/nsmb.1569; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mantha AK, 2008, J MOL BIOL, V379, P28, DOI 10.1016/j.jmb.2008.03.052; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2007, NAT STRUCT MOL BIOL, V14, P252, DOI 10.1038/nsmb0407-252; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Schlosser I, 2005, ONCOGENE, V24, P520, DOI 10.1038/sj.onc.1208198; Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Sidorenko VS, 2007, DNA REPAIR, V6, P317, DOI 10.1016/j.dnarep.2006.10.022; Tell G, 2009, ANTIOXID REDOX SIGN, V11, P601, DOI 10.1089/ars.2008.2194; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	41	127	132	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3691	3702		10.1038/onc.2010.120	http://dx.doi.org/10.1038/onc.2010.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418916				2022-12-17	WOS:000279108600009
J	Lindberg, N; Kastemar, M; Olofsson, T; Smits, A; Uhrbom, L				Lindberg, Nanna; Kastemar, M.; Olofsson, T.; Smits, A.; Uhrbom, L.			Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma	ONCOGENE			English	Article						glioma; cell of origin; neural stem cell; oligodendrocyte progenitor cell; glial cell; PDGF	NEURAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; GROWTH-FACTOR RECEPTOR; PDGF ALPHA-RECEPTOR; IN-VIVO; GENE-TRANSFER; NG2 PROTEOGLYCAN; SONIC HEDGEHOG; NUCLEOTIDE 3'-PHOSPHODIESTERASE; MEDULLOBLASTOMA FORMATION	Gliomas are primary brain tumors mainly affecting adults. The cellular origin is unknown. The recent identification of tumor-initiating cells in glioma, which share many similarities with normal neural stem cells, has suggested the cell of origin to be a transformed neural stem cell. In previous studies, using the RCAS/tv-a mouse model, platelet-derived growth factor B (PDGF-B)induced gliomas have been generated from nestin or glial fibrillary acidic protein-expressing cells, markers of neural stem cells. To investigate if committed glial progenitor cells could be the cell of origin for glioma, we generated the Ctv-a mouse where tumor induction would be restricted to myelinating oligodendrocyte progenitor cells (OPCs) expressing 2',3'-cyclic nucleotide 3'-phosphodiesterase. We showed that PDGF-B transfer to OPCs could induce gliomas with an incidence of 33%. The majority of tumors resembled human WHO grade II oligodendroglioma based on close similarities in histopathology and expression of cellular markers. Thus, with the Ctv-a mouse we have showed that the cell of origin for glioma may be a committed glial progenitor cell. Oncogene (2009) 28, 2266-2275; doi: 10.1038/onc.2009.76; published online 27 April 2009	[Lindberg, Nanna; Kastemar, M.; Olofsson, T.; Uhrbom, L.] Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Uppland, Sweden; [Smits, A.] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University Hospital	Uhrbom, L (corresponding author), Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskoldsvag 20, SE-75185 Uppsala, Uppland, Sweden.	lene.uhrbom@genpat.uu.se	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763	Swedish Cancer Society; Swedish Research Council; Association for International Cancer Research; Lars Hiertas Minne; Jeansson's Foundation; Magn. Bergvall's Foundation; Ake Wiberg's Foundation; Department of Genetics and Pathology; Medical Faculty of Uppsala University	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research; Lars Hiertas Minne; Jeansson's Foundation; Magn. Bergvall's Foundation; Ake Wiberg's Foundation; Department of Genetics and Pathology; Medical Faculty of Uppsala University	We thank Michel Gravel for the mouse Cnp promoter DNA and Karin Forsberg-Nilsson for the pTG8 plasmid. This work was supported by grants from The Swedish Cancer Society, The Swedish Research Council, Association for International Cancer Research, Lars Hiertas Minne, Jeansson's Foundation, Magn. Bergvall's Foundation, Ake Wiberg's Foundation, the Department of Genetics and Pathology and the Medical Faculty of Uppsala University.	BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Calver AR, 1998, NEURON, V20, P869, DOI 10.1016/S0896-6273(00)80469-9; Chandross KJ, 1999, J NEUROSCI, V19, P759, DOI 10.1523/jneurosci.19-02-00759.1999; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dunlap SM, 2007, P NATL ACAD SCI USA, V104, P11736, DOI 10.1073/pnas.0703145104; Ferletta M, 2007, MOL CANCER RES, V5, P891, DOI 10.1158/1541-7786.MCR-07-0113; Fults D, 2002, NEOPLASIA, V4, P32, DOI 10.1038/sj.neo.7900200; Gravel M, 1998, J NEUROSCI RES, V53, P393; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holland EC, 2000, AM J PATHOL, V157, P1031, DOI 10.1016/S0002-9440(10)64615-9; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; JUNG M, 1995, EUR J NEUROSCI, V7, P1245, DOI 10.1111/j.1460-9568.1995.tb01115.x; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; ONeill RC, 1997, J NEUROSCI RES, V50, P248; Polito A, 2005, J ANAT, V207, P707, DOI 10.1111/j.1469-7580.2005.00454.x; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SCHERER SS, 1994, NEURON, V12, P1363, DOI 10.1016/0896-6273(94)90451-0; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; TCHOUGOUNOVA E, 2007, ONCOGENE; Uhrbom L, 2001, J NEURO-ONCOL, V53, P297, DOI 10.1023/A:1012208314436; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 2002, CANCER RES, V62, P5551; VOGEL US, 1988, J NEUROCHEM, V50, P1667, DOI 10.1111/j.1471-4159.1988.tb02461.x; Yuan XQ, 2002, J NEUROSCI RES, V70, P529, DOI 10.1002/jnr.10368	45	127	130	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 11	2009	28	23					2266	2275		10.1038/onc.2009.76	http://dx.doi.org/10.1038/onc.2009.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	456XM	19421151				2022-12-17	WOS:000266886300003
J	Tanos, B; Rodriguez-Boulan, E				Tanos, B.; Rodriguez-Boulan, E.			The epithelial polarity program: machineries involved and their hijacking by cancer	ONCOGENE			English	Review						epithelial polarity; vesicular trafficking; polarity proteins; polarity lipids; epithelial mesenchymal transition; epithelial tumors	DARBY CANINE KIDNEY; GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; BASOLATERAL PLASMA-MEMBRANE; INFLUENZA-VIRUS HEMAGGLUTININ; TUMOR-SUPPRESSOR PROTEIN; CLATHRIN ADAPTER COMPLEXES; GPI-ANCHORED PROTEINS; TRANS-GOLGI NETWORK; MDCK CELLS	The Epithelial Polarity Program (EPP) adapts and integrates three ancient cellular machineries to construct an epithelial cell. The polarized trafficking machinery adapts the cytoskeleton and ancestral secretory and endocytic machineries to the task of sorting and delivering different plasma membrane (PM) proteins to apical and basolateral surface domains. The domain-identity machinery builds a tight junctional fence (TJ) between apical and basolateral PM domains and adapts ancient polarity proteins and polarity lipids on the cytoplasmic side of the PM, which have evolved to perform a diversity of polarity tasks across cells and species, to provide 'identity' to each epithelial PM domain. The 3D organization machinery utilizes adhesion molecules as positional sensors of other epithelial cells and the basement membrane and small GTPases as integrators of positional information with the activities of the domain-identity and polarized trafficking machineries. Cancer is a disease mainly of epithelial cells (90% of human cancers are carcinomas that derive from epithelial cells) that hijacks the EPP machineries, resulting in loss of epithelial polarity, which often correlates in extent with the aggressiveness of the tumor. Here, we review how the EPP integrates its three machineries and the strategies used by cancer to hijack them.	[Tanos, B.; Rodriguez-Boulan, E.] Weill Cornell Med Coll, Dept Ophthalmol, Margaret Dyson Vis Res Inst, New York, NY 10065 USA; [Rodriguez-Boulan, E.] Weill Cornell Med Coll, Dept Cell & Dev Biol, New York, NY 10065 USA	Cornell University; Cornell University	Rodriguez-Boulan, E (corresponding author), Weill Cornell Med Coll, Dept Ophthalmol, Margaret Dyson Vis Res Inst, 1300 York Ave, New York, NY 10065 USA.	boulan@med.cornell.edu		Tanos, Barbara/0000-0002-7045-9496	NIH [GM 34107, EY08538]; Dyson Foundation; Research to Prevent Blindness Foundation; NATIONAL EYE INSTITUTE [R01EY008538] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dyson Foundation; Research to Prevent Blindness Foundation(Research to Prevent Blindness (RPB)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Aparna Lakkaraju for her artistic support and Marcelino Cereijido for useful comments on the manuscript. This study was supported by NIH Grants GM 34107 and EY08538 to ERB, by the Dyson Foundation and by the Research to Prevent Blindness Foundation.	Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; Anders M, 2003, P NATL ACAD SCI USA, V100, P1943, DOI 10.1073/pnas.0337599100; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; Aranda V, 2008, ONCOGENE, V27, P6878, DOI 10.1038/onc.2008.340; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; Baas AF, 2004, TRENDS CELL BIOL, V14, P312, DOI 10.1016/j.tcb.2004.04.001; Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; Balkovetz DF, 2006, AM J PHYSIOL-RENAL, V290, pF572, DOI 10.1152/ajprenal.00135.2005; Bao J, 2003, P NATL ACAD SCI USA, V100, P2438, DOI 10.1073/pnas.0437945100; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Benjamin JM, 2008, SEMIN CANCER BIOL, V18, P53, DOI 10.1016/j.semcancer.2007.08.003; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bodemann BO, 2008, NAT REV CANCER, V8, P133, DOI 10.1038/nrc2296; Bonifacino JS, 2004, NAT REV MOL CELL BIO, V5, P23, DOI 10.1038/nrm1279; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BOULAN ER, 1980, CELL, V20, P45, DOI 10.1016/0092-8674(80)90233-0; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown PS, 2000, TRAFFIC, V1, P124, DOI 10.1034/j.1600-0854.2000.010205.x; Cancino J, 2007, MOL BIOL CELL, V18, P4872, DOI 10.1091/mbc.E07-06-0563; Cao C, 2006, BIOCHEM J, V400, P225, DOI 10.1042/BJ20060816; Cereijido M, 2004, PHYSIOL REV, V84, P1229, DOI 10.1152/physrev.00001.2004; CEREIJIDO M, 1978, J CELL BIOL, V77, P853, DOI 10.1083/jcb.77.3.853; Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Cohen D, 2004, J CELL BIOL, V164, P717, DOI 10.1083/jcb.200308104; Cohen D, 2001, TRAFFIC, V2, P556, DOI 10.1034/j.1600-0854.2001.20805.x; Comer FI, 2007, CELL, V128, P239, DOI 10.1016/j.cell.2007.01.010; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Dardousis K, 2007, MOL THER, V15, P94, DOI 10.1038/sj.mt.6300003; Deborde S, 2008, NATURE, V452, P719, DOI 10.1038/nature06828; Delacour D, 2006, CURR BIOL, V16, P408, DOI 10.1016/j.cub.2005.12.046; Delacour D, 2007, TRAFFIC, V8, P379, DOI 10.1111/j.1600-0854.2007.00539.x; Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058; Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185; DIAKONOVA M, 1995, J CELL SCI, V108, P2499; Dikic I, 2007, EUR J CELL BIOL, V86, P505, DOI 10.1016/j.ejcb.2007.04.005; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Ellis MA, 2006, AM J PHYSIOL-RENAL, V291, pF707, DOI 10.1152/ajprenal.00161.2006; Etienne-Manneville S, 2003, CURR OPIN CELL BIOL, V15, P67, DOI 10.1016/S0955-0674(02)00005-4; Etienne-Manneville S, 2008, ONCOGENE, V27, P6970, DOI 10.1038/onc.2008.347; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fields IC, 2007, J CELL BIOL, V177, P477, DOI 10.1083/jcb.200610047; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Folsch H, 2003, J CELL BIOL, V163, P351, DOI 10.1083/jcb.200309020; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Frankel P, 2005, EMBO J, V24, P54, DOI 10.1038/sj.emboj.7600497; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Fullekrug J, 2004, ANN NY ACAD SCI, V1014, P164, DOI 10.1196/annals.1294.017; FUTTER CE, 1995, J BIOL CHEM, V270, P10999, DOI 10.1074/jbc.270.18.10999; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gan YB, 2002, NAT CELL BIOL, V4, P605, DOI 10.1038/ncb827; Gao L, 2002, CURR BIOL, V12, P221, DOI 10.1016/S0960-9822(01)00663-7; Gassama-Diagne A, 2006, NAT CELL BIOL, V8, P963, DOI 10.1038/ncb1461; Gibson MC, 2003, CURR OPIN CELL BIOL, V15, P747, DOI 10.1016/j.ceb.2003.10.008; GILBERT T, 1991, J CELL SCI, V100, P451; GILBERT T, 1991, J CELL BIOL, V113, P275, DOI 10.1083/jcb.113.2.275; Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Gravotta D, 2007, P NATL ACAD SCI USA, V104, P1564, DOI 10.1073/pnas.0610700104; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Hansel DE, 2004, CLIN CANCER RES, V10, P6152, DOI 10.1158/1078-0432.CCR-04-0285; Hara-Chikuma M, 2008, J MOL MED-JMM, V86, P221, DOI 10.1007/s00109-007-0272-4; Hara-Chikuma M, 2008, MOL CELL BIOL, V28, P326, DOI 10.1128/MCB.01482-07; He C, 2002, J BIOL CHEM, V277, P38284, DOI 10.1074/jbc.M104646200; Hezel AF, 2008, ONCOGENE, V27, P6908, DOI 10.1038/onc.2008.342; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Hurd TW, 2003, NAT CELL BIOL, V5, P137, DOI 10.1038/ncb923; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jacob R, 2004, J BIOL CHEM, V279, P3680, DOI 10.1074/jbc.C300503200; Jacob R, 2001, CURR BIOL, V11, P1444, DOI 10.1016/S0960-9822(01)00446-8; Janvier K, 2003, J CELL BIOL, V163, P1281, DOI 10.1083/jcb.200307157; Jaulin F, 2007, DEV CELL, V13, P511, DOI 10.1016/j.devcel.2007.08.001; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Ji C, 2008, CANCER CHEMOTH PHARM, V62, P857, DOI 10.1007/s00280-007-0674-6; Joberty G, 2000, NAT CELL BIOL, V2, P531, DOI 10.1038/35019573; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keller P, 1997, J CELL SCI, V110, P3001; King LS, 2004, NAT REV MOL CELL BIO, V5, P687, DOI 10.1038/nrm1469; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; Kolsch V, 2008, J CELL SCI, V121, P551, DOI 10.1242/jcs.023333; Kotelevets L, 2004, FASEB J, V18, P115, DOI 10.1096/fj.04-1942fje; Kreitzer G, 2000, NAT CELL BIOL, V2, P125, DOI 10.1038/35000081; Kreitzer G, 2003, NAT CELL BIOL, V5, P126, DOI 10.1038/ncb917; Kroschewski R, 1999, NAT CELL BIOL, V1, P8, DOI 10.1038/8977; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Langevin J, 2005, DEV CELL, V9, P365, DOI 10.1016/j.devcel.2005.07.013; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; LEGALL AH, 1994, FASEB J, V8, pA17; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; LEITINGER B, 1995, P NATL ACAD SCI USA, V92, P10109, DOI 10.1073/pnas.92.22.10109; Lemmers C, 2002, J BIOL CHEM, V277, P25408, DOI 10.1074/jbc.M202196200; Lin D, 2000, NAT CELL BIOL, V2, P540, DOI 10.1038/35019582; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Low SH, 1998, J CELL BIOL, V141, P1503, DOI 10.1083/jcb.141.7.1503; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Lu H, 2005, NAT CELL BIOL, V7, P1232, DOI 10.1038/ncb1324; Lu ZM, 2000, MOL CELL BIOL, V20, P462, DOI 10.1128/MCB.20.2.462-467.2000; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Martin-Belmonte F, 2008, CURR OPIN CELL BIOL, V20, P227, DOI 10.1016/j.ceb.2008.01.001; Martin-Belmonte F, 2007, CELL CYCLE, V6, P1957, DOI 10.4161/cc.6.16.4583; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Massimi P, 2008, ONCOGENE, V27, P1800, DOI 10.1038/sj.onc.1210810; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Merlot S, 2003, J CELL SCI, V116, P3471, DOI 10.1242/jcs.00703; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053; Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008; Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Mostov K, 2003, NAT CELL BIOL, V5, P287, DOI 10.1038/ncb0403-287; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Musch A, 2004, TRAFFIC, V5, P1, DOI 10.1046/j.1600-0854.2003.00149.x; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Musch A, 2001, EMBO J, V20, P2171, DOI 10.1093/emboj/20.9.2171; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Nejsum LN, 2007, J CELL BIOL, V178, P323, DOI 10.1083/jcb.200705094; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Odorizzi G, 1997, J CELL BIOL, V137, P1255, DOI 10.1083/jcb.137.6.1255; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; Owen DJ, 2004, ANNU REV CELL DEV BI, V20, P153, DOI 10.1146/annurev.cellbio.20.010403.104543; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Oztan A, 2007, MOL BIOL CELL, V18, P3978, DOI 10.1091/mbc.E07-02-0097; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Paladino S, 2004, J CELL BIOL, V167, P699, DOI 10.1083/jcb.200407094; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perret E, 2005, CURR OPIN CELL BIOL, V17, P423, DOI 10.1016/j.ceb.2005.06.008; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089; Rai T, 2006, AM J PHYSIOL-CELL PH, V290, pC298, DOI 10.1152/ajpcell.00356.2005; Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; REMY L, 1990, BIOL CELL, V69, P129, DOI 10.1016/0248-4900(90)90339-5; Rittmeyer EN, 2008, J CELL SCI, V121, P391, DOI 10.1242/jcs.016881; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1978, P NATL ACAD SCI USA, V75, P5071, DOI 10.1073/pnas.75.10.5071; Roh MH, 2003, J CELL SCI, V116, P2895, DOI 10.1242/jcs.00500; Rojas R, 2001, MOL BIOL CELL, V12, P2257, DOI 10.1091/mbc.12.8.2257; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Salazar G, 2002, MOL BIOL CELL, V13, P1677, DOI 10.1091/mbc.01-08-0403; SALVAREZZA SB, MOL BIOL CE IN PRESS; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Schock F, 2002, ANNU REV CELL DEV BI, V18, P463, DOI 10.1146/annurev.cellbio.18.022602.131838; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Sheff DR, 2002, MOL BIOL CELL, V13, P262, DOI 10.1091/mbc.01-07-0320; Shen Y, 2008, J BIOL CHEM, V283, P5127, DOI 10.1074/jbc.M703300200; Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219; Shipitsin M, 2004, MOL CELL BIOL, V24, P5746, DOI 10.1128/MCB.24.13.5746-5756.2004; Shoshani L, 2005, MOL BIOL CELL, V16, P1071, DOI 10.1091/mbc.E04-03-0267; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Sorkin A, 2001, BIOCHEM SOC T, V29, P480, DOI 10.1042/BST0290480; Sorkin A, 2000, J CELL SCI, V113, P4375; Spiczka KS, 2008, J CELL SCI, V121, P2880, DOI 10.1242/jcs.031641; Stein MP, 2003, ADV DRUG DELIVER REV, V55, P1421, DOI 10.1016/j.addr.2003.07.009; Stephens L, 2008, CURR BIOL, V18, pR485, DOI 10.1016/j.cub.2008.04.048; Storrs CH, 2007, J VIROL, V81, P4080, DOI 10.1128/JVI.02545-06; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; van Ijzendoorn SCD, 2003, INT REV CYTOL, V232, P59, DOI 10.1016/S0074-7696(03)32002-9; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANZEIJL MJAH, 1990, CELL REGUL, V1, P921, DOI 10.1091/mbc.1.12.921; VEGASALAS DE, 1987, J CELL BIOL, V104, P1249, DOI 10.1083/jcb.104.5.1249; Verkman AS, 2008, J MOL MED, V86, P523, DOI 10.1007/s00109-008-0303-9; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang F, 2006, ACTA PHARMACOL SIN, V27, P395, DOI 10.1111/j.1745-7254.2006.00318.x; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang JX, 2002, INT J MOL SCI, V3, P4, DOI 10.3390/i3010004; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wellner RB, 2005, TISSUE ENG, V11, P1449, DOI 10.1089/ten.2005.11.1449; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Wu WJ, 2003, CELL, V114, P715, DOI 10.1016/S0092-8674(03)00688-3; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 2004, J CELL SCI, V117, P559, DOI 10.1242/jcs.00893; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yip SC, 2007, J CELL SCI, V120, P3138, DOI 10.1242/jcs.005298; Zhang XY, 2005, J CELL BIOL, V170, P273, DOI 10.1083/jcb.200502055; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200; Zhao M, 1999, MOL BIOL CELL, V10, P1259, DOI 10.1091/mbc.10.4.1259	239	127	131	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2008	27	55					6939	6957		10.1038/onc.2008.345	http://dx.doi.org/10.1038/onc.2008.345			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	375IU	19029936				2022-12-17	WOS:000261108200007
J	Tsantoulis, PK; Kotsinas, A; Sfikakis, PP; Evangelou, K; Sideridou, M; Levy, B; Mo, L; Kittas, C; Wu, XR; Papavassiliou, AG; Gorgoulis, VG				Tsantoulis, P. K.; Kotsinas, A.; Sfikakis, P. P.; Evangelou, K.; Sideridou, M.; Levy, B.; Mo, L.; Kittas, C.; Wu, X-R; Papavassiliou, A. G.; Gorgoulis, V. G.			Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study	ONCOGENE			English	Article						fragile sites; DNA damage; cancer; nucleic acid repetitive sequences; preneoplastic lesions; replication stress	DNA-DAMAGE RESPONSE; INDUCED SENESCENCE; CANCER; TUMORIGENESIS; FLEXIBILITY; BREAKPOINTS; INSTABILITY; ACTIVATION; CHECKPOINT; BREAKAGE	Common fragile sites (CFSs) are regions of the genome prone to breakage by replication inhibitors ( extrinsic replication stress). Recently, we and others observed that oncogene-induced replication stress (RS) induces DNA damage from the earliest stages of cancer. Our aim was to perform a genome-wide analysis in precancerous and cancerous experimental models to examine whether allelic imbalance occurs within CFSs. Subsequently, CFSs sequence characteristics were assessed. We used a growth-factor-induced human skin hyperplasia and a H-ras-induced mouse hyperplastic urothelium as preneoplastic models, along with an inducible U2OS-CDT1(Tet-ON) cancer cell line model, all bearing established oncogene-induced RS stimuli. Human DNA was analysed with Affymetrix SNP microarrays, while mouse DNA was analysed with Nimblegen array CGH. We studied 56 aphidicolin-type CFSs and 1914 regions of control, nonfragile DNA. Our theoretical in silico analysis spanned 2.16 billion nonoverlapping bases on human chromosomes 1-22. Our results provide direct experimental evidence indicating that genomic alterations were more common within CFSs in epidermal and urothelial preneoplastic lesions as well as in cancer. CFSs were on average less flexible than nonfragile regions, contained more guanine-cytosine (GC) and Alu sequences. Importantly, regions with loss-of-heterozygosity were also less flexible and had a higher Alu percentage.	[Tsantoulis, P. K.; Kotsinas, A.; Evangelou, K.; Sideridou, M.; Kittas, C.; Gorgoulis, V. G.] Univ Athens, Sch Med, Dept Histol & Embryol, Mol Carcinogenesis Grp, GR-11527 Athens, Greece; [Sfikakis, P. P.] Univ Athens, Sch Med, Dept Propedeut & Internal Med 1, GR-11527 Athens, Greece; [Levy, B.] Columbia Univ, Coll Phys & Surg, Clin Cytogenet Lab, New York, NY USA; [Mo, L.; Wu, X-R] NYU, Sch Med, Dept Urol, New York, NY 10003 USA; [Papavassiliou, A. G.] Univ Athens, Sch Med, Dept Biochem, GR-11527 Athens, Greece	Athens Medical School; National & Kapodistrian University of Athens; Athens Medical School; National & Kapodistrian University of Athens; Columbia University; New York University; Athens Medical School; National & Kapodistrian University of Athens	Gorgoulis, VG (corresponding author), Antaiou 53 St, GR-11146 Athens, Greece.	papavas@med.uoa.gr; histoclub@ath.forthnet.gr	Gorgoulis, Vassilis/AAD-3630-2019; Evangelou, Konstantinos/AAG-5092-2020; Karamouzis, Michalis/AAD-2860-2020; Sfikakis, Petros/AAD-7289-2019; Tsantoulis, Petros/AAM-1653-2020; Tsantoulis, Petros/AAO-5211-2021	Gorgoulis, Vassilis/0000-0001-9001-4112; Evangelou, Konstantinos/0000-0002-2462-5748; Tsantoulis, Petros/0000-0003-3613-6682; Wu, Xue-Ru/0000-0001-6058-6291				Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104; Arlt MF, 2006, DNA REPAIR, V5, P1126, DOI 10.1016/j.dnarep.2006.05.010; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batzer MA, 2002, NAT REV GENET, V3, P370, DOI 10.1038/nrg798; Berking C, 2004, CANCER RES, V64, P807, DOI 10.1158/0008-5472.CAN-03-3438; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Glover TW, 2006, CANCER LETT, V232, P4, DOI 10.1016/j.canlet.2005.08.032; GLOVER TW, 1988, AM J HUM GENET, V43, P265; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helmrich A, 2007, INT J CANCER, V120, P48, DOI 10.1002/ijc.22049; Helmrich A, 2006, GENOME RES, V16, P1222, DOI 10.1101/gr.5335506; HIRSCH B, 1991, HUM GENET, V87, P302; IHAKA R, 1996, J COMPUTATIONAL GRAP, V5, P299, DOI DOI 10.2307/1390807; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mishmar D, 1999, AM J HUM GENET, V64, P908, DOI 10.1086/302299; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Mo L, 2007, J CLIN INVEST, V117, P314, DOI 10.1172/JCI30062; Morelli C, 2002, ONCOGENE, V21, P7266, DOI 10.1038/sj.onc.1205573; Murnane JP, 2006, DNA REPAIR, V5, P1082, DOI 10.1016/j.dnarep.2006.05.030; Olshen AB, 2004, BIOSTATISTICS, V5, P557, DOI 10.1093/biostatistics/kxh008; Olson WK, 1998, P NATL ACAD SCI USA, V95, P11163, DOI 10.1073/pnas.95.19.11163; Packer MJ, 2000, J MOL BIOL, V295, P71, DOI 10.1006/jmbi.1999.3236; SARAI A, 1989, BIOCHEMISTRY-US, V28, P7842, DOI 10.1021/bi00445a046; Smith DI, 2007, SEMIN CANCER BIOL, V17, P31, DOI 10.1016/j.semcancer.2006.10.003; Toledo F, 2000, NUCLEIC ACIDS RES, V28, P4805, DOI 10.1093/nar/28.23.4805; Vaziri C, 2003, MOL CELL, V11, P997, DOI 10.1016/S1097-2765(03)00099-6; Wistuba II, 2000, CANCER RES, V60, P1949; Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	35	127	129	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3256	3264		10.1038/sj.onc.1210989	http://dx.doi.org/10.1038/sj.onc.1210989			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18084328				2022-12-17	WOS:000256111400004
J	Iwamaru, A; Kondo, Y; Iwado, E; Aoki, H; Fujiwara, K; Yokoyama, T; Mills, GB; Kondo, S				Iwamaru, A.; Kondo, Y.; Iwado, E.; Aoki, H.; Fujiwara, K.; Yokoyama, T.; Mills, G. B.; Kondo, S.			Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells	ONCOGENE			English	Article						rapamycin; autophagy; glioma; mTOR; siRNA	TUMOR-SUPPRESSOR; CANCER-THERAPY; GROWTH-CONTROL; MTOR; INHIBITION; PATHWAY; KINASE; AKT; TOR; BECLIN-1	The mammalian target of rapamycin ( mTOR) plays a central role in regulating the proliferation of malignant glioma cells, and mTOR-specific inhibitors such as rapamycin analogs are considered as promising therapy for malignant gliomas. However, the efficacy of mTOR inhibitors alone in the treatment of patients with malignant gliomas is only modest, potentially because these agents rather than acting as mTOR kinase inhibitors instead interfere with the function of only mTOR/raptor (regulatory-associated protein of mTOR) complex and thus do not perturb all mTOR functions. The purpose of this study was to determine whether global inhibition of the mTOR molecule enhances the antitumor effect of rapamycin on malignant glioma cells. We showed that rapamycin induced autophagy and that inhibition of autophagy by small interfering RNA ( siRNA) directed against autophagy-related gene Beclin 1 attenuated the cytotoxicity of rapamycin in rapamycin-sensitive tumor cells, indicating that the autophagy was a primary mediator of rapamycin's antitumor effect rather than a protective response. Exogenous expression of an mTOR mutant interfering with its kinase activity markedly enhanced the incidence of rapamycin-induced autophagy. Moreover, silencing of mTOR with siRNA augmented the inhibitory effect of rapamycin on tumor cell viability by stimulating autophagy. Importantly, not only rapamycin-sensitive malignant glioma cells with PTEN mutations but also rapamycin-resistant malignant glioma cells with wild-type PTEN were sensitized to rapamycin by mTOR siRNA. These results indicate that rapamycin-induced autophagy is one of the agent's antitumor effects and that silencing or inhibiting mTOR kinase activity could enhance the effectiveness of rapamycin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Baylor College of Medicine	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit BSRB 1004, Houston, TX 77030 USA.	seikondo@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA108558, R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 088936, CA 108558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Edinger AL, 2003, CANCER RES, V63, P8451; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mitchell P, 2005, LANCET NEUROL, V4, P413, DOI 10.1016/S1474-4422(05)70118-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Nepomuceno RR, 2003, CANCER RES, V63, P4472; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Peralba JM, 2003, CLIN CANCER RES, V9, P2887; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Sekulic A, 2000, CANCER RES, V60, P3504; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	48	127	127	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1840	1851		10.1038/sj.onc.1209992	http://dx.doi.org/10.1038/sj.onc.1209992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001313				2022-12-17	WOS:000245117700002
J	Pim, D; Massimi, P; Dilworth, SM; Banks, L				Pim, D; Massimi, P; Dilworth, SM; Banks, L			Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A	ONCOGENE			English	Article						PKB/Akt; PI3 kinase; human papillomavirus; E7; PP2A	HUMAN-PAPILLOMAVIRUS TYPE-16; PLECKSTRIN HOMOLOGY DOMAIN; MIDDLE-T-ANTIGEN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSFORMING ACTIVITY; BINDING-PROTEIN; PHOSPHATASE 2A; CELL-SURVIVAL; IN-VITRO; AKT	Protein kinase B (PKB) or Akt is one of several second messenger kinases that are activated by cell attachment and growth factor signaling, and that transmit signals to the cell nucleus to inhibit apoptosis and thereby increase cell survival during proliferation. Other viral proteins target this pathway by increasing PKB/Akt phosphorylation, and this pathway has been implicated in the transformation of human keratinocytes by HPV E6 and E7, together with activated notch 1. Here, we examine how HPV E7 expression affects the phosphorylation of PKB. We show that HPV-16 E7 increases the level of phosphorylation of PKB in response to serum stimulation, by a mechanism independent of downregulation of PTEN phosphatase, a known inhibitor of the PI3K (PI3 kinase) pathway. The use of specific antibodies shows that some proportion of PKB/Akt that is phosphorylated both on threonine 308 and serine 473 is maintained in the presence of E7 in a PI3 kinase-independent manner, and is activated for phosphorylation of BAD, a known downstream target of PKB/Akt. Use of E7 mutants has ruled out both an inhibition of IGFBP-3, a known E7 target and PKB/Akt modulator, and the interaction of E7 with cellular pocket proteins, as being the mechanism for the PKB/Akt stimulation. PKB binds PP2A and is a known substrate of PP2A. Here, we show that HPV E7 also binds to both the 35 kDa catalytic and 65 kDa structural subunits of PP2A, an interaction that sequesters these subunits and inhibits their interaction with PKB, thereby maintaining PKB/Akt signaling by inhibiting its dephosphorylation.	Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy; Univ London Imperial Coll Sci & Technol, Dept Metab Med, London W12 0NN, England	International Center for Genetic Engineering & Biotechnology (ICGEB); Imperial College London	Pim, D (corresponding author), Int Ctr Genet Engn & Biotechnol, Padriciano 99,Area Sci Pk, I-34012 Trieste, Italy.	pim@icgeb.org			Biotechnology and Biological Sciences Research Council [C19979, BBS/B/06962] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BANKS L, 1990, ONCOGENE, V5, P1383; Borgatti P, 1997, EUR J IMMUNOL, V27, P2805, DOI 10.1002/eji.1830271110; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Fujisaki H, 2002, EXP CELL RES, V280, P255, DOI 10.1006/excr.2002.5639; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; ISHIWATARI H, 1994, J MED VIROL, V44, P243, DOI 10.1002/jmv.1890440306; Johnston D, 1999, CANCER RES, V59, P968; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; Massimi P, 1997, J GEN VIROL, V78, P2607, DOI 10.1099/0022-1317-78-10-2607; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229; MUNGER K, 1989, J VIROL, V63, P4417; PALLAS DC, 1992, J VIROL, V66, P886, DOI 10.1128/JVI.66.2.886-893.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Pankov R, 2003, J BIOL CHEM, V278, P18671, DOI 10.1074/jbc.M300879200; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; Pim D, 1997, ONCOGENE, V15, P257, DOI 10.1038/sj.onc.1201202; Pouliot N, 2002, EXP DERMATOL, V11, P387, DOI 10.1034/j.1600-0625.2002.110501.x; Rangarajan A, 2001, VIROLOGY, V286, P23, DOI 10.1006/viro.2001.0867; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; Sayama K, 2002, J BIOL CHEM, V277, P40390, DOI 10.1074/jbc.M112423200; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stambolic V, 1999, ONCOGENE, V18, P6094, DOI 10.1038/sj.onc.1203126; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; Summers SA, 1998, BIOCHEM BIOPH RES CO, V246, P76, DOI 10.1006/bbrc.1998.8575; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Velling T, 2004, EMBO REP, V5, P901, DOI 10.1038/sj.embor.7400234; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Westbrook TF, 2002, MOL CELL BIOL, V22, P7041, DOI 10.1128/MCB.22.20.7041-7052.2002; Xu WP, 2003, CANCER RES, V63, P7777; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	50	127	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7830	7838		10.1038/sj.onc.1208935	http://dx.doi.org/10.1038/sj.onc.1208935			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16044149				2022-12-17	WOS:000233463000002
J	Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D				Cismasiu, VB; Adamo, K; Gecewicz, J; Duque, J; Lin, QS; Avram, D			BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter	ONCOGENE			English	Article						BCL11B; NuRD; transcriptional repression	METASTASIS-ASSOCIATED PROTEIN-1; ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REPRESSION; SIR2-ALPHA PROTEIN; CELL-FATE; P53; SUBUNIT; FAMILY; SIR2; GENE	BCL11 genes play crucial roles in lymphopoiesis and have been associated with hematopoietic malignancies. Specifically, disruption of the BCL11B (B-cell chronic lymphocytic leukemia/lymphoma 11B) locus is linked to T-cell acute lymphoblastic leukemia, and the loss of heterozygosity in mice results in T-cell lymphoma. BCL11 proteins are related C2H2 zinc-finger transcription factors that act as transcriptional repressors. Here, we demonstrate the association of the endogenous BCL11B with the nucleosome remodeling and histone deacetylase (NuRD) complex, one of the major transcriptional corepressor complexes in mammalian cells. BCL11B complexes from T lymphocytes possess trichostatin A-sensitive histone deacetylase activity, confirming the functionality of the complexes. Analysis of the BCL11B-NuRD association demonstrated that BCL11B directly interacted with the metastasis-associated proteins MTA1 and MTA2 through the amino-terminal region. We provide evidence for the functional requirement of MTA1 in transcriptional repression mediated by BCL11B through the following: (1) overexpression of MTA1 enhanced the transcriptional repression mediated by BCL11B, (2) knockdown of MTA1 expression by small interfering RNA inhibited BCL11B transcriptional repression activity and (3) MTA1 was specifically recruited to a BCL11B targeted promoter. Taken together, these data support the hypothesis that the NuRD complex mediates transcriptional repression function of BCL11B.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; SUNY Albany, Ctr Funct Genom, Rensselaer, NY 12144 USA	Albany Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Avram, D (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave MC 165, Albany, NY 12208 USA.	avramd@mail.amc.edu	Cismasiu, Valeriu Bogdan/F-1512-2011	Lin, Qishan/0000-0002-1756-1432	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002194] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01-AR02194] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Avram D, 2002, BIOCHEM J, V368, P555, DOI 10.1042/BJ20020496; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Douagi I, 2002, SEMIN IMMUNOL, V14, P361, DOI 10.1016/S1044532302000702; Durum SK, 2003, NAT IMMUNOL, V4, P512, DOI 10.1038/ni0603-512; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Georgopoulos K, 2002, NAT REV IMMUNOL, V2, P162, DOI 10.1038/nri747; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Gururaja T, 2002, J PROTEOME RES, V1, P253, DOI 10.1021/pr0255147; HONG W, 2005, IN PRESS EMBO J; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kiefer SM, 2002, J BIOL CHEM, V277, P14869, DOI 10.1074/jbc.M200052200; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; Kowalski K, 2002, J BIOL CHEM, V277, P35720, DOI 10.1074/jbc.M204663200; Kumar R, 2003, SEMIN ONCOL, V30, P30, DOI 10.1053/j.seminoncol.2003.08.005; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Liberg D, 1999, CRIT REV IMMUNOL, V19, P127; Lin AC, 2004, J BIOL CHEM, V279, P55017, DOI 10.1074/jbc.M411240200; Liu PT, 2003, NAT IMMUNOL, V4, P525, DOI 10.1038/ni925; Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McBurney MW, 2003, MOL CANCER RES, V1, P402; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Medina KL, 2005, CURR OPIN HEMATOL, V12, P203, DOI 10.1097/01.moh.0000160735.67596.a0; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Murawsky CM, 2001, EMBO REP, V2, P1089, DOI 10.1093/embo-reports/kve252; Nakamura T, 2000, MOL CELL BIOL, V20, P3178, DOI 10.1128/MCB.20.9.3178-3186.2000; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Senawong T, 2005, ARCH BIOCHEM BIOPHYS, V434, P316, DOI 10.1016/j.abb.2004.10.028; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; Warren LA, 2003, CURR OPIN IMMUNOL, V15, P166, DOI 10.1016/S0952-7915(03)00011-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yao YL, 2003, J BIOL CHEM, V278, P42560, DOI 10.1074/jbc.M302955200; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	58	127	133	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6753	6764		10.1038/sj.onc.1208904	http://dx.doi.org/10.1038/sj.onc.1208904			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16091750				2022-12-17	WOS:000232527800003
J	Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR				Venkataraman, S; Jiang, XH; Weydert, C; Zhang, YP; Zhang, HJ; Goswami, PC; Ritchie, JM; Oberley, LW; Buettner, GR			Manganese superoxide dismutase overexpression inhibits the growth of androgen-independent prostate cancer cells	ONCOGENE			English	Article						superoxide dismutase; prostate cancer; reactive oxygen species; cell cycle; overexpression; hydrogen peroxide	NORMAL HUMAN FIBROBLASTS; NF-KAPPA-B; ANTIOXIDANT ENZYMES; CARCINOMA-CELLS; TYROSINE PHOSPHORYLATION; MALIGNANT PHENOTYPE; OXIDATIVE STRESS; FREE-RADICALS; GENE-TRANSFER; H2O2 RELEASE	This study investigates the role of the antioxidant enzyme manganese superoxide dismutase (MnSOD) in androgen-independent human prostate cancer (PC-3) cells' growth rate in vitro and in vivo. MnSOD levels were found to be lower in parental PC-3 cells compared to nonmalignant, immortalized human prostate epithelial cells (P69SV40T). To unravel the role of MnSOD in the prostate cancer phenotype, PC-3 cells were stably transfected with MnSOD cDNA plasmid. The MnSOD protein and activity levels in clones overexpressing MnSOD were increased seven- to eightfold. These cell lines showed elongated cell doubling time, reduced anchorage-independent growth in soft agar compared to parental PC-3 (Wt) cells, and reduced growth rate of PC-3 tumor xenografts in athymic nude mice. Flow cytometric studies showed an increase in membrane potential in the MnSOD-overexpressing clone (Mn32) compared to Wt and Neo cells. Also, production of extracellular H2O2 was increased in the MnSOD-overexpressing clones. As determined by DNA cell cycle analysis, the proportion of cells in G(1) phase was enhanced by MnSOD overexpression. Therefore, MnSOD not only regulates cell survival but also affects PC-3 cell proliferation by retarding G(1) to S transition. Our results are consistent with MnSOD being a tumor suppressor gene in human prostate cancer.	Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Buettner, GR (corresponding author), Univ Iowa, Free Rad & Radiat Biol Program, ESR Facil, EMRB 68, Iowa City, IA 52242 USA.	garry-buettner@uiowa.edu		Buettner, Garry/0000-0002-5594-1903; Goswami, Prabhat/0000-0002-5700-2096	NCI NIH HHS [CA 66081, CA 81090] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066081, R01CA081090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEN RG, 1989, FREE RADICAL BIO MED, V6, P631, DOI 10.1016/0891-5849(89)90071-3; Antunes F, 2000, FEBS LETT, V475, P121, DOI 10.1016/S0014-5793(00)01638-0; BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bae VL, 1998, PROSTATE, V34, P275, DOI 10.1002/(SICI)1097-0045(19980301)34:4<275::AID-PROS5>3.0.CO;2-G; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barnouin K, 2002, J BIOL CHEM, V277, P13761, DOI 10.1074/jbc.M111123200; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEERS RF, 1952, J BIOL CHEM, V195, P133; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chin CWS, 2003, J PATHOL, V200, P308, DOI 10.1002/path.1363; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; da Silva MM, 2003, AM J PHYSIOL-HEART C, V285, pH154, DOI 10.1152/ajpheart.00955.2002; Foster CS, 1999, BJU INT, V83, P171; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Jung K, 1997, FREE RADICAL BIO MED, V23, P127, DOI 10.1016/S0891-5849(96)00613-2; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; Lam EWN, 1997, CANCER RES, V57, P5550; Lam EWN, 2000, J DENT RES, V79, P1410, DOI 10.1177/00220345000790061001; LAWRENCE RA, 1976, BIOCHEM BIOPH RES CO, V71, P952, DOI 10.1016/0006-291X(76)90747-6; Li JJ, 1998, FASEB J, V12, P1713, DOI 10.1096/fasebj.12.15.1713; Li N, 1998, J CELL PHYSIOL, V175, P359, DOI 10.1002/(SICI)1097-4652(199806)175:3<359::AID-JCP14>3.0.CO;2-0; Li N, 1998, PROSTATE, V35, P221, DOI 10.1002/(SICI)1097-0045(19980515)35:3<221::AID-PROS8>3.0.CO;2-J; Li SJ, 2000, CANCER RES, V60, P3927; Liochev SI, 1997, FREE RADICAL BIO MED, V23, P668, DOI 10.1016/S0891-5849(97)00060-9; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Liu RG, 1997, HUM GENE THER, V8, P585, DOI 10.1089/hum.1997.8.5-585; Menon SG, 2003, CANCER RES, V63, P2109; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1985, CRC HDB METHODS OXYG, P217; OBERLEY LW, 1986, MODERN AGING RES, V8, P352; OBERLEY TD, 1991, FREE RADICAL BIO MED, V10, P79, DOI 10.1016/0891-5849(91)90024-W; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Palazzotti B, 1999, INT J CANCER, V82, P145, DOI 10.1002/(SICI)1097-0215(19990702)82:1<145::AID-IJC24>3.3.CO;2-2; Palmeira CM, 1996, J PHARMACOL TOX MET, V35, P35, DOI 10.1016/1056-8719(95)00131-X; PANUS PC, 1993, FREE RADICAL BIO MED, V14, P217, DOI 10.1016/0891-5849(93)90013-K; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rodriguez AM, 2000, FREE RADICAL BIO MED, V29, P801, DOI 10.1016/S0891-5849(00)00362-2; SAS Institute, 2001, SAS SYST WIND VERS 8; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Wang D, 1997, Chin Med Sci J, V12, P76; Weydert C, 2003, MOL CANCER THER, V2, P361; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 1999, CANCER RES, V59, P6276; Zhang Y, 2002, CANCER RES, V62, P1205; Zhong WX, 1996, CELL GROWTH DIFFER, V7, P1175	56	127	133	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					77	89		10.1038/sj.onc.1208145	http://dx.doi.org/10.1038/sj.onc.1208145			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15543233				2022-12-17	WOS:000226125800010
J	Vogel, C; Kienitz, A; Hofmann, I; Muller, R; Bastians, H				Vogel, C; Kienitz, A; Hofmann, I; Muller, R; Bastians, H			Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy	ONCOGENE			English	Article						cell cycle checkpoint; genomic instability; cell cycle; mad2	MAMMALIAN-CELLS; PROTEIN-KINASE; DNA-DAMAGE; KINETOCHORE LOCALIZATION; TETRAPLOIDY CHECKPOINT; PREMATURE ANAPHASE; PROMOTING COMPLEX; TUMOR-SUPPRESSOR; G(1) ARREST; MAD2	Treatment of cells with microtubule inhibitors results in activation of the mitotic spindle assembly checkpoint, leading to mitotic arrest before anaphase. Upon prolonged treatment, however, cells can adapt and exit mitosis aberrantly, resulting in the occurrence of tetraploid cells in G1. Those cells subsequently arrest in postmitotic G1 due to the activation of a p53-dependent G1 checkpoint. Failure of the G1 checkpoint leads to endoreduplication and further polyploidization. Using HCT116 and isogenic p53-deficient or spindle checkpoint compromised derivatives, we show here that not only p53 but also a functional spindle assembly checkpoint is required for postmitotic G1 checkpoint function. During transient mitotic arrest, p53 stabilization and activation is triggered by a pathway independent of ATM/ATR, Chk1 and Chk2. We further show that a prolonged spindle checkpoint-mediated mitotic arrest is required for proper postmitotic G1 checkpoint function. In addition, we demonstrate that polyploid cells are inhibited to re-enter mitosis by an additional checkpoint acting in G2. Thus, during a normal cell cycle, polyploidization and subsequent aneuploidization is prevented by the function of the mitotic spindle checkpoint, a p53-dependent G1 checkpoint and an additional G2 checkpoint.	Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35037 Marburg, Germany	Philipps University Marburg	Bastians, H (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35037 Marburg, Germany.	bastians@imt.uni-marburg.de	Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chan Gordon K, 2003, Prog Cell Cycle Res, V5, P431; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Di Leonardo A, 1997, CANCER RES, V57, P1013; Duesberg P, 2003, CELL CYCLE, V2, P202, DOI 10.4161/cc.2.3.382; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Gorbsky GJ, 1998, J CELL BIOL, V141, P1193, DOI 10.1083/jcb.141.5.1193; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jullien D, 2002, J CELL SCI, V115, P71; Khan SH, 1998, CANCER RES, V58, P396; Kohn EA, 2003, CANCER RES, V63, P31; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Meek DW, 2000, PATHOL BIOL, V48, P246; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Tsvetkov L, 2003, J BIOL CHEM, V278, P8468, DOI 10.1074/jbc.M211202200; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1	36	127	128	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6845	6853		10.1038/sj.onc.1207860	http://dx.doi.org/10.1038/sj.onc.1207860			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286707				2022-12-17	WOS:000223750700001
J	Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G				Oeggerli, M; Tomovska, S; Schraml, P; Calvano-Forte, D; Schafroth, S; Simon, R; Gasser, T; Mihatsch, MJ; Sauter, G			E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer	ONCOGENE			English	Article						bladder cancer; 6p22; E2F3; amplification; FISH; IHC	COMPARATIVE GENOMIC HYBRIDIZATION; TISSUE MICROARRAY ANALYSIS; CHROMOSOMAL IMBALANCES; TRANSCRIPTION FACTORS; GENE AMPLIFICATION; COPY NUMBER; S-PHASE; CARCINOMA; P53; EXPRESSION	E2F3 is located in the 6p22 bladder amplicon and encodes a transcription factor important for cell cycle regulation and DNA replication. To further investigate the role of E2F3 in bladder cancer, a tissue microarray containing samples from 2317 bladder tumors was used for gene copy number and expression analysis by means of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). E2F3 amplification was strongly associated with invasive tumor phenotype and high tumor grade (P<0.0001 each). None of 272 pTaG1/G2 tumors, but 35 of 311 pT1-4 carcinomas (11.3%), had E2F3 amplification. A high E2F3 expression level was associated with high grade, advanced stage, and E2F3 gene amplification (P<0.0001 each). To evaluate whether E2F3 expression correlates with tumor proliferation, the Ki67 labeling index (LI) was analysed for each tumor. There was a strong association between a high Ki67 LI and E2F3 expression (P < 0.0001), which was independent of grade and stage. We conclude that E2F3 is frequently amplified and overexpressed in invasively growing bladder cancer (stage pT1-4). E2F3 expression appears to provide a growth advantage to tumor cells by activating cell proliferation in a subset of bladder tumors.	Univ Basel, Inst Pathol, CH-4031 Basel, Switzerland; Inst Pathol, CH-4031 Basel, Switzerland; Urol Clin, CH-4410 Liestal, Switzerland	University of Basel	Sauter, G (corresponding author), Univ Basel, Inst Pathol, Schoenbeinstr 40, CH-4031 Basel, Switzerland.			Simon, Ronald/0000-0003-0158-4258				Anantharaman V, 2001, FEMS MICROBIOL LETT, V197, P215, DOI 10.1111/j.1574-6968.2001.tb10606.x; Bruch J, 2000, CANCER RES, V60, P4526; Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; FARR CJ, 1993, MAMM GENOME, V4, P577, DOI 10.1007/BF00361388; Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2; Hui R, 1997, ONCOGENE, V15, P1617, DOI 10.1038/sj.onc.1201311; Humbert PO, 2000, GENE DEV, V14, P690; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309; KONDO I, 1983, CYTOGENET CELL GENET, V35, P9, DOI 10.1159/000131829; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; LIPPONEN PK, 1993, BRIT J UROL, V72, P451, DOI 10.1111/j.1464-410X.1993.tb16176.x; Liukkonen T, 1999, EUR UROL, V36, P393, DOI 10.1159/000020039; MITELMAN F, 1994, CATALOG CHROMOSOME A; Moch H, 1997, UROL RES, V25, pS25, DOI 10.1007/BF00942044; Mostofi FK, 1973, HISTOLOGICAL TYPING; Nakopoulou L, 1998, HUM PATHOL, V29, P146, DOI 10.1016/S0046-8177(98)90225-8; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nocito A, 2001, J PATHOL, V194, P349, DOI 10.1002/1096-9896(200107)194:3<349::AID-PATH887>3.0.CO;2-D; Pfister C, 1998, EUR UROL, V33, P278, DOI 10.1159/000019580; Polanowska J, 2000, GENE CHROMOSOME CANC, V28, P126, DOI 10.1002/(SICI)1098-2264(200005)28:1<126::AID-GCC15>3.3.CO;2-7; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; Rabbani F, 1999, J NATL CANCER I, V91, P874, DOI 10.1093/jnci/91.10.874; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Richter J, 1999, CANCER RES, V59, P5687; Richter J, 2000, AM J PATHOL, V157, P787, DOI 10.1016/S0002-9440(10)64592-0; Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1; Richter J, 1997, CANCER RES, V57, P2860; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sauter G., 1994, Pathology Research and Practice, V190, P281; Simon R, 2000, INT J ONCOL, V17, P1025; Simon R, 2003, INT J CANCER, V107, P764, DOI 10.1002/ijc.11477; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Simon R, 1998, J PATHOL, V185, P345; Simon R, 2001, CANCER RES, V61, P4514; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Union for International Cancer Control (UICC), 1992, TNM CLASS MAL TUM; Veltman JA, 2003, CANCER RES, V63, P2872; VOORTER C, 1995, AM J PATHOL, V146, P1341; Wagner U, 1997, AM J PATHOL, V151, P753; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481; Zhao JM, 1999, CANCER RES, V59, P4658	50	127	138	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 22	2004	23	33					5616	5623		10.1038/sj.onc.1207749	http://dx.doi.org/10.1038/sj.onc.1207749			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KT	15122326				2022-12-17	WOS:000222629500006
J	Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B				Huerta-Yepez, S; Vega, M; Jazirehi, A; Garban, H; Hongo, F; Cheng, GH; Bonavida, B			Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-kappa B and inhibition of Bcl-(xL) expression	ONCOGENE			English	Article						NF-kappa B; prostate cancer; nitric oxide; TRAIL; apoptosis	CANCER-CELLS; UP-REGULATION; DNA-BINDING; BCL-X; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTOR; PROTEIN-KINASE; ACTINOMYCIN-D; MITOCHONDRIA; OVEREXPRESSION	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selective in the induction of apoptosis in cancer cells with minimal toxicity to normal tissues and this prompted its potential therapeutic application in cancer. However, not all cancers are sensitive to TRAIL-mediated apoptosis and, therefore, TRAIL-resistant cancer cells must be sensitized first to become sensitive to TRAIL. Treatment of prostate cancer (CaP) cell lines (DU145, PC-3, CL-1, and LNCaP) with nitric oxide donors (e.g. (Z)-1-[2-(2-aminoethyl)-N-(2-ammonio-ethyl)amino]diazen-1-ium-1, 2- diolate ( DETANONOate)) sensitized CaP cells to TRAIL-induced apoptosis and synergy was achieved. The mechanism by which DETANONOate mediated the sensitization was examined. DETANONOate inhibited the constitutive NF-kappaB activity as assessed by EMSA. Also, p50 was S-nitrosylated by DETANONOate resulting in inhibition of NF-kappaB. Inhibition of NF-kappaB activity by the chemical inhibitor Bay 11-7085, like DETANONOate, sensitized CaP to TRAIL apoptosis. In addition, DETANONOate downregulated the expression of Bcl-2 related gene (Bcl-(xL)) which is under the transcriptional regulation of NF-kappaB. The regulation of NF-kappaB and Bcl-(xL) by DETANONOate was corroborated by the use of Bcl-(xL) and Bcl-kappaB reporter systems. DETANONOate inhibited luciferase activity in the wild type and had no effect on the mutant cells. Inhibition of NF-kappaB resulted in downregulation of Bcl-(xL) expression and sensitized CaP to TRAIL-induced apoptosis. The role of Bcl-(xL) in the regulation of TRAIL apoptosis was corroborated by inhibiting Bcl-(xL) function by the chemical inhibitor 2-methoxyantimycin A(3) and this resulted in sensitization of the cells to TRAIL apoptosis. Signaling by DETANONOate and TRAIL for apoptosis was examined. DETANONOate altered the mitochondria by inducing membrane depolarization and releasing modest amounts of cytochrome c and Smac/DIABLO in the absence of downstream activation of caspases 9 and 3. However, the combination of DETANONOate and TRAIL resulted in activation of the mitochondrial pathway and activation of caspases 9 and 3, and induction of apoptosis. These findings demonstrate that DETANONOate-mediated sensitization of CaP to TRAIL-induced apoptosis is via inhibition of constitutive NF-kappaB activity and Bcl-(xL) expression.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; Hosp Infectol, CMN La Raza, IMSS, Unidad Invest Med Inmunol & Infectol, Mexico City, DF, Mexico; Univ Calif Los Angeles, David Geffen Sch Med, Johnsson Comprehens Cacn Ctr, Dept Mol Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; Instituto Mexicano del Seguro Social; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Bonavida, B (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 10833 Le Conte Ave,A2-060 CHS, Los Angeles, CA 90095 USA.	bbonavida@mednet.ucla.edu	Vega, Mario/AAZ-4315-2020	Vega, Mario I/0000-0002-3932-2483; Garban, Hermes/0000-0001-7754-5357	FIC NIH HHS [D43 TW00013-14] Funding Source: Medline; NCI NIH HHS [P50 CA92131-01A1] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000013] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P50CA092131] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altuwaijri S, 2003, CANCER RES, V63, P7106; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Chawla-Sarkar M, 2003, J BIOL CHEM, V278, P39461, DOI 10.1074/jbc.M306111200; Chinenov Y, 1998, J BIOL CHEM, V273, P6203, DOI 10.1074/jbc.273.11.6203; Connelly L, 2001, J IMMUNOL, V166, P3873, DOI 10.4049/jimmunol.166.6.3873; de Jong S, 2001, CANCER METAST REV, V20, P51, DOI 10.1023/A:1013112624971; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; Di Nardo A, 2000, BRIT J DERMATOL, V143, P491, DOI 10.1111/j.1365-2133.2000.03700.x; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; Garban HJ, 2001, J BIOL CHEM, V276, P8918, DOI 10.1074/jbc.M008471200; Gasparian AV, 2002, J CELL SCI, V115, P141; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; Hersey P, 2003, J CELL PHYSIOL, V196, P9, DOI 10.1002/jcp.10256; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Huerta-Yepez S, 2003, 94 ANN M AM ASS CANC, V44, P918; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Jazirehi AR, 2003, MOL CANCER THER, V2, P1183; Jazirehi AR, 2001, CLIN CANCER RES, V7, P3874; Jun CD, 1999, J IMMUNOL, V162, P3395; Katsuyama K, 1998, ARTERIOSCL THROM VAS, V18, P1796, DOI 10.1161/01.ATV.18.11.1796; Lebedeva IV, 2000, MOL BIOL+, V34, P875, DOI 10.1023/A:1026679826610; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li XY, 2001, CANCER RES, V61, P1699; LINDMARK R, 1983, J IMMUNOL METHODS, V62, P1, DOI 10.1016/0022-1759(83)90104-7; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P1727, DOI 10.1093/nar/21.8.1727; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; Mori N, 2001, VIRUS GENES, V22, P279, DOI 10.1023/A:1011158021749; Munshi A, 2002, CANCER CHEMOTH PHARM, V50, P46, DOI 10.1007/s00280-002-0465-z; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Ng CP, 2002, MOL CANCER THER, V1, P1051; Ng CP, 2002, ADV CANCER RES, V85, P145, DOI 10.1016/S0065-230X(02)85005-9; Nyormoi O, 2003, CELL DEATH DIFFER, V10, P558, DOI 10.1038/sj.cdd.4401209; Palayoor ST, 1999, ONCOGENE, V18, P7389, DOI 10.1038/sj.onc.1203160; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P233, DOI 10.1006/bbrc.2002.6452; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Rokhlin OW, 2002, PROSTATE, V52, P1, DOI 10.1002/pros.10074; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SCHMIDT HHHW, 1992, FEBS LETT, V307, P102, DOI 10.1016/0014-5793(92)80910-9; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Shigeno M, 2003, ONCOGENE, V22, P1653, DOI 10.1038/sj.onc.1206139; So HS, 1998, BIOCHEM BIOPH RES CO, V247, P809, DOI 10.1006/bbrc.1998.8788; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Tillman DM, 2003, CANCER RES, V63, P5118; Tso CL, 2000, CANCER J, V6, P220; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VEGA M, 2004, IN PRESS ONCOGENE; Wajant H, 2002, APOPTOSIS, V7, P449, DOI 10.1023/A:1020039225764; Zisman A, 2001, J IMMUNOTHER, V24, P459, DOI 10.1097/00002371-200111000-00003	64	127	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					4993	5003		10.1038/sj.onc.1207655	http://dx.doi.org/10.1038/sj.onc.1207655			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15048072				2022-12-17	WOS:000222237300005
J	Cameron, ER; Neil, JC				Cameron, ER; Neil, JC			The Runx genes: lineage-specific oncogenes and tumor suppressors	ONCOGENE			English	Article						Runx; Amh1; corebinding factor; oncogene; leukemia	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MYOSIN HEAVY-CHAIN; T(8/21) FUSION PROTEIN; AML1 TRANSCRIPTION FACTOR; T-CELL DEVELOPMENT; CBF-BETA-SMMHC; DNA-BINDING; AML1/PEBP2-ALPHA-B GENE; POINT MUTATIONS	The Runx genes present a challenge to the simple binary classification of cancer genes as oncogenes or tumor suppressors. There is evidence that loss of function of two of the three mammalian Runx genes promotes cancer, but in a highly lineage-restricted manner. In human leukemias, the RUNX1 gene is involved in various chromosomal translocation events that create oncogenic fusion proteins, at least some of which appear to function as dominant-negative inhibitors of the normal gene product. Paradoxically, evidence is mounting that structurally intact Runx genes are also oncogenic when overexpressed. All the three murine genes act as targets for transcriptional activation by retroviral insertional mutagenesis, and the oncogenic potential of Runx2 has been confirmed in transgenic mice. Moreover, the RUNX1 gene is often amplified or overexpressed in cases of acute leukemia. The state of progress in elucidating the oncogenic roles of the Runx genes is the subject of this review, and we draw together recent observations in a tentative model for the effects of Runx deregulation on hematopoietic cell differentiation. We suggest that lineage-specific factors determine the sensitivity to the oncogenic effects of loss or overexpression of Runx factors.	Univ Glasgow, Sch Vet, Inst Comparat Med, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow	Cameron, ER (corresponding author), Univ Glasgow, Sch Vet, Inst Comparat Med, Mol Oncol Lab, Glasgow G61 1QH, Lanark, Scotland.	e.r.cameron@vet.gla.ac.uk						Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Al-Obaidi MSJ, 2002, LEUKEMIA, V16, P669, DOI 10.1038/sj/leu/2402435; Alvarez Y, 2003, CANCER GENET CYTOGEN, V140, P58, DOI 10.1016/S0165-4608(02)00639-8; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Bernardin F, 2002, ONCOGENE, V21, P3247, DOI 10.1038/sj.onc.1205447; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Busson-Le Coniat M, 2001, GENE CHROMOSOME CANC, V32, P244, DOI 10.1002/gcc.1188; Cameron ER, 2003, BLOOD CELL MOL DIS, V30, P194, DOI 10.1016/S1079-9796(03)00031-7; Canon J, 2000, SEMIN CELL DEV BIOL, V11, P327, DOI 10.1006/scdb.2000.0185; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Coffman JA, 2003, CELL BIOL INT, V27, P315, DOI 10.1016/S1065-6995(03)00018-0; Dal Cin P, 2001, GENE CHROMOSOME CANC, V30, P407, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1107>3.0.CO;2-C; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Downing JR, 2000, SEMIN CELL DEV BIOL, V11, P347, DOI 10.1006/scdb.2000.0183; Durst KL, 2003, MOL CELL BIOL, V23, P607, DOI 10.1128/MCB.23.2.607-619.2003; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; ERICKSON P, 1992, BLOOD, V80, P1825; Fears S, 1997, P NATL ACAD SCI USA, V94, P1949, DOI 10.1073/pnas.94.5.1949; Frank R, 1995, ONCOGENE, V11, P2667; Frank RC, 1999, ONCOGENE, V18, P1701, DOI 10.1038/sj.onc.1202459; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Harewood L, 2003, LEUKEMIA, V17, P547, DOI 10.1038/sj.leu.2402849; Hasle H, 2001, LANCET ONCOL, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Hayashi K, 2001, J IMMUNOL, V167, P4957, DOI 10.4049/jimmunol.167.9.4957; Hiebert SW, 1996, MOL CELL BIOL, V16, P1349; Hilgenfeld E, 2001, BRIT J HAEMATOL, V113, P305, DOI 10.1046/j.1365-2141.2001.02723.x; Kakazu N, 1999, GENE CHROMOSOME CANC, V26, P336, DOI 10.1002/(SICI)1098-2264(199912)26:4<336::AID-GCC8>3.3.CO;2-8; Kanno Y, 1998, MOL CELL BIOL, V18, P4252, DOI 10.1128/MCB.18.7.4252; Kim R, 2003, J VIROL, V77, P2056, DOI 10.1128/JVI.77.3.2056-2062.2003; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kogan SC, 1998, P NATL ACAD SCI USA, V95, P11863, DOI 10.1073/pnas.95.20.11863; Kurokawa M, 1996, J BIOL CHEM, V271, P16870, DOI 10.1074/jbc.271.28.16870; Kurokawa M, 1996, ONCOGENE, V12, P883; Lange B, 2000, BRIT J HAEMATOL, V110, P512, DOI 10.1046/j.1365-2141.2000.02027.x; Lanza C, 1997, LEUKEMIA, V11, P820, DOI 10.1038/sj.leu.2400651; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Levanon D, 2002, EMBO J, V21, P3454, DOI 10.1093/emboj/cdf370; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; Lou JR, 2000, ONCOGENE, V19, P2695, DOI 10.1038/sj.onc.1203588; Lukasik SM, 2002, NAT STRUCT BIOL, V9, P674, DOI 10.1038/nsb831; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Lutterbach B, 1999, P NATL ACAD SCI USA, V96, P12822, DOI 10.1073/pnas.96.22.12822; Mathew S, 2001, LEUKEMIA, V15, P468, DOI 10.1038/sj.leu.2401989; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Mikhail FM, 2002, LEUKEMIA, V16, P658, DOI 10.1038/sj.leu.2402399; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morel F, 2002, CANCER GENET CYTOGEN, V137, P142, DOI 10.1016/S0165-4608(02)00566-6; Niini T, 2000, HAEMATOLOGICA, V85, P362; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; Penther D, 2002, LEUKEMIA, V16, P1131, DOI 10.1038/sj.leu.2402479; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Preudhomme C, 2000, BLOOD, V96, P2862, DOI 10.1182/blood.V96.8.2862.h8002862_2862_2869; Robertson AJ, 2002, MECH DEVELOP, V117, P327, DOI 10.1016/S0925-4773(02)00201-0; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROWLEY JD, 1981, LANCET, V2, P1020; Shields PG, 2000, J CLIN ONCOL, V18, P2309, DOI 10.1200/JCO.2000.18.11.2309; Shimada H, 2000, BLOOD, V96, P655; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Stewart M, 2002, J VIROL, V76, P4364, DOI 10.1128/JVI.76.9.4364-4369.2002; Stewart M, 1997, P NATL ACAD SCI USA, V94, P8646, DOI 10.1073/pnas.94.16.8646; Stewart M, 1996, J GEN VIROL, V77, P443, DOI 10.1099/0022-1317-77-3-443; Streubel B, 2001, CANCER GENET CYTOGEN, V124, P42, DOI 10.1016/S0165-4608(00)00318-6; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; Uchida H, 1999, ONCOGENE, V18, P1015, DOI 10.1038/sj.onc.1202383; Vaillant F, 2002, J IMMUNOL, V169, P2866, DOI 10.4049/jimmunol.169.6.2866; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Wheeler JC, 2000, SEMIN CELL DEV BIOL, V11, P369, DOI 10.1006/scdb.2000.0184; Wotton S, 2002, CANCER RES, V62, P7181; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; ZAIMAN AL, 1995, J VIROL, V69, P2898, DOI 10.1128/JVI.69.5.2898-2906.1995	86	127	131	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 24	2004	23	24					4308	4314		10.1038/sj.onc.1207130	http://dx.doi.org/10.1038/sj.onc.1207130			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823BZ	15156187				2022-12-17	WOS:000221586000016
J	Zhao, H; Dupont, J; Yakar, S; Karas, M; LeRoith, D				Zhao, H; Dupont, J; Yakar, S; Karas, M; LeRoith, D			PTEN inhibits cell proliferation and induces apoptosis by downregulating cell surface IGF-IR expression in prostate cancer cells	ONCOGENE			English	Article						PTEN; IGF-IR; prostate cancer; protein synthesis; apoptosis	ADENOVIRAL-MEDIATED EXPRESSION; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; INSULIN; RECEPTOR; ACTIVATION; PHOSPHORYLATION; DEGRADATION; METASTASIS; BREAST	PTEN is a tumor suppressor gene that is frequently mutated in human tumors. It functions primarily as a lipid phosphatase and plays a key role in the regulation of phosphatidylinositol-3'-kinase. PTEN appears to play a crucial role in modulating apoptosis by reducing the levels of PtdIns(3,4,5) P3, a phospholipid that activates AKT, a central regulator of apoptosis. To understand the role of PTEN in regulating cell proliferation and apoptosis, we stably overexpressed PTEN in PC3 cells, which are prostate cancer cells that lack PTEN. Overexpression of PTEN in two different clones inhibited cell proliferation and increased serum starvation-induced apoptosis, as compared to control cells. Interestingly, PTEN overexpression resulted in a 44 - 60% reduction in total insulin-like growth factor-I receptor (IGF-IR) protein levels and a 49 - 64% reduction in cell surface IGF-IR expression. [S-35] methionine pulse experiments in PC3 cells overexpressing PTEN demonstrated that these cells synthesize significantly lower levels of the IGF-IR precursor, whereas PTEN overexpression had no effect on IGF-IR degradation. Taken together, our results show that PTEN can regulate cell proliferation and apoptosis through inhibition of IGF-IR synthesis. These results have important implications for understanding the roles of PTEN and the IGF-IR in prostate cancer cell tumorigenesis.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Diabet Branch, NIH, Room 8D12,Bldg 10, Bethesda, MD 20892 USA.	derek@helix.nih.gov		Zhao, Hong/0000-0003-4616-3123				Beresford SA, 2001, J INTERF CYTOK RES, V21, P313, DOI 10.1089/107999001300177501; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chakraborty M, 2001, CANCER RES, V61, P7255; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 2002, CLIN CANCER RES, V8, P1904; Dong JT, 2001, CLIN CANCER RES, V7, P304; Dupont J, 2002, J CLIN INVEST, V110, P815, DOI [10.1172/JCI200213829, 10.1172/JCI0213829]; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Fernandez M, 2002, CLIN CANCER RES, V8, P1695; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gomez-Manzano C, 2003, ANN NEUROL, V53, P109, DOI 10.1002/ana.10396; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Jullien J, 2002, J BIOL CHEM, V277, P38700, DOI 10.1074/jbc.M202348200; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Koul D, 2002, INT J ONCOL, V21, P469; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; REISS K, 1992, ONCOGENE, V7, P2243; Seely BL, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-15; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Stambolic V, 2002, TRENDS PHARMACOL SCI, V23, P104, DOI 10.1016/S0165-6147(00)01984-2; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Tanno S, 2001, CANCER RES, V61, P589; Tomic-Carruthers N, 1998, BIOCHEM BIOPH RES CO, V244, P728, DOI 10.1006/bbrc.1998.8333; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Weng LP, 2002, HUM MOL GENET, V11, P1687, DOI 10.1093/hmg/11.15.1687; Weng LP, 2001, HUM MOL GENET, V10, P237, DOI 10.1093/hmg/10.3.237; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Weng LP, 2001, HUM MOL GENET, V10, P605, DOI 10.1093/hmg/10.6.605; Wu YP, 2002, CANCER RES, V62, P1030; Yamada KM, 2001, J CELL SCI, V114, P2375	37	127	146	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					786	794		10.1038/sj.onc.1207162	http://dx.doi.org/10.1038/sj.onc.1207162			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737113				2022-12-17	WOS:000188304900017
J	Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D				Wu, WC; Shu, XD; Hovsepyan, H; Mosteller, RD; Broek, D			VEGF receptor expression and signaling in human bladder tumors	ONCOGENE			English	Article						VEGF; sphingosine kinase; bladder tumor	ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE-C; VASCULAR-PERMEABILITY FACTOR; SPHINGOSINE KINASE; GENE-PRODUCT; IN-VITRO; CELLS; ACTIVATION; CANCER; RAS	Overexpression of vascular endothelial growth factor receptors (VEGFRs) has been reported in a variety of tumor types. Here we find that 11 out of the 14 bladder tumor cell tines examined express one or more VEGF receptors. Analysis of the T24 bladder tumor cell line reveals a functional autocrine loop involving VEGF and the Flk-1 receptor. Blocking VEGF expression in T24 cells results in a decrease in DNA synthesis. The Flk-1 receptor in T24 cells is phosphorylated in response to VEGF-121 or VEGF-165, and an Flk-1 inhibitor blocks VEGF to ERK signaling. We report that VEGF stimulation of T24 cells results in activation of H- and N-Ras and this is dependent on cellular sphingosine kinase I (SPK1) activity. Previously, we found VEGF-induced activation of Ras appears to be independent of a Ras-guanine nucleotide exchange factors (GEFs). Here we report that sphingosine can stimulate Ras-GTPase activating protein (GAP) activity in vitro, and sphingosine-I-phosphate (SPP) can block the stimulatory effects of sphingosine. We present a model where the balance between sphingosine and SPP regulates Ras-GAP activity such that stimulation of SPK1 favors downregulation of Ras-GAP and thereby the activation of Ras proteins. These data highlight a VEGF pathway that may be involved in the survival and proliferation of bladder tumor cells as well as other tumor cell types.	Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California	Broek, D (corresponding author), Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.				NCI NIH HHS [CA50261] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050261] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1995, METHOD ENZYMOL, V255, P161; BROWN LF, 1993, AM J PATHOL, V143, P1255; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Crew JP, 1997, CANCER RES, V57, P5281; Dias S, 2000, J CLIN INVEST, V106, P511, DOI 10.1172/JCI8978; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu B, 1995, BIOCHEM BIOPH RES CO, V217, P721, DOI 10.1006/bbrc.1995.2832; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Meister B, 1999, EUR J CANCER, V35, P445, DOI 10.1016/S0959-8049(98)00387-6; ObergWelsh C, 1997, MOL CELL ENDOCRINOL, V126, P125, DOI 10.1016/S0303-7207(96)03977-9; Podar K, 2002, J BIOL CHEM, V277, P7875, DOI 10.1074/jbc.M109068200; Price DJ, 2001, CELL GROWTH DIFFER, V12, P129; Sawano A, 2001, BLOOD, V97, P785, DOI 10.1182/blood.V97.3.785; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Shu XD, 2002, MOL CELL BIOL, V22, P7758, DOI 10.1128/MCB.22.22.7758-7768.2002; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Strawn LM, 1996, CANCER RES, V56, P3540; Strizzi L, 2001, J PATHOL, V193, P468, DOI 10.1002/path.824; TAKAHASHI T, 1995, BIOCHEM BIOPH RES CO, V209, P218, DOI 10.1006/bbrc.1995.1492; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; Veikkola T, 2000, CANCER RES, V60, P203; Von Marschall Z, 2000, GASTROENTEROLOGY, V119, P1358, DOI 10.1053/gast.2000.19578; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	35	127	141	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 29	2003	22	22					3361	3370		10.1038/sj.onc.1206285	http://dx.doi.org/10.1038/sj.onc.1206285			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776187				2022-12-17	WOS:000183128500002
J	Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D				Nair, A; Venkatraman, M; Maliekall, TT; Nair, B; Karunagaran, D			NF-kappa B is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix	ONCOGENE			English	Article						NF-kappa B; Re1A; I kappa B; cervical cancer; immunohistochemistry	BREAST-CANCER; INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; DNA-BINDING; EXPRESSION; ALPHA; PROTEIN; INHIBITOR; DEATH; GENES	We demonstrate, for the first time, that the transcription factor NF-kappaB is constitutively activated during human cervical cancer progression. Immunohistochemical analysis was done using 106 paraffin-embedded cervical tissue specimens of different histological grades. In normal cervical tissue and low-grade squamous intraepithelial lesions, p50, RelA and IkappaB-alpha were mainly localized in the cytosol, whereas in high-grade lesions and squamous cell carcinomas, p50-RelA heterodimers translocated into the nucleus with a concurrent decrease in IkappaB-alpha protein. By Western blot analysis, p50 and RelA were detectable mainly in the cytosolic and nuclear extracts in normal and cancer tissues, respectively, and cytosolic IkappaB-alpha expression was detectable in normal but not in cancer cervical tissues. NF-kappaB DNA-binding activity increased during cervical cancer progression and the binding complex was mainly composed of the p50-RelA heterodimers as revealed by electrophoretic mobility shift assays. Semi-quantitative RT-PCR analysis, however, showed increased levels of IkappaB-alpha mRNA in cancer samples presumably because of feedback regulation as a result of enhanced NF-kappaB DNA-binding activity and a consequent functional activation of NF-kappaB. Further immunohistochemical analysis with an antibody to phospho IkappaB-alpha revealed that phosphorylation occurs mainly in squamous intraepithelial lesions, suggesting that the IkappaB-alpha gets phosphorylated initially and degraded as the tumor progressed.	Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India; Doctors Diagnost & Res Ctr, Dept Pathol, Thiruvananthapuram 695011, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Karunagaran, D (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Biol, Thiruvananthapuram 695014, Kerala, India.		Karunagaran, Devarajan/A-8148-2010	Karunagaran, Devarajan/0000-0001-9331-8947; Maliekal, Tessy/0000-0002-7311-7950				Anto RJ, 2000, J BIOL CHEM, V275, P15601, DOI 10.1074/jbc.C000105200; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Barabas E, 2001, BRAZ J MED BIOL RES, V34, P1271, DOI 10.1590/S0100-879X2001001000006; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Budunova IV, 1999, ONCOGENE, V18, P7423, DOI 10.1038/sj.onc.1203104; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Cain JM, 2000, SCIENCE, V288, P1753, DOI 10.1126/science.288.5472.1753; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chopra V, 1998, CANCER INVEST, V16, P152, DOI 10.3109/07357909809050029; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Cusack JC, 2001, CANCER RES, V61, P3535; Dejardin E, 1999, ONCOGENE, V18, P2567, DOI 10.1038/sj.onc.1202599; Fontaine V, 2000, VIROLOGY, V272, P40, DOI 10.1006/viro.2000.0363; Grendys EC, 1997, GYNECOL ONCOL, V65, P343, DOI 10.1006/gyno.1997.4649; Hazelbag S, 2001, GYNECOL ONCOL, V83, P235, DOI 10.1006/gyno.2001.6378; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Hockel M, 1999, CANCER RES, V59, P4525; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Li JJ, 2000, MOL CARCINOGEN, V29, P159, DOI 10.1002/1098-2744(200011)29:3<159::AID-MC5>3.0.CO;2-W; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Manna SK, 1999, J IMMUNOL, V162, P2095; Mori N, 1999, BLOOD, V93, P2360; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; Nair S. Asha, 1997, General and Diagnostic Pathology, V142, P297; Nair SA, 1998, TUMORI J, V84, P583, DOI 10.1177/030089169808400514; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nees M, 2001, J VIROL, V75, P4283, DOI 10.1128/JVI.75.9.4283-4296.2001; Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827; Nguyen HN, 1999, SEMIN SURG ONCOL, V16, P217, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<217::AID-SSU4>3.0.CO;2-U; Pillai MR, 1996, CANCER EPIDEM BIOMAR, V5, P329; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Schoell WMJ, 1999, SEMIN SURG ONCOL, V16, P203, DOI 10.1002/(SICI)1098-2388(199904/05)16:3<203::AID-SSU2>3.0.CO;2-C; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Suk K, 2001, FEBS LETT, V495, P66, DOI 10.1016/S0014-5793(01)02335-3; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; VAN AD, 1996, SCIENCE, V274, P787; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wei LH, 2001, ONCOGENE, V20, P5799, DOI 10.1038/sj.onc.1204733; WOODWORTH CD, 1995, P NATL ACAD SCI USA, V92, P2840, DOI 10.1073/pnas.92.7.2840; Yang JM, 2001, CANCER RES, V61, P4901; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	54	127	150	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 9	2003	22	1					50	58		10.1038/sj.onc.1206043	http://dx.doi.org/10.1038/sj.onc.1206043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	631KL	12527907				2022-12-17	WOS:000180166900006
J	Kuo, ML; Chuang, SE; Lin, MT; Yang, SY				Kuo, ML; Chuang, SE; Lin, MT; Yang, SY			The involvement of PI3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interlenkin-6	ONCOGENE			English	Article						interleukin-6; Mcl-1; apoptosis; PI3-K/Akt pathway	BETA-INDUCED APOPTOSIS; 3-KINASE/AKT SIGNALING PATHWAY; PROTEIN-KINASE CASCADE; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; LIVER-REGENERATION; TRANSDUCER GP130; C-JUN; AKT	Interleukin-6 (IL-6) is a pleitrophic cytokine that not only regulates growth and differentiation of many cell types, but also induces production of acute phase proteins (A4P) in hepatocytes. Our previous works have demonstrated that both PI 3-K/Akt and STAT3 pathways mere concomitantly activated and cooperatively mediated the anti-apoptotic effect of IL-6. This investigation reports that IL-6 protected cells against apoptosis induced by a variety of agents including, TGF-beta, Uv and retinoic acid (RA) in Hep3B cells, suggesting that IL-6 is a fundamental determinant of hepatic cell survival. Mel-1, but not other Bcl-2 family members, was rapidly up-regulated by IL-6, with a peak (approximately 3-4-fold) appearing at 4 h. Transient transfection of cells with a mcl-1 antisense vector, resulting in a 50-60% reduction of the anti-apoptotic effect of IL-6, indicating that Mcl-1 is a downstream effector of IL-6. Which signaling pathway transduced by IL-6 responsible for the Mcl-1 up-regulation was further investigated. In Hep3B cells, the JAK/STAT3, ERR, and PI 3-K/Abt pathways mere activated by IL-6 stimulation. Blocking JAK/STAT3 activation with a dominant-negative mutant STAT3F or a JAK inhibitor AG490 could not influence IL-6-mediated Mcl-1 up-regulation. Similarly, PD98059 treatment, a MEK specific inhibitor, also failed to inhibit Mcl-1 expression. However, the IL-6-induced Mcl-1 upregulation was effectively attenuated in the presence of PI 3-K inhibitors, LY294002 and wortmannin. Expression of dominant-negative Akt, but not Etk, could abrogate the IL-6-induced increase of Mcl-1. In conclusion, our results suggest that the anti-apoptotic effect of IL-6 is mediated, at least in part, bai Mcl-1 expression and that is mainly through the PI 3-K/Akt-dependent pathway.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan; Natl Hlth Res Inst, Div Canc Res, Taipei, Taiwan; Natl Taiwan Hosp, Dept Surg, Taipei, Taiwan	National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei 10764, Taiwan.		Chuang, Shuang-En/D-2080-2010; Kuo, Min-Liang/C-4872-2009	LIN, MING-TSAN/0000-0001-7313-7057; KUO, MIN-LIANG/0000-0002-7139-0144				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Andrejko KM, 1998, AM J PHYSIOL-GASTR L, V275, pG1423, DOI 10.1152/ajpgi.1998.275.6.G1423; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Hockenbery D M, 1992, Semin Immunol, V4, P413; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kovalovich K, 2000, HEPATOLOGY, V31, P149, DOI 10.1002/hep.510310123; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KUMAR G, 1994, J IMMUNOL, V153, P4436; Kuo ML, 1996, CARCINOGENESIS, V17, P815, DOI 10.1093/carcin/17.4.815; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Malaguarnera M, 1997, J GASTROENTEROL, V32, P211, DOI 10.1007/BF02936370; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Minshall C, 1996, J IMMUNOL, V156, P939; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Ogata A, 1997, J IMMUNOL, V159, P2212; Oyanagi Y, 1999, LIVER, V19, P464, DOI 10.1111/j.1478-3231.1999.tb00078.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REYNOLDS JE, 1994, CANCER RES, V54, P6348; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Toretsky JA, 1999, CANCER RES, V59, P5745; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	50	127	129	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2001	20	6					677	685		10.1038/sj.onc.1204140	http://dx.doi.org/10.1038/sj.onc.1204140			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	399HR	11314001				2022-12-17	WOS:000166806000003
J	Brennan, PJ; Kumogai, T; Berezov, A; Murali, R; Greene, MI				Brennan, PJ; Kumogai, T; Berezov, A; Murali, R; Greene, MI			HER2/Neu: mechanisms of dimerization/oligomerization	ONCOGENE			English	Article						erbB; kinase; growth factor; signaling; tumor	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; NIH 3T3 CELLS; EGF-RECEPTOR; TRANSMEMBRANE DOMAIN; NEU-ONCOGENE; EXTRACELLULAR DOMAIN; LIGAND-BINDING; SIGNAL-TRANSDUCTION; POINT MUTATION		Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.		Mieszkowska, Magdalena/O-6753-2017	Murali, Ramachandran/0000-0002-8384-2793				Adelsman MA, 1996, J VIROL, V70, P2533, DOI 10.1128/JVI.70.4.2533-2544.1996; AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BEGUINOT L, 1995, J CELL BIOCH A S, V19, P11; BONISCHNETZLER M, 1987, P NATL ACAD SCI USA, V84, P7832, DOI 10.1073/pnas.84.22.7832; BRANDTRAUF PW, 1990, P NATL ACAD SCI USA, V87, P8660, DOI 10.1073/pnas.87.21.8660; BRANDTRAUF PW, 1989, J PROTEIN CHEM, V8, P679, DOI 10.1007/BF01025608; BRANDTRAUF PW, 1995, J PROTEIN CHEM, V14, P33, DOI 10.1007/BF01902842; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; CAMETT DC, 1997, J BIOL CHEM, V272, P12052; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CAO H, 1992, EMBO J, V11, P923, DOI 10.1002/j.1460-2075.1992.tb05131.x; CARRAWAY KL, 1989, J BIOL CHEM, V264, P8699; CARRAWAY KL, 1993, J BIOL CHEM, V268, P23860; Chamberlin SG, 1998, BBA-PROTEIN STRUCT M, V1384, P223, DOI 10.1016/S0167-4838(97)00203-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; Chen LI, 1997, J CELL BIOL, V137, P619, DOI 10.1083/jcb.137.3.619; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869; Domagala T, 2000, GROWTH FACTORS, V18, P11, DOI 10.3109/08977190009003231; DOUGALL WC, 1994, ONCOGENE, V9, P2109; FANGER BO, 1989, FASEB J, V3, P71, DOI 10.1096/fasebj.3.1.2783412; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GREENFIELD C, 1989, EMBO J, V8, P4115, DOI 10.1002/j.1460-2075.1989.tb08596.x; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Jorissen RN, 2000, PROTEIN SCI, V9, P310; KASHLES O, 1988, P NATL ACAD SCI USA, V85, P9567, DOI 10.1073/pnas.85.24.9567; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LAX I, 1991, J BIOL CHEM, V266, P13828; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; LEVEA CM, 1993, RECEPTOR, V3, P293; Livnah O, 1998, NAT STRUCT BIOL, V5, P993, DOI 10.1038/2965; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MOHAMMADI M, 1993, BIOCHEMISTRY-US, V32, P8742, DOI 10.1021/bi00085a004; Moscatello DK, 1996, ONCOGENE, V13, P85; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Odaka M, 1997, J BIOCHEM-TOKYO, V122, P116; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; QIAN XL, 1995, ONCOGENE, V10, P211; Qian XL, 1999, J BIOL CHEM, V274, P574, DOI 10.1074/jbc.274.2.574; Qian XL, 1996, ONCOGENE, V13, P2149; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; Sajot N, 2000, EUR BIOPHYS J BIOPHY, V28, P648, DOI 10.1007/s002490050005; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Saxon ML, 1999, J BIOL CHEM, V274, P28356, DOI 10.1074/jbc.274.40.28356; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHREIBER AB, 1981, P NATL ACAD SCI-BIOL, V78, P7535, DOI 10.1073/pnas.78.12.7535; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Shak S, 1999, SEMIN ONCOL, V26, P71; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; SOROKIN A, 1995, ONCOGENE, V11, P1531; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STERNBERG MJE, 1989, NATURE, V339, P587, DOI 10.1038/339587a0; Summerfield AE, 1996, J BIOL CHEM, V271, P19656, DOI 10.1074/jbc.271.33.19656; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1997, EMBO J, V16, P4938, DOI 10.1093/emboj/16.16.4938; VANBELZEN N, 1988, J CELL PHYSIOL, V134, P413, DOI 10.1002/jcp.1041340312; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEBER W, 1984, J BIOL CHEM, V259, P4631; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	89	127	138	3	15	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 11	2000	19	53					6093	6101		10.1038/sj.onc.1203967	http://dx.doi.org/10.1038/sj.onc.1203967			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	387KH	11156522				2022-12-17	WOS:000166121400002
J	Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR				Bench, AJ; Nacheva, EP; Hood, TL; Holden, JL; French, L; Swanton, S; Champion, KM; Li, J; Whittaker, P; Stavrides, G; Hunt, AR; Huntly, BJP; Campbell, LJ; Bentley, DR; Deloukas, P; Green, AR		UK Canc Cytogenetics Grp	Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC/BAC contig and identification of candidate genes	ONCOGENE			English	Article						chromosome 20; tumour suppressor genes; myeloproliferative disorders; myelodysplastic syndromes	MYELOPROLIFERATIVE DISORDERS; MYELODYSPLASTIC SYNDROMES; MOLECULAR ANALYSIS; HUMAN GENOME; LEUKEMIA; MAP; REFINEMENT; LIBRARIES; SEGMENT; YEAST	Deletion of the long arm of chromosome 20 represents the most common chromosomal abnormality associated with the myeloproliferative disorders (MPDs) and is also found in other myeloid malignancies including myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Previous studies have identified a common deleted region (CDR) spanning approximately 8 Mb. We have now used G-banding, FISH or microsatellite PCR to analyse 113 patients with a 20q deletion associated with a myeloid malignancy. Our results define a new MPD CDR of 2.7 Mb, an MDS/AML CDR of 2.6 Mb and a combined 'myeloid' CDR of 1.7 Mb, We have also constructed the most detailed physical map of this region to date - a bacterial clone map spanning 5 Mb of the chromosome which contains 456 bacterial clones and 202 DNA markers. Fifty-one expressed sequences were localized within this contig of which 37 lie within the MPD CDR and 20 within the MDS/AML CDR, Of the 16 expressed sequences (sis genes and 10 unique ESTs) within the 'myeloid' CDR, five were expressed in both normal bone marrow and purified CD34 positive cells. These data identify a set of genes which are both positional and expression candidates for the target gene(s) on 20q.	Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Sangor Ctr, Hinxton CB10 1SA, Cambs, England; St Vincents Hosp, Victorian Canc Cytogenet Serv, Fitzroy, Vic 3065, Australia	University of Cambridge; Wellcome Trust Sanger Institute; St Vincent's Hospital Melbourne	Green, AR (corresponding author), Univ Cambridge, Dept Haematol, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.		Deloukas, Panos/B-2922-2013; huntly, brian JP/E-6725-2014	Deloukas, Panos/0000-0001-9251-070X; huntly, brian JP/0000-0003-0312-161X; Hunt, Adrienne/0000-0002-1227-0310; Green, Anthony/0000-0002-9795-0218				Ahuja HG, 1999, BLOOD, V94, P3258, DOI 10.1182/blood.V94.9.3258.421a40_3258_3261; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASIMAKOPOULOS FA, 1994, BLOOD, V84, P3086, DOI 10.1182/blood.V84.9.3086.bloodjournal8493086; Asimakopoulos FA, 1996, BLOOD, V87, P1561, DOI 10.1182/blood.V87.4.1561.bloodjournal8741561; Asimakopoulos FA, 1996, BLOOD, V88, P2690, DOI 10.1182/blood.V88.7.2690.bloodjournal8872690; Bench AJ, 1998, GENOMICS, V49, P351, DOI 10.1006/geno.1998.5231; BENCH AJ, 1998, MYELOPROLIFERATIVE D, P819; BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BERNARDI G, 1993, GENE, V135, P57, DOI 10.1016/0378-1119(93)90049-9; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; DEWALD GW, 1993, CANCER GENET CYTOGEN, V68, P60, DOI 10.1016/0165-4608(93)90075-W; Fenaux P, 1996, SEMIN HEMATOL, V33, P127; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gregory SG, 1997, GENOME RES, V7, P1162, DOI 10.1101/gr.7.12.1162; HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S; HOLLINGS PE, 1994, GENE CHROMOSOME CANC, V11, P21, DOI 10.1002/gcc.2870110105; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; KRALOVICS R, 1998, MYELOPROLIFERATIVE D, P803; Kritis AA, 1996, GENE, V173, P275, DOI 10.1016/0378-1119(96)00183-7; LEBEAU MM, 1985, P NATL ACAD SCI USA, V82, P6692; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; MITELMAN F, 1995, CATALOG CHROMOSOME A; MORRIS CM, 1989, BLOOD, V74, P1768; NACHEVA E, 1995, CANCER GENET CYTOGEN, V80, P87, DOI 10.1016/0165-4608(94)00150-A; NACHEVA E, 1995, CANCER GENET CYTOGEN, V82, P9, DOI 10.1016/0165-4608(94)00286-K; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; ROSS MT, 1997, GENOME MAPPING, P165; ROULSTON D, 1993, BLOOD, V82, P3424; Saville MK, 1998, ADV CANCER RES, V72, P109; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Stoffel M, 1996, P NATL ACAD SCI USA, V93, P3937, DOI 10.1073/pnas.93.9.3937; Wang PW, 1998, GENE CHROMOSOME CANC, V21, P75, DOI 10.1002/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; WHITE NJ, 1994, BLOOD, V83, P2809, DOI 10.1182/blood.V83.10.2809.2809	39	127	132	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3902	3913		10.1038/sj.onc.1203728	http://dx.doi.org/10.1038/sj.onc.1203728			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10952764				2022-12-17	WOS:000088614300009
J	Wicking, C; Smyth, I; Bale, A				Wicking, C; Smyth, I; Bale, A			The hedgehog signalling pathway in tumorigenesis and development	ONCOGENE			English	Article						patched; hedgehog; basal cell carcinoma	BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; SONIC-HEDGEHOG; HUMAN HOMOLOG; SIGNALING PATHWAY; PATCHED GENE; CUBITUS-INTERRUPTUS; CHOLESTEROL HOMEOSTASIS; CHRONIC ARSENICISM	The hedgehog signalling pathway is responsible for the embryonic patterning of a range of tissues, and it is now known that dysregulation of this pathway can result in the formation of several tumour types. This cascade is regulated at the cell surface by the opposing actions of the patched and smoothened molecules which together form a receptor complex for hedgehog. The discovery that inactivation of the human patched gene is responsible for familial and sporadic forms of basal cell carcinoma firmly established a role for dysregulation of hedgehog signalling in tumorigenesis. Other key members of this pathway have also been shown to be involved in tumour formation, as have more distal downstream targets of hedgehog signalling. Since it appears that tumorigenesis results from constitutive activation of hedgehog responsive genes, the identification of novel downstream targets of hedgehog signalling in given cell types is likely to increase our understanding of the molecular processes underlying tumour formation.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	University of Queensland; Yale University	Wicking, C (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.		; Wicking, Carol/J-1814-2014	Smyth, Ian/0000-0002-1727-7829; Wicking, Carol/0000-0002-7225-3803				Alcedo J, 1996, CELL, V86, P221, DOI 10.1016/S0092-8674(00)80094-X; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Aszterbaum M, 1998, J INVEST DERMATOL, V110, P885, DOI 10.1046/j.1523-1747.1998.00222.x; ASZTERBAUM M, 1998, AM J HUM GENET, V63, pA39; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; Bellusci S, 1997, DEVELOPMENT, V124, P53; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Bodak N, 1999, P NATL ACAD SCI USA, V96, P5117, DOI 10.1073/pnas.96.9.5117; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; CHONGHAI T, 1975, MED J AUSTRALIA, V2, P424, DOI 10.5694/j.1326-5377.1975.tb105939.x; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAH H, 1997, NAT MED, V3, P788; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Goodrich LV, 1999, DEV BIOL, V211, P323, DOI 10.1006/dbio.1999.9311; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1995, DERMATOL CLIN, V13, P113, DOI 10.1016/S0733-8635(18)30114-1; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hardcastle Z, 1998, DEVELOPMENT, V125, P2803; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kang S, 1997, NAT GENET, V15, P266, DOI 10.1038/ng0397-266; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Lam CW, 1999, ONCOGENE, V18, P833, DOI 10.1038/sj.onc.1202360; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Maesawa C, 1998, GENE CHROMOSOME CANC, V21, P276, DOI 10.1002/(SICI)1098-2264(199803)21:3<276::AID-GCC15>3.3.CO;2-H; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Marigo V, 1996, P NATL ACAD SCI USA, V93, P9346, DOI 10.1073/pnas.93.18.9346; MARKEY AC, 1992, BRIT J DERMATOL, V126, P154, DOI 10.1111/j.1365-2133.1992.tb07813.x; McGarvey TW, 1998, ONCOGENE, V17, P1167, DOI 10.1038/sj.onc.1202045; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; Motoyama J, 1998, MECH DEVELOP, V78, P81, DOI 10.1016/S0925-4773(98)00149-X; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nakjang Yaovares, 1994, Journal of Dermatology (Tokyo), V21, P660; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Pietsch T, 1997, CANCER RES, V57, P2085; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Porter JA, 1996, SCIENCE, V274, P255, DOI 10.1126/science.274.5285.255; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; Radhakrishna U, 1997, NAT GENET, V17, P269, DOI 10.1038/ng1197-269; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Rodriguez I, 1997, NATURE, V389, P614, DOI 10.1038/39343; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Sasaki H, 1999, DEVELOPMENT, V126, P3915; SCOTTO J, 1996, CANC EPIDEMIOLOGY PR, P1313; SHANLEY S, 1994, AM J MED GENET, V50, P282, DOI 10.1002/ajmg.1320500312; Sidransky D, 1996, NAT GENET, V14, P7, DOI 10.1038/ng0996-7; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; Smyth I, 1999, HUM MOL GENET, V8, P291, DOI 10.1093/hmg/8.2.291; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5; Unden AB, 1997, CANCER RES, V57, P2336; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Vasiliauskas D, 1999, MECH DEVELOP, V82, P79, DOI 10.1016/S0925-4773(99)00014-3; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; Vorechovsky I, 1997, CANCER RES, V57, P4677; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; WEEDON D, 1991, MALIGNANT SKIN TUMOU, P109; Wicking C, 1997, AM J HUM GENET, V60, P21; Wicking C, 1998, ONCOGENE, V16, P1091, DOI 10.1038/sj.onc.1201644; Wolter M, 1997, CANCER RES, V57, P2581; Wong SS, 1998, J AM ACAD DERMATOL, V38, P179, DOI 10.1016/S0190-9622(98)70596-1; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; YEH S, 1973, HUM PATHOL, V4, P469, DOI 10.1016/S0046-8177(73)80060-7; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216	93	127	140	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	1999	18	55					7844	7851		10.1038/sj.onc.1203282	http://dx.doi.org/10.1038/sj.onc.1203282			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	268GL	10630637	Bronze			2022-12-17	WOS:000084405900001
J	Delavaine, L; La Thangue, NB				Delavaine, L; La Thangue, NB			Control of E2F activity by p21(Waf1/Cip1)	ONCOGENE			English	Article						E2F; p21; repression; cell cycle	DEPENDENT DNA-REPLICATION; CELL-CYCLE REGULATION; RNA POLYMERASE-II; C-TERMINAL REGION; TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; E7 ONCOPROTEIN; P21; INHIBITOR	Cyclin-dependent kinase inhibitors (cdkis), such as p21, are believed to control proliferation through an ability to function as stoichiometric antagonists of cyclin-dependent kinases (cdks). The p21 gene is a direct transcriptional target for the p53 protein, and its activation is likely to be important in effecting the p53 response, It is widely accepted that p21 can influence cell cycle progression by controlling the activity of cdks that act on the retinoblastoma tumour suppressor protein (pRb) which, in a hypophosphorylated state, associates with E2F transcription factors to prevent the activation of genes required for progression into S phase, Phosphorylation of pRb by G1 cdk complexes releases E2F and thereby enables progress through the cell cycle, Here, we describe results which suggest a p21-dependent mechanism that facilitates the regulation of E2F through a pathway that is independent of the cdk control of pRb activity. As p21 can associate with E2F subunits, it is possible that these effects are exerted through a complex with E2F. Furthermore, we find that p21 can regulate transcription in vitro. The results suggest that p21 may control E2F activity through a pathway that acts independently of pRb.	Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	La Thangue, NB (corresponding author), Univ Glasgow, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALI SA, 1995, BIOTECHNIQUES, V18, P746; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CHEN J, 1994, NATURE, V374, P386; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1996, CURR TOP MICROBIOL I, V208, P1; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; KRETZSCHMAR M, 1993, P NATL ACAD SCI USA, V90, P11508, DOI 10.1073/pnas.90.24.11508; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Missero C, 1996, GENE DEV, V10, P3065, DOI 10.1101/gad.10.23.3065; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SLANSKY JE, 1993, MOL CELL BIOL, V13, P7201; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V378, P312; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAMANIAN M, 1993, MOL BIOL CELL, V4, P389, DOI 10.1091/mbc.4.4.389; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	127	134	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5381	5392		10.1038/sj.onc.1202923	http://dx.doi.org/10.1038/sj.onc.1202923			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498892				2022-12-17	WOS:000082718600003
J	Fan, SJ; Wang, JA; Yuan, RQ; Rockwell, S; Andres, J; Zlatapolskiy, A; Goldberg, ID; Rosen, EM				Fan, SJ; Wang, JA; Yuan, RQ; Rockwell, S; Andres, J; Zlatapolskiy, A; Goldberg, ID; Rosen, EM			Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); c-Met; breast cancer; adriamycin (doxorubicin); apoptosis	HEPATOCYTE GROWTH-FACTOR; HUMAN BREAST-CANCER; C-MYC; MEDIATED APOPTOSIS; MET PROTOONCOGENE; IN-VIVO; TUMOR; INDUCTION; DEATH; GENE	Scatter factor (SF) (hepatocyte growth factor) is a cytokine that may play a role in human breast cancer invasiveness and angiogenesis, We now report that SF can block the induction of apoptosis by various DNA damaging-agents, including cytotoxic agents used in breast cancer therapy. SF protected MDA-MB-453 human breast cancer cells, EMT6 mouse mammary tumor cells and MDCK renal epithelial cells against apoptosis induced by adriamycin (ADR), X-rays, ultraviolet radiation, and other agents. Protection was observed in assays of DNA fragmentation, cell viability (;MTT), and clonogenic survival. Protection of MDA-MB-453 cells against ADR was dose- and time-dependent; maximal protection required pre-incubation with 75-100 ng/ml of SF for 48 h or more. Protection required functional SF receptor (c-Met), but was not dependent on p53. Western blotting analysis revealed that pre-treatment of MDA-MB-453 cells with SF inhibited the ADR-induced decreases in the levels of Bcl-X-L, an anti-apoptotic protein related to Bcl-2; and the dose-response and time course characteristics for SF-mediated increases in the Bcl-X-L protein levels of ADR-treated cells were consistent with the degrees of protection against apoptosis observed under the same conditions. Furthermore, Bcl-X-L levels were not down-regulated by ADR in MDA-MB-231 breast cancer cells, consistent with the finding that SF failed to protect these cells against ADR, despite the fact that they contain functional c-Mrt receptor. In contrast to Bcl-X-L, SF blocked ADR-induced increases in c-Myc and inhibited the expression of p2(WAF1/CIP1) and of the BRCA1 protein in MDA-MB-453 cells. However, SF did not cause significant changes in the cell cycle distribution of ADR-treated cells. These findings suggest that SF-mediated protection of human breast cancer cells may involve inhibition of one or more pathways required for the activation of apoptosis and may particularly target the anti-apoptotic mitochondrial membrane pore-forming protein Bcl-X-L as a component of the protective mechanism. By implication, the accumulation of SF within human breast cancers may contribute to the development of a radio- or chemoresistant phenotype.	Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA	Northwell Health; Yeshiva University; Yale University	Rosen, EM (corresponding author), Long Isl Jewish Med Ctr, Albert Einstein Coll Med, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.		Rockwell, Sara/B-8458-2009		NATIONAL CANCER INSTITUTE [R01CA064869] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64869] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY MC, 1988, CANCER RES, V48, P589; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; APTE SS, 1995, GENOMICS, V26, P292; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1994, CANCER RES, V5, P5824; FAN SJ, 1995, CANCER RES, V55, P1649; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; Hermann M., 1994, NUCLEIC ACIDS RES, V22, P5506; HURLIN PJ, 1994, COLD SPRING HARB SYM, V59, P109, DOI 10.1101/SQB.1994.059.01.014; HURLIN PJ, 1993, EMBO J, V94, P5646; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Lamszus K, 1997, LAB INVEST, V76, P339; Laterra J, 1997, LAB INVEST, V76, P565; Lenahan MK, 1996, ONCOGENE, V12, P1847; LOKKER NA, 1992, EMBO J, V11, P2403; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Packham G, 1996, ONCOGENE, V13, P461; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; Rao VN, 1996, ONCOGENE, V12, P523; Reed John C., 1995, Current Opinion in Oncology, V7, P541, DOI 10.1097/00001622-199511000-00012; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROCKWELL S, 1981, CANCER RES, V41, P527; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SATTLER MM, 1996, NATURE, V382, P335; SCHECHTER RL, 1992, BIOCHEM CELL BIOL, V70, P349, DOI 10.1139/o92-054; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; SHEIKH MS, 1995, ONCOGENE, V11, P1899; STOKER M, 1987, NATURE, V327, P238; TAKANO H, 1992, ANTI-CANCER DRUG, V3, P323, DOI 10.1097/00001813-199208000-00002; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; YAMASHITA J, 1994, CANCER RES, V54, P1630; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yao Y, 1996, AM J PATHOL, V149, P1707; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	49	127	132	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					131	141		10.1038/sj.onc.1201943	http://dx.doi.org/10.1038/sj.onc.1201943			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674697				2022-12-17	WOS:000074706700001
J	Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA				Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA			pp60(c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM	ONCOGENE			English	Article						migration; focal adhesions; cytoskeleton; tyrosine phosphorylation	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; MEMBRANE INTERACTIONS; PP60C-SRC EXPRESSION	The tyrosine kinase pp60(c-src) has been implicated as a regulator of focal adhesion formation and cell spreading. Here we show that c-src also regulates cell motility and is a key component in the signaling pathway triggered by the motogenic hyaluronan receptor RHAMM, which has been shown to regulate focal adhesion turnover and to regulate ras. Fibroblasts derived from mice lacking src, (src (-/-), have a random locomotion rate that is significantly slower than the corresponding wild-type fibroblasts. Cell locomotion in these mutant cells is restored by the expression of c-src containing a functional kinase domain, but not by the expression of a kinase-deficient src or by a truncated src containing only functional SH2 and SH3 domains. RHAMM is also required for the restoration of src (-/-) cell locomotion. Thus, the motility of cells expressing c-src is reduced to src (-/-) levels by anti-RHAMM blocking antibodies while the cell locomotion of src (-/-) fibroblasts remains unaffected by anti-RHAMM antibodies. We predict that src acts downstream of RHAMM in the regulation of motility, since the expression of a dominant negative src significantly inhibits RHAMM-dependent ras and serum regulated cell locomotion, the expression of v-src enhances cell motility in a RHAMM independent fashion, and there is a physical and functional association between src and RHAMM in ras-transformed cells. However, we suggest that RHAMM regulates focal adhesion turnover via additional src-independent mechanisms. Thus, v-src is unable to turnover focal adhesions in the absence of RHAMM. These results directly demonstrate for the first time a role for src in the regulation of cell locomotion and confirm a key and complex role for src in the regulation of the actin cycle.	HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Manitoba; University of Manitoba								Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOCKHOLT SM, 1993, MOL BIOL CELL S, V4; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, GENE, V163, P233, DOI 10.1016/0378-1119(95)00398-P; ENTWISTLE J, 1996, IN PRESS J CELL BIOC; FLY CM, 1994, J NEUROCHEM, V62, P923; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KUNDRA V, 1994, ONCOGENE, V9, P1429; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCarthy J., 1993, Critical Reviews in Oral Biology and Medicine, V4, P619; NAKAMURA N, 1993, J CELL SCI, V106, P1057; NEET K, 1995, MOL CELL BIOL, V15, P4908; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHIENG J, 1991, INVAS METAST, V11, P38; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARTIN AW, 1988, CANCER RES, V48, P6050; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1990, ONCOGENE, V5, P1437; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SANKAR S, 1995, AM J PATHOL, V147, P601; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Savani RC, 1995, INT J TISSUE REACT, V17, P141; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOOLE BP, 1989, BIOL HYAL CIB FDN S, V143, P150; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TURLEY E, 1989, EXP CELL RES, V182, P340, DOI 10.1016/0014-4827(89)90239-5; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VALLES AM, 1990, CELL REGUL, V1, P975, DOI 10.1091/mbc.1.13.975; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANG B, 1993, UNPUB	87	127	134	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2213	2224						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950989				2022-12-17	WOS:A1996VV14500019
J	Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F				Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F			A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias	ONCOGENE			English	Article						telomerase; leukemia; progression; PCR	HUMAN-LYMPHOCYTES; CELLS; IMMORTALITY; TRANSFORMATION; LENGTH; CANCER; EVENT	Telomerase activation is important for carcinogenesis. However, the timing and magnitude of the activation during cancer development are unknown. In this study, a new PCR-based method for measuring telomerase activity was developed and shown to be very useful for quantitative analysis of human telomerase. Using this assay, blood or bone marrow cells from healthy donors, and patients with chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) were examined as to their relative activity. Telomerase activity present in normal peripheral blood cells was generally very low. However, significant activity was detected occasionally in samples derived from younger healthy donors. Striking telomerase activation was observed at the time of the blastic crisis in CML: no samples from chronic phase cases showed significant activity, while all cases with a well established crisis showed strong activity. Most AML cases were telomerase-positive. Quantitative analyses revealed that the relative titer varied among the AML patients, from as low as found in normal cells to as high as found in cell lines. However, a tendency that the activity was higher in relapsed cases than in fresh ones was suggested. In summary, telomerase was activated during the progression of the clinical stages in leukemias. This observation suggests that shortened telomeres and increased telomerase activity might be necessary for cancer cells to undergo clonal evolution towards more malignant phenotypes in advanced stages.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; KITASATO UNIV,SCH MED,DEPT INTERNAL MED,SAGAMIHARA,KANAGAWA 228,JAPAN; TEIKYO UNIV,SCH MED,DEPT INTERNAL MED 4,TAKATSU KU,KAWASAKI,KANAGAWA 213,JAPAN; SHOWA UNIV,FUJIGAOKA HOSP,SCH MED,DEPT HEMATOL,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology; Kitasato University; Teikyo University; Showa University			Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; BEDI A, 1994, BLOOD, V83, P2038; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FERRE F, 1994, POLYM CHAIN REACTION, P67; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1993, COLD SPRING HARB SYM, V58, P719, DOI 10.1101/SQB.1993.058.01.079; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1994, COLD SPRING HARB SYM, V64, P1; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OHYASHIKI K, 1994, CANCER GENET CYTOGEN, V78, P64, DOI 10.1016/0165-4608(94)90047-7; PAITYSZEK MA, 1995, METHODS CELL SCI, V17, P1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Sambrook J, 1989, MOL CLONING LAB MANU; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; TAKAUCHI K, 1994, JPN J CANCER RES, V85, P127, DOI 10.1111/j.1349-7006.1994.tb02071.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	33	127	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2265	2274						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950994				2022-12-17	WOS:A1996VV14500024
J	Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK				Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK			Association of CDKN2A/p16(INK4A) with human head and neck keratinocyte replicative senescence: Relationship of dysfunction to immortality and neoplasia	ONCOGENE			English	Article						CDKN2; p16; immortality; keratinocyte; senescence; SCC	SQUAMOUS-CELL CARCINOMA; HUMAN-DIPLOID FIBROBLASTS; PRIMARY TUMORS; GENE-PRODUCT; TELOMERASE ACTIVITY; CYCLE INHIBITION; P16/CDKN2 GENE; LUNG-CANCER; LINES; EXPRESSION	We have previously suggested that a gene mapping to chromosome 9p21 could contribute to replicative senescence and suppress cullular immortality in squamous neoplasia. Two candidate genes, the cyclin D-1/cyclin-dependent kinase inhibitors CDKN2A/p16(INK4A) (p16) and CDKN2B/p15(INK4B) (p15) have now been identified in this region and we show here that p16 is upregulated when normal human keratinocytes undergo replicative senescence but not when they undergo differentiation. Furthermore, all of 19 immortal neoplastic keratinocyte head and neck lines, including nine showing loss of heterozygosity (LOH) at 9p21, showed undetectable p16 expression, whereas five of six senescent neoplastic cultures showed normal levels of expression. The retinoblastoma protein (pRb) appeared functional in all the cell lines and cultures examined. The mechanism of p16 inactivation appeared to be transcriptional silencing in 10 of 18 lines and homozygous deletions in the rest. Treatment of two of the immortal cell lines which had transcriptionally silent wild type p16 genes with 5aza-2deoxycytidine resulted in the re-expression of p16, thus implicating DNA methylation as one mechanism of transcriptional silencing in the immortal SCC-HN lines. We observed no cases of p16 point mutation. In contrast, the p15 gene was rarely transcriptionally silent and was not deleted in any of the cell lines which showed p16 deletions. Our results show that p16 dysfunction correlates strongly with keratinocyte immortalisation but less strongly with the stage of tumour progression. P16 dysfunction was not related to the neoplastic state or the length of time spent in vitro. The results also suggest that p16 but not p15 is involved in the keratinocyte replicative senescence programme. However, two neoplastic cell cultures which lacked p16 expression were still mortal, suggesting that the loss of p16 is a necessary but insufficient condition for human keratinocyte immortality.	BEATSON INST CANC RES,CRC BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV BIRMINGHAM,SCH MED,CRC INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	Beatson Institute; University of Birmingham; University of Cambridge								ARAP W, 1995, CANCER RES, V55, P1351; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; BROWN KW, 1987, BRIT J CANCER, V56, P545, DOI 10.1038/bjc.1987.240; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; BURNS JE, 1994, BRIT J CANCER, V70, P591, DOI 10.1038/bjc.1994.356; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUFMANN WF, 1995, CANCER RES, V55, P493; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LOUGHRAN O, 1996, UNPUB; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAGAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, CELL, V83, P993; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILKE MS, 1988, LAB INVEST, V58, P660; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YEAGER T, 1995, CANCER RES, V55, P493; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG SY, 1994, CANCER RES, V54, P5050	59	127	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					561	568						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760298				2022-12-17	WOS:A1996VB32800013
J	MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A				MOSSIE, K; JALLAL, B; ALVES, F; SURES, I; PLOWMAN, GD; ULLRICH, A			COLON-CARCINOMA KINASE-4 DEFINES A NEW SUBCLASS OF THE RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Note						RECEPTOR TYROSINE KINASE FAMILY; COLON CARCINOMA; SIGNAL TRANSDUCTION	GROWTH-FACTOR RECEPTOR; HUMAN INSULIN-RECEPTOR; SIGNAL TRANSDUCTION; STRUCTURAL BASIS; HUMAN-BREAST; CELLS; EXPRESSION; GENE; CDNA; SUPERFAMILY	Complementary DNA (cDNA) encoding a novel member of the receptor tyrosine kinase (RTK) family has been isolated from colon carcinoma tissue. Colon carcinoma kinase 4 (CCK-4) mRNA is highly expressed in human lung tissue and at lower levels in the thyroid gland and ovary. While no mRNA was found in human adult colon tissues, expression varied remarkably in colon carcinoma-derived cell lines. CCK-4 cDNA encodes a chicken KLG-related, 1071 amino acid-long transmembrane glycoprotein containing several genetic alterations within the RTK consensus sequences. These define CCK-4 as a catalytically inactive member of the RTK family of proteins and, in analogy to HER3, suggest a potentially tumor-characteristic role as a signal amplifier or modulator for an as yet unidentified kinase-competent partner.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY; SUGEN INC,REDWOOD CITY,CA 94063	Max Planck Society			PLOWMAN, Greg D/E-2012-2011					ALIMANDI M, 1995, ONCOGENE, V10, P1813; ALVES F, 1995, ONCOGENE, V10, P609; BROWN LF, 1993, CANCER RES, V553, P4727; CARTER TH, 1994, CRIT REV ONCOGENESIS, V5, P389, DOI 10.1615/CritRevOncog.v5.i4.40; CHOU YH, 1991, P NATL ACAD SCI USA, V88, P4897, DOI 10.1073/pnas.88.11.4897; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Faletto D L, 1993, EXS, V65, P107; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Kluftinger A M, 1992, Surg Oncol, V1, P97, DOI 10.1016/0960-7404(92)90062-P; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; Mendelsohn J, 1992, J Natl Cancer Inst Monogr, P125; MORAN MF, 1988, ONCOGENE, V3, P665; MURGUE B, 1994, CANCER RES, V54, P5206; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PATI UK, 1992, GENE, V114, P285, DOI 10.1016/0378-1119(92)90589-H; Plowman G. D., 1994, DRUG NEWS PERSPECT, V7, P334; Sambrook J., 1989, MOL CLONING LAB MANU; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHIBUYA M, 1990, ONCOGENE, V5, P519; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOYOTA M, 1993, TUMOR BIOL, V14, P295, DOI 10.1159/000217842; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Yamori T, 1993, Gan To Kagaku Ryoho, V20, P393; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	127	137	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 16	1995	11	10					2179	2184						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TF297	7478540				2022-12-17	WOS:A1995TF29700031
J	GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL				GOGA, A; LIU, X; HAMBUCH, TM; SENECHAL, K; MAJOR, E; BERK, AJ; WITTE, ON; SAWYERS, CL			P53 DEPENDENT GROWTH SUPPRESSION BY THE C-ABL NUCLEAR TYROSINE KINASE	ONCOGENE			English	Article						CELL CYCLE; GROWTH ARREST; ONCOGENE; TUMOR; SUPPRESSOR GENES	TATA-BINDING PROTEIN; CELL-CYCLE ARREST; WILD-TYPE P53; RETINOBLASTOMA PROTEIN; P53-DEFICIENT MICE; ACTIVATION DOMAIN; GENE-PRODUCT; MUTATION; DNA; PHOSPHORYLATION	Growth suppression by the Rb and p53 tumor suppressor proteins is mediated through effects on cell cycle regulatory proteins at the G1/S transition. Because overexpression of c-Abl induces G1 arrest in fibroblasts, we reasoned that c-Abl may also affect cell cycle proteins which regulate G1. We used fibroblasts containing disruptions of the Rb or p53 genes to genetically test the role of these proteins in c-Abl growth suppression. We find that c-Abl requires p53 but not Rb to suppress growth, c-Abl binds p53 in vitro and enhances p53 dependent transcription from a promoter containing p53 DNA binding sites. An Abl mutant which no longer binds p53 does not enhance p53 transcriptional activity and fails to suppress growth. These findings provide a novel link between a growth inhibitory tyrosine kinase and the p53 tumor suppressor protein.	UNIV CALIF LOS ANGELES,SCH MED,INST MOLEC BIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles			BERK, ARNOLD/AAF-7052-2020; Sawyers, Charles/G-5327-2016					AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1993, ONCOGENE, V8, P2457; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MATTIONI T, 1995, ONCOGENE, V10, P1325; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NEVINS JR, 1992, SCIENCE, V258, P424; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SERRANO M, 1993, NATURE, V16, P704; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRUANT R, 1993, J BIOL CHEM, V268, P2284; TSUKADA T, 1993, ONCOGENE, V8, P3313; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190	63	127	132	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					791	799						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651743				2022-12-17	WOS:A1995RQ46900023
J	DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC				DEPREZ, RHL; RIEGMAN, PHJ; GROEN, NA; WARRINGA, UL; VANBIEZEN, NA; MOLIJN, AC; BOOTSMA, D; DEJONG, PJ; MENON, AG; KLEY, NA; SEIZINGER, BR; ZWARTHOFF, EC			CLONING AND CHARACTERIZATION OF MN1, A GENE FROM CHROMOSOME 22Q11, WHICH IS DISRUPTED BY A BALANCED TRANSLOCATION IN A MENINGIOMA	ONCOGENE			English	Article						22Q11; BALANCED TRANSLOCATION; CAG REPEAT; MENINGIOMA; LEUKEMIA	TUMOR-SUPPRESSOR; NEUROFIBROMATOSIS; HETEROZYGOSITY; IDENTIFICATION; CARCINOMAS; TYPE-2; BRAIN	We have isolated a gene, called MN1, which resides on chromosome 22 and which was found to be disrupted by a balanced translocation (4;22) in meningioma 32. The MN1 gene spans about 70 kb and consists of at least two large exons of approximately 4.7 kb and 2.8 kb, The MN1 cDNA codes for a protein of 1319 amino acids when the first methionine in the open reading frame is used. The MN1 cDNA contains two CAG repeats, one of which codes for a string of 28 glutamines, The t(4;22) disrupts the S-exon within the open reading frame, In meningioma 32 no expression of the MN1 mRNA is observed, These results suggest that inactivation of the MN1 gene in this tumour may contribute to its pathogenesis.	ERASMUS UNIV ROTTERDAM, DEPT PATHOL, 3000 DR ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, DEPT CELL BIOL & GENET, 3000 DR ROTTERDAM, NETHERLANDS; ROSWELL PK CANC INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA; UNIV CINCINNATI, MED CTR, DEPT MOLEC GENET, CINCINNATI, OH 45267 USA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT MOLEC GENET & CELL BIOL, PRINCETON, NJ 08543 USA	Erasmus University Rotterdam; Erasmus University Rotterdam; Roswell Park Cancer Institute; University System of Ohio; University of Cincinnati; Bristol-Myers Squibb			Riegman, Peter/GLS-0041-2022; POPOVICI, Cornel/A-2027-2009	POPOVICI, Cornel/0000-0001-8226-3127				BIEGEL JA, 1990, J NEUROSURG, V73, P710, DOI 10.3171/jns.1990.73.5.0710; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; DEPREZ RHL, 1991, AM J HUM GENET, V48, P783; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; DEPREZ RHL, 1994, GENE CHROMOSOME CANC, V9, P24; DUMANSKI JP, 1990, CANCER RES, V50, P5863; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GOYNS MH, 1984, LEUKEMIA RES, V8, P547, DOI 10.1016/0145-2126(84)90003-1; JAMES CD, 1990, GENE CHROMOSOME CANC, V2, P94, DOI 10.1002/gcc.2870020204; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LARSSON C, 1990, GENE CHROMOSOME CANC, V2, P191, DOI 10.1002/gcc.2870020305; NEWSHAM I, 1994, GENOMICS, V19, P433, DOI 10.1006/geno.1994.1091; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; PEYRARD M, 1994, HUM MOL GENET, V3, P1393, DOI 10.1093/hmg/3.8.1393; PULST SM, 1993, NEUROLOGY, V43, P2096, DOI 10.1212/WNL.43.10.2096; REY JA, 1993, CANCER GENET CYTOGEN, V66, P1, DOI 10.1016/0165-4608(93)90140-H; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P452; RUTTLEDGE MH, 1994, GENE CHROMOSOME CANC, V10, P122, DOI 10.1002/gcc.2870100207; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; VANBIEZEN NA, 1993, GENOMICS, V15, P206, DOI 10.1006/geno.1993.1036; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VISKOCHIL D, 1990, CELL, V62, P87; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Warren S T, 1993, Curr Opin Neurobiol, V3, P752, DOI 10.1016/0959-4388(93)90149-S; ZANG KD, 1982, CANCER GENET CYTOGEN, V6, P249, DOI 10.1016/0165-4608(82)90063-2; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	35	127	129	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	1995	10	8					1521	1528						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU681	7731706				2022-12-17	WOS:A1995QU68100007
J	CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R				CHENG, NC; VANROY, N; CHAN, A; BEITSMA, M; WESTERVELD, A; SPELEMAN, F; VERSTEEG, R			DELETION MAPPING IN NEUROBLASTOMA CELL-LINES SUGGESTS 2 DISTINCT TUMOR-SUPPRESSOR GENES IN THE 1P35-36-REGION, ONLY ONE OF WHICH IS ASSOCIATED WITH N-MYC AMPLIFICATION	ONCOGENE			English	Article						NEUROBLASTOMA; TUMOR SUPPRESSOR GENES; N-MYC; CHROMOSOME 1	NEURO-BLASTOMA; EMBRYONIC LETHALITY; HUMAN CHROMOSOME-1; SHORT ARM; HETEROZYGOSITY; EXPRESSION; DNA; TUMORIGENICITY; MORPHOLOGY; ONCOGENE	Neuroblastoma is characterized by deletions of the short arm of chromosome 1 (1p) and amplification of the N-myc oncogene, We have made somatic cell hybrids of two human neuroblastoma cell lines, one with and one without N-myc expression and amplification, The expression of the amplified N-myc gene is completely switched off in the hybrids, This suggests that N-myc expression results from loss of a repressor function, As N-myc amplification is associated with loss of heterozygosity (LOH) of 1p36, we analysed 1p deletions in 16 neuroblastoma cell lines, The seven cell lines without N-myc amplification have no deletions or relatively small deletions, with an SRO on 1p36.23-33. This suggests that a tumor suppressor gene maps in this region, All nine cell lines with N-myc amplification have larger deletions, with an SRO from 1p35-36.1 to the telomere, This suggests that a second tumor suppressor gene which is associated with N-myc amplification maps more proximally, Fine mapping of 1p36 deletions in the two cell lines of the fusion experiment suggests that the distal locus is not a repressor of N-myc expression, but the more proximal locus could be a candidate for this function.	UNIV AMSTERDAM, ACAD MED CTR, DEPT HUMAN GENET, 1100 DE AMSTERDAM, NETHERLANDS; STATE UNIV GHENT, DEPT MED GENET, GHENT, BELGIUM	University of Amsterdam; Academic Medical Center Amsterdam; Ghent University			speleman, frank/AAR-5184-2020; Versteeg, Rogier/AAQ-1765-2020	speleman, frank/0000-0002-6628-8559; Versteeg, Rogier/0000-0001-7172-0388				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1981, CANCER RES, V41, P4678; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; COWELL JK, 1983, CANCER GENET CYTOGEN, V9, P273, DOI 10.1016/0165-4608(83)90011-0; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GRADY EF, 1987, CANCER RES, V47, P2931; HELSON L, 1980, HUMAN CANCER ITS CHA, P86; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUTHIER V, 1992, HUM MOL GENET, V1, P63; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SEEGER RC, 1977, CANCER RES, V37, P1364; SRIVATSAN ES, 1991, PROG CLIN BIOL RES, V366, P91; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; SUZUKI T, 1989, CANCER RES, V49, P1095; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANROY N, 1994, GENE CHROMOSOME CANC, V10, P103, DOI 10.1002/gcc.2870100205; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1994, ADV NEUROBLASTOMA RE, V4, P3; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	41	127	129	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 19	1995	10	2					291	297						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838528				2022-12-17	WOS:A1995QC62400008
J	NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M				NATOLI, G; AVANTAGGIATI, ML; CHIRILLO, P; PURI, P; IANNI, A; BALSANO, C; LEVRERO, M			RAS-DEPENDENT AND RAF-DEPENDENT ACTIVATION OF C-JUN TRANSCRIPTIONAL ACTIVITY BY THE HEPATITIS-B VIRUS TRANSACTIVATOR PX	ONCOGENE			English	Article							X-GENE PRODUCT; PROTEIN-KINASE; HEPATOCELLULAR-CARCINOMA; CELLS; PHOSPHORYLATION; EXPRESSION; PROTOONCOGENE; PROMOTERS; SERINE-63; GROWTH	The mechanisms by which pX, the transactivator of the Hepatitis B Virus (HBV), exerts its effects on transcription of viral and cellular genes have not yet been fully clarified. While previous reports suggested the possibility of a direct interaction of pX, which lacks intrinsic DNA-binding activity, with components of the cellular transcription machinery, more recent investigations support the hypothesis that pX might activate cellular kinases involved in transcriptional regulation and growth control. We analysed the mechanisms of c-Jun transcription factor activation by pX and in particular the role of cellular proteins involved in the transduction of mitogenic signals (namely Ha-Ras and Raf-1). In both HeLa and undifferentiated F9 cells pX was able to increase the activity of exogenous transfected c-Jun but not of c-Jun proteins bearing mutations in the serine residues located in the amino-terminal transcriptional activation domain. We show by use of Ha-Ras and Raf-1 dominant negative mutants that both Ha-Ras and Raf-1 are required for pX-induced activation of c-Jun transcriptional activity. In addition we show that pX is able to cooperate with Raf-1 in c-Jun activation. Our results are consistent with the hypothesis that at least one site of action of pX is peripheral and is located upstream of the Ras genes products.	UNIV ROMA LA SAPIENZA,POLICLIN UMBERTO 1,FDN ANDREA CESALPINO,I-00161 ROME,ITALY; UNIV CAGLIARI,IST MED INTERNA,CAGLIARI,ITALY; UNIV LAQUILA,DIPARTIMENTO MED INTERNA,I-67100 LAQUILA,ITALY	Sapienza University Rome; University Hospital Sapienza Rome; University of Cagliari; University of L'Aquila	NATOLI, G (corresponding author), UNIV ROMA LA SAPIENZA,IST CLIN MED 1,VIALE POLICLIN 155,I-00161 ROME,ITALY.		Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018; Balsano, Clara/AAK-9870-2020; Levrero, Massimo/G-5680-2016	Balsano, Clara/0000-0002-9615-7031; Natoli, Gioacchino/0000-0003-0711-2411; Puri, Pier Lorenzo/0000-0003-4964-0095; Levrero, Massimo/0000-0002-4978-0875				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUFIERO B, 1990, EMBO J, V9, P497, DOI 10.1002/j.1460-2075.1990.tb08136.x; AVANTAGGIATI ML, 1993, ONCOGENE, V8, P1567; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BALSANO C, 1994, IN PRESS J HEPATOL; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEASLEY RP, 1981, LANCET, V2, P1129; BLASI E, 1985, NATURE, V318, P667, DOI 10.1038/318667a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHISAKA O, 1987, GENE, V60, P183; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEITELSON MA, 1993, ONCOGENE, V8, P1109; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; HU KQ, 1990, P NATL ACAD SCI USA, V87, P7140, DOI 10.1073/pnas.87.18.7140; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KOIKE K, 1989, MOL BIOL MED, V6, P151; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LEE TH, 1991, J VIROL, V65, P5939; LEVRERO M, 1990, J VIROL, V64, P3082, DOI 10.1128/JVI.64.6.3082-3086.1990; LEVRERO M, 1990, VIROLOGY, V174, P299, DOI 10.1016/0042-6822(90)90079-7; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; SCHEK N, 1991, ONCOGENE, V6, P1735; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SETO E, 1988, P NATL ACAD SCI USA, V85, P8286, DOI 10.1073/pnas.85.21.8286; SETO E, 1990, NATURE, V344, P72, DOI 10.1038/344072a0; SIDDIQUI A, 1987, P NATL ACAD SCI USA, V84, P2513, DOI 10.1073/pnas.84.8.2513; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; TAKADA S, 1994, ONCOGENE, V9, P341; TWU JS, 1989, P NATL ACAD SCI USA, V86, P2046, DOI 10.1073/pnas.86.6.2046; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; TWU JS, 1993, VIROLOGY, V192, P346, DOI 10.1006/viro.1993.1041; UNGER T, 1990, EMBO J, V9, P1889, DOI 10.1002/j.1460-2075.1990.tb08315.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; ZAHM P, 1988, ONCOGENE, V3, P169; ZHOU DX, 1990, J VIROL, V64, P4025, DOI 10.1128/JVI.64.8.4025-4028.1990	46	127	128	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					2837	2843						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084589				2022-12-17	WOS:A1994PG82200009
J	LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW				LANG, FF; MILLER, DC; PISHARODY, S; KOSLOW, M; NEWCOMB, EW			HIGH-FREQUENCY OF P53 PROTEIN ACCUMULATION WITHOUT P53 GENE MUTATION IN HUMAN JUVENILE PILOCYTIC, LOW-GRADE AND ANAPLASTIC ASTROCYTOMAS	ONCOGENE			English	Note							17P ALLELIC LOSS; ACTIVATING MUTATIONS; BREAST-CANCER; EXPRESSION; HETEROZYGOSITY; OVEREXPRESSION; FORMS; CHROMOSOME-17; CARCINOMA; ONCOGENE	We analysed 31 non-glioblastoma astrocytomas for alterations in p53 protein expression and for mutations in the p53 gene. Immunohistochemistry detected p53 protein accumulation in 71% (five of seven) of juvenile pilocytic astrocytomas (WHO grade I), 63% (five of eight) of astrocytomas (WHO grade II), and 63% (10 of 16) of anaplastic astrocytomas (WHO grade III). The single strand conformation polymorphism (SSCP) assay of exons 2-11 of the p53 gene and direct DNA sequencing identified p53 mutations in 14% (one of seven) of grade I, 25% (two of eight) of grade II, and 19% (three of 16) of grade III astrocytomas. This is the first report of a p53 mutation in grade I juvenile pilocytic astrocytomas. Immunohistochemistry and SSCP analyses gave concordant results in 55% (17 of the 31) of the tumors. A total of 14 tumors, 60-80% within each grade, showed p53 protein accumulation in the absence of detectable mutations of the p53 gene. No mdm-2 gene amplification was found in these tumors. The similar frequency of p53 alterations in tumors of grades I-III suggests that the p53 gene plays a significant role early in the formation of astrocytomas rather than late in tumor progression to higher grade. The data suggest that mechanisms other than p53 gene inactivation by mutation or mdm-2 complex formation result in the accumulation of P53 protein in > 70% of non-glioblastoma astrocytomas.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,DEPT NEUROSURG,NEW YORK,NY 10016; KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016	New York University; New York University					NCI NIH HHS [CA 40533] Funding Source: Medline; PHS HHS [P30-16087] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040533, R23CA040533, R29CA040533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARTEK J, 1991, ONCOGENE, V6, P1699; BENNETT WP, 1992, CANCER RES, V52, P6092; BRUNER JM, 1991, MODERN PATHOL, V4, P671; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAMPO E, 1991, CANCER RES, V51, P4436; CATTORETTI G, 1988, INT J CANCER, V41, P178, DOI 10.1002/ijc.2910410204; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; CUNNINGHAM J, 1992, CANCER RES, V52, P1974; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULTS D, 1992, CANCER RES, V52, P674; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; KLEIHUES P, 1993, HISTOLOGIC TYPING TU; KOHLER MF, 1992, CANCER RES, V52, P1622; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAM NJ, 1993, CANCER RES, V53, P2235; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LEACH FS, 1993, CANCER RES, V53, P2231; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P31, DOI 10.1097/00005072-199301000-00005; MARKS JR, 1991, CANCER RES, V51, P2979; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEWCOMB EW, 1993, BRAIN PATHOL, V3, P229, DOI 10.1111/j.1750-3639.1993.tb00749.x; NEWCOMB EW, 1993, GROWTH CONTROL NEOPL, P53; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; OKAZAKI H, 1989, FUNDAMENTALS NEUROPA, P205; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; REIFENBERGER G, 1993, CANCER RES, V53, P2736; RUBIO MP, 1993, CANCER RES, V53, P3465; SAXENA A, 1992, CANCER RES, V52, P6716; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; STRETCH JR, 1991, CANCER RES, V51, P5976; SZENASY J, 1983, CHILD BRAIN, V10, P39; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WAGATA T, 1993, CANCER RES, V53, P846; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303	45	127	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					949	954						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108140				2022-12-17	WOS:A1994MW55100033
J	MAISONPIERRE, PC; GOLDFARB, M; YANCOPOULOS, GD; GAO, GX				MAISONPIERRE, PC; GOLDFARB, M; YANCOPOULOS, GD; GAO, GX			DISTINCT RAT GENES WITH RELATED PROFILES OF EXPRESSION DEFINE A TIE RECEPTOR TYROSINE KINASE FAMILY	ONCOGENE			English	Article							CLONING; DOMAINS; MOUSE	We have isolated rat cDNAs that encode two related receptor-like tyrosine kinases. One of these receptors, TIE-1, is the rat homolog of a recently described human receptor-like kinase termed TIE (Partanen et al., 1992). The related TIE-2 receptor has the same organization of amino acid sequence motifis characteristic of TIE-1: two immunoglobulin-like domains, three epidermal growth factor (EGF)-like domains and three fibronectin III-like repeats in the extracellular region and a short kinase insert sequence and C-terminal tail in the intracellular region. The amino acid sequences of the intracellular and extracellular regions of TIE-1 and TIE-2 are 79% and 32% identical respectively. Both tie genes are broadly expressed in embryonic, neonatal and adult tissues, accounted for largely by their coexpression in endothelial cells. The tie-2 gene is also uniquely expressed in several additional embryonic tissues, including the lens epithelium and the heart epicardium.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University	MAISONPIERRE, PC (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.							DUMONT DJ, 1992, ONCOGENE, V7, P1471; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUB O, 1991, DEVELOPMENT, V112, P397; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; STARK KL, 1991, DEVELOPMENT, V113, P641; STRUELI M, 1988, J EXP MED, V168, P1523; TAKAHASHI M, 1988, ONCOGENE, V3, P571; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	19	127	144	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1993	8	6					1631	1637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	7684830				2022-12-17	WOS:A1993LE06400027
J	SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL				SMITH, K; HOULBROOK, S; GREENALL, M; CARMICHAEL, J; HARRIS, AL			TOPOISOMERASE-II-ALPHA COAMPLIFICATION WITH ERBB2 IN HUMAN PRIMARY BREAST-CANCER AND BREAST-CANCER CELL-LINES - RELATIONSHIP TO M-AMSA AND MITOXANTRONE SENSITIVITY	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; DNA TOPOISOMERASES; PROTEIN OVEREXPRESSION; PROGNOSTIC-SIGNIFICANCE; CHROMOSOME BREAKAGE; DRUG-ACTION; EXPRESSION; GENE; PROLIFERATION; CARCINOMA	Topoisomerase IIalpha (topo IIalpha) is a key enzyme in DNA replication and a target for many anti-cancer drugs. High levels are associated with sensitivity to topoisomerase II inhibitors. Because its chromosome location is similar to erbB2 (17q21-22), which is frequently amplified in breast cancer, co-amplification of these genes was assessed. In 117 primary breast cancers, 25 were amplified for erbB2. Three of these cases showed co-amplification of topo IIalpha. Topo IIbeta was not amplified. Four human breast cancer cell lines were assessed for erbB2 and topo IIalpha co-amplification. They were also analysed for sensitivity to the topoisomerase inhibitors m-AMSA and mitoxantrone. The most sensitive cell line was SKBr3, which was the only one with erbB2 amplification. Topo IIalpha was co-amplified to a similar extent as in tumours. This suggests that patients whose tumours show topo IIalpha amplification should be assessed specifically for therapy with topoisomerase inhibitors.	UNIV OXFORD,JOHN RADCLIFFE HOSP,IMPERIAL CANC RES FUND,INST MOLEC MED,MOLEC ONCOL LABS,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,DEPT SURG,OXFORD OX3 9DU,ENGLAND	University of Oxford; University of Oxford			Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				BAE YS, 1988, P NATL ACAD SCI USA, V85, P2076, DOI 10.1073/pnas.85.7.2076; BARNES DM, 1988, BRIT J CANCER, V58, P448, DOI 10.1038/bjc.1988.238; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUGG BY, 1991, P NATL ACAD SCI USA, V88, P7654, DOI 10.1073/pnas.88.17.7654; CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHUNG TDY, 1989, P NATL ACAD SCI USA, V86, P9431, DOI 10.1073/pnas.86.23.9431; DAVIES SM, 1988, J BIOL CHEM, V263, P17724; DAVIES SM, 1989, NUCLEIC ACIDS RES, V17, P1337, DOI 10.1093/nar/17.4.1337; DILLEHAY LE, 1989, MUTAT RES, V215, P15, DOI 10.1016/0027-5107(89)90213-3; DRAKE FH, 1987, J BIOL CHEM, V262, P16739; DRAKE FH, 1989, BIOCHEMISTRY-US, V28, P8154, DOI 10.1021/bi00446a029; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EPSTEIN RJ, 1989, BIOCHEM BIOPH RES CO, V160, P12, DOI 10.1016/0006-291X(89)91613-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FREAKE HC, 1981, BIOCHEM BIOPH RES CO, V101, P1131, DOI 10.1016/0006-291X(81)91565-5; FRICHE E, 1991, CANCER RES, V51, P4213; GLIKIN GC, 1986, EMBO J, V5, P151, DOI 10.1002/j.1460-2075.1986.tb04189.x; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HARRIS AL, 1990, LANCET, V335, P186, DOI 10.1016/0140-6736(90)90277-C; HECK MMS, 1986, J CELL BIOL, V103, P2569, DOI 10.1083/jcb.103.6.2569; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HINDS M, 1991, CANCER RES, V51, P4729; HOFKER MH, 1985, HUM GENET, V70, P148, DOI 10.1007/BF00273073; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HONG JH, 1990, BIOMED PHARMACOTHER, V44, P41, DOI 10.1016/0753-3322(90)90068-K; HORAK E, 1991, ONCOGENE, V6, P2277; HSIANG YH, 1988, CANCER RES, V48, P3230; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KEITH WN, 1992, IN PRESS GENES CHROM; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LONG BH, 1991, CANCER RES, V51, P5275; NELSON WG, 1987, CANCER RES, V47, P3246; NICHOLSON S, 1988, INT J CANCER, V42, P36, DOI 10.1002/ijc.2910420108; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; PENG J, 1988, P NATL ACAD SCI USA, V85, P7177; PERREN TJ, 1991, BRIT J CANCER, V63, P328, DOI 10.1038/bjc.1991.78; PLUMB JA, 1989, CANCER RES, V49, P4435; RILKE F, 1991, INT J CANCER, V49, P44, DOI 10.1002/ijc.2910490109; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROWE TC, 1986, CANCER RES, V46, P2021; SAINTRUF C, 1991, ONCOGENE, V6, P403; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; SULLIVAN DM, 1986, BIOCHEMISTRY-US, V25, P2248, DOI 10.1021/bi00356a060; SULLIVAN DM, 1987, CANCER RES, V47, P3973; TSAIPFLUGFELDER M, 1988, P NATL ACAD SCI USA, V85, P7177, DOI 10.1073/pnas.85.19.7177; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WRIGHT C, 1992, BRIT J CANCER, V65, P271, DOI 10.1038/bjc.1992.54; WRIGHT C, 1989, CANCER RES, V49, P2087; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; 1980, EUR J CANCER, V16, P1313; 1992, LANCET, V339, P71	65	127	130	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8096076				2022-12-17	WOS:A1993KT22000015
J	STRASSER, A; HARRIS, AW; CORY, S				STRASSER, A; HARRIS, AW; CORY, S			E-MU-BCL-2 TRANSGENE FACILITATES SPONTANEOUS TRANSFORMATION OF EARLY PRE-B AND IMMUNOGLOBULIN-SECRETING CELLS BUT NOT T-CELLS	ONCOGENE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; LIGHT CHAIN GENE; HUMAN FOLLICULAR LYMPHOMA; C-MYC ONCOGENE; BCL-2 GENE; CHROMOSOME-TRANSLOCATION; VARIANT TRANSLOCATION; MEMBRANE PROTEIN; ACTIVATION; EXPRESSION	To assess the lymphoid tumorigenic potential of bcl-2, mice of five independent strains expressing a bcl-2 transgene in B and/or T cells were monitored for disease up to 12 months of age. Lymphoma prevalence was minimal in the T lineage but significant, although low (3-15%), in the B lineage. The principal types of tumors were plasmacytomas secreting immunoglobulin and novel lymphomas that expressed markers such as Sca-1, CD4, Thy-1, CD34 and CD45(B220), consistent with an origin very early in B-lymphoid development. Rearrangement of the c-myc gene was common in the plasmacytomas, implying a synergistic role for myc and bcl-2 in their etiology, but was not detected in the lymphomas.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Cory, Suzanne/E-1642-2013; Strasser, Andreas/C-7581-2013	Cory, Suzanne/0000-0002-6818-3451; Strasser, Andreas/0000-0002-5020-4891	NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER; NCI NIH HHS [CA43540] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AISENBERG AC, 1988, BLOOD, V71, P969; ALLEN JD, 1991, GENE DEV, V5, P509, DOI 10.1101/gad.5.4.509; ARMITAGE JO, 1988, J NATL CANCER I, V80, P576, DOI 10.1093/jnci/80.8.576; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROWN J, 1991, INT IMMUNOL, V3, P175, DOI 10.1093/intimm/3.2.175; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; FREDRICKSON GG, 1989, J EXP MED, V169, P1473, DOI 10.1084/jem.169.4.1473; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HILLION J, 1991, ONCOGENE, V6, P169; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORNING SJ, 1984, NEW ENGL J MED, V311, P1471, DOI 10.1056/NEJM198412063112303; HUA C, 1990, ONCOGENE, V5, P233; KIEM HP, 1990, ONCOGENE, V5, P1815; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; KUDO A, 1987, EMBO J, V6, P2267, DOI 10.1002/j.1460-2075.1987.tb02500.x; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; LEE MS, 1987, BLOOD, V70, P90; LIMPENS J, 1991, ONCOGENE, V6, P2271; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUFTI GJ, 1983, BLOOD, V62, P1142; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; PORTLOCK CS, 1979, ANN INTERN MED, V90, P10, DOI 10.7326/0003-4819-90-1-10; RAGHOEBIER S, 1991, BLOOD, V77, P1560; RECHAVI G, 1989, LEUKEMIA, V3, P57; RICHARDSON ME, 1987, BLOOD, V70, P444; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; STETLERSTEVENSON M, 1990, J NATL CANCER I, V82, P855, DOI 10.1093/jnci/82.10.855; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEISS LM, 1987, NEW ENGL J MED, V317, P1185, DOI 10.1056/NEJM198711053171904; WU L, 1991, NATURE, V349, P71, DOI 10.1038/349071a0; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZELENETZ AD, 1991, J EXP MED, V173, P197, DOI 10.1084/jem.173.1.197; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; ZUTTER M, 1991, BLOOD, V78, P1062	64	127	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1993	8	1					1	9						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423986				2022-12-17	WOS:A1993KN00500001
J	DOWNING, JR; REYNOLDS, AB				DOWNING, JR; REYNOLDS, AB			PDGF, CSF-1, AND EGF INDUCE TYROSINE PHOSPHORYLATION OF P120, A PP60SRC TRANSFORMATION-ASSOCIATED SUBSTRATE	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; FMS PROTO-ONCOGENE; GTPASE ACTIVATING PROTEIN; CELLULAR SRC GENE; FACTOR-I RECEPTOR; KINASE-ACTIVITY; GROWTH-FACTOR; STRUCTURAL ALTERATION; CARBOXY TERMINUS; POINT MUTATION	Transformation by activated pp60c-src has been correlated by genetic analysis with the tyrosine phosphorylation of a 120 kilodalton (kDa) protein, p120. We now demonstrate tyrosine phosphorylation of p120 following stimulation of cells by growth factors whose receptors have intrinsic tyrosine-specific protein kinase activity. Stimulation of quiescent NIH3T3 cells with platelet-derived growth factor (PDGF) resulted in the tyrosine phosphorylation of p120 that was maximal by 5 min and returned to background levels by 30 min. p120 was also phosphorylated on tyrosine after addition of colony-stimulating factor 1 (CSF-1) or epidermal growth factor (EGF) to NIH3T3 cells engineered to express high levels of their respective receptors. Two additional src substrates, p110 and p85, were analysed under identical assay conditions. PDGF, CSF-1, and EGF induced only a minimal increase in the tyrosine phosphorylation of p85 and no change in the phosphorylation of p110. Thus, the marked ligand-induced tyrosine phosphorylation of p120 was a property not shared by the other src substrates examined. Immunoblotting with antibodies to p120 and the ras GTPase activating protein, GAP, suggests that p120 and GAP are unrelated. In addition, the amino acid sequences of four cyanogen bromide peptides derived from p120 showed no homology to GAP or to sequences in either the PIR or Swiss-Prot databases. These data suggest that tyrosine phosphorylation of p120 may contribute to both signal transduction through growth factor receptors and pp60src induced transformation.	ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital			Downing, James R./N-8102-2018		NATIONAL CANCER INSTITUTE [P30CA021765, K08CA001429] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765, CA-01429] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; BUSS JE, 1984, MOL CELL BIOL, V4, P2697, DOI 10.1128/MCB.4.12.2697; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANIEL TO, 1985, P NATL ACAD SCI USA, V82, P2684, DOI 10.1073/pnas.82.9.2684; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KANNER SB, IN PRESS MOL CELL BI; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NORI M, 1990, MOL CELL BIOL, V10, P4155, DOI 10.1128/MCB.10.8.4155; OHTSUKA M, 1984, INT J CANCER, V34, P855, DOI 10.1002/ijc.2910340618; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; Shalloway D., 1984, CANCER CELL, V2, P9; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	55	127	132	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					607	613						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1851549				2022-12-17	WOS:A1991FR93900016
J	Murakami, S; Shahbazian, D; Surana, R; Zhang, W; Chen, H; Graham, GT; White, SM; Weiner, LM; Yi, C				Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G. T.; White, S. M.; Weiner, L. M.; Yi, C.			Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							COLONY-STIMULATING FACTOR; SUPPRESSOR-CELLS; GM-CSF; BONE-MARROW; PROMOTES RESISTANCE; LUNG-CANCER; MUTANT KRAS; PROGRESSION; INFILTRATION; MACROPHAGES	Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high degree of inflammation and profound immune suppression. Here we identify Yes-associated protein (Yap) as a critical regulator of the immunosuppressive microenvironment in both mouse and human PDAC. Within Kras: p53 mutant pancreatic ductal cells, Yap drives the expression and secretion of multiple cytokines/chemokines, which in turn promote the differentiation and accumulation of myeloid-derived suppressor cells (MDSCs) both in vitro and in vivo. Pancreas-specific knockout of Yap or antibody-mediated depletion of MDSCs promoted macrophage reprogramming, reactivation of T cells, apoptosis of Kras mutant neoplastic ductal cells and pancreatic regeneration after acute pancreatitis. In primary human PDAC, YAP expression levels strongly correlate with an MDSC gene signature, and high expression of YAP or MDSC-related genes predicts decreased survival in PDAC patients. These results reveal multifaceted roles of YAP in PDAC pathogenesis and underscore its promise as a therapeutic target for this deadly disease.	[Murakami, S.; Shahbazian, D.; Surana, R.; Zhang, W.; Chen, H.; Graham, G. T.; White, S. M.; Weiner, L. M.; Yi, C.] Georgetown Univ Med Ctr, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20057 USA; [Zhang, W.] Nankai Univ, Coll Life Sci, Dept Canc Res, Tianjin, Peoples R China	Georgetown University; Nankai University	Yi, C (corresponding author), Georgetown Univ Med Ctr, Lombardi Comprehens Canc Ctr, 3970 Reservoir Rd NW, Washington, DC 20057 USA.	cy232@georgetown.edu		Graham, Garrett/0000-0002-1097-0962	NIH [R01CA187090, R01CA50633]; V Foundation and the Advocure foundation; Cancer Center [CA051008]; Lombardi Cancer Center Shared Resources; NATIONAL CANCER INSTITUTE [R01CA187090, T32CA009686, R01CA050633, P30CA051008] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); V Foundation and the Advocure foundation; Cancer Center; Lombardi Cancer Center Shared Resources; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs T Jacks (MIT), DJ Pan ( Johns Hopkins) and CV Wright (Vanderbilt) for producing and sharing the original mouse strains used in this study. We are grateful for the helpful suggestions and critical comments of our manuscript from Dr S Ostrand-Rosenberg (UMBC). We would also like to thank Dr Karen Creswell from the Flow Cytometry and Cell Sorting Shared Resource (FCSR) for her technical guidance. We appreciate the technical assistance from FCSR, Microscopy & Imaging Shared Resource (MISR), Histopathology & Tissue Shared Resource (HTSR) and Genomics & Epigenomics Shared Resource (GESR) at Lombardi Cancer Center Shared Resources. We thank the husbandry staff and technicians of the Division of Comparative Medicine (DCM) at Georgetown University for support in our animal studies. CY is supported by NIH (R01CA187090), the V Foundation and the Advocure foundation. LMW is the PI of NIH (R01CA50633), and Cancer Center Support Grant (CA051008) that also supports the Lombardi Cancer Center Shared Resources.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALDERSON MR, 1991, J EXP MED, V173, P923, DOI 10.1084/jem.173.4.923; Bardeesy N, 2001, SEMIN CANCER BIOL, V11, P201, DOI 10.1006/scbi.2000.0371; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Bhatia M, 2004, AM J PHYSIOL-GASTR L, V286, pG189, DOI 10.1152/ajpgi.00304.2003; Brembeck FH, 2003, CANCER RES, V63, P2005; Calabro L, 2013, LANCET ONCOL, V14, P1104, DOI 10.1016/S1470-2045(13)70381-4; Carriere C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027725; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; FAHEY TJ, 1992, J IMMUNOL, V148, P2764; FALK LA, 1988, J LEUKOCYTE BIOL, V43, P148, DOI 10.1002/jlb.43.2.148; Feig C, 2012, CLIN CANCER RES, V18, P4266, DOI 10.1158/1078-0432.CCR-11-3114; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Grippo PJ, 2003, CANCER RES, V63, P2016; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061; Jaffee EM, 2002, CANCER CELL, V2, P25, DOI 10.1016/S1535-6108(02)00093-4; Jensen JN, 2005, GASTROENTEROLOGY, V128, P728, DOI 10.1053/j.gastro.2004.12.008; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Katoh H, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/159269; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Khaled YS, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/879897; Kim MH, 2016, EMBO J, V35, P462, DOI 10.15252/embj.201592081; Kitamura T, 2015, J EXP MED, V212, P1043, DOI 10.1084/jem.20141836; Kurahara H, 2013, PANCREAS, V42, P155, DOI 10.1097/MPA.0b013e318254f2d1; Lacey DC, 2012, J IMMUNOL, V188, P5752, DOI 10.4049/jimmunol.1103426; Le DT, 2013, J IMMUNOTHER, V36, P382, DOI 10.1097/CJI.0b013e31829fb7a2; Lechner MG, 2010, J IMMUNOL, V185, P2273, DOI 10.4049/jimmunol.1000901; Li XG, 2017, GUT, V66, P157, DOI 10.1136/gutjnl-2015-310514; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lindell DM, 2001, INFECT IMMUN, V69, P6364, DOI 10.1128/IAI.69.10.6364-6369.2001; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601; Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010; Markowitz J, 2015, CANCER IMMUNOL IMMUN, V64, P149, DOI 10.1007/s00262-014-1618-8; Mok S, 2014, CANCER RES, V74, P153, DOI 10.1158/0008-5472.CAN-13-1816; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Munigala S, 2014, CLIN GASTROENTEROL H, V12, P1143, DOI 10.1016/j.cgh.2013.12.033; Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010; Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417; Obermajer N, 2011, CANCER RES, V71, P7463, DOI 10.1158/0008-5472.CAN-11-2449; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parker KH, 2015, ADV CANCER RES, V128, P95, DOI 10.1016/bs.acr.2015.04.002; Phan VT, 2013, P NATL ACAD SCI USA, V110, P6079, DOI 10.1073/pnas.1303302110; Plouffe SW, 2015, TRENDS MOL MED, V21, P212, DOI 10.1016/j.molmed.2015.01.003; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; Royal RE, 2010, J IMMUNOTHER, V33, P828, DOI 10.1097/CJI.0b013e3181eec14c; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Schutte M, 1997, CANCER RES, V57, P3126; Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sierra-Filardi E, 2014, J IMMUNOL, V192, P3858, DOI 10.4049/jimmunol.1302821; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Strauss L, 2015, CANCER CELL, V28, P253, DOI 10.1016/j.ccell.2015.07.006; Stromnes IM, 2014, GUT, V63, P1769, DOI 10.1136/gutjnl-2013-306271; Surana R, 2014, CANCER IMMUNOL RES, V2, P1103, DOI 10.1158/2326-6066.CIR-14-0103; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Tuveson DA, 2006, CANCER RES, V66, P242, DOI 10.1158/0008-5472.CAN-05-2305; Wang GC, 2016, CANCER DISCOV, V6, P80, DOI 10.1158/2159-8290.CD-15-0224; Xue J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8158; Zeng LJ, 2014, J CANCER, V5, P754, DOI 10.7150/jca.10238; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049; Zhang YL, 2009, J IMMUNOL, V182, P3801, DOI 10.4049/jimmunol.0801548; Zhao F, 2009, IMMUNOLOGY, V128, P141, DOI 10.1111/j.1365-2567.2009.03105.x; Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115; Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723	76	126	128	1	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	9					1232	1244		10.1038/onc.2016.288	http://dx.doi.org/10.1038/onc.2016.288			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EN2SV	27546622	Green Accepted			2022-12-17	WOS:000395861300007
J	Kawada, M; Seno, H; Kanda, K; Nakanishi, Y; Akitake, R; Komekado, H; Kawada, K; Sakai, Y; Mizoguchi, E; Chiba, T				Kawada, M.; Seno, H.; Kanda, K.; Nakanishi, Y.; Akitake, R.; Komekado, H.; Kawada, K.; Sakai, Y.; Mizoguchi, E.; Chiba, T.			Chitinase 3-like 1 promotes macrophage recruitment and angiogenesis in colorectal cancer	ONCOGENE			English	Article						chitinase; tumor; microenvironment; chemokine; MAPK	COLONIC EPITHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SERUM YKL-40; TUMOR ANGIOGENESIS; BACTERIAL ADHESION; PROTEIN; CHEMOKINES; INFLAMMATION; CLASSIFICATION; GLYCOPROTEIN	Chitinase 3-like 1 (CHI3L1), one of the mammalian members of the chitinase family, is expressed in several types of human cancer, and elevated serum level of CHI3L1 is suggested to be a biomarker of poor prognosis in advanced cancer patients. However, the overall biological function of CHI3L1 in human cancers still remains unknown. Studies were performed to characterize the role of CHI3L1 in cancer pathophysiology utilizing human colorectal cancer samples and human cell lines. Plasma protein and tissue mRNA expression levels of CHI3L1 in colorectal cancer were strongly upregulated. Immunohistochemical analysis showed that CHI3L1 was expressed in cancer cells, and CHI3L1 expression had a significant association with the number of infiltrated macrophages and microvessel density (MVD). By utilizing transwell migration and tube-formation assays, overexpression of CHI3L1 in SW480 cells (human colon cancer cells) enhanced the migration of THP-1 cells (human macrophage cells) and HUVECs (human endothelial cells), and the tube formation of HUVECs. The knockdown of CHI3L1 by RNA interference or the neutralization of CHI3L1 by anti-CHI3L1 antibody displayed strong suppression of CHI3L1-induced migration and tube formation. Cell proliferation assay showed that CHI3L1 overexpression significantly enhanced the proliferation of SW480 cells. Enzyme-linked immunosorbent assay (ELISA) analysis showed that CHI3L1 increased the secretion of inflammatory chemokines, IL-8 and monocyte chemoattractant protein-1 (MCP-1), from SW480 cells through mitogen-activated protein kinase (MAPK) signaling pathway. Both neutralization of IL-8 or MCP-1 and inhibition or knockdown of MAPK in SW480 cells significantly inhibited CHI3L1-induced migration and tube formation. In a xenograft mouse model, overexpression of CHI3L1 in HCT116 cells (human colon cancer cells) enhanced the tumor growth as well as macrophage infiltration and MVD. In conclusion, CHI3L1 expressed in colon cancer cells promotes cancer cell proliferation, macrophage recruitment and angiogenesis. Thus, the inhibition of CHI3L1 activity may be a novel therapeutic strategy for human colorectal cancer. Oncogene (2012) 31, 3111-3123; doi:10.1038/onc.2011.498; published online 7 November 2011	[Kawada, M.; Seno, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Shogoin, Kyoto 6068507, Japan; [Kawada, M.] Japan Soc Promot Sci JSPS, Tokyo, Japan; [Kawada, K.; Sakai, Y.] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; [Mizoguchi, E.] Harvard Univ, Sch Med, Dept Med, Gastrointestinal Unit, Boston, MA USA; [Mizoguchi, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Study Inflammatory Bowel Dis, Boston, MA USA	Kyoto University; Japan Society for the Promotion of Science; Kyoto University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kawada, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Shogoin, Kyoto 6068507, Japan.	kawadam@kuhp.kyoto-u.ac.jp; seno@kuhp.kyoto-u.ac.jp		Seno, Hiroshi/0000-0002-8509-8128	Japan Society for the Promotion of Science (JSPS) [20790493, 21-40033, 23590937, 21229009]; Ministry of Health, Labor and Welfare, Japan; National Institutes of Health in USA [R01DK80070]; Research Foundation of Translational Research Center, Kyoto University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, R01DK080070] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [23590937, 21229009] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Health, Labor and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); National Institutes of Health in USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Research Foundation of Translational Research Center, Kyoto University; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (20790493, 21-40033, 23590937, 21229009), and Health and Labor Science Research Grants for Research on Intractable Diseases, and Research on Hepatitis from the Ministry of Health, Labor and Welfare, Japan, and Research Foundation of Translational Research Center, Kyoto University and by a research grant (R01DK80070) from the National Institutes of Health in USA.	Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; Ben-Baruch A, 2006, CANCER METAST REV, V25, P357, DOI 10.1007/s10555-006-9003-5; Chen CC, 2011, AM J PATHOL, V179, P1494, DOI 10.1016/j.ajpath.2011.05.038; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Eurich K, 2009, WORLD J GASTROENTERO, V15, P5249, DOI 10.3748/wjg.15.5249; Guo XY, 2008, J BIOL CHEM, V283, P19864, DOI 10.1074/jbc.M800798200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Herrera-Estrella A, 1999, EXS, V87, P171; Johansen JS, 2006, CANCER EPIDEM BIOMAR, V15, P194, DOI 10.1158/1055-9965.EPI-05-0011; Johansen JS, 2006, DAN MED BULL, V53, P172; Kawada K, 2009, MOL CELL BIOL, V29, P4508, DOI 10.1128/MCB.00015-09; Kawada M, 2008, LAB INVEST, V88, P883, DOI 10.1038/labinvest.2008.47; Kawada Mayumi, 2007, Keio Journal of Medicine, V56, P21, DOI 10.2302/kjm.56.21; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Ling H, 2004, BIOCHEM J, V380, P651, DOI 10.1042/BJ20040099; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mizoguchi E, 2006, GASTROENTEROLOGY, V130, P398, DOI 10.1053/j.gastro.2005.12.007; Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349-7006.2008.00853.x; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; REJMAN JJ, 1988, BIOCHEM BIOPH RES CO, V150, P329, DOI 10.1016/0006-291X(88)90524-4; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Singh S, 2007, CANCER METAST REV, V26, P453, DOI 10.1007/s10555-007-9068-9; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286	34	126	132	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2012	31	26					3111	3123		10.1038/onc.2011.498	http://dx.doi.org/10.1038/onc.2011.498			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	967UX	22056877	Green Submitted, Green Accepted			2022-12-17	WOS:000305934400001
J	Shen, S; Kepp, O; Michaud, M; Martins, I; Minoux, H; Metivier, D; Maiuri, MC; Kroemer, RT; Kroemer, G				Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Minoux, H.; Metivier, D.; Maiuri, M. C.; Kroemer, R. T.; Kroemer, G.			Association and dissociation of autophagy, apoptosis and necrosis by systematic chemical study	ONCOGENE			English	Article						high-content screen; autophagy; cell death; systematic analysis; cancer therapy	PROGRAMMED CELL-DEATH; DEGRADATION; INHIBITION; STRESS; LYSOSOMES; INDUCTION; PROTEINS; DISEASE; MTORC1; LC3	To address the question of whether established or experimental anticancer chemotherapeutics can exert their cytotoxic effects by autophagy, we performed a high-content screen on a set of cytotoxic agents. We simultaneously determined parameters of autophagy, apoptosis and necrosis on cells exposed to similar to 1400 compounds. Many agents induced a 'pure' autophagic, apoptotic or necrotic phenotype, whereas less than 100 simultaneously induced autophagy, apoptosis and necrosis. A systematic analysis of the autophagic flux induced by the most potent 80 inducers of GFP-LC3 puncta among the NCI panel agents showed that 59 among them truly induced autophagy. The remaining 21 compounds were potent inducers of apoptosis or necrosis, yet failed to stimulate an autophagic flux, which were characterized as microtubule inhibitors. Knockdown of ATG7 was efficient in preventing GFP-LC3 puncta, yet failed to attenuate cell death by the agents that induce GFP-LC3 puncta. Thus there is not a single compound that would induce cell death by autophagy in our screening, underscoring the idea that cell death is rarely, if ever, executed by autophagy in human cells. Oncogene (2011) 30, 4544-4556; doi: 10.1038/onc.2011.168; published online 16 May 2011	[Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Metivier, D.; Maiuri, M. C.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Shen, S.; Kepp, O.; Michaud, M.; Martins, I.; Metivier, D.; Maiuri, M. C.] Univ Paris 11, Villejuif, France; [Minoux, H.; Kroemer, R. T.] Sanofi Aventis, Struct Design & Informat, Vitry Sur Seine, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Paris, France; [Kroemer, G.] Univ Paris 05, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Sanofi-Aventis; Sanofi France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	KROEMER, Guido/B-4263-2013; Kepp, Oliver/GPX-8627-2022; Kroemer, Guido/AAY-9859-2020; SHEN, Shensi/AAW-2735-2020; Kepp, Oliver/N-2763-2017	KROEMER, Guido/0000-0002-9334-4405; SHEN, Shensi/0000-0002-5087-8220; Kepp, Oliver/0000-0002-6081-9558	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR); European Commission; Fondation pour la Recherche Medicale (FRM); Fondation Bettencourt-Schueller; Institut National du Cancer (INCa); Canceropole Ile-de-France; European Commission Apo-Sys; La Ligue contre le Cancer	Ligue Nationale contre le Cancer (Equipes labellisee); Agence Nationale pour la Recherche (ANR)(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Fondation Bettencourt-Schueller; Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); European Commission Apo-Sys(European CommissionEuropean Commission Joint Research Centre); La Ligue contre le Cancer(Ligue nationale contre le cancer)	GK is supported by the Ligue Nationale contre le Cancer (Equipes labellisee), Agence Nationale pour la Recherche (ANR), European Commission (Active p53, Apo-Sys, ChemoRes, ApopTrain), Fondation pour la Recherche Medicale (FRM), Fondation Bettencourt-Schueller, Institut National du Cancer (INCa) and Canceropole Ile-de-France. SS is supported by European Commission Apo-Sys and IM is supported by La Ligue contre le Cancer.	Akdemir F, 2006, DEVELOPMENT, V133, P1457, DOI 10.1242/dev.02332; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; ARLIN ZA, 1992, J CLIN ONCOL, V10, P169; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berry DL, 2007, CELL, V131, P1137, DOI 10.1016/j.cell.2007.10.048; Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Carmona-Gutierrez D, 2006, MOL CELL, V24, P167, DOI 10.1016/j.molcel.2006.10.004; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Degterev A, 2008, NAT REV MOL CELL BIO, V9, P378, DOI 10.1038/nrm2393; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Golstein P, 2003, NAT REV MOL CELL BIO, V4, P798, DOI 10.1038/nrm1224; Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Gottlieb RA, 2010, ANNU REV PHYSIOL, V72, P45, DOI 10.1146/annurev-physiol-021909-135757; Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Korolchuk VI, 2009, MOL CELL, V33, P517, DOI 10.1016/j.molcel.2009.01.021; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lee CY, 2001, DEVELOPMENT, V128, P1443; Lee JS, 2009, NAT CELL BIOL, V11, P1355, DOI 10.1038/ncb1980; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lipinski MM, 2010, DEV CELL, V18, P1041, DOI 10.1016/j.devcel.2010.05.005; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Monga M, 2002, LEUKEMIA, V16, P520, DOI 10.1038/sj.leu.2402464; Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Radhakrishnan SK, 2006, CANCER RES, V66, P9731, DOI 10.1158/0008-5472.CAN-06-1576; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Shen S, 2010, CELL CYCLE, V9, P377, DOI 10.4161/cc.9.2.10468; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Steller H, 2008, CELL DEATH DIFFER, V15, P1132, DOI 10.1038/cdd.2008.50; Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Webb JL, 2004, INT J BIOCHEM CELL B, V36, P2541, DOI 10.1016/j.biocel.2004.02.003; Xia HG, 2010, AUTOPHAGY, V6, P61, DOI 10.4161/auto.6.1.10326; Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076; Yuan Junying, 2004, Cell, VS116, pS53, DOI 10.1016/S0092-8674(04)00028-5; Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104	55	126	131	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 10	2011	30	45					4544	4556		10.1038/onc.2011.168	http://dx.doi.org/10.1038/onc.2011.168			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	846IO	21577201				2022-12-17	WOS:000296890700002
J	Fennell, DA; Chacko, A; Mutti, L				Fennell, D. A.; Chacko, A.; Mutti, L.			BCL-2 family regulation by the 20S proteasome inhibitor bortezomib	ONCOGENE			English	Review						mitochondria; proteasome; BAX; BAK; BIM; NOXA	PRO-APOPTOTIC PROTEIN; MANTLE-CELL LYMPHOMA; CYTOCHROME-C RELEASE; BH3 MIMETIC ABT-737; BIM MESSENGER-RNA; BH3-ONLY PROTEIN; ENDOPLASMIC-RETICULUM; MITOCHONDRIAL DYSFUNCTION; KAPPA-B; CASPASE ACTIVATION	Bortezomib (Velcade, PS341) was licensed in 2003 as a first-in-class 20S proteasome inhibitor indicated for treatment of multiple myeloma, and is currently being evaluated clinically in a range of solid tumours. The mechanisms underlying its cancer cell toxicity are complex. A growing body of evidence suggests proteasome inhibition-dependent regulation of the BCL-2 family is a critical requirement. In particular, the stabilization of BH3-only proteins BIK, NOXA and BIM, appear to be essential for effecting BAX- and BAK-dependent cell death. These mechanisms are reviewed and the implications for favourable novel drug interactions are highlighted.	[Fennell, D. A.; Chacko, A.] Queens Univ Belfast, Thorac Oncol Res Grp, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland; [Mutti, L.] Med Gen Lab Oncol Clin, Vercelli, Italy	Queens University Belfast	Fennell, DA (corresponding author), City Hosp, No Ireland Canc Ctr, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.fennell@qub.ac.uk	Mutti, Luciano/A-3545-2011	Mutti, Luciano/0000-0002-1578-2637				Abrams MT, 2004, J BIOL CHEM, V279, P55809, DOI 10.1074/jbc.M411767200; Adachi M, 2005, CELL DEATH DIFFER, V12, P192, DOI 10.1038/sj.cdd.4401529; Adams J, 1999, CANCER RES, V59, P2615; Adams J, 1998, BIOORG MED CHEM LETT, V8, P333, DOI 10.1016/S0960-894X(98)00029-8; Adams KW, 2007, J BIOL CHEM, V282, P6192, DOI 10.1074/jbc.M610643200; An JB, 2004, MOL CANCER THER, V3, P727; An WG, 2000, LEUKEMIA, V14, P1276, DOI 10.1038/sj.leu.2401812; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Anderson KC, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.10.001; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; Arnoult D, 2003, EMBO J, V22, P4385, DOI 10.1093/emboj/cdg423; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; BOYD JM, 1995, ONCOGENE, V11, P1921; Bross PF, 2004, CLIN CANCER RES, V10, P3954, DOI 10.1158/1078-0432.CCR-03-0781; Brunelle JK, 2007, MOL CELL BIOL, V27, P1222, DOI 10.1128/MCB.01535-06; Campas C, 2006, EXP HEMATOL, V34, P1663, DOI 10.1016/j.exphem.2006.07.008; Canfield SE, 2006, MOL CANCER THER, V5, P2043, DOI 10.1158/1535-7163.MCT-05-0437; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen S, 2007, CANCER RES, V67, P782, DOI 10.1158/0008-5472.CAN-06-3964; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; Clohessy JG, 2006, J BIOL CHEM, V281, P5750, DOI 10.1074/jbc.M505688200; Concannon CG, 2007, ONCOGENE, V26, P1681, DOI 10.1038/sj.onc.1209974; Coquelle A, 2006, CELL DEATH DIFFER, V13, P873, DOI 10.1038/sj.cdd.4401881; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duechler M, 2005, EUR J HAEMATOL, V74, P407, DOI 10.1111/j.1600-0609.2004.00406.x; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fahy BN, 2005, CANCER CHEMOTH PHARM, V56, P46, DOI 10.1007/s00280-004-0944-5; Fanucchi MP, 2006, J CLIN ONCOL, V24, P5025, DOI 10.1200/JCO.2006.06.1853; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Germain M, 2002, J BIOL CHEM, V277, P18053, DOI 10.1074/jbc.M201235200; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Henson ES, 2003, J CELL BIOCHEM, V89, P1177, DOI 10.1002/jcb.10597; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Hideshima T, 2001, CANCER RES, V61, P3071; Hinds MG, 2007, CELL DEATH DIFFER, V14, P128, DOI 10.1038/sj.cdd.4401934; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kirichok Y, 2004, NATURE, V427, P360, DOI 10.1038/nature02246; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LeBlanc R, 2002, CANCER RES, V62, P4996; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lin X, 2007, ONCOGENE, V26, P3972, DOI 10.1038/sj.onc.1210166; Ling YH, 2003, CLIN CANCER RES, V9, P1145; Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; MacLaren AP, 2001, CELL DEATH DIFFER, V8, P210, DOI 10.1038/sj.cdd.4400801; Marani M, 2004, ONCOGENE, V23, P2431, DOI 10.1038/sj.onc.1207364; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Mathai JP, 2005, J BIOL CHEM, V280, P23829, DOI 10.1074/jbc.M500800200; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; MAURER F, 1906, HDB VERGLEICHENDEN 1, V3, P1; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Mei YD, 2005, ONCOGENE, V24, P7224, DOI 10.1038/sj.onc.1208873; Moore VD, 2007, J CLIN INVEST, V117, P112, DOI 10.1172/JCI28281; Mori S, 2004, CANCER-AM CANCER SOC, V100, P1673, DOI 10.1002/cncr.20164; Morishima N, 2004, J BIOL CHEM, V279, P50375, DOI 10.1074/jbc.M408493200; Mortenson MM, 2005, LUNG CANCER, V49, P163, DOI 10.1016/j.lungcan.2005.01.006; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nijhawan D, 2003, GENE DEV, V17, P1475, DOI 10.1101/gad.1093903; Nikrad M, 2005, MOL CANCER THER, V4, P443; Nussbaum AK, 1998, P NATL ACAD SCI USA, V95, P12504, DOI 10.1073/pnas.95.21.12504; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pagano M, 2003, CANCER CELL, V4, P251, DOI 10.1016/S1535-6108(03)00243-5; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Seo YW, 2003, J BIOL CHEM, V278, P48292, DOI 10.1074/jbc.M308785200; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Sturm I, 2006, CELL DEATH DIFFER, V13, P619, DOI 10.1038/sj.cdd.4401782; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tahir SK, 2007, CANCER RES, V67, P1176, DOI 10.1158/0008-5472.CAN-06-2203; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; Teicher BA, 1999, CLIN CANCER RES, V5, P2638; Tong T, 2005, MOL CELL BIOL, V25, P4488, DOI 10.1128/MCB.25.11.4488-4500.2005; Tong Y, 2001, MOL CANCER THER, V1, P95; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Warr MR, 2005, FEBS LETT, V579, P5603, DOI 10.1016/j.febslet.2005.09.028; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Witters LM, 2007, ONCOL REP, V17, P465; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yasuda M, 1999, CANCER RES, V59, P533; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; Zhang LZ, 2004, J BIOL CHEM, V279, P20858, DOI 10.1074/jbc.M310643200; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhu HB, 2005, CANCER BIOL THER, V4, P781, DOI 10.4161/cbt.4.7.1897; Zhu HB, 2005, ONCOGENE, V24, P4993, DOI 10.1038/sj.onc.1208683	128	126	132	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1189	1197		10.1038/sj.onc.1210744	http://dx.doi.org/10.1038/sj.onc.1210744			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17828309				2022-12-17	WOS:000253407000001
J	Bultman, SJ; Herschkowitz, JI; Godfrey, V; Gebuhr, TC; Yaniv, M; Perou, CM; Magnuson, T				Bultman, S. J.; Herschkowitz, J. I.; Godfrey, V.; Gebuhr, T. C.; Yaniv, M.; Perou, C. M.; Magnuson, T.			Characterization of mammary tumors from Brg1 heterozygous mice	ONCOGENE			English	Article						BRG1; SWF/SNF; breast cancer; haploin-sufficiency; genomic instability	SWI/SNF COMPLEX; CELL-CYCLE; CHROMATIN; EXPRESSION; CANCER; INACTIVATION; PROGRESSION; SUPPRESSOR	Mammalian SWI/SNF-related complexes have been implicated in cancer based on some of the subunits physically interacting with retinoblastoma (RB) and other proteins involved in carcinogenesis. Additionally, several subunits are mutated or not expressed in tumor-derived cell lines. Strong evidence for a role in tumorigenesis in vivo, however, has been limited to SNF5 mutations that result primarily in malignant rhabdoid tumors (MRTs) in humans and MRTs as well as other sarcomas in mice. We previously generated a null mutation of the Brg1 catalytic subunit in the mouse and reported that homozygotes die during embryogenesis. Here, we demonstrate that Brg1 heterozygotes are susceptible to mammary tumors that are fundamentally different than Snf5 tumors. First, mammary tumors are carcinomas not sarcomas. Second, Brg1(+/-) tumors arise because of haploinsufficiency rather than loss of heterozygosity. Third, Brg1(+/-) tumors exhibit genomic instability but not polyploidy based on array comparative genomic hybridization results. We monitored Brg1(+/-), Brm(-/-) double-mutant mice but did not observe any tumors resembling those from Snf5 mutants, indicating that the Brg1(+/-) and Snf5(+/-) tumor phenotypes do not differ simply because Brg1 has a closely related paralog whereas Snf5 does not. These findings demonstrate that BRG1 and SNF5 are not functionally equivalent but protect against cancer in different ways. We also demonstrate that Brg1(+/-) mammary tumors have relatively heterogeneous gene expression profiles with similarities and differences compared to other mouse models of breast cancer. The Brg1(+/-)expression profiles are not particularly similar to mammary tumors from Wap-T121 transgenic line where RB is perturbed. We were also unable to detect a genetic interaction between the Brg1(+/-) and Rb+/- tumor phenotypes. These latter findings do not support a BRG1-RB interaction in vivo.	[Bultman, S. J.; Herschkowitz, J. I.; Gebuhr, T. C.; Perou, C. M.; Magnuson, T.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA; [Bultman, S. J.; Herschkowitz, J. I.; Gebuhr, T. C.; Perou, C. M.; Magnuson, T.] Univ N Carolina, Carolina Genome Sci Ctr, Chapel Hill, NC USA; [Godfrey, V.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC USA; [Yaniv, M.] Inst Pasteur, Dept Dev Biol, Gene Express & Res Unit, Paris, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Bultman, SJ (corresponding author), Univ N Carolina, Dept Genet, 103 Mason Farm Rd,4340B MBRB, Chapel Hill, NC 27599 USA.	Scott_Bultman@med.unc.edu	Perou, Charles M/H-9934-2014	Perou, Charles M/0000-0001-9827-2247	NICHD NIH HHS [R01 HD036655] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD036655] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Dauvillier S, 2001, MECH DEVELOP, V101, P221, DOI 10.1016/S0925-4773(00)00560-8; Doan DN, 2004, ONCOGENE, V23, P3462, DOI 10.1038/sj.onc.1207472; Guidi CJ, 2006, CANCER RES, V66, P8076, DOI 10.1158/0008-5472.CAN-06-1451; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Simin K, 2004, PLOS BIOL, V2, P194, DOI 10.1371/journal.pbio.0020022; Snijders AM, 2005, GENOME RES, V15, P302, DOI 10.1101/gr.2902505; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Yang TL, 2004, GENE CHROMOSOME CANC, V41, P250, DOI 10.1002/gcc.20080	17	126	130	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2008	27	4					460	468		10.1038/sj.onc.1210664	http://dx.doi.org/10.1038/sj.onc.1210664			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17637742				2022-12-17	WOS:000252426100006
J	Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG				Miller, CT; Lin, L; Casper, AM; Lim, J; Thomas, DG; Orringer, MB; Chang, AC; Chambers, AF; Giordano, TJ; Glover, TW; Beer, DG			Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma	ONCOGENE			English	Article						MET oncogene; esophageal adenocarcinoma; gene amplification; FRA7G	RECEPTOR TYROSINE KINASE; BREAST-CANCER CELLS; LUNG ADENOCARCINOMAS; GENE AMPLIFICATION; ANTITUMOR-ACTIVITY; UNITED-STATES; GROWTH; TUMOR; OVEREXPRESSION; DYSPLASIA	Esophageal adenocarcinoma (EA) is characterized by a poor prognosis making the identification of clinically targetable proteins essential for improving patient outcome. We report the involvement of multiple alterations of the MET pathway in EA development and progression. Microarray analysis of Barrett's metaplasia, dysplasia, and EA revealed overexpression of the MET oncogene in EAs but only those with MET gene amplication. STS-amplication mapping revealed that the boundary of the MET amplicon in these EAs is defined by fragile site FRA7G. We also identified an amplicon at 11p13 that resulted in amplication and overexpression of CD44, a gene involved in MET autophosphorylation upon HGF stimulation. Tissue microarrays with phospho-MET-specific antibodies demonstrated a uniformly high abundance of MET activation in primary EA and cells metastatic to lymph nodes but to a lesser extent in a subset of metaplastic and dysplastic Barrett's samples. Increased expression of multiple genes in the MET pathway associated with invasive growth, for example, many MMPs and osteopontin, also was found in EAs. Treatment of EA-derived cell lines with geldanamycin, an inhibitor for tyrosine kinases including MET receptor kinase, reduced cell migration and induced EA cell apoptosis. The data indicate that upregulation of the MET pathway may contribute to the poor outcome of EA patients and that therapeutic agents targeting this pathway may help improve patient survival.	Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; London Reg Canc Ctr, Dept Oncol, London, England	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Beer, DG (corresponding author), Univ Michigan, Sch Med, Dept Surg, Sect Gen Thorac Surg, MSRB 2 B560,Box 0686, Ann Arbor, MI 48109 USA.	dgbeer@umich.edu	Chambers, Ann F/L-6285-2015	Chambers, Ann F/0000-0002-9509-5123; Giordano, Thomas/0000-0003-0641-8873; Chang, Andrew/0000-0001-9506-0425; Casper, Anne/0000-0003-4975-5749	NATIONAL CANCER INSTITUTE [R01CA071606, R01CA043222] Funding Source: NIH RePORTER; NCI NIH HHS [CA43222, CA71606] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cao B, 2001, P NATL ACAD SCI USA, V98, P7443, DOI 10.1073/pnas.131200498; Christensen JG, 2003, CANCER RES, V63, P7345; Ciullo M, 2002, HUM MOL GENET, V11, P2887, DOI 10.1093/hmg/11.23.2887; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; Farrow DC, 1996, CANCER CAUSE CONTROL, V7, P322, DOI 10.1007/BF00052937; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Fukuda Y, 2000, GENE CHROMOSOME CANC, V29, P315, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1047>3.0.CO;2-E; Gonzalez MV, 1997, J CLIN PATHOL, V50, P212, DOI 10.1136/jcp.50.3.212; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; Hughes SJ, 1998, P NATL ACAD SCI USA, V95, P12410, DOI 10.1073/pnas.95.21.12410; Hughes SJ, 1997, CANCER RES, V57, P5571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Kim SJ, 2003, CLIN CANCER RES, V9, P5161; Kong-Beltran M, 2004, CANCER CELL, V6, P75, DOI 10.1016/j.ccr.2004.06.013; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Lin J, 2004, CLIN CANCER RES, V10, P5708, DOI 10.1158/1078-0432.CCR-04-0468; Lin L, 2000, CANCER RES, V60, P1341; Lin L, 2002, CANCER RES, V62, P5273; Matsuyama A, 2003, P NATL ACAD SCI USA, V100, P14988, DOI 10.1073/pnas.2336256100; Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Miller CT, 2003, CANCER RES, V63, P4136; NALDINI L, 1991, EMBO J, V10, P2857; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Recio JA, 2003, CANCER RES, V63, P1576; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Rosenberg C, 2002, CANCER GENET CYTOGEN, V135, P35, DOI 10.1016/S0165-4608(01)00639-2; Sage EH, 2003, J BIOL CHEM, V278, P37849, DOI 10.1074/jbc.M302946200; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Weber GF, 2002, CANCER RES, V62, P2281; Weber GF, 2001, BBA-REV CANCER, V1552, P61, DOI 10.1016/S0304-419X(01)00037-3; Wong DJ, 1997, CANCER RES, V57, P2619; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhang YW, 2004, CANCER CELL, V6, P5, DOI 10.1016/j.ccr.2004.07.003	47	126	137	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2006	25	3					409	418		10.1038/sj.onc.1209057	http://dx.doi.org/10.1038/sj.onc.1209057			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	003WY	16186806				2022-12-17	WOS:000234714100009
J	Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R				Singh, RP; Dhanalakshmi, S; Agarwal, C; Agarwal, R			Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappa B: implications for angioprevention and antiangiogenic therapy	ONCOGENE			English	Article						endothelial cells; cell cycle arrest; apoptosis; Akt; NF-kappa B; silibinin	DEPENDENT KINASE INHIBITORS; TUMOR-NECROSIS-FACTOR; PROSTATE-CANCER; INDUCED APOPTOSIS; BCL-2 FAMILY; ANGIOGENESIS; ACTIVATION; EXPRESSION; PROLIFERATION; MITOCHONDRIA	Recently, we observed that suppression of tumor xenograft growth by silibinin was associated with reduction in tumor vasculature and an increased apoptosis. Here, we provide evidence for molecular events associated with antiangiogenic efficacy of pharmacologically achievable doses of silibinin in endothelial cell culture system. Our data show that silibinin almost completely (P<0.001) inhibits growth of human umbilical vein endothelial cells (HUVEC) and human microvascular endothelial cells (HMVEC-dermal origin) together with induction of cell death in a dose- and time-dependent manner. Growth inhibition was associated with a strong induction of G1 arrest accompanied by an increase in Kip1/p27, Cip1/p21 and p53. Apoptosis induction (up to 14- to 17-fold in both cell lines, P<0.001) was an underlying mechanism in silibinin-induced death of endothelial cells. In the studies elucidating the molecular events involved in apoptosis, silibinin caused loss of mitochondrial membrane potential and an increase in cytochrome c release from mitochondria. An increase in Bax and a decrease in Mcl-1 proteins were also observed. Silibinin-induced apoptosis involved both caspase-dependent and -independent mechanisms. Silibinin also decreased survivin level and inhibited Akt and NF-kappaB signaling. Two different PI-3K inhibitors, wortmannin and LY294002, showed Akt-independent activation of NF-kappaB. Further, silibinin showed a concentration-dependent strong inhibition of capillary tube formation on matrigel, retraction and disintegration of preformed capillary network, inhibition of matrigel invasion and migration, and a decrease in matrix metalloproteinase-2 secretion by HUVEC. Together, these findings identify pleiotropic mechanisms for antiangiogenic efficacy of silibinin, and suggest its usefulness in angioprevention and antiangiogenic therapy.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Agarwal, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, 4200 E 9th Ave,Box C238, Denver, CO 80262 USA.	rajesh.agarwal@uchsc.edu		Singh, Rana Pratap/0000-0003-4261-7044	NATIONAL CANCER INSTITUTE [R01CA091883, R01CA102514] Funding Source: NIH RePORTER; NCI NIH HHS [CA91883, CA102514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal C, 2003, ONCOGENE, V22, P8271, DOI 10.1038/sj.onc.1207158; Ali IU, 2001, UROLOGY, V57, P143, DOI 10.1016/S0090-4295(00)00961-4; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brakenhielm E, 2001, FASEB J, V15, P1798, DOI 10.1096/fj.01-0028fje; Brawer MK, 1996, CANCER, V78, P345, DOI 10.1002/(SICI)1097-0142(19960715)78:2<345::AID-CNCR25>3.0.CO;2-V; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen JH, 2004, BIOCHEM PHARMACOL, V67, P1337, DOI 10.1016/j.bcp.2003.12.015; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; COSSARIZZA A, 1993, BIOCHEM BIOPH RES CO, V197, P40, DOI 10.1006/bbrc.1993.2438; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; Fotsis T, 1997, CANCER RES, V57, P2916; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Gingis-Velitski S, 2004, J BIOL CHEM, V279, P23536, DOI 10.1074/jbc.M400554200; GRANA X, 1995, ONCOGENE, V11, P211; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gu QY, 2004, RADIAT RES, V161, P692, DOI 10.1667/RR3158; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hofseth LJ, 2004, TRENDS PHARMACOL SCI, V25, P177, DOI 10.1016/j.tips.2004.02.009; Jiang C, 2000, BIOCHEM BIOPH RES CO, V276, P371, DOI 10.1006/bbrc.2000.3474; Jiang C, 2000, MOL CARCINOGEN, V29, P236, DOI 10.1002/1098-2744(200012)29:4<236::AID-MC1006>3.0.CO;2-E; Jones MK, 1999, NAT MED, V5, P1418; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li YW, 2002, CLIN CANCER RES, V8, P2369; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Malyankar UM, 2000, J BIOL CHEM, V275, P20959, DOI 10.1074/jbc.C000290200; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Ozes ON, 1999, NATURE, V401, P82; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Qi J H, 1999, Angiogenesis, V3, P371, DOI 10.1023/A:1026565908445; Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Singh RP, 2003, CURR CANCER DRUG TAR, V3, P205, DOI 10.2174/1568009033481985; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2002, CANCER RES, V62, P3063; Singh RP, 2004, CURR CANCER DRUG TAR, V4, P1, DOI 10.2174/1568009043481605; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Waddick KG, 1999, BIOCHEM PHARMACOL, V57, P9, DOI 10.1016/S0006-2952(98)00224-X; Wellington K, 2001, BIODRUGS, V15, P465, DOI 10.2165/00063030-200115070-00005; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yoo HY, 2004, INT J MOL MED, V13, P81; Zandi E, 1999, MOL CELL BIOL, V19, P4547	67	126	129	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1188	1202		10.1038/sj.onc.1208276	http://dx.doi.org/10.1038/sj.onc.1208276			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558015				2022-12-17	WOS:000226898700006
J	Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R				Menendez, JA; Vellon, L; Mehmi, I; Teng, PK; Griggs, DW; Lupu, R			A novel CYR61-triggered 'CYR61-alpha(v)beta(3) integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway	ONCOGENE			English	Article						CYR61; CCN1; heregulin; alpha(v)beta(3); paclitaxel; taxol; ERK1/ERK2 MAPK; chemotherapy; breast cancer	TISSUE GROWTH-FACTOR; TAXOL-INDUCED APOPTOSIS; IMMEDIATE-EARLY GENE; PACLITAXEL-INDUCED CYTOTOXICITY; INTESTINAL EPITHELIAL-CELLS; KINASE KINASE INHIBITION; VEIN ENDOTHELIAL-CELLS; HUMAN SKIN FIBROBLASTS; CCN FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE	The angiogenic inducer CYR61 is differentially over-expressed in breast cancer cells exhibiting high levels of Heregulin (HRG), a growth factor closely associated with a metastatic breast cancer phenotype. Here, we examined whether CYR61, independently of HRG, actively regulates breast cancer cell survival and chemosensitivity, and the pathways involved. Forced expression of CYR61 in HRG-negative MCF-7 cells notably upregulated the expression of its own integrin receptor alpha(v)beta(3) (>200 times). Small peptidomimetic alpha(v)beta(3) integrin antagonists dramatically decreased cell viability of CYR61-overexpressing MCF-7 cells, whereas control MCF-7/V remained insensitive. Mechanistically, functional blockade of alpha(v)beta(3) specifically abolished CYR6-induced hyperactivation of ERK1/ERK2 MAPK, whereas the activation status of AKT did not decrease. Moreover, CYR61 overexpression rendered MCF-7 cells significantly resistant (>10-fold) to Taxol-induced cytotoxicity. Remarkably, alpha(v)beta(3) inhibition converted the CYR61-induced Taxol-resistant phenotype into a hypersensitive one. Thus, the augmentation of Taxol-induced apoptotic cell death in the presence of alpha(v)beta(3) antagonists demonstrated a strong synergism as verified by the terminal transferase-mediated dUTP nick-end labeling (TUNEL) assay and by flow cytometric analysis for DNA content. Indeed, functional blockade of alpha(v)beta(3), similarly to the pharmacological MAPK inhibitor U0126, synergistically increased both the proportion of CYR61-overexpressing breast cancer cells in the G(2) phase of the cell cycle and the appearance of sub-G(1) hypodiploid (apoptotic) cells caused by Taxol. Strikingly, CYR61 overexpression impaired the accumulation of wild-type p53 following Taxol exposure, while inhibition of alpha(v)beta(3) or ERK1/ERK2 MAPK signalings completely restored Taxol-induced upregulation of p53. Moreover, antisense downregulation of CYR61 expression abolished the anchorage-independent growth of breast cancer cells engineered to overexpress HRG, and significantly increased their sensitivity to Taxol. Our data provide evidence that CYR61 is sufficient to promote breast cancer cell proliferation, cell survival, and Taxol resistance through a alpha(v)beta(3)-activated ERK1/ERK2 MAPK signaling. The identification of a 'CYR61-alpha(v)beta(3) autocrine loop' in the epithelial compartment of breast carcinoma strongly suggests that targeting alpha(v)beta(3) may simultaneously prevent breast cancer angiogenesis, growth, and chemo resistance.	Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, Evanston, IL 60201 USA; Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; Pharmacia Corp, Discovery Res, Oncol Pharmacol, St Louis, MO USA	Northwestern University; Feinberg School of Medicine; Pfizer	Lupu, R (corresponding author), Evanston Northwestern Healthcare Res Inst, Dept Med, Breast Canc Translat Res Lab, 1001 Univ Pl, Evanston, IL 60201 USA.	r-lupu@northwestern.edu	MENENDEZ, JAVIER A/C-6148-2016	MENENDEZ, JAVIER A/0000-0001-8733-4561				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Atlas E, 2003, MOL CANCER RES, V1, P165; Babic AM, 1999, MOL CELL BIOL, V19, P2958; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brigstock DR, 2003, J CLIN PATHOL-MOL PA, V56, P127, DOI 10.1136/mp.56.2.127; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Gasparini G, 1998, CLIN CANCER RES, V4, P2625; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Griggs David William, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P263; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Harris LN, 1998, CLIN CANCER RES, V4, P1005; Hortobagyi GN, 1997, SEMIN ONCOL, V24, pS30; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Lupu R, 1996, BREAST CANCER RES TR, V38, P57, DOI 10.1007/BF01803784; MacKeigan JP, 2002, CLIN CANCER RES, V8, P2091; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; McDaid HM, 2001, MOL PHARMACOL, V60, P290, DOI 10.1124/mol.60.2.290; Menendez JA, 2003, ENDOCR-RELAT CANCER, V10, P141, DOI 10.1677/erc.0.0100141; Meyer Debra Mary, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P825; Meyer T, 1998, BRIT J CANCER, V77, P530, DOI 10.1038/bjc.1998.86; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; OKELLY J, 2002, P AM ASS CANC RES, V42; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perez, 1998, Oncologist, V3, P373; Planque N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-15; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Rasouli-Nia A, 1998, CLIN CANCER RES, V4, P1111; Reinmuth N, 2003, CANCER RES, V63, P2079; Roberts MS, 2003, J BIOL CHEM, V278, P1975, DOI 10.1074/jbc.M208607200; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Seidman R, 2001, EXP CELL RES, V268, P84, DOI 10.1006/excr.2001.5262; STAEBLER A, 1994, BREAST CANCER RES TR, V31, P175, DOI 10.1007/BF00666151; Torres K, 1998, CANCER RES, V58, P3620; Tsai MS, 2003, ONCOGENE, V22, P761, DOI 10.1038/sj.onc.1206130; Tsai MS, 2002, ONCOGENE, V21, P8178, DOI 10.1038/sj.onc.1205682; Tsai MS, 2000, CANCER RES, V60, P5603; VELLON L, 2004, P AM ASSOC CANC RES, V45, P74; Wiseman LR, 1998, DRUG AGING, V12, P305, DOI 10.2165/00002512-199812040-00005; Xie D, 2004, CANCER RES, V64, P1987, DOI 10.1158/0008-5472.CAN-03-0666; Xie D, 2001, CANCER RES, V61, P8917; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5; Yu CR, 2001, MOL PHARMACOL, V60, P143, DOI 10.1124/mol.60.1.143; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu DH, 2001, SEMIN ONCOL, V28, P12; Yu DH, 1996, ONCOGENE, V13, P1359; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Zhang LF, 2002, CARCINOGENESIS, V23, P1251, DOI 10.1093/carcin/23.7.1251; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	69	126	133	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					761	779		10.1038/sj.onc.1208238	http://dx.doi.org/10.1038/sj.onc.1208238			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592521				2022-12-17	WOS:000226577100003
J	Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O				Vasilcanu, D; Girnita, A; Girnita, L; Vasilcanu, R; Axelson, M; Larsson, O			The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway	ONCOGENE			English	Article						IGF-1R; Akt; apoptosis; dominant-negative mutants	IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; CELL-DEATH; CANCER; AUTOPHOSPHORYLATION; MITOGENESIS; EXPRESSION; MELANOMA; ANTIBODY; DOMAIN	The insulin-like growth factor-1 receptor (IGF-1R) is crucial for many functions in neoplastic cells, for example, antiapoptosis. Recently, we demonstrated that the cyclolignan PPP efficiently inhibited phosphorylation of IGF-1R without interfering with insulin receptor activity. PPP preferentially reduced phosphorylated Akt, as compared to phosphorylated Erk1/2, and caused apoptosis. Now, we aimed to investigate how PPP inhibits the IGF-1R tyrosine kinase (IGF-1RTK) and the PI3K/Akt apoptotic pathway. Using a baculovirus driven IGF-1RTK we found that PPP interfered with tyrosine phosphorylation in the activation loop of the kinase domain. Specifically, it blocked phosphorylation of tyrosine (Y) 1136, while sparing the two others (Y1131 and Y1135). To explore the impact of inhibition of Y1136 on Akt phosphorylation we transfected P6 cells (overexpressing IGF-1R) and malignant melanoma cells with different IGF-1R mutants, including Y1136F (tyrosine replaced by phenylalanine). Y1136F was found to strongly decrease IGF-1 stimulated phosphorylation of Akt. Conversely, Akt phosphorylation was weakly affected in the Y1131F transfectant. Taken together, our data suggest that the preferential inhibition of phosphorylated Akt, after PPP treatment, may be due to specific inhibition of Y1136. PPP was proven not to interfere directly with Akt or any of its downstream molecules in the apoptotic pathway.	Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Dept Clin Chem, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital	Larsson, O (corresponding author), Karolinska Hosp, CCK, Div Cellular & Mol Tumor Pathol, Dept Pathol & Oncol, R8-04, SE-17176 Stockholm, Sweden.	olle.larsson@onkpat.ki.se	Girnita, Ada/AAC-4518-2020; Girnita, Leonard/A-4168-2008	Girnita, Leonard/0000-0003-0280-9500				Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bouchard WJ, 2003, EXP HEMATOL, V31, P446, DOI 10.1016/S0301-472X(03)00083-3; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; BUCHARDT O, 1986, J PHARM SCI, V75, P1076, DOI 10.1002/jps.2600751111; Cann AD, 1998, BIOCHEMISTRY-US, V37, P11289, DOI 10.1021/bi9809122; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Girnita L, 2000, CANCER RES, V60, P5278; Girnita L, 2003, P NATL ACAD SCI USA, V100, P8247, DOI 10.1073/pnas.1431613100; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Kanter-Lewensohn L, 2000, MOL CELL ENDOCRINOL, V165, P131, DOI 10.1016/S0303-7207(00)00253-7; KATO H, 1993, J BIOL CHEM, V268, P2655; Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Roith D, 1999, ISR MED ASSOC J, V1, P25; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LI SW, 1994, J BIOL CHEM, V269, P32558; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; Parang K, 2001, NAT STRUCT BIOL, V8, P37; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; ROHLIK QT, 1987, BIOCHEM BIOPH RES CO, V149, P276, DOI 10.1016/0006-291X(87)91635-4; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; STANNARD B, 1995, ENDOCRINOLOGY, V136, P4918, DOI 10.1210/en.136.11.4918; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Yam A, 2001, J BIOL CHEM, V276, P24409, DOI 10.1074/jbc.M102358200; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	38	126	129	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7854	7862		10.1038/sj.onc.1208065	http://dx.doi.org/10.1038/sj.onc.1208065			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15334055				2022-12-17	WOS:000224331600011
J	Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT				Yokota, N; Mainprize, TG; Taylor, MD; Kohata, T; Loreto, M; Ueda, S; Dura, W; Grajkowska, W; Kuo, JS; Rutka, JT			Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization	ONCOGENE			English	Article						medulloblastoma; developmentally regulated gene; differentially expressed gene; subtractive suppression hybridization; cerebellum; external granule cell	PRIMITIVE NEUROECTODERMAL TUMORS; POLYMERASE-CHAIN-REACTION; RNA-BINDING PROTEIN; NERVOUS-SYSTEM; HOMEOBOX GENES; AXONAL GUIDANCE; MESSENGER-RNA; CELL FATE; BRAIN; RECEPTORS	To increase our understanding of the molecular pathogenesis of medulloblastoma (MB), we utilized the technique of suppression subtractive hybridization (SSH) to identify genes that are dysregulated in MB when compared to cerebellum. SSH-enriched cDNA libraries from both human and Ptch(+/-) heterozygous murine MBs were generated by subtracting common cDNAs from corresponding non-neoplastic cerebellum. For the human classic MB library, total human cerebellar RNA was used as control tissue; for the Ptch(+/-) heterozygous MB, non-neoplastic cerebellum from an unaffected Ptch(+/-) littermate was used as the control. Through differential screening of these libraries, over 100 upregulated tumor cDNA fragments were isolated, sequenced and identified with the NCBI BLAST program. From these, we selected genes involved in cellular proliferation, antiapoptosis, and cerebellar differentiation for further analysis. Upregulated genes identified in the human MB library included Unc33-like protein (ULIP), SOX4, Neuronatin (NNAT), the mammalian homologue of Drosophila BarH-like 1(BARHL1), the nuclear matix protein NRP/B (ENC1), and the homeobox OTX2 gene. Genes found to be upregulated in the murine MB library included cyclin D2 (Ccnd2), thymopoietin (Tmpo), Musashi-1 (Msh1), protein phosphatase 2A inhibitor-2 (I-2pp2a), and Unc5h4(D). Using semiquantitative reverse transcription-polymerase chain reaction (RT-PCR), the mRNA expression levels for these genes were markedly higher in human MBs than in cerebellum. Western blot analysis was used to further confirm the overexpression of a subset of these genes at the protein level. Notch pathway overactivity was demonstrated in the TE671 MB cell line expressing high levels of MSH1 through HES1-Luciferase transfections. This study has revealed a panel of developmentally regulated genes that may be involved in the pathogenesis of MB.	Univ Toronto, Arthur Sonia Labatt Brain Tumor Res Ctr, Toronto, ON, Canada; Univ Toronto, Div Neurosurg, Toronto, ON, Canada; Hamamatsu Univ Sch Med, Dept Neurosurg, Hamamatsu, Shizuoka 43131, Japan; Univ Warsaw, Dept Pathol, Warsaw, Poland	University of Toronto; University of Toronto; Hamamatsu University School of Medicine; University of Warsaw	Rutka, JT (corresponding author), Hosp Sick Children, Div Neurosurg, Suite 1502,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	james.rutka@sickkids.ca	Kuo, John S/D-3561-2013	Kuo, John S/0000-0001-6809-4806; Taylor, Michael/0000-0001-7009-3466; Grajkowska, Wieslawa/0000-0001-8318-5781				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bayani J, 2000, J NEUROSURG, V93, P437, DOI 10.3171/jns.2000.93.3.0437; BONCINELLI E, 1993, J NEUROBIOL, V24, P1356, DOI 10.1002/neu.480241008; Buhren J, 2000, J NEUROPATH EXP NEUR, V59, P229; Bulfone A, 2000, HUM MOL GENET, V9, P1443, DOI 10.1093/hmg/9.9.1443; Byk T, 1996, J NEUROSCI, V16, P688; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; FRANTZ GD, 1994, J NEUROSCI, V14, P5725; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Imai T, 2001, MOL CELL BIOL, V21, P3888, DOI 10.1128/MCB.21.12.3888-3900.2001; Ji W, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-12; Kanemura Y, 2001, DIFFERENTIATION, V68, P141, DOI 10.1046/j.1432-0436.2001.680208.x; KOZMIK Z, 1995, P NATL ACAD SCI USA, V92, P5709, DOI 10.1073/pnas.92.12.5709; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LI W, 1992, GENETICS, V132, P675; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Michiels EMC, 1999, PHYSIOL GENOMICS, V1, P83, DOI 10.1152/physiolgenomics.1999.1.2.83; Okano H, 2002, J CELL SCI, V115, P1355; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Ross ME, 1996, J NEUROSCI, V16, P210; Rostomily RC, 1997, CANCER RES, V57, P3526; Rubin JB, 2002, CANCER CELL, V2, P7, DOI 10.1016/S1535-6108(02)00090-9; Saito T, 1998, DEV BIOL, V199, P216, DOI 10.1006/dbio.1998.8889; Sambrook J., 1989, MOL CLONING; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Solecki DJ, 2001, NEURON, V31, P557, DOI 10.1016/S0896-6273(01)00395-6; Taylor MD, 2000, NEUROSURGERY, V47, P888, DOI 10.1097/00006123-200010000-00020; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Vincent S, 1996, INT J ONCOL, V8, P901; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; Wang LH, 1996, J NEUROSCI, V16, P6197; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wetmore C, 2001, CANCER RES, V61, P513; Yokota N, 1996, CANCER RES, V56, P377; Yokota N, 2002, INT J CANCER, V101, P198, DOI 10.1002/ijc.10559; Yokota N, 2001, STROKE, V32, P168, DOI 10.1161/01.STR.32.1.168; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200	50	126	133	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 22	2004	23	19					3444	3453		10.1038/sj.onc.1207475	http://dx.doi.org/10.1038/sj.onc.1207475			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15064731				2022-12-17	WOS:000220975000019
J	Eger, A; Stockinger, A; Park, J; Langkopf, E; Mikula, M; Gotzmann, J; Mikulits, W; Beug, H; Foisner, R				Eger, A; Stockinger, A; Park, J; Langkopf, E; Mikula, M; Gotzmann, J; Mikulits, W; Beug, H; Foisner, R			beta-Catenin and TGF beta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition	ONCOGENE			English	Article						carcinogenesis; catenins; cell adhesion; TGF beta; E-cadherin; LEF/TCF	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; COLORECTAL-CANCER; HA-RAS; WNT; BINDING; ACTIVATION; EXPRESSION; SMAD; PROMOTER	Several signalling pathways contribute to the regulation of epithelial to mesenchymal transition (EMT), either during developmentally regulated processes or in cancer progression and metastasis. Induction of EMT in fully polarized mouse mammary epithelial cells (EpH4) by an inducible c-fos estrogen receptor (FosER) oncoprotein involves loss of E-cadherin expression, nuclear translocation of beta-catenin, and autocrine production of TGFbeta. Reporter assays demonstrate that both beta-catenin/LEF-TCF- and TGFbeta-Smad-dependent signalling activities are upregulated, probably coregulating mesenchymal-specific gene expression during EMT. Stable expression of E-cadherin in mesenchymal FosER cells decreased beta-catenin activity and reduced cell proliferation. However, these cells still exhibited a defect in epithelial polarization and expressed E-cadherin/beta-catenin complexes in the entire plasma membrane. On the other hand, inhibition of TGFbeta-Smad signalling in mesenchymal FosER cells induced. at, cobblestone-like clusters of cells, which relocalized beta-catenin to the plasma membrane but still lacked detectable E-cadherin. Interestingly, inhibition of TGFbeta signalling in the E-cadherin-expressing mesenchymal FosER cells caused their reversion to a polarized epithelial phenotype, in which E-cadherin, beta-catenin, and ZO-1 were localized at their correct lateral plasma membrane domains. These results demonstrate that loss of E-cadherin can contribute to increased LEF/TCF-beta-catenin signalling, which in turn cooperates with autocrine TGFbeta signalling to maintain an undifferentiated mesenchymal phenotype.	Univ Vienna, Vienna Bioctr, Dept Med Biochem, Univ Dept,Max F Perutz Labs, A-1030 Vienna, Austria; Boehringer Ingelheim PharmaGmbHKG, Biberach, Germany; Univ Vienna, Inst Canc Res, A-1010 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Boehringer Ingelheim; University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Foisner, R (corresponding author), Univ Vienna, Vienna Bioctr, Dept Med Biochem, Univ Dept,Max F Perutz Labs, Dr Bohrgasse 9, A-1030 Vienna, Austria.	roland.foisner@univie.ac.at	Mikulits, Wolfgang/AAH-4043-2021; Foisner, Roland/AAD-1833-2019	Mikula, Mario/0000-0001-5782-0681; Mikulits, Wolfgang/0000-0003-4612-7106; Foisner, Roland/0000-0003-4734-4647; Gotzmann, Josef/0000-0001-6392-2115				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Barker N, 2001, TRENDS MOL MED, V7, P535, DOI 10.1016/S1471-4914(01)02215-8; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birchmeier C, 1996, ACTA ANAT, V156, P217; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Duband JL, 1995, ACTA ANAT, V154, P63; Eger A, 2000, PROTOPLASMA, V211, P125; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Germain S, 2000, GENE DEV, V14, P435; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Gotzmann J, 2002, J CELL SCI, V115, P1189; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Iavarone A, 1997, NATURE, V387, P417; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Letamendia A, 2001, J BONE JOINT SURG AM, V83A, pS31; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Michaelson JS, 2001, ONCOGENE, V20, P5093, DOI 10.1038/sj.onc.1204586; Naishiro Y, 2001, CANCER RES, V61, P2751; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Orsulic S, 1999, J CELL SCI, V112, P1237; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tian YC, 2002, AM J PATHOL, V160, P1619, DOI 10.1016/S0002-9440(10)61109-1; Uyttendaele H, 1998, DEV BIOL, V196, P204, DOI 10.1006/dbio.1998.8863; Vallin J, 2001, J BIOL CHEM, V276, P30350, DOI 10.1074/jbc.M103167200; Viebahn C, 1995, ACTA ANAT, V154, P79; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940	54	126	131	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2004	23	15					2672	2680		10.1038/sj.onc.1207416	http://dx.doi.org/10.1038/sj.onc.1207416			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	810OZ	14755243				2022-12-17	WOS:000220714900009
J	Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH				Yuan, BZ; Jefferson, AM; Baldwin, KT; Thorgeirsson, SS; Popescu, NC; Reynolds, SH			DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas	ONCOGENE			English	Article						DLC-1; tumor suppressor gene; non-small cell lung carcinoma; aberrant DNA methylation; tumorigenicity	ABERRANT PROMOTER METHYLATION; HUMAN BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; CLINICAL IMPLICATIONS; RAS TRANSFORMATION; UNITED-STATES; RHOGAP; PATHOGENESIS; IMBALANCES; EXPRESSION	The deleted in liver cancer (DLC-1) gene at chromosome 8p21-22 is altered mainly by genomic deletion or aberrant promoter methylation in a large number of human cancers such as breast, liver, colon and prostate and is known to have an inhibitory effect on breast and liver tumor cell growth. Given the high frequency of deletion involving region 8p21-22 in human non-small cell lung carcinoma (NSCLC), we examined alterations of DLC-1 in a series of primary tumors and tumor cell lines and tested effects of DLC-1 on tumor cell growth. A significant decrease or absence of the DLC-1 mRNA expression was found in 95% of primary NSCLC (20/21) and 58% of NSCLC cell lines (11/19). Transcriptional silencing of DLC-1 was primarily associated with aberrant DNA methylation, rather than genomic deletion as 5-aza-2'-deoxycytidine induced reactivation of DLC-1 expression in 82% (9/11) NSCLC cell lines showing downregulated DLC-1. It was further evidenced by an aberrant DLC-1 promoter methylation pattern, which was detected by Southern blotting in 73% (8/11) of NSCLC cell lines with downregulation of the gene. The transfer of DLC-1 into three DLC-1 negative cell lines caused a significant inhibition in cell proliferation and/or a decrease in colony formation. Furthermore, stable transfer of DLC-1 abolished tumorigenicity in nude mice of two cell lines, suggesting that DLC-1 plays a role in NSCLC by acting as a bona. de new tumor suppressor gene.	NIOSH, Lab Genet Susceptibil, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yuan, BZ (corresponding author), 1095 Willowdale Rd,Mailstop L-3014, Morgantown, WV 26505 USA.	bby1@cdc.gov			NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Belinsky SA, 2002, CANCER RES, V62, P2370; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Girard L, 2000, CANCER RES, V60, P4894; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jemal A, 2001, JNCI-J NATL CANCER I, V93, P277, DOI 10.1093/jnci/93.4.277; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Kurimoto F, 2001, INT J MOL MED, V8, P89; Minna JD, 2002, CANCER J, V8, pS41; Ng IOL, 2000, CANCER RES, V60, P6581; Niklinski J, 2001, EUR J CANCER PREV, V10, P213, DOI 10.1097/00008469-200106000-00004; Park SW, 2003, INT J ONCOL, V23, P133; Pei JM, 2001, GENE CHROMOSOME CANC, V31, P282, DOI 10.1002/gcc.1145; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Shopland DR, 1995, ENVIRON HEALTH PERSP, V103, P131, DOI 10.2307/3432300; Soria JC, 2002, CANCER RES, V62, P351; Steenland K, 1996, AM J IND MED, V29, P474, DOI 10.1002/(SICI)1097-0274(199605)29:5<474::AID-AJIM6>3.0.CO;2-M; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Vecchione A, 2001, CLIN CANCER RES, V7, P1546; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wistuba II, 1999, CANCER RES, V59, P1973; Yin XL, 2002, CANCER GENET CYTOGEN, V134, P71, DOI 10.1016/S0165-4608(01)00611-2; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zheng SQL, 2003, MUTAT RES-FUND MOL M, V528, P45, DOI 10.1016/S0027-5107(03)00081-2; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	34	126	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2004	23	7					1405	1411		10.1038/sj.onc.1207291	http://dx.doi.org/10.1038/sj.onc.1207291			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	775HZ	14661059				2022-12-17	WOS:000189035800007
J	Kauppila, S; Maaty, WSA; Chen, P; Tomar, RS; Eby, MT; Chapo, J; Chew, S; Rathore, N; Zachariah, S; Sinha, SK; Abrams, JM; Chaudhary, PM				Kauppila, S; Maaty, WSA; Chen, P; Tomar, RS; Eby, MT; Chapo, J; Chew, S; Rathore, N; Zachariah, S; Sinha, SK; Abrams, JM; Chaudhary, PM			Eiger and its receptor, Wengen, comprise a TNF-like system in Drosophila	ONCOGENE			English	Article						Eiger; Wengen; Darth; TNF; apoptosis; JNK; dTRAF2	SUPERFAMILY; ACTIVATION; KINASE; DEATH; PROTEINS; BINDING; PATHWAY; MEMBER; REAPER; EMBRYO	In mammals, members of the tumor necrosis factor (TNF) family play an important role in the regulation of cellular proliferation, differentiation and programmed cell death. We describe isolation and characterization of an orthologous ligand/receptor axis in Drosophila. The ligand, designated Eiger, is a type II membrane glycosylated protein, which can be cleaved at residue 145 and released from the cell surface as a soluble factor, thereby representing the first potential cytokine to be described in Drosophila. Eiger exists in two alternatively spliced isoforms, Eiger long (Eiger-L) and Eiger short (Eiger-s), both of which are expressed throughout development and in the adult. We also describe the isolation and characterization of a novel Drosophila member of the TNF receptor family, designated Wengen, which is a type I membrane protein that can physically interact with the recently described TRAF2 homolog dTRAF2. Both Eiger and Wengen are expressed in distinctive patterns during embryogenesis and Eiger is responsive to genotoxic stress. Forced expression of Eiger-L, Eiger-s or Wengen, caused apoptotic cell death which could be rescued by caspase inhibitors or the JNK phosphatase Puckered. In addition, Eiger-induced cell killing was attenuated by RNAi-mediated suppression of Wengen. Our results illustrate that Eiger and Wengen represent proximal components of an evolutionarily conserved TNF-like signaling pathway in Drosophila.	Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, Dallas, TX 75390 USA; Univ Texas, Div Hematol Oncol, SW Med Ctr, Dallas, TX 75390 USA; Univ Texas, Dept Cell Biol, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Abrams, JM (corresponding author), Univ Texas, Hamon Ctr Therapeut Oncol Res, SW Med Ctr, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018		NIA NIH HHS [R01 AG12466] Funding Source: Medline; NIDCR NIH HHS [1R01 DE015189-01] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE015189] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012466] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Baker SJ, 1996, ONCOGENE, V12, P1; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043; Chen P, 1998, DEV BIOL, V201, P202, DOI 10.1006/dbio.1998.9000; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Igaki T, 2002, EMBO J, V21, P3009, DOI 10.1093/emboj/cdf306; Kanda H, 2002, J BIOL CHEM, V277, P28372, DOI 10.1074/jbc.C200324200; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Liu HZ, 1999, CURR BIOL, V9, P101, DOI 10.1016/S0960-9822(99)80023-2; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Moreno E, 2002, CURR BIOL, V12, P1263, DOI 10.1016/S0960-9822(02)00954-5; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; Shen BH, 2001, P NATL ACAD SCI USA, V98, P8596, DOI 10.1073/pnas.141235698; Sinha SK, 2002, J BIOL CHEM, V277, P44953, DOI 10.1074/jbc.M207923200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523	20	126	133	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2003	22	31					4860	4867		10.1038/sj.onc.1206715	http://dx.doi.org/10.1038/sj.onc.1206715			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894227				2022-12-17	WOS:000184344600009
J	Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC				Yuan, BZ; Zhou, XL; Durkin, ME; Zimonjic, DB; Gumundsdottir, K; Eyfjord, JE; Thorgeirsson, SS; Popescu, NC			DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity	ONCOGENE			English	Article						tumor suppressor gene; breast cancer; colon cancer; prostate cancer; tumorigenicity; metastasis	TUMOR-SUPPRESSOR GENE; CHROMOSOME 8P DELETION; HEPATOCELLULAR-CARCINOMA; RHO GTPASES; METASTASIS; IDENTIFICATION; ASSOCIATION; LINKAGE; PROTEIN; CLONING	The human DLC-1 (deleted in liver cancer 1) gene was cloned from a primary human hepatocellular carcinoma (HCC) and mapped to the chromosome 8p21-22 region frequently deleted in common human cancers and suspected to harbor tumor suppressor genes. DLC-1 was found to be deleted or downregulated in a significant number of HCCs. We expanded our investigations to other cancers with recurrent deletions of 8p22, and in this study examined alterations of DLC-1 in primary human breast tumors, human breast, colon, and prostate tumor cell lines. Genomic deletion of DLC-1 was observed in 40% of primary breast tumors, whereas reduced or undetectable levels of DLC-1 mRNA were seen in 70% of breast, 70% of colon, and 50% of prostate tumor cell lines To see whether DLC-1 expression affects cell growth and tumorigenicity, two breast carcinoma cell lines lacking the expression of endogenous gene were transfected with the DLC-1 cDNA. In both cell lines, DLC-1 transfection caused significant growth inhibition and reduction of colony formation. Furthermore, introduction of the DLC-1 cDNA abolished the in vivo tumorigenicity in nude mice, suggesting that the DLC-1 gene plays a role in breast cancer by acting as a bona fide tumor suppressor gene.	NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA; Iceland Canc Soc, Reykjavik, Iceland	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, Canc Res Ctr, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, ZIABC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Cabeza-Arvelaiz Y, 2001, ONCOGENE, V20, P4169, DOI 10.1038/sj.onc.1204539; Durkin ME, 2002, GENE, V288, P119, DOI 10.1016/S0378-1119(02)00462-6; Euer N, 2002, ANTICANCER RES, V22, P733; Gustafson CE, 1996, CANCER RES, V56, P5238; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Jenkins R, 1998, GENE CHROMOSOME CANC, V21, P131, DOI 10.1002/(SICI)1098-2264(199802)21:2<131::AID-GCC9>3.0.CO;2-1; Martinez-Climent JA, 2001, BLOOD, V98, P3479, DOI 10.1182/blood.V98.12.3479; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Ng IOL, 2000, CANCER RES, V60, P6581; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Tikoo A, 2000, GENE, V257, P23, DOI 10.1016/S0378-1119(00)00387-5; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Xu J, 2001, AM J HUM GENET, V69, P341, DOI 10.1086/321967; YAREMKO ML, 1998, GENE CHROMOSOME CANC, V21, P189; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 1999, CYTOGENET CELL GENET, V87, P189, DOI 10.1159/000015462; YUAN BZ, IN PRESS CANC GENET; YUAN BZ, 2000, P AM ASSOC CANC RES, V41, P105; Zimonjic DB, 2000, INT J ONCOL, V16, P221; Zitzelsberger H, 1997, HISTOCHEM CELL BIOL, V108, P403, DOI 10.1007/s004180050181	29	126	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					445	450		10.1038/sj.onc.1206064	http://dx.doi.org/10.1038/sj.onc.1206064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545165				2022-12-17	WOS:000180379100013
J	Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T				Klejman, A; Rushen, L; Morrione, A; Slupianek, A; Skorski, T			Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571	ONCOGENE			English	Article						BCR/ABL; PI-3k; STI571; wortmannin; combination therapy	ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; DNA-BINDING ACTIVITY; BCR-ABL; CELL-LINES; CONSTITUTIVE ACTIVATION; CLINICAL RESISTANCE	BCR/ABL fusion tyrosine kinase is responsible for the initiation and maintenance of the Philadelphia chromosome (Ph-1)-positive chronic myelogenous leukemia (CML) and a cohort of acute lymphocytic leukemias (ALL). STI571 (Gleevec), a novel anti-leukemia drug targeting BCR/ABL kinase can induce remissions of the Ph-1-positive leukemias. STI571 was recently combined with the standard cytostatic drugs to achieve better therapeutic results and to overcome emerging drug resistance mechanisms. We decided to search for a more specific partner compound for ST1571. Our previous studies showed that a signaling protein phosphatidylinositol-3 kinase (PI-3k) is essential for the growth of CML cells, but not of normal hematopoietic cells (Blood, 86:726,1995). Therefore the anti-Ph-1-leukemia effect of the combination of BCR/ABL kinase inhibitor ST1571 and PI-3k inhibitor wortmannin (WT) or LY294002 (LY) was tested. We showed that ST1571 + WT exerted a synergistic effect against the Ph-1-positive cell lines, but did not affect the growth of Ph-1-negative cell line. Moreover, the combinations of STI571+WT or STI571+LY were effective in the inhibition of clonogenic growth of CML-chronic phase and CML-blast crisis patient cells, while sparing normal bone marrow cells. Single colony RT-PCR assay showed that colonies arising from the mixture of CML cells and normal bone marrow cells after treatment with STI571+WT were selectively depleted of BCR/ABL-positive cells. Biochemical analysis of the CML cells after the treatment revealed that combination of ST1571 + WT caused a more pronounced activation of caspase-3 and induced massive apoptosis, in comparison to ST1571 and WT alone. In conclusion, combination of ST1571 + WT or ST1571 + LY may represent a novel approach against the Ph-1-positive leukemias.	Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jefferson University	Skorski, T (corresponding author), Temple Univ, Ctr Biotechnol, Coll Sci & Technol, Bio Life Sci Bldg,Room 419,1900 N 12th St, Philadelphia, PA 19122 USA.	tskorski@astro.temple.edu	Klejman, Agata/AAC-1844-2021	Klejman, Agata/0000-0001-6083-9957	NCI NIH HHS [CA87300] Funding Source: Medline; NIDDK NIH HHS [K01 DK02896] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002896] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arico M, 2000, NEW ENGL J MED, V342, P998, DOI 10.1056/NEJM200004063421402; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chai SK, 1997, J IMMUNOL, V159, P4720; Clift RA, 1996, BONE MARROW TRANSPL, V17, pS1; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DHUT S, 1990, LEUKEMIA, V4, P745; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Gordon MY, 1999, LEUKEMIA, V13, pS65, DOI 10.1038/sj.leu.2401281; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gratwohl A, 1996, BONE MARROW TRANSPL, V17, pS7; Haseyama Y, 1999, BLOOD, V94, P1568, DOI 10.1182/blood.V94.5.1568.417a07_1568_1577; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kano Y, 2001, BLOOD, V97, P1999, DOI 10.1182/blood.V97.7.1999; Kardinal C, 2001, BLOOD, V98, P1773, DOI 10.1182/blood.V98.6.1773; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Marley SB, 2000, EXP HEMATOL, V28, P551, DOI 10.1016/S0301-472X(00)00142-9; Neshat MS, 2000, MOL CELL BIOL, V20, P1179, DOI 10.1128/MCB.20.4.1179-1186.2000; Nguyen MHH, 2001, J BIOL CHEM, V276, P32704, DOI 10.1074/jbc.M103100200; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Nielsen M, 1996, J IMMUNOL, V157, P5350; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Sacchi S, 1999, CANCER-AM CANCER SOC, V86, P2632, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Silver RT, 1999, BLOOD, V94, P1517; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1995, J EXP MED, V182, P1645, DOI 10.1084/jem.182.6.1645; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; SKORSKI T, 1993, J CLIN INVEST, V92, P194, DOI 10.1172/JCI116549; Skorski T, 1996, BLOOD, V88, P1005, DOI 10.1182/blood.V88.3.1005.1005; Skorski T, 1997, J NATL CANCER I, V89, P124, DOI 10.1093/jnci/89.2.124; Slupianek A, 2001, CANCER RES, V61, P2194; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Sun XM, 2001, BLOOD, V97, P2008, DOI 10.1182/blood.V97.7.2008; TALPAZ M, 1987, CANCER, V59, P664, DOI 10.1002/1097-0142(19870201)59:3+<664::AID-CNCR2820591316>3.0.CO;2-Y; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thiesing JT, 2000, BLOOD, V96, P3195, DOI 10.1182/blood.V96.9.3195.h8003195_3195_3199; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Topaly J, 2001, LEUKEMIA, V15, P342, DOI 10.1038/sj.leu.2402041; Van Etten RA, 2001, BLOOD CELL MOL DIS, V27, P201, DOI 10.1006/bcmd.2000.0370; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Yu CR, 2002, CANCER RES, V62, P188	85	126	132	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2002	21	38					5868	5876		10.1038/sj.onc.1205724	http://dx.doi.org/10.1038/sj.onc.1205724			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	585JD	12185586				2022-12-17	WOS:000177520900006
J	Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V				Paumelle, R; Tulasne, D; Kherrouche, Z; Plaza, S; Leroy, C; Reveneau, S; Vandenbunder, B; Fafeur, V			Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway	ONCOGENE			English	Article						HGF/SF; RAS; ERK; ETS; morphogenesis	RECEPTOR TYROSINE KINASE; SCATTER FACTOR; MAP-KINASE; EPITHELIAL-CELLS; PROTEIN-KINASES; PHOSPHORYLATION; DOMAIN; EXPRESSION; TRANSDUCTION; MOTILITY	Hepatocyte growth factor/scatter factor (HGF/SF) induces scattering and morphogenesis of epithelial cells through the activation of the MET tyrosine kinase receptor. Although the activated MET receptor recruits a number of signaling proteins, little is known of the downstream signaling pathways activated by HGF/SF. In this study, we wished to examine the signaling pathway leading to activation of the ETS1 transcription factor. Using in vitro and in vivo kinase assays, we found that HGF/SF activates the ERK1 MAP kinase, leading to the phosphorylation of the threonine 38 residue of ETS1 within a putative MAP kinase phosphorylation site (PLLT38P). This threonine residue was neither phosphorylated by JNK1, nor by p38 MAP kinases and was required for the induction of transcriptional activity of ETS1 by HGF/SF. Using kinase and transcription assays, we further demonstrated that phosphorylation and activation of ETS1 occurs downstream of a RAS-RAF-MEK-ERK pathway. The functional involvement of this pathway in HGF/SF action was demonstrated using U0126, a pharmacological inhibitor of MEK, which blocked phosphorylation and activation of ETS1, RAS-dependent transcriptional responses, cell scattering and morphogenesis. These data demonstrated that ETS1 is a downstream target of HGF/SF acting through a RAS-RAF-MEK-ERK pathway and provides a signaling pathway leading to the regulation of gene expression by HGF/SF.	Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Fafeur, V (corresponding author), Inst Pasteur, Inst Biol Lille, CNRS, FRE 2353, BP 447, F-59021 Lille, France.	veronique.fefeur@ibl.fr	KHERROUCHE, Zoulika/L-6549-2019; Paumelle, Réjane/R-6675-2018; Tulasne, David/A-8705-2008; Tulasne, David/AAR-5287-2020; plaza, serge/F-5290-2015; Fafeur, Veronique/L-9072-2018; KHERROUCHE, Zoulika/HHN-0213-2022	Paumelle, Réjane/0000-0002-4489-0717; Tulasne, David/0000-0002-6764-7242; 				Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; CHEN JH, 1990, ONCOGENE RES, V5, P277; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; Gambarotta G, 1996, ONCOGENE, V13, P1911; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kim KR, 2000, ONCOGENE, V19, P1764, DOI 10.1038/sj.onc.1203502; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Paumelle R, 2000, MOL BIOL CELL, V11, P3751, DOI 10.1091/mbc.11.11.3751; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rabault B, 1996, ONCOGENE, V13, P877; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Terauchi R, 2000, EXP CELL RES, V256, P411, DOI 10.1006/excr.2000.4850; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	44	126	140	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2002	21	15					2309	2319		10.1038/sj.onc.1205297	http://dx.doi.org/10.1038/sj.onc.1205297			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	535FY	11948414				2022-12-17	WOS:000174635600003
J	Lundblad, V				Lundblad, V			Telomere maintenance without telomerase	ONCOGENE			English	Article						telomerase; EST1; ALT; recombination; break-induced replication	SACCHAROMYCES-CEREVISIAE; HUMAN-CELLS; YEAST TELOMERE; RECOMBINATION; REPLICATION; LENGTH; ELONGATION; SENESCENCE; ENDS; BACTERIOPHAGE-T4	Recombination-dependent maintenance of telomeres, first discovered in budding yeast, has revealed an alternative pathway for telomere maintenance that does not require the enzyme telomerase. Experiments conducted in two budding yeasts, S. cerevisiae and K. lactis, have shown recombination can replenish terminal G-rich telomeric tracts that would otherwise shorten in the absence of telomerase, as well as disperse and amplify sub-telomeric repeat elements. Investigation of the genetic requirements for this process have revealed that at least two different recombination pathways, defined by RAD50 and RAD51, can promote telomere maintenance. Although critically short telomeres are very recombinogenic, recombination among telomeres that have only partially shortened in the absence of telomerase can also contribute to telomerase-independent survival. These observations provide new insights into the mechanism(s) by which recombination can restore telomere function in yeast, and suggest future experiments for the investigation of potentially similar pathways in human cells.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine	Lundblad, V (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.							BAIRD DM, 1995, EMBO J, V14, P5433, DOI 10.1002/j.1460-2075.1995.tb00227.x; Baird DM, 2000, AM J HUM GENET, V66, P235, DOI 10.1086/302721; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; Biessmann H, 1997, CHROMOSOMA, V106, P63, DOI 10.1007/s004120050225; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bosco G, 1998, GENETICS, V150, P1037; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Bucholc M, 2001, MOL CELL BIOL, V21, P6559, DOI 10.1128/MCB.21.19.6559-6573.2001; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; DUNN B, 1984, CELL, V39, P191, DOI 10.1016/0092-8674(84)90205-8; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; FORMOSA T, 1986, J BIOL CHEM, V261, P6107; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grobelny JV, 2001, HUM MOL GENET, V10, P1953, DOI 10.1093/hmg/10.18.1953; Hackett JA, 2001, CELL, V106, P275, DOI 10.1016/S0092-8674(01)00457-3; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Hughes TR, 2000, CURR BIOL, V10, P809, DOI 10.1016/S0960-9822(00)00562-5; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kass-Eisler A, 2000, TRENDS BIOCHEM SCI, V25, P200, DOI 10.1016/S0968-0004(00)01557-7; KRAMER KM, 1993, GENE DEV, V7, P2345, DOI 10.1101/gad.7.12a.2345; Le S, 1999, GENETICS, V152, P143; Lendvay TS, 1996, GENETICS, V144, P1399; Li BB, 1996, GENE DEV, V10, P1310, DOI 10.1101/gad.10.11.1310; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Malkova A, 2001, GENE DEV, V15, P1055, DOI 10.1101/gad.875901; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; McEachern MJ, 2001, MOL CELL, V7, P695, DOI 10.1016/S1097-2765(01)00215-5; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; Morris DK, 1997, CURR BIOL, V7, P969, DOI 10.1016/S0960-9822(06)00416-7; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Novick RP, 1998, TRENDS BIOCHEM SCI, V23, P434, DOI 10.1016/S0968-0004(98)01302-4; Perrem K, 2001, MOL CELL BIOL, V21, P3862, DOI 10.1128/MCB.21.12.3862-3875.2001; Reddel RR, 2001, RADIAT RES, V155, P194, DOI 10.1667/0033-7587(2001)155[0194:ALOTIH]2.0.CO;2; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Teng SC, 2000, MOL CELL, V6, P947, DOI 10.1016/S1097-2765(00)00092-7; Teng SC, 1999, MOL CELL BIOL, V19, P8083; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WILKIE AOM, 1991, CELL, V64, P595, DOI 10.1016/0092-8674(91)90243-R; Yeager TR, 1999, CANCER RES, V59, P4175; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	58	126	133	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					522	531		10.1038/sj.onc.1205079	http://dx.doi.org/10.1038/sj.onc.1205079			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850777				2022-12-17	WOS:000173390500004
J	Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D				Kannan, K; Kaminski, N; Rechavi, G; Jakob-Hirsch, J; Amariglio, N; Givol, D			DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1	ONCOGENE			English	Article						apoptosis; ts-p53; DNA microarray; clustering; Apaf-1	TEMPERATURE-SENSITIVE MUTANT; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; EXPRESSION PATTERNS; SUMO-1 MODIFICATION; CELL-DEATH; C-JUN; INTERLEUKIN-6; INHIBITION; GELSOLIN	The transcription regulation activity of p53 controls cellular response to a variety of stress conditions, leading to growth arrest and apoptosis. Despite major progress in the understanding of the global effects of p53 on cellular function the pathways by which p53 activates apoptosis are not well defined. To study genes activated in the p53 induced apoptotic process, we used a mouse myeloid leukemic cell line (LTR6) expressing the temperature-sensitive p53 (val135) that undergoes apoptosis upon shifting the temperature to 32 degreesC. We analysed the gene expression profile at different time points after p53 activation using oligonucleotide microarray capable of detecting similar to 11 000 mRNA species. Cluster analysis of the p53-regulated genes indicate a pattern of early and late induced sets of genes. We show that 91 and 44 genes were substantially up and down regulated, respectively, by p53. Functional classification of these genes reveals that they are involved in many aspects of cell function, in addition to growth arrest and apoptosis, Comparison of p53 regulated gene expression profile in LTR6 cells to that of a human lung cancer cell line (H1299) that undergoes growth arrest but not apoptosis demonstrates that only 15% of the genes are common to both systems. This observation supports the presence of two distinct transcriptional programs in response to p53 signaling, one leading to growth arrest and the other to apoptosis. The proapoptotic genes induced only in LTR6 cells like Apaf-1, Sumo-1 and gelsolin among others may suggest a possible explanation for apoptosis in LTR6 cells.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Funct Genom Unit, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Chaim Sheba Med Ctr, Dept Pediat Hematol Oncol, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University	Givol, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.			Kaminski, Naftali/0000-0001-5917-4601				Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Kaminski N, 2000, Ann N Y Acad Sci, V919, P1; Kannan K, 2000, FEBS LETT, V470, P77, DOI 10.1016/S0014-5793(00)01291-6; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; Maxwell SA, 2000, P NATL ACAD SCI USA, V97, P13009, DOI 10.1073/pnas.230445997; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	30	126	132	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 7	2001	20	26					3449	3455		10.1038/sj.onc.1204446	http://dx.doi.org/10.1038/sj.onc.1204446			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423996				2022-12-17	WOS:000169248800016
J	Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G				Wang, HC; Zeng, ZC; Bui, TA; Sonoda, E; Takata, M; Takeda, S; Iliakis, G			Efficient rejoining of radiation-induced DNA double-strand breaks in vertebrate cells deficient in genes of the RAD52 epistasis group	ONCOGENE			English	Review						double-strand breaks (DSB); homologous recombination; RAD51; RAD51B; RAD52; RAD54; KU70; repair	DEPENDENT PROTEIN-KINASE; RECOMBINATIONAL REPAIR GENE; FIELD GEL-ELECTROPHORESIS; HOMOLOGY-DIRECTED REPAIR; SENSITIVE IRS MUTANTS; SACCHAROMYCES-CEREVISIAE; V(D)J RECOMBINATION; IONIZING-RADIATION; LIGASE IV; PROKARYOTIC RECA	Rejoining of ionizing radiation (IR) induced DNA DSBs usually follows biphasic kinetics with a fast (t(50): 5-30 min) component attributed to DNA-PK-dependent non-homologous endjoining (NHEJ) and a slow (t(50): 1-20 h), as of yet uncharacterized, component. To examine whether homologous recombination (HR) contributes to DNA DSB rejoining, a systematic genetic study was undertaken using the hyper-recombinogenic DT40 chicken cell line and a series of mutants defective in HR, We show that DT40 cells rejoin IR-induced DNA DSBs with half times of 13 min and 4.5 h and contributions by the fast (78%) and the slow (22%) components similar to those of other vertebrate cells with 1000-fold lower levels of HR, We also show that deletion of RAD51B, RAD52 and RAD54 leaves unchanged the rejoining half times and the contribution of the slow component, as does also a conditional knock out mutant of RAD51, A significant reduction (to 37%) in the contribution of the fast component is observed in Ku70 / DT40 cells, but the slow component, operating with a half time of 18.4 h, is still able to rejoin the majority (63%) of DSBs, ri double mutant Ku70(-/-)/RAD54 / shows similar half times to Ku70(-/-) cells. Thus, variations in HR by several orders of magnitude leave unchanged the kinetics of rejoining of DNA DSBs, and fail to modify the contribution of the slow component in a way compatible with a dependence on HR, We propose that, in contrast to yeast, cells of vertebrates are 'hard-wired' in the utilization of NHEJ as the main pathway for rejoining of IR-induced DNA DSBs and speculate that the contribution of homologous recombination repair (HRR) is at a stage after the initial rejoining.	Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19107 USA; Kyoto Univ, Fac Med, Bayer Chair Dept Mol Immunol & Allergol, Sakyo Ku, Kyoto 6068501, Japan; JST, CREST, Tsukuba, Ibaraki, Japan	Jefferson University; Kyoto University; Japan Science & Technology Agency (JST)	Iliakis, G (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Ctr, Dept Radiat Oncol, Thompson Bldg Room B-1, Philadelphia, PA 19107 USA.			Takata, Minoru/0000-0002-4926-3675; Takeda, Shunichi/0000-0002-7924-7991	NCI NIH HHS [P30-CA56036, CA42026] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042026, P30CA056036] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; BADIE C, 1995, RADIAT RES, V144, P26, DOI 10.2307/3579232; BASES R, 1986, RADIAT RES, V105, P259, DOI 10.2307/3576551; BASES R, 1990, INT J RADIAT BIOL, V58, P35, DOI 10.1080/09553009014551421; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bennett CB, 1997, CANCER RES, V57, P1970; Bennett CB, 1996, MOL CELL BIOL, V16, P4414; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BEZZUBOVA OY, 1994, EXPERIENTIA, V50, P270, DOI 10.1007/BF01924010; BEZZUBOVA OY, 1993, NUCLEIC ACIDS RES, V21, P5945, DOI 10.1093/nar/21.25.5945; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; CHEONG N, 1992, MUTAT RES, V274, P111, DOI 10.1016/0921-8777(92)90058-B; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; CONTOPOULOU CR, 1987, YEAST, V3, P71, DOI 10.1002/yea.320030203; D'Mello SR, 1998, J NEUROCHEM, V70, P1809; Dibiase SJ, 2000, CANCER RES, V60, P1245; DIKOMEY E, 1986, INT J RADIAT BIOL, V50, P893, DOI 10.1080/09553008614551311; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Evans JW, 1996, RADIAT RES, V145, P39, DOI 10.2307/3579193; FRANKENBERGSCHWAGER M, 1989, RADIOTHER ONCOL, V14, P307, DOI 10.1016/0167-8140(89)90143-6; FRANKENBERGSCHWAGER M, 1990, RADIAT ENVIRON BIOPH, V29, P273, DOI 10.1007/BF01210408; FRANKENBURGSCHWAGER M, 1994, INT J RADIAT BIOL, V66, P543, DOI 10.1080/09553009414551591; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1998, J BIOL CHEM, V273, P24708, DOI 10.1074/jbc.273.38.24708; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENNER WD, 1983, J BIOL CHEM, V258, P711; HO KSY, 1975, MUTAT RES, V30, P327, DOI 10.1016/0165-1218(75)90058-0; ILIAKIS G, 1992, INT J RADIAT BIOL, V61, P315, DOI 10.1080/09553009214550991; ILIAKIS G, 1991, BIOESSAYS, V13, P641; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P343, DOI 10.1080/09553009114550321; ILIAKIS GE, 1991, INT J RADIAT BIOL, V59, P321, DOI 10.1080/09553009114550311; Ivanov EL, 1996, GENETICS, V142, P693; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1990, MUTAGENESIS, V5, P15, DOI 10.1093/mutage/5.1.15; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; Lewis LK, 1999, GENETICS, V152, P1513; Lewis LK, 1998, MOL CELL BIOL, V18, P1891, DOI 10.1128/MCB.18.4.1891; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lieber MR, 1997, CURR OPIN GENET DEV, V7, P99, DOI 10.1016/S0959-437X(97)80116-5; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Lobrich M, 1995, P NATL ACAD SCI USA, V92, P12050, DOI 10.1073/pnas.92.26.12050; LOVETT ST, 1994, GENE, V142, P103, DOI 10.1016/0378-1119(94)90362-X; METZGER L, 1991, INT J RADIAT BIOL, V59, P1325, DOI 10.1080/09553009114551201; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Nevaldine B, 1997, RADIAT RES, V147, P535, DOI 10.2307/3579619; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OKAYASU R, 1993, RADIAT RES, V138, P34; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Peng L, 1998, GENOMICS, V54, P529, DOI 10.1006/geno.1998.5536; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Petrini J H, 1997, Semin Immunol, V9, P181, DOI 10.1006/smim.1997.0067; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; RESNICK MA, 1976, J THEOR BIOL, V59, P97, DOI 10.1016/S0022-5193(76)80025-2; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Rothstein R, 2000, GENE DEV, V14, P1; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schoenmakers EFPM, 1999, CANCER RES, V59, P19; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Siede W, 1996, GENETICS, V142, P91; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Taghian DG, 1997, MOL CELL BIOL, V17, P6386, DOI 10.1128/MCB.17.11.6386; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; THACKER J, 1990, MUTAT RES, V235, P49, DOI 10.1016/0921-8777(90)90057-C; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; VAINIO O, 1995, IMMUNOL TODAY, V16, P365, DOI 10.1016/0167-5699(95)80002-6; Wachsberger PR, 1999, RADIAT RES, V151, P398, DOI 10.2307/3579826; WARD JF, 1985, RADIAT RES, V104, pS103, DOI 10.2307/3576637; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; WIEBEZAHN KF, 1981, NUCLEIC ACIDS RES, P3139; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	105	126	132	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2212	2224		10.1038/sj.onc.1204350	http://dx.doi.org/10.1038/sj.onc.1204350			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402316				2022-12-17	WOS:000168404500003
J	Bruey, JM; Paul, C; Fromentin, A; Hilpert, S; Arrigo, AP; Solary, E; Garrido, C				Bruey, JM; Paul, C; Fromentin, A; Hilpert, S; Arrigo, AP; Solary, E; Garrido, C			Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo	ONCOGENE			English	Article						small heat shock protein; colon carcinoma; apoptosis; tumorigenesis	HEAT-SHOCK-PROTEIN; COLON-CANCER-CELLS; NECROSIS-FACTOR-ALPHA; CONFLUENCE-DEPENDENT RESISTANCE; SMALL STRESS PROTEINS; ACTIN POLYMERIZATION; PROTECTIVE ACTIVITY; REGRESSIVE TUMORS; TNF-ALPHA; PHOSPHORYLATION	HSP27 form oligomeric structures up to 800 Kda, In cultured cells, the equilibrium between small and large oligomers shifted towards smaller oligomers when phosphorylated on serine residues. To further explore HSP27 structural organization and its repercussion in HSP27 antiapoptotic and tumorigenic properties, we transfected colon cancer REG cells with wild type HSP27 and two mutants in which the phosphorylatable serine residues have been replaced by alanine (to mimic the non phosphorylated protein) or aspartate (to mimic the phosphorylated protein). In growing cells, wild type and alanine mutant formed small and large oligomers and demonstrated antiapoptotic activity while aspartate mutant only formed small multimers and had no antiapoptotic activity, In a cell-free system, only large oligomeric structures interfered with cytochrome c-induced caspase activation, thereby inhibiting apoptosis, The inability of the aspartate mutant to form large oligomers and to protect tumor cells from apoptosis was overcome by growing the cells in vivo, either in syngeneic animals or nude mice, These observations were reproduced by culturing the cells at confluence in vitro, In conclusion (1) large oligomers are the structural organization of HSP27 required for its antiapoptotic activity and (2) cell-cell contacts induce the formation of large oligomers, whatever the status of phosphorylatable serines, thereby increasing cell tumorigenicity.	Fac Med & Pharm, INSERM U517, F-21000 Dijon, France; Univ Lyon 1, CNRS, UMR 5534, F-69622 Villeurbanne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Garrido, C (corresponding author), Fac Med & Pharm, INSERM U517, 7 Blvd Jeanne Arc, F-21000 Dijon, France.		Garrido, Carolina/GWM-5557-2022; Paul, Catherine/F-8376-2019; Garrido, carmen/G-1633-2018	Garrido, carmen/0000-0003-1368-1493; Paul, Catherine/0000-0002-7657-5535; Solary, Eric/0000-0002-8629-1341				ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 1994, BIOL HEAT SHOCK PROT, P335; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Beresford PJ, 1998, J IMMUNOL, V161, P161; CAIGNARD A, 1985, INT J CANCER, V36, P373; DEJONG WW, 1988, J BIOL CHEM, V263, P5141; DIMANCHEBOITREL MT, 1992, INT J CANCER, V50, P677, DOI 10.1002/ijc.2910500502; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1996, EUR J BIOCHEM, V237, P653, DOI 10.1111/j.1432-1033.1996.0653p.x; Garrido C, 1998, CANCER RES, V58, P5495; Garrido C, 1997, CANCER RES, V57, P2661; HOUT J, 1991, CANCER RES, V51, P5245; JAKOB U, 1993, J BIOL CHEM, V268, P1517; KATO K, 1994, J BIOL CHEM, V269, P11274; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MARTIN F, 1983, INT J CANCER, V32, P623, DOI 10.1002/ijc.2910320517; MEHLEN P, 1995, J CELL BIOCHEM, V58, P248, DOI 10.1002/jcb.240580213; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MEHLEN P, 1995, J IMMUNOL, V154, P363; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Mehlen P, 1997, BIOCHEM BIOPH RES CO, V241, P187, DOI 10.1006/bbrc.1997.7635; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, 1995, BIOCHEM J, V312, P367, DOI 10.1042/bj3120367; MEHLEN P, 1994, EUR J BIOCHEM, V221, P321; MIRON T, 1991, J CELL BIOL, V114, P255, DOI 10.1083/jcb.114.2.255; PELLETIER H, 1990, CANCER RES, V50, P6626; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SHIMIZU T, 1989, IMMUNOBIOLOGY, V178, P401, DOI 10.1016/S0171-2985(89)80062-2; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9	41	126	129	1	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 5	2000	19	42					4855	4863		10.1038/sj.onc.1203850	http://dx.doi.org/10.1038/sj.onc.1203850			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039903				2022-12-17	WOS:000089757800008
J	Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T				Honda, K; Mihara, H; Kato, Y; Yamaguchi, A; Tanaka, H; Yasuda, H; Furukawa, K; Urano, T			Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin-proteasome pathway	ONCOGENE			English	Article						Aurora2; degradation; anaphase-promoting complex; ubiquitin-proteasome pathway	CHROMOSOME SEGREGATION; CELL-CYCLE; IN-VIVO; YEAST; PROTEOLYSIS; EXPRESSION; BINDING; IPL1; TRANSFORMATION; LOCALIZATION	Human Aurora2 was originally identified by its close homology to yeast IPL1 and fly aurora, which are key regulators of chromosome segregation and a family of serine/threonine kinases, Here we demonstrate that the Aurora2 protein is degraded rapidly after G2/M phase release in mammalian cells. Aurora2 protein has a rapid turnover rate with a half-life of approximately 2 h, Tn eukaryotic cells, the ubiquitin-proteasome pathway is the major mechanism for the targeted degradation of unstable proteins, The treatment of mammalian cells with proteasome inhibitors blocks Aurora2 degradation. Furthermore, Aurora2 is polyubiquitinated in vivo and in vitro using anaphase-promoting complex (APC), These results demonstrate that Aurora2 protein is turned over through the APC-ubiquitin-proteasome pathway.	Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Fukui Med Sch, Dept Surg 1, Fukui 9101193, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Hachioji, Tokyo 1920392, Japan	Nagoya University; University of Fukui; Tokyo University of Pharmacy & Life Sciences	Urano, T (corresponding author), Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai-machi, Nagoya, Aichi 4660065, Japan.			Urano, Takeshi/0000-0003-3383-3554				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Maki CG, 1996, CANCER RES, V56, P2649; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; URANO T, 1993, ONCOGENE, V8, P1371; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANAI A, 1997, ONCOGENE, V14, P2493; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	30	126	129	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 1	2000	19	24					2812	2819		10.1038/sj.onc.1203609	http://dx.doi.org/10.1038/sj.onc.1203609			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	320LX	10851084				2022-12-17	WOS:000087403600002
J	Wei, Y; Fabre, M; Branchereau, S; Gauthier, F; Perilongo, G; Buendia, MA				Wei, Y; Fabre, M; Branchereau, S; Gauthier, F; Perilongo, G; Buendia, MA			Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas	ONCOGENE			English	Article						beta-catenin; nuclear/cytoplasmic staining; liver; hepatoblastoma; APC; E-cadherin	FAMILIAL ADENOMATOUS POLYPOSIS; APC GENE; HEPATOCELLULAR CARCINOMAS; SOMATIC MUTATIONS; COLORECTAL-CANCER; CADHERIN; COMPLEX; PATHWAY; EXON-3; MOUSE	Wnt/beta-catenin signaling is frequently activated in cancer cells by stabilizing mutations of beta-catenin or loss-of-function mutations of the APC tumor suppressor gene. We have analysed the role of beta-catenin in the pathogenesis of hepatoblastoma (HB), an embryonic liver tumor occurring mainly in children under 2 years of age. Sequence analysis of the beta-catenin NH2-terminal domain in 18 epithelial and mixed HBs revealed missense mutations in the GSK3 beta phosphorylation motif or interstitial deletions in 12 tumors (67%), In the remaining cases, no truncating mutation of APC could be evidenced. Immunohistochemical analysis of beta-catenin in 11 HBs demonstrated nuclear/cytoplasmic accumulation of the protein in all tumors analysed, with predominant nuclear beta-catenin immunostaining in undifferentiated cells, Membranous beta-catenin localization was preserved only in fetal-type tumoral hepatocytes and was associated with E-cadherin expression. Moreover, are show that beta-catenin is aberrantly overexpressed in a large spectrum of tumor components, including hepatocyte-like cells at various differentiation stages and heterologous elements such as squamous, osteoid and chrondroid tissues, and in occasional other mesenchymally-derived cells. These data strongly suggest that activation of beta-catenin signaling is an obligatory step in HE pathogenesis, and raise the possibility that it interferes with developmental signals that specify different tissue types at early stages of hepatic differentiation.	Inst Pasteur, Unite Recombinaison & Express Genet, INSERM U163, F-75724 Paris 15, France; Hop Bicetre, Lab Anat & Cytol Pathol, Le Kremlin Bicetre, France; Hop Bicetre, Serv Chirurg Pediat, Le Kremlin Bicetre, France; Univ Padua, Dipartimento Pediat, I-35128 Padua, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Padua	Buendia, MA (corresponding author), Inst Pasteur, Unite Recombinaison & Express Genet, INSERM U163, 28 Rue Dr Roux, F-75724 Paris 15, France.		Wei, Yu/A-7289-2016	PERILONGO, GIORGIO/0000-0002-3712-0386				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Blaker H, 1999, GENE CHROMOSOME CANC, V25, P399; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DESDOUETS C, 1995, J HEPATOL, V23, P569, DOI 10.1016/0168-8278(95)80064-6; Garcia-Rostan G, 1999, CANCER RES, V59, P1811; Giardiello FM, 1996, GUT, V39, P867, DOI 10.1136/gut.39.6.867; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; Iwao K, 1998, CANCER RES, V58, P1021; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koch A, 1999, CANCER RES, V59, P269; Koesters R, 1999, CANCER RES, V59, P3880; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KURAHASHI H, 1995, CANCER RES, V55, P5007; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Miyoshi Y, 1998, CANCER RES, V58, P2524; Oda H, 1996, CANCER RES, V56, P3320; Olschwang S, 1997, P NATL ACAD SCI USA, V94, P12122, DOI 10.1073/pnas.94.22.12122; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Sparks AB, 1998, CANCER RES, V58, P1130; STOCKER JT, 1997, LIVER CANC; VANTHIEU JT, 1999, AM J PATHOL, V155, P703; Voeller HJ, 1998, CANCER RES, V58, P2520; Wei Y, 1998, J VIROL, V72, P2089, DOI 10.1128/JVI.72.3.2089-2096.1998; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	32	126	128	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 27	2000	19	4					498	504		10.1038/sj.onc.1203356	http://dx.doi.org/10.1038/sj.onc.1203356			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	280LL	10698519	Bronze			2022-12-17	WOS:000085104200003
J	Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR				Murthy, SS; Shen, T; De Rienzo, A; Lee, WC; Ferriola, PC; Jhanwar, SC; Mossman, BT; Filmus, J; Testa, JR			Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma	ONCOGENE			English	Article						proteoglycan; mesothelioma; differential mRNA display; gene regulation; tumor suppressor gene; promoter methylation	ASBESTOS; GLYPICAN; GROWTH; CELLS; INOCULATION; CARCINOMA; MUTATIONS; RATS; NF2	Gene expression changes in rat asbestos-induced malignant mesothelioma (MM) cells were investigated by differential mRNA display. A mRNA transcript identified by this approach was abundant in normal rat mesothelial cells but not expressed in rat MM cell lines. Northern blot analysis confirmed that this transcript is uniformly silenced in rat MM cell lines and primary tumors. Nucleotide sequence analysis revealed that this transcript is encoded by the rat glypican 3 gene (GPC3), whose human homolog is mutated in the Simpson-Golabi-Behmel overgrowth syndrome. Allelic loss at the GPC3 locus was infrequent (6.9%) in MM cell lines, and no mutations were found. GPC3 transcript levels were markedly decreased in 16 of 18 primary tumors and 17 of 22 human MM cell Lines. Most of the cell lines were shown to have aberrant methylation of the GPC3 promoter region. In two of four human MM cell lines tested, GPC3 expression was restored after 2-deoxy 5-azacytidine (DAC)-mediated demethylation of its promoter region. Ectopic expression of GPC3 inhibited in vitro colony formation of human MM cells, Collectively, these data suggest that down-regulation of GPC3 is a common occurrence in MM and that GPC3, an X-linked recessive overgrowth gene, may encode a negative regulator of mesothelial cell growth.	Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA; Chem Ind Inst Toxicol, Res Triangle Pk, NC 27709 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA; Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	Fox Chase Cancer Center; Memorial Sloan Kettering Cancer Center; University of Vermont; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Testa, JR (corresponding author), Fox Chase Canc Ctr, Human Genet Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45745, CA-06927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BonnehBarkay D, 1997, J BIOL CHEM, V272, P12415, DOI 10.1074/jbc.272.19.12415; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; CHENG JQ, 1994, CANCER RES, V54, P5547; CRAIGHEAD JE, 1987, AM J PATHOL, V129, P448; CRAIGHEAD JE, 1987, HUM PATHOL, V18, P544, DOI 10.1016/S0046-8177(87)80354-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; DAVIS JMG, 1974, J NATL CANCER I, V52, P1823, DOI 10.1093/jnci/52.6.1823; Duenas-Gonzalez A, 1998, J CELL BIOL, V141, P1407, DOI 10.1083/jcb.141.6.1407; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FUNAKI K, 1991, CANCER RES, V51, P4059; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HILL RJ, 1990, J EXP PATHOL, V71, P105; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; JANSSEN YMW, 1995, CANCER RES, V55, P2085; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIBBUS BL, 1988, CANCER RES, V48, P6455; Lin HC, 1999, CANCER RES, V59, P807; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; SEKIDO Y, 1995, CANCER RES, V55, P1227; Song HH, 1997, J BIOL CHEM, V272, P7574, DOI 10.1074/jbc.272.12.7574; Steinfeld R, 1996, J CELL BIOL, V133, P405, DOI 10.1083/jcb.133.2.405; TAGUCHI T, 1993, CANCER RES, V53, P4349; WAGNER J C, 1960, Br J Ind Med, V17, P260; WAGNER JC, 1973, BRIT J CANCER, V28, P173, DOI 10.1038/bjc.1973.134; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	29	126	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 20	2000	19	3					410	416		10.1038/sj.onc.1203322	http://dx.doi.org/10.1038/sj.onc.1203322			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	276JC	10656689				2022-12-17	WOS:000084873700012
J	Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ				Aguilar, Z; Akita, RW; Finn, RS; Ramos, BL; Pegram, MD; Kabbinavar, FF; Pietras, RJ; Pisacane, P; Sliwkowski, MX; Slamon, DJ			Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells	ONCOGENE			English	Article						heregulin; NDF; HER-2; growth factor; epithelial cells	EPIDERMAL GROWTH-FACTOR; ACETYLCHOLINE-RECEPTOR SYNTHESIS; CANCER-CELLS; EGF RECEPTOR; TUMOR-CELLS; TYROSINE PHOSPHORYLATION; BASEMENT-MEMBRANE; NEU ONCOGENE; ERBB-FAMILY; LIGAND	The heregulins are a family of ligands with ability to induce phosphorylation of the p185(HER-2/neu) receptor. Various investigators have reported a variety of responses of mouse and human breast and ovarian cells to this family of ligands including growth stimulation, growth inhibition, apoptosis and induction of differentiation in cells expressing the HER-2/neu receptor. Some of the disparity in the literature has been attributed to variations in the cell lines studied, ligand dose applied, methodologies utilized or model system evaluated (i.e. in vitro or in vivo). To evaluate the effects of heregulin on normal and malignant human breast and ovarian epithelial cells expressing known levels of the HER-2/ neu receptor, this report presents the use of several different assays, performed both in vitro and in vivo, in vitro proliferation assays, direct cell counts, clonogenicity under anchorage-dependent and aochorage-independent conditions, as well as the in vivo effects of heregulin on human cells growing in nude mice to address heregulin activity. Using a total of five different biologic assays in nine different cell lines, across two different epithelia and over a one log heregulin dose range, we obtained results that clearly indicate a growth-stimulatory role for this ligand in human breast and ovarian epithelial cells, We find no evidence that heregulin has any growth-inhibitory effects in human epithelial cells. We also quantitated the amount of each member of the type I receptor tyrosine kinase family (RTK I, i.e. HER-1, HER-2, HER-3 and HER-4) in the cell lines employed and correlated this to their respective heregulin responses. These data demonstrate that HER-2/neu overexpression itself affects the expression of other RTK I members and that cells expressing the highest levels of HER-2/neu have the greatest response to HRG.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech	Slamon, DJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.			Pietras, Richard/0000-0002-2846-3192	NATIONAL CANCER INSTITUTE [P01CA032737] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA32737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608; BACUS SS, 1993, CANCER RES, V53, P5251; Bacus SS, 1996, ONCOGENE, V12, P2535; BARCELLOSHOFF MH, 1989, DEVELOPMENT, V105, P223; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Carraway KL, 1997, NATURE, V387, P512, DOI 10.1038/387512a0; Chang H, 1997, NATURE, V387, P509, DOI 10.1038/387509a0; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; Daly JM, 1997, CANCER RES, V57, P3804; DOBASHI K, 1991, P NATL ACAD SCI USA, V88, P8582, DOI 10.1073/pnas.88.19.8582; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FRESHNEY RI, 1985, ANTICANCER RES, V5, P111; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Grasso AW, 1997, ONCOGENE, V15, P2705, DOI 10.1038/sj.onc.1201447; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1988, P NATL ACAD SCI USA, V85, P5102, DOI 10.1073/pnas.85.14.5102; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; Kopp DM, 1997, J NEUROSCI, V17, P6697; Krane IM, 1996, ONCOGENE, V12, P1781; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; Leung HY, 1997, BRIT J UROL, V79, P212, DOI 10.1046/j.1464-410X.1997.30412.x; LEVI ADO, 1995, J NEUROSCI, V15, P1329; Lewis GD, 1996, CANCER RES, V56, P1457; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314; Niemann C, 1998, J CELL BIOL, V143, P533, DOI 10.1083/jcb.143.2.533; PAIK S, 1991, METHOD ENZYMOL, V198, P290; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1990, ONCOGENE, V5, P953; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Raabe TD, 1997, J NEUROSCI RES, V50, P755; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Schaefer G, 1997, ONCOGENE, V15, P1385, DOI 10.1038/sj.onc.1201317; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; Stampfer M R, 1994, Cancer Treat Res, V71, P29; TARAHOVSKI A, 1991, BIOCHEMISTRY-US, V30, P3543; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YARDEN Y, 1991, BIOCHEMISTRY-US, V30, P3543, DOI 10.1021/bi00228a027; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	72	126	131	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	1999	18	44					6050	6062		10.1038/sj.onc.1202993	http://dx.doi.org/10.1038/sj.onc.1202993			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	249XU	10557094	Green Published			2022-12-17	WOS:000083359100011
J	Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL				Sidoti-de Fraisse, C; Rincheval, V; Risler, Y; Mignotte, B; Vayssiere, JL			TNF-alpha activates at least two apoptotic signaling cascades	ONCOGENE			English	Article						apoptosis; caspase; mitochondria; ROS	TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; NF-KAPPA-B; MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; SUPEROXIDE-DISMUTASE; MEDIATED APOPTOSIS; REDOX REGULATION; NEURONAL DEATH; BCL-2	Apoptosis, the process whereby cells activate an intrinsic death program, can be induced in HeLa cells by TNF-alpha treatment. The aims of the present study were (i) to examine the precise role and the origin of Reactive Oxygen Species (ROS) in the TNF-alpha-induced programmed cell death, (ii) to characterize and order the morphological and mitochondrial changes associated with this process and (iii) to link these events with the activation of caspases, Analyses were performed on TNF-alpha-treated cells in the presence of an anti-oxidant, or of a general caspase inhibitor, To assess the role of mitochondria in the cell death signal transduction, these studies were also realized on HeLa-variant cell lines lacking functional mitochondrial respiratory chain. We show that at least two separate signaling cascades, both mediated by Z-VAD-sensitive caspase(s), contribute to the TNF-alpha-induced apoptosis of HeLa cells, One signaling pathway involves an early mitochondria-dependent ROS production, the other being ROS-independent.	CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France; Univ Versailles St Quentin Yvelines, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Vayssiere, JL (corresponding author), CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France.		Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bojes HK, 1997, BIOCHEM J, V325, P315, DOI 10.1042/bj3250315; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Ellerby LM, 1996, J NEUROCHEM, V67, P1259; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; FranceLanord V, 1997, J NEUROCHEM, V69, P1612; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAMEN S, 1995, FEBS LETT, V376, P15, DOI 10.1016/0014-5793(95)01236-1; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; Gudz TI, 1997, J BIOL CHEM, V272, P24154, DOI 10.1074/jbc.272.39.24154; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HSU H, 1995, CELL, V8145, P495; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Marchetti P, 1996, CANCER RES, V56, P2033; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SATO N, 1995, J IMMUNOL, V154, P3194; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUSIN SA, 1996, J EXP MED, V184, P1; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	73	126	128	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 1	1998	17	13					1639	1651		10.1038/sj.onc.1202094	http://dx.doi.org/10.1038/sj.onc.1202094			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124UH	9796693	Green Published			2022-12-17	WOS:000076200100002
J	Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK				Houldsworth, J; Xiao, H; Murty, VVVS; Chen, WY; Ray, B; Reuter, VE; Bosl, GJ; Chaganti, RSK			Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation	ONCOGENE			English	Article						TP53; mutation; resistance; germ cell tumor	P53 PROTEIN; TESTICULAR CANCER; SUPPRESSOR GENE; GROWTH ARREST; APOPTOSIS; EXPRESSION; TESTIS; DEATH	Male germ cell tumors (GCTs) are uniquely sensitive to cisplatin-based chemotherapy, with more than 90% of newly diagnosed cases cured. The underlying cause for resistance to treatment in 20-30% of metastatic lesions remains to be identified. Unlike other solid tumors, no mutations in the TP53 gene have been identified to date in random panels of GCT specimens, which could account for the exquisite sensitivity of these tumors to genotoxic insult. However, in a panel of resistant GCTs that did either not respond to cisplatin-based chemotherapy or subsequently relapsed and resulted in the death of the patient, we have now identified a subset of tumors to contain TP53 mutations within exons 6-9. A cell line derived from one of these tumors (228A) displayed the same TP53 mutation as the tumor specimen, expressed only mutant TP53 mRNA, and exhibited a relative resistance to cisplatin in vitro in comparison to a cell line (218A) derived from a responsive tumor with wild-type TP53. The resistant cell line displayed a much reduced apoptotic cell death and did not exhibit an induction of transcription of the p53-responsive genes WAF1 and MDM2 following cisplatin treatment, compared to that observed in the sensitive cell line. The levels of bax, an agonist of apoptosis, were found to be reduced in the resistant cell line. The simplest explanation for the resistance of this subset of GCTs that are resistant to cisplatin-based chemotherapy, is the inability of the cells to mount an apoptotic response following exposure due to a functionally inactivating mutation in the TP53 gene.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Chaganti, RSK (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARTKOVA J, 1991, INT J CANCER, V49, P196, DOI 10.1002/ijc.2910490209; BOSL GJ, 1997, CANC PRINCIPLES PRAC; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHAGANTI RSK, 1996, COMPREHENSIVE TXB GE, P932; Chresta CM, 1996, CANCER RES, V56, P1834; ELDIERY WS, 1993, CELL, V75, P817; Harris CC, 1996, CARCINOGENESIS, V17, P1187, DOI 10.1093/carcin/17.6.1187; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; PENG HQ, 1993, CANCER RES, V53, P3574; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386	22	126	129	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2345	2349		10.1038/sj.onc.1201770	http://dx.doi.org/10.1038/sj.onc.1201770			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620551				2022-12-17	WOS:000073428000006
J	Pierce, AM; Fisher, SM; Conti, CJ; Johnson, DG				Pierce, AM; Fisher, SM; Conti, CJ; Johnson, DG			Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development	ONCOGENE			English	Article						E2F; Rb; ras; cyclin D1; mouse skin model	TRANSCRIPTION FACTOR E2F1; S-PHASE ENTRY; RETINOBLASTOMA GENE-PRODUCT; GROWTH SUPPRESSION; CELL-PROLIFERATION; FIBROBLASTS LEADS; KINASE-ACTIVITY; DNA-SYNTHESIS; CYCLIN D1; PROTEIN	In cell culture studies, overexpression of the E2F1 transcription factor has been shown to stimulate proliferation, induce apoptosis, and cooperate with an activated ras gene to oncogenically transform primary rodent cells. To study the effect of increased E2F1 activity on epithelial growth and tumorigenesis in vivo, transgenic mice expressing E2F1 under the control of a keratin 5 (K5) promoter were generated. Expression of E2F1 in the epidermis results in hyperplasia but does not inhibit terminal differentiation. In a transgenic line expressing high levels of E2F1, mice have decreased hair growth likely as a result of aberrant apoptosis in developing hair follicles. Coexpression of a cyclin D1 transgene with E2F1 augments epidermal hyperplasia and further disrupts hair follicle development suggesting that hypophosphorylated Rb antagonizes the proliferative and apoptotic-promoting activities of E2F1. Finally, the E2F1 transgene is found to cooperate with a v-Ha-ras transgene to induce skin tumors in double transgenic animals. These findings confirm that many of the activities ascribed to E2F1 through in vitro studies can be reproduced in vivo and demonstrate for the first time that deregulated E2F activity can contribute to tumor development.	Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Carcinogenesis, Div Sci Pk Res, POB 389, Smithville, TX 78957 USA.			Johnson, David/0000-0002-6223-1790	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD053229] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA042157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42157] Funding Source: Medline; NICHD NIH HHS [N01-HD-5-3229] Funding Source: Medline; NIGMS NIH HHS [GM55521] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADNANE J, 1995, J BIOL CHEM, V270, P8837, DOI 10.1074/jbc.270.15.8837; ALDAZ CM, 1989, SKIN TUMORS EXPT CLI, P227; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Geng Y, 1996, ONCOGENE, V12, P1173; Guy CT, 1996, MOL CELL BIOL, V16, P685; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1995, ONCOGENE, V11, P1685; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lukas J, 1996, MOL CELL BIOL, V16, P1047; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; SALA A, 1994, CANCER RES, V54, P1402; SCHULZE A, 1994, ONCOGENE, V9, P3475; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	49	126	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 12	1998	16	10					1267	1276		10.1038/sj.onc.1201666	http://dx.doi.org/10.1038/sj.onc.1201666			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546428				2022-12-17	WOS:000072422000005
J	Tymms, MJ; Ng, AYN; Thomas, RS; Schutte, BC; Zhou, JO; Eyre, HJ; Sutherland, GR; Seth, A; Rosenberg, M; Papas, T; Debouck, C; Kola, I				Tymms, MJ; Ng, AYN; Thomas, RS; Schutte, BC; Zhou, JO; Eyre, HJ; Sutherland, GR; Seth, A; Rosenberg, M; Papas, T; Debouck, C; Kola, I			A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer	ONCOGENE			English	Article						transcription factor; lung cancer; breast cancer; ETS; ELF; prostate cancer	DNA-BINDING SPECIFICITIES; TRANSCRIPTION FACTOR PU.1; HUMAN-BREAST-CANCER; T-CELLS; ONCOGENE FAMILY; MOLECULAR CHARACTERIZATION; CHROMOSOMAL TRANSLOCATION; MYELOMONOCYTIC LEUKEMIA; DIFFERENTIAL EXPRESSION; INSITU HYBRIDIZATION	The ETS family of genes are implicated in cancers such as Ewings sarcoma, acute myeloid leukemia and chronic myelomoncytic leukemia. Further, they have important functions in embryonic development. Hence, identification and characterization of members of this family are important. We identify a novel ETS family member, ELF3, and report its human and murine cDNA sequences. The mouse cDNA has an alternatively spliced transcript with an extra 60 bp inserted. Hence we present the organization of the murine Elf3 gene together with its exon/intron structure. This gene consists of 9 exons and 8 introns spanning 4.8 kb. ELF3 binds and transactivates ETS sequences and interestingly also shows the ability to bind a GGAT-Iike purine core, a preferential ETS1/ETS2 type binding site. The expression of ELF3, unlike most other ETS family members, is absent in hematopoietic cells and hematopoietic organs in humans and mice. Intriguingly, the gene is specifically expressed in cell lines of epithelial origin and in organs such as lung, stomach, intestine, kidney that have specialized epithelial cells. We localize the human gene to 1q32.2, a region that is amplified in epithelial tumors of the breast, lung and prostate. Finally, we show that ELF3 expression is increased in a lung carcinoma and adenocarcinoma, as compared to normal tissue. ELF3 is also expressed in cell lines derived from lung cancers. These results suggest that this novel ETS gene may be involved in lung tumorigenesis.	MONASH UNIV,INST REPROD & DEV,MOL GENET & DEV GRP,MELBOURNE,VIC 3168,AUSTRALIA; UNIV IOWA,DEPT PEDIAT,IOWA CITY,IA 52242; WOMENS & CHILDRENS HOSP,CTR MED GENET,DEPT CYTOGENET & MOL GENET,ADELAIDE,SA 5006,AUSTRALIA; UNIV TORONTO,FAC MED,DEPT PATHOL,TORONTO,ON,CANADA; UNIV TORONTO,FAC DENT,TORONTO,ON,CANADA; WOMENS COLL HOSP,TORONTO,ON MDS 1A8,CANADA; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406; MED UNIV S CAROLINA,HOLLINGS ONCOL CTR,CTR MOL & STRUCT BIOL,CHARLESTON,SC 29425	Monash University; University of Iowa; Womens & Childrens Hospital Australia; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; GlaxoSmithKline; Medical University of South Carolina			Thomas, Ross/C-6434-2008; Kola, Ismail/C-5254-2013; Sutherland, Grant Robert/D-2606-2012		NICHD NIH HHS [P30-HD-27748] Funding Source: Medline; NIDCR NIH HHS [2P50-DE-09170] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE009170] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi J, 1996, COMPUTER SCI MONOGRA; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; BARRIOS L, 1990, CANCER GENET CYTOGEN, V49, P107, DOI 10.1016/0165-4608(90)90170-F; BELLO MJ, 1990, INT J CANCER, V45, P50, DOI 10.1002/ijc.2910450111; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BREATHNACH R, 1978, P NATL ACAD SCI USA, V75, P4853, DOI 10.1073/pnas.75.10.4853; BRITOBABAPULLE V, 1981, CANCER GENET CYTOGEN, V4, P215, DOI 10.1016/0165-4608(81)90015-7; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; DOUGLASS EC, 1985, J NATL CANCER I, V75, P51; EYRE HJ, 1993, CYTOGENET CELL GENET, V62, P181, DOI 10.1159/000133467; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Gambarotta G, 1996, ONCOGENE, V13, P1911; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HART AH, 1995, ONCOGENE, V10, P1423; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HROMAS R, 1994, INT J HEMATOL, V59, P257; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; IDA K, 1995, INT J CANCER, V63, P500, DOI 10.1002/ijc.2910630407; IKEDA K, 1995, J BIOL CHEM, V270, P8108, DOI 10.1074/jbc.270.14.8108; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KLEMSZ M, 1994, GENOMICS, V20, P291, DOI 10.1006/geno.1994.1169; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KUO CJ, 1991, EMBO J, V10, P2231, DOI 10.1002/j.1460-2075.1991.tb07759.x; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUKEIS R, 1993, GENE CHROMOSOME CANC, V8, P262, DOI 10.1002/gcc.2870080409; MAO XH, 1994, J BIOL CHEM, V269, P18216; MESNARD L, 1995, CIRC RES, V76, P687, DOI 10.1161/01.RES.76.4.687; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; OKA HH, 1993, CANCER RES, V53, P5104; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; OSHIMURA M, 1976, J NATL CANCER I, V56, P183, DOI 10.1093/jnci/56.1.183; PANDIS N, 1992, GENE CHROMOSOME CANC, V5, P235, DOI 10.1002/gcc.2870050310; RAO VN, 1992, ONCOGENE, V7, P2335; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; REDDY SPM, 1995, J BIOL CHEM, V270, P26451, DOI 10.1074/jbc.270.44.26451; REICHMANN A, 1984, CANCER GENET CYTOGEN, V12, P295, DOI 10.1016/0165-4608(84)90062-1; RIED T, 1995, CANCER RES, V55, P5415; SCHULZ RA, 1993, ONCOGENE, V8, P3369; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sumarsono SH, 1996, NATURE, V379, P534, DOI 10.1038/379534a0; THE SM, 1992, ONCOGENE, V7, P2471; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMAS RS, 1997, IN PRESS ONCOGENE, V14; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; Tymms M J, 1995, Methods Mol Biol, V37, P31; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WELTE T, 1994, EUR J BIOCHEM, V223, P997, DOI 10.1111/j.1432-1033.1994.tb19078.x; WERNERT N, 1992, AM J PATHOL, V140, P119; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; Wu JE, 1996, DEV DYNAM, V206, P169, DOI 10.1002/(SICI)1097-0177(199606)206:2<169::AID-AJA6>3.0.CO;2-G; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; YIP MY, 1991, CANCER GENET CYTOGEN, V51, P235, DOI 10.1016/0165-4608(91)90136-I; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	97	126	135	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2449	2462		10.1038/sj.onc.1201427	http://dx.doi.org/10.1038/sj.onc.1201427			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395241				2022-12-17	WOS:A1997YE96300007
J	ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y				ChotteauLelievre, A; Desbiens, X; Pelczar, H; Defossez, PA; deLaunoit, Y			Differential expression patterns of the PEA3 group transcription factors through murine embryonic development	ONCOGENE			English	Article						murine embryogenesis; ets genes; PEA3 group; transcription factor	ETS GENE FAMILY; DNA-BINDING DOMAIN; CHICK-EMBRYO; CHROMOSOMAL TRANSLOCATION; MOLECULAR-CLONING; ONCOGENE FAMILY; MESSENGER-RNAS; V-MYB; CELLS; LEUKEMIA	ERM, ER81 and PEA3 are three highly related transcription factors belonging to the ETS family. Together they form the PEA3 group within this family. Little data is yet available regarding the roles of these three genes during embryonic development. A prerequisite to investigations in this field is to obtain an accurate spatio-temporal expression map for the erm, er81 and pea3 genes. To this end, we have used in situ hybridization to compare their expression patterns during critical stages of murine embryogenesis. We report that all three genes are expressed in numerous developing organs coming from different embryonic tissues. The three genes appeared co-expressed in different organs but presented specific sites of expression, so that the resultant expression pattern could in fact reveal several distinct functions depending upon isolated and/or various combinations of the PEA3 member expression. These results suggest that erm, er81 and pea3 genes are differentially regulated, probably to serve important functions as cell proliferation control, tissue interaction mediator or cell differentiation, all over successive steps of the mouse organogenesis.	INST BIOL LILLE,UMR 319 CNRS,INST PASTEUR,F-59021 LILLE,FRANCE; USTL,CTR BIOL CELLULAIRE,UNITE DYNAM CELLULES EMBRYONNAIRES & CANCEREUSES,VILLENEUVE DASCQ,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille				Defossez, Pierre-Antoine/0000-0002-6463-9263				BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Buttice G, 1996, ONCOGENE, V13, P2297; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DelannoyCourdent A, 1996, INT J DEV BIOL, V40, P1097; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; FAFEUR V, 1997, IN PRESS CELL GROWTH; Ganan Y, 1996, DEVELOPMENT, V122, P2349; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, ONCOGENE, V13, P1745; JANKNECHT R, 1996, MOL CELL BIOL, V16, P1551; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laget MP, 1996, ONCOGENE, V12, P1325; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; QUEVA C, 1993, ONCOGENE, V8, P2511; QUEVA C, 1992, DEVELOPMENT, V114, P125; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SATO H, 1993, ONCOGENE, V8, P395; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Shindoh M, 1996, AM J PATHOL, V148, P693; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; VANBENBUNDER B, 1989, DEVELOPMENT, V109, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Yang BS, 1996, MOL CELL BIOL, V16, P538; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	63	126	130	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 21	1997	15	8					937	952		10.1038/sj.onc.1201261	http://dx.doi.org/10.1038/sj.onc.1201261			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XR767	9285689				2022-12-17	WOS:A1997XR76700007
J	Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK				Joy, A; Moffett, J; Neary, K; Mordechai, E; Stachowiak, EK; Coons, S; RankinShapiro, J; Florkiewicz, RZ; Stachowiak, MK			Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells	ONCOGENE			English	Article						growth factor; nuclear localization; astrocytes; glioma; cell proliferation	FIBROBLAST GROWTH-FACTOR; MOLECULAR-WEIGHT FORMS; MESSENGER-RNA LEVELS; HUMAN-BRAIN TUMORS; GENE-EXPRESSION; FACTOR RECEPTOR; FACTOR BFGF; IMMUNOHISTOCHEMICAL LOCALIZATION; PROGENITOR CELLS; BASIC FGF	FGF-2 has been implicated in the neoplastic transformation of glioma cells and in the transition of normal quiescent astrocytes to a proliferating, reactive state. In the present study we have observed that in human glial cells, levels and subcellular localization of FGF-2 are different in quiescent and proliferating cells. FGF-2 was detected in the cytoplasm of non-reactive astrocytes in human brain sections. In contrast FGF-2 was located within the cytoplasm and nuclei of reactive astrocytes in gliotic brain tissue and in neoplastic cells of glioma tumors. In vitro, FGF-2 was found predominantly in the nucleus of subconfluent proliferating astrocytes, but was detected only in the cytoplasm of density arrested quiescent astrocytes. Our results suggest that reduced cell contact stimulates nuclear accumulation of FGF-2, accompanying mitotic activation of reactive human astrocytes. FGF-2 was constitutively localized to the nucleus of continuously proliferating glioma cells independent of cell density. A role for intracellular FGF-2 was further suggested by the observation that glioma cells that are not stimulated to proliferate by extracellular FGF-2 proliferated faster when transfected with FGF-2 expressing vectors. This increased proliferation correlated with nuclear accumulation of FGF-2. Cell proliferation was attenuated by 5'-deoxy-5'-methylthioadenosine, a FGF-2 receptor tyrosine kinase inhibitor that acts within the cell, but was unaffected by myo-inositol hexakis [dihydrogen phosphate] that disrupts FGF-2 binding to plasma membrane receptors. Our results indicate that FGF-2 serves as a nuclear regulator of proliferation in astrocytic cells. In glioma cells, the constitutive presence of FGF-2 in the nucleus may promote proliferation that is insensitive to cell contact inhibition.	BARROW NEUROL INST, PHOENIX, AZ 85013 USA; SCRIPPS RES INST, LA JOLLA, CA 92037 USA	Barrow Neurological Institute; Scripps Research Institute					NHLBI NIH HHS [HL49376-01A1] Funding Source: Medline; NIDDK NIH HHS [DK-18811] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049376] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK018811] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; ASCH AS, 1986, P NATL ACAD SCI USA, V83, P2904, DOI 10.1073/pnas.83.9.2904; BERENS M E, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P46; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BINGER DD, 1981, J NEUROPATHOL EXP NE, V40, P201; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOYLE WT, 1985, MOL CELL BIOL, V11, P3017; BRASAEMLE DL, 1988, BIOTECHNIQUES, V6, P418; BRIDSTOCK DR, 1991, GROWTH FACTORS, V4, P189; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; COURDEC B, 1991, CELL REGUL, V2, P709; ENG LF, 1992, PROG BRAIN RES, V94, P353; ENGELE J, 1992, DEV BIOL, V152, P363, DOI 10.1016/0012-1606(92)90143-5; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GUALANDRIS A, 1993, GROWTH FACTORS, V8, P49, DOI 10.3109/08977199309029134; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; Latham KE, 1996, ONCOGENE, V12, P827; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; MAHER PA, 1993, J BIOL CHEM, V268, P4244; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; Moffett J, 1996, P NATL ACAD SCI USA, V93, P2470, DOI 10.1073/pnas.93.6.2470; MOFFETT J, 1994, J INT DEV NEUROSC S1, V12, P77; MORRISON RS, 1994, CANCER RES, V54, P2794; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MORRISON RS, 1994, IN VITRO CELL DEV-AN, V30A, P783; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MURPHY PR, 1988, MOL ENDOCRINOL, V2, P591, DOI 10.1210/mend-2-7-591; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; POWELL PP, 1991, J CELL PHYSIOL, V148, P202, DOI 10.1002/jcp.1041480204; PUCHACZ E, 1993, BRAIN RES, V610, P39, DOI 10.1016/0006-8993(93)91214-D; RAY J, 1995, J NEUROCHEM, V64, P503; ROSENBLUM ML, 1978, CANCER, V41, P2305, DOI 10.1002/1097-0142(197806)41:6<2305::AID-CNCR2820410632>3.0.CO;2-U; SCHECHTER JE, 1992, TISSUE CELL, V24, P791, DOI 10.1016/0040-8166(92)90015-Y; SHERMAN L, 1993, DEVELOPMENT, V118, P131; Shibata F, 1991, GROWTH FACTORS, V4, P277, DOI 10.3109/08977199109043913; Stachowiak MK, 1996, MOL BIOL CELL, V7, P1299, DOI 10.1091/mbc.7.8.1299; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; VIJAYAN VK, 1993, INT J DEV NEUROSCI, V11, P257, DOI 10.1016/0736-5748(93)90084-Q; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOODWARD WR, 1992, J NEUROSCI, V12, P142; ZAGZAG D, 1990, CANCER RES, V50, P7393	57	126	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					171	183		10.1038/sj.onc.1200823	http://dx.doi.org/10.1038/sj.onc.1200823			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010219				2022-12-17	WOS:A1997WC81800005
J	Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F				Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F			Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence	ONCOGENE			English	Article						p53; senescence; immortalisation; transactivation; beta-galactosidase; DNA damage	HUMAN-DIPLOID FIBROBLASTS; DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; MAMMALIAN-CELLS; HUMAN CANCER; IMMORTALIZATION; EXPRESSION; PROTEIN; DAMAGE	Wild-type p53 is necessary for the growth arrest of human diploid fibroblasts (HDF) (and many other cell types) at the end of their proliferative lifespan. Although p53 may actively mediate senescence, possibly in response to telomere erosion, it is however equally possible that it is merely a permissive factor required for response to some other inducer. To address this question, we have generated stable transfectants of early passage HDF, represented here by clone LacZ21, in which expression of a beta-galactosidase reporter construct reflects p53 transactivation activity. During continuous passage, the proportion of beta-gal positive LacZ21 cells remained below 2% for 25 population doublings (pd), first became significantly increased after 29 pd, and thereafter increased rapidly, reaching a maximum of 88% in fully-senescent cells (32 pd), which exceeded the response observed following an optimum dose (20 J/m(2)) of u.v. radiation. Correspondingly, the proportion of cells incorporating bromodeoxyuridine (BrdU) (initially 45-50%) began to fall at 29 pd and thereafter dropped rapidly to below 1% by pd 32. There was therefore a near-perfect reciprocal relationship between reporter construct expression and DNA synthesis as cells approached senescence. Furthermore, a dominant-negative p53 mutant (introduced by retroviral transduction) rescued LacZ21 cells from senescence and generated colonies with extended lifespan in which beta-gal expression was totally abolished. These data, although not excluding the need for other p53 functions, strongly suggest that p53-mediated transactivation of growth regulatory genes is a direct trigger, rather than a permissive factor, for cellular senescence.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			Blaydes, Jeremy/AAC-6939-2019; Gire, Veronique/N-7553-2017; Gire, Véronique/AAC-2218-2020	Blaydes, Jeremy/0000-0001-8525-0209; Gire, Veronique/0000-0002-9009-2185				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLAYDES JP, 1995, ONCOGENE, V10, P307; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FRIEDRICH VL, 1993, J NEUROSCI RES, V36, P88, DOI 10.1002/jnr.490360110; GUDAS J, 1995, ONCOGENE, V11, P253; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; RENZING J, 1995, ONCOGENE, V10, P1865; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1993, ONCOGENE, V8, P1407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119	37	126	130	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2097	2104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950976				2022-12-17	WOS:A1996VV14500006
J	Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F				Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F			Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo	ONCOGENE			English	Article						I-kappa B; NF-kappa B; signal induced proteolysis	BINDING-PROTEIN EBP1; INHIBITOR; ACTIVATION; MEMBERS; FAMILY; DNA	Activation of transcription factor NF-kappa B involves signal-induced degradation of the protein inhibitor I kappa B-alpha and release of NF-kappa B which translocates to the nucleus where it influences transcription of responsive genes, Although multiple regions of I kappa B-alpha are involved in this process, the N-terminal region of the protein has been identified as a regulatory region that is required for signal induced phosphorylation and degradation, The sensitivity of I kappa B-alpha degradation to peptide aldehydes which inhibit of the proteasome and the detection of forms of I kappa B-alpha indicate that I kappa B-alpha is degraded by the ubiquitin-proteasome pathway. To identify lysine residues that represent the ubiquitin addition, a series of lysine to mutations were introduced into I kappa B-alpha and the mutant proteins tested for their ability to function in vivo, Exposure of COS7 cells, cotransfected with I kappa B-alpha and a TNF-responsive NF-kappa B reporter gene, resulted in stimulation of reporter activity as a consequence of I kappa B-alpha degradation, In contrast, this effect was drastically reduced when an I kappa B-alpha mutant carrying serine to alanine changes at amino-acids, 32 and 36, which blocks both signal-induced phosphorylation and ubiquitin conjugation of the protein, was co-transfected with the reporter gene. Likewise, a mutant form of I kappa B-alpha containing lysine to arginine changes at positions 21 and 22 (K21R, K22R) severely reduces TNF-induced activation of the NF-kappa B-dependent reporter gene, Examination of the metabolism of mutant I kappa B-alpha molecules reveals that, while the K21R, K22R mutant inhibits the DNA-binding activity of NF-kappa B and undergoes signal induced phosphorylation, it is neither ubiquitinated nor degraded in response to TNF, Thus, it is likely that after signal-induced phosphorylation of I kappa B-alpha. on serine residues 32 and 36, lysine residues 21 and 22 are major sites of ubiquitin ligation which target the protein for rapid degradation by the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75015 PARIS,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald T/F-9338-2011; Arenzana-Seisdedos, Fernando/E-5835-2016	Hay, Ronald T/0000-0001-7113-9024; 				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLARK L, 1989, J MOL BIOL, V206, P615, DOI 10.1016/0022-2836(89)90570-6; CLARK L, 1989, NUCLEIC ACIDS RES, V17, P499, DOI 10.1093/nar/17.2.499; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	52	126	131	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2425	2435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649784				2022-12-17	WOS:A1996UQ22000021
J	Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J				Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J			Expression of cyclin D1 and EMS1 in bladder tumours; Relationship with chromosome 11q13 amplification	ONCOGENE			English	Article						contactin; cyclin D1; EMS1; amplification; bladder tumor	HUMAN CARCINOMAS; GENES; IDENTIFICATION; SUBSTRATE; OVEREXPRESSION; CANCER; ONCOGENE; TUMORS; INT-2; HST	11q13 amplifications have been found in several cancers, including bladder tumours,However, the biological significance of this genetic alteration is not yet fully understood, To get more insight into the role of 11q13 amplification in bladder tumour development, we have studied the level of amplification and expression of 4 (protoonco)genes lying within the amplicon: cyclin D1, FGF3, FGF4 and EMS1 DNA amplification was found in 5/46 tumours, There was no correlation between amplification and clinico-pathological data. No expression of FGF3 and FGF4 was detected whereas both cyclin D1 and EMS1 were expressed at higher level in tumours with amplifications, Thus cyclin D1 and EMS1, but not FGF3 and FGF4, are likely to play a pathogenic role in the 11q13 amplification in bladder cancer, However, amplification is not the unique way of activation of these genes, Indeed, in situ hybridisation and Northern blot analysis have shown that most bladder tumours have a fair to high expression of cyclin D1 and EMS1 in contrast to normal urothelium with a moderate expression, Interestingly, a trend towards higher expression occurs in superficial versus invasive tumours (8.8+/-2.0 versus 1.9+/-0.4; P approximate to 13% for cyclin D1 and 4.5 +/- 1.4 versus 2.0 +/- 0.4; P approximate to 8% for EMS1), Moreover, the 9 tumours with low expression are all highly malignant, leading to the hypothesis that the tumours developing through a cyclin D1/EMS1 independent pathway are more aggressive.	UNIV LEIDEN HOSP, DEPT PATHOL, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Bringuier, PP (corresponding author), UNIV NIJMEGEN HOSP, UROL RES LAB, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Schalken, Jack A/B-1277-2014	Schalken, Jack A/0000-0001-8274-7797				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; GILLETT C, 1994, CANCER RES, V54, P1812; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; KNOWLES MA, 1994, CANCER RES, V54, P531; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mostofi FK, 1973, INT HISTOLOGICAL CLA; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA N, 1994, CANCER RES, V54, P3107; PETERS G, 1994, J CELL SCI, P89; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAMIMI Y, 1993, CANCER RES, V53, P5512; THEILLET C, 1989, ONCOGENE, V4, P915; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; *UICC, 1992, TNM CLASS INT UN CAN; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	36	126	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1747	1753						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622895				2022-12-17	WOS:A1996UG45800017
J	Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S				Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S			Activation of the JNK pathway by distantly related protein kinases, MEKK and MUK	ONCOGENE			English	Article						ERK; Jun; MAP kinase; Raf; SAPK	C-JUN; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; DOMAIN; ONCOGENE; PHOSPHORYLATION; IDENTIFICATION; AP-1; RAF; FOS	JNK/SAPKs are identified as new members of the MAPK family; they phosphorylate c-Jun protein in response to several cellular stimuli including ultraviolet irradiation, TNF and osmotic shock. We have identified a protein kinase, MUK, as an activator of the JNK-pathway, whose kinase domain shows significant homology to MAPKKK-related proteins such as c-Raf and MEKK. The over-expression of MUK or MEK kinase (MEKK) in NIH3T3 or COS1 cells results in the activation of JNK1 and the accumulation of a hyper-phosphorylated form of c-Jun. While MEKK also activates the ERK pathway, MUK is a rather selective activator of the JNK pathway, On the other hand, c-Raf activates the JNK pathway only slightly despite its remarkable ability to activate the ERK pathway. Even though we originally identified MUK as a MAPKKK-related protein kinase, a greater similarity to mixed lineage kinase (MLK) is found not only in the catalytic domain but also in the 'leucine-zipper'-like motifs located at the C-terminal side of the catalytic domain. The structural divergence between MUK and MEKK reveals the multiplicity of signaling pathways that activate JNK/SAPKs.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	Hirai, S (corresponding author), YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, 3-9 FUKU URA, YOKOHAMA, KANAGAWA 236, JAPAN.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORROW DS, 1993, EUR J BIOCHEM, V213, P701; EROE K, 1994, ONCOGENE, V9, P935; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ING YL, 1994, ONCOGENE, V9, P1745; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KATOH M, 1995, ONCOGENE, V10, P1447; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	51	126	131	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					641	650						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637721				2022-12-17	WOS:A1996TV59700021
J	KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D				KERANGUEVEN, F; ESSIOUX, L; DIB, A; NOGUCHI, T; ALLIONE, F; GENEIX, J; LONGY, M; LIDEREAU, R; EISINGER, F; PEBUSQUE, MJ; JACQUEMIER, J; BONAITIPELLIE, C; SOBOL, H; BIRNBAUM, D			LOSS OF HETEROZYGOSITY AND LINKAGE ANALYSIS IN BREAST-CARCINOMA - INDICATION FOR A PUTATIVE 3RD SUSCEPTIBILITY GENE ON THE SHORT ARM OF CHROMOSOME-8	ONCOGENE			English	Note						BREAST CANCER; CHROMOSOME 8; DELETIONS; TUMOR SUPPRESSOR GENES; MICROSATELLITES; LINKAGE ANALYSIS	TUMOR-SUPPRESSOR GENES; FAMILIAL BREAST; OVARIAN-CANCER; COLORECTAL-CANCER; ALLELIC LOSS; DELETION; POLYMORPHISMS; ALLELOTYPE	We have analysed losses of heterozygosity (LOH) at eight markers from the p12-p22 region of human chromosome 8 in a panel of 113 breast tumors. LOH were detected in almost half of the tumors. The most frequently deleted region included microsatellite (CA)n repeats markers D8S258, D8S133 and D8S259, located at 8p12-p22, while markers NEFL and LPL appeared less frequently altered. In parallel, linkage analysis was performed using the same informative markers, to test for the involvement of chromosome 8p loci in familial breast cancer. Positive cumulative multipoint lod score of 2.51 at Theta=0.0 was obtained with markers NEFL and D8S259. These results suggest that region 8p12-p22 carries at least one tumor suppressor gene involved in sporadic and perhaps also in familial breast cancer.	INST J PAOLI I CALMETTES,BIOL TUMEURS LAB,F-13009 MARSEILLE,FRANCE; INSERM,U155,PARIS,FRANCE; INSERM,U119,MARSEILLE,FRANCE; INST J PAOLI I CALMETTES,DEPT NUCL MED,F-13009 MARSEILLE,FRANCE; FDN BERGONIE,F-33076 BORDEAUX,FRANCE; CTR RENE HUGUENIN,ST CLOUD,FRANCE; INST J PAOLI I CALMETTES,DEPT ANATOMOPATHOL,F-13009 MARSEILLE,FRANCE	UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Bergonie; Rene Huguenin Hospital; UNICANCER; Institut Paoli-Calmette (IPC)				Eisinger, Francois/0000-0002-8794-0681				BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BIECHE I, 1992, B CANCER, V79, P1115; BOVA GS, 1993, CANCER RES, V53, P3869; BOWCOCK AM, 1993, BREAST CANCER RES TR, V28, P121, DOI 10.1007/BF00666425; BUETOW KH, 1994, NAT GENET, V6, P391, DOI 10.1038/ng0494-391; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLIBY W, 1993, CANCER RES, V53, P2393; CROPP CS, 1994, CANCER RES, V54, P2548; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DEVILEE P, 1991, ONCOGENE, V6, P1705; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1994, ONCOL REP, V1, P393; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KUNIMI K, 1991, GENOMICS, V11, P530, DOI 10.1016/0888-7543(91)90059-N; LALLE P, 1994, ONCOGENE, V9, P437; LATHROP GM, 1984, P NATL ACAD SCI USA, V81, P3343; LATIL A, 1994, GENE CHROMOSOME CANC, V11, P119, DOI 10.1002/gcc.2870110208; LINDBLOM A, 1993, CANCER RES, V53, P4356; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MAZOYER S, 1993, AM J HUM GENET, V52, P754; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1991, LANCET, V338, P82; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; OTT J, 1989, P NATL ACAD SCI USA, V86, P4175, DOI 10.1073/pnas.86.11.4175; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SOBOL H, 1994, LANCET, V344, P1151, DOI 10.1016/S0140-6736(94)90655-6; SOBOL H, 1992, HUM GENET, V89, P381; STEICHENGERSDOR.E, 1994, AM J HUM GENET, V55, P870; THEILLET C, 1989, ONCOGENE, V4, P915; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WASYLYSHYN ML, 1991, SURGERY, V110, P265; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEEKS DE, 1990, AM J HUM GENET S, V47, pA204; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; Wood S, 1993, Cytogenet Cell Genet, V64, P134; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; YAREMKO L, 1994, GENE CHROMOSOME CANC, V10, P1	54	126	128	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1023	1026						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898921				2022-12-17	WOS:A1995QL03800026
J	YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR				YAVUZER, U; KEENAN, E; LOWINGS, P; VACHTENHEIM, J; CURRIE, G; GODING, CR			THE MICROPHTHALMIA GENE-PRODUCT INTERACTS WITH THE RETINOBLASTOMA PROTEIN IN-VITRO AND IS A TARGET FOR DEREGULATION OF MELANOCYTE-SPECIFIC TRANSCRIPTION	ONCOGENE			English	Article						MICROPHTHALMIA RETINOBLASTOMA; MELANOCYTE-SPECIFIC TRANSCRIPTION; E1A; TRANSCRIPTION REPRESSION; BASIC HELIX-LOOP-HELIX FACTOR	ADENOVIRUS E1A PROTEINS; TYROSINASE-RELATED PROTEIN; OCTAMER-BINDING-PROTEIN; HEAVY-CHAIN ENHANCER; DNA-SYNTHESIS; REGULATORY FUNCTIONS; INDIVIDUAL PRODUCTS; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; CELLULAR PROTEIN	Little is known of the molecular mechanisms underlying the differentiation of the melanocyte from the melanoblast or the progression from the melanocyte to a malignant melanoma. Since the adenovirus E1A products have proved a useful tool for understanding control of differentiation in other systems, we explored the possibility of using E1A as a probe for factors controlling melanocyte-specific gene expression and differentiation. The results obtained show that the adenovirus E1A 13S, but not the 12S, product can transform the highly pigmented and TPA-dependent melanocyte cell line melan-a, Transformation is characterised by a morphological change, loss of TPA-dependence, the ability to grow in soft agar and strikingly, loss of pigmentation which correlates with loss of expression of the melanocyte-specific TRP-1 and tyrosinase genes, Cotransfection assays demonstrated that repression of TRP-1 by E1A correlated with E1A binding to p105Rb and p300, with the target in the TRP-1 promoter being the M-box, an 11 bp basic-Helix-loop-Helix (bHLH) factor-binding motif conserved between melanocyte-specific promoters, Consistent with the M-box acting as a target for E1a-mediated transcription repression, we also show that the basic-helix-loop-helix-leucine zipper (bHLH-LZ) protein (Mi) encoded by the microphthalmia gene (mi), which is required for pigment cell differentiation, is a positive acting transcription factor which can interact with the retinoblastoma product in vitro and activate the TRP-1 promoter, Moreover, expression of the mi gene was reduced around 50-fold in the non-pigmented E1a-transformed melan-a cells compared to the nontransformed melan-a cell line, with ectopic expression of Mi able to prevent repression of the tyrosinase and TRP-1 promoters in the presence of E1A, Mi therefore appears to play a crucial role in melanocyte-specific gene expression. The parallels between repression of myogenesis and muscle cell bHLH factors, and Mi and melanocyte differentiation are discussed.	MARIE CURIE RES INST, EUKARYOT TRANSCRIPT LAB, OXTED RH8 0TL, SURREY, ENGLAND				Vachtenheim, Jiri/I-6232-2017; Yavuzer, Ugur/C-1599-2016	Vachtenheim, Jiri/0000-0002-4923-9296; Goding, Colin/0000-0002-1614-3909				BEERMANN F, 1990, EMBO J, V9, P2819, DOI 10.1002/j.1460-2075.1990.tb07470.x; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BENNETT DC, 1990, DEVELOPMENT, V110, P471; BENNETT DC, 1989, ENVIRON HEALTH PERSP, V80, P49, DOI 10.2307/3430731; BENTLEY NJ, 1994, IN PRESS MOL CELL BI; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BORRELLI E, 1986, P NATL ACAD SCI USA, V83, P2846, DOI 10.1073/pnas.83.9.2846; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAUN T, 1992, GENE DEV, V6, P888, DOI 10.1101/gad.6.5.888; CARUSO M, 1993, ONCOGENE, V8, P267; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ST, 1992, J VIROL, V66, P7452, DOI 10.1128/JVI.66.12.7452-7460.1992; CONE RD, 1988, MOL CELL BIOL, V8, P1036, DOI 10.1128/MCB.8.3.1036; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; DERY CV, 1987, ONCOGENE, V2, P15; DOOLEY TP, 1988, ONCOGENE, V3, P531; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FLINT J, 1989, ANNU REV GENET, V23, P141, DOI 10.1146/annurev.genet.23.1.141; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRISCH SM, 1990, ONCOGENE, V5, P75; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAGEMEIER C, 1994, EMBO J, V13, P2897, DOI 10.1002/j.1460-2075.1994.tb06584.x; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3799, DOI 10.1093/nar/19.14.3799; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEFF T, 1986, MOL CELL BIOL, V6, P201, DOI 10.1128/MCB.6.1.201; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PORTER SD, 1994, DEVELOPMENT, V120, P2103; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROCHETTEEGLY C, 1990, GENE DEV, V4, P137, DOI 10.1101/gad.4.1.137; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1991, J BIOL CHEM, V266, P15895; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SMITH DH, 1988, MOL CELL BIOL, V8, P3882, DOI 10.1128/MCB.8.9.3882; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; STEIN RW, 1987, MOL CELL BIOL, V7, P1164, DOI 10.1128/MCB.7.3.1164; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; TANAKA S, 1990, DEVELOPMENT, V108, P223; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUKAMOTO K, 1992, PIGM CELL RES, P181; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1986, MOL CELL BIOL, V6, P4019, DOI 10.1128/MCB.6.11.4019; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEEKS DL, 1985, NUCLEIC ACIDS RES, V13, P5389, DOI 10.1093/nar/13.14.5389; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	86	126	130	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					123	134						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824265				2022-12-17	WOS:A1995QA98000015
J	HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T				HARADA, H; KONDO, T; OGAWA, S; TAMURA, T; KITAGAWA, M; TANAKA, N; LAMPHIER, MS; HIRAI, H; TANIGUCHI, T			ACCELERATED EXON SKIPPING OF IRF-1 MESSENGER-RNA IN HUMAN MYELODYSPLASIA/LEUKEMIA - A POSSIBLE MECHANISM OF TUMOR-SUPPRESSOR INACTIVATION	ONCOGENE			English	Article							REGULATORY FACTOR-I; ACUTE NONLYMPHOCYTIC LEUKEMIA; INTERFERON-INDUCIBLE GENES; POLYMERASE CHAIN-REACTION; CELL LUNG-CARCINOMA; PRE-MESSENGER-RNA; P53 GENE; IFN-BETA; RETINOBLASTOMA ANTIONCOGENE; TRANSCRIPTIONAL ACTIVATOR	The transcription factor IRF-1 has been shown to function as a tumor suppressor. Here we report that a significant proportion of the IRF-1 mRNA detected in normal human hematopoietic cells and cultured cell lines lacks exon 2 (containing the AUG initiation codon) and 3 as a result of exon skipping. Surprisingly, when we examined the bone marrow and peripheral mononuclear cells from patients with myelodysplastic syndrome (MDS) or leukemia secondary to MDS, we could still detect the exon-skipped form but little or none of the intact IRF-1 mRNA. This appears to be the result of accelerated exon skipping since we could find no mutations within the exons and splicing junctions from these patients. The exon-skipped form of IRF-1 lacking exons 2 and 3 displayed neither DNA binding nor tumor suppressive activities. Thus this accelerated exon skipping may cause the inactivation of IRF-1 and thereby contribute to the development of human hematopoietic malignancies.	OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Osaka University; University of Tokyo			Harada, Hisashi/H-2815-2019; Kondo, Takeshi/G-2103-2012	Harada, Hisashi/0000-0001-5993-1289; Kondo, Takeshi/0000-0001-7455-5824; Tanaka, Nobuyuki/0000-0002-6373-2220; Kitagawa, Motoo/0000-0003-1036-840X				ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; BOULTWOOD J, 1993, BLOOD, V82, P2611; CHA Y, 1993, DNA CELL BIOL, V11, P605; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOTI A, 1990, BRIT J HAEMATOL, V76, P143, DOI 10.1111/j.1365-2141.1990.tb07849.x; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GALLAGHER R, 1979, BLOOD, V54, P713; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARADA H, 1994, MOL CELL BIOL, V14, P1500, DOI 10.1128/MCB.14.2.1500; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; ITOH S, 1989, NUCLEIC ACIDS RES, V17, P8372, DOI 10.1093/nar/17.20.8372; ITOH S, 1991, GENOMICS, V10, P1097, DOI 10.1016/0888-7543(91)90208-V; KAELIN WG, 1991, ORIGINS OF HUMAN CANCER, P423; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KATO K, 1990, MOL CELL BIOL, V10, P486, DOI 10.1128/MCB.10.2.486; KIMURA T, 1994, SCIENCE, V264, P1921, DOI 10.1126/science.8009222; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LEBEAU MM, 1989, CANCER CEL, V7, P53; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; LEBEAU MM, 1986, J CLIN ONCOL, V4, P325, DOI 10.1200/JCO.1986.4.3.325; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MAKINO R, 1990, Technique (Philadelphia), V2, P295; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MARUYAMA M, 1989, NUCLEIC ACIDS RES, V17, P3292, DOI 10.1093/nar/17.8.3292; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MORI N, 1990, ONCOGENE, V5, P1713; NIMER SD, 1987, BLOOD, V70, P1705; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PEDERSEN B, 1991, LEUKEMIA, V5, P566; PEDERSENBJERGAARD J, 1990, BLOOD, V76, P1083; PINE R, 1992, J VIROL, V66, P4470, DOI 10.1128/JVI.66.7.4470-4478.1992; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; RUFFNER H, 1993, P NATL ACAD SCI USA, V90, P11503, DOI 10.1073/pnas.90.24.11503; SAMESHIMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P697, DOI 10.1016/S0006-291X(05)80091-9; SHARP PA, 1987, SCIENCE, V235, P766, DOI 10.1126/science.3544217; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STARK GR, 1992, J INTERFERON RES, V12, P147, DOI 10.1089/jir.1992.12.147; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUGIMOTO K, 1993, BLOOD, V81, P3022; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; TANAKA N, 1991, IN PRESS CANCER LETT; UEGAKI K, 1993, PROTEIN ENG, V6, P195, DOI 10.1093/protein/6.2.195; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; YULEE LY, 1990, MOL CELL BIOL, V10, P3087, DOI 10.1128/MCB.10.6.3087	69	126	128	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3313	3320						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936656				2022-12-17	WOS:A1994PM65800025
J	SHIMIZU, E; COXON, A; OTTERSON, GA; STEINBERG, SM; KRATZKE, RA; KIM, YW; FEDORKO, J; OIE, H; JOHNSON, BE; MULSHINE, JL; MINNA, JD; GAZDAR, AF; KAYE, FJ				SHIMIZU, E; COXON, A; OTTERSON, GA; STEINBERG, SM; KRATZKE, RA; KIM, YW; FEDORKO, J; OIE, H; JOHNSON, BE; MULSHINE, JL; MINNA, JD; GAZDAR, AF; KAYE, FJ			RB PROTEIN STATUS AND CLINICAL CORRELATION FROM 171 CELL-LINES REPRESENTING LUNG-CANCER, EXTRAPULMONARY SMALL-CELL CARCINOMA, AND MESOTHELIOMA	ONCOGENE			English	Article							RETINOBLASTOMA GENE-PRODUCT; ALTERED EXPRESSION; SUSCEPTIBILITY GENE; COLORIMETRIC ASSAY; BLADDER-CANCER; PHOSPHORYLATION; CYCLE; ABNORMALITIES; GROWTH; DNA	We have studied RB protein expression in 171 cell lines derived from patients with small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pulmonary carcinoid, mesothelioma, and extrapulmonary small cell cancer (EPSC) and have correlated this data with clinical outcome. We detected absent or aberrant RB protein expression in 66/75 SCLC, 12/80 NSCLC, 1/6 carcinoid, 0/5 mesothelioma, and 4/5 EPSC samples. In addition, we observed integration of human papilloma virus (HPV) DNA in the single EPSC cell line that retained wildtype RB protein. We did not detect integration of HPV, SV40 or adenoviral DNA in other tumor samples with wildtype RB status. We also noted a stable, hypophosphorylated mutant RB in 12 SCLC and 3 NSCLC samples which might have been falsely interpreted as wildtype by current immunohistochemical techniques. Analysis of the matched clinical data showed no associations between RB status and age, sex, extent of disease, performance status, smoking history, and previous treatment. In addition, retrospective analyses showed no consistent correlation of RB protein expression with either best clinical response, overall survival, or in vitro chemotherapeutic drug sensitivity. The stable expression of RB after gene transfection into RB(-) SCLC cells, however, resulted in a trend toward increased in vitro resistance to etoposide, cisplatin and doxorubicin.	NCI, NAVY ONCOL BRANCH, BETHESDA, MD 20889 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20889 USA; NCI, BIOSTAT SECT, BETHESDA, MD 20889 USA; DIV CANC PREVENT & CONTROL, BIOMARKERS SECT, GAITHERSBURG, MD 20850 USA; UNIV TEXAS, SW MED CTR, SIMMONS CANC CTR, DALLAS, TX 75235 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			kaye, frederic/E-2437-2011					BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; CARMICHAEL J, 1987, CANCER RES, V47, P936; CARNEY DN, 1985, CANCER RES, V45, P2913; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUTREAL PA, 1991, ONCOGENE, V6, P1109; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENSEL CH, 1990, CANCER RES, V50, P3067; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kratzke R A, 1992, Cancer Treat Res, V63, P61; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEVINS JR, 1992, SCIENCE, V258, P424; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OOKAWA K, 1993, ONCOGENE, V8, P2175; OTTERSON GA, 1993, ONCOGENE, V8, P949; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RYGAARD K, 1990, CANCER RES, V50, P5312; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SCHIFFMAN MH, 1991, J CLIN MICROBIOL, V29, P573, DOI 10.1128/JCM.29.3.573-577.1991; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; TAKAHASHI T, 1992, CANCER RES, V52, P2340; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; XU HJ, 1991, CANCER RES, V51, P2735; XU HJ, 1991, ONCOGENE, V6, P1139; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; YOKOTA J, 1988, ONCOGENE, V3, P471	47	126	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1994	9	9					2441	2448						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058306				2022-12-17	WOS:A1994PC05400002
J	RANE, SG; REDDY, EP				RANE, SG; REDDY, EP			JAK3 - A NOVEL JAK KINASE ASSOCIATED WITH TERMINAL DIFFERENTIATION OF HEMATOPOIETIC-CELLS	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; COLONY-STIMULATING FACTOR; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3; RECEPTOR; LINE; EXPRESSION; LEUKEMIA; PATHWAY	The Janus Kinases (JAK) JAK1, JAK2, and TYK2 are protein tyrosine kinases which play a pivotal role in the signal transduction process mediated by cytokines. These kinases appear to transduce signals via their substrates which modulate programs of gene expression specific to the respective signals. It is becoming increasingly evident that certain cytokines such as Granulocyte Colony Stimulating Factor (GCSF) can transmit signals for both cellular proliferation and differentiation. It is at present unclear whether both of these signals are transmitted by the same JAK kinase or whether an entire family of such kinases are involved in this process. To determine if additional members of JAK kinase family exist, we designed a polymerase chain reaction based strategy which resulted in the identification of a new member of the JAK kinase family. This new kinase, which we have named JAK3 is encoded by a 4.3 kb mRNA transcript. Nucleotide sequence analysis of a full length cDNA derived from this mRNA revealed that it encodes an open reading frame of 3897 bp. The protein encoded by this mRNA contains the double catalytic domain characteristic of the JAK family kinases. The most striking difference between JAK3 and the other JAK kinases is the presence of two stretches of additional amino acid sequence of 147 and 28 residues which span between amino acid positions 322 to 469 and 632 to 660 respectively. Expression studies indicate that JAK3 is expressed at very low levels in immature hematopoietic cells, but its expression is dramatically up-regulated during terminal differentiation of these cells, These results suggest that JAK3 plays an important role in the differentiation of hematopoietic cells.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P30CA012227, P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA 12227, CA 52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Ausubel FM., 2006, ENZYMATIC MANIPULATI; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; ROVERA G, 1987, ONCOGENE, V1, P29; RUI H, 1994, J BIOL CHEM, V269, P5364; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	26	126	137	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2415	2423						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	7518579				2022-12-17	WOS:A1994NX62900037
J	ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW				ROUSSEL, MF; DAVIS, JN; CLEVELAND, JL; GHYSDAEL, J; HIEBERT, SW			DUAL CONTROL OF MYC EXPRESSION THROUGH A SINGLE DNA-BINDING SITE TARGETED BY ETS FAMILY PROTEINS AND E2F-1	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; STIMULATING FACTOR-I; HUMAN C-MYC; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATION; CELL-CYCLE; PUTATIVE ONCOGENE; LEUKEMIA-VIRUS; NUCLEAR FACTOR; GENE-PRODUCT	NIH3T3 cells expressing a mutant colony-stimulating factor-1 receptor (CSF-1R) containing a phenylalanine for tyrosine substitution in the tyrosine kinase domain at codon 809 exhibit defective myc regulation and do not enter S phase when stimulated by CSF-1. Enforced expression of either ets-1 or ets-2 in these cells restores their mitogenic response, albeit less efficiently than myc itself, suggesting that ets proteins may regulate c-myc expression. Ets-1 transactivates reporter genes driven by the human and mouse c-myc promoters through the binding site for the transcription factor E2F, the latter being required for E1A- and serum-induced c-mye expression. Analysis of E2F-1 sequences identified a minimal DNA binding domain that is related to those of ets proteins. Although E2F and ets proteins interact with similar consensus DNA binding sites, in vitro binding assays revealed that E2F can bind DNA as a homodimer, whereas ets proteins bind these sites as monomers. E2F and ets proteins do not form heterodimers in vitro and do not transactivate c-mye synergistically. Thus, E2F-1 and ets family members may independently regulate c-mye transcription through the same binding site at different times following growth factor stimulation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; INST CURIE, CNRS, URA 1443, F-91405 ORSAY, FRANCE	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	ROUSSEL, MF (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.		GHYSDAEL, Jacques/F-3377-2013; Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [CA-47064, CA-56819] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047064, R01CA056819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; Ghysdael J, 1991, CURR OPIN CELL BIOL, V3, P484, DOI 10.1016/0955-0674(91)90077-C; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1991, J VIROL, V65, P3547, DOI 10.1128/JVI.65.7.3547-3552.1991; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIPP M, 1989, ONCOGENE, V4, P535; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCKEON C, 1988, CANCER RES, V48, P4307; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; POGNONEC P, 1990, ONCOGENE, V5, P603; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1993, CURR OPIN HEMATOL, V1, P11; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0	59	126	126	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1994	9	2					405	415						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290253				2022-12-17	WOS:A1994MW24800007
J	PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC				PERONA, R; ESTEVE, P; JIMENEZ, B; BALLESTERO, RP; CAJAL, SR; LACAL, JC			TUMORIGENIC ACTIVITY OF RHO GENES FROM APLYSIA-CALIFORNICA	ONCOGENE			English	Article							GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE; PARTIAL-PURIFICATION; ESCHERICHIA-COLI; BRAIN CYTOSOL; RAS; PRODUCT; SUBSTRATE; FAMILY; SEQUENCE	rho genes have been found in both lower and higher eucaryotes. They code for proteins of 21 kDa, highly conserved in evolution, which belong to the superfamily of ras GTPases. Among the members of this superfamily there are proteins with a regulatory function, such as ras, and proteins involved in vesicular trafficking, such as the family of rab proteins. We have investigated the putative role of rho proteins from Aplysia californica as transforming GTPases utilizing the wild-type and a Val-14 mutant, equivalent to the oncogenic Val-12 mutation of ras genes found in animal and human tumors. Overexpression of either rho gene was sufficient to confer anchorage- and serum-independent growth. Moreover, when introduced into nude mice, selected clones generated from either gene were able to induce tumors, although those carrying the mutated version were more efficient. Pathological analysis indicated that generated tumors corresponded to well-differentiated fibrosarcomas with distinct and intersecting bundles and spindle cells. By contrast, ras-induced tumors were poorly differentiated fibrosarcomas. Thus, our results indicate that under appropriate conditions rho genes function as oncogenes and may have a role in the regulation of proliferation in fibroblast cells.	CSIC,INST INVEST BIOMED,ARTURO DUPERIER 4,MADRID 6,SPAIN; CLIN PUERTA HIERRO,DEPT PATOL,MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda			Lacal, Juan Carlos/AAL-2235-2020; Cuenca, Benilde Jimenez/K-9959-2014; Espinosas, Maribel/H-8083-2012; Ramon y Cajal, Santiago/H-4955-2016; Lacal, Juan Carlos/N-9064-2015	Ramon y Cajal, Santiago/0000-0002-3867-1390; Lacal, Juan Carlos/0000-0002-1908-2777; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Perez-Ballestero, Rafael/0000-0001-8251-2875				AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; ANDERSON PS, 1987, MOL CELL BIOL, V7, P3620, DOI 10.1128/MCB.7.10.3620; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; AVRAHAM H, 1990, BIOCHEM BIOPH RES CO, V168, P114, DOI 10.1016/0006-291X(90)91682-I; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIECKMANN D, 1991, NATURE, V351, P400; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; LACAL JC, 1986, EMBO J, V5, P679, DOI 10.1002/j.1460-2075.1986.tb04267.x; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MOHR C, 1990, FEBS LETT, V275, P168, DOI 10.1016/0014-5793(90)81464-Y; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; REIBEL L, 1991, BIOCHEM BIOPH RES CO, V175, P451, DOI 10.1016/0006-291X(91)91585-Z; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 1989, MOL CLONING LAB MANU; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHIGESKUNI K, 1989, MOL BRAIN RES, V6, P167; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; TOKI C, 1989, BIOCHEM BIOPH RES CO, V164, P333, DOI 10.1016/0006-291X(89)91722-1; VINCENT S, 1992, MOL CELL BIOL, V12, P3138, DOI 10.1128/MCB.12.7.3138; WIELAND T, 1990, FEBS LETT, V274, P111, DOI 10.1016/0014-5793(90)81342-L; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	37	126	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1993	8	5					1285	1292						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KY328	8479750				2022-12-17	WOS:A1993KY32800021
J	DAVID, YB; PRIDEAUX, VR; CHOW, V; BENCHIMOL, S; BERNSTEIN, A				DAVID, YB; PRIDEAUX, VR; CHOW, V; BENCHIMOL, S; BERNSTEIN, A			INACTIVATION OF THE P53-ONCOGENE BY INTERNAL DELETION OR RETROVIRAL INTEGRATION IN ERYTHROLEUKEMIC CELL-LINES INDUCED BY FRIEND-LEUKEMIA VIRUS	ONCOGENE			English	Article									MT SINAI HOSP, RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, DEPT MED GENET & MED BIOPHYS, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto				Benchimol, Samuel/0000-0003-3433-890X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BECKER A, 1975, P NATL ACAD SCI USA, V72, P581, DOI 10.1073/pnas.72.2.581; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLARK SP, 1983, P NATL ACAD SCI-BIOL, V80, P5037, DOI 10.1073/pnas.80.16.5037; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HOHN B, 1975, J MOL BIOL, V98, P93, DOI 10.1016/S0022-2836(75)80103-3; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MOWAT M, 1983, J VIROL, V47, P471, DOI 10.1128/JVI.47.3.471-477.1983; MUNROE DG, 1988, ONCOGENE, V2, P621; OLIFF A, 1983, J VIROL, V46, P718, DOI 10.1128/JVI.46.3.718-725.1983; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1981, BIOL NORMAL HUMAN GR, P59; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROTTER V, 1983, J IMMUNOL, V181, P329; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHOHAT O, 1987, ONCOGENE, V1, P277; SOUSSI T, 1987, ONCOGENE, V1, P71; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEPHENSON JR, 1971, P NATL ACAD SCI USA, V68, P1542, DOI 10.1073/pnas.68.7.1542; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WENDLING F, 1981, P NATL ACAD SCI-BIOL, V78, P3614, DOI 10.1073/pnas.78.6.3614; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS B, 1979, J VIROL, V24, P555; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	48	126	128	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1988	3	2					179	185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q0534	2842714				2022-12-17	WOS:A1988Q053400008
J	Adamo, P; Ladomery, MR				Adamo, P.; Ladomery, M. R.			The oncogene ERG: a key factor in prostate cancer	ONCOGENE			English	Review							TRANSCRIPTION FACTOR ERG; TMPRSS2-ERG GENE FUSION; ETS-RELATED GENE; DNA-BINDING MOTIF; HEMATOPOIETIC STEM-CELLS; T-LYMPHOBLASTIC LEUKEMIA; HUMAN MYELOID-LEUKEMIA; ANDROGEN RECEPTOR; SERINE-PROTEASE; CHROMOSOMAL TRANSLOCATION	ETS-related gene (ERG) is a member of the E-26 transformation-specific (ETS) family of transcription factors with roles in development that include vasculogenesis, angiogenesis, haematopoiesis and bone development. ERG's oncogenic potential is well known because of its involvement in Ewing's sarcoma and leukaemia. However, in the past decade ERG has become highly associated with prostate cancer development, particularly as a result of a gene fusion with the promoter region of the androgeninduced TMPRRSS2 gene. We review ERG's structure and function, and its role in prostate cancer. We discuss potential new therapies that are based on targeting ERG.	[Adamo, P.] Univ Leicester, Leicester Royal Infirm, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Ladomery, M. R.] Univ W England, Fac Hlth & Appl Sci, Dept Biol Biomed & Analyt Sci, Frenchay Campus,Coldharbour Lane, Bristol BS16 1QY, Avon, England	University of Leicester; University of West England	Ladomery, MR (corresponding author), Univ W England, Fac Hlth & Appl Sci, Dept Biol Biomed & Analyt Sci, Frenchay Campus,Coldharbour Lane, Bristol BS16 1QY, Avon, England.	Michael.Ladomery@uwe.ac.uk			Rotary Club of Bristol; Bristol Urological Institute; Funds for Women Graduates; University of the West of England, Bristol; Bristol Urological Institute [BUI256]	Rotary Club of Bristol; Bristol Urological Institute; Funds for Women Graduates; University of the West of England, Bristol; Bristol Urological Institute	Dr P Adamo was supported by the Rotary Club of Bristol, The Bristol Urological Institute, Funds for Women Graduates and the University of the West of England, Bristol. Dr MR Ladomery was supported by a grant from the Bristol Urological Institute (BUI256). We would also like to thank Dr Ian Wilson for providing constructive feedback.	Abate-Shen C, 2008, DIFFERENTIATION, V76, P717, DOI 10.1111/j.1432-0436.2008.00292.x; Anderson MK, 1999, DEVELOPMENT, V126, P3131; ANTON IA, 1988, NATURE, V336, P719, DOI 10.1038/336719a0; Baldus CD, 2006, J CLIN ONCOL, V24, P4714, DOI 10.1200/JCO.2006.06.1580; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bastus NC, 2010, CANCER RES, V70, P9544, DOI 10.1158/0008-5472.CAN-10-1638; Basuyaux JP, 1997, J BIOL CHEM, V272, P26188, DOI 10.1074/jbc.272.42.26188; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Berezovska OP, 2006, CELL CYCLE, V5, P1886; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bertram S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035876; Bertram S, 2010, J VIROL, V84, P10016, DOI 10.1128/JVI.00239-10; Birdsey GM, 2008, BLOOD, V111, P3498, DOI 10.1182/blood-2007-08-105346; Birdsey GM, 2015, DEV CELL, V32, P82, DOI 10.1016/j.devcel.2014.11.016; Birdsey GM, 2012, BLOOD, V119, P894, DOI 10.1182/blood-2011-04-350025; Bjorkman M, 2008, INT J CANCER, V123, P2774, DOI 10.1002/ijc.23885; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bottcher-Friebertshauser E, 2010, J VIROL, V84, P5605, DOI 10.1128/JVI.00140-10; Bohne A, 2009, LEUKEMIA RES, V33, P817, DOI 10.1016/j.leukres.2008.11.012; Bosco A, 2013, DEVELOPMENT, V140, P372, DOI 10.1242/dev.089094; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Bowen KA, 2009, ANTICANCER RES, V29, P4439; Brase JC, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-507; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Buttice G, 1996, ONCOGENE, V13, P2297; Cai JA, 2010, TRANSL ONCOL, V3, P195, DOI 10.1593/tlo.09328; Camuzeaux B, 2005, BIOCHEM BIOPH RES CO, V332, P1107, DOI 10.1016/j.bbrc.2005.05.057; Carrere S, 1998, ONCOGENE, V16, P3261, DOI 10.1038/sj.onc.1201868; Carver BS, 2009, NATURE, V457, pE1, DOI 10.1038/nature07738; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Casey OM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041668; Cerveira N, 2006, NEOPLASIA, V8, P826, DOI 10.1593/neo.06427; Chatterjee P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060408; Chen YW, 2010, AM J PATHOL, V176, P2986, DOI 10.2353/ajpath.2010.090665; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843; Cox MK, 2014, EXP CELL RES, V328, P410, DOI 10.1016/j.yexcr.2014.08.015; Coyne HJ, 2012, J MOL BIOL, V421, P67, DOI 10.1016/j.jmb.2012.05.010; Dai Mei-Jie, 2008, Zhonghua Yi Xue Za Zhi, V88, P669; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Deramaudt TB, 2001, GENE, V274, P169, DOI 10.1016/S0378-1119(01)00610-2; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; Fine SW, 2010, MODERN PATHOL, V23, P1325, DOI 10.1038/modpathol.2010.120; Fortson WS, 2011, INT J ONCOL, V39, P111, DOI 10.3892/ijo.2011.1014; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Furusato B, 2008, MODERN PATHOL, V21, P67, DOI 10.1038/modpathol.3800981; Garrett-Sinha LA, 2013, CELL MOL LIFE SCI, V70, P3375, DOI 10.1007/s00018-012-1243-7; Glowacka I, 2011, J VIROL, V85, P4122, DOI 10.1128/JVI.02232-10; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467; Gordanpour A, 2011, ANTICANCER RES, V31, P403; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Green SM, 2010, J BIOL CHEM, V285, P18496, DOI 10.1074/jbc.M109.096958; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Gutierrez-Hartmann A, 2007, TRENDS ENDOCRIN MET, V18, P150, DOI 10.1016/j.tem.2007.03.002; Haffner MC, 2010, NAT GENET, V42, P668, DOI 10.1038/ng.613; Hagen RM, 2014, AM J CLIN PATHOL, V142, P533, DOI 10.1309/AJCPH88QHXARISUP; Hagglof C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086824; HART AH, 1995, ONCOGENE, V10, P1423; Hart M, 2013, FEBS J, V280, P2105, DOI 10.1111/febs.12236; Hatesuer B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003774; Hawksworth D, 2010, PROSTATE CANCER P D, V13, P311, DOI 10.1038/pcan.2010.31; Heo SH, 2010, J CELL PHYSIOL, V224, P734, DOI 10.1002/jcp.22175; Hermans KG, 2006, CANCER RES, V66, P10658, DOI 10.1158/0008-5472.CAN-06-1871; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Hu Y, 2008, CLIN CANCER RES, V14, P4719, DOI 10.1158/1078-0432.CCR-08-0531; Huang KC, 2014, CLIN TRANSL ONCOL, V16, P973, DOI 10.1007/s12094-014-1182-x; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Iljin K, 2006, CANCER RES, V66, P10242, DOI 10.1158/0008-5472.CAN-06-1986; Iwamoto M, 2000, J CELL BIOL, V150, P27, DOI 10.1083/jcb.150.1.27; Iwamoto M, 2007, DEV BIOL, V305, P40, DOI 10.1016/j.ydbio.2007.01.037; Iwamoto M, 2013, BIRTH DEFECTS RES C, V99, P192, DOI 10.1002/bdrc.21042; Jolma A, 2010, GENOME RES, V20, P861, DOI 10.1101/gr.100552.109; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; Kao CJ, 2014, ONCOGENE, V33, P2495, DOI 10.1038/onc.2013.200; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; Kim J, 2014, ONCOGENE, V33, P5183, DOI 10.1038/onc.2013.461; Kim S, 2006, MOL CELL BIOL, V26, P2467, DOI 10.1128/MCB.26.7.2467-2478.2006; Kim TS, 2006, MOL CELL BIOL, V26, P965, DOI 10.1128/MCB.26.3.965-975.2006; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Lapointe J, 2007, MODERN PATHOL, V20, P467, DOI 10.1038/modpathol.3800759; Larroux C, 2006, EVOL DEV, V8, P150, DOI 10.1111/j.1525-142X.2006.00086.x; Lathen C, 2014, CIRCULATION, V130, P1179, DOI 10.1161/CIRCULATIONAHA.113.007822; Lau DKW, 2012, PROTEIN SCI, V21, P1716, DOI 10.1002/pro.2151; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Laxman B, 2006, NEOPLASIA, V8, P885, DOI 10.1593/neo.06625; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Leinonen KA, 2013, CANCER EPIDEM BIOMAR, V22, P2333, DOI 10.1158/1055-9965.EPI-13-0333-T; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Lin BY, 1999, CANCER RES, V59, P4180; Liu WN, 2007, GENE CHROMOSOME CANC, V46, P972, DOI 10.1002/gcc.20482; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Mackereth CD, 2004, J MOL BIOL, V342, P1249, DOI 10.1016/j.jmb.2004.07.094; Mani RS, 2011, CANCER RES, V71, P5387, DOI 10.1158/0008-5472.CAN-11-0876; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; McLaughlin F, 2001, BLOOD, V98, P3332, DOI 10.1182/blood.V98.12.3332; Meadows SM, 2011, SEMIN CELL DEV BIOL, V22, P976, DOI 10.1016/j.semcdb.2011.09.009; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Mehra R, 2007, MODERN PATHOL, V20, P538, DOI 10.1038/modpathol.3800769; Mohamed AA, 2010, J CANCER, V1, P197; Mosquera JM, 2008, CLIN CANCER RES, V14, P3380, DOI 10.1158/1078-0432.CCR-07-5194; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Netto GJ, 2010, HISTOPATHOLOGY, V57, P633, DOI 10.1111/j.1365-2559.2010.03659.x; Ng AP, 2011, BLOOD, V118, P2454, DOI 10.1182/blood-2011-03-344739; Nhili R, 2013, NUCLEIC ACIDS RES, V41, P125, DOI 10.1093/nar/gks971; Nikolova-Krstevski V, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-72; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Owczarek CM, 2004, GENE, V324, P65, DOI 10.1016/j.gene.2003.09.047; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Pettersson A, 2012, CANCER EPIDEM BIOMAR, V21, P1497, DOI 10.1158/1055-9965.EPI-12-0042; PRASAD DDK, 1994, ONCOGENE, V9, P669; Rahim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019343; Rainis L, 2005, CANCER RES, V65, P7596, DOI 10.1158/0008-5472.CAN-05-0147; Rajput AB, 2007, J CLIN PATHOL, V60, P1238, DOI 10.1136/jcp.2006.043810; RAO VN, 1987, SCIENCE, V237, P635, DOI 10.1126/science.3299708; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; Regan MC, 2013, P NATL ACAD SCI USA, V110, P13374, DOI 10.1073/pnas.1301726110; Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109; Rickman DS, 2010, NEOPLASIA, V12, P1031, DOI 10.1593/neo.10866; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; Robert G, 2013, PROSTATE, V73, P113, DOI 10.1002/pros.22546; Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008; Rouzier C, 2008, CANCER GENET CYTOGEN, V183, P21, DOI 10.1016/j.cancergencyto.2008.01.021; Rubin MA, 2006, LAB INVEST, V86, P1099, DOI 10.1038/labinvest.3700477; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Salek-Ardakani S, 2009, CANCER RES, V69, P4665, DOI 10.1158/0008-5472.CAN-09-0075; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Schachterle W, 2012, DEV BIOL, V361, P439, DOI 10.1016/j.ydbio.2011.10.023; Schwartzman J, 2011, EPIGENETICS-US, V6, P1248, DOI 10.4161/epi.6.10.17727; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; Setlur SR, 2008, JNCI-J NATL CANCER I, V100, P815, DOI 10.1093/jnci/djn150; Shao L, 2012, CLIN CANCER RES, V18, P6648, DOI 10.1158/1078-0432.CCR-12-2715; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Shwartz A, 2013, DEVELOPMENT, V140, P2746, DOI 10.1242/dev.093138; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Singareddy R, 2013, MOL CANCER RES, V11, P1349, DOI 10.1158/1541-7786.MCR-12-0705; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Soller W, 2006, EUR UROL SUPPL, V5, P789, DOI 10.1016/S1569-9056(06)61261-X; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sperone A, 2010, ATHEROSCLEROSIS, V213, pE17, DOI 10.1016/j.atherosclerosis.2010.08.039; Sreenath Taduru L, 2011, J Carcinog, V10, P37, DOI 10.4103/1477-3163.91122; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Taichman RS, 2002, CANCER RES, V62, P1832; Thangapazham R, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-16; Thoms JAI, 2011, BLOOD, V117, P7079, DOI 10.1182/blood-2010-12-317990; Tian TV, 2014, ONCOGENE, V33, P2204, DOI 10.1038/onc.2013.176; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tsourlakis MC, 2014, AM J PATHOL, V184, P609, DOI 10.1016/j.ajpath.2013.11.007; Tsuzuki S, 2011, BLOOD, V117, P3858, DOI 10.1182/blood-2010-11-320515; Vanaja DK, 2003, CANCER RES, V63, P3877; Velaeti S, 2014, TUMOR BIOL, V35, P9597, DOI 10.1007/s13277-014-2250-0; Verger A, 2001, J BIOL CHEM, V276, P17181, DOI 10.1074/jbc.M010208200; Vijayaraj P, 2012, DEVELOPMENT, V139, P3973, DOI 10.1242/dev.081596; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wang S, 2014, P NATL ACAD SCI USA, V111, P4251, DOI 10.1073/pnas.1322198111; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066; Winnes M, 2007, ONCOL REP, V17, P1033; Wright ME, 2003, MOL ENDOCRINOL, V17, P1726, DOI 10.1210/me.2003-0031; Wu DY, 2011, TRENDS ENDOCRIN MET, V22, P474, DOI 10.1016/j.tem.2011.07.006; Wu LT, 2013, CANCER RES, V73, P6068, DOI 10.1158/0008-5472.CAN-13-0882; Xiao J, 2012, PROSTATE, V72, P1514, DOI 10.1002/pros.22501; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yang L, 2003, BIOCHEM J, V369, P651, DOI 10.1042/BJ20020854; Yeap LS, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-12; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yuan L, 2012, J BIOL CHEM, V287, P6582, DOI 10.1074/jbc.M111.300236; Yuan L, 2011, BLOOD, V118, P1145, DOI 10.1182/blood-2010-10-315275; Yuan P, 2009, GENE DEV, V23, P2507, DOI 10.1101/gad.1831909; Zammarchi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049721; Zhang SL, 2010, DIAGN MOL PATHOL, V19, P151, DOI 10.1097/PDM.0b013e3181bb216a; Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	205	125	133	4	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					403	414		10.1038/onc.2015.109	http://dx.doi.org/10.1038/onc.2015.109			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25915839	Bronze			2022-12-17	WOS:000369056700001
J	Li, Q; Yao, Y; Eades, G; Liu, Z; Zhang, Y; Zhou, Q				Li, Q.; Yao, Y.; Eades, G.; Liu, Z.; Zhang, Y.; Zhou, Q.			Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer	ONCOGENE			English	Article						microRNAs; ductal carcinoma in situ; cancer stem cells; basal-like breast cancer	CARCINOMA IN-SITU; SURGICAL ADJUVANT BREAST; MESENCHYMAL TRANSITION; MARKERS CD44; EXPRESSION; WOMEN; ALDH1; SOX9; IDENTIFICATION; SULFORAPHANE	The major goal of breast cancer prevention is to reduce the incidence of ductal carcinoma in situ (DCIS), an early stage of breast cancer. However, the biology behind DCIS formation is not well understood. It is suspected that cancer stem cells (CSCs) are already programmed in pre-malignant DCIS lesions and that these tumor-initiating cells may determine the phenotype of DCIS. MicroRNA (miRNA) profiling of paired DCIS tumors revealed that loss of miR-140 is a hallmark of DCIS lesions. Previously, we have found that miR-140 regulates CSCs in luminal subtype invasive ductal carcinoma. Here, we find that miR-140 has a critical role in regulating stem cell signaling in normal breast epithelium and in DCIS. miRNA profiling of normal mammary stem cells and cancer stem-like cells from DCIS tumors revealed that miR-140 is significantly downregulated in cancer stem-like cells compared with normal stem cells, linking miR-140 and dysregulated stem cell circuitry. Furthermore, we found that SOX9 and ALDH1, the most significantly activated stem-cell factors in DCIS stem-like cells, are direct targets of miR-140. Currently, targeted therapies (tamoxifen) are only able to reduce DCIS risk in patients with estrogen receptor alpha (ER alpha)-positive disease. We examined a model of ER alpha-negative/basal-like DCIS and found that restoration of miR-140 via a genetic approach or with the dietary compound sulforaphane decreased SOX9 and ALDH1, and reduced tumor growth in vivo. These results support that a miR-140/ALDH1/SOX9 axis is critical to basal CSC self-renewal and tumor formation in vivo, suggesting that the miR-140 pathway may be a promising target for preventative strategies in patients with basal-like DCIS.	[Li, Q.; Yao, Y.; Eades, G.; Liu, Z.; Zhang, Y.; Zhou, Q.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Zhou, Q (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, 108 North Greene St,RM 337, Baltimore, MD 21201 USA.	qzhou@som.umaryland.edu	Li, Qinglin/K-2570-2015	Li, Qinglin/0000-0002-4125-1944	Maryland Stem Cell Fund; FAMRI; ACS; NCI; NATIONAL CANCER INSTITUTE [R01CA157779, P30CA134274, R01CA163820, T32CA154274] Funding Source: NIH RePORTER	Maryland Stem Cell Fund; FAMRI; ACS(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from Maryland Stem Cell Fund, FAMRI, ACS and NCI R01 (QZ), and NCI T32 training (GE).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; de Beca FF, 2013, J CLIN PATHOL, V66, P187, DOI 10.1136/jclinpath-2012-201169; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Ernster VL, 2002, J NATL CANCER I, V94, P1546; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fisher B, 2001, SEMIN ONCOL, V28, P400, DOI 10.1053/sonc.2001.26151; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fowble B, 1997, INT J RADIAT ONCOL, V38, P949, DOI 10.1016/S0360-3016(97)00153-3; George WD, 2003, LANCET, V362, P95, DOI 10.1016/S0140-6736(03)13859-7; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; LENNINGTON WJ, 1994, CANCER, V73, P118, DOI 10.1002/1097-0142(19940101)73:1<118::AID-CNCR2820730121>3.0.CO;2-R; Leonard GD, 2004, JNCI-J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164; Li CI, 2005, CANCER EPIDEM BIOMAR, V14, P1008, DOI 10.1158/1055-9965.EPI-04-0849; Liu SL, 2012, J MAMMARY GLAND BIOL, V17, P15, DOI 10.1007/s10911-012-9242-8; Livasy CA, 2007, HUM PATHOL, V38, P197, DOI 10.1016/j.humpath.2006.08.017; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; Takai Daiya, 2003, In Silico Biology, V3, P235; Takebe N, 2010, CLIN CANCER RES, V16, P3106, DOI 10.1158/1078-0432.CCR-09-2934; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111; Yamashita S, 2012, J BIOL CHEM, V287, P22206, DOI 10.1074/jbc.M112.343194; Yang J, 2011, FEBS LETT, V585, P2992, DOI 10.1016/j.febslet.2011.08.013; Zhou WJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-653	48	125	132	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2589	2600		10.1038/onc.2013.226	http://dx.doi.org/10.1038/onc.2013.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752191	Green Accepted			2022-12-17	WOS:000336502700005
J	Yi, C; Wang, Q; Wang, L; Huang, Y; Li, L; Liu, L; Zhou, X; Xie, G; Kang, T; Wang, H; Zeng, M; Ma, J; Zeng, Y; Yun, JP				Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Kang, T.; Wang, H.; Zeng, M.; Ma, J.; Zeng, Y.; Yun, J-P			MiR-663, a microRNA targeting p21(waf1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma	ONCOGENE			English	Article						microRNAs; miR-663; cell cycle; p21; nasopharyngeal carcinoma	EPSTEIN-BARR-VIRUS; CELL-GROWTH; POSTTRANSCRIPTIONAL REGULATION; EXPRESSION PROFILES; C-MYC; P21; ARREST; INHIBITION; GENES; P53	MicroRNAs (miRNAs) may function as either oncogenes or tumor suppressors in the malignant progression of different tumor types. MiR-663 was recently reported to be decreased and identified as a tumor suppressor in gastric cancer. We also verified its role in repressing cell proliferation of a gastric cancer cell line. In this study, however, miR-663 was found to be upregulated in nasopharyngeal carcinoma (NPC) cells compared with human immortalized nasopharyngeal epithelium cells, using a miRNA microarray, and this higher expression was confirmed in NPC tissue samples. Indeed, inhibition of miR-663 impaired the proliferation of NPC cells in vitro and the NPC tumor growth of xenografts in nude mice. Mechanistically, miR-663 directly targeted p21(WAF1/CIP1) to promote the cellular G1/S transition, as the inhibitory effects of miR-663 on the G1/S transition could be rescued by p21(WAF1/CIP1) silencing. Our results imply that miR-663 may act as an oncogene in NPC. The newly identified miR-663/p21(WAF1/CIP1) axis clarifies the molecular mechanism of NPC cell proliferation and represents a novel strategy for the diagnosis and treatment of patients with NPC. Oncogene (2012) 31, 4421-4433; doi: 10.1038/onc.2011.629; published online 16 January 2012	[Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510060, Guangdong, Peoples R China; [Yi, C.; Wang, Q.; Wang, L.; Huang, Y.; Li, L.; Liu, L.; Zhou, X.; Xie, G.; Kang, T.; Wang, H.; Zeng, M.; Ma, J.; Zeng, Y.; Yun, J-P] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol S China, Guangzhou 510060, Guangdong, Peoples R China; [Kang, T.; Wang, H.; Zeng, M.; Zeng, Y.] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, Guangzhou 510060, Guangdong, Peoples R China; [Ma, J.] Sun Yat Sen Univ, Ctr Canc, Dept Radiat Oncol, Guangzhou 510060, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Yun, JP (corresponding author), Sun Yat Sen Univ, Ctr Canc, Dept Pathol, 651 Dongfeng Rd E, Guangzhou 510060, Guangdong, Peoples R China.	yunjp@mail.sysu.edu.cn	Wang, Linli/R-5688-2018	Wang, Linli/0000-0002-8380-6135	National Natural Science Foundation of China [30973506, 81172345]; 863 Project [2006AA02A404]; Science Foundation of Key Hospital Clinical Program of Ministry of Health, China [2010-178]; Project of State Key Laboratory of Oncology in South China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 863 Project(National High Technology Research and Development Program of China); Science Foundation of Key Hospital Clinical Program of Ministry of Health, China; Project of State Key Laboratory of Oncology in South China	We thank Jun Li for kindly providing the human gastric cancer cells MKN-45 and SCG-7901. This work was supported by grants from the National Natural Science Foundation of China (30973506 and 81172345), the 863 Project (2006AA02A404), the Science Foundation of Key Hospital Clinical Program of Ministry of Health, China (2010-178), and the Project of State Key Laboratory of Oncology in South China.	Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bei JX, 2010, NAT GENET, V42, P599, DOI 10.1038/ng.601; Borgdorff V, 2010, ONCOGENE, V29, P2262, DOI 10.1038/onc.2009.497; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chen HC, 2009, BRIT J CANCER, V100, P1002, DOI 10.1038/sj.bjc.6604948; Chen H, 2010, NEUROL RES, V32, P603, DOI 10.1179/174313209X455691; Child ES, 2006, CELL CYCLE, V5, P1313, DOI 10.4161/cc.5.12.2863; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gottwein E, 2010, J VIROL, V84, P5229, DOI 10.1128/JVI.00202-10; He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Kong QL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000940; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lehmann U, 2007, Verh Dtsch Ges Pathol, V91, P214; Lei X, 1999, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V13, P406; Li GR, 2009, MECH AGEING DEV, V130, P731, DOI 10.1016/j.mad.2009.09.002; Li HM, 2004, ONCOGENE, V23, P4488, DOI 10.1038/sj.onc.1207580; Li XS, 1996, CANCER RES, V56, P5055; Liao Wen-Ting, 2005, Ai Zheng, V24, P1317; Lin CS, 2000, J MOL BIOL, V303, P7, DOI 10.1006/jmbi.2000.4121; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Lung RWM, 2009, NEOPLASIA, V11, P1174, DOI 10.1593/neo.09888; Maes OC, 2009, J CELL PHYSIOL, V221, P109, DOI 10.1002/jcp.21834; Marasa BS, 2010, AGING-US, V2, P333, DOI 10.18632/aging.100159; McDermott AL, 2001, CLIN OTOLARYNGOL, V26, P82, DOI 10.1046/j.1365-2273.2001.00449.x; Mei J, 2011, MOL CELL BIOL, V31, P3584, DOI 10.1128/MCB.05821-11; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Ni CW, 2011, AM J PHYSIOL-HEART C, V300, pH1762, DOI 10.1152/ajpheart.00829.2010; Orom UA, 2006, GENE, V372, P137, DOI 10.1016/j.gene.2005.12.031; Pan JA, 2010, ONCOL REP, V24, P105, DOI 10.3892/or_00000834; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pizzimenti S, 2009, FREE RADICAL BIO MED, V46, P282, DOI 10.1016/j.freeradbiomed.2008.10.035; Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105; Shi W, 2010, INT J CANCER, V126, P2036, DOI 10.1002/ijc.24880; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Te JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010344; Tili E, 2010, BIOCHEM PHARMACOL, V80, P2057, DOI 10.1016/j.bcp.2010.07.003; Tili E, 2010, CARCINOGENESIS, V31, P1561, DOI 10.1093/carcin/bgq143; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang Min, 2005, Ai Zheng, V24, P1230; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Wang ZZ, 2010, INT J ONCOL, V37, P1315, DOI 10.3892/ijo_00000783; Wei WI, 2005, LANCET, V365, P2041, DOI 10.1016/S0140-6736(05)66698-6; Wong P, 2010, CANCER RES, V70, P3833, DOI 10.1158/0008-5472.CAN-09-3268; Wong TS, 2011, J CANCER RES CLIN, V137, P415, DOI 10.1007/s00432-010-0898-4; Wu S, 2010, ONCOGENE, V29, P2302, DOI 10.1038/onc.2010.34; Xia HP, 2010, BIOCHEM BIOPH RES CO, V391, P535, DOI 10.1016/j.bbrc.2009.11.093; Xiao JY, 2009, CELL CYCLE, V8, P889, DOI 10.4161/cc.8.6.7898; Xu S, 2011, ONCOGENE, V30, P2219, DOI 10.1038/onc.2010.596; Yun JP, 2007, BRIT J CANCER, V96, P477, DOI 10.1038/sj.bjc.6603574; Zeng YX, 2002, SEMIN CANCER BIOL, V12, P443, DOI 10.1016/S1044579X02000871; Zhang LM, 2010, CARCINOGENESIS, V31, P559, DOI 10.1093/carcin/bgp335; Zhang MF, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-110; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727	76	125	131	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2012	31	41					4421	4433		10.1038/onc.2011.629	http://dx.doi.org/10.1038/onc.2011.629			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	018YR	22249270				2022-12-17	WOS:000309704500001
J	Bonavia, R; Inda, MM; Vandenberg, S; Cheng, SY; Nagane, M; Hadwiger, P; Tan, P; Sah, DWY; Cavenee, WK; Furnari, FB				Bonavia, R.; Inda, M. M.; Vandenberg, S.; Cheng, S-Y; Nagane, M.; Hadwiger, P.; Tan, P.; Sah, D. W. Y.; Cavenee, W. K.; Furnari, F. B.			EGFRvIII promotes glioma angiogenesis and growth through the NF-kappa B, interleukin-8 pathway	ONCOGENE			English	Article						glioblastoma; EGFR; Delta EGFR; angiogenesis; NF-kappa B; IL-8	SIGNAL-TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTOR AP-1; FACTOR RECEPTOR COMMON; BREAST-CANCER CELLS; IN-VITRO; TYROSINE PHOSPHORYLATION; GLIOBLASTOMA-MULTIFORME; TUMOR-GROWTH; BRAIN-TUMOR; STEM-CELL	Sustaining a high growth rate requires tumors to exploit resources in their microenvironment. One example of this is the extensive angiogenesis that is a typical feature of high-grade gliomas. Here, we show that expression of the constitutively active mutant epidermal growth factor receptor, Delta EGFR (EGFRvIII, EGFR*, de2-7EGFR) is associated with significantly higher expression levels of the pro-angiogenic factor interleukin (IL)-8 in human glioma specimens and glioma stem cells. Furthermore, the ectopic expression of Delta EGFR in different glioma cell lines caused up to 60-fold increases in the secretion of IL-8. Xenografts of these cells exhibit increased neovascularization, which is not elicited by cells overexpressing wildtype (wt) EGFR or DEGFR with an additional kinase domain mutation. Analysis of the regulation of IL-8 by site-directed mutagenesis of its promoter showed that DEGFR regulates its expression through the transcription factors nuclear factor (NF)-kappa B, activator protein 1 (AP-1) and CCAAT/enhancer binding protein (C/EBP). Glioma cells overexpressing Delta EGFR showed constitutive activation and DNA binding of NF-kappa B, overexpression of c-Jun and activation of its upstream kinase c-Jun N-terminal kinase (JNK) and overexpression of C/EBP beta. Selective pharmacological or genetic targeting of the NF-kappa B or AP-1 pathways efficiently blocked promoter activity and secretion of IL-8. Moreover, RNA interference-mediated knock-down of either IL-8 or the NF-kappa B subunit p65, in Delta EGFR-expressing cells attenuated their ability to form tumors and to induce angiogenesis when injected subcutaneously into nude mice. On the contrary, the overexpression of IL-8 in glioma cells lacking Delta EGFR potently enhanced their tumorigenicity and produced highly vascularized tumors, suggesting the importance of this cytokine and its transcription regulators in promoting glioma angiogenesis and tumor growth. Oncogene (2012) 31, 4054-4066; doi: 10.1038/onc.2011.563; published online 5 December 2011	[Bonavia, R.; Inda, M. M.; Cavenee, W. K.; Furnari, F. B.] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Bonavia, R.; Vandenberg, S.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; [Vandenberg, S.; Cavenee, W. K.; Furnari, F. B.] Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; [Cheng, S-Y] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Nagane, M.] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan; [Hadwiger, P.; Tan, P.] Alnylam Europe AG, Kulmbach, Germany; [Sah, D. W. Y.] Alnylam Pharmaceut Inc, Cambridge, MA USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kyorin University	Furnari, FB (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.	ffurnari@ucsd.edu		Furnari, Frank/0000-0003-1909-4361	Goldhirsh Foundation; NIH [P01-CA95616, RO1CA130966]; Pennsylvania Department of Health; Innovative Research Scholar Award of the Hillman Foundation; Gobierno de Navarra, Spain; American Brain Tumor Association in Honor of Walter Terlik; Federazione Italiana Ricerca Cancro; NATIONAL CANCER INSTITUTE [P01CA095616, R01CA130966] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [22591618] Funding Source: KAKEN	Goldhirsh Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; Innovative Research Scholar Award of the Hillman Foundation; Gobierno de Navarra, Spain; American Brain Tumor Association in Honor of Walter Terlik; Federazione Italiana Ricerca Cancro(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Donna Harclerode and Donald Pizzo for technical assistance with immunostaining and Dr Cameron Brennan for providing the GBM tumorspheres. This work was supported by an award from the Goldhirsh Foundation (to FBF), and NIH Grant P01-CA95616 (to WKC, FBF), as well as NIH RO1CA130966, a grant with Pennsylvania Department of Health and an Innovative Research Scholar Award of the Hillman Foundation (to SYC). WKC is a fellow of the National Foundation for Cancer Research. MM Inda thanks the Gobierno de Navarra, Spain, and the American Brain Tumor Association in Honor of Walter Terlik for the fellowships received. R Bonavia was supported by a fellowship from Federazione Italiana Ricerca Cancro.	Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Biernat W, 2004, BRAIN PATHOL, V14, P131, DOI 10.1111/j.1750-3639.2004.tb00045.x; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Brew R, 2000, CYTOKINE, V12, P78, DOI 10.1006/cyto.1999.0518; BROWN PH, 1993, ONCOGENE, V8, P877; Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848; Chen DY, 2003, ONCOGENE, V22, P4348, DOI 10.1038/sj.onc.1206532; Feldkamp MM, 1999, INT J CANCER, V81, P118, DOI 10.1002/(SICI)1097-0215(19990331)81:1<118::AID-IJC20>3.0.CO;2-5; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Heimberger AB, 2005, CLIN CANCER RES, V11, P1462, DOI 10.1158/1078-0432.CCR-04-1737; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HURTT MR, 1992, J NEUROPATH EXP NEUR, V51, P84, DOI 10.1097/00005072-199201000-00010; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Le Page C, 2005, PROSTATE, V65, P306, DOI 10.1002/pros.20291; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Magnus N, 2010, BLOOD, V116, P815, DOI 10.1182/blood-2009-10-250639; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; Narita Y, 2002, CANCER RES, V62, P6764; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; Nishikawa Ryo, 2004, Brain Tumor Pathol, V21, P53, DOI 10.1007/BF02484510; Norden AD, 2008, LANCET NEUROL, V7, P1152, DOI 10.1016/S1474-4422(08)70260-6; Petit AMV, 1997, AM J PATHOL, V151, P1523; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHLEGEL J, 1994, INT J CANCER, V56, P72; Shinojima N, 2003, CANCER RES, V63, P6962; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Yao C, 2007, INT J CANCER, V121, P1949, DOI 10.1002/ijc.22930; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200	57	125	127	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4054	4066		10.1038/onc.2011.563	http://dx.doi.org/10.1038/onc.2011.563			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22139077	Green Accepted			2022-12-17	WOS:000308688800006
J	Liu, J; Weiss, HL; Rychahou, P; Jackson, LN; Evers, BM; Gao, T				Liu, J.; Weiss, H. L.; Rychahou, P.; Jackson, L. N.; Evers, B. M.; Gao, T.			Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis	ONCOGENE			English	Article						PHLPP; colon cancer cells; Akt; protein kinase C; tumorigenesis	PROTEIN-KINASE-C; BREAST-CANCER; CELLS; GENE; AKT; GROWTH; CARCINOGENESIS; PHOSPHATASE; INVASION; P27	PHLPP (PH domain leucine-rich repeats protein phosphatase) represents a family of novel Ser/Thr protein phosphatases. Two highly related isoforms in this family, PHLPP1 and PHLPP2, have been identified to serve as negative regulators of Akt and protein kinase C by dephosphorylating the kinases directly. In this study, we examined the expression pattern of both PHLPP isoforms in colorectal cancer specimens and the adjacent normal mucosa using immunohistochemical staining. We found that the expression of PHLPP1 or PHLPP2 isoform was lost or decreased in 78 and 86% of tumor tissues, respectively. Stable overexpression of either PHLPP isoform in colon cancer cells decreased the rate of cell proliferation and sensitized the cells to growth inhibition induced by the phosphoinositide-3 kinase inhibitor, LY294002, whereas knockdown of either PHLPP isoform by shRNA promoted the proliferation of DLD1 cells. In addition, we demonstrated that the PHLPP-mediated growth inhibition in colon cancer cells was largely rescued by overexpression of a constitutively active Akt. Moreover, reexpression of either PHLPP isoform in HCT116 cells inhibited tumor growth in vivo. Taken together, our results strongly support a tumor suppressor role of PHLPP in colon cancer.	[Gao, T.] Univ Texas Galveston, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; [Liu, J.] Sichuan Univ, W China Med Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610064, Sichuan, Peoples R China; [Liu, J.; Weiss, H. L.; Evers, B. M.; Gao, T.] Univ Texas Galveston, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA; [Weiss, H. L.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Rychahou, P.; Jackson, L. N.; Evers, B. M.] Univ Texas Galveston, Med Branch, Dept Surg, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Sichuan University; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Gao, T (corresponding author), Univ Texas Galveston, Med Branch, Dept Pharmacol & Toxicol, 301 Univ Blvd, Galveston, TX 77555 USA.	tigao@utmb.edu		Rychahou, Piotr/0000-0001-7352-9122	NIH [K01 CA10209-05]; American Cancer Society [RSG0822001TBE, R01CA104748]; NATIONAL CANCER INSTITUTE [K01CA102098, R01CA104748] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank UTMB. ow cytometry core for assistance with the. ow cytometry analysis, and Dr Alexandra Newton at University of California San Diego for providing the wild- type and mutant Akt and PKC bII expression constructs. This work was supported by NIH K01 CA10209-05(TG), American Cancer Society RSG0822001TBE (TG) and R01CA104748 (BME).	Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gokmen-Polar Y, 2001, CANCER RES, V61, P1375; Hershko DD, 2006, CANCER-AM CANCER SOC, V107, P668, DOI 10.1002/cncr.22073; Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104; Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Murray NR, 1999, J CELL BIOL, V145, P699, DOI 10.1083/jcb.145.4.699; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877; REINER A, 1990, CANCER RES, V50, P7057; Rosner M, 2006, MUTAT RES-REV MUTAT, V613, P10, DOI 10.1016/j.mrrev.2006.03.001; Saaf AM, 2007, MOL BIOL CELL, V18, P4245, DOI 10.1091/mbc.E07-04-0309; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033	21	125	136	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					994	1004		10.1038/onc.2008.450	http://dx.doi.org/10.1038/onc.2008.450			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079341	Green Accepted			2022-12-17	WOS:000263457400006
J	Tai, KY; Shieh, YS; Lee, CS; Shiah, SG; Wu, CW				Tai, K-Y; Shieh, Y-S; Lee, C-S; Shiah, S-G; Wu, C-W			Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-kappa B and Brg-1	ONCOGENE			English	Article						Axl; Brg-1; ERK; MMP-9; NF-kappa B	RECEPTOR TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATION; DIFFERENTIAL ACTIVATION; ENDOTHELIAL-CELLS; DNA METHYLATION; BREAST-CANCER; EXPRESSION; CARCINOMA; CHROMATIN; PATHWAYS	Activity of the Axl receptor tyrosine kinase is positively correlated with tumor metastasis; however, its detailed role in the mechanism of tumor invasion is still not completely understood. Here, we show that Axl enhances the expression of matrix metalloproteinase 9 ( MMP-9), required for Axl-mediated invasion both in vitro and in vivo. We found that the highly selective MEK1/2 inhibitors U0126 and PD98059, and the expressed dominant-negative form of extracellular signal-regulated kinase ( ERK), completely block Axl-mediated MMP-9 activation. In contrast, the phosphatidylinositol 3-kinase inhibitor LY294002 and wortmannin had little effect on activation. Interestingly, however, the Axl ligand Gas6 is not involved in Axl-mediated MMP-9 activation. Mutation of Glu59(Axl) and Thr77(Axl) dramatically reduced Gas6-Axl binding but continued to induce MMP-9 activation. In addition, overexpression of Axl-activated ERK and enhanced nuclear factor-kappa B (NF-kappa B) transactivation and brahma-related gene-1 ( Brg-1) translocation. Exposure to the NF-kappa B inhibitor silibinin, which inhibits I kappa B alpha kinase activity, or overexpression of the dominant-negative mutant I kappa B and Brg-1 strikingly inhibited Axl-mediated MMP-9 activation. These data indicate that coordination of ERK signaling and NF-kappa B and Brg-1 activation are indispensable to regulation of Axl-dependent MMP-9 gene transcription. Together with previous data, our results provide a plausible mechanism for Axl-mediated tumor invasion and establish a functional link between the Axl and MMP-9 signaling pathways.	[Tai, K-Y; Lee, C-S; Shiah, S-G; Wu, C-W] Natl Hlth Res Inst, Inst Canc Res, Miaoli 350, Miaoli County, Taiwan; [Shieh, Y-S] Natl Defense Med Ctr, Sch Dent, Taipei, Taiwan	National Health Research Institutes - Taiwan; National Defense Medical Center	Shiah, SG (corresponding author), Natl Hlth Res Inst, Inst Canc Res, 35 Keyan Rd,Zhunan Town, Miaoli 350, Miaoli County, Taiwan.	920114@nhri.org.tw; ken@nhri.org.tw	Shiah, Shine-Gwo/D-2087-2010	Shiah, Shine-Gwo/0000-0002-1003-973X; Tai, Kang-Yu/0000-0001-6867-3365				Banine F, 2005, CANCER RES, V65, P3542, DOI 10.1158/0008-5472.CAN-04-3554; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Budagian V, 2005, EMBO J, V24, P4260, DOI 10.1038/sj.emboj.7600874; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Fingleton B, 2006, FRONT BIOSCI-LANDMRK, V11, P479, DOI 10.2741/1811; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; Genersch E, 2000, J CELL SCI, V113, P4319; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hasanbasic I, 2004, AM J PHYSIOL-HEART C, V287, pH1207, DOI 10.1152/ajpheart.00020.2004; Holland SJ, 2005, CANCER RES, V65, P9294, DOI 10.1158/0008-5472.CAN-05-0993; Ito T, 1999, THYROID, V9, P563, DOI 10.1089/thy.1999.9.563; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; Jin S, 2005, J BIOCHEM BIOPH METH, V65, P20, DOI 10.1016/j.jbbm.2005.08.006; Lakka SS, 2002, ONCOGENE, V21, P5601, DOI 10.1038/sj.onc.1205646; Lay JD, 2007, CANCER RES, V67, P3878, DOI 10.1158/0008-5472.CAN-06-3191; Liu Y, 2006, J BIOL CHEM, V281, P31359, DOI 10.1074/jbc.M604478200; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Melaragno MG, 1999, TRENDS CARDIOVAS MED, V9, P250, DOI 10.1016/S1050-1738(00)00027-X; Meric F, 2002, CLIN CANCER RES, V8, P361; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; NEUBAUER A, 1993, SEMIN HEMATOL, V30, P34; Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273; Sasaki T, 2006, EMBO J, V25, P80, DOI 10.1038/sj.emboj.7600912; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Singh RAK, 2004, J IMMUNOL, V173, P7299, DOI 10.4049/jimmunol.173.12.7299; Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499; Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Wang W, 2003, CURR TOP MICROBIOL, V274, P143; Wu CW, 2002, ANTICANCER RES, V22, P1071; Yao J, 2001, ONCOGENE, V20, P8066, DOI 10.1038/sj.onc.1204944; Zeigler ME, 1999, J CELL PHYSIOL, V180, P271	38	125	150	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	2008	27	29					4044	4055		10.1038/onc.2008.57	http://dx.doi.org/10.1038/onc.2008.57			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	321RV	18345028				2022-12-17	WOS:000257325100004
J	Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB				Su, ZZ; Emdad, L; Sauane, M; Lebedeva, IV; Sarkar, D; Gupta, P; James, CD; Randolph, A; Valerie, K; Walter, MR; Dent, P; Fisher, PB			Unique aspects of mda-7/IL-24 antitumor bystander activity: establishing a role for secretion of MDA-7/IL-24 protein by normal cells	ONCOGENE			English	Article						cancer gene therapy; apoptosis; radiation sensitization; tumor cell invasion; diffusion bystander assay; normal-cell-secreted mda-7/IL-24	DIFFERENTIATION-ASSOCIATED GENE-7; APOPTOSIS INDUCING CYTOKINE; PROSTATE-CANCER CELLS; HUMAN-MELANOMA CELLS; PANCREATIC-CANCER; MDA-7 GENE; IN-VITRO; SUBTRACTION HYBRIDIZATION; GLIOMA-CELLS; ENHANCES RADIOSENSITIVITY	Melanoma differentiation associated gene-7 (mda-7) was cloned using subtraction hybridization from terminally differentiated human melanoma cells. Based on structural and functional properties, mda-7 is now recognized as interleukin-24 (IL-24), a new member of the expanding IL-10 gene family. Unique properties of mda-7/IL-24 include its ability to selectively induce growth suppression, apoptosis and radiosensitization in diverse human cancer cells, without causing similar effects in normal cells. The utility of mda-7/IL-24, administered by means of a replication-incompetent adenovirus, as a gene therapy for cancer has recently received validation in patients, highlighting an important phenomenon initially observed in pancreatic tumor cells, namely a 'potent bystander apoptosis-inducing effect' in adjacent tumor cells not initially receiving this gene product. We presently investigated the contribution of mda-7/IL-24 secreted by normal cells in mediating this 'bystander effect', and document that normal cells induced to produce mda-7/IL-24 following infection with recombinant adenoviruses expressing this cytokine secrete mda-7/IL-24, which modifies the anchorage-independent growth, invasiveness, survival and sensitivity to radiation of cancer cells that contain functional IL-20/IL-22 receptors, but not in cancer cells that lack a complete set of receptors. Moreover, the combination of secreted mda-7/IL-24 and radiation engenders a 'bystander antitumor effect' not only in inherently mda-7/IL-24 or radiation-sensitive cancer cells, but also in tumor cells overexpressing the antiapoptotic proteins bcl-2 or bcl-xL and displaying resistance to either treatment alone. The present studies provide definitive evidence that secreted mda-7/IL-24 from normal cells can induce direct antitumor and radiation-enhancing effects that are dependent on the presence of canonical receptors for this cytokine on tumor cells. Moreover, we now describe a novel means of enhancing mda-7/IL-24's therapeutic potential by targeting normal cells to produce and release this cancer-specific apoptosis-inducing cytokine, a strategy that could be employed as an innovative way of using this unique gene product for treating metastatic disease.	Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA; Mayo Clin, Dept Oncol, Div Med Oncol, Rochester, MN 55905 USA; Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Neurosurg, New York, NY 10032 USA; Columbia Univ, Med Ctr, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY 10032 USA	Columbia University; Mayo Clinic; Virginia Commonwealth University; University of Alabama System; University of Alabama Birmingham; Columbia University; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Pathol,Herbert Irving Comprehens Canc Ctr, 630 W 168th St,Black Bldg,Rm 1501, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008; James, Charles D/E-2721-2012; Valerie, Kristoffer/AAL-8299-2021	Lebedeva, Irina V/0000-0002-1693-9392; James, Charles D/0000-0002-1027-203X; 	NATIONAL CANCER INSTITUTE [R01CA097318, P01CA104177, R01CA088906, R01CA098712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047300] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052825] Funding Source: NIH RePORTER; NCI NIH HHS [CA098712, CA097318, CA088906, CA104177] Funding Source: Medline; NIAID NIH HHS [AI47300] Funding Source: Medline; NIDDK NIH HHS [DK52825] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAE VL, 1994, INT J CANCER, V58, P721, DOI 10.1002/ijc.2910580517; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Caudell EG, 2002, J IMMUNOL, V168, P6041, DOI 10.4049/jimmunol.168.12.6041; Chada S, 2005, MOL THER, V11, P724, DOI 10.1016/j.ymthe.2004.12.021; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Emdad L, 2005, J CELL PHYSIOL, V202, P135, DOI 10.1002/jcp.20097; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; Frank DK, 1998, CLIN CANCER RES, V4, P2521; Gazdar AF, 2001, P NATL ACAD SCI USA, V98, P10028, DOI 10.1073/pnas.191379998; Gopalkrishnan RV, 2004, INT IMMUNOPHARMACOL, V4, P635, DOI 10.1016/j.intimp.2004.01.015; Hilgers W, 1999, GENE CHROMOSOME CANC, V26, P1; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hruban RH, 2001, CANCER J, V7, P251; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; Jiang HP, 1995, ONCOGENE, V11, P2477; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Kawabe S, 2002, MOL THER, V6, P637, DOI 10.1006/mthe.2002.0714; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, SEMIN CANCER BIOL, V13, P169, DOI 10.1016/S1044-579X(02)00134-7; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; Madireddi MT, 2000, ADV EXP MED BIOL, V465, P239; MELBER K, 1989, CANCER RES, V49, P3650; Mhashilkar AM, 2001, MOL MED, V7, P271, DOI 10.1007/BF03401847; Nishikawa T, 2004, MOL THER, V9, P818, DOI 10.1016/j.ymthe.2004.03.014; Novak JP, 2002, J BIOL CHEM, V277, P47517, DOI 10.1074/jbc.M205114200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; PESTKA S, 2003, ENCY HORMONES, P507; Ramesh R, 2004, MOL THER, V9, P510, DOI 10.1016/j.ymthe.2004.01.019; RAMESH R, 2003, CANCER RES, V63, P5113; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Saeki T, 2002, ONCOGENE, V21, P4558, DOI 10.1038/sj.onc.1205553; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199; Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958; Sauane M, 2004, CANCER RES, V64, P2988, DOI 10.1158/0008-5472.CAN-04-0200; Sauane M, 2003, J CELL PHYSIOL, V196, P334, DOI 10.1002/jcp.10309; Sauane M, 2003, CYTOKINE GROWTH F R, V14, P35, DOI 10.1016/S1359-6101(02)00074-6; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2002, ONCOGENE, V21, P3592, DOI 10.1038/sj.onc.1205445; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Su ZZ, 2005, P NATL ACAD SCI USA, V102, P1059, DOI 10.1073/pnas.0409141102; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; Yacoub A, 2003, MOL CANCER THER, V2, P623	58	125	136	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7552	7566		10.1038/sj.onc.1208911	http://dx.doi.org/10.1038/sj.onc.1208911			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16044151				2022-12-17	WOS:000233333800005
J	Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I				Murillo, MM; del Castillo, G; Sanchez, A; Fernandez, M; Fabregat, I			Involvement of EGF receptor and c-Src in the survival signals induced by TGF-beta 1 in hepatocytes	ONCOGENE			English	Article						apoptosis; TGF-beta; Akt; EGFR; c-Src; hepatocytes	GROWTH-FACTOR-BETA; NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR SNAIL; TGF-BETA; FETAL HEPATOCYTES; CELL SURVIVAL; APOPTOSIS; METASTASIS; ACTIVATION; KINASE	Transforming growth factor beta1 (TGF-beta 1) belongs to a family of polypeptide factors, whose cytostatic and apoptotic functions help restrain the growth of mammalian cells. Although solid data established the role of TGF-beta's as suppressor factors in tumorigenic processes, in the context of an advanced stage of disease, TGF-beta's could also play a pro-oncogenic role. We have previously shown that TGF-beta 1 induces both pro- and antiapoptotic signals in foetal rat hepatocytes. In this work, we have focused on its antiapoptotic mechanism. We show that TGF-beta 1 activates the epidermal growth factor receptor ( EGFR) and phosphorylates c-Src. EGFR is required for Akt activation. Blocking EGFR signalling amplifies the apoptotic response to TGF-beta 1. TGF-beta 1 induced a rapid activation of the tumour necrosis factor-alpha-converting enzyme (TACE/ADAM ( a disintegrin and metalloprotease) 17). Inhibitors of TACE considerably attenuated Akt activation, which suggests that TGF-beta 1 activates EGF signalling in hepatocytes by promoting shedding of EGF-like ligands. The activation of c-Src by TGF-beta 1 is EGFR dependent and is required for full Akt phosphorylation and cell survival. Inhibition of EGFR does not block the epithelial-mesenchymal transition (EMT) induced by TGF-beta 1 in hepatocytes, which indicates that activation of EGFR plays an essential role in impairing apoptosis, but it is dispensable for the EMT process.	IDIBELL, Inst Recerca Oncol, Barcelona 08907, Spain; Univ Complutense Madrid, Fac Farm, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Complutense University of Madrid	Fabregat, I (corresponding author), IDIBELL, Inst Recerca Oncol, Gran Via S-N,Km 2-7, Barcelona 08907, Spain.	ifabregat@iro.es	Fernández, Margarita/H-9077-2015; Sánchez, Aránzazu/H-7810-2015; Murillo, Miguel/C-6964-2008; Fabregat, Isabel/H-7038-2015	Fernández, Margarita/0000-0001-7207-2028; Sánchez, Aránzazu/0000-0001-9145-6633; Fabregat, Isabel/0000-0003-0136-8440				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2002, J CLIN INVEST, V109, P1533, DOI 10.1172/JCI200215970; Argast GM, 2004, J BIOL CHEM, V279, P34530, DOI 10.1074/jbc.M405703200; Arteaga CL, 2004, CANCER CELL, V5, P525, DOI 10.1016/j.ccr.2004.05.028; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Gotzmann J, 2002, J CELL SCI, V115, P1189; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jin GX, 2002, ANAL BIOCHEM, V302, P269, DOI 10.1006/abio.2001.5549; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KARI C, 2003, CANCER CELL, V5, P525; Kim JT, 2002, J BIOL CHEM, V277, P31938, DOI 10.1074/jbc.M201178200; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Park SS, 2004, ONCOGENE, V23, P6272, DOI 10.1038/sj.onc.1207856; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sanchez A, 1999, EXP CELL RES, V252, P281, DOI 10.1006/excr.1999.4624; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1053/jhep.1997.v26.pm0009328316; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Valdes F, 2002, MOL CANCER RES, V1, P68; Valdes F, 2004, EXP CELL RES, V292, P209, DOI 10.1016/j.yexcr.2003.08.015; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001	42	125	128	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2005	24	28					4580	4587		10.1038/sj.onc.1208664	http://dx.doi.org/10.1038/sj.onc.1208664			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	940PT	15856020				2022-12-17	WOS:000230157100011
J	Kimura, H; Stephen, D; Joyner, A; Curran, T				Kimura, H; Stephen, D; Joyner, A; Curran, T			Gli1 is important for medulloblastoma formation in Ptc1+/- mice	ONCOGENE			English	Article						medulloblastoma; Patched1; Gli1	BASAL-CELL CARCINOMAS; PRIMITIVE NEUROECTODERMAL TUMORS; CENTRAL-NERVOUS-SYSTEM; GRANULE NEURON PRECURSORS; SONIC HEDGEHOG; MOUSE CEREBELLUM; PATCHED MUTANTS; P53(-/-) MICE; HUMAN HOMOLOG; SHH PATHWAY	Germline mutations in the human homolog of the patched1 (PTCH1) are associated with basal cell nevus carcinoma syndrome (BCNS or Gorlin syndrome), which is characterized by developmental anomalies, radiation hypersensitivity and a predisposition to medulloblastomas and skin tumors. Patched1 (Ptc1) functions as a receptor for Sonic hedgehog (Shh) in a wide range of biological processes. Binding of Shh to Ptc1 results in activation of Smoothened (Smo), which in turn stimulates expression of downstream target genes including Ptc1 and Gli1. Gli1 is a member of a family of DNA-binding zinc-finger proteins, including Gli2 and Gli3, that function in transcription control. Here, we report that inactivation of both Gli1 alleles in Ptc1(+/-) mice significantly reduces spontaneous medulloblastoma formation. Therefore, Gli1 is not only a marker of pathway activation but also plays a functional role in medulloblastoma formation. Interestingly, Gli2 levels were elevated in medulloblastoma cells but not in normal granule neuron precursors during cerebellar development in mice lacking Gli1. In cultured fibroblasts, Gli1 was more potent than Gli2 at inducing cell transformation. These results demonstrate that Gli1 plays a central role in medulloblastoma formation in Ptc1(+/-) mice and that Gli2 may also contribute to oncogenesis.	St Jude Childrens Res Hosp, Dept Dev Neurobiol, Memphis, TN 38105 USA; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Dev Genet Program,Skirball Inst Biomol Med, Dept Cell Biol, New York, NY 10016 USA	St Jude Children's Research Hospital; Howard Hughes Medical Institute; New York University; New York University	Curran, T (corresponding author), St Jude Childrens Res Hosp, Dept Dev Neurobiol, 332 N Lauderdale St, Memphis, TN 38105 USA.	tom.curran@stjude.org	Curran, Tom/D-7515-2011; Curran, Thomas/AAE-7631-2019; Curran, Tom/C-1164-2008; Curran, Tom/F-5234-2018	Curran, Thomas/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551	NATIONAL CANCER INSTITUTE [P01CA096832] Funding Source: NIH RePORTER; NCI NIH HHS [CA096832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai CB, 2002, DEVELOPMENT, V129, P4753; Bai CYB, 2001, DEVELOPMENT, V128, P5161; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Calzada-Wack J, 2002, CARCINOGENESIS, V23, P727, DOI 10.1093/carcin/23.5.727; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Corrales JMD, 2004, DEVELOPMENT, V131, P5581, DOI 10.1242/dev.01438; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dong J, 2000, Hum Mutat, V16, P89, DOI 10.1002/1098-1004(200007)16:1<89::AID-HUMU18>3.3.CO;2-Z; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200; Klein RS, 2001, DEVELOPMENT, V128, P1971; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koyabu Y, 2001, J BIOL CHEM, V276, P6889, DOI 10.1074/jbc.C000773200; Lee Y, 2003, CANCER RES, V63, P5428; Lewis PM, 2004, DEV BIOL, V270, P393, DOI 10.1016/j.ydbio.2004.03.007; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Mo R, 1997, DEVELOPMENT, V124, P113; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Park HL, 2000, DEVELOPMENT, V127, P1593; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Raffel C, 1997, CANCER RES, V57, P842; Reifenberger J, 1998, CANCER RES, V58, P1798; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Taylor MD, 2002, NAT GENET, V31, P306, DOI 10.1038/ng916; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2000, CANCER RES, V60, P2239; Wetmore C, 2001, CANCER RES, V61, P513; Wolter M, 1997, CANCER RES, V57, P2581; Xie JW, 1997, CANCER RES, V57, P2369; Zhao Q, 2002, P NATL ACAD SCI USA, V99, P5704, DOI 10.1073/pnas.082092399; Zurawel RH, 2000, GENE CHROMOSOME CANC, V27, P44, DOI 10.1002/(SICI)1098-2264(200001)27:1<44::AID-GCC6>3.0.CO;2-V; Zurawel RH, 2000, GENE CHROMOSOME CANC, V28, P77, DOI 10.1002/(SICI)1098-2264(200005)28:1<77::AID-GCC9>3.0.CO;2-Y	53	125	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4026	4036		10.1038/sj.onc.1208567	http://dx.doi.org/10.1038/sj.onc.1208567			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806168				2022-12-17	WOS:000229680300003
J	White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM				White, PS; Thompson, PM; Gotoh, T; Okawa, ER; Igarashi, J; Kok, M; Winter, C; Gregory, SG; Hogarty, MD; Maris, JM; Brodeur, GM			Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; chromosome; human; pair 1; genes; suppressor; tumor; loss of heterozygosity; deletion mapping	TUMOR-SUPPRESSOR-GENE; CHROMOSOME 1P DELETIONS; SHORT ARM; MOLECULAR ANALYSIS; CELL-LINE; DROSOPHILA-HAIRY; BAND 1P36; DISTAL 1P; TRANSLOCATION; HETEROZYGOSITY	Substantial genomic and functional evidence from primary tumors and cell lines indicates that a consistent region of distal chromosome 1p is deleted in a sizable proportion of human neuroblastomas, suggesting that this region contains one or more tumor suppressor genes. To determine systematically and precisely the location and extent of 1p deletion in neuroblastomas, we performed allelic loss studies of 737 primary neuroblastomas and genotype analysis of 46 neuroblastoma cell lines. Together, the results defined a single region within 1p36.3 that was consistently deleted in 25% of tumors and 87% of cell lines. Two neuroblastoma patients had constitutional deletions of distal 1p36 that overlapped the tumor-defined region. The tumor- and constitutionally-derived deletions together defined a smallest region of consistent deletion (SRD) between D1S2795 and D1S253. The 1p36.3 SRD was deleted in all but one of the 184 tumors with 1p deletion. Physical mapping and DNA sequencing determined that the SRD minimally spans an estimated 729 kb. Genomic content and sequence analysis of the SRD identified 15 characterized, nine uncharacterized, and six predicted genes in the region. The RNA expression profiles of 21 of the genes were investigated in a variety of normal tissues. The SHREW1 and KCNAB2 genes both had tissue-restricted expression patterns, including expression in the nervous system. In addition, a novel gene (CHD5) with strong homology to proteins involved in chromatin remodeling was expressed mainly in neural tissues. Together, these results suggest that one or more genes involved in neuroblastoma tumorigenesis or tumor progression are likely contained within this region.	Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Duke Univ, Sch Med, Ctr Human Genet, Durham, NC 27710 USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Duke University; University of Pennsylvania; Pennsylvania Medicine	White, PS (corresponding author), Childrens Hosp Philadelphia, Div Oncol, Rm 1407 CHOP N,34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	white@genome.chop.edu		Gregory, Simon/0000-0002-7805-1743	NATIONAL CANCER INSTITUTE [R01CA039771, R01CA087847] Funding Source: NIH RePORTER; NCI NIH HHS [CA039771, CA087847] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abel F, 2002, BRIT J CANCER, V86, P596, DOI 10.1038/sj.bjc.6600111; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BARKER PE, 1993, ONCOGENE, V8, P3353; Bauer A, 2001, GENE CHROMOSOME CANC, V31, P228, DOI 10.1002/gcc.1139; Bentley DR, 2001, NATURE, V409, P942, DOI 10.1038/35057165; Bharti S, 2004, MOL BIOL CELL, V15, P397, DOI 10.1091/mbc.E03-05-0281; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; Birney E, 2004, GENOME RES, V14, P925, DOI 10.1101/gr.1860604; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caron H, 2001, GENE CHROMOSOME CANC, V30, P168, DOI 10.1002/1098-2264(200102)30:2<168::AID-GCC1072>3.0.CO;2-E; Casciano I, 1996, ONCOGENE, V12, P2101; Cerignoli F, 2002, CANCER RES, V62, P1196; De Toledo M, 2001, ONCOGENE, V20, P7307, DOI 10.1038/sj.onc.1204921; DRACOPOLI NC, 1988, AM J HUM GENET, V43, P462; Eggert A, 2000, BIOTECHNIQUES, V28, P681, DOI 10.2144/00284st04; Ejeskar K, 2000, CYTOGENET CELL GENET, V89, P62, DOI 10.1159/000015566; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; Godfried MB, 2002, EUR J CANCER, V38, P1513, DOI 10.1016/S0959-8049(02)00137-5; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Heilstedt HA, 2003, AM J HUM GENET, V72, P1200, DOI 10.1086/375179; Heilstedt HA, 2001, EPILEPSIA, V42, P1103, DOI 10.1046/j.1528-1157.2001.08801.x; Hogarty MD, 2002, CANCER RES, V62, P6481; Hogarty MD, 2000, MED PEDIATR ONCOL, V35, P512, DOI 10.1002/1096-911X(20001201)35:6<512::AID-MPO2>3.0.CO;2-D; Huang S, 2001, EUR J CLIN INVEST, V31, P907, DOI 10.1046/j.1365-2362.2001.00892.x; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; Janoueix-Lerosey I, 2004, ONCOGENE, V23, P5912, DOI 10.1038/sj.onc.1207784; Jensen SJ, 1997, GENOMICS, V42, P126, DOI 10.1006/geno.1997.4714; Judson H, 2000, HUM GENET, V106, P406, DOI 10.1007/s004390000257; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Katoh M, 2004, INT J ONCOL, V25, P529; Katoh M, 2003, INT J ONCOL, V23, P1219; Krona C, 2003, ONCOGENE, V22, P2343, DOI 10.1038/sj.onc.1206324; Letovsky SI, 1998, NUCLEIC ACIDS RES, V26, P94, DOI 10.1093/nar/26.1.94; Maris JM, 1997, EUR J CANCER, V33, P1991, DOI 10.1016/S0959-8049(97)00279-7; Maris JM, 2000, J CLIN ONCOL, V18, P1888, DOI 10.1200/JCO.2000.18.9.1888; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2001, MED PEDIATR ONCOL, V36, P32, DOI 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0; Maris JM, 1996, CANCER RES, V56, P3421; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Mathysen D, 2004, EUR J CANCER, V40, P1255, DOI 10.1016/j.ejca.2004.01.013; McCormack K, 2002, J BIOL CHEM, V277, P13219, DOI 10.1074/jbc.M111465200; Mollet G, 2002, NAT GENET, V32, P300, DOI 10.1038/ng996; Mora J, 2000, J MOL DIAGN, V2, P37, DOI 10.1016/S1525-1578(10)60613-7; Murphy K, 2004, BIOINFORMATICS, V20, P588, DOI 10.1093/bioinformatics/btg466; Nakatani K, 2004, INT J ONCOL, V24, P1407; Nishimura M, 1998, GENOMICS, V49, P69, DOI 10.1006/geno.1998.5213; Ohira M, 2000, ONCOGENE, V19, P4302, DOI 10.1038/sj.onc.1203786; Satge D, 2003, CANCER GENET CYTOGEN, V147, P89, DOI 10.1016/S0165-4608(03)00203-6; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; Shapria SK, 1997, AM J HUM GENET, V61, P642, DOI 10.1086/515520; Spieker N, 2001, GENE CHROMOSOME CANC, V31, P172, DOI 10.1002/gcc.1130.abs; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Thompson PM, 2003, ONCOGENE, V22, P1002, DOI 10.1038/sj.onc.1206211; Thompson PM, 2001, CANCER RES, V61, P679; Van Roy N, 2002, GENE CHROMOSOME CANC, V35, P113, DOI 10.1002/gcc.10034; VANDERDRIFT P, 1995, GENE CHROMOSOME CANC, V14, P35, DOI 10.1002/gcc.2870140107; Wheeler DL, 2004, NUCLEIC ACIDS RES, V32, pD35, DOI 10.1093/nar/gkh073; White PS, 1997, EUR J CANCER, V33, P1957, DOI 10.1016/S0959-8049(97)00311-0; White PS, 2001, MED PEDIATR ONCOL, V36, P37, DOI 10.1002/1096-911X(20010101)36:1<37::AID-MPO1010>3.0.CO;2-L; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520; White PS, 1999, GENOME RES, V9, P978, DOI 10.1101/gr.9.10.978; White PS, 2000, NEUROBLASTOMA, P57; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472	69	125	133	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2684	2694		10.1038/sj.onc.1208306	http://dx.doi.org/10.1038/sj.onc.1208306			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15829979				2022-12-17	WOS:000228356700010
J	Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M				Wischhusen, J; Naumann, U; Ohgaki, H; Rastinejad, F; Weller, M			CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death	ONCOGENE			English	Article						p53; glioma; CP-31398; conformation; drug engineering	WILD-TYPE P53; IN-VITRO; P53-INDUCED APOPTOSIS; CANCER-CELLS; MUTANT P53; DNA-DAMAGE; GENE; EXPRESSION; DRUG; PROTEIN	CP-31398 is a prototype small molecule that stabilizes the active conformation of p53 and promotes p53 activity in cancer cell lines with mutant or wild-type p53. Here, we report that CP-31398 induces p53 reporter gene activity and p21 expression in all of 11 glioma cell lines harboring wild-type or mutant p53, but not in p53-null LN-308 cells. Upon prolonged exposure to CP-31398, all glioma cell lines undergo caspase-independent and bcl-x(L)-insensitive cell death with EC50 concentrations of 10-36 muM. By comparing p53 wild-type U87MG and p53-null LN-308 cells expressing the temperature-sensitive p53(V135A) mutant, we delineate two pathways of CP-31398-induced cell death: an early, p53-dependent pathway that requires (new p53) protein synthesis and a late, p53-independent pathway characterized by aurintricarboxylic acid -sensitive calcium release and epiphenomenal free radical formation. Post-transcriptional repression of p53 synthesis by an intracellularly transcribed short interfering RNA confirmed the presence of these two pathways of cell death. These observations point out some of the liabilities of CP-31398 as a prototype p53-based therapeutic and de. ne a rationale for further refinement of small molecules that specifically target the p53 pathway, but lack the p53-independent effects.	Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany; Int Agcy Res Canc, F-69372 Lyon 08, France; Pfizer Inc, Global Res & Dev, Canc Drug Discovery Grp, Groton, CT 06340 USA	Eberhard Karls University of Tubingen; World Health Organization; International Agency for Research on Cancer (IARC); Pfizer	Weller, M (corresponding author), Univ Tubingen, Sch Med, Dept Neurol, Mol Neurooncol Lab, D-72076 Tubingen, Germany.	michael.weller@uni-tuebingen.de		Weller, Michael/0000-0002-1748-174X				Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Dringen R, 1998, BRAIN RES PROTOC, V2, P223, DOI 10.1016/S1385-299X(97)00047-0; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Glaser T, 1999, ONCOGENE, V18, P5044, DOI 10.1038/sj.onc.1202882; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; JIANG ZY, 1991, LIPIDS, V26, P853, DOI 10.1007/BF02536169; Kaku S, 2001, BIOCHEM BIOPH RES CO, V280, P204, DOI 10.1006/bbrc.2000.4060; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lotem J, 1996, P NATL ACAD SCI USA, V93, P9166, DOI 10.1073/pnas.93.17.9166; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Naumann U, 1998, ONCOGENE, V17, P1567, DOI 10.1038/sj.onc.1202071; Naumann U, 1998, INT J CANCER, V77, P645, DOI 10.1002/(SICI)1097-0215(19980812)77:4<645::AID-IJC27>3.0.CO;2-3; Naumann U, 2001, CANCER RES, V61, P5833; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362; Schmidt F, 2001, EUR J PHARMACOL, V412, P21, DOI 10.1016/S0014-2999(00)00923-7; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang WG, 2003, MOL CELL BIOL, V23, P2171, DOI 10.1128/MCB.23.6.2171-2181.2003; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; WELLER M, 1992, BRAIN RES, V594, P160, DOI 10.1016/0006-8993(92)91043-E; Weller M, 1998, INT J CANCER, V79, P640; Wick W, 1999, J PHARMACOL EXP THER, V289, P1306; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	34	125	129	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8233	8245		10.1038/sj.onc.1207198	http://dx.doi.org/10.1038/sj.onc.1207198			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614447				2022-12-17	WOS:000186541500002
J	Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM				Rodriguez, S; Jafer, O; Goker, H; Summersgill, BM; Zafarana, G; Gillis, AJM; van Gurp, RJHLM; Oosterhuis, JW; Lu, YJ; Huddart, R; Cooper, CS; Clark, J; Looijenga, LHJ; Shipley, JM			Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1	ONCOGENE			English	Article						testicular germ cell tumors of adolescents and adults; isochromosome 12p; amplification; microarray expression profiling; comparative expressed sequence hybridization; candidate genes	COMPARATIVE GENOMIC HYBRIDIZATION; BREAST-CANCER; IN-SITU; C-MYC; IDENTIFICATION; TESTIS; OVERREPRESENTATION; CHROMOSOME-12; TUMORIGENESIS; MICROARRAYS	Gain of 12p material is invariably associated with testicular germ cell tumors (TGCTs) of adolescents and adults, most usually as an isochromosome 12p. We analyzed TGCTs with i(12p) using a global approach to expression profiling targeting chromosomes (comparative expressed sequence hybridization, CESH). This indicated overexpression of genes from 12p11.2-p12.1 relative to testis tissue and fibroblasts. The nonseminoma subtype showed higher levels of expression than seminomas. Notably, 12p11.2-p12.1 is amplified in about 10% of TGCTs and CESH analysis of such amplicon cases showed high levels of overexpression from this region. Microarray analysis, including cDNA clones representing most UniGene clusters from 12p11.2-p12.1, was applied to DNA and RNA from 5 TGCTs with amplification of 12p11.2-p12.1 and seven TGCTs with gain of the entire short arm of chromosome 12. Expression profiles were consistent with the CESH data and overexpression of EST595078, MRPS35 and LDHB at 12p11.2-p12.1 was detected in most TGCTs. High-level overexpression of BCAT1 was specific to nonseminomas and overexpression of genes such as CMAS, EKI1, KRAS2, SURB7 and various ESTs correlated with their amplification. Genes such as CCND2, GLU3, LRP6 and HPH1 at 12p13 were also overexpressed. The overexpressed sequences identified, particularly those in the region amplified, represent candidate genes for involvement in TGCT development.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Erasmus MC Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Josephine Nefkens Inst,Pathol Lab Expt Pathooncol, NL-3000 DR Rotterdam, Netherlands; Inst Canc Res, Sect Paediat Oncol, Sutton SM2 5NG, Surrey, England; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Surrey, England; Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Shipley, JM (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; huddart, robert/0000-0003-3604-1990; Zafarana, Gaetano/0000-0003-1391-4488; Shipley, Janet/0000-0001-6748-8678; Lu, Yong-Jie/0000-0001-6174-6621				ATKIN NB, 1982, LANCET, V2, P1349; BALDINI A, 1990, AM J HUM GENET, V46, P784; Ben-Yosef T, 1998, ONCOGENE, V17, P165, DOI 10.1038/sj.onc.1201939; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Bourdon V, 2002, CANCER RES, V62, P6218; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Hayes DF, 2002, SEMIN ONCOL, V29, P231, DOI 10.1053/sonc.2002.32899; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Lu YJ, 2001, P NATL ACAD SCI USA, V98, P9197, DOI 10.1073/pnas.161272798; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; Olie RA, 1996, BRIT J CANCER, V74, P133, DOI 10.1038/bjc.1996.328; OLIE RA, 1995, GENE CHROMOSOME CANC, V12, P110, DOI 10.1002/gcc.2870120205; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rao PH, 1998, CANCER RES, V58, P4260; Roelofs H, 2000, AM J PATHOL, V157, P1155, DOI 10.1016/S0002-9440(10)64631-7; Rorth M, 2000, SCAND J UROL NEPHROL, V34, P166, DOI 10.1080/00365590050509896; Rosenberg C, 2000, ONCOGENE, V19, P5858, DOI 10.1038/sj.onc.1203950; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Skotheim RI, 2002, CANCER RES, V62, P2359; SUIJKERBUIJK RF, 1993, CANCER GENET CYTOGEN, V70, P85, DOI 10.1016/0165-4608(93)90173-J; Summersgill B, 1998, DIAGN MOL PATHOL, V7, P260, DOI 10.1097/00019606-199810000-00005; Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889; Summersgill B, 1998, BRIT J CANCER, V77, P305, DOI 10.1038/bjc.1998.47; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; von Eyben FE, 2000, ACTA ONCOL, V39, P509, DOI 10.1080/028418600750013438; Windstetter D, 1997, Eur J Med Res, V2, P431; Zafarana G, 2002, CANCER RES, V62, P1822	34	125	130	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1880	1891		10.1038/sj.onc.1206302	http://dx.doi.org/10.1038/sj.onc.1206302			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660824				2022-12-17	WOS:000181678200015
J	Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S				Cruet-Hennequart, S; Maubant, S; Luis, J; Gauduchon, P; Staedel, C; Dedhar, S			alpha(v) integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells	ONCOGENE			English	Article						integrins; ILK; signal transduction; cell cycle; ovarian cancer	FORKHEAD TRANSCRIPTION FACTORS; EXTRACELLULAR-MATRIX; CYCLE PROGRESSION; PROTEIN-KINASE; ALPHA-V-BETA-3 INTEGRINS; GROWTH-FACTOR; BETA-CATENIN; LINE IGROV1; PTEN GENE; ADHESION	Integrins regulate both adhesion and signaling processes involved in proliferation and survival. alpha(v)beta(3) and alpha(v)beta(5) integrins have been shown to mediate cell adhesion and migration. Here we used human ovarian cancer cell lines (IGROV1, SKOV-3) that express alpha(v)beta(3) and alpha(v)beta(5) to study their role in cell proliferation and the signaling pathways involved. We found that alpha(v) integrins regulate cell proliferation through activation of integrin-linked kinase (ILK). An anti-alpha(v)-blocking antibody specifically inhibits the growth of IGROV1 and SKOV-3. The inhibition of cell proliferation involves 043 in IGROV1 cells, and both alpha(v)beta(3) and alpha(v)beta(5) in SKOV-3 cells. The reduced growth rate induced by alpha(v) integrin blockade is linked in both cell lines to G1/S cell cycle arrest. alpha(v) integrin blockade by neutralizing antibody as well as cyclic-RGD peptide caused an inhibition of ILK activity and phosphorylation of PKB/Akt on serine-473 but not on threonine-308, and was accompanied by an increase in p27(Kip1) expression. Overexpression of wild-type ILK rescued the phosphorylation of PKB/Akt on serine-473 in cells treated with anti-alpha(v) antibody. Inhibition of ILK by a pharmacological inhibitor results in inhibition of cell proliferation, PKB/Akt phosphorylation and increase of p27(Kip1). These results demonstrate that alpha(v) integrins regulate ovarian cancer cell proliferation through ILK.	British Columbia Canc Agcy, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp & Hlth Sci Ctr, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada; Ctr Francois Baclesse, UPRES EA 1772, Grp Reg Etud Canc, F-14076 Caen 05, France; Fac Pharm Marseille, UMR CNRS 6032, Lab Biochim & Biol Cellulaire, F-13085 Marseille, France; Univ Bordeaux 2, INSERM, U386, F-33076 Bordeaux, France	British Columbia Cancer Agency; University of British Columbia; University of British Columbia; University of British Columbia; UNICANCER; Centre Francois Baclesse; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Dedhar, S (corresponding author), British Columbia Canc Agcy, Jack Bell Res Ctr, 2660 Oak St, Vancouver, BC V6H 3Z6, Canada.		LUIS, José/M-3071-2013; GAUDUCHON, Pascal/K-6492-2015	Staedel, Cathy/0000-0003-0488-0239; Dedhar, Shoukat/0000-0003-4355-1657				Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Auersperg N, 1998, SEMIN ONCOL, V25, P281; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; CARREIRAS F, 1995, INT J CANCER, V63, P530, DOI 10.1002/ijc.2910630413; Carreiras F, 1999, INT J CANCER, V80, P285; Carreiras F, 1999, GYNECOL ONCOL, V72, P312, DOI 10.1006/gyno.1998.5262; Caruso DA, 2001, CELL DEATH DIFFER, V8, P665, DOI 10.1038/sj.cdd.4400865; Casalini P, 2001, J BIOL CHEM, V276, P12449, DOI 10.1074/jbc.M009732200; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DESHANE J, 1994, GENE THER, V1, P332; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Friedlander DR, 1996, CANCER RES, V56, P1939; Friedrich EB, 2002, J BIOL CHEM, V277, P16371, DOI 10.1074/jbc.M201240200; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gottschalk AR, 2001, CANCER RES, V61, P2105; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hapke S, 2001, J BIOL CHEM, V276, P26340, DOI 10.1074/jbc.M100181200; Hellstrom I, 2001, CANCER RES, V61, P2420; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Hulleman E, 2001, CELL MOL LIFE SCI, V58, P80, DOI 10.1007/PL00000780; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; LEHMANN M, 1994, CANCER RES, V54, P2102; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Li FG, 1999, J CELL SCI, V112, P4589; Liu SC, 2000, J CELL SCI, V113, P3563; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Minaguchi T, 1999, CANCER RES, V59, P6063; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Obata K, 1998, CANCER RES, V58, P2095; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Petitclerc E, 1999, CANCER RES, V59, P2724; PFAFF M, 1994, J BIOL CHEM, V269, P20233; Poulain L, 1998, INT J CANCER, V78, P454, DOI 10.1002/(SICI)1097-0215(19981109)78:4<454::AID-IJC11>3.0.CO;2-6; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Saito M, 2000, INT J CANCER, V85, P160, DOI 10.1002/(SICI)1097-0215(20000115)85:2<160::AID-IJC2>3.3.CO;2-X; Seger D, 2001, J BIOL CHEM, V276, P16998, DOI 10.1074/jbc.M003766200; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; van Leeuwen R L, 1996, Exp Dermatol, V5, P308; Wong NC, 1998, CLIN EXP METASTAS, V16, P50; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	57	125	126	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1688	1702		10.1038/sj.onc.1206347	http://dx.doi.org/10.1038/sj.onc.1206347			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642872				2022-12-17	WOS:000181580500011
J	Reisman, DN; Strobeck, MW; Betz, BL; Sciariotta, J; Funkhouser, W; Murchardt, C; Yaniv, M; Sherman, LS; Knudsen, ES; Weissman, BE				Reisman, DN; Strobeck, MW; Betz, BL; Sciariotta, J; Funkhouser, W; Murchardt, C; Yaniv, M; Sherman, LS; Knudsen, ES; Weissman, BE			Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression	ONCOGENE			English	Article						chromatin remodeling; RB; CD44; tumor suppression	CHROMATIN-REMODELING COMPLEX; SWI-SNF COMPLEX; CENTRAL-NERVOUS-SYSTEM; YEAST SWI/SNF COMPLEX; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; RHABDOID TUMOR; ACTIVE CHROMATIN; BREAST-CANCER	Mammalian cells express two homologs of the SWI2 subunit of the SWI/SNF chromatin-remodeling complex called BRGI and BRM. Whether the SWI/SNF complexes formed by these two subunits perform identical or different functions remains an important question. In this report, we show concomitant down-regulation of BRGI and BRM in six human tumor cell lines. This down-regulation occurs at the level of mRNA abundance. We tested whether BRM could affect aberrant cellular functions attributed to BRGI in tumor cell lines. By transient transfection, we found that BRM can restore RB-mediated cell cycle arrest. induce expression of CD44 protein and suppress Cyclin A expression. Therefore, BRM may be consistently down-regulated with BRGI during neoplastic progression because they share some redundant functions. However, assorted tissues from BRM null/BRG1-positive mice lack CD44 expression, suggesting that BRM-containing SWI/SNF complexes regulate expression of this gene under physiological conditions. Our studies further define the mechanism by which chromatin-remodeling complexes participate in RB-mediated cell cycle arrest and provide additional novel evidence that the functions of SWI/SNF complexes containing BRG1 or BRM are not completely interchangeable.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Inst Pasteur, Dept Biotechnol, CNRS, URA 1644,Unite Virus Oncogenes, F-75724 Paris 15, France	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University System of Ohio; University of Cincinnati; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Weissman, BE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NCI NIH HHS [T32 CA 09156, CA 82525, CA 63176] Funding Source: Medline; NIDCR NIH HHS [DE/CA 12355] Funding Source: Medline; NINDS NIH HHS [NS 39550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063176, T32CA009156, R01CA082525] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039550] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Biegel JA, 2000, CLIN CANCER RES, V6, P2759; Biegel JA, 2000, GENE CHROMOSOME CANC, V28, P31, DOI 10.1002/(SICI)1098-2264(200005)28:1<31::AID-GCC4>3.0.CO;2-Y; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bourachot B, 1999, MOL CELL BIOL, V19, P3931; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; DeCristofaro MF, 2001, J CELL PHYSIOL, V186, P136; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Herrlich P, 1998, CELL ADHES COMMUN, V6, P141, DOI 10.3109/15419069809004470; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Iau PTC, 2001, EUR J CANCER, V37, P300, DOI 10.1016/S0959-8049(00)00378-6; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Krebs JE, 2000, CRIT REV EUKAR GENE, V10, P1; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; LAURENT BC, 1993, COLD SPRING HARB SYM, V58, P257, DOI 10.1101/SQB.1993.058.01.030; LAURENT BC, 1991, P NATL ACAD SCI USA, V88, P2687, DOI 10.1073/pnas.88.7.2687; Lee CH, 1999, P NATL ACAD SCI USA, V96, P12311, DOI 10.1073/pnas.96.22.12311; Lee D, 1999, NATURE, V399, P487, DOI 10.1038/20966; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Nie ZQ, 2000, MOL CELL BIOL, V20, P8879, DOI 10.1128/MCB.20.23.8879-8888.2000; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rosty C, 1998, GENE CHROMOSOME CANC, V21, P82, DOI 10.1002/(SICI)1098-2264(199802)21:2<82::AID-GCC2>3.0.CO;2-3; Santisteban MS, 2000, CELL, V103, P411, DOI 10.1016/S0092-8674(00)00133-1; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Schnitzler GR, 1998, COLD SPRING HARB SYM, V63, P535, DOI 10.1101/sqb.1998.63.535; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Sherman L, 1996, CURR TOP MICROBIOL, V213, P249; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; SumiIchinose C, 1997, MOL CELL BIOL, V17, P5976, DOI 10.1128/MCB.17.10.5976; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Wong AKC, 2000, CANCER RES, V60, P6171; Wu C, 1998, COLD SPRING HARB SYM, V63, P525, DOI 10.1101/sqb.1998.63.525; Wu DY, 2000, J VIROL, V74, P8893, DOI 10.1128/JVI.74.19.8893-8903.2000; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	68	125	132	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2002	21	8					1196	1207		10.1038/sj.onc.1205188	http://dx.doi.org/10.1038/sj.onc.1205188			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850839				2022-12-17	WOS:000173729400007
J	Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA				Saez, C; Japon, MA; Ramos-Morales, F; Romero, F; Segura, DI; Tortolero, M; Pintor-Toro, JA			hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias	ONCOGENE			English	Article						hpttg; pituitary adenomas; oncogene; tumorigenesis; mammary adenocarcinoma; pulmonary adenocarcinoma	RAS MUTATIONS; TUMORS; GENE; PROTEIN; ORIGIN; PTTG	The role of oncogenes in pituitary tumorigenesis remains elusive since few genetic changes have been identified so far in pituitary tumors. Pituitary tumor-transforming gene (pttg) has been recently cloned from rat GH4 pituitary tumor cells. We have previously isolated and characterized hpttg from human thymus, In the present study, we analyse the expression of hpttg mRNA in a series of human pituitary adenomas. We show that hpttg is highly expressed in the majority of pituitary adenomas while only very low levels of mRNA can be detected in normal pituitary gland by Northern blot analysis. hPTTG protein was immunolocalized mainly in the cytoplasm of adenoma cells. Other common extra-cranial malignant tumors were also analysed by immunohistochemistry. Interestingly, strong hPTTG immunoreactivity was detected in most adenocarcinomas of mammary and pulmonary origins.	CSIC, Inst Recursos Nat & Agrobiol, E-41080 Seville, Spain; Hosp Univ Virgen del Rocio, Dept Anat Patol, Seville 41013, Spain; Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS); Virgen del Rocio University Hospital; University of Sevilla	Pintor-Toro, JA (corresponding author), CSIC, Inst Recursos Nat & Agrobiol, Apdo 1052, E-41080 Seville, Spain.		Romero, Francisco/K-2101-2014; IBIS, TUMORIGENESIS/P-3506-2015; Sáez, Carmen/B-9468-2015; Tortolero, Maria/K-5744-2014; Ramos-Morales, Francisco/C-5734-2008; Japón, Miguel A/L-2555-2017; Pintor-Toro, Jose/L-4737-2014	Romero, Francisco/0000-0002-9588-6881; Sáez, Carmen/0000-0002-8600-0508; Tortolero, Maria/0000-0003-1797-9940; Ramos-Morales, Francisco/0000-0002-1151-4547; Japón, Miguel A/0000-0002-5980-5044; Pintor-Toro, Jose/0000-0002-9060-5243				ALEXANDER JM, 1990, J CLIN INVEST, V86, P336, DOI 10.1172/JCI114705; ALVARO V, 1993, J CLIN ENDOCR METAB, V77, P1125, DOI 10.1210/jc.77.5.1125; ASA SL, 1992, ENDOCRINOLOGY, V131, P2083, DOI 10.1210/en.131.5.2083; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CRYNS VL, 1993, J CLIN ENDOCR METAB, V77, P644, DOI 10.1210/jc.77.3.644; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; HERMAN V, 1993, J CLIN ENDOCR METAB, V77, P50, DOI 10.1210/jc.77.1.50; HERMAN V, 1990, J CLIN ENDOCR METAB, V71, P1427, DOI 10.1210/jcem-71-6-1427; KARGA HJ, 1992, J CLIN ENDOCR METAB, V74, P914, DOI 10.1210/jc.74.4.914; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LYONS J, 1990, SCIENCE, V249, P255; MCANDREW J, 1995, ENDOCRINOLOGY, V136, P4479, DOI 10.1210/en.136.10.4479; PEI L, 1994, J CLIN ENDOCR METAB, V78, P842, DOI 10.1210/jc.78.4.842; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SPADA A, 1994, EUR J ENDOCRINOL, V130, P43, DOI 10.1530/eje.0.1300043; Strausberg RL, 1997, NAT GENET, V15, P415, DOI 10.1038/ng0497supp-415; SUMI T, 1993, ENDOCR PATHOL, V4, P95, DOI 10.1007/BF02914458; THAPAR K, 1995, BAILLIERE CLIN ENDOC, V9, P243, DOI 10.1016/S0950-351X(95)80322-X; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhuang ZP, 1997, CANCER RES, V57, P5446	22	125	139	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 23	1999	18	39					5473	5476		10.1038/sj.onc.1202914	http://dx.doi.org/10.1038/sj.onc.1202914			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498901				2022-12-17	WOS:000082718600012
J	Sheikh, MS; Huang, Y; Fernandez-Salas, EA; El-Deiry, WS; Friess, H; Amundson, S; Yin, J; Meltzer, SJ; Holbrook, NJ; Fornace, AJ				Sheikh, MS; Huang, Y; Fernandez-Salas, EA; El-Deiry, WS; Friess, H; Amundson, S; Yin, J; Meltzer, SJ; Holbrook, NJ; Fornace, AJ			The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract	ONCOGENE			English	Article						p53; DNA damage; apoptosis	INDUCED APOPTOSIS; DEATH DOMAIN; FACTOR-ALPHA; P53; TRAIL; IDENTIFICATION; EXPRESSION; KILLER/DR5; PROTEIN; FAMILY	Both DR4 and DR5 have recently been identified as membrane death receptors that are activated by their ligand TRAIL to engage the intracellular apoptotic machinery. TRID (also named as TRAIL-R3) is an antagonist decoy receptor and lacks the cytoplasmic death domain, TRID protects from TRAIL-induced apoptosis by competing with DR4 and DR5 for binding to TRAIL, TRID has been shown to be overexpressed in normal human tissues but not in malignantly transformed cell lines. DR5 is a p53-regulated gene and me have recently reported that DR5 expression is induced in response to genotoxic stress in both a p53-dependent and independent manner (Sheikh et nl., 1998). In the current study, we demonstrate that TRID gene expression is also induced by the genotoxic agents ionizing radiation and methyl methanesulfonate (MR IS) in predominantly p53 mild-type cells, whereas UV-irradiation does not induce TRID gene expression, Consistent with these results, exogenous wild-type p53 also upregulates the expression of endogenous TRID in p53-null cells. Thus, TRID appears to be a p53 target gene that is regulated by genotoxic stress in a p53-dependent manner. Using primary gastrointestinal tract (GIT) tumors and their matching normal tissue, we also demonstrate for the first time that TRID expression is enhanced in primary tumors of the GIT, It is, therefore, possible that TRID overexpressing GIT tumors may gain a selective growth advantage by escaping from TRAIL-induced apoptosis.	NCI, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NIA, Gene Express & Aging Sect, Biol Chem Lab, NIH, Baltimore, MD 21224 USA; NCI, Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Oncol Mol Lab, Philadelphia, PA 19104 USA; Univ Bern, Inselspital, Dept Visceral & Transplantat Surg, CH-3010 Bern, Switzerland; Univ Maryland, Dept Med, GI Div, Baltimore, MD 21201 USA; Baltimore VA Hosp, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Howard Hughes Medical Institute; University of Pennsylvania; University of Bern; University Hospital of Bern; University System of Maryland; University of Maryland Baltimore	Sheikh, MS (corresponding author), NCI, Div Basic Sci, NIH, Rm 5 C09,Bldg 37, Bethesda, MD 20892 USA.		El-Deiry, Wafik/AAJ-6080-2020; Fornace, Albert J/A-7407-2008	El-Deiry, Wafik/0000-0002-9577-8266; Fornace, Albert J/0000-0001-9695-085X	NCI NIH HHS [CA78843, CA77057] Funding Source: Medline; NIDDK NIH HHS [DK47717] Funding Source: Medline; DIVISION OF BASIC SCIENCES - NCI [Z01BC007184] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA077057, R01CA078843] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047717] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; Friedlander P, 1996, J BIOL CHEM, V271, P25468, DOI 10.1074/jbc.271.41.25468; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Guo XZ, 1998, CANCER RES, V58, P753; ISSACS JT, 1994, CURR OPIN ONCOL, V6, P82; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4996; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1998, FEBS LETT, V424, P41, DOI 10.1016/S0014-5793(98)00135-5; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zhan QM, 1996, ONCOGENE, V13, P2287	24	125	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 15	1999	18	28					4153	4159		10.1038/sj.onc.1202763	http://dx.doi.org/10.1038/sj.onc.1202763			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	216FP	10435597				2022-12-17	WOS:000081431000013
J	Jones, N; Dumont, DJ				Jones, N; Dumont, DJ			The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R	ONCOGENE			English	Article						signal transduction; endothelial cells; angiopoietins; Tek/Tie2; receptor tyrosine kinase	GTPASE-ACTIVATING PROTEIN; IRS-1 PTB DOMAIN; TYROSINE KINASE; INSULIN-RECEPTOR; ENDOTHELIAL-CELLS; ADAPTER PROTEIN; TIE2 RECEPTOR; MOLECULAR-CLONING; 2-HYBRID SYSTEM; VASCULAR SYSTEM	Tek/Tie2 is an endothelial cell-specific receptor tyrosine kinase that has been shown to play a role in vascular development of the mouse. Targeted mutagenesis of both Tek and its agonistic ligand, Angiopoietin-1, result in embryonic lethality, demonstrating that the signal transduction pathway(s) mediated by this receptor are crucial for normal embryonic development. In an attempt to identify downstream signaling partners of the Tek receptor, we have used the yeast two-hybrid system to identify phosphotyrosine-dependent interactions. Using this approach, we have identified a novel docking molecule called Dok-R, which has sequence and structural homology to p62(dok) and IRS-3. Mapping of the phospho tyrosine-interaction domain within Dok-R shows that Dok-R interacts with Tek through a PTB domain. Dok-R is coexpressed with Tek in a number of endothelial cell lines. We show that coexpression of Dok-R with activated Tek results in tyrosine phosphorylation of Dok-R and that rasGAP and Nck coimmunoprecipitate with phosphorylated Dok-R. Furthermore, Dok-R is constitutively bound to Crk presumably through the proline rich tail of Dok-R. The cloning of Dok-R represents the first downstream substrate of the activated Tek receptor, and suggests that Tek can signal through a multitude of pathways.	Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Dumont, DJ (corresponding author), Univ Toronto, AMGEN, Toronto, ON M5G 2C1, Canada.							Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Charest A, 1996, J BIOL CHEM, V271, P8424, DOI 10.1074/jbc.271.14.8424; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; DUMONT DJ, 1992, ONCOGENE, V7, P1471; DUMONT DJ, 1995, DEV DYNAM, V203, P80, DOI 10.1002/aja.1002030109; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HENKEMEYER M, 1995, NATURE, V377, P695, DOI 10.1038/377695a0; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; HUANG LW, 1995, ONCOGENE, V11, P2097; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; Koblizek TI, 1997, EUR J BIOCHEM, V244, P774, DOI 10.1111/j.1432-1033.1997.00774.x; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lavan BE, 1997, J BIOL CHEM, V272, P11439; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Matsuda M, 1996, CELL SIGNAL, V8, P335, DOI 10.1016/0898-6568(96)00067-8; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PANDEY A, 1994, J BIOL CHEM, V269, P30154; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rockow S, 1996, ONCOGENE, V12, P2351; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SOSNOWSKI RG, 1993, J CELL BIOL, V121, P113, DOI 10.1083/jcb.121.1.113; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; TANAKA S, 1993, MOL CELL BIOL, V14, P5495; Tang JP, 1997, ONCOGENE, V15, P1823, DOI 10.1038/sj.onc.1201351; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZIEGLER SF, 1993, ONCOGENE, V8, P663	66	125	132	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1097	1108		10.1038/sj.onc.1202115	http://dx.doi.org/10.1038/sj.onc.1202115			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764820				2022-12-17	WOS:000075598400005
J	Chaturvedi, P; Reddy, MVR; Reddy, EP				Chaturvedi, P; Reddy, MVR; Reddy, EP			Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation	ONCOGENE			English	Article						STATs; JAKs; Src kinases; IL-3; myeloid cell proliferation	PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; GRANULOCYTIC DIFFERENTIATION; CYTOKINE; INTERLEUKIN-3; FAMILY; BINDS; GAMMA; LINE	Interaction of IL-3 with its receptor is known to activate STAT-3 via phosphorylation of Tyrosine 701, which facilitates its dimerization and translocation to the nucleus, leading to the transcription of its target genes, In this communication, we have investigated the nature of tyrosine kinases that mediate STAT-3 phosphorylation during IL-3-mediated activation of myeloid cell proliferation, Our results show that interaction of IL-3 with its receptor leads to the activation of c-Src kinase activity, which in turn facilitates the binding of c-Src to STAT-3, This association leads to the phosphorylation of STAT-3, allowing this transcription factor to translocate to the nucleus, Expression of a dominant negative mutant of src (AMSrc) in these cells results in a block to IL-3 mediated phosphorylation of STAT-3, and its ability to bind to DNA, On the other hand, expression of a dominant negative mutant of JAK2 (JTK2KE) had no effect on IL-3-mediated activation of STAT-3. Our results also show that AMSrc does not affect the phosphorylation of JAK2, suggesting that JAK and STAT phosphorylation events are mediated by two independent pathways, Inhibition of c-Src activation by AMSrc, which leads to a block to STAT-3 activation, results in a dramatic inhibition of cell proliferation mediated by IL-3, Howe,er, expression of AMSrc does not activate apoptotic pathways, In contrast, expression of JAK2KE results in accelerated apoptosis of 32Dc13 cells grown in the absence of IL-3 with concomitant down-regulation of Erk-2 kinase activity. These results suggest that Src family kinases mediate the phosphorylation of STATs and play a critical role in signal transduction pathways associated with myeloid cell proliferation while JAK kinases mediate the activation of Erk-2 pathway which appears to provide antiapoptotic signals, Thus the activation of JAKs and STATs appear to be two independent but related events, which dictate two separate biological outcomes, the combination of which results in proliferation and survival of myeloid precursor cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA68239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; Darnell JE, 1996, RECENT PROG HORM RES, V51, P391; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Gaozza E, 1997, ONCOGENE, V15, P3127, DOI 10.1038/sj.onc.1201575; Giordano V, 1997, J IMMUNOL, V158, P4097; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Kotenko SV, 1996, J BIOL CHEM, V271, P17174, DOI 10.1074/jbc.271.29.17174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEHMANN J, 1994, J IMMUNOL, V153, P165; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P5133; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROVERA G, 1987, ONCOGENE, V1, P29; SACHS L, 1994, P SOC EXP BIOL MED, V206, P170; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Watanabe S, 1996, J ALLERGY CLIN IMMUN, V98, pS183, DOI 10.1016/S0091-6749(96)70065-9; Watanabe Sumiko, 1997, Leukemia (Basingstoke), V11, P76; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	39	125	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1749	1758		10.1038/sj.onc.1201972	http://dx.doi.org/10.1038/sj.onc.1201972			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582023				2022-12-17	WOS:000072807600013
J	Erber, R; Conradt, C; Homann, N; Enders, C; Finckh, M; Dietz, A; Weidauer, H; Bosch, FX				Erber, R; Conradt, C; Homann, N; Enders, C; Finckh, M; Dietz, A; Weidauer, H; Bosch, FX			TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer	ONCOGENE			English	Article						TP53; mutation types; clinical course; head and neck cancer	HUMAN P53 MUTANTS; COLORECTAL-CANCER; GENE; PROTEIN; EXPRESSION; TUMORS; GAIN; TRANSACTIVATION; PROGRESSION; SURVIVAL	Recent studies have suggested that different mutation types within the core domain of the tumour suppressor protein p53, i.e. DNA contact mutations and structural mutations, confer different biological properties, We have analysed in 86 head and neck squamous cell carcinomas (HNSCC), whether these p53 mutation types have a differential clinical impact, Thirty-seven missense mutations were identified, Thirteen of these (36%) were DNA contact mutations, occurring in the L3 loop, in the H2 loop sheet helix motif, in the S10 beta strand and in Zinc binding residues, Microsatellite marker analysis revealed a selective association between these mutations and the loss of wild-type alleles (100% LOH vs 50% LOH in tumours with structural mutations; P=0.0034, Fisher's exact, 2-tailed), In comparison to structural mutations or to the absence of mutations in the core domain, DNA contact mutations were associated with higher tumour stages (84.6% vs 62%), a higher incidence of lymph node metastasis (91.7% vs 56%; P=0.014, Fisher's exact, 2-tailed), a shortened recurrence-free survival (8.1 months vs 23.7 months, P=0.047, log rank test) and overall survival (11 months vs 29.2 months; P=0.003, log rank test), The latter was also the case when only stage IV tumours were analysed (P=0.0055, log rank test), These data indicate that in HNSCC, TP53 DNA contact mutations confer a strong selection pressure to eliminate mild-type alleles, and that they result in an accelerated tumour progression and reduced therapeutic responsiveness.	Heidelberg Univ, Hals Nasen Ohren Klin, Mol Biol Lab, D-69120 Heidelberg, Germany; Heidelberg Univ, Inst Med Biometrie, D-69120 Heidelberg, Germany; Klinikum Buch, Hals Nasen Ohren Klin, D-13122 Berlin, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Heidelberg Univ, Hals Nasen Ohren Klin, Mol Biol Lab, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Erber, Ralf/B-6790-2008; Erber, Ralf/AAF-3002-2020					Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; AHOMADEGBE JC, 1995, ONCOGENE, V10, P1217; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BOYLE JO, 1993, CANCER RES, V53, P4477; BRACHMAN DG, 1992, CANCER RES, V52, P4832; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FORRESTER K, 1995, ONCOGENE, V10, P2103; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; GOH HS, 1995, CANCER RES, V55, P5217; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; HSIAO M, 1994, AM J PATHOL, V145, P702; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN JY, 1995, ONCOGENE, V10, P2387; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NEES M, 1993, CANCER RES, V53, P4189; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; ROLLEY N, 1995, ONCOGENE, V11, P763; SODER AI, 1995, CANCER RES, V55, P5030; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041	27	125	126	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	1998	16	13					1671	1679		10.1038/sj.onc.1201690	http://dx.doi.org/10.1038/sj.onc.1201690			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582015				2022-12-17	WOS:000072807600005
J	Blagosklonny, MV				Blagosklonny, MV			Loss of function and p53 protein stabilization	ONCOGENE			English	Review						p53; stabilization; mutant; transactivating function	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; MUTANT P53; SV40-TRANSFORMED CELLS; TRANSFORMED-CELLS; BREAST-CANCER; METABOLIC STABILIZATION; ACTIVATING MUTATIONS; DNA-BINDING; T-ANTIGEN	Wild-type (wt) p53 protein is rapidly degraded, has a short half-life and low intracellular levels. Stabilization of wt p53 protein following an appropriate stimulus (for example DNA damage) is a physiological regulation to increase function. Tn contrast, stabilization of p53 protein in the absence of a stimulus is always a hallmark of loss of function secondary to a mutation, or interaction with viral or cellular oncoproteins. It is generally accepted that stability of p53 protein depends on its intrinsic biochemical properties such as conformation or protein/protein interactions. However, I will discuss evidence that the stability of p53 is not a consequence of its intrinsic properties, but instead is determined by feedback control of its function. In the absence of an appropriate stimulus, a cell needs to keep p53 levels low, since increased levels can lead to apoptosis. To precisely regulate p53 levels, a cell must sense its level; and sensing its transactivating function, is the simplest way to sense p53. Following an appropriate stimulus (for example, DIVA damage), the cell senses a state of 'relative' p53 deficiency and adapts by reducing p53 degradation. When the state of p53 deficiency is a consequence of a mutation or interaction with viral oncoproteins, the cell does not sense p53, and again attempts to adapt by reducing p53 degradation. However, in the latter case, the increase in levels does not restore function, and the adaptation continues until degradation of p53 protein is maximally inhibited. In this case, no further inhibition of degradation is possible after DNA-damage or pharmacological inhibition of proteasomes. Thus lack of wt p53 function always results in increased p53 levels and nonregulation.			Blagosklonny, MV (corresponding author), NCI,MED BRANCH,NIH,BLDG 10,BETHESDA,MD 20892, USA.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARTEK J, 1990, ONCOGENE, V5, P893; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; BRAITHWAITE A, 1989, J VIROL, V63, P1782; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEITRICH C, 1996, P NATL ACAD SCI USA, V93, P10815; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DEPPERT W, 1989, CURR TOP MICROBIOL, V144, P77; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453; ELLEDGE RM, 1994, CANCER RES, V54, P3752; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HALL PA, 1991, LANCET, V338, P513, DOI 10.1016/0140-6736(91)90586-E; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUBBUTAT MH, 1997, MOL CELL BIOL, V17, P4680; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; Maki CG, 1996, CANCER RES, V56, P2649; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATHESWARAN S, 1995, GENE DEV, V96, P2143; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; REIHSAUS E, 1990, ONCOGENE, V5, P137; ROLLEY N, 1995, ONCOGENE, V11, P763; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SRIVASTAVA S, 1992, ONCOGENE, V7, P987; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TISHLER RB, 1995, CANCER RES, V55, P6021; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOJTESEK B, 1993, J CELL SCI, V105, P607; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZHANG W, 1994, ONCOGENE, V9, P2513; Zhang WL, 1997, ONCOGENE, V14, P255, DOI 10.1038/sj.onc.1200841	67	125	127	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 16	1997	15	16					1889	1893		10.1038/sj.onc.1201374	http://dx.doi.org/10.1038/sj.onc.1201374			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YA872	9365234				2022-12-17	WOS:A1997YA87200002
J	Li, SN; Chang, YS; Liu, ST				Li, SN; Chang, YS; Liu, ST			Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus	ONCOGENE			English	Article						Epstein-Barr virus; BNLF1; latent membrane protein	NASOPHARYNGEAL CARCINOMA; MAMMALIAN-CELLS; BNLF-1 GENE; TRANSFORMATION; LYMPHOCYTES; EXPRESSION; DNA; REPLICATION; INFECTION; PLASMIDS	A previous study has shown that the BNLF1 of Epstein-Barr virus (EBV),isolated from a nasopharyngeal carcinoma biopsy (BNLF1-1510), was able to transform Balb/3T3 cells,On the other hand, BNLF1 of a prototype virus B95-8 (BNLF1-958) was not transforming unless the gene was transcribed from a strong promoter, In this study, we have generated chimeric BNLF1 by exchanging the DNA fragments between BNLF1-1510 and BNLF1-958 and examined their expression and transformation ability in Balb/3T3 cells, Results showed that transformation of Balb/3T3 cells by BNLF1-1510 was not due to the excessive expression of the gene, Transfection of Balb/3T3 cells with chimeric BNLF1 showed that the genes with 3' 453 bp sequence of BNLF1-1510 were oncogenic to the cells, Study also revealed that changing the numbers of the 33 bp repeats in the 3' region of the two BNLF1s did not affect the transformation characteristics. On the other hand, deletion of a 30 bp sequence of BNLF1-958, which is absent in BNLF1-1510, changed the gene oncogenic to oncogenic and insertion of sequence into BNLF1-1510 abolished the transformation ability, BNLF1 without this 30 bp sequence was also found in the tumours of other EBV-related neoplastic disease, suggesting that absence of this 30 bp sequence in BNLF1 may be associated with the oncogenesis of these diseases.	CHANG GUNG COLL MED & TECHNOL,DEPT IMMUNOL & MICROBIOL,GENET MOLEC LAB,TAYUAN 333,TAIWAN; NATL YANG MING UNIV,GRAD INST MICROBIOL & IMMUNOL,TAIPEI 112,TAIWAN	Chang Gung University; National Yang Ming Chiao Tung University								BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BROUSSET P, 1994, BLOOD, V84, P2447; CHANG YS, 1995, INT J CANCER, V62, P673, DOI 10.1002/ijc.2910620605; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN ML, 1995, VIRUS RES, V37, P75; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GRAHAM F, 1973, VIROLOGY, V52, P452; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUEN DS, 1995, ONCOGENE, V10, P549; JENG KCG, 1994, J CLIN MICROBIOL, V32, P28, DOI 10.1128/JCM.32.1.28-31.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KIEFF E, 1990, VIROLOGY, P1889; KNECHT H, 1995, ONCOGENE, V10, P523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALS G, 1995, CELL, V80, P387; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1981, CANCER RES, V41, P4226; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SU IJ, 1991, BLOOD, V77, P799; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WALLING DM, 1995, J INFECT DIS, V171, P1122, DOI 10.1093/infdis/171.5.1122; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	47	125	137	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2129	2135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668338				2022-12-17	WOS:A1996UP28300011
J	ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C				ROUSSELOT, P; HARDAS, B; PATEL, A; GUIDEZ, F; GAKEN, J; CASTAIGNE, S; DEJEAN, A; DETHE, H; DEGOS, L; FARZANEH, F; CHOMIENNE, C			THE PML-RAR-ALPHA GENE-PRODUCT OF THE T(1517) TRANSLOCATION INHIBITS RETINOIC ACID-INDUCED GRANULOCYTIC DIFFERENTIATION AND MEDIATED TRANSACTIVATION IN HUMAN MYELOID CELLS	ONCOGENE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA; MAMMALIAN-CELLS; T(15-17) TRANSLOCATION; RESPONSIVE ELEMENT; EXPRESSION; PROTEINS; THERAPY; INVITRO; BINDING	Acute promyelocytic leukemia (APL) is characterized by an arrest of granulocytic differentiation and a reciprocal t(15;17) translocation fusing the PML gene to the retinoic acid receptor alpha (RAR alpha) gene. PML was recently identified as a potential transcription factor. In non hematopoietic cells, the transfected PML-RAR alpha product binds all trans retinoic acid and exhibits altered transactivating properties when compared with RAR alpha. A major question raised by these observations is whether PML-RAR alpha contributes to the inhibition of myeloid differentiation. We find that in myeloid cell lines responsive to retinoic acid, PML-RAR alpha blocks retinoic acid mediated transactivation and totally abrogates the retinoic acid mediated granulocytic differentiation. These findings strongly suggest that PML-RAR alpha may, by blocking normal retinoic acid dependent myeloid differentiation, participate in the leukemogenesis of APL. The fact that high doses of all-trans retinoic acid relieve the inhibitory effect of PML-RAR alpha corroborates the therapeutic effect of all-trans retinoic acid in APL patients.	KINGS COLL,SCH MED & DENT,MOLEC MED UNIT,LONDON,ENGLAND; INST PASTEUR,INSERM,U163,PARIS,FRANCE; HOP ST LOUIS,SERV CLIN MALAD SANG,PARIS,FRANCE; INST HEMATOL,UPR 43,PARIS,FRANCE; LAB BIOL CELLULAIRE HEMATOPOIET,PARIS,FRANCE	University of London; King's College London; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite			Dejean, Anne/L-5145-2018; Guidez, Fabien/P-4220-2019; Farzaneh, Farzin/B-4902-2009; Guidez, Fabien/B-3750-2009	Guidez, Fabien/0000-0003-1380-4473; Farzaneh, Farzin/0000-0002-9275-2415; 				ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BREITMAN TR, 1981, BLOOD, V57, P1000; BREITMAN TR, 1983, CANCER SURV, V2, P265; CASTAIGNE S, 1990, BLOOD, V76, P1704; CASTAIGNE S, 1992, BLOOD, V79, P3110; CHEN Z, 1993, EMBO J, V12, P111; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHOMIENNE C, 1990, LEUKEMIA, V4, P802; CHOMIENNE C, 1989, LANCET, V1, P746; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DEGOS L, 1990, LANCET, V11, P1140; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRATAS C, 1993, LEUKEMIA, V7, P1156; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; ITANI T, 1987, GENE, V56, P267; JONES ME, 1978, AM J MED, V75, P673; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LARSON RA, 1984, AM J MED, V76, P827, DOI 10.1016/0002-9343(84)90994-X; LEFEBVRE P, 1991, LEUKEMIA, V5, P1054; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; NERVI C, 1992, CANCER RES, V52, P3687; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; SAKASHITA A, 1993, BLOOD, V81, P1009; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	44	125	127	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					545	551						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248	8290265				2022-12-17	WOS:A1994MW24800022
J	RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW				RAO, GN; LASSEGUE, B; GRIENDLING, KK; ALEXANDER, RW			HYDROGEN-PEROXIDE STIMULATES TRANSCRIPTION OF C-JUN IN VASCULAR SMOOTH-MUSCLE CELLS - ROLE OF ARACHIDONIC-ACID	ONCOGENE			English	Article								We reported previously that hydrogen peroxide induces DNA synthesis in rat aortic smooth muscle (RASM) cells. In the present paper we studied the mechanism by which hydrogen peroxide induces c-jun mRNA, an early response gene whose activation is required for mitogen-stimulated cell growth. Hydrogen peroxide induced c-jun mRNA in growth-arrested RASM cells in a time dependent manner. This stimulation was significantly inhibited by mepacrine, a phospholipase A2 (PLA2) inhibitor. Arachidonic acid, a PLA2 product, also increased c-jun mRNA with a time course similar to that of hydrogen peroxide. The increases in c-jun mRNA induced by hydrogen peroxide and arachidonic acid were significantly reduced (55%) by down-regulation of protein kinase C with a phorbol ester. Furthermore, the effect of hydrogen peroxide on c-jun mRNA was also reduced by NDGA, an inhibitor of the lipoxygenase-cytochrome P450 monooxygenase system, suggesting that metabolism of arachidonic acid through this pathway is required for the induction of c-jun mRNA by oxidants. Both hydrogen peroxide and arachidonic acid significantly increased c-jun transcription as demonstrated by nuclear run-on assays. Together these observations suggest that: (1) the induction of c-jun mRNA by hydrogen peroxide is mediated by PLA2-dependent arachidonic acid release and metabolism through the lipoxygenase-cytochrome P450 mono-oxygenase system; (2) PKC appears to be involved in this signaling pathway and (3) the induction of c-jun mRNA by hydrogen peroxide in RASM cells is due to increased transcription.			RAO, GN (corresponding author), EMORY UNIV, SCH MED, DIV CARDIOL, ATLANTA, GA 30322 USA.			Griendling, Kathy/0000-0002-9456-8582; Lassegue, Bernard/0000-0003-4924-6506				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AUWERX J, 1992, ONCOGENE, V7, P2271; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BRIGHTMAN AO, 1992, BIOCHIM BIOPHYS ACTA, V1105, P109, DOI 10.1016/0005-2736(92)90168-L; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CERUTTI PA, 1991, CANCER CELL-MON REV, V3, P1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOPER DR, 1989, BIOCHEM BIOPH RES CO, V161, P327, DOI 10.1016/0006-291X(89)91600-8; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEUTSCH PJ, 1988, P NATL ACAD SCI USA, V85, P7922, DOI 10.1073/pnas.85.21.7922; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FORCE T, 1991, J BIOL CHEM, V266, P6650; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUY GR, 1993, J BIOL CHEM, V268, P2141; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HOEFFLER JP, 1989, MOL ENDOCRINOL, V3, P868, DOI 10.1210/mend-3-5-868; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; KARIN M, 1991, HORMONAL CONTROL REG, P235; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LARSSON R, 1988, J BIOL CHEM, V263, P17452; LARSSON R, 1989, CANCER RES, V49, P5627; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MURAKAMI Y, 1991, P NATL ACAD SCI USA, V88, P3947, DOI 10.1073/pnas.88.9.3947; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; PALUMBO EJ, 1992, BIOCHEM BIOPH RES CO, V187, P1439, DOI 10.1016/0006-291X(92)90463-U; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RUDLAND PS, 1977, BIOCHEM BIOPH RES CO, V75, P556, DOI 10.1016/0006-291X(77)91508-X; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SHIBANUMA M, 1988, J CELL PHYSIOL, V136, P379, DOI 10.1002/jcp.1041360224; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAVO P, 1980, BLOOD VESSELS, V17, P110; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; TSUNAWAKI S, 1986, J BIOL CHEM, V261, P1563	61	125	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1993	8	10					2759	2764						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378085				2022-12-17	WOS:A1993LX34300017
J	MORRIS, JF; MADDEN, SL; TOURNAY, OE; COOK, DM; SUKHATME, VP; RAUSCHER, FJ				MORRIS, JF; MADDEN, SL; TOURNAY, OE; COOK, DM; SUKHATME, VP; RAUSCHER, FJ			CHARACTERIZATION OF THE ZINC FINGER PROTEIN ENCODED BY THE WT1 WILMS-TUMOR LOCUS	ONCOGENE			English	Article							HUMAN CHROMOSOME-11; MAMMALIAN-CELLS; BINDING; GENE; FOS; DELETION; GROWTH; JUN; DIFFERENTIATION; PURIFICATION	We analysed the biochemical properties of the transcription factor encoded by the putative tumor-suppressor gene present at the WT1 Wilms' tumor locus. A gene containing the full-length amino acid coding sequence of human wt1 was reconstructed from synthetic oligonucleotides and cloned into expression vectors for in vitro and in vivo protein synthesis. Polyclonal rabbit antibodies specific for the WT1 protein were raised to an Escherichia coli-produced 91 amino acid N-terminal segment and to a 136 amino acid C-terminal segment, which contains the zinc finger domain. WT1 produced by in vitro translation migrated as a 52 kDa protein on sodium dodecylsulfate-polyacrylamide gels and bound to the EGR consensus sequence in gel-retardation assays. Expression of the wt1 gene via transient transfection in COS-1 cells revealed a 52 kDa protein which was immunoprecipitated by both the N-terminal- and C-terminal-specific antisera. Immunofluorescence studies of wt1-transfected COS-1 cells revealed that the WT1 protein was localized to the nucleus. Metabolic labeling with [P-32]orthophosphate failed to reveal significant phosphorylation of the WT1 protein in COS-1 cells. Two immunoreactive WT polypeptides of 52 and 54kDa were observed in murine embryonic stem cells and COS-1 kidney cells and may represent previously identified splicing variants of WT1. These antisera should be useful in characterizing the structure and function of the WT1 protein in human Wilms' tumor specimens.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	The Wistar Institute; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009, R01CA023413] Funding Source: NIH RePORTER; NCI NIH HHS [CA-52009, CA-47983-04, CA-23413] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1701; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; DILLON PJ, 1990, BIOTECHNIQUES, V9, P298; DILLON PJ, 1990, J VIROL, V64, P4428, DOI 10.1128/JVI.64.9.4428-4437.1990; FEARON ER, 1984, NATURE, V309, P176, DOI 10.1038/309176a0; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P184; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; MADDEN SL, 1991, IN PRESS SCIENCE; MATSUNAGA E, 1981, HUM GENET, V57, P231; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; ORKIN SH, 1984, NATURE, V309, P172, DOI 10.1038/309172a0; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1984, NATURE, V309, P174, DOI 10.1038/309174a0; RICCARDI VM, 1978, PEDIATRICS, V61, P604; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0	33	125	133	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2339	2348						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1662794				2022-12-17	WOS:A1991GX73500024
J	MILNER, J; WATSON, JV				MILNER, J; WATSON, JV			ADDITION OF FRESH MEDIUM INDUCES CELL-CYCLE AND CONFORMATION CHANGES IN P53, A TUMOR SUPPRESSOR PROTEIN	ONCOGENE			English	Article									MRC, MED RES COUNCIL CTR, CLIN ONCOL UNIT, CAMBRIDGE, ENGLAND	UK Research & Innovation (UKRI); Medical Research Council UK (MRC)	MILNER, J (corresponding author), UNIV CAMBRIDGE, DEPT PATHOL, CAMBRIDGE, ENGLAND.							BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; COOK A, 1990, IN PRESS BR J CANCER; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GAMBLE J, 1988, VIROLOGY, V162, P452, DOI 10.1016/0042-6822(88)90486-2; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KARN J, 1989, ONCOGENE, V4, P773; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; MILNER J, 1987, ONCOGENE, V1, P453; MILNER J, 1981, VIROLOGY, V112, P785, DOI 10.1016/0042-6822(81)90327-5; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980; ROVINSKI B, 1988, ONCOGENE, V2, P445; SMITH PJ, 1985, EXP CELL RES, V159, P37, DOI 10.1016/S0014-4827(85)80035-5; STURZBECHER HW, 1987, ONCOGENE, V1, P201; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1987, NATURE, V325, P741, DOI 10.1038/325741a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	41	125	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1990	5	11					1683	1690						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EL401	2176282				2022-12-17	WOS:A1990EL40100011
J	ZHANG, X; SILVA, E; GERSHENSON, D; HUNG, MC				ZHANG, X; SILVA, E; GERSHENSON, D; HUNG, MC			AMPLIFICATION AND REARRANGEMENT OF C-ERB B-PROTO-ONCOGENES IN CANCER OF HUMAN FEMALE GENITAL-TRACT	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT TUMOR BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT GYNECOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA045265] Funding Source: NIH RePORTER; NCI NIH HHS [CA 45265] Funding Source: Medline; NCRR NIH HHS [RR-5511] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BERGER MS, 1988, CANCER RES, V48, P1238; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; HUNG MC, 1986, BIOCHEM BIOPH RES CO, V141, P1109, DOI 10.1016/S0006-291X(86)80158-9; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HUNG MC, 1986, UCLA S MOL CELLULAR, V40, P391; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RAINES MA, 1985, P NATL ACAD SCI USA, V82, P2287, DOI 10.1073/pnas.82.8.2287; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SEBBA K, 1985, P NATL ACAD SCI USA, V82, P6497; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STECK PA, 1988, CANCER RES, V48, P5433; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; ZHOU DJ, 1987, CANCER RES, V47, P6123	33	125	129	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1989	4	8					985	989						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AJ297	2569708				2022-12-17	WOS:A1989AJ29700006
J	Deng, SJ; Chen, HY; Ye, Z; Deng, SC; Zhu, S; Zeng, Z; He, C; Liu, ML; Huang, K; Zhong, JX; Xu, FY; Li, Q; Liu, Y; Wang, CY; Zhao, G				Deng, Shi-jiang; Chen, Heng-yu; Ye, Zeng; Deng, Shi-chang; Zhu, Shuai; Zeng, Zhu; He, Chi; Liu, Ming-liang; Huang, Kang; Zhong, Jian-xin; Xu, Feng-yu; Li, Qiang; Liu, Yang; Wang, Chun-you; Zhao, Gang			Hypoxia-induced LncRNA-BX111 promotes metastasis and progression of pancreatic cancer through regulating ZEB1 transcription	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; LONG NONCODING RNAS; CELLS; PROLIFERATION; HIF-1-ALPHA; INVASION; YB-1; CONTRIBUTES; EXPRESSION; MIGRATION	The contribution of long noncoding RNAs (lncRNAs) to pancreatic cancer progression and the regulatory mechanisms of their expression are attractive areas. In the present study, the overexpression of lncRNA-BX111887 (BX111) in pancreatic cancer tissues was detected by microarray and further validated in a cohort of pancreatic cancer tissues. We further demonstrated that knockdown or overexpression of BX111 dramatically repressed or enhanced proliferation and invasion of pancreatic cancer cells. Mechanically, BX111 activated transcription of ZEB1, a key regulator for epithelia-mesenchymal transition (EMT), via recruiting transcriptional factor Y-box protein (YB1) to its promoter region. Moreover, we revealed that BX111 transcription was induced by hypoxia-inducible factor (HIF-1 alpha) in response to hypoxia. In addition, BX111 contributed to the hypoxia- induced EMT of pancreatic cells by regulating expression of ZEB1 and its downstream proteins E-cadherin and MMP2. Coincidence with in vitro results, BX111 depletion effectively inhibited growth and metastasis of xenograft tumor in vivo. The clinical samples of pancreatic cancer further confirmed a positive association between BX111 and ZEB1. Moreover, high BX111 expression was correlated with late TNM stage, lymphatic invasion and distant metastasis, as well as short overall survival time in patients. Taken together, our findings implicate a hypoxia- induced lncRNA contributes to metastasis and progression of pancreatic cancer, and suggest BX111 might be applied as a potential biomarker and therapeutic target for pancreatic cancer.	[Deng, Shi-jiang; Chen, Heng-yu; Ye, Zeng; Deng, Shi-chang; Zhu, Shuai; Zeng, Zhu; He, Chi; Liu, Ming-liang; Huang, Kang; Zhong, Jian-xin; Xu, Feng-yu; Li, Qiang; Liu, Yang; Wang, Chun-you; Zhao, Gang] Huazhong Univ Sci & Technol, Union Hosp, Dept Pancreat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Dept Pancreat Surg, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.	gangzhao@hust.edu.cn	fuliyun_new, fuliyun_new/AAZ-4437-2020	Huang, Kang/0000-0003-1169-598X	National Science Foundation Committee (NSFC) of China [81372666, 81672406, 81502076]	National Science Foundation Committee (NSFC) of China(National Natural Science Foundation of China (NSFC))	This study was supported from the National Science Foundation Committee (NSFC) of China (Grant number: 81372666 and 81672406 to Gang Zhao; No. 81502076 to Shi-chang Deng)	Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cheng YT, 2015, ONCOTARGET, V6, P10840, DOI 10.18632/oncotarget.3450; Chou CC, 2015, ONCOTARGET, V6, P8271, DOI 10.18632/oncotarget.3186; Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642; Deng SC, 2015, ONCOTARGET, V6, P39661, DOI 10.18632/oncotarget.5350; Evdokimova V, 2006, CELL CYCLE, V5, P1143, DOI 10.4161/cc.5.11.2784; Evdokimova V, 2009, CELL CYCLE, V8, P2901, DOI 10.4161/cc.8.18.9537; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gomez-Maldonado L, 2015, ONCOGENE, V34, P2609, DOI 10.1038/onc.2014.200; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jooste V, 2016, INT J CANCER, V139, P1073, DOI 10.1002/ijc.30166; Kang SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112754; Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Krzywinski M, 2013, NAT METHODS, V10, P1139, DOI 10.1038/nmeth.2738; Lau E, 2014, NAT REV GENET, V15, DOI 10.1038/nrg3795; Lei JJ, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-66; Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008; Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830; McCarty G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119837; Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Salnikov AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046391; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Sun YW, 2014, BRIT J CANCER, V111, P2131, DOI 10.1038/bjc.2014.520; Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008; Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010; Zhan HX, 2016, CANCER LETT, V374, P261, DOI 10.1016/j.canlet.2016.02.018; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zhang WC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116634; Zhou KR, 2017, NUCLEIC ACIDS RES, V45, pD43, DOI 10.1093/nar/gkw965; Zhu Y, 2016, J CELL MOL MED, V20, P688, DOI 10.1111/jcmm.12769	38	124	133	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5811	5828		10.1038/s41388-018-0382-1	http://dx.doi.org/10.1038/s41388-018-0382-1			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29970904				2022-12-17	WOS:000448943100001
J	Pure, E; Blomberg, R				Pure, Ellen; Blomberg, Rachel			Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics	ONCOGENE			English	Review							DIPEPTIDYL-PEPTIDASE-IV; PHASE-II TRIAL; FAP-TARGETING IMMUNOLIPOSOMES; MEMBRANE-ASSOCIATED PROTEASES; MESENCHYMAL STEM-CELLS; ALPHA-BASED VACCINES; STROMAL CELLS; TUMOR MICROENVIRONMENT; ANTITUMOR IMMUNITY; SERINE-PROTEASE	Fibroblast activation protein (FAP) is a cell-surface serine protease that acts on various hormones and extracellular matrix components. FAP is highly upregulated in a wide variety of cancers, and is often used as a marker for pro-tumorigenic stroma. It has also been proposed as a molecular target of cancer therapies, and, especially in recent years, a great deal of research has gone into design and testing of diverse FAP-targeted treatments. Yet despite this growing field of research, our knowledge of FAP's basic biology and functional roles in various cancers has lagged behind its use as a tumor-stromal marker. In this review, we summarize and analyze recent advances in understanding the functions of FAP in cancer, most notably its prognostic value in various tumor types, cellular effects on various cell types, and potential as a therapeutic target. We highlight outstanding questions in the field, the answers to which could shape preclinical and clinical studies of FAP.	[Pure, Ellen; Blomberg, Rachel] Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Pure, E (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.	epure@upenn.edu			NATIONAL CANCER INSTITUTE [R01CA141144, R01CA180070, R21CA169741] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA141144, R01 CA180070, R21 CA169741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackermann AM, 2016, MOL METAB, V5, P233, DOI 10.1016/j.molmet.2016.01.002; Aertgeerts K, 2005, J BIOL CHEM, V280, P19441, DOI 10.1074/jbc.C500092200; Akinboye ES, 2016, PROSTATE, V76, P703, DOI 10.1002/pros.23162; AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; Arnold JN, 2014, CANCER IMMUNOL RES, V2, P121, DOI 10.1158/2326-6066.CIR-13-0150; Augoff K, 2014, ONCOL REP, V31, P2820, DOI 10.3892/or.2014.3162; Avery D, 2018, MATRIX BIOL, V67, P90, DOI 10.1016/j.matbio.2017.12.003; Bainbridge TW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12900-8; Baird SK, 2015, APOPTOSIS, V20, P1483, DOI 10.1007/s10495-015-1166-5; Baird SK, 2015, CLIN EXP METASTAS, V32, P507, DOI 10.1007/s10585-015-9723-4; Brennen WN, 2014, PROSTATE, V74, P1308, DOI 10.1002/pros.22847; Brunker P, 2016, MOL CANCER THER, V15, P946, DOI 10.1158/1535-7163.MCT-15-0647; Busek P, 2016, TUMOR BIOL, V37, P13961, DOI 10.1007/s13277-016-5274-9; Busek P, 2016, PANCREATOLOGY, V16, P829, DOI 10.1016/j.pan.2016.06.001; Busek P, 2015, HISTOCHEM CELL BIOL, V143, P497, DOI 10.1007/s00418-014-1292-0; Chen LL, 2017, BIOCHEM BIOPH RES CO, V487, P8, DOI 10.1016/j.bbrc.2017.03.039; Chen MH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14421; Christiansen VJ, 2007, ARCH BIOCHEM BIOPHYS, V457, P177, DOI 10.1016/j.abb.2006.11.006; Chung KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088772; Coppage AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151269; Cui YH, 2016, ONCOL REP, V35, P2952, DOI 10.3892/or.2016.4637; Deng LJ, 2017, J MED CHEM, V60, P5320, DOI 10.1021/acs.jmedchem.6b01755; Ding LX, 2014, ONCOL LETT, V7, P699, DOI 10.3892/ol.2014.1788; Du H, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0147-z; Dunshee DR, 2016, J BIOL CHEM, V291, P5986, DOI 10.1074/jbc.M115.710582; Dvorakova P, 2017, J MED CHEM, V60, P8385, DOI 10.1021/acs.jmedchem.7b00767; Eager RM, 2009, CLIN ONCOL-UK, V21, P464, DOI 10.1016/j.clon.2009.04.007; Eager RM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-263; Errarte P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169105; Fan MH, 2016, J BIOL CHEM, V291, P8070, DOI 10.1074/jbc.M115.701433; Fang JX, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.7; Fang JX, 2016, INT J CANCER, V138, P1013, DOI 10.1002/ijc.29831; Feng XW, 2017, INT J NANOMED, V12, DOI 10.2147/IJN.S139039; Ghersi G, 2006, CANCER RES, V66, P4652, DOI 10.1158/0008-5472.CAN-05-1245; Goldstein LA, 1997, BBA-MOL BASIS DIS, V1361, P11, DOI 10.1016/S0925-4439(97)00032-X; Gong C, 2014, CANCER RES, V74, P4341, DOI 10.1158/0008-5472.CAN-14-0125; Gong QY, 2016, ANAL CHEM, V88, P8309, DOI 10.1021/acs.analchem.6b02231; Grindel BJ, 2014, MATRIX BIOL, V36, P64, DOI 10.1016/j.matbio.2014.04.005; Guo J, 2015, INT J CLIN EXP PATHO, V8, P10014; Ha Q, 2014, NANOSCALE, V6, P8318, DOI 10.1039/c4nr01415d; Ha SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099955; Hamson EJ, 2014, PROTEOM CLIN APPL, V8, P454, DOI 10.1002/prca.201300095; Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863; Hu M, 2017, OMI AJ INTEGR BIOL, V2, P38; Huang T, 2015, MOL THER-ONCOLYTICS, V2, DOI 10.1038/mto.2015.3; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Jackson KW, 2015, NEOPLASIA, V17, P43, DOI 10.1016/j.neo.2014.11.002; Jacob M, 2012, CURR MOL MED, V12, P1220, DOI 10.2174/156652412803833607; Jansen K, 2014, J MED CHEM, V57, P3053, DOI 10.1021/jm500031w; Ji TJ, 2016, ANGEW CHEM INT EDIT, V55, P1050, DOI 10.1002/anie.201506262; Jia BN, 2016, ENDOCRINOLOGY, V157, P3023, DOI 10.1210/en.2016-1035; Jia J, 2014, BMC CELL BIOL, V15, DOI 10.1186/1471-2121-15-16; Jiang GM, 2015, ONCOTARGET, V6, P25932, DOI 10.18632/oncotarget.4577; Jung YY, 2015, TUMOR BIOL, V36, P8685, DOI 10.1007/s13277-015-3594-9; Kahounova Z, 2018, CYTOM PART A, V93A, P941, DOI 10.1002/cyto.a.23101; Kakarla S, 2013, MOL THER, V21, P1611, DOI 10.1038/mt.2013.110; Kawase T, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0340-0; Ke MR, 2017, EUR J MED CHEM, V127, P200, DOI 10.1016/j.ejmech.2016.12.056; Keane FM, 2011, FEBS J, V278, P1316, DOI 10.1111/j.1742-4658.2011.08051.x; Kim GJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105094; Kim MG, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw186; Knopf JD, 2015, BBA-MOL CELL RES, V1853, P2515, DOI 10.1016/j.bbamcr.2015.07.013; Koczorowska MM, 2016, MOL ONCOL, V10, P40, DOI 10.1016/j.molonc.2015.08.001; Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300; Krepela E, 2017, BIOCHEM BIOPH RES CO, V491, P126, DOI 10.1016/j.bbrc.2017.07.061; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kuo SW, 2012, BIOMATERIALS, V33, P5013, DOI 10.1016/j.biomaterials.2012.03.080; Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805; Lee KN, 2006, BLOOD, V107, P1397, DOI 10.1182/blood-2005-08-3452; Lessard J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122065; Li MM, 2016, MOL MED REP, V13, P2476, DOI 10.3892/mmr.2016.4868; Liao YH, 2017, ONCOTARGET, V8, P30050, DOI 10.18632/oncotarget.16274; Liu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116683; Lo A, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92232; Lo A, 2015, CANCER RES, V75, P2800, DOI 10.1158/0008-5472.CAN-14-3041; Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532; Lopez JI, 2016, HUM PATHOL, V54, P100, DOI 10.1016/j.humpath.2016.03.009; Luo N, 2014, TRANSL RES, V163, P232, DOI 10.1016/j.trsl.2013.11.008; Luo Y, 2017, CYTOKINE GROWTH FACT; Lv BB, 2016, CANCER GENOM PROTEOM, V13, P201; Mazur A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150287; Meng MY, 2016, TUMOR BIOL, V37, P10317, DOI 10.1007/s13277-016-4825-4; Mhawech-Fauceglia P, 2015, CANCER MICROENVIRON, V8, P23, DOI 10.1007/s12307-014-0153-7; Miao ZF, 2014, TUMOR BIOL, V35, P6105, DOI 10.1007/s13277-014-1808-1; MONSKY WL, 1994, CANCER RES, V54, P5702; Mueller SC, 1999, J BIOL CHEM, V274, P24947, DOI 10.1074/jbc.274.35.24947; Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874; Niedermeyer J, 2001, INT J DEV BIOL, V45, P445; Osborne B, 2014, BBA-PROTEINS PROTEOM, V1844, P1248, DOI 10.1016/j.bbapap.2014.03.015; Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211; Park CK, 2016, BREAST CANCER RES TR, V159, P55, DOI 10.1007/s10549-016-3929-2; Park JE, 1999, J BIOL CHEM, V274, P36505, DOI 10.1074/jbc.274.51.36505; Park JI, 2016, TRANSL ONCOL, V9, P79, DOI 10.1016/j.tranon.2015.12.001; Park SY, 2015, BREAST CANCER RES TR, V149, P727, DOI 10.1007/s10549-015-3291-9; Park YJ, 2016, CANCER LETT, V370, P222, DOI 10.1016/j.canlet.2015.10.021; Patsouras D, 2015, MOL MED REP, V11, P4585, DOI 10.3892/mmr.2015.3259; Pearl ML, 2015, GYNECOL ONCOL, V137, P229, DOI 10.1016/j.ygyno.2015.03.002; Prossnitz ER, 2014, MOL CELL ENDOCRINOL, V389, P71, DOI 10.1016/j.mce.2014.02.002; Qi SJ, 2009, ACS APPL MATER INTER, V1, P30, DOI 10.1021/am800027d; Rabenhold M, 2015, J CONTROL RELEASE, V201, P56, DOI 10.1016/j.jconrel.2015.01.022; RETTIG WJ, 1993, CANCER RES, V53, P3327; Rettig WJ, 1986, CANC RES, V46; Roberts EW, 2013, J EXP MED, V210, P1137, DOI 10.1084/jem.20122344; Ruan P, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171027; Ruger R, 2014, J CONTROL RELEASE, V186, P1, DOI 10.1016/j.jconrel.2014.04.050; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; SCANLAN MJ, 1994, P NATL ACAD SCI USA, V91, P5657, DOI 10.1073/pnas.91.12.5657; Sorrentino C, 2016, ONCOTARGET, V7, P64274, DOI 10.18632/oncotarget.11729; Tansi FL, 2017, ACTA BIOMATER, V54, P281, DOI 10.1016/j.actbio.2017.03.033; Tansi FL, 2016, DATA BRIEF, V9, P143, DOI 10.1016/j.dib.2016.08.058; Tansi FL, 2016, BIOMATERIALS, V88, P70, DOI 10.1016/j.biomaterials.2016.02.028; Tchou J, 2013, HUM PATHOL, V44, P2549, DOI 10.1016/j.humpath.2013.06.016; Teichgraber V, 2015, ADV MED SCI-POLAND, V60, P264, DOI 10.1016/j.advms.2015.04.006; Tulley S, 2014, J BIOL CHEM, V289, P15280, DOI 10.1074/jbc.M114.568501; Tyulkina DV, 2016, DOKL BIOCHEM BIOPHYS, V470, P319, DOI 10.1134/S1607672916050033; Verdelli C, 2015, ENDOCR-RELAT CANCER, V22, P87, DOI 10.1530/ERC-14-0161; Wang H, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.122; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang LL, 2017, ONCOTARGET, V8, P26323, DOI 10.18632/oncotarget.15461; Waster P, 2017, BRIT J CANCER, V117, P535, DOI 10.1038/bjc.2017.182; Wei MT, 2017, ONCOTARGET, V8, P42262, DOI 10.18632/oncotarget.15040; Wen XY, 2017, ONCOL RES, V25, P629, DOI 10.3727/096504016X14768383625385; Werner S, 2016, CLIN CANCER RES, V22, P1725, DOI 10.1158/1078-0432.CCR-15-1268; Wolczyk D, 2016, CELL ONCOL, V39, P353, DOI 10.1007/s13402-016-0280-x; Wong PF, 2016, PEPTIDES, V75, P80, DOI 10.1016/j.peptides.2015.11.004; Wonganu B, 2016, BBA-BIOMEMBRANES, V1858, P1876, DOI 10.1016/j.bbamem.2016.05.001; Wu XF, 2017, ONCOTARGET, V8, P52614, DOI 10.18632/oncotarget.17538; Xia Q, 2017, IMMUNOPHARM IMMUNOT, V39, P37, DOI 10.1080/08923973.2016.1269337; Xia Q, 2016, CELL IMMUNOL, V310, P89, DOI 10.1016/j.cellimm.2016.08.006; Xia Q, 2016, VACCINE, V34, P4526, DOI 10.1016/j.vaccine.2016.07.054; Xia Q, 2016, CANCER IMMUNOL IMMUN, V65, P613, DOI 10.1007/s00262-016-1827-4; Yang J, 2016, AM J TRANSL RES, V8, P3429; Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973; Zhang Jiping, 2010, Front Biosci (Elite Ed), V2, P1154; Zhang MZ, 2015, ONCOL LETT, V10, P34, DOI 10.3892/ol.2015.3151; Zhang Y, 2016, ONCOTARGET, V7, P23282, DOI 10.18632/oncotarget.7818; Zhang YC, 2015, INT J NANOMED, V10, P1625, DOI 10.2147/IJN.S75954; Zhen EY, 2016, BIOCHEM J, V473, P605, DOI 10.1042/BJ20151085; Zhen ZP, 2017, NANO LETT, V17, P862, DOI 10.1021/acs.nanolett.6b04150; Zi FM, 2014, CANCER BIOL THER, V15, P1413, DOI 10.4161/cbt.29924; Zi FM, 2015, MOL MED REP, V11, P3203, DOI 10.3892/mmr.2015.3197	141	124	129	4	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4343	4357		10.1038/s41388-018-0275-3	http://dx.doi.org/10.1038/s41388-018-0275-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720723	Green Accepted			2022-12-17	WOS:000441144300001
J	Lincet, H; Icard, P				Lincet, H.; Icard, P.			How do glycolytic enzymes favour cancer cell proliferation by nonmetabolic functions?	ONCOGENE			English	Review							AUTOCRINE MOTILITY FACTOR; PYRUVATE-KINASE M2; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GAPDH; PHOSPHOGLYCERATE MUTASE 1; NUCLEAR TRANSLOCATION; BREAST-CANCER; HEXOKINASE 2; ALDOLASE-A; TRIOSEPHOSPHATE ISOMERASE; POOR-PROGNOSIS	Cancer cells enhance their glycolysis, producing lactate, even in the presence of oxygen. Glycolysis is a series of ten metabolic reactions catalysed by enzymes whose expression is most often increased in tumour cells. HKII and phosphoglucose isomerase (PGI) have mainly an antiapoptotic effect; PGI and glyceraldehyde-3-phosphate dehydrogenase activate survival pathways (Akt and so on); phosphofructokinase 1 and triose phosphate isomerase participate in cell cycle activation; aldolase promotes epithelial mesenchymal transition; PKM2 enhances various nuclear effects such as transcription, stabilisation and so on. This review outlines the multiple non-glycolytic roles of glycolytic enzymes, which are essential for promoting cancer cells' survival, proliferation, chemoresistance and dissemination.	[Lincet, H.; Icard, P.] Locally Aggress Canc Biol & Therapy Unit BioTICLA, Caen, France; [Lincet, H.] Normandie Univ, Caen, France; [Lincet, H.] Francois Baclesse Ctr Canc, Caen, France; [Icard, P.] Ecole Polytech, Lab Informat, Palaiseau, France	Institut Polytechnique de Paris	Lincet, H (corresponding author), Ctr Francois Baclesse, Locally Aggress Canc Biol & Therapy Unit BioTICLA, EA 4656, Av Gen Harris, F-14032 Caen, France.	h.lincet@baclesse.fr	ICARD, Philippe/K-6510-2015					Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Araki K, 2009, J BIOL CHEM, V284, P32305, DOI 10.1074/jbc.M109.008250; ASAKA M, 1994, J CLIN LAB ANAL, V8, P144, DOI 10.1002/jcla.1860080306; Atsumi T, 2002, CANCER RES, V62, P5881; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Buscaglia CA, 2006, J BIOL CHEM, V281, P1324, DOI 10.1074/jbc.M506346200; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Canete-Soler R, 2005, J NEUROSCI, V25, P4353, DOI 10.1523/JNEUROSCI.0885-05.2005; Carujo S, 2006, ONCOGENE, V25, P4033, DOI 10.1038/sj.onc.1209433; Chaerkady R, 2008, J PROTEOME RES, V7, P4289, DOI 10.1021/pr800197z; Chaneton B, 2012, NATURE, V491, P458, DOI 10.1038/nature11540; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chen GA, 2002, CLIN CANCER RES, V8, P2298; Chen J, 2014, TUMOR BIOL, V35, P3743, DOI 10.1007/s13277-013-1496-2; Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004; Chen M, 2010, CANCER RES, V70, P8977, DOI 10.1158/0008-5472.CAN-10-2513; Chesney J, 2006, CURR OPIN CLIN NUTR, V9, P535, DOI 10.1097/01.mco.0000241661.15514.fb; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Colell A, 2009, CELL DEATH DIFFER, V16, P1573, DOI 10.1038/cdd.2009.137; Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Demarse NA, 2009, J MOL BIOL, V394, P789, DOI 10.1016/j.jmb.2009.09.062; Desai S, 2013, ONCOTARGET, V5, P1; Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902; Di Michele M, 2010, J PROTEOMICS, V73, P879, DOI 10.1016/j.jprot.2009.11.012; Du S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085804; Evans MJ, 2007, MOL BIOSYST, V3, P495, DOI 10.1039/b705113a; Evans MJ, 2005, NAT BIOTECHNOL, V23, P1303, DOI 10.1038/nbt1149; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Funasaka T, 2005, FASEB J, V19, P1422, DOI 10.1096/fj.05-3699com; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gao ZH, 2000, BIOCHEM BIOPH RES CO, V268, P562, DOI 10.1006/bbrc.2000.2168; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRISOLIA S, 1968, BIOCHEMISTRY-US, V7, P1115, DOI 10.1021/bi00843a032; Gruning NM, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.130232; Gruning NM, 2011, CELL METAB, V14, P415, DOI 10.1016/j.cmet.2011.06.017; Guo CM, 2013, CLIN TRANSL ONCOL, V15, P167, DOI 10.1007/s12094-012-0924-x; Haga A, 2003, INT J CANCER, V107, P707, DOI 10.1002/ijc.11449; Hallows WC, 2012, J BIOL CHEM, V287, P3850, DOI 10.1074/jbc.M111.317404; Hamaguchi T, 2008, INT J ONCOL, V33, P725, DOI 10.3892/ijo_00000058; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hinkle PC, 2005, BBA-BIOENERGETICS, V1706, P1, DOI 10.1016/j.bbabio.2004.09.004; Hitosugi T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2759; Hitosugi T, 2012, CANCER CELL, V22, P585, DOI 10.1016/j.ccr.2012.09.020; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200; Huang JS, 2009, BRAIN RES, V1279, P1, DOI 10.1016/j.brainres.2009.05.011; Huang QJ, 2011, J BIOL CHEM, V286, P42211, DOI 10.1074/jbc.M111.296905; Huang W, 2014, ACTA BIOCH BIOPH SIN, V46, P204, DOI 10.1093/abbs/gmt154; Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Iqbal MA, 2014, FEBS LETT, V588, P2685, DOI 10.1016/j.febslet.2014.04.011; Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025; Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85; Jenkins CM, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.203661; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Joo HY, 2012, BIOCHEM BIOPH RES CO, V424, P681, DOI 10.1016/j.bbrc.2012.07.006; Kao AW, 1999, J BIOL CHEM, V274, P17742, DOI 10.1074/jbc.274.25.17742; Kho DH, 2013, CANCER RES, V73, P1411, DOI 10.1158/0008-5472.CAN-12-2149; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kosugi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028234; Krasnov GS, 2013, EXPERT OPIN THER TAR, V17, P681, DOI 10.1517/14728222.2013.775253; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Kruger A, 2011, ANTIOXID REDOX SIGN, V15, P311, DOI 10.1089/ars.2010.3797; Krynetski EY, 2003, CANCER RES, V63, P100; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Kwee SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046591; Laplante M, 2013, J CELL SCI, V126, P1713, DOI 10.1242/jcs.125773; Lau SK, 2004, AM J CLIN PATHOL, V122, P61, DOI 10.1309/9R6673QEC06D86Y4; Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009; Lee WH, 2010, TOXICOLOGY, V278, P224, DOI 10.1016/j.tox.2010.02.005; Leite TC, 2007, BIOCHEM J, V408, P123, DOI 10.1042/BJ20070687; Lew CR, 2012, J BIOL CHEM, V287, P42554, DOI 10.1074/jbc.M112.405969; Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256; Li J, 2014, CLIN TRANSL ONCOL, V16, P200, DOI 10.1007/s12094-013-1063-8; Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Liu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091606; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Lu J, 2008, BIOCHEM BIOPH RES CO, V369, P948, DOI 10.1016/j.bbrc.2008.02.122; Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010; Lv L, 2013, MOL CELL, V52, P340, DOI 10.1016/j.molcel.2013.09.004; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mamczur P, 2013, BBA-MOL CELL RES, V1833, P2812, DOI 10.1016/j.bbamcr.2013.07.013; Mathupala SP, 2010, BBA-BIOENERGETICS, V1797, P1225, DOI 10.1016/j.bbabio.2010.03.025; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Mehla K, 2014, BBA-REV CANCER, V1845, P126, DOI 10.1016/j.bbcan.2014.01.001; MEYERSIEGLER K, 1992, CARCINOGENESIS, V13, P2127, DOI 10.1093/carcin/13.11.2127; Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977; Min JW, 2013, BIOCHEM BIOPH RES CO, V440, P137, DOI 10.1016/j.bbrc.2013.09.041; MUKAI T, 1986, J BIOL CHEM, V261, P3347; Mukherjee J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057610; NABI IR, 1992, CANCER METAST REV, V11, P5, DOI 10.1007/BF00047599; Nath S, 2014, TRENDS MOL MED, V20, P332, DOI 10.1016/j.molmed.2014.02.007; Nicholls C, 2012, P NATL ACAD SCI USA, V109, P13308, DOI 10.1073/pnas.1206672109; Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492; Niinaka Y, 1998, CANCER RES, V58, P2667; Niinaka Y, 2010, CANCER RES, V70, P9483, DOI 10.1158/0008-5472.CAN-09-3880; NOGUCHI T, 1987, J BIOL CHEM, V262, P14366; NOGUCHI T, 1986, J BIOL CHEM, V261, P3807; Palmieri D, 2009, MOL CANCER RES, V7, P1438, DOI 10.1158/1541-7786.MCR-09-0234; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Peschiaroli A, 2013, ONCOGENE, V32, P797, DOI 10.1038/onc.2012.100; Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049; Poschmann G, 2009, MOL CELL PROTEOMICS, V8, P1105, DOI 10.1074/mcp.M800422-MCP200; Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Ren FL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-81; Rider MH, 2004, BIOCHEM J, V381, P561, DOI 10.1042/BJ20040752; RONAI Z, 1992, BIOCHIM BIOPHYS ACTA, V1130, P20, DOI 10.1016/0167-4781(92)90456-A; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Saez DE, 2000, J CELL BIOCHEM, V78, P62, DOI 10.1002/(SICI)1097-4644(20000701)78:1<62::AID-JCB6>3.3.CO;2-N; Satou W, 2004, BIOCHEM BIOPH RES CO, V315, P845, DOI 10.1016/j.bbrc.2004.01.142; Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sharma NK, 2013, J PROTEOMICS, V79, P277, DOI 10.1016/j.jprot.2012.12.020; Shen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047476; SHINOHARA Y, 1994, CANCER LETT, V82, P27, DOI 10.1016/0304-3835(94)90142-2; Sirover MA, 2012, J CELL BIOCHEM, V113, P2193, DOI 10.1002/jcb.24113; Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870; Stryer L, 1981, BIOCHEMISTRY; Takahashi Y, 1998, EUR J BIOCHEM, V254, P497, DOI 10.1046/j.1432-1327.1998.2540497.x; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tristan C, 2011, CELL SIGNAL, V23, P317, DOI 10.1016/j.cellsig.2010.08.003; Tsutsumi S, 2003, CANCER RES, V63, P242; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; VANSCHAFTINGEN E, 1980, BIOCHEM J, V192, P897, DOI 10.1042/bj1920897; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Ventura M, 2010, INT J BIOCHEM CELL B, V42, P1672, DOI 10.1016/j.biocel.2010.06.014; Wang HJ, 2014, P NATL ACAD SCI USA, V111, P279, DOI 10.1073/pnas.1311249111; Wang LY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067542; Wang X, 2008, J CANCER RES CLIN, V134, P995, DOI 10.1007/s00432-008-0367-5; Watanabe H, 1996, CANCER RES, V56, P2960; Wierenga RK, 2010, CELL MOL LIFE SCI, V67, P3961, DOI 10.1007/s00018-010-0473-9; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wong N, 2014, CANC LETT IN PRESS; Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816; Yang J, 2010, J THEOR BIOL, V266, P231, DOI 10.1016/j.jtbi.2010.06.009; Yang P, 2014, CELL SIGNAL, V26, P1853, DOI 10.1016/j.cellsig.2014.03.020; Yang WW, 2013, CANCER LETT, V339, P153, DOI 10.1016/j.canlet.2013.06.008; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Yi W, 2012, SCIENCE, V337, P975, DOI 10.1126/science.1222278; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; You ZM, 2014, ASIAN PAC J CANCER P, V15, P1099, DOI 10.7314/APJCP.2014.15.3.1099; Zhang XL, 2013, PATHOL RES PRACT, V209, P510, DOI 10.1016/j.prp.2013.06.005; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689	165	124	127	3	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	29					3751	3759		10.1038/onc.2014.320	http://dx.doi.org/10.1038/onc.2014.320			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM9BV	25263450				2022-12-17	WOS:000358001600001
J	Chen, X; Wu, Q; Tan, L; Porter, D; Jager, MJ; Emery, C; Bastian, BC				Chen, X.; Wu, Q.; Tan, L.; Porter, D.; Jager, M. J.; Emery, C.; Bastian, B. C.			Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations	ONCOGENE			English	Article						GNAQ/GNA11; MAPK signaling; protein kinase C; combined PKC and MEK inhibition; melanoma; PKC inhibitor	PROTEIN-KINASE-C; PROMOTING PHORBOL ESTERS; SIGNAL-REGULATED KINASE; PHASE-II; BRAF INHIBITION; ALPHA-SUBUNIT; LUNG-CANCER; PATHWAY; RESISTANCE; RAF	Uveal melanoma (UM) is a genetically and biologically distinct type of melanoma, and once metastatic there is no effective treatment currently available. Eighty percent of UMs harbor mutations in the G alpha(q) family members GNAQ and GNA11. Understanding the effector pathways downstream of these oncoproteins is important to identify opportunities for targeted therapy. We report consistent activation of the protein kinase C (PKC) and MAPK pathways as a consequence of GNAQ or GNA11 mutation. PKC inhibition with AEB071 or AHT956 suppressed PKC and MAPK signalling and induced G1 arrest selectively in melanoma cell lines carrying GNAQ or GNA11 mutations. In contrast, treatment with two different MEK inhibitors, PD0325901 and MEK162, inhibited the proliferation of melanoma cell lines irrespective of their mutation status, indicating that in the context of GNAQ or GNA11 mutation MAPK activation can be attributed to activated PKC. AEB071 significantly slowed the growth of tumors in an allograft model of GNAQ(Q209L)-transduced melanocytes, but did not induce tumor shrinkage. In vivo and in vitro studies showed that PKC inhibitors alone were unable to induce sustained suppression of MAP-kinase signaling. However, combinations of PKC and MEK inhibition, using either PD0325901or MEK162, led to sustained MAP-kinase pathway inhibition and showed a strong synergistic effect in halting proliferation and in inducing apoptosis in vitro. Furthermore, combining PKC and MEK inhibition was efficacious in vivo, causing marked tumor regression in a UM xenograft model. Our data identify PKC as a rational therapeutic target for melanoma patients with GNAQ or GNA11 mutations and demonstrate that combined MEK and PKC inhibition is synergistic, with superior efficacy compared to treatment with either approach alone.	[Chen, X.; Bastian, B. C.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Chen, X.; Wu, Q.; Bastian, B. C.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA; [Tan, L.; Porter, D.; Emery, C.] Novartis, Novartis Inst BioMed Res, Cambridge, MA USA; [Jager, M. J.] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands	Memorial Sloan Kettering Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Novartis; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Emery, C (corresponding author), Novartis Inst BioMed Res, Cambridge, MA 02139 USA.	caroline.emery@novartis.com; Boris.Bastian@ucsf.edu	Jager, Martine/AAR-3525-2020	Jager, Martine/0000-0003-2261-3820; chen, xu/0000-0003-2524-4979; Bastian, Boris/0000-0003-1836-6062	National Cancer Institute [CA142873]; Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE [R01CA142873] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Melanoma Research Alliance Team Science Award; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant CA142873 from the National Cancer Institute and a Melanoma Research Alliance Team Science Award.	ARITA Y, 1992, CANCER RES, V52, P4514; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bosco R, 2011, MINI-REV MED CHEM, V11, P185, DOI 10.2174/138955711795049899; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Clement-Duchene C, 2012, LUNG CANCER, V78, P57, DOI 10.1016/j.lungcan.2012.06.003; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; EGAN KM, 1988, SURV OPHTHALMOL, V32, P239, DOI 10.1016/0039-6257(88)90173-7; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Friday BB, 2008, CANCER RES, V68, P6145, DOI 10.1158/0008-5472.CAN-08-1430; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; GRAGOUDAS ES, 1991, OPHTHALMOLOGY, V98, P383; Griewank KG, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2012.00971.x; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gronberg BH, 2012, LUNG CANCER, V78, P63, DOI 10.1016/j.lungcan.2012.07.007; HEEMSKERK FMJ, 1993, BIOCHEM BIOPH RES CO, V190, P236, DOI 10.1006/bbrc.1993.1036; HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448_2.x; Hubbard KB, 2006, CELL SIGNAL, V18, P135, DOI 10.1016/j.cellsig.2005.08.004; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Lamba S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006833; Lehar J, 2009, NAT BIOTECHNOL, V27, P659, DOI 10.1038/nbt.1549; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; McLean IW, 2004, CAN J OPHTHALMOL, V39, P343, DOI 10.1016/S0008-4182(04)80004-8; Millward MJ, 2006, BRIT J CANCER, V95, P829, DOI 10.1038/sj.bjc.6603331; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Naylor TL, 2011, CANCER RES, V71, P2643, DOI 10.1158/0008-5472.CAN-10-2525; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714; Pratilas CA, 2009, P NATL ACAD SCI USA, V106, P4519, DOI 10.1073/pnas.0900780106; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Singh Arun D, 2005, Ophthalmol Clin North Am, V18, P75, DOI 10.1016/j.ohc.2004.07.002; Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sturm OE, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001212; Teicher BA, 2006, CLIN CANCER RES, V12, P5336, DOI 10.1158/1078-0432.CCR-06-0945; THELEN M, 1991, NATURE, V351, P320, DOI 10.1038/351320a0; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Urtreger AJ, 2012, IUBMB LIFE, V64, P18, DOI 10.1002/iub.574; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Wagner J, 2009, J MED CHEM, V52, P6193, DOI 10.1021/jm901108b; Wu XQ, 2012, MOL CANCER THER, V11, P1905, DOI 10.1158/1535-7163.MCT-12-0121; Wu XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029622	49	124	128	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4724	4734		10.1038/onc.2013.418	http://dx.doi.org/10.1038/onc.2013.418			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24141786	Green Accepted			2022-12-17	WOS:000343239500003
J	Johansson, J; Berg, T; Kurzejamska, E; Pang, MF; Tabor, V; Jansson, M; Roswall, P; Pietras, K; Sund, M; Religa, P; Fuxe, J				Johansson, J.; Berg, T.; Kurzejamska, E.; Pang, M-F; Tabor, V.; Jansson, M.; Roswall, P.; Pietras, K.; Sund, M.; Religa, P.; Fuxe, J.			MiR-155-mediated loss of C/EBP beta shifts the TGF-beta response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer	ONCOGENE			English	Article						CCAAT-enhancer binding protein beta; epithelial-mesenchymal transition; transforming growth factor-beta; Breast cancer; metastasis	BINDING-PROTEIN-BETA; BONE MORPHOGENETIC PROTEIN-7; CELL-PROLIFERATION; TARGETING RHOA; MAMMARY-GLAND; C-MYC; TUMOR; SMAD; REPRESSION; PLASTICITY	During breast cancer progression, transforming growth factor-beta (TGF-beta) switches from acting as a growth inhibitor to become a major promoter of epithelial-mesenchymal transition (EMT), invasion and metastasis. However, the mechanisms involved in this switch are not clear. We found that loss of CCAAT-enhancer binding protein beta (C/EBP beta), a differentiation factor for the mammary epithelium, was associated with signs of EMT in triple-negative human breast cancer, and in invasive areas of mammary tumors in MMTV-PyMT mice. Using an established model of TGF-beta-induced EMT in mouse mammary gland epithelial cells, we discovered that C/EBP beta was repressed during EMT by miR-155, an oncomiR in breast cancer. Depletion of C/EBP beta potentiated the TGF-beta response towards EMT, and contributed to evasion of the growth inhibitory response to TGF-beta. Furthermore, loss of C/EBP beta enhanced invasion and metastatic dissemination of the mouse mammary tumor cells to the lungs after subcutaneous injection into mice. The mechanism by which loss of C/EBP beta promoted the TGF-beta response towards EMT, invasion and metastasis, was traced to a previously uncharacterized role of C/EBP beta as a transcriptional activator of genes encoding the epithelial junction proteins E-cadherin and coxsackie virus and adenovirus receptor. The results identify miR-155-mediated loss of C/EBP beta as a mechanism, which promotes breast cancer progression by shifting the TGF-beta response from growth inhibition to EMT, invasion and metastasis.	[Johansson, J.; Berg, T.; Pang, M-F; Tabor, V.; Roswall, P.; Pietras, K.; Fuxe, J.] Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, S-17177 Stockholm, Sweden; [Kurzejamska, E.; Religa, P.] Karolinska Inst, Dept Med, Ctr Mol Med, S-17177 Stockholm, Sweden; [Kurzejamska, E.] Med Univ Warsaw, Dept Internal Med, Warsaw, Poland; [Jansson, M.; Sund, M.] Umea Univ, Dept Surg & Perioperat Sci, Umea, Sweden; [Pietras, K.] Lund Univ, Dept Lab Med Malmo, Ctr Canc, Malmo, Sweden	Karolinska Institutet; Karolinska Institutet; Medical University of Warsaw; Umea University; Lund University	Fuxe, J (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Vasc Biol, Scheeles V 2, S-17177 Stockholm, Sweden.	jonas.fuxe@ki.se	Fuxe, Jonas/T-4433-2017; Pietras, Kristian/ABG-2097-2021; Pietras, Kristian/ABE-8727-2020	Fuxe, Jonas/0000-0003-4576-9377; Pietras, Kristian/0000-0001-6738-4705; Sund, Malin/0000-0002-7516-9543; Tabor, Vedrana/0000-0001-9224-208X; Pang, Mei Fong/0000-0002-3030-1272; Kurzejamska, Ewa/0000-0002-8050-6516; Religa, Piotr/0000-0002-3884-2954	Swedish Research Council; Swedish Childhood Cancer Foundation; Swedish Cancer Society; Strategic Cancer Foundation (StratCan) at Karolinska Institute; Swedish Society of Medical Research; Vasterbotten County Council (VLL); Cancerforskningsfonden Norrland; Swedish Cancer Society an European Union RD Found; Foundation for Polish Science; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Strategic Cancer Foundation (StratCan) at Karolinska Institute; Swedish Society of Medical Research; Vasterbotten County Council (VLL); Cancerforskningsfonden Norrland; Swedish Cancer Society an European Union RD Found; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); Karolinska Institutet(Karolinska Institutet)	We thank Mina Bissell (Berkeley University), Carl-Henrik Heldin (Uppsala University) and Marene Landstrom (Umea University) for valuable input on the manuscript. We also thank Mathilda Sjoberg (Karolinska Institutet) for assistance with lentivirus infections and Anette Berglund (Umea University) for handling of human tissue samples. This work was supported by research grants from the Swedish Research Council, the Swedish Childhood Cancer Foundation, the Swedish Cancer Society and the Strategic Cancer Foundation (StratCan) at Karolinska Institute to JF, by a fellowship from the Swedish Society of Medical Research to TB, as well as research grants from Vasterbotten County Council (VLL) and Cancerforskningsfonden Norrland to MS. VT was supported by a grant from the Swedish Cancer Society, PR was supported by the Swedish Cancer Society an European Union RD Found, Ewa Kurzejamska was supported by Foundation for Polish Science and the Karolinska Institutet.	Arnal-Estape A, 2010, CANCER RES, V70, P9927, DOI 10.1158/0008-5472.CAN-10-0869; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778; Buijs JT, 2007, CANCER RES, V67, P8742, DOI 10.1158/0008-5472.CAN-06-2490; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Costinean S, 2009, BLOOD, V114, P1374, DOI 10.1182/blood-2009-05-220814; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Gomis RR, 2006, P NATL ACAD SCI USA, V103, P12747, DOI 10.1073/pnas.0605333103; Gotoh T, 1997, J BIOL CHEM, V272, P3694, DOI 10.1074/jbc.272.6.3694; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Jeong H, 2012, HISTOPATHOLOGY, V60, pE87, DOI 10.1111/j.1365-2559.2012.04195.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173; McEarchern JA, 2001, INT J CANCER, V91, P76, DOI 10.1002/1097-0215(20010101)91:1<76::AID-IJC1012>3.0.CO;2-8; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; Seagroves TN, 1998, GENE DEV, V12, P1917, DOI 10.1101/gad.12.12.1917; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Terry S, 2010, PHYSIOLOGY, V25, P16, DOI 10.1152/physiol.00034.2009; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tseng YH, 2008, NATURE, V454, P1000, DOI 10.1038/nature07221; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Vincent T, 2009, NAT CELL BIOL, V11, P943, DOI 10.1038/ncb1905; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Zahnow CA, 2001, CANCER RES, V61, P261; Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888; Zhang LA, 2010, FEBS LETT, V584, P4646, DOI 10.1016/j.febslet.2010.10.038; Zuo L, 2012, BREAST CANCER RES, V12, pR34	46	124	129	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5614	5624		10.1038/onc.2013.322	http://dx.doi.org/10.1038/onc.2013.322			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23955085	hybrid, Green Published			2022-12-17	WOS:000328461400006
J	Zhang, XT; Kang, LG; Ding, L; Vranic, S; Gatalica, Z; Wang, ZY				Zhang, X. T.; Kang, L. G.; Ding, L.; Vranic, S.; Gatalica, Z.; Wang, Z-Y			A positive feedback loop of ER-alpha 36/EGFR promotes malignant growth of ER-negative breast cancer cells	ONCOGENE			English	Article						EGFR; ER-alpha 36; estrogen signaling; ER-negative breast cancer	ESTROGEN-RECEPTOR-ALPHA; VARIANT; EXPRESSION; PROLIFERATION; ESTRADIOL	It is prevailingly thought that estrogen signaling is not involved in development of estrogen receptor (ER)negative breast cancer. However, there is evidence indicating that ovariectomy prevents the development of both ER-positive and -negative breast cancer, suggesting that estrogen signaling is involved in the development of ER-negative breast cancer. Previously, our laboratory cloned a variant of ER-alpha, ER-alpha 36, and found that ER-alpha 36 mediated nongenomic estrogen signaling and is highly expressed in ER-negative breast cancer cells. In this study, we found that ER-alpha 36 was highly expressed in 10/12 cases of triple-negative breast cancer. We investigated the role of mitogenic estrogen signaling mediated by ER-alpha 36 in malignant growth of triple-negative breast cancer MDA-MB-231 and MDA-MB-436 cells that express high levels of ER-alpha 36 and found that these cells strongly responded to mitogenic estrogen signaling both in vitro and in vivo. Knockdown of ER-alpha 36 expression in these cells using the small hairpin RNA method diminished their responsiveness to estrogen. ER-alpha 36 physically interacted with the EGFR/Src/Shc complex and mediated estrogen-induced phosphorylation of epidermal growth factor receptor (EGFR) and Src. EGFR signaling activated ER-alpha 36 transcription through an AP1 site in the ER-alpha 36 promoter, and ER-alpha 36 expression was able to stabilize EGFR protein. Our results, thus demonstrated that ER-alpha 36 mediates nongenomic estrogen signaling through the EGFR/Src/ERK signaling pathway in ER-negative breast cancer cells and suggested that a subset of ER-negative breast tumors that expresses ER-alpha 36, retains responsiveness to mitogenic estrogen signaling. Oncogene (2011) 30, 770-780; doi:10.1038/onc.2010.458; published online 11 October 2010	[Zhang, X. T.; Kang, L. G.; Wang, Z-Y] Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA; [Ding, L.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Oncol, Hangzhou 310003, Zhejiang, Peoples R China; [Vranic, S.; Gatalica, Z.; Wang, Z-Y] Creighton Univ, Sch Med, Dept Pathol, Omaha, NE 68178 USA; [Vranic, S.] Univ Sarajevo, Ctr Clin, Dept Pathol, Sarajevo 71000, Bosnia & Herceg	Creighton University; Zhejiang University; Creighton University; University of Sarajevo	Wang, ZY (corresponding author), Creighton Univ, Sch Med, Dept Med Microbiol & Immunol, Criss 3,Room 355,2500 Calif Plaza, Omaha, NE 68178 USA.	zywang@creighton.edu	Vranic, Semir/J-4113-2012; Vranic, Semir/I-6823-2019; Kang, Lianguo/D-7780-2012	Vranic, Semir/0000-0001-9743-7265; 	National Institute of Health [DK84328]; Nebraska Tobacco Settlement Biomedical Research Program Award [LB-595, LB692]; American Cancer Society [ACS/08/004]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070016] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Tobacco Settlement Biomedical Research Program Award; American Cancer Society(American Cancer Society); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institute of Health Grant DK84328 and by the Nebraska Tobacco Settlement Biomedical Research Program Award (LB-595 and LB692) to ZY Wang. Dr Semir Vranic was a research fellow at Creighton University Medical School, Omaha, NE, USA and had been supported by a UICC American Cancer Society Beginning Investigators Fellowship (ACSBI) (ACS/08/004) funded by the American Cancer Society.	[Anonymous], 1992, Lancet, V339, P1; Behrens D, 2007, MOL CELL ENDOCRINOL, V274, P19, DOI 10.1016/j.mce.2007.05.012; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; FRIEDL A, 1994, EUR J CANCER, V30A, P1559, DOI 10.1016/0959-8049(94)00293-E; FRIEDL A, 1989, CANCER RES, V49, P4758; Geisler J, 2002, J CLIN ONCOL, V20, P751, DOI 10.1200/JCO.2002.20.3.751; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Kang LG, 2010, J CELL MOL MED, V14, P1485, DOI 10.1111/j.1582-4934.2009.00877.x; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Lazennec G, 2001, ENDOCRINOLOGY, V142, P4120, DOI 10.1210/en.142.9.4120; Lee LMJ, 2008, ANTICANCER RES, V28, P479; Lin SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009013; MAHFOUDI A, 1995, P NATL ACAD SCI USA, V92, P4206, DOI 10.1073/pnas.92.10.4206; Narod SA, 2001, ANN NY ACAD SCI, V952, P36, DOI 10.1111/j.1749-6632.2001.tb02726.x; NISSENMEYER R, 1964, ACTA UNION INT CONTR, V20, P527; Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008-5472.CAN-03-2446; Rai D, 2005, MOL ENDOCRINOL, V19, P1606, DOI 10.1210/me.2004-0468; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Shi L, 2009, J CLIN ONCOL, V27, P3423, DOI 10.1200/JCO.2008.17.2254; Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691; Tong D, 2002, BREAST CANCER RES TR, V71, P249, DOI 10.1023/A:1014465916473; Tsai EM, 2001, CANCER RES, V61, P8390; Wang ZY, 2006, P NATL ACAD SCI USA, V103, P9063, DOI 10.1073/pnas.0603339103; Wang ZY, 2005, BIOCHEM BIOPH RES CO, V336, P1023, DOI 10.1016/j.bbrc.2005.08.226; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Zou Y, 2009, FEBS LETT, V583, P1368, DOI 10.1016/j.febslet.2009.03.047	26	124	132	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	7					770	780		10.1038/onc.2010.458	http://dx.doi.org/10.1038/onc.2010.458			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	722OT	20935677	Green Accepted			2022-12-17	WOS:000287444600002
J	Toomey, EC; Schiffman, JD; Lessnick, SL				Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.			Recent advances in the molecular pathogenesis of Ewing's sarcoma	ONCOGENE			English	Review						Ewing's sarcoma; EWS/FLI; ETS; microsatellites	GROWTH-FACTOR-I; MESENCHYMAL PROGENITOR CELLS; COMPARATIVE GENOMIC HYBRIDIZATION; EWS/FLI-1 FUSION GENE; PRIMITIVE NEUROECTODERMAL TUMORS; EWS-ETS ONCOPROTEINS; EMBRYONIC STEM-CELLS; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; DNA-BINDING	Tumor development is a complex process resulting from interplay between mutations in oncogenes and tumor suppressors, host susceptibility factors, and cellular context. Great advances have been made by studying rare tumors with unique clinical, genetic, or molecular features. Ewing's sarcoma serves as an excellent paradigm for understanding tumorigenesis because it exhibits some very useful and important characteristics. For example, nearly all cases of Ewing's sarcoma contain the (11;22)(q24;q12) chromosomal translocation that encodes the EWS/FLI oncoprotein. Besides the t(11;22), however, many cases have otherwise simple karyotypes with no other demonstrable abnormalities. Furthermore, it seems that an underlying genetic susceptibility to Ewing's sarcoma, if it exists, must be rare. These two features suggest that EWS/FLI is the primary mutation that drives the development of this tumor. Finally, Ewing's sarcoma is an aggressive tumor that requires aggressive treatment. Thus, improved understanding of the pathogenesis of this tumor will not only be of academic interest, but may also lead to new therapeutic approaches for individuals afflicted with this disease. The purpose of this review is to highlight recent advances in understanding the molecular pathogenesis of Ewing's sarcoma, while considering the questions surrounding this disease that still remain and how this knowledge may be applied to developing new treatments for patients with this highly aggressive disease. Oncogene (2010) 29, 4504-4516; doi: 10.1038/onc.2010.205; published online 14 June 2010	[Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.] Huntsman Canc Inst, Ctr Childrens Canc Res, Salt Lake City, UT 84112 USA; [Toomey, E. C.; Schiffman, J. D.; Lessnick, S. L.] Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Schiffman, J. D.; Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT USA	Huntsman Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Huntsman Canc Inst, Ctr Childrens Canc Res, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu		Wiles, Elizabeth/0000-0001-7269-7466	St Baldrick's Foundation; The Harriet H Samuelsson Foundation; National Cancer Institute [R01CA140394, R21CA138295]; American Cancer Society [RSG0618801MGO]; Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Terri Anna Perine Sarcoma Fund; Huntsman Cancer Institute; Huntsman Cancer Foundation; NIH [P30CA042014]; NATIONAL CANCER INSTITUTE [P30CA042014, R01CA140394, R21CA138295] Funding Source: NIH RePORTER	St Baldrick's Foundation; The Harriet H Samuelsson Foundation; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Alex's Lemonade Stand Foundation; Liddy Shriver Sarcoma Initiative; Terri Anna Perine Sarcoma Fund; Huntsman Cancer Institute; Huntsman Cancer Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize for the omission of many important topics and references due to space constraints. JDS acknowledges support from St Baldrick's Foundation and The Harriet H Samuelsson Foundation. SLL acknowledges support from the National Cancer Institute (R01CA140394 and R21CA138295), the American Cancer Society (RSG0618801MGO), Alex's Lemonade Stand Foundation, the Liddy Shriver Sarcoma Initiative, the Terri Anna Perine Sarcoma Fund, and the Huntsman Cancer Institute and Huntsman Cancer Foundation. We also acknowledge NIH support to the Huntsman Cancer Institute (P30CA042014).	AMBROS IM, 1991, CANCER, V67, P1886, DOI 10.1002/1097-0142(19910401)67:7<1886::AID-CNCR2820670712>3.0.CO;2-U; Amiel A, 2003, CANCER GENET CYTOGEN, V140, P107, DOI 10.1016/S0165-4608(02)00659-3; Armengol G, 1997, BRIT J CANCER, V75, P1403, DOI 10.1038/bjc.1997.242; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Bachmaier R, 2009, ONCOGENE, V28, P1280, DOI 10.1038/onc.2008.484; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Beauchamp E, 2009, J BIOL CHEM, V284, P9074, DOI 10.1074/jbc.M806233200; Benini S, 2001, CLIN CANCER RES, V7, P1790; BENJAMIN RS, 2007, CONN TISS ONC SOC 14; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; Brisset S, 2001, CANCER GENET CYTOGEN, V130, P57, DOI 10.1016/S0165-4608(01)00454-X; Brownhill SC, 2007, BRIT J CANCER, V96, P1914, DOI 10.1038/sj.bjc.6603819; Burdach S, 2009, CELL CYCLE, V8, P1991, DOI 10.4161/cc.8.13.8929; Cavazzana A O, 1988, Prog Clin Biol Res, V271, P487; Chansky HA, 2004, J ORTHOPAED RES, V22, P910, DOI 10.1016/j.orthres.2003.12.008; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Cironi L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002634; Codrington R, 2005, PLOS BIOL, V3, P1459, DOI 10.1371/journal.pbio.0030242; COMSTOCK KE, 1994, ARCH BIOCHEM BIOPHYS, V311, P487, DOI 10.1006/abbi.1994.1266; DAHLIN DC, 1961, J BONE JOINT SURG AM, V43, P185, DOI 10.2106/00004623-196143020-00004; de Alava E, 2000, CANCER-AM CANCER SOC, V89, P783, DOI 10.1002/1097-0142(20000815)89:4<783::AID-CNCR10>3.0.CO;2-Q; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; DICKMAN PS, 1982, LAB INVEST, V47, P375; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Erkizan HV, 2009, NAT MED, V15, P750, DOI 10.1038/nm.1983; Ewing, 1921, P NEW YORK PATHOL S, V21, P17; FELLINGER EJ, 1991, AM J PATHOL, V139, P317; Ferreira BI, 2008, ONCOGENE, V27, P2084, DOI 10.1038/sj.onc.1210845; Fuchs B, 2004, CLIN ORTHOP RELAT R, P64, DOI 10.1097/01.blo.0000141385.77071.8d; Fuchs B, 2004, CLIN CANCER RES, V10, P1344, DOI 10.1158/1078-0432.CCR-03-0038; GANGWAL K, 2010, GENES CANC, V2, P177; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Guillon N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004932; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Haldar M, 2007, CANCER CELL, V11, P375, DOI 10.1016/j.ccr.2007.01.016; HAMILTON G, 1991, THYMUS, V18, P33; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hattinger CM, 2002, BRIT J CANCER, V86, P1763, DOI 10.1038/sj.bjc.6600332; Herrero-Martin D, 2009, BRIT J CANCER, V101, P80, DOI 10.1038/sj.bjc.6605104; Horowitz Marc E., 1997, P831; Hu-Lieskovan S, 2005, CANCER RES, V65, P4633, DOI 10.1158/0008-5472.CAN-04-2857; Huang HY, 2005, J CLIN ONCOL, V23, P548, DOI 10.1200/JCO.2005.02.081; JEON IS, 1995, ONCOGENE, V10, P1229; Joo J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007608; KADIN ME, 1971, CANCER-AM CANCER SOC, V27, P257, DOI 10.1002/1097-0142(197102)27:2<257::AID-CNCR2820270203>3.0.CO;2-8; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; Kang HG, 2007, CANCER RES, V67, P3094, DOI 10.1158/0008-5472.CAN-06-3259; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Klevernic IV, 2009, BIOCHEM J, V418, P625, DOI 10.1042/BJ20082097; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; KOVAR H, 1990, ONCOGENE, V5, P1067; Kovar H, 1997, ONCOGENE, V15, P2225, DOI 10.1038/sj.onc.1201397; Kovar H, 2005, SEMIN CANCER BIOL, V15, P189, DOI 10.1016/j.semcancer.2005.01.004; Kovar Heinrich, 1998, Current Opinion in Oncology, V10, P334, DOI 10.1097/00001622-199807000-00010; Kovar H, 2006, CANCER RES, V66, P9786, DOI 10.1158/0008-5472.CAN-06-0205; Kurmasheva RT, 2009, CANCER RES, V69, P7662, DOI 10.1158/0008-5472.CAN-09-1693; Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; Lin PP, 2008, CANCER RES, V68, P8968, DOI 10.1158/0008-5472.CAN-08-0573; Linabery AM, 2008, CANCER-AM CANCER SOC, V113, P2575, DOI 10.1002/cncr.23866; LIPINSKI M, 1986, J CELL BIOCHEM, V31, P289, DOI 10.1002/jcb.240310406; LIPINSKI M, 1987, INT J CANCER, V40, P81, DOI 10.1002/ijc.2910400115; LIPINSKI M, 1987, CANCER RES, V47, P183; Luo W, 2009, ONCOGENE, V28, P4126, DOI 10.1038/onc.2009.262; Manara MC, 2010, CLIN CANCER RES, V16, P530, DOI 10.1158/1078-0432.CCR-09-0816; MAO XH, 1994, J BIOL CHEM, V269, P18216; Maurici D, 1998, CANCER GENET CYTOGEN, V100, P106, DOI 10.1016/S0165-4608(97)00028-9; May WA, 1997, NAT GENET, V17, P495, DOI 10.1038/ng1297-495; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Meyers P A, 2000, Curr Treat Options Oncol, V1, P247, DOI 10.1007/s11864-000-0036-7; Miyagawa Y, 2008, MOL CELL BIOL, V28, P2125, DOI 10.1128/MCB.00740-07; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Ng TL, 2007, J MOL DIAGN, V9, P459, DOI 10.2353/jmoldx.2007.070009; Ohali A, 2003, J CLIN ONCOL, V21, P3836, DOI 10.1200/JCO.2003.05.059; OHNO T, 1993, CANCER RES, V53, P5859; Olmos D, 2010, LANCET ONCOL, V11, P129, DOI 10.1016/S1470-2045(09)70354-7; Olsen RJ, 2001, ONCOGENE, V20, P1756, DOI 10.1038/sj.onc.1204268; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Ozaki T, 2001, GENE CHROMOSOME CANC, V32, P164, DOI 10.1002/gcc.1178; Peter M, 1997, ONCOGENE, V14, P1159, DOI 10.1038/sj.onc.1200933; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Riggi N, 2005, CANCER RES, V65, P11459, DOI 10.1158/0008-5472.CAN-05-1696; Riggi N, 2008, CANCER RES, V68, P2176, DOI 10.1158/0008-5472.CAN-07-1761; Riggi N, 2009, EXPERT REV ANTICANC, V9, P1025, DOI 10.1586/ERA.09.81; Roberts P, 2008, GENE CHROMOSOME CANC, V47, P207, DOI 10.1002/gcc.20523; Rocchi A, 2010, J CLIN INVEST, V120, P668, DOI 10.1172/JCI36667; Rorie CJ, 2004, CANCER RES, V64, P1266, DOI 10.1158/0008-5472.CAN-03-3274; Sanchez G, 2008, P NATL ACAD SCI USA, V105, P6004, DOI 10.1073/pnas.0710748105; Savola S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-17; Schuck A, 2002, STRAHLENTHER ONKOL, V178, P701, DOI 10.1007/s00066-002-0992-x; Scotlandi K, 2000, CANCER RES, V60, P5134; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1996, CANCER RES, V56, P4570; Scotlandi K, 1998, CANCER RES, V58, P4127; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Scotlandi K, 2009, J CLIN ONCOL, V27, P2209, DOI 10.1200/JCO.2008.19.2542; Selvarajah S, 2007, CANCER GENET CYTOGEN, V174, P35, DOI 10.1016/j.cancergencyto.2006.11.011; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shing DC, 2003, CANCER RES, V63, P4568; Shing DC, 2002, CYTOGENET GENOME RES, V97, P20, DOI 10.1159/000064063; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Szymczyna BR, 2000, J BIOL CHEM, V275, P28363, DOI 10.1074/jbc.M004294200; Takashima Y, 2007, CELL, V129, P1377, DOI 10.1016/j.cell.2007.04.028; Tan AY, 2009, J MOL CELL BIOL, V1, P82, DOI 10.1093/jmcb/mjp025; Tarkkanen M, 1999, CANCER GENET CYTOGEN, V114, P35, DOI 10.1016/S0165-4608(99)00031-X; Teitell MA, 1999, LAB INVEST, V79, P1535; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Thompson AD, 1999, ONCOGENE, V18, P5506, DOI 10.1038/sj.onc.1202928; Tirado OM, 2006, CANCER RES, V66, P9937, DOI 10.1158/0008-5472.CAN-06-0927; Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027; TOLCHER AW, 2007, J CLIN ONCOL S, P3002; Tolhuis B, 2006, NAT GENET, V38, P694, DOI 10.1038/ng1792; Torchia EC, 2003, CANCER RES, V63, P3464; Torchia EC, 2007, MOL CELL BIOL, V27, P7918, DOI 10.1128/MCB.00099-07; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Toretsky JA, 2006, CANCER RES, V66, P5574, DOI 10.1158/0008-5472.CAN-05-3293; TRICHE TJ, 1987, MAJOR PROBLEMS PATHO, P145; TURCCAREL C, 1984, CANCER GENET CYTOGEN, V12, P1, DOI 10.1016/0165-4608(84)90002-5; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; VANVALEN F, 1992, J CANCER RES CLIN, V118, P269, DOI 10.1007/BF01208615; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WANG CC, 1953, NEW ENGL J MED, V248, P571, DOI 10.1056/NEJM195304022481401; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wei G, 2000, CANCER-AM CANCER SOC, V89, P793, DOI 10.1002/1097-0142(20000815)89:4<793::AID-CNCR11>3.0.CO;2-M; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Yeny CT, 2005, CANCER RES, V65, P8698, DOI 10.1158/0008-5472.CAN-05-1704; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zwerner JP, 2008, ONCOGENE, V27, P3282, DOI 10.1038/sj.onc.1210991	152	124	133	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2010	29	32					4504	4516		10.1038/onc.2010.205	http://dx.doi.org/10.1038/onc.2010.205			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	638AQ	20543858	Green Accepted			2022-12-17	WOS:000280862300002
J	Yamaguchi, K; Mandai, M; Oura, T; Matsumura, N; Hamanishi, J; Baba, T; Matsui, S; Murphy, SK; Konishi, I				Yamaguchi, K.; Mandai, M.; Oura, T.; Matsumura, N.; Hamanishi, J.; Baba, T.; Matsui, S.; Murphy, S. K.; Konishi, I.			Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes	ONCOGENE			English	Article						ovarian clear cell carcinoma; microarray; carcinogenesis; signature	EXPRESSION PROFILES; POOR-PROGNOSIS; CANCER-CELLS; MOLECULAR MARKER; BREAST-CANCER; CHEMORESISTANCE; METHYLATION; PATTERNS; HYPOXIA-INDUCIBLE-FACTOR-1-ALPHA; ENDOMETRIOSIS	Ovarian clear cell carcinoma (OCCC) shows unique clinical features including an association with endometriosis and poor prognosis. We previously reported that the contents of endometriotic cysts, especially high concentrations of free iron, are a possible cause of OCCC carcinogenesis through iron-induced persistent oxidative stress. In this study, we conducted gene expression microarray analysis using 38 ovarian cancer cell lines and identified genes commonly expressed in both OCCC cell lines and clinical samples, which comprise an OCCC gene signature. The OCCC signature reproducibly predicts OCCC specimens in other microarray data sets, suggesting that this gene profile reflects the inherent biological characteristics of OCCC. The OCCC signature contains known markers of OCCC, such as hepatocyte nuclear factor-1 beta (HNF-1 beta) and versican (VCAN), and other genes that reflect oxidative stress. Expression of OCCC signature genes was induced by treatment of immortalized ovarian surface epithelial cells with the contents of endometriotic cysts, indicating that the OCCC signature is largely dependent on the tumor microenvironment. Induction of OCCC signature genes is at least in part epigenetically regulated, as we found hypomethylation of HNF-1 beta and VCAN in OCCC cell lines. This genome-wide study indicates that the tumor microenvironment induces specific gene expression profiles that contribute to the development of distinct cancer subtypes. Oncogene (2010) 29, 1741-1752; doi:10.1038/onc.2009.470; published online 11 January 2010	[Yamaguchi, K.; Mandai, M.; Matsumura, N.; Hamanishi, J.; Baba, T.; Konishi, I.] Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, Kyoto 6068507, Japan; [Yamaguchi, K.; Murphy, S. K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Durham, NC 27710 USA; [Oura, T.] Kyoto Univ, Grad Sch Publ Hlth, Dept Biostat, Sakyo Ku, Kyoto 6068507, Japan; [Matsui, S.] Inst Stat Math, Dept Data Sci, Res Org Informat & Syst, Tokyo, Japan	Kyoto University; Duke University; Kyoto University; Research Organization of Information & Systems (ROIS); Institute of Statistical Mathematics (ISM) - Japan	Mandai, M (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gynecol & Obstet, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	mandai@kuhp.kyoto-u.ac.jp	Yamaguchi, Ken/Y-6633-2018; Murphy, Susan/R-3903-2019; Hamanishi, Junzo/AAX-3318-2020	Yamaguchi, Ken/0000-0002-7669-1405; Murphy, Susan/0000-0001-8298-7272; BABA, Tsukasa/0000-0003-0066-3747; Matsumura, Noriomi/0000-0002-4512-7975; Hamanishi, Junzo/0000-0002-7750-0623				Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Aggarwal BB, 2009, CLIN CANCER RES, V15, P425, DOI 10.1158/1078-0432.CCR-08-0149; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bonome T, 2008, CANCER RES, V68, P5478, DOI 10.1158/0008-5472.CAN-07-6595; Brinton LA, 1997, AM J OBSTET GYNECOL, V176, P572, DOI 10.1016/S0002-9378(97)70550-7; Cattaruzza S, 2004, FASEB J, V18, P779, DOI 10.1096/fj.03-0660fje; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Cheng WJ, 2005, NAT MED, V11, P531, DOI 10.1038/nm1230; Dinulescu DM, 2005, NAT MED, V11, P63, DOI 10.1038/nm1173; Garcia-Escudero R, 2008, MOL CARCINOGEN, V47, P573, DOI 10.1002/mc.20430; Gibson G, 2008, NAT REV GENET, V9, P575, DOI 10.1038/nrg2383; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawthorne VS, 2009, MOL CANCER RES, V7, P592, DOI 10.1158/1541-7786.MCR-08-0316; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Issa JPJ, 2001, CANCER RES, V61, P3573; Itamochi H, 2008, CANCER SCI, V99, P653, DOI 10.1111/j.1349-7006.2008.00747.x; Ito M, 2007, J UROLOGY, V178, P1073, DOI 10.1016/j.juro.2007.05.012; Kato N, 2008, HISTOPATHOLOGY, V52, P682, DOI 10.1111/j.1365-2559.2008.03006.x; Lau CK, 2009, CLIN CANCER RES, V15, P3462, DOI 10.1158/1078-0432.CCR-08-2127; Lee S, 2007, GYNECOL ONCOL, V106, P311, DOI 10.1016/j.ygyno.2007.03.041; Maeda T, 2005, BRIT J CANCER, V93, P116, DOI 10.1038/sj.bjc.6602662; Marquez RT, 2005, CLIN CANCER RES, V11, P6116, DOI 10.1158/1078-0432.CCR-04-2509; Newton MA, 2007, ANN APPL STAT, V1, P85, DOI 10.1214/07-AOAS104; Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Sandberg R, 2005, P NATL ACAD SCI USA, V102, P2052, DOI 10.1073/pnas.0408105102; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.E03-05-0279; Schwartz DR, 2002, CANCER RES, V62, P4722; Shimizu M, 1999, CANCER, V85, P669, DOI 10.1002/(SICI)1097-0142(19990201)85:3<669::AID-CNCR17>3.0.CO;2-F; Skirnisdottir I, 2005, INT J ONCOL, V26, P177; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takano M, 2006, BRIT J CANCER, V94, P1369, DOI 10.1038/sj.bjc.6603116; Takemoto Y, 2004, CLIN CANCER RES, V10, P7418, DOI 10.1158/1078-0432.CCR-04-0279; Tsuchiya A, 2003, AM J PATHOL, V163, P2503, DOI 10.1016/S0002-9440(10)63605-X; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamaguchi K, 2008, CLIN CANCER RES, V14, P32, DOI 10.1158/1078-0432.CCR-07-1614; Zaffanello M, 2008, MED SCI MONITOR, V14, pRA78; Zorn KK, 2005, CLIN CANCER RES, V11, P6422, DOI 10.1158/1078-0432.CCR-05-0508	46	124	126	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1741	1752		10.1038/onc.2009.470	http://dx.doi.org/10.1038/onc.2009.470			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062075				2022-12-17	WOS:000276022800004
J	Morrish, F; Isern, N; Sadilek, M; Jeffrey, M; Hockenbery, DM				Morrish, F.; Isern, N.; Sadilek, M.; Jeffrey, M.; Hockenbery, D. M.			c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry	ONCOGENE			English	Review						NMR; isotopomer; stable isotope labeling; O-linked N-acetylglucosamine; glucose	BETA-N-ACETYLGLUCOSAMINE; PROGRESSION; PROLIFERATION; TRANSCRIPTION; GENES	Cell proliferation requires the coordinated activity of cytosolic and mitochondrial metabolic pathways to provide ATP and building blocks for DNA, RNA and protein synthesis. Many metabolic pathway genes are targets of the c-myc oncogene and cell-cycle regulator. However, the contribution of c-Myc to the activation of cytosolic and mitochondrial metabolic networks during cell-cycle entry is unknown. Here, we report the metabolic fates of [U-C-13] glucose in serum-stimulated myc(-/-) and myc(+/+) fibroblasts by C-13 isotopomer NMR analysis. We demonstrate that endogenous c-myc increased C-13 labeling of ribose sugars, purines and amino acids, indicating partitioning of glucose carbons into C1/folate and pentose phosphate pathways, and increased tricarboxylic acid cycle turnover at the expense of anaplerotic flux. Myc expression also increased global O-linked N-acetylglucosamine protein modi. cation, and inhibition of hexosamine biosynthesis selectively reduced growth of Myc-expressing cells, suggesting its importance in Myc-induced proliferation. These data reveal a central organizing function for the Myc oncogene in the metabolism of cycling cells. The pervasive deregulation of this oncogene in human cancers may be explained by its function in directing metabolic networks required for cell proliferation. Oncogene ( 2009) 28, 2485-2491; doi: 10.1038/onc.2009.112; published online 18 May 2009	[Morrish, F.; Hockenbery, D. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Isern, N.] Pacific NW Natl Lab, High Field NMR Facil, WR Wiley Environm Mol Sci Lab, Richland, WA 99352 USA; [Sadilek, M.] Univ Washington, Dept Chem, Seattle, WA 98195 USA; [Sadilek, M.] Univ Texas SW, Adv Imaging Res Ctr, Dallas, TX USA	Fred Hutchinson Cancer Center; United States Department of Energy (DOE); Pacific Northwest National Laboratory; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas	Hockenbery, DM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N,D2-190, Seattle, WA 98109 USA.	dhockenb@fhcrc.org		Isern, Nancy/0000-0001-9571-8864	NIH [R21 DK070297, P41 RR02301]; Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC [RO1CA106650-02]; University of Texas Southwestern Medical Center [H47669-16]; Department of Veterans Affairs Merit Review Award to CR Malloy [RR02584]; NATIONAL CANCER INSTITUTE [R01CA106650] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002584, P41RR002301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK070297] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Metabolome database; MDL database; Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory; Development of the program tca-CALC; University of Texas Southwestern Medical Center; Department of Veterans Affairs Merit Review Award to CR Malloy(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank John Sedivy for cell lines. This work utilized the MMC database supported by NIH grants R21 DK070297 and P41 RR02301, the MDL database (www.mdl.imb.liu.se) and the Human Metabolome database (www.hmbd.ca). A portion of this research was performed at EMSL, a national scienti. c user facility sponsored by the Department of Energy's Office of Biological and Environmental Research at Pacific Northwest National Laboratory. This work was funded by RO1CA106650-02 (DH). Development of the program tca-CALC (University of Texas Southwestern Medical Center) was supported by H47669-16, a Department of Veterans Affairs Merit Review Award to CR Malloy, and RR02584.	Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DEAN M, 1986, J BIOL CHEM, V261, P9161; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hunt AN, 2004, ADV ENZYME REGUL, V44, P173; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; MALLOY CR, 1990, AM J PHYSIOL, V259, pH987, DOI 10.1152/ajpheart.1990.259.3.H987; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390; Morrish F, 2008, CELL CYCLE, V7, P1054, DOI 10.4161/cc.7.8.5739; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5793, DOI 10.1128/MCB.22.16.5793-5800.2002; Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200; Peet AC, 2007, NMR BIOMED, V20, P692, DOI 10.1002/nbm.1181; Schorl C, 2003, MOL BIOL CELL, V14, P823, DOI 10.1091/mbc.E02-10-0649; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; TOLLEFSBOL TO, 1990, BIOCHEM MED METAB B, V44, P282, DOI 10.1016/0885-4505(90)90073-A; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103	21	124	132	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2009	28	27					2485	2491		10.1038/onc.2009.112	http://dx.doi.org/10.1038/onc.2009.112			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	468HD	19448666	Green Accepted			2022-12-17	WOS:000267806800001
J	Rodriguez-Gonzalez, A; Cyrus, K; Salcius, M; Kim, K; Crews, CM; Deshaies, RJ; Sakamoto, KM				Rodriguez-Gonzalez, A.; Cyrus, K.; Salcius, M.; Kim, K.; Crews, C. M.; Deshaies, R. J.; Sakamoto, K. M.			Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer	ONCOGENE			English	Article						steroid hormone receptors; ubiquitination; degradation; breast cancer; prostate cancer	HUMAN ANDROGEN RECEPTOR; ESTROGEN-RECEPTOR; COMBINATORIAL CHEMISTRY; RESPONSIVE ELEMENT; GROWTH-FACTOR; CELL-LINES; IN-VIVO; ALPHA; GENE; PROTEIN	Proteolysis targeting chimeric molecules (Protacs) target proteins for destruction by exploiting the ubiquitin-dependent proteolytic system of eukaryotic cells. We designed two Protacs that contain the peptide 'degron' from hypoxia-inducible factor-1 alpha, which binds to the Von-Hippel-Lindau (VHL) E3 ubiquitin ligase complex, linked to either dihydroxytestosterone that targets the androgen receptor (AR; Protac-A), or linked to estradiol (E2) that targets the estrogen receptor-alpha (ER alpha; Protac-B). We hypothesized that these Protacs would recruit hormone receptors to the VHL E3 ligase complex, resulting in the degradation of receptors, and decreased proliferation of hormone-dependent cell lines. Treatment of estrogen-dependent breast cancer cells with Protac-B induced the degradation of ER alpha in a proteasome-dependent manner. Protac-B inhibited the proliferation of ER alpha-dependent breast cancer cells by inducing G(1) arrest, inhibition of retinoblastoma phosphorylation and decreasing expression of cyclin D1, progesterone receptors A and B. Protac-B treatment did not affect the proliferation of estrogen-independent breast cancer cells that lacked ERa expression. Similarly, Protac-A treatment of androgen-dependent prostate cancer cells induced G(1) arrest but did not affect cells that do not express AR. Our results suggest that Protacs specifically inhibit the proliferation of hormone-dependent breast and prostate cancer cells through degradation of the ERa and AR, respectively.	[Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Sakamoto, K. M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, Los Angeles, CA 90095 USA; [Rodriguez-Gonzalez, A.; Deshaies, R. J.; Sakamoto, K. M.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [Cyrus, K.; Kim, K.] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Pharmacol, New Haven, CT USA; [Salcius, M.; Crews, C. M.] Yale Univ, Dept Chem, New Haven, CT USA; [Deshaies, R. J.] CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; [Sakamoto, K. M.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; California Institute of Technology; University of Kentucky; Yale University; Yale University; Yale University; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Sakamoto, KM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Gwynne Hazen Cherry Labs,Jonsson Comprehens Canc, A2-412 MDCC CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	kms@ucla.edu	Deshaies, Raymond/B-8354-2014; Crews, Craig M./ABH-9346-2020	Deshaies, Raymond/0000-0002-3671-9354; Crews, Craig M./0000-0002-8456-2005; Sakamoto, Kathleen/0000-0003-0494-8838	National Institutes of Health [CA-16042, AI-28697]; Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA; Department of Defense (USA) Prostate Cancer Research [W81XWH-06-1-0192]; Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright [EX 2005-0517, NIH R21 R21 CA118631];  [NIH R21 CA108545]; NATIONAL CANCER INSTITUTE [R21CA118631, P30CA016042, R21CA108545] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Jonsson Cancer Center; UCLA AIDS Institute; David Geffen School of Medicine at UCLA(University of California System); Department of Defense (USA) Prostate Cancer Research(United States Department of Defense); Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright(Spanish Government); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Tammy Phung for her kind assistance in the flow cytometry performance in the UCLA Jonsson Comprehensive Cancer Center and Center for AIDS Research FlowCore Facility that is supported by the National Institutes of Health awards CA-16042 and AI-28697, by the Jonsson Cancer Center, the UCLA AIDS Institute and the David Geffen School of Medicine at UCLA. This work was supported by NIH R21 CA108545 (KMS), Department of Defense (USA) Prostate Cancer Research Program W81XWH-06-1-0192 (AR), Postdoctoral fellowship Ministerio de Educacion y Ciencia (Spain) MEC/Fulbright EX 2005-0517 (AR) and NIH R21 R21 CA118631 (CMC). RJD is an Investigator of the Howard Hughes Medical Institute.	Alarid ET, 2003, ENDOCRINOLOGY, V144, P3469, DOI 10.1210/en.2002-0092; Bakin RE, 2003, CANCER RES, V63, P1981; Bargagna-Mohan P, 2005, BIOORG MED CHEM LETT, V15, P2724, DOI 10.1016/j.bmcl.2005.04.008; Blundell TL, 1996, NATURE, V384, P23; Borras M, 1996, J STEROID BIOCHEM, V57, P203, DOI 10.1016/0960-0760(95)00272-3; Broach JR, 1996, NATURE, V384, P14; Bubendorf L, 1999, CANCER RES, V59, P803; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Buzdar AU, 2003, ONCOLOGIST, V8, P335, DOI 10.1634/theoncologist.8-4-335; Clarke R, 1996, Cancer Treat Res, V87, P263; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CULIG Z, 1994, CANCER RES, V54, P5474; Culig ZR, 2003, J UROLOGY, V170, P1363, DOI 10.1097/01.ju.0000075099.20662.7f; DAUVOIS S, 1992, P NATL ACAD SCI USA, V89, P4037, DOI 10.1073/pnas.89.9.4037; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; Ellis MJ, 2001, J CLIN ONCOL, V19, P3808, DOI 10.1200/JCO.2001.19.18.3808; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Franco OE, 2003, PROSTATE, V56, P319, DOI 10.1002/pros.10258; GADDIPATI JP, 1994, CANCER RES, V54, P2861; Godoy-Tundidor S, 2002, CLIN CANCER RES, V8, P2356; Hogan JC, 1996, NATURE, V384, P17; HUGGINS C, 1967, CANCER RES, V27, P1925; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kirschberg TA, 2003, ORG LETT, V5, P3459, DOI 10.1021/ol035234c; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Linja MJ, 2001, CANCER RES, V61, P3550; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Moul JW, 2000, J UROLOGY, V163, P1632, DOI 10.1016/S0022-5347(05)67511-8; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pink JJ, 1996, CANCER RES, V56, P2321; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Rau KM, 2005, ENDOCR-RELAT CANCER, V12, P511, DOI 10.1677/erc.1.01026; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Sakamoto KM, 2003, MOL CELL PROTEOMICS, V2, P1350, DOI 10.1074/mcp.T300009-MCP200; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; SANTEN RJ, 1992, J CLIN ENDOCR METAB, V75, P685, DOI 10.1210/jc.75.3.685; Savarese DM, 2001, J CLIN ONCOL, V19, P2509, DOI 10.1200/JCO.2001.19.9.2509; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; Schneekloth JS, 2004, J AM CHEM SOC, V126, P3748, DOI 10.1021/ja039025z; Taplin ME, 1999, CANCER RES, V59, P2511; Thiele B, 1999, J CLIN ENDOCR METAB, V84, P1751, DOI 10.1210/jc.84.5.1751; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Verdine GL, 1996, NATURE, V384, P11; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008	51	124	184	14	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2008	27	57					7201	7211		10.1038/onc.2008.320	http://dx.doi.org/10.1038/onc.2008.320			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	379GG	18794799	Green Accepted			2022-12-17	WOS:000261384100007
J	Rigby, RJ; Simmons, JG; Greenhalgh, CJ; Alexander, WS; Lund, PK				Rigby, R. J.; Simmons, J. G.; Greenhalgh, C. J.; Alexander, W. S.; Lund, P. K.			Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon	ONCOGENE			English	Article						SOCS3; colon; cancer; mouse model	GROWTH-HORMONE; STAT3 ACTIVATION; TRANSGENIC MICE; CELL-GROWTH; CANCER; HYPERMETHYLATION; CARCINOMA; INACTIVATION; SUPPRESSORS; INHIBITION	Intestinal injury or chronic inflammation induce cytokines that promote crypt regeneration and mucosal repair. If excessive or prolonged, such mechanisms may increase colon cancer risk. Factors that terminate or limit cytokine action in intestinal epithelial cells (IEC) may protect against crypt hyperplasia and neoplasia. We hypothesized that suppressor of cytokine signaling-3 (SOCS3) is such a factor. Mice with Vilin-promoter/Cre-recombinase (VC)mediated IEC-specific SOCS3 gene disruption (VC/HO), WT/HO littermates with floxed but intact SOCS3 genes and VC/WT mice were studied. Colon was examined after acute dextran sodium sulfate (DSS)-induced mucosal injury or after azoxymethane (AOM) and chronic DSS. Signaling pathways were examined in colon, cultured IEC or colon cancer cell lines. VC/HO mice showed no basal phenotype. After acute DSS, VC/HO exhibited enhanced crypt proliferation and crypt hyperplasia and reduced transforming growth factor ( TGF) beta expression in colon. Inflammation and mucosal damage were similar across genotypes. Following AOM/DSS, VC/HO mice had increased size, number and load of colonic tumors and increased STAT3 and nuclear factor-kappa B (NF-kappa B) activation in colon. In vitro, SOCS3 overexpression reduced proliferation, IL-6-mediated STAT3 activation and tumor necrosis factor (TNF) alpha-mediated NF-kappa B activation. We conclude that cytokine induction of SOCS3 normally provides an intrinsic mechanism to limit injury-induced crypt hyperproliferation and inflammation-associated colon cancer by regulating both STAT3 and NF-kappa B pathways.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Rigby, RJ (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, Rm 6336,MBRB,CB 7545,103 Mason Farm Rd, Chapel Hill, NC 27599 USA.	rachael_rigby@med.unc.edu	, Histology Research Core Facility/ABF-6317-2021; Rigby, Rachael/C-8206-2011	Rigby, Rachael/0000-0002-6605-9609	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonzi T, 2004, CYTOKINE, V26, P45, DOI 10.1016/j.cyto.2003.12.002; Becker C, 2004, IMMUNITY, V21, P491, DOI 10.1016/j.immuni.2004.07.020; Campbell JS, 2001, J CLIN INVEST, V107, P1285, DOI 10.1172/JCI11867; Chen Z, 2006, P NATL ACAD SCI USA, V103, P8137, DOI 10.1073/pnas.0600666103; Chun KG, 2003, PHOTONIC NETW COMMUN, V6, P83, DOI 10.1023/A:1023642926131; Croker BA, 2003, NAT IMMUNOL, V4, P540, DOI 10.1038/ni931; Greenhalgh CJ, 2002, GASTROENTEROLOGY, V123, P2064, DOI 10.1053/gast.2002.37068; Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Itzkowitz S, 2003, J CLIN GASTROENTEROL, V36, P70; Judd LM, 2004, GASTROENTEROLOGY, V126, P196, DOI 10.1053/j.gastro.2003.10.066; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Landi S, 2003, CANCER RES, V63, P3560; Miller ME, 2004, GASTROENTEROLOGY, V127, P570, DOI 10.1053/j.gastro.2004.05.016; Miller Megan E., 2000, Regulatory Peptides, V94, P67, DOI 10.1016/S0167-0115(00)80135-4; Miscia S, 2002, CELL GROWTH DIFFER, V13, P13; Mizoguchi E, 2003, GASTROENTEROLOGY, V125, P148, DOI 10.1016/S0016-5085(03)00665-6; Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x; Nakamura Y, 2005, CARCINOGENESIS, V26, P665, DOI 10.1093/carcin/bgi003; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ogata H, 2006, ONCOGENE, V25, P2520, DOI 10.1038/sj.onc.1209281; Ogata H, 2006, GASTROENTEROLOGY, V131, P179, DOI 10.1053/j.gastro.2006.04.025; Oshimo Y, 2004, INT J CANCER, V112, P1003, DOI 10.1002/ijc.20521; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Schneider M, 2000, HAEMOPHILIA, V6, P38; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; ULSHEN MH, 1993, GASTROENTEROLOGY, V104, P973, DOI 10.1016/0016-5085(93)90263-C; Wang LX, 2003, J IMMUNOL, V171, P3194, DOI 10.4049/jimmunol.171.6.3194; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Williams KL, 2001, GASTROENTEROLOGY, V120, P925, DOI 10.1053/gast.2001.22470; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938	35	124	128	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2007	26	33					4833	4841		10.1038/sj.onc.1210286	http://dx.doi.org/10.1038/sj.onc.1210286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	191ZL	17297444				2022-12-17	WOS:000248170400008
J	Le, LQ; Parada, LF				Le, L. Q.; Parada, L. F.			Tumor microenvironment and neurofibromatosis type I: connecting the GAPs	ONCOGENE			English	Review						neurofibromin; tumor microenvironment; mast cell; neurofibroma; NF1; GAP	GENE-PRODUCT; MAST-CELLS; ADENYLYL-CYCLASE; DROSOPHILA NF1; SCHWANN-CELLS; MOUSE MODEL; PROTEIN; MICE; INACTIVATION; MICROTUBULES	The human disease von Recklinghausen's neurofibromatosis (Nf1) is one of the most common genetic disorders. It is caused by mutations in the NF1 tumor suppressor gene, which encodes a GTPase activating protein ( GAP) that negatively regulates p21- RAS signaling. Dermal and plexiform neurofibromas as well as malignant peripheral nerve sheath tumors and other malignant tumors, are significant complications in Nf1. Neurofibromas are complex tumors and composed mainly of abnormal local cells including Schwann cells, endothelial cells, fibroblasts and additionally a large number of infiltrating inflammatory mast cells. Recent work has indicated a role for the microenvironment in plexiform neurofibroma genesis. The emerging evidence points to mast cells as crucial contributors to neurofibroma tumorigenesis. Therefore, further understanding of the molecular interactions between Schwann cells and their environment will provide tools to develop new therapies aimed at delaying or preventing tumor formation in Nf1 patients.	Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, Dept Dev Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, Kent Waldref Fdn, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Dermatol, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Phys Sci Training Program, Dallas, TX 75230 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Le, LQ (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Lu.Le.@UTSouthwestern.edu	Parada, luis F/B-9400-2014	Le, Lu/0000-0003-2817-5382	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS052606] Funding Source: NIH RePORTER; NINDS NIH HHS [P50 NS052606, P50 NS052606-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arun D, 2004, CURR OPIN NEUROL, V17, P101, DOI 10.1097/00019052-200404000-00004; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2003, CANCER RES, V63, P8573; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Castle B, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e109; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Dasgupta B, 2003, J NEUROSCI, V23, P8949; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; EASTON DF, 1993, AM J HUM GENET, V53, P305; FERNER RE, 2006, EUR J HUM GENET; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V19, P265, DOI 10.1007/BF01233074; Guo HF, 1997, SCIENCE, V276, P795, DOI 10.1126/science.276.5313.795; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Ismat FA, 2006, J CLIN INVEST, V116, P2378, DOI 10.1172/JCI28341; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jentarra Garilyn, 2006, Semin Pediatr Neurol, V13, P43, DOI 10.1016/j.spen.2006.01.010; Lakkis MM, 2000, J NEUROSCI RES, V62, P755, DOI 10.1002/1097-4547(20001215)62:6<755::AID-JNR1>3.3.CO;2-N; Levy P, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-20; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; Mousley CJ, 2006, BIOCHEM SOC T, V34, P346, DOI 10.1042/BST0340346; Page PZ, 2006, AM J MED GENET A, V140A, P1893, DOI 10.1002/ajmg.a.31422; Parada LF, 2005, COLD SH Q B, V70, P173, DOI 10.1101/sqb.2005.70.025; Parada LF, 2000, BBA-REV CANCER, V1471, pM13, DOI 10.1016/S0304-419X(00)00014-7; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; Szudek J, 2000, GENET EPIDEMIOL, V19, P429, DOI 10.1002/1098-2272(200012)19:4<429::AID-GEPI13>3.3.CO;2-E; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Theoharides TC, 2004, TRENDS IMMUNOL, V25, P235, DOI 10.1016/j.it.2004.02.013; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; Trovo-Marqui AB, 2006, CLIN GENET, V70, P1, DOI 10.1111/j.1399-0004.2006.00639.x; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Ward BA, 2005, PEDIATR NEUROL, V32, P221, DOI 10.1016/j.pediatrneurol.2004.11.002; Weiss P, 1999, ISRAEL MED ASSOC J, V1, P89; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4; Yang FC, 2003, J CLIN INVEST, V112, P1851, DOI 10.1172/JCI200319195; Yang FC, 2006, HUM MOL GENET, V15, P2421, DOI 10.1093/hmg/ddl165; Yohay Kaleb H, 2006, Semin Pediatr Neurol, V13, P21, DOI 10.1016/j.spen.2006.01.007; Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	45	124	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4609	4616		10.1038/sj.onc.1210261	http://dx.doi.org/10.1038/sj.onc.1210261			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297459	Green Accepted			2022-12-17	WOS:000248037900001
J	Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY				Lau, SH; Sham, JST; Xie, D; Tzang, CH; Tang, D; Ma, N; Hu, L; Wang, Y; Wen, JM; Xiao, G; Zhang, WM; Lau, GKK; Yang, M; Guan, XY			Clusterin plays an important role in hepatocellular carcinoma metastasis	ONCOGENE			English	Article						clusterin; hepatocellular carcinoma; metastasis; YKL-40; microarray	SMOOTH-MUSCLE-CELLS; SERUM YKL-40; PROSTATE-CANCER; MIGRATION; MARKER; GENE; OVEREXPRESSION; MICROARRAY; EXPRESSION; PROTEIN	To identify genes associated with tumor metastasis in hepatocellular carcinoma (HCC), gene expression profiles between a pair of primary HCC (H2-P) and their matched metastatic HCC (H2-M) were compared. Overexpression of clusterin (CLU) was found in H2-M cells. To determine the roles CLU played in HCC metastasis, CLU was transfected into H2-P cells. Overexpression of CLU in H2-P cells increased cell migration by twofold in vitro and formation of metastatic tumor nodules in liver by eightfold in vivo. To evaluate the correlation of CLU expression with HCC metastasis, the expression levels of CLU in HCCs were investigated using a tissue microarray (TMA) containing 104 pairs of primary HCCs and their matched metastases. The frequency of CLU overexpression increased significantly in metastatic HCCs (59.1%) compared with that in primary tumors (32.6%, P < 0.001). To gain additional insight into the function of CLU, the expression pro. le of H2P-CLU was compared with vector-transfected H2-P cells by cDNA microarray. A total of 35 upregulated and 14 downregulated genes were detected in H2P-CLU. One of the upregulated genes known as YKL-40, which is implicated in matrix-remodeling and metastasis, was further studied using TMA. A significant correlation (P < 0.001) between the expression levels of YKL-40 and CLU was observed, implying that the CLU-YKL-40 pathway may play an important role in HCC metastasis.	Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; Ctr Canc, State Key Lab Oncol So China, Guangzhou, Peoples R China; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China; Sun Yat Sen Univ, Dept Pathol, Guangzhou, Peoples R China; Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; City University of Hong Kong; Naval Medical University; Sun Yat Sen University; University of Hong Kong	Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Room 109,Estate Bldg,10 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.	xyguan@hkucc.hku.hk	Lau, George/AAQ-2085-2021; Yang, Mengsu/I-5750-2015; Yang, Mo/C-4455-2009; /A-3639-2009; Guan, Xin-Yuan/A-3639-2009	Yang, Mengsu/0000-0003-2083-2296; /0000-0003-1874-9805; Guan, Xin-Yuan/0000-0002-4485-6017				BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Dehn H, 2003, ACTA OBSTET GYN SCAN, V82, P287, DOI 10.1034/j.1600-0412.2003.00010.x; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hu L, 2004, CANCER GENET CYTOGEN, V148, P80, DOI 10.1016/S0165-4608(03)00206-1; Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483; Johansen JS, 2004, LUNG CANCER-J IASLC, V46, P333, DOI 10.1016/j.lungcan.2004.05.010; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Lau SH, 2005, ACTA PHARMACOL SIN, V26, P659, DOI 10.1111/j.1745-7254.2005.00126.x; Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Millis AJT, 2001, J CELL PHYSIOL, V186, P210, DOI 10.1002/1097-4652(200102)186:2<210::AID-JCP1019>3.0.CO;2-N; Mitsunobu M, 1996, CLIN EXP METASTAS, V14, P520, DOI 10.1007/BF00115112; Miyake H, 2002, J UROLOGY, V167, P2203, DOI 10.1016/S0022-5347(05)65129-4; Miyata M, 2001, CIRCULATION, V104, P1407, DOI 10.1161/hc3701.095583; NAGAO T, 1990, ANN SURG, V211, P28, DOI 10.1097/00000658-199001000-00005; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404; Redondo M, 2000, AM J PATHOL, V157, P393, DOI 10.1016/S0002-9440(10)64552-X; Steinberg J, 1997, CLIN CANCER RES, V3, P1707; Tang ZY, 2004, J CANCER RES CLIN, V130, P187, DOI 10.1007/s00432-003-0511-1; Tanwar MK, 2002, CANCER RES, V62, P4364; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2002, CANCER-AM CANCER SOC, V95, P2346, DOI 10.1002/cncr.10963; Xie D, 2005, CANCER-AM CANCER SOC, V103, P277, DOI 10.1002/cncr.20765	29	124	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 23	2006	25	8					1242	1250		10.1038/sj.onc.1209141	http://dx.doi.org/10.1038/sj.onc.1209141			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	015FO	16247463				2022-12-17	WOS:000235537500011
J	Croonquist, PA; Van Ness, B				Croonquist, PA; Van Ness, B			The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype	ONCOGENE			English	Article						myeloma; ras; EZH2	HISTONE METHYLTRANSFERASE ACTIVITY; THERAPEUTIC RESPONSE; H3 METHYLTRANSFERASE; ACTIVATING MUTATIONS; DROSOPHILA ENHANCER; MULTIPLE-MYELOMA; PROSTATE-CANCER; LINE ANBL6; GENE; DIFFERENTIATION	Three distinct proliferative signals for multiple myeloma (MM) cell lines induce enhancer of zeste homolog 2 (ezh2) transcript expression. EZH2 is a polycomb group protein that mediates repression of gene transcription at the chromatin level through its methyltransferase activity. Normal bone marrow plasma cells do not express ezh2; however, gene expression is induced and correlates with tumor burden during progression of this disease. We therefore investigated how EZH2 expression is deregulated in MM cell lines and determined the consequence of this activity on proliferation and transformation. We found that EZH2 protein expression is induced by interleukin 6 (IL-6) in growth factor-dependent cell lines and is constitutive in IL-6-independent cell lines. Furthermore, EZH2 expression correlates with proliferation and B-cell terminal differentiation. Significantly, EZH2 protein inhibition by short interference RNA treatment results in MM cell growth arrest. Conversely, EZH2 ectopic overexpression induces growth factor independence. We found that the growth factor-independent proliferative phenotype in MM cell lines harboring a mutant N- or K-ras gene requires EZH2 activity. Finally, this is the first report to demonstrate that EZH2 has oncogenic activity in vivo, and that cell transformation and tumor formation require histone methyltransferase activity.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Minnesota, Grad Program Mol Cellular Dev Biol & Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Van Ness, B (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, Canc Ctr Res Bldg,MMC 806,6-160 Jackson Hall,321, Minneapolis, MN 55455 USA.	vanne001@umn.edu			NATIONAL CANCER INSTITUTE [P01CA062242, T32CA009138] Funding Source: NIH RePORTER; NCI NIH HHS [CA09138, CA62242] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acs P, 1997, J BIOL CHEM, V272, P28793, DOI 10.1074/jbc.272.45.28793; Bajusz I, 2001, GENETICS, V159, P1135; Billadeau D, 1997, CANCER RES, V57, P2268; BILLADEAU D, 1995, CANCER RES, V55, P3640; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Carrington EA, 1996, DEVELOPMENT, V122, P4073; Chen-Kiang S, 1995, Curr Top Microbiol Immunol, V194, P189; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Cheung WC, 2002, LEUKEMIA, V16, P1182, DOI 10.1038/sj.leu.2402481; Cheung WC, 2001, LEUKEMIA, V15, P264, DOI 10.1038/sj.leu.2402022; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Fukuyama T, 2000, BRIT J HAEMATOL, V108, P842, DOI 10.1046/j.1365-2141.2000.01914.x; JELINEK DF, 1993, CANCER RES, V53, P5320; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Novina CD, 2002, NAT MED, V8, P681, DOI 10.1038/nm725; Raaphorst FM, 2001, J IMMUNOL, V166, P5925, DOI 10.4049/jimmunol.166.10.5925; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rowley M, 2000, BLOOD, V96, P3175, DOI 10.1182/blood.V96.9.3175.h8003175_3175_3180; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Westendorf JJ, 1996, LEUKEMIA, V10, P866; Zhan FH, 2003, BLOOD, V101, P1128, DOI 10.1182/blood-2002-06-1737; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	33	124	134	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6269	6280		10.1038/sj.onc.1208771	http://dx.doi.org/10.1038/sj.onc.1208771			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	16007202				2022-12-17	WOS:000231877100008
J	Larsson, J; Karlsson, S				Larsson, J; Karlsson, S			The role of Smad signaling in hematopoiesis	ONCOGENE			English	Review						Smad signaling; hematopoiesis; stem cells	GROWTH-FACTOR-BETA; PROGENITOR-CELL PROLIFERATION; BONE MORPHOGENETIC PROTEIN-4; RETROVIRAL GENE-TRANSFER; NECROSIS-FACTOR-ALPHA; EX-VIVO EXPANSION; RECEPTOR-TYPE II; C-KIT LIGAND; TGF-BETA; STEM-CELLS	The TGF-beta family of ligands, including TGF-b, bone morphogenetic protein (BMP) and activin, signal through Smad pathways to regulate the fate of hematopoietic progenitor and stem cells during development and postnatally. BMP regulates hematopoietic stem cell (HSC) specification during development, while TGF-beta 1, 2 and 3 are not essential for the generation of HSCs. BMP4 can increase proliferation of human hematopoietic progenitors, while TGF-beta acts as a negative regulator of hematopoietic progenitor and stem cells in vitro. In contrast, TGF-beta signaling deficiency in vivo does not affect proliferation of HSCs and does not affect lineage choice either. Therefore, the outcome of Smad signaling is very context dependent in hematopoiesis and regulation of hematopoietic stem and progenitor cells is more complicated in the bone marrow microenvironment in vivo than is seen in liquid cultures ex vivo. Smad signaling regulates hematopoiesis by crosstalk with other regulatory signals and future research will de. ne in more detail how the various pathways interact and how the knowledge obtained can be used to develop advanced cell therapies.	Lund Univ, Inst Lab Med, S-22184 Lund, Sweden; Lund Univ, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, S-22184 Lund, Sweden; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Regenerat Med & Technol, Boston, MA 02115 USA	Lund University; Lund University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Karlsson, S (corresponding author), Lund Univ, Inst Lab Med, BMC A12, S-22184 Lund, Sweden.	Stefan.karlsson@molmed.lu.se						Adolfsson J, 2001, IMMUNITY, V15, P659, DOI 10.1016/S1074-7613(01)00220-5; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Amsellem S, 2003, NAT MED, V9, P1423, DOI 10.1038/nm953; Antonchuk J, 2002, CELL, V109, P39, DOI 10.1016/S0092-8674(02)00697-9; Attar EC, 2004, LEUKEMIA, V18, P1760, DOI 10.1038/sj.leu.2403515; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bartelmez SH, 2000, BLOOD, V96, p474A; Batard P, 2000, J CELL SCI, V113, P383; Baum C, 2003, BLOOD, V101, P2099, DOI 10.1182/blood-2002-07-2314; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Bhatia M, 1999, J EXP MED, V189, P1139, DOI 10.1084/jem.189.7.1139; Bjornsson JM, 2003, MOL CELL BIOL, V23, P3872, DOI 10.1128/MCB.23.11.3872-3883.2003; Bjornsson JM, 2001, BLOOD, V98, P3301, DOI 10.1182/blood.V98.12.3301; Blank U, 2004, BLOOD, V104, p162A, DOI 10.1182/blood.V104.11.561.561; Borge OJ, 1996, BLOOD, V88, P2859, DOI 10.1182/blood.V88.8.2859.bloodjournal8882859; Brakebusch C, 2002, IMMUNITY, V16, P465, DOI 10.1016/S1074-7613(02)00281-9; Brun ACM, 2004, BLOOD, V103, P4126, DOI 10.1182/blood-2003-10-3557; Bruno E, 1998, BLOOD, V91, P1917, DOI 10.1182/blood.V91.6.1917.1917_1917_1923; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Buske C, 2002, BLOOD, V100, P862, DOI 10.1182/blood-2002-01-0220; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Chadwick K, 2005, BLOOD, V105, P1905, DOI 10.1182/blood-2004-03-0881; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Chang H, 1999, DEVELOPMENT, V126, P1631; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Chen CZ, 2002, P NATL ACAD SCI USA, V99, P15468, DOI 10.1073/pnas.202614899; Chen CZ, 2003, IMMUNITY, V19, P525, DOI 10.1016/S1074-7613(03)00265-6; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Cumano A, 2000, VACCINE, V18, P1621, DOI 10.1016/S0264-410X(99)00496-X; Dao MA, 1998, P NATL ACAD SCI USA, V95, P13006, DOI 10.1073/pnas.95.22.13006; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; De Felice LD, 2005, CANCER RES, V65, P1505, DOI 10.1158/0008-5472.CAN-04-3063; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DEMARTIN R, 1987, EMBO J, V6, P3673, DOI 10.1002/j.1460-2075.1987.tb02700.x; DERYNCK R, 1988, EMBO J, V7, P3737, DOI 10.1002/j.1460-2075.1988.tb03257.x; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Domen J, 1999, MOL MED TODAY, V5, P201, DOI 10.1016/S1357-4310(99)01464-1; DUBOIS CM, 1994, BLOOD, V83, P3138; DUBOIS CM, 1990, J EXP MED, V172, P737, DOI 10.1084/jem.172.3.737; DYBEDAL I, 1995, BLOOD, V86, P949; Dybedal I, 1997, BLOOD, V90, P3395, DOI 10.1182/blood.V90.9.3395; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Fan XL, 2002, J IMMUNOL, V168, P755, DOI 10.4049/jimmunol.168.2.755; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel NO, 2000, BLOOD, V96, P2022; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Fujiwara Y, 1996, P NATL ACAD SCI USA, V93, P12355, DOI 10.1073/pnas.93.22.12355; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Garbe A, 1997, BRIT J HAEMATOL, V99, P951, DOI 10.1046/j.1365-2141.1997.4893291.x; Gekas C, 2005, DEV CELL, V8, P365, DOI 10.1016/j.devcel.2004.12.016; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GOEY H, 1989, J IMMUNOL, V143, P877; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Grady WM, 1999, CANCER RES, V59, P320; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hatzfeld A, 1996, HUM GENE THER, V7, P207, DOI 10.1089/hum.1996.7.2-207; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horcher M, 2001, IMMUNITY, V14, P779, DOI 10.1016/S1074-7613(01)00153-4; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; Imai Y, 2001, ONCOGENE, V20, P88, DOI 10.1038/sj.onc.1204057; Imbert AM, 1998, EXP HEMATOL, V26, P374; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; JACOBSEN FW, 1995, BLOOD, V86, P2957; JACOBSEN SEW, 1991, BLOOD, V77, P1706; JACOBSEN SEW, 1991, BLOOD, V78, P2239, DOI 10.1182/blood.V78.9.2239.bloodjournal7892239; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; KELLER JR, 1988, J EXP MED, V168, P737, DOI 10.1084/jem.168.2.737; KELLER JR, 1990, BLOOD, V75, P596; KELLER JR, 1995, BLOOD, V86, P1757, DOI 10.1182/blood.V86.5.1757.bloodjournal8651757; Kim SJ, 2003, LEUKEMIA, V17, P1731, DOI 10.1038/sj.leu.2403069; Kimura S, 1998, P NATL ACAD SCI USA, V95, P1195, DOI 10.1073/pnas.95.3.1195; Knaus PI, 1996, MOL CELL BIOL, V16, P3480; Komuro Hiroaki, 1999, Neoplasia (New York), V1, P253, DOI 10.1038/sj.neo.7900033; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Krosl J, 2003, NAT MED, V9, P1428, DOI 10.1038/nm951; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; KULESSA H, 1995, GENE DEV, V9, P1250, DOI 10.1101/gad.9.10.1250; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Lacaud G, 2001, ANN NY ACAD SCI, V938, P96; Langer JC, 2004, J EXP MED, V199, P5, DOI 10.1084/jem.20030980; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Lenox LE, 2005, BLOOD, V105, P2741, DOI 10.1182/blood-2004-02-0703; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Leveen P, 2002, BLOOD, V100, P560, DOI 10.1182/blood.V100.2.560; LI CL, 1994, BLOOD, V84, P408, DOI 10.1182/blood.V84.2.408.bloodjournal842408; Li W, 2001, BIOCHEM BIOPH RES CO, V286, P1163, DOI 10.1006/bbrc.2001.5529; Liu B, 2003, BLOOD, V101, P124, DOI 10.1182/blood-2002-02-0398; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Lux A, 1999, J BIOL CHEM, V274, P9984, DOI 10.1074/jbc.274.15.9984; Lyman SD, 1998, BLOOD, V91, P1101, DOI 10.1182/blood.V91.4.1101; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; MADISEN L, 1988, DNA-J MOLEC CELL BIO, V7, P1, DOI 10.1089/dna.1988.7.1; Maeno M, 1996, BLOOD, V88, P1965, DOI 10.1182/blood.V88.6.1965.bloodjournal8861965; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Mikkola HKA, 2002, J HEMATOTH STEM CELL, V11, P9, DOI 10.1089/152581602753448504; Miller CL, 1996, EXP HEMATOL, V24, P185; Miyake N, 2004, BLOOD, V104, p469A, DOI 10.1182/blood.V104.11.1688.1688; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; North T, 1999, DEVELOPMENT, V126, P2563; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; OGAWA M, 1993, BLOOD, V81, P2844; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Orkin SH, 2000, NAT REV GENET, V1, P57, DOI 10.1038/35049577; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; OTTMANN OG, 1988, J IMMUNOL, V140, P2661; Park C, 2004, DEVELOPMENT, V131, P2749, DOI 10.1242/dev.01130; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; Ramsfjell V, 1996, BLOOD, V88, P4481, DOI 10.1182/blood.V88.12.4481.bloodjournal88124481; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; Roelen BAJ, 1997, DEV DYNAM, V209, P418, DOI 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.3.CO;2-J; Rolink AG, 1999, NATURE, V401, P603, DOI 10.1038/44164; Ruscetti FW, 2001, INT J HEMATOL, V74, P18, DOI 10.1007/BF02982545; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Schiemann WP, 1999, BLOOD, V94, P2854, DOI 10.1182/blood.V94.8.2854.420k07_2854_2861; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SING GK, 1988, BLOOD, V72, P1504; Sitnicka E, 1996, BLOOD, V88, P82; Snyder A, 2004, J CELL BIOCHEM, V93, P224, DOI 10.1002/jcb.20191; Soma T, 1996, BLOOD, V87, P4561, DOI 10.1182/blood.V87.11.4561.bloodjournal87114561; Sorrentino BP, 2004, NAT REV IMMUNOL, V4, P878, DOI 10.1038/nri1487; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; Stier S, 2003, BLOOD, V102, P1260, DOI 10.1182/blood-2002-10-3053; Stier S, 2002, BLOOD, V99, P2369, DOI 10.1182/blood.V99.7.2369; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Takeuchi C, 2002, LEUKEMIA, V16, P956, DOI 10.1038/sj.leu.2402408; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Tavian M, 1996, BLOOD, V87, P67, DOI 10.1182/blood.V87.1.67.bloodjournal87167; ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008; TEN DP, 1988, P NATL ACAD SCI USA, V85, P4715; Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Veiby OP, 1996, J IMMUNOL, V157, P2953; Villanueva A, 1998, ONCOGENE, V17, P1969, DOI 10.1038/sj.onc.1202118; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; Wolfraim LA, 2004, NEW ENGL J MED, V351, P552, DOI 10.1056/NEJMoa031197; Woods NB, 2003, BLOOD, V101, P1284, DOI 10.1182/blood-2002-07-2238; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang LP, 2005, BLOOD, V105, P2717, DOI 10.1182/blood-2004-06-2159; Yang LP, 2005, J IMMUNOL, V174, P752, DOI 10.4049/jimmunol.174.2.752; Yang X, 1999, DEVELOPMENT, V126, P1571; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6; Yoder MC, 2001, BLOOD, V98, P3, DOI 10.1182/blood.V98.1.3; Yu J, 1998, GENE THER, V5, P1265, DOI 10.1038/sj.gt.3300732; Yuan YZ, 2004, NAT CELL BIOL, V6, P436, DOI 10.1038/ncb1126; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; ZHANG Y, 1995, BLOOD, V86, P2930; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	192	124	132	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2005	24	37					5676	5692		10.1038/sj.onc.1208920	http://dx.doi.org/10.1038/sj.onc.1208920			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	958MQ	16123801				2022-12-17	WOS:000231452800003
J	Bernard, D; Martinez-Leal, JF; Rizzo, S; Martinez, D; Hudson, D; Visakorpi, T; Peters, G; Carnero, A; Beach, D; Gil, J				Bernard, D; Martinez-Leal, JF; Rizzo, S; Martinez, D; Hudson, D; Visakorpi, T; Peters, G; Carnero, A; Beach, D; Gil, J			CBX7 controls the growth of normal and tumor-derived prostate cells by repressing the Ink4a/Arf locus	ONCOGENE			English	Article						polycomb; prostate; CBX7; transformation	POLYCOMB-GROUP PROTEINS; MOLECULAR-GENETICS; STEM-CELLS; CANCER; EZH2; GENES; BMI-1; TRANSFORMATION; METHYLATION; MECHANISMS	Control of cell proliferation by Polycomb group proteins (PcG) is an important facet of cellular homeostasis and its disruption can promote tumorigenesis. We recently described CBX7 as a novel PcG protein controlling the growth of normal cells. In an attempt to identify a putative role of CBX7 in tumorigenesis, we analysed CBX7 expression in a panel of cancer cell lines and primary tissues. CBX7 was highly expressed in three different prostate cancer cell lines and present at elevated levels in normal prostate. Ablation of CBX7 expression using short hairpin RNAs (shRNA) resulted in upregulation of p16(Ink4a) and p14(Arf) in both LNCaP and PC-3 prostate cell lines. CBX7 knockdown caused an impairment of cell growth that was dependent on the status of the p14(Arf)/p53 and p16(Ink4a)/Rb pathways in both normal and cancer prostate cells. CBX7 overexpression in LNCaP cells resulted in a slight growth advantage in both androgen-dependent and independent conditions. Moreover, CBX7 expression cooperated with c-Myc in rendering LNCaP cells insensitive to growth arrest by androgen receptor inhibition. Together, these data suggest that CBX7 represses p16(Ink4a) and p14(Arf) expression in normal and tumor-derived prostate cells, affecting their growth depending on the status of the p16(Ink4a)/Rb and the p14(Arf)/p53 pathways.	London Res Inst, Canc Res UK, Mol Oncol Lab, London WC2A 3PX, England; Free Univ Brussels, Fac Med, Mol Virol Lab, Brussels, Belgium; Ctr Nacl Invest Oncol, Expt Therapeut Program, Madrid 28029, Spain; Inst Canc Res, Prostate Stem Cell Lab, Sutton SM2 5NG, Surrey, England; UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England; Tampere Univ, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, FIN-33014 Tampere, Finland; Ctr Cutaneous Biol, Inst Cell & Mol Sci, London E1 2AT, England	Cancer Research UK; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of London; Institute of Cancer Research - UK; University of London; University College London; Tampere University; Tampere University; Tampere University Hospital; University of London; Queen Mary University London	Gil, J (corresponding author), London Res Inst, Canc Res UK, Mol Oncol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	jesus.gil@cancer.org.uk	Leal, Juan F Martinez/N-6328-2013; Martinez, Lola/ABG-2474-2020; Martinez, Lola/L-2308-2014; Gil, Jesus/C-7739-2012; IBIS, CANCER/P-3323-2015; Bernard, David/D-6265-2018	Leal, Juan F Martinez/0000-0002-7538-0875; Martinez, Lola/0000-0001-6273-6724; Gil, Jesus/0000-0002-4303-6260; Visakorpi, Tapio/0000-0002-5004-0364; Bernard, David/0000-0002-1557-2074; Carnero, Amancio/0000-0003-4357-3979				Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bea S, 2001, CANCER RES, V61, P2409; Bernard D, 2003, J CLIN INVEST, V112, P1724; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chi SG, 1997, CLIN CANCER RES, V3, P1889; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hudson DL, 2000, LAB INVEST, V80, P1243, DOI 10.1038/labinvest.3780132; Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; KANNO M, 1995, EMBO J, V14, P5672, DOI 10.1002/j.1460-2075.1995.tb00254.x; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kirmizis A, 2003, MOL CANCER THER, V2, P113; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lu S, 1997, CANCER RES, V57, P4511; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Muyrers-Chen I, 2001, BBA-REV CANCER, V1552, P15, DOI 10.1016/S0304-419X(01)00032-4; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; Pasini D, 2004, CELL CYCLE, V3, P396; Porkka KP, 2004, EUR UROL, V45, P683, DOI 10.1016/j.eururo.2004.01.012; Raaphorst FM, 2000, AM J PATHOL, V157, P709, DOI 10.1016/S0002-9440(10)64583-X; Satijn DPE, 1997, MOL CELL BIOL, V17, P6076, DOI 10.1128/MCB.17.10.6076; Tokimasa S, 2001, EXP HEMATOL, V29, P93, DOI 10.1016/S0301-472X(00)00620-2; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Visakorpi T, 2003, UROLOGY, V62, P3, DOI 10.1016/S0090-4295(03)00776-3; VISAKORPI T, 1995, CANCER RES, V55, P342; Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	43	124	130	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 25	2005	24	36					5543	5551		10.1038/sj.onc.1208735	http://dx.doi.org/10.1038/sj.onc.1208735			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	956JN	15897876				2022-12-17	WOS:000231296100002
J	Winkles, JA; Alberts, GF				Winkles, JA; Alberts, GF			Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues	ONCOGENE			English	Article						polo-like kinase; gene; mRNA; cell cycle; tumor	POLO-LIKE-KINASE; PROTEIN-SERINE/THREONINE KINASE; INTEGRIN-BINDING PROTEIN; SERINE-THREONINE KINASE; PROGNOSTIC-SIGNIFICANCE; DROSOPHILA-POLO; DOWN-REGULATION; MESSENGER-RNA; INDUCIBLE KINASE; CYCLE REGULATION	The four mammalian polo-like kinase (Plk) family members are critical regulators of cell cycle progression, mitosis, cytokinesis, and the DNA damage response. Research conducted to date has primarily investigated the expression patterns, structural features, substrates, and subcellular distribution of these important serine-threonine kinases. Here, we review the published data describing the regulation of Plk1, 2, 3, or 4 gene expression either during mammalian cell cycle progression or in tissue samples. These studies have demonstrated that the Plk family genes are differentially expressed following growth factor stimulation of quiescent fibroblasts. Furthermore, although Plk1 and Plk2 mRNA and protein levels are coordinately regulated during cell cycle progression, this is not the case for Plk3. In addition, the Plk1, 2 and 4 proteins have relatively short intracellular half-lives, but Plk3 is very stable. The Plk family genes are also differentially regulated in stressed cells; for example, when DNA-damaging agents are added to cycling cells, Plk1 expression decreases, but Plk2 and Plk3 expression increases. Finally, Plk1, 2, 3, and 4 are expressed to varying degrees in different human tissue types and it has been reported that Plk1 expression is increased and Plk3 expression is decreased in tumor specimens. These results indicate that the differential regulation of Plk family member gene expression is one cellular strategy for controlling Plk activity in mammalian cells.	Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Amaxa Biosyst, Gaithersburg, MD 20877 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Winkles, JA (corresponding author), Univ Maryland, Sch Med, Dept Surg, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	jwinkles@som.umaryland.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts GF, 2004, CELL CYCLE, V3, P678; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Anger M, 2003, MOL REPROD DEV, V65, P245, DOI 10.1002/mrd.10289; Bahassi EM, 2002, ONCOGENE, V21, P6633, DOI 10.1038/sj.onc.1205850; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Blank M, 2003, CANCER RES, V63, P8241; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; CLAY FJ, 1993, P NATL ACAD SCI USA, V90, P4882, DOI 10.1073/pnas.90.11.4882; Dai W, 2002, ONCOGENE, V21, P6195, DOI 10.1038/sj.onc.1205710; Dai W, 2002, INT J ONCOL, V20, P121; Dai W, 2000, GENE CHROMOSOME CANC, V27, P332, DOI 10.1002/(SICI)1098-2264(200003)27:3<332::AID-GCC15>3.0.CO;2-K; Dietzmann K, 2002, J CANCER RES CLIN, V128, P265, DOI 10.1007/s00432-002-0330-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; Fode C, 1996, MOL CELL BIOL, V16, P4665; Georgescu SP, 1997, J MOL CELL CARDIOL, V29, P929, DOI 10.1006/jmcc.1996.0334; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HAMANAKA R, 1994, CELL GROWTH DIFFER, V5, P249; Harris PLR, 2000, NEUROBIOL AGING, V21, P837, DOI 10.1016/S0197-4580(00)00218-9; Holtrich U, 2000, ONCOGENE, V19, P4832, DOI 10.1038/sj.onc.1203845; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Karn T, 1997, ONCOL REP, V4, P505; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; LAKE RJ, 1993, MOL CELL BIOL, V13, P7793, DOI 10.1128/MCB.13.12.7793; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Li B, 1996, J BIOL CHEM, V271, P19402, DOI 10.1074/jbc.271.32.19402; Liby K, 2001, DNA SEQUENCE, V11, P527, DOI 10.3109/10425170109041337; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; Ma S, 2003, MOL CANCER RES, V1, P376; MATSUBARA N, 1995, MOL REPROD DEV, V41, P407, DOI 10.1002/mrd.1080410403; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimizu-Yoshida Y, 2001, BIOCHEM BIOPH RES CO, V289, P491, DOI 10.1006/bbrc.2001.5993; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Strebhardt K, 2000, JAMA-J AM MED ASSOC, V283, P479, DOI 10.1001/jama.283.4.479; Syed V, 1998, ENDOCRINOLOGY, V139, P3503, DOI 10.1210/en.139.8.3503; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Takai N, 1999, REPROD FERT DEVELOP, V11, P31, DOI 10.1071/RD99012; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; Weichert W, 2004, BRIT J CANCER, V90, P815, DOI 10.1038/sj.bjc.6601610; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726; Winkles JA, 1998, PROG NUCLEIC ACID RE, V58, P41; Wolf G, 2000, PATHOL RES PRACT, V196, P753, DOI 10.1016/S0344-0338(00)80107-7; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; Yoshimatsu J, 1999, RES COMMUN MOL PATH, V106, P3; Yuan JP, 1997, AM J PATHOL, V150, P1165; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	66	124	130	3	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2005	24	2					260	266		10.1038/sj.onc.1208219	http://dx.doi.org/10.1038/sj.onc.1208219			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	885UR	15640841				2022-12-17	WOS:000226183100006
J	Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ				Schroeder, JA; Al Masri, A; Adriance, MC; Tessier, JC; Kotlarczyk, KL; Thompson, MC; Gendler, SJ			MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation	ONCOGENE			English	Article						mucin; involution; apoptosis; breast cancer; mammary gland	CARCINOMA-ASSOCIATED ANTIGEN; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; C-SRC; BREAST; APOPTOSIS; EXPRESSION; CLONING; TRANSCRIPTION; ASSOCIATION	MUC1 is a transmembrane mucin that was initially cloned from malignant mammary epithelial cells as a tumor antigen. More than 90% of human breast carcinomas overexpress MUC1. Numerous studies have demonstrated an interaction between MUC1 and other oncogenic proteins such as beta-catenin, erbB receptors and c-Src, but a functional role for MUC1 in transformation has not been identified. We previously reported the development of transgenic mice that overexpress human MUC1 in the mouse mammary gland (MMTV-MUC1). Analysis of these transgenic mice at an early age demonstrated the ability of MUC1 to potentiate EGF-dependent activation of MAP kinase signaling pathways in the lactating mammary gland. We now report that multiparous MMTV-MUC1 transgenic mice stochastically develop unifocal mammary gland carcinomas late in life. Molecular analysis of these tumors shows a tumor-specific coimmunoprecipitation between MUC1 and beta-catenin. Examination of the contralateral glands in MMTV-MUC1 transgenics demonstrates that the development of frank carcinomas is accompanied by a failure of multiparous glands to undergo postlactational involution. Furthermore, uniparous MMTV-MUC1 transgenic mice display decreased postlactational apoptosis, elevated whey acidic protein expression and aberrant pErk2 activation. These findings are the first to determine that MUC1 overexpression promotes in vivo transformation of the mammary gland.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Coll Med, Tumor Biol Program, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix	Gendler, SJ (corresponding author), Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Coll Med, 13400 E Shea Blvd,SC Johnson Med Res Bldg, Scottsdale, AZ 85259 USA.	gendler.sandra@mayo.edu		schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA064389, F32CA081703] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA81703, F32 CA081703, R01CA64389, F32 CA081703-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BURDON T, 1991, J BIOL CHEM, V266, P6909; Flury N, 1997, EUR J BIOCHEM, V249, P421, DOI 10.1111/j.1432-1033.1997.00421.x; Garrity MM, 2003, MODERN PATHOL, V16, P389, DOI 10.1097/01.MP.0000062657.30170.92; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; Grant S, 2002, FRONT BIOSCI-LANDMRK, V7, pD376, DOI 10.2741/grant; Huang L, 2003, CANCER BIOL THER, V2, P702; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; LAN MS, 1990, J BIOL CHEM, V265, P15294; Li Y, 2003, CANCER BIOL THER, V2, P187, DOI 10.4161/cbt.2.2.282; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; Mahler JF, 1996, TOXICOL PATHOL, V24, P710, DOI 10.1177/019262339602400606; Marti A, 1999, J MAMMARY GLAND BIOL, V4, P145, DOI 10.1023/A:1018721107061; Meerzaman D, 2001, AM J PHYSIOL-LUNG C, V281, pL86, DOI 10.1152/ajplung.2001.281.1.L86; Mueller H, 2000, INT J CANCER, V89, P384, DOI 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R; PANDEY P, 1995, CANCER RES, V55, P4000; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Schroeder JA, 2003, ONCOGENE, V22, P1324, DOI 10.1038/sj.onc.1206291; SCHROEDER JA, 2001, J BIOL CHEM, V22, P22; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1995, MAMM GENOME, V6, P885, DOI 10.1007/BF00292441; Strange R, 2001, MICROSC RES TECHNIQ, V52, P171, DOI 10.1002/1097-0029(20010115)52:2<171::AID-JEMT1003>3.3.CO;2-K; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; Wen YF, 2003, J BIOL CHEM, V278, P38029, DOI 10.1074/jbc.M304333200; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yan Y, 2002, J BIOL CHEM, V277, P33422, DOI 10.1074/jbc.M201147200; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	35	124	139	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5739	5747		10.1038/sj.onc.1207713	http://dx.doi.org/10.1038/sj.onc.1207713			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15221004				2022-12-17	WOS:000222629800003
J	Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M				Sato, N; Fukushima, N; Matsubayashi, H; Goggins, M			Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling	ONCOGENE			English	Article						hypomethylation; maspin; SERPINB5; S100P; microarray	TUMOR-SUPPRESSOR GENE; HUMAN BREAST-CANCER; DNA METHYLATION; ABERRANT METHYLATION; CPG-ISLANDS; EPITHELIAL-CELLS; MULTIPLE GENES; DUCTAL ADENOCARCINOMA; PLASMINOGEN-ACTIVATOR; OVARIAN-CARCINOMA	DNA hypomethylation is one of the major epigenetic alterations in human cancers. We have previously shown that genes identified as hypomethylated in pancreatic cancer are expressed in pancreatic cancer cell lines, but not in normal pancreatic ductal epithelium and can be reexpressed in nonexpressing cells using 'epigenetic modifying agents' such as DNA methyltransferase inhibitors. To identify additional targets for aberrant hypomethylation in pancreatic cancer, we used oligonucleotide microarrays to screen for genes that displayed expression patterns associated with hypomethylation. This analysis identified a substantial number of candidates including previously reported hypomethylated genes. A subset of eight genes were selected for further methylation analysis, and two cancer-related genes, maspin and S100P, were found to be aberrantly hypomethylated in a large fraction of pancreatic cancer cell lines and primary pancreatic carcinomas. Combined treatment with 5-aza-2'-deoxycytidie and trichostatin A resulted in synergistic induction of maspin and S100P mRNA in MiaPaCa2 cells where both genes were methylated. Furthermore, there was an inverse correlation between methylation and mRNA expression level for maspin and S100P in a large panel of pancreatic cancer cell lines. We also found a significant difference in the methylation patterns of maspin and two previously identified hypomethylated genes (trefoil factor 2 and lipocalin 2) between pancreatic and breast cancer cell lines, suggesting cancer-type specificity for some hypomethylation patterns. Thus, our present results confirm that DNA hypomethylation is a frequent epigenetic event in pancreatic cancer, and suggest that gene expression pro. ling may help to identify potential targets affected by this epigenetic alteration.	Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Goggins, M (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 632 Ross Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	mgoggins@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA090709, P50CA062924] Funding Source: NIH RePORTER; NCI NIH HHS [CA62924, CA90709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Da Silva IDCG, 2000, INT J ONCOL, V16, P231; DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2001, CANCER RES, V61, P3225; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Fukushima N, 2003, BRIT J CANCER, V89, P338, DOI 10.1038/sj.bjc.6601039; Fukushima N, 2002, AM J PATHOL, V160, P1573, DOI 10.1016/S0002-9440(10)61104-2; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Goggins M, 1999, ANN ONCOL, V10, P4, DOI 10.1023/A:1008307913019; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Gupta A, 2003, CANCER RES, V63, P664; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iacobuzio-Donahue CA, 2003, AM J PATHOL, V162, P1151, DOI 10.1016/S0002-9440(10)63911-9; Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Koltzscher M, 2003, MOL BIOL CELL, V14, P2372, DOI 10.1091/mbc.E02-09-0553; Liang G, 2002, CANCER RES, V62, P961; Logsdon CD, 2003, CANCER RES, V63, P2649; Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8; Maass N, 2001, CLIN CANCER RES, V7, P812; Mackay A, 2003, ONCOGENE, V22, P2680, DOI 10.1038/sj.onc.1206349; Matsubayashi H, 2003, CLIN CANCER RES, V9, P1446; Mousses S, 2002, CANCER RES, V62, P1256; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Ryu B, 2002, CANCER RES, V62, P819; Sato N, 2003, CANCER RES, V63, P4158; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Sato N, 2003, CANCER RES, V63, P3735; Sato N, 2003, ONCOGENE, V22, P5021, DOI 10.1038/sj.onc.1206807; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Smiraglia DJ, 2001, HUM MOL GENET, V10, P1413, DOI 10.1093/hmg/10.13.1413; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sood AK, 2002, CLIN CANCER RES, V8, P2924; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; Ueki T, 2000, CANCER RES, V60, P1835; Ueki T, 2001, CANCER RES, V61, P8540; Yao XM, 2003, J CLIN INVEST, V111, P265, DOI 10.1172/JCI200315109; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	52	124	141	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	2004	23	8					1531	1538		10.1038/sj.onc.1207269	http://dx.doi.org/10.1038/sj.onc.1207269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	778BP	14716296				2022-12-17	WOS:000189219500006
J	Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y				Maeda, O; Usami, N; Kondo, M; Takahashi, M; Goto, H; Shimokata, K; Kusugami, K; Sekido, Y			Plakoglobin (gamma-catenin) has TCF/LEF family-dependent transcriptional activity in beta-catenin-deficient cell line	ONCOGENE			English	Article						plakoglobin; beta-catenin; malignant mesothelioma; transcriptional activity; Wnt signaling cascade	3P21.3 HOMOZYGOUS DELETION; HUMAN LUNG-CANCER; MALIGNANT MESOTHELIOMA; CYCLIN D1; MUTATIONS; PATHWAY; TARGET; APC; GROWTH; GENE	beta-Catenin is an essential element for the transcriptional activation of target genes in the Wnt signaling cascade and is also a cell adhesion molecule that couples with cadherins. Although plakoglobin (gamma-catenin), a closely related homologue of beta-catenin, is also known to be a cell adhesion molecule, its function as a transcriptional factor has not been revealed in detail. Using a human malignant mesothelioma cell line, NCI-H28, in which we have identified a homozygous deletion of the beta-catenin gene, we studied whether plakoglobin has a T-cell factor/ lymphocyte enhancer factor (TCF/LEF) family-dependent transcriptional activity. Transfection with the wildtype plakoglobin expression vector induced accumulation of plakoglobin in the nucleus. Immunoprecipitation assay with cotransfection of plakoglobin and either TCF-4 or LEF-1 detected binding of plakoglobin to TCF-4 or LEF-1. Luciferase reporter assay demonstrated transcriptional activity of the wild-type plakoglobin when transfected with TCF/LEF, although plakoglobin showed less activity than beta-catenin. Exogenous plakoglobin was also shown to promote entrance of exogenous beta-catenin into the nuclei. Furthermore, small interfering RNA directed against plakoglobin suppressed expression of endogenous plakoglobin and its transcriptional activity, suggesting that endogenous plakoglobin has a weak transcriptional activity. These results suggest that plakoglobin can activate the Wnt signaling cascade directly without interaction of beta-catenin, and that plakoglobin has multiple functions as a transcriptional activator and a cell adhesion molecule like beta-catenin.	Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Internal Med, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Thorac Surg, Showa Ku, Nagoya, Aichi 4668560, Japan; Nagoya Univ, Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668560, Japan	Nagoya University; Nagoya University; Nagoya University; Nagoya University	Sekido, Y (corresponding author), Nagoya Univ, Sch Med, Dept Clin Prevent Med, Showa Ku, Tsurumai Cho 65, Nagoya, Aichi 4668560, Japan.	ysekido@med.nagoya-u.ac.jp	Takahashi, Masahide/AAN-4770-2020; Kondo, Masashi/I-7378-2014; TAKAHASHI, Masahide/I-7244-2014; Sekido, Yoshitaka/P-9756-2015	Takahashi, Masahide/0000-0002-2803-2683; Sekido, Yoshitaka/0000-0002-2428-3848				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Barker N, 2000, BIOESSAYS, V22, P961; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Clements WM, 2002, CANCER RES, V62, P3503; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2000, GENE DEV, V14, P1319; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SEKIDO Y, 1994, CANCER RES, V54, P4988; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sparks AB, 1998, CANCER RES, V58, P1130; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueda M, 2001, BRIT J CANCER, V85, P64, DOI 10.1054/bjoc.2001.1863; Usami N, 2003, ONCOGENE, V22, P7922, DOI 10.1038/sj.onc.1206533; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Winn RA, 2002, ONCOGENE, V21, P7497, DOI 10.1038/sj.onc.1205963; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	33	124	126	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					964	972		10.1038/sj.onc.1207254	http://dx.doi.org/10.1038/sj.onc.1207254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14661054				2022-12-17	WOS:000188486600012
J	Surmacz, E				Surmacz, E			Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor	ONCOGENE			English	Review						insulin-like growth factor receptor; anti-cancer drugs; antibodies; tyrosine kinase inhibitors; antisense; triple helix; dominant-negative mutants	BREAST-CANCER-CELLS; DOMINANT-NEGATIVE MUTANT; TYROSINE KINASE INHIBITORS; CHRONIC MYELOID-LEUKEMIA; IGF-I; TUMOR-GROWTH; ANTISENSE RNA; DOWN-REGULATION; TRASTUZUMAB HERCEPTIN; TRANSFORMED PHENOTYPE	Neoplastic transformation is often related to abnormal activation of growth factor receptors and their signaling pathways. The concept of targeting specific tumorigenic receptors and/or signaling molecules has been validated by the development and successful clinical application of drugs acting against the epidermal growth factor receptor 2 (HER2/neu, Erb2), the epidermal growth factor receptor 1 ( EGFR, HER1), the Brc-Abl kinase, the platelet-derived growth factor receptor, and c-kit. This review will focus on the next promising therapeutic target, the insulin-like growth factor I receptor ( IGF-IR). IGF-IR has been implicated in a number of neoplastic diseases, including several common carcinomas. From a pharmaceutical standpoint, of particular importance is that IGF-IR appears to be required for many transforming agents ( genetic, viral, chemical) to act, but is not obligatory for the function of normal adult cells. The tumorigenic potential of IGF-IR is mediated through its antiapoptotic and transforming signaling, and in some cases through induction of prometastatic pathways. Preclinical studies demonstrated that downregulation of IGF-IR reversed the neoplastic phenotype and sensitized cells to antitumor treatments. The strategies to block IGF-IR function employed anti-IGF-IR antibodies, small-molecule inhibitors of the IGF-IR tyrosine kinase, antisense oligodeoxynucleotides and antisense RNA, small inhibitory RNA, triple helix, dominant-negative mutants, and various compounds reducing ligand availability. The experience with these strategies combined with the knowledge gained with current anti-growth factor receptor drugs should streamline the development of anti-IGF-IR therapeutics.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University	Surmacz, E (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, 233 S 10th St,BLSB 631, Philadelphia, PA 19107 USA.	eva.surmacz@mail.tju.edu						Adachi Y, 2002, GASTROENTEROLOGY, V123, P1191, DOI 10.1053/gast.2002.36023; Adams TE, 2000, CELL MOL LIFE SCI, V57, P1050, DOI 10.1007/PL00000744; Andrews DW, 2001, J CLIN ONCOL, V19, P2189, DOI 10.1200/JCO.2001.19.8.2189; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; Bartucci M, 2001, CANCER RES, V61, P6747; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Baserga R, 1996, TRENDS BIOTECHNOL, V14, P150, DOI 10.1016/0167-7799(96)10023-8; Baserga Renato, 1998, P269; Blakesley VA, 1996, ENDOCRINOLOGY, V137, P410, DOI 10.1210/en.137.2.410; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; Butler AA, 1998, CANCER RES, V58, P3021; Chernicky CL, 2000, CANCER GENE THER, V7, P384, DOI 10.1038/sj.cgt.7700126; Coppola D, 1999, CANCER RES, V59, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; De Meyts P, 2002, NAT REV DRUG DISCOV, V1, P769, DOI 10.1038/nrd917; Djavan B, 2001, WORLD J UROL, V19, P225, DOI 10.1007/s003450100220; Doerr ME, 1996, J BIOL CHEM, V271, P2443, DOI 10.1074/jbc.271.5.2443; Druckmann R, 2002, MATURITAS, V41, pS65; Druker BJ, 2002, EUR J CANCER, V38, pS70, DOI 10.1016/S0959-8049(02)80606-2; Dunn SE, 1998, CANCER RES, V58, P3353; Dunn SE, 1997, CANCER RES, V57, P4667; Dunn SE, 2001, CANCER RES, V61, P1367; Favelyukis S, 2001, NAT STRUCT BIOL, V8, P1058, DOI 10.1038/nsb721; Fry DW, 2003, EXP CELL RES, V284, P131, DOI 10.1016/S0014-4827(02)00095-2; Giovannucci E, 2001, J NUTR, V131, p3109S, DOI 10.1093/jn/131.11.3109S; Guo N, 2003, GROWTH HORM IGF RES, V13, P44, DOI 10.1016/S1096-6374(02)00121-1; Guvakova MA, 1999, EXP CELL RES, V251, P244, DOI 10.1006/excr.1999.4566; Hailey J, 2002, MOL CANCER THER, V1, P1349; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Hernandez-Boluda JC, 2002, DRUG TODAY, V38, P601, DOI 10.1358/dot.2002.38.9.696536; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Hongo A, 1996, ONCOGENE, V12, P1231; Hongo A, 1998, CANCER RES, V58, P2477; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; KALEBIC T, 1994, CANCER RES, V54, P5531; Kalebic T, 1998, INT J CANCER, V76, P223, DOI 10.1002/(SICI)1097-0215(19980413)76:2<223::AID-IJC9>3.0.CO;2-Z; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Lee CT, 1996, CANCER RES, V56, P3038; Lee CT, 2003, CANCER GENE THER, V10, P57, DOI 10.1038/sj.cgt.7700524; Levitzki A, 2002, EUR J CANCER, V38, pS11, DOI 10.1016/S0959-8049(02)80598-6; Li SL, 2000, CANCER IMMUNOL IMMUN, V49, P243, DOI 10.1007/s002620000115; LI SL, 1993, BIOCHEM BIOPH RES CO, V196, P92, DOI 10.1006/bbrc.1993.2220; Liu YM, 1998, CANCER RES, V58, P570; Long L, 1998, CANCER RES, V58, P3243; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; Mauro L, 2003, J CELL PHYSIOL, V194, P108, DOI 10.1002/jcp.10207; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Mira E, 1999, ENDOCRINOLOGY, V140, P1657, DOI 10.1210/en.140.4.1657; Muller M, 1998, INT J CANCER, V77, P567, DOI 10.1002/(SICI)1097-0215(19980812)77:4<567::AID-IJC16>3.0.CO;2-3; Nakamura K, 2000, CANCER RES, V60, P760; Navab R, 2001, J BIOL CHEM, V276, P13644, DOI 10.1074/jbc.M100019200; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; O'Connor R, 2000, BIOCHEM SOC T, V28, P47, DOI 10.1042/bst0280047; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; OCONNOR R, 1998, ADV BIOCHEM ENG BIOT, V62, P138; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Pavelic J, 2002, MOL MED, V8, P149, DOI 10.1007/BF03402007; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PIETRZKOWSKI Z, 1992, CANCER RES, V52, P6447; PIETRZKOWSKI Z, 1993, CANCER RES, V53, P1102; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; Pollak M, 2000, EUR J CANCER, V36, P1224, DOI 10.1016/S0959-8049(00)00102-7; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 2001, CLIN CANCER RES, V7, P2134; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rininsland F, 1997, P NATL ACAD SCI USA, V94, P5854, DOI 10.1073/pnas.94.11.5854; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Sachdev D, 2003, CANCER RES, V63, P627; Scharf JG, 2001, J CLIN PATHOL-MOL PA, V54, P138, DOI 10.1136/mp.54.3.138; Scotlandi K, 1998, CANCER RES, V58, P4127; Scotlandi K, 2002, INT J CANCER, V101, P11, DOI 10.1002/ijc.10537; Seely BL, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-15; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Trojan LA, 2002, ACTA BIOCHIM POL, V49, P979; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; Zhang DL, 2003, ONCOGENE, V22, P974, DOI 10.1038/sj.onc.1206197; Zia F, 1996, J CELL BIOCHEM, P269; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	110	124	141	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 29	2003	22	42					6589	6597		10.1038/sj.onc.1206772	http://dx.doi.org/10.1038/sj.onc.1206772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	728DV	14528284				2022-12-17	WOS:000185700700016
J	Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B				Jourdan, M; Veyrune, JL; De Vos, J; Redal, N; Couderc, G; Klein, B			A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells	ONCOGENE			English	Article						myeloma; IL-6; apoptosis; Mcl-1	HUMAN MULTIPLE-MYELOMA; INTERLEUKIN-6 TRANSGENIC MICE; BCL-2 FAMILY; B-CELLS; MONOCLONAL-ANTIBODIES; CHROMOSOME 1Q21; PLASMA-CELLS; EXPRESSION; LINES; APOPTOSIS	Interleukin-6 (IL-6) is a major survival factor for malignant plasma cells involved in multiple myeloma. Using an RNase protection assay, we looked for gene expression of 10 anti- and proapoptotic Bcl-2-family proteins in 12 IL-6-dependent human myeloma cell lines (HMCL). A high Mcl-1 gene expression was found in all HMCLs and the other genes were variably expressed. Out of the 10 Bcl-2-family members, only the Mcl-1 gene was regulated by IL-6. Upon starvation of IL-6, Mcl-1 gene expression decreased in association with myeloma cell apoptosis and was upregulated after adding IL-6 again in association with myeloma cell survival. A constitutive Mcl-1 expression was induced with an Mcl-1-GFP retrovirus in two IL-6-dependent HMCLs. The Mcl-1 HMCLs have a marked reduced apoptosis upon IL-6 starvation compared to HMCLs transduced with control GFP retrovirus and may grow without adding IL-6. These data emphasize the major role of Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.	INSERM, U475, F-34197 Montpellier, France; CHU Montpellier, Unit Cellular Therapy, F-34197 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; CHU de Montpellier	Klein, B (corresponding author), INSERM, U475, 99 Rue Puech Villa, F-34197 Montpellier, France.	klein@montp.inserm.fr	De Vos, John/A-5703-2010	De Vos, John/0000-0003-1880-4130				Bae J, 2001, APOPTOSIS, V6, P319, DOI 10.1023/A:1011319901057; Bingle CD, 2000, J BIOL CHEM, V275, P22136, DOI 10.1074/jbc.M909572199; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; CRAIG RW, 1994, GENOMICS, V23, P457, DOI 10.1006/geno.1994.1523; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Gu ZJ, 2000, LEUKEMIA, V14, P188, DOI 10.1038/sj.leu.2401632; HAMILTON MS, 1991, LEUKEMIA, V5, P768; Harada N, 1998, LEUKEMIA, V12, P1817, DOI 10.1038/sj.leu.2401168; Hatzivassiliou G, 2001, IMMUNITY, V14, P277, DOI 10.1016/S1074-7613(01)00109-1; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Keung YK, 1998, CANCER GENET CYTOGEN, V106, P135, DOI 10.1016/S0165-4608(97)00316-6; KLEIN B, 1989, BLOOD, V73, P517; KLEIN B, 2003, BIOL MULTIPLE MYELOM; Kuss AW, 1999, EUR J IMMUNOL, V29, P3077, DOI 10.1002/(SICI)1521-4141(199910)29:10<3077::AID-IMMU3077>3.0.CO;2-R; Le Baccon P, 2001, GENE CHROMOSOME CANC, V32, P250, DOI 10.1002/gcc.1189; Liautard J, 1997, CYTOKINE, V9, P233, DOI 10.1006/cyto.1996.0159; LOKHORST HM, 1994, BLOOD, V84, P2269; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1991, EUR J IMMUNOL, V21, P1759, DOI 10.1002/eji.1830210727; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rassidakis GZ, 2002, AM J PATHOL, V160, P2309, DOI 10.1016/S0002-9440(10)61178-9; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; SHIMIZU S, 1989, J EXP MED, V169, P339, DOI 10.1084/jem.169.1.339; Spets H, 1997, BRIT J HAEMATOL, V98, P126, DOI 10.1046/j.1365-2141.1997.1903004.x; SUEMATSU S, 1992, P NATL ACAD SCI USA, V89, P232, DOI 10.1073/pnas.89.1.232; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Tarte K, 2002, BLOOD, V100, P1113, DOI 10.1182/blood.V100.4.1113.h81602001113_1113_1122; UCHIYAMA H, 1993, BLOOD, V82, P3712; Westendorf JJ, 1996, LEUKEMIA, V10, P866; YANG T, 1995, J CELL BIOL, V128, P1173, DOI 10.1083/jcb.128.6.1173; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; ZHANG XG, 1994, BLOOD, V83, P3654; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	42	124	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2003	22	19					2950	2959		10.1038/sj.onc.1206423	http://dx.doi.org/10.1038/sj.onc.1206423			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771946	Green Submitted, Green Accepted			2022-12-17	WOS:000182824800010
J	Chen, C; Bhalala, HV; Qiao, H; Dong, JT				Chen, C; Bhalala, HV; Qiao, H; Dong, JT			A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer	ONCOGENE			English	Article						chromosome 13; 13q21; KLF5; hemizygous deletion; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN NEOPLASMS; FACTOR FAMILY; GENE; 13Q21; PROGRESSION; DELETION	The 13q21 tumor suppressor locus, as defined by chromosomal deletion, harbors the KLF5 transcription factor which may have tumor suppressor function. To investigate whether KLF5 plays a role in breast cancer, we evaluated all genes and/or expressed sequence tags (ESTs) within a 3.3 Mb common region of deletion at 13q21. Of these, only KLF5 mRNA was expressed at high levels in non-neoplastic breast epithelial cells and in normal human mammary tissue, but at lower levels in various breast cancer cell tines. Using the real time TaqMan PCR assay, hemizygous deletion at KLF5 was detected in 13 out of 30, or 43% of breast cancer cell lines tested, and various degrees of loss of expression were detected in 21 out of 30, or 70% of these cell lines. Each of the cases with hemizygous deletion also exhibited loss of KLF5 expression, suggesting that loss of expression can result from chromosomal deletion, and that KLF5 may undergo haploinsufficiency during carcinogenesis. Only one of the 30 breast cancer cell lines tested exhibited a mutation in KLF5, and neither promoter methylation nor homozygous deletion was detected in any of the cell lines. In contrast, loss of heterozygosity (LOH) was frequently detected at KLF5. Re-expression of wild-type KLF5 in T-47D breast cancer cells significantly inhibited colony formation in these cells. Of the KLF5-transfected clones that did form colonies, none were found to express KLF5 mRNA. These findings suggest that loss of function by deletion and/or loss of expression frequently occurs at KLF5, and KLF5 suppresses tumor cell growth in breast cancer.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365-B Clifton Rd,Suite B4100, Atlanta, GA 30322 USA.			Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA87921, CA85560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085560, R01CA087921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong JT, 2000, CANCER RES, V60, P3880; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Roylance R, 1999, CANCER RES, V59, P1433; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Tirkkonen M, 1997, CANCER RES, V57, P1222; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8	18	124	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6567	6572		10.1038/sj.onc.1205817	http://dx.doi.org/10.1038/sj.onc.1205817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242654				2022-12-17	WOS:000178202300002
J	Tham, WH; Zakian, VA				Tham, WH; Zakian, VA			Transcriptional silencing at Saccharomyces telomeres: implications for other organisms	ONCOGENE			English	Review						telomere; TPE; heterochromatin; telomerase; Ku complex; Sir proteins	D-GLUCOSYL-HYDROXYMETHYLURACIL; CELL-CYCLE PROGRESSION; DNA-BINDING PROTEIN; YEAST TELOMERES; FISSION YEAST; CHROMOSOME STABILITY; GENE-EXPRESSION; SIR4 PROTEINS; SCHIZOSACCHAROMYCES-POMBE; PLASMODIUM-FALCIPARUM	Telomeres are the natural ends of eukaryotic chromosomes. In most organisms, telomeres consist of simple, repeated DNA with the strand running 5' to 3' towards the end of the chromosome being rich in G residues. In cases where the very end of the chromosome has been examined, the G-strand is extended to form a short, single stranded tail. The chromatin structure of telomeric regions often has features that distinguish them from other parts of the genome. Because telomeres protect chromosome ends from degradation and end-to-end fusions and prevent the loss of terminal DNA by serving as a substrate for telomerase, the), are essential for the stable maintenance of eukaryotic chromosomes. In addition to their essential functions, telomeres in diverse organisms are specialized sites for gene expression. Transcription of genes located next to telomeres is repressed, a phenomenon termed telomere position effect (TPE). TPE is best characterized in the yeast Saccharomyces cerevisiae. This article will focus on the silencing properties of Saccharomyces telomeres and end with speculation on the role of TPE in yeasts and other organisms.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Tham, Wai-Hong/L-3173-2018	Tham, Wai-Hong/0000-0001-7950-8699				Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Baur JA, 2001, SCIENCE, V292, P2075, DOI 10.1126/science.1062329; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Boulton SJ, 1998, EMBO J, V17, P1819, DOI 10.1093/emboj/17.6.1819; Bourns BD, 1998, MOL CELL BIOL, V18, P5600, DOI 10.1128/MCB.18.9.5600; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHAN CSM, 1983, J MOL BIOL, V168, P505, DOI 10.1016/S0022-2836(83)80299-X; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Craven RJ, 2000, MOL CELL BIOL, V20, P2378, DOI 10.1128/MCB.20.7.2378-2384.2000; Cryderman DE, 1999, EMBO J, V18, P3724, DOI 10.1093/emboj/18.13.3724; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; di Fagagna FD, 2001, CURR BIOL, V11, P1192, DOI 10.1016/S0960-9822(01)00328-1; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Haber JE, 1999, CELL, V97, P829, DOI 10.1016/S0092-8674(00)80795-3; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARLEY CB, 1995, TELOMERES, P247; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HORN D, 1995, CELL, V83, P555, DOI 10.1016/0092-8674(95)90095-0; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LAMAN H, 1995, MOL CELL BIOL, V15, P3608; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Laroche T, 2000, J STRUCT BIOL, V129, P159, DOI 10.1006/jsbi.2000.4240; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; Li BB, 2000, CELL, V101, P471, DOI 10.1016/S0092-8674(00)80858-2; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Louis EJ, 1995, YEAST, V11, P1553, DOI 10.1002/yea.320111604; LOUIS EJ, 1994, GENETICS, V136, P789; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Mangahas JL, 2001, MOL BIOL CELL, V12, P4078, DOI 10.1091/mbc.12.12.4078; Marcand S, 1996, GENE DEV, V10, P1297, DOI 10.1101/gad.10.11.1297; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; McAinsh AD, 1999, CURR BIOL, V9, P963, DOI 10.1016/S0960-9822(99)80424-2; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Mishra K, 1999, CURR BIOL, V9, P1123, DOI 10.1016/S0960-9822(99)80483-7; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Ritchie KB, 2000, GENETICS, V155, P475; Rudenko G, 1998, TRENDS MICROBIOL, V6, P113, DOI 10.1016/S0966-842X(97)01200-6; Runge KW, 1996, MOL CELL BIOL, V16, P3094; RUSSELL P, 1986, CELL, V45, P781, DOI 10.1016/0092-8674(86)90550-7; Samper E, 2000, EMBO REP, V1, P244, DOI 10.1093/embo-reports/kvd051; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANDELL LL, 1994, P NATL ACAD SCI USA, V91, P12061, DOI 10.1073/pnas.91.25.12061; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; SNYDER M, 1988, MOL CELL BIOL, V8, P2184, DOI 10.1128/MCB.8.5.2184; STAVENHAGEN JB, 1994, GENE DEV, V8, P1411, DOI 10.1101/gad.8.12.1411; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsukamoto Y, 2001, CURR BIOL, V11, P1328, DOI 10.1016/S0960-9822(01)00372-4; van Leeuwen F, 1998, P NATL ACAD SCI USA, V95, P2366, DOI 10.1073/pnas.95.5.2366; Vega-Palas MA, 2000, MOL GEN GENET, V263, P287, DOI 10.1007/s004380051170; VegaPalas MA, 1997, NAT GENET, V15, P232, DOI 10.1038/ng0397-232; WILEY EA, 1995, GENETICS, V139, P67; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139; Zou S, 1996, GENE DEV, V10, P634, DOI 10.1101/gad.10.5.634	105	124	125	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	2002	21	4					512	521		10.1038/sj.onc.1205078	http://dx.doi.org/10.1038/sj.onc.1205078			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	513QU	11850776				2022-12-17	WOS:000173390500003
J	Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER				Clifford, SC; Astuti, D; Hooper, L; Maxwell, PH; Ratcliffe, PJ; Maher, ER			The pVHL-associated SCF ubiquitin ligase complex: Molecular genetic analysis of elongin B and C, Rbx1 and HIF-1 alpha in renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; elongin B; elongin C; Rbx1; HIF-1 alpha; VHL; genomic organization; chromosomal localization; mutation	TUMOR-SUPPRESSOR GENE; INDUCIBLE FACTOR 1-ALPHA; HUMAN HOMOLOG; BETA-CATENIN; ALLELE LOSS; VHL; MUTATIONS; PROTEIN; CANCER; ACTIVATION	The VHL gene product (pVHL) forms a multimeric complex with the elongin B and C, Cul2 and Rbx1 proteins (VCBCR complex), which is homologous to the SCF family of ubiquitin ligase complexes. The VCBCR complex binds HIF-1 alpha and HIF-2 alpha, transcription factors critically involved in cellular responses to hypoxia, and targets them for ubiquitin-mediated proteolysis. Germline mutations in the VHL gene cause susceptibility to haemangioblastomas, renal cell carcinoma (RCC), phaeochromocytoma and other tumours. In addition somatic inactivation of the VHL gene occurs in most sporadic clear cell RCC (CC-RCC). However, the absence of somatic VHL inactivation in 30-40% of CC-RCC implies the involvement of other gatekeeper genes in CC-RCC development. We reasoned that in CC-RCC without VHL inactivation, other pVHL-interacting proteins might be defective. To assess the role of elongin B/C, Rbx1 and HIF-1 alpha in RCC tumorigenesis we (a) mapped the genes to chromosomes 8q(cen) (elongin C), 16p13.3 (elongin B) and 22q11.2 (Rbx1) by FISH, monochromosomal somatic cell hybrid panel screening and in silico GenBank homology searching; (b) determined the genomic organisation of elongin C (by direct sequencing of PAC clones), Rbx1 and elongin B (by GenBank homology searching); and (c) performed mutation analysis of exons comprising the coding regions of elongins B, C and Rbx1 and the oxygen-dependent degradation domain of HIF-1 alpha by SSCP screening and direct sequencing in 35 sporadic clear cell RCC samples without VHL gene inactivation and in 13 individuals with familial non-VHL clear cell RCC. No coding region sequence variations were detected for the elongin 13, elongin C or Rbx1 genes. Two amino acid substitutions (Pro582Ser and Ala588Thr) were identified in the oxygen-dependent degradation/pVHL binding domain of HIF-1 alpha, however neither substitution was observed exclusively in tumour samples. Association analysis in panels of CC-RCC and non-neoplastic samples using the RFLPs generated by each variant did not reveal allelic frequency differences between RCC patients and controls (P >0.32 by chi-squared analysis). Nevertheless, the significance of these variations and their potential for modulation of HIF-1 alpha function merits further investigation in both other tumour types and in non-neoplastic disease. Taken together with our previous Cul2 mutation analysis these data suggest that development of sporadic and familial RCC is not commonly contributed to by genetic events altering the destruction domain of HIF-1 alpha, or components of the HIF-alpha destruction complex other than VHL itself. Although (a) activation of HIF could occur through mutation of another region of HIF-a, and (b) epigenetic silencing of elongin B/C, Cul2 or Rbx1 cannot be excluded, these findings suggest that pVHL may represent the sole mutational target through which the VCBR complex is disrupted in CC-RCC. HIF response is activated in CC-RCC tumorigenesis.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Birmingham, Div Reprod & Child Hlth, Sect Med & Mol Genet, Birmingham B15 2TT, W Midlands, England	University of Oxford; Wellcome Centre for Human Genetics; University of Birmingham	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Div Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	e.r.maher@bham.ac.uk	Maxwell, Patrick H/C-5557-2008; MAHER, EAMONN R/A-9507-2008	Maxwell, Patrick H/0000-0002-0338-2679; MAHER, EAMONN R/0000-0002-6226-6918; Astuti, Dewi/0000-0003-4205-6160; Ratcliffe, Peter/0000-0002-2853-806X; Clifford, Steve/0000-0003-4893-2184				Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 1998, GENE CHROMOSOME CANC, V22, P200, DOI 10.1002/(SICI)1098-2264(199807)22:3<200::AID-GCC5>3.0.CO;2-#; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Duerr EM, 1999, J CLIN ENDOCR METAB, V84, P3207, DOI 10.1210/jc.84.9.3207; Fearon ER, 1997, SCIENCE, V278, P1043, DOI 10.1126/science.278.5340.1043; FOSTER K, 1994, BRIT J CANCER, V69, P230, DOI 10.1038/bjc.1994.44; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ioannou P.A., 1996, CURRENT PROTOCOLS HU; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Kadota M, 2000, ONCOL REP, V7, P529; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KELSELL DP, 1995, ANN HUM GENET, V59, P233, DOI 10.1111/j.1469-1809.1995.tb00743.x; KNOWLES MA, 1993, ONCOGENE, V8, P1357; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lininger RA, 1998, HUM PATHOL, V29, P1113, DOI 10.1016/S0046-8177(98)90422-1; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Perinchery G, 1999, INT J ONCOL, V14, P495; Poli-Frederico RC, 2000, HEAD NECK-J SCI SPEC, V22, P585, DOI 10.1002/1097-0347(200009)22:6<585::AID-HED7>3.0.CO;2-4; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schofield DE, 1996, GENE CHROMOSOME CANC, V15, P10, DOI 10.1002/(SICI)1098-2264(199601)15:1<10::AID-GCC2>3.3.CO;2-1; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, GENOMICS, V34, P437, DOI 10.1006/geno.1996.0311; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sparks AB, 1998, CANCER RES, V58, P1130; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; THE BT, 1997, LANCET, V349, P848; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2; Wolter M, 1997, CANCER RES, V57, P2581; Woodward ER, 2000, J MED GENET, V37, P348, DOI 10.1136/jmg.37.5.348; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201	41	124	131	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2001	20	36					5067	5074		10.1038/sj.onc.1204602	http://dx.doi.org/10.1038/sj.onc.1204602			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526493				2022-12-17	WOS:000170439800018
J	Fisher, GH; Orsulic, S; Holland, E; Hively, WP; Li, Y; Lewis, BC; Williams, BO; Varmus, HE				Fisher, GH; Orsulic, S; Holland, E; Hively, WP; Li, Y; Lewis, BC; Williams, BO; Varmus, HE			Development of a flexible and specific gene delivery system for production of murine tumor models	ONCOGENE			English	Article						avian sarcoma leukosis virus; breast cancer; cancer models; gliomagenesis; melanoma; retroviral gene vectors	ROUS-SARCOMA VIRUS; A AVIAN-LEUKOSIS; RETROVIRAL VECTORS; TRANSGENIC MICE; LUNG-TUMORS; II CELL; EXPRESSION; MOUSE; SUSCEPTIBILITY; GLIOBLASTOMAS	To develop models of human cancer ne have expressed the avian retroviral receptor, TVA, under a variety of mammalian promoters in transgenic mice, thus rendering mice susceptible to infection with avian leukosis virus-derived gene vectors. TVA-based retroviral gene transfer offers advantages ol er current murine models of human cancer. A single transgenic mouse line can be used to evaluate multiple genetic lesions, individually and in combination. Furthermore, mutant genes are introduced somatically into animals, as occurs in the majority of naturally occurring turners. Because the avian viral vectors replicate only in avian cells, the viral receptor in infected transgenic mouse cells remains available for multiple rounds of infection with different ASLV vectors. We discuss the theoretical and practical aspects of using recombinant avian retroviruses with TVA transgenic mice to generate cancer models.	NCI, Varmus Lab, NIH, DBS, Bethesda, MD 20892 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; UTMD Anderson Cancer Center	Varmus, HE (corresponding author), NCI, Varmus Lab, NIH, DBS, 49 Convent Dr,Bldg 49,4A56, Bethesda, MD 20892 USA.		Li, Yi/A-7635-2009; Williams, Bart/A-3539-2013	Li, Yi/0000-0002-9976-518X; Williams, Bart/0000-0002-5261-5301				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; BELINSKY SA, 1992, CANCER RES, V52, P3164; BOERKOEL CF, 1993, VIROLOGY, V195, P669, DOI 10.1006/viro.1993.1418; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ELSASSER HP, 1986, EXOCRINE PANCREAS BI, P45; Federspiel MJ, 1996, P NATL ACAD SCI USA, V93, P4931, DOI 10.1073/pnas.93.10.4931; FEDERSPIEL MJ, 1994, P NATL ACAD SCI USA, V91, P11241, DOI 10.1073/pnas.91.23.11241; GLASSER SW, 1994, AM J PHYSIOL-LUNG C, V267, pL489, DOI 10.1152/ajplung.1994.267.5.L489; GREENHOUSE JJ, 1988, J VIROL, V62, P4809, DOI 10.1128/JVI.62.12.4809-4812.1988; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Ichimura K, 1996, ONCOGENE, V13, P1065; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KORFHAGEN TR, 1990, P NATL ACAD SCI USA, V87, P6122, DOI 10.1073/pnas.87.16.6122; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; Murphy GJ, 1999, P NATL ACAD SCI USA, V96, P3065, DOI 10.1073/pnas.96.6.3065; Nagasawa H, 1996, LAB ANIM, V30, P127, DOI 10.1258/002367796780865727; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; OOMEN LCJM, 1991, EXP LUNG RES, V17, P283, DOI 10.3109/01902149109064419; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RE FC, 1992, MOL CARCINOGEN, V5, P155, DOI 10.1002/mc.2940050211; REHM S, 1988, CANCER RES, V48, P148; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Sarzotti M, 1997, Curr Opin Hematol, V4, P48; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; STEEL KP, 1992, DEVELOPMENT, V115, P1111; VOELKER DR, 1989, LUNG CELL BIOL, P487; WARD JM, 1985, AM J PATHOL, V118, P493; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; YOUNG JAT, 1993, J VIROL, V67, P1811, DOI 10.1128/JVI.67.4.1811-1816.1993	37	124	131	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 20	1999	18	38					5253	5260		10.1038/sj.onc.1203087	http://dx.doi.org/10.1038/sj.onc.1203087			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240CP	10498877				2022-12-17	WOS:000082808400003
J	Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K				Toyama, T; Iwase, H; Watson, P; Muzik, H; Saettler, E; Magliocco, A; DiFrancesco, L; Forsyth, P; Garkavtsev, I; Kobayashi, S; Riabowol, K			Suppression of ING1 expression in sporadic breast cancer	ONCOGENE			English	Article						ING1; tumour suppressor gene; breast cancer; SSCP; mutation; expression	CANDIDATE TUMOR-SUPPRESSOR; PREFERENTIAL LOSS; DNA METHYLATION; MESSENGER-RNA; BRCA1; GROWTH; GENE; IDENTIFICATION; HYBRIDIZATION; INHIBITOR	Down regulation of the ING1 candidate tumour suppressor promotes growth in soft agar and focus formation in vitro and tumour formation in vivo. ING1 encodes a nuclear, cell cycle-regulated protein, overexpression of which efficiently blocks cell growth and is capable of inducing apoptosis in different experimental systems. Here we present the first report of ING1 mutation and expression analysis in a total of 452 cancer samples. One germline missense alteration and three germline silent alterations were detected in 377 primary breast cancers while marked (2-10-fold) decreases in ING1 mRNA expression were seen in 44% of primary breast cancers and in ten of ten breast cancer cell lines examined. Furthermore, the majority of breast cancers (58%) showing decreased ING1 expression had metastasized to regional lymph nodes whereas only 9% of cancers with elevated ING1 expression, compared to adjacent normal tissues, were metastatic. Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.	Univ Calgary, Fac Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada; Nagoya City Univ, Sch Med, Dept Surg 2, Mizuho Ku, Nagoya, Aichi 4678601, Japan; Univ Manitoba, Fac Med, Dept Pathol, Winnipeg, MB R3E 0W3, Canada; Univ Saskatchewan, Royal Hosp, Coll Med, Dept Pathol, Saskatoon, SK S7N 0W8, Canada; Foothills Prov Gen Hosp, Dept Pathol, Calgary, AB T2N 2T9, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Nagoya City University; University of Manitoba; University of Saskatchewan; University of Calgary	Riabowol, K (corresponding author), Univ Calgary, Fac Med, Dept Biochem & Mol Biol, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Magliocco, Anthony M/E-5723-2010	Watson, Peter/0000-0002-1642-0638; Toyama, Tatsuya/0000-0003-4713-7795				Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dobrovic A, 1997, CANCER RES, V57, P3347; Garkavtsev I, 1997, HYBRIDOMA, V16, P537, DOI 10.1089/hyb.1997.16.537; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; Helbing CC, 1997, CANCER RES, V57, P1255; HERMAN JG, 1995, CANCER RES, V55, P4525; Iwase H, 1996, CANCER LETT, V108, P179, DOI 10.1016/S0304-3835(96)04406-0; *JAP BREAST CANC S, 1992, GEN RUL CLIN PATH RE, P1; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Maestro R, 1996, CANCER RES, V56, P1146; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOTOMURA K, 1988, Genomics, V2, P180, DOI 10.1016/0888-7543(88)90101-2; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; WONG H, 1994, ANAL BIOCHEM, V223, P251, DOI 10.1006/abio.1994.1581; YAMASHITA H, 1993, JPN J CANCER RES, V84, P871, DOI 10.1111/j.1349-7006.1993.tb02060.x; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414	28	124	141	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 16	1999	18	37					5187	5193		10.1038/sj.onc.1202905	http://dx.doi.org/10.1038/sj.onc.1202905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235RE	10498868				2022-12-17	WOS:000082555700007
J	Yokomizo, A; Mai, M; Tindall, DJ; Cheng, L; Bostwick, DG; Naito, S; Smith, DI; Liu, WG				Yokomizo, A; Mai, M; Tindall, DJ; Cheng, L; Bostwick, DG; Naito, S; Smith, DI; Liu, WG			Overexpression of the wild type p73 gene in human bladder cancer	ONCOGENE			English	Article						p73; overexpression; allelic expression; imprinting; bladder cancer	TUMOR-SUPPRESSOR GENES; P53 MUTATIONS; NEUROBLASTOMA; CARCINOMA; PROTEIN	p73, a first p53 relative, was recently identified and shown to be monoallelically expressed in a number of different human tissues. To determine the potential role of this gene in human bladder cancer, we investigated p73 expression levels, allelic expression patterns, and analysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and in seven bladder cancer cell lines. In a comparison between normal and turner tissues using quantitative RT-PCR analysis, me found that p73 was overexpressed in 22/23 bladder cancers, sometimes as great as 20-fold. Allelic expression analysis using a C/T polymorphism in exon 2 and a newly identified T/C polymorphism in exon 5 revealed that p73 was biallelically expressed in both normal bladder and cancer tissues, suggesting that p73 is not imprinted in bladder tissue. Mutation screening of the p73 gene in bladder cancer DNAs using denaturing high-performance liquid chromatography analysis and DNA sequencing revealed no tumor-specific mutations in any coding exons of the p73 gene, These data suggest that the p73 is unlikely to be a tumor suppressor gene, but that overexpression of p73 may contribute to tumorigenesis in bladder cancer.	Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55095 USA; Mayo Clin, Dept Urol Res, Rochester, MN 55905 USA; Kyushu Univ, Fac Med, Dept Urol, Fukuoka 812, Japan	Mayo Clinic; Mayo Clinic; Kyushu University	Liu, WG (corresponding author), Mayo Clin, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55095 USA.				NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CordonCardo C, 1997, SEMIN DIAGN PATHOL, V14, P123; CORDONCARDO C, 1994, INT J CANCER, V56, P347, DOI 10.1002/ijc.2910560309; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; Goto K, 1997, MODERN PATHOL, V10, P428; JAMES CD, 1988, CANCER RES, V48, P5546; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KNOWLES MA, 1994, CANCER RES, V54, P531; Liu WG, 1998, NUCLEIC ACIDS RES, V26, P1396, DOI 10.1093/nar/26.6.1396; Mai M, 1998, CANCER RES, V58, P2347; Mai M, 1998, ONCOGENE, V17, P1739, DOI 10.1038/sj.onc.1202099; Mai M, 1998, GENOMICS, V51, P359, DOI 10.1006/geno.1998.5387; MIYAZAKI K, 1993, J BIOL CHEM, V268, P14387; Naito S, 1996, Hum Cell, V9, P49; Oefner P. J., 1995, American Journal of Human Genetics, V57, pA266; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SARKIS AS, 1993, J NATL CANCER I, V85, P53, DOI 10.1093/jnci/85.1.53; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; Tazaki H, 1988, Hum Cell, V1, P78; VERSTEEG R, 1995, EUR J CANCER, V31A, P538, DOI 10.1016/0959-8049(95)00037-J; Yokomizo A, 1998, ONCOGENE, V17, P475, DOI 10.1038/sj.onc.1201956; Yokomizo A, 1998, INT J ONCOL, V13, P101	23	124	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 25	1999	18	8					1629	1633		10.1038/sj.onc.1202474	http://dx.doi.org/10.1038/sj.onc.1202474			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169VX	10102633				2022-12-17	WOS:000078770700013
J	Cayrol, C; Ducommun, B				Cayrol, C; Ducommun, B			Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21	ONCOGENE			English	Article						cyclin-dependent kinases; p21Cip1; PCNA; degradation	S-PHASE; INHIBITOR; P27(KIP1); PROTEIN; PATHWAY; G(1); PHOSPHORYLATION; CELLS; PROGRESSION; RADIATION	The cyclin-dependent kinase (CDK) inhibitor p21(Cip1/Waf1) plays an essential role in the control of cell proliferation by modulating the activity of cyclin/CDK complexes in response to various intracellular or extracellular signals. Small variations in p21 expression levels may determine whether it acts as an inhibitor or an assembly factor for cyclin/CDK complexes. It is therefore critical to better characterize the mechanisms regulating p21 abundance. Here, we show, using a tetracycline-regulated system in p53-deficient DLD-1 human colon cancer cells, that p21 protein levels and stability are regulated by the proteasome-dependent degradation pathway and by association with its partners, CDKs and PCNA, A p21 mutant deficient for interaction with CDKs, p21(CDK-), displayed an enhanced stability and greatly reduced sensitivity to proteasome-mediated proteolysis, indicating that association with cyclin/CDK complexes may trigger p21 degradation. In contrast, a p21 mutant impaired in the interaction with PCNA, p21(PCNA-), exhibited a decreased stability, suggesting that association with PCNA protects p21 from proteasome-dependent degradation. Furthermore, the abundance of p21 itself, in addition to protein-protein interactions, may also modulate p21 stability since we found that high levels of p21 expression overcome proteasome-dependent regulation of p21 accumulation.	Univ Toulouse 3, CNRS, IPBS, F-31077 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Ducommun, B (corresponding author), Univ Toulouse 3, CNRS, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.		DUCOMMUN, Bernard/B-3208-2008; CAYROL, Corinne/C-2106-2011	CAYROL, Corinne/0000-0002-7813-4397; DUCOMMUN, Bernard/0000-0002-7126-8368				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; GOUBIN F, 1995, ONCOGENE, V10, P2281; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hirai A, 1997, J BIOL CHEM, V272, P13; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	34	124	126	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2437	2444		10.1038/sj.onc.1202189	http://dx.doi.org/10.1038/sj.onc.1202189			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824154				2022-12-17	WOS:000076927300003
J	Soucek, L; Helmer-Citterich, M; Sacco, A; Jucker, R; Cesareni, G; Nasi, S				Soucek, L; Helmer-Citterich, M; Sacco, A; Jucker, R; Cesareni, G; Nasi, S			Design and properties of a myc derivative that efficiently homodimerizes	ONCOGENE			English	Article						myc; bHLHZip domain; molecular modelling; protein dimerization; cell proliferation	HELIX-LOOP-HELIX; C-MYC; DNA-BINDING; E-BOX; CELL-GROWTH; TRANSCRIPTIONAL ACTIVATION; RAS COTRANSFORMATION; MAX HETERODIMERS; TRANSGENIC MICE; LEUCINE ZIPPERS	bHLH and bHLHZip are highly conserved structural domains mediating DNA binding and specific protein-protein interactions. They are present in a family of transcription factors, acting as dimers, and their selective dimerization is utilized to switch on and off cell proliferation, differentiation or apoptosis, Myc is a bHLHZip protein involved in growth control and cancer, which operates in a network with the structurally related proteins Max, Mad and Mnt, It does not form homodimers, working as a heterodimer with Max; Mas, instead, forms homodimers and heterodimers with Mad and Mnt. Myc/Max dimers activate gene transcription, while Mad/Max and Mnt/Max complexes are Myc/Mas antagonists and act as repressors. Modifying the molecular recognition of dimers may provide a tool for interfering with MSc function and, in general, for directing the molecular switches operated via bHLH(Zip) proteins. By molecular modelling mutagenesis, we analysed the contribution of amino acids to the molecular recognition of Myc, creating bHLHZip domains with altered dimerization specificity. We report that Myc recognition specificity is encoded in a short region within the leucine zipper; mutation of four amino acids generates a protein, Omomyc, that homodimerizes efficiently and can still heterodimerize with wild type Myc and Max, Omomyc sequestered Myc in complexes with low DNA binding efficiency, preventing binding to Max and inhibiting Myc transcriptional activator function. Consistently with these results, Omomyc produced a proliferation arrest in NIH3T3 cells, These data demonstrate the feasibility of interfering with fundamental biological processes, such as proliferation, by modifying the dimerization selectivity of a bHLHZip protein; this may facilitate the design of peptides of potential pharmacological interest.	Univ La Sapienza, CNR, Ctr Acidi Nucl, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Biol, I-00173 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Rome Tor Vergata	Nasi, S (corresponding author), Univ La Sapienza, CNR, Ctr Acidi Nucl, I-00185 Rome, Italy.		Soucek, Laura/AAG-8377-2019; Soucek, Laura/AAG-7393-2019; Cesareni, Gianni/AAW-1382-2020	Soucek, Laura/0000-0002-4750-7971; Helmer-Citterich, Manuela/0000-0001-9530-7504				Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Ausiello G, 1997, PROTEINS, V28, P556, DOI 10.1002/(SICI)1097-0134(199708)28:4<556::AID-PROT9>3.3.CO;2-C; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CORY S, 1988, ANNU REV IMMUNOL, V6, P25; CROUCH DH, 1990, ONCOGENE, V5, P683; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAVIGNE P, 1995, J MOL BIOL, V254, P505, DOI 10.1006/jmbi.1995.0634; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BC, 1997, MOL CELL BIOL, V17, P4967, DOI 10.1128/MCB.17.9.4967; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; LONGO F, 1995, BIOCHEM BIOPH RES CO, V206, P326, DOI 10.1006/bbrc.1995.1045; MARCHETTI A, 1995, J MOL BIOL, V248, P541, DOI 10.1006/jmbi.1995.0241; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Miller J.H., 1972, EXPT MOL GENETICS; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; MUHLEGOLL C, 1995, BIOCHEMISTRY-US, V34, P13554, DOI 10.1021/bi00041a035; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PENN LJZ, 1990, EMBO J, V9, P113; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZU X, 1997, GENE DEV, V11, P654	61	124	127	1	17	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2463	2472		10.1038/sj.onc.1202199	http://dx.doi.org/10.1038/sj.onc.1202199			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824157				2022-12-17	WOS:000076927300006
J	Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD				Patel, AS; Schechter, GL; Wasilenko, WJ; Somers, KD			Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro	ONCOGENE			English	Article						cortactin; overexpression; motility; invasion	HUMAN BREAST-CANCER; CYCLIN-DEPENDENT KINASES; TYROSINE PHOSPHORYLATION; ALTERED EXPRESSION; HUMAN CARCINOMAS; CONTACT SITES; AMPLIFICATION; CORTACTIN; SUBSTRATE; ONCOGENE	Cortactin, a p80/85 protein first identified as a src kinase substrate, is thought to be involved in the signaling pathway of mitogenic receptors and adhesion molecules mediating cytoskeletal reorganization. The cortactin gene, EMS1, maps to chromosome 11q13, a region amplified in head and neck squamous cell carcinomas (HNSCC) and breast cancer, which display lymph node metastasis and an unfavorable clinical outcome. To further address the role of cortactin in the malignant phenotype of cells, we stably overexpressed cortactin in NIH3T3 fibroblasts and evaluated the effects of elevated cortactin on cellular proliferation, motility and invasiveness. Cortactin overexpressing cells did not display any striking morphological changes, nor any significant differences in cell proliferation or saturation density as compared to control NIH3T3 cells. Furthermore, the cortactin overexpressing cells were anchorage dependent for growth. Interestingly, cortactin overexpressing cells were more motile and invasive in modified Boyden chamber assays. These results suggest that overexpression of cortactin may play a role in tumor progression by influencing tumor cell migration and invasion.	Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA; Eastern Virginia Med Sch, Dept Otolaryngol Head & Neck Surg, Head & Neck Tumor Biol Program, Norfolk, VA 23501 USA	Eastern Virginia Medical School; Eastern Virginia Medical School	Somers, KD (corresponding author), Eastern Virginia Med Sch, Dept Immunol Microbiol, Norfolk, VA 23501 USA.							ADELAIDE J, 1988, ONCOGENE, V2, P413; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Campbell DH, 1996, INT J CANCER, V68, P485, DOI 10.1002/(SICI)1097-0215(19961115)68:4<485::AID-IJC14>3.0.CO;2-4; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CUNNINGHAM CC, 1992, CANCER METAST REV, V11, P69; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FANTL V, 1993, CANCER SURV, V18, P77; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KARLSEDER J, 1994, GENE CHROMOSOME CANC, V9, P42, DOI 10.1002/gcc.2870090108; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MULLER D, 1994, ORAL ONCOL, V30B, P113; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Patel AM, 1996, ONCOGENE, V12, P31; PETERS G, 1995, BREAST CANCER RES TR, V33, P125, DOI 10.1007/BF00682720; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1992, CANCER RES, V52, P5229; SCHUURING E, 1992, ONCOGENE, V7, P355; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1993, ARCH OTOLARYNGOL, V119, P1238; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU L, 1994, INT J CANCER, V59, P383, DOI 10.1002/ijc.2910590316; ZHAN X, 1993, J BIOL CHEM, V268, P24427	33	124	131	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3227	3232		10.1038/sj.onc.1201850	http://dx.doi.org/10.1038/sj.onc.1201850			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681820				2022-12-17	WOS:000074343600002
J	Weissenberger, J; Steinbach, JP; Malin, G; Spada, S; Rulicke, T; Aguzzi, A				Weissenberger, J; Steinbach, JP; Malin, G; Spada, S; Rulicke, T; Aguzzi, A			Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice	ONCOGENE			English	Article						astrocytoma; transgenic mouse model; tumor angiogenesis; tumor progression	ENDOTHELIAL GROWTH-FACTOR; FIBRILLARY ACIDIC PROTEIN; ROUS-SARCOMA VIRUS; BRAIN-TUMORS; GENE-PRODUCT; IN-VIVO; C-SRC; NEURAL TRANSPLANTS; TRANSFORMING GENE; T-ANTIGEN	We have generated a transgenic mouse model for astrocytoma by expressing the v-src kinase under control of the glial fibrillary acidic protein (GFAP) gene regulatory elements in astrocytes, Abnormal astrogliosis was observed in all transgenic animals already at 2 weeks postnatally, frequently followed by the development of dysplastic changes, Later, small proliferative foci arose, and overt astrocytoma developed in the brain and spinal cord in 14.4% of mice after a follow up time of 65 weeks, While early lesions were histologically consistent with low-grade astrocytoma, at later stages most tumors were highly mitotic and frankly malignant, Vascular endothelial growth factor (VEGF) was expressed by tumor cells already at early stages, suggesting induction by v-src, and it was most pronounced in pseudopalisading cells surrounding necrotic areas, implying additional upregulation by hypoxia, In larger lesions, mitotic activity and expression of flk-1, the cognate receptor of VEGF were induced in endothelial cells, Therefore, end-stage tumors mimicked the morphological and molecular characteristics of human glioblastoma multiforme, Time course and stochastic nature of the process indicate that v-src did not suffice for malignant transformation, and that astrocytomas were the result of a multistep process necessitating co-operation of additional genetic events.	UNIV ZURICH HOSP,DEPT PATHOL,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,CENT BIOL LAB,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital			Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				AGUZZI A, 1991, ONCOGENE, V6, P113; AGUZZI A, 1996, TRANSGENICS, V2, P29; BILZER T, 1989, NEUROTOXICOL TERATOL, V11, P551, DOI 10.1016/0892-0362(89)90036-6; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BURGER PC, 1988, CANCER RES, V48, P2871; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DANKS RA, 1995, CANCER RES, V55, P4302; EIBL RH, 1994, AM J PATHOL, V144, P556; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GALEA E, 1995, J NEUROSCI RES, V41, P452, DOI 10.1002/jnr.490410404; HAGUENAU F, 1981, NEUROCHIRURGIE, V27, P251; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hogan B., 1994, MANIPULATING MOUSE E; HOLASH JA, 1993, P NATL ACAD SCI USA, V90, P11069, DOI 10.1073/pnas.90.23.11069; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JEN J, 1994, CANCER RES, V54, P6353; KAWAHARA E, 1988, AM J SURG PATHOL, V12, P115, DOI 10.1097/00000478-198802000-00004; KLEIHUES P, 1989, IARC SCI PUBL, P121; KLEIHUES P, HISTOLOGICAL TYPING; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBE RE, 1989, CELL, V59, P433, DOI 10.1016/0092-8674(89)90028-7; LEVINSON AD, 1978, CELL, V15, P561, DOI 10.1016/0092-8674(78)90024-7; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARINO S, 1995, LAB INVEST, V73, P103; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Millauer B, 1996, CANCER RES, V56, P1615; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MUCKE L, 1991, NEW BIOL, V3, P465; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; OHGAKI H, 1995, VIRCHOWS ARCH, V427, P113, DOI 10.1007/BF00196514; PLATE KH, 1994, INT J CANCER, V59, P520, DOI 10.1002/ijc.2910590415; PLATE KH, 1993, CANCER RES, V53, P5822; SANDS WA, 1994, EUR J IMMUNOL, V24, P2345, DOI 10.1002/eji.1830241013; SARKAR S, 1991, J NEUROCHEM, V57, P675, DOI 10.1111/j.1471-4159.1991.tb03799.x; SATO KI, 1995, BIOCHEM BIOPH RES CO, V210, P844, DOI 10.1006/bbrc.1995.1735; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; TAKENAKA N, 1985, BRAIN RES, V337, P201, DOI 10.1016/0006-8993(85)90055-1; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; VONDEIMLING A, 1994, CANCER RES, V54, P1397	50	124	128	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 1	1997	14	17					2005	2013		10.1038/sj.onc.1201168	http://dx.doi.org/10.1038/sj.onc.1201168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WW809	9160879				2022-12-17	WOS:A1997WW80900001
J	Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF				Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF			Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: Activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q	ONCOGENE			English	Article						human papillomavirus; keratinocytes; allelotyping; loss of heterozygosity; telomerase; immortalization	SQUAMOUS-CELL CARCINOMAS; EPITHELIAL-CELLS; CERVICAL-CARCINOMA; GENETIC-ANALYSIS; UTERINE CERVIX; CHROMOSOME 3P; CANCER; DIFFERENTIATION; SENESCENCE; HETEROZYGOSITY	This study aimed at resolving cellular genetic alterations in the process of in vitro immortalization of human keratinocytes by human papillomavirus (HPV) types 16 and 18. Four cell lines of primary human foreskin keratinocytes transfected with HPV 16 and HPV 18, respectively, were analysed during the transition from the mortal to immortal state, All cell lines showed strong telomerase activity at the immortal state, whereas no or only weak telomerase activity was detected in mortal precursor cells, This was consistent with telomere stabilization or restoration only observed in immortal cells, HPV physical state and copy number appeared constant during immortalization and HPV E6/E7 transcripts were present throughout, Immortalization was associated with clonal allele losses at 3p combined with either 11q or 18q or at 10p, dependent on the cell line, Moreover, a correlation was evident between the onset of telomerase activity and allele loss at 30 or 10p, All immortalized cells retained the capability to differentiate after growth in the presence of physiological calcium and serum, Moreover, one of the immortal cell lines displayed terminal differentiation after organotypic culturing on collagen rafts, The data suggest that (a) several pathways exist for HPV mediated immortalization that may involve genes residing at 3p, 10p, 11q and/or 18q; (b) 3p and 10p may encode genes involved in telomerase regulation; and (c) immortalization lit vitro can be correlated with a spectrum of morphological changes varying from mild to severe dysplasia.	FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, UNIT MOL PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Alabama System; University of Alabama Birmingham				Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BLANTON RA, 1991, AM J PATHOL, V138, P673; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN TM, 1993, CANCER RES, V53, P1167; Chung GTY, 1995, ONCOGENE, V11, P2591; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HERMSEN MAJ, 1996, IN PRESS HUMAN PATHO; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KARLSEN F, 1994, INT J CANCER, V58, P787, DOI 10.1002/ijc.2910580606; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; SASAKI M, 1994, CANCER RES, V54, P6090; SEAGON S, 1994, CANCER RES, V54, P5593; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Snijders P J, 1994, Curr Top Microbiol Immunol, V186, P177; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANLEY M, 1994, PAPILLOMAVIRUS REP, V5, P141; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; WALBOOMERS JMM, 1988, AM J PATHOL, V131, P587; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1990, CANCER RES, V50, P3709	49	124	126	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1249	1257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808699				2022-12-17	WOS:A1996VJ20200016
J	Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS			SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells	ONCOGENE			English	Article						ovarian cancer; SPARC; tumor suppressor; RNA fingerprinting	MESSENGER-RNA; INSITU HYBRIDIZATION; ENDOTHELIAL-CELLS; OSTEONECTIN; EXPRESSION; GLYCOPROTEIN; GENE; SEQUENCES; SECRETION; TISSUES	SPARC, also termed osteonectin, BM-40 and 43K protein, is an acidic, cysteine-rich component of the extracellular matrix that has been shown to be directly regulated by progesterone and dexamethasone and indirectly by cytokines. By RNA fingerprinting technique, we cloned a SPARC homolog from the normal human ovarian surface epithelial (HOSE) cells and demonstrated that it is expressed at high levels in the normal HOSE cells but at much lower levels in ovarian carcinoma cells in vitro and in vivo. Subsequently, we transfected the full length SPARC cDNA into an ovarian carcinoma cell line SKOV3 and showed that it reduced the growth rate of the cancer cell line in culture and reduced the cell's ability to induce tumours in nude mice. These results suggest that SPARC may play an important role in growth and and differentiation of the HOSE cells and support the hypothesis that SPARC functions as a tumor suppressor.	PACIFIC NW LAB, RICHLAND, WA 99352 USA; CHINESE UNIV HONG KONG, DEPT ANAT, SHA TIN, HONG KONG	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Chinese University of Hong Kong	Mok, SC (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, LAB GYNECOL ONCOL, DEPT OBSTET GYNECOL & REPROD BIOL, BOSTON, MA 02115 USA.		Chan, Wood Yee/R-6692-2018; Wong, K.-k./AAA-6589-2020	Chan, Wood Yee/0000-0002-7114-1463; Wong, K.-k./0000-0002-0375-6669	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P1919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HOWE CC, 1990, EXP CELL RES, V188, P185, DOI 10.1016/0014-4827(90)90158-7; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANKAT-BUTTGEREIT B, 1991, Journal of Dermatological Science, V2, P300, DOI 10.1016/0923-1811(91)90054-2; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NERI M, 1992, EUR J BIOCHEM, V205, P569, DOI 10.1111/j.1432-1033.1992.tb16814.x; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NOMURA S, 1989, J BIOL CHEM, V264, P12201; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; PIVER MS, 1992, GYNECOL ONCOL, P250; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P579, DOI 10.1139/o92-089; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049	31	124	130	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1895	1901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649850				2022-12-17	WOS:A1996UK49800008
J	Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K				Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K			Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1	ONCOGENE			English	Article						Ras; Raf; 14-3-3 protein; signal transduction	KINASE-KINASE; RAF-1 KINASE; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PURIFICATION; ANTIBODIES; ONCOGENE; DOMAIN; BRAIN; MIL	The serine/threonine protein kinase c-Raf-1 interacts with a number of cellular proteins including 14-3-3 isoforms which may be regulators or substrates of c-Raf-1 in signal transduction pathways, In vivo and in vitro binding analyses of c-Raf-1 and mutant proteins with 14-3-3 zeta indicate bivalent binding of 14-3-3 zeta to the amino terminus as well as to the carboxy terminus of c-Raf-1, Although 14-3-3 zeta and Ras use different binding regions on the amino terminal regulatory domain of c-Raf-1 (c-Raf-NT), 14-3-3 zeta is displaced from the amino terminus upon binding of activated Ras, In contrast, if c-Raf-1 full length is analysed instead of the separately expressed c-Raf-NT, binding of 14-3-3 zeta is only slightly effected by co-expression of activated Ras, This is explained by a second binding site of 14-3-3 zeta at the carboxy terminus of c-Raf-1. The mutant c-Raf-NT (S259A) cannot bind 14-3-3 zeta, suggesting a regulatory role of this in vivo phosphorylation site, However, c-Raf-NT phosphorylated or unphosphorylated at S259, is able to bind 14-3-3 zeta, Even though 14-3-3 zeta can be phosphorylated in vivo, only the unphosphorylated form binds to the amino terminus of c-Raf-1, The data presented indicate, that 14-3-3 zeta binds to c-Raf-1 in a bivalent fashion in unstimulated cells, 14-3-3 zeta is displaced from the amino terminus but not from the carboxy terminus of c-Raf-1 by binding of activated Ras to c-Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND; NATL INST MED RES, LAB PROT STRUCT, LONDON NW7 1AA, ENGLAND	University of Zurich; MRC National Institute for Medical Research				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAMAL S, 1995, ONCOGENE, V10, P2095; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; NIEHOF M, 1994, BIOCHEM BIOPH RES CO, V203, P1560, DOI 10.1006/bbrc.1994.2364; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1994, ONCOGENE, V9, P2751; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	124	126	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					609	619						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637718				2022-12-17	WOS:A1996TV59700018
J	DEJARDIN, E; BONIZZI, G; BELLAHCENE, A; CASTRONOVO, V; MERVILLE, MP; BOURS, V				DEJARDIN, E; BONIZZI, G; BELLAHCENE, A; CASTRONOVO, V; MERVILLE, MP; BOURS, V			HIGHLY-EXPRESSED P100/P52 (NFKB2) SEQUESTERS OTHER NF-KAPPA-B-RELATED PROTEINS IN THE CYTOPLASM OF HUMAN BREAST-CANCER CELLS	ONCOGENE			English	Article						TRANSCRIPTION FACTORS; NF-KAPPA-B; NFKB2; BREAST CANCER	DNA-BINDING SUBUNIT; V-REL ONCOGENE; TRANSCRIPTION FACTORS; P65 SUBUNIT; C-REL; ANTISENSE INHIBITION; ONCOPROTEIN BCL-3; GENE-EXPRESSION; P50; PRECURSOR	Several observations have suggested that NF-kappa B transcription factors could be involved in carcinogenesis. To investigate the possibility that members of the NF-kappa B family participate in the molecular control of the transformed phenotype, we examined the expression of these proteins in human breast cancer cell lines as web as in primary tumors. Western Immunoblots demonstrated high expression of the p52 precursor p100 (NFKB2) in several breast cancer cell lines while human mammary epithelial cells express this protein only faintly. Eighteen primary breast tumors out of 24 displayed significant expression of the p100/p52 protein. In MDA-MB-435 cells, overexpressed p100 and p52 are predominantly cytoplasmic and coimmunoprecipitation experiments demonstrated that p100 sequesters the heterodimer p50/p65 in the cytoplasm. We demonstrate that most p65 protein is complexed with p100 in these cells while it is complexed predominantly with I kappa B-alpha in cell lines expressing less p100. Our data strengthen the hypothesis that NF-kappa B could be involved in carcinogenesis and suggest that the p100/p52 NF-kappa B submit could play a role in the development of human breast cancers, possibly by sequestering other NF-kappa B-related proteins in the cytoplasm.	UNIV LIEGE,DEPT MED ONCOL,B-4000 LIEGE,BELGIUM; UNIV LIEGE,DEPT MED CHEM,B-4000 LIEGE,BELGIUM; UNIV LIEGE,METASTASIS RES LAB,B-4000 LIEGE,BELGIUM	University of Liege; University of Liege; University of Liege			Dejardin, Emmanuel/AAE-9076-2021					ABMAYR SM, 1990, CURRENT PROTOCOLS MO; ANISOWICZ A, 1991, J IMMUNOL, V147, P250; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; DODRZANSKI P, 1993, MOL CELL BIOL, V13, P1572; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; MATHEW S, 1993, ONCOGENE, V8, P191; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MOORE BE, 1988, MUTAT RES, V195, P79, DOI 10.1016/0165-1110(88)90016-4; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PEPIN N, 1994, VIROLOGY, V204, P706, DOI 10.1006/viro.1994.1586; PLASKIN D, 1993, J EXP MED, V177, P1651; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SATO H, 1993, ONCOGENE, V8, P395; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WU HY, 1994, J BIOL CHEM, V269, P20067; ZHANG JD, 1994, ONCOGENE, V9, P1931	54	124	127	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1835	1841						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478612				2022-12-17	WOS:A1995TD09400019
J	KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J				KONDO, S; BARNETT, GH; HARA, H; MORIMURA, T; TAKEUCHI, J			MDM2 PROTEIN CONFERS THE RESISTANCE OF A HUMAN GLIOBLASTOMA CELL-LINE TO CISPLATIN-INDUCED APOPTOSIS	ONCOGENE			English	Article						MDM2; CISPLATIN; P53; GLIOMA AND APOPTOSIS	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; DNA-DAMAGING AGENTS; CANCER-CHEMOTHERAPY; ANTICANCER AGENTS; GENE; INDUCTION; EXPRESSION; ACTIVATION; GROWTH	Induction of apoptosis in tumor cells is an important mechanism of chemotherapy-induced cell death. The tumor-suppressor gene p53 is required for the efficient activation of apoptosis following chemotherapy. However,, the molecular mechanism regulating p53-associated apoptosis remains controversial. In this study, we show that the expression of both wild-type p53 and MDM2 (murine double minute 2) proteins was induced when cisdiamminedichloroplatinum (cisplatin) caused apoptosis in human glioblastoma U87-MG cells, which expressed neither wild-type p53 nor MDM2 protein prior to treatment, Overexpression of MDM2 in U87-MG cells transfected with human mdm2 expression vector conferred the resistance of tumor cell to cisplatin-induced apoptosis, In contrast, the treatment with mdm2 antisense oligonucleotide targeted against mdm2 mRNA increased the susceptibility of tumor cells to apoptosis. Changes in expression level of MDM2 protein, however, did not affect the expression of wild-type p53 protein. These findings suggest that MDM2 protein may act as a negative regulator of cisplatin-induced apoptosis, and moreover, may play an important role in the development of resistance to cisplatin in human tumors.	NATL UTANO HOSP,DEPT CLIN RES CTR,KYOTO,JAPAN; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO,JAPAN		KONDO, S (corresponding author), CLEVELAND CLIN FDN,CTR CANC,CTR BRAIN TUMOR,DEPT NEUROSURG,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.							AKELLA R, 1992, EUR J IMMUNOL, V22, P1069, DOI 10.1002/eji.1830220429; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CAI DW, 1993, HUM GENE THER, V4, P617, DOI 10.1089/hum.1993.4.5-617; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COTTER TG, 1992, ANTICANCER RES, V12, P773; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJIWARA T, 1994, CANCER RES, V54, P2287; HARPER JW, 1993, CELL, V75, P805; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KONDO S, 1994, BRIT J CANCER, V69, P627, DOI 10.1038/bjc.1994.123; KONDO S, 1994, CANCER RES, V54, P2928; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PRICE BD, 1994, CANCER RES, V54, P896; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	49	124	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2001	2006						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761100				2022-12-17	WOS:A1995QZ92600014
J	Goldschneider, D; Mehlen, P				Goldschneider, D.; Mehlen, P.			Dependence receptors: a new paradigm in cell signaling and cancer therapy	ONCOGENE			English	Review						dependence receptors; apoptosis; caspase; tumor progression; cancer therapy	NERVE GROWTH-FACTOR; REPULSIVE GUIDANCE MOLECULE; P75 NEUROTROPHIN RECEPTOR; TUMOR-SUPPRESSOR GENE; FOREBRAIN CHOLINERGIC NEURONS; ANAPLASTIC LYMPHOMA KINASE; AMYLOID PRECURSOR PROTEIN; PRODUCT INDUCES APOPTOSIS; LIPID RAFT LOCALIZATION; AFFINITY NGF RECEPTOR	Dependence receptors (DRs) now form a family of more than a dozen membrane receptors that are not linked by their structure, but by common functional traits. The most notable is their ability to trigger two opposite signaling pathways: in the presence of ligand, these receptors activate classic signaling pathways implicated in cell survival, migration and differentiation. In the absence of ligand, they do not stay inactive, rather they elicit an apoptotic signal. Thus, cells expressing this kind of receptor are dependent on the presence of ligand in the extracellular environment to survive. This review will recapitulate the increasing data regarding the molecular mechanisms associated with DRs, their potential implication during development, as well as their deregulation during tumorigenesis and, finally, their emergence as new possible therapeutic targets for cancer treatment. Oncogene (2010) 29, 1865-1882; doi:10.1038/onc.2010.13; published online 22 February 2010	[Goldschneider, D.; Mehlen, P.] Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, Equipe Labellisee La Ligue,CNRS,UMR5238, F-69008 Lyon, Rhone, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Centre Leon Berard	Mehlen, P (corresponding author), Univ Lyon, Ctr Leon Berard, Canc & Dev Lab, Equipe Labellisee La Ligue,CNRS,UMR5238, 28 Rue Laennec, F-69008 Lyon, Rhone, France.	mehlen@lyon.fnclcc.fr						Allouche M, 2007, CELL CYCLE, V6, P1533, DOI 10.4161/cc.6.13.4433; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Baloh RH, 2000, CURR OPIN NEUROBIOL, V10, P103, DOI 10.1016/S0959-4388(99)00048-3; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bernet A, 2007, GASTROENTEROLOGY, V133, P1840, DOI 10.1053/j.gastro.2007.08.009; Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Canibano C, 2007, EMBO J, V26, P2015, DOI 10.1038/sj.emboj.7601636; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Castets M, 2009, DEV CELL, V16, P614, DOI 10.1016/j.devcel.2009.02.006; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; Charrier JB, 1999, DEVELOPMENT, V126, P4771; Charrier JB, 2001, DEVELOPMENT, V128, P4011; Chen YQ, 1999, ONCOGENE, V18, P2747, DOI 10.1038/sj.onc.1202629; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; Clark Peter E, 2003, Methods Mol Med, V81, P255; Cohen LY, 2005, CELL DEATH DIFFER, V12, P243, DOI 10.1038/sj.cdd.4401568; Coulson EJ, 2000, J BIOL CHEM, V275, P30537, DOI 10.1074/jbc.M005214200; Craft N, 1998, CANCER METAST REV, V17, P421, DOI 10.1023/A:1006141806801; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Delloye-Bourgeois C, 2009, J EXP MED, V206, P833, DOI 10.1084/jem.20082299; Delloye-Bourgeois C, 2009, JNCI-J NATL CANCER I, V101, P237, DOI 10.1093/jnci/djn491; Depaepe V, 2005, NATURE, V435, P1244, DOI 10.1038/nature03651; Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Fitamant J, 2008, P NATL ACAD SCI USA, V105, P4850, DOI 10.1073/pnas.0709810105; Forcet C, 2001, P NATL ACAD SCI USA, V98, P3416, DOI 10.1073/pnas.051378298; Foveau B, 2007, CELL DEATH DIFFER, V14, P752, DOI 10.1038/sj.cdd.4402080; Fox BP, 2004, BIOCHEM BIOPH RES CO, V318, P882, DOI 10.1016/j.bbrc.2004.04.102; Frade JM, 1996, NATURE, V383, P166; Fujita Y, 2008, CELL DEATH DIFFER, V15, P1593, DOI 10.1038/cdd.2008.92; Furne C, 2006, P NATL ACAD SCI USA, V103, P4128, DOI 10.1073/pnas.0507864103; Furne C, 2008, P NATL ACAD SCI USA, V105, P14465, DOI 10.1073/pnas.0803645105; Furne C, 2009, BBA-MOL CELL RES, V1793, P231, DOI 10.1016/j.bbamcr.2008.09.009; Geisbrecht BV, 2003, J BIOL CHEM, V278, P32561, DOI 10.1074/jbc.M302943200; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Grady WM, 2007, GASTROENTEROLOGY, V133, P2045, DOI 10.1053/j.gastro.2007.10.034; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kang JS, 2004, J CELL BIOL, V167, P493, DOI 10.1083/jcb.200405039; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Kato H, 2000, BRIT J CANCER, V82, P459, DOI 10.1054/bjoc.1999.0943; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kim DH, 2001, ONCOGENE, V20, P1765, DOI 10.1038/sj.onc.1204302; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; KLINGELHUTZ AJ, 1993, ONCOGENE, V8, P95; Koike C, 2002, ONCOGENE, V21, P2670, DOI 10.1038/sj.onc.1205370; Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A; Koo EH, 2002, TRAFFIC, V3, P763, DOI 10.1034/j.1600-0854.2002.31101.x; Kotzbauer PT, 1996, NATURE, V384, P467, DOI 10.1038/384467a0; Lee DK, 2003, J STEROID BIOCHEM, V84, P41, DOI 10.1016/S0960-0760(03)00005-0; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lejmi E, 2008, P NATL ACAD SCI USA, V105, P12491, DOI 10.1073/pnas.0804008105; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEVIMONTALCINI R, 1963, DEV BIOL, V7, P653, DOI 10.1016/0012-1606(63)90149-0; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Link BC, 2007, ANN SURG ONCOL, V14, P2591, DOI 10.1245/s10434-007-9469-6; Liu J, 2002, J BIOL CHEM, V277, P26281, DOI 10.1074/jbc.M204679200; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Lourenco FC, 2009, CELL DEATH DIFFER, V16, P655, DOI 10.1038/cdd.2008.191; Lu XW, 2004, NATURE, V432, P179, DOI 10.1038/nature03080; Lykissas MG, 2007, CURR NEUROVASC RES, V4, P143, DOI 10.2174/156720207780637216; Maisse C, 2008, EXP CELL RES, V314, P2544, DOI 10.1016/j.yexcr.2008.06.001; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Matsunaga E, 2004, NAT CELL BIOL, V6, P749, DOI 10.1038/ncb1157; Mazelin L, 2004, NATURE, V431, P80, DOI 10.1038/nature02788; Mehlen P, 2005, CELL MOL LIFE SCI, V62, P2599, DOI 10.1007/s00018-005-5191-3; Mehlen P, 2004, J CLIN ONCOL, V22, P3420, DOI 10.1200/JCO.2004.02.019; Mehlen P, 2004, CELL MOL LIFE SCI, V61, P1854, DOI 10.1007/s00018-004-3467-7; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Mehlen P, 2003, BIOL CELL, V95, P425, DOI 10.1016/S0248-4900(03)00072-8; Meyerhardt JA, 1997, ONCOGENE, V14, P1129, DOI 10.1038/sj.onc.1200935; Mille F, 2009, CELL DEATH DIFFER, V16, P1344, DOI 10.1038/cdd.2009.75; Mille F, 2009, NAT CELL BIOL, V11, P739, DOI 10.1038/ncb1880; Minichiello L, 1995, DEVELOPMENT, V121, P4067; Monnier PP, 2002, NATURE, V419, P392, DOI 10.1038/nature01041; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Mourali J, 2006, MOL CELL BIOL, V26, P6209, DOI 10.1128/MCB.01515-05; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Naumann T, 2002, J NEUROSCI, V22, P2409, DOI 10.1523/JNEUROSCI.22-07-02409.2002; Nelson KA, 2002, AM J EPIDEMIOL, V155, P883, DOI 10.1093/aje/155.10.883; Nguyen TVV, 2008, J NEUROCHEM, V104, P1065, DOI 10.1111/j.1471-4159.2007.05031.x; Niederkofler V, 2004, J NEUROSCI, V24, P808, DOI 10.1523/JNEUROSCI.4610-03.2004; Paradisi A, 2008, GASTROENTEROLOGY, V135, P1248, DOI 10.1053/j.gastro.2008.06.080; Paradisi A, 2009, P NATL ACAD SCI USA, V106, P17146, DOI 10.1073/pnas.0901767106; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Peterziel H, 2007, J NEUROCHEM, V103, P2491, DOI 10.1111/j.1471-4159.2007.04962.x; Pflug B, 1998, MOL CARCINOGEN, V23, P106, DOI 10.1002/(SICI)1098-2744(199810)23:2<106::AID-MC7>3.0.CO;2-W; Puschel AW, 1999, MECH DEVELOP, V83, P65, DOI 10.1016/S0925-4773(99)00035-0; Qin ST, 2007, MOL CELL NEUROSCI, V34, P243, DOI 10.1016/j.mcn.2006.11.002; Rabizadeh S, 2000, J MOL NEUROSCI, V15, P215, DOI 10.1385/JMN:15:3:215; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rajasekharan S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-239; Raveh T, 2001, EXP CELL RES, V264, P185, DOI 10.1006/excr.2000.5134; Ricard J, 2006, MOL CELL NEUROSCI, V31, P713, DOI 10.1016/j.mcn.2006.01.002; Rodrigues S, 2007, ONCOGENE, V26, P5615, DOI 10.1038/sj.onc.1210347; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; Saito M, 1999, ONCOLOGY-BASEL, V56, P134, DOI 10.1159/000011954; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; SANTISTEBAN DA, 1994, J CHILD ADOLES SUBST, V3, P9, DOI 10.1300/J029v03n02_02; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schmidtmer J, 2004, GENE EXPR PATTERNS, V4, P105, DOI 10.1016/S1567-133X(03)00144-3; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Scott RP, 2001, J BIOL CHEM, V276, P1450, DOI 10.1074/jbc.M006157200; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shibata D, 1996, NEW ENGL J MED, V335, P1727, DOI 10.1056/NEJM199612053352303; Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Sieber OM, 2000, MOL MED TODAY, V6, P462; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Srinivasan K, 2003, DEV CELL, V4, P371, DOI 10.1016/S1534-5807(03)00054-6; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Stupack D.G., 2002, SCI STKE, P7; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Stupack DG, 2005, CELL DEATH DIFFER, V12, P1021, DOI 10.1038/sj.cdd.4401658; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun XF, 1999, J CLIN ONCOL, V17, P1745, DOI 10.1200/JCO.1999.17.6.1745; Tang XL, 2008, NAT CELL BIOL, V10, P698, DOI 10.1038/ncb1732; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; Tanikawa C, 2003, NAT CELL BIOL, V5, P216, DOI 10.1038/ncb943; Tauszig-Delamasure S, 2007, P NATL ACAD SCI USA, V104, P13361, DOI 10.1073/pnas.0701243104; TESSAROLLO L, 1994, P NATL ACAD SCI USA, V91, P11844, DOI 10.1073/pnas.91.25.11844; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405; Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tikhomirov O, 2005, ONCOGENE, V24, P3906, DOI 10.1038/sj.onc.1208534; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Velcich A, 1999, ONCOGENE, V18, P2599, DOI 10.1038/sj.onc.1202610; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; Wang H, 2008, BIOCHEM BIOPH RES CO, V370, P594, DOI 10.1016/j.bbrc.2008.03.152; Wang JJL, 2000, J NEUROSCI RES, V60, P587, DOI 10.1002/(SICI)1097-4547(20000601)60:5<587::AID-JNR3>3.0.CO;2-1; Wang R, 2009, MOL CELL, V33, P692, DOI 10.1016/j.molcel.2009.02.016; Wicking C, 2001, CANCER LETT, V173, P1, DOI 10.1016/S0304-3835(01)00676-0; Williams ME, 2003, J BIOL CHEM, V278, P17483, DOI 10.1074/jbc.M300415200; Wilson BD, 2006, SCIENCE, V313, P640, DOI 10.1126/science.1124704; Wilson NH, 2006, DEV BIOL, V296, P485, DOI 10.1016/j.ydbio.2006.06.018; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yamashiro DJ, 1997, EUR J CANCER, V33, P2054, DOI 10.1016/S0959-8049(97)00309-2; Yeo TT, 1997, J NEUROSCI, V17, P7594	177	123	130	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	13					1865	1882		10.1038/onc.2010.13	http://dx.doi.org/10.1038/onc.2010.13			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	577CV	20173780				2022-12-17	WOS:000276199600001
J	Kovall, RA				Kovall, R. A.			More complicated than it looks: assembly of Notch pathway transcription complexes	ONCOGENE			English	Review						CSL; Mastermind; signal transduction; transcriptional regulation; protein-protein interactions	T-CELL LEUKEMIA; CRYSTAL-STRUCTURE; ANKYRIN DOMAIN; CAENORHABDITIS-ELEGANS; MASTERMIND; CSL; ACTIVATION; PROTEINS; RECEPTOR; ROLES	The Notch pathway is a short-range signaling mechanism between neighboring cells that results in changes in gene expression. Extracellular interactions between Notch receptors and ligands trigger proteolytic cleavage of the receptor Notch. Following cleavage, the freed intracellular domain of Notch (NotchIC) moves from the cytoplasm to the nucleus, engaging the DNA-binding transcription factor CBF-1, Su(H), Lag-1 (CSL) - the nuclear effector of the pathway. NotchIC, together with the transcriptional coactivator Mastermind, form a ternary complex with CSL that activates transcription from genes that are responsive to Notch signaling. Illuminating the molecular details that underlie formation of the transcriptionally active CSL-NotchIC-Mastermind ternary complex is key for understanding how genes are turned on in response to a Notch signal. Recently, several studies using biophysical and computational methods have scrutinized how the CSL-NotchIC-Mastermind ternary complex forms and the role individual domains play in this process. These detailed analyses have provided a wealth of molecular insights into the assembly of a Notch pathway active transcription complex but have also raised several intriguing, yet confounding questions. This review will focus on the findings of these recent biophysical studies and provide speculative models that address these unanswered questions.	Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Coll Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kovall, RA (corresponding author), Univ Cincinnati, Dept Mol Genet Biochem & Microbiol, Coll Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	kovallra@ucmail.uc.edu	Kovall, Rhett/A-3106-2008		NIH; University of Cincinnati Barrett Cancer Center	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Cincinnati Barrett Cancer Center	I thank the members of my laboratory for the stimulating discussions regarding Notch signaling, which spurred the writing of this review. In particular, I thank Jeffrey Wilson and David Friedmann for editing the manuscript and assistance with creation of the figures. I am also very grateful for the biophysical expertise and constructive criticism provided by my departmental colleagues Andrew Herr and Tom Thompson. This work was supported by grants from the NIH and the University of Cincinnati Barrett Cancer Center.	Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bergqvist S, 2006, J MOL BIOL, V360, P421, DOI 10.1016/j.jmb.2006.05.014; Bertagna A, 2008, BIOCHEM SOC T, V36, P157, DOI 10.1042/BST0360157; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Chiang MY, 2006, MOL CELL BIOL, V26, P6261, DOI 10.1128/MCB.02478-05; Christensen S, 1996, DEVELOPMENT, V122, P1373; Del Bianco C, 2008, J MOL BIOL, V376, P131, DOI 10.1016/j.jmb.2007.11.061; Dyson HJ, 2005, NAT REV MOL CELL BIO, V6, P197, DOI 10.1038/nrm1589; Ehebauer MT, 2005, BIOCHEM J, V392, P13, DOI 10.1042/BJ20050515; Friedmann DR, 2008, J BIOL CHEM, V283, P14781, DOI 10.1074/jbc.M709501200; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; High FA, 2008, NAT REV GENET, V9, P49, DOI 10.1038/nrg2279; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kimble J, 2007, ANNU REV CELL DEV BI, V23, P405, DOI 10.1146/annurev.cellbio.23.090506.123326; Koch U, 2007, CELL MOL LIFE SCI, V64, P2746, DOI 10.1007/s00018-007-7164-1; Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Lubman OY, 2005, PROTEIN SCI, V14, P1274, DOI 10.1110/ps.041184105; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Mosavi LK, 2004, PROTEIN SCI, V13, P1435, DOI 10.1110/ps.03554604; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Ruas JL, 2007, CURR OPIN LIPIDOL, V18, P508, DOI 10.1097/MOL.0b013e3282efe49d; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Tanigaki K, 2007, NAT IMMUNOL, V8, P451, DOI 10.1038/ni1453; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Zhou SF, 2001, MOL CELL BIOL, V21, P6222, DOI 10.1128/MCB.21.18.6222-6232.2001; Zweifel ME, 2003, PROTEIN SCI, V12, P2622, DOI 10.1110/ps.03279003	45	123	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2008	27	38					5099	5109		10.1038/onc.2008.223	http://dx.doi.org/10.1038/onc.2008.223			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	344GM	18758478	Bronze			2022-12-17	WOS:000258914900003
J	van Gent, DC; van der Burg, M				van Gent, D. C.; van der Burg, M.			Non-homologous end-joining, a sticky affair	ONCOGENE			English	Review						DNA repair; V(D)J recombination; DNA double-strand break repair; severe combined immuno-deficiency; DNA damage response; chromosomal instability	DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; DNA-LIGASE-IV; SEVERE COMBINED IMMUNODEFICIENCY; INCREASED GENOMIC INSTABILITY; COMBINED IMMUNE-DEFICIENCY; ARTEMIS GENE-MUTATIONS; LEAKY SCID PHENOTYPE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT	Rejoining of broken chromosomes is crucial for cell survival and prevention of malignant transformation. Most mammalian cells rely primarily on the non-homologous end-joining pathway of DNA double-strand break (DSB) repair to accomplish this task. This review focuses both on the core non-homologous end-joining machinery, which consists of DNA-dependent protein kinase and the ligase IV/XRCC4 complex, and on accessory factors that facilitate rejoining of a subset of the DSBs. We discuss how the ATM protein kinase and the Mre11/Rad50/Nbs1 complex might function in DSB repair and what role ionizing radiation-induced foci may play in this process.	[van Gent, D. C.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, NL-3000 CA Rotterdam, Netherlands; [van der Burg, M.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Immunol, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Gent, DC (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Cell Biol & Genet, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.vangent@erasmusmc.nl		van Gent, Dik C./0000-0003-1473-8148				Ahnesorg P, 2006, CELL, V124, P301, DOI 10.1016/j.cell.2005.12.031; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Bryans M, 1999, MUTAT RES-DNA REPAIR, V433, P53, DOI 10.1016/S0921-8777(98)00063-9; Buck D, 2006, CELL, V124, P287, DOI 10.1016/j.cell.2005.12.030; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Capp JP, 2007, NUCLEIC ACIDS RES, V35, P3551, DOI 10.1093/nar/gkm243; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Celeste A, 2003, NAT CELL BIOL, V5, P675, DOI 10.1038/ncb1004; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Costantini S, 2007, DNA REPAIR, V6, P712, DOI 10.1016/j.dnarep.2006.12.007; Cui XP, 2005, MOL CELL BIOL, V25, P10842, DOI 10.1128/MCB.25.24.10842-10852.2005; Darroudi F, 2007, MUTAT RES-FUND MOL M, V615, P111, DOI 10.1016/j.mrfmmm.2006.11.029; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; Deckbar D, 2007, J CELL BIOL, V176, P749, DOI 10.1083/jcb.200612047; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; Digweed M, 1999, BIOESSAYS, V21, P649, DOI 10.1002/(SICI)1521-1878(199908)21:8<649::AID-BIES4>3.0.CO;2-O; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2007, MOL CELL BIOL, V27, P1581, DOI 10.1128/MCB.01962-06; Drouet J, 2005, J BIOL CHEM, V280, P7060, DOI 10.1074/jbc.M410746200; Ege M, 2005, BLOOD, V105, P4179, DOI 10.1182/blood-2004-12-4861; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Goodarzi AA, 2006, EMBO J, V25, P3880, DOI 10.1038/sj.emboj.7601255; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR BIOL, V8, P873, DOI 10.1016/S0960-9822(07)00349-1; Gu JF, 2007, NUCLEIC ACIDS RES, V35, P5755, DOI 10.1093/nar/gkm579; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hsu HL, 2002, DNA REPAIR, V1, P225, DOI 10.1016/S1568-7864(01)00018-0; Iliakis G, 2004, CYTOGENET GENOME RES, V104, P14, DOI 10.1159/000077461; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Junop MS, 2000, EMBO J, V19, P5962, DOI 10.1093/emboj/19.22.5962; Kabotyanski EB, 1998, NUCLEIC ACIDS RES, V26, P5333, DOI 10.1093/nar/26.23.5333; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Kobayashi N, 2003, HUM GENET, V112, P348, DOI 10.1007/s00439-002-0897-x; Koch CA, 2004, EMBO J, V23, P3874, DOI 10.1038/sj.emboj.7600375; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JW, 2004, J BIOL CHEM, V279, P805, DOI 10.1074/jbc.M307913200; LEE K, 2001, J ARTIFICIAL LIFE RO, V4, P182; Lee Y, 2007, NEUROSCIENCE, V145, P1365, DOI 10.1016/j.neuroscience.2006.07.026; Li LY, 2002, J IMMUNOL, V168, P6323, DOI 10.4049/jimmunol.168.12.6323; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Ma YM, 2005, J BIOL CHEM, V280, P33839, DOI 10.1074/jbc.M507113200; Mari PO, 2006, P NATL ACAD SCI USA, V103, P18597, DOI 10.1073/pnas.0609061103; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; McKinnon PJ, 2004, EMBO REP, V5, P772, DOI 10.1038/sj.embor.7400210; Meek K, 2007, MOL CELL BIOL, V27, P3881, DOI 10.1128/MCB.02366-06; Modesti M, 2003, J MOL BIOL, V334, P215, DOI 10.1016/j.jmb.2003.09.031; Moreno-Herrero F, 2005, NATURE, V437, P440, DOI 10.1038/nature03927; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2003, J CLIN INVEST, V111, P381, DOI 10.1172/JCI200316774; Nikjoo H, 1998, INT J RADIAT BIOL, V73, P355, DOI 10.1080/095530098142176; Noordzij JG, 2003, BLOOD, V101, P1446, DOI 10.1182/blood-2002-01-0187; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pannicke U, 2004, EMBO J, V23, P1987, DOI 10.1038/sj.emboj.7600206; Poinsignon C, 2004, J EXP MED, V199, P315, DOI 10.1084/jem.20031142; Reddy YVR, 2004, J BIOL CHEM, V279, P39408, DOI 10.1074/jbc.M406432200; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Ristic D, 2003, NUCLEIC ACIDS RES, V31, P5229, DOI 10.1093/nar/gkg729; Rooney S, 2003, J EXP MED, V197, P553, DOI 10.1084/jem.20021891; Rooney S, 2002, MOL CELL, V10, P1379, DOI 10.1016/S1097-2765(02)00755-4; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schatz DG, 2004, IMMUNOL REV, V200, P5, DOI 10.1111/j.0105-2896.2004.00173.x; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Sibanda BL, 2001, NAT STRUCT BIOL, V8, P1015, DOI 10.1038/nsb725; Singleton BK, 1999, MOL CELL BIOL, V19, P3267; Slijepcevic P, 2006, DNA REPAIR, V5, P1299, DOI 10.1016/j.dnarep.2006.05.038; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spagnolo L, 2006, MOL CELL, V22, P511, DOI 10.1016/j.molcel.2006.04.013; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Taylor AMR, 2004, DNA REPAIR, V3, P1219, DOI 10.1016/j.dnarep.2004.04.009; Teo SH, 2000, CURR BIOL, V10, P165, DOI 10.1016/S0960-9822(00)00317-1; Tsai CJ, 2007, P NATL ACAD SCI USA, V104, P7851, DOI 10.1073/pnas.0702620104; Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077; van der Burg M, 2006, J CLIN INVEST, V116, P137, DOI 10.1172/JCI26121; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; van Heemst D, 2004, DNA REPAIR, V3, P43, DOI 10.1016/j.dnarep.2003.09.004; VANDERBURG M, 2007, IN PRESS EUR J IMMUN; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; Verkaik NS, 2002, EUR J IMMUNOL, V32, P701, DOI 10.1002/1521-4141(200203)32:3<701::AID-IMMU701>3.0.CO;2-T; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang JH, 2005, DNA REPAIR, V4, P556, DOI 10.1016/j.dnarep.2005.02.001; Ward IM, 2003, J BIOL CHEM, V278, P19579, DOI 10.1074/jbc.C300117200; Weterings E, 2004, DNA REPAIR, V3, P1425, DOI 10.1016/j.dnarep.2004.06.003; Weterings E, 2003, NUCLEIC ACIDS RES, V31, P7238, DOI 10.1093/nar/gkg889; WU PY, 2007, IN PRESS J BIOL CHEM; Xu XZ, 2003, FASEB J, V17, P1842, DOI 10.1096/fj.03-0310com; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Zha S, 2007, P NATL ACAD SCI USA, V104, P4518, DOI 10.1073/pnas.0611734104; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	117	123	124	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2007	26	56					7731	7740		10.1038/sj.onc.1210871	http://dx.doi.org/10.1038/sj.onc.1210871			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SL	18066085				2022-12-17	WOS:000251537900003
J	Min, JN; Huang, L; Zimonjic, DB; Moskophidis, D; Mivechi, NF				Min, J-N; Huang, L.; Zimonjic, D. B.; Moskophidis, D.; Mivechi, N. F.			Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors	ONCOGENE			English	Article						Hsf1; p53; tumorigenesis; molecular chaperone	HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; MICE; TUMORIGENESIS; CANCER; APOPTOSIS; INFLAMMATION; PATHWAYS; CELLS	A hallmark in the pathogenesis of cancer is the increased expression of heat shock proteins (Hsps) and other molecular chaperones observed in many tumor types, which is considered to be an adaptive response to enhance tumor cell survival. Heat shock transcription factor 1 (Hsf1) is a major transactivator of Hsp induction and has been proposed to affect tumor initiation and progression, regulating expression of Hsps and other molecular targets. In this report, we provide direct in vivo evidence that Hsf1 plays a critical role in the evolution of spontaneous tumors arising in p53 -/- mice. Thus, loss of Hsf1 function did not prolong tumor- free survival, but surprisingly altered the spectrum of tumors that arose in p53(-/-) mice. Tumor development is rapid in p53(-/-) mice, which predominantly (about 70%) succumb to lymphomas. In contrast, hsf1(-/-) p53(-/-) mice rarely develop lymphomas (<8%), but succumb to other tumor types including testicular carcinomas and soft tissue sarcomas. Our findings suggest that an increase in p53- independent apoptotic cell death in association with altered cytokine signaling and suppressed production of in. flammatory factors in hsf1(-/-) mice may contribute to selective lymphoma suppression. In conclusion, the data presented here link the loss of Hsf1- dependent function to decreased susceptibility to spontaneous lymphomagenesis, which may have implications for cancer prevention and therapy.	Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, Augusta, GA 30912 USA; NCI, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mivechi, NF (corresponding author), Med Coll Georgia, Ctr Mol Chaperone Radiobiol & Canc Virol, 1410 Laney Walker Blvd, CN 3153, Augusta, GA 30912 USA.	dmoskophidis@mcg.edu; nmivechi@mcg.edu	Zimonjic, Drazen/AAX-7513-2020		NATIONAL CANCER INSTITUTE [Z01BC010038, R01CA062130, R01CA121951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070451] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA121951, CA62130] Funding Source: Medline; NIGMS NIH HHS [GM070451] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bukau B, 2006, CELL, V125, P443, DOI 10.1016/j.cell.2006.04.014; Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Donehower LA, 1997, CANCER SURV, V29, P329; Flohe SB, 2003, J IMMUNOL, V170, P2340, DOI 10.4049/jimmunol.170.5.2340; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hill R, 2005, CELL, V123, P1001, DOI 10.1016/j.cell.2005.09.030; Inouye S, 2004, J BIOL CHEM, V279, P38701, DOI 10.1074/jbc.M405986200; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jiang LI, 2001, MAMM GENOME, V12, P89, DOI 10.1007/s003350010257; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Knowlton AA, 2006, CARDIOVASC RES, V69, P7, DOI 10.1016/j.cardiores.2005.10.009; Leonard WJ, 2005, NAT REV IMMUNOL, V5, P688, DOI 10.1038/nri1688; Li ZW, 2006, BLOOD REV, V20, P333, DOI 10.1016/j.blre.2005.08.003; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Takaki E, 2006, J BIOL CHEM, V281, P4931, DOI 10.1074/jbc.M506911200; Wang YQ, 2004, J BIOL CHEM, V279, P32651, DOI 10.1074/jbc.M401475200; Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Zhang Y, 2002, J CELL BIOCHEM, V86, P376, DOI 10.1002/jcb.10232; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	30	123	130	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 2	2007	26	35					5086	5097		10.1038/sj.onc.1210317	http://dx.doi.org/10.1038/sj.onc.1210317			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	196MT	17310987				2022-12-17	WOS:000248487400007
J	Fischer, ANM; Fuchs, E; Mikula, M; Huber, H; Beug, H; Mikulits, W				Fischer, A. N. M.; Fuchs, E.; Mikula, M.; Huber, H.; Beug, H.; Mikulits, W.			PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression	ONCOGENE			English	Article						hepatocyte; epithelial to mesenchymal transition; TGF-beta; PDGF; beta-catenin	GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; TUMOR PROGRESSION; CANCER PROGRESSION; DOWN-REGULATION; LIVER-INJURY; STEM-CELLS; PROLIFERATION; HEPATOCYTES; PATHWAY	The cooperation of Ras - extracellular signal-regulated kinase/mitogen-activated protein kinase and transforming growth factor (TGF)-beta signaling provokes an epithelial to mesenchymal transition (EMT) of differentiated p19(ARF) null hepatocytes, which is accompanied by a shift in malignancy and gain of metastatic properties. Upon EMT, TGF-beta induces the secretion and autocrine regulation of platelet-derived growth factor (PDGF) by upregulation of PDGF-A and both PDGF receptors. Here, we demonstrate by loss-of-function analyses that PDGF provides adhesive and migratory properties in vitro as well as proliferative stimuli during tumor formation. PDGF signaling resulted in the activation of phosphatidylinositol-3 kinase, and furthermore associated with nuclear beta-catenin accumulation upon EMT. Hepatocytes expressing constitutively active beta-catenin or its negative regulator Axin were employed to study the impact of nuclear beta-catenin. Unexpectedly, active P-catenin failed to accelerate proliferation during tumor formation, but in contrast, correlated with growth arrest. Nuclear localization of beta-catenin was accompanied by strong expression of the Cdk inhibitor p16(INK4A) and the concomitant induction of the beta-catenin target genes cyclin D1 and c-myc. In addition, active beta-catenin revealed protection of malignant hepatocytes against anoikis, which provides a prerequisite for the dissemination of carcinoma. From these data, we conclude that TGF-beta acts tumor progressive by induction of PDGF signaling and subsequent activation of beta-catenin, which endows a subpopulation of neoplastic hepatocytes with features of cancer stem cells.	Med Univ Vienna, Inst Canc Res, Dept Med 1 Div, A-1090 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Med Univ Vienna, Inst Canc Res, Dept Med 1 Div, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Mikulits, Wolfgang/AAH-4043-2021	Mikulits, Wolfgang/0000-0003-4612-7106; Mikula, Mario/0000-0001-5782-0681				Artemenko Y, 2005, J CELL PHYSIOL, V204, P646, DOI 10.1002/jcp.20314; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Friedl J, 2000, CANCER BIOTHER RADIO, V15, P477, DOI 10.1089/cbr.2000.15.477; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Lu DS, 2005, P NATL ACAD SCI USA, V102, P18567, DOI 10.1073/pnas.0509316102; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Matsuzaki K, 2000, CANCER RES, V60, P1394; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Pinzani M, 1996, AM J PATHOL, V148, P785; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304-3835(03)00013-2	50	123	127	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3395	3405		10.1038/sj.onc.1210121	http://dx.doi.org/10.1038/sj.onc.1210121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130832				2022-12-17	WOS:000246579600009
J	Barolo, S				Barolo, S.			Transgenic Wnt/TCF pathway reporters: all you need is Lef?	ONCOGENE			English	Review						Wnt; beta-catenin; Tcf/Lef; transgenic reporter; cell signaling pathway; transcription	BETA-CATENIN; TRANSCRIPTION FACTORS; AXIS SPECIFICATION; SIGNALING PATHWAY; GENE-EXPRESSION; TARGET GENE; STEM-CELLS; IN-VIVO; WNT; DROSOPHILA	The Wnt signaling pathway controls a large and diverse set of cell fate decisions in embryonic development, adult organ maintenance and disease. At the transcriptional level, Wnt/beta-catenin signaling is primarily mediated by the T-cell factor (TCF)/Lef-1 family of transcription factors, referred to here as TCFs. In order to track Wnt pathway activity during animal development, several laboratories have built transgenic reporter constructs containing multimerized TCF binding sites. Most of these reporters are active at multiple known sites of Wnt signaling, and several act as faithful reporters of pathway activity in specific contexts. However, multimerized TCF reporters should not be assumed to give a complete or definitive readout of Wnt signaling in vivo. Direct comparisons reveal discrepancies among reporters; in addition, there is good reason to expect that some important types of pathway activity, including target gene de-repression and TCF-independent Wnt or beta-catenin signaling, will not be accurately reported by such constructs. This review will discuss various transgenic Wnt/beta-catenin/TCF reporters, address the fidelity and completeness of their Wnt responsiveness, and contrast their in vivo transcriptional responses with those of natural Wnt target genes. Finally, three caveats to the interpretation of multimerized TCF reporter expression patterns will be proposed.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Barolo, S (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.	sbarolo@umich.edu						Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Carr M, 2005, DEV GENES EVOL, V215, P402, DOI 10.1007/s00427-005-0488-7; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DasGupta R, 1999, DEVELOPMENT, V126, P4557; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Denayer T, 2006, FEBS LETT, V580, P393, DOI 10.1016/j.febslet.2005.11.084; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Fathke C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-4; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Geng X, 2003, FEBS LETT, V547, P1, DOI 10.1016/S0014-5793(03)00639-2; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hatini V, 2001, MOL CELL, V7, P151, DOI 10.1016/S1097-2765(01)00163-0; Haynes TL, 1996, NUCLEIC ACIDS RES, V24, P5034, DOI 10.1093/nar/24.24.5034; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maduro MF, 2005, DEV BIOL, V285, P510, DOI 10.1016/j.ydbio.2005.06.022; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mohamed OA, 2004, DEV DYNAM, V231, P416, DOI 10.1002/dvdy.20135; Nakaya MA, 2005, DEVELOPMENT, V132, P5425, DOI 10.1242/dev.02149; Newfeld SJ, 2002, GENETICS, V161, P685; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; ROOSE J, 1999, THESIS U HOSP UTRECH; SHTUTMAN M, 1999, P NATL ACAD SCI USA, V275, P21203; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Spychala J, 1999, J BIOL CHEM, V274, P22705, DOI 10.1074/jbc.274.32.22705; Staal FJT, 2004, J IMMUNOL, V172, P1099, DOI 10.4049/jimmunol.172.2.1099; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Theil T, 2002, DEVELOPMENT, V129, P3045; van Beest M, 2000, J BIOL CHEM, V275, P27266; VOLK T, 1994, DEVELOPMENT, V120, P59; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Yang X, 2000, DEVELOPMENT, V127, P3695; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	63	123	128	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7505	7511		10.1038/sj.onc.1210057	http://dx.doi.org/10.1038/sj.onc.1210057			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143294				2022-12-17	WOS:000242514900008
J	Marderosian, M; Sharma, AP; Funk, AP; Vartanian, R; Masri, J; Jo, OD; Gera, JF				Marderosian, M.; Sharma, A. P.; Funk, A. P.; Vartanian, R.; Masri, J.; Jo, O. D.; Gera, J. F.			Tristetraprolin regulates Cyclin D1 and c-myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling	ONCOGENE			English	Article						akt; mTOR; rapamycin; cyclin D1; c-myc; tristetraprolin; mRNA stability	ACTIVATED PROTEIN-KINASE; AU-RICH ELEMENTS; ENHANCED SENSITIVITY; BINDING PROTEIN; DOWN-REGULATION; CELL-GROWTH; EXPRESSION; TRANSLATION; INVOLVEMENT; TURNOVER	The differential expression of the critical cell cycle control proteins cyclin D1 and c-myc has been shown to result in Akt-dependent hypersensitivity of tumor cells to mTOR inhibitors. We have previously demonstrated that the differential utilization of internal ribosome entry sites within the mRNAs of these transcripts allows maintenance of protein synthesis in the face of rapamycin ( rapa) exposure in an Akt-dependent manner. Here, we demonstrate that in addition to this mechanism, cyclin D1 and c-myc mRNA stability is also coordinately regulated following rapa treatment depending on Akt activity status. We identify A/U-rich response elements within the 3' untranslated regions ( UTRs) of these transcripts, which confer the observed differential stabilities and show that the RNA-binding protein, tristetraprolin (TTP), interacts with these elements. We also present evidence that TTP accumulates in response to rapa exposure, binds to the cis-acting elements within the cyclin D1 and c-myc 3' UTRs and is differentially serine phosphorylated in an Akt-dependent manner. Furthermore, the differential phosphorylation status of TTP results in its sequestration by 14-3-3 proteins in quiescent Akt-containing cells. Finally, siRNA-mediated knockdown of TTP expression or inhibiting a known regulator of TTP phosphorylation, p38 MAP kinase, abolishes the effects on cyclin D1 and c-myc mRNA stability. We assume that the differential control of cyclin D1 and c-myc mRNA stability and translational efficiency constitutes a coordinate response to rapa contributing to the maintenance of expression of these determinants in rapa-resistant quiescent Akt-containing cells following exposure.	Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Sepulveda, CA 91343 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Gera, JF (corresponding author), Greater Los Angeles VA Healthcare Syst, Dept Res & Dev, Bldg 1,Rm C111A, Sepulveda, CA 91343 USA.	gera@ucla.edu	Sharma, Anil/AAY-4145-2021	Gera, Joseph/0000-0002-2908-6894	NCI NIH HHS [R01-CA-109312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA109312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2005, CURR BIOL, V15, pR139, DOI 10.1016/j.cub.2005.02.015; Anderson P, 2002, J CELL SCI, V115, P3227; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Brooks SA, 2004, J IMMUNOL, V172, P7263, DOI 10.4049/jimmunol.172.12.7263; Brooks SA, 2002, ARTHRITIS RHEUM, V46, P1362, DOI 10.1002/art.10235; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Dean JLE, 2003, J BIOL CHEM, V278, P39470, DOI 10.1074/jbc.M306345200; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Easton JB, 2004, EXPERT OPIN THER TAR, V8, P551, DOI 10.1517/14728222.8.6.551; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Han QW, 2002, J BIOL CHEM, V277, P48379, DOI 10.1074/jbc.M209542200; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; Kahvejian A, 2001, COLD SPRING HARB SYM, V66, P293, DOI 10.1101/sqb.2001.66.293; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; Lai WS, 2005, J BIOL CHEM, V280, P34365, DOI 10.1074/jbc.M506757200; Lemm I, 2002, MOL CELL BIOL, V22, P3959, DOI 10.1128/MCB.22.12.3959-3969.2002; Liao Y, 2003, MOL CELL BIOL, V23, P6836, DOI 10.1128/MCB.23.19.6836-6848.2003; Lin SK, 2000, MOL CELL BIOL, V20, P7903, DOI 10.1128/MCB.20.21.7903-7913.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmidlin M, 2004, EMBO J, V23, P4760, DOI 10.1038/sj.emboj.7600477; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shi YJ, 2002, CANCER RES, V62, P5027; Shim J, 2002, MOL CELLS, V14, P323; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Stoecklin G, 2004, EMBO J, V23, P1313, DOI 10.1038/sj.emboj.7600163; Stoecklin G, 2002, EMBO J, V21, P4709, DOI 10.1093/emboj/cdf444; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2004, J BIOL CHEM, V279, P48376, DOI 10.1074/jbc.M409014200; Wilson GM, 2003, J BIOL CHEM, V278, P33029, DOI 10.1074/jbc.M305772200; Wilusz CJ, 2004, TRENDS GENET, V20, P491, DOI 10.1016/j.tig.2004.07.011	52	123	129	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2006	25	47					6277	6290		10.1038/sj.onc.1209645	http://dx.doi.org/10.1038/sj.onc.1209645			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	094CY	16702957	Bronze			2022-12-17	WOS:000241218200005
J	Dumitru, CA; Gulbins, E				Dumitru, C. A.; Gulbins, E.			TRAIL activates acid sphingomyelinase via a redox mechanism and releases ceramide to trigger apoptosis	ONCOGENE			English	Article						ceramide; acid sphingomyelinase; TRAIL; apoptosis; tumor therapy; redox	RICH MEMBRANE RAFTS; CYTOTOXIC LIGAND TRAIL; COLON-CANCER CELLS; LIPID RAFTS; SIGNALING COMPLEX; DEATH RECEPTOR; CASPASE-8 ACTIVATION; DENDRITIC CELLS; DOWN-REGULATION; IN-VIVO	We have previously shown that activation of the acid sphingomyelinase (ASM), the release of ceramide and the formation of ceramide-enriched membrane domains are central for the induction of apoptosis by CD95. Here, we demonstrate that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and CD95 activate the ASM via a redox mechanism resulting in release of ceramide and formation of ceramide-enriched membrane platforms. Ceramide-enriched membrane platforms serve to cluster DR5 upon stimulation. Antioxidants prevent TRAIL-mediated stimulation of ASM, the release of ceramide, the formation of ceramide-enriched membrane platforms and the induction of apoptosis by TRAIL. Further, ASM-deficient splenocytes fail to cluster DR5 in ceramide-enriched membrane domains upon TRAIL stimulation and resist TRAIL-induced apoptosis, events that were restored by addition of natural C-16-ceramide. A dose-response analysis indicates that ceramide-enriched membrane platforms greatly sensitized tumor cells to TRAIL-induced apoptosis. Our data indicate that ceramide-enriched membrane platforms are required for the signaling of TRAIL-DR5 complexes under physiological conditions.	Univ Duisburg Essen, Dept Mol Biol, D-45122 Essen, Germany	University of Duisburg Essen	Gulbins, E (corresponding author), Univ Duisburg Essen, Dept Mol Biol, Hufeandstr 55, D-45122 Essen, Germany.	erich.gulbins@uni-essen.de	Gulbins, Erich/L-6989-2014	Gulbins, Erich/0000-0002-3117-1342				Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Aouad SM, 2004, J IMMUNOL, V172, P2316, DOI 10.4049/jimmunol.172.4.2316; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bhardwaj A, 2003, J CLIN IMMUNOL, V23, P317, DOI 10.1023/A:1025319031417; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Delmas D, 2004, ONCOGENE, V23, P8979, DOI 10.1038/sj.onc.1208086; Delmas D, 2003, J BIOL CHEM, V278, P41482, DOI 10.1074/jbc.M304896200; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; El-Zawahry A, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-2; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; Eramo A, 2004, EUR J IMMUNOL, V34, P1930, DOI 10.1002/eji.200324786; Esen M, 2001, APOPTOSIS, V6, P431, DOI 10.1023/A:1012445925628; Fanzo JC, 2003, CANCER BIOL THER, V2, P392, DOI 10.4161/cbt.2.4.442; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003; Grassme H, 2003, ONCOGENE, V22, P5457, DOI 10.1038/sj.onc.1206540; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; GRAZIADEI L, 1990, NATURE, V347, P396, DOI 10.1038/347396a0; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; Gulbins E, 2000, METHOD ENZYMOL, V322, P382; Hayakawa Y, 2004, J IMMUNOL, V172, P123, DOI 10.4049/jimmunol.172.1.123; Hueber AO, 2002, EMBO REP, V3, P190, DOI 10.1093/embo-reports/kvf022; Janssen EM, 2005, NATURE, V434, P88, DOI 10.1038/nature03337; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jendrossek V, 2002, CANCER CHEMOTH PHARM, V50, P71, DOI 10.1007/s00280-002-0440-8; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Nurminen TA, 2002, J AM CHEM SOC, V124, P12129, DOI 10.1021/ja017807r; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Qiu HW, 2003, J BIOL CHEM, V278, P32744, DOI 10.1074/jbc.M303022200; Reinehr R, 2005, J BIOL CHEM, V280, P27179, DOI 10.1074/jbc.M414361200; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; ROSENMAN SJ, 1993, J LEUKOCYTE BIOL, V53, P1; Scheel-Toellner D, 2004, BIOCHEM SOC T, V32, P679, DOI 10.1042/BST0320679; Scheel-Toellner D, 2004, BLOOD, V104, P2557, DOI 10.1182/blood-2004-01-0191; Scheel-Toellner D, 2002, BIOCHEM BIOPH RES CO, V297, P876, DOI 10.1016/S0006-291X(02)02311-2; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Shakor ABA, 2004, J BIOL CHEM, V279, P36778, DOI 10.1074/jbc.M402170200; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Um HD, 1996, J IMMUNOL, V156, P3469; Ursini-Siegel J, 2002, J IMMUNOL, V169, P5505, DOI 10.4049/jimmunol.169.10.5505; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Viola A, 1999, SCIENCE, V283, P680, DOI 10.1126/science.283.5402.680; Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1999, CANCER RES, V59, P2770; Yamada H, 1999, BIOCHEM BIOPH RES CO, V265, P130, DOI 10.1006/bbrc.1999.1641; YIN XM, 2005, HEPATOLOGY, V42, P956	68	123	129	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 14	2006	25	41					5612	5625		10.1038/sj.onc.1209568	http://dx.doi.org/10.1038/sj.onc.1209568			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	085IZ	16636669				2022-12-17	WOS:000240599100003
J	Bruix, J; Hessheimer, AJ; Forner, A; Boix, L; Vilana, R; Llovet, JM				Bruix, J; Hessheimer, AJ; Forner, A; Boix, L; Vilana, R; Llovet, JM			New aspects of diagnosis and therapy of hepatocellular carcinoma	ONCOGENE			English	Review						hepatocellular carcinoma; early detection; diagnosis; treatment	RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS RADIOFREQUENCY ABLATION; DONOR LIVER-TRANSPLANTATION; GAMMA-CARBOXY PROTHROMBIN; ETHANOL INJECTION; ALPHA-FETOPROTEIN; PROGNOSTIC PREDICTION; SURGICAL RESECTION; IMPROVES PROGNOSIS; IMAGING DIAGNOSIS	Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is the most frequent cause of death in these patients. The main risk factors for its development are hepatitis B and C virus infection, alcoholism and aflatoxin intake. If acquistion of risk factors is not prevented and cirrhosis is established, the sole option to improve survival is to detect the tumor at an early stage when effective therapy may be indicated. Early detection plans should be based on hepatic ultrasonography every 6 months, whereas determination of tumor markers is not efficient. Upon detection of a hepatic nodule, there is a need to establish unequivocal diagnosis, either through biopsy or through the application of non-invasive criteria based on the specific radiology appearance of the tumor: fast arterial uptake of contrast followed by venous washout. Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. These options provide a high rate of complete responses and are assumed to improve survival that should exceed 50% at 5 years. If the tumor is diagnosed at an advanced stage, the sole option that improves survival is transarterial chemoembolization. Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression.	Univ Barcelona, BCLC Grp, Liver Unit, IDIBAPS,Digest Dis Inst,Hosp Clin, E-08036 Barcelona, Catalonia, Spain; Univ Barcelona, BCLC Grp, Dept Radiol, IDIBAPS,Hosp Clin, E-08036 Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bruix, J (corresponding author), Univ Barcelona, BCLC Grp, Liver Unit, IDIBAPS,Digest Dis Inst,Hosp Clin, Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	bruix@ub.edu	Llovet, Josep M/D-4340-2014; Hessheimer, Amelia/N-1855-2019; Forner, Alejandro/C-8884-2016; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Hessheimer, Amelia/0000-0002-7247-5051; Forner, Alejandro/0000-0002-9014-4950; Llovet, Josep M/0000-0003-0547-2667; Bruix, Jordi/0000-0002-9826-0753				Beaugrand M, 2005, SEMIN LIVER DIS, V25, P201, DOI 10.1055/s-2005-871199; BISMUTH H, 1993, TRANSPLANT P, V25, P1066; Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; BRUIX J, 1994, HEPATOLOGY, V20, P643, DOI 10.1002/hep.1840200315; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2003, LIVER TRANSPLANT, V9, P700, DOI 10.1053/jlts.2003.50124; Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Burrel M, 2003, HEPATOLOGY, V38, P1034, DOI 10.1053/jhep.2003.50409; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; DiStasi M, 1997, SCAND J GASTROENTERO, V32, P1168; Freeman RB, 2004, LIVER TRANSPLANT, V10, P7, DOI 10.1002/lt.20024; Garcia-Retortillo M, 2004, HEPATOLOGY, V40, P699, DOI 10.1002/hep.20357; Giorgio A, 2005, AM J ROENTGENOL, V184, P207, DOI 10.2214/ajr.184.1.01840207; Gondolesi GE, 2004, ANN SURG, V239, P142, DOI 10.1097/01.sla.0000109022.32391.eb; Grieco A, 2005, GUT, V54, P411, DOI 10.1136/gut.2004.048124; Grimaldi C, 1998, J CLIN ONCOL, V16, P411, DOI 10.1200/JCO.1998.16.2.411; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Ishizuka H, 1999, INTERNAL MED, V38, P927, DOI 10.2169/internalmedicine.38.927; IZUNO K, 1995, HEPATO-GASTROENTEROL, V42, P387; Jonas S, 2001, HEPATOLOGY, V33, P1080, DOI 10.1053/jhep.2001.23561; Kawasaki S, 2002, HEPATO-GASTROENTEROL, V49, P53; Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N; Kumada T, 1999, J HEPATOL, V30, P125, DOI 10.1016/S0168-8278(99)80016-6; Lau WY, 1999, LANCET, V353, P797, DOI 10.1016/S0140-6736(98)06475-7; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350; Lencioni R, 2005, SEMIN LIVER DIS, V25, P162, DOI 10.1055/s-2005-871196; Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718; Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003; Livraghi T, 1999, RADIOLOGY, V210, P655, DOI 10.1148/radiology.210.3.r99fe40655; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; LIVRAGHI T, 1995, RADIOLOGY, V197, P101, DOI 10.1148/radiology.197.1.7568806; Llovet JM, 2005, SEMIN LIVER DIS, V25, P181, DOI 10.1055/s-2005-871198; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Llovet JM, 2002, GUT, V50, P123, DOI 10.1136/gut.50.1.123; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 1998, HEPATOLOGY, V27, P1572, DOI 10.1002/hep.510270616; Llovet JM, 2001, HEPATOLOGY, V33, P1124, DOI 10.1053/jhep.2001.24233; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Majno P, 2005, J HEPATOL, V42, pS134, DOI 10.1016/j.jhep.2004.12.010; Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636; Marrero JA, 2003, HEPATOLOGY, V37, P1114, DOI 10.1053/jhep.2003.50195; Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sala M, 2005, SEMIN LIVER DIS, V25, P171, DOI 10.1055/s-2005-871197; Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465; Sala M, 2004, LIVER TRANSPLANT, V10, P1294, DOI 10.1002/lt.20202; Sharma P, 2004, LIVER TRANSPLANT, V10, P36, DOI 10.1002/lt.20012; Sherman M, 2001, J HEPATOL, V34, P603, DOI 10.1016/S0168-8278(01)00025-3; Shibata T, 2002, RADIOLOGY, V223, P331, DOI 10.1148/radiol.2232010775; Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009; Shiratori Y, 2003, ANN INTERN MED, V138, P299, DOI 10.7326/0003-4819-138-4-200302180-00008; Steinmuller T, 2002, TRANSPLANT P, V34, P2263, DOI 10.1016/S0041-1345(02)03228-1; SUEHIRO T, 1994, CANCER-AM CANCER SOC, V73, P2464, DOI 10.1002/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Tateishi R, 2005, CANCER-AM CANCER SOC, V103, P1201, DOI 10.1002/cncr.20892; Todo S, 2004, ANN SURG, V240, P451, DOI 10.1097/01.sla.0000137129.98894.42; Torzilli G, 1999, ARCH SURG-CHICAGO, V134, P984, DOI 10.1001/archsurg.134.9.984; Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2; Trinchet JC, 2004, HEPATOLOGY, V40, P1361, DOI 10.1002/hep.20474; Yuen MF, 2002, HEPATOLOGY, V36, P687, DOI 10.1053/jhep.2002.35071; Zhang BH, 2004, J CANCER RES CLIN, V130, P417, DOI 10.1007/s00432-004-0552-0	74	123	132	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3848	3856		10.1038/sj.onc.1209548	http://dx.doi.org/10.1038/sj.onc.1209548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799626				2022-12-17	WOS:000238559600012
J	Seeff, LB; Hoofnagle, JH				Seeff, L. B.; Hoofnagle, J. H.			Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B; hepatitis C	CHRONIC LIVER-DISEASE; UNITED-STATES; WORLDWIDE INCIDENCE; VIRAL-HEPATITIS; VIRUS; CANCER; TRENDS; POPULATION; BURDEN; PREVALENCE	Hepatocellular carcinoma (HCC) ranks among the 10 most common cancers worldwide. It evolves from several chronic liver diseases, most of which culminate in cirrhosis. As the most common causes, other than alcoholic cirrhosis, are chronic hepatitis B and C infections, its prevalence worldwide is linked to the prevalence of these two viruses. Thus, the highest rates are in southeast Asia and sub-Saharan Africa, the world's most populous nations, where hepatitis B virus infection is endemic. In most western countries, hepatitis C virus infection is the predominant cause, and hepatitis B-related liver cancer occurs largely among immigrants from countries of high hepatitis B endemicity. In most western countries, the incidence and mortality from HCC is increasing as a consequence of the chronic sequelae of the 'epidemic' of hepatitis C of the 1960 - 1980s. In the US, modeling of this infection predicts a continued rise in liver cancer over the next decade. Surveillance by the National Cancer Institute and the Centers for Disease Control confirms the increasing incidence of and mortality from HCC to the year 2000, although subsequent analyses suggest a slowing or possibly decline in the rate of increase. Whether this trend will continue requires further evaluation.	NIDDK, Liver Dis Res Branch, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Seeff, LB (corresponding author), NIDDK, Liver Dis Res Branch, Div Digest Dis & Nutr, NIH, 27A Ctr Dr,Room 9A27, Bethesda, MD 20892 USA.	seeffL@EXTRA.NIDDK.NIH.GOV						Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; BRUIX J, 1989, LANCET, V2, P1004; Caldwell SH, 2004, GASTROENTEROLOGY, V127, pS97, DOI 10.1053/j.gastro.2004.09.021; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020; Delarocque-Astagneau E, 2005, ANN EPIDEMIOL, V15, P551, DOI 10.1016/j.annepidem.2004.12.006; Deuffic S, 1999, J VIRAL HEPATITIS, V6, P411, DOI 10.1046/j.1365-2893.1999.00178.x; Dyer Z, 2005, ALIMENT PHARM THER, V22, P17, DOI 10.1111/j.1365-2036.2005.02504.x; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Hankey BF, 1999, CANCER EPIDEM BIOMAR, V8, P1117; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; HUTTON MD, 2001, J REGISTRY MANAGE, V28, P113; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939; McGlynn KA, 2001, INT J CANCER, V94, P290, DOI 10.1002/ijc.1456; *NAT CANC I, 2005, SEER; *NAT CTR CHRON DIS, 2005, NAT PROGR CANC REG C; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; REIS LAG, 2005, SEER CANC STAT REV 1; Warren JL, 2002, MED CARE, V40, P3; Wong JB, 2000, AM J PUBLIC HEALTH, V90, P1562, DOI 10.2105/AJPH.90.10.1562; World Health Organization, 2003, WORLD HLTH REP SHAP	33	123	135	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3771	3777		10.1038/sj.onc.1209560	http://dx.doi.org/10.1038/sj.onc.1209560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799618				2022-12-17	WOS:000238559600004
J	Liu, YJ; Xu, Y; Yu, Q				Liu, YJ; Xu, Y; Yu, Q			Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively	ONCOGENE			English	Article						ADAMTS-1; tumor metastasis; invasion; proteolytic cleavage; heparin-binding EGF; amphiregulin	NECROSIS-FACTOR-ALPHA; CD44-MEDIATED TUMOR INVASION; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; CELL-SURFACE; METALLOPROTEINASE-DISINTEGRIN; IN-VIVO; EXTRACELLULAR-MATRIX; CONVERTING-ENZYME; TYPE-1 REPEATS	The exact role of a disintegrin and metalloproteinase with thrombospondin motifs-1 (ADAMTS-1) and the underlying mechanism of its involvement in tumor metastasis have not been established. We have now demonstrated that overexpression of ADAMTS-1 promotes pulmonary metastasis of TA3 mammary carcinoma and Lewis lung carcinoma cells and that a proteinase-dead mutant of ADAMTS-1 (ADAMTS-1E/Q) inhibits their metastasis, indicating that the prometastatic activity of ADAMTS-1 requires its metalloproteinase activity. Overexpression of ADAMTS-1 in these cells promoted tumor angiogenesis and invasion, shedding of the transmembrane precursors of heparin-binding epidermal growth factor (EGF) and amphiregulin (AR), and activation of the EGF receptor and ErbB-2, while overexpression of ADAMTS-1E/Q inhibited these events. Furthermore, we found that ADAMTS-1 undergoes auto-proteolytic cleavage to generate the NH2- and COOH-terminal cleavage fragments containing at least one thrombospondin-type-I-like motif and that overexpression of the NH2- terminal ADAMTS-1 fragment and the COOH-terminal ADAMTS-1 fragment can inhibit pulmonary tumor metastasis. These fragments also inhibited Erk1/2 kinase activation induced by soluble heparin-binding EGF and AR. Taken together, our results suggest that the proteolytic status of ADAMTS-1 determines its effect on tumor metastasis, and that the ADAMTS-1E/Q and the ADAMTS-1 fragments likely inhibit tumor metastasis by negatively regulating the availability and activity of soluble heparin-binding EGF and AR.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenn.edu			NATIONAL CANCER INSTITUTE [R01CA116510] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL074117] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA116510, R01 CA116510-01A1] Funding Source: Medline; NHLBI NIH HHS [R01 HL074117, R01HL074117] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Billings SD, 2003, AM J PATHOL, V163, P2451, DOI 10.1016/S0002-9440(10)63600-0; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bostwick DG, 2004, PROSTATE, V58, P164, DOI 10.1002/pros.10322; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; Colige A, 2005, J BIOL CHEM, V280, P34397, DOI 10.1074/jbc.M506458200; COOK PW, 1992, CANCER RES, V52, P3224; EBERT M, 1994, CANCER RES, V54, P3959; Flannery CR, 2002, J BIOL CHEM, V277, P42775, DOI 10.1074/jbc.M205309200; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; HAMID AS, 2000, CANCER RES, V60, P7094; Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2; Herren B, 2002, NEWS PHYSIOL SCI, V17, P73, DOI 10.1152/nips.01373.2001; Iruela-Arispe ML, 1999, CIRCULATION, V100, P1423, DOI 10.1161/01.CIR.100.13.1423; Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Jackson LF, 2003, EMBO J, V22, P2704, DOI 10.1093/emboj/cdg264; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KITADAI Y, 1993, JPN J CANCER RES, V84, P879, DOI 10.1111/j.1349-7006.1993.tb02061.x; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; Kuno K, 2004, BIOCHEM BIOPH RES CO, V319, P1327, DOI 10.1016/j.bbrc.2004.05.105; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; Lee DC, 2003, ANN NY ACAD SCI, V995, P22, DOI 10.1111/j.1749-6632.2003.tb03207.x; LEJEUNE S, 1993, CANCER RES, V53, P3597; Luque A, 2003, J BIOL CHEM, V278, P23656, DOI 10.1074/jbc.M212964200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Masui T, 2001, CLIN CANCER RES, V7, P3437; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; Miao WM, 2001, CANCER RES, V61, P7830; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nokihara H, 2000, CANCER RES, V60, P7002; NORMANNO N, 1995, BREAST CANCER RES TR, V35, P293, DOI 10.1007/BF00665981; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; Panico L, 1996, INT J CANCER, V65, P51, DOI 10.1002/(SICI)1097-0215(19960103)65:1<51::AID-IJC9>3.3.CO;2-N; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pfeifer A, 2000, P NATL ACAD SCI USA, V97, P12227, DOI 10.1073/pnas.220399597; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424; Rodriguez-Manzaneque JC, 2000, J BIOL CHEM, V275, P33471, DOI 10.1074/jbc.M002599200; Russell DL, 2003, J BIOL CHEM, V278, P42330, DOI 10.1074/jbc.M300519200; Sahin U, 2004, J CELL BIOL, V164, P769, DOI 10.1083/jcb.200307137; SALOMON DS, 1995, BREAST CANCER RES TR, V33, P103, DOI 10.1007/BF00682718; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Streit M, 2000, EMBO J, V19, P3272, DOI 10.1093/emboj/19.13.3272; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tucker RP, 2004, INT J BIOCHEM CELL B, V36, P969, DOI 10.1016/j.biocel.2003.12.011; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349; Visscher DW, 1997, BREAST CANCER RES TR, V45, P75, DOI 10.1023/A:1005845512804; Volpert OV, 1998, P NATL ACAD SCI USA, V95, P6343, DOI 10.1073/pnas.95.11.6343; Xu Y, 2004, CANCER RES, V64, P6119, DOI 10.1158/0008-5472.CAN-04-1054; Xu Y, 2004, J BIOL CHEM, V279, P41179, DOI 10.1074/jbc.M400292200; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yamazaki S, 2003, J CELL BIOL, V163, P469, DOI 10.1083/jcb.200307035; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163	69	123	131	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2452	2467		10.1038/sj.onc.1209287	http://dx.doi.org/10.1038/sj.onc.1209287			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16314835	Green Accepted			2022-12-17	WOS:000236948000004
J	Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C				Garcia, MJ; Pole, JCM; Chin, SF; Teschendorff, A; Naderi, A; Ozdag, H; Vias, M; Kranjac, T; Subkhankulova, T; Paish, C; Ellis, I; Brenton, JD; Edwards, PAW; Caldas, C			A 1Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes	ONCOGENE			English	Article						8p11-12 amplicon; breast cancer; array-CGH; minimal region of amplification; candidate oncogene	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; CHROMOSOME ARM 8P; CELL-LINES; COLORECTAL-CANCER; HOMOZYGOUS DELETION; DNA AMPLIFICATION; PROGNOSTIC INDEX; BINDING-PROTEIN; MICROARRAYS	Amplification of 8p11-12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11-12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray pro. ling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11-12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplication. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11-12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.	Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, Res Ctr, MRC, Cambridge CB2 2XZ, England; City Hosp NHS Trust, Dept Histopathol, Breast Unit, Nottingham NG5 1PB, England	University of Cambridge; University of Cambridge; Nottingham University Hospital NHS Trust; Nottingham City Hospital	Caldas, C (corresponding author), Univ Cambridge, Canc Gemon Program, Dept Oncol Hutchison, MRC,Res Ctr, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Brenton, James D/B-3174-2008; Özdag, Hilal/C-9929-2009; Edwards, Paul A/M-8291-2014; Caldas, Carlos/U-7250-2019; García, María J/G-1361-2016; Caldas, Carlos/A-7543-2008	Brenton, James D/0000-0002-5738-6683; Özdag, Hilal/0000-0001-7940-2499; Edwards, Paul A/0000-0002-4789-3374; Caldas, Carlos/0000-0003-3547-1489; García, María J/0000-0002-2236-9912; Naderi, Ali/0000-0001-7142-7616; chin, suet-feung/0000-0001-5697-1082; Ellis, Ian/0000-0001-5292-8474				Adelaide J, 2003, GENE CHROMOSOME CANC, V37, P333, DOI 10.1002/gcc.10218; Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S; Agresti A., 2003, CATEGORICAL DATA ANA; Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Bautista S, 1998, GENE CHROMOSOME CANC, V22, P268, DOI 10.1002/(SICI)1098-2264(199808)22:4<268::AID-GCC2>3.0.CO;2-T; Bayani J, 2002, CANCER RES, V62, P3466; Bhattacharya N, 2004, EXP MOL PATHOL, V76, P264, DOI 10.1016/j.yexmp.2004.01.002; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Bova GS, 1996, GENOMICS, V35, P46, DOI 10.1006/geno.1996.0321; Cabart P, 2001, J BIOL CHEM, V276, P43056, DOI 10.1074/jbc.M108515200; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; CLARKE C, 1994, EPITHELIAL CELL BIOL, V3, P38; Courtay-Cahen C, 2000, GENOMICS, V66, P15, DOI 10.1006/geno.2000.6178; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; EMI M, 1992, CANCER RES, V52, P5368; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Flanagan JM, 2004, GENE CHROMOSOME CANC, V40, P247, DOI 10.1002/gcc.20039; Forozan F, 2000, CANCER RES, V60, P4519; Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367; Greshock J, 2004, GENOME RES, V14, P179; HAYBITTLE JL, 1982, BRIT J CANCER, V45, P361, DOI 10.1038/bjc.1982.62; Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762; Hyman E, 2002, CANCER RES, V62, P6240; Ikegawa S, 1999, J HUM GENET, V44, P337, DOI 10.1007/s100380050172; Ikegawa S, 1999, CYTOGENET CELL GENET, V85, P227, DOI 10.1159/000015298; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Ladomery M, 2002, ANN HUM GENET, V66, P331, DOI 10.1017/S0003480002001215; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Parker C, 2001, BRIT J CANCER, V85, P1958, DOI 10.1054/bjoc.2001.2178; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Pribill I, 2001, CANCER GENET CYTOGEN, V129, P23, DOI 10.1016/S0165-4608(01)00419-8; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Rew DA, 2003, EUR J SURG ONCOL, V29, P764, DOI 10.1016/S0748-7983(03)00083-0; Sambrook JF, 2001, MOL CLONING LAB MANU, V1-3; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; TODD JH, 1987, BRIT J CANCER, V56, P489, DOI 10.1038/bjc.1987.230; Toomes C, 2003, GENE CHROMOSOME CANC, V37, P132, DOI 10.1002/gcc.10191; Ugolini F, 1999, ONCOGENE, V18, P1903, DOI 10.1038/sj.onc.1202739; Wang XZ, 1999, ONCOGENE, V18, P5718, DOI 10.1038/sj.onc.1202950; Yamamoto Y, 2004, ONCOGENE, V23, P3889, DOI 10.1038/sj.onc.1207495; Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48	49	123	128	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2005	24	33					5235	5245		10.1038/sj.onc.1208741	http://dx.doi.org/10.1038/sj.onc.1208741			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	951XB	15897872				2022-12-17	WOS:000230964600010
J	Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH				Qian, Y; Zhong, XS; Flynn, DC; Zheng, JZ; Qiao, M; Wu, CY; Dedhar, S; Shi, XL; Jiang, BH			ILK mediates actinfilament rearrangements and cell migration and invasion through PI3K/Akt/Rac1 signaling	ONCOGENE			English	Article						ILK; PI3K; Akt; p70S6K1; Rac1; actin filaments	INTEGRIN-LINKED KINASE; ENDOTHELIAL GROWTH-FACTOR; ACTIN CYTOSKELETON; PROTEIN-KINASE; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; FOCAL ADHESION; AKT; PHOSPHORYLATION	One of the hallmarks of integrin signaling is an increase in cell migration and invasion, both of which are associated with actin. lament rearrangements. Integrin-linked kinase ( ILK) is a cytoplasmic effector of integrin receptors. ILK is known to be involved in multiple cellular functions. However, the signaling pathways involved in ILK-mediated cellular structure and motility remain to be elucidated. Here, we have demonstrated that overexpression of ILK was sufficient to induce actin. lament rearrangements, to form cell motility structures, and to increase cell migration and invasion in a phosphatidylinositol 3-kinase (PI3K)-dependent manner. This corresponds with the activation of both Akt and p70 ribosomal protein S6 kinase (p70S6K1). Overexpression of dominant-negative mutants of Akt inhibited ILK-dependent activation of p70S6K1, indicating that Akt is upstream of p70S6K1 in response to ILK signaling. Overexpression of ILK was sufficient to induce Rac1 activation, which was abolish by a PI3K inhibitor, indicating that Rac1 activity is involved in ILK signaling in a PI3K dependent manner. Inhibition of Akt, Rac1, or p70S6K1 inhibited the effects of ILK on actin. laments and cell migration, suggesting a regulatory role of the PI3K/Akt/p70S6K1/Rac1 signaling pathway in response to ILK signaling. We have shown that overexpression of a dominant-negative ILK was sufficient to abolish fibronectin peptide (PHSRN)-induced rearrangements of actin. laments and cell migration and invasion. Taken together, our results identify a mechanism through which ILK can regulate both integrin-associated rearrangements of actin. laments and cell migration and invasion at the integrin receptor - proximal region.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA; W Virginia Univ, Mary Babb Randolph Canc Ctr, Morgantown, WV 26506 USA; W Virginia Univ, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Univ British Columbia, Vancouver, BC V6H 3Z6, Canada; British Columbia Canc Agcy, Vancouver, BC V6H 3Z6, Canada; Vancouver Hosp, Jack Bell Res Ctr, Vancouver, BC V6H 3Z6, Canada	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); West Virginia University; West Virginia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of British Columbia; British Columbia Cancer Agency; University of British Columbia	Qian, Y (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26506 USA.	yaq2@cdc.gov; bhjiang@hsc.wvu.edu	Shi, Xianglin/B-8588-2012	Jiang, Bing-Hua/0000-0003-4526-2031; Dedhar, Shoukat/0000-0003-4355-1657	NATIONAL CANCER INSTITUTE [R01CA060731, R29CA060731] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NCI NIH HHS [CA60731] Funding Source: Medline; NCRR NIH HHS [RR16440] Funding Source: Medline; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Defilippi P, 1999, MICROSC RES TECHNIQ, V47, P67, DOI 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.3.CO;2-G; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gerthoffer WT, 2001, J APPL PHYSIOL, V91, P963, DOI 10.1152/jappl.2001.91.2.963; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Hill MM, 2002, CURR BIOL, V12, P1251, DOI 10.1016/S0960-9822(02)00973-9; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Liu YP, 2002, CELL SIGNAL, V14, P145, DOI 10.1016/S0898-6568(01)00246-7; Livant DL, 2000, CANCER RES, V60, P309; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Persad S, 2003, CANCER METAST REV, V22, P375, DOI 10.1023/A:1023777013659; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2003, J BIOL CHEM, V278, P16189, DOI 10.1074/jbc.M207517200; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Stupack DG, 2000, IMMUNOL RES, V21, P83, DOI 10.1385/IR:21:2-3:83; Svoboda KKH, 1999, ANAT REC, V254, P348, DOI 10.1002/(SICI)1097-0185(19990301)254:3<348::AID-AR5>3.0.CO;2-5; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; VAN AL, 1997, GENE DEV, V11, P2295; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yoganathan N, 2002, PHARMACOL THERAPEUT, V93, P233, DOI 10.1016/S0163-7258(02)00192-4; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	43	123	134	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3154	3165		10.1038/sj.onc.1208525	http://dx.doi.org/10.1038/sj.onc.1208525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735674				2022-12-17	WOS:000228728100009
J	Zhou, XL; Thorgeirsson, SS; Popescu, NC				Zhou, XL; Thorgeirsson, SS; Popescu, NC			Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells	ONCOGENE			English	Article						DLC-1 function; cell growth inhibition; cell migration inhibition; apoptosis reduction of tumorigenicity	CHROMOSOME 8P DELETION; RHO GTPASES; IN-VIVO; METASTASIS; PROTEINS; LINES; DISEASE; DOMAIN; START; DEATH	The gene deleted in liver cancer-1 (DLC-1) is located on human chromosome 8p21-22, a region thought to harbor tumor suppressor genes on the basis of its frequent deletion or loss of heterozygosity in a variety of human cancers, including hepatocellular carcinoma (HCC). Deletion or altered expression of DLC-1 is common in HCC. In the current study, the subcellular localization of Dlc-1 protein was determined by immunostaining with antibody to DLC-1 and the possible tumor growth suppressor activity of DLC-1 was investigated by examining the effects of of DLC-1 cDNA transfection in two human HCC cell lines lacking expression of the endogenous gene. The results show that Dlc-1protein is localized in the cell cytoplasm, and the restoration of DLC-1 expression in HCC cells resulted in caspase-3-mediated apoptosis, inhibition of cell growth and invasiveness in vitro as well as in reduction of the ability of the cells to form tumors in athymic nude mice. These observations thus support the notion that Dlc-1 protein is involved in hepatocarcinogenesis and has oncosuppressive activity in HCC.	NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Ctr Canc Res, Expt Carcinogenesis Lab, Bldg 37,Room 4128,37 Convent Dr,MSC 4264, Bethesda, MD 20892 USA.	popescun@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010038, Z01BC010038] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Ching YP, 2003, J BIOL CHEM, V278, P10824, DOI 10.1074/jbc.M208310200; Euer N, 2002, ANTICANCER RES, V22, P733; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HE L, 1984, IN VITRO CELL DEV B, V20, P493, DOI 10.1007/BF02619623; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kahng YS, 2003, J GASTROEN HEPATOL, V18, P430, DOI 10.1046/j.1440-1746.2003.02997.x; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Keck CL, 1999, CANCER GENET CYTOGEN, V111, P37, DOI 10.1016/S0165-4608(98)00210-6; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Ng IOL, 2000, CANCER RES, V60, P6581; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Peck J, 2002, FEBS LETT, V528, P27, DOI 10.1016/S0014-5793(02)03331-8; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; Qin LX, 1999, CANCER RES, V59, P5662; Qin LX, 2001, J CANCER RES CLIN, V127, P482, DOI 10.1007/s004320100236; Sekimata M, 1999, J BIOL CHEM, V274, P17757, DOI 10.1074/jbc.274.25.17757; Soccio RE, 2003, J BIOL CHEM, V278, P22183, DOI 10.1074/jbc.R300003200; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zimonjic DB, 1999, HEPATOLOGY, V29, P1208, DOI 10.1002/hep.510290410	27	123	139	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	2004	23	6					1308	1313		10.1038/sj.onc.1207246	http://dx.doi.org/10.1038/sj.onc.1207246			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	773HH	14647417				2022-12-17	WOS:000188892200016
J	Dubrova, YE				Dubrova, YE			Radiation-induced transgenerational instability	ONCOGENE			English	Article						instability; mutation; radiation; germline; mouse; cancer	INDUCED GENOMIC INSTABILITY; INDUCED CHROMOSOMAL INSTABILITY; PATERNAL X-IRRADIATION; LUNG-TUMOR INDUCTION; F-1 MICE BORN; IONIZING-RADIATION; 2 GENERATIONS; GERM-LINE; MALE-RATS; MINISATELLITE MUTATIONS	To date, the analysis of mutation induction has provided an irrefutable evidence for an elevated germline mutation rate in the parents directly exposed to ionizing radiation and a number of chemical mutagens. However, the results of numerous publications suggest that radiation may also have an indirect effect on genome stability, which is transmitted through the germ line of irradiated parents to their offspring. This review describes the phenomenon of transgenerational instability and focuses on the data showing increased cancer incidence and elevated mutation rates in the germ line and somatic tissues of the offspring of irradiated parents. The possible mechanisms of transgenerational instability are also discussed.	Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	University of Leicester	Dubrova, YE (corresponding author), Univ Leicester, Dept Genet, Univ Rd, Leicester LE1 7RH, Leics, England.	yed2@le.ac.uk	Dubrova, Yuri/ABA-7148-2020	Dubrova, Yuri/0000-0001-5281-7539				AUROUX MR, 1988, J ANDROL, V9, P153; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barber R, 2000, MUTAT RES-FUND MOL M, V457, P79, DOI 10.1016/S0027-5107(00)00130-5; Baulch JE, 2001, MUTAGENESIS, V16, P17, DOI 10.1093/mutage/16.1.17; Bois P, 1998, GENOMICS, V49, P122, DOI 10.1006/geno.1998.5228; BRANDRIFF B, 1981, SCIENCE, V211, P1431, DOI 10.1126/science.7466400; Burruel VR, 1997, MUTAT RES-FUND MOL M, V381, P59, DOI 10.1016/S0027-5107(97)00148-6; Carls N, 1999, CARCINOGENESIS, V20, P2351, DOI 10.1093/carcin/20.12.2351; CATTANACH BM, 1995, INT J RADIAT BIOL, V67, P607, DOI 10.1080/09553009514550721; Cattanach BM, 1998, MUTAT RES-FUND MOL M, V403, P1, DOI 10.1016/S0027-5107(97)00322-9; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; Daher A, 1998, CARCINOGENESIS, V19, P1553, DOI 10.1093/carcin/19.9.1553; Dickinson HO, 2002, INT J CANCER, V99, P437, DOI 10.1002/ijc.10385; Dubrova YE, 2000, MUTAT RES-FUND MOL M, V453, P17, DOI 10.1016/S0027-5107(00)00068-3; Dubrova YE, 1998, P NATL ACAD SCI USA, V95, P6251, DOI 10.1073/pnas.95.11.6251; Dubrova YE, 2000, NATURE, V405, P37, DOI 10.1038/35011135; Dubrova YE, 2002, MUTAT RES-FUND MOL M, V499, P143, DOI 10.1016/S0027-5107(01)00284-6; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FOMENKO LA, 2001, BIOL BULL, V28, P419; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GENEROSO WM, 1979, P NATL ACAD SCI USA, V76, P435, DOI 10.1073/pnas.76.1.435; GIBBS M, 1993, GENOMICS, V17, P121, DOI 10.1006/geno.1993.1292; GOODHEAD DT, 1988, HEALTH PHYS, V55, P231, DOI 10.1097/00004032-198808000-00015; HALES BF, 1992, TERATOLOGY, V45, P671, DOI 10.1002/tera.1420450612; Harrouk W, 2000, MUTAT RES-DNA REPAIR, V461, P229, DOI 10.1016/S0921-8777(00)00053-7; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Hoyes KP, 2001, RADIAT RES, V156, P488, DOI 10.1667/0033-7587(2001)156[0488:TEOPPC]2.0.CO;2; KELLY R, 1989, GENOMICS, V5, P844, DOI 10.1016/0888-7543(89)90126-2; Kropacova K, 2002, J RADIAT RES, V43, P125, DOI 10.1269/jrr.43.125; Limoli CL, 2000, ADV SPACE RES, V25, P2107, DOI 10.1016/S0273-1177(99)01062-5; Limoli CL, 2001, FREE RADICAL BIO MED, V31, P10, DOI 10.1016/S0891-5849(01)00542-1; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Lord BI, 1998, BRIT J CANCER, V78, P301, DOI 10.1038/bjc.1998.491; Luke GA, 1997, MUTAGENESIS, V12, P147, DOI 10.1093/mutage/12.3.147; LUNING KG, 1976, MUTAT RES, V34, P539, DOI 10.1016/0027-5107(76)90229-3; LYON MF, 1986, GENETIC TOXICOLOGY B, P449; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; NAPALKOV NP, 1989, PERINATAL MULTIGENRA; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; NOMURA T, 1982, NATURE, V296, P575, DOI 10.1038/296575a0; NOMURA T, 1983, MUTAT RES, V121, P59, DOI 10.1016/0165-7992(83)90087-8; Pearce MS, 2002, J R STAT SOC A STAT, V165, P523; Pils S, 1999, MUTAT RES-FUND MOL M, V429, P85, DOI 10.1016/S0027-5107(99)00101-3; Ponnaiya B, 1997, RADIAT RES, V147, P121, DOI 10.2307/3579411; Rakyan VK, 2001, BIOCHEM J, V356, P1, DOI 10.1042/0264-6021:3560001; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; RODERICK TH, 1963, RADIAT RES, V20, P631, DOI 10.2307/3571354; Roemer I, 1997, CURR BIOL, V7, P277, DOI 10.1016/S0960-9822(06)00124-2; SEARLE AG, 1974, ADV RADIAT BIOL, V4, P131; Shimura T, 2002, MOL CELL BIOL, V22, P2220, DOI 10.1128/MCB.22.7.2220-2228.2002; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Tawn EJ, 2000, MUTAT RES-GEN TOX EN, V465, P45, DOI 10.1016/S1383-5718(99)00210-7; TURUSOV VS, 1990, CANCER LETT, V55, P227, DOI 10.1016/0304-3835(90)90123-F; Ullrich RL, 1999, RADIAT RES, V152, P170, DOI 10.2307/3580090; Vance MM, 2002, INT J RADIAT BIOL, V78, P513, DOI [10.1080/095530002317577330, 10.1080/09553000110112444]; Vilarino-Guell C, 2003, MUTAT RES-FUND MOL M, V526, P63, DOI 10.1016/S0027-5107(03)00016-2; VOROBTSOVA IE, 1993, MUTAT RES, V287, P207, DOI 10.1016/0027-5107(93)90013-6; Vorobtsova IE, 2000, MUTAGENESIS, V15, P33, DOI 10.1093/mutage/15.1.33; Watson GE, 1997, INT J RADIAT BIOL, V71, P497, DOI 10.1080/095530097143824; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Wiley LM, 1997, RADIAT RES, V148, P145, DOI 10.2307/3579571; Yauk CL, 2002, MUTAT RES-FUND MOL M, V500, P147, DOI 10.1016/S0027-5107(02)00005-2; Yu YJ, 2001, CANCER RES, V61, P1820; Zhang SL, 1998, P NATL ACAD SCI USA, V95, P2429, DOI 10.1073/pnas.95.5.2429	70	123	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					7087	7093		10.1038/sj.onc.1206993	http://dx.doi.org/10.1038/sj.onc.1206993			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557814				2022-12-17	WOS:000185903900014
J	Suzuki, K; Ojima, M; Kodama, S; Watanabe, M				Suzuki, K; Ojima, M; Kodama, S; Watanabe, M			Radiation-induced DNA damage and delayed induced genomic instability	ONCOGENE			English	Article						genomic instability; DNA damage; repair; p53 and chromatin	DOUBLE-STRAND BREAKS; CHROMOSOMAL INSTABILITY; REPRODUCTIVE DEATH; LETHAL MUTATIONS; GENETIC INSTABILITY; PLATING EFFICIENCY; OXIDATIVE STRESS; MAMMALIAN-CELLS; ALPHA-PARTICLES; X-IRRADIATION	Ionizing radiation induces genomic instability, which is transmitted over many generations after irradiation through the progeny of surviving cells. Induced genomic instability is manifested as the expression of the following delayed effects: delayed reproductive death or lethal mutation, chromosomal instability, and mutagenesis. Since induced genomic instability accumulates gene mutations (actually genomic instability is the process whereby gene mutation increases subtle difference) and gross chromosomal rearrangements, it has been thought to play a role in radiation-induced carcinogenesis. Radiation-induced genomic instability exerts its effects for prolonged periods of time, suggesting the presence of a mechanism by which the initial DNA damage in the surviving cells is memorized. Recent studies have shown that such memory transmission causes delayed DNA breakage, which in turn plays a role in the induction of delayed phenotypes. Although radiation-induced genomic instability has been studied for years, many questions remain to be answered. This review summarizes the current data on radiation-induced genomic instability. In particular, the mechanism(s) involved in the initiation and perpetuation of radiation-induced genomic instability, and a role of delayed activation of p53 protein are discussed.	Nagasaki Univ, Grad Sch Biomed Sci, Course Life Sci & Radiat Res, Dept Radiol & Radiat Biol,Div Radiat Biol, Nagasaki 8528521, Japan	Nagasaki University	Suzuki, K (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Course Life Sci & Radiat Res, Dept Radiol & Radiat Biol,Div Radiat Biol, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	kzsuzuki@net.nagasaki-u.ac.jp						Barcellos-Hoff MH, 2001, RADIAT RES, V156, P618, DOI 10.1667/0033-7587(2001)156[0618:ESTTMA]2.0.CO;2; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; CHANG WSP, 1992, MUTAT RES, V270, P191, DOI 10.1016/0027-5107(92)90130-T; CHONG SY, 1995, BBA-GENE STRUCT EXPR, V1264, P103, DOI 10.1016/0167-4781(95)00133-2; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Cremer M, 2001, CHROMOSOME RES, V9, P541, DOI 10.1023/A:1012495201697; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; Desmaze C, 1999, CYTOGENET CELL GENET, V86, P288, DOI 10.1159/000015321; Figgitt M, 1999, INT J RADIAT BIOL, V75, P811, DOI 10.1080/095530099139863; FITZEK M, 1993, RADIAT ENVIRON BIOPH, V32, P33, DOI 10.1007/BF01213128; GORGOJO L, 1989, INT J RADIAT BIOL, V55, P619, DOI 10.1080/09553008914550661; Grosovsky AJ, 1996, MOL CELL BIOL, V16, P6252; Harper K, 1997, EXP HEMATOL, V25, P263; HOLMBERG K, 1993, MUTAT RES, V286, P321, DOI 10.1016/0027-5107(93)90197-N; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687; KADHIM MA, 1992, NATURE, V355, P738, DOI 10.1038/355738a0; Kadhim MA, 1996, INT J RADIAT BIOL, V69, P167, DOI 10.1080/095530096145995; Kaplan MI, 1998, RADIAT RES, V150, P382, DOI 10.2307/3579656; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Kiefer J, 1999, MUTAT RES-FUND MOL M, V431, P429, DOI 10.1016/S0027-5107(99)00184-0; Li CY, 2001, CANCER RES, V61, P428; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liang L, 2002, MUTAT RES-FUND MOL M, V502, P69, DOI 10.1016/S0027-5107(02)00029-5; Limoli CL, 1998, CANCER RES, V58, P3712; Limoli CL, 1997, CANCER RES, V57, P4048; Limoli CL, 1997, CANCER RES, V57, P5557; Limoli CL, 1999, RADIAT RES, V151, P677, DOI 10.2307/3580206; Little JB, 1998, INT J RADIAT BIOL, V74, P663, DOI 10.1080/095530098140925; Little JB, 1997, RADIAT RES, V148, P299, DOI 10.2307/3579514; Lo AWI, 2002, MOL CELL BIOL, V22, P4836, DOI 10.1128/MCB.22.13.4836-4850.2002; Lorimore SA, 2003, INT J RADIAT BIOL, V79, P15, DOI 10.1080/0955300021000045664; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; Marshall WF, 2002, CURR BIOL, V12, pR185, DOI 10.1016/S0960-9822(02)00724-8; MENDONCA MS, 1989, RADIAT RES, V119, P387, DOI 10.2307/3577629; Morgan WF, 2002, MUTAT RES-FUND MOL M, V504, P91, DOI 10.1016/S0027-5107(02)00083-0; Morgan WF, 1996, RADIAT RES, V146, P247, DOI 10.2307/3579454; Morgan WF, 1998, MUTAT RES-FUND MOL M, V404, P125, DOI 10.1016/S0027-5107(98)00104-3; Mothersill C, 1998, INT J RADIAT BIOL, V74, P673, DOI 10.1080/095530098140934; Mothersill C, 1998, MUTAGENESIS, V13, P421, DOI 10.1093/mutage/13.5.421; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Moynahan ME, 1997, P NATL ACAD SCI USA, V94, P8988, DOI 10.1073/pnas.94.17.8988; Nagasawa H, 1999, RADIAT RES, V152, P552, DOI 10.2307/3580153; Narayanan PK, 1997, CANCER RES, V57, P3963; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; OLGA A, 2002, RADIAT RES, V158, P486; Oren M, 2002, BIOCHEM PHARMACOL, V64, P865, DOI 10.1016/S0006-2952(02)01149-8; PAMPFER S, 1989, INT J RADIAT BIOL, V55, P85, DOI 10.1080/09553008914550091; Parada LA, 2002, TRENDS CELL BIOL, V12, P425, DOI 10.1016/S0962-8924(02)02351-6; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Ponnaiya B, 1997, RADIAT RES, V147, P288, DOI 10.2307/3579335; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; PUCK TT, 1956, J EXP MED, V103, P653, DOI 10.1084/jem.103.5.653; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Roy K, 1999, J RADIAT RES, V40, P311, DOI 10.1269/jrr.40.311; Roy K, 2000, RADIAT RES, V154, P659, DOI 10.1667/0033-7587(2000)154[0659:HRXRID]2.0.CO;2; SABATIER L, 1992, NATURE, V357, P548, DOI 10.1038/357548a0; SEYMOUR CB, 1986, INT J RADIAT BIOL, V50, P167, DOI 10.1080/09553008614550541; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; SINCLAIR WK, 1964, RADIAT RES, V21, P584, DOI 10.2307/3571653; Singleton BK, 2002, CANCER RES, V62, P6263; Smith LE, 1998, MUTAGENESIS, V13, P435, DOI 10.1093/mutage/13.5.435; Suzuki K, 1998, RADIAT RES, V150, P375, DOI 10.2307/3579655; Suzuki K, 2003, CANCER RES, V63, P936; Suzuki K, 1997, J RADIAT RES, V38, P55, DOI 10.1269/jrr.38.55; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; Tanabe H, 2002, MUTAT RES-FUND MOL M, V504, P37, DOI 10.1016/S0027-5107(02)00077-5; Trott KR, 1998, INT J RADIAT BIOL, V74, P787, DOI 10.1080/095530098141078; Trott KR, 2000, RADIAT ENVIRON BIOPH, V39, P79, DOI 10.1007/s004110000047; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wang P, 1997, P NATL ACAD SCI USA, V94, P12018, DOI 10.1073/pnas.94.22.12018; Wang P, 2002, NUCLEIC ACIDS RES, V30, P2639, DOI 10.1093/nar/gkf369; Yamada Y, 1996, RADIAT RES, V145, P481, DOI 10.2307/3579070; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	82	123	133	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2003	22	45					6988	6993		10.1038/sj.onc.1206881	http://dx.doi.org/10.1038/sj.onc.1206881			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557802				2022-12-17	WOS:000185903900002
J	Khalili, K; Del Valle, L; Otte, J; Weaver, M; Gordon, J				Khalili, K; Del Valle, L; Otte, J; Weaver, M; Gordon, J			Human neurotropic polyomavirus, JCV, and its role in careinogenesis	ONCOGENE			English	Article						PML; oncogene; cancer; brain	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CENTRAL-NERVOUS-SYSTEM; PRIMITIVE NEUROECTODERMAL TUMORS; HUMAN PAPOVAVIRUS JC; VIRUS-DNA SEQUENCES; BASIC-PROTEIN GENE; FETAL GLIAL-CELLS; LARGE T-ANTIGENS; TRANSGENIC MICE; BRAIN-TUMORS	A number of recent studies have reported the detection of the ubiquitous human polyomavirus, JC virus (JCV), in samples derived from several types of neural as well as non-neural human tumors. The human neurotropic JCV was first identified as the etiologic agent of the fatal demyelinating disease, progressive multifocal leukoencephalopathy, which usually occurs in individuals with defects in cell-mediated immunity, including AIDS. However, upon mounting evidence of the oncogenic potential of the viral regulatory protein, T-antigen, and JCV's oncogenecity in a broad range of animal models, studies were initiated to determine its potential involvement in human carcinogenesis. Initially, the most frequently observed tumors in rodent models, including medulloblastoma, astrocytoma, glioblastoma, and other neural-origin tumors were analysed. These studies were followed by analysis of non-neural tumors such as colorectal carcinomas. In a subset of each tumor type examined, JC viral genomic DNA sequences could be detected by PCR and confirmed by Southern blot hybridization or direct sequencing. In a smaller subset of the tumors, the expression of T-antigen was observed by immunohistochemical analysis. Owing to the established functions of T-antigen including its ability to interact with tumor suppressor proteins such as Rb and p53, and its ability to influence chromosomal stability, potential mechanisms of JCV T-antigen-mediated cellular dysregulation are discussed. Further, as increasing evidence suggests that T-antigen is not required for maintenance of a transformed phenotype, a hit-and-run model for T-antigen-induced transformation is proposed.	Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Ctr Neurovirol & Canc Biol, Coll Sci & Technol, 1900 N 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206				AKATANI K, 1994, J MED VIROL, V43, P13, DOI 10.1002/jmv.1890430104; Arrington AS, 2001, HUMAN POLYOMAVIRUSES; ASSOULINE JG, 1991, J VIROL, V65, P1002, DOI 10.1128/JVI.65.2.1002-1006.1991; ATWOOD WJ, 1992, VIROLOGY, V190, P716, DOI 10.1016/0042-6822(92)90909-9; BARONVANEVERCOOREN A, 1992, LAB INVEST, V66, P39; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Bofill-Mas S, 2001, J VIROL, V75, P10290, DOI 10.1128/JVI.75.21.10290-10299.2001; Boldorini R, 1998, J NEUROVIROL, V4, P242, DOI 10.3109/13550289809114524; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; BRUN A, 1984, CANCER, V53, P1714, DOI 10.1002/1097-0142(19840415)53:8<1714::AID-CNCR2820530816>3.0.CO;2-T; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; CORALLINI A, 2001, HUMAN POLYOMAVIRUSES; Darbinyan A, 2002, ONCOGENE, V21, P5574, DOI 10.1038/sj.onc.1205744; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P3332; Del Valle L, 2002, NEUROLOGY, V58, P895, DOI 10.1212/WNL.58.6.895; Del Valle L, 2001, CANCER RES, V61, P4287; Del Valle L, 2002, JNCI-J NATL CANCER I, V94, P267, DOI 10.1093/jnci/94.4.267; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; Devireddy LR, 1996, J MED VIROL, V49, P205; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Enam S, 2002, CANCER RES, V62, P7093; Franks RR, 1996, ONCOGENE, V12, P2573; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Frye S, 1997, J VIROL METHODS, V63, P81, DOI 10.1016/S0166-0934(96)02117-9; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; Gordon J, 2000, ONCOGENE, V19, P4840, DOI 10.1038/sj.onc.1203849; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Hara K, 1998, J VIROL, V72, P5335, DOI 10.1128/JVI.72.7.5335-5342.1998; KITAMURA T, 1994, J CLIN MICROBIOL, V32, P2359, DOI 10.1128/JCM.32.10.2359-2363.1994; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lazutka JR, 1996, CANCER LETT, V109, P177, DOI 10.1016/S0304-3835(96)04448-5; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; LUDLOW JW, 1995, VIRUS RES, V35, P113, DOI 10.1016/0168-1702(94)00094-S; LYNCH KJ, 1994, VIROLOGY, V204, P819, DOI 10.1006/viro.1994.1600; MAJOR EO, 1987, J VIROL, V61, P1435, DOI 10.1128/JVI.61.5.1435-1441.1987; MAJOR EO, 1985, P NATL ACAD SCI USA, V82, P1257, DOI 10.1073/pnas.82.4.1257; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MAJOR EO, 1989, J NEUROPATH EXP NEUR, V48, P425, DOI 10.1097/00005072-198907000-00004; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MATSUDA M, 1987, JNCI-J NATL CANCER I, V79, P585; MOLENAAR WM, 1994, CRIT REV ONCOL HEMAT, V17, P1, DOI 10.1016/1040-8428(94)90036-1; MONACO MCG, 1998, J VIROL, P9918; NAGASHIMA K, 1984, AM J PATHOL, V116, P455; Neel JV, 1996, P NATL ACAD SCI USA, V93, P2690, DOI 10.1073/pnas.93.7.2690; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; Ricciardiello L, 2000, GASTROENTEROLOGY, V119, P1228, DOI 10.1053/gast.2000.19269; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RICHARDSON E, 1961, NEW ENGL J MED, V265, P815, DOI 10.1056/NEJM196110262651701; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Shinohara T, 1997, VIROLOGY, V228, P269, DOI 10.1006/viro.1996.8409; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; VACANTE DA, 1989, VIROLOGY, V170, P353, DOI 10.1016/0042-6822(89)90425-X; Walker D L, 1983, Prog Clin Biol Res, V105, P99; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WOODRUFF JM, 2000, PATHOLOGY GENETICS T; WROBLEWSKA Z, 1980, ARCH VIROL, V65, P141, DOI 10.1007/BF01317325; ZURHEIN GM, 1979, NATL CANCER I MONOGR, V51, P205	71	123	126	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 11	2003	22	33					5181	5191		10.1038/sj.onc.1206559	http://dx.doi.org/10.1038/sj.onc.1206559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910255				2022-12-17	WOS:000184615100009
J	Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP				Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP			Frequent hypermethylation of the RASSF1A gene in prostate cancer	ONCOGENE			English	Article						RASSF1A; methylation; tumor suppressor gene; prostate cancer	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; ANDROGEN RECEPTOR GENE; CPG ISLAND; EPIGENETIC INACTIVATION; METHYLATION PATTERNS; BREAST CANCERS; LUNG-CANCER; PROGRESSION; PROMOTER	Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7-10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.	Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Human Genet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA.				NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns P, 2001, CLIN CANCER RES, V7, P2727; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lerman MI, 2000, CANCER RES, V60, P6116; Li LC, 2000, CANCER RES, V60, P702; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lo KW, 2001, CANCER RES, V61, P3877; Marcelli M, 2000, CANCER RES, V60, P944; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Ozen M, 2000, ANTICANCER RES, V20, P1905; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Rokman A, 2001, CANCER RES, V61, P6038; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Singal R, 2001, CANCER RES, V61, P4820; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wang L, 2001, CANCER RES, V61, P6494; Wistuba II, 2000, CANCER RES, V60, P1949; Wu YQ, 2001, CANCER RES, V61, P8651; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	47	123	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6835	6840		10.1038/sj.onc.1205814	http://dx.doi.org/10.1038/sj.onc.1205814			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360410				2022-12-17	WOS:000178315800014
J	Kartasheva, NN; Contente, A; Lenz-Stoppler, C; Roth, J; Dobbelstein, M				Kartasheva, NN; Contente, A; Lenz-Stoppler, C; Roth, J; Dobbelstein, M			p53 induces the expression of its antagonist p73 Delta N, establishing an autoregulatory feedback loop	ONCOGENE			English	Article						apoptosis; mdm2; p53; p73; promoter	TUMOR-SUPPRESSOR PROTEIN; CANCER CELL-LINES; LARGE T-ANTIGEN; WILD-TYPE P53; DNA-BINDING; P73 GENE; ADENOVIRUS TYPE-5; TRANSCRIPTION ANALYSES; P53-RELATED PROTEIN; VIRAL ONCOPROTEINS	The p53 tumor suppressor protein activates transcription and induces cell death. A close homologue of p53, termed p73, is expressed in transactivating (TA) forms that induce growth arrest and apoptosis much like p53. However, the p73 gene contains a second promoter, giving rise to the expression of p73DeltaN, a species of p73 proteins that lack the N-terminal transactivation domain. We show here that the expression of p73DeltaN is induced by p53 on the mRNA and protein level. The promoter that regulates p73DeltaN expression in human cells was cloned and found to be activated by p53, as well as by p73TA, directly through a specific DNA element. The p73DeltaN proteins, that are thereby expressed, bound to p53-responsive promoter DNA, competed with p53 for DNA binding, antagonized the activation of transcription by p53, and prevented p53-induced cell death. In addition, a transcriptional repressor domain was identified within the splicing variant p73DeltaNalpha. The combination of p73DeltaNalpha and mdm2 antagonized p53 more strongly than either p73Nalpha or mdm2 alone. Blocking endogenous p73DeltaN by a trans dominant fragment, or its removal by siRNA, increased the activity of a p53-responsive promoter in cells that contain a wild type p53 gene. Thus, the induction of p73DeltaN expression by p53 establishes an autoregulatory feedback loop that keeps the trigger of cell death under tight control.	Univ Marburg, Inst Virol, D-35037 Marburg, Germany; Univ Marburg, Abt Gastroenterol & Stoffwechsel, D-35043 Marburg, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Philipps University Marburg; Philipps University Marburg; Russian Academy of Sciences	Dobbelstein, M (corresponding author), Univ Marburg, Inst Virol, Robert Koch Str 17, D-35037 Marburg, Germany.			Dobbelstein, Matthias/0000-0001-5052-3967				Arita D, 1997, JPN J CANCER RES, V88, P39, DOI 10.1111/j.1349-7006.1997.tb00299.x; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BIEDLER JL, 1973, CANCER RES, V33, P2643; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Dobbelstein M, 1998, J GEN VIROL, V79, P3079, DOI 10.1099/0022-1317-79-12-3079; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Freedman DA, 1999, CELL MOL LIFE SCI, V55, P96, DOI 10.1007/s000180050273; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Hagiwara K, 1999, CANCER RES, V59, P4165; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashino F, 1998, P NATL ACAD SCI USA, V95, P15683, DOI 10.1073/pnas.95.26.15683; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2001, APOPTOSIS, V6, P17, DOI 10.1023/A:1009663809458; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Koch P, 2001, CANCER RES, V61, P5941; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Liefer KM, 2000, CANCER RES, V60, P4016; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Nishi H, 1999, INT J ONCOL, V15, P1149; Nomoto S, 1998, CANCER RES, V58, P1380; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prabhu NS, 1998, INT J ONCOL, V13, P5; Reichelt M, 1999, ARCH VIROL, V144, P621, DOI 10.1007/s007050050530; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Roth J, 2000, ONCOGENE, V19, P1834, DOI 10.1038/sj.onc.1203500; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Roth J, 1999, J GEN VIROL, V80, P3251, DOI 10.1099/0022-1317-80-12-3251; RUTZKY LP, 1980, CANCER RES, V40, P1443; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; STIEWE T, 2002, J BIOL CHEM, V13, P13; Takahashi H, 1998, CANCER RES, V58, P2076; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Weigel S, 2000, J VIROL, V74, P764, DOI 10.1128/JVI.74.2.764-772.2000; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	76	123	125	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	2002	21	31					4715	4727		10.1038/sj.onc.1205584	http://dx.doi.org/10.1038/sj.onc.1205584			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101410				2022-12-17	WOS:000176716300001
J	Reed, CC; Gauldie, J; Iozzo, RV				Reed, CC; Gauldie, J; Iozzo, RV			Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin	ONCOGENE			English	Article						decorin proteoglycan; adenovirus gene therapy; colon carcinoma; squamous carcinoma	LEUCINE-RICH PROTEOGLYCANS; GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; DOWN-REGULATION; UP-REGULATION; EXPRESSION; CARCINOMA; CELLS; INHIBITION; REGULATORS	There is mounting evidence that decorin inhibits the growth of various tumor cell lines when either over-expressed in vitro or provided as a recombinant protein. The mechanism of action is primarily via a protracted inactivation of the epidermal growth factor receptor (EGFR) tyrosine kinase. In this study we explored the possibility of retarding the growth of tumor xenografts by decorin gene delivery into the growing neoplastic tissues. We demonstrate that transient transgene expression of replication-deficient adenovirus-containing decorin causes a significant growth inhibition of colon and squamous carcinoma tumor xenografts. These cytostatic effects were achieved with relatively low viral titers and correlated with a reduced proliferative index and an attenuation of the EGFR phosphorylation in vivo. Thus, decorin gene therapy helps in retarding the growth of human tumors in immunocompromised animals and could represent a new independent or adjunctive therapeutic modality against cancer.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; Thomas Jefferson Univ, Kimmel Canc Ctr, Cellular Biol & Signaling Program, Philadelphia, PA 19107 USA	Jefferson University; McMaster University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249,JAH,1020 Locust St, Philadelphia, PA 19107 USA.	iozzo@lac.jci.tju.edu	Iozzo, Renato/AAS-1980-2020	Iozzo, Renato/0000-0002-5908-5112	NCI NIH HHS [R01 CA39481, R01 CA47282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039481, R01CA047282] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADANY R, 1990, J BIOL CHEM, V265, P11389; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; COPPOCK DL, 1993, CELL GROWTH DIFFER, V4, P483; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; Fischer JW, 2001, ARTERIOSCL THROM VAS, V21, P777, DOI 10.1161/01.ATV.21.5.777; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1999, P NATL ACAD SCI USA, V96, P3092, DOI 10.1073/pnas.96.6.3092; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; MANN DM, 1990, J BIOL CHEM, V265, P5317; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miyasaka Y, 2001, BRIT J CANCER, V85, P228, DOI 10.1054/bjoc.2001.1901; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nash MA, 1999, CANCER RES, V59, P6192; Patel S, 1998, J BIOL CHEM, V273, P3121, DOI 10.1074/jbc.273.6.3121; Ramamurthy P, 1996, J BIOL CHEM, V271, P19578, DOI 10.1074/jbc.271.32.19578; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Santra M, 2000, J BIOL CHEM, V275, P35153, DOI 10.1074/jbc.M006821200; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; Shridhar V, 2001, CANCER RES, V61, P5895; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Xaus J, 2001, BLOOD, V98, P2124, DOI 10.1182/blood.V98.7.2124; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	38	123	138	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3688	3695		10.1038/sj.onc.1205470	http://dx.doi.org/10.1038/sj.onc.1205470			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032837				2022-12-17	WOS:000175676000004
J	Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD				Croxton, R; Ma, YH; Song, LX; Haura, EB; Cress, WD			Direct repression of the Mcl-1 promoter by E2F1	ONCOGENE			English	Article						apoptosis; cell cycle; E2F; Mcl-1; microarray	S-PHASE ENTRY; BCL-2 FAMILY-MEMBER; DNA-SYNTHESIS; RETINOBLASTOMA PROTEIN; SIGNALING PATHWAY; BINDING PROTEIN; STABILIZES P53; CYTOCHROME-C; CELL-DEATH; APOPTOSIS	E2F1 induces apoptosis via both p53-dependent and p53-independent mechanisms. The direct targets in the p53-independent pathway remain enigmatic; however, the induction of this pathway does not require the transactivation domain of E2F1. Using cells that are defective in p53 activation, we show that E2F1 potently represses the expression of Mcl-1 - an anti-apoptotic Bcl-2 family member whose depletion results in apoptosis. We also show that this transcriptional repression is direct and dependent upon E2F1's DNA-binding domain, but does not require the transactivation domain of E2F1. Consistent with this DNA binding requirement of E2F1 to repress Mcl-1, we show that E2F1 binds to the Mcl-1 promoter both in vitro and in vivo, and have identified the DNA element (- 143/ -117) within this promoter that is required for E2F1 binding and repression. Additionally, cell lines constitutively expressing Mcl-1 are resistant to E2F1-mediated apoptosis - suggesting that Mcl-1 downregulation is a necessary event in the p53-independent apoptotic process. Thus, we identify a p53 family-independent mechanism of E2F1-induced apoptosis in which E2F1 directly represses Mcl-1 expression.	H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Clin Invest Program, H Lee Moffitt Comprehens Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Inst Biomol Sci, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Cress, WD (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.	cressd@moffitt.usf.edu			NCI NIH HHS [CA78214] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078214] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dong YB, 1999, CANCER, V86, P2021, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2021::AID-CNCR20>3.0.CO;2-1; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Flores AM, 1998, ONCOGENE, V16, P1289, DOI 10.1038/sj.onc.1201633; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; He YW, 2000, ONCOGENE, V19, P3422, DOI 10.1038/sj.onc.1203682; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Hsu SY, 2000, PHYSIOL REV, V80, P593, DOI 10.1152/physrev.2000.80.2.593; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hunt KK, 1997, CANCER RES, V57, P4722; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Kowalik TF, 1998, CELL GROWTH DIFFER, V9, P113; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaThangue NB, 1996, BIOCHEM SOC T, V24, P54; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Liu TJ, 1999, CANCER GENE THER, V6, P163, DOI 10.1038/sj.cgt.7700007; Lomo J, 1996, CANCER RES, V56, P40; MIYASHITA T, 1995, CELL, V80, P293; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; REYNOLDS JE, 1994, CANCER RES, V54, P6348; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Takahashi Y, 2000, GENE DEV, V14, P804; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Yang HL, 2000, CLIN CANCER RES, V6, P1579; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhao RB, 2000, GENE DEV, V14, P981; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239; Zhu JW, 1999, CELL GROWTH DIFFER, V10, P829	72	123	126	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2002	21	9					1359	1369		10.1038/sj.onc.1205157	http://dx.doi.org/10.1038/sj.onc.1205157			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	521VA	11857079				2022-12-17	WOS:000173861000006
J	Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT				Kim, DH; Nelson, HH; Wiencke, JK; Christiani, DC; Wain, JC; Mark, EJ; Kelsey, KT			Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer	ONCOGENE			English	Article						DAP-kinase; k-ras; p53; methylation; nonsmall cell lung cancer	TUMOR-SUPPRESSOR GENES; DNA METHYLATION; CPG ISLAND; SIGNALING PATHWAY; HYPERMETHYLATION; METHYLTRANSFERASE; PROTEIN; DEATH; IDENTIFICATION; APOPTOSIS	Death associated protein (DAP)-kinase is a 16 kDa calmodulin-dependent serine/threonine kinase that carries a death domain at its C-terminus. DAP-kinase functions as a positive mediator of apoptosis that is induced by interferon-gamma. Recent studies suggest that DAP-kinase is involved in tumor metastasis and that it can be inactivated by methylation of CpG islands in the promoter region of the gene in some human tumors. However, little is known about the factors that are associated with the occurrence of DAP-kinase promoter methylation. We investigated both the possible associations of tobacco carcinogen and asbestos exposure with DAP-kinase promoter methylation, and the demographic and clinical factors associated with DAP-kinase promoter methylation in non-small cell lung cancer (NSCLC), One hundred and eighty-five patients diagnosed with NSCLC undergoing surgical resection from June, 1992 through December, 1996 at Massachusetts General Hospital participated in this study, Methylation-Specific PCR (MSP), performed using fresh-frozen tissue, was used to determine the methylation status of the promoter region of the DAP-kinase gene. Forty-seven (25%) of 185 tumors showed DAP-kinase promoter methylation. There was a significant association between methylation and an advanced pathologic stage (P=0.003, Fisher's exact test). Methylation of the DAP-kinase promoter was also associated with an increase in tumor size (P=0.009, Fisher's exact test) and lymph node involvement (P=0.04), No association was found between promoter methylation of DAP-kinase and k-ras or p53 mutation. In addition there was no association with a history of exposure to tobacco or asbestos. Controlling for age, sex, and histology, the odds ratios describing the association of DAP-kinase hypermethylation with stage were 2.70 (1.13-6.45), 3.11 (1.37-7.08) and 7.77 (1.21-50.03) in stages II, III and IV, respectively. Stage I cases with DAP-kinase promoter methylation had worse overall survival, but with the small sample size and limited follow-up this did not reach statistical significance. Our findings suggest that methylation of the promoter region of the DAP-kinase gene is not associated with exposure to tobacco or asbestos. However, they strongly suggest that DAP-kinase may be important in the progression of non-small cell lung cancer from early to late stage disease.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, Lab Mol Epidemiol, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Pulm & Crit Care Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg,Thorac Surg Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Kelsey, KT (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave,Bldg 1,Rm 207, Boston, MA 02115 USA.		Kelsey, Karl T/I-1252-2014	Nelson, Heather/0000-0003-1901-9513	NATIONAL CANCER INSTITUTE [R01CA074386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006409, P30ES000002] Funding Source: NIH RePORTER; NCI NIH HHS [CA08357, CA74386, CA06717] Funding Source: Medline; NIEHS NIH HHS [ES00002, ES/CA 06409] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Belinsky SA, 1996, P NATL ACAD SCI USA, V93, P4045, DOI 10.1073/pnas.93.9.4045; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eguchi K, 1997, CANCER RES, V57, P4913; ELDEIRY WA, 1990, P NATL ACAD SCI USA, V88, P3470; Esteller M, 1999, CANCER RES, V59, P67; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Inbal B, 1997, NATURE, V390, P180, DOI 10.1038/36599; Issa JPJ, 1996, CANCER RES, V56, P3655; Jones P A, 1990, Adv Cancer Res, V54, P1, DOI 10.1016/S0065-230X(08)60806-4; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Katzenellenbogen RA, 1999, BLOOD, V93, P4347, DOI 10.1182/blood.V93.12.4347.412k31_4347_4353; Kissil JL, 1998, MOL MED TODAY, V4, P268, DOI 10.1016/S1357-4310(98)01263-5; Kissil JL, 1997, ONCOGENE, V15, P403, DOI 10.1038/sj.onc.1201172; Laird PW, 1996, ANNU REV GENET, V30, P441, DOI 10.1146/annurev.genet.30.1.441; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327; NELSON HH, 1999, CANCER RES, V20, P667; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Tang XM, 2000, JNCI-J NATL CANCER I, V92, P1511, DOI 10.1093/jnci/92.18.1511; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; VIALLET J, 1990, AM J RESP CELL MOL, V2, P225, DOI 10.1165/ajrcmb/2.3.225; WANG X, 1995, CANCER EPIDEM BIOMAR, V4, P543; WU J, 1990, P NATL ACAD SCI USA, V90, P8891	29	123	133	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 29	2001	20	14					1765	1770		10.1038/sj.onc.1204302	http://dx.doi.org/10.1038/sj.onc.1204302			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	415YJ	11313923				2022-12-17	WOS:000167750900009
J	Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG				Fulci, G; Labuhn, M; Maier, D; Lachat, Y; Hausmann, O; Hegi, ME; Janzer, RC; Merlo, A; Van Meir, EG			p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma	ONCOGENE			English	Article						p14arf; p16; mdm2; egfr; brain tumor; tumor suppressor	CELL LUNG-CANCER; HIGH-GRADE GLIOMAS; TUMOR-SUPPRESSOR; HOMOZYGOUS DELETION; BRAIN-TUMORS; CDK4 AMPLIFICATION; MALIGNANT GLIOMAS; ONCOPROTEIN MDM2; P16(INK4A) GENE; P19(ARF)	P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently: deleted in human tumors, Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci, To examine this question we performed a multigenic analysis on 29 gliomas, We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26, Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis, The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV, either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%), These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and Loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.	CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Neurosurg, Mol Neurooncol Lab, Atlanta, GA 30322 USA; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; CHU Vaudois, Univ Hosp, Dept Neuropathol, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Emory University; Emory University; University of Basel; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Van Meir, EG (corresponding author), CHU Vaudois, Univ Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, CH-1011 Lausanne, Switzerland.		Hegi, Monika/O-4796-2015	Hegi, Monika/0000-0003-0855-6495; Van Meir, Erwin G./0000-0003-2444-7707				Biernat W, 1997, ACTA NEUROPATHOL, V94, P303, DOI 10.1007/s004010050711; BIERNAT W, 1997, NEUROPATHOL EXP NEUR, V56, P180; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; Chiariello E, 1998, ONCOGENE, V16, P541, DOI 10.1038/sj.onc.1201689; Costello JF, 1997, CANCER RES, V57, P1250; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; DURO D, 1995, ONCOGENE, V11, P21; FRYE RA, 1989, ONCOGENE, V4, P1153; Fueyo J, 1998, NEUROLOGY, V51, P1250, DOI 10.1212/WNL.51.5.1250; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Gazzeri S, 1998, CANCER RES, V58, P3926; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Hayashi Y, 1997, BRAIN PATHOL, V7, P871, DOI 10.1111/j.1750-3639.1997.tb00890.x; HE J, 1994, CANCER RES, V54, P5804; Hegi ME, 1997, INT J CANCER, V73, P57, DOI 10.1002/(SICI)1097-0215(19970926)73:1<57::AID-IJC10>3.0.CO;2-2; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; HUNTER SB, 1995, J NEUROPATH EXP NEUR, V54, P57, DOI 10.1097/00005072-199501000-00007; Ichimura K, 2000, CANCER RES, V60, P417; JEN J, 1994, CANCER RES, V54, P6353; Kamb A, 1994, Nat Genet, V8, P23; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kleihues P, 1994, Recent Results Cancer Res, V135, P25; LANDERS JE, 1994, ONCOGENE, V9, P2745; Maddalena AS, 1999, BRAIN PATHOL, V9, P627; Maier D, 1998, ONCOGENE, V16, P3331, DOI 10.1038/sj.onc.1201832; Maier D, 1997, ONCOGENE, V15, P997, DOI 10.1038/sj.onc.1201209; MAO L, 1995, CANCER RES, V55, P2995; MeyerPuttlitz B, 1997, AM J PATHOL, V151, P853; Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32; Nakamura H, 1998, ONCOGENE, V16, P1009, DOI 10.1038/sj.onc.1201618; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; SCHMIDT EE, 1994, CANCER RES, V54, P6321; STONE S, 1995, CANCER RES, V55, P2988; Sure U, 1997, J NEUROPATH EXP NEUR, V56, P782; Teng DHF, 1997, CANCER RES, V57, P5221; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang SI, 1997, CANCER RES, V57, P4183; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	48	123	124	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2000	19	33					3816	3822		10.1038/sj.onc.1203700	http://dx.doi.org/10.1038/sj.onc.1203700			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AG	10949938				2022-12-17	WOS:000088568400016
J	Ye, DW; Mendelsohn, J; Fan, Z				Ye, DW; Mendelsohn, J; Fan, Z			Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225	ONCOGENE			English	Article						EGF receptor; HER2; mAb; p27(Kip1); CDK; cell cycle	MONOCLONAL-ANTIBODY; BREAST-CANCER; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; CARCINOMA-CELLS; OVARIAN-CANCER; G(1) ARREST; NEU; HETERODIMERIZATION; P27(KIP1)	Overexpression of epidermal growth factor (EGF) receptor and HER2 (p185(neu)) may both contribute to the growth of human cancers. A humanized anti-HER2 monoclonal antibody (mAb) 4D5 and a human-mouse chimeric anti-EGF receptor mAb C225 are currently being investigated in clinical trials for their anti-tumor activities. In the present study, we have examined the effect of concurrent treatment of OVCA 420 human ovarian cancer cells with mAb C225 and mAb 4D5, Exposure of OVCA420 cells to saturating concentrations of C225 (20 nM) for 7 days resulted in 40-50% growth inhibition, and exposure to 20 nM mAb 4D5 also resulted in 30-40% growth inhibition. The growth inhibition of OVCA420 cells by mAb C225 or 4D5 was associated with an increased G1 cell population; an increased level of a cyclin-dependent kinase (CDK) inhibitor p27(Kip1) with increased association of p27(Kip1) with CDK2, CDK4 and CDK6; and decreased activities of these CDKs, Combination treatment with concurrent exposure to mAbs C225 and 4D5 resulted in additive anti-proliferative effects on these cells, which was accompanied by enhanced G1 cell distribution, a greater increase in the levels of p27(Kip1) and a greater decrease in the activities of CDK kinases, The anti-proliferative effects and related changes in cell cycle regulators induced by mAb 4D5, mAb C225 or the combination of the two mAbs could be reversed by concurrent exposure to exogenous EGF, Our data suggest the potential fruitful cooperation of anti-EGF receptor mAb and anti-HER2 mAb in the treatment of human cancers stimulated by EGF receptor and HER2 signals.	Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Cancer Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA68425, CA42060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA042060, R01CA042060, P50CA068425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; BOS M, 1996, P AN M AM SOC CLIN, V15, P443; Chou J. L., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P10; COBLEIGH MA, 1998, P AN M AM SOC CLIN, V17, pA97; DIVGI CR, 1991, J NATL CANCER I, V83, P97, DOI 10.1093/jnci/83.2.97; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; FALCEY J, 1997, P AN M AM SOC CLIN, V16, pA383; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; Goldstein NI, 1995, CLIN CANCER RES, V1, P1311; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; JARDINES L, 1993, PATHOBIOLOGY, V61, P268, DOI 10.1159/000163805; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PEGRAM M, 1995, P AN M AM SOC CLIN, V14, P106; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; Peng D, 1996, CANCER RES, V56, P3666; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Prewett M, 1996, J IMMUNOTHER, V19, P419, DOI 10.1097/00002371-199611000-00006; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Reese DM, 1997, STEM CELLS, V15, P1, DOI 10.1002/stem.150001; SCOTT GK, 1991, J BIOL CHEM, V266, P14300; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHOTT S, 1990, STAT HLTH PROFESSION, P151; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; Wu XP, 1996, ONCOGENE, V12, P1397	39	123	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					731	738		10.1038/sj.onc.1202319	http://dx.doi.org/10.1038/sj.onc.1202319			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989823				2022-12-17	WOS:000078394400018
J	Dhanasekaran, N; Tsim, ST; Dermott, JM; Onesime, D				Dhanasekaran, N; Tsim, ST; Dermott, JM; Onesime, D			Regulation of cell proliferation by G proteins	ONCOGENE			English	Review						G proteins; oncogene; signaling; ERK; JNK; Ras	MUTANT ALPHA-SUBUNIT; MUSCARINIC ACETYLCHOLINE-RECEPTOR; GTPASE-DEFICIENT G-ALPHA(16); NUCLEOTIDE EXCHANGE FACTOR; EMBRYONAL CARCINOMA-CELLS; HETEROTRIMERIC G-PROTEINS; RAS-DEPENDENT ACTIVATION; KINASE SIGNALING PATHWAY; BETA-GAMMA-SUBUNITS; SWISS 3T3 CELLS	G Proteins provide signal transduction mechanisms to seven transmembrane receptors. Recent studies have indicated that the alpha-subunits as well as the beta gamma-subunits of these proteins regulate several critical signaling pathways involved in cell proliferation, differentiation and apoptosis. Of the 17 alpha-subunits that have been cloned, at least ten of them have been shown to couple mitogenic signaling in fibroblast cells. Activating mutations in G alpha(s), G alpha(12), and G alpha(12) have been correlated with different types of tumors. In addition, the ability of the beta gamma-subunits to activate mitogenic pathways in different cell-types has been defined. The present review briefly summarizes the diverse and novel signaling pathways regulated by the alpha- as well as the beta gamma-subunits of G proteins in regulating cell proliferation.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Dhanasekaran, N (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.				NIGMS NIH HHS [GM49897] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; Althoefer H, 1997, J BIOL CHEM, V272, P24380, DOI 10.1074/jbc.272.39.24380; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARAGAY AM, 1995, J BIOL CHEM, V270, P20073, DOI 10.1074/jbc.270.34.20073; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; Buckbinder L, 1997, P NATL ACAD SCI USA, V94, P7868, DOI 10.1073/pnas.94.15.7868; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chen JF, 1997, J MOL MED, V75, P283, DOI 10.1007/s001090050113; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Collins LR, 1997, ONCOGENE, V15, P595, DOI 10.1038/sj.onc.1201220; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COPELAND NG, 1979, CELL, V17, P993, DOI 10.1016/0092-8674(79)90338-6; CORRE I, 1995, BLOOD, V86, P1776, DOI 10.1182/blood.V86.5.1776.bloodjournal8651776; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CZECH MP, 1988, J BIOL CHEM, V263, P11017; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; DHANASEKARAN N, 1994, J BIOL CHEM, V269, P11802; Dhanasekaran N, 1998, BIOL SIGNAL RECEPT, V7, P109; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Fleming IN, 1997, J BIOL CHEM, V272, P33105, DOI 10.1074/jbc.272.52.33105; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, MOL BIOL CELL, V3, P123, DOI 10.1091/mbc.3.1.123; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Ham J, 1997, MOL CELL ENDOCRINOL, V127, P41, DOI 10.1016/S0303-7207(96)03987-1; HAUSDORFF WP, 1992, P NATL ACAD SCI USA, V89, P5720, DOI 10.1073/pnas.89.13.5720; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; Hermouet S, 1996, CELL SIGNAL, V8, P159, DOI 10.1016/0898-6568(95)02049-7; HERMOUET S, 1996, CELL SIGNAL, V5, P215; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Jho EH, 1997, J BIOL CHEM, V272, P24468, DOI 10.1074/jbc.272.39.24468; Jho EH, 1997, J BIOL CHEM, V272, P24461, DOI 10.1074/jbc.272.39.24461; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KALINEC G, 1992, MOL CELL BIOL, V12, P4687, DOI 10.1128/MCB.12.10.4687; KATAOKA R, 1993, J BIOL CHEM, V268, P19851; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; KROLL SD, 1992, J BIOL CHEM, V267, P23183; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu JL, 1997, J BIOL CHEM, V272, P29438, DOI 10.1074/jbc.272.47.29438; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; LOWNDES JM, 1991, J BIOL CHEM, V266, P14193; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marrero MB, 1997, J BIOL CHEM, V272, P24684, DOI 10.1074/jbc.272.39.24684; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; Moore KA, 1997, BIOCHEM J, V326, P17, DOI 10.1042/bj3260017; Moxham CM, 1996, NATURE, V379, P840, DOI 10.1038/379840a0; MUCA C, 1994, ONCOGENE, V9, P3647; Offermanns S, 1996, J BIOL CHEM, V271, P26044, DOI 10.1074/jbc.271.42.26044; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; PRASAD MVVSV, 1994, ONCOGENE, V9, P2425; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; QIAN NX, 1994, J BIOL CHEM, V269, P17417; RAHMATULLAH M, 1995, J BIOL CHEM, V270, P2946, DOI 10.1074/jbc.270.7.2946; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROCCA GJD, 1997, J BIOL CHEM, V272, P19125; RODBELL M, 1971, J BIOL CHEM, V246, P1872; ROSS EM, 1977, J BIOL CHEM, V252, P6966; SA G, 1994, J BIOL CHEM, V269, P3219; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Tolkacheva T, 1997, ONCOGENE, V15, P727, DOI 10.1038/sj.onc.1201229; TORDJMAN K, 1993, J CLIN ENDOCR METAB, V77, P765, DOI 10.1210/jc.77.3.765; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; Vallar L, 1996, CANCER SURV, V27, P325; VALLAR L, 1987, NATURE, V330, P566, DOI 10.1038/330566a0; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wadsworth SJ, 1997, J BIOL CHEM, V272, P28829, DOI 10.1074/jbc.272.46.28829; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG HY, 1992, NATURE, V358, P334, DOI 10.1038/358334a0; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WILKIE TM, 1991, P NATL ACAD SCI USA, V88, P10049, DOI 10.1073/pnas.88.22.10049; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WONG YH, 1995, ONCOGENE, V10, P1927; WU DQ, 1992, J BIOL CHEM, V267, P1811; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XU N, 1993, P NATL ACAD SCI USA, V90, P11354; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; Yan K, 1997, J BIOL CHEM, V272, P2056; YANG LJ, 1993, J BIOL CHEM, V268, P3739; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zeiger MA, 1996, ENDOCRINOLOGY, V137, P5392, DOI 10.1210/en.137.12.5392; Zhang YH, 1996, ONCOGENE, V12, P2377; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	139	123	128	4	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1383	1394		10.1038/sj.onc.1202242	http://dx.doi.org/10.1038/sj.onc.1202242			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779986				2022-12-17	WOS:000076161900007
J	Schwartzberg, PL				Schwartzberg, PL			The many faces of Src: multiple functions of a prototypical tyrosine kinase	ONCOGENE			English	Review						Src; tyrosine kinase; PDGF-R; integrin	FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; C-SRC; SH3 DOMAIN; CELL-TRANSFORMATION; BINDING-SITE; PROTEIN; FAMILY; ACTIVATION; PHOSPHORYLATION	c-src was first isolated as the normal cellular homologue of v-src, the transforming gene of Rous Sarcoma virus (Stehelin et al., 1976). As the first proto-oncogene described and one of the first molecules demonstrated to have tyrosine kinase activity, Src has provided a prototype for understanding signal transduction involving tyrosine phosphorylation. Comparison between c-src and activated or transforming mutants of Src including v-src, combined with recent data on the structure of Src family kinases has provided new insight into their regulation. In this review, I will discuss the function of the various domains of Src in light of these mutational and structural studies.	Natl Human Genome Res Inst, Lab Genet Dis Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Schwartzberg, PL (corresponding author), Natl Human Genome Res Inst, Lab Genet Dis Res, NIH, Bethesda, MD 20892 USA.							Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOCKHOLT SM, 1995, CELL ADHES COMMUN, V3, P91, DOI 10.3109/15419069509081279; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLY CM, 1994, J NEUROCHEM, V62, P923; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOLDBERG AR, 1980, COLD SPRING HARB SYM, V44, P991, DOI 10.1101/SQB.1980.044.01.107; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Lowell CA, 1996, BLOOD, V87, P1780; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEFF L, 1996, J BONE MINER RES, V11, pS290; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROCHE S, 1995, MOL CELL BIOL, V15, P1102; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SHALLOWAY D, 1992, CIBA F SYMP, V170, P248; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Swierczynski SL, 1996, DEV BIOL, V179, P135, DOI 10.1006/dbio.1996.0246; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vuori K, 1996, MOL CELL BIOL, V16, P2606; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	65	123	128	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	1998	17	11			SI		1463	1468		10.1038/sj.onc.1202176	http://dx.doi.org/10.1038/sj.onc.1202176			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124BW	9779992	Bronze			2022-12-17	WOS:000076161900013
J	Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC				Yang, XL; Chernenko, G; Hao, YW; Ding, ZH; Pater, MM; Pater, A; Tang, SC			Human BAG-1/RAP46 protein is generated as four isoforms by alternative translation initiation and overexpressed in cancer cells	ONCOGENE			English	Article						four hBAG-1 isoforms; alternative translation initiation; subcellular localization; overexpression; cancer	BCL-2 PROTOONCOGENE EXPRESSION; SUBCELLULAR-DISTRIBUTION; CDNA CLONING; BAG-1; IDENTIFICATION; LOCALIZATION; CARCINOMA; RECEPTOR; APOPTOSIS; PRODUCTS	Previously, a Bcl-2-interacting protein, BAG-I, was cloned from mouse cells and was shown to interact with several other proteins and to be important for inhibition of apoptosis. Human BAG-1 (hBAG-1) cDNA, recently isolated by us and two other groups, has been shown to be identical to a hormone receptor-binding protein, RAP46. However, different molecular masses of hBAG-1 protein products were noted by these three groups. Here we demonstrated that hBAG-1 protein was expressed as four isoforms, designated p50, p46, p33 and p29, with apparent molecular masses of 50 kDa, 46 kDa, 33 kDa and 29 kDa, respectively. Deletion, site-directed mutagenesis and in vitro transcription/translation analysis showed that the four protein products of hBAG-1 were expressed by alternative initiation from four different start codons through a leaky scanning mechanism. Furthermore, we demonstrated that the distinct forms of hBAG-1. have different subcellular localizations, suggesting that they may have distinct functions in the cells. Characterization of hBAG-1 RNA and protein also showed that hBAG-1 was overexpressed in human cervical, breast and lung cancer cell lines. Taken together, these data clarify the conflicting observations reported in the literature and suggest that hBAG-1 is expressed as four forms of protein products, which may play a differential role in apoptosis and oncogenesis of human cells.	Mem Univ Newfoundland, Fac Med, St Johns, NF A1B 3V6, Canada; Newfoundland Canc Treatment & Res Fdn, Dr H Bliss Murphy Canc Ctr, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Tang, SC (corresponding author), Mem Univ Newfoundland, Fac Med, 300 Prince Philip Dr, St Johns, NF A1B 3V6, Canada.							AOKI M, 1993, J BIOL CHEM, V268, P22723; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; HALDAR S, 1994, CANCER RES, V54, P2095; IKEGAKI N, 1994, CANCER RES, V54, P6; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LIANG XH, 1995, J CELL BIOCHEM, V57, P509, DOI 10.1002/jcb.240570316; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; Lu QL, 1996, HUM PATHOL, V27, P102, DOI 10.1016/S0046-8177(96)90362-7; ORRENIUS S, 1995, J INTERN MED, V237, P529, DOI 10.1111/j.1365-2796.1995.tb00881.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Sambrook J, 1989, MOL CLONING LAB MANU; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Takayama S, 1996, GENOMICS, V35, P494, DOI 10.1006/geno.1996.0389; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	27	123	128	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					981	989		10.1038/sj.onc.1202032	http://dx.doi.org/10.1038/sj.onc.1202032			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747877				2022-12-17	WOS:000075560900006
J	Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V				Li, RZ; Sutphin, PD; Schwartz, D; Matas, D; Almog, N; Wolkowicz, R; Goldfinger, N; Pei, HP; Prokocimer, M; Rotter, V			Mutant p53 protein expression interferes with p53-independent apoptotic pathways	ONCOGENE			English	Article						p53-dependent; p53-independent; apoptosis; chemotherapeutic drugs	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; P53-DEPENDENT APOPTOSIS; INDEPENDENT PATHWAYS; CANCER-CHEMOTHERAPY; DNA-DAMAGE; IONIZING-RADIATION; GAMMA-IRRADIATION; FUNCTIONAL P53; LYMPHOID-CELLS	Loss of normal p53 function was found frequently to interfere with response of cancer cells to conventional anticancer therapies. Since more than half of all human cancers possess p53 mutations, we decided to explore the involvement of mutant p53 in drug induced apoptosis. To further evaluate the relationship between the p53-dependent and p53-independent apoptotic pathways, and to elucidate the function of mutant p53 in modulating these processes, we investigated the role of a p53 temperature-sensitive (ts) mutant in a number of apoptotic pathways induced by chemotherapeutic drugs that are currently used in cancer therapy. To that end, me studied the M1/2, myeloid p53 non-producer cells, and M1/2-derived temperature-sensitive I; mutant p53 expressing clones. Apoptosis caused by DIVA damage induced with gamma-irradiation, doxorubicin or cisplatin, was enhanced in cells expressing wild type p53 as compared to that seen in parental p53 non-producer cells; mutant p53 expressing clones mere found to be more resistant to apoptosis induced by these factors. Actinomycin D, a potent inhibitor of transcription, as well as a DNA. damaging agent, abrogated the restraint apoptosis mediated by mutant p53. These observations suggest that while loss of wild type p53 function clearly reduces the rate of apoptosis, p53 mutations may result in a gain of function which significantly interferes with chemotherapy induced apoptosis. Therefore, to achieve a successful cancer therapy, it is critical to consider the specific relationship between a given mutation in p53 and the chemotherapy selected.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Allred D. C., 1993, BREAST CANCER RES TR, V27, P131; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; Chresta CM, 1996, CANCER RES, V56, P1834; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORY S, 1994, PHILOS T R SOC B, V345, P289, DOI 10.1098/rstb.1994.0108; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIJIT FJ, 1988, CANCER RES, V48, P6058; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; EASTMAN A, 1995, METHOD CELL BIOL, V46, P41; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GLYNN JM, 1991, BIOCHEM SOC T, V20, pS84; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; Hamada M, 1996, J CANCER RES CLIN, V122, P360, DOI 10.1007/BF01220804; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; Harris CC, 1996, BRIT J CANCER, V73, P261, DOI 10.1038/bjc.1996.47; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Iwamoto KS, 1996, CANCER RES, V56, P3862; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LEVINE JA, 1997, CELL, V88, P323; LEWIS JG, 1995, J LEUKOCYTE BIOL, V57, P635, DOI 10.1002/jlb.57.4.635; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LING YH, 1993, CANCER RES, V53, P1845; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOTEM J, 1994, CELL GROWTH DIFFER, V5, P321; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAKRIS A, 1995, LANCET, V345, P1181, DOI 10.1016/S0140-6736(95)91014-X; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; Oliver R T, 1996, Curr Opin Oncol, V8, P252; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peled A, 1996, CANCER RES, V56, P2148; Peled A, 1996, EXP HEMATOL, V24, P728; ROSENBERG B, 1985, CANCER, V55, P2303, DOI 10.1002/1097-0142(19850515)55:10<2303::AID-CNCR2820551002>3.0.CO;2-L; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; Soddu S, 1996, J CELL BIOL, V134, P1; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; WYLLIE FS, 1995, ONCOGENE, V10, P49; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZALESKIS G, 1994, MOL PHARMACOL, V46, P901; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHUANG SM, 1995, CANCER RES, V55, P486	81	123	127	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 25	1998	16	25					3269	3277		10.1038/sj.onc.1201867	http://dx.doi.org/10.1038/sj.onc.1201867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV810	9681825				2022-12-17	WOS:000074343600007
J	Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD				Sekido, Y; Ahmadian, M; Wistuba, II; Latif, F; Bader, S; Wei, MH; Duh, FM; Gazdar, AF; Lerman, MI; Minna, JD			Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene	ONCOGENE			English	Article						breast cancer; chromosome 3; homozygous deletion; somatic mutation; breakpoint cloning; lung cancer	CELL LUNG-CANCER; CHROMOSOME 3P; HUMAN SEMAPHORIN; LINE U2020; FHIT GENE; CARCINOMAS; HETEROZYGOSITY; IDENTIFICATION; 3P14.2	Chromosome 3p abnormalities and allele loss are frequent in lung and breast cancers, and several lung cancer cell lines exhibit homozygous deletions of 3p indicating potential sites of tumor suppressor genes at regions 3p21.3, 3p14.2 and 3p12. We have identified and characterized a nem 3p21.3 homozygous deletion in a breast cancer cell line and the primary tumor that overlaps those previously described in small cell lung cancer (SCLC), This homozygous deletion is approximately 220 kb in length and represents a somatically acquired change in the primary breast cancer. Cloning and sequencing of the breakpoint demonstrated that this resulted from an interstitial deletion and precisely pinpoints this deletion within the three SCLC homozygous deletions previously reported. This deletion significantly narrows the minimum common deleted region to 120 kb and is distinct from the previously reported region that suppresses tumor formation of the murine A9 fibrosarcoma cells, These findings suggest that a common homozygous deletion region on 3p21.3 is important in both lung and breast cancers. It is likely that this very well characterized region either contains one tumor suppressor gene common to both tumor types or two closely linked tumor suppressor genes specific for each tumor.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; NCI, Frederick Canc Res & Dev Ctr, Immunobiol Lab, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Biol Carcinogenesis & Dev Program, SAIC Frederick, Frederick, MD 21702 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sekido, Yoshitaka/P-9756-2015	Sekido, Yoshitaka/0000-0002-2428-3848	NATIONAL CANCER INSTITUTE [R01CA071618] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA71618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian M, 1997, CANCER RES, V57, P3664; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CHEN LC, 1994, CANCER RES, V54, P3021; DALY MC, 1993, ONCOGENE, V8, P1721; Deng GR, 1996, SCIENCE, V274, P2057, DOI 10.1126/science.274.5295.2057; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; Fong KM, 1997, CANCER RES, V57, P2256; Hayashi S, 1997, CANCER RES, V57, P1981; HIBI K, 1992, ONCOGENE, V7, P445; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; Latif F, 1997, HUM GENET, V99, P334, DOI 10.1007/s004390050368; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Negrini M, 1996, CANCER RES, V56, P3173; Ong ST, 1997, GENE CHROMOSOME CANC, V20, P16, DOI 10.1002/(SICI)1098-2264(199709)20:1<16::AID-GCC3>3.0.CO;2-C; PANDIS N, 1995, GENE CHROMOSOME CANC, V12, P173, DOI 10.1002/gcc.2870120304; PANDIS N, 1993, GENE CHROMOSOME CANC, V6, P151, DOI 10.1002/gcc.2870060304; Roche J, 1996, ONCOGENE, V12, P1289; Sambrook J, 1989, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5794; SEKIDO Y, 1994, ONCOGENE, V9, P1599; Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Todd MC, 1996, ONCOGENE, V13, P2387; Todd S, 1997, CANCER RES, V57, P1344; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; Xiang RH, 1996, GENOMICS, V32, P39, DOI 10.1006/geno.1996.0074; YAMAKAWA K, 1993, ONCOGENE, V8, P327	35	123	137	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3151	3157		10.1038/sj.onc.1201858	http://dx.doi.org/10.1038/sj.onc.1201858			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671394				2022-12-17	WOS:000074261300008
J	Orend, G; Hunter, T; Ruoslahti, E				Orend, G; Hunter, T; Ruoslahti, E			Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21(Cip1) and p27(Kip1) in anchorage-independent cells	ONCOGENE			English	Article						anchorage; p21Cip1; p27Kip1; cyclin E; cdk2; cell adhesion; cell cycle	BREAST-CANCER; NEOPLASTIC TRANSFORMATION; PROGNOSTIC MARKER; CDK INHIBITOR; EXPRESSION; GROWTH; OVEREXPRESSION; TRANSCRIPTION; PROLIFERATION; INACTIVATION	Loss of attachment to an extracellular matrix substrate arrests the growth of untransformed cells in the G1 phase. This anchorage-dependent cell cycle arrest is linked to increased expression of the p21(Cip1) (p21) and p27(Kip1) (p27) cyclin-dependent kinase inhibitors. The result is a loss of cdk2-associated kinase activity, especially that of cyclin E-cdk2, The levels of p21 and p27 are also upregulated in unattached transformed cells, but cyclin E-cdk2 activity remains high, and the cells are able to grow in an anchorage-independent manner. Increased expression of cyclin E and cdk2 appears to be partially responsible for the maintenance of cyclin E-cdk2 activity in transformed cells. To explore further the regulation of cyclin E-cdk2 in transformed cells, we have analysed the subcellular distribution of cyclin-cdk complexes and their inhibitors in normal human fibroblasts, their transformed counterparts, and in various human tumor cell lines. In substrate-attached normal fibroblasts, cyclin E and cdk2 were exclusively in the nuclear fraction, associated with one another. When normal fibroblasts were detached and held in suspension, cyclin E-cdk2 complexes remained nuclear, but were now found associated with the p21 and p27 cdk inhibitors and lacked histone I-Il phosphorylating activity. In contrast, the transformed fibroblasts and tumor cells, which are anchorage-independent, had more than half of their cyclin E, cdk2, p21 and p27 in the cytoplasmic fraction, both in attached and suspended cultures. The cytoplasmic p21 and p27 were bound to cyclin E-cdk2, as well as to complexes containing cyclin A and cyclin D. The nuclear cyclin E-cdk2 complexes from the transformed cells grown in suspension contained only low levels of p21 and p27 and had histone H1 kinase activity, Thus, at least three mechanisms contribute to keeping cyclin E-cdk2 complexes active in suspended anchorage-independent cells: cyclin E and cdk2 are upregulated, as reported previously, cdk inhibitors are sequestered away from the nucleus by cytoplasmic cyclin-cdk complexes, and the binding of the inhibitors to nuclear cyclin E-cdk2 complexes is impaired.	Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; Salk Institute	Ruoslahti, E (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, La Jolla, CA 92037 USA.		Orend, Gertraud/E-8446-2015	Orend, Gertraud/0000-0003-2522-1195	NCI NIH HHS [CA 30199, CA 42507, CA 28896] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028896, P30CA030199, R35CA042507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dou QP, 1996, NAT MED, V2, P254, DOI 10.1038/nm0396-254a; DUTTA A, 1995, P NATL ACAD SCI USA, V92, P5386, DOI 10.1073/pnas.92.12.5386; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KAKUNAGA T, 1978, P NATL ACAD SCI USA, V75, P1334, DOI 10.1073/pnas.75.3.1334; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARIDOR G, 1993, J CELL SCI, V106, P535; Medcalf ASC, 1996, CANCER RES, V56, P4582; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Miyajima M, 1996, J NEUROSCI RES, V46, P108, DOI 10.1002/(SICI)1097-4547(19961001)46:1<108::AID-JNR13>3.0.CO;2-1; Mumberg D, 1996, ONCOGENE, V13, P2493; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; RHEINWALD JG, 1974, CELL, V2, P287, DOI 10.1016/0092-8674(74)90023-3; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Samid D., 1989, CLIN BIOTECHNOL, V1, P21; Schulze A, 1996, MOL CELL BIOL, V16, P4632; SEWING A, 1994, J CELL SCI, V107, P581; StCroix B, 1996, NAT MED, V2, P1204; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; ZerfassThome K, 1996, ONCOGENE, V13, P2323; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; Zou XM, 1997, GENE DEV, V11, P654, DOI 10.1101/gad.11.5.654	44	123	126	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2575	2583		10.1038/sj.onc.1201791	http://dx.doi.org/10.1038/sj.onc.1201791			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632134				2022-12-17	WOS:000073698200002
J	Yu, DH; Liu, BL; Tian, J; Sun, DT; Price, JE; Singletary, SE; Ibrahim, N; Hortobagyi, GN; Hung, MC				Yu, DH; Liu, BL; Tian, J; Sun, DT; Price, JE; Singletary, SE; Ibrahim, N; Hortobagyi, GN; Hung, MC			Overexpression of both p185(c-erbB2) and p170(mdr-1) renders breast cancer cells highly resistant to taxol	ONCOGENE			English	Article						HER-2/neu; oncogene; p-glycoprotein; breast cancer; taxol	TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; MULTIDRUG-RESISTANCE; NEU ONCOGENE; C-ERBB-2 EXPRESSION; PROTO-ONCOGENE; DNA-REPAIR; GENE; MECHANISMS	We recently found that overexpression of p185(c-erbB2) in c-erbB2 transfected MDA-MB-435 breast cancer cells (435.eB transfectants) confers a 5-9-fold increase in Taxol resistance. To examine whether Taxol resistance is a common phenomenon in other c-erbB2 overexpressing breast cancer cell lines, we tested a panel of human breast cancer cell lines established from different patients and expressing p185(c-erbB2) at different levels for their sensitivity to Taxol and Taxotere, a synthetic taxoid. Higher expression of p185(c-erbB2) in these breast cancer cell Lines indeed correlated well with resistance to Taxol and Taxotere, and the degree of resistance was about 100-fold that in c-erbB2-overexpressing 435.eB transfectants, demonstrating that these breast cancer cells are highly resistant to Taxol, Since mdr-1-encoded p-glycoprotein (p170(mdr-1)) has been implicated in Taxol resistance, we next examined the p170(mdr-1) levels in these breast cancer cell lines that are highly resistant to Taxol, Higher levels of p170(mdr-1) expression were found in several breast cancer cell lines that are highly resistant to Taxol, Since these same breast cancer cell lines also expressed higher levels of p185(c-erbB2), we sought to determine the relative contribution of p185(c-erbB2) and p170(mdr-1) overexpression to Taxol resistance. We first specifically down-regulated cell surface p185(c-erbB2) using anti-p185(c-erbB2) monoclonal antibodies and assayed sensitivity of these cells to Taxol, We next specifically inactivated p170(mdr-1) function using p170(mdr-1) blockers (thioridazine or verapamil) and again assayed Taxol sensitivity. Both p185(c-erbB2) down-regulation and p170(mdr-1) blockade significantly sensitized the breast cancer cell lines to Taxol, The results indicate that overexpression of either p185(c-erbB2) or p170(mdr-1) renders human breast cancer cells resistant to Taxol. Furthermore, p185(c-erbB2) synergizes with p170(mdr-1) conferring higher degrees of Taxol resistance. Finally, combination therapy (down-regulation of p185(c-erbB2) plus blocking p170(mdr-1) plus administration of Taxol) may be beneficial to breast cancer patients whose tumors express high levels of both p185(c-erbB2) and p170(mdr-1).	Univ Texas, Md Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Cell Biol, Houston, TX 77030 USA; Univ Texas, Md Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), Univ Texas, Md Anderson Canc Ctr, Dept Surg Oncol, Box 107,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Yu, Dihua/0000-0001-6231-9381; Liu, Bolin/0000-0003-0150-8650	NCI NIH HHS [CA58880, CA60488, CA60856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R29CA060488, R01CA060856, R01CA060488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1992, CANCER RES, V52, P2580; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERKOVA N, 1995, ANTICANCER RES, V15, P863; CHEVALLIER B, 1995, J CLIN ONCOL, V13, P314, DOI 10.1200/JCO.1995.13.2.314; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; EFFERTH T, 1993, CANCER LETT, V70, P197, DOI 10.1016/0304-3835(93)90231-W; FOJO AT, 1987, J CLIN ONCOL, V5, P1922, DOI 10.1200/JCO.1987.5.12.1922; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LACROIX H, 1989, ONCOGENE, V4, P145; MILLER SJ, 1994, INT J ONCOL, V4, P599; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; Tan M, 1997, CANCER RES, V57, P1199; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tsai CM, 1996, CANCER RES, V56, P1068; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; Yu DH, 1996, ONCOGENE, V13, P1359; Zhang LS, 1996, ONCOGENE, V12, P571	30	123	133	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2087	2094		10.1038/sj.onc.1201729	http://dx.doi.org/10.1038/sj.onc.1201729			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572489				2022-12-17	WOS:000073177200006
J	Voz, ML; Astrom, AK; Kas, K; Mark, J; Stenman, G; Van de Ven, WJM				Voz, ML; Astrom, AK; Kas, K; Mark, J; Stenman, G; Van de Ven, WJM			The recurrent translocation t(5;8)(p13;q12) in pleomorphic adenomas results in upregulation of PLAG1 gene expression under control of the LIFR promoter	ONCOGENE			English	Article						PLAG1; LIFR; chromosome translocation; pleomorphic adenoma	LEUKEMIA INHIBITORY FACTOR; CYTOKINE RECEPTOR SUPERFAMILY; TUMORS	We have previously shown that the PLAG1 gene on chromosome 8q12 is consistently rearranged in pleomorphic adenomas of the salivary glands with t(3;8)(p21;q12) translocations, The t(3;8) results in promoter swapping between the PLAG1 gene, which encodes a novel zinc finger protein, and the constitutively expressed gene for beta-catenin (CTNNB1), a protein with roles in cell-cell adhesion and the WG/WNT signalling pathway, In order to assess the importance of other translocation partner genes of PLAG1, and their possible relationship to CTNNB1, we have characterized a second recurrent translocation, i.e. the t(5;8)(p13;q12), This translocation leads to ectopic expression of a chimeric transcript consisting of sequences from the ubiquitously expressed gene for the leukemia inhibitory factor receptor (LIFR) and PLAG1, As for the t(3;8), the fusions occurred in the 5'-noncoding regions of both genes, exchanging regulatory control elements while preserving the coding sequences. The results of the current as well as previous studies indicate that ectopic expression of PLAG1 under the control of promoters of distinct translocation partner genes is a general pathogenetic mechanism for pleomorphic adenomas with 8q12 aberrations.	Catholic Univ Louvain, Ctr Human Genet, Oncol Mol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Gothenburg Univ, Sahlgrens Hosp, Dept Pathol, Canc Genet Lab, SE-41345 Gothenburg, Sweden; Cent Hosp, Dept Pathol, SE-54185 Skovde, Sweden	Universite Catholique Louvain; Sahlgrenska University Hospital; University of Gothenburg	Van de Ven, WJM (corresponding author), Catholic Univ Louvain, Ctr Human Genet, Oncol Mol Lab, Herestr 49, B-3000 Louvain, Belgium.							ASHAR HR, 1995, CELL, V82, P57; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BULLERDIEK J, 1993, CANCER GENET CYTOGEN, V65, P27, DOI 10.1016/0165-4608(93)90054-P; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; Eaton S, 1996, TRENDS CELL BIOL, V6, P287, DOI 10.1016/0962-8924(96)20026-1; GEARING DP, 1993, GENOMICS, V18, P148, DOI 10.1006/geno.1993.1441; GEARING DP, 1993, ADV IMMUNOL, V53, P31, DOI 10.1016/S0065-2776(08)60497-6; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; Ilyas M, 1997, J PATHOL, V182, P128; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Owczarek CM, 1996, J BIOL CHEM, V271, P5495, DOI 10.1074/jbc.271.10.5495; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Roijer E, 1996, GENE CHROMOSOME CANC, V17, P166; Sambrook J, 1989, MOL CLONING LAB MANU; SANDROS J, 1990, CANCER GENET CYTOGEN, V44, P153, DOI 10.1016/0165-4608(90)90042-9; SCHOENMAKERS EFPM, 1995, GENOMICS, V29, P665, DOI 10.1006/geno.1995.9952; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Tomida M, 1996, J BIOCHEM-TOKYO, V120, P201; [No title captured]	22	123	127	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1409	1416		10.1038/sj.onc.1201660	http://dx.doi.org/10.1038/sj.onc.1201660			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525740				2022-12-17	WOS:000072572400005
J	Amundadottir, LT; Leder, P				Amundadottir, LT; Leder, P			Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes	ONCOGENE			English	Article						signal transduction; mammary; transformation; oncogenes	EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; HUMAN-BREAST-CANCER; GAP-ASSOCIATED PROTEINS; V-HA-RAS; TRANSGENIC MICE; TYROSINE KINASE; MAP KINASE; TGF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE	We have assessed five signal transduction pathways to determine the role each might play in the malignant transformation of mammary epithelium initiated by neu, heregulin/NDF, TGF alpha, v-Ha-ras and c-myc in transgenic mice. The study involves a molecular and pharmacologic assessment of Erk/MAP kinase, Jnk/SAP kinase, PI 3-kinase, protein kinase C, and the Src-related kinases Lck and Fyn., Our results indicate that oncogenes capable of transforming mammary gland epithelium activate and require specific signal transduction pathways, For example, mammary tumors initiated by neu, v-Ha-ras as and c-myc have high levels of active Erk/MAP kinase and their anchorage independent growth is strongly inhibited by PD098059, an inhibitor of Mek/ MAP kinase kinase, By contrast, Erk/MAP I;kinase activity is weak in tumors initiated by TI;TFG alpha and heregulin/NDF and the corresponding cell lines are not growth inhibited by PD098059, Similarly, PI 3-kinase is strongly activated in neu, TGF alpha;! and heregulin/NDF initiated tumor cell lines, but not in c-myc or v-Ha-rns initiated tumor cell lines, The anchorage independent growth of all these tumor cell lines are, however, inhibited by the specific PI 3-kinase inhibitor LY294001. Further illustrating this oncogene-based specificity, PP1, a specific inhibitor of the Src-like kinases, Lck and Fyn, blocks anchorage-independent cell growth only in the TGF alpha;cl initiated mammary tumor cell line, Taken together with additional observations, we conclude that certain oncogenes reliably require the recruitment/activation of specific signal transduction pathways, Such specific relationships between the initiating oncogene and a required pathway may reflect a direct activating effect or the parallel activation of a pathway that is a necessary oncogenic collaborator for transformation in the mammary gland, The work points to a molecular basis for targeting therapy when an initiating oncogene can be implicated; for example, because of amplification, increased expression, genetic alteration, or heritable characteristics.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Amundadottir, LT (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.		Amundadottir, Laufey T/L-7656-2016	Amundadottir, Laufey T/0000-0003-1859-8971				AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; Amundadottir LT, 1996, ONCOGENE, V13, P757; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CHRYSOGELOS SA, 1994, BREAST CANCER RES TR, V29, P29, DOI 10.1007/BF00666179; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DANKORT AL, 1997, MOL CELL BIOL, V17, P5410; DAVIDSON NE, 1996, MAMMARY TUMOR CELL C, P91; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dolnikov A, 1996, ONCOGENE, V12, P1189; Dubik D, 1996, Cancer Treat Res, V83, P171; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; ELLIS C, 1991, ONCOGENE, V6, P895; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENNIPMAN A, 1989, CANCER RES, V49, P516; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Huang CS, 1996, MOL CELL BIOL, V16, P6427; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; JACOBS C, 1983, CANCER RES, V43, P1696; JANES PW, 1994, ONCOGENE, V9, P3601; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kitsberg DI, 1996, ONCOGENE, V13, P2507; Krane IM, 1996, ONCOGENE, V12, P1781; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LUTTRELL DK, 1988, MOL CELL BIOL, V8, P497, DOI 10.1128/MCB.8.1.497; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTE BM, 1995, ONCOGENE, V10, P167; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PARK S, 1992, J BIOL CHEM, V267, P17194; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SeppLorenzino L, 1996, ONCOGENE, V12, P1679; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; SOLTOFF SP, 1992, COLD SPRING HARB SYM, V57, P75, DOI 10.1101/SQB.1992.057.01.010; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782; TAMAOKI T, 1990, BIO-TECHNOL, V8, P732, DOI 10.1038/nbt0890-732; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; vanderGeer P, 1997, MOL CELL BIOL, V17, P1840, DOI 10.1128/MCB.17.4.1840; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WEBSTER MA, 1995, P NATL ACAD SCI USA, V92, P7849, DOI 10.1073/pnas.92.17.7849; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WYSS R, 1987, ANTICANCER RES, V7, P721	69	123	131	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					737	746		10.1038/sj.onc.1201829	http://dx.doi.org/10.1038/sj.onc.1201829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488037	Bronze			2022-12-17	WOS:000071931800005
J	Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ				Grasso, AW; Wen, DZ; Miller, CM; Rhim, JS; Pretlow, TG; Kung, HJ			ErbB kinases and NDF signaling in human prostate cancer cells	ONCOGENE			English	Article						ErbB3; receptor tyrosine kinase; tyrosine phosphorylation; prostate cancer	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; ACTIVATED PROTEIN-KINASE; MAMMARY EPITHELIAL-CELLS; PHOSPHOLIPASE C-GAMMA; FACTOR RECEPTOR FAMILY; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; TUMOR-CELLS; MAP KINASE	Prostate carcinoma (PCA) is the most commonly diagnosed malignancy in American men. Our knowledge of PCA growth regulation lags behind that of other cancers, such as breast and colon carcinomas. Among receptor tyrosine kinases, the ErbB family is most frequently implicated in neoplasia. We report here the expression of ErbB family kinases and their ligands in PCA cell lines and a xenograft. While ErbB1/EGFR, ErbB2/NEU, and ErbB3 were always observed in a distinct pattern, ErbB4 was not observed. Interestingly, while TGF-alpha was expressed in the majority of PCA lines, the ligand Neu Differentiation Factor/Heregulin (NDF) was expressed only in an immortalized, non-transformed prostate epithelial line. Concomitantly, there was a significant difference in biological response to these ligands, NDF inhibited LNCaP growth and induced an epithelial-like morphological change, in contrast to TGF-alpha, which accelerated cell growth. We also performed the first comprehensive analysis of NDF signaling in a prostate line, LNCaP stimulated with NDF demonstrated crosstalk between ErbB3 and ErbB2 which did not involve ErbB1. NDF also turned on several cascades, including those of PI3-K, ERK/MAPK, mHOG/p38 and JNK/SAPK, but not those of PLC gamma or the STAT family. This signaling pattern is distinct from that of TGF-alpha. The activation of mHOG by ErbB2 or ErbB3 has not been reported, and may contribute to the unusual phenotype, PI3-K activation is characterized by the formation of a striking 'activation complex' vith multiple tyrosine-phosphorylated species, including ErbB3. Our studies provide a framework in which to dissect the growth and differentiation signals of prostate cancer cells.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOL BIOL & MICROBIOL,CLEVELAND,OH 44106; AMGEN INC,THOUSAND OAKS,CA 91320; CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,CLEVELAND,OH 44106; NCI,BIOCHEM PHYSIOL LAB,FREDERICK,MD 21702	Case Western Reserve University; Amgen; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kung, Hsing-Jien/C-7651-2013		NCI NIH HHS [CA39207, CA57179] Funding Source: Medline; NIDDK NIH HHS [DK52659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA057179, R01CA057179, R37CA039207, R01CA039207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bacus SS, 1996, ONCOGENE, V12, P2535; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Byrne RL, 1996, BRIT J UROL, V77, P627, DOI 10.1046/j.1464-410X.1996.09721.x; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAMETT DC, 1995, J BIOL CHEM, V270, P19022, DOI 10.1074/jbc.270.32.19022; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAUFMANNZEH A, 1997, NATURE, V385, P5442; KIM HH, 1994, J BIOL CHEM, V269, P24747; KIM JW, 1990, J BIOL CHEM, V265, P3940; Kitanaka A, 1996, BLOOD, V88, P590, DOI 10.1182/blood.V88.2.590.bloodjournal882590; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kubota Y, 1996, LEUKEMIA, V10, P720; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE MS, 1994, INT J ONCOL, V4, P821; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MYERS RB, 1994, J NATL CANCER I, V86, P1140, DOI 10.1093/jnci/86.15.1140; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OHMICHI M, 1992, NEURON, V9, P769, DOI 10.1016/0896-6273(92)90039-G; OWENS RB, 1976, J NATL CANCER I, V56, P843, DOI 10.1093/jnci/56.4.843; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIGNATARO OP, 1990, J BIOL CHEM, V265, P1718; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sen J, 1996, J IMMUNOL, V156, P4535; SEPPLORENZINO L, 1996, ONCOGENE, V11, P1679; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOMIYAMA K, 1995, BIOCHEM BIOPH RES CO, V212, P263, DOI 10.1006/bbrc.1995.1965; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WAHL MI, 1990, J BIOL CHEM, V265, P3944; WAINSTEIN MA, 1994, CANCER RES, V54, P6049; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; Yao R, 1996, ONCOGENE, V13, P343; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang K, 1996, J BIOL CHEM, V271, P3884; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	87	123	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 27	1997	15	22					2705	2716		10.1038/sj.onc.1201447	http://dx.doi.org/10.1038/sj.onc.1201447			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YH468	9400997				2022-12-17	WOS:A1997YH46800008
J	Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A				Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A			CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases	ONCOGENE			English	Article						CD95 (APO-1/FAS); DISC; MAP kinase; apoptosis; signal transduction	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING-ENZYME; FACTOR RECEPTOR SUPERFAMILY; ACTIN STRESS FIBERS; PROTEIN-KINASE; INDUCED APOPTOSIS; FAS ANTIGEN; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS	Triggering of CD95 (APO-1/Pas) on different T- and B-cell lines resulted in the induction of a number of kinases (35 kDa, 38 kDa, 46 kDa and 54 kDa) that phosphorylate c-Jun and to a lesser extent Histone H1. Activation of these kinases was independent of protein biosynthesis and preceded apoptotic DNA degradation. The kinase activation pattern was specific for CD95 triggering since a variety of physical or chemical inducers of T- and B-cell apoptosis activated different kinases. The kinase activities at 46 and 54 kDa contained members of the stress-activated family of protein kinases (JNK/SAPK). Activation of the CD95-specific set of kinases was prevented by treating cells with the ICE-inhibiting peptide N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk) or by overexpression of the cow pox virus serpin CrmA. However, despite inhibition of ICE-like proteases the death signal was readily initiated at the cell membrane since a CD95 death-inducing signaling complex (DISC) was formed. Thus, our results demonstrate that ICE-like proteases in the CD95 pathway function downstream of the DISC but upstream of SAP kinases.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; GERMAN CANC RES CTR,DIV IMMUNOGENET,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	Hannover Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; CAHILL, Michael/J-8035-2012	dixit, vishva m/0000-0001-6983-0326; CAHILL, Michael/0000-0002-8593-8844; Peter, Marcus Ernst/0000-0003-3216-036X				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIJAWAKI T, 1992, J IMMUNOL, V149, P3753; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; PETER ME, 1995, CELL DEATH DIFFER, P163; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SCHULZEOSTHOFF K, 1996, IN PRESS CELL DEATH, V3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SKOWRONSKI EW, 1996, IN PRESS CELL GROWTH; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	76	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2087	2096						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950975				2022-12-17	WOS:A1996VV14500005
J	BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C				BRUMMER, J; NEUMAIER, M; GOPFERT, C; WAGENER, C			ASSOCIATION OF PP60(C-SRC) WITH BILIARY GLYCOPROTEIN (CD66A), AN ADHESION MOLECULE OF THE CARCINOEMBRYONIC ANTIGEN FAMILY DOWN-REGULATED IN COLORECTAL CARCINOMAS	ONCOGENE			English	Article						SRC; TYROSINE KINASE; ONCOGENE; TUMOR-SUPPRESSOR; CELL ADHESION	GENE FAMILY; MONOCLONAL-ANTIBODIES; MODEL SYSTEM; ECTO-ATPASE; CELL-LINES; MEMBER; EXPRESSION; PP60C-SRC; CLONING; PROTEIN	CD66a, also known as 'biliary glycoprotein (BGP)', is the human homologue of a cell adhesion molecule (CAM) of the rat (Cell-CAM). CD66a, which belongs to the carcinoembryonic antigen family and the immunoglobulin superfamily, is expressed in cells of myeloid and epithelial origin. The cytoplasmic domain of the major isoform of CD66a (CD66a(cyt)) contains. two tyrosine residues in amino acid motifs potentially interacting with protein tyrosine kinases of the Src family. Here we provide evidence that CD66a is associated with pp60(c-src). From membrane fractions of granulocytes and the colonic cell line HT29, phosphokinase activity was co-immunoprecipitated with CD66a when monoclonal CD66 antibodies or an antiserum against the recombinant cytoplasmic domain of CD66a were used. From the dissociated immunecomplexes, a phosphokinase of M(r) 60 000 was reprecipitated using antibodies against pp60(c-src). In vitro, the recombinant cytoplasmic domain was a substrate and binding partner of pp60(c-src). Phosphopeptides corresponding to the tyrosine containing amino acid sequences of CD66a, activated the kinase activity of pp60(c-src) to a greater extent than a phosphopeptide containing Tyr(527) from the SH2-binding regulatory domain of pp60(c-src). The down-regulation of CD66a in about 80% of colorectal carcinomas may contribute to a dysregulation of pp60(c-src) in colorectal cancer.	UNIV HAMBURG, HOSP EPPENDORF, MED KLIN, KLIN CHEM ABT, D-20246 HAMBURG, GERMANY	University of Hamburg								AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; HARLOW E, 1988, ANTIBODIES LABORATOR; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; HSIEH JT, 1995, CANCER RES, V55, P190; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; LIN SH, 1989, J BIOL CHEM, V264, P14408; NAGEL G, 1993, EUR J BIOCHEM, V214, P27, DOI 10.1111/j.1432-1033.1993.tb17892.x; NEUMAIER M, 1985, J IMMUNOL, V135, P3604; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; SKUBITZ KM, 1993, FEBS LETT, V318, P200, DOI 10.1016/0014-5793(93)80021-L; SKUBITZ KM, 1994, LEUKOCYTE TYPINE, V5; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STOCKS SC, 1993, BIOCHEM BIOPH RES CO, V195, P478, DOI 10.1006/bbrc.1993.2068; STOFFEL A, 1993, J IMMUNOL, V150, P4978; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; THOMPSON J, 1994, J BIOL CHEM, V269, P32924; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; WAGENER C, 1983, J IMMUNOL, V130, P2302; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	25	123	123	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	1995	11	8					1649	1655						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TC535	7478590				2022-12-17	WOS:A1995TC53500024
J	MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D				MARTE, BM; GRAUSPORTA, D; JESCHKE, M; FABBRO, D; HYNES, NE; TAVERNA, D			NDF HEREGULIN ACTIVATES MAP KINASE AND P70/P85 S6 KINASE DURING PROLIFERATION OR DIFFERENTIATION OF MAMMARY EPITHELIAL-CELLS	ONCOGENE			English	Article						TYPE I RECEPTOR TYROSINE KINASES; HC11 CELLS; BREAST TUMOR CELLS; ERBB-2; PROTEIN KINASE C	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; HUMAN-BREAST-CANCER; PROTEIN-KINASE; MONOCLONAL-ANTIBODIES; ERBB-2 RECEPTOR; NEU ONCOGENE; TYROSINE PHOSPHORYLATION; C-ERBB-2 PROTOONCOGENE; EXTRACELLULAR DOMAIN	Neu differentiation factors (NDF) are a novel family of polypeptide factors which activate sub-class I tyrosine kinase receptors. In all mammary epithelial cells analysed in this study, NDF activates the same signalling pathways while it induces different, cell-specific biological effects. In AU565 cells which are growth inhibited, as well as in T47D or HC11 cells which proliferate in response to NDF, the MAP kinase isoforms p44(ERK1) and p42(ERK2) and the p70/p85 S6 kinase are activated. NDF stimulates tyrosine phosphorylation and the in vitro kinase activity of ErbB-2. When PKC is activated by TPA, NDF is no longer able to activate ErbB-2 in T47D cells, leading to a blockage of cell proliferation. Activation of ErbB-2 by point mutation, or by monoclonal antibodies, also stimulates both the MAPK and the p70/p85 S6 kinase pathways. The same monoclonal antibodies can induce AU565 cell differentiation. In summary, during growth or differentiation of mammary epithelial cells, NDF stimulates several independent signalling pathways which can also be triggered by ErbB-2 stimulation alone. PKC activation blocks the biological effect induced by NDF through negative modulation of ErbB-2.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; CIBA GEIGY LTD,DIV PHARMACEUT,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research; Novartis			taverna, daniela/J-8358-2016	taverna, daniela/0000-0002-6365-527X				AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; ANDERSON NG, 1993, BIOCHEM BIOPH RES CO, V193, P284, DOI 10.1006/bbrc.1993.1621; BACUS SS, 1993, CANCER RES, V53, P5251; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; BORNER C, 1987, INT J CANCER, V40, P344, DOI 10.1002/ijc.2910400310; CAO HN, 1991, ONCOGENE, V6, P705; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; DSOUZA B, 1993, ONCOGENE, V8, P1797; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HARWERTH IM, 1993, BRIT J CANCER, V68, P1140, DOI 10.1038/bjc.1993.494; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; HYNES NE, 1989, J CELL BIOCHEM, V39, P167, DOI 10.1002/jcb.240390208; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KORNILOVA ES, 1992, ONCOGENE, V7, P511; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEMOINE NR, 1990, ONCOGENE, V5, P237; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIERCE JH, 1991, ONCOGENE, V6, P1189; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SEGATTO O, 1993, ONCOGENE, V8, P2105; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YARDEN Y, 1990, P NATL ACAD SCI USA, V87, P2569, DOI 10.1073/pnas.87.7.2569	59	123	124	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 5	1995	10	1					167	175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824269				2022-12-17	WOS:A1995QA98000019
J	KERPPOLA, TK; CURRAN, T				KERPPOLA, TK; CURRAN, T			A CONSERVED REGION ADJACENT TO THE BASIC DOMAIN IS REQUIRED FOR RECOGNITION OF AN EXTENDED DNA-BINDING SITE BY MAF/NRL FAMILY PROTEINS	ONCOGENE			English	Article							NF-KAPPA-B; FOS-JUN; MAF ONCOGENE; TRANSCRIPTION; GENE; ACTIVATION; COMPLEX; EXPRESSION; ENHANCER; PROMOTER	The c-maf proto-oncogene and the neural retina specific gene nul encode members of a subfamily of bZIP proteins that form heterodimers with Fos and Jun. We have determined the DNA binding specificities of various homo- and heterodimeric combinations among Nrl, Maf, Fos and Jun. Fos-Jun heterodimers and Jun homodimers bound to a palindromic TGAC(G)TCA recognition sequence as previously demonstrated. Maf and Nrl homodimers also bound to palindromic recognition sites with the consensus sequence TGC(N)(6-7)GCA. Fos-Nrl, Jun-Nrl and Fos-Maf heterodimers bound to nonpalindromic recognition sequences with the consensus sequence TGAC(N)(3-4)GCA. These results indicate that Nrl and Maf have a DNA binding specificity distinct from that of Fos and Jun, and that each subunit in the dimer independently recognizes one half of the recognition sequence. This allows combinatorial determination of target gene specificity. Specific recognition of the extended DNA binding sequence by Maf requires an ancillary DNA binding region on the amino terminal side of the basic domain that is conserved among Maf/Nrl family members. Thus, heterodimer formation among distantly related bZIP family members can generate novel DNA binding specificities and the addition of an auxiliary DNA binding domain to the simple bZIP motif can facilitate the recognition of extended binding sites.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011; Kerppola, Tom/AAG-4457-2022; Kerppola, Tom/AFK-6155-2022; Curran, Tom/F-5234-2018; Curran, Tom/C-1164-2008	Curran, Thomas/0000-0003-1444-7551; Kerppola, Tom/0000-0002-0611-9446; Kerppola, Tom/0000-0002-0611-9446; Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERGELSON S, 1994, ONCOGENE, V9, P565; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; CURRAN T, 1988, CELL, V55, P305; DICCIANNI MB, 1992, NUCLEIC ACIDS RES, V20, P5153, DOI 10.1093/nar/20.19.5153; DRANGINIS AM, 1990, NATURE, V347, P682, DOI 10.1038/347682a0; EARNEST DJ, 1990, EXP NEUROL, V109, P353, DOI 10.1016/S0014-4886(05)80027-5; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; PAOLELLA DN, 1994, SCIENCE, V264, P1130, DOI 10.1126/science.8178171; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; RYSECK RP, 1991, ONCOGENE, V6, P533; SAGAR SM, 1990, MOL BRAIN RES, V7, P17, DOI 10.1016/0169-328X(90)90068-O; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	36	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3149	3158						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936637				2022-12-17	WOS:A1994PM65800006
J	OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T				OHASHI, K; MIZUNO, K; KUMA, K; MIYATA, T; NAKAMURA, T			CLONING OF THE CDNA FOR A NOVEL RECEPTOR TYROSINE KINASE, SKY, PREDOMINANTLY EXPRESSED IN BRAIN	ONCOGENE			English	Note							GROWTH-FACTOR RECEPTOR; C-MET PROTOONCOGENE; SIGNAL TRANSDUCTION; LEUKEMIA-CELLS; PROTEIN; FAMILY; ONCOGENES; DOMAINS; GENE; PRODUCT	Based on homology to the tyrosine kinase domain of the chick erythroblastosis virus oncogene v-sea, we cloned a cDNA encoding a novel receptor tyrosine kinase from a human hepatoma HepG2 cDNA library. The encoded protein, which we termed 'Sky', contains an intracellular tyrosine kinase domain and a unique extracellular domain with two immunoglobulin (Ig)-like domains and two fibronectin type III (FN III) domains; The overall structure of Sky is homologous to the reported sequence of the oncogenic Axl/Ufo receptor tyrosine kinase. Phylogenetic analysis in the tyrosine kinase domain shows that Sky, Axl/Ufo, Ark, and v-Ryk form a subfamily distinct from other tyrosine kinases. Northern blot analysis revealed that sky mRNA is expressed predominantly in brain and faintly in tissues of other organs. As the combination of Ig-like and FN III domains is often observed in neural cell adhesion molecules and receptor protein tyrosine phosphatases, Sky may be involved in cell adhesion processes, particularly in the central nervous system.	KYUSHU UNIV,FAC SCI,DEPT BIOL,FUKUOKA 812,JAPAN; KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KYOTO 60601,JAPAN; OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 565,JAPAN	Kyushu University; Kyoto University; Osaka University			Mizuno, Kensaku/G-8631-2015; Ohashi, Kazumasa/U-7028-2019	Ohashi, Kazumasa/0000-0001-7617-403X				BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; FAUST M, 1992, ONCOGENE, V7, P1287; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIGUCHI O, 1992, FEBS LETT, V301, P282, DOI 10.1016/0014-5793(92)80257-H; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; JIA R, 1992, J VIROL, V66, P5975, DOI 10.1128/JVI.66.10.5975-5987.1992; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUMA K, 1993, MOL BIOL EVOL, V10, P539; Kuma K, 1991, CURR OPIN STRUC BIOL, V1, P384, DOI 10.1016/0959-440X(91)90036-S; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; MIZUNO K, 1993, HEPATOCYTE GROWTH FA, P1; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	36	123	137	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1994	9	3					699	705						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW551	8108112				2022-12-17	WOS:A1994MW55100004
J	ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M				ISHIZAKA, Y; KOBAYASHI, S; USHIJIMA, T; HIROHASHI, S; SUGIMURA, T; NAGAO, M			DETECTION OF RETTPC PTC TRANSCRIPTS IN THYROID ADENOMAS AND ADENOMATOUS GOITER BY AN RT PCR METHOD	ONCOGENE			English	Article							CARCINOMA CELL-LINE; PROTO-ONCOGENE; PAPILLARY CARCINOMAS; TYROSINE KINASE; HIGH-FREQUENCY; II ONCOGENE; ACTIVATION; CLONING; REARRANGEMENT; EXPRESSION	A reverse transcriptase-polymerase chain reaction (RT-PCR) method was adopted for detecting transcripts specific for ret(TPC)/PTC, an activated form of the ret proto-oncogene reported to be found specifically in human papillary thyroid carcinomas. By this sensitive method ret(TPC)/PTC transcript could be detected in about 500 fg of total RNA of TPC-1, a ret(TPC)/PTC transcript-positive cell line. In Japanese patients, one of 11 papillary thyroid carcinomas, four of 19 follicular adenomas and one of two adenomatous goiters were positive for the transcript, indicating that the involvement of ret(TPC)/PTC is not specific to papillary thyroid carcinomas. In several independent RT-PCR experiments using different portions of the same positive carcinoma tissue, ret(TPC)/PTC transcript was always detected. On the other hand, the transcript was not always positive in different RNA samples from benign cases, suggesting that positive carcinomas are probably composed of clonal cell populations all expressing ret(TPC)/PTC, whereas adenomas and adenomatous goiter comprise heterogeneous populations: both positive and negative for ret(TPC)/PTC transcript. Activation of the ret proto-oncogene might therefore be involved in malignant conversion to thyroid carcinomas.	NAGOYA CITY UNIV,SCH MED,DEPT SURG,NAGOYA,AICHI 467,JAPAN; NATL CANC CTR,RES INST,DIV PATHOL,TOKYO 104,JAPAN	Nagoya City University; National Cancer Center - Japan	ISHIZAKA, Y (corresponding author), NATL CANC CTR,RES INST,DIV CARCINOGENESIS,1-1 TSUKIJI 5,CHUO KU,TOKYO 104,JAPAN.		Ushijima, Toshikazu/AAP-5742-2021	Ushijima, Toshikazu/0000-0003-3405-7817				BONGARZONE I, 1989, ONCOGENE, V4, P1457; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DONGHI R, 1989, ONCOGENE, V4, P521; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hedinger C, 1988, HISTOLOGICAL TYPING; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ISHIZAKA Y, 1989, ONCOGENE, V4, P1519; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; ISHIZAKA Y, 1989, JPN J CANCER RES, V80, P1149, DOI 10.1111/j.1349-7006.1989.tb01645.x; ISHIZAKA Y, 1988, ONCOGENE RES, V3, P193; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KAWASAKI ES, 1989, PCR TECHNOLOGY PRINC, P89; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; LEMOINE NR, 1989, ONCOGENE, V4, P159; OSADA H, 1989, JPN J CANCER RES, V80, P711, DOI 10.1111/j.1349-7006.1989.tb01702.x; Sambrook J., 1989, MOL CLONING LAB MANU; SAMPSON RJ, 1969, J AMER MED ASSOC, V209, P65; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; YAGAWA K, 1966, 25 P JAP CANC ASS AN, P106; YAGAWA K, 1962, 25TH P JAP CANC ASS, P106; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204; 1988, HISTOLOGICAL TYPING	27	123	125	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1991	6	9					1667	1672						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX274	1717926				2022-12-17	WOS:A1991GX27400023
J	MERCER, WE; AMIN, M; SAUVE, GJ; APPELLA, E; ULLRICH, SJ; ROMANO, JW				MERCER, WE; AMIN, M; SAUVE, GJ; APPELLA, E; ULLRICH, SJ; ROMANO, JW			WILD-TYPE HUMAN P53 IS ANTIPROLIFERATIVE IN SV40-TRANSFORMED HAMSTER-CELLS	ONCOGENE			English	Article									NCI,CELL BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	MERCER, WE (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,3400 N BROAD ST,PHILADELPHIA,PA 19140, USA.				NCI NIH HHS [CA 42866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042866] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V62, P156; CRAWFORD L, 1983, INT REV EXP PATHOL, V25, P1; Crawford L V, 1984, Mol Biol Med, V2, P261; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; EHRHART JC, 1988, ONCOGENE, V3, P595; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELIYAHU D, 1988, ONCOGENE, V3, P313; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; Gai X X, 1988, Oncogene Res, V3, P377; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRSCHHORN RR, 1984, VIROLOGY, V134, P220, DOI 10.1016/0042-6822(84)90287-3; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KACZMAREK L, 1986, J BIOL CHEM, V261, P802; KLESSIG DF, 1984, MOL CELL BIOL, V4, P1354, DOI 10.1128/MCB.4.7.1354; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; MARTINIS J, 1978, P NATL ACAD SCI USA, V75, P2320, DOI 10.1073/pnas.75.5.2320; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1989, EXP CELL RES, V181, P531, DOI 10.1016/0014-4827(89)90109-2; MERCER WE, 1985, EXP CELL RES, V160, P31, DOI 10.1016/0014-4827(85)90233-2; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; MUNROE DG, 1988, ONCOGENE, V2, P621; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OREN M, 1985, BIOCHIM BIOPHYS ACTA, V823, P67, DOI 10.1016/0304-419X(85)90015-0; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SHEN YM, 1982, MOL CELL BIOL, V2, P1145, DOI 10.1128/MCB.2.9.1145; SHOHAT O, 1987, ONCOGENE, V1, P277; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TUCK SP, 1989, ONCOGENE RES, V4, P81; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WOLF D, 1985, P NATL ACAD SCI USA, V82, P790, DOI 10.1073/pnas.82.3.790; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	62	123	125	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					973	980						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	2165234				2022-12-17	WOS:A1990DP41500004
J	Deng, Z; Rong, Y; Teng, Y; Zhuang, X; Samykutty, A; Mu, J; Zhang, L; Cao, P; Yan, J; Miller, D; Zhang, HG				Deng, Z.; Rong, Y.; Teng, Y.; Zhuang, X.; Samykutty, A.; Mu, J.; Zhang, L.; Cao, P.; Yan, J.; Miller, D.; Zhang, H-G			Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis	ONCOGENE			English	Article							SUPPRESSOR-CELLS; BREAST-CANCER; THERAPEUTIC AGENTS; DRUG-RESISTANCE; CHEMOTHERAPY; EXPRESSION; MICRORNA-126-5P; INTERLEUKIN-33; BIOGENESIS; CORRELATE	Acquired resistance to chemotherapy remains a major stumbling block in cancer treatment. Chronic inflammation has a crucial role in induction of chemoresistance and results, in part, from the induction and expansion of inflammatory cells that include myeloidderived suppressor cells (MDSCs) and IL-13(+) Th2 cells. The mechanisms that lead to induction of activated MDSCs and IL-13(+) Th2 cells have not yet been identified. Here we demonstrated that doxorubicin (DOX) treatment of 4T1 breast tumor-bearing mice led to the induction of IL-13R(+) miR-126a(+) MDSCs (DOX-MDSC). DOX-MDSC promote breast tumor lung metastasis through MDSC miR-126a(+) exosomal-mediated induction of IL-13(+) Th2 cells and tumor angiogenesis. The induction of DOX-MDSC is regulated in a paracrine manner. DOX treatment not only increases interleukin (IL)-33 released from breast tumor cells, which is crucial for the induction of IL-13(+) Th2 cells, but it also participates in the induction of IL-13 receptors and miR-126a expressed on/in the MDSCs. IL-13 released from IL-13(+) Th2 cells then promotes the production of DOX-MDSC and MDSC miR-126a(+) exosomes via MDSC IL-13R. MDSC miR-126a+ exosomes further induce IL13(+) Th2 cells in a positive feed-back loop manner. We also showed that MDSC miR-126a rescues DOX-induced MDSC death in a S100A8/A9-dependent manner and promotes tumor angiogenesis. Our findings provide insight into the MDSC exosomal-mediated chemoresistance mechanism, which will be useful for the design of inhibitors targeting the blocking of induction of miR-126a(+) MDSCs.	[Deng, Z.; Rong, Y.; Teng, Y.; Zhuang, X.; Samykutty, A.; Mu, J.; Zhang, L.; Cao, P.; Yan, J.; Miller, D.; Zhang, H-G] Univ Louisville, Dept Microbiol & Immunol, James Graham Brown Canc Ctr, CTRB 309,505 Hancock St, Louisville, KY 40292 USA; [Zhang, H-G] Robley Rex VA Med Ctr, Louisville, KY USA	University of Louisville	Deng, Z; Zhang, HG (corresponding author), Univ Louisville, Dept Microbiol & Immunol, James Graham Brown Canc Ctr, CTRB 309,505 Hancock St, Louisville, KY 40292 USA.	z0deng01@louisville.edu; H0Zhan17@louisville.edu	samykutty, Abhilash/J-6575-2019; Yan, Jun/A-8988-2008	samykutty, Abhilash/0000-0003-3551-045X; 	National Institutes of Health (NIH) [R01AT008617, UH3TR000875]; Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants; Research Career Scientist (RCS) Award; US Department of Veterans Affairs; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UH3TR000875, UH2TR000875] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [R01AT008617] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants; Research Career Scientist (RCS) Award; US Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the National Institutes of Health (NIH) (R01AT008617, UH3TR000875) and the Louisville Veterans Administration Medical Center (VAMC) Merit Review Grants (to H-G Zhang). H-G Zhang is supported by a Research Career Scientist (RCS) Award, funded by the US Department of Veterans Affairs. We thank Dr Jerald Ainsworth for editorial assistance.	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Agudo J, 2014, NAT IMMUNOL, V15, P54, DOI 10.1038/ni.2767; Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545; Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9; Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Burke MC, 2014, J PROTEOME RES, V13, P5965, DOI 10.1021/pr500854x; Chairoungdua A, 2010, J CELL BIOL, V190, P1079, DOI 10.1083/jcb.201002049; Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135; Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; de Leeuw DC, 2014, CANCER RES, V74, P2094, DOI 10.1158/0008-5472.CAN-13-1733; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Garlanda C, 2009, TRENDS IMMUNOL, V30, P439, DOI 10.1016/j.it.2009.06.001; Ghiringhelli F, 2014, EXPERT REV CLIN IMMU, V10, P19, DOI 10.1586/1744666X.2014.865520; Goerke SM, 2015, BIOL CHEM, V396, P245, DOI 10.1515/hsz-2014-0259; Guabiraba R, 2014, MUCOSAL IMMUNOL, V7, P1079, DOI 10.1038/mi.2013.124; Guduric-Fuchs J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-357; Joshi BH, 2009, IMMUNOTHERAPY-UK, V1, P321, DOI 10.2217/IMT.09.8; Koch R, 2016, CLIN CANCER RES, V22, P395, DOI 10.1158/1078-0432.CCR-15-0577; Koppers-Lalic D, 2014, CELL REP, V8, P1649, DOI 10.1016/j.celrep.2014.08.027; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Lieberman J, 2013, CELL, V153, P9, DOI 10.1016/j.cell.2013.03.019; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Ohshima K, 2014, PROTEOMICS, V14, P2297, DOI 10.1002/pmic.201300477; Ohshima K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013247; Ozkok A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/967826; Payne KK, 2013, BREAST CANCER RES TR, V142, P45, DOI 10.1007/s10549-013-2733-5; Ran S, 2015, CANCER RES, V75, P2405, DOI 10.1158/0008-5472.CAN-14-3525; Reichenbach DK, 2015, BLOOD, V125, P3183, DOI 10.1182/blood-2014-10-606830; Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009; Schmieder A, 2012, CYTOKINE, V60, P514, DOI 10.1016/j.cyto.2012.06.286; Schober A, 2014, NAT MED, V20, P368, DOI 10.1038/nm.3487; Seidelin JB, 2011, MUCOSAL IMMUNOL, V4, P496, DOI 10.1038/mi.2011.22; Shen J, 2015, CANCER RES, V75, P783, DOI 10.1158/0008-5472.CAN-14-2568; Shibayama Y, 2015, ONCOL REP, V33, P2176, DOI 10.3892/or.2015.3839; Suzuki A, 2015, CYTOKINE, V75, P79, DOI 10.1016/j.cyto.2015.05.026; Talmadge JE, 2013, NAT REV CANCER, V13, P739, DOI 10.1038/nrc3581; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Umansky V, 2012, CANCER IMMUNOL IMMUN, V61, P275, DOI 10.1007/s00262-011-1164-6; Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009; Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067; Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood-2014-03-562439; Wang QL, 2015, CANCER RES, V75, P2520, DOI 10.1158/0008-5472.CAN-14-3095; Wang QL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2886; Xiang XY, 2010, AM J PATHOL, V177, P1606, DOI 10.2353/ajpath.2010.100245; Xiang Y, 2014, ONCOGENE, V33, P378, DOI 10.1038/onc.2012.575; Yang Z, 2015, INT J CLIN EXP PATHO, V8, P8869; Yin Y, 2013, CANCER IMMUNOL RES, V1, P256, DOI 10.1158/2326-6066.CIR-13-0073	54	122	129	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					639	651		10.1038/onc.2016.229	http://dx.doi.org/10.1038/onc.2016.229			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27345402	Green Accepted			2022-12-17	WOS:000394167700006
J	Weber, CE; Kothari, AN; Wai, PY; Li, NY; Driver, J; Zapf, MAC; Franzen, CA; Gupta, GN; Osipo, C; Zlobin, A; Syn, WK; Zhang, J; Kuo, PC; Mi, Z				Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Franzen, C. A.; Gupta, G. N.; Osipo, C.; Zlobin, A.; Syn, W. K.; Zhang, J.; Kuo, P. C.; Mi, Z.			Osteopontin mediates an MZF1-TGF-beta 1-dependent transformation of mesenchymal stem cells into cancer-associated fibroblasts in breast cancer	ONCOGENE			English	Article							GENE-EXPRESSION; STROMAL FIBROBLASTS; PLASMA OSTEOPONTIN; PROMOTES FIBROSIS; TUMOR-GROWTH; TGF-BETA; METASTASIS; ACTIVATION; CARCINOMA; INVASION	Interactions between tumor cells and cancer-associated fibroblasts (CAFs) in the tumor microenvironment significantly influence cancer growth and metastasis. Transforming growth factor-beta (TGF-beta) is known to be a critical mediator of the CAF phenotype, and osteopontin (OPN) expression in tumors is associated with more aggressive phenotypes and poor patient outcomes. The potential link between these two pathways has not been previously addressed. Utilizing in vitro studies using human mesenchymal stem cells (MSCs) and MDA-MB231 (OPN+) and MCF7 (OPN-) human breast cancer cell lines, we demonstrate that OPN induces integrin-dependent MSC expression of TGF-beta 1 to mediate adoption of the CAF phenotype. This OPN-TGF-beta 1 pathway requires the transcription factor, myeloid zinc finger 1 (MZF1). In vivo studies with xenotransplant models in NOD-scid mice showed that OPN expression increases cancer growth and metastasis by mediating MSC-to-CAF transformation in a process that is MZF1 and TGF-beta 1 dependent. We conclude that tumor-derived OPN engenders MSC-to-CAF transformation in the microenvironment to promote tumor growth and metastasis via the OPN-MZF1-TGF-beta 1 pathway.	[Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Gupta, G. N.; Syn, W. K.; Kuo, P. C.; Mi, Z.] Loyola Univ Chicago, Loyola Univ, Dept Surg, Med Ctr, Maywood, IL USA; [Weber, C. E.; Kothari, A. N.; Wai, P. Y.; Li, N. Y.; Driver, J.; Zapf, M. A. C.; Franzen, C. A.; Gupta, G. N.; Osipo, C.; Zlobin, A.; Zhang, J.; Kuo, P. C.; Mi, Z.] Loyola Univ Chicago, Inst Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL USA; [Franzen, C. A.; Gupta, G. N.] Loyola Univ Chicago, Dept Urol, Cardinal Bernardin Canc Ctr, Med Ctr,Loyola Univ, Maywood, IL USA; [Syn, W. K.] Barts Hlth NHS Trust, Liver Unit, London, England; [Syn, W. K.] Inst Hepatol, Regenerat & Repair, London, England	Loyola University Chicago; Loyola University Chicago; Loyola University Chicago; Barts Health NHS Trust; University of London; University College London	Kuo, PC (corresponding author), Loyola Univ, Med Ctr, Dept Surg, EMS Bldg,Room 3244,2160 S First Ave, Maywood, IL 60153 USA.	pkuo@lumc.edu	Syn, Wing-Kin/AAB-8406-2020	Li, Neill/0000-0001-9149-4859; Zapf, Matthew/0000-0001-5544-8900; Franzen, Carrie/0000-0002-1127-8599	NIH [GM65113, CA155306, UL1 RR024128]; NATIONAL CANCER INSTITUTE [R21CA155306] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065113, T32GM008750, R56GM065113] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This research was supported by NIH grants: GM65113, CA155306 and UL1 RR024128. We thank Andy Hall, Research Histology Manager, at the University of Illinois at Chicago Research Resources Center who performed all immunohistochemical staining and mounting. We also thank Dr Dariusz Borys, of the Loyola Department of Pathology, for assistance with the imaging of slides.	Anderberg C, 2009, CANCER RES, V69, P369, DOI 10.1158/0008-5472.CAN-08-2724; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bhattacharya SD, 2012, ANN SURG, V255, P319, DOI 10.1097/SLA.0b013e31823e3a1c; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Boxall SA, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/975871; Bramwell VHC, 2006, CLIN CANCER RES, V12, P3337, DOI 10.1158/1078-0432.CCR-05-2354; Brauer HA, 2013, CLIN CANCER RES, V19, P571, DOI 10.1158/1078-0432.CCR-12-2123; BROWN LF, 1994, AM J PATHOL, V145, P610; Casey TM, 2008, BREAST CANCER RES TR, V110, P39, DOI 10.1007/s10549-007-9684-7; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Davis C, 2011, MICROSC MICROANAL, V17, P528, DOI 10.1017/S1431927611000043; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; Direkze NC, 2004, CANCER RES, V64, P8492, DOI 10.1158/0008-5472.CAN-04-1708; Dumont N, 2013, NEOPLASIA, V15, P249, DOI 10.1593/neo.121950; Elkabets M, 2011, J CLIN INVEST, V121, P784, DOI 10.1172/JCI43757; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Gao MQ, 2010, J CELL SCI, V123, P3507, DOI 10.1242/jcs.072900; Hawinkels LJ, 2012, ONCOGENE, V33, P97, DOI [DOI 10.1038/ONC.2012.536, DOI 10.1038/onc.2012.536]; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; HROMAS R, 1995, CANCER RES, V55, P3610; Hsieh YH, 2006, BIOCHEM BIOPH RES CO, V339, P217, DOI 10.1016/j.bbrc.2005.11.015; Hsieh YH, 2007, CHINESE J PHYSIOL, V50, P9; Huang WH, 2013, ONCOGENE, V32, P4343, DOI 10.1038/onc.2012.458; Ireson CR, 2006, MOL CANCER THER, V5, P2957, DOI 10.1158/1535-7163.MCT-06-0172; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KENG PC, 1990, INT J RADIAT ONCOL, V18, P1061, DOI 10.1016/0360-3016(90)90441-L; Kidd S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030563; KIM SJ, 1989, J BIOL CHEM, V264, P402; Kohan M, 2009, AM J RESP CELL MOL, V41, P290, DOI 10.1165/rcmb.2008-0307OC; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Korpal M, 2009, NAT MED, V15, P960, DOI 10.1038/nm.1943; Lenga Y, 2008, CIRC RES, V102, P319, DOI 10.1161/CIRCRESAHA.107.160408; Mak GWY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042210; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Matsuzaki H, 2007, J ORAL PATHOL MED, V36, P30; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Mi ZY, 2011, CARCINOGENESIS, V32, P477, DOI 10.1093/carcin/bgr009; Mi Zhiyong, 2009, BMC Res Notes, V2, P119, DOI 10.1186/1756-0500-2-119; Mi ZY, 2009, MOL THER, V17, P153, DOI 10.1038/mt.2008.235; Mi ZY, 2004, J BIOL CHEM, V279, P46659, DOI 10.1074/jbc.M407952200; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Mishra PJ, 2011, METHODS MOL BIOL, V717, P245, DOI 10.1007/978-1-61779-024-9_14; Miyazaki KI, 2008, INVEST OPHTH VIS SCI, V49, P1367, DOI 10.1167/iovs.07-1007; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Mudduluru G, 2010, MOL CANCER RES, V8, P159, DOI 10.1158/1541-7786.MCR-09-0326; Nicholas SB, 2010, KIDNEY INT, V77, P588, DOI 10.1038/ki.2009.518; O'Regan A, 2000, INT J EXP PATHOL, V81, P373, DOI 10.1046/j.1365-2613.2000.00163.x; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Otto WR, 2011, FIBROGENESIS TISSUE, V4, DOI 10.1186/1755-1536-4-20; Pang H, 2013, CANCER EPIDEMIOL, V37, P985, DOI 10.1016/j.canep.2013.08.005; Patani N, 2008, ANTICANCER RES, V28, P4105; Qi W, 2008, BIOCHEM J, V416, P453, DOI 10.1042/BJ20080651; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Que-Gewirth NS, 2007, GENE THER, V14, P283, DOI 10.1038/sj.gt.3302900; Rafn B, 2012, MOL CELL, V45, P764, DOI 10.1016/j.molcel.2012.01.029; Rodrigues LR, 2007, CANCER EPIDEM BIOMAR, V16, P1087, DOI 10.1158/1055-9965.EPI-06-1008; Shevde LA, 2006, CLIN EXP METASTAS, V23, P123, DOI 10.1007/s10585-006-9013-2; Singhal H, 1997, CLIN CANCER RES, V3, P605; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Su G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046685; Syn WK, 2011, HEPATOLOGY, V53, P106, DOI 10.1002/hep.23998; Szalay G, 2009, CIRC RES, V104, P851, DOI 10.1161/CIRCRESAHA.109.193805; Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tuck AB, 2001, J MAMMARY GLAND BIOL, V6, P419, DOI 10.1023/A:1014734930781; Tuck AB, 2007, J CELL BIOCHEM, V102, P859, DOI 10.1002/jcb.21520; Udagawa T, 2006, FASEB J, V20, P95, DOI 10.1096/fj.04-3669com; Vetrone SA, 2009, J CLIN INVEST, V119, P1583, DOI 10.1172/JCI37662; Wai PY, 2008, CANCER METAST REV, V27, P103, DOI 10.1007/s10555-007-9104-9; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Wang L, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt96; Wolak T, 2009, KIDNEY INT, V76, P32, DOI 10.1038/ki.2009.90; Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0; Worthington JJ, 2011, TRENDS BIOCHEM SCI, V36, P47, DOI 10.1016/j.tibs.2010.08.002; Xu LN, 2013, GENET MOL RES, V12, P5863, DOI 10.4238/2013.November.22.14; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yu KN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015623	80	122	131	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2015	34	37					4821	4833		10.1038/onc.2014.410	http://dx.doi.org/10.1038/onc.2014.410			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR0YP	25531323	Green Accepted			2022-12-17	WOS:000361050000003
J	Ferraldeschi, R; Welti, J; Luo, J; Attard, G; de Bono, JS				Ferraldeschi, R.; Welti, J.; Luo, J.; Attard, G.; de Bono, J. S.			Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects	ONCOGENE			English	Review							IN-SITU HYBRIDIZATION; NH2-TERMINAL TRANSACTIVATION DOMAIN; MEDIATE ENZALUTAMIDE RESISTANCE; HUMAN CYTOCHROME P450(17-ALPHA); POLYMERASE PARP INHIBITORS; CIRCULATING TUMOR-CELLS; LIGAND-BINDING DOMAIN; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; SPLICE VARIANTS	Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. However, over time, most tumors become resistant to ADT. The view of castration-resistant prostate cancer (CRPC) has changed dramatically in the last several years. Progress in understanding the disease biology and mechanisms of castration resistance led to significant advancements and to paradigm shift in the treatment. Accumulating evidence showed that prostate cancers develop adaptive mechanisms for maintaining AR signaling to allow for survival and further evolution. The aim of this review is to summarize molecular mechanisms of castration resistance and provide an update in the development of novel agents and strategies to more effectively target the AR signaling pathway.	[Ferraldeschi, R.; Welti, J.; Attard, G.; de Bono, J. S.] Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton SM2 5PT, Surrey, England; [Ferraldeschi, R.; Welti, J.; Attard, G.; de Bono, J. S.] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [Luo, J.] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Johns Hopkins University	de Bono, JS (corresponding author), Inst Canc Res, Prostate Canc Targeted Therapy Grp, Sutton SM2 5PT, Surrey, England.	Johann.De-Bono@icr.ac.uk		Attard, Gerhardt/0000-0002-4811-7983; de Bono, Johann S/0000-0002-2034-595X; Welti, Jonathan/0000-0002-9433-8138	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Amgen; Astellas; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Enzon; Exelixis; Genentech; GlaxoSmithKline; Medivation; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Supergen; Takeda; Janssen-Cilag; Veridex; Roche/Ventana; Millennium Pharmaceuticals; Ipsen; Cancer Research UK [13239] Funding Source: researchfish; National Institute for Health Research [CL-2008-22-001] Funding Source: researchfish; Prostate Cancer UK [PG12-49] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Amgen(Amgen); Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); Dendreon; Enzon; Exelixis; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Medivation; Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Supergen; Takeda(Takeda Pharmaceutical Company Ltd); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Veridex; Roche/Ventana; Millennium Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Ipsen(Ipsen); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Prostate Cancer UK; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Abiraterone acetate was developed at The Institute of Cancer Research (ICR), which therefore has a commercial interest in the development of this agent. JSdB received consulting fees from Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology), consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen and Takeda, and grant support from AstraZeneca and Genentech. GA received consulting fees and travel support from Janssen-Cilag, Veridex, Roche/Ventana and Millennium Pharmaceuticals, lecture fees from Janssen-Cilag, Ipsen, Takeda and Sanofi-Aventis and grant support from AstraZeneca and Genentech. GA is on the ICR rewards to inventors list of abiraterone acetate.	Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Araujo JC, 2013, LANCET ONCOL, V14, P1307, DOI 10.1016/S1470-2045(13)70479-0; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Askew EB, 2012, MOL CELL ENDOCRINOL, V348, P403, DOI 10.1016/j.mce.2011.03.026; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2010, CLIN CANCER RES, V16, P1340, DOI 10.1158/1078-0432.CCR-09-2253; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Balbas MD, 2013, ELIFE, V2, DOI 10.7554/eLife.00499; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960-0760(96)00225-7; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960-0760(94)90131-7; Beer TM, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.lba1; Beltran H, 2013, J CLIN ONCOL, V31, P1782, DOI 10.1200/JCO.2012.48.4667; Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744; Bergerat JP, 2009, HUM MUTAT, V30, P145, DOI 10.1002/humu.20848; Bianchini D, 2014, EUR J CANCER, V50, P78, DOI 10.1016/j.ejca.2013.08.020; Bianchini D, 2013, BRIT J CANCER, V109, P2579, DOI 10.1038/bjc.2013.619; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Bubendorf L, 1999, CANCER RES, V59, P803; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cariaga-Martinez AE, 2013, CELL SIGNAL, V25, P1586, DOI 10.1016/j.cellsig.2013.03.019; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001; Chang KH, 2013, CELL, V154, P1074, DOI 10.1016/j.cell.2013.07.029; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chmelar R, 2007, INT J CANCER, V120, P719, DOI 10.1002/ijc.22365; Choi JI, 2011, KOREAN J UROL, V52, P461, DOI 10.4111/kju.2011.52.7.461; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Coffey K, 2012, J ENDOCRINOL, V215, P221, DOI 10.1530/JOE-12-0238; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Cutress ML, 2008, J CELL SCI, V121, P957, DOI 10.1242/jcs.022103; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Di Lorenzo G, 2002, CLIN CANCER RES, V8, P3438; Eisner JR, 2012, J CLIN ONCOL, V30; Ferraldeschi R, 2013, CANCER J, V19, P34, DOI 10.1097/PPO.0b013e31827e0b6f; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; GELLER J, 1978, J CLIN ENDOCR METAB, V46, P440; Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110; Georget V, 2002, BIOCHEMISTRY-US, V41, P11824, DOI 10.1021/bi0259150; Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106; Godoy A, 2011, PROSTATE, V71, P1033, DOI 10.1002/pros.21318; Grad JM, 2001, ENDOCRINOLOGY, V142, P1107, DOI 10.1210/en.142.3.1107; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Ha S, 2013, ONCOGENE, V32, P3992, DOI 10.1038/onc.2012.412; Haapala K, 2007, HUM PATHOL, V38, P474, DOI 10.1016/j.humpath.2006.09.008; Handratta VD, 2005, J MED CHEM, V48, P2972, DOI 10.1021/jm040202w; Hara T, 2003, CANCER RES, V63, P149; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heath EI, 2013, J CLIN ONCOL S, V31; Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1941, CANCER RES, V1, P293; Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696; Joseph JD, 2013, CANCER DISCOV, V3, DOI 10.1158/2159-8290.CD-13-0226; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Jung ME, 2010, J MED CHEM, V53, P2779, DOI 10.1021/jm901488g; Kaku T, 2011, BIOORGAN MED CHEM, V19, P6383, DOI 10.1016/j.bmc.2011.08.066; Kikuchi A., 2013, J CLIN ONCOL, V31, pa5046; Koivisto P, 1997, CANCER RES, V57, P314; Kolvenbag GJCM, 1998, PROSTATE CANCER P D, V1, P307, DOI 10.1038/sj.pcan.4500262; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Kraus WL, 2008, CURR OPIN CELL BIOL, V20, P294, DOI 10.1016/j.ceb.2008.03.006; Lamont KR, 2011, MOL ENDOCRINOL, V25, P897, DOI 10.1210/me.2010-0469; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Lavery DN, 2008, BIOCHEMISTRY-US, V47, P3360, DOI 10.1021/bi702221e; Lavery DN, 2008, BIOCHEMISTRY-US, V47, P3352, DOI 10.1021/bi702220p; Leversha MA, 2009, CLIN CANCER RES, V15, P2091, DOI 10.1158/1078-0432.CCR-08-2036; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Li YM, 2011, CANCER RES, V71, P2108, DOI 10.1158/0008-5472.CAN-10-1998; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Linja MJ, 2001, CANCER RES, V61, P3550; Liu LL, 2014, ONCOGENE, V33, P3140, DOI 10.1038/onc.2013.284; Liu Y, 2010, ONCOGENE, V29, P3208, DOI 10.1038/onc.2010.103; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Logothetis CJ, 2012, LANCET ONCOL, V13, P1210, DOI 10.1016/S1470-2045(12)70473-4; Loriot Y, 2013, ANN ONCOL, V24, P1807, DOI 10.1093/annonc/mdt136; Lu S, 2000, MOL ENDOCRINOL, V14, P753, DOI 10.1210/me.14.5.753; Luo J, 2013, EUR UROL, V64, P339, DOI 10.1016/j.eururo.2013.05.012; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Massard C, 2012, 2012 ESMO C VIENN AU; Michaelson MD, 2014, J CLIN ONCOL, V32, P76, DOI 10.1200/JCO.2012.48.5268; Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335; Miyoshi Y, 2000, PROSTATE, V43, P225, DOI 10.1002/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7; Montgomery B, 2014, ASIAN J ANDROL, V16, P354, DOI 10.4103/1008-682X.125392; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mosquera JM, 2013, NEOPLASIA, V15, P1, DOI 10.1593/neo.121550; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003; Noonan KL, 2013, ANN ONCOL, V24, P1802, DOI 10.1093/annonc/mdt138; O'Donnell A, 2004, BRIT J CANCER, V90, P2317, DOI 10.1038/sj.bjc.6601879; Okegawa T, 2010, INT J UROL, V17, P950, DOI 10.1111/j.1442-2042.2010.02620.x; Oksala R., 2013, ASCO M, V31, P65; Osguthorpe DJ, 2011, BIOCHEMISTRY-US, V50, P4105, DOI 10.1021/bi102059z; Pacey S, 2011, CLIN CANCER RES, V17, P1561, DOI 10.1158/1078-0432.CCR-10-1927; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Plymate SR, 2013, ANDROGEN RESPONSIVE; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022; Prescott J, 2006, CANCER LETT, V231, P12, DOI 10.1016/j.canlet.2004.12.037; Rathkopf DE, 2013, J CLIN ONCOL, V31, P3525, DOI 10.1200/JCO.2013.50.1684; Ravindranathan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2912; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Richards J, 2012, CANCER RES, V72, P2176, DOI 10.1158/0008-5472.CAN-11-3980; Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sahu B, 2013, CANCER RES, V73, P1570, DOI 10.1158/0008-5472.CAN-12-2350; Sandhu SK, 2013, ANN ONCOL, V24, P1416, DOI 10.1093/annonc/mdt074; Sandhu SK, 2013, LANCET ONCOL, V14, P882, DOI 10.1016/S1470-2045(13)70240-7; Schaufele F, 2005, P NATL ACAD SCI USA, V102, P9802, DOI 10.1073/pnas.0408819102; SCHER HI, 1993, J CLIN ONCOL, V11, P1566, DOI 10.1200/JCO.1993.11.8.1566; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Schiewer MJ, 2012, CANCER DISCOV, V2, P1134, DOI 10.1158/2159-8290.CD-12-0120; Schrader AJ, 2014, EUR UROL, V65, P30, DOI 10.1016/j.eururo.2013.06.042; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shu SK, 2010, J BIOL CHEM, V285, P33045, DOI 10.1074/jbc.M110.121129; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Simard J, 1997, UROLOGY, V49, P580, DOI 10.1016/S0090-4295(97)00029-0; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Smith MR, 2012, ANN ONCOL, V23, P303; Sonpavde G, 2010, ANN ONCOL, V21, P319, DOI 10.1093/annonc/mdp323; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Szmulewitz RZ, 2012, PROSTATE, V72, P157, DOI 10.1002/pros.21416; Taplin ME, 2012, J CLIN ONCOL, V30; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tombal B, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.4_suppl.62; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Uemura M, 2008, CANCER SCI, V99, P81, DOI 10.1111/j.1349-7006.2007.00656.x; Unni E, 2004, CANCER RES, V64, P7156, DOI 10.1158/0008-5472.CAN-04-1121; van de Wijngaart DJ, 2012, MOL CELL ENDOCRINOL, V352, P57, DOI 10.1016/j.mce.2011.08.007; van Royen ME, 2007, J CELL BIOL, V177, P63, DOI 10.1083/jcb.200609178; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wallen MJ, 1999, J PATHOL, V189, P559; Waltering KK, 2009, CANCER RES, V69, P8141, DOI 10.1158/0008-5472.CAN-09-0919; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Willder JM, 2013, BRIT J CANCER, V108, P139, DOI 10.1038/bjc.2012.480; Wiren KM, 1997, ENDOCRINOLOGY, V138, P2291, DOI 10.1210/en.138.6.2291; WOLF DA, 1993, MOL ENDOCRINOL, V7, P924, DOI 10.1210/me.7.7.924; Wu JD, 2006, J CELL BIOCHEM, V99, P392, DOI 10.1002/jcb.20929; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Yu ZY, 2014, CLIN CANCER RES, V20, P1590, DOI 10.1158/1078-0432.CCR-13-1863; Zhang LY, 2009, AM J PATHOL, V175, P489, DOI 10.2353/ajpath.2009.080727; Zhang YX, 2011, MOL CANCER THER, V10, P2309, DOI 10.1158/1535-7163.MCT-11-0329; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhu Q, 2008, ONCOGENE, V27, P4569, DOI 10.1038/onc.2008.91; Zoubeidi A, 2007, CANCER RES, V67, P10455, DOI 10.1158/0008-5472.CAN-07-2057	172	122	128	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 2	2015	34	14					1745	1757		10.1038/onc.2014.115	http://dx.doi.org/10.1038/onc.2014.115			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE9IQ	24837363	Green Accepted			2022-12-17	WOS:000352158000002
J	Deblois, G; St-Pierre, J; Giguere, V				Deblois, G.; St-Pierre, J.; Giguere, V.			The PGC-1/ERR signaling axis in cancer	ONCOGENE			English	Review						nuclear receptors; metabolism; mitochondrion; Warburg effect	ESTROGEN-RELATED-RECEPTOR; ALPHA ERR-ALPHA; PPAR-GAMMA COACTIVATOR; HUMAN BREAST-CANCER; ORPHAN NUCLEAR RECEPTORS; TRANSCRIPTIONAL CONTROL; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; CLINICAL-SIGNIFICANCE; METABOLIC REGULATOR	Proliferating cells need to produce a large amount of energy and, at the same time, need to maintain a constant supply of biosynthetic precursors of macromolecules that are used as building blocks for generating new cells. Indeed, many cancer cells undergo a switch from mitochondrial to glycolytic metabolism and display a truncated tricarboxylic acid cycle to match these specific metabolic requirements of proliferation. Understanding the mechanisms by which cancer cells reprogram various metabolic pathways to satisfy their unique bioenergetic requirements has become an active field of research. Concomitantly, it has emerged that members of a family of orphan nuclear receptors known as the estrogen-related receptors (ERRs), working in concert with members of the PPAR gamma coactivator (PGC)-1 family, act as central transcriptional regulators of metabolic gene networks involved in maintaining energy homeostasis in normal cells. Recent studies have suggested that the PGC-1/ERR transcriptional axis is also important in the metabolic reprogramming of cancer cells. This review focuses on the functional integration of the PGC-1/ERR axis with known oncogenes and the observation that modulation of the activity of this axis can have both pro- and anti-proliferative properties.	[Deblois, G.; St-Pierre, J.; Giguere, V.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Deblois, G.; St-Pierre, J.; Giguere, V.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Deblois, G (corresponding author), McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada.	vincent.giguere@mcgill.ca	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099; Giguere, Vincent/0000-0001-9567-3694	Canadian Institutes for Health Research [MOP-64275, MOP-106603]; Program Project Grant from the Terry Fox Foundation [TFF-116128]; predoctoral traineeship award from the US Department of Defense Breast Cancer Research Program [W81XWH-10-1-0489]	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Program Project Grant from the Terry Fox Foundation; predoctoral traineeship award from the US Department of Defense Breast Cancer Research Program	This work was supported by grants from the Canadian Institutes for Health Research to VG (MOP-64275) and JSt-P (MOP-106603) and a Program Project Grant from the Terry Fox Foundation to VG and JSt-P (TFF-116128). GD was supported by a predoctoral traineeship award (W81XWH-10-1-0489) from the US Department of Defense Breast Cancer Research Program. JSt-P is an FRSQ research scholar.	Alaynick WA, 2007, CELL METAB, V6, P13, DOI 10.1016/j.cmet.2007.06.007; [Anonymous], 2013, ONCOGENE, P3483; Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2007, MOL CANCER RES, V5, P71, DOI 10.1158/1541-7786.MCR-06-0227; Ba Yi, 2008, Zhonghua Zhongliu Zazhi, V30, P593; Bardet PL, 2005, EVOL DEV, V7, P223, DOI 10.1111/j.1525-142X.2005.05025.x; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bianco S, 2012, J STEROID BIOCHEM, V130, P180, DOI 10.1016/j.jsbmb.2011.03.014; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Cavallini A, 2005, EUR J CANCER, V41, P1487, DOI 10.1016/j.ejca.2005.04.008; Cervera AM, 2008, CANCER RES, V68, P4058, DOI 10.1158/0008-5472.CAN-07-5580; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Chen J, 2007, DEV CELL, V13, P325, DOI 10.1016/j.devcel.2007.07.011; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Chisarnore MJ, 2009, MOL CANCER THER, V8, P672, DOI 10.1158/1535-7163.MCT-08-1028; Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deblois G, 2011, BBA-MOL BASIS DIS, V1812, P1032, DOI 10.1016/j.bbadis.2010.12.009; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Dufour CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002143; Dwyer MA, 2010, CANCER RES, V70, P9298, DOI 10.1158/0008-5472.CAN-10-0226; Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024; Feng B, 2009, NAT CELL BIOL, V11, P197, DOI 10.1038/ncb1827; Fisher KW, 2011, MOL CELL BIOL, V31, P2453, DOI 10.1128/MCB.05255-11; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; Fujimoto J, 2007, J STEROID BIOCHEM, V104, P301, DOI 10.1016/j.jsbmb.2007.03.016; Fujimura T, 2010, CANCER SCI, V101, P646, DOI 10.1111/j.1349-7006.2009.01451.x; Gaillard S, 2007, MOL ENDOCRINOL, V21, P62, DOI 10.1210/me.2006-0179; Gaillard S, 2006, MOL CELL, V24, P797, DOI 10.1016/j.molcel.2006.10.012; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gao M, 2006, INT J GYNECOL CANCER, V16, P827, DOI 10.1111/j.1525-1438.2006.00527.x; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Girnun GD, 2012, SEMIN CELL DEV BIOL, V23, P381, DOI 10.1016/j.semcdb.2012.01.007; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Heck S, 2009, CANCER RES, V69, P5184, DOI 10.1158/0008-5472.CAN-08-3062; Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Huss JM, 2007, CELL METAB, V6, P25, DOI 10.1016/j.cmet.2007.06.005; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ijichi N, 2011, J STEROID BIOCHEM, V123, P1, DOI 10.1016/j.jsbmb.2010.09.002; Jarzabek K, 2009, J STEROID BIOCHEM, V113, P127, DOI 10.1016/j.jsbmb.2008.12.005; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Klimcakova E, 2012, CANCER RES, V72, P1538, DOI 10.1158/0008-5472.CAN-11-2967; Klomp JA, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-59; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Michalek RD, 2011, P NATL ACAD SCI USA, V108, P18348, DOI 10.1073/pnas.1108856108; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Stein RA, 2006, ENDOCR-RELAT CANCER, V13, pS25, DOI 10.1677/erc.1.01292; Stein RA, 2008, CANCER RES, V68, P8805, DOI 10.1158/0008-5472.CAN-08-1594; Stein RA, 2009, J STEROID BIOCHEM, V114, P106, DOI 10.1016/j.jsbmb.2009.02.010; Sun PM, 2005, J MOL MED, V83, P457, DOI 10.1007/s00109-005-0639-3; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Tennessen JM, 2011, CELL METAB, V13, P139, DOI 10.1016/j.cmet.2011.01.005; Tiraby C, 2011, CANCER RES, V71, P2518, DOI 10.1158/0008-5472.CAN-10-1315; Tremblay AM, 2010, MOL ENDOCRINOL, V24, P22, DOI 10.1210/me.2009-0254; Tremblay Annie M, 2007, Nucl Recept Signal, V5, pe009, DOI 10.1621/nrs.05009; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005; WARBURG O, 1956, SCIENCE, V124, P269; Watkins G, 2004, ONCOL REP, V12, P483; Wirtenberger M, 2006, CARCINOGENESIS, V27, P2201, DOI 10.1093/carcin/bgl067; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11	94	122	125	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3483	3490		10.1038/onc.2012.529	http://dx.doi.org/10.1038/onc.2012.529			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	23208510				2022-12-17	WOS:000322220800001
J	Yeramian, A; Moreno-Bueno, G; Dolcet, X; Catasus, L; Abal, M; Colas, E; Reventos, J; Palacios, J; Prat, J; Matias-Guiu, X				Yeramian, A.; Moreno-Bueno, G.; Dolcet, X.; Catasus, L.; Abal, M.; Colas, E.; Reventos, J.; Palacios, J.; Prat, J.; Matias-Guiu, X.			Endometrial carcinoma: molecular alterations involved in tumor development and progression	ONCOGENE			English	Review						endometrial carcinoma; genetics; microsatellite instability; molecular alterations; beta-catenin; apoptosis; chromosomal instability	GENE-EXPRESSION PROFILES; DIFFERENT HISTOLOGIC TYPES; FOLATE BINDING-PROTEIN; MIXED MULLERIAN TUMORS; K-RAS MUTATIONS; MICROSATELLITE INSTABILITY; BETA-CATENIN; MICROARRAY ANALYSIS; MATRIX METALLOPROTEINASE-2; PROMOTER HYPERMETHYLATION	In the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence has been estimated at 10-20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I, endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue deleted on chromosome 70, PIK3CA, K-RAS and CTNNB1 (beta-catenin), and type II exhibiting TP53 mutations and chromosomal instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors. Oncogene (2013) 32, 403-413; doi: 10.1038/onc.2012.76; published online 19 March 2012	[Yeramian, A.; Dolcet, X.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Dept Pathol & Mol Genet, IRBLLEIDA, Lleida, Spain; [Yeramian, A.; Dolcet, X.; Matias-Guiu, X.] Univ Lleida, Hosp Univ Arnau de Vilanova, Res Lab, IRBLLEIDA, Lleida, Spain; [Moreno-Bueno, G.] UAM, CSIC UAM, IdiPAZ Inst Invest Sanitaria La Paz, Inst Invest Biomed Alberto Sols,Dept Bioquim, Madrid, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Canc Ctr, Madrid, Spain; [Catasus, L.; Prat, J.] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Inst Invest Biorned IBB SantPau, Dept Pathol, Barcelona, Spain; [Abal, M.] Complejo Hosp Santiago de Compostela, Oncol Res Lab, Santiago De Compostela, Spain; [Colas, E.; Reventos, J.] Vail dHebron Res Inst, Biomed Res Unit, Barcelona, Spain; [Colas, E.; Reventos, J.] Univ Hosp, Barcelona, Spain; [Palacios, J.] Hosp Univ Virgen del Rocio, Dept Pathol, Seville, Spain; [Palacios, J.] Inst Biomed Sevilla IBIS, Seville, Spain	Universitat de Lleida; University Hospital Arnau de Vilanova; Universitat de Lleida; University Hospital Arnau de Vilanova; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Texas System; UTMD Anderson Cancer Center; Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau; Complexo Hospitalario Universitario de Santiago de Compostela; University of Barcelona; Hospital Clinic de Barcelona; Virgen del Rocio University Hospital; Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS)	Matias-Guiu, X (corresponding author), Hosp Arnau Vilanova, Dept Pathol & Mol Genet, Ave Alcalde Rovira Roure 80, Lleida 25198, Spain.	xmatias@arnau.scs.es	Moreno-Bueno, Gema/K-9354-2016; Palacios, Jose/AAV-3765-2020; Prat, Jaime/G-4679-2011; matias-guiu, xavier/C-3039-2009; Catasus, Lluis/K-4620-2013; Catasus, Luis/G-6811-2011; Dolcet, Xavi/B-5665-2009; Yeramian, Andree/P-6724-2019; yeramian, andree/B-5936-2009	Moreno-Bueno, Gema/0000-0002-5030-6687; matias-guiu, xavier/0000-0002-7201-6605; Catasus, Lluis/0000-0001-6075-6238; Dolcet, Xavi/0000-0003-1921-0449; yeramian, andree/0000-0002-9569-6316; Abal Posada, Miguel/0000-0003-3533-7781	FIS [PI100922, PI080410, 2009SGR794, RD06/0020/1034, RD06/0020/0013, RD06/0020/0058, RD06/0020/0015]; Fundacion Mutua Madrilena [AP75732010]; Fundacion Asociacion Espanola contra el Cancer; programa de intensificacion de Is investigacion, Instituto Carlos III; Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion [JCI-2008-1969]	FIS(Instituto de Salud Carlos III); Fundacion Mutua Madrilena(Instituto de Salud Carlos III); Fundacion Asociacion Espanola contra el Cancer; programa de intensificacion de Is investigacion, Instituto Carlos III; Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This work was supported by grants from FIS PI100922, Fundacion Mutua Madrilena AP75732010, FIS PI080410, 2009SGR794, RD06/0020/1034, RD06/0020/0013, RD06/0020/0058, RD06/0020/0015, Fundacion Asociacion Espanola contra el Cancer and programa de intensificacion de Is investigacion, Instituto Carlos III. AY holds a postdoctoral fellowship from Programa Juan de la Cierva, Ministerio de Ciencia e Innovacion (JCI-2008-1969).	Allard JE, 2007, GYNECOL ONCOL, V107, P52, DOI 10.1016/j.ygyno.2007.05.018; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Bignotti E, 2008, BRIT J CANCER, V99, P768, DOI 10.1038/sj.bjc.6604546; Blechschmidt K, 2007, DIAGN MOL PATHOL, V16, P222, DOI 10.1097/PDM.0b013e31806219ae; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Bussaglia E, 2000, HUM PATHOL, V31, P312, DOI 10.1016/S0046-8177(00)80244-0; Cao QJ, 2004, INT J GYNECOL PATHOL, V23, P321, DOI 10.1097/01.pgp.0000139646.32997.3a; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.0.CO;2-I; Catasus L, 1998, LAB INVEST, V78, P1439; Catasus L, 1998, HUM PATHOL, V29, P1160, DOI 10.1016/S0046-8177(98)90430-0; Catasus L, 2008, MODERN PATHOL, V21, P131, DOI 10.1038/modpathol.3800992; Catasus L, 2010, MODERN PATHOL, V23, P694, DOI 10.1038/modpathol.2010.44; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Chen YH, 2011, EXP MOL PATHOL, V91, P373, DOI 10.1016/j.yexmp.2011.04.005; Dainty LA, 2007, GYNECOL ONCOL, V105, P563, DOI 10.1016/j.ygyno.2006.10.063; Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538; Dolcet X, 2005, LAB INVEST, V85, P885, DOI 10.1038/labinvest.3700286; Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Espinosa I, 2010, AM J SURG PATHOL, V34, P1708, DOI 10.1097/PAS.0b013e3181f32168; Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2; Fukuchi T, 1998, CANCER RES, V58, P3526; Gatius S, 2011, MODERN PATHOL, V24, P1500, DOI 10.1038/modpathol.2011.110; Guan B, 2011, AM J SURG PATHOL, V35, P625, DOI 10.1097/PAS.0b013e318212782a; Hayes MP, 2010, GYNECOL ONCOL, V116, P286, DOI 10.1016/j.ygyno.2009.11.012; Hayes MP, 2009, GYNECOL ONCOL, V113, P370, DOI 10.1016/j.ygyno.2008.12.021; Huvila J, 2009, INT J GYNECOL CANCER, V19, P1226, DOI 10.1111/IGC.0b013e3181b33be0; Kobayashi K, 1999, JPN J CANCER RES, V90, P55, DOI 10.1111/j.1349-7006.1999.tb00665.x; KOBAYASHI K, 1995, GENE CHROMOSOME CANC, V14, P128, DOI 10.1002/gcc.2870140207; Lagarda H, 2001, J PATHOL, V193, P193, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; Llaurado M, 2012, INT J CANCER, V130, P1532, DOI 10.1002/ijc.26148; Llobet D, 2008, ONCOGENE, V27, P2513, DOI 10.1038/sj.onc.1210924; Llobet D, 2010, EUR J CANCER, V46, P836, DOI 10.1016/j.ejca.2009.12.025; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; Llobet D, 2011, AM J PATHOL, V178, P1529, DOI 10.1016/j.ajpath.2010.12.041; Lopez-Garcia MA, 2010, SEMIN DIAGN PATHOL, V27, P274, DOI 10.1053/j.semdp.2010.09.005; Machin P, 2002, HUM PATHOL, V33, P206, DOI 10.1053/hupa.2002.30723; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Matias-Guiu X, 2010, SEMIN DIAGN PATHOL, V27, P197, DOI 10.1053/j.semdp.2010.08.001; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; McCluggage WG, 2002, INT J GYNECOL CANCER, V12, P687, DOI 10.1046/j.1525-1438.2002.01151.x; Milam MR, 2007, AM J OBSTET GYNECOL, V196, P247, DOI 10.1016/j.ajog.2006.10.872; Monge M, 2007, CANCER RES, V67, P6753, DOI 10.1158/0008-5472.CAN-06-4487; Monge M, 2009, J PROTEOME RES, V8, P4676, DOI 10.1021/pr900390t; Montserrat N, 2012, HUM PATHOL, V43, P632, DOI 10.1016/j.humpath.2011.06.021; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Moreno-Bueno G, 2002, ONCOGENE, V21, P7981, DOI 10.1038/sj.onc.1205924; Moreno-Bueno G, 2006, CLIN CANCER RES, V12, P3865, DOI 10.1158/1078-0432.CCR-06-0284; Morrison C, 2006, J CLIN ONCOL, V24, P2376, DOI 10.1200/JCO.2005.03.4827; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagase S, 1996, BRIT J CANCER, V74, P1979, DOI 10.1038/bjc.1996.663; Oda K, 2005, CANCER RES, V65, P10669, DOI 10.1158/0008-5472.CAN-05-2620; Palacios J, 2001, VIRCHOWS ARCH, V193, P193; Pallares J, 2004, J PATHOL, V204, P569, DOI 10.1002/path.1666; Pallares J, 2008, MODERN PATHOL, V21, P691, DOI 10.1038/modpathol.2008.38; Pallares J, 2009, AM J PATHOL, V174, P287, DOI 10.2353/ajpath.2009.080552; Pijnenborg JMA, 2006, GYNECOL ONCOL, V100, P397, DOI 10.1016/j.ygyno.2005.09.056; Pijnenborg JMA, 2005, J PATHOL, V205, P597, DOI 10.1002/path.1738; Pijnenborg JMA, 2004, INT J GYNECOL CANCER, V14, P947, DOI 10.1111/j.1048-891X.2004.014534.x; Pijnenborg JMA, 2004, GYNECOL ONCOL, V94, P550, DOI 10.1016/j.ygyno.2004.05.020; Planaguma J, 2004, CANCER RES, V64, P8846, DOI 10.1158/0008-5472.CAN-04-2066; Planaguma J, 2011, HUM PATHOL, V42, P57, DOI 10.1016/j.humpath.2010.01.025; Pollock PM, 2007, ONCOGENE, V26, P7158, DOI 10.1038/sj.onc.1210529; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Risinger JI, 2003, CANCER RES, V63, P6; RISINGER JI, 1993, CANCER RES, V53, P5100; Romero-Perez L, HMGA2 EPITHELI UNPUB; Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540; Santacana M, 2012, HISTOPATHOLOGY, V60, P460, DOI 10.1111/j.1365-2559.2011.04106.x; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shedden KA, 2005, CLIN CANCER RES, V11, P2123, DOI 10.1158/1078-0432.CCR-04-2061; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SHERMAN ME, 1995, HUM PATHOL, V26, P1268, DOI 10.1016/0046-8177(95)90204-X; Soslow RA, 2010, SEMIN DIAGN PATHOL, V27, P261, DOI 10.1053/j.semdp.2010.09.003; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Tashiro H, 1997, AM J PATHOL, V150, P177; Tashiro H, 1997, CANCER RES, V57, P3935; Tritz D, 1997, HUM PATHOL, V28, P607, DOI 10.1016/S0046-8177(97)90084-8; Urick ME, 2011, CANCER RES, V71, P4061, DOI 10.1158/0008-5472.CAN-11-0549; Velasco A, 2006, HUM PATHOL, V37, P1465, DOI 10.1016/j.humpath.2006.05.007; Velasco A, 2011, HUM PATHOL, V42, P185, DOI 10.1016/j.humpath.2010.08.001; Wiegand KC, 2011, J PATHOL, V224, P328, DOI 10.1002/path.2911; Yao YY, 2010, INT J GYNECOL OBSTET, V110, P125, DOI 10.1016/j.ijgo.2010.03.020; Yeramian A, 2011, LAB INVEST, V91, P859, DOI 10.1038/labinvest.2011.58	87	122	129	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2013	32	4					403	413		10.1038/onc.2012.76	http://dx.doi.org/10.1038/onc.2012.76			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	098LR	22430211	Green Published			2022-12-17	WOS:000315551300001
J	Sreekanth, CN; Bava, SV; Sreekumar, E; Anto, RJ				Sreekanth, C. N.; Bava, S. V.; Sreekumar, E.; Anto, R. J.			Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer	ONCOGENE			English	Article						chemical carcinogenesis; survival factors; xenograft tumors; natural products; chemosensitization; apoptosis	FACTOR-KAPPA-B; TAXOL-INDUCED APOPTOSIS; MULTIDRUG-RESISTANCE; TRANSCRIPTION FACTOR; OVARIAN-CANCER; DOWN-REGULATION; UTERINE CERVIX; P-GLYCOPROTEIN; BREAST-CANCER; CONSTITUTIVE ACTIVATION	The microtubule-targeting antineoplastic agent, paclitaxel, is highly efficacious against a wide spectrum of human cancers. However, dose-limiting toxicity and development of drug resistance limit its clinical application. Development of novel strategies that overcome chemoresistance and sensitize cancer cells to paclitaxel can enhance the therapeutic effect of this drug. We have previously shown that curcumin, a natural polyphenol, enhances paclitaxel-induced cytotoxicity in vitro through downregulation of nuclear factor (NF)-kappa B and Akt pathways. This study was undertaken to determine whether this synergism exists in vivo and to elucidate the underlying molecular mechanisms. Mouse cervical multistage squamous cell carcinoma model using 3-methylcholanthrene (3-MC) and a xenograft model of human cervical cancer in nonobese diabetic severe combined immunodeficient ( NOD-SCID) mice using HeLa cells were used to evaluate the synergism. We observed that the combined treatment of curcumin and paclitaxel induced a synergestic reduction in the tumor incidence as well as tumor volume of animals compared with the individual treatments of paclitaxel or curcumin, although curcumin alone could not induce any significant effect at the concentration used. The results suggest that a suboptimal concentration of curcumin augments the antitumor action of paclitaxel by down-regulating the activation and downstream signaling of antiapoptotic factors and survival signals such as NF-kappa B, Akt and mitogen-activated protein kinases that have significant roles in proliferation, survival, angiogenesis and metastasis. This study revealed for the first time that 3-MC-induced tumorigenesis in mice is associated with a strong constitutive activation of NF-kappa B activity. Furthermore, we also observed that pre-exposure of carcinoma cells isolated from 3-MC-induced tumors to curcumin potentiates paclitaxel-induced apoptosis. Overall, the findings of this preclinical study provide a strong rationale for the validation of this combination through clinical trials. As curcumin could effectively downregulate all these survival signals induced by paclitaxel, we suggest it as a potent chemosensitizer to improve the therapeutic index of paclitaxel. Oncogene (2011) 30, 3139-3152; doi:10.1038/onc.2011.23; published online 14 February 2011	[Sreekanth, C. N.; Bava, S. V.; Anto, R. J.] Rajiv Gandhi Ctr Biotechnol, Div Canc Res, Integrated Canc Res Program, Thiruvananthapuram 695014, Kerala, India; [Sreekumar, E.] Rajiv Gandhi Ctr Biotechnol, Mol Virol Lab, Thiruvananthapuram, Kerala, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB)	Anto, RJ (corresponding author), Rajiv Gandhi Ctr Biotechnol, Div Canc Res, Integrated Canc Res Program, Thycaud PO, Thiruvananthapuram 695014, Kerala, India.	rjanto@rgcb.res.in	Narayanapillai, Sreekanth Chanickal/AAQ-4442-2020		Department of Biotechnology, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	This work was supported by the Department of Biotechnology, Government of India. We thank Dr Marie Lue Antony, Dr TR Santhoshkumar and Arun Kumar T Thulasidasan for technical advice and help and Dr Thara Somanathan for verifying the histopathology data.	Aggarwal BB, 2005, CLIN CANCER RES, V11, P7490, DOI 10.1158/1078-0432.CCR-05-1192; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal BB, 2007, MOL TARGETS THERAPEU; Aggarwal S, 2006, MOL PHARMACOL, V69, P195, DOI 10.1124/mol.105.017400; Ahn KS, 2007, CURR MOL MED, V7, P619, DOI 10.2174/156652407782564363; Ahn KS, 2008, BIOCHEM PHARMACOL, V75, P907, DOI 10.1016/j.bcp.2007.10.010; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Anuchapreeda S, 2002, BIOCHEM PHARMACOL, V64, P573, DOI 10.1016/S0006-2952(02)01224-8; Banerjee S, 2002, CANCER RES, V62, P4945; Bava SV, 2011, INT J BIOCHEM CELL B, V43, P331, DOI 10.1016/j.biocel.2010.09.011; Bava SV, 2005, J BIOL CHEM, V280, P6301, DOI 10.1074/jbc.M410647200; Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Brake T, 2005, P NATL ACAD SCI USA, V102, P2490, DOI 10.1073/pnas.0409883102; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chang YF, 1996, CANCER, V77, P14, DOI 10.1002/(SICI)1097-0142(19960101)77:1<14::AID-CNCR4>3.0.CO;2-N; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; CHHABRA SK, 1995, ONCOLOGY, V52, P32; Choi BH, 2008, CANCER LETT, V259, P111, DOI 10.1016/j.canlet.2007.10.003; Gagnon V, 2008, APOPTOSIS, V13, P259, DOI 10.1007/s10495-007-0165-6; Ganta S, 2009, MOL PHARMACEUT, V6, P928, DOI 10.1021/mp800240j; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; Hokeness K, 2005, ONCOL REP, V13, P965; Hou XL, 2008, INT J PHARM, V358, P224, DOI 10.1016/j.ijpharm.2008.03.010; HUSSAIN SP, 1991, CANCER LETT, V56, P231, DOI 10.1016/0304-3835(91)90007-5; Inoue M, 2008, INT J CANCER, V123, P2696, DOI 10.1002/ijc.23867; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kim SH, 2007, ANN NY ACAD SCI, V1095, P82, DOI 10.1196/annals.1397.012; Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009; Kuo HC, 2006, TOXICOL APPL PHARM, V210, P55, DOI 10.1016/j.taap.2005.06.020; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; Kutuk O, 2008, CANCER RES, V68, P7985, DOI 10.1158/0008-5472.CAN-08-1418; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Leland GD, 2002, CULTURE EPITHELIAL C, Vsecond, P277; Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300; Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Logan RM, 2007, ORAL ONCOL, V43, P395, DOI 10.1016/j.oraloncology.2006.04.011; Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200; Marupudi NI, 2007, EXPERT OPIN DRUG SAF, V6, P609, DOI 10.1517/14740338.6.5.609; MURPHY ED, 1961, JNCI-J NATL CANCER I, V27, P611; Nair A, 2003, ONCOGENE, V22, P50, DOI 10.1038/sj.onc.1206043; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Narayanan NK, 2009, INT J CANCER, V125, P1, DOI 10.1002/ijc.24336; Prasad S, 2010, MOL CELL BIOCHEM, V336, P25, DOI 10.1007/s11010-009-0267-2; Reuter S, 2008, BIOCHEM PHARMACOL, V76, P1340, DOI 10.1016/j.bcp.2008.07.031; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Saunders DE, 1997, INT J CANCER, V70, P214, DOI 10.1002/(SICI)1097-0215(19970117)70:2<214::AID-IJC13>3.0.CO;2-I; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sumitomo M, 1999, J UROLOGY, V161, P674, DOI 10.1016/S0022-5347(01)61993-1; Sur I, 2008, INT REV IMMUNOL, V27, P205, DOI 10.1080/08830180802130319; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tang XM, 2006, CANCER, V107, P2637, DOI 10.1002/cncr.22315; Thevenod F, 2000, J BIOL CHEM, V275, P1887, DOI 10.1074/jbc.275.3.1887; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yagi H, 2009, INT J CANCER, V124, P1429, DOI 10.1002/ijc.24031; Yusuf RZ, 2003, CURR CANCER DRUG TAR, V3, P1, DOI 10.2174/1568009033333754; Zhang ZF, 2006, ANN THORAC SURG, V82, P243, DOI 10.1016/j.athoracsur.2006.01.049; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	65	122	126	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	28					3139	3152		10.1038/onc.2011.23	http://dx.doi.org/10.1038/onc.2011.23			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	792FQ	21317920				2022-12-17	WOS:000292726300003
J	Majeti, R				Majeti, R.			Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells	ONCOGENE			English	Review						acute myeloid leukemia; cancer stem cells; monoclonal antibodies	ACUTE MYELOGENOUS LEUKEMIA; LECTIN-LIKE MOLECULE-1; RECEPTOR-ALPHA CHAIN; ABILITY IN-VITRO; INTERLEUKIN-3 RECEPTOR; PROGENITOR CELLS; GEMTUZUMAB OZOGAMICIN; IMMUNODEFICIENT MICE; RESIDUAL DISEASE; INITIATING CELLS	Accumulating evidence indicates that many human cancers are organized as a cellular hierarchy initiated and maintained by self-renewing cancer stem cells. This cancer stem cell model has been most conclusively established for human acute myeloid leukemia (AML), although controversies still exist regarding the identity of human AML stem cells (leukemia stem cell (LSC)). A major implication of this model is that, in order to eradicate the cancer and cure the patient, the cancer stem cells must be eliminated. Monoclonal antibodies have emerged as effective targeted therapies for the treatment of a number of human malignancies and, given their target antigen specificity and generally minimal toxicity, are well positioned as cancer stem cell-targeting therapies. One strategy for the development of monoclonal antibodies targeting human AML stem cells involves first identifying cell surface antigens preferentially expressed on AML LSC compared with normal hematopoietic stem cells. In recent years, a number of such antigens have been identified, including CD123, CD44, CLL-1, CD96, CD47, CD32, and CD25. Moreover, monoclonal antibodies targeting CD44, CD123, and CD47 have demonstrated efficacy against AML LSC in xenotransplantation models. Hopefully, these antibodies will ultimately prove to be effective in the treatment of human AML. Oncogene (2011) 30, 1009-1019; doi:10.1038/onc.2010.511; published online 15 November 2010	[Majeti, R.] Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Div Hematol,Dept Internal Med,Canc Ctr, Stanford, CA 94305 USA; [Majeti, R.] Stanford Univ, Sch Med, Inst Stem Cell Biol & Regenerat Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Majeti, R (corresponding author), Stanford Univ, Sch Med, Stanford Inst Stem Cell Biol & Regenerat Med, Div Hematol,Dept Internal Med,Canc Ctr, 265 Campus Dr,G3021B, Stanford, CA 94305 USA.	rmajeti@stanford.edu		Majeti, Ravindra/0000-0002-5814-0984	American Association for Cancer Research; Burroughs Wellcome Fund	American Association for Cancer Research; Burroughs Wellcome Fund(Burroughs Wellcome Fund)	I would like to acknowledge Mark Chao and Max Jan for critical review of the manuscript and Irv Weissman for support and mentorship. This work was supported in part by a grant from the American Association for Cancer Research. RM holds a Career Award for Medical Scientists from the Burroughs Wellcome Fund. RM has filed the US Patent Application Serial No. 12/321,215 entitled 'Methods For Manipulating Phagocytosis Mediated by CD47'.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; Ailles LE, 1997, BLOOD, V90, P2555, DOI 10.1182/blood.V90.7.2555.2555_2555_2564; Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Bakker ABH, 2004, CANCER RES, V64, P8443, DOI 10.1158/0008-5472.CAN-04-1659; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Blair A, 1998, BLOOD, V92, P4325, DOI 10.1182/blood.V92.11.4325; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Burnett AK, 2006, SEMIN HEMATOL, V43, P96, DOI 10.1053/j.seminhematol.2006.01.003; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Charrad RS, 1999, NAT MED, V5, P669, DOI 10.1038/9518; Cheson BD, 2008, NEW ENGL J MED, V359, P613, DOI 10.1056/NEJMra0708875; CRAIG W, 1993, J EXP MED, V177, P1331, DOI 10.1084/jem.177.5.1331; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dick JE, 2008, BLOOD, V112, P4793, DOI 10.1182/blood-2008-08-077941; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Florian S, 2006, LEUKEMIA LYMPHOMA, V47, P207, DOI 10.1080/10428190500272507; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Gramatzki M, 1998, EXP HEMATOL, V26, P1209; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046; Jawad M, 2010, LEUKEMIA, V24, P74, DOI 10.1038/leu.2009.199; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Levis M, 2005, BLOOD, V106, P673, DOI 10.1182/blood-2004-05-1902; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2007, CELL STEM CELL, V1, P635, DOI 10.1016/j.stem.2007.10.001; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; MURRAY L, 1995, BLOOD, V85, P368; Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Roberts A. W., 2008, BLOOD, V112, p2956a; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Stasi R, 2008, CANCER TREAT REV, V34, P49, DOI 10.1016/j.ctrv.2007.09.001; Subramanian S, 2006, BLOOD, V107, P2548, DOI 10.1182/blood-2005-04-1463; Takenaka K, 2007, NAT IMMUNOL, V8, P1313, DOI 10.1038/ni1527; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Terwijn M, 2009, EUR J CANCER, V45, P1692, DOI 10.1016/j.ejca.2009.02.021; Testa U, 2004, LEUKEMIA, V18, P219, DOI 10.1038/sj.leu.2403224; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; Vardiman JW, 2009, BLOOD, V114, P937, DOI 10.1182/blood-2009-03-209262; WANG PL, 1992, J IMMUNOL, V148, P2600; Yalcintepe L, 2006, BLOOD, V108, P3530, DOI 10.1182/blood-2006-04-013813; Zhao XX, 2010, HAEMATOL-HEMATOL J, V95, P71, DOI 10.3324/haematol.2009.009811	66	122	138	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	9					1009	1019		10.1038/onc.2010.511	http://dx.doi.org/10.1038/onc.2010.511			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	729PX	21076471				2022-12-17	WOS:000287964100001
J	Pursiheimo, JP; Rantanen, K; Heikkinen, PT; Johansen, T; Jaakkola, PM				Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Johansen, T.; Jaakkola, P. M.			Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62	ONCOGENE			English	Article						ATG8; autophagy; HIF; prolyl hydroxylase; pVHL; sequestosome 1	SIGNALING ADAPTER P62; UNFOLDED PROTEIN RESPONSE; PROLINE HYDROXYLATION; IMPORTANT MEDIATOR; BODY FORMATION; CANCER-CELLS; HIF-ALPHA; DISEASE; INHIBITION; INCLUSIONS	Sequestosome 1 (SQSTM1/p62) is a multifunctional protein involved in signal transduction, protein degradation and cell transformation. Hypoxia is a common feature of solid tumours that promotes cancer progression. Here, we report that p62 is downregulated in hypoxia in carcinoma cells and that the expression is rapidly restored in response to reoxygenation. The hypoxic p62 down-regulation did not occur at the mRNA level and was independent of the hypoxic signal mediators hypoxia-inducible factor (HIF) and von Hippel-Lindau tumour suppressor protein as well as the activity of HIF-prolyl hydroxylases and was not mediated by proteosomal destruction. Autophagy was activated in hypoxia and was required for p62 degradation. The hypoxic degradation of p62 was blocked by autophagy inhibitors as well as by the attenuation of Atg8/LC3 expression. Downregulation of p62 was required for hypoxic extracellular regulated kinase (ERK)-1/2 phosphorylation. Attenuation of p62 in normoxia activated and forced expression of p62 in hypoxia blocked the activation of ERK-1/2. The results demonstrate that hypoxic activation of autophagy induces clearance of p62 protein and implies a role for p62 in the regulation of hypoxic cancer cell survival responses.	[Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Jaakkola, P. M.] Univ Turku, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Pursiheimo, J-P; Rantanen, K.; Heikkinen, P. T.; Jaakkola, P. M.] Abo Akad Univ, Turku, Finland; [Johansen, T.] Univ Tromso, Inst Med Biol, Dept Biochem, Tromso, Norway; [Jaakkola, P. M.] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; UiT The Arctic University of Tromso; University of Turku	Jaakkola, PM (corresponding author), Univ Turku, Turku Ctr Biotechnol, Tykistokatu 6B, FIN-20520 Turku, Finland.	panjaa@utu.fi	Jaakkola, Panu M/B-4355-2012; Johansen, Terje/AAY-1753-2021; Johansen, Terje/N-2971-2015	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Jaakkola, Panu/0000-0002-2365-4985	Academy of Finland [200779, 210282, 8109024]; Emil Aaltonen Foundation; Sigrid Juselius Foundation; Norwegian Research Council (FUGE); Norwegian Cancer Society	Academy of Finland(Academy of Finland); Emil Aaltonen Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Norwegian Research Council (FUGE)(Research Council of Norway); Norwegian Cancer Society(Norwegian Cancer Society)	Taina Kalevo-Mattila is acknowledged for expert technical assistance. The study was supported by The Academy of Finland (grants 200779, 210282 and 8109024), Emil Aaltonen Foundation and Sigrid Juselius Foundation to PMJ, and by grants from the Norwegian Research Council (FUGE) and Norwegian Cancer Society to TJ. PMJ is a research fellow of the Finnish Cancer Institute.	Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; EKSTROM P, 1984, J NEUROCHEM, V43, P1342, DOI 10.1111/j.1471-4159.1984.tb05392.x; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Geetha T, 2005, MOL CELL, V20, P301, DOI 10.1016/j.molcel.2005.09.014; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jokilehto T, 2006, CLIN CANCER RES, V12, P1080, DOI 10.1158/1078-0432.CCR-05-2022; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Koumenis C, 2006, MOL CANCER RES, V4, P423, DOI 10.1158/1541-7786.MCR-06-0150; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; Kuusisto E, 2001, BIOCHEM BIOPH RES CO, V280, P223, DOI 10.1006/bbrc.2000.4107; Kwon DS, 2006, EUR J CELL BIOL, V85, P1189, DOI 10.1016/j.ejcb.2006.06.001; Lamark T, 2003, J BIOL CHEM, V278, P34568, DOI 10.1074/jbc.M303221200; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lim JH, 2006, MOL PHARMACOL, V70, P1856, DOI 10.1124/mol.106.028076; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Martin P, 2006, EMBO J, V25, P3524, DOI 10.1038/sj.emboj.7601250; Masson N, 2004, FEBS LETT, V570, P166, DOI 10.1016/j.febslet.2004.06.040; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Nakaso K, 2004, BRAIN RES, V1012, P42, DOI 10.1016/j.brainres.2004.03.029; Paludan C, 2005, SCIENCE, V307, P593, DOI 10.1126/science.1104904; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rodriguez A, 2006, CELL METAB, V3, P211, DOI 10.1016/j.cmet.2006.01.011; Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325; Thuerauf DJ, 2006, CIRC RES, V99, P275, DOI 10.1161/01.RES.0000233317.70421.03; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Wooten MW, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/62079; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Zatloukal K, 2002, AM J PATHOL, V160, P255, DOI 10.1016/S0002-9440(10)64369-6; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200	45	122	123	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2009	28	3					334	344		10.1038/onc.2008.392	http://dx.doi.org/10.1038/onc.2008.392			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395UZ	18931699				2022-12-17	WOS:000262550300003
J	Dow, LE; Elsum, IA; King, CL; Kinross, KM; Richardson, HE; Humbert, PO				Dow, L. E.; Elsum, I. A.; King, C. L.; Kinross, K. M.; Richardson, H. E.; Humbert, P. O.			Loss of human Scribble cooperates with H-Ras to promote cell invasion through deregulation of MAPK signalling	ONCOGENE			English	Article						scribble; invasion; cancer; Ras	BREAST EPITHELIAL-CELLS; LARGE TUMOR-SUPPRESSOR; PROTEASOME-MEDIATED DEGRADATION; PAPILLOMAVIRUS E6 PROTEINS; EPIDERMAL-GROWTH-FACTOR; DISCS-LARGE; TGF-BETA; MALIGNANT PROGRESSION; ONCOGENIC RAS; CYCLE ARREST	Activating mutations in genes of the Ras-mitogen-activated protein kinase (MAPK) pathway occur in approximately 30% of all human cancers; however, mutation of Ras alone is rarely sufficient to induce tumour development. Scribble is a polarity regulator recently isolated from a Drosophila screen for events that cooperate with Ras mutation to promote tumour progression and cell invasion. In mammals, Scribble regulates directed cell migration and wound healing in vivo; however, no role has been identified for mammalian Scribble in oncogenic transformation. Here we show that in human epithelial cells expressing oncogenic Ras or Raf, loss of Scribble promotes invasion of cells through extracellular matrix in an organotypic culture system. Further, we show that the mechanism by which this occurs is in the regulation of MAPK signalling by Scribble. The suppression of MAPK signalling is a highly conserved function of Scribble as it also prevents Raf-mediated defects in Drosophila wing development. Our data identify Scribble as an important mediator of MAPK signalling and provide a molecular basis for the observation that Scribble expression is decreased in many invasive human cancers.	[Dow, L. E.; Elsum, I. A.; King, C. L.; Kinross, K. M.; Humbert, P. O.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 8006, Australia; [Richardson, H. E.] Peter MacCallum Canc Ctr, Div Res, Cell Cycle & Dev Labs, Melbourne, Vic 8006, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Div Res, Locked Bag 1,A'Beckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Richardson, Helena E/A-8080-2013; Humbert, Patrick O/L-4264-2016	Richardson, Helena E/0000-0003-3852-4953; Humbert, Patrick O/0000-0002-1366-6691; Elsum, Imogen/0000-0003-4525-0727; Dow, Lukas/0000-0001-7048-1418				Abdelilah-Seyfried S, 2003, DEVELOPMENT, V130, P1927, DOI 10.1242/dev.00420; AGUILARCORDOVA E, 1991, ONCOGENE, V6, P1601; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dow LE, 2007, ONCOGENE, V26, P5692, DOI 10.1038/sj.onc.1210639; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Dow LE, 2007, INT REV CYTOL, V262, P253, DOI 10.1016/S0074-7696(07)62006-3; Frese KK, 2006, EMBO J, V25, P1406, DOI 10.1038/sj.emboj.7601030; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Giunciuglio D, 1995, INT J CANCER, V63, P815, DOI 10.1002/ijc.2910630612; Goode S, 1997, GENE DEV, V11, P2532, DOI 10.1101/gad.11.19.2532; Humbert PO, 2006, TRENDS CELL BIOL, V16, P622, DOI 10.1016/j.tcb.2006.10.005; Joiakim A, 2003, DRUG METAB DISPOS, V31, P1279, DOI 10.1124/dmd.31.11.1279; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim ES, 2004, INT J ONCOL, V25, P1375; Kim MS, 2003, CANCER RES, V63, P5454; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; McLachlan RW, 2007, J MOL MED-JMM, V85, P545, DOI 10.1007/s00109-007-0198-x; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Park JI, 2003, ONCOGENE, V22, P4314, DOI 10.1038/sj.onc.1206478; Pegtel DM, 2007, CURR BIOL, V17, P1623, DOI 10.1016/j.cub.2007.08.035; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Schreiber K, 2004, ONCOGENE, V23, P3972, DOI 10.1038/sj.onc.1207507; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Seton-Rogers SE, 2004, CELL CYCLE, V3, P597, DOI 10.4161/cc.3.5.886; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Settle M, 2003, ONCOGENE, V22, P1916, DOI 10.1038/sj.onc.1206240; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STOREY A, 1993, ONCOGENE, V8, P919; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Woodhouse E, 1998, DEV GENES EVOL, V207, P542, DOI 10.1007/s004270050145; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Woodworth CD, 2000, CANCER RES, V60, P4397; Yin GY, 2004, MOL CELL BIOL, V24, P875, DOI 10.1128/MCB.24.2.875-885.2004; Zhang HY, 2006, NAT CELL BIOL, V8, P227, DOI 10.1038/ncb1368	59	122	126	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 9	2008	27	46					5988	6001		10.1038/onc.2008.219	http://dx.doi.org/10.1038/onc.2008.219			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	358BO	18641685	Green Accepted			2022-12-17	WOS:000259891600002
J	Uttamsingh, S; Bao, X; Nguyen, KT; Bhanot, M; Gong, J; Chan, JK; Liu, F; Chu, TT; Wang, LH				Uttamsingh, S.; Bao, X.; Nguyen, K. T.; Bhanot, M.; Gong, J.; Chan, JL-K; Liu, F.; Chu, T. T.; Wang, L-H			Synergistic effect between EGF and TGF-beta 1 in inducing oncogenic properties of intestinal epithelial cells	ONCOGENE			English	Article						EGF; TGF-beta 1; EMT; invasion; colony formation	GROWTH-FACTOR-BETA; ANCHORAGE-INDEPENDENT GROWTH; TRANSCRIPTION FACTOR SNAIL; E-CADHERIN; TGF-BETA; PHOSPHATIDYLINOSITOL 3-KINASE; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; CANCER-CELLS; TRANSFORMATION	Transforming growth factor (TGF)-beta 1 has a biphasic effect on rat intestinal epithelial (RIE) cells. By itself, TGF-beta 1 functions as a tumor suppressor by inhibiting the growth, migration and invasion of RIE cells. We show in this study that in conjunction with epidermal-growth factor (EGF), TGF-beta 1 helped to augment migration, invasion and anchorage-independent growth (AIG) compared to that by EGF alone. EGF plus TGF-beta 1 induced a dramatic morphological change characteristic of epithelial-mesenchymal transition (EMT). The mechanism for this enhanced effect of TGF-beta 1 and EGF on oncogenic properties was explored by analysis of EGF- and TGF-beta 1-mediated signaling pathways and complementary DNA arrays. TGF-beta 1 augmented EGF-mediated signaling of mitogen-activated protein kinase (MAPK) and AKT by enhancing and prolonging the activation of the former and prolonging the activation of the latter. Inhibition of MAPK, but not phosphoinositide-3 kinase (PI3K), abolished TGF-beta 1 plus EGF-induced EMT and down-regulation of E-cadherin at mRNA and protein levels. By contrast, cell migration and invasion were sensitive to inhibition of either MAPK or PI3 kinase. TGF-beta 1 plus EGF-induced AIG was significantly more resistant to inhibition of PI3K and MAPK compared to that induced by EGF alone. EGF and TGF-beta 1 synergistically induced the expression of a series of proteases including matrix metalloproteinase (MMP) 1 (collagenase), MMP3, MMP9, MMP10, MMP14 and cathepsin. Among them, the expression of MMP1, MMP3, MMP9 and MMP10 was MAPK dependent. Inhibition of the MMPs or cathepsin significantly blocked EGF plus TGF-beta 1-induced invasion, but had no effect on colony formation. Phospholipase C (PLC) and Cox2 induced by EGF plus TGF-beta 1 also played a significant role in invasion, whereas PLC was also important for colony formation. Our study reveals specific signaling functions and induction of genes differentially required for enhanced effect of EGF- and TGF-beta 1-induced oncogenic properties, and helps to explain the tumor-promoting effect of TGF-beta 1 in human cancer with elevated expression or activation of TGF-beta 1 and receptor protein tyrosine kinases.	[Uttamsingh, S.; Bao, X.; Nguyen, K. T.; Bhanot, M.; Gong, J.; Chan, JL-K; Wang, L-H] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Liu, F.] Rutgers State Univ, Ernest Mario Sch Pharm, Ctr Adv Biotechnol & Med, Piscataway, NJ USA; [Liu, F.] Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Piscataway, NJ USA; [Chu, T. T.] Mt Sinai Sch Med, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Gong, Jianli/G-1212-2011; Wang, Lu-Hai/E-3986-2010		NATIONAL CANCER INSTITUTE [R01CA055054, R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA29339, CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF1202, DOI 10.1152/ajprenal.00406.2005; GLICK AB, 1994, GENE DEV, V8, P2429, DOI 10.1101/gad.8.20.2429; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Itoh Y, 2002, ESSAYS BIOCHEM, V38, P21, DOI 10.1042/bse0380021; JONG SMJ, 1987, ONCOGENE RES, V1, P7; Kizaka-Kondoh S, 2000, FEBS LETT, V466, P160, DOI 10.1016/S0014-5793(99)01784-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nguyen KT, 2000, ONCOGENE, V19, P5385, DOI 10.1038/sj.onc.1203911; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stolz DB, 1997, J CELL PHYSIOL, V170, P57; Tang BW, 1998, NAT MED, V4, P802, DOI 10.1038/nm0798-802; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang LH, 2004, MT SINAI J MED, V71, P361; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Yan CH, 2007, J CELL PHYSIOL, V211, P19, DOI 10.1002/jcp.20948	28	122	125	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2008	27	18					2626	2634		10.1038/sj.onc.1210915	http://dx.doi.org/10.1038/sj.onc.1210915			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	289LW	17982486				2022-12-17	WOS:000255057000012
J	Yang, MH; Chang, SY; Chiou, SH; Liu, CJ; Chi, CW; Chen, PM; Teng, SC; Wu, KJ				Yang, M-H; Chang, S-Y; Chiou, S-H; Liu, C-J; Chi, C-W; Chen, P-M; Teng, S-C; Wu, K-J			Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer	ONCOGENE			English	Article						head and neck cancer; epithelial-mesenchymal transition; metastasis; NBS1; Snail	TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMAS; DISTANT METASTASES; TUMOR-CELLS; EXPRESSION; INVASION; GENE; INVOLVEMENT; REPRESSOR; COMPLEX	Major causes of head and neck squamous cell carcinoma (HNSCC)-related deaths are cervical node and distant metastasis. We previously demonstrated that overexpression of the DNA double-strand break repair protein Nijmegen breakage syndrome 1 (NBS1) is a prognostic marker of advanced HNSCCs. Epithelial-mesenchymal transition (EMT) was demonstrated to be the major mechanism responsible for mediating invasiveness and metastasis of late-stage cancers. We therefore investigated the role of NBS1 overexpression in mediating EMT and metastasis. NBS1 overexpression was associated with metastasis of HNSCC patients using tissue microarray immunohistochemistry approach. Induction of EMT was observed in an NBS1-overexpressing HNSCC cell line (FADUNBS), whereas short-interference RNA ( siRNA)mediated repression of endogenous NBS1 reversed the shift of EMT markers. Increased migration/invasiveness of FADUNBS was shown by in vitro and in vivo assays. NBS1 overexpression upregulated the expression of an EMT regulator Snail and its downstreamtarget matrix metalloproteinase-2. EMT phenotypes and increased migration/invasiveness of FADUNBS cells were reversed by siRNA-mediated repression of Snail expression or a phosphatidylinositol 3-kinase-specific inhibitor. In HNSCC samples, co-expression of NBS1/Snail in primary tumors correlated with metastasis and the worst prognosis. These results indicate that NBS1 overexpression induces EMT through the upregulation of Snail expression, and coexpression of NBS1/Snail predicts metastasis in HNSCCs.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Vet Gen Hosp, Genom Med Res Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Otolaryngol, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan; Taipei Mackay Mem Hosp, Dept Dent, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pharmacol, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Linong St,Sect 2, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Yang, Muh-Hwa/AAE-4691-2020; Wu, Kou-Juey/P-4654-2015	TENG, SHU-CHUN/0000-0002-6492-2560				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bentz BG, 2000, HEAD NECK-J SCI SPEC, V22, P71, DOI 10.1002/(SICI)1097-0347(200001)22:1<71::AID-HED11>3.0.CO;2-G; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P189, DOI 10.1159/000055738; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; Lu WS, 2004, CANCER LETT, V214, P205, DOI 10.1016/j.canlet.2003.08.012; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; *ROC DEP HLTH EX Y, 2005, CANC REG ANN REP TAI; Sauter ER, 1999, CLIN CANCER RES, V5, P775; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsai HJ, 2006, J BIOL CHEM, V281, P13717, DOI 10.1074/jbc.M600649200; Yang MH, 2006, CLIN CANCER RES, V12, P507, DOI 10.1158/1078-0432.CCR-05-1231; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zhang Y, 2005, CANCER RES, V65, P5544, DOI 10.1158/0008-5472.CAN-04-4368; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	26	122	124	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1459	1467		10.1038/sj.onc.1209929	http://dx.doi.org/10.1038/sj.onc.1209929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936774				2022-12-17	WOS:000244558800010
J	Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED				Shashidhar, S; Lorente, G; Nagavarapu, U; Nelson, A; Kuo, J; Cummins, J; Nikolich, K; Urfer, R; Foehr, ED			GPR56 is a GPCR that is overexpressed in gliomas and functions in tumor cell adhesion	ONCOGENE			English	Article						CPR56; TM7XN1; glioma; adhesion; PAI-1; alpha-actinin	PROTEIN-COUPLED RECEPTORS; ALPHA-LATROTOXIN CIRL; PROTEOLYSIS; INHIBITION; DOMAINS	GPR56 ( also known as TM7XN1) is a newly discovered orphan G-protein-coupled receptor ( GPCR) of the secretin family that has a role in the development of neural progenitor cells and has been linked to developmental malformations of the human brain. GPR56 diverges from other secretin-like family members in that it has an extremely large N-terminal extracellular region (381 amino acids) and contains a novel feature among this new subclass, consisting of four cysteine residues that define a GPCR proteolytic site (GPS motif) located just before the first transmembrane spanning domain. The rest of the amino-terminal domain contains a large number of possible N- and O-linked glycosylation sites similar to mucin-like proteins. These features suggest a role in cell cell, or cell-matrix interactions. Here, we demonstrate upregulation of GPR56 in glioblastoma multiforme tumors using functional genomics. Immunohistochemistry studies confirmed the expression of GPR56 protein in a majority of glioblastoma/astrocytoma tumor samples with undetectable levels of expression in normal adult brain tissue. Immunofluorescence analysis of human glioma cells using anti-GPR56 antibodies demonstrate that GPR56 is expressed on the leading edge of membranefilopodia and colocalizes with alpha-actinin. Purified recombinant GPR56 extracellular domain protein inhibits glioma cell adhesion and causes abnormal cytoskeletal morphology and cell rounding. These results indicate that the extracellular domain may compete for unidentified ligand(s), and block the normal function of GPR56 in cell attachment. In reporter assays, overexpression of GPR56 activates the NF-kappaB, PAI-1 and TCF transcriptional response elements. These pathways have been implicated in cytoskeletal signaling, adhesion and tumor biology. The above results indicate that GPR56 serves as an adhesion GPCR and is involved in adhesion signaling.	AGY Therapeut Inc, San Francisco, CA 94080 USA		Foehr, ED (corresponding author), AGY Therapeut Inc, 270 E Grand Ave, San Francisco, CA 94080 USA.	efoehr@agyinc.com						Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; Berger F, 2004, LANCET ONCOL, V5, P511, DOI 10.1016/S1470-2045(04)01531-1; BERGER M, 1999, GLIOMAS; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fredriksson R, 2002, FEBS LETT, V531, P407, DOI 10.1016/S0014-5793(02)03574-3; Haier J, 2002, CLIN EXP METASTAS, V19, P665, DOI 10.1023/A:1021316531912; Hamann J, 2000, INT IMMUNOL, V12, P439, DOI 10.1093/intimm/12.4.439; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Honda K, 1998, J CELL BIOL, V140, P1383, DOI 10.1083/jcb.140.6.1383; Kierszenbaum AL, 2003, MOL REPROD DEV, V64, P1, DOI 10.1002/mrd.10224; Krasnoperov V, 2002, J BIOL CHEM, V277, P46518, DOI 10.1074/jbc.M206415200; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Muller S, 2003, ONCOGENE, V22, P6661, DOI 10.1038/sj.onc.1206763; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; Singh SK, 2003, CANCER RES, V63, P5821; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Woods AJ, 2002, J BIOL CHEM, V277, P6428, DOI 10.1074/jbc.M109446200; Zendman AJW, 1999, FEBS LETT, V446, P292, DOI 10.1016/S0014-5793(99)00230-6	23	122	127	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1673	1682		10.1038/sj.onc.1208395	http://dx.doi.org/10.1038/sj.onc.1208395			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15674329				2022-12-17	WOS:000227345100003
J	Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H				Zhang, DW; Hirota, T; Marumoto, T; Shimizu, M; Kunitoku, N; Sasayama, T; Arima, Y; Feng, LP; Suzuki, M; Takeya, M; Saya, H			Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models	ONCOGENE			English	Article						Aurora-A; mitosis; mammary gland; p53; Cre-loxP	SPINDLE ASSEMBLY CHECKPOINT; CENTROSOME AMPLIFICATION; TETRAPLOIDY CHECKPOINT; CHROMOSOME SEGREGATION; PROTEIN-KINASE; BREAST-CANCER; APOPTOSIS; CELLS; GENE; P53	Aurora-A, a serine/threonine mitotic kinase, was reported to be overexpressed in various human cancers, and its overexpression induces aneuploidy, centrosome amplification and tumorigenic transformation in cultured human and rodent cells. However, the underlying mechanisms and pathological settings by which Aurora-A promotes tumorigenesis are largely unknown. Here, we created a transgenic mouse model to investigate the involvement of Aurora-A overexpression in the development of mammary glands and tumorigenesis using a Cre-loxP system. The conditional expression of Aurora-A resulted in significantly increased binucleated cell formation and apoptosis in the mammary epithelium. The surviving mammary epithelial cells composed hyperplastic areas after a short latency. Induction of Aurora-A overexpression in mouse embryonic fibroblasts prepared from the transgenic mice also led to aberrant mitosis and binucleated cell formation followed by apoptosis. The levels of p53 protein were remarkably increased in these Aurora-A-overexpressing cells, and the apoptosis was significantly suppressed by deletion of p53. Given that no malignant tumor formation was found in the Aurora-A-overexpressing mouse model after a long latency, additional factors, such as p53 inactivation, are required for the tumorigenesis of Aurora-A-overexpressing mammary epithelium. Our findings indicated that this mouse model is a useful system to study the physiological roles of Aurora-A and the genetic pathways of Aurora-A-induced carcinogenesis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Saitama Med Sch, Dept Pathol, Omiya, Japan; Kumamoto Univ, Inst Resource Dev & Anal, Ctr Anim Resources & Dev, Div Transgen Technol, Kumamoto, Japan; Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Saitama Medical University; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013; Arima, Yoshimi/J-8057-2013	Sasayama, Takashi/0000-0002-5593-9045				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; ARAKI K, 1995, P NATL ACAD SCI USA, V92, P160, DOI 10.1073/pnas.92.1.160; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; FRANCISCO L, 1994, CELL MOL BIOL RES, V40, P207; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; HOGAN B, 1994, MANIPULATING MOUSE E; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li DH, 2003, CLIN CANCER RES, V9, P991; Lund LR, 1996, DEVELOPMENT, V122, P181; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Miyoshi Y, 2001, INT J CANCER, V92, P370, DOI 10.1002/ijc.1200; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Tanaka T, 1999, CANCER RES, V59, P2041; TSUKADA T, 1993, ONCOGENE, V8, P3313; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	122	125	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8720	8730		10.1038/sj.onc.1208153	http://dx.doi.org/10.1038/sj.onc.1208153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15480417				2022-12-17	WOS:000225165100002
J	Bajou, K; Maillard, C; Jost, M; Lijnen, HR; Gils, A; Declerck, P; Carmeliet, P; Foidart, JM; Noel, A				Bajou, K; Maillard, C; Jost, M; Lijnen, HR; Gils, A; Declerck, P; Carmeliet, P; Foidart, JM; Noel, A			Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth	ONCOGENE			English	Article						PAI-1; cancer invasion; tumoral angiogenesis; serine protease; protease inhibitor	BREAST-CANCER; CHOROIDAL NEOVASCULARIZATION; UROKINASE RECEPTOR; CELL-MIGRATION; MOUSE MODEL; SYSTEM; METASTASIS; TYPE-1; MICE; VASCULARIZATION	Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells ( after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.	Univ Liege, CRCE, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Katholieke Univ Leuven, Fac Med, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	University of Liege; KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Noel, A (corresponding author), Univ Liege, CRCE, Lab Tumor & Dev Biol, Tour Pathol B23, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Carmeliet, Peter/AAQ-5140-2020; Lijnen, Roger/AAA-4085-2020; Declerck, Paul J/A-2330-2017	Carmeliet, Peter/0000-0001-7961-1821; Declerck, Paul J/0000-0003-1259-9105; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Almholt K, 2003, ONCOGENE, V22, P4389, DOI 10.1038/sj.onc.1206601; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Curino A, 2002, ONCOGENE, V21, P8830, DOI 10.1038/sj.onc.1205951; Czekay RP, 2003, J CELL BIOL, V160, P781, DOI 10.1083/jcb.200208117; Deng G, 2001, J CELL PHYSIOL, V189, P23, DOI 10.1002/jcp.1133; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Eitzman DT, 1996, BLOOD, V87, P4718; Foekens JA, 2000, CANCER RES, V60, P636; Gutierrez LS, 2000, CANCER RES, V60, P5839; Isogai C, 2001, CANCER RES, V61, P5587; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Lambert V, 2003, INVEST OPHTH VIS SCI, V44, P2791, DOI 10.1167/iovs.02-1179; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lijnen HR, 2004, J THROMB HAEMOST, V2, P16, DOI 10.1111/j.1538-7836.2003.00533.x; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Masson Veronique, 2002, Biological Procedures Online, V4, P24, DOI 10.1251/bpo30; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Stephens RW, 1998, BREAST CANCER RES TR, V52, P99, DOI 10.1023/A:1006115218786	26	122	129	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2004	23	41					6986	6990		10.1038/sj.onc.1207859	http://dx.doi.org/10.1038/sj.onc.1207859			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	852JD	15286708	Green Submitted			2022-12-17	WOS:000223750700015
J	Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A				Asnaghi, L; Calastretti, A; Bevilacqua, A; D'Agnano, I; Gatti, G; Canti, G; Delia, D; Capaccioli, S; Nicolin, A			Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt	ONCOGENE			English	Article						mTOR; BCL-2; microtubules; Akt; p70S6K; apoptosis	P70 S6 KINASE; MAMMALIAN TARGET; CELL-SURVIVAL; RAPAMYCIN; PROTEIN; GROWTH; LIFE; DEATH; INHIBITION; PATHWAY	The serine/threonine kinase mTOR, the major sensor of cell growth along the PI3K/Akt pathway, can be activated by agents acting on microtubules. Damaged microtubules induce phosphorylation of the Bcl-2 protein and lower the threshold of programmed cell death, both of which are inhibited by rapamycin. In HEK293 cells expressing Akt mutants, the level of Bcl-2 phosphorylation and the threshold of apoptosis induced by taxol or by nocodazole are significantly modified. In cells expressing dominant-negative Akt (DN-Akt), Bcl-2 phosphorylation and p70S6K(Thr421/Ser424) phosphorylation induced by taxol or nocodazole were significantly enhanced as compared to cells expressing constitutively active Akt (CA-Akt) and inhibited by rapamycin. Moreover, DN-Akt cells were more sensitive to antitubule agents than CA-Akt cells. In nocodazole-treated HEK293 cells sorted according to cell cycle, the p70S6K(Thr421/Ser424) phosphorylation was associated to the G2/M fraction. More relevant, nocodazole inhibited, in a dose-response manner, mTOR phosphorylation at Ser2448. This activity, potentiated in DN-Akt cells, was not detectable in CA-Akt cells. Our results suggest that death signals originating from damaged microtubules in G2/M can compete with G1 survival pathways at the level of mTOR. These findings have implications for cancer therapy and drug resistance.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy; CNR, Inst Biochem Technol, I-20090 Milan, Italy; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Florence, Inst Gen Pathol, I-50134 Florence, Italy	University of Milan; Consiglio Nazionale delle Ricerche (CNR); Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Florence	Nicolin, A (corresponding author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	angelo.nicolin@unimi.it	D'Agnano, Igea/AAR-7282-2020; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Gatti, Giuliana/0000-0001-8844-4543; D'Agnano, Igea/0000-0002-2646-9224				Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; Agami R, 2002, CANCER LETT, V177, P111, DOI 10.1016/S0304-3835(01)00785-6; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Bevilacqua A, 2003, J CELL PHYSIOL, V195, P356, DOI 10.1002/jcp.10272; Bevilacqua A, 2003, J BIOL CHEM, V278, P23451, DOI 10.1074/jbc.M210620200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen J, 2002, BIOCHEM PHARMACOL, V64, P1071, DOI 10.1016/S0006-2952(02)01263-7; Church AC, 2003, QJM-INT J MED, V96, P91, DOI 10.1093/qjmed/hcg014; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DU L, 2003, P 94 AACR ANN M TOR; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Fisher DE, 2001, APOPTOSIS, V6, P7, DOI 10.1023/A:1009659708549; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Haldar S, 1998, CANCER RES, V58, P1609; Haldar S, 1997, CANCER RES, V57, P229; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Koyasu S, 2003, NAT IMMUNOL, V4, P313, DOI 10.1038/ni0403-313; Kozma SC, 2002, BIOESSAYS, V24, P65, DOI 10.1002/bies.10031; Krystal GW, 2002, MOL CANCER THER, V1, P913; Kurzrock R, 2003, ANN INTERN MED, V138, P819, DOI 10.7326/0003-4819-138-10-200305200-00010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Le XF, 2003, ONCOGENE, V22, P484, DOI 10.1038/sj.onc.1206175; Ling YH, 2002, MOL CANCER THER, V1, P841; Ling YH, 1998, J BIOL CHEM, V273, P18984, DOI 10.1074/jbc.273.30.18984; Mayer TU, 2003, TRENDS CELL BIOL, V13, P270, DOI 10.1016/S0962-8924(03)00077-1; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Pene F, 2002, ONCOGENE, V21, P6587, DOI 10.1038/sj.onc.1205923; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Sekulic A, 2000, CANCER RES, V60, P3504; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5; Werlen G, 2003, SCIENCE, V299, P1859, DOI 10.1126/science.1067833; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	63	122	128	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2004	23	34					5781	5791		10.1038/sj.onc.1207698	http://dx.doi.org/10.1038/sj.onc.1207698			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	837KW	15208671				2022-12-17	WOS:000222629800007
J	Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE				Nilsen, H; Stamp, G; Andersen, S; Hrivnak, G; Krokan, HE; Lindahl, T; Barnes, DE			Gene-targeted mice lacking the Ung uracil-DNA glycosylase develop B-cell lymphomas	ONCOGENE			English	Article						uracil-DNA glycosylase; B-cell lymphoma; gene-targeted mice; antibody diversity	BASE EXCISION-REPAIR; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; DEFICIENCY CAUSES; MISINCORPORATION; MUTATIONS; TUMORIGENESIS; ACCUMULATION; SUPPRESSION	Mice deficient in the Ung uracil-DNA glycosylase have an increased level of uracil in their genome, consistent with a major role of Ung counteracting U:A base pairs arising by misincorporation of dUMP during DNA replication. A complementary uracil-excising activity apparently acts on premutagenic U:G lesions resulting from deamination of cytosine throughout the genome. However, Ung specifically processes U:G lesions targeted to immunoglobulin variable (V) genes during somatic hypermutation and class-switch recombination. Gene-targeted Ung(-/-) null mice remained tumour-free and showed no overt pathological phenotype up to similar to12 months of age. We have monitored a large cohort of ageing Ung(-/-) mice and, beyond 18 months of age, they had a higher morbidity than Ung(+/+) controls. Post-mortem analyses revealed pathological changes in lymphoid organs, abnormal lymphoproliferation, and a greatly increased incidence of B-cell lymphomas in older Ung-deficient mice. These are the first data reporting the development of spontaneous malignancies in mice due to deficiency in a DNA glycosylase. Furthermore, they support a specific role for Ung in the immune system, with lymphomagenesis being related to perturbed processing of antibody genes in germinal centre B cells.	Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England; Univ London Imperial Coll Sci Technol & Med, Dept Histopathol, Fac Med, London W12 0NN, England; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, Fac Med, N-7489 Trondheim, Norway	Cancer Research UK; Imperial College London; Norwegian University of Science & Technology (NTNU)	Lindahl, T (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, Canc Res UK, London Res Inst, S Mimms EN6 3LD, Herts, England.	lindahl@cancer.org.uk	Nilsen, Hilde/F-6432-2014	Nilsen, Hilde/0000-0003-2115-2663				Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Elder RH, 2002, J BIOL CHEM, V277, P50487, DOI 10.1074/jbc.M208153200; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; GOULIAN M, 1980, P NATL ACAD SCI-BIOL, V77, P1956, DOI 10.1073/pnas.77.4.1956; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kvaloy K, 2001, MUTAT RES-DNA REPAIR, V461, P325, DOI 10.1016/S0921-8777(00)00063-X; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Martin A, 2002, P NATL ACAD SCI USA, V99, P12304, DOI 10.1073/pnas.192442899; MCDONALD JP, 2003, IN PRESS J EXP MED; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Ocampo MTA, 2002, MOL CELL BIOL, V22, P6111, DOI 10.1128/MCB.22.17.6111-6121.2002; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Sakumi K, 2003, CANCER RES, V63, P902; Scharer OD, 2001, BIOESSAYS, V23, P270, DOI 10.1002/1521-1878(200103)23:3<270::AID-BIES1037>3.0.CO;2-J; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Stevenson FK, 2001, ADV CANCER RES, V83, P81, DOI 10.1016/S0065-230X(01)83004-9; Takao M, 2002, EMBO J, V21, P3486, DOI 10.1093/emboj/cdf350; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299; Wright BE, 2002, CANCER RES, V62, P5641	35	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 21	2003	22	35					5381	5386		10.1038/sj.onc.1206860	http://dx.doi.org/10.1038/sj.onc.1206860			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JC	12934097				2022-12-17	WOS:000184735000002
J	Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H				Takino, T; Koshikawa, N; Miyamori, H; Tanaka, M; Sasaki, T; Okada, Y; Seiki, M; Sato, H			Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases	ONCOGENE			English	Article						MMP; KiSS-1; cleavage	PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR; PROMOTES ACTIVATION; EXPRESSION; IDENTIFICATION; INVASION; BINDING; PEPTIDE; CELLS; ALPHA	A human placenta cDNA library was screened by the expression cloning method for gene products that interact with matrix metalloproteinases (MMPs), and we isolated a cDNA whose product formed a stable complex with pro-MMP-2 and pro-MMP-9. The cDNA encoded the metastasis suppressor gene KiSS-1. KiSS-1 protein was shown to form a complex with pro-MMP. KiSS-1 protein is known to be processed to peptide ligand of a G-protein-coupled receptor (hOT7T175) named metastin, and suppresses metastasis of tumors expressing the receptor. Active MMP-2, MMP-9, MT1-MMP, MT3-MMP and MT5-MMP cleaved the Gly(118)-Leu(119) peptide bond of not only full-length KiSS-1 protein but also metastin decapeptide. Metastin decapeptide induced formation of focal adhesion and actin stress fibers in cells expressing the receptor, and digestion of metastin decapeptide by MMP abolished its ligand activity. Migration of HT1080 cells expressing hOT7T175 that harbor a high-level MMP activity was only slightly suppressed by either metastin decapeptide or MMP inhibitor BB-94 alone, but the combination of metastin decapeptide and BB-94 showed a synergistic effect in blocking cell migration. We propose that metastin could be used as an antimetastatic agent in combination with MMP inhibitor, or MMP-resistant forms of metastin could be developed and may also be efficacious.	Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, Kanazawa, Ishikawa 9200934, Japan; Univ Tokyo, Inst Med Sci, Dept Canc Cell Res, Tokyo 1088639, Japan; Kanazawa Univ, Canc Res Inst, Dept Chemotherapy, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Keio Univ, Sch Med, Dept Pathol, Tokyo 1608582, Japan	Kanazawa University; University of Tokyo; Kanazawa University; Kanazawa University; Keio University	Sato, H (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Virol & Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	vhsato@kenroku.kanazawa-u.ac.jp	SATO, Hiroshi/D-8454-2015; Seiki, Motoharu/K-9443-2015; TAKINO, Takahisa/D-8460-2015; Koshikawa, Naohiko/S-7306-2017; Okada, Yasunori/B-5550-2014	Koshikawa, Naohiko/0000-0002-4539-888X; Okada, Yasunori/0000-0001-9208-4755				BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hiller O, 2000, J BIOL CHEM, V275, P33008, DOI 10.1074/jbc.M001836200; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Jaworski DM, 2000, BRAIN RES, V860, P174, DOI 10.1016/S0006-8993(00)02035-7; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Levi E, 1996, P NATL ACAD SCI USA, V93, P7069, DOI 10.1073/pnas.93.14.7069; Llano E, 1999, CANCER RES, V59, P2570; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Murray MJ, 1999, SEMIN REPROD ENDOCR, V17, P275, DOI 10.1055/s-2007-1016235; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakada M, 2001, CANCER RES, V61, P8896; NOMURA H, 1995, CANCER RES, V55, P3263; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shimada T, 1999, EUR J BIOCHEM, V262, P907, DOI 10.1046/j.1432-1327.1999.00459.x; Shirasaki F, 2001, CANCER RES, V61, P7422; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Ueno H, 1997, CANCER RES, V57, P2055; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Velasco G, 2000, CANCER RES, V60, P877; WOESSNER JF, 1991, J RHEUMATOL, V18, P99; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200	38	122	140	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4617	4626		10.1038/sj.onc.1206542	http://dx.doi.org/10.1038/sj.onc.1206542			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879005	Green Submitted			2022-12-17	WOS:000184157000001
J	Pozzi, A; LeVine, WF; Gardner, HA				Pozzi, A; LeVine, WF; Gardner, HA			Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis	ONCOGENE			English	Article						angiostatin; MMP9; doxycycline; angiogenesis	CHEMICALLY-MODIFIED TETRACYCLINES; INTEGRIN ALPHA-1-BETA-1; INHIBITION; DOXYCYCLINE; EXPRESSION; ANGIOSTATIN; ACTIVATION; METASTASIS; CARCINOMA; COLLAGEN	Angiogenesis is essential for tumor growth and blocking this process might be a valid tool for the control of cancer growth. We showed previously that tumor angiogenesis in integrin alpha1-null mice is reduced compared to that of wild type animals and that over-expression of matrix metalloproteinase 9 (MMP-9) in the alpha1-null and consequent generation of angiostatin (an inhibitor of endothetial cell growth) from circulating plasminogen was implicated in the mechanism of tumor inhibition. Our findings suggested that secretion of excess MMPs generates inhibitors of endothelial cell proliferation, including but not necessarily limited to angiostatin, resulting ultimately in auto-inhibition of angiogenesis. Thus MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor angiogenesis and tumor growth. In order to determine whether MMP-9 expression was directly involved in the regulation of tumor growth, we specifically inhibited or enhanced MMP-9 synthesis in vitro and in vivo, and subsequently analysed primary endothelial cell proliferation and angiostatin synthesis, as well as tumor vascularization and development. We provide evidence that reduction of plasma levels of MMP-9 in either normal or integrin alpha1-null mice leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. In contrast, specifically enhancing MMP-9 expression in vivo caused a reduction in tumor vascularization. These findings are the opposite to other studies suggesting a pro-tumorigenic role for MMP-9, and may account for some of the recently observed failures of anti MMP therapy in tumor treatment.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr N, Dept Med, Div Nephrol & Hypertens, Room B-3109, Nashville, TN 37232 USA.				NIAMS NIH HHS [AR44514] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044514, R55AR044514, R01AR044514] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Axisa B, 2000, J CHROMATOGR B, V744, P359, DOI 10.1016/S0378-4347(00)00261-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bettany J T, 1998, Adv Dent Res, V12, P136; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Curci JA, 2000, J VASC SURG, V31, P325, DOI 10.1016/S0741-5214(00)90163-0; Fife R S, 1998, Adv Dent Res, V12, P94; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Gardner H, 1999, J CELL SCI, V112, P263; Hanemaaijer R, 1998, Adv Dent Res, V12, P114; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 2001, CANCER RES, V61, P1272; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Rivas MJG, 1998, HEPATOLOGY, V28, P986, DOI 10.1002/hep.510280413; Sang Q X, 1998, Cell Res, V8, P171; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SIPOS EP, 1994, ANN NY ACAD SCI, V732, P263, DOI 10.1111/j.1749-6632.1994.tb24741.x; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; Sobrin L, 2000, INVEST OPHTH VIS SCI, V41, P1703; Soloway PD, 1996, ONCOGENE, V13, P2307; Sorsa T, 1998, J RHEUMATOL, V25, P975; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; VANDENBOGERT C, 1985, LEUKEMIA RES, V9, P617, DOI 10.1016/0145-2126(85)90142-0; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xiang R, 1998, CANCER RES, V58, P3918	34	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					272	281		10.1038/sj.onc.1205045	http://dx.doi.org/10.1038/sj.onc.1205045			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803470				2022-12-17	WOS:000173026200011
J	Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS				Conner, EA; Lemmer, ER; Omori, M; Wirth, PJ; Factor, VM; Thorgeirsson, SS			Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis	ONCOGENE			English	Article						hepatocellular adenoma; hepatocellular carcinoma; c-myc; p53; mouse	CELL-CYCLE CONTROL; GROWTH-FACTOR-ALPHA; C-MYC; HEPATOCELLULAR-CARCINOMA; S-PHASE; MICE; CANCER; TRANSCRIPTION; EXPRESSION; APOPTOSIS	Deregulation of E2F transcriptional control has been implicated in oncogenic transformation. Consistent with this idea, we recently demonstrated that during hepatocarcinogenesis in c-myc/TGF alpha double transgenic mice, there is increased expression of E2F-1 and E2F-2, as well as induction of putative E2F target genes. Therefore, we generated transgenic mice expressing E2F-1 under the control of the albumin enhancer/promoter to test the hypothesis that E2F family members may contribute to liver tumor development. Overexpression of E2F-1 resulted in mild but persistent increases in cell proliferation and death during postnatal liver growth, and no increases in hepatic regenerative growth in response to partial hepatectomy. Nevertheless, from 2 months postnatally E2F-1 transgenic mice exhibited prominent hepatic histological abnormalities including preneoplastic foci adjacent to portal tracts and pericentral large cell dysplasia. From 6 to 8 months onward, there was an abrupt increase in the number of neoplastic nodules ('adenomas') with 100% incidence by 10 months. Some adenomas shelved evidence of malignant transformation, and two of six mice killed at IZ months showed trabecular hepatocellular carcinoma. Endogenous c-myc was up-regulated in the early stages of E2F-1 hepatocarcinogenesis, whereas p53 was overexpressed in the tumors, suggesting that both E2F-1-mediated proliferation and apoptosis are operative but at different stages of hepatocarcinogenesis. In conclusion, E2F-1 overexpression in the liver causes dysplasia and tumors and suggests a cooperation between E2F-1 and c-myc oncogenes during liver oncogenesis.	NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, NIH, Expt Carcinogenesis Lab, Div Basic Sci, 37 Convent Dr MSC4255,Bldg 37,Room 3C28, Bethesda, MD 20892 USA.				DIVISION OF BASIC SCIENCES - NCI [Z01BC005750] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; COHEN C, 1986, CANCER, V57, P1535, DOI 10.1002/1097-0142(19860415)57:8<1535::AID-CNCR2820570816>3.0.CO;2-8; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DEPHINHO RA, 1991, ADV CANCER RES, V57, P1; Dynlacht BD, 1997, NATURE, V389, P149, DOI 10.1038/38225; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Factor VM, 1997, HEPATOLOGY, V26, P1434; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRITH CH, 1979, J ENVIRON PATHOL TOX, V3, P329; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Guy CT, 1996, MOL CELL BIOL, V16, P685; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Higgins GM, 1931, ARCH PATHOL, V12, P186; Holmberg C, 1998, ONCOGENE, V17, P143, DOI 10.1038/sj.onc.1201915; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson DG, 2000, MOL CARCINOGEN, V27, P151, DOI 10.1002/(SICI)1098-2744(200003)27:3<151::AID-MC1>3.0.CO;2-C; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Lukas ER, 1999, MOL CARCINOGEN, V25, P295, DOI 10.1002/(SICI)1098-2744(199908)25:4<295::AID-MC8>3.0.CO;2-9; Macleod K, 1999, CURR OPIN GENET DEV, V9, P31, DOI 10.1016/S0959-437X(99)80005-7; Macleod KF, 1999, J PATHOL, V187, P43, DOI 10.1002/(SICI)1096-9896(199901)187:1<43::AID-PATH246>3.0.CO;2-P; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; MURAKAMI H, 1993, CANCER RES, V53, P1719; Nagy P, 1996, HEPATOLOGY, V23, P71, DOI 10.1053/jhep.1996.v23.pm0008550051; NEVINS JR, 1992, SCIENCE, V258, P424; Pierce AM, 1998, ONCOGENE, V16, P1267, DOI 10.1038/sj.onc.1201666; Pierce AM, 1999, MOL CELL BIOL, V19, P6408; Pierce AM, 1998, P NATL ACAD SCI USA, V95, P8858, DOI 10.1073/pnas.95.15.8858; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; ROUNBEHIER R, 2000, P AM ASSOC CANC RES, V41, P394; Santoni-Rugiu E, 1998, CANCER RES, V58, P123; SCHERR C, 1994, CELL, V79, P551; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1	40	122	126	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2000	19	44					5054	5062		10.1038/sj.onc.1203885	http://dx.doi.org/10.1038/sj.onc.1203885			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	365CD	11042693				2022-12-17	WOS:000089930100002
J	Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E				Doong, H; Price, J; Kim, YS; Gasbarre, C; Probst, J; Liotta, LA; Blanchette, J; Rizzo, K; Kohn, E			CAIR-1/BAG-3 forms an EGF-regulated ternary complex with phospholipase C-gamma and Hsp70/Hsc70	ONCOGENE			English	Article						calcium; EGF; phospholipase C; Hsp70/Hsc70; signal transduction	SIGNAL-TRANSDUCTION; BCL-2-BINDING PROTEIN; MOLECULAR CHAPERONES; CALCIUM INFLUX; SH3 DOMAINS; CELL-DEATH; RECEPTOR; ACTIVATION; INHIBITION; C-GAMMA-1	CAIR-1/BAG-3 forms an EGF-regulated ternary complex with Hsp70/Hsc70 and latent phospholipase C-gamma (PLC-gamma). The expression of CAIR-1, CAI stressed-1, was induced in A2058 human melanoma cells by continuous exposure to CAI, an inhibitor of non voltage-gated calcium influx. CAIR-1 sequence is identical, save 2 amino acids, to BAG-3 also cloned recently as Bis, a member of the bcl-2-associated athanogene family. We show that CAIR-I/BAG-3 binds to Hsp70/Hsc70 in intact cells and this binding is increased by short term exposure to CAI (P<0.007). CAIR-1/BAG-3 is phosphorylated in vivo in the absence of stimulation. Basal phosphorylation is inhibited by treatment with d-erythrosphingosine (d-ES), a broad inhibitor of the protein kinase C family. CAIR-1/BAG-3 contains several PXXP SH3 binding domains leading to the hypothesis that it is a partner protein of phospholipase C-gamma. PLC-gamma is bound to CAIR-1/BAG-3 in unstimulated cells, It is increased by CAI or d-ES (P=0.05) treatment, and abrogated by EGF (r(2)=0.99); d-ES treatment blocks the EGF-mediated dissociation, We show that CAIR-1/BAG-3 binds to PLC-gamma and Hsp701/Hsc70 through separate and distinct domains. Hsp70/Hsc70 binds to the BAG domain of BAGs-1 and -3, CAIR-1/BAG-3 from control and EGF-treated cell lysates bound selectively to the SH3 domain of PLC-gamma, but not its N-SH2 or C-SH2 domains, Confirming the SH3 interaction, PLC-gamma was pulled down by CAIR-1/BAG-3 PXXP-GST fusions, but GST-PXXP constructs confronted with lysates from EGF-treated cells did not bind PLC-gamma as was seen in intact cells. Hsp70/Hsc70 was brought down by the PLC-gamma SH3 construct equally from native and EGF-treated cells, but did not bind the PXXP construct under either condition. We propose that CAIR-1/BAG-3 may act as a multifunctional signaling protein linking the Hsp70/Hsc70 pathway with those necessary for activation of the EGF receptor tyrosine kinase signaling pathways.	NCI, Mol Signaling Sect, Pathol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kohn, E (corresponding author), 10 Ctr Dr,10-2A33, Bethesda, MD 20892 USA.			Price, John/0000-0002-8244-1023				BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chang JS, 1997, CANCER RES, V57, P5465; Chen D, 1996, J BIOL CHEM, V271, P6328, DOI 10.1074/jbc.271.11.6328; FELDER CC, 1991, J PHARMACOL EXP THER, V257, P967; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; HAMPSON IN, 1992, NUCLEIC ACIDS RES, V20, P2899, DOI 10.1093/nar/20.11.2899; HATA A, 1993, J BIOL CHEM, V268, P9122; Hu YL, 1996, ONCOGENE, V12, P1865; Khoshyomn S, 1999, NEUROSURGERY, V44, P568, DOI 10.1097/00006123-199903000-00073; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHN EC, 1992, CANCER RES, V52, P3208; KOHN EC, 1994, CANCER RES, V54, P935; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; KOHN EC, 1994, J BIOL CHEM, V269, P21505; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; SCHLIEF R, 1994, ADV ECHO AGENTS, V4, P5; Smith MR, 1998, CARCINOGENESIS, V19, P177, DOI 10.1093/carcin/19.1.177; Stuart JK, 1998, J BIOL CHEM, V273, P22506, DOI 10.1074/jbc.273.35.22506; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Turner T, 1997, CLIN CANCER RES, V3, P2275; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; WAHL MI, 1988, SCIENCE, V241, P968, DOI 10.1126/science.2457254; Yang H, 1998, ANTICANCER RES, V18, P1399; YANG LJ, 1994, J BIOL CHEM, V269, P7156; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	34	122	128	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 7	2000	19	38					4385	4395		10.1038/sj.onc.1203797	http://dx.doi.org/10.1038/sj.onc.1203797			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	353JW	10980614				2022-12-17	WOS:000089271900009
J	Deng, CX; Scott, F				Deng, CX; Scott, F			Role of the tumor suppressor gene Brca1 in genetic stability and mammary gland tumor formation	ONCOGENE			English	Article						Brca1; p53; centrosome; G(2)-M checkpoint; tumorigenesis	CANCER-SUSCEPTIBILITY GENES; EARLY EMBRYONIC LETHALITY; FAMILIAL BREAST-CANCER; SPLICE VARIANTS BRCA1A; CELL-CYCLE; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVATION; CENTROSOME AMPLIFICATION; NUCLEAR PHOSPHOPROTEIN; MEIOTIC CELLS	Germline mutations in the tumor suppressor BRCA1 predispose women to breast and ovarian cancers. Current evidence demonstrates that mutations in BRCA1 do not directly result in tumor formation, but instead cause genetic instability, subjecting cells to high risks of malignant transformation, In an animal model in which Brca1 is mutated specifically in mammary epithelium, tumorigenesis occurs in mutant glands at low frequency after a long latency. Notably, introduction of a p53-null allele significantly enhanced mammary gland tumor formation in Brca1 conditional mutant mice. These results are consistent with a model that Brca1 is a caretaker gene, whose absence causes genetic instability and triggers further alterations, including inactivation of tumor suppressor genes and/or activation of oncogenes, leading to tumor formation.	NIDDKD, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Deng, CX (corresponding author), NIDDKD, Genet Dev & Dis Branch, NIH, 10-9N105, Bethesda, MD 20892 USA.		deng, chuxia/N-6713-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK056001, Z01DK056001] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; BENNETT LM, 1995, GENOMICS, V29, P576, DOI 10.1006/geno.1995.9963; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brody LC, 1998, MEDICINE, V77, P208, DOI 10.1097/00005792-199805000-00006; Brugarolas J, 1997, NAT MED, V3, P721, DOI 10.1038/nm0797-721; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Chen YM, 1996, CANCER RES, V56, P3168; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cui JQ, 1998, ONCOL REP, V5, P585; Cui JQ, 1998, ONCOL REP, V5, P591; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Dennis C, 1999, NAT GENET, V22, P10, DOI 10.1038/8714; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Easton D, 1997, NAT GENET, V16, P210, DOI 10.1038/ng0797-210; Eisinger F, 1997, LANCET, V350, P1101, DOI 10.1016/S0140-6736(05)70461-X; Ellisen LW, 1998, ANNU REV MED, V49, P425; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hagmann M, 1999, SCIENCE, V284, P723, DOI 10.1126/science.283.5403.777; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Larson JS, 1997, CANCER RES, V57, P3351; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 1996, CANCER RES, V56, P4578; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paterson JWE, 1998, DIS MARKERS, V13, P261, DOI 10.1155/1998/298530; Pihan GA, 1998, CANCER RES, V58, P3974; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tanaka T, 1999, CANCER RES, V59, P2041; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu CF, 1996, SEMIN CANCER BIOL, V7, P33, DOI 10.1006/scbi.1996.0005; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	77	122	125	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1059	1064		10.1038/sj.onc.1203269	http://dx.doi.org/10.1038/sj.onc.1203269			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713690				2022-12-17	WOS:000085796400012
